<SEC-DOCUMENT>0000914475-23-000011.txt : 20230209
<SEC-HEADER>0000914475-23-000011.hdr.sgml : 20230209
<ACCEPTANCE-DATETIME>20230209160245
ACCESSION NUMBER:		0000914475-23-000011
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		94
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230209
DATE AS OF CHANGE:		20230209

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEUROCRINE BIOSCIENCES INC
		CENTRAL INDEX KEY:			0000914475
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330525145
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22705
		FILM NUMBER:		23606138

	BUSINESS ADDRESS:	
		STREET 1:		12780 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		(858) 617-7600

	MAIL ADDRESS:	
		STREET 1:		12780 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>nbix-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:218564f8-ce6a-495b-ab09-3ced376fc2a9,g:579af41c-0e49-45b3-bd8f-934603ccb3b3,d:d795223301944418ba8c3fb3bc02f08e--><html xmlns:nbix="http://www.neurocrine.com/20221231" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:srt="http://fasb.org/srt/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>nbix-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV80L2ZyYWc6Zjc1ZTJmYjM0ZWU3NGIyMmFjMThjZmJlNDc4NzJkNWYvdGFibGU6MDg1NjU2MTQ1YjZjNDhjM2JhYWZmNGQ3M2FlZjdlNjYvdGFibGVyYW5nZTowODU2NTYxNDViNmM0OGMzYmFhZmY0ZDczYWVmN2U2Nl8zLTEtMS0xLTEzOTA2Mg_1e0af2c1-047f-49b2-a706-b05fd584bf82">false</ix:nonNumeric><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV80L2ZyYWc6Zjc1ZTJmYjM0ZWU3NGIyMmFjMThjZmJlNDc4NzJkNWYvdGFibGU6MDg1NjU2MTQ1YjZjNDhjM2JhYWZmNGQ3M2FlZjdlNjYvdGFibGVyYW5nZTowODU2NTYxNDViNmM0OGMzYmFhZmY0ZDczYWVmN2U2Nl80LTEtMS0xLTEzOTA2Mg_4c0ded36-9687-4059-bf67-4b1854978904">2022</ix:nonNumeric><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV80L2ZyYWc6Zjc1ZTJmYjM0ZWU3NGIyMmFjMThjZmJlNDc4NzJkNWYvdGFibGU6MDg1NjU2MTQ1YjZjNDhjM2JhYWZmNGQ3M2FlZjdlNjYvdGFibGVyYW5nZTowODU2NTYxNDViNmM0OGMzYmFhZmY0ZDczYWVmN2U2Nl81LTEtMS0xLTEzOTA2Mg_b5e88375-ce37-4af3-a289-5820466f257e">FY</ix:nonNumeric><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV80L2ZyYWc6Zjc1ZTJmYjM0ZWU3NGIyMmFjMThjZmJlNDc4NzJkNWYvdGFibGU6MDg1NjU2MTQ1YjZjNDhjM2JhYWZmNGQ3M2FlZjdlNjYvdGFibGVyYW5nZTowODU2NTYxNDViNmM0OGMzYmFhZmY0ZDczYWVmN2U2Nl82LTEtMS0xLTEzOTA2Mg_f52c30e8-e167-4106-89e0-504fdd35a398">0000914475</ix:nonNumeric><ix:nonNumeric contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzE2LTAtMS0xLTE0NDY4Ng_07167cb8-6fd5-4735-8780-8b07212a106b">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonNumeric contextRef="ifbefd953596945ebb57cb8b4260d4036_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzIyMzk4_faec3abd-c6f8-404f-adcd-432a19a48776">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i52de095faa4e4144bb37c3dd09f49c99_D20211231-20211231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NTk5NDY_b11908b6-457c-4872-91a0-7e1b27137ced">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonNumeric contextRef="i52de095faa4e4144bb37c3dd09f49c99_D20211231-20211231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NjA1MDc_b11908b6-457c-4872-91a0-7e1b27137ced">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonNumeric contextRef="i52de095faa4e4144bb37c3dd09f49c99_D20211231-20211231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NjA3NTA_b11908b6-457c-4872-91a0-7e1b27137ced">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonNumeric contextRef="i52de095faa4e4144bb37c3dd09f49c99_D20211231-20211231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NjEwNzc_b11908b6-457c-4872-91a0-7e1b27137ced">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonFraction unitRef="segment" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzMvZnJhZzo4YjE2MDBjYzI4MTg0YzdlOWNiYTg4Yzg0MDZlYmNmNC90ZXh0cmVnaW9uOjhiMTYwMGNjMjgxODRjN2U5Y2JhODhjODQwNmViY2Y0XzQ3_060008ea-65f9-48d5-9445-1b304ba4094c">one</ix:nonFraction><ix:nonFraction unitRef="segment" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzMvZnJhZzo4YjE2MDBjYzI4MTg0YzdlOWNiYTg4Yzg0MDZlYmNmNC90ZXh0cmVnaW9uOjhiMTYwMGNjMjgxODRjN2U5Y2JhODhjODQwNmViY2Y0XzQ3_601a319f-9f60-409c-bb6d-782d428d1ad0">one</ix:nonFraction><ix:nonNumeric contextRef="i52de095faa4e4144bb37c3dd09f49c99_D20211231-20211231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNDc2NA_b11908b6-457c-4872-91a0-7e1b27137ced">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i35bad398da4e4adb94afe6a3edc6fbd6_D20170502-20170502" decimals="8" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTEvZnJhZzpjZDIyOGFmMDZjMDg0NDk3YTg2ZWFlNWQ5NWUxMWQ0OC90YWJsZTpjMTZkN2IzMzU3N2E0ZmE1YmJlNzMyYjBiNGE5NmRkYS90YWJsZXJhbmdlOmMxNmQ3YjMzNTc3YTRmYTViYmU3MzJiMGI0YTk2ZGRhXzItMS0xLTEtMTM5MDYy_b2b328c1-3792-43e5-865f-adacc7c277d1">0.00131711</ix:nonFraction><ix:nonNumeric contextRef="i9b22ddd5cfee4bba8e30c82f31d98316_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzIwMTc_50d14189-4f30-4d95-85d1-8b0107a221f2">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="ife8d2c8c602c417081f5a70afe7b7414_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzU0OTc1NTg0OTAyMA_025ee6ff-3e68-4066-aa62-f80b858bd74f">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="if8d41d8e8ddc41f1ba3f1ca687d9551d_I20220208" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90ZXh0cmVnaW9uOjU1NzA4M2I5OTQyZTQ5ZGNiMzRhNmEyZjc1ZjExNGFjXzcxNDY4MjU1ODI4MDk_9da6dfa7-7ad5-4e15-990b-61663bd419f1">P13Y7M</ix:nonNumeric><ix:nonNumeric contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpmYjg1MmU0NGUwYmY0ZDA3YTVmNjZhM2QxM2VkNmYxMC90YWJsZXJhbmdlOmZiODUyZTQ0ZTBiZjRkMDdhNWY2NmEzZDEzZWQ2ZjEwXzEwLTAtMS0xLTEzOTA2Mg_85571070-dcc5-4354-8358-dbaa0e075ba0">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="nbix-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic07db2f2e87d4ef895cb2823ce1bd349_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i7a07412530754a858e0fecb90db3cba4_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i4dad9397c8114dc994a1d55e36926d3d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i092dab9242464bf7bd7bddb6a8629472_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i5fc4cf231a09409ca4f633d2a52d1059_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib02b2e314d9843b6beb8c5b163f3331b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieadd249b6bd54f3f882b31ca68b01cd6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i639fef176a3f4b5ca32c8c373750fe46_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3a57832bc8048d593cd85c6dc2a6362_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6e4c87aa559406d86302c9502431650_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5487fc19d1994eb39121318350a3e13a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0742d6ae0d04338b0b3b537053da2dd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i925cca476463400d82eec5ed1c25941d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a17ccdbf08849ba857638d5a36314ed_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9e7a539304246b48b58f35e4a888e14_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9a3f2cd6f5941a6bcecb7ae1f54d627_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fe0390d99064b149bfb4f7d84cd1ab2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d19e967388d41128ce3a6f556f600be_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0ee7b0ff1c946b390b1cd119381b62f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1660cd4b7b54e359345103c0e942aa8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f63238a40484e0ab018374a8829b7a0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78e8a22fcfd640478484ade7992b19eb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f7dfb474ad94c65bc4bb9ac91172dc9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a88ab4de251408db4aa98552134a56a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7e33c1feaa549568d96ca0b5a1289e4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6eb7229899cc4ef8a964dc3ed073c87c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a5dcf16fd4c454093a5adc50ec3dbf4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7839db0dc61d4c4e8853cf6e19e54d9a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b99420940c34cd38a2ca2831819f03a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic68171adb3f24de9bed3bd6b62a8b5f1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1431ff2fdef24f178c1a21ede2c5c504_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72e83c4aadc74dfe9f04f4780dec95d0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5ed360a12ed4ff2b4e907ef5bc21e00_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd0f70dc50c24e3ebdef035671ebad8d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6110ec902f424e9786d861ac3a49b372_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia89fc8fb19434c28a5b37e944ef95c17_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica83f9a3025b4dce8f0663374896f3ea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90432f146b89477b90abd98f33694f6b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9398bcb69b16420d9cf3703d6c3c8b15_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2faddbeacae241608429e772b0492fe7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5989ae77b9e4f9bab21d80812e7179d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i423520348d804b1da2a2f946632d1239_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b9ae80dc18341fabe82e98052d1b03a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbefd953596945ebb57cb8b4260d4036_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i369eac3be33e4aaeb739e76899443560_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8a35373f04d4f25aabbae9b053dfc86_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nbix:LargestFourCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i3ee7b53986f840f69575c96ddd148ff6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nbix:LargestFourCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42a4d7de80254904a89f6619754861e0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b5b4f7eab2446ce84ea30524cbd6aa0_I20170502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52de095faa4e4144bb37c3dd09f49c99_D20211231-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-31</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b26f825c6434881a754e7e6c53ed556_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>nbix:segment</xbrli:measure></xbrli:unit><xbrli:context id="i49d358b74dad468eb33569aa9c5ac1c8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:HeptaresTherapeuticsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07a1cddc781641a8845184519e26357f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:HeptaresTherapeuticsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1528f057e30c40d383e6a6ca39cf5e6c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:HeptaresTherapeuticsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f5830ad533c4847b9f38b89925e51ec_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7449f5d91b314ce9840e1b298ee98b5a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b886e104da64c1fa92f25fa93dc1395_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i868635e691954212a665a735b175d9cc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:IdorsiaPharmaceuticalsLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i440c81bdf19642fba2eda39e1baadf0e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:IdorsiaPharmaceuticalsLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd82456387ea428d8220b9c69e68b5a5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61160aa576a54fed889d400313bcb4aa_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib362d8b9fffd4556aaef9b4388175d10_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1de27f6ad9554d338fb10badbf2b6cc6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia98ab6db9c434e4dbbefda09d3b887fb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dd2cca8016742d7affa71c15d311c24_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56425aa7040a45e28f54bc219c6c40d3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb20bc9532234865b09c7dc5f22a26fc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5b5c0571ff04f84bac746f261a35bef_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3558292be26a40eea22ad957b4eb1826_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7701cdc56953401b8c556dba9626d9e9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68a2f3aa551740a2a1bc3a14aaf7c9fa_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic667970352ec4acca922a861f9e43c76_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42ebb9eaffae4c9eac346888ea44b0d4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67a8f10be8224d60b4e1657e6dade015_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:BIALPortelaCaSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59539b84d7aa486da424a835877b0fc9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic013c8b18d624578b99159e4ff5581c7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a3cc531fe0541f4b8e3a1edcfbd0a17_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee6e68341d9841438fa8702438a7dac5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f13730346f24079965eeb3a7fe0ff59_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idda4399247c446cebc1ede65c5bec2b9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61790d0b66be4586a7c469931f4ab4d7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d60a74b87dc498c97bc171751a50ac9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d13692c26a440998d78e8fffc7d8570_D20221101-20221101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nbix:DiurnalGroupPlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a8688d19b0c4b7f9f790a262226d2ea_I20221101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nbix:DiurnalGroupPlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a6f8fd190a2433584205fa45bfd8bcb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i001676d240734d81bdb16bacb8df878e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dc4af282e2e4830bb4c5589ec647f1f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e6ecccda3454d2d97a48bbbed7a06c4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc59d3c4ac034bfc85c224da99f57d0f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76c8c1dcfb3247a6b15b3036d4069cbc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="security"><xbrli:measure>nbix:security</xbrli:measure></xbrli:unit><xbrli:context id="id63f24106d73460cb43b5496689583ba_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea0e6362bc9a41baa6232f3d791b1b30_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b718dc4ea4045ddb88690b0606e023f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8286a497677b4b46a9e257151dfe0240_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e2f6bb95ef942549f5717766447bf89_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b0d1aff1c264abba7252395e73cacd2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9258781d2d9a48c3abc627b4e38a38f6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icacc4e9a05c844698340e3f6ee1020e9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3469d1c34084c0caf63fea3b7ad7ad0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55208f6888cb4f1aa1161cb859460aa3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88ef2bfe4b974f9dbf50fa97b715887d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb0138cfa605465396a47f3dd519480e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8f1b78aab9747879b7bf25dd9a9712c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic12ec9940933424ea6839c2a0d9170e3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e86195663524f63a9bd0a9f18bf1cbf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5eb4267dd8494bd9b9dcaabe2416461d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i654c80e71bff4d869218415b7e3dc0a0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i007cfabe3a8849bab803ba60c015eab2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a9b7472fc7b4972acb2ac9f7cef302d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibeb578648cbe47d9949ee6e34fe0ad99_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae37ac3f84054636b37554762cc34e63_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie46d509c4cb348eeba80e5d4d37e4475_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i439770d7fd6f4f859128c5157c9235a1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2b42a9d8bc44f1ea40843385e1e20d1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10967d72424a4f7791a64e8d6c259d64_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia49862c3506f4b74acff88c95716b232_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61c8a28f6dfe4ed090fe32a6157f5e6c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i592eaf87071c432cb1c6e78bf7a7e092_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4474116f1b674daca505b919ccc95074_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i699cec09a8334f4c8b6ac965045cb456_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ddb56fada71460eba444fd3d97f4b69_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib57d06337718492f9cfef217012538ee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fd315b303184968b952d7bb6d9c6472_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e1a8fc8f38c4c8aa7c1dae7f202b3b4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idec09e5a03864099989354c76b828527_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31b04184eff74bf4b5192930aacadfec_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26120348d6074f35b090ebbda6b3fcf0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc55062153d94ad7b8d61e6d19057c50_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if47e96c65cb74988b1f42acee047add6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d61b3503a4e475e8484e3f0377b2a11_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf22fe030fdf4397978434417c7b8788_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23f85f7c13a54d018aba01edd3e7dbf6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69926a6399c34cf885a190c0d20df7f3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5a5bad1ec804fe58946f735c8b3b59a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3416e3592d234d7aa0dc1a6d0c4492e2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if164f03cdc61491492728ca7e7517143_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a0f1b836d0749b486fff5c035616613_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19826127b8b3400a9e18b46be425bc61_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ce1cf497c004f079441d676651e2808_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8373d29f581740ec8093f00de6a55275_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id96df92d50994507814aa00688b39486_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedb24ff2ca7b44618a98e55d5e02fb8a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i170c112de5b842e4b59047014a54dcc0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fc84fce9b6f4f4494703d493708167e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i607d3acd1b9a45c49ba0983930259c41_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i738cf7daafb54a76adcadab34123ba8f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e243caf058841239f5b24d4011ad3df_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i202b3b88d9ac4d138f5675ec9220d37e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4971e09f913f4c90bd8fd83e1d0fcd54_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3f57bcb850140d7aa4beb063512caf3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd3d786e58da41c8ab668363ea9b72d4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie68e2d5dfa5744d28e808e7184b1ac64_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1910f568982940418f0b3f4ef8742b36_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea06eb619bca46279cd1e26fd668574c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35bad398da4e4adb94afe6a3edc6fbd6_D20170502-20170502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-02</xbrli:startDate><xbrli:endDate>2017-05-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id330e3069fc840d18f4175221a90fd47_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48eccd3ba1b3454495acdad169d5d6f5_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i629ba4e4ef664986a91d0ae915e45857_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb0ec417ca564717bb097aa83567533a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i601493722ddc4060955049e1e99ec96e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaee95a0d57144ecaa3a678d3909bf7b2_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bf8e6cfdf3742479b08b59beb60be53_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48dd18e80c3e4426a4bf9c87e59b2aa4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5ecf9e10df34a7a853f2e59470d0f7f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17f7971a67b44e4798fe7f7d49131fe4_D20170502-20170502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbix:DebtInstrumentConversionAxis">nbix:ConversionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-02</xbrli:startDate><xbrli:endDate>2017-05-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="d"><xbrli:measure>utr:D</xbrli:measure></xbrli:unit><xbrli:context id="if30740e0928241cb97cfb0ed6563a982_I20170502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbix:DebtInstrumentConversionAxis">nbix:ConversionPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfcb863f462042bbaf5db27efbc920d6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbix:DebtInstrumentConversionAxis">nbix:ConversionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i134fefee8f064cab9634e36d3fc21cfa_D20170502-20170502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbix:DebtInstrumentConversionAxis">nbix:ConversionPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-02</xbrli:startDate><xbrli:endDate>2017-05-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18d39a0874004a4dbfac9a59054c0309_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6282ace541846298e168b3652f98351_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfdc712fb9f342aca6ae054a16698cef_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib36cc15a97d94e96a193bf977c9bcc64_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cfcd3b4d7074f90897906a633ffcd5c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad805873aae044c699ba94c98221a05f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nbix:ScientificEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a4a256d6b68420ca9418a64a947bc8b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nbix:ScientificEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5947e62d00f451eb3a24072ec5328d8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d163cbc8c3d4cef88df04d4844d353c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ae1d4d52be44bc3bc2ba9cfc000d178_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f931f023a9b4e74be1c9df8a59da030_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7d26b322bb24bff8ec6e47dcf836515_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nbix:StockOptionsRestrictedStockAndConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idaf8254dea124bfb9e7456439c9c6107_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nbix:StockOptionsRestrictedStockAndConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2bedeff3c8c43e6a805d773f9fd4669_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nbix:StockOptionsRestrictedStockAndConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25f7e10858b24f7fae2103c935cfd949_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nbix:Amended2020EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i213982ce809548e292c18f6215fa9e6b_D20220518-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nbix:Amended2020EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-18</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id479e592bc6b4c9fb00c946120287b70_I20110531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nbix:TwoThousandAndElevenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2011-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i695a8fab0f384006baa1447f58213de8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nbix:Amended2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bdd80fdaea2455ba085c93bafcf958a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56babcc72eb54154a6b2bbf854d97490_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8089736b115438bae00a39b3e804807_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8bb02545f4e412b99ba7d4bcfab2fbd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3dd11bd409d4809a79dea85436f4401_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i901a3c0cc12a478b90f47154a36d3711_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6946e8304b548468ab27182f7a4d25b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7178f777b084a969408727f29c9743f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85732a5f6db74d908155c57c3c4f6f54_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic76478c478fb48838837717f4d08aac5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45d277e0630f42518902ef7c75a787b7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb26118589cd4a7f9365abf100167588_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87dac2801c32400a82446d8538afc4cf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2383f1847c08462b992435e6a74d3b13_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4445191c2fc34a93a6035559db9ca75f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76fab03eca0a475d8e8c0d679f6b27b8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d5d3961550840ffb667ec48e12d4486_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9983074f75e943bf8e1b6ffe1be8dfaa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0960363045f4c3fa3cbebd5f5dd1c92_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab54417bdda84f5da649889184df892f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3f2d647e6d24e838c79ec0e84ee0b98_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b22ddd5cfee4bba8e30c82f31d98316_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67cf3f5a803b4310944b01aeae80d081_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60b1905034ee4ddfb0d307e7deb147c0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife8d2c8c602c417081f5a70afe7b7414_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic887499617c2453682a9ed77390375fe_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i229630d0b4d149969094372fd9771fee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf71df6caa1445c7a59724087fa5d3fa_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i216211ef6a3c4bf293c5a051308c8517_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71608a5505e146ccaf00cf18ac3af453_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec21f5b659784393b128ecb098d076d0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cd52a694c0b4753b93edf35c2915881_D20220208-20220208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-08</xbrli:startDate><xbrli:endDate>2022-02-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8d41d8e8ddc41f1ba3f1ca687d9551d_I20220208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="renewaloption"><xbrli:measure>nbix:renewalOption</xbrli:measure></xbrli:unit><xbrli:context id="ic8bcdc018b3641e5b570fb899c943e20_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5576346c88f84a9aa3ea6be5a075ead3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iced58b51ca3c40e3942fff0f7f450577_I20230108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-08</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="id795223301944418ba8c3fb3bc02f08e_1"></div><div style="min-height:31.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington,&#160;D.C. 20549</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGV4dHJlZ2lvbjo5NDlhN2EyZWRhZmI0ZWUyYTk5OGFlNWRjMThmOTIyY18zMjY0_e689d1fb-db1e-4205-88c8-f94dd09db2ee">10-K</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:549.00pt"><tr><td style="width:1.0pt"></td><td style="width:12.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:469.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGFibGU6MzlkNDcxNDJhZDgzNDkzNzg5MzU1YzE0NmZhOWFkZWYvdGFibGVyYW5nZTozOWQ0NzE0MmFkODM0OTM3ODkzNTVjMTQ2ZmE5YWRlZl8wLTAtMS0xLTEzOTA2Mg_71393ac0-3855-402b-aa9f-5be97bcaa9d4">&#9745;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGV4dHJlZ2lvbjo5NDlhN2EyZWRhZmI0ZWUyYTk5OGFlNWRjMThmOTIyY18zMjYx_2b1ea06b-18d2-4da3-96a5-da6c2153a094"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGV4dHJlZ2lvbjo5NDlhN2EyZWRhZmI0ZWUyYTk5OGFlNWRjMThmOTIyY18zMjYx_1bf46a56-9501-496e-9508-94f138614a26">December&#160;31</ix:nonNumeric>, 2022</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:549.00pt"><tr><td style="width:1.0pt"></td><td style="width:12.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:487.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGFibGU6MzFiOWM1MGU4ODQ3NGIxNDkyNWEwZmY2OGMwZjIyOWEvdGFibGVyYW5nZTozMWI5YzUwZTg4NDc0YjE0OTI1YTBmZjY4YzBmMjI5YV8wLTAtMS0xLTEzOTA2Mg_95f85c5f-2579-4d6b-8762-bb238073a3c0">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from __________to__________</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission file number </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGV4dHJlZ2lvbjo5NDlhN2EyZWRhZmI0ZWUyYTk5OGFlNWRjMThmOTIyY18zMjcx_8a9d18ee-1a27-45f5-b38a-ff27583ee8bf">0-22705</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGV4dHJlZ2lvbjo5NDlhN2EyZWRhZmI0ZWUyYTk5OGFlNWRjMThmOTIyY18zMjcy_e06d5e6f-c757-442b-9523-445ed4e70f4c">NEUROCRINE BIOSCIENCES, INC.</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:549.00pt"><tr><td style="width:1.0pt"></td><td style="width:102.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:49.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:164.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:175.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGFibGU6NjkwNzMyYTE2YzcxNDk3YTgwM2JiZTZmYzI5ZDY4NDQvdGFibGVyYW5nZTo2OTA3MzJhMTZjNzE0OTdhODAzYmJlNmZjMjlkNjg0NF8wLTAtMS0xLTEzOTA2Mg_5874c26e-3dfd-43ee-9910-0612ffec2f29">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGFibGU6NjkwNzMyYTE2YzcxNDk3YTgwM2JiZTZmYzI5ZDY4NDQvdGFibGVyYW5nZTo2OTA3MzJhMTZjNzE0OTdhODAzYmJlNmZjMjlkNjg0NF8wLTQtMS0xLTEzOTA2Mg_c0577915-573b-450c-9e0f-d0106ba9ae29">33-0525145</ix:nonNumeric></span></td></tr><tr style="height:21pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGFibGU6NjkwNzMyYTE2YzcxNDk3YTgwM2JiZTZmYzI5ZDY4NDQvdGFibGVyYW5nZTo2OTA3MzJhMTZjNzE0OTdhODAzYmJlNmZjMjlkNjg0NF8zLTAtMS0xLTEzOTA2Mg_04a888b9-b727-4de7-bf71-f1d5b34faaab">12780 El Camino Real,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGFibGU6NjkwNzMyYTE2YzcxNDk3YTgwM2JiZTZmYzI5ZDY4NDQvdGFibGVyYW5nZTo2OTA3MzJhMTZjNzE0OTdhODAzYmJlNmZjMjlkNjg0NF8zLTEtMS0xLTEzOTA2Mg_d76dd1df-0648-4fbf-abb4-8781a7f42b1a">San&#160;Diego,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGFibGU6NjkwNzMyYTE2YzcxNDk3YTgwM2JiZTZmYzI5ZDY4NDQvdGFibGVyYW5nZTo2OTA3MzJhMTZjNzE0OTdhODAzYmJlNmZjMjlkNjg0NF8zLTItMS0xLTEzOTA2Mg_cb865987-80ad-400e-b6f3-681b1195fc65">California</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGFibGU6NjkwNzMyYTE2YzcxNDk3YTgwM2JiZTZmYzI5ZDY4NDQvdGFibGVyYW5nZTo2OTA3MzJhMTZjNzE0OTdhODAzYmJlNmZjMjlkNjg0NF8zLTQtMS0xLTEzOTA2Mg_01a7d682-20cd-4138-9de5-4aa639ac15f1">92130</ix:nonNumeric></span></td></tr><tr style="height:12pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGV4dHJlZ2lvbjo5NDlhN2EyZWRhZmI0ZWUyYTk5OGFlNWRjMThmOTIyY18zMjYy_dd853f04-17ba-47a6-9baf-9aa422cf0274">858</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGV4dHJlZ2lvbjo5NDlhN2EyZWRhZmI0ZWUyYTk5OGFlNWRjMThmOTIyY18zMjcz_e5ef6d3a-1387-4f33-95fe-83dd6403d5b4">617-7600</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.053%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.141%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGFibGU6Y2ZhNDE2Y2UzMTg4NGZjNjk3NjAwNzRmMDQ3NTliZjIvdGFibGVyYW5nZTpjZmE0MTZjZTMxODg0ZmM2OTc2MDA3NGYwNDc1OWJmMl8wLTAtMS0xLTEzOTA2Mg_c8641494-4121-4b80-9606-6b8e2d58304a">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGFibGU6Y2ZhNDE2Y2UzMTg4NGZjNjk3NjAwNzRmMDQ3NTliZjIvdGFibGVyYW5nZTpjZmE0MTZjZTMxODg0ZmM2OTc2MDA3NGYwNDc1OWJmMl8wLTItMS0xLTEzOTA2Mg_d765480c-1447-43aa-aa63-4d8b76b85733">NBIX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGFibGU6Y2ZhNDE2Y2UzMTg4NGZjNjk3NjAwNzRmMDQ3NTliZjIvdGFibGVyYW5nZTpjZmE0MTZjZTMxODg0ZmM2OTc2MDA3NGYwNDc1OWJmMl8wLTQtMS0xLTEzOTA2Mg_df69a2d1-281d-4417-b26c-78c07194edac">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Title of each class)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Trading Symbol)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Name of each exchange on which registered)</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act:</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">None</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Title of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">class</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">)</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;<ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGV4dHJlZ2lvbjo5NDlhN2EyZWRhZmI0ZWUyYTk5OGFlNWRjMThmOTIyY18zMjY1_44ff449f-2d5d-4aa5-ac6b-39ae8fe28aa3">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGV4dHJlZ2lvbjo5NDlhN2EyZWRhZmI0ZWUyYTk5OGFlNWRjMThmOTIyY18zMjY5_09f2f3dd-6966-4f41-8f62-004bcb5bbc31">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;<ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGV4dHJlZ2lvbjo5NDlhN2EyZWRhZmI0ZWUyYTk5OGFlNWRjMThmOTIyY18zMjc0_6ae967bf-529a-47a8-b6d8-803b7d4315b0">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;&#160;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;<ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGV4dHJlZ2lvbjo5NDlhN2EyZWRhZmI0ZWUyYTk5OGFlNWRjMThmOTIyY18zMjYz_6755f574-4014-4011-8617-9e526e1aa973">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.863%"><tr><td style="width:1.0%"></td><td style="width:15.179%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.075%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.221%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.146%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGFibGU6NjNjN2QzOGVjNDcxNGYxOTlmN2UyZTg4ODQ4ZDNjYTIvdGFibGVyYW5nZTo2M2M3ZDM4ZWM0NzE0ZjE5OWY3ZTJlODg4NDhkM2NhMl8wLTAtMS0xLTEzOTA2Mg_8c7fa84e-29e4-4d8d-bb45-5ee784d4aa25">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9745;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGFibGU6NjNjN2QzOGVjNDcxNGYxOTlmN2UyZTg4ODQ4ZDNjYTIvdGFibGVyYW5nZTo2M2M3ZDM4ZWM0NzE0ZjE5OWY3ZTJlODg4NDhkM2NhMl8wLTEwLTEtMS0xMzkwNjI_528078ba-b90d-47f7-9562-aa20add5dcc8">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGFibGU6NjNjN2QzOGVjNDcxNGYxOTlmN2UyZTg4ODQ4ZDNjYTIvdGFibGVyYW5nZTo2M2M3ZDM4ZWM0NzE0ZjE5OWY3ZTJlODg4NDhkM2NhMl8wLTEzLTEtMS0xMzkwNjI_8333250b-7d19-42a2-8cce-65480c483f70">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGV4dHJlZ2lvbjo5NDlhN2EyZWRhZmI0ZWUyYTk5OGFlNWRjMThmOTIyY18zMjY3_7a8aed9d-d5ee-4068-bf75-b72c2819af7c">&#9745;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167; 240.10D-1(b).&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act). Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGV4dHJlZ2lvbjo5NDlhN2EyZWRhZmI0ZWUyYTk5OGFlNWRjMThmOTIyY18zMjcw_e2fc7fce-635d-4074-a012-8d7c8a5ba899">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate market value of registrant&#8217;s common stock held by non-affiliates of the registrant, computed by reference to the closing price as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter, June 30, 2022, was $<ix:nonFraction unitRef="usd" contextRef="ic07db2f2e87d4ef895cb2823ce1bd349_I20220630" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGV4dHJlZ2lvbjo5NDlhN2EyZWRhZmI0ZWUyYTk5OGFlNWRjMThmOTIyY18yODQ0_d4b78842-10ae-4c05-bc4b-914b50754e67">8,097,146,859</ix:nonFraction>.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of January&#160;31, 2023, <ix:nonFraction unitRef="shares" contextRef="i7a07412530754a858e0fecb90db3cba4_I20230131" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGV4dHJlZ2lvbjo5NDlhN2EyZWRhZmI0ZWUyYTk5OGFlNWRjMThmOTIyY18yODU4_f5157723-2111-4d13-95a4-4702b525c92f">96,587,911</ix:nonFraction> shares of the registrant&#8217;s common stock were outstanding.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGV4dHJlZ2lvbjo5NDlhN2EyZWRhZmI0ZWUyYTk5OGFlNWRjMThmOTIyY18zMjY4_53b45824-4ad4-4cfc-a6e8-f90e2d4cd0c7" escape="true">Portions of the registrant&#8217;s definitive proxy statement relating to the registrant&#8217;s annual meeting of stockholders to be filed pursuant to Regulation 14A within 120 days following the end of the registrant&#8217;s fiscal year ended December&#160;31, 2022 are incorporated by reference into Part III of this Form 10-K.</ix:nonNumeric></span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="id795223301944418ba8c3fb3bc02f08e_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.189%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#id795223301944418ba8c3fb3bc02f08e_10">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id795223301944418ba8c3fb3bc02f08e_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id795223301944418ba8c3fb3bc02f08e_16">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id795223301944418ba8c3fb3bc02f08e_58">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id795223301944418ba8c3fb3bc02f08e_58">20</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id795223301944418ba8c3fb3bc02f08e_64">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id795223301944418ba8c3fb3bc02f08e_64">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id795223301944418ba8c3fb3bc02f08e_67">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id795223301944418ba8c3fb3bc02f08e_67">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id795223301944418ba8c3fb3bc02f08e_70">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id795223301944418ba8c3fb3bc02f08e_70">50</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id795223301944418ba8c3fb3bc02f08e_73">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id795223301944418ba8c3fb3bc02f08e_73">50</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#id795223301944418ba8c3fb3bc02f08e_76">PART&#160;II</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id795223301944418ba8c3fb3bc02f08e_79">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id795223301944418ba8c3fb3bc02f08e_79">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id795223301944418ba8c3fb3bc02f08e_88">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id795223301944418ba8c3fb3bc02f08e_82">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id795223301944418ba8c3fb3bc02f08e_103">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id795223301944418ba8c3fb3bc02f08e_103">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id795223301944418ba8c3fb3bc02f08e_106">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id795223301944418ba8c3fb3bc02f08e_106">63</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id795223301944418ba8c3fb3bc02f08e_172">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id795223301944418ba8c3fb3bc02f08e_172">94</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id795223301944418ba8c3fb3bc02f08e_175">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id795223301944418ba8c3fb3bc02f08e_175">94</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id795223301944418ba8c3fb3bc02f08e_184">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id795223301944418ba8c3fb3bc02f08e_184">97</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id795223301944418ba8c3fb3bc02f08e_1733">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id795223301944418ba8c3fb3bc02f08e_1733">97</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#id795223301944418ba8c3fb3bc02f08e_187">PART&#160;III</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id795223301944418ba8c3fb3bc02f08e_190">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id795223301944418ba8c3fb3bc02f08e_190">98</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id795223301944418ba8c3fb3bc02f08e_193">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id795223301944418ba8c3fb3bc02f08e_193">98</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id795223301944418ba8c3fb3bc02f08e_196">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id795223301944418ba8c3fb3bc02f08e_196">98</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id795223301944418ba8c3fb3bc02f08e_199">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id795223301944418ba8c3fb3bc02f08e_199">98</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id795223301944418ba8c3fb3bc02f08e_202">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id795223301944418ba8c3fb3bc02f08e_202">98</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#id795223301944418ba8c3fb3bc02f08e_205">PART&#160;IV</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id795223301944418ba8c3fb3bc02f08e_208">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id795223301944418ba8c3fb3bc02f08e_208">99</a></span></div></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INGREZZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, NEUROCRINE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the related Neurocrine logos are registered trademarks of Neurocrine Biosciences, Inc. Any other brand names or trademarks appearing in this Annual Report that are not the property of Neurocrine Biosciences, Inc. are the property of their respective holders.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="id795223301944418ba8c3fb3bc02f08e_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART&#160;I</span></div><div id="id795223301944418ba8c3fb3bc02f08e_13"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form&#160;10-K and the information incorporated herein by reference contain forward-looking statements that involve a number of risks and uncertainties. Although our forward-looking statements reflect the good faith judgment of our management, these statements can only be based on facts and factors currently known by us. Consequently, these forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from results and outcomes discussed in the forward-looking statements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements can be identified by the use of forward-looking words such as &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;hopes,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;plan,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;continue,&#8221; &#8220;seeks,&#8221; &#8220;pro forma,&#8221; or &#8220;anticipates,&#8221; or other similar words (including their use in the negative), or by discussions of future matters such as the development of new products, technology enhancements, possible changes in legislation and other statements that are not historical. These statements include but are not limited to statements under the captions &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and &#8220;Business,&#8221; as well as other sections in this report. You should be aware that the occurrence of any of the events discussed under the heading in Part I titled &#8220;Item&#160;1A. Risk Factors&#8221; and elsewhere in this report could substantially harm our business, results of operations and financial condition and that if any of these events occurs, the trading price of our common stock could decline and you could lose all or a part of the value of your shares of our common stock.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cautionary statements made in this report are intended to be applicable to all related forward-looking statements wherever they may appear in this report. We urge you not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. Except as required by law, we assume no obligation to update our forward-looking statements, even if new information becomes available in the future.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="id795223301944418ba8c3fb3bc02f08e_16"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 1. Business</span></div><div id="id795223301944418ba8c3fb3bc02f08e_19"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The Company&#8217;s diverse portfolio includes United States Food and Drug Administration, or FDA, approved treatments for tardive dyskinesia, Parkinson&#8217;s disease, endometriosis* and uterine fibroids* and a diversified portfolio of advanced clinical-stage programs in multiple therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions and we will continue to relentlessly pursue medicines to ease the burden of debilitating diseases and disorders. (*in collaboration with AbbVie Inc., or AbbVie)</span></div><div id="id795223301944418ba8c3fb3bc02f08e_22"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product Pipeline</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Commercially Available Medicines</span></div><div style="text-align:center"><img src="nbix-20221231_g1.jpg" alt="nbix-20221231_g1.jpg" style="height:453px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"/></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INGREZZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> (valbenazine). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We launched INGREZZA in the United States in May 2017 as the first FDA-approved product for the treatment of tardive dyskinesia. INGREZZA net product sales totaled $1.4 billion for 2022, $1.1 billion for 2021 and $993.1 million for 2020 and represent nearly all of our total net product sales.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INGREZZA provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 mg, 60 mg and 80 mg capsules), with a recommended dose of 40 mg taken for the first seven days of treatment and an option to take 40 mg, 60 mg or 80 mg thereafter, depending on the patient&#8217;s dosing needs.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DYSVAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> (valbenazine). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mitsubishi Tanabe Pharma Corporation, or MTPC, launched DYSVAL in Japan in June 2022 for the treatment of tardive dyskinesia. In 2021, MTPC received approvals for marketing authorization for valbenazine for the treatment of tardive dyskinesia in Indonesia, Singapore, South Korea and Thailand and has submitted a filing for marketing authorization, which is currently under review, in Malaysia. We out-licensed the rights to valbenazine in Japan and other select Asian markets to MTPC in 2015, in which markets valbenazine is a royalty-bearing product for us.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tardive dyskinesia is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients. The condition is associated with prolonged use of treatments that block dopamine receptors in the brain, such as antipsychotics commonly prescribed to treat mental illnesses such as schizophrenia, bipolar disorder, depression and certain anti-nausea medications. In patients with tardive dyskinesia, these treatments are thought to result in irregular dopamine signaling in a region of the brain that controls movement. The symptoms of tardive dyskinesia can be severe and are often persistent and irreversible. Tardive dyskinesia affects an estimated 600,000 people in the United States.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ONGENTYS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> (opicapone). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We launched ONGENTYS in the United States in September 2020 as an FDA-approved add-on treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing motor fluctuations. We acquired the United States and Canada rights to ONGENTYS in February 2017.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parkinson&#8217;s disease is a chronic, progressive and debilitating neurodegenerative disorder that is caused by low dopamine levels produced in the brain. Dopamine helps transmit signals between the areas of the brain that control all purposeful movements, including talking, walking and writing. As Parkinson&#8217;s disease progresses, dopamine production steadily decreases, resulting in increased problems with motor symptoms including slowed movement, tremor, rigidity, impaired posture and balance and difficulty with speech and writing. Parkinson&#8217;s disease affects an estimated 1 million people in the United States and more than 10 million people worldwide.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ORILISSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> (elagolix tablets). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie launched ORILISSA in the United States in August 2018 as an FDA-approved oral medication for the management of moderate to severe endometriosis pain in women. We out-licensed the global rights to elagolix to AbbVie in 2010. Elagolix is a royalty-bearing product for us.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Endometriosis affects nearly 200&#160;million women worldwide, including more than 10&#160;million women in the United States.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ORIAHNN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> (elagolix, estradiol, and norethindrone acetate capsules and elagolix capsules). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie launched ORIAHNN in the United States in June 2020 as the first FDA-approved non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. We out-licensed the global rights to elagolix to AbbVie in 2010. Elagolix is a royalty-bearing product for us.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uterine fibroids are benign hormonally responsive tumors that form in the wall of the uterus with a prevalence rate of at least 25% and are a leading indication for hysterectomy, resulting in the performance of more than 200,000 hysterectomies per year in the United States alone.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ALKINDI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> / ALKINDI SPRINKLE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> (hydrocortisone). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alkindi was launched in its core markets (the United Kingdom, Germany, Austria and Italy) in 2018 as replacement therapy of adrenal insufficiency in infants, children and adolescents (aged 18 years and younger) and subsequently outside of its core markets through a network of distribution partners, including in the United States, where Alkindi is marketed as Alkindi Sprinkle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by our partner, Eton Pharmaceuticals, Inc., or Eton Pharmaceuticals. Alkindi Sprinkle has been granted orphan drug designation for the treatment of pediatric adrenal insufficiency in the United States, where it is a royalty-bearing product for us.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adrenal insufficiency is a rare condition caused by inadequate production of steroid hormones in the cortex of the adrenal glands. Adrenal insufficiency can result in severe fatigue and, if left untreated, adrenal crisis that may be life threatening.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EFMODY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> (hydrocortisone modified-release hard capsules). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efmody was launched in the United Kingdom, Germany and Austria in 2021 for the treatment of classic congenital adrenal hyperplasia, or CAH, in adolescents and adults (aged 12 years and older) and subsequently in the Netherlands through a distribution partner.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CAH is a rare condition usually caused by deficiency of the enzyme 21-hydroxylase, which is required to produce the adrenal steroid hormone, cortisol. The block in the cortisol production pathway causes the over-production of male steroid hormones (androgens), which are precursors to cortisol. CAH is congenital (inherited at birth), affects both sexes and can lead to increased mortality, infertility and severe development defects, including ambiguous genitalia, premature sexual development and short stature. CAH affects an estimated 30,000 people in the United States and 50,000 people in Europe.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Our Pipeline of Investigational Therapies</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><img src="nbix-20221231_g2.jpg" alt="nbix-20221231_g2.jpg" style="height:410px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"/></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Neurology</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chorea in Huntington Disease (valbenazine &#8211; VMAT2 Inhibitor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, we presented data from the KINECT-HD study, a Phase III randomized, double-blind, placebo-controlled clinical study that evaluated the efficacy, safety and tolerability of valbenazine in 120 adult patients with chorea associated with Huntington disease. In the study, valbenazine met the primary endpoint of significant (p &lt; 0.0001) improvement in chorea severity versus placebo, as measured by the Unified Huntington&#8217;s Disease Rating Scale Total Maximal Chorea Score, with improvements beginning in Week 2. Clinically meaningful results, demonstrated by greater response rates, were seen by clinicians (CGI-C) and patients (PGI-C) for valbenazine versus placebo. In addition, the safety profile was consistent with the known safety profile of valbenazine. In December 2022, the FDA accepted our supplemental new drug application, or sNDA, for valbenazine for the treatment of chorea associated with Huntington disease. The agency set a Prescription Drug User Fee Act target action date of August 20, 2023.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Huntington disease is a hereditary progressive neurodegenerative disorder, in which destruction of neuronal cells within the brain results in motor, cognitive, and psychiatric symptoms. Symptoms generally appear between the ages of 30 to 50 and worsen over a 10 to 25-year period. Many patients with Huntington disease experience chorea, a troublesome involuntary movement disorder, in which patients develop sudden, irregular, unpredictable and non-stereotyped movements. Chorea can affect various body parts, and may interfere with speech, swallowing, posture, and gait. Approximately 90% of the estimated 30,000 people affected by Huntington disease in the United Sates will develop chorea over the course of the disease. Valbenazine has been granted orphan drug designation for the treatment of chorea associated with Huntington disease in the United States.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dyskinetic Cerebral Palsy (valbenazine &#8211; VMAT2 Inhibitor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have initiated a Phase III randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy, safety and tolerability of valbenazine for the treatment of dyskinetic cerebral palsy in 80 pediatric and adult patients (aged 6 to 70 years). We anticipate having top-line data for this clinical study in 2024.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dyskinetic cerebral palsy is a non-progressive, permanent disorder marked by involuntary movement and is a result of damage to the fetal or infant brain&#8217;s basal ganglia. The basal ganglia are responsible for submitting messages to the body to help coordinate and control movements. When damaged, voluntary movements are compromised, resulting in involuntary and abnormal movements. It affects development and movement and has long term effects on patients&#8217; quality of life. The long-term outlook for patients with dyskinetic cerebral palsy will depend upon the severity of the brain damage and how well the treatment works. Dyskinetic cerebral palsy affects up to 15% of the estimated 500,000 to 1 million people affected by cerebral palsy in the United States.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Epilepsy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Epilepsy is one of the most common neurological disorders and is characterized by abnormal electrical activity in the brain that leads to unpredictable seizures that can vary in frequency, from less than one seizure per year to several seizures per day. A description of our investigational treatments for potential use in epilepsy follows.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SCN8A-DEE (NBI-921352 &#8211; Nav1.6 Sodium Channel Inhibitor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have initiated the KAYAK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> study, a Phase II randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy, safety and pharmacokinetics of NBI-921352 as adjunctive therapy in 52 adolescent patients (aged 12 to 21 years) with SCN8A-DEE. In January 2022, the study protocol was amended to include pediatric patients (aged 2 to 11 years) with SCN8A-DEE.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SCN8A-DEE is a rare, extremely severe, single-gene epilepsy caused by mutations in the SCN8A gene that activates Nav1.6, the most highly expressed sodium channel in the excitatory pathways of the central nervous system. Children born with SCN8A-DEE typically start experiencing seizures between birth and 18 months of age, and most have multiple seizures per day. Other symptoms include learning difficulties, muscle spasms, low or high muscle tone, poor coordination, developmental delay and features similar to autism. As SCN8a mutations were discovered only recently, prevalence estimates will be determined in the future as awareness of and access to genetic surveillance increases. NBI-921352 has been granted orphan drug and rare pediatric disease designations for the treatment of SCN8A-DEE in the United States.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Focal Onset Seizures (NBI-921352 &#8211; Nav1.6 Sodium Channel Inhibitor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have initiated a Phase II randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy, safety and pharmacokinetics of NBI-921352 as adjunctive therapy in 100 adult patients with focal onset seizures. We anticipate having top-line data for this clinical study in the second half of 2023.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Focal epilepsy is a neurological condition in which the predominant symptom is recurring seizures that affect one hemisphere of the brain. Focal epilepsies are also known as partial-onset seizures and include idiopathic location-related epilepsies, frontal lobe epilepsy, temporal lobe epilepsy, parietal lobe epilepsy and occipital lobe epilepsy. It is estimated that focal onset seizures affect 1.8 million adults in the United States, approximately 35% of whom are refractory to existing treatments.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Neuroendocrinology</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Classic Congenital Adrenal Hyperplasia, or CAH.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CAH is a rare condition usually caused by deficiency of the enzyme 21-hydroxylase, which is required to produce the adrenal steroid hormone, cortisol. The block in the cortisol production pathway causes the over-production of male steroid hormones (androgens), which are precursors to cortisol. CAH is congenital (inherited at birth), affects both sexes and can lead to increased mortality, infertility and severe development defects, including ambiguous genitalia, premature sexual development and short stature. CAH affects an estimated 30,000 people in the United States and 50,000 people in Europe.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CAH in Adults (crinecerfont &#8211; CRF1 Antagonist</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have completed enrollment of the CAHtalyst study, a global, registrational Phase III randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of crinecerfont in 165 adult patients with CAH, followed by an open-label treatment period. We anticipate having top-line data for this clinical study in the second half of 2023.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CAH in Pediatrics (crinecerfont &#8211; CRF1 Antagonist</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have completed enrollment of a global, registrational Phase III randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of crinecerfont in 81 pediatric patients (aged 2 to 17 years) with CAH. Crinecerfont has been granted orphan drug designation for the treatment of CAH in the United States and the European Union. We anticipate having top-line data for this clinical study in the second half of 2023.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adrenal Insufficiency (DNL-0200 &#8211; hydrocortisone modified-release hard capsules</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have initiated the CHAMPAIN study, a Phase II randomized, double-blind, double-dummy, two-way crossover clinical study to evaluate the efficacy, safety and tolerability of twice-daily DNL-0200 compared with once-daily Plenadren</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (modified-release hydrocortisone) in 67 adult patients with primary adrenal insufficiency.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adrenal insufficiency is a rare condition caused by inadequate production of steroid hormones in the cortex of the adrenal glands. Adrenal insufficiency can result in severe fatigue and, if left untreated, adrenal crisis that may be life threatening.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Neuropsychiatry</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Schizophrenia.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schizophrenia is a spectrum of serious neuropsychiatric brain diseases in which people interpret reality abnormally. Schizophrenia may result in some combination of hallucinations, delusions and extremely disordered thinking and behavior that impairs daily life. People with schizophrenia typically require lifelong treatment. Early treatment may help improve long-term prognosis and get symptoms under control before serious complications develop. Schizophrenia affects an estimated 3.5 million people in the United States. A description of our investigational treatments for potential use in schizophrenia follows.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adjunctive Treatment of Schizophrenia (valbenazine &#8211; VMAT2 Inhibitor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, we initiated a Phase III randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy, safety and tolerability of valbenazine when administered orally once daily as adjunctive treatment in 400 adolescent and adult patients (aged 13 years and older) with schizophrenia who have had an inadequate response to antipsychotics. We anticipate having top-line data for this clinical study in 2024.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, we initiated a second Phase III randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy, safety and tolerability of valbenazine when administered orally once daily as adjunctive treatment in 400 adolescent and adult patients (aged 13 years and older) with schizophrenia who have had an inadequate response to antipsychotics.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 30% of the estimated 3.5 million people affected by schizophrenia in the United States fail to respond to current antipsychotic therapy.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Schizophrenia (NBI-1117568 &#8211; Muscarinic M4 Agonist</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have initiated a Phase II multi-center, randomized, double-blind, placebo-controlled, multi-arm, multi-stage clinical study to evaluate the efficacy, safety and tolerability of NBI-1117568 in 213 adult patients with schizophrenia who are experiencing an acute exacerbation or relapse of symptoms.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All currently approved antipsychotic medications are believed to work through direct action on monoaminergic receptors, with approximately 40% of patients reporting negative side effects and approximately 30% not benefiting adequately from these medications.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cognitive Impairment Associated with Schizophrenia, or CIAS (luvadaxistat</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8211; DAAO Inhibitor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have initiated a Phase II randomized, double-blind, parallel, placebo-controlled clinical study to evaluate the efficacy, safety, tolerability and pharmacokinetics of luvadaxistat when administered orally once daily as adjunctive treatment in 308 adult patients with CIAS.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CIAS, which may include deficits in attention, working memory and executive function, has a negative impact on patients&#8217; quality of life and ability to function. Although cognitive symptoms in schizophrenia are well characterized, no formal diagnostic criteria exist. Furthermore, no pharmacological agents are approved to treat the condition, and no marketed therapy tested to date has established clear, meaningful efficacy, which underscores the difficulty of drug development in this arena and accentuates the unmet need for proven treatment options. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 80% of the estimated 3.5 million people affected by schizophrenia in the United States experience clinically relevant cognitive impairment.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Depressive Disorder.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major depressive disorder is one of the leading causes of disability and is characterized by a persistently depressed mood or loss of interest in daily activities that is present most of the day in addition to other symptoms that can impact normal daily functioning, relationships and overall quality of life. Treatments range from selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, atypical antipsychotics, tricyclic antidepressants and psychotherapies, among others. Major depressive disorder affects more than 16 million people in the United States. A description of our investigational treatments for potential use in major depressive disorder follows.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inadequate Response to Treatment in Major Depressive Disorder (NBI-1065845 &#8211; AMPA Potentiator</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have initiated a Phase II randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of NBI-1065845 as adjunctive treatment in 212 adult patients with inadequate response to treatment in major depressive disorder. We anticipate having top-line data for this clinical study in 2024. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While there are a number of marketed treatments for major depressive disorder, approximately 30% of the more than 16 million people affected by the disorder in the United States do not adequately respond to treatment.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anhedonia in Major Depressive Disorder (NBI-1065846 &#8211; GPR139 Agonist</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have initiated a Phase II randomized, double-blind, placebo-controlled, two-period cross-over, Proof of Activity clinical study to evaluate the effects of NBI-1065846 as adjunctive treatment in 88 adult patients with major depressive disorder experiencing anhedonia. We anticipate having top-line data for this clinical study in the second half of 2023. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anhedonia is characterized by the inability to experience pleasure and has been associated with changes in neurotransmitter levels involved in the brain&#8217;s reward system. Anhedonia is a core symptom of major depressive disorder and also frequently presents in people with bipolar depression, schizophrenia, substance-abuse disorders, Parkinson&#8217;s disease, diabetes and coronary artery disease.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) VMAT2 is a protein concentrated in the human brain that is essential for the transmission of nerve impulses between neurons. VMAT2 is primarily responsible for packaging and transporting monoamines (dopamine, norepinephrine, serotonin and histamine) in neurons. Specifically, dopamine enables neurotransmission among nerve cells that are involved in voluntary and involuntary motor control.</span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) NBI-921352 is a potent, highly selective Nav1.6 sodium channel inhibitor being developed to treat pediatric patients with SCN8A-DEE and other potential indications, including adult focal epilepsy. We acquired the global rights to NBI-921352 in December 2019.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Crinecerfont&#160;is a potent, selective, orally active, corticotropin-releasing factor1, or CRF1, receptor antagonist as demonstrated in a range of in vitro and in vivo assays. CRF1 is a hypothalamic hormone released directly into the hypophyseal portal vasculature which acts on the CRF1 receptor, a G protein-coupled receptor, or GPCR, in the anterior pituitary to stimulate the release of the adrenocorticotropin hormone, or ACTH. The primary role of ACTH is the stimulation of the synthesis and release of adrenal steroids, including cortisol. Cortisol from the adrenals have a negative feedback role at the level of the hypothalamus that decreases CRF1 release as well as at the level of the pituitary to inhibit the release of ACTH. This tight control loop is known as the hypothalamic-pituitary-adrenal axis. Blockade of CRF1 receptors at the pituitary has been shown to decrease the release of ACTH, which in turn decreases the production of adrenal steroids including androgens, and potentially the symptoms associated with CAH. Lower ACTH levels would also reduce the amount of exogenous corticosteroid necessary for CAH patients to thrive avoiding the side-effects currently associated with excessive steroid therapy.</span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) DNL-0200 is a modified-release preparation of hydrocortisone that mimics the physiological circadian rhythm of cortisol and has been specifically designed for patients with diseases of cortisol deficiency, such as adrenal insufficiency and CAH.</span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) NBI-1117568 is a potential first-in-class muscarinic M4 receptor agonist with the potential to be developed for the treatment of schizophrenia. As a selective M4 orthosteric agonist, NBI-1117568 offers the potential for an improved safety profile without the need for combination therapy to ameliorate off-target effects or for cooperativity with acetylcholine. Muscarinic receptors are central to brain function and validated as drug targets in psychosis and cognitive disorders. We acquired the global rights to NBI-1117568 in December 2021.</span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6) Luvadaxistat is a potential first-in-class D-Amino Acid Oxidase, or DAAO, inhibitor with the potential to be developed for the treatment of cognitive impairment associated with schizophrenia. We acquired the global rights to luvadaxistat in June 2020.</span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7) NBI-1065845 is a potential first-in-class Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazole Propionic Acid, or AMPA, potentiator with the potential to be developed for the treatment of inadequate response to treatment in major depressive disorder. We acquired the global rights to NBI-1065845 in June 2020. NBI-1065845 is currently designated as a 50:50 profit-share product with Takeda Pharmaceutical Company Limited, which retains a one-time opt-out right to convert the designation to a royalty-bearing product.</span></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8) NBI-1065846 is a potential first-in-class G Protein-Coupled Receptor 139, or GPR139, agonist with the potential to be developed for the treatment of anhedonia in major depressive disorder. We acquired the global rights NBI-1065846 in June 2020. NBI-1065846 is currently designated as a 50:50 profit-share product with Takeda Pharmaceutical Company Limited, which retains a one-time opt-out right to convert the designation to a royalty-bearing product.</span></div><div id="id795223301944418ba8c3fb3bc02f08e_25"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Business Strategy</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our core business strategy is to continue applying our unique insight into neuroscience to advance medicines for the treatment of under-addressed neurological, neuroendocrine and neuropsychiatric disorders to relieve suffering for people with great needs, but few options.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We focus our internal research and development efforts on innovative therapies with improved probabilities of technical and commercial success by taking a portfolio approach to managing our pipeline that balances the size of market opportunities with clear and defined clinical and regulatory paths to approval. In addition, from time to time we supplement our internal efforts by acquiring businesses or in-licensing certain rights to commercial products or clinical programs to enhance and capitalize on our commercial and development capabilities.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we were able to help more people affected by tardive dyskinesia than ever before, reflecting sustained growth for INGREZZA as we continued to invest in our branded direct-to-consumer INGREZZA advertising campaign launched in May 2021 and completed the reorganization and expansion of our sales force in April 2022, transitioning from a single team structure to three distinct teams dedicated to psychiatry, neurology and long-term care, respectively.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Going forward, key elements of our commercial strategy include maximizing the opportunity in INGREZZA through consistent and effective commercial execution, continued development of valbenazine as the best-in-class treatment for new patient populations, including for the potential treatment of chorea associated with Huntington disease, dyskinetic cerebral palsy and schizophrenia, and to lead the evolving understanding of VMAT2 biology and its role in disease.</span></div><div id="id795223301944418ba8c3fb3bc02f08e_28"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Collaboration and License Agreements</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 2 to the consolidated financial statements for more information on our significant collaboration and license agreements.</span></div><div id="id795223301944418ba8c3fb3bc02f08e_31"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We actively seek to protect our products, product candidates, and related inventions and improvements that we consider important to our business. We own a portfolio of United States and ex-United States patents and patent applications, and have also licensed rights to a number of United States and ex-United States patents and patent applications. Our owned and licensed patents and patent applications cover or relate to our products and product candidates, including certain formulations, uses to treat particular conditions, methods of administration, drug delivery technologies and delivery profiles, and methods of manufacturing.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a description of the United States and ex-United States patents to INGREZZA and the following product candidates:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">INGREZZA, our highly selective VMAT2 inhibitor approved in the United States (and other countries) for the treatment of tardive dyskinesia, is covered by 20 issued, FDA Orange Book-listed United States patents which are set to expire between 2027 and 2040. Patent term extension corresponding to regulatory approval delay of 552 days has been received for United States Patent No. 8,039,627, which now expires in 2031 and covers valbenazine, the active pharmaceutical ingredient contained in INGREZZA. In Japan and in certain other East Asian markets, we are actively pursuing most of the patents corresponding to those listed in the FDA&#8217;s Orange Book entry for INGREZZA.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Valbenazine, our highly selective VMAT2 inhibitor under clinical development for the treatment of chorea associated with Huntington disease, is covered by at least 12 of the issued United States patents currently listed in the FDA&#8217;s Orange Book entry for INGREZZA. Issued patents and pending patent applications that also cover the treatment of chorea associated with Huntington disease are set to expire between 2027 and 2043.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Valbenazine, additionally under clinical development for dyskinetic cerebral palsy (DCP) and for adjunctive treatment of schizophrenia (ATS), is covered by issued patents and pending patent applications set to expire between 2027 and 2042, including several issued, Orange Book-listed United States patents.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Crinecerfont, a CRF1 receptor antagonist under clinical development for the treatment of congenital adrenal hyperplasia (CAH) in adults and children, is covered by United States Patent Nos. 10,905,690 and 11,311,544, among other patents and pending patent applications, set to expire between 2035 and 2041 (not including any potential patent term extensions).</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also own, or have licensed rights to, patents covering our other products and earlier stage product candidates. In addition to the potential patent term extensions referenced above, the products and product candidates in our pipeline may be subject to additional terms of exclusivity that we may obtain by future patent issuances.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, the United States, European Union, and Japan each provide data and marketing exclusivity for new medicinal compounds. If this protection is available, no competitor may use the original applicant&#8217;s data as the basis of a generic marketing application during the period of data and marketing exclusivity, which is measured from the date of marketing approval by the FDA or corresponding foreign regulatory authority. This period of exclusivity is generally five years in the United States, six years in Japan and 10 years in the European Union, except that for biologics, the period of exclusivity in the United States is 12 years under the Biologics Price Competition and Innovation Act. In addition, if granted orphan drug designation, certain of our product candidates, including, for example, crinecerfont, may also be eligible for marketing exclusivity in the United States for seven years and in the European Union for 10 years.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Part I Item 1A. Risk Factors for a discussion of the challenges we may face in obtaining or maintaining patent and/or trade secret protection and Item 3. Legal Proceedings f</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or a description of our legal proceedings related to intellectual property matters.</span></div><div id="id795223301944418ba8c3fb3bc02f08e_34"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Manufacturing and Supply</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely on, and intend to continue to rely on, third-party manufacturers for the production of INGREZZA and our product candidates. Raw materials, active pharmaceutical ingredients, or API, and other supplies required for the production of INGREZZA and our product candidates are sourced from various third-party manufacturers and suppliers in quantities adequate to meet our needs. Continuing adequate supply of such raw materials and API is assured through our long-term commercial supply and manufacturing agreements with multiple manufacturers and our continued focus on the expansion and diversification of our third-party manufacturing relationships. In addition, we rely on BIAL &#8211; Portela &amp; Ca, S.A. for the commercial supply of ONGENTYS.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our outsourced manufacturing strategy enables us to direct our financial resources to the maximization of our opportunities with INGREZZA and ONGENTYS, investment in our internal R&amp;D programs and expansion of our clinical pipeline through business development opportunities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our third-party manufacturers, suppliers and service providers may be subject to routine current Good Manufacturing Practice, or cGMP, inspections by the FDA or comparable agencies in other jurisdictions. We depend on our third-party partners and our quality system oversight of them for continued compliance with cGMP requirements and applicable foreign standards.</span></div><div id="id795223301944418ba8c3fb3bc02f08e_37"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Marketing, Sales and Distribution</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our specialty sales force consists of approximately 350 experienced sales professionals located in the United States and is divided into three dedicated sales teams focused on psychiatry, neurology and long-term care.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For INGREZZA, our customers in the United States consist of a limited network of specialty pharmacy providers that deliver INGREZZA to patients by mail, wholesale distributors that distribute INGREZZA primarily to certain specialty pharmacies, and specialty distributors that distribute INGREZZA primarily to closed-door pharmacies and government facilities. For ONGENTYS, our customers in the United States consist primarily of wholesale distributors. We rely on third-party service providers to perform a variety of functions related to the packaging, storage and distribution of INGREZZA and ONGENTYS.</span></div><div id="id795223301944418ba8c3fb3bc02f08e_40"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business activities are subject to extensive regulation by the United States and other countries. Regulation by government authorities in the United States and foreign countries is a significant factor in the development, manufacture, distribution, tracking, marketing and sale of our proposed products and in our ongoing research and product development activities. All of our products in development will require regulatory approval by government agencies prior to commercialization. The process of obtaining these approvals and the subsequent compliance with appropriate federal and state statutes and regulations require the expenditure of substantial time and financial resources.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, federal and state healthcare laws restrict business practices in the pharmaceutical industry. These laws include, without limitation, federal and state fraud and abuse laws, false claims laws, data privacy and security laws, as well as transparency laws regarding payments or other items of value provided to healthcare providers. We have a comprehensive compliance program designed to ensure our business practices remain compliant.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Anti-Kickback Statute makes it illegal for any person or entity to knowingly and willfully, directly or indirectly, solicit, receive, offer, or pay any remuneration that is intended to induce the referral of business, including the purchase, order, lease of any good, facility, item or service for which payment may be made under a federal healthcare program, such as Medicare or Medicaid.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal civil and criminal false claims laws and the federal civil monetary penalties law, which prohibit among other things, any person or entity from knowingly presenting, or causing to be presented, for payment to, or approval by, federal programs, including Medicare and Medicaid, claims for items or services, including drugs, that are false or fraudulent or not provided as claimed and knowingly making, or causing to be made, a false record or to avoid or decrease an obligation to pay money to the federal government.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal criminal statutes that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their privacy and security regulations, which impose certain obligations, including the adoption of administrative, physical and technical safeguards to protect individually identifiable health information on covered entities subject to HIPAA (i.e., health plans, healthcare clearinghouses and certain healthcare providers) and their business associates that perform certain services for or on their behalf involving the use or disclosure of individually identifiable health information as well as their covered subcontractors. If we or the third parties on which we rely fail, or are perceived to have failed, to address or comply with applicable HIPAA obligations, we could face significant consequences, including but not limited to: government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-action claims); additional reporting requirements and/or oversight; bans on processing personal data; orders to destroy or not use personal data; and imprisonment of company officials.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners) and teaching hospitals, as well as information regarding ownership and investment interests held by physicians and their immediate family members.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, many states have similar healthcare statutes or regulations that may be broader in scope and may apply regardless of payor. Additionally, to the extent that our product is sold in a foreign country, we may be subject to similar foreign laws.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with these laws, where applicable, can result in significant penalties, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, and additional reporting requirements and regulatory oversight, any of which could adversely affect our ability to operate our business and our results of operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Development and Marketing Approval for Products. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical studies generally are conducted in laboratory animals to evaluate the potential safety and efficacy of a product. Drug developers submit the results of preclinical studies to the FDA as a part of an investigational new drug application, or IND, before clinical trials can begin in humans. Typically, clinical evaluation involves a time consuming and costly three-phase process.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials are conducted with a small number of subjects to determine the early safety profile, maximum tolerated dose and pharmacokinetic properties of the product in human volunteers or in patients with the target disease.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials are conducted with groups of patients afflicted with a specific disease in order to determine preliminary efficacy, optimal dosages and expanded evidence of safety.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Larger, multi-center, comparative clinical trials are conducted with patients afflicted with a specific disease in order to determine safety and efficacy as primary support for regulatory approval by the FDA to market a product candidate for a specific disease.</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA closely monitors the progress of each of the three phases of clinical trials that are conducted in the United States and may, at its discretion, re-evaluate, alter, suspend or terminate the testing based upon the data accumulated to that point and the FDA&#8217;s assessment of the risk/benefit ratio to the patient. Institutional Review Boards, Institutional Ethics Committees and Data Safety Monitoring Boards also closely monitor the conduct of our trials and may also place holds on our clinical trials or recommend that we voluntarily do so. Clinical trials conducted in foreign countries are also subject to oversight by regulatory authorities in those countries.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once Phase&#160;III trials are completed, drug developers submit the results of preclinical studies and clinical trials to the FDA in the form of an NDA for approval to commence commercial sales. In most cases, the submission of an NDA is subject to a substantial application user fee. Under the Prescription Drug User Fee Act, or PDUFA, the FDA has a goal of ten months from the date of filing of a standard NDA for a new molecular entity to review and act on the submission. The FDA generally has a six-month review goal of priority NDAs.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the Pediatric Research Equity Act of 2003 as amended and reauthorized, certain applications or supplements to an application must contain data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults or full or partial waivers from the pediatric data requirements.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA also may require submission of a risk evaluation and mitigation strategy to ensure that the benefits of the drug outweigh its risks. The risk evaluation and mitigation strategy could include medication guides, physician communication plans, assessment plans and/or additional elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an application for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective for its intended use and whether the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product&#8217;s continued safety, quality and purity.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with current Good Manufacturing Practice requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with Good Clinical Practice requirements.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter generally contains a statement of specific conditions that must be met in order to secure final approval of the application and may require additional clinical or preclinical testing in order for FDA to reconsider the application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase IV clinical trials, be conducted to further assess a drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a risk evaluation and mitigation strategy, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will also have to complete an approval process similar to that in the United States in order to commercialize our product candidates in each foreign country. The approval procedure and the time required for approval vary from country to country and may involve additional testing. Foreign approvals may not be granted on a timely basis, or at all. In addition, regulatory approval of prices is required in most countries other than the United States, except for a certain limited number of drugs sold to certain Medicare beneficiaries beginning in 2023. The resulting prices may not be sufficient to generate an acceptable return to us or our corporate collaborators.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, there are currently two potential tracks for seeking marketing approval for a product not authorized in any European Union member state: a decentralized procedure and a centralized procedure. In the decentralized procedure, identical applications for marketing authorization are submitted simultaneously to the national regulatory agencies. Regulatory review is led by one member state (the reference-member state), and its assessment&#8212;based on safety, quality and efficacy&#8212;is reviewed and approved (assuming there are no concerns that the product poses a serious risk to public health) by the other member states from which the applicant is seeking approval (the concerned-member states). The decentralized procedure leads to a series of single national approvals in all relevant countries. In the centralized procedure, which is required of all products derived from biotechnology, a company submits a single marketing authorization application to the European Medicines Agency, or EMA, which conducts an evaluation of the dossier, drawing upon its scientific resources across Europe. If the drug product is proven to fulfill the requirements for quality, safety and efficacy, the EMA&#8217;s Committee for Medicinal Products for Human Use, or CHMP, adopts a positive opinion, which is transmitted to the European Commission for final decision on grant of the marketing authorization. While the EC generally follows the CHMP&#8217;s opinion, it is not bound to do so. Subsequent commercialization is enabled by country-by-country reimbursement approval.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan Drug Designation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States, or if it affects more than 200,000, there is no reasonable expectation that sales of the drug in the United States will be sufficient to offset the costs of developing and making the drug available in the United States Orphan drug designation must be requested before submitting an NDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA approves a sponsor&#8217;s marketing application for a designated orphan drug for use in the rare disease or condition for which it was designated, the sponsor is eligible for a seven-year period of marketing exclusivity, during which the FDA may not approve another sponsor&#8217;s marketing application for a drug with the same active moiety and intended for the same use or indication as the approved orphan drug, except in limited circumstances, such as if a subsequent sponsor demonstrates its product is clinically superior. During a sponsor&#8217;s orphan drug exclusivity period, competitors, however, may receive approval for drugs with different active moieties for the same indication as the approved orphan drug, or for drugs with the same active moiety as the approved orphan drug, but for different indications. Orphan drug exclusivity could block the approval of one of our products for seven years if a competitor obtains approval for a drug with the same active moiety intended for the same indication before we do, unless we are able to demonstrate that grounds for withdrawal of the orphan drug exclusivity exist, or that our product is clinically superior. Further, if a designated orphan drug receives marketing approval for an indication broader than the rare disease or condition for which it received orphan drug designation, it may not be entitled to exclusivity.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislation similar to the Orphan Drug Act has been enacted in other countries outside of the United States, including the European Union. The orphan legislation in the European Union is available for therapies addressing conditions that affect five or fewer out of 10,000 persons, are life&#8209;threatening or chronically debilitating conditions and for which no satisfactory treatment is authorized. The market exclusivity period is for 10 years, although that period can be reduced to six years if, at the end of the fifth year, available evidence establishes that the product does not justify maintenance of market exclusivity.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-Approval Requirements. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There also are continuing, annual program user fee requirements for any marketed products, as well as new application fees for supplemental applications with clinical data.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase IV clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with current Good Manufacturing Practices, or cGMP, requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions. Other potential consequences include, among other things:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning letters or holds on post-approval clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of products; or</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indication(s) and in accordance with the provisions of the approved label. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. The FDA does not regulate behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products.</span></div><div id="id795223301944418ba8c3fb3bc02f08e_43"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reimbursement</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In the United States and other countries, sales of any products for which we receive regulatory approval will depend, in part, on the extent to which third-party payors provide coverage and establish adequate reimbursement levels for such drug products.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, third-party payors include federal and state healthcare programs, government authorities, private managed care providers, private health insurers and other organizations. No uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our drug products to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained in the first instance or applied consistently.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payors are increasingly challenging the price, examining the medical necessity and reviewing the cost-effectiveness of drug products and medical services, in addition to questioning their safety, efficacy and clinical appropriateness. Such payors may limit coverage to specific drug products on an approved list, also known as a formulary, which might not include all of the FDA-approved drugs for a particular indication.&#160;We may need to conduct expensive pharmaco-economic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain the FDA approvals. Nonetheless, our products or product candidates, including INGREZZA, may not be considered medically necessary or cost-effective.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the process for determining whether a third-party payor will provide coverage for a drug product may be separate from the process for setting the price of a drug product or for establishing the reimbursement rate that such a payor will pay for the drug product. A payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a drug product does not assure that other payors will also provide coverage for the drug product. Adequate third-party payor reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The marketability of any product or product candidates for which we or our collaborators receive regulatory approval for commercial sale may suffer if third-party payors fail to provide coverage and adequate reimbursement. In addition, emphasis on managed care in the United States has increased and we expect will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div id="id795223301944418ba8c3fb3bc02f08e_46"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Enacted Healthcare Reform Measures</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States and some foreign jurisdictions have enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. In the United States, the pharmaceutical industry and the cost of prescription drugs has been a continuous focus of these efforts and has been significantly affected by major legislative initiatives.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most recently, in August 2022, President Biden signed into law the Inflation Reduction Act of 2022, or the IRA, which, among other things, (1) directs the Secretary of the U.S. Department of Health and Human Services, or HHS, to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare, (2) redesigns the Medicare Part D prescription drug benefit to lower patient out-of-pocket costs and increase manufacturer liability and (3) requires drug manufacturers to pay rebates on drugs whose prices increase greater than the rate of inflation. The IRA also extends enhanced subsidies for individuals purchasing health insurance coverage in the ACA marketplaces through plan year 2025 and eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost to $2,000 through a newly established manufacturer discount program. These provisions will take effect progressively starting in 2023, although they may be subject to legal challenges. It is currently unclear how the IRA will be implemented; however, it is likely to have a significant impact on the pharmaceutical industry and prescription drug pricing. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the IRA targets high-expenditure drugs that have been on the market for several years without generic or biosimilar competition, we have qualified for the small biotech manufacturer exemption that is set to expire in 2029. However, the qualification for this exemption is subject to various requirements and there is no assurance that we will continue to qualify for this exemption in the future. Further, the loss of this exemption or the potential loss of this exemption, including as a result of a potential acquisition or strategic transaction, could have an adverse impact on our business.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most significant prior revisions to federal law governing the pharmaceutical industry and prescription drug pricing was enacted through the March 2010 the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively the ACA. This</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">law was intended to broaden access to health insurance by reducing the number of uninsured persons, reducing or constraining the growth of healthcare spending, enhancing remedies against fraud and abuse, adding transparency requirements for the healthcare and health insurance industries, imposing taxes and fees on the health industry and imposing additional health policy reforms. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that these health reform measures, may result in more rigorous coverage criteria and lower reimbursement for prescription drugs, as well as result in additional downward pressure on any price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private third-party payors. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other significant legislative changes impacting the pharmaceutical industry and prescription drug pricing have been adopted since the ACA was enacted. These changes include, among others, aggregate reductions to Medicare payments to providers of up to 2% per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013 and, due to subsequent legislative amendments, including the Investment and Jobs Act, will remain in effect through 2031, except for a temporary suspension from May 1, 2020 through March 31, 2022. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 4% in the final fiscal year of this sequestration.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to examine and/or control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Proposed Healthcare Reform Measures</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States and some foreign jurisdictions are considering a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and may be significantly affected by major legislative initiatives.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently unable to predict what other additional legislation or regulation, if any, relating to the health care industry may be enacted in the future or what effect recently enacted federal legislation or any such additional legislation or regulation would have on our business.</span></div><div id="id795223301944418ba8c3fb3bc02f08e_49"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are subject to rapid and intense technological change. We face, and will continue to face, competition in the development and marketing of our products and product candidates from academic institutions, government agencies, research institutions and biotechnology and pharmaceutical companies. Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approval and marketing than we do.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition may also arise from, among other things, new drug development technologies, new or improved treatment options for preventing or reducing the incidence of disease in diseases our products treat and new small molecule or other classes of therapeutic agents. Such developments by competitors could reduce or eliminate the use of our products or may limit the utility and application of ongoing clinical trials for our product candidates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tardive Dyskinesia.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INGREZZA competes with AUSTEDO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (deutetrabenazine), which was approved by the FDA for the treatment of tardive dyskinesia in adults in August 2017 and is marketed by Teva Pharmaceutical Industries, and several clinical development-stage programs targeting tardive dyskinesia and related movement disorders. Additionally, there are a number of commercially available medicines used to treat tardive dyskinesia off-label, such as XENAZINE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (tetrabenazine) and generic equivalents, and various antipsychotic medications (e.g., clozapine), anticholinergics, benzodiazepines (off-label), and botulinum toxin.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Parkinson&#8217;s Disease. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ONGENTYS competes with two other FDA-approved COMT inhibitors and their generic equivalents. Additionally, there are a number of alternative adjunctive treatment options (FDA-approved and in clinical development) for Parkinson&#8217;s patients which compete with ONGENTYS, including various L-dopa preparations, dopamine agonists, MAO-B inhibitors and others. In terms of potential future competition, there are several programs in late-stage clinical development.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Endometriosis and Uterine Fibroids. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ORILISSA and ORIAHNN each compete with several FDA-approved products for the treatment of endometriosis, uterine fibroids, infertility and central precocious puberty. Additionally, there is also competition from surgical intervention, including hysterectomies and ablations. Separate from these options, there are many programs in clinical development which serve as potential future competition. Lastly, there are numerous medicines used to treat the symptoms of disease (vs. endometriosis or uterine fibroids directly) which may also serve as competition: oral contraceptives, NSAIDs and other pain medications, including opioids.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Classic Congenital Adrenal Hyperplasia, or CAH.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For CAH, high doses of corticosteroids are the current standard of care to both correct the endogenous cortisol deficiency as well as reduce the excessive ACTH levels. In the United States alone, there are more than two dozen companies manufacturing steroid-based products. In addition, there are several programs in clinical development targeting CAH and several companies developing medicinal treatments for CAH.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Epilepsy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investigational treatments for potential use in epilepsy may in the future compete with numerous approved anti-seizure medications and development-stage programs being pursued by several other companies. Commonly used anti-seizure medications include phenytoin, levetiracetam, brivaracetam, cenobamate, carbamazepine, clobazam, lamotrigine, valproate, oxcarbazepine, topiramate, lacosamide, perampanel and cannabidiol, among others. There are currently no FDA-approved treatments specifically indicated for the early infantile epileptic encephalopathy SCN8A-DEE; however, a number of different anti-seizure medications are currently used in these patient populations. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Neuropsychiatry.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our investigational treatments for potential use in schizophrenia and depression may in the future compete with several development-stage programs being pursued by other companies. Currently, there are no FDA-approved treatments specifically indicated for CIAS; however, there are a number of different anti-psychotic medications currently used in these patient populations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our investigational treatments for potential use in neurology, neuroendocrinology and neuropsychiatry may in the future compete with numerous approved products and development-stage programs being pursued by several other companies.</span></div><div id="id795223301944418ba8c3fb3bc02f08e_52"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Human Capital</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Employees.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have grown to a team of more than 1,200 employees as of December&#160;31, 2022, primarily employed in the United States. Our highly qualified and experienced team, which includes scientists, physicians and professionals across sales, marketing, manufacturing, regulatory, finance and other essential functions are critical to our success. We also leverage temporary workers to provide flexibility for our business needs. During 2022, we added more than 250 new employees to our team, reflecting the completion of our sales force expansion to approximately 350 experienced sales professionals.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to add additional employees in 2023 with a focus on expanding our research and development organization. We continually evaluate our business needs and opportunities and balance in-house expertise and capacity with external expertise and capacity. Currently, we rely on third-party contract manufacturers.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Culture.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our human capital management investments is evidenced by our low employee turnover, a number which is regularly reviewed by our Board of Directors as part of their oversight of our human capital strategy. In recognition of our efforts, in 2022, we were ranked in #8 in Fortune Best Small &amp; Medium Workplaces in Biopharma</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Engagement, Talent Development &amp; Benefits.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our future success largely depends upon our continued ability to attract and retain highly skilled employees. We provide our employees with competitive salaries and bonuses, opportunities for equity ownership, development programs that enable continued learning and growth and a robust employment package that promotes well-being across all aspects of their lives, including health care, retirement planning and paid time off. As part of our promotion and retention efforts, we also invest in ongoing leadership development programs as well as offer tuition reimbursement. In addition, we regularly conduct employee surveys to gauge employee engagement and identify areas of focus.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Diversity &amp; Inclusion.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Much of our success is rooted in the diversity of our teams and our commitment to inclusion. We value diversity at all levels and continue to focus on extending our diversity and inclusion initiatives across our entire workforce. We believe that our business benefits from the different perspectives a diverse workforce brings, and we pride ourselves on having a strong, inclusive and positive culture based on our shared mission and values.</span></div><div id="id795223301944418ba8c3fb3bc02f08e_55"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were originally incorporated in California in January 1992 and reincorporated in Delaware in May 1996. Our principal executive offices are located at 12780 El Camino Real, San Diego, California 92130. Our telephone number is (858) 617-7600.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Annual Reports on Form&#160;10-K, Quarterly Reports on Form&#160;10-Q, Current Reports on Form&#160;8-K and amendments to reports filed pursuant to Sections&#160;13(a) and 15(d) of the Securities Exchange Act of 1934, as amended, are available free of charge on our website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.neurocrine.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as soon as reasonably practicable after such reports are available on the Securities and Exchange Commission, or SEC, website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Additionally, copies of our Annual Report will be made available, free of charge, upon written request. Information found on, or accessible through, our website is not a part of, and is not incorporated into, this Annual Report on Form 10-K.</span></div><div id="id795223301944418ba8c3fb3bc02f08e_58"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;1A. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Risk Factors</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following information sets forth risk factors that could cause our actual results to differ materially from those contained in forward-looking statements we have made in this Annual Report on Form&#160;10-K and those we may make from time to time. If any of the following risks actually occur, our business, operating results, prospects or financial condition could be harmed. Additional risks not presently known to us, or that we currently deem immaterial, may also affect our business operations.</span></div><div id="id795223301944418ba8c3fb3bc02f08e_61"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Summary Risk Factors</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face risks and uncertainties related to our business, many of which are beyond our control.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, risks associated with our business include:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to continue to successfully commercialize INGREZZA, ONGENTYS, or any of our other products, or any of our product candidates if they are approved in the future.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If physicians and patients do not continue to accept INGREZZA or do not accept ONGENTYS, or do not accept any of our other products, or our sales and marketing efforts are not effective, we may not generate sufficient revenue.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Governmental and third-party payors may impose additional sales and pharmaceutical pricing controls on our products or further limit coverage and/or reimbursement for our products that could negatively impact our product revenues and impact or delay sustained profitability.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business could be adversely affected by the effects of health pandemics or epidemics, including the COVID-19 pandemic, which could also cause significant disruption in the operations of third-party manufacturers, contract research organizations, or CROs, or other third parties upon whom we rely.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face intense competition, and if we are unable to compete effectively, the demand for our products may be reduced.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Because the development of our product candidates is subject to a substantial degree of technological uncertainty, we may not succeed in developing any of our product candidates.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our clinical trials may be delayed for safety or other reasons, or fail to demonstrate the safety and efficacy of our product candidates, which could prevent or significantly delay their regulatory approval.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Several of our planned clinical trial sites have been impacted and could be delayed or suspended as a result of the conflict between Russia and Ukraine.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend on our current collaborators for the development and commercialization of several of our products and product candidates and may need to enter into future collaborations to develop and commercialize certain of our product candidates.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Use of our approved products or those of our collaborators could be associated with side effects or adverse events.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have recently increased the size of our organization and will need to continue to increase the size of our organization. We may encounter difficulties with managing our growth, which could adversely affect our results of operations.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to retain and recruit qualified scientists and other employees or if any of our key senior executives discontinues his or her employment with us, it may delay our development efforts or impact our commercialization of INGREZZA, ONGENTYS, or any of our other products, or any product candidate approved by the FDA in the future.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We currently have no manufacturing capabilities. If third-party manufacturers of INGREZZA, ONGENTYS, or any of our other products, or any of our product candidates fail to devote sufficient time and resources to our concerns, or if their performance is substandard, our clinical trials and product introductions may be delayed, and our costs may rise.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We currently depend on a limited number of third-party suppliers. The loss of these suppliers, or delays or problems in the supply of INGREZZA, ONGENTYS, or any of our other products, could materially and adversely affect our ability to successfully commercialize INGREZZA, ONGENTYS, or any of our other products.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We license some of our core technologies and drug candidates from third parties. If we default on any of our obligations under those licenses, or violate the terms of these licenses, we could lose our rights to those technologies and drug candidates or be forced to pay damages.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to protect our intellectual property, our competitors could develop and market products based on our discoveries, which may reduce demand for our products.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Health care reform measures and other recent legislative initiatives could adversely affect our business.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our indebtedness and liabilities could limit the cash flow available for our operations, expose us to risks that could adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a history of losses and expect to increase our expenses for the foreseeable future, and we may not be able to sustain profitability.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our customers are concentrated and therefore the loss of a significant customer may harm our business.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we cannot raise additional funding, we may be unable to complete development of our product candidates or establish commercial and manufacturing capabilities in the future.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risks Related to Our Company</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to continue to successfully commercialize INGREZZA, ONGENTYS, or any of our other products, or any of our product candidates if they are approved in the future.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to produce INGREZZA revenues consistent with expectations ultimately depends on our ability to continue to successfully commercialize INGREZZA and secure adequate third-party reimbursement. Our experience in marketing and selling pharmaceutical products began with INGREZZA&#8217;s approval in 2017, when we hired our sales force and established our distribution and reimbursement capabilities, all of which are necessary to successfully commercialize our current and future products. We have continued to invest in our commercial infrastructure and distribution capabilities in the past four years, including the expansion of our specialty sales force, which we announced in the third quarter of 2021 and completed in April 2022. While our team members and consultants have experience marketing and selling pharmaceutical products, we may face difficulties related to managing the rapid growth of our personnel and infrastructure, and there can be no guarantee that we will be able to maintain the personnel, systems, arrangements and capabilities necessary to continue to successfully commercialize INGREZZA, or to successfully commercialize ONGENTYS or any of our other products, or any product candidate approved by the FDA in the future. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our business has been and may continue to be adversely affected by the effects of health pandemics or epidemics, including the ongoing COVID-19 pandemic. In parts of the country where the pandemic is having a greater impact, some hospitals, community mental health facilities, and other healthcare facilities continue to have policies that limit access of our sales representatives, medical affairs personnel and patients to such facilities. These policies are likely to change from time to time as communities or regions grapple with outbreaks. These facilities also may be facing staffing shortages that impact their ability to see patients and conduct necessary screenings. In addition, many health care practitioners have adopted telehealth for patient interactions, which may impact the ability of the health care practitioner to screen for and diagnose tardive dyskinesia. Further, during the COVID-19 pandemic, the use of physician telehealth services increased significantly, fueled by an expansion of coverage and reimbursement from government and other payors. The limitations that telehealth places on the ability to conduct a thorough visual and physical examination may impact the ability of providers to screen for movement disorders, leading to potentially fewer patients to be diagnosed and referred for treatment. The ultimate impact of the COVID-19 pandemic, including any lasting effects on the way we conduct our business, is highly uncertain and subject to continued change. If we fail to maintain successful marketing, sales and reimbursement capabilities, our product revenues may suffer.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If physicians and patients do not continue to accept INGREZZA or do not accept ONGENTYS, or do not accept any of our other products, or our sales and marketing efforts are not effective, we may not generate sufficient revenue.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of INGREZZA, ONGENTYS, or any of our other products will depend upon the acceptance of those products as safe and effective by the medical community and patients.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market acceptance of INGREZZA, ONGENTYS, or any of our other products could be affected by a number of factors, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of receipt of marketing approvals for additional indications;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the safety and efficacy of the products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pricing of our products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of healthcare payor coverage and adequate reimbursement for the products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public perception regarding any products we may develop;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of existing competitor products addressing our target markets or the emergence of equivalent or superior products; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost-effectiveness of the products.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the medical community, patients and payors do not continue to accept our products as being safe, effective, superior and/or cost-effective, we may not generate sufficient revenue.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governmental and third-party payors may impose sales and pharmaceutical pricing controls on our products or limit coverage and/or reimbursement for our products or impose policies that could limit our product revenues and delay sustained profitability.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to continue to commercialize INGREZZA successfully or to successfully commercialize ONGENTYS or any of our other products, will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available. The continuing efforts of government and third-party payors to contain or reduce the costs of health care and the price of prescription drugs through various means may impact our revenues. These payors&#8217; efforts could decrease the price that we receive for any products we may develop and sell in the future.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the out-of-pocket cost of our products. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available regardless of whether they are approved by the FDA for that particular use. Coverage decisions by payors for our competitors' products may also impact coverage for our products.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities and other third-party payors are developing increasingly sophisticated methods of controlling healthcare costs, such as by limiting coverage and the amount of reimbursement for particular medications. Further, no uniform policy requirement for coverage and reimbursement for drug products exists among third-party payors in the United States. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. In addition, communications from government officials, media outlets, and others regarding health care costs and pharmaceutical pricing could have a negative impact on our stock price, even if such communications do not ultimately impact coverage or reimbursement decisions for our products.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may also be significant delays in obtaining coverage and reimbursement for newly approved drugs or indications, and coverage may be more limited than the purposes for which the drug is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may be unable to successfully commercialize INGREZZA, ONGENTYS, or any of our other products, or any other product candidate for which we obtain marketing approval in the future. Our inability to promptly obtain coverage and profitable reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition. Further, a majority of our current revenue is derived from federal healthcare program payors, including Medicare and Medicaid. Thus, changes in government reimbursement policies, reductions in payments and/or our suspension or exclusion from participation in federal healthcare programs could have a material adverse effect on our business.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, during the COVID-19 pandemic, the use of physician telehealth services has rapidly increased, fueled by an unprecedented expansion of coverage and reimbursement across insurers. The limitations that telehealth places on the ability to conduct a thorough physical examination may impact the ability of providers to screen for movement disorders, leading to fewer patients being diagnosed and/or treated.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be adversely affected by the effects of health pandemics or epidemics, including the COVID-19 pandemic, which could also cause significant disruption in the operations of third-party manufacturers CROs, or other third parties upon whom we rely.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business could be adversely affected by the effects of health pandemics or epidemics, which could also cause significant disruption in the operations of third-party manufacturers, CROs and other third parties upon whom we rely. As a result of the ongoing COVID-19 pandemic, we may experience disruptions that could severely impact our supply chain, ongoing and future clinical trials and commercialization of INGREZZA, ONGENTYS, or any of our other products. For example, the COVID-19 pandemic has resulted in travel restrictions and the shutdown or delay of business activities in various regions. In response to the COVID-19 pandemic, we implemented a remote work model for all employees except certain key essential members involved in business-critical activities.&#160;Most of our field-based employees have resumed in-person interactions in accordance with location-specific guidance. Our office-based employees have returned to the office under flexible work guidelines to help balance business needs, employee health, well-being and safety and the evolving work environment. However, as the effects of the pandemic continue to rapidly evolve with the emergence of new COVID-19 variants and spikes or surges in infection and hospitalization rates, a remote work model may nevertheless need to be reinstated at some point in the future. The effects of a remote and flexible work model may negatively impact productivity, disrupt our business and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. Remote work may also create increased risks to our information technology systems and data, as more of our employees utilize network connections, computers and devices outside our premises or network, including working at home, while in transit and in public locations. In addition, we may face several challenges or disruptions upon a return back to the workplace, including re-integration challenges by our employees and distractions to management related to such transition. These and similar, and perhaps more severe, disruptions in our operations due to the COVID-19 pandemic could negatively impact our business, operating results and financial condition. We continue to evaluate the impact of the COVID-19 pandemic on our business and will update our plans and policies as needed going forward.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quarantines, stay at home orders, travel restrictions and other state and local restrictions, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related to COVID-19 or other infectious diseases, could impact personnel at third-party manufacturing facilities in the United States and other countries, or the availability or cost of materials, which would disrupt our supply chain.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, clinical site initiation and patient enrollment may be delayed due to concerns for patient safety and prioritization of healthcare resources toward the COVID-19 pandemic. Some patients may not be able to comply with clinical trial protocols if quarantines impede patient travel or interrupt healthcare services. Similarly, our ability to recruit and retain patients, principal investigators and site staff may be hindered, which would adversely impact our clinical trial operations. Increases in COVID-19 cases or hospitalizations in the future could cause us or any of our clinical sites to again limit or suspend our patient enrollment and screening activities.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic may be difficult to assess or predict, the pandemic has caused disruption in the global financial markets. This disruption, if sustained or recurrent, could make it more difficult for us to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the COVID-19 pandemic could materially affect our business and the value of our common stock.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of the COVID-19 pandemic continue to evolve. The ultimate impact of the COVID-19 pandemic or a similar health pandemic or epidemic is highly uncertain and subject to continued change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, healthcare systems or the global economy as a whole. These effects could have a material impact on our operations, or the operations of third parties on whom we rely.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face intense competition, and if we are unable to compete effectively, the demand for our products may be reduced.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are subject to rapid and intense technological change. We face, and will continue to face, competition in the development and marketing of our products and product candidates from academic institutions, government agencies, research institutions and biotechnology and pharmaceutical companies.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition may also arise from, among other things:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other drug development technologies;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">methods of preventing or reducing the incidence of disease, including vaccines; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new small molecule or other classes of therapeutic agents.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developments by others (including the development of generic equivalents) may render our product candidates or technologies obsolete or noncompetitive.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are commercializing and performing research on or developing products for the treatment of several disorders including endometriosis, tardive dyskinesia, uterine fibroids, essential tremor, classic congenital adrenal hyperplasia, pain, Parkinson&#8217;s disease and other neurology, neuroendocrinology and neuropsychiatry-related diseases and disorders, and there are a number of competitors to our products and product candidates. If one or more of our competitors&#8217; products or programs are successful (including the development of generic equivalents), the market for our products may be reduced or eliminated.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">INGREZZA competes with AUSTEDO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (deutetrabenazine), which was approved by the FDA for the treatment of tardive dyskinesia in adults in August 2017 and is marketed by Teva Pharmaceutical Industries, and several clinical development-stage programs targeting tardive dyskinesia and related movement disorders. Additionally, there are a number of commercially available medicines used to treat tardive dyskinesia off-label, such as XENAZINE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (tetrabenazine) and generic equivalents, and various antipsychotic medications (e.g., clozapine), anticholinergics, benzodiazepines (off-label), and botulinum toxin.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ONGENTYS competes with two other FDA-approved COMT inhibitors and their generic equivalents. Additionally, there are a number of alternative adjunctive treatment options (FDA-approved and in clinical development) for Parkinson&#8217;s patients which compete with ONGENTYS, including various L-dopa preparations, dopamine agonists, MAO-B inhibitors and others. In terms of potential future competition, there are several programs in late-stage clinical development.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ORILISSA and ORIAHNN each compete with several FDA-approved products for the treatment of endometriosis, uterine fibroids, infertility and central precocious puberty. Additionally, there is also competition from surgical intervention, including hysterectomies and ablations. Separate from these options, there are many programs in clinical development which serve as potential future competition. Lastly, there are numerous medicines used to treat the symptoms of disease (vs. endometriosis or uterine fibroids directly) which may also serve as competition: oral contraceptives, NSAIDs and other pain medications, including opioids.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For CAH, high doses of corticosteroids are the current standard of care to both correct the endogenous cortisol deficiency as well as reduce the excessive ACTH levels. In the United States alone, there are more than two dozen companies manufacturing steroid-based products. In addition, there are several programs in clinical development targeting CAH and several companies developing medicinal treatments for CAH.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our investigational treatments for potential use in epilepsy may in the future compete with numerous approved anti-seizure medications and development-stage programs being pursued by several other companies. Commonly used anti-seizure medications include phenytoin, levetiracetam, brivaracetam, cenobamate, carbamazepine, clobazam, lamotrigine, valproate, oxcarbazepine, topiramate, lacosamide, perampanel and cannabidiol, among others. There are currently no FDA-approved treatments specifically indicated for the early infantile epileptic encephalopathy SCN8A-DEE; however, a number of different anti-seizure medications are currently used in these patient populations.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our investigational treatments for potential use in schizophrenia and depression may in the future compete with several development-stage programs being pursued by other companies. Currently, there are no FDA-approved treatments specifically indicated for cognitive impairment associated with schizophrenia, or CIAS; however, there are a number of different anti-psychotic medications currently used in these patient populations.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our investigational treatments for potential use in neurology, neuroendocrinology and neuropsychiatry may in the future compete with numerous approved products and development-stage programs being pursued by several other companies.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compared to us, many of our competitors and potential competitors have substantially greater:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">capital resources;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales and marketing experience;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">research and development resources, including personnel and technology;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory experience;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preclinical study and clinical testing experience;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing, marketing and distribution experience; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">production facilities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, increased competition in certain disorders or therapies may make it more difficult for us to recruit or enroll patients in our clinical trials for similar disorders or therapies.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because the development of our product candidates is subject to a substantial degree of technological uncertainty, we may not succeed in developing any of our product candidates.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Only a small number of research and development programs ultimately result in commercially successful drugs. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential products that appear to be promising at early stages of development may not reach the market for a number of reasons. These reasons include the possibilities that the potential products may:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be found ineffective or cause harmful side effects during preclinical studies or clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fail to receive necessary regulatory approvals on a timely basis or at all;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be precluded from commercialization by proprietary rights of third parties;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be difficult to manufacture on a large scale; or</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be uneconomical to commercialize or fail to achieve market acceptance.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our product candidates encounters any of these potential problems, we may never successfully market that product candidate.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our clinical trials may be delayed for safety or other reasons or fail to demonstrate the safety and efficacy of our product candidates, which could prevent or significantly delay their regulatory approval.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining regulatory approval for the sale of any of our potential products, we must subject these product candidates to extensive preclinical and clinical testing to demonstrate their safety and efficacy for humans. Clinical trials are expensive, time-consuming and may take years to complete and the outcomes are uncertain.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the clinical trials of our product candidates, we face the risks that:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or similar foreign regulatory authority may not allow an IND or foreign equivalent filings required to initiate human clinical studies for our drug candidates or the FDA may require additional preclinical studies as a condition of the initiation of Phase I clinical studies, or additional clinical studies for progression from Phase&#160;I to Phase&#160;II, or Phase&#160;II to Phase&#160;III, or for NDA approval;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product candidate may not prove to be effective or as effective as other competing product candidates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may discover that a product candidate may cause harmful side effects or results of required toxicology or other studies may not be acceptable to the FDA;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trial results may not replicate the results of previous trials;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or similar foreign regulatory authorities may require use of new or experimental endpoints that may prove insensitive to treatment effects;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or the FDA or similar foreign regulatory authorities may suspend the trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results may not be statistically significant;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical site initiation or patient recruitment and enrollment may be slower or more difficult than expected;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA may not accept the data from any trial or trial site outside of the United States;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients may drop out of the trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen disruptions or delays may occur, caused by man-made or natural disasters or public health pandemics or epidemics or other business interruptions, including, for example, the COVID-19 pandemic and the conflict between Russia and Ukraine; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory requirements may change.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These risks and uncertainties impact all of our clinical programs and any of the clinical, regulatory or operational events described above could change our planned clinical and regulatory activities. In addition, due to the impact of the COVID-19 pandemic, clinical site initiation and new patient enrollment has been negatively impacted. Additionally, any of these events described above could result in suspension of a program and/or obviate any filings for necessary regulatory approvals.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, late-stage clinical trials are often conducted with patients having the most advanced stages of disease. During the course of treatment, these patients can die or suffer other adverse medical effects for reasons that may not be related to the pharmaceutical agent being tested but which can nevertheless adversely affect clinical trial conduct, completion and results. Any failure or substantial delay in completing clinical trials for our product candidates may severely harm our business.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the clinical trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, approval of our product candidates may be significantly delayed, or we may be required to expend significant additional resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Several of our planned clinical trial sites have been impacted and could be delayed or suspended as a result of the conflict between Russia and Ukraine.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, Russia commenced a military invasion of Ukraine. We have planned clinical trial sites in both Russia and Ukraine, but no patients yet enrolled. Ongoing geopolitical turmoil and continuing military action in the region, together with widening sanctions imposed on Russia, have caused us to suspend all planned clinical trial activities in Russia and Ukraine. Alternative clinical trial sites that would fully and timely compensate for our planned clinical trial activities in Ukraine and Russia may not be available and we may need to find other countries in which to conduct such activities. Our planned clinical development timelines for valbenazine and luvadaxistat could be significantly delayed, which would increase our development costs and delay the development and/or regulatory approval process of such product candidates and jeopardize our ability to commence product sales and generate revenues.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on our current collaborators for the development and commercialization of several of our products and product candidates and may need to enter into future collaborations to develop and commercialize certain of our product candidates.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on our current collaborators for the development and commercialization of several of our products and product candidates and may need to enter into future collaborations to develop and commercialize certain of our product candidates. For example, we depend on AbbVie for the manufacture and commercialization of ORILISSA and ORIAHNN and for the continued development of elagolix. We collaborate with MTPC for the commercialization of DYSVAL in Japan and for the continued development and commercialization of valbenazine for movement disorders in other select Asian markets. We also rely on BIAL for the commercial supply of ONGENTYS. In addition, we collaborate with Xenon Pharmaceuticals, Inc. for the development of NBI-921352, Idorsia Pharmaceuticals Ltd. for the development of NBI-827104, Takeda Pharmaceutical Company Limited for the development of luvadaxistat, NBI-1065845 and NBI-1065846 and Heptares Therapeutics Limited for the development of NBI-1117568.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and future collaborations and licenses could subject us to a number of risks, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may sell, transfer or divest assets or programs related to our partnered product or product candidates; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to undertake the expenditure of substantial operational, financial and management resources; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to assume substantial actual or contingent liabilities; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to control the amount and timing of resources that our strategic collaborators devote to the development or commercialization of our products or product candidates; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to influence our strategic collaborator&#8217;s decisions regarding the development and collaboration of our partnered product and product candidates, and as a result, our collaboration partners may not pursue or prioritize the development and commercialization of those partnered products and product candidates in a manner that is in our best interest;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may select indications or design clinical trials in a way that may be less successful than if we were doing so; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may not conduct collaborative activities in a timely manner, provide insufficient funding, terminate a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new version of a product candidate for clinical testing; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may not pursue further development and commercialization of products resulting from the strategic collaboration arrangement or may elect to discontinue research and development programs; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disagreements or disputes may arise between us and our strategic collaborators that result in delays or in costly litigation or arbitration that diverts management&#8217;s attention and consumes resources; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may experience financial difficulties; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may not properly maintain, enforce or defend our intellectual property rights or may use our proprietary information in a manner that could jeopardize or invalidate our proprietary information or expose us to potential litigation; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators could terminate the arrangement or allow it to expire, which would delay the development and commercialization and may increase the cost of developing and commercializing our products or product candidates; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators could develop, either alone or with others, products or product candidates that may compete with ours. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these issues arise, it may delay and/or negatively impact the development and commercialization of drug candidates and, ultimately, our generation of product revenues.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to successfully commercialize ONGENTYS.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we received FDA approval for ONGENTYS as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in adult Parkinson&#8217;s disease patients, and in September 2020, we launched the commercial sale of ONGENTYS with our existing commercial infrastructure. The successful commercialization of ONGENTYS is subject to many risks, and there are numerous examples of unsuccessful product launches and failures, including by pharmaceutical companies with more experience and resources than us. If we are unable to effectively train our employees and equip them with effective materials, including medical and sales literature to help them inform and educate health care practitioners about the benefits of ONGENTYS and its proper administration, our commercialization of ONGENTYS may not be successful. Even if we are successful in effectively training and equipping our sales force, there are many factors that could cause the commercialization of ONGENTYS to be unsuccessful, including a number of factors that are outside our control. Health care practitioners may not prescribe ONGENTYS and patients may be unwilling to use ONGENTYS if insurance coverage is not provided or reimbursement is inadequate. In addition, our ability to train our employees and effectively communicate with potential prescribers could be adversely affected by the effects of health pandemics or epidemics, including the ongoing COVID-19 pandemic.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of our approved products or those of our collaborators could be associated with side effects or adverse events.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As with most pharmaceutical products, use of our approved products or those of our collaborators could be associated with side effects or adverse events which can vary in severity (from minor adverse reactions to death) and frequency (infrequent or prevalent). Side effects or adverse events associated with the use of our products or those of our collaborators may be observed at any time, including after a product is commercialized, and reports of any such side effects or adverse events may negatively impact demand for our or our collaborators&#8217; products or affect our or our collaborators&#8217; ability to maintain regulatory approval for such products. Side effects or other safety issues associated with the use of our approved products or those of our collaborators could require us or our collaborators to modify or halt commercialization of these products or expose us to product liability lawsuits which will harm our business. We or our collaborators may be required by regulatory agencies to conduct additional studies regarding the safety and efficacy of our products which we have not planned or anticipated. Furthermore, there can be no assurance that we or our collaborators will resolve any issues related to any product related adverse events to the satisfaction of the FDA or any regulatory agency in a timely manner or ever, which could harm our business, prospects and financial condition.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have recently increased the size of our organization and will need to continue to increase the size of our organization. We may encounter difficulties with managing our growth, which could adversely affect our results of operations.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had more than 1,200 full-time employees. Although we have substantially increased the size of our organization, we may need to add additional qualified personnel and resources, especially with the recent increase in the size of our sales force. Our current infrastructure may be inadequate to support our development and commercialization efforts and expected growth. Future growth will impose significant added responsibilities on our organization, including the need to identify, recruit, maintain and integrate additional employees, and may take time away from running other aspects of our business, including development and commercialization of our product candidates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future financial performance and our ability to commercialize INGREZZA, ONGENTYS, and any of our other products, or any of our product candidates that receive regulatory approval in the future, will partially depend on our ability to manage any future growth effectively. In particular, as we commercialize INGREZZA and ONGENTYS, we will need to support the training and ongoing activities of our sales force and will likely need to continue to expand the size of our employee base for managerial, operational, financial and other resources. To that end, we must be able to successfully:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manage our development efforts effectively;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">integrate additional management, administrative and manufacturing personnel;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further develop our marketing and sales organization; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compensate our employees on adequate terms in an increasingly competitive, inflationary market;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attract and retain personnel; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain sufficient administrative, accounting and management information systems and controls.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to accomplish these tasks or successfully manage our operations and, accordingly, may not achieve our research, development and commercialization goals. Our failure to accomplish any of these goals could harm our financial results and prospects.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to retain and recruit qualified scientists and other employees or if any of our key senior executives discontinues his or her employment with us, it may delay our development efforts or impact our commercialization of INGREZZA, ONGENTYS, or any of our other products, or any product candidate approved by the FDA in the future.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on the principal members of our management, commercial and scientific staff. The loss of any of these people could impede the achievement of our objectives, including the successful commercialization of INGREZZA, ONGENTYS, or any of our other products, or any product candidate approved by the FDA in the future. Furthermore, recruiting and retaining qualified scientific personnel to perform research and development work in the future, along with personnel with experience marketing and selling pharmaceutical products, is critical to our success. We may be unable to attract and retain personnel on acceptable terms given effects of the COVID-19 pandemic, as well as the competition among biotechnology, pharmaceutical and health care companies, universities and non-profit research institutions for experienced scientists and individuals with experience marketing and selling pharmaceutical products. We may face particular retention challenges in light of the recent rapid growth in our personnel and infrastructure and the perceived impact of those changes upon our corporate culture. In addition, we rely on a significant number of consultants to assist us in formulating our research and development strategy and our commercialization strategy. Our consultants may have commitments to, or advisory or consulting agreements with, other entities that may limit their availability to us.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have no manufacturing capabilities. If third-party manufacturers of INGREZZA, ONGENTYS, or any of our other products, or any of our product candidates fail to devote sufficient time and resources to our concerns, or if their performance is substandard, our clinical trials and product introductions may be delayed, and our costs may rise.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have in the past utilized, and intend to continue to utilize, third-party manufacturers to produce the drug compounds we use in our clinical trials and for the commercialization of our products. We have limited experience in manufacturing products for commercial purposes and do not currently have any manufacturing facilities. Establishing internal commercial manufacturing capabilities would require significant time and resources, and we may not be able to timely or successfully establish such capabilities. Consequently, we depend on, and will continue to depend on, several contract manufacturers for all production of products for development and commercial purposes, including INGREZZA and ONGENTYS. If we are unable to obtain or retain third-party manufacturers, we will not be able to develop or commercialize our products, including INGREZZA and ONGENTYS. The manufacture of our products for clinical trials and commercial purposes is subject to specific FDA regulations, including current Good Manufacturing Practice regulations. Our third-party manufacturers, including BIAL and its suppliers, might not comply with FDA regulations relating to manufacturing our products for clinical trials and commercial purposes or other regulatory requirements now or in the future. Our reliance on contract manufacturers also exposes us to the following risks:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contract manufacturers may encounter difficulties in achieving volume production, quality control or quality assurance, and also may experience shortages in qualified personnel. As a result, our contract manufacturers might not be able to meet our clinical schedules or adequately manufacture our products in commercial quantities when required;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">switching manufacturers may be difficult because the number of potential manufacturers is limited. It may be difficult or impossible for us to find a replacement manufacturer quickly on acceptable terms, or at all;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to successfully produce, store or distribute our products; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">drug manufacturers are subject to ongoing periodic unannounced inspection by the FDA, the United States Drug Enforcement Administration, and other agencies to ensure strict compliance with cGMP and other government regulations and corresponding foreign standards. We do not have control over third-party manufacturers&#8217; compliance with these regulations and standards.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current dependence upon third parties for the manufacture of our products may reduce our profit margin, if any, on the sale of INGREZZA, ONGENTYS, or any of our other products, or our future products and our ability to develop and deliver products on a timely and competitive basis.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently depend on a limited number of third-party suppliers. The loss of these suppliers, or delays or problems in the supply of INGREZZA, ONGENTYS, or any of our other products, could materially and adversely affect our ability to successfully commercialize INGREZZA, ONGENTYS, or any of our other products.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture of pharmaceutical products requires significant expertise and capital investment, including the development of process controls required to consistently produce the active pharmaceutical ingredients, or API, the finished drug product and packaging in sufficient quantities while meeting detailed product specifications on a repeated basis. Manufacturers of pharmaceutical products may encounter difficulties in production, such as difficulties with production costs and yields, process controls, quality control and quality assurance, including testing of stability, impurities and impurity levels and other product specifications by validated test methods, compliance with strictly enforced United States, state and non-United States regulations, and disruptions or delays caused by man-made or natural disasters, pandemics or epidemics, or other business interruptions, including, for example, the COVID-19 pandemic and the conflict between Russia and Ukraine. We depend on a limited number of suppliers for the production and packaging of INGREZZA and its API. If our third-party suppliers for INGREZZA encounter these or any other manufacturing, quality or compliance difficulties, we may be unable to meet commercial demand for INGREZZA, which could materially and adversely affect our ability to successfully commercialize INGREZZA. In addition, under the terms of our agreement with BIAL, although we are responsible for the management of all ONGENTYS commercialization activities, we rely on BIAL and its suppliers to supply all drug product for the commercialization of ONGENTYS. BIAL relies on third-party contract manufacturers to produce ONGENTYS. These contract manufacturers may encounter difficulties in achieving volume production, quality control, or quality assurance. As a result, these contract manufacturers may not be able to adequately produce ONGENTYS in commercial quantities when required, which may impact our ability to deliver ONGENTYS on a timely basis.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if our suppliers fail or refuse to supply us with INGREZZA or its API for any reason, it would take a significant amount of time and expense to qualify a new supplier. The FDA and similar international regulatory bodies must approve manufacturers of the active and inactive pharmaceutical ingredients and certain packaging materials used in pharmaceutical products. The loss of a supplier could require us to obtain regulatory clearance and to incur validation and other costs associated with the transfer of the API or product manufacturing processes. If there are delays in qualifying new suppliers or facilities or if a new supplier is unable to meet FDA or a similar international regulatory body&#8217;s requirements for approval, there could be a shortage of INGREZZA, which could materially and adversely affect our ability to successfully commercialize INGREZZA. If BIAL is unable or refuses to supply us with ONGENTYS drug product for any reason, or does not meet FDA or international regulators&#8217; requirements for approval, we have limited opportunity to qualify a new supplier. This could materially and adversely affect our ability to successfully commercialize ONGENTYS.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The independent clinical investigators and contract research organizations that we rely upon to conduct our clinical trials may not be diligent, careful or timely, and may make mistakes, in the conduct of our trials.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on independent clinical investigators and CROs to conduct our clinical trials under their agreements with us. The investigators are not our employees, and we cannot control the amount or timing of resources that they devote to our programs. If our independent investigators fail to devote sufficient time and resources to our drug development programs, or if their performance is substandard, or not in compliance with Good Clinical Practices, it may delay or prevent the approval of our regulatory applications and our introduction of new treatments. The CROs we contract with for execution of our clinical trials play a significant role in the conduct of the trials and the subsequent collection and analysis of data. Failure of the CROs to meet their obligations could adversely affect clinical development of our products. Moreover, these independent investigators and CROs may also have relationships with other commercial entities, some of which may compete with us. If independent investigators and CROs assist our competitors at our expense, it could harm our competitive position.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not and will not have access to all information regarding the products and product candidates we licensed to AbbVie.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not and will not have access to all information regarding elagolix, including potentially material information about commercialization plans, medical information strategies, clinical trial design and execution, safety reports from clinical trials, safety reports, regulatory affairs, process development, manufacturing and other areas known by AbbVie. In addition, we have confidentiality obligations under our agreement with AbbVie. Thus, our ability to keep our shareholders informed about the status of elagolix will be limited by the degree to which AbbVie keeps us informed and allows us to disclose such information to the public. If AbbVie fails to keep us informed about commercialization efforts related to elagolix, or the status of the clinical development or regulatory approval pathway of other product candidates licensed to it, we may make operational and/or investment decisions that we would not have made had we been fully informed, which may materially and adversely affect our business and operations.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to ongoing obligations and continued regulatory review for INGREZZA. Additionally, our other product candidates, if approved, could be subject to labeling and other post-marketing requirements and restrictions.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory approvals for any of our product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase IV clinical trials, and surveillance to monitor the safety and efficacy of the product candidate. For example, with respect to the FDA&#8217;s approval of INGREZZA for tardive dyskinesia in April 2017, we are subject to certain post-marketing requirements and commitments. In addition, with respect to INGREZZA, and any product candidate that the FDA or a comparable foreign regulatory authority approves, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with Good Clinical Practices for any clinical trials that we conduct post-approval. Failure to comply with these ongoing regulatory requirements, or later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, may result in, among other things:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of the product, changes in the product&#8217;s label, withdrawal of the product from the market, or voluntary or mandatory product recalls;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning or untitled letters or holds on clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of product license approvals;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse inspection findings or other activities that temporarily delay manufacture and distribution of our products;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of products; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any of these events may adversely affect our business, prospects and ability to achieve or sustain profitability on a sustained basis.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the market opportunities for our products and product candidates are smaller than we believe they are, our expected revenues may be adversely affected, and our business may suffer.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the diseases that INGREZZA, ONGENTYS and our other product candidates are being developed to address are in underserved and underdiagnosed populations. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who will seek treatment utilizing our products or product candidates, may not be accurate. If our estimates of the prevalence or number of patients potentially on therapy prove to be inaccurate, the market opportunities for INGREZZA, ONGENTYS and our other product candidates may be smaller than we believe they are, our prospects for generating expected revenue may be adversely affected and our business may suffer.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We license some of our core technologies and drug candidates from third parties. If we default on any of our obligations under those licenses, or violate the terms of these licenses, we could lose our rights to those technologies and drug candidates or be forced to pay damages.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on licenses from third parties for some of our key technologies. These licenses typically subject us to various commercialization, reporting and other obligations. If we fail to comply with these obligations, we could lose important rights. If we were to default on our obligations under any of our licenses, we could lose some or all of our rights to develop, market and sell products covered by these licenses. For example, BIAL may terminate our license agreement, pursuant to which we have rights to commercialize ONGENTYS, if we fail to use commercially reasonable efforts to comply with specified obligations under the license agreement, or if we otherwise breach the license agreement. In addition, several of our collaboration and license agreements allow our licensors to terminate such agreements if we challenge the validity or enforceability of certain intellectual property rights or if we commit a material breach in whole or in part of the agreement and do not cure such breach within the agreed upon cure period. In addition, if we were to violate any of the terms of our licenses, we could become subject to damages. Likewise, if we were to lose our rights under a license to use proprietary research tools, it could adversely affect our existing collaborations or adversely affect our ability to form new collaborations. We also face the risk that our licensors could, for a number of reasons, lose patent protection or lose their rights to the technologies we have licensed, thereby impairing or extinguishing our rights under our licenses with them.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The conditional conversion feature of the 2024 Notes, if triggered, may adversely affect our financial condition, operating results, or liquidity.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the conditional conversion feature of the 2024 Notes had been triggered, allowing holders of 2024 Notes to convert their 2024 Notes at any time during the period beginning on January 1, 2023 and ending at the close of business on March 31, 2023. The future conditional convertibility of the 2024 Notes will be monitored at each quarterly reporting date and analyzed dependent upon market prices of our common stock during the prescribed measurement periods, and as a result, it is possible that holders of 2024 Notes will continue to be entitled to convert their 2024 Notes at any time during specified periods at their option. If one or more of the holders of the 2024 Notes elects to convert their 2024 Notes, we would be required to settle the principal amount of our conversion obligation in cash, which could adversely affect our liquidity.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our indebtedness and liabilities could limit the cash flow available for our operations, expose us to risks that could adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, we sold $517.5&#160;million aggregate principal amount of the 2024 Notes. In the fourth quarter of 2020, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $136.2&#160;million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9&#160;million in cash. In the second quarter of 2022, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $210.8 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $279.0 million in cash. As of December&#160;31, 2022, $170.4 million aggregate principal amount of the 2024 Notes remained outstanding. We may also incur additional indebtedness to meet future financing needs. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our indebtedness could have significant negative consequences for our security holders and our business, results of operations and financial condition by, among other things:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increasing our vulnerability to adverse economic and industry conditions;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limiting our ability to obtain additional financing;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requiring the dedication of a substantial portion of our cash flow from operations to service our indebtedness, which will reduce the amount of cash available for other purposes;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limiting our flexibility to plan for, or react to, changes in our business;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diluting the interests of our existing stockholders as a result of issuing shares of our common stock upon conversion of the 2024 Notes; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">placing us at a possible competitive disadvantage with competitors that are less leveraged than us or have better access to capital.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business may not generate sufficient funds, and we may otherwise be unable to maintain sufficient cash reserves, to pay amounts due under the 2024 Notes and any additional indebtedness that we may incur. In addition, our cash needs may increase in the future. In addition, any future indebtedness that we may incur may contain financial and other restrictive covenants that limit our ability to operate our business, raise capital or make payments under our other indebtedness. If we fail to comply with these covenants or to make payments under our indebtedness when due, then we would be in default under that indebtedness, which could, in turn, result in that and our other indebtedness becoming immediately payable in full.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a history of losses and expect to increase our expenses for the foreseeable future, and we may not be able to sustain profitability.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred significant net losses and negative cash flow from operations. As of December&#160;31, 2022, we had an accumulated deficit of $406.8 million as a result of historical operating losses.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received FDA approval for INGREZZA for tardive dyskinesia in April 2017 and for ONGENTYS for Parkinson&#8217;s disease in April 2020. Our partner AbbVie received FDA approval for ORILISSA for endometriosis in July 2018 and for ORIAHNN for uterine fibroids in May 2020. Additionally, our partner MTPC received Japanese Ministry of Health, Labour and Welfare approval for DYSVAL for the treatment of tardive dyskinesia in March 2022. However, we have not yet obtained regulatory approvals for any other product candidates. Even if we continue to succeed in commercializing INGREZZA, or if we successfully commercialize ONGENTYS or are successful in developing and commercializing any of our other product candidates, we may not be able to sustain profitability. We also expect to continue to incur significant operating and capital expenditures as we:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercialize INGREZZA for tardive dyskinesia;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercialize ONGENTYS for Parkinson&#8217;s disease;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek regulatory approvals for our product candidates or for additional indications for our current products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">develop, formulate, manufacture and commercialize our product candidates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in-license or acquire new product development opportunities;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">implement additional internal systems and infrastructure; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire additional clinical, scientific, sales and marketing personnel.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to increase our expenses and other investments in the coming years as we fund our operations and capital expenditures. Thus, our future operating results and profitability may fluctuate from period to period due to the factors described above, and we will need to generate significant revenues to achieve and maintain profitability and positive cash flow on a sustained basis. We may not be able to generate these revenues, and we may never achieve profitability on a sustained basis in the future. Our failure to maintain or increase profitability on a sustained basis could negatively impact the market price of our common stock.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that we or our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is commonplace in the biotechnology industry, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because our operating results may vary significantly in future periods, our stock price may decline.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly revenues, expenses and operating results have fluctuated in the past and are likely to fluctuate significantly in the future. Our financial results are unpredictable and may fluctuate, for among other reasons, due to seasonality and timing of customer purchases and commercial sales of INGREZZA, impact of the commercial launch of ONGENTYS and ORIAHNN, royalties from out-licensed products, the impact of Medicare Part D coverage, our achievement of product development objectives and milestones, clinical trial enrollment and expenses, research and development expenses and the timing and nature of contract manufacturing, contract research payments, fluctuations in our effective tax rate, and disruptions caused by man-made or natural disasters or public health pandemics or epidemics or other business interruptions, including, for example, the COVID-19 pandemic and the conflict between Russia and Ukraine. Because a majority of our costs are predetermined on an annual basis, due in part to our significant research and development costs, small declines in revenue could disproportionately affect financial results in a quarter. Thus, our future operating results and profitability may fluctuate from period to period, and even if we become profitable on a quarterly or annual basis, we may not be able to sustain or increase our profitability. Moreover, as our company and our market capitalization have grown, our financial performance has become increasingly subject to quarterly and annual comparisons with the expectations of securities analysts or investors. The failure of our financial results to meet these expectations, either in a single quarterly or annual period over a sustained period time, could cause our stock price to decline.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flows, financial condition or results of operations.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2022, the Tax Cuts and Jobs Act of 2017 eliminated the option to deduct research and development expenses for tax purposes in the year incurred and requires taxpayers to capitalize and subsequently amortize such expenses over five years for research activities conducted in the United States and over 15 years for research activities conducted outside the United States. Unless the United States Department of the Treasury issues regulations that narrow the application of this provision to a smaller subset of our research and development expenses or the provision is deferred, modified, or repealed by Congress, we expect a material decrease in our cash flows from operations and an offsetting similarly sized increase in our net deferred tax assets over these amortization periods. The actual impact of this provision will depend on multiple factors, including the amount of research and development expenses we will incur and whether we conduct our research and development activities inside or outside the United States.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, new income, sales, use, excise or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business and financial condition. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, Tax Cut and Jobs Act of 2017, the Coronavirus Aid, Relief, and Economic Security Act and the Inflation Reduction Act enacted many significant changes to the United States tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to such legislation may affect us, and certain aspects of such legislation could be repealed or modified in future legislation. Furthermore, it is uncertain if and to what extent various states will conform to federal tax laws. Future tax reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future United States tax expense.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net operating loss, or NOL, carryforwards generated in tax years beginning on or prior to December 31, 2017, are only permitted to be carried forward for 20 years under applicable United States tax law. Under current law, our federal NOLs generated in tax years beginning after December 31, 2017, may be carried forward indefinitely, but the deductibility of such federal NOLs in tax years beginning after December 31, 2020, is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to federal tax laws. In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change, by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change NOL carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. Based on completed Section 382 analysis done, we do not believe we have experienced any previous ownership changes, but the determination is complex and there can be no assurance we are correct. Furthermore, we may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, our pre-2018 NOL carryforwards may expire prior to being used and our NOL carryforwards generated in tax years beginning after December 31, 2017, will be subject to a percentage limitation and, if we undergo an ownership change (or if we previously underwent such an ownership change), our ability to use all of our pre-change NOLs and other pre-change tax attributes (such as research tax credits) to offset our post-change income or taxes may be limited. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. As a result, we may be unable to use all or a material portion of our NOLs and other tax attributes, which could adversely affect our future cash flows.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each such place. Nevertheless, our effective tax rate may be different than experienced in the past due to numerous factors, including the impact of stock-based compensation, changes in the mix of our profitability from jurisdiction to jurisdiction, the results of examinations and audits of our tax filings, our inability to secure or sustain acceptable agreements with tax authorities, changes in accounting for income taxes and changes in tax laws. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations and may result in tax obligations in excess of amounts accrued in our financial statements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, on December 31, 2020, we determined, based on our facts and circumstances, that it was more likely than not that a substantial portion of our deferred tax assets would be realized and, as a result, substantially all of our valuation allowance against our deferred tax assets was released. Therefore, beginning in 2021, we commenced recording income tax expense at an estimated tax rate that will likely approximate statutory tax rates, which could result in a significant reduction in our net income and net income per share.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock is volatile.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market prices for securities of biotechnology and pharmaceutical companies historically have been highly volatile, and the market for these securities has from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. The COVID-19 pandemic, for example, has negatively affected the stock market and investor sentiment and has resulted in significant volatility. Furthermore, especially as we and our market capitalization have grown, the price of our common stock has been increasingly affected by quarterly and annual comparisons with the valuations and recommendations of the analysts who cover our business. If our results do not meet these analysts&#8217; forecasts, the expectations of our investors or the financial guidance we provide to investors in any period, which is based on assumptions that may be incorrect or that may change from quarter to quarter, the market price of our common stock could decline. Over the course of the last 12 months, the price of our common stock has ranged from approximately $72 per share to approximately $129 per share. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock may fluctuate in response to many factors, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of INGREZZA and our other products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the status and cost of our post-marketing commitments for INGREZZA;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of our clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reports of safety issues related to INGREZZA, ONGENTYS, ORILISSA, ORIAHNN, DYSVAL, or any of our other products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments concerning new and existing collaboration agreements;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of technological innovations or new therapeutic products by us or others;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic and market conditions, including economic and market conditions affecting the biotechnology industry;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments in patent or other proprietary rights;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments related to the FDA and foreign regulatory agencies;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future sales of our common stock by us or our stockholders;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">comments by securities analysts;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in our operating results;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential litigation matters and developments in existing litigation matters, such as the ANDA litigation matters;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">government regulation;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">government and third-party payor coverage and reimbursement;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of any of our product candidates, if approved, to achieve commercial success;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruptions caused by man-made or natural disasters, pandemics or epidemics or other business interruptions, including, for example, the COVID-19 pandemic and the conflict between Russia and Ukraine; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public concern as to the safety of our drugs.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are a member of the S&amp;P MidCap 400 index. If we cease to be represented in the S&amp;P MidCap 400 index, or other indexes or indexed products, as a result of our market capitalization falling below the threshold for inclusion in the index, certain institutional shareholders may, due to their internal policies and investment guidelines, be required to sell their shareholdings. Such sales may result in further negative pressure on our stock price and, when combined with reduced trading volume and liquidity, could adversely affect the value of your investment and your ability to sell your shares.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our customers are concentrated and therefore the loss of a significant customer may harm our business.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into agreements for the distribution of INGREZZA with a limited number of specialty pharmacy providers and distributors, and all of our product sales of INGREZZA are to these customers. Four of these customers represented approximately 89% of our total product revenue for the twelve months ended December&#160;31, 2022 and approximately 95% of our accounts receivable balance as of December&#160;31, 2022. If any of these significant customers becomes subject to bankruptcy, is unable to pay us for our products or is acquired by a company that wants to terminate the relationship with us, or if we otherwise lose any of these significant customers, our revenue, results of operations and cash flows would be adversely affected. Even if we replace the loss of a significant customer, we cannot predict with certainty that such transition would not result in a decline in our revenue, results of operations and cash flows.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we cannot raise additional funding, we may be unable to complete development of our product candidates or establish commercial and manufacturing capabilities in the future.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may require additional funding to continue our research and development programs, to conduct preclinical studies and clinical trials, for operating expenses, to pursue regulatory approvals for our product candidates, for the costs involved in filing and prosecuting patent applications and enforcing or defending patent claims, if any, and the cost of product in-licensing and any possible acquisitions. In addition, we may require additional funding to establish manufacturing and marketing capabilities in the future. We believe that our existing capital resources and anticipated revenues will be sufficient to satisfy our current and projected funding requirements for at least the next 12&#160;months. However, these resources might be insufficient to conduct research and development programs, the cost of product in-taking and possible acquisitions, fully commercialize products and operate the company to the full extent currently planned. If we cannot obtain adequate funds, we may be required to significantly curtail our commercial plans or one or more of our research and development programs or obtain funds through additional arrangements with corporate collaborators or others that may require us to relinquish rights to some of our technologies or product candidates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the commercial success of INGREZZA, ONGENTYS, ORILISSA, ORIAHNN, DYSVAL, and/or any of our other products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">debt services obligations on the 2024 Notes;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued scientific progress in our R&amp;D and clinical development programs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the magnitude and complexity of our research and development programs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">progress with preclinical testing and clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and costs involved in obtaining regulatory approvals;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost involved in filing and pursuing patent applications, enforcing patent claims, or engaging in interference proceedings or other patent litigation;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competing technological and market developments;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments related to any future litigation;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of commercialization activities and arrangements, including advertising campaigns;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing our product candidates; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the COVID-19 pandemic on our business; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of any strategic alliances, collaborations, product in-licensing, or acquisitions.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to seek additional funding through strategic alliances and may seek additional funding through public or private sales of our securities, including equity securities. In addition, during the second quarter of 2017, we issued the 2024 Notes and we have previously financed capital purchases and may continue to pursue opportunities to obtain additional debt financing in the future. In the fourth quarter of 2020, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $136.2&#160;million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9&#160;million in cash. In the second quarter of 2022, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $210.8 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $279.0 million in cash. As of December&#160;31, 2022, $170.4 million aggregate principal amount of the 2024 Notes remained outstanding. Additional equity or debt financing might not be available on reasonable terms, if at all. In addition, disruptions due to the COVID-19 pandemic could make it more difficult for us to access capital. Any additional equity financings will be dilutive to our stockholders and any additional debt financings may involve operating covenants that restrict our business.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compliance with changing regulation of corporate governance and public disclosure may result in additional expenses.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changing laws, regulations and standards relating to corporate governance and public disclosure, including the Dodd-Frank Wall Street Reform and Consumer Protection Act, new SEC regulations and Nasdaq rules, are creating uncertainty for companies such as ours. These laws, regulations and standards are subject to varying interpretations in some cases due to their lack of specificity, and as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies, which could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We are committed to maintaining high standards of corporate governance and public disclosure. As a result, our efforts to comply with evolving laws, regulations and standards have resulted in, and are likely to continue to result in, increased selling, general and administrative expenses and management time related to compliance activities. If we fail to comply with these laws, regulations and standards, our reputation may be harmed and we might be subject to sanctions or investigation by regulatory authorities, such as the SEC. Any such action could adversely affect our financial results and the market price of our common stock.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Increasing use of social media could give rise to liability and result in harm to our business.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our employees are increasingly utilizing social media tools and our website as a means of communication. Despite our efforts to monitor social media communications, there is risk that the unauthorized use of social media by our employees to communicate about our products or business, or any inadvertent disclosure of material, nonpublic information through these means, may result in violations of applicable laws and regulations, which may give rise to liability and result in harm to our business. In addition, there is also risk of inappropriate disclosure of sensitive information, which could result in significant legal and financial exposure and reputational damages that could potentially have a material adverse impact on our business, financial condition and results of operations. Furthermore, negative posts or comments about us or our products on social media could seriously damage our reputation, brand image and goodwill.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risks Related to Our Industry</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect our intellectual property, our competitors could develop and market products based on our discoveries, which may reduce demand for our products.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend on our ability to, among other things:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain patent protection for our products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preserve our trade secrets;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prevent third parties from infringing upon our proprietary rights; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operate without infringing upon the proprietary rights of others, both in the United States and internationally.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the substantial length of time and expense associated with bringing new products through the development and regulatory approval processes in order to reach the marketplace, the pharmaceutical industry places considerable importance on obtaining patent and trade secret protection for new technologies, products and processes. Accordingly, we intend to seek patent protection for our proprietary technology and compounds. However, we face the risk that we may not obtain any of these patents and that the breadth of claims we obtain, if any, may not provide adequate protection of our proprietary technology or compounds.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely upon unpatented trade secrets and improvements, unpatented know-how and continuing technological innovation to develop and maintain our competitive position, which we seek to protect, in part, through confidentiality agreements with our commercial collaborators, employees and consultants. We also have invention or patent assignment agreements with our employees and some, but not all, of our commercial collaborators and consultants. However, if our employees, commercial collaborators or consultants breach these agreements, we may not have adequate remedies for any such breach, and our trade secrets may otherwise become known or independently discovered by our competitors.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, although we own a number of patents, the issuance of a patent is not conclusive as to its validity or enforceability, and third parties may challenge the validity or enforceability of our patents. We cannot assure you how much protection, if any, will be given to our patents if we attempt to enforce them and they are challenged in court or in other proceedings. It is possible that a competitor may successfully challenge our patents or that challenges will result in limitations of their coverage. Moreover, competitors may infringe our patents or successfully avoid them through design innovation. In addition, potential competitors have in the past and may in the future file an ANDA with the FDA seeking approval to market a generic version of our products, or our competitors&#8217; products, before the expiration of the patents covering our products or our competitors&#8217; products, as applicable. To prevent infringement or unauthorized use, we have in the past and may in the future need to file infringement claims, which are expensive and time-consuming. For example, we are currently engaged in various intellectual property litigation matters against potential competitors related to INGREZZA. Refer to Item 1. Legal Proceedings f</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or a more detailed description of these matters.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition, in an infringement proceeding a court may decide that a patent of ours or a patent of a competitor is not valid or is unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover its technology. Derivation proceedings declared by the United States Patent and Trademark Office may be necessary to determine the priority of inventions with respect to our patent applications (or those of our licensors) or a patent of a competitor. Litigation or derivation proceedings may fail and, even if successful, may result in substantial costs and be a distraction to management. Litigation or derivation proceedings, including proceedings of a competitor, may also result in a competitor entering the marketplace faster than expected. We cannot assure you that we will be able to prevent misappropriation of our proprietary rights, particularly in countries where the laws may not protect such rights as fully as in the United States.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Enacted health care reform measures and other recent legislative initiatives could adversely affect our business.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The business and financial condition of pharmaceutical and biotechnology companies are affected by the efforts of governmental and third-party payors to contain or reduce the costs of health care and to lower drug prices. In the United States, comprehensive health care reform legislation has been enacted by the Federal government to implement government control over the pricing of prescription pharmaceuticals. Moreover, in some foreign jurisdictions, pricing of prescription pharmaceuticals is also subject to government control. Additionally, other federal and state legislation impose obligations on manufacturers of pharmaceutical products, among others, related to disclosure of new drug products introduced to the market and increases in drug prices above a specified threshold.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in August 2022, President Biden signed into law the Inflation Reduction Act of 2022, or the IRA, which, among other things, (1) directs the Secretary of the U.S. Department of Health and Human Services, or HHS, to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare, (2) redesigns the Medicare Part D prescription drug benefit to lower patient out-of-pocket costs and increase manufacturer liability and (3) requires drug manufacturers to pay rebates on drugs whose prices increase greater than the rate of inflation. The IRA also extends enhanced subsidies for individuals purchasing health insurance coverage in the ACA marketplaces through plan year 2025 and eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost to $2,000 through a newly established manufacturer discount program. These provisions will take effect progressively starting in 2023, although they may be subject to legal challenges. It is currently unclear how the IRA will be implemented; however, it is likely to have a significant impact on the pharmaceutical industry and prescription drug pricing. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the IRA targets high-expenditure drugs that have been on the market for several years without generic or biosimilar competition, we have qualified for the small biotech manufacturer exemption that is set to expire in 2029. However, the qualification for this exemption is subject to various requirements and there is no assurance that we will continue to qualify for this exemption in the future. Further, the loss of this exemption or the potential loss of this exemption, including as a result of a potential acquisition or strategic transaction, could have an adverse impact on our business.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the IRA&#8217;s enactment, the most significant recent federal legislation impacting the pharmaceutical industry occurred in March 2010. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, was signed into law, which was intended to broaden access to health insurance and reduce the number of uninsured individuals, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add transparency requirements for the healthcare and health insurance industries, impose taxes and fees on the health industry and impose additional health policy reforms.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been adopted since the ACA was enacted. These changes include aggregate reductions to Medicare payments to providers of up to 2%&#160;per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013 and, due to subsequent legislative amendments to the statute, including the Infrastructure Investment and Jobs Act, will remain in effect until 2031, except for a temporary suspension from May 1, 2020 through March 31, 2022 due to the COVID-19 pandemic. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 4% in the final fiscal year of this sequestration. The American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. The implementation of these cost containment measures may prevent us from being able to generate revenue, attain sustained profitability or commercialize our drugs, particularly since the majority of our current revenue is derived from federal healthcare programs, including Medicare and Medicaid.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Proposed health care reform measures and other prospective legislative initiatives could adversely affect our business.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States and some foreign jurisdictions are considering a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. The business and financial condition of pharmaceutical and biotechnology companies may be affected by the efforts of governmental and third-party payors to contain or reduce the costs of health care and to lower drug prices. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. We expect that there will continue to be a number of federal and state proposals to implement government control over the pricing of prescription pharmaceuticals. In addition, increasing emphasis on reducing the cost of health care in the United States will continue to put pressure on the pricing and reimbursement of prescription pharmaceuticals.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The heightened governmental scrutiny over pharmaceutical pricing practices has resulted in several Congressional hearings and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. For example, in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. Further, the Biden administration released an additional executive order on October 14, 2022, directing HHS to submit a report within 90 days on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries. It is unclear whether this executive order or similar policy initiatives will be implemented in the future.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently unable to predict what other additional legislation or regulation, if any, relating to the health care industry may be enacted in the future or what effect recently enacted federal legislation or any such additional legislation or regulation would have on our business. The pendency or approval of such proposals or reforms could result in a decrease in our stock price or limit our ability to raise capital or to enter into collaboration agreements for the further development and commercialization of our programs and products.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any relationships with healthcare professionals, principal investigators, consultants, customers (actual and potential) and third-party payors in connection with our current and future business activities are and will continue to be subject, directly or indirectly, to federal and state healthcare laws. If we are unable to comply, or have not fully complied, with such laws, we could&#160;face penalties, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business operations and activities may be directly, or indirectly, subject to various federal and state healthcare laws, including without limitation, fraud and abuse laws, false claims laws, data privacy and security laws, as well as transparency laws regarding payments or other items of value provided to healthcare providers. These laws may restrict or prohibit a wide range of business activities, including, but not limited to, research, manufacturing, distribution, pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. These laws may impact, among other things, our current activities with principal investigators and research subjects, as well as current and future sales, marketing, patient co-payment assistance and education programs.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such laws include:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal civil and criminal false claims laws, including the federal civil False Claims Act, and Civil Monetary Penalties Laws, which impose criminal and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Health Insurance Portability and Accountability Act, or HIPAA, which imposes criminal and civil liability for, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and its (HITECH) implementing regulations, which also imposes obligations, including mandatory contractual terms, on covered entities, including certain healthcare providers, health plans and healthcare clearinghouses, as well as their business associates and their covered subcontractors, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to CMS information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners) and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by physicians and their immediate family members; and</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analogous state, local and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third party payors, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures or drug pricing; state laws that require disclosure of price increases above certain identified thresholds as well as of new commercial launches in the state; state and local laws that require the registration of pharmaceutical sales representatives; state and local &#8220;drug take back&#8221; laws and regulations; and state and foreign laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. While our interactions with healthcare professionals, including our speaker programs and other arrangements have been structured to comply with these laws and related guidance, it is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws. For example, we maintain a patient assistance program to help eligible patients afford our products. These types of programs have become the subject of governmental scrutiny, and numerous organizations, including pharmaceutical manufacturers, have been subject to litigation, enforcement actions and settlements related to their patient assistance programs. If our operations or activities are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to, without limitation, significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, any sales of our product once commercialized outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We could face liability if a regulatory authority determines that we are promoting INGREZZA, ONGENTYS or any of our product candidates that receives regulatory approval, for &#8220;off-label&#8221; uses.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company may not promote &#8220;off-label&#8221; uses for its drug products. An off-label use is the use of a product for an indication that is not described in the product&#8217;s FDA-approved label in the United States or for uses in other jurisdictions that differ from those approved by the applicable regulatory agencies. Physicians, on the other hand, may prescribe products for off-label uses. Although the FDA and other regulatory agencies do not regulate a physician&#8217;s choice of drug treatment made in the physician&#8217;s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA approved labeling. A company that is found to have promoted off-label use of its product may be subject to significant liability, including civil and criminal sanctions. We intend to comply with the requirements and restrictions of the FDA and other regulatory agencies with respect to our promotion of our products, including INGREZZA and ONGENTYS, but we cannot be sure that the FDA or other regulatory agencies will agree that we have not violated their restrictions. As a result, we may be subject to criminal and civil liability. In addition, our management&#8217;s attention could be diverted to handle any such alleged violations. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA or any other governmental agency initiates an enforcement action against us, or if we are the subject of a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> suit brought by a private plaintiff on behalf of the government, and it is determined that we violated prohibitions relating to the promotion of products for unapproved uses, we could be subject to substantial civil or criminal fines or damage awards and other sanctions such as consent decrees and corporate integrity agreements pursuant to which our activities would be subject to ongoing scrutiny and monitoring to ensure compliance with applicable laws and regulations. Any such fines, awards or other sanctions would have an adverse effect on our revenue, business, financial prospects and reputation.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our information technology systems or data is or were compromised, we could experience adverse impacts resulting from such compromise, including, but not limited to, interruptions to our operations such as our clinical trials, claims that we breached our data protection obligations, harm to our reputation, and a loss of customers or sales.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent on information technology systems and infrastructure, including mobile technologies, to operate our business. In the ordinary course of our business, we collect, use, safeguard, share and transfer, or collectively, process, confidential and sensitive electronic information on our networks and in our data centers. This information includes, among other things, de-identified or pseudonymous sensitive personal data (including health data), our intellectual property and proprietary information, the confidential information of our collaborators and licensees, and the personal data of our employees. It is important to our operations and business strategy that this electronic information remains secure and is perceived to be secure. The size and complexity of our information technology systems, and those of third-party vendors with whom we contract, and the volume of data we retain, make such systems potentially vulnerable to breakdown, malicious intrusion, security breaches, ransomware attacks, social engineering attacks, supply-chain attacks, and other cyber-attacks. Cyber-attacks, malicious internet-based activity, online and offline fraud, and other similar activities threaten the confidentiality, integrity, and availability of our sensitive information and information technology systems, and those of the third parties upon which we rely. Such threats continue to rise, are increasingly difficult to detect, and come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors. Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we and the third parties upon which we rely may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, as well as our ability to conduct clinical trials. Ransomware attacks are also becoming increasingly prevalent and severe, </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and can lead to significant interruptions in our operations, loss of sensitive data and income, reputational harm, and diversion of funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. To alleviate the financial, operational and reputational impact of a ransomware attack, it may be preferable to make extortion payments, but we may be unwilling or unable to do so (including, for example, if applicable laws or regulations prohibit such payments). Similarly, supply chain attacks have increased in frequency and severity, and we cannot guarantee that third parties in our supply chain have not been compromised or that they do not contain exploitable defects or bugs that could result in a breach of or disruption to our information technology systems and infrastructure or the information technology systems and infrastructure of third parties that support our operations. Furthermore, if the COVID-19 pandemic requires us to reinstate a remote workforce model, our information technology systems and data will be at increased risk as more of our employees work from home, utilizing network connections outside our premises.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, natural disasters, public health pandemics or epidemics (including, for example, the COVID-19 pandemic), terrorism, war and geopolitical conflicts (including, for example, the conflict between Russia and Ukraine) and telecommunication and electrical failures may result in damage to or the interruption or impairment of key business processes, or the loss or corruption of confidential information, including intellectual property, proprietary business information and personal data. Information security risks have significantly increased in recent years in part due to the proliferation of new technologies and the increased sophistication and activities of organized crime, hackers, terrorists and other external parties, including foreign private parties and state actors.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As cyber threats continue to evolve, we may be required to expend significant additional resources to continue to modify or enhance our protective measures or to investigate and remediate any information security vulnerabilities. Our efforts to identify and remediate such vulnerabilities may not be successful and we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities. Further, we may be unable to detect such vulnerabilities in the future because such threats and techniques change frequently, are often sophisticated in nature and may not be detected until after a security breach has occurred.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may rely on third-party service providers and technologies to operate critical business systems to process sensitive information in a variety of contexts, including, without limitation, cloud-based infrastructure, data center facilities, encryption and authentication technology, employee email and other functions. We may also rely on third-party service providers to provide other products, services, parts, or otherwise to operate our business, including clinical trial sites and investigators, contractors, manufacturers, suppliers and consultants. Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. If our third-party service providers or CROs experience a security incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although to our knowledge we, or the third parties upon who we rely, have not experienced any material incident or disruption to date, we and our vendors have been the target of cybersecurity incidents of this nature and expect them to continue. While we have implemented security measures to protect our data security and information technology systems, such measures may not prevent such events.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we (or a third party upon whom we rely) experience a security breach or are perceived to have experienced a security breach, we may experience adverse consequences. Such consequences may include: government enforcement actions (for example, investigations, fines, penalties, audits and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm (including but not limited to</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">damage to our patient, partner, or employee relationships)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; monetary fund diversions; interruptions in our operations (including availability of data); financial loss; and other similar harms. Similarly, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. In addition, theft of our intellectual property or proprietary business information could require substantial expenditures to remedy. Applicable data privacy and security obligations may also require us to notify relevant stakeholders of security breaches or incidents. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts, with for example third parties or CROs, may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We also cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to obtain or maintain orphan drug designation or other regulatory exclusivity for some of our product candidates, our competitive position would be harmed.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to any patent protection, we rely on forms of regulatory exclusivity to protect our products such as orphan drug designation. A product candidate that receives orphan drug designation can benefit from a streamlined regulatory process as well as potential commercial benefits following approval. Currently, this designation provides market exclusivity in the United States for seven years and the European Union for 10 years if a product is the first such product approved for such orphan indication. This market exclusivity does not, however, pertain to indications other than those for which the drug was specifically designated in the approval, nor does it prevent other types of drugs from receiving orphan designations or approvals in these same indications. Further, even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the new drug is clinically superior to the orphan product or a market shortage occurs.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, orphan exclusivity may be reduced to 6 years if the drug no longer satisfies the original designation criteria or can be lost altogether if the marketing authorization holder consents to a second orphan drug application or cannot supply enough drug, or when a second applicant demonstrates its drug is &#8220;clinically superior&#8221; to the original orphan drug. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not have adequate patent protection for our products, then the relative importance of obtaining regulatory exclusivity is even greater. We may not be successful obtaining orphan drug designations for any indications and, even if we succeed, such product candidates with such orphan drug designations may fail to achieve FDA approval. Even if a product candidate with orphan drug designation may receive marketing approval from the FDA, it may fail to result in or maintain orphan drug exclusivity upon approval, which would harm our competitive position.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The technologies we use in our research as well as the drug targets we select may infringe the patents or violate the proprietary rights of third&#160;parties.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that third parties will not assert patent or other intellectual property infringement claims against us or our collaborators with respect to technologies used in potential products. If a patent infringement suit were brought against us or our collaborators, we or our collaborators could be forced to stop or delay developing, manufacturing or selling potential products that are claimed to infringe a third party&#8217;s intellectual property unless that party grants us or our collaborators rights to use its intellectual property. In such cases, we could be required to obtain licenses to patents or proprietary rights of others in order to continue to commercialize our products. However, we may not be able to obtain any licenses required under any patents or proprietary rights of third parties on acceptable terms, or at all. Even if our collaborators or we were able to obtain rights to the third party&#8217;s intellectual property, these rights may be non-exclusive, thereby giving our competitors access to the same intellectual property. Ultimately, we may be unable to commercialize some of our potential products or may have to cease some of our business operations as a result of patent infringement claims, which could severely harm our business.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business operations may subject us to disputes, claims and lawsuits, which may be costly and time-consuming and could materially and adversely impact our financial position and results of operations.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may become involved in disputes, claims and lawsuits relating to our business operations. In particular, we may face claims related to the safety of our products, intellectual property matters, employment matters, tax matters, commercial disputes, competition, sales and marketing practices, environmental matters, personal injury, insurance coverage and acquisition or divestiture-related matters. Any dispute, claim or lawsuit may divert management&#8217;s attention away from our business, we may incur significant expenses in addressing or defending any dispute, claim or lawsuit, and we may be required to pay damage awards or settlements or become subject to equitable remedies that could adversely affect our operations and financial results. For example, we are currently engaged in various intellectual property litigation matters against potential competitors related to INGREZZA. Refer to Item 1. Legal Proceedings f</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or a more detailed description of these matters.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation related to these disputes may be costly and time-consuming and could materially and adversely impact our financial position and results of operations if resolved against us. In addition, the uncertainty associated with litigation could lead to increased volatility in our stock price.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, principal investigators, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees and independent contractors, such as principal investigators, consultants, commercial partners and vendors, or by employees of our commercial partners could include failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with manufacturing standards we have established, to comply with federal and state healthcare fraud and abuse laws, to report financial information or data accurately, to maintain the confidentiality of our trade secrets or the trade secrets of our commercial partners, or to disclose unauthorized activities to us. In particular, sales, marketing and other business arrangements in the healthcare industry are subject to extensive laws intended to prevent fraud, kickbacks, self-dealing and other abusive practices. Employee and independent contractor misconduct could also involve the improper use of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. Any action against our employees, independent contractors, principal investigators, consultants, commercial partners or vendors for violations of these laws could result in significant civil, criminal and administrative penalties, fines and imprisonment.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential product liability exposure far in excess of our insurance coverage.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of any of our potential products in clinical trials, and the sale of any approved products, including INGREZZA and ONGENTYS, may expose us to liability claims. These claims might be made directly by consumers, health care providers, pharmaceutical companies or others selling our products. We have product liability insurance coverage for our clinical trials in the amount of $45.0 million per occurrence and $45.0 million in the aggregate. In addition, we have product liability insurance related to the sale of INGREZZA and ONGENTYS in the amount of $45.0 million per occurrence and $45.0 million in the aggregate. However, our insurance may not reimburse us or may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability from any current or future clinical trials or approved products. A successful product liability claim, or series of claims, brought against us would decrease our cash reserves and could cause our stock price to fall. Furthermore, regardless of the eventual outcome of a product liability claim, any product liability claim against us may decrease demand for our approved products, including INGREZZA and ONGENTYS, damage our reputation, result in regulatory investigations that could require costly recalls or product modifications, cause clinical trial participants to withdrawal, result in costs to defend the related litigation, decrease our revenue, and divert management&#8217;s attention from managing our business.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our activities involve hazardous materials, and we may be liable for any resulting contamination or injuries.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research activities involve the controlled use of hazardous materials. We cannot eliminate the risk of accidental contamination or injury from these materials. If an accident occurs, a court may hold us liable for any resulting damages, which may harm our results of operations and cause us to use a substantial portion of our cash reserves, which would force us to seek additional financing.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to stringent and changing obligations related to data privacy and information security. Our actual or perceived failure to comply with such obligations could have a material adverse effect on our reputation, business, financial condition or results of operations.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, processing) confidential and sensitive information, including personal data, proprietary and confidential business data, trade secrets, intellectual property, data we collect about clinical trial participants in connection with clinical trials, and sensitive third-party data, on our networks and in our data centers. We are subject to numerous federal, state, local and foreign laws, orders, codes, regulations and regulatory guidance regarding privacy, data protection, information security and the processing of personal information (including clinical trial data), the number and scope of which are expanding, changing, subject to differing applications and interpretations, and may be inconsistent among jurisdictions. Our data processing activities may also subject us to other data privacy and security obligations, such as industry standards, external and internal privacy and security policies, contracts and other obligations that govern the processing of data by us and by third parties on our behalf.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laws regarding privacy, data protection, information security and the processing of personal data are becoming increasingly common in the United States at both the federal and state level. For example, the California Consumer Privacy Act, or CCPA, which went into effect in 2020, imposes obligations on businesses to which it applies. These obligations include, without limitation, providing specific disclosures in privacy notices, affording California residents certain rights related to their personal data, and requiring businesses subject to the CCPA to implement certain measures to effectuate California residents&#8217; personal data rights. The CCPA allows for statutory fines for noncompliance (up to $7,500 per violation). In addition, the California Privacy Rights Act of 2020, or the CPRA, which became effective January 1, 2023, expands the CCPA by establishing a new California Privacy Protection Agency to implement and enforce the CCPA (as amended), which could increase the risk of an enforcement action. Other states have also enacted data privacy laws. For example, Virginia passed its Consumer Data Protection Act, Colorado passed the Colorado Privacy Act, and Utah passed the Utah Consumer Privacy Act, all of which become effective in 2023. Similar laws are being considered in several other states, as well as at the federal and local levels. These developments may further complicate compliance efforts, and may increase legal risk and compliance costs for us and the third parties upon whom we rely.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), imposes specific requirements relating to the privacy, security, and transmission of individually identifiable health information. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laws in Europe regarding privacy, data protection, information security and the processing of personal data have also been significantly reformed and continue to undergo reform. For example, the European Union&#8217;s General Data Protection Regulation, or the EU GDPR, and the United Kingdom&#8217;s GDPR, or the UK GDPR, impose strict requirements for processing the personal data of individuals located, respectively, within the European Economic Area, or EEA, and the United Kingdom, or the UK. The EU GDPR and the UK GDPR enhance data protection obligations for processors and controllers of personal data, including, for example, obligations relating to: processing health and other sensitive data; obtaining consent of individuals; providing notice to individuals regarding data processing activities; responding to data subject requests; taking certain measures when engaging third-party processors; notifying data subjects and regulators of data breaches; and implementing safeguards to protect the security and confidentiality of personal data. The EU GDPR and the UK GDPR impose substantial fines for breaches of data protection requirements. For example, under the EU GDPR, such fines can be up to four percent of global revenue or 20 million euros, whichever is greater, and also allow for private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests. The EU GDPR, the UK GDPR and other changes in laws or regulations associated with the enhanced protection of certain types of sensitive data, such as EU regulations governing clinical trial data and other healthcare data, could require us to change our business practices or lead to government enforcement actions, private litigation or significant penalties against us and could have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to additional foreign data laws. For example, in Canada, the Personal Information Protection and Electronic Documents Act (&#8220;PIPEDA&#8221;) and various related provincial laws, as well as Canada&#8217;s Anti-Spam Legislation (&#8220;CASL&#8221;), may apply to our operations. As another example, the General Data Protection Law (Lei Geral de Prote&#231;&#227;o de Dados Pessoais, or &#8220;LGPD&#8221;) (Law No. 13,709/2018) may apply to our operations. The LGPD broadly regulates processing personal data of individuals in Brazil and imposes compliance obligations and penalties comparable to those of the EU GDPR. We also target customers in Asia and may be subject to new and emerging data privacy regimes in Asia, including Japan&#8217;s Act on the Protection of Personal Information and Singapore&#8217;s Personal Data Protection Act.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we may transfer personal data from Europe and other jurisdictions to the United States or other countries. Certain jurisdictions have enacted data localization laws and cross-border personal data transfers laws. For example, absent appropriate safeguards or other circumstances, the EU GDPR may restrict the transfer of personal data to countries outside of the EEA, such as the United States, which the European Commission does not consider to provide an adequate level of personal data protection. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the EEA and UK&#8217;s standard contractual clauses, these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States. If we cannot implement a valid compliance mechanism for cross-border personal data transfers, we may face increased exposure to regulatory actions, substantial fines and injunctions against processing or transferring personal data from Europe or elsewhere. The inability to import personal data to the United States may significantly and negatively impact our business operations, including by limiting our ability to conduct clinical trial activities in Europe and elsewhere; limiting our ability to collaborate with parties subject to European and other data protection laws or requiring us to increase our personal data processing capabilities in Europe and/or elsewhere at significant expense. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations related to data privacy and security are quickly changing in an increasingly stringent fashion. These obligations may be subject to differing applications and interpretations, which may be inconsistent among jurisdictions or in conflict. Preparing for and complying with these obligations requires us to devote significant resources (including, without limitation, financial and time-related resources). These obligations may necessitate changes to our information technologies, systems and practices and those of any third parties that process personal data on our behalf. In addition, these obligations may even require us to change to our business model.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we endeavor to comply with all applicable data privacy and security obligations, we may at times fail (or be perceived to have failed) to do so. Moreover, despite our efforts, our personnel or third-parties upon whom we rely may fail to comply such obligations that impacts our compliance posture. If we fail, or are perceived to have failed, to address or comply with data privacy and security obligations, we could face significant consequences. These consequences may include, but are not limited to, government enforcement actions, litigation, additional reporting requirements and/or oversight, bans on processing personal data, imprisonment of company officials, and orders to destroy or not use personal data. Any of these events could have a material adverse effect on our reputation, business, financial condition or results of operations.</span></div><div id="id795223301944418ba8c3fb3bc02f08e_64"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 1B. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Unresolved Staff Comments</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="id795223301944418ba8c3fb3bc02f08e_67"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;2. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Properties</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters are located in San Diego, California. We believe that our property and equipment are generally well maintained, in good operating condition and suitable for the conduct of our business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of our leased facilities, which include our corporate headquarters and consist of office space and research and development laboratories, follow. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.893%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.081%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Address</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Square Feet</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12780 El Camino Real, San Diego, California</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office Space, Research and Development Laboratories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12790 El Camino Real, San Diego, California</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office Space</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10420 Wateridge Circle, San Diego, California</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and Development Laboratories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12777 High Bluff Drive, San Diego, California</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office Space</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12770 El Camino Real, San Diego, California</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office Space</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2022, we entered into a lease agreement for a four-building campus facility consisting of up to approximately 535,000 gross square feet, to be constructed in San Diego, California, pursuant to which we also secured a six-year option for the construction of a fifth building consisting of up to approximately 121,000 gross square feet and an option to purchase the entire campus facility, which will consist of office space and research and development laboratories, in the future. Upon completion of construction, we expect to utilize the campus facility as our new corporate headquarters and expect to begin subleasing our existing leased facilities.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><div id="id795223301944418ba8c3fb3bc02f08e_70"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;3. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Legal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Proceedings</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021 and 2022, we received notices from (i) Teva Pharmaceuticals Development, Inc., (ii) Lupin Limited, (iii) Crystal Pharmaceutical (Suzhou) Co. Ltd., (iv) Sandoz Inc. and (v) Zydus Pharmaceuticals (USA) Inc. that each company had filed an abbreviated new drug application, or ANDA, with the FDA seeking approval of a generic version of INGREZZA. These companies represented that their respective ANDAs each contained a Paragraph IV Patent Certification alleging that certain of our patents covering INGREZZA are invalid and/or will not be infringed by the manufacture, use or sale of the medicine for which the ANDA was submitted.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We filed suit in the United States District Court for the District of Delaware during 2021 and 2022, against (i) Teva Pharmaceuticals, Inc., Teva Pharmaceuticals Development, Inc., Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd. (entity dismissed), (ii) Lupin Limited, Lupin Pharmaceuticals, Inc., Lupin Inc. and Lupin Atlantis Holdings S.A., (iii) Crystal Pharmaceutical (Suzhou) Co., Ltd., Crystal Pharmatech Co., Ltd., (iv) Sandoz Inc., Sandoz International GmbH (entity dismissed) and Sandoz AG (entity dismissed) and (v) Zydus Pharmaceuticals (USA) Inc., Zydus Worldwide DMCC, Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited d/b/a Zydus Cadila) and Zydus Healthcare (USA) LLC (entity dismissed). Sandoz Inc. has been joined in the cases against Crystal Pharmaceutical (Suzhou) Co., Ltd. and Crystal Pharmatech Co., Ltd. These cases have been consolidated in the United States District Court for the District of Delaware and the trial is currently scheduled for January 2, 2024.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also filed suit in the United States District Court for the District of New Jersey during 2021 and 2022 against Zydus Pharmaceuticals (USA) Inc., Zydus Worldwide DMCC, Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited d/b/a Zydus Cadila) and Zydus Healthcare (USA) LLC and these cases were dismissed in favor of continued prosecution of the Delaware proceedings against the same entities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may also become subject to other legal proceedings or claims arising in the ordinary course of our business. We currently believe that none of the claims or actions pending against us is likely to have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Given the unpredictability inherent in litigation, however, we cannot predict the outcome of these matters.</span></div><div id="id795223301944418ba8c3fb3bc02f08e_73"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;4. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Mine Safety Disclosures</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="id795223301944418ba8c3fb3bc02f08e_76"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART&#160;II</span></div><div id="id795223301944418ba8c3fb3bc02f08e_79"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 5. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is traded on the Nasdaq Global Select Market under the symbol &#8220;NBIX&#8221;.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">January&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there were approximately 44 stockholders of record of our common stock. We have not paid any cash dividends on our common stock since inception and do not anticipate paying cash dividends in the foreseeable future.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about our equity compensation plans is incorporated herein by reference to Item&#160;12 of Part&#160;III of this Annual Report on Form&#160;10-K.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities and Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no unregistered sales of our equity securities and we did not repurchase any of our equity securities during 2022.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Performance Graph and Cumulative Total Return*</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph presents the cumulative total stockholder return assuming the investment of $100 on December&#160;31, 2017 (and the reinvestment of dividends thereafter) in each of (i)&#160;Neurocrine Biosciences, Inc.&#8217;s common stock, (ii)&#160;the Nasdaq Composite Index and (iii)&#160;the Nasdaq Biotechnology Index. The comparisons in the graph below are based upon historical data and are not indicative of, or intended to forecast, future performance of our common stock or Indexes.</span></div><div style="text-align:center"><img src="nbix-20221231_g3.jpg" alt="nbix-20221231_g3.jpg" style="height:380px;margin-bottom:5pt;vertical-align:text-bottom;width:613px"/></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The material in this section is not &#8220;soliciting material&#8221;, is not deemed &#8220;filed&#8221; with the Securities and Exchange Commission, or SEC, and is not to be incorporated by reference into any of our SEC filings whether made before or after the date hereof and irrespective of any general incorporation language in any such SEC filing except to the extent we specifically incorporate this section by reference.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="id795223301944418ba8c3fb3bc02f08e_82"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations section contains forward-looking statements pertaining to, among other things, the commercialization of our product and product candidates, the expected continuation of our collaborative agreements, the receipt of research and development payments thereunder, the future achievement of various milestones in product development and the receipt of payments related thereto, the potential receipt of royalty payments, preclinical testing and clinical trials of potential products, the period of time that our existing capital resources will meet our funding requirements, and our financial results of operations. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various risks and uncertainties, including those set forth in this Annual Report on Form&#160;10-K under the heading &#8220;Item&#160;1A. Risk&#160;Factors.&#8221; See &#8220;Forward-Looking Statements&#8221; in Part&#160;I of this Annual Report on Form&#160;10-K.</span></div><div id="id795223301944418ba8c3fb3bc02f08e_85"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The Company&#8217;s diverse portfolio includes United States Food and Drug Administration, or FDA, approved treatments for tardive dyskinesia, Parkinson&#8217;s disease, endometriosis* and uterine fibroids* and a diversified portfolio of advanced clinical-stage programs in multiple therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions and we will continue to relentlessly pursue medicines to ease the burden of debilitating diseases and disorders. (*in collaboration with AbbVie Inc., or AbbVie)</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We launched INGREZZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (valbenazine) in the United States in May 2017 as the first FDA-approved drug for the treatment of tardive dyskinesia and launched ONGENTYS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (opicapone) in the United States in September 2020 as an FDA-approved add-on treatment for levodopa/carbidopa in patients with Parkinson's disease experiencing motor fluctuations. INGREZZA net product sales represent nearly all of our total net product sales.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner Mitsubishi Tanabe Pharma Corporation, or MTPC, launched DYSVAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (valbenazine) in Japan in June 2022 for the treatment of tardive dyskinesia. We receive royalties at tiered percentage rates on MTPC net sales of DYSVAL.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner AbbVie launched ORILISSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(elagolix tablets) in the United States in August 2018 for the treatment of moderate to severe pain associated with endometriosis and launched ORIAHNN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(elagolix, estradiol and norethindrone acetate capsules and elagolix capsules) in the United States in June 2020 for the treatment of heavy menstrual bleeding related to uterine fibroids in premenopausal women. We receive royalties at tiered percentage rates on AbbVie net sales of elagolix.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Business Highlights</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">INGREZZA net product sales for 2022 increased $345.9 million, or 32.0%, to $1.4 billion, driven by increased new patient starts and increased total prescriptions on higher customer demand and increased commercial activities, including continued investment in our branded direct-to-consumer INGREZZA advertising campaign launched in May 2021 and deployment of our expanded sales force in April 2022.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Total debt outstanding decreased by $210.8 million to $170.4 million following our repurchase of approximately 55% of total debt outstanding in the second quarter of 2022. The total aggregate repurchase price of $279.0 million was paid in cash and resulted in the recognition of a $70.0 million loss on extinguishment.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">On November 1, 2022, we acquired Diurnal in an all-cash transaction, for an aggregate value of $55.2 million to accelerate the establishment of our clinical development and commercial capabilities in the United Kingdom to the benefit of patient communities and other stakeholders.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">On January 8, 2023, we entered into a new strategic collaboration with Voyager Therapeutics, Inc., or Voyager, under which we agreed to pay Voyager $175 million upfront, including a $39 million equity investment, to acquire the worldwide rights to Voyager&#8217;s GBA1 gene therapy program for Parkinson&#8217;s disease and other GBA1-mediated diseases and three gene therapy programs directed to rare central nervous system targets, each enabled by Voyager&#8217;s next-generation TRACER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> capsids. The effectiveness of the collaboration agreement and the closing of the sale and issuance of Voyager common stock are expected to be completed before the end of the first quarter of 2023 and are subject to certain conditions including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and other customary closing conditions.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pipeline Highlights</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In December 2022, the FDA accepted our supplemental new drug application, or sNDA, for valbenazine for the treatment of chorea associated with Huntington disease. The agency set a Prescription Drug User Fee Act target action date of August 20, 2023.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In 2022, we initiated a second Phase III clinical study of valbenazine as adjunctive treatment in patients with schizophrenia who have had an inadequate response to antipsychotics and a Phase II clinical study of NBI-1117568 in patients with schizophrenia who are experiencing an acute exacerbation or relapse of symptoms.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In December 2022, we announced our Phase II study of NBI-827104 in EE-CSWS did not meet specified endpoints. We continue to analyze the complete dataset from this study to determine next steps in the further development of NBI-827104.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In August 2022, we announced the Phase IIa study of NBI-827104 in essential tremor did not meet specified endpoints. Based on the totality of data from the Phase IIa study, at this time, we do not plan to proceed further with the clinical development of NBI-827104 in essential tremor.</span></div><div style="margin-bottom:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">We recently completed enrollment in our adult and pediatric registrational studies of crinecerfont to treat congenital adrenal hyperplasia with top-line data expected for each study in the second half of 2023.</span></div><div style="margin-bottom:6pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Impacts of Macro-Economic Factors on Our Business</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Global Pandemic.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor the impact of the COVID-19 pandemic on our business, including our clinical trials, third-party manufacturers, suppliers and service providers. We remain committed to (1) prioritizing the safety, health and well-being of patients and their caregivers, healthcare providers, and our employees; (2) ensuring patients with tardive dyskinesia are well supported and have continued uninterrupted access to INGREZZA, for which we have not experienced and currently do not expect any supply disruption; and (3) advancing our clinical studies.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 may impact our financial condition and results of operations remains uncertain and is dependent on numerous evolving factors, including the measures being taken by authorities to mitigate against the spread of COVID-19, the emergence of new variants and the availability and successful administration of effective vaccines. For more information on the risks and uncertainties associated with the evolving effects of COVID-19 on our business, our ability to generate sales of and revenues from our approved products and our clinical development and regulatory efforts, refer to Part I Item 1A. Risk Factors.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Russia/Ukraine Conflict.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, Russia commenced a military invasion of Ukraine. The ongoing geopolitical turmoil and continuing military action in the region, together with widening sanctions imposed on Russia, have caused us to suspend all planned clinical trial activities for valbenazine and luvadaxistat in Russia and Ukraine.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The duration and impact of the conflict between Russia and Ukraine is highly unpredictable and the extent to which the conflict may impact certain of our clinical development and regulatory efforts remains uncertain. For more information on the risks and uncertainties associated with the evolving effects of the conflict between Russia and Ukraine on our business and certain of our clinical development and regulatory efforts, refer to Part I Item 1A. Risk Factors.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inflation Reduction Act.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, President Biden signed into law the Inflation Reduction Act of 2022, or the IRA, which, among other things, (1) directs the Secretary of the U.S. Department of Health and Human Services, or HHS, to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare, (2) redesigns the Medicare Part D prescription drug benefit to lower patient out-of-pocket costs and increase manufacturer liability and (3) requires drug manufacturers to pay rebates on drugs whose prices increase greater than the rate of inflation. These provisions will take effect progressively starting in 2023, although they may be subject to legal challenges. It is currently unclear how the IRA will be implemented; however, it is likely to have a significant impact on the pharmaceutical industry and prescription drug pricing. While the IRA targets high-expenditure drugs that have been on the market for several years without generic or biosimilar competition, we have qualified for the small biotech manufacturer exemption that is set to expire in 2029. However, the qualification for this exemption is subject to various requirements and there is no assurance that we will continue to qualify for this exemption in the future. Further, the loss of this exemption or the potential loss of this exemption, including as a result of a potential acquisition or strategic transaction, could have an adverse impact on our business. For more information on the risks and uncertainties associated with the evolving effects of the IRA on our business, refer to Part I Item 1A. Risk Factors.</span></div><div id="id795223301944418ba8c3fb3bc02f08e_88"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revenues</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Net Product Sales by Sales Product.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INGREZZA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,427.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ONGENTYS and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,440.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,090.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increases in total net product sales from 2020 to 2021 and from 2021 to 2022 primarily reflected increased INGREZZA net product sales driven by increased new patient starts and increased total prescriptions on higher customer demand and increased commercial activities.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenues by Category.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestones</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2022, total collaboration revenue primarily reflected the achievement of a $20.0 million milestone in connection with MTPC's first commercial sale of DYSVAL in Japan in June 2022 and royalties earned on AbbVie net sales of elagolix.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2021, total collaboration revenue primarily reflected the achievement of a $15.0 million milestone in connection with MTPC's marketing authorization application submission for valbenazine for the treatment of tardive dyskinesia in Japan and royalties earned on AbbVie net sales of elagolix.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2020, total collaboration revenue primarily reflected the achievement of a $30.0 million milestone in connection with AbbVie&#8217;s receipt of FDA approval of ORIAHNN for uterine fibroids and royalties earned on AbbVie net sales of elagolix.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Operating Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenues. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increases in cost of revenues from 2020 to 2021 and from 2021 to 2022 primarily reflected increased INGREZZA net product sales driven by increased new patient starts and increased total prescriptions on higher customer demand and increased commercial activities.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Research and Development by Category. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs, and business development opportunities. Costs are reflected in the applicable development stage based upon the program status when incurred. Therefore, the same program could be reflected in different development stages in the same reporting period. For several of our programs, the research and development activities are part of our collaborative arrangements.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Late stage </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Early stage </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and discovery </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestones</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities and other </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Late Stage.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consists of costs incurred for product candidates in Phase II registrational studies and all subsequent activities.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2022 compared to 2021, the increase in late stage expenses primarily reflected continued investment in our Phase III programs for crinecerfont in CAH and valbenazine in schizophrenia.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2021 compared to 2020, the increase in late stage expenses primarily reflected continued investment in Phase III programs for crinecerfont in CAH and valbenazine in Huntington disease and initiation of a Phase III program for valbenazine in schizophrenia, partially offset by lower spend due to our termination of the NBIb-1817 program in Parkinson&#8217;s disease, which became effective in August 2021.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Early Stage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consists of costs incurred for product candidates after the approval of an investigational new drug application by the applicable regulatory agency through Phase II non-registrational studies. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2022 compared to 2021, the increase in early stage expenses primarily reflected continued investment in our Phase II programs for NBI-921352 in epilepsy, luvadaxistat in schizophrenia, and NBI-1065845 and NBI-1065846 in major depressive disorder, and initiation of a Phase II program for NBI-1117568 in schizophrenia.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2021 compared to 2020, the increase in early stage expenses primarily reflected continued enrollment in our Phase II programs for NBI-827104 in EE-CSWS and essential tremor and initiation of Phase II programs for NBI-921352 in focal onset seizures and SCN8A-DEE.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Discovery.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consists of expenses incurred prior to the approval of an investigational new drug application by the applicable regulatory agency.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2022 compared to 2021, the increase in research and discovery expenses reflected continued investment in our preclinical development programs, including psychiatry, epilepsy and gene therapy programs.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2021 compared to 2020, the increase in research and discovery expenses primarily reflected a full year of investment in certain of our in-licensed preclinical psychiatry and epilepsy programs, partially offset by lower spend on our preclinical gene therapy programs.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestones.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Consist of development and regulatory milestone expenses incurred in connection with our collaborative arrangements.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we recognized milestone expenses of $30.0 million in connection with the FDA's acceptance of our investigational new drug application for NBI-1117568 in schizophrenia, $7.3 million in connection with the FDA's acceptance of our amended KAYAK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">study protocol, and $5.0 million in connection with the approval of our clinical trial application for NBI-1070770 in major depressive disorder.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we recognized milestone expense of $5.4 million in connection with the European Union&#8217;s approval of our clinical trial application for NBI-921352 in epilepsy.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we recognized milestone expense of $20.0 million in connection with the FDA&#8217;s approval of ONGENTYS for Parkinson&#8217;s disease.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Payroll and Benefits.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Consists of costs incurred for salaries and wages, payroll taxes, benefits and stock-based compensation associated with employees involved in research and development activities. Stock-based compensation may fluctuate from period to period based on factors that are not within our control, such as our stock price on the dates stock-based grants are issued.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2022 compared to 2021, the change in payroll and benefits expenses primarily reflected higher headcount, including an increase of $9.3 million in non-cash stock-based compensation expense driven by an August 2021 equity grant of approximately 0.5 million restricted stock units to our full-time employees other than our executive officers, which are vesting over a two-year period, and performance-based restricted stock units to our executive officers for which attainment of the performance-based criteria was achieved in 2022.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2021 compared to 2020, the change in payroll and benefits expenses primarily reflected higher headcount, including an increase of $14.7 million in non-cash stock-based compensation expense partially driven by a $6.4 million charge related to the modification of certain stock-based awards.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Facilities and Other.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consists of indirect costs incurred for the benefit of multiple programs, including depreciation, information technology, and other facility-based expenses, such as rent expense.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Acquired In-Process Research and Development, or IPR&amp;D.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we recognized $100.3 million of IPR&amp;D expense in connection with our payment of the upfront fee pursuant to our collaboration with Heptares Therapeutics Limited.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we recognized $46.0 million and $118.5 million, respectively, of IPR&amp;D expenses in connection with our payments of the upfront fees pursuant to our collaborations with Idorsia Pharmaceuticals Ltd. and Takeda Pharmaceutical Limited.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative, or SG&amp;A. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2022 compared to 2021, the increase in SG&amp;A expenses was primarily driven by continued investment in our commercial initiatives, including our branded direct-to-consumer INGREZZA advertising campaign launched in May 2021 and deployment of our expanded sales force in April 2022, reflecting increased payroll and benefits expenses on higher headcount, including an increase of $29.6 million in non-cash stock-based compensation expense partially driven by an August 2021 equity grant of approximately 0.5 million restricted stock units to our full-time employees other than our executive officers, which are vesting over a two-year period, and performance-based restricted stock units to our executive officers for which attainment of the performance-based criteria was achieved in 2022.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2021 compared to 2020, the increase in SG&amp;A expenses primarily reflected increased investment in support of our commercial initiatives, including the launch of our branded direct-to-consumer INGREZZA advertising campaign in May 2021, and increased payroll and benefits expenses on higher headcount, including an increase of $19.5 million in non-cash stock-based compensation expense.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Other Expense, Net.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income and other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2022 compared to 2021, the change in other expense, net, primarily reflected a debt extinguishment charge of $70.0 million in connection with the repurchase of our convertible senior notes in the second quarter of 2022, periodic fluctuations in the fair values of our equity security investments, decreased interest expense on lower total debt outstanding and the adoption of ASU 2020-06 on January 1, 2022, and higher yields on our debt security investments.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2021 compared to 2020, the change in other expense, net, primarily reflected periodic fluctuations in the fair values of our equity security investments, lower yields on our debt security investments, and a non-recurring debt extinguishment charge of $18.4 million in connection with the repurchase of our convertible senior notes in the fourth quarter of 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Provision for (Benefit from) Income Taxes.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(300.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2022, the effective tax rate varied from the federal and state statutory rates primarily due to credits generated for research activities and certain nondeductible expenses, including the premium paid on the repurchase of our convertible senior notes in the second quarter of 2022. In addition, all federal net operating loss carry forwards have been fully utilized and we began making federal estimated tax payments in 2022.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2021, the effective tax rate varied from the federal and state statutory rates primarily due to excess tax benefits associated with stock-based compensation and credits generated for research activities. In the first quarter of 2021, we began recording a provision for income taxes using an effective tax rate that approximated federal and state statutory rates. Due to our ability to offset any pre-tax income against federal net operating losses, no federal cash tax was paid in 2021.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2020, the benefit from income taxes reflected a $296.3 million benefit associated with the release of substantially all of our valuation allowance against our deferred tax assets on December 31, 2020. The effective tax rate for 2020 varied from the statutory rate primarily due to changes in our valuation allowance, net of other permanent book/tax differences, tax credits generated and impacts of changes in tax laws.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Net Income.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2022 compared to 2021, the change in net income primarily reflected increased INGREZZA net product sales, lower upfront payments for asset acquisitions, continued investment in our commercial initiatives and expanded clinical portfolio, and a debt extinguishment charge of $70.0 million in connection with the repurchase of our convertible senior notes in the second quarter of 2022.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2021 compared to 2020, the change in net income primarily reflected increased INGREZZA net product sales driven by increased total prescriptions, decreased milestone expenses in connection with certain of our collaborative arrangements, lower upfront payments for asset acquisitions, a non-recurring debt extinguishment charge of $18.4 million in connection with the repurchase of our convertible senior notes in the fourth quarter of 2020, increased investment in our commercial initiatives and expanded clinical portfolio, and a non-recurring benefit of $296.3 million in 2020 resulting from the release of substantially all of our valuation allowance against our deferred tax assets on December 31, 2020.</span></div><div id="id795223301944418ba8c3fb3bc02f08e_91"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing capital resources, funds generated by anticipated INGREZZA net product sales and investment income will be sufficient to satisfy our current and projected funding requirements for at least the next 12&#160;months. However, we cannot guarantee that our existing capital resources and anticipated revenues will be sufficient to conduct and complete all of our research and development programs or commercialization activities as planned. We may seek to access the public or private equity markets whenever conditions are favorable or pursue opportunities to obtain additional debt financing in the future. We may also seek additional funding through strategic alliances or other financing mechanisms. However, we cannot provide assurance that adequate funding will be available on terms acceptable to us, if at all. In addition, the disruption of global financial markets caused by the COVID-19 pandemic, if sustained or recurrent, could make it more difficult for us to access capital, which could in the future negatively affect our liquidity.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Information Regarding Our Financial Condition.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and marketable securities</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working Capital:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,453.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">972.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total working capital</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Information Regarding Our Cash Flows.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(130.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Operating Activities.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2022 compared to 2021, the change in cash flows from operating activities primarily reflected increased INGREZZA net product sales, lower upfront payments for asset acquisitions, and continued investment in our commercial initiatives and expanded clinical portfolio. In addition, we experienced an increase in accounts receivable driven by increased INGREZZA net product sales on extended customer payment terms attributed to the expansion of our distribution network at the end of 2021 and an increase in accrued liabilities driven by increased revenue-related reserves for discounts and allowances on higher INGREZZA net product sales and the timing of payments.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2021 compared to 2020, the change in cash flows from operating activities primarily reflected increased INGREZZA net product sales, lower upfront payments for asset acquisitions, lower milestone payments in connection with certain of our collaborative arrangements, and increased investment in our commercial initiatives and expanded clinical portfolio.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Investing Activities.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2022 compared to 2021, the change in cash flows from investing activities primarily reflected our acquisition of Diurnal in November 2022 for $42.7 million in cash, which is net of cash acquired, timing differences in the purchases, sales, and maturities of our marketable security investments, and a $7.7 million equity investment in Xenon associated with the FDA&#8217;s acceptance of our amended KAYAK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">study protocol.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2021 compared to 2020, the change in cash flows from investing activities primarily reflected timing differences in the purchases, sales, and maturities of our marketable security investments and a $4.6 million equity investment in Xenon associated with the European Union&#8217;s approval of our clinical trial application for NBI-921352 in focal onset seizures.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Financing Activities.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2022 compared to 2021,  the change in cash flows from financing activities primarily reflected the repurchase of $210.8 million aggregate principal amount of our convertible senior notes for an aggregate repurchase price of $279.0 million in cash in the second quarter of 2022 and increased proceeds from issuances of our common stock under benefit plans.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2021 compared to 2020, the change in cash flows from financing activities primarily reflected the non-recurring repurchase of $136.2 million aggregate principal amount of our convertible senior notes for an aggregate repurchase price of $186.9 million in cash in the fourth quarter of 2020.</span></div><div id="id795223301944418ba8c3fb3bc02f08e_94"></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Material Cash Requirements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the pharmaceutical industry, it can take a significant amount of time and capital resources to successfully complete all stages of research and development and commercialize a product candidate, which ultimate length of time and spend required cannot be accurately estimated as it varies substantially according to the type, complexity, novelty and intended use of a product candidate. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The funding necessary to execute our business strategies is subject to numerous uncertainties and we may be required to make substantial expenditures if unforeseen difficulties arise in certain areas of our business. In particular, our future capital requirements will depend on many factors, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the commercial success of INGREZZA, ONGENTYS, ORILISSA, ORIAHNN and/or DYSVAL;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued scientific progress in our research and clinical development programs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the magnitude and complexity of our research and development programs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">progress with preclinical testing and clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and costs involved in obtaining regulatory approvals;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of commercialization activities and arrangements, including our advertising campaigns;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing of our product candidates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in filing and pursuing patent applications, enforcing patent claims, or engaging in interference proceedings or other patent litigation;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competing technological and market developments;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments related to any future litigation; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the COVID-19 pandemic on our business.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the foregoing factors, we have significant future capital requirements, including:</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">External Business Developments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our independent efforts to develop and market products, we may enter into collaboration and license agreements or acquire businesses from time-to-time to enhance our drug development and commercial capabilities. With respect to our existing collaboration and license agreements, we may be required to make potential future payments of up to $10.8 billion upon the achievement of certain event-based milestones. Refer to Note 2 to the consolidated financial statements for more information on our significant collaboration and license agreements.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2022, we acquired Diurnal in an all-cash transaction, for an aggregate value of $55.2&#160;million to accelerate the establishment of our clinical development and commercial capabilities in the United Kingdom to the benefit of patient communities and other stakeholders. Refer to Note 3 to the consolidated financial statements for more information on our acquisition of Diurnal.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2023, we entered into a new strategic collaboration with Voyager, under which we agreed to pay Voyager $175 million upfront, including a $39 million equity investment, to acquire the worldwide rights to Voyager&#8217;s GBA1 gene therapy program for Parkinson&#8217;s disease and other GBA1-mediated diseases and three gene therapy programs directed to rare central nervous system targets, each enabled by Voyager&#8217;s next-generation TRACER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> capsids. The effectiveness of the collaboration agreement and the closing of the sale and issuance of Voyager common stock are expected to be completed prior to the end of the first quarter of 2023 and are subject to certain conditions including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and other customary closing conditions.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Senior Notes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;2, 2017, we completed a private placement of $517.5 million in aggregate principal amount of 2.25% fixed-rated convertible senior notes due May&#160;15, 2024, or the 2024 Notes. In the fourth quarter of 2020 and second quarter of 2022, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $136.2 million and $210.8 million, respectively, aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9 million and $279.0 million, respectively, in cash. As of December&#160;31, 2022, $170.4 million aggregate principal amount of the 2024 Notes remained outstanding.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At our election, we may redeem all or any portion of the 2024 Notes under certain circumstances. Further, as the conditional conversion feature of the 2024 Notes was triggered as of December 31, 2022, holders of the 2024 Notes may convert the 2024 Notes at any time during the period beginning on January 1, 2023, and ending at the close of business on March 31, 2023. With respect to the 2024 Notes, unless earlier converted, redeemed, or repurchased, we would be required to pay interest of $3.8 million in 2023 and $1.9 million in 2024 and pay the aggregate principal amount outstanding of $170.4 million upon maturity of the 2024 Notes.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by us. There are customary events of default with respect to the 2024 Notes, including that upon certain events of default, 100% of the principal and accrued and unpaid interest on the notes would become due and payable.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 6 to the consolidated financial statements for more information on the 2024 Notes.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating leases that have commenced have terms that expire beginning 2024 through 2031 and consist of office space and research and development laboratories, including our corporate headquarters. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;8, 2022, we entered into a lease agreement for a four-building campus facility to be constructed in San Diego, California, pursuant to which we also secured a six-year option for the construction of a fifth building and an option to purchase the entire campus facility, which will consist of office space and research and development laboratories, in the future. Upon completion of construction, we expect to utilize the campus facility as our new corporate headquarters and expect to begin subleasing our existing leased facilities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 12 to the consolidated financial statements for more information on our leases, including a presentation of our approximate future minimum lease payments under non-cancelable operating leases.</span></div><div id="id795223301944418ba8c3fb3bc02f08e_97"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our discussion and analysis of our financial condition and results of operations is based upon financial statements that we have prepared in accordance with accounting principles generally accepted in the United&#160;States of America, or GAAP. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses, and related disclosures. On an on-going basis, we evaluate these estimates, including those related to revenue recognition. Estimates are based on historical experience, information received from third parties and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. Historically, revisions to our estimates have not resulted in a material change to the financial statements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The items in our financial statements requiring significant estimates and judgments are as follows:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, payors and other third parties. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Rebates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to pay rebates for mandated discounts under the Medicaid Drug Rebate Program. The liability for such rebates consists of invoices received for claims from prior quarters that remain unpaid, or for which an invoice has not been received, and estimated rebates for the current applicable reporting period, which are primarily based on actual historical rebates, estimated payor mix, state and federal regulations and related contractual terms. Estimated rebates are recorded as a reduction of revenue in the period the related sale is recognized. To date, actual government rebates have not differed materially from our estimates.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax provision is computed under the asset and liability method. Significant estimates are required in determining our income tax provision. Some of these estimates are based on interpretations of existing tax laws or regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our income tax provision in the period of such reversal. On December 31, 2020, based on our evaluation of various factors, such as our achievement of a cumulative three-year income position as of December 31, 2020, as well as our consideration of forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration, we released substantially all of our valuation allowance against our deferred tax assets and recorded a corresponding income tax benefit. We continue to maintain a valuation allowance against our California state deferred tax assets.</span></div><div id="id795223301944418ba8c3fb3bc02f08e_100"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Additional Information</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 1 to the consolidated financial statements for information on accounting pronouncements that have impacted or are expected to materially impact our consolidated financial condition, results of operations, or cash flows.</span></div><div id="id795223301944418ba8c3fb3bc02f08e_103"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 7A. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to interest rate risk on our short-term investments. The primary objective of our investment activities is to preserve principal while at the same time maximizing yields without significantly increasing risk. To achieve this objective, we invest in highly liquid and high-quality government and other debt securities. To minimize our exposure due to adverse shifts in interest rates, we invest in short-term securities and ensure that the maximum average maturity of our investments does not exceed 12 months. If a 1% change in interest rates were to have occurred on December&#160;31, 2022, this change would not have had a material effect on the fair value of our investment portfolio as of that date. Due to the short holding period of our investments, we have concluded that we do not have a material financial market risk exposure.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><div id="id795223301944418ba8c3fb3bc02f08e_106"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;8. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Financial Statements and Supplementary Data</span></div><div id="id795223301944418ba8c3fb3bc02f08e_109"></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.509%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id795223301944418ba8c3fb3bc02f08e_112">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (PCAOB ID: <ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMDkvZnJhZzowZDE5OWE4YzRjMDU0M2UyODViZDI1OTg0M2M5ZmI1MC90YWJsZTowZDJiNjllY2VmYjI0YmM3ODc3NjliYTI4OGQ3MzZkMC90YWJsZXJhbmdlOjBkMmI2OWVjZWZiMjRiYzc4Nzc2OWJhMjg4ZDczNmQwXzEtMC0xLTEtMTM5MDYyL3RleHRyZWdpb246OTUxMDc2ODE0Nzk1NDQ0Njg4ZWY3NTE4YjU5YzRkNGNfNzE_c888568b-b882-4487-83f9-96db3a167cf1">42</ix:nonNumeric>)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id795223301944418ba8c3fb3bc02f08e_112">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id795223301944418ba8c3fb3bc02f08e_115">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id795223301944418ba8c3fb3bc02f08e_115">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id795223301944418ba8c3fb3bc02f08e_118">Consolidated Statements of Income and Comprehensive Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id795223301944418ba8c3fb3bc02f08e_118">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id795223301944418ba8c3fb3bc02f08e_121">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id795223301944418ba8c3fb3bc02f08e_121">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id795223301944418ba8c3fb3bc02f08e_124">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id795223301944418ba8c3fb3bc02f08e_124">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id795223301944418ba8c3fb3bc02f08e_127">Notes to the Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id795223301944418ba8c3fb3bc02f08e_127">70</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><div id="id795223301944418ba8c3fb3bc02f08e_112"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">To the Stockholders and the Board of Directors of Neurocrine Biosciences, Inc.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Neurocrine Biosciences, Inc. (the &#8220;Company&#8221;) as of December 31, 2022 and 2021, the related consolidated statements of income and comprehensive income, stockholders&#8217; equity, and cash flows for each of the three years in the period ended December 31, 2022, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February&#160;9, 2023 expressed an unqualified opinion thereon.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of ASU No. 2020-06</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 1 to the consolidated financial statements, the Company changed its method of accounting for convertible debt instruments as a result of the adoption of Accounting Standards Update (ASU) No. 2020-06, Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40), effective January 1, 2022.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below providing a separate opinion on the critical audit matter or on the account or disclosure to which it relates.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.394%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Reserves for government rebates related to product sales</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells drugs to specialty pharmacies and specialty distributors in the US (collectively, &#8220;customers&#8221;). As described in Note 1 to the consolidated financial statements, the Company recognizes revenues for sales of INGREZZA to its customers after deducting management&#8217;s estimates of reserves, including drug coverage gap rebates, it will provide under government rebate programs (&#8220;government rebates&#8221;). Estimated government rebates are presented within accounts payable and accrued liabilities on the consolidated balance sheet.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing the estimates of government rebates was complex and judgmental due to the level of uncertainty involved in management&#8217;s assumptions used in the measurement process. In particular, management was required to estimate, for product that remains in the distribution channel at December 31, 2022, the portion of product that is expected to be subject to a government rebate and the applicable contractual government rebate percentage by payor type underlying the revenue and the applicable rebate amount applicable for the payor type.</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.394%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We tested the Company&#8217;s internal controls over management&#8217;s process for estimating the portion of product that is expected to be subject to a government rebate for product that remains in the distribution channel at December 31, 2022. This included controls over management&#8217;s review of significant assumptions and other inputs into the estimation of government rebates including the accuracy of data used in the calculation.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To test management&#8217;s estimate of government rebate reserves our audit procedures included, among others, evaluating the methodologies used, testing the significant assumptions discussed above and testing the completeness and accuracy of the underlying data used by the Company in its analyses. Specifically, we compared the significant assumptions to third-party reports used by the Company to estimate product remaining in the distribution channel at December 31, 2022. In addition, we compared the underlying government rebate percentages used in the Company&#8217;s analyses to those published by the applicable government entity.  We assessed the historical accuracy of management&#8217;s rebate estimates, tested payments of rebates and performed a sensitivity analysis of significant assumptions to evaluate the changes in the rebate allowance that would result from changes in the assumptions.</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTIvZnJhZzo5YTY3NzcxNWZlODc0ODUwOTFhZThkYTZiZWQxNzMxNi90ZXh0cmVnaW9uOjlhNjc3NzE1ZmU4NzQ4NTA5MWFlOGRhNmJlZDE3MzE2XzEwOTk1MTE2NDI0MDc_28a766d5-ea66-46dc-af80-7e65ade0866b">Ernst&#160;&amp; Young LLP</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 1992.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTIvZnJhZzo5YTY3NzcxNWZlODc0ODUwOTFhZThkYTZiZWQxNzMxNi90ZXh0cmVnaW9uOjlhNjc3NzE1ZmU4NzQ4NTA5MWFlOGRhNmJlZDE3MzE2XzEwOTk1MTE2NDI0MDg_74c79d34-3603-402b-9571-20b89c49e93c">San Diego, California</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;9, 2023</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="id795223301944418ba8c3fb3bc02f08e_115"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzQtMS0xLTEtMTM5MDYy_7d88d2a6-a63b-4a40-b443-388987a05f81">262.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzQtMy0xLTEtMTM5MDYy_420e945e-8ce5-4036-ba01-4eb04d60a18d">340.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzUtMS0xLTEtMTM5MDYy_5c7a6eff-8cfe-4e30-813c-d3f88363beef">726.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzUtMy0xLTEtMTM5MDYy_57479d49-d19b-4f70-ab6e-1928400ba4da">370.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzYtMS0xLTEtMTM5MDYy_ece3759d-e9f4-4ce8-b865-a1334aa80186">350.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzYtMy0xLTEtMTM5MDYy_c5e56e86-de51-4b7a-b363-667236182ee7">185.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzctMS0xLTEtMTM5MDYy_66d6b95d-0946-4546-bacf-3ec65405303e">35.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzctMy0xLTEtMTM5MDYy_517095fa-3e65-4714-90d4-a6f687a328a9">30.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzgtMS0xLTEtMTM5MDYy_d465a0d4-8b65-43e3-a937-925b84a10fb3">79.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzgtMy0xLTEtMTM5MDYy_5e207fe6-6c06-4a1f-85ec-d2589e7d3851">45.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzktMS0xLTEtMTM5MDYy_0305e29e-7114-4537-ae8f-97d29b580fac">1,453.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzktMy0xLTEtMTM5MDYy_00417097-878c-4f2d-936b-6b0182497258">972.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzEwLTEtMS0xLTEzOTA2Mg_2431415e-0029-4217-8fd4-bd7165650d61">305.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzEwLTMtMS0xLTEzOTA2Mg_b420578d-dd8e-46dc-a1d9-dc9a2f933d87">315.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzExLTEtMS0xLTEzOTA2Mg_460f7283-0cb9-4640-9498-68db8de69e85">299.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzExLTMtMS0xLTEzOTA2Mg_0af6b5f8-408b-44a8-88bf-0962a150d5ee">560.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzEyLTEtMS0xLTEzOTA2Mg_13a653a3-735a-4a4f-97cc-3fe2aa60f203">87.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzEyLTMtMS0xLTEzOTA2Mg_391f4017-f2b7-4885-89b5-5e15d478cb06">97.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzEzLTEtMS0xLTEzOTA2Mg_c2af92ee-03b2-46f7-ad21-8648926ef58b">102.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzEzLTMtMS0xLTEzOTA2Mg_bd0d83ed-0c22-434d-9726-83b6621088e9">63.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzE0LTEtMS0xLTEzOTA2Mg_15e8ba2b-02ff-4ac7-b91a-e17448ceda32">58.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzE0LTMtMS0xLTEzOTA2Mg_c785f941-d105-40d0-afbd-7278fe5ddde7">58.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzE1LTEtMS0xLTE1OTY3NQ_2d3a99c7-0b72-45e1-b112-538dbe4bc0f2">37.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzE1LTMtMS0xLTE1OTY3NQ_41b22751-79b4-459e-89f6-23d1ea66d57d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzE1LTEtMS0xLTEzOTA2Mg_a8edbf62-615e-4078-a024-0ec3c10f3dc8">25.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzE1LTMtMS0xLTEzOTA2Mg_7eae4173-d1b3-4c6c-aa96-d256f6ed186b">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzE2LTEtMS0xLTEzOTA2Mg_18ac2bf0-ad6a-415e-81bc-cb085fa63a08">2,368.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzE2LTMtMS0xLTEzOTA2Mg_07964962-98e0-4c48-b84b-3b76295feeab">2,072.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzIwLTEtMS0xLTEzOTA2Mg_34001b47-8ec6-475f-a2f1-6b6190dd3b73">347.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzIwLTMtMS0xLTEzOTA2Mg_123640a5-8dc6-4b73-9405-670cbe78784d">225.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:ConvertibleDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzIxLTEtMS0xLTEzOTA2Mg_06d87f8d-6243-4452-a794-511d94d1b6c7">169.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:ConvertibleDebtCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzIxLTMtMS0xLTEzOTA2Mg_f174bf38-c128-4306-a93d-910bbfbb15b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzIyLTEtMS0xLTEzOTA2Mg_15da109b-bdb3-4969-b684-7ac6c1486cbd">20.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzIyLTMtMS0xLTEzOTA2Mg_941b8a84-9e9b-4ae2-8f4e-085e739c349d">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzIzLTEtMS0xLTEzOTA2Mg_f88f82ff-4a9b-4ad0-9015-257b2a80f8a2">537.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzIzLTMtMS0xLTEzOTA2Mg_1da9b122-b111-438d-8416-09e80cfd2c6b">245.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzI0LTEtMS0xLTEzOTA2Mg_f33ef9ba-7a8e-4332-9ea7-86b5cb90ed70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:ConvertibleDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzI0LTMtMS0xLTEzOTA2Mg_f1146f79-daec-40ff-876c-66bf23e15a94">335.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzI1LTEtMS0xLTEzOTA2Mg_4c4e08e1-2fba-43b0-b965-2083f5563d33">93.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzI1LTMtMS0xLTEzOTA2Mg_b1cd2be5-4c30-40ce-85d0-91e4189cea07">105.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzI2LTEtMS0xLTEzOTA2Mg_8a8ad718-44d3-44fe-980b-c8501b5a9a41">29.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzI2LTMtMS0xLTEzOTA2Mg_8f10b4a0-e19c-4ea0-b7c7-bf7226d2b01f">12.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzI3LTEtMS0xLTEzOTA2Mg_a5f987ac-3cc8-4c57-a210-2b5a8880a0e8">660.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzI3LTMtMS0xLTEzOTA2Mg_957ed284-c779-4da4-870b-a7d1321b2e96">698.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:14.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMwLTAtMS0xLTEzOTA2Mi90ZXh0cmVnaW9uOmM4N2YxZTIzMmM0MTRjYzg4MWI0NGE2NmU5MDZkMTAxXzIy_21cc254e-8df2-427d-83c4-6a60e2a301d5"><ix:nonFraction unitRef="usdPerShare" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMwLTAtMS0xLTEzOTA2Mi90ZXh0cmVnaW9uOmM4N2YxZTIzMmM0MTRjYzg4MWI0NGE2NmU5MDZkMTAxXzIy_73056a57-c295-458d-bf8e-b040efdf0284">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMwLTAtMS0xLTEzOTA2Mi90ZXh0cmVnaW9uOmM4N2YxZTIzMmM0MTRjYzg4MWI0NGE2NmU5MDZkMTAxXzM2_04cb343c-613e-4f03-aedf-5997c1ecd347"><ix:nonFraction unitRef="shares" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMwLTAtMS0xLTEzOTA2Mi90ZXh0cmVnaW9uOmM4N2YxZTIzMmM0MTRjYzg4MWI0NGE2NmU5MDZkMTAxXzM2_a8406b56-e4e1-415a-847f-3a7a047c1549">5.0</ix:nonFraction></ix:nonFraction> million shares authorized; <ix:nonFraction unitRef="shares" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMwLTAtMS0xLTEzOTA2Mi90ZXh0cmVnaW9uOmM4N2YxZTIzMmM0MTRjYzg4MWI0NGE2NmU5MDZkMTAxXzU4_af32f3e6-1c2f-43ff-a474-8cc1bdc22956"><ix:nonFraction unitRef="shares" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMwLTAtMS0xLTEzOTA2Mi90ZXh0cmVnaW9uOmM4N2YxZTIzMmM0MTRjYzg4MWI0NGE2NmU5MDZkMTAxXzU4_cef4a5ff-c60d-4fef-8ee3-956b2f6cf355"><ix:nonFraction unitRef="shares" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMwLTAtMS0xLTEzOTA2Mi90ZXh0cmVnaW9uOmM4N2YxZTIzMmM0MTRjYzg4MWI0NGE2NmU5MDZkMTAxXzU4_d1f7e0ba-fc20-4faf-a595-c51425ffc68b"><ix:nonFraction unitRef="shares" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMwLTAtMS0xLTEzOTA2Mi90ZXh0cmVnaW9uOmM4N2YxZTIzMmM0MTRjYzg4MWI0NGE2NmU5MDZkMTAxXzU4_fad599ca-9be9-4664-8cbf-d796725aef8a">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMwLTEtMS0xLTEzOTA2Mg_74dcc676-231a-4507-ad6e-d18964209501">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMwLTMtMS0xLTEzOTA2Mg_396fc95e-076d-45df-a549-932fbc7bad13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:14.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMxLTAtMS0xLTEzOTA2Mi90ZXh0cmVnaW9uOjE1ZWNhZGNhOGVhMjQ0MTk4N2EwYjk1YmEyOGRmMDQ5XzE5_bad1a00e-f1c3-487d-869d-c048dadd7d9d"><ix:nonFraction unitRef="usdPerShare" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMxLTAtMS0xLTEzOTA2Mi90ZXh0cmVnaW9uOjE1ZWNhZGNhOGVhMjQ0MTk4N2EwYjk1YmEyOGRmMDQ5XzE5_fd07d181-0054-448e-bdce-9e83210e14c2">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMxLTAtMS0xLTEzOTA2Mi90ZXh0cmVnaW9uOjE1ZWNhZGNhOGVhMjQ0MTk4N2EwYjk1YmEyOGRmMDQ5XzMz_17f74f47-8cd2-482c-aa40-72c0c24c074c"><ix:nonFraction unitRef="shares" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMxLTAtMS0xLTEzOTA2Mi90ZXh0cmVnaW9uOjE1ZWNhZGNhOGVhMjQ0MTk4N2EwYjk1YmEyOGRmMDQ5XzMz_78514a11-03a4-4a46-b044-37b6c698f524">220.0</ix:nonFraction></ix:nonFraction> million shares authorized; <ix:nonFraction unitRef="shares" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMxLTAtMS0xLTEzOTA2Mi90ZXh0cmVnaW9uOjE1ZWNhZGNhOGVhMjQ0MTk4N2EwYjk1YmEyOGRmMDQ5XzU1_c3a04999-0521-433d-be22-11ee2860050f"><ix:nonFraction unitRef="shares" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMxLTAtMS0xLTEzOTA2Mi90ZXh0cmVnaW9uOjE1ZWNhZGNhOGVhMjQ0MTk4N2EwYjk1YmEyOGRmMDQ5XzU1_f3f8661c-ed58-4931-9b51-a79d4c0100ab">96.5</ix:nonFraction></ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMxLTAtMS0xLTEzOTA2Mi90ZXh0cmVnaW9uOjE1ZWNhZGNhOGVhMjQ0MTk4N2EwYjk1YmEyOGRmMDQ5XzYy_332052f9-f5bf-46d6-9b63-124ff967bd4a"><ix:nonFraction unitRef="shares" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMxLTAtMS0xLTEzOTA2Mi90ZXh0cmVnaW9uOjE1ZWNhZGNhOGVhMjQ0MTk4N2EwYjk1YmEyOGRmMDQ5XzYy_9ec3e64f-6523-44f8-b07f-b3b0f18603dc">94.9</ix:nonFraction></ix:nonFraction> million shares issued and outstanding, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMxLTEtMS0xLTEzOTA2Mg_ba281561-1b27-4083-ab00-f4e56f8b4ebf">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMxLTMtMS0xLTEzOTA2Mg_79e5e9b8-d8cc-4b2b-bc8a-90f0401b5565">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMyLTEtMS0xLTEzOTA2Mg_609a0e6b-6d56-43a6-b895-582a6edee966">2,122.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMyLTMtMS0xLTEzOTA2Mg_7c2e2a72-7ff5-4142-8445-a7eddf2eaae2">2,011.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMzLTEtMS0xLTEzOTA2Mg_909f568e-007b-4b96-8adf-62562f1c8686">7.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMzLTMtMS0xLTEzOTA2Mg_5cc81d9c-61dd-4060-92db-ba9d638733b4">1.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzM0LTEtMS0xLTEzOTA2Mg_dcde9ced-d4ed-4520-8cbb-a92680738a08">406.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzM0LTMtMS0xLTEzOTA2Mg_aa7848b1-bd99-4372-ae2b-bb374d67353d">635.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzM1LTEtMS0xLTEzOTA2Mg_f35d34e8-762e-4ac4-92c2-4672df479068">1,707.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzM1LTMtMS0xLTEzOTA2Mg_830b272e-4a42-4c9b-84b5-b9ab9d660a7d">1,374.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzM2LTEtMS0xLTEzOTA2Mg_d1a56d1e-3040-468e-9a12-aecf45951e94">2,368.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzM2LTMtMS0xLTEzOTA2Mg_831b67e4-1b84-4224-b7c8-e67d11065fd6">2,072.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="id795223301944418ba8c3fb3bc02f08e_118"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AND COMPREHENSIVE INCOME</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product sales, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc4cf231a09409ca4f633d2a52d1059_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzMtMS0xLTEtMTM5MDYy_f30af27e-ed42-41b7-b440-514b36bc5c11">1,440.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib02b2e314d9843b6beb8c5b163f3331b_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzMtMy0xLTEtMTM5MDYy_d5366caa-9132-46c4-9ab5-ffdb2171cb02">1,090.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieadd249b6bd54f3f882b31ca68b01cd6_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzMtNS0xLTEtMTM5MDYy_6de3df9a-2c06-4342-a186-401a122417c0">994.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i639fef176a3f4b5ca32c8c373750fe46_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzQtMS0xLTEtMTM5MDYy_9bbf3b2b-a317-43b4-94be-ae06c4b87288">47.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3a57832bc8048d593cd85c6dc2a6362_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzQtMy0xLTEtMTM5MDYy_6b3b6ca5-a4aa-4eae-9c3a-6a67c9eadb2f">43.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e4c87aa559406d86302c9502431650_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzQtNS0xLTEtMTM5MDYy_a230a769-1305-4a9e-b630-bb97ff98f225">51.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzUtMS0xLTEtMTM5MDYy_5b0b9a15-7eaf-4219-856a-78f21e6399de">1,488.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzUtMy0xLTEtMTM5MDYy_b8bf14fe-673d-49aa-83bd-efcf4e86c404">1,133.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzUtNS0xLTEtMTM5MDYy_467e0cc5-1958-4695-be88-271b271c38e5">1,045.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzctMS0xLTEtMTM5MDYy_268bf74a-eabd-443a-ae34-42c712bf2b9e">23.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzctMy0xLTEtMTM5MDYy_1cadd107-6ead-4a23-8478-688ffd1d9918">14.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzctNS0xLTEtMTM5MDYy_94d9a669-bdfe-4506-beb6-bcb4c1031c02">10.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzgtMS0xLTEtMTM5MDYy_5a9120b2-1841-4f74-a80c-5f8d7f603ed6">463.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzgtMy0xLTEtMTM5MDYy_b638a411-6b2c-4c3b-90b3-48931b4283ea">328.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzgtNS0xLTEtMTM5MDYy_0ff13715-af8a-4434-ab66-3674855b5ec2">275.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzktMS0xLTEtMTM5MDYy_738d76a6-550d-4d26-bdb3-ed30fb0b9a75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzktMy0xLTEtMTM5MDYy_747c2aa8-9ffe-4eef-b4e0-924337bc4c90">105.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzktNS0xLTEtMTM5MDYy_ddb3a0e8-f4a5-491f-86da-a05910a23b53">164.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzEwLTEtMS0xLTEzOTA2Mg_f824d1be-6688-435a-84e1-c21fa91b7523">752.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzEwLTMtMS0xLTEzOTA2Mg_c1c6d886-4ce6-4e55-8f68-bb5d95595d5a">583.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzEwLTUtMS0xLTEzOTA2Mg_424b59df-e3db-435f-83a0-925e5371f7fa">433.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzExLTEtMS0xLTEzOTA2Mg_c36fd5d8-4a48-4fc8-b4da-c4d4bdc0ee41">1,239.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzExLTMtMS0xLTEzOTA2Mg_6e27c5b6-5aba-4f02-be80-bf7feee68851">1,031.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzExLTUtMS0xLTEzOTA2Mg_28e25748-9ce7-42e7-8173-5da14ad4a36f">882.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzEyLTEtMS0xLTEzOTA2Mg_d410cba1-beed-4fc1-93e5-c6156fb77215">249.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzEyLTMtMS0xLTEzOTA2Mg_7eea631e-69d7-4fd7-a7c3-62efda208246">102.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzEyLTUtMS0xLTEzOTA2Mg_21cffb17-8028-4157-8800-1acaf7ca5a09">163.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (expense) income: </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzE0LTEtMS0xLTEzOTA2Mg_b8483a90-19fa-48d6-af3a-6d00bf4d7d4c">7.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzE0LTMtMS0xLTEzOTA2Mg_eaee69d6-15b9-414d-bceb-11e7031bc76f">25.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzE0LTUtMS0xLTEzOTA2Mg_c0974d9b-5e66-4284-9e1f-4b68f1b40e6f">32.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain (loss) on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzE1LTEtMS0xLTEzOTA2Mg_f143cb61-9d78-435d-b765-096135e8495f">30.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzE1LTMtMS0xLTEzOTA2Mg_0eb43425-7811-46ed-a21b-36b559fe539a">20.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzE1LTUtMS0xLTEzOTA2Mg_dd83d60c-1638-4953-a8a0-b525710f626e">17.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzE2LTEtMS0xLTEzOTA2Mg_ec9f7e1d-c2bc-4e95-a6b5-62494f218ea4">70.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzE2LTMtMS0xLTEzOTA2Mg_eec6223a-211c-440d-9ace-e344a32ed4a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzE2LTUtMS0xLTEzOTA2Mg_74d3c9af-e985-413a-b619-8fcd71c48424">18.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment income and other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="nbix:InvestmentIncomeAndOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzE3LTEtMS0xLTEzOTA2Mg_8efa2674-7ad3-43f4-8b48-273ba8cfa093">11.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="nbix:InvestmentIncomeAndOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzE3LTMtMS0xLTEzOTA2Mg_2469bf01-8d10-4dfc-b4e7-61ea74be81ca">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="nbix:InvestmentIncomeAndOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzE3LTUtMS0xLTEzOTA2Mg_094aa4df-8395-469f-a8b8-4787068878ab">12.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzE4LTEtMS0xLTEzOTA2Mg_b6448f16-5a73-498c-a07c-8473a173fd95">35.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzE4LTMtMS0xLTEzOTA2Mg_e73834e5-b790-4198-940d-6d58efee42aa">1.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzE4LTUtMS0xLTEzOTA2Mg_85988397-60a9-4bf8-8736-00400bd3ada6">56.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before provision for (benefit from) income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzE5LTEtMS0xLTEzOTA2Mg_49fe5997-d12a-4295-8638-4a9b1dd02c41">213.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzE5LTMtMS0xLTEzOTA2Mg_59bf6390-5d42-4945-b432-6edf1f7671b6">101.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzE5LTUtMS0xLTEzOTA2Mg_1bf9fd98-32ce-452d-b9e7-0547ad49f911">106.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzIwLTEtMS0xLTEzOTA2Mg_5040c680-3725-4528-8446-4e64d4d42291">59.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzIwLTMtMS0xLTEzOTA2Mg_7753ed81-d031-471b-99ec-7cc54f313ccf">11.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzIwLTUtMS0xLTEzOTA2Mg_cb3d7e03-e08d-44a9-b871-22f4a438f275">300.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzIxLTEtMS0xLTEzOTA2Mg_9bd0d171-904d-45de-8d6b-84402cc9d6da">154.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzIxLTMtMS0xLTEzOTA2Mg_c64a57e9-11a3-4c67-8b0e-6664bbfc6058">89.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzIxLTUtMS0xLTEzOTA2Mg_7f691186-d086-4293-945a-b6caa0a58729">407.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzIyLTEtMS0xLTE1NDk0OA_91de403b-5ca8-4f66-b4ae-afbddbafdf59">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzIyLTMtMS0xLTE1NDk1NQ_fe521fab-5ae4-4e2f-af9f-d4cbb3f4ffb5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzIyLTUtMS0xLTE1NDk1OQ_e48a355e-6025-40fe-8841-7118aadb5e9b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized (loss) gain on debt securities available-for-sale, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzIyLTEtMS0xLTEzOTA2Mg_211d682f-50b7-4e1e-992c-b7b7eef13dd6">9.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzIyLTMtMS0xLTEzOTA2Mg_aa05c4e2-20de-45ff-bae9-023a4183c00d">3.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzIyLTUtMS0xLTEzOTA2Mg_363ac106-029f-4d96-8bc0-ed8323a83a52">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzIzLTEtMS0xLTEzOTA2Mg_3934fa46-df99-4573-b56f-b45810690655">148.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzIzLTMtMS0xLTEzOTA2Mg_c4f7a149-5d15-4e8c-9319-4dc24c2255cb">86.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzIzLTUtMS0xLTEzOTA2Mg_c0bdfeb3-b842-4c97-9c40-35e2ec6c98ce">407.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per share, basic</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzI0LTEtMS0xLTEzOTA2Mg_9064c675-4e97-4adf-b9dd-cf61acec71ba">1.61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzI0LTMtMS0xLTEzOTA2Mg_93d441bd-4cae-43be-8fe4-bef6e6300a6c">0.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzI0LTUtMS0xLTEzOTA2Mg_072a1952-0bdc-44a6-b6ea-4072420e4406">4.38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per share, diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzI1LTEtMS0xLTEzOTA2Mg_8928e5d4-698c-4378-8bf5-83345173c666">1.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzI1LTMtMS0xLTEzOTA2Mg_04095a57-8df9-4fac-a608-464178dd13be">0.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzI1LTUtMS0xLTEzOTA2Mg_51b183cd-dc26-481a-8af2-16aef2767941">4.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzI2LTEtMS0xLTEzOTA2Mg_6bbfb488-0fc2-4a55-81cb-d5edb09ec681">95.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzI2LTMtMS0xLTEzOTA2Mg_5edf2d70-4720-49d4-b207-775af8225833">94.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzI2LTUtMS0xLTEzOTA2Mg_1f62954e-f575-4d25-b9b3-96ed26a018b5">93.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzI3LTEtMS0xLTEzOTA2Mg_7621b5b2-3226-47c7-9698-6f24388a692e">98.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzI3LTMtMS0xLTEzOTA2Mg_b5845dc5-95cc-4086-a30a-a0281eb367e1">97.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzI3LTUtMS0xLTEzOTA2Mg_e53aff8f-ad04-4c40-abb8-b6b8325e6259">97.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="id795223301944418ba8c3fb3bc02f08e_121"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.316%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.281%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Income (Loss) </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5487fc19d1994eb39121318350a3e13a_I20191231" decimals="INF" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzItMS0xLTEtMTM5MDYy_0338f6d5-bfe9-496a-8748-dfd4cd3ba422">92.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5487fc19d1994eb39121318350a3e13a_I20191231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzItMy0xLTEtMTM5MDYy_2b980438-5245-41d2-9ffa-844ee4941425">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0742d6ae0d04338b0b3b537053da2dd_I20191231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzItNS0xLTEtMTM5MDYy_ae1a34fb-49c0-4fd4-81e8-6552ba05f8ca">1,768.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925cca476463400d82eec5ed1c25941d_I20191231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzItNy0xLTEtMTM5MDYy_53a3883a-b83b-4dae-9343-e8e6ef0adb17">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a17ccdbf08849ba857638d5a36314ed_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzItOS0xLTEtMTM5MDYy_565dc8fd-39e2-414c-ba98-7c391fc0a27c">1,132.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9e7a539304246b48b58f35e4a888e14_I20191231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzItMTEtMS0xLTEzOTA2Mg_0b946f47-f9d5-4882-87d6-f5388054436b">636.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9a3f2cd6f5941a6bcecb7ae1f54d627_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzMtOS0xLTEtMTM5MDYy_788d83aa-b1c7-4506-958a-6b20047207a7">407.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzMtMTEtMS0xLTEzOTA2Mg_49de1a07-83ec-4f64-91f0-314cdde487da">407.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fe0390d99064b149bfb4f7d84cd1ab2_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzQtNy0xLTEtMTM5MDYy_27de39f8-805b-4791-9533-4d9e303fa689">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzQtMTEtMS0xLTEzOTA2Mg_be379a94-2cd7-4dd0-9f2f-8af733c71792">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d19e967388d41128ce3a6f556f600be_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzUtNS0xLTEtMTM5MDYy_5222e7ae-e4ad-480e-95f8-077aaa878511">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzUtMTEtMS0xLTEzOTA2Mg_ddc423c6-ee57-423f-8bef-4263c10bf653">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity component of repurchased convertible senior notes, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d19e967388d41128ce3a6f556f600be_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzYtNS0xLTEtMTM5MDYy_5ecc9df6-752b-46ff-a6ed-ba7aff22ce92">47.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzYtMTEtMS0xLTEzOTA2Mg_69dc0ad8-d88f-4fc5-a6b4-509a1e82bdf9">47.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances of common stock under stock plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie0ee7b0ff1c946b390b1cd119381b62f_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzctMS0xLTEtMTM5MDYy_94e75899-bd98-426a-a7aa-6f41d9b3a9db">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d19e967388d41128ce3a6f556f600be_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzctNS0xLTEtMTM5MDYy_0585f49a-8ca6-4b6f-82b5-405ebf62131e">29.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzctMTEtMS0xLTEzOTA2Mg_c37488ae-cca9-4abb-a15e-41b5852eab41">29.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie1660cd4b7b54e359345103c0e942aa8_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzgtMS0xLTEtMTM5MDYy_0d57119e-5bce-4ff8-8026-4902c090671d">93.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1660cd4b7b54e359345103c0e942aa8_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzgtMy0xLTEtMTM5MDYy_e0443bc2-b348-4aa3-9b2b-dedef92878fd">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f63238a40484e0ab018374a8829b7a0_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzgtNS0xLTEtMTM5MDYy_ad23f674-35c2-46bf-b325-9e4609f0f677">1,849.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e8a22fcfd640478484ade7992b19eb_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzgtNy0xLTEtMTM5MDYy_e358f8cb-c3ee-4b35-8491-b4cc4c1d17a0">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f7dfb474ad94c65bc4bb9ac91172dc9_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzgtOS0xLTEtMTM5MDYy_73338f62-aa83-4440-a86d-c253a95b16b9">725.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a88ab4de251408db4aa98552134a56a_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzgtMTEtMS0xLTEzOTA2Mg_6d5b8123-1efc-4240-8bb3-16abb29b411d">1,126.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7e33c1feaa549568d96ca0b5a1289e4_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzktOS0xLTEtMTM5MDYy_d08b26c8-6cee-4ec3-b32e-28649a7f8f2c">89.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzktMTEtMS0xLTEzOTA2Mg_f9b05340-fb85-4f79-bb78-102b8107caec">89.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6eb7229899cc4ef8a964dc3ed073c87c_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzEwLTctMS0xLTEzOTA2Mg_b52af0de-540d-42ee-ac75-ad336dcd5e10">3.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzEwLTExLTEtMS0xMzkwNjI_3b90b59f-718d-4155-8530-8b20fe2cecaa">3.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5dcf16fd4c454093a5adc50ec3dbf4_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzExLTUtMS0xLTEzOTA2Mg_d3319fbd-ed04-44bd-9d97-258bd0235b1b">134.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzExLTExLTEtMS0xMzkwNjI_d04233a4-f85e-4cd8-80b2-cbfb91a96aed">134.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances of common stock under stock plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7839db0dc61d4c4e8853cf6e19e54d9a_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzEyLTEtMS0xLTEzOTA2Mg_a4b66bb1-de46-47a4-9ad0-1d968c692190">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5dcf16fd4c454093a5adc50ec3dbf4_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzEyLTUtMS0xLTEzOTA2Mg_a4d7d1ba-6fc7-484d-b521-d21139bd4369">27.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzEyLTExLTEtMS0xMzkwNjI_1c25b08d-74e9-48ab-a16f-6b1c73c90a4c">27.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5b99420940c34cd38a2ca2831819f03a_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzEzLTEtMS0xLTEzOTA2Mg_99c3562c-24d6-4a37-b734-dbbeb5f7714b">94.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b99420940c34cd38a2ca2831819f03a_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzEzLTMtMS0xLTEzOTA2Mg_a7cee5b1-83be-4722-b07f-f2111ca20517">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic68171adb3f24de9bed3bd6b62a8b5f1_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzEzLTUtMS0xLTEzOTA2Mg_ac9c7a18-82fe-44ca-9681-18caf2e4c02d">2,011.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1431ff2fdef24f178c1a21ede2c5c504_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzEzLTctMS0xLTEzOTA2Mg_1f69ff25-f300-45c2-b948-a64d9654734a">1.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e83c4aadc74dfe9f04f4780dec95d0_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzEzLTktMS0xLTEzOTA2Mg_45e244ac-50a2-4374-8cd8-4228327e67ec">635.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzEzLTExLTEtMS0xMzkwNjI_a5521df2-9e3a-47ee-bc2a-df2693699688">1,374.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5ed360a12ed4ff2b4e907ef5bc21e00_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzE0LTktMS0xLTEzOTA2Mg_2b9fa284-e3af-4cec-8caa-5bfcca7f2457">154.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzE0LTExLTEtMS0xMzkwNjI_4b6c8771-0e5b-4aef-b964-36055062e2e6">154.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd0f70dc50c24e3ebdef035671ebad8d_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzE1LTctMS0xLTEzOTA2Mg_906ef4ff-63a1-4e68-aa4c-e723cba1c057">6.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzE1LTExLTEtMS0xMzkwNjI_2b9f45e0-9821-4650-bf90-51d25f23adf9">6.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzE2LTAtMS0xLTE0NDY4Ng_07167cb8-6fd5-4735-8780-8b07212a106b">Cumulative-effect adjustment due to adoption of ASU 2020-06</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6110ec902f424e9786d861ac3a49b372_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzE2LTUtMS0xLTE0NDI5OA_bf961e78-d933-4e82-8d25-256d2d135181">106.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia89fc8fb19434c28a5b37e944ef95c17_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzE2LTktMS0xLTE0NDMwMQ_4f265b26-5d55-43c3-be2a-fa63ed73990d">74.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica83f9a3025b4dce8f0663374896f3ea_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzE2LTExLTEtMS0xNDQzMDE_474a53be-7a7d-429b-b719-093a3b81f7a3">32.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90432f146b89477b90abd98f33694f6b_D20220101-20221231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzE2LTUtMS0xLTEzOTA2Mg_f0489695-5b3b-4c33-b5f5-432bb9eabf59">173.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzE2LTExLTEtMS0xMzkwNjI_140f3c07-7cb1-41cb-8edd-1e44876ed26d">173.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances of common stock under stock plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9398bcb69b16420d9cf3703d6c3c8b15_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzE3LTEtMS0xLTEzOTA2Mg_b5175d6a-e588-4efe-bb13-4a3b6c236174">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90432f146b89477b90abd98f33694f6b_D20220101-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzE3LTUtMS0xLTEzOTA2Mg_4d42633b-0a41-4e11-a299-5a90d0b9d28e">44.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzE3LTExLTEtMS0xMzkwNjI_99783052-7458-44a6-84e3-1cee714cbf26">44.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2faddbeacae241608429e772b0492fe7_I20221231" decimals="INF" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzE4LTEtMS0xLTEzOTA2Mg_bb732e81-1a6a-4aad-ae77-948c5d5404bc">96.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2faddbeacae241608429e772b0492fe7_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzE4LTMtMS0xLTEzOTA2Mg_dce960e9-4c76-4b43-9b08-9521a87e9b8a">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5989ae77b9e4f9bab21d80812e7179d_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzE4LTUtMS0xLTEzOTA2Mg_67e2b298-f578-4fc0-a509-447b155c0c8f">2,122.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i423520348d804b1da2a2f946632d1239_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzE4LTctMS0xLTEzOTA2Mg_3b962dec-2652-4419-a307-3338440c141b">7.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b9ae80dc18341fabe82e98052d1b03a_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzE4LTktMS0xLTEzOTA2Mg_95366976-9566-46da-8f9c-003e139b452c">406.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzE4LTExLTEtMS0xMzkwNjI_940a40c5-fcce-447e-af9b-08cdb5bebe94">1,707.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="id795223301944418ba8c3fb3bc02f08e_124"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzMtMS0xLTEtMTM5MDYy_49a26619-acb3-42f8-a265-a0e3211a2d83">154.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzMtMy0xLTEtMTM5MDYy_91f2df98-0ad8-47f5-90f0-d579cd028857">89.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzMtNS0xLTEtMTM5MDYy_d99fd5dd-fa21-4016-b855-7e5ed0f8a887">407.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzUtMS0xLTEtMTM5MDYy_607988c6-90ab-48f5-88f7-2f8f2be883e3">173.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzUtMy0xLTEtMTM5MDYy_0e7887c8-ce7b-4abb-ac75-50696747cab9">134.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzUtNS0xLTEtMTM5MDYy_8e8b5604-f4ec-4e7a-b626-23df2808cd81">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzYtMS0xLTEtMTM5MDYy_5cb75860-0308-4acf-b27a-256b1b6553e4">15.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzYtMy0xLTEtMTM5MDYy_cb280b56-60c8-411b-a84e-c46e20279b61">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzYtNS0xLTEtMTM5MDYy_088ac90f-afd3-4003-b1a2-962248beddf4">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzctMS0xLTEtMTM5MDYy_1929737d-9d04-4eb3-85c2-dd37fb135ab0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzctMy0xLTEtMTM5MDYy_46a4570d-2524-4268-b182-bdae5eef979e">16.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzctNS0xLTEtMTM5MDYy_73800a04-d6a8-4fa6-957d-248301349463">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzgtMS0xLTEtMTM5MDYy_78618dc5-ec6e-4e40-af89-0dbd0d18ea73">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzgtMy0xLTEtMTM5MDYy_4fff50e5-c852-4664-9bf6-20bcccea9af8">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzgtNS0xLTEtMTM5MDYy_6bed529d-0311-4299-afa0-9d7e2e44fef4">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzktMS0xLTEtMTQ0Njg4_aac17e89-9b71-4146-b442-97b8b96e03ca">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzktMy0xLTEtMTQ0Njg4_28e496f3-ad43-4cee-a65d-80b4b761b519">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzktNS0xLTEtMTQ0Njg4_67a84755-f1bd-44ab-b8cd-5f88381f2ac6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzktMS0xLTEtMTM5MDYy_304f1a78-a492-499b-8203-2bc41f223125">30.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzktMy0xLTEtMTM5MDYy_25e98bcc-3d69-469b-949e-46ffe608fd17">20.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzktNS0xLTEtMTM5MDYy_45f24f89-6a57-4d44-afa8-5d4e95fbdfb9">17.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzEwLTEtMS0xLTEzOTA2Mg_2fb96d71-5fba-46a0-a80d-cddc342d9f9a">19.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzEwLTMtMS0xLTEzOTA2Mg_7fbc892f-38df-4244-a074-383e2d099007">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzEwLTUtMS0xLTEzOTA2Mg_62e5cf8b-c15d-431b-b7db-bbe10e059317">310.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzExLTEtMS0xLTEzOTA2Mg_ad16e86c-8327-49bf-a317-f2f5159b7d0a">70.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzExLTMtMS0xLTEzOTA2Mg_21da8804-0145-47d1-b465-5468b3c88f1e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzExLTUtMS0xLTEzOTA2Mg_9783336f-8c1c-4a96-88ec-f07fcc548e65">18.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzEyLTEtMS0xLTEzOTA2Mg_bc7574c4-526a-4cab-9164-4826181551d1">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzEyLTMtMS0xLTEzOTA2Mg_f61378f3-408a-4d98-8b0b-f7a6d858b329">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzEyLTUtMS0xLTEzOTA2Mg_7a142865-0165-4d3c-bea6-35c0419cb5c1">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzE0LTEtMS0xLTEzOTA2Mg_3e3763bc-090c-40df-9833-dcf59e684a1d">162.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzE0LTMtMS0xLTEzOTA2Mg_8559ea87-8d20-41fb-8bff-8d44484cbe32">28.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzE0LTUtMS0xLTEzOTA2Mg_65797047-bb7a-437f-b076-ab3154b806f1">30.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzE1LTEtMS0xLTEzOTA2Mg_8de08df2-54d5-4213-b062-aa3b19440d12">2.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzE1LTMtMS0xLTEzOTA2Mg_21d402d8-dbf3-4f56-b1f6-def4b43099d0">2.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzE1LTUtMS0xLTEzOTA2Mg_363f0a19-55c7-4fd3-ae46-82d1b8eaaa8f">10.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzE2LTEtMS0xLTEzOTA2Mg_94f9783c-c534-4c9d-a67b-09f9d92ba3b3">114.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzE2LTMtMS0xLTEzOTA2Mg_585964db-de9b-442c-9a2d-9790faca5886">56.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzE2LTUtMS0xLTEzOTA2Mg_c57f7628-b013-40a4-92cf-31e90ebd3411">26.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzE3LTEtMS0xLTEzOTA2Mg_29d9f80b-8984-409e-a5cb-74c1590fadf4">17.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzE3LTMtMS0xLTEzOTA2Mg_a4ec212d-d034-4014-b76f-a65abf4b1dd1">9.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzE3LTUtMS0xLTEzOTA2Mg_c2251131-e63d-422c-8a17-784202ed807e">23.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzE4LTEtMS0xLTEzOTA2Mg_5abaf7e9-8968-4dff-a58a-b5cec37ab2d6">339.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzE4LTMtMS0xLTEzOTA2Mg_c72a85af-526f-49b6-8ac9-d57707132e46">256.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzE4LTUtMS0xLTEzOTA2Mg_89d27ece-3c6c-4d0e-9d71-b6fd0362063b">228.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzIxLTEtMS0xLTEzOTA2Mg_077ca221-5c2b-4346-bb44-806975f64960">621.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzIxLTMtMS0xLTEzOTA2Mg_7a5f1560-9a06-490e-ac75-8eacb5740ee7">800.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzIxLTUtMS0xLTEzOTA2Mg_855982e6-a97e-4b8b-9cb0-fe7b5ad8bfc6">735.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales and maturities of debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzIyLTEtMS0xLTEzOTA2Mg_05b52e81-34c7-4904-a704-be8feff0f7eb">511.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzIyLTMtMS0xLTEzOTA2Mg_99ca0a45-9ce3-41be-bd72-4f52c5115fca">697.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzIyLTUtMS0xLTEzOTA2Mg_62cbcb82-5d74-40b4-b5af-a5f07192e018">750.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of business, net of cash acquired </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzI0LTEtMS0xLTE0NDY3Mg_a5e14d69-0f0f-49f3-94e2-8eef08e14466">42.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzI0LTMtMS0xLTE0NDY3Mg_de59cd40-7a26-4aa3-9e39-dca0977bbf99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzI0LTUtMS0xLTE0NDY3Mg_acc523fa-4f15-4aa4-9e22-240f5aad254d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsToAcquireRestrictedInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzI0LTEtMS0xLTEzOTA2Mg_b1206cc5-eb91-4490-b73d-0f31e1226780">7.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireRestrictedInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzI0LTMtMS0xLTEzOTA2Mg_488368d3-6074-4a1a-9ded-72423c4aa910">4.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireRestrictedInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzI0LTUtMS0xLTEzOTA2Mg_63d42227-4590-4ece-ac91-78119e1981bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzI1LTEtMS0xLTEzOTA2Mg_d48d9688-d993-4b51-869b-ca45f5fdf92c">16.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzI1LTMtMS0xLTEzOTA2Mg_4492530f-e143-46e2-af97-9e68a9d6001b">23.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzI1LTUtMS0xLTEzOTA2Mg_c40e10e7-72cb-4553-a938-87cf992c1d0b">10.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzI2LTEtMS0xLTEzOTA2Mg_f0c843c9-f1ee-473e-8249-181131fab018">177.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzI2LTMtMS0xLTEzOTA2Mg_5a315a64-4ed6-448a-b2c5-74c42dbf7198">130.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzI2LTUtMS0xLTEzOTA2Mg_29cff954-6143-4fda-a454-c6a9f7c45ed2">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances of common stock under benefit plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzI5LTEtMS0xLTEzOTA2Mg_8f0b6615-6a94-4cdf-b136-19f67b4948aa">44.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzI5LTMtMS0xLTEzOTA2Mg_74de0a7a-2e4f-4aa4-b501-abecce2dc9ef">27.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzI5LTUtMS0xLTEzOTA2Mg_81224a6e-9b8c-4f8e-87ce-7e2d0f7d01b8">29.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchases of convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:RepaymentsOfConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzMwLTEtMS0xLTEzOTA2Mg_69382533-5783-4311-9902-072d1c958fb4">279.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:RepaymentsOfConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzMwLTMtMS0xLTEzOTA2Mg_facb7393-19e3-4070-9cf3-f470fd8059c0">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:RepaymentsOfConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzMwLTUtMS0xLTEzOTA2Mg_2fc5c0cb-9136-4f70-ac13-c8e4689bc420">186.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzMxLTEtMS0xLTEzOTA2Mg_bb893a91-e420-4965-96bb-a4a124e865ef">234.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzMxLTMtMS0xLTEzOTA2Mg_2835c221-17ab-4186-b115-320b62731056">27.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzMxLTUtMS0xLTEzOTA2Mg_1883f4f5-6e0e-414a-95f5-84329f828cb7">157.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzMzLTEtMS0xLTE2Mjg2Ng_5b0652e5-8a73-4296-aaf0-19413d94c18d">1.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzMzLTMtMS0xLTE2Mjg3Mw_30a8555a-9712-4e16-840e-cdc1903ea3e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzMzLTUtMS0xLTE2Mjg4MA_a864ec28-d387-4be3-9eb5-cefc9ed7ad65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in cash and cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzMyLTEtMS0xLTEzOTA2Mg_958b1548-dc2a-4f50-97cb-c02245eacb1d">73.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzMyLTMtMS0xLTEzOTA2Mg_67684bbe-a878-48ed-8ab2-ec71eb4c8c03">153.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzMyLTUtMS0xLTEzOTA2Mg_8a808b78-ec0c-4db7-ab9f-4d5bdcd3ece3">74.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzMzLTEtMS0xLTEzOTA2Mg_39a7f121-6a4c-45ad-b591-1f7e385e80aa">344.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a88ab4de251408db4aa98552134a56a_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzMzLTMtMS0xLTEzOTA2Mg_1b4db030-a67c-43d2-9f5b-f45f7ed458e3">190.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9e7a539304246b48b58f35e4a888e14_I20191231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzMzLTUtMS0xLTEzOTA2Mg_9395811d-2c79-463b-93b4-ae75f4f178f0">115.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzM0LTEtMS0xLTEzOTA2Mg_963d1e44-b092-43bd-a87a-104b124e8af1">270.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzM0LTMtMS0xLTEzOTA2Mg_2d3667a5-b884-4655-a042-7464cf1b7168">344.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a88ab4de251408db4aa98552134a56a_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzM0LTUtMS0xLTEzOTA2Mg_5f4b6342-0f94-4e99-892f-108fa2bf094e">190.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental Disclosure:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash capital expenditures</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzM3LTEtMS0xLTEzOTA2Mg_53e10ea0-d838-49e3-a41e-f0b1f6d5f777">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzM3LTMtMS0xLTEzOTA2Mg_3b95a863-02de-41fc-8810-f4f546d2e990">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzM3LTUtMS0xLTEzOTA2Mg_ad19d7f1-a225-4bcf-94b4-8d9a3693552a">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets acquired through operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzM4LTEtMS0xLTEzOTA2Mg_1aa74f07-6081-48e5-bcda-e2f6e9bae7a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzM4LTMtMS0xLTEzOTA2Mg_5ce48be2-ef34-4222-b589-38665fec8e63">23.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzM4LTUtMS0xLTEzOTA2Mg_073400eb-e5a1-4b5a-bdad-7ebaf161dde8">12.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for interest </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzM5LTEtMS0xLTEzOTA2Mg_5933ccef-c843-4d26-96c7-f745ce351e0a">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzM5LTMtMS0xLTEzOTA2Mg_ffe84b82-cc41-41d4-85d1-5cb42797008d">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzM5LTUtMS0xLTEzOTA2Mg_758dcf87-c4c4-4567-83c3-541b43afc4ad">11.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzQwLTEtMS0xLTEzOTA2Mg_e8b2d8b5-9a7a-4c25-8ddd-44a7bad0d8e0">14.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzQwLTMtMS0xLTEzOTA2Mg_abdaa349-48af-4cdd-82ea-de9de9d35ace">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzQwLTUtMS0xLTEzOTA2Mg_3eefb3b6-3153-4d10-9e0d-7e083dfa3c35">15.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="id795223301944418ba8c3fb3bc02f08e_127"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="id795223301944418ba8c3fb3bc02f08e_130"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.&#160;<ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI4NTEy_a0576aeb-f9a3-45e5-b759-417de8c9ef8b" continuedAt="i185b8887f78f4ae7b7d5934c74d0602f" escape="true">Organization and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i185b8887f78f4ae7b7d5934c74d0602f" continuedAt="i588654ad53ba49e189a420bbd8cb9327"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="nbix:OrganizationAndBusinesDescriptionPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI4NTEz_66c3f847-fae0-49ac-80f9-b58d8abe4b25" escape="true"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization and Business. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neurocrine Biosciences, Inc. and its subsidiaries, or Neurocrine Biosciences, the Company, we, our or us, is a neuroscience-focused biopharmaceutical company focused on discovering, developing and delivering innovative therapies to help ease the burden of debilitating disorders and diseases.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a single business segment, which includes all activities related to the research, development and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine and neuropsychiatric disorders.</span></div></ix:nonNumeric><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI4NTE0_8f77c789-300a-4e2f-9981-1a5f855823d4" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Neurocrine Biosciences as well as our wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></ix:nonNumeric></div><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI4NTAw_c262cbea-658f-46d7-83cf-02fde2ffc8a6" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.</span></ix:nonNumeric></div><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI4NTA5_eb2c241c-b0ad-4758-879a-3df00026a3da" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments that are readily convertible into cash without penalty and have an original maturity of three months or less at the time of purchase to be cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></ix:nonNumeric></div><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:ReceivablesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI4NTE2_af3f4a18-ea83-4949-bdd8-5dedf1be24d9" escape="true"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded net of customer allowances for prompt payment discounts, chargebacks, and any allowance for credit losses. Our estimate for the allowance for credit losses, which has not been significant to date, is determined based on existing contractual payment terms, actual payment patterns of our customers, and individual customer circumstances.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our exposure to credit losses may increase if our customers are adversely affected by changes in healthcare laws, coverage and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current COVID-19 pandemic, or other customer-specific factors. It is possible that there could be a material adverse impact from potential adjustments of the carrying amount of trade receivables as customers&#8217; cash flows are impacted by their response to the COVID-19 pandemic.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI4NTAx_dff549be-f894-4b05-a3d0-3d5073461c32" escape="true"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities consist of investments in certificates of deposit, corporate debt securities and securities of government-sponsored entities. We classify debt securities as available-for-sale. Debt securities available-for-sale are recorded at fair value, with unrealized gains and losses included in other comprehensive income or loss, net of tax. We exclude accrued interest from both the fair value and amortized cost basis of debt securities. A debt security is placed on nonaccrual status at the time any principal or interest payments become <ix:nonNumeric contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI2MTk_f6a323ca-5211-427d-a37b-6f1650f75c53">90</ix:nonNumeric> days delinquent. Interest accrued but not received for a debt security placed on nonaccrual status is reversed against interest income.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income includes amortization of purchase premium or discount. Premiums and discounts on debt securities are amortized using the effective interest rate method. Gains and losses on sales of debt securities are recorded on the trade date in investment income and other, net, and determined using the specific identification method.</span></div></ix:nonNumeric><div style="margin-bottom:3pt"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:CreditLossFinancialInstrumentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI4NTA1_9f3e74b1-523e-4f34-ac86-9b10096c8f13" continuedAt="ia2c3bc046db2433c870608b1de74034a" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allowance for Credit Losses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For debt securities available-for-sale in an unrealized loss position, we first assess whether we intend to sell, or it is more likely than not that we will be required to sell, the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.</span></ix:nonNumeric></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i588654ad53ba49e189a420bbd8cb9327" continuedAt="i30349c745983446a829e6b267dfdb7d6"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia2c3bc046db2433c870608b1de74034a">Accrued interest receivables on debt securities available-for-sale were $<ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:InterestReceivableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzQ1NzQ_79224275-3cae-4293-bd73-776c78d504ad">4.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:InterestReceivableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzU0OTc1NTg2NTQ2MA_7002c419-3386-49bb-b78c-a30276c2a0b2">2.2</ix:nonFraction> million, respectively, as of December&#160;31, 2022 and 2021. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized cost basis of the debt security. Uncollectible accrued interest receivables associated with an impaired debt security are reversed against interest income upon identification of the impairment. <ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzUwMDk_1f9ab590-9e72-48e8-beff-b695f3bacec1"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzUwMDk_6d0efb6c-0605-4e3f-99e5-b7652948a043"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzUwMDk_fe5226b2-5a23-4d6c-a9cf-3cfb1ab7e31f">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> accrued interest receivables were written off during 2022, 2021 or 2020.</ix:continuation></span></div><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI4NTE3_30663884-0c37-4b62-a67e-7abf0110c2bf" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record cash equivalents, debt securities available-for-sale and equity security investments at fair value based on a fair value hierarchy that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The fair value hierarchy consists of the following three levels:</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in debt securities available-for-sale are classified as Level 2 and carried at fair value. We estimate the fair value of debt securities available-for-sale by utilizing third-party pricing services. These pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. Such inputs include market pricing based on real-time trade data for similar instruments, issuer credit spreads, benchmark yields, broker/dealer quotes and other observable inputs. We validate valuations obtained from third-party pricing services by understanding the models used, obtaining market values from other pricing sources and analyzing data in certain instances.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We deem transfers between levels of the fair value hierarchy to have occurred at the end of the reporting period during which the event or change in circumstances that caused the transfer occurred.</span></div></ix:nonNumeric><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI4NTAy_713869b6-3be2-4ca1-aa9a-61c7c5bb4882" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is valued at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on the first-in, first-out method. We assess the valuation of our inventory on a quarterly basis and adjust the value for excess and obsolete inventory to the extent management determines that the cost cannot be recovered based on estimates about future demand. Inventory costs resulting from these adjustments are recognized as cost of sales in the period in which they are incurred. When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#8217;s judgment, we capitalize pre-launch inventory costs prior to regulatory approval.</span></ix:nonNumeric></div><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI4NTEw_f1626c6b-3168-4f5e-8320-b14f533caf12" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets using the straight-line method. Equipment is depreciated over an average estimated useful life of <ix:nonNumeric contextRef="ifbefd953596945ebb57cb8b4260d4036_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2Xzg1Njc_154f2b20-8ebb-4e9e-a9f9-405016b0032f">3</ix:nonNumeric> to <ix:nonNumeric contextRef="i369eac3be33e4aaeb739e76899443560_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2Xzg1NzM_f81d7bc9-1d82-40fa-acd7-03af1334e1fb">7</ix:nonNumeric> years. Leasehold improvements are depreciated over the shorter of their estimated useful lives or the remaining lease term. Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2Xzg3MTk_4187aa3f-3d6e-4599-a1d5-d90953be134d">15.1</ix:nonFraction> million for 2022, $<ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2Xzg3MzA_4158498a-c259-45bd-8bfd-f7995bbe1b9f">10.9</ix:nonFraction> million for 2021 and $<ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2Xzg3NDQ_9d4c8037-1dd0-4f1d-ab39-94a0d756f1d6">8.6</ix:nonFraction> million for 2020.</span></ix:nonNumeric></div><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzIxOTkwMjMyOTYzNDY_abb1bebc-b26f-4867-be3c-d99eb11ad2d5" continuedAt="ibee907cf9eb6455393e7987c59362f4f" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. In addition, costs that we incur to complete the business combination, such as legal and other professional fees, are expensed as selling, general and administrative when incurred.</span></ix:nonNumeric></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i30349c745983446a829e6b267dfdb7d6" continuedAt="ic03ecc9fdac5426bb03abe55ceccae4b"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzU0OTc1NTgxNzk2NzM_4d10e98d-221e-4168-87b5-656582f9289d" escape="true"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill, Intangible Assets and Other Long-Lived Assets. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired, including intangible assets and in-process research and development, or IPR&amp;D, and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&amp;D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;D asset is amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;D asset is expensed in the period of abandonment.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and IPR&amp;D are not amortized; however, they are reviewed for impairment at least annually, as of October 1, and more frequently if an event occurs indicating the potential for impairment. Goodwill and IPR&amp;D are considered to be impaired if the carrying value of the reporting unit or IPR&amp;D asset exceeds its respective fair value.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform our goodwill impairment analysis at the reporting unit level, which aligns with our reporting structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of the reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the reporting unit with the carrying value, including goodwill. If the carrying amount of the reporting unit exceed the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our identifiable intangible assets with a finite life are typically comprised of acquired product rights. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#8217; respective estimated useful lives.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform regular reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.</span></div></ix:nonNumeric><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzIxOTkwMjMzMDE2NTg_a3e81d84-9f9a-4566-b28a-6e7f35f17896" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign currency.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Assets and liabilities are translated into the reporting currency using the exchange rates in effect on the consolidated balance sheet dates. Equity accounts are translated at historical rates, except for the change in retained earnings during the period, which is the result of the income statement translation process. Revenue and expense accounts are translated using the weighted average exchange rate during the period. The cumulative translation adjustments associated with the net assets of foreign subsidiaries are recorded in accumulated other comprehensive income (loss) in the accompanying consolidated statements of stockholders&#8217; equity.</span></ix:nonNumeric></div><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI4NTE5_f86278ad-0eca-469a-b2e9-3d2d85d422d2" continuedAt="i7ebc6eaea82c4027b3bfc8f3f3c62ee7" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue when the customer obtains control of promised goods or services in an amount that reflects the consideration which we expect to receive in exchange for such goods or services. Revenue is recognized using a five-step model: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.</span></ix:nonNumeric></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic03ecc9fdac5426bb03abe55ceccae4b" continuedAt="idf7c09a19df2403781743689433d009b"><ix:continuation id="i7ebc6eaea82c4027b3bfc8f3f3c62ee7" continuedAt="i68f079e9665d47aa95b8b20aeeb66040"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the United States, we sell INGREZZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (valbenazine) primarily to specialty pharmacy providers and distributors and ONGENTYS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (opicapone) primarily to wholesale distributors. We recognize net product sales when the customer obtains control of our product, which occurs at a point in time, typically upon delivery of our product to the customer.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, payors, and other third parties. Such estimates are based on information received from external sources (such as written or oral information obtained from our customers with respect to their period-end inventory levels and sales to end-users during the reporting period), as supplemented by management&#8217;s judgement. Our process for estimating reserves established for these variable consideration components does not differ materially from historical practices. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant categories of sales discounts and allowances are as follows:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Discounts.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Product discounts are based on payment terms extended to our customers at the time of sale, which include incentives offered for prompt payment. We maintain a reserve for product discounts based on our historical experience, including the timing of customer payments. To date, actual product discounts have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are obligated to pay rebates for mandated discounts under the Medicaid Drug Rebate Program. The liability for such rebates consists of invoices received for claims from prior quarters that remain unpaid, or for which an invoice has not been received, and estimated rebates for the current applicable reporting period. Such estimates are based on actual historical rebates by state, estimated payor mix, state and federal regulations, and relevant contractual terms, as supplemented by management&#8217;s judgement. Our rebate accrual calculations require us to project the magnitude of our sales that will be subject to these rebates. There is a significant time-lag in our receiving rebate notices from each state (generally, several months or longer after a sale is recognized). Estimated rebates are recorded as a reduction of revenue in the period the related sale is recognized. To date, actual government rebates have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The difference between the list price, or the price at which we sell our products to our customers, and the contracted price, or the price at which our customers sell our products to qualified healthcare professionals, is charged back to us by our customers. In addition to actual chargebacks received, we maintain a reserve for chargebacks based on estimated contractual discounts on product inventory levels on-hand in our distribution channel. To date, actual chargebacks have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payor and Pharmacy Rebates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are obligated to pay rebates as a percentage of sales under payor and pharmacy contracts. We estimate these rebates based on actual historical rebates, contractual rebate percentages, sales made through the payor channel, and purchases made by pharmacies. To date, actual payor and pharmacy rebates have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient Financial Assistance.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> To help patients afford our products, we offer free trial vouchers to qualifying new patients and financial assistance to qualified patients with prescription drug copay requirements. We accrue for patient financial assistance based on estimated claims and the cost per claim we expect to receive in connection with inventory that remains in the distribution channel at period end. To date, actual patient financial assistance has not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distributor and Other Fees.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In connection with the sales of our products, we pay distributor and other fees, which are generally recorded as a reduction of revenue, to certain customers that provide us with inventory management, data, and/or distribution services. Costs associated with such services are expensed as selling, general and administrative to the extent we can demonstrate a separable benefit and fair value for such services. To date, actual distributor and other fees have not differed materially from our estimates.</span></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="idf7c09a19df2403781743689433d009b" continuedAt="i8f663d4e573e4417902ea813f8f8763e"><ix:continuation id="i68f079e9665d47aa95b8b20aeeb66040"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We offer our customers product return rights primarily limited to errors in shipment, damaged product, and expiring product, provided it is within a specified period of the product expiration date, as set forth in the associated distribution agreement. Where actual returns history is not available, we estimate a returns allowance based on benchmarking data for similar products and industry experience. Such estimates are recorded as a reduction of revenue in the period the related sale is recognized. Once product is returned, it is destroyed. To date, actual product returns have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenues. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into collaboration and license agreements under which we out-license certain rights to our product candidates to third parties. The terms of these arrangements typically include payment to us for one or more of the following: non-refundable, up-front license fees; development, regulatory, and/or commercial milestone payments; and royalties on net sales of the out-licensed products.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use, and benefit from, the license. For licenses that are bundled with other promises, we assess the nature of the combined performance obligation to determine whether it is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestones.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the inception of each arrangement that includes development, regulatory, and/or commercial milestones, we evaluate whether achieving the milestones is considered probable and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Amounts for milestones that are not within our control, such as when achievement of a specified event is dependent on the development activities of a third party or approvals from regulators, are not considered probable of being achieved until such specified event occurs. Revenue is recognized from the satisfaction of performance obligations in the amount billable to the customer.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For arrangements that include sales-based royalties, and under which the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Each quarterly period, sales-based royalties are recorded based on estimated quarterly net sales of the associated collaboration products. Differences between actual results and estimated amounts are adjusted for in the period in which they become known, which typically follows the quarterly period in which the estimate was made. To date, actual royalties received have not differed materially from our estimates.</span></div></ix:continuation><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI4NTA2_da3be698-a6c1-40d3-a6f3-95f50e35c746" escape="true"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents and debt securities available-for-sale. We have established guidelines to limit our exposure to credit risk by diversifying our investment portfolio with low-risk investment-grade debt securities with maturities of up to three years and by placing our investments with high-credit-quality financial institutions to maintain liquidity. To date, we have not experienced any credit losses and do not believe we are exposed to any significant credit risk in connection with these financial instruments.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into agreements for the distribution of INGREZZA with a limited number of specialty pharmacy providers and distributors and all of our product sales of INGREZZA are to these customers. Four of these customers represented approximately <ix:nonFraction unitRef="number" contextRef="ib8a35373f04d4f25aabbae9b053dfc86_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NTY2NTc_7e2ba347-f0dd-4519-b2d7-cf2424f18783">89</ix:nonFraction>% of our total product sales for 2022 and approximately <ix:nonFraction unitRef="number" contextRef="i3ee7b53986f840f69575c96ddd148ff6_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NTY3Mzc_6d798cb4-ee50-43a8-b524-1bb640269ac2">95</ix:nonFraction>% of our accounts receivable balance as of December&#160;31, 2022.</span></div></ix:nonNumeric><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:CostOfSalesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI4NTAz_5c267712-c99b-47f6-af6d-4f1a999588a0" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenues. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenues includes third-party manufacturing, transportation, freight, and indirect overhead costs primarily for the manufacture and distribution of INGREZZA and ONGENTYS drug product sold, manufacturing costs in connection with our supply of valbenazine drug product under our collaboration with Mitsubishi Tanabe Pharma Corporation, royalty fees on net sales of elagolix, amortization of intangible assets, and adjustments for excess and obsolete inventory to the extent management determines that the cost cannot be recovered based on estimates about future demand.</span></ix:nonNumeric></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i8f663d4e573e4417902ea813f8f8763e" continuedAt="ide0b197124eb4d7fb436bb8aaeee7905"><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI4NTEx_a365c7c2-8fbf-4ef4-adac-ecdfceff3ae3" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development, or R&amp;D. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses primarily consist of preclinical and clinical trial costs, payroll and benefits costs, including stock-based compensation associated with employees involved in R&amp;D activities, certain facility-based costs, and costs associated with our collaborative arrangements, including event-based milestones. All such costs are expensed as R&amp;D when incurred.</span></ix:nonNumeric></div><div style="margin-bottom:6pt"><ix:continuation id="ibee907cf9eb6455393e7987c59362f4f"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Acquisitions. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for acquisitions of assets (or groups of assets) that do not meet the definition of a business using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets (or group of assets) acquired on the basis of their relative fair value(s) on the measurement date. No goodwill is recognized in an asset acquisition. Intangible assets acquired in an asset acquisition for use in R&amp;D activities which have no alternative future use are expensed as IPR&amp;D on the acquisition date. Future costs to develop these assets are expensed as R&amp;D when incurred.</span></ix:continuation></div><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI4NTIw_3aafbbb8-4650-477f-846e-e9db1edf138f" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Expense. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs are expensed as selling, general and administrative when incurred. Advertising expense was $<ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2OTM0MjM_320831f9-ac3d-4fc6-b34b-ed476496708d">149.7</ix:nonFraction> million for 2022, $<ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2OTM0NTI_6648c7ac-892c-4216-9424-b72cc516caec">139.8</ix:nonFraction> million for 2021 and $<ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2OTM0ODA_d0c07ff9-770b-4d9e-b898-f6720fba745a">64.8</ix:nonFraction> million for 2020.</span></ix:nonNumeric></div><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI4NTIx_45bccba0-23f3-4e34-8aac-37eabbee2ce4" escape="true"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant stock options to purchase our common stock to eligible employees and directors and also grant certain employees restricted stock units, or RSUs, and performance-based restricted stock units, or PRSUs. Additionally, we allow employees to participate in an employee stock purchase plan, or ESPP.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of stock options and shares to be issued under the ESPP using the Black-Scholes option-pricing model on the date of grant. RSUs are valued based on the closing price of our common stock on the date of grant. The fair value of equity instruments expected to vest is recognized and amortized on a straight-line basis over the requisite service period of the award, which is generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzIyMzk4_faec3abd-c6f8-404f-adcd-432a19a48776">three</span> to <ix:nonNumeric contextRef="i369eac3be33e4aaeb739e76899443560_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzIyNDA0_36d6648b-eb9c-4143-8c0f-0d70690457a5">four years</ix:nonNumeric>; however, certain provisions in our equity compensation plans provide for shorter vesting periods under certain circumstances. The fair value of shares to be issued under the ESPP is recognized and amortized on a straight-line basis over the purchase period, which is generally <ix:nonNumeric contextRef="i42a4d7de80254904a89f6619754861e0_D20220101-20221231" name="nbix:ESPPPurchasePeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzIyNjg1_bdfadde1-ac36-47ec-8f9c-af3f5fcaae45">six months</ix:nonNumeric>. PRSUs vest upon the achievement of certain predefined company-specific performance-based criteria. Expense related to PRSUs is generally recognized ratably over the expected performance period once the predefined performance-based criteria for vesting becomes probable.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI4NTA4_51867a14-294c-475b-b5a0-8bc7f0b33326" escape="true"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our income tax provision is computed under the asset and liability method. Significant estimates are required in determining our income tax provision. Some of these estimates are based on interpretations of existing tax laws or regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our income tax provision in the period of such reversal.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities based on the technical merits of the position. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ide0b197124eb4d7fb436bb8aaeee7905"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI4NTIy_a255666a-4faf-4950-be92-966680749335" escape="true"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings Per Share.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share are computed using the weighted average number of common shares outstanding during the period. Diluted earnings per share are computed using the treasury stock method and reflect the weighted average number of common and potentially dilutive shares outstanding during the period, excluding those which effect would be anti-dilutive.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we entered into the First Supplemental Indenture to the 2017 Indenture, pursuant to which we irrevocably elected to settle the principal amount of the <ix:nonFraction unitRef="number" contextRef="i4b5b4f7eab2446ce84ea30524cbd6aa0_I20170502" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NTc2MTQ_8d782fd5-97a8-4b26-8dc2-09f8a81a0d3b">2.25</ix:nonFraction>% fixed-rate convertible senior notes due May&#160;15, 2024, or the 2024 Notes, in cash upon conversion and to settle any conversion premium in either cash or shares of our common stock. As a result, only the shares required to settle any conversion premium are considered dilutive under the if-converted method. Further, PRSUs for which the performance condition has not been achieved are excluded from the calculation of diluted earnings per share.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI4NTA0_cb2b4fb5-57e5-402d-8d56-2d37bc7d53a8" escape="true"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NTk5NDY_b11908b6-457c-4872-91a0-7e1b27137ced">ASU 2020-06</span>.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In August 2020, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2020-06,&#160;Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity's own equity. Among other changes, <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NjA1MDc_b11908b6-457c-4872-91a0-7e1b27137ced">ASU 2020-06</span> removed the separation models for convertible instruments with cash or beneficial conversion features. Instead, entities now account for convertible debt instruments wholly as debt, unless certain other conditions are met. The adoption of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NjA3NTA_b11908b6-457c-4872-91a0-7e1b27137ced">ASU 2020-06</span> prospectively reduces reported interest expense and increases (decreases) reported net income (loss), and resulted in a reclassification of certain conversion feature balance sheet amounts from stockholders&#8217; equity to liabilities as it relates to the <ix:nonFraction unitRef="number" contextRef="i4b5b4f7eab2446ce84ea30524cbd6aa0_I20170502" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NjEwMDU_8d782fd5-97a8-4b26-8dc2-09f8a81a0d3b">2.25</ix:nonFraction>% fixed-rate convertible senior notes due May&#160;15, 2024, or the 2024 Notes. We adopted <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NjEwNzc_b11908b6-457c-4872-91a0-7e1b27137ced">ASU 2020-06</span> on January&#160;1, 2022, using the modified retrospective transition method, which allowed for a cumulative-effect adjustment in the period of adoption and did not require restatement of prior period amounts. Under this transition method, the cumulative effect of the accounting change increased the carrying amount of the 2024 Notes by $<ix:nonFraction unitRef="usd" contextRef="i7b26f825c6434881a754e7e6c53ed556_I20211231" decimals="-5" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NjEzOTQ_ab6805cc-c8e2-4d42-a97f-fd70c8b37e80">42.2</ix:nonFraction> million, reduced deferred tax liabilities by $<ix:nonFraction unitRef="usd" contextRef="i7b26f825c6434881a754e7e6c53ed556_I20211231" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NjE0MzU_b1a7c797-e094-4508-8b50-c99e7fa1d9e0">9.9</ix:nonFraction> million, reduced additional paid-in capital by $<ix:nonFraction unitRef="usd" contextRef="i7b26f825c6434881a754e7e6c53ed556_I20211231" decimals="-5" sign="-" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NjE0Nzg_2e77ce7d-d0e0-4cfd-b7f4-f2955414de9a">106.8</ix:nonFraction> million and reduced the accumulated deficit by $<ix:nonFraction unitRef="usd" contextRef="i7b26f825c6434881a754e7e6c53ed556_I20211231" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NjE1MjE_fd21ee6f-67bc-4df7-b9cc-b168c633a8ba">74.5</ix:nonFraction> million.</span></div></ix:nonNumeric></ix:continuation><div id="id795223301944418ba8c3fb3bc02f08e_139"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzIxNTEy_71ed5d03-83ed-468c-9de0-73c635ca247d" continuedAt="i357160b66bee49468d87a0700b0a5410" escape="true">Collaboration and License Agreements</ix:nonNumeric></span></div><ix:continuation id="i357160b66bee49468d87a0700b0a5410" continuedAt="ia64b8d6e9ed840be98ac17c62d19317b"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our existing collaboration and license agreements, we may be required to make potential future payments of up to $<ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-8" name="nbix:PotentialMilestonePayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzE3Nw_fbda8826-2355-486f-bdec-e93992497c03">10.8</ix:nonFraction> billion upon the achievement of certain event-based milestones. Such contingent payments are recorded when paid or payable.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Heptares Therapeutics Limited, or Heptares.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We entered into a collaboration and license agreement with Heptares, which became effective in December 2021, to develop and commercialize certain compounds containing sub-type selective muscarinic M1, M4, or dual M1/M4 receptor agonists, which compounds we have the exclusive rights to develop, manufacture and commercialize worldwide, excluding in Japan, where Heptares retains the rights to develop, manufacture, and commercialize all compounds comprised of M1 receptor agonists, subject to certain exceptions. With respect to such rights retained by Heptares, we retain the rights to opt in to profit sharing arrangements, pursuant to which we and Heptares will equally share in the operating profits and losses for such compounds in Japan. Subject to specified conditions, we may elect to exercise such opt-in rights with respect to each such compound either before initiation of the first proof of concept Phase II clinical trial for such compound or following our receipt from Heptares of the top-line data from such clinical trial for such compound. We are responsible for all development, manufacturing, and commercialization costs of any collaboration product. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Heptares $<ix:nonFraction unitRef="usd" contextRef="i49d358b74dad468eb33569aa9c5ac1c8_D20210101-20211231" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzE1NjI_5330120c-b0ff-46fc-8e85-66d9fd14496a">100.0</ix:nonFraction> million upfront, which, including certain transaction-related costs, was expensed as IPR&amp;D in 2021. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the FDA's acceptance of our investigational new drug application for NBI-1117568 for the treatment of schizophrenia in June 2022, we paid Heptares a milestone of $<ix:nonFraction unitRef="usd" contextRef="i07a1cddc781641a8845184519e26357f_D20220101-20221231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzE5NTY_99cee119-cfbe-41c8-9573-281789255a5e">30.0</ix:nonFraction> million, which was expensed as R&amp;D in 2022.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Heptares may be entitled to receive potential future payments of up to $<ix:nonFraction unitRef="usd" contextRef="i1528f057e30c40d383e6a6ca39cf5e6c_I20221231" decimals="-8" name="nbix:PotentialMilestonePayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzIxMjI_629c6727-caff-4fbe-9fbb-e636fa9baaad">2.6</ix:nonFraction> billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia64b8d6e9ed840be98ac17c62d19317b" continuedAt="id4d223748c29450e85e2ec9751e48c17"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until the date on which the royalty term for such licensed product has expired in such country. On a licensed product-by-licensed product and country-by-country basis, royalty payments would commence on the first commercial sale of a licensed product and terminate on the later of (i) the expiration of the last patent covering such licensed product in such country, (ii) a number of years from the first commercial sale of such licensed product in such country and (iii) the expiration of regulatory exclusivity for such licensed product in such country.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate the agreement in its entirety or with respect to one or more targets upon 180 days&#8217; written notice to Heptares during the research collaboration term and upon 90 days&#8217; written notice to Heptares following the expiration of the research collaboration term. Following the expiration of the research collaboration term, Heptares may terminate the agreement on a target-by-target basis in the event that we do not conduct any material development activities outside of Japan with respect to a certain compound or licensed product within the applicable target class for a continuous period of not less than 365 days and do not commence any such activities within 120 days of receiving written notice. Either party may terminate the agreement, subject to specified conditions, (i) in the event of material breach by the other party, subject to a cure period, (ii) if the other party challenges the validity or enforceability of certain intellectual property rights, subject to a cure period, or (iii) if the other party becomes insolvent or takes certain actions related to insolvency.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Pharmaceutical Company Limited, or Takeda.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2020, we entered into an exclusive license agreement with Takeda, pursuant to which we acquired the exclusive rights to develop and commercialize certain early-to-mid stage psychiatry compounds, including luvadaxistat, NBI-1065845, NBI-1065846 and four non-clinical stage compounds. Luvadaxistat and the 4 non-clinical stage compounds have each been designated as a royalty-bearing product. NBI-1065845 and NBI-1065846 are currently each designated as a profit-share product. We are responsible for all manufacturing, development, and commercialization costs of any royalty-bearing product. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to NBI-1065845 and NBI-1065846, we and Takeda will equally share in the operating profits and losses. Takeda retains the rights to opt-out of the profit-sharing arrangements, pursuant to which Takeda would be entitled to receive potential future payments upon the achievement of certain event-based milestones with respect to such compounds and receive royalties on the future net sales of such compounds (in lieu of equally sharing in the operating profits and losses). Takeda may elect to exercise such opt-out right for such compound immediately following the completion of a second Phase II clinical trial for such compound, or, under certain circumstances related to the development and commercialization activities to be performed by us, before the initiation of a Phase III clinical trial for such compound.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Takeda $<ix:nonFraction unitRef="usd" contextRef="i0f5830ad533c4847b9f38b89925e51ec_D20200101-20201231" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzU1NzY_c6250dda-c7d0-4519-95b2-c2cbb0d81935">120.0</ix:nonFraction> million upfront, which, including certain transaction-related costs, was expensed as IPR&amp;D in 2020. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the approval of our clinical trial application for NBI-1070770 for the treatment of major depressive disorder in July 2022, we paid Takeda a milestone of $<ix:nonFraction unitRef="usd" contextRef="i7449f5d91b314ce9840e1b298ee98b5a_D20220101-20221231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzEwOTk1MTE2NTAxMjc_8a065020-b2dc-41e7-8801-6cd8349df8c7">5.0</ix:nonFraction> million, which was expensed as R&amp;D in 2022.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Takeda may be entitled to receive potential future payments of up to $<ix:nonFraction unitRef="usd" contextRef="i6b886e104da64c1fa92f25fa93dc1395_I20221231" decimals="-8" name="nbix:PotentialMilestonePayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzEwOTk1MTE2NTEzNzc_63ee740b-a493-4784-b266-2deb42b26282">1.9</ix:nonFraction> billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any royalty-bearing product.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until the date on which, (i) for any royalty-bearing product, the royalty term has expired in such country; and (ii) for any profit-share product, for so long as we continue to develop, manufacture, or commercialize such licensed product.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a licensed product-by-licensed product and country-by-country basis, royalty payments would commence on the first commercial sale of a royalty-bearing product and terminate on the later of (i) the expiration of the last patent covering such royalty-bearing product in such country, (ii) a number of years from the first commercial sale of such royalty-bearing product in such country and (iii) the expiration of regulatory exclusivity for such royalty-bearing product in such country.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id4d223748c29450e85e2ec9751e48c17" continuedAt="i948ebb6edca14084aaa6cd159bcfafab"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate the agreement in its entirety or in one or more (but not all) of the United States, Japan, the European Union and the United Kingdom, or, collectively, the major markets, upon six months&#8217; written notice to Takeda (i) with respect to all licensed products prior to the first commercial sale of the first licensed product for which first commercial sale occurs, or (ii) with respect to all licensed products in one or more given target classes, as defined in the agreement, prior to the first commercial sale of the first licensed product in such target class for which first commercial sale occurs. We may terminate the agreement in its entirety or in one or more (but not all) of the major markets upon 12 months&#8217; written notice to Takeda (i) with respect to all licensed products following the first commercial sale of the first licensed product for which first commercial sale occurs, or (ii) with respect to all licensed products in one or more given target classes following the first commercial sale of the first licensed product in such target class for which first commercial sale occurs. Takeda may terminate the agreement, subject to specified conditions, (i) if we challenge the validity or enforceability of certain Takeda intellectual property rights or (ii) on a target class-by-target class basis, in the event that we do not conduct any material development or commercialization activities with respect to any licensed product within such target class for a specified continuous period. Subject to a cure period, either party may terminate the agreement in the event of any material breach, solely with respect to the target class of a licensed product to which such material breach relates, or in its entirety in the event of any material breach that relates to all licensed products.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Idorsia Pharmaceuticals Ltd., or Idorsia.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2020, we entered into a collaboration and license agreement with Idorsia, pursuant to which we acquired the global rights to NBI-827104, a potent, selective, orally active and brain penetrating T-type calcium channel blocker in clinical development for the treatment of a rare pediatric epilepsy and other potential indications, including essential tremor. We are responsible for all manufacturing, development, and commercialization costs of any collaboration product.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Idorsia $<ix:nonFraction unitRef="usd" contextRef="i868635e691954212a665a735b175d9cc_D20200101-20201231" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzkyODQ_db16b7bd-1be6-4575-a734-c4cc6a633fdb">45.0</ix:nonFraction> million upfront, which was expensed as IPR&amp;D in 2020. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. Under the terms of the agreement, Idorsia may be entitled to receive potential future payments of up to $<ix:nonFraction unitRef="usd" contextRef="i440c81bdf19642fba2eda39e1baadf0e_I20221231" decimals="-8" name="nbix:PotentialMilestonePayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5Xzk1NTU_8fa4e1af-e3bb-40ab-8dfc-8186763b43af">1.7</ix:nonFraction> billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate the agreement, in its entirety or with respect to a particular compound or development candidate, upon 90 days&#8217; written notice to Idorsia. Further, in the event a party commits a material breach and fails to cure such material breach within 90 days after receiving written notice thereof, the non-breaching party may terminate the agreement in its entirety immediately upon written notice to the breaching party.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Xenon Pharmaceuticals Inc., or Xenon. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we entered into a collaboration and license agreement with Xenon to identify, research and develop sodium channel inhibitors, including NBI-921352 and three preclinical candidates, which compounds we have the exclusive rights to develop and commercialize. We are responsible for all development and manufacturing costs of any collaboration product, subject to certain exceptions.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Xenon $<ix:nonFraction unitRef="usd" contextRef="idd82456387ea428d8220b9c69e68b5a5_I20191231" decimals="-5" name="nbix:UpfrontPaymentsMade" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzEwNjE1_9eae4d9c-fc4f-4724-a5a9-4258c2fad853">50.0</ix:nonFraction> million upfront, including a purchase of approximately <ix:nonFraction unitRef="shares" contextRef="i61160aa576a54fed889d400313bcb4aa_D20190101-20191231" decimals="-5" name="nbix:SaleOfStockNumberOfSharesSoldInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzEwNjY1_6ffb0d7c-b9f3-4268-ba44-a6c7942142c2">1.4</ix:nonFraction> million shares of Xenon common stock (at $<ix:nonFraction unitRef="usdPerShare" contextRef="idd82456387ea428d8220b9c69e68b5a5_I20191231" decimals="3" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzEwNzAx_406d66d7-415d-42ff-bb41-14ac082c5ffb">14.196</ix:nonFraction> per share). We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. The purchased shares were recorded at a fair value of $<ix:nonFraction unitRef="usd" contextRef="idd82456387ea428d8220b9c69e68b5a5_I20191231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzEwODg4_296fc093-26c7-44db-b606-49404d7b9d5d">14.1</ix:nonFraction> million after considering Xenon&#8217;s stock price on the measurement date and certain transfer restrictions applicable to the shares. The remaining $<ix:nonFraction unitRef="usd" contextRef="ib362d8b9fffd4556aaef9b4388175d10_D20190101-20191231" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzExMDI3_e7a1b81e-4f3b-4d7a-bb5e-715f865d01e1">36.2</ix:nonFraction> million of the purchase price, which includes certain transaction-related costs, was expensed as IPR&amp;D in 2019.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the European Union&#8217;s approval of our clinical trial application for NBI-921352 for the treatment of focal onset seizures in adults in September 2021, we paid Xenon a regulatory milestone of $<ix:nonFraction unitRef="usd" contextRef="i1de27f6ad9554d338fb10badbf2b6cc6_I20211231" decimals="-5" name="nbix:MilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzExMzQz_7fda1285-3948-47b4-9824-c158edec19e4">10.0</ix:nonFraction> million, including a purchase of approximately <ix:nonFraction unitRef="shares" contextRef="ia98ab6db9c434e4dbbefda09d3b887fb_D20210101-20211231" decimals="-5" name="nbix:SaleOfStockNumberOfSharesSoldInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzExMzg1_ce8412e1-4d27-483b-8dbe-426b208768e4">0.3</ix:nonFraction> million shares of Xenon common stock (at $<ix:nonFraction unitRef="usdPerShare" contextRef="i1de27f6ad9554d338fb10badbf2b6cc6_I20211231" decimals="4" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzExNDIx_7e3b4c64-fe19-49a2-95db-cc7b5d6fa684">19.9755</ix:nonFraction> per share). The purchased shares were recorded at a fair value of $<ix:nonFraction unitRef="usd" contextRef="i1de27f6ad9554d338fb10badbf2b6cc6_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzExNDkw_5080612d-f9d5-4bed-954b-df36074327c0">4.6</ix:nonFraction> million after considering Xenon&#8217;s stock price on the measurement date and certain transfer restrictions applicable to the shares. The remaining $<ix:nonFraction unitRef="usd" contextRef="i1dd2cca8016742d7affa71c15d311c24_D20210101-20211231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzExNjI5_ac78ebf4-a9df-4e70-b36e-749edb8db20d">5.4</ix:nonFraction> million of the milestone payment was expensed as R&amp;D in 2021.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the FDA's acceptance of our amended KAYAK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">study protocol in January 2022, we paid Xenon a regulatory milestone of $<ix:nonFraction unitRef="usd" contextRef="i56425aa7040a45e28f54bc219c6c40d3_I20221231" decimals="-5" name="nbix:MilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzExODIx_a8491912-a11f-471b-8b21-b741a74b6ee2">15.0</ix:nonFraction> million, including a purchase of approximately <ix:nonFraction unitRef="shares" contextRef="ieb20bc9532234865b09c7dc5f22a26fc_D20220101-20221231" decimals="-5" name="nbix:SaleOfStockNumberOfSharesSoldInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzExODYz_34ef2452-6e95-4cfd-8165-e1925c53a2ff">0.3</ix:nonFraction> million shares of Xenon common stock (at $<ix:nonFraction unitRef="usdPerShare" contextRef="i56425aa7040a45e28f54bc219c6c40d3_I20221231" decimals="3" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzExODk5_f9ad4cdb-3a7a-4bc2-b84f-51a96c837e12">31.855</ix:nonFraction> per share). The purchased shares were recorded at a fair value of $<ix:nonFraction unitRef="usd" contextRef="i56425aa7040a45e28f54bc219c6c40d3_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzExOTY4_8d108318-bc84-4f5f-8017-6c3c7f210deb">7.7</ix:nonFraction> million after considering Xenon&#8217;s stock price on the measurement date. The remaining $<ix:nonFraction unitRef="usd" contextRef="ia5b5c0571ff04f84bac746f261a35bef_D20220101-20221231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzEyMDQ4_7112f759-f87e-428f-900d-5c6b5851c893">7.3</ix:nonFraction> million of the milestone payment was expensed as R&amp;D in 2022.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i948ebb6edca14084aaa6cd159bcfafab" continuedAt="i07df401f536d4f419f4f5a8f24b1e5ce"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Xenon may be entitled to receive potential future payments of up to $<ix:nonFraction unitRef="usd" contextRef="i56425aa7040a45e28f54bc219c6c40d3_I20221231" decimals="-8" name="nbix:PotentialMilestonePayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzEyMjI4_cf76ea95-a51e-44a0-820e-b5a769df6c20">1.7</ix:nonFraction> billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product. Xenon retains the right to elect to co-develop one product in a major indication, pursuant to which Xenon would receive a mid-single digit percentage increase in royalties earned on the future net sales of such product in the United States and we and Xenon would equally share in the development costs of such product in the applicable indication, except where such development costs relate solely to the regulatory approval of such product outside the United States.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until the expiration of the royalty term for such product in such country. Upon the expiration of the royalty term for a particular licensed product and country, the license obtained by us with respect to such product and country will become fully paid, royalty free, perpetual and irrevocable. We may terminate the agreement upon 90 days&#8217; written notice to Xenon, provided that such unilateral termination will not be effective for certain products until we have used commercially reasonable efforts to complete certain specified clinical studies. Either party may terminate the agreement in the event of a material breach in whole or in part, subject to specified conditions.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voyager Therapeutics, Inc., or Voyager.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we entered into a collaboration and license agreement with Voyager, pursuant to which we acquired certain rights to develop and commercialize the NBIb-1817 for Parkinson&#8217;s disease program, Friedreich&#8217;s ataxia program and two undisclosed programs. We are responsible for all development costs of any collaboration product, subject to certain co-development and co-commercialization rights retained by Voyager. In February 2021, we notified Voyager of our termination of the NBIb-1817 for Parkinson&#8217;s disease program, which became effective August 2, 2021. The termination did not apply to any program other than the NBIb-1817 for Parkinson&#8217;s disease program.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Voyager $<ix:nonFraction unitRef="usd" contextRef="i3558292be26a40eea22ad957b4eb1826_I20191231" decimals="-5" name="nbix:UpfrontPaymentsMade" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzE0NDEy_01b931df-8627-4304-9925-f4d0b44b64cb">165.0</ix:nonFraction> million upfront, including a purchase of approximately <ix:nonFraction unitRef="shares" contextRef="i7701cdc56953401b8c556dba9626d9e9_D20190101-20191231" decimals="-5" name="nbix:SaleOfStockNumberOfSharesSoldInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzE0NDYy_b4ee26f7-bdb0-41f3-8dc3-6cc561077885">4.2</ix:nonFraction> million shares of Voyager common stock (at $<ix:nonFraction unitRef="usdPerShare" contextRef="i3558292be26a40eea22ad957b4eb1826_I20191231" decimals="4" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzE0NTAw_47704e80-1c2c-400a-8ab8-d407167962e2">11.9625</ix:nonFraction> per share). We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. The purchased shares were recorded at a fair value of $<ix:nonFraction unitRef="usd" contextRef="i3558292be26a40eea22ad957b4eb1826_I20191231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzE0Njg3_f681f560-848a-4a1d-b886-5a0718748d3f">54.7</ix:nonFraction> million after considering Voyager&#8217;s stock price on the measurement date and certain transfer restrictions applicable to the shares. The remaining $<ix:nonFraction unitRef="usd" contextRef="i68a2f3aa551740a2a1bc3a14aaf7c9fa_D20190101-20190331" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzE0ODI4_a95e006a-785b-4b32-b813-f83962a12f7f">113.1</ix:nonFraction> million of the purchase price, which includes certain transaction-related costs, was expensed as IPR&amp;D in 2019. In addition, we paid Voyager $<ix:nonFraction unitRef="usd" contextRef="ic667970352ec4acca922a861f9e43c76_D20190401-20190630" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzE0OTY0_79670aad-5b78-47d3-b807-6b09a86c5256">5.0</ix:nonFraction> million upfront, which was expensed as IPR&amp;D in 2019, to acquire the rights outside the United States to the Friedreich&#8217;s ataxia program.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Voyager may be entitled to receive potential future payments of up to $<ix:nonFraction unitRef="usd" contextRef="i42ebb9eaffae4c9eac346888ea44b0d4_I20221231" decimals="-8" name="nbix:PotentialMilestonePayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzE1MjAx_d1f5b294-3b14-4cb9-acf0-8ca5199e6c2a">1.3</ix:nonFraction> billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless terminated earlier, the agreement will continue in effect until the expiration of the last to expire royalty term with respect to any collaboration product or the last expiration or termination of any exercised co-development and co-commercialization rights by Voyager as provided for in the agreement. We may terminate the agreement upon 180 days&#8217; written notice to Voyager prior to the first commercial sale of any collaboration product or upon one year after the date of notice if such notice is provided after the first commercial sale of any collaboration product.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BIAL &#8211; Portela &amp; Ca, S.A., or BIAL.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We acquired the United States and Canada rights to ONGENTYS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(opicapone) from BIAL in 2017, and launched ONGENTYS in the United States in September 2020 as an FDA-approved add-on treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing motor fluctuations. We are responsible for all commercialization costs of ONGENTYS in the United States and Canada and rely on BIAL for the commercial supply of ONGENTYS.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the license agreement, BIAL may be entitled to receive potential future payments of up to $<ix:nonFraction unitRef="usd" contextRef="i67a8f10be8224d60b4e1657e6dade015_I20221231" decimals="-5" name="nbix:PotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzE2NTEw_9940066b-db6e-4ea1-a48c-fe187bc5896d">75.0</ix:nonFraction> million upon the achievement of certain event-based milestones. In addition, with respect to ONGENTYS, in the event we fail to meet certain minimum sales requirements for a particular year in comparison to our annual sales forecast for such year, we would be obligated to pay BIAL an amount equal to the difference between the actual net sales and minimum sales requirements for such year. Further, upon our written request to BIAL 12 months prior to the estimated expiration of the term of a licensed product, we will negotiate the continuation of BIAL&#8217;s supply of such licensed product after the term. After the term, and if BIAL is no longer supplying such licensed product, BIAL would be entitled to receive a low double-digit royalty on our future quarterly net sales of such licensed product.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i07df401f536d4f419f4f5a8f24b1e5ce"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until a generic product with respect to such licensed product is sold in a country and sales of such generic product are greater than a specified percentage of total sales of such licensed product in such country.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate the agreement upon nine months&#8217; written notice to BIAL. BIAL may terminate the agreement in the event we fail to meet the minimum sales requirements for any two years, or under certain circumstances involving a change of control of Neurocrine Biosciences. Under certain circumstances where BIAL elects to terminate the agreement in connection with a change of control of Neurocrine Biosciences, BIAL would be obligated to pay us a termination fee. Either party may terminate the agreement if the other party materially breaches the agreement and does not cure the breach within a specified notice period, or upon the other party&#8217;s insolvency.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mitsubishi Tanabe Pharma Corporation, or MTPC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We out-licensed the rights to valbenazine in Japan and other select Asian markets to MTPC in 2015. In December 2020, we entered into a commercial supply agreement with MTPC, pursuant to which we agreed to supply MTPC with valbenazine drug product for commercial use in Japan and other select Asian markets. MTPC is responsible for all development, manufacturing, and commercialization costs of valbenazine in such markets.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, MTPC launched DYSVAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (valbenazine) in Japan for the treatment of tardive dyskinesia. In connection with MTPC's first commercial sale of DYSVAL in Japan, we received a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i59539b84d7aa486da424a835877b0fc9_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzEwOTk1MTE2NTI3OTg_c3eff52c-d7c2-4615-8c8d-06e47a8c4451">20.0</ix:nonFraction> million in 2022. ASC 606 provides a royalty exception for a sales-based or usage-based royalty promised in exchange for a license of intellectual property. Under the royalty exception, the milestone would be recognized as revenue only when the later of (1) the subsequent sale or usage occurs or (2) the performance obligation to which some or all of the sales-based or usage-based royalty has been allocated has been satisfied (or partially satisfied). As the milestone related to a license of intellectual property and was contingent upon MTPC&#8217;s first commercial sale of DYSVAL in Japan, the milestone was recognized as revenue in the second quarter of 2022. In addition, we receive royalties at tiered percentage rates on MTPC net sales of DYSVAL.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our license agreement with MTPC, we may be entitled to receive potential future payments of up to $<ix:nonFraction unitRef="usd" contextRef="ic013c8b18d624578b99159e4ff5581c7_I20221231" decimals="-5" name="nbix:PotentialMilestonePaymentReceipts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzE5OTI1_21675e6c-0d02-441b-86f2-a2bbf1765636">30.0</ix:nonFraction> million upon the achievement of certain sales-based milestones and are entitled to receive royalties at tiered percentage rates on future MTPC net sales of valbenazine for the longer of <ix:nonNumeric contextRef="i5a3cc531fe0541f4b8e3a1edcfbd0a17_D20220101-20221231" name="nbix:PatentTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzIwMTA2_2733a95f-9842-4681-9780-9b87d6c11b30">10</ix:nonNumeric> years or the life of the related patent rights. MTPC may terminate the agreement upon 180 days&#8217; written notice to us. In such event, all out-licensed product rights would revert to us.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AbbVie Inc., or AbbVie. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We out-licensed the global rights to elagolix to AbbVie in 2010. AbbVie is responsible for all development and commercialization costs of elagolix.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, AbbVie launched ORILISSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(elagolix tablets) in the United States for the treatment of moderate to severe pain associated with endometriosis. In June 2020, AbbVie launched ORIAHNN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(elagolix, estradiol and norethindrone acetate capsules and elagolix capsules) in the United States for the treatment of heavy menstrual bleeding related to uterine fibroids in premenopausal women. We receive royalties at tiered percentage rates on AbbVie net sales of elagolix and recognized elagolix royalty revenue of $<ix:nonFraction unitRef="usd" contextRef="iee6e68341d9841438fa8702438a7dac5_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzE2NDkyNjc0NzI3NTg_3a197b10-37fe-457e-921c-7b7d8f700a38">21.2</ix:nonFraction>&#160;million for 2022, $<ix:nonFraction unitRef="usd" contextRef="i6f13730346f24079965eeb3a7fe0ff59_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzIxOTkwMjMyODU4NDE_797871e5-29fa-473c-80a9-f12b82bc3c01">22.3</ix:nonFraction>&#160;million for 2021 and $<ix:nonFraction unitRef="usd" contextRef="idda4399247c446cebc1ede65c5bec2b9_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzIxOTkwMjMyODU4NTc_13f4bb00-76ec-4b8e-97ec-bc2af9785385">19.2</ix:nonFraction>&#160;million for 2020.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our license agreement with AbbVie, we may be entitled to receive potential future payments of up to $<ix:nonFraction unitRef="usd" contextRef="i61790d0b66be4586a7c469931f4ab4d7_I20221231" decimals="-5" name="nbix:PotentialMilestonePaymentReceipts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzIxMTUw_a4e75db5-3247-44f5-9fa4-74f620623c79">366.0</ix:nonFraction> million upon the achievement of certain event-based milestones and are entitled to receive royalties at tiered percentage rates on future AbbVie net sales of elagolix for the longer of <ix:nonNumeric contextRef="i6d60a74b87dc498c97bc171751a50ac9_D20220101-20221231" name="nbix:PatentTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzIxMzMw_ff0502a2-f19b-469f-afc5-f503c2c4e361">10</ix:nonNumeric> years or the life of the related patent rights. AbbVie may terminate the agreement upon 180 days&#8217; written notice to us. In such event, all out-licensed product rights would revert to us.</span></div></ix:continuation><div id="id795223301944418ba8c3fb3bc02f08e_136"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzYvZnJhZzoxZWZhN2M0YWRmZjE0MThhYjVjOWE2MDhlMmYyMWMxOC90ZXh0cmVnaW9uOjFlZmE3YzRhZGZmMTQxOGFiNWM5YTYwOGUyZjIxYzE4XzQ5NDc4MDIzMjg4MDE_35ee2751-b398-4069-b62d-82d35cde606f" continuedAt="i1bd5bf7ba91d4c4696d8f3b6f0084eb4" escape="true">Diurnal Acquisition</ix:nonNumeric></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1bd5bf7ba91d4c4696d8f3b6f0084eb4" continuedAt="i3760c1b90c7147aca1851a321ae2b85c">On November 1, 2022, we completed our acquisition of Diurnal Group plc, or Diurnal, a United Kingdom-headquartered, specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. We believe our acquisition of Diurnal presents an opportunity to accelerate the establishment of our clinical development and commercial capabilities in the United Kingdom to the benefit of patient communities and other stakeholders.</ix:continuation></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3760c1b90c7147aca1851a321ae2b85c"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate purchase price of this acquisition was $<ix:nonFraction unitRef="usd" contextRef="i9d13692c26a440998d78e8fffc7d8570_D20221101-20221101" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzYvZnJhZzoxZWZhN2M0YWRmZjE0MThhYjVjOWE2MDhlMmYyMWMxOC90ZXh0cmVnaW9uOjFlZmE3YzRhZGZmMTQxOGFiNWM5YTYwOGUyZjIxYzE4XzIxOTkwMjMyNTkzNDg_033e0b2a-d53a-45a3-bdaa-c00e3781af2a">55.2</ix:nonFraction>&#160;million in cash. The acquisition was accounted for in accordance with FASB ASC 805 as a Business Combinations and, accordingly, Diurnal&#8217;s results of operations have been consolidated in Neurocrine Biosciences&#8217; financial statements since the date of acquisition. Pro forma results of operations for the years ended December 31, 2022 and 2021 would not be materially different as a result of this acquisition and therefore are not presented. In connection with the acquisition, we recognized transaction costs of $<ix:nonFraction unitRef="usd" contextRef="i9d13692c26a440998d78e8fffc7d8570_D20221101-20221101" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzYvZnJhZzoxZWZhN2M0YWRmZjE0MThhYjVjOWE2MDhlMmYyMWMxOC90ZXh0cmVnaW9uOjFlZmE3YzRhZGZmMTQxOGFiNWM5YTYwOGUyZjIxYzE4XzE2NDkyNjc0NTQ3MTY_c62417cb-4444-4e5a-94b4-8127b7c51663">1.7</ix:nonFraction>&#160;million, which were expensed as selling, general and administrative and primarily consisted of investment banker, advisory, legal and other professional fees.</span></div><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzYvZnJhZzoxZWZhN2M0YWRmZjE0MThhYjVjOWE2MDhlMmYyMWMxOC90ZXh0cmVnaW9uOjFlZmE3YzRhZGZmMTQxOGFiNWM5YTYwOGUyZjIxYzE4XzQ5NDc4MDIzMjg4MDU_0d925d7d-ac46-4978-b144-8736af07d04c" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the consideration paid for Diurnal and the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consideration</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d13692c26a440998d78e8fffc7d8570_D20221101-20221101" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzYvZnJhZzoxZWZhN2M0YWRmZjE0MThhYjVjOWE2MDhlMmYyMWMxOC90YWJsZTplYjMzZjRlMDRiNjQ0MTcxOGEwY2I5NWY0ZmU1ZjJlMC90YWJsZXJhbmdlOmViMzNmNGUwNGI2NDQxNzE4YTBjYjk1ZjRmZTVmMmUwXzItMS0xLTEtMTQ0MDQx_73bda619-664f-4d32-813d-c403dd0a32c2">55.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d13692c26a440998d78e8fffc7d8570_D20221101-20221101" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzYvZnJhZzoxZWZhN2M0YWRmZjE0MThhYjVjOWE2MDhlMmYyMWMxOC90YWJsZTplYjMzZjRlMDRiNjQ0MTcxOGEwY2I5NWY0ZmU1ZjJlMC90YWJsZXJhbmdlOmViMzNmNGUwNGI2NDQxNzE4YTBjYjk1ZjRmZTVmMmUwXzUtMS0xLTEtMTQ0MDQx_1f911b39-adb7-489d-bec6-416521ea97b3">55.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Recognized amounts of identifiable assets acquired and liabilities assumed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a8688d19b0c4b7f9f790a262226d2ea_I20221101" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzYvZnJhZzoxZWZhN2M0YWRmZjE0MThhYjVjOWE2MDhlMmYyMWMxOC90YWJsZTplYjMzZjRlMDRiNjQ0MTcxOGEwY2I5NWY0ZmU1ZjJlMC90YWJsZXJhbmdlOmViMzNmNGUwNGI2NDQxNzE4YTBjYjk1ZjRmZTVmMmUwXzEtMS0xLTEtMTQzNTk0_baff9cde-87b1-4c1e-ac7f-b76c128e6ee9">12.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a8688d19b0c4b7f9f790a262226d2ea_I20221101" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzYvZnJhZzoxZWZhN2M0YWRmZjE0MThhYjVjOWE2MDhlMmYyMWMxOC90YWJsZTplYjMzZjRlMDRiNjQ0MTcxOGEwY2I5NWY0ZmU1ZjJlMC90YWJsZXJhbmdlOmViMzNmNGUwNGI2NDQxNzE4YTBjYjk1ZjRmZTVmMmUwXzctMS0xLTEtMTYwMDYx_d478eef6-2756-4d32-b5eb-8df4aeccf74a">32.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a8688d19b0c4b7f9f790a262226d2ea_I20221101" decimals="-5" name="nbix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsAcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzYvZnJhZzoxZWZhN2M0YWRmZjE0MThhYjVjOWE2MDhlMmYyMWMxOC90YWJsZTplYjMzZjRlMDRiNjQ0MTcxOGEwY2I5NWY0ZmU1ZjJlMC90YWJsZXJhbmdlOmViMzNmNGUwNGI2NDQxNzE4YTBjYjk1ZjRmZTVmMmUwXzQtMS0xLTEtMTQzNTk0_995a0651-e4d0-434a-bc2d-f6fcb98f16e8">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a8688d19b0c4b7f9f790a262226d2ea_I20221101" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzYvZnJhZzoxZWZhN2M0YWRmZjE0MThhYjVjOWE2MDhlMmYyMWMxOC90YWJsZTplYjMzZjRlMDRiNjQ0MTcxOGEwY2I5NWY0ZmU1ZjJlMC90YWJsZXJhbmdlOmViMzNmNGUwNGI2NDQxNzE4YTBjYjk1ZjRmZTVmMmUwXzYtMS0xLTEtMTQzNTk0_eda5f66e-b14d-43ea-839b-959e7d81bd00">12.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a8688d19b0c4b7f9f790a262226d2ea_I20221101" decimals="-5" name="nbix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndOtherAccruedExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzYvZnJhZzoxZWZhN2M0YWRmZjE0MThhYjVjOWE2MDhlMmYyMWMxOC90YWJsZTplYjMzZjRlMDRiNjQ0MTcxOGEwY2I5NWY0ZmU1ZjJlMC90YWJsZXJhbmdlOmViMzNmNGUwNGI2NDQxNzE4YTBjYjk1ZjRmZTVmMmUwXzExLTEtMS0xLTE0NDA0Mw_5d056b64-cb95-4894-8e86-9df89b95777c">10.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total identifiable net assets acquired</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a8688d19b0c4b7f9f790a262226d2ea_I20221101" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzYvZnJhZzoxZWZhN2M0YWRmZjE0MThhYjVjOWE2MDhlMmYyMWMxOC90YWJsZTplYjMzZjRlMDRiNjQ0MTcxOGEwY2I5NWY0ZmU1ZjJlMC90YWJsZXJhbmdlOmViMzNmNGUwNGI2NDQxNzE4YTBjYjk1ZjRmZTVmMmUwXzctMS0xLTEtMTQzNTk0_983da9cf-7183-4414-a108-5f233eaef05f">50.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a8688d19b0c4b7f9f790a262226d2ea_I20221101" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzYvZnJhZzoxZWZhN2M0YWRmZjE0MThhYjVjOWE2MDhlMmYyMWMxOC90YWJsZTplYjMzZjRlMDRiNjQ0MTcxOGEwY2I5NWY0ZmU1ZjJlMC90YWJsZXJhbmdlOmViMzNmNGUwNGI2NDQxNzE4YTBjYjk1ZjRmZTVmMmUwXzE0LTEtMS0xLTE0NDA0NA_369f170e-96fe-4fca-af70-636b1bc66733">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="id795223301944418ba8c3fb3bc02f08e_142"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90ZXh0cmVnaW9uOjJlYjkwZGUyMDczYjRkMWQ5ZWM4NzZjZDIwYTNlMWExXzExOTg_9d6e818b-fb42-4fad-a497-b0c4554b02e0" continuedAt="i760d245a28d14be48d5aaddf25852d6a" escape="true">Debt Securities</ix:nonNumeric></span></div><ix:continuation id="i760d245a28d14be48d5aaddf25852d6a" continuedAt="i088e0eb98e0e46169be9010a0f1dfac4"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90ZXh0cmVnaW9uOjJlYjkwZGUyMDczYjRkMWQ5ZWM4NzZjZDIwYTNlMWExXzExOTk_12fbe71f-90f6-4688-8445-d3c0a665b8d2" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income (loss) and fair value of debt securities available-for-sale, aggregated by major security type and contractual maturity.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.075%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Contractual<br/>Maturity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a6f8fd190a2433584205fa45bfd8bcb_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzItMy0xLTEtMTM5MDYy_3e386e66-5cb7-427d-8fab-41b1a2fd25af">156.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a6f8fd190a2433584205fa45bfd8bcb_I20221231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzItNS0xLTEtMTM5MDYy_0221ad20-9f68-484e-84a0-a11b1ffa33e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a6f8fd190a2433584205fa45bfd8bcb_I20221231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzItNy0xLTEtMTM5MDYy_50897855-cdb4-4335-b363-90296a0eb6e6">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a6f8fd190a2433584205fa45bfd8bcb_I20221231" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzItOS0xLTEtMTM5MDYy_25bb3eb9-41d4-40ef-8f75-a28e784590d2">156.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i001676d240734d81bdb16bacb8df878e_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzItMTEtMS0xLTEzOTA2Mg_598fa9fd-c71e-46a3-b460-216b59774dd2">204.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i001676d240734d81bdb16bacb8df878e_I20211231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzItMTMtMS0xLTEzOTA2Mg_d2c6ed7f-484d-4001-8d9e-8bee3df31c65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i001676d240734d81bdb16bacb8df878e_I20211231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzItMTUtMS0xLTEzOTA2Mg_6e4e5380-2a61-4dc5-8351-7d71b0904a13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i001676d240734d81bdb16bacb8df878e_I20211231" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzItMTctMS0xLTEzOTA2Mg_04668cea-35a0-4a74-9c43-a2ba65970a12">204.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dc4af282e2e4830bb4c5589ec647f1f_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzMtMy0xLTEtMTM5MDYy_505d2910-73c1-4db6-b507-e0e2ab9f5b75">296.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dc4af282e2e4830bb4c5589ec647f1f_I20221231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzMtNS0xLTEtMTM5MDYy_dd33c003-4c03-4184-9eb9-c0017a8ab9f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2dc4af282e2e4830bb4c5589ec647f1f_I20221231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzMtNy0xLTEtMTM5MDYy_15cdbe8a-cb59-406f-8c08-b24c6124a80f">3.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dc4af282e2e4830bb4c5589ec647f1f_I20221231" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzMtOS0xLTEtMTM5MDYy_f13d6360-7ea0-4025-95bc-f5003fb2146e">293.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e6ecccda3454d2d97a48bbbed7a06c4_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzMtMTEtMS0xLTEzOTA2Mg_3577d3b6-d7b4-46e2-b1a7-83559999bc99">128.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e6ecccda3454d2d97a48bbbed7a06c4_I20211231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzMtMTMtMS0xLTEzOTA2Mg_127d1175-bc7a-4b04-9145-24124bc9ce1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e6ecccda3454d2d97a48bbbed7a06c4_I20211231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzMtMTUtMS0xLTEzOTA2Mg_d1813ace-1455-4594-99c0-57047cf5ab8c">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e6ecccda3454d2d97a48bbbed7a06c4_I20211231" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzMtMTctMS0xLTEzOTA2Mg_fbdd69d4-8e65-4bdd-909b-4b2779d98b1f">128.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc59d3c4ac034bfc85c224da99f57d0f_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzQtMy0xLTEtMTM5MDYy_9ba4fa76-b067-4d69-8ffd-c53a66b14257">283.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc59d3c4ac034bfc85c224da99f57d0f_I20221231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzQtNS0xLTEtMTM5MDYy_fa662529-10e1-4bc0-8bdc-ab3032832a84">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc59d3c4ac034bfc85c224da99f57d0f_I20221231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzQtNy0xLTEtMTM5MDYy_d2025924-ca1d-444a-944f-6cc6241ab902">6.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc59d3c4ac034bfc85c224da99f57d0f_I20221231" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzQtOS0xLTEtMTM5MDYy_120deac8-a580-4ff0-a80b-9c9cf88fdc35">277.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76c8c1dcfb3247a6b15b3036d4069cbc_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzQtMTEtMS0xLTEzOTA2Mg_bbaa74fa-028f-4f32-952c-15a0584a0fb2">37.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76c8c1dcfb3247a6b15b3036d4069cbc_I20211231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzQtMTMtMS0xLTEzOTA2Mg_fbe38e35-2e33-4278-8a74-a06cbe2a7def">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76c8c1dcfb3247a6b15b3036d4069cbc_I20211231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzQtMTUtMS0xLTEzOTA2Mg_f367737b-3c47-46e4-82f0-edb032c3109c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76c8c1dcfb3247a6b15b3036d4069cbc_I20211231" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzQtMTctMS0xLTEzOTA2Mg_90cf8d7a-de29-4f76-bbcb-1a4db88eb007">37.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzUtMy0xLTEtMTM5MDYy_91931eea-382c-46fb-9326-15a690812a70">735.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzUtNS0xLTEtMTM5MDYy_02ee5f5c-326b-480d-a8c8-a05883be7f31">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzUtNy0xLTEtMTM5MDYy_fe4780a3-f5c4-468b-90cd-b161695e7d9a">9.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzUtOS0xLTEtMTM5MDYy_660f02fe-5f5e-4c5c-a936-4329256a07ac">726.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzUtMTEtMS0xLTEzOTA2Mg_996106e0-b089-4351-8a4e-909a56dc0b3b">370.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzUtMTMtMS0xLTEzOTA2Mg_f8fc0479-0921-4177-bae4-ad024a4f8d95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzUtMTUtMS0xLTEzOTA2Mg_ea7b7016-9583-426e-9648-6e863ec1b92d">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzUtMTctMS0xLTEzOTA2Mg_25537f00-1130-4091-ae5f-5c84e215d317">370.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 to 3 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dc4af282e2e4830bb4c5589ec647f1f_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzctMy0xLTEtMTM5MDYy_1221f67e-4257-44c2-9b9d-1f593fe9f5c4">259.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dc4af282e2e4830bb4c5589ec647f1f_I20221231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzctNS0xLTEtMTM5MDYy_df1c4ce6-adaa-4f17-8e6c-ad050e15400c">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2dc4af282e2e4830bb4c5589ec647f1f_I20221231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzctNy0xLTEtMTM5MDYy_d865ef90-ea1f-4065-8470-d7ae25b954f0">4.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dc4af282e2e4830bb4c5589ec647f1f_I20221231" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzctOS0xLTEtMTM5MDYy_e691f368-3b25-43e2-9fef-18849de74671">255.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e6ecccda3454d2d97a48bbbed7a06c4_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzctMTEtMS0xLTEzOTA2Mg_9dedc74d-138a-4c88-ae7d-720f35e3436b">358.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e6ecccda3454d2d97a48bbbed7a06c4_I20211231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzctMTMtMS0xLTEzOTA2Mg_45d226f9-5b77-401d-91e5-6d4d86b5d034">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e6ecccda3454d2d97a48bbbed7a06c4_I20211231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzctMTUtMS0xLTEzOTA2Mg_3805495f-6136-40d3-b4c0-103cdcfff682">1.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e6ecccda3454d2d97a48bbbed7a06c4_I20211231" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzctMTctMS0xLTEzOTA2Mg_ce086329-f89d-4d4b-b6f2-2e555c6c4f46">357.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 to 3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc59d3c4ac034bfc85c224da99f57d0f_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzgtMy0xLTEtMTM5MDYy_415c96d9-d609-47cd-a736-eea8c680a34f">45.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc59d3c4ac034bfc85c224da99f57d0f_I20221231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzgtNS0xLTEtMTM5MDYy_86711686-924b-4fef-ace4-8a974df45f9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc59d3c4ac034bfc85c224da99f57d0f_I20221231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzgtNy0xLTEtMTM5MDYy_1dc29d3d-bd02-4e77-9ae3-273b0b177dbb">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc59d3c4ac034bfc85c224da99f57d0f_I20221231" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzgtOS0xLTEtMTM5MDYy_7fe264d4-c9db-43e0-8315-00bbe5f18157">44.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76c8c1dcfb3247a6b15b3036d4069cbc_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzgtMTEtMS0xLTEzOTA2Mg_87fa9e89-3053-4325-8d45-7fc73410b227">204.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76c8c1dcfb3247a6b15b3036d4069cbc_I20211231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzgtMTMtMS0xLTEzOTA2Mg_8ecdb91d-baf1-425e-895e-83335a24e829">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76c8c1dcfb3247a6b15b3036d4069cbc_I20211231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzgtMTUtMS0xLTEzOTA2Mg_19176066-a2c9-4366-a5b2-1f28d2c518c2">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76c8c1dcfb3247a6b15b3036d4069cbc_I20211231" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzgtMTctMS0xLTEzOTA2Mg_6bf26ffb-3e29-4fe8-a822-20d8939ff9c9">203.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzktMy0xLTEtMTM5MDYy_04babe93-fce9-4b1e-9f2a-0175852ae8e2">304.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzktNS0xLTEtMTM5MDYy_4c922fff-7141-4b6c-b70a-3f3514318271">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzktNy0xLTEtMTM5MDYy_f156df97-2207-42a5-91b8-2cea6b4276ab">5.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzktOS0xLTEtMTM5MDYy_13d77070-0a36-4c73-a4e8-101ef9e9f8db">299.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzktMTEtMS0xLTEzOTA2Mg_01978005-59f0-4726-9b01-e5bea9d50ed7">563.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzktMTMtMS0xLTEzOTA2Mg_2a0ec82c-27a1-4fdd-a2ce-11f19c2a3209">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzktMTUtMS0xLTEzOTA2Mg_6c08bd73-3de1-4cc3-810f-1700ad9be894">2.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzktMTctMS0xLTEzOTA2Mg_40c34db4-c5e3-4867-a141-3e87b92f9d70">560.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, our security portfolio consisted of <ix:nonFraction unitRef="security" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="INF" name="nbix:DebtSecuritiesAvailableForSalePositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90ZXh0cmVnaW9uOjJlYjkwZGUyMDczYjRkMWQ5ZWM4NzZjZDIwYTNlMWExXzMyOA_eafcc19c-f170-4fdc-8b9a-6e689faa7f75">253</ix:nonFraction> debt securities available-for-sale, including <ix:nonFraction unitRef="security" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90ZXh0cmVnaW9uOjJlYjkwZGUyMDczYjRkMWQ5ZWM4NzZjZDIwYTNlMWExXzM3Nw_e0c71297-868a-4963-b46c-40a726f9b07f">199</ix:nonFraction> such securities that were in an unrealized loss position but of high credit quality. Unrealized losses on these investments were primarily due to changes in interest rates. We do not intend to sell these investments and it is not more likely than not that we will be required to sell these investments before recovery of their amortized cost basis. No allowance for credit losses was recognized as of December&#160;31, 2022 or 2021.</span></div></ix:continuation><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90ZXh0cmVnaW9uOjJlYjkwZGUyMDczYjRkMWQ5ZWM4NzZjZDIwYTNlMWExXzExOTc_19fe1764-afe7-444b-a056-ebf51d7288b1" continuedAt="i9f7d591ff7364fc6890f450f33dbe80c" escape="true"></ix:nonNumeric><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i088e0eb98e0e46169be9010a0f1dfac4"><ix:continuation id="i9f7d591ff7364fc6890f450f33dbe80c"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents debt securities available-for-sale that were in an unrealized loss position as of December&#160;31, 2022, aggregated by major security type and length of time in a continuous loss position.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a6f8fd190a2433584205fa45bfd8bcb_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTpjNDk3MjE4MGRhY2I0ODA1ODY0ODE4NzgwYzg1ZWIxYi90YWJsZXJhbmdlOmM0OTcyMTgwZGFjYjQ4MDU4NjQ4MTg3ODBjODVlYjFiXzItMS0xLTEtMTM5MDYy_911933e5-41d6-48bb-a504-29b9b9033665">32.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a6f8fd190a2433584205fa45bfd8bcb_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTpjNDk3MjE4MGRhY2I0ODA1ODY0ODE4NzgwYzg1ZWIxYi90YWJsZXJhbmdlOmM0OTcyMTgwZGFjYjQ4MDU4NjQ4MTg3ODBjODVlYjFiXzItMy0xLTEtMTM5MDYy_0f220a9a-889b-4e23-9912-63e66804a02c">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a6f8fd190a2433584205fa45bfd8bcb_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTpjNDk3MjE4MGRhY2I0ODA1ODY0ODE4NzgwYzg1ZWIxYi90YWJsZXJhbmdlOmM0OTcyMTgwZGFjYjQ4MDU4NjQ4MTg3ODBjODVlYjFiXzItNS0xLTEtMTM5MDYy_e18aeecb-d3cf-43c0-9e23-1d668442d00a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a6f8fd190a2433584205fa45bfd8bcb_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTpjNDk3MjE4MGRhY2I0ODA1ODY0ODE4NzgwYzg1ZWIxYi90YWJsZXJhbmdlOmM0OTcyMTgwZGFjYjQ4MDU4NjQ4MTg3ODBjODVlYjFiXzItNy0xLTEtMTM5MDYy_c3e5f89a-3adf-468f-9e7a-4889a718af49">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a6f8fd190a2433584205fa45bfd8bcb_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTpjNDk3MjE4MGRhY2I0ODA1ODY0ODE4NzgwYzg1ZWIxYi90YWJsZXJhbmdlOmM0OTcyMTgwZGFjYjQ4MDU4NjQ4MTg3ODBjODVlYjFiXzItOS0xLTEtMTM5MDYy_26c060d7-5b6a-40a2-add7-b0209af557c9">32.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a6f8fd190a2433584205fa45bfd8bcb_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTpjNDk3MjE4MGRhY2I0ODA1ODY0ODE4NzgwYzg1ZWIxYi90YWJsZXJhbmdlOmM0OTcyMTgwZGFjYjQ4MDU4NjQ4MTg3ODBjODVlYjFiXzItMTEtMS0xLTEzOTA2Mg_eb414ad6-b893-4dba-8247-3e8a687f5f99">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dc4af282e2e4830bb4c5589ec647f1f_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTpjNDk3MjE4MGRhY2I0ODA1ODY0ODE4NzgwYzg1ZWIxYi90YWJsZXJhbmdlOmM0OTcyMTgwZGFjYjQ4MDU4NjQ4MTg3ODBjODVlYjFiXzMtMS0xLTEtMTM5MDYy_659c0f87-7f43-4a2f-baf5-f50398d79695">199.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2dc4af282e2e4830bb4c5589ec647f1f_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTpjNDk3MjE4MGRhY2I0ODA1ODY0ODE4NzgwYzg1ZWIxYi90YWJsZXJhbmdlOmM0OTcyMTgwZGFjYjQ4MDU4NjQ4MTg3ODBjODVlYjFiXzMtMy0xLTEtMTM5MDYy_49e1834a-7505-410b-a2e2-73c1d0b52ef7">1.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dc4af282e2e4830bb4c5589ec647f1f_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTpjNDk3MjE4MGRhY2I0ODA1ODY0ODE4NzgwYzg1ZWIxYi90YWJsZXJhbmdlOmM0OTcyMTgwZGFjYjQ4MDU4NjQ4MTg3ODBjODVlYjFiXzMtNS0xLTEtMTM5MDYy_47bd9db7-c837-4ead-abd0-d3b6646b8188">299.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2dc4af282e2e4830bb4c5589ec647f1f_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTpjNDk3MjE4MGRhY2I0ODA1ODY0ODE4NzgwYzg1ZWIxYi90YWJsZXJhbmdlOmM0OTcyMTgwZGFjYjQ4MDU4NjQ4MTg3ODBjODVlYjFiXzMtNy0xLTEtMTM5MDYy_3460620b-8a14-4a91-967c-bf5106cbb09a">5.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dc4af282e2e4830bb4c5589ec647f1f_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTpjNDk3MjE4MGRhY2I0ODA1ODY0ODE4NzgwYzg1ZWIxYi90YWJsZXJhbmdlOmM0OTcyMTgwZGFjYjQ4MDU4NjQ4MTg3ODBjODVlYjFiXzMtOS0xLTEtMTM5MDYy_57c06038-5e9f-486d-bce9-7771b8702631">498.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2dc4af282e2e4830bb4c5589ec647f1f_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTpjNDk3MjE4MGRhY2I0ODA1ODY0ODE4NzgwYzg1ZWIxYi90YWJsZXJhbmdlOmM0OTcyMTgwZGFjYjQ4MDU4NjQ4MTg3ODBjODVlYjFiXzMtMTEtMS0xLTEzOTA2Mg_3ad8062b-24ba-42af-ae92-a540d0e1f447">7.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc59d3c4ac034bfc85c224da99f57d0f_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTpjNDk3MjE4MGRhY2I0ODA1ODY0ODE4NzgwYzg1ZWIxYi90YWJsZXJhbmdlOmM0OTcyMTgwZGFjYjQ4MDU4NjQ4MTg3ODBjODVlYjFiXzQtMS0xLTEtMTM5MDYy_776eb9e3-aedb-4c3d-8285-34f740779f78">107.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc59d3c4ac034bfc85c224da99f57d0f_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTpjNDk3MjE4MGRhY2I0ODA1ODY0ODE4NzgwYzg1ZWIxYi90YWJsZXJhbmdlOmM0OTcyMTgwZGFjYjQ4MDU4NjQ4MTg3ODBjODVlYjFiXzQtMy0xLTEtMTM5MDYy_218e4267-fd62-447b-8e13-8d108cb58e1c">2.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc59d3c4ac034bfc85c224da99f57d0f_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTpjNDk3MjE4MGRhY2I0ODA1ODY0ODE4NzgwYzg1ZWIxYi90YWJsZXJhbmdlOmM0OTcyMTgwZGFjYjQ4MDU4NjQ4MTg3ODBjODVlYjFiXzQtNS0xLTEtMTM5MDYy_69dd39bb-bdca-4cc5-b979-84736040c6b0">198.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc59d3c4ac034bfc85c224da99f57d0f_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTpjNDk3MjE4MGRhY2I0ODA1ODY0ODE4NzgwYzg1ZWIxYi90YWJsZXJhbmdlOmM0OTcyMTgwZGFjYjQ4MDU4NjQ4MTg3ODBjODVlYjFiXzQtNy0xLTEtMTM5MDYy_f14d6b54-9600-4209-b7c5-39deb3cf1897">4.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc59d3c4ac034bfc85c224da99f57d0f_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTpjNDk3MjE4MGRhY2I0ODA1ODY0ODE4NzgwYzg1ZWIxYi90YWJsZXJhbmdlOmM0OTcyMTgwZGFjYjQ4MDU4NjQ4MTg3ODBjODVlYjFiXzQtOS0xLTEtMTM5MDYy_713fe567-319e-4697-ac97-87f91531ee8d">306.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc59d3c4ac034bfc85c224da99f57d0f_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTpjNDk3MjE4MGRhY2I0ODA1ODY0ODE4NzgwYzg1ZWIxYi90YWJsZXJhbmdlOmM0OTcyMTgwZGFjYjQ4MDU4NjQ4MTg3ODBjODVlYjFiXzQtMTEtMS0xLTEzOTA2Mg_75040b27-c652-42df-aabd-82a39a611f11">7.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents debt securities available-for-sale that were in an unrealized loss position as of December&#160;31, 2021, aggregated by major security type and length of time in a continuous loss position.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e6ecccda3454d2d97a48bbbed7a06c4_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZToxZmQyODYwMzg4ZDk0ZDY3ODBhYTBhM2FjNmM2ZThiMy90YWJsZXJhbmdlOjFmZDI4NjAzODhkOTRkNjc4MGFhMGEzYWM2YzZlOGIzXzItMS0xLTEtMTM5MDYy_d34a56d8-c0b8-4e3f-b183-3d57059729fd">428.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e6ecccda3454d2d97a48bbbed7a06c4_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZToxZmQyODYwMzg4ZDk0ZDY3ODBhYTBhM2FjNmM2ZThiMy90YWJsZXJhbmdlOjFmZDI4NjAzODhkOTRkNjc4MGFhMGEzYWM2YzZlOGIzXzItMy0xLTEtMTM5MDYy_268463fb-f1bc-4b97-b902-9700cc6015df">1.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e6ecccda3454d2d97a48bbbed7a06c4_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZToxZmQyODYwMzg4ZDk0ZDY3ODBhYTBhM2FjNmM2ZThiMy90YWJsZXJhbmdlOjFmZDI4NjAzODhkOTRkNjc4MGFhMGEzYWM2YzZlOGIzXzItNS0xLTEtMTM5MDYy_2b8a7c15-69ce-4060-a30c-dac7b6ddef60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e6ecccda3454d2d97a48bbbed7a06c4_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZToxZmQyODYwMzg4ZDk0ZDY3ODBhYTBhM2FjNmM2ZThiMy90YWJsZXJhbmdlOjFmZDI4NjAzODhkOTRkNjc4MGFhMGEzYWM2YzZlOGIzXzItNy0xLTEtMTM5MDYy_daafae54-b55c-45b3-b0d0-25d93412875f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e6ecccda3454d2d97a48bbbed7a06c4_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZToxZmQyODYwMzg4ZDk0ZDY3ODBhYTBhM2FjNmM2ZThiMy90YWJsZXJhbmdlOjFmZDI4NjAzODhkOTRkNjc4MGFhMGEzYWM2YzZlOGIzXzItOS0xLTEtMTM5MDYy_3b5947fb-a7d1-4c51-b15e-87dbf99ff518">428.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e6ecccda3454d2d97a48bbbed7a06c4_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZToxZmQyODYwMzg4ZDk0ZDY3ODBhYTBhM2FjNmM2ZThiMy90YWJsZXJhbmdlOjFmZDI4NjAzODhkOTRkNjc4MGFhMGEzYWM2YzZlOGIzXzItMTEtMS0xLTEzOTA2Mg_cb91e726-6f7c-41fa-9a82-b4770f0d902b">1.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76c8c1dcfb3247a6b15b3036d4069cbc_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZToxZmQyODYwMzg4ZDk0ZDY3ODBhYTBhM2FjNmM2ZThiMy90YWJsZXJhbmdlOjFmZDI4NjAzODhkOTRkNjc4MGFhMGEzYWM2YzZlOGIzXzMtMS0xLTEtMTM5MDYy_3acb220a-a2c7-4f3e-93b6-bc3597582f08">230.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76c8c1dcfb3247a6b15b3036d4069cbc_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZToxZmQyODYwMzg4ZDk0ZDY3ODBhYTBhM2FjNmM2ZThiMy90YWJsZXJhbmdlOjFmZDI4NjAzODhkOTRkNjc4MGFhMGEzYWM2YzZlOGIzXzMtMy0xLTEtMTM5MDYy_96d5ac88-1fea-4238-91dd-febe0ba1de75">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76c8c1dcfb3247a6b15b3036d4069cbc_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZToxZmQyODYwMzg4ZDk0ZDY3ODBhYTBhM2FjNmM2ZThiMy90YWJsZXJhbmdlOjFmZDI4NjAzODhkOTRkNjc4MGFhMGEzYWM2YzZlOGIzXzMtNS0xLTEtMTM5MDYy_14026b03-b3a3-414a-a9c1-1d64f606f8ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76c8c1dcfb3247a6b15b3036d4069cbc_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZToxZmQyODYwMzg4ZDk0ZDY3ODBhYTBhM2FjNmM2ZThiMy90YWJsZXJhbmdlOjFmZDI4NjAzODhkOTRkNjc4MGFhMGEzYWM2YzZlOGIzXzMtNy0xLTEtMTM5MDYy_d2b3eac3-e988-4f0e-8a2a-4e9377ed7ef9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76c8c1dcfb3247a6b15b3036d4069cbc_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZToxZmQyODYwMzg4ZDk0ZDY3ODBhYTBhM2FjNmM2ZThiMy90YWJsZXJhbmdlOjFmZDI4NjAzODhkOTRkNjc4MGFhMGEzYWM2YzZlOGIzXzMtOS0xLTEtMTM5MDYy_a9fe6300-df61-4687-bc33-834d270d064d">230.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76c8c1dcfb3247a6b15b3036d4069cbc_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZToxZmQyODYwMzg4ZDk0ZDY3ODBhYTBhM2FjNmM2ZThiMy90YWJsZXJhbmdlOjFmZDI4NjAzODhkOTRkNjc4MGFhMGEzYWM2YzZlOGIzXzMtMTEtMS0xLTEzOTA2Mg_8e566e13-2e0a-44b0-8228-a0f070f5dd2e">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div id="id795223301944418ba8c3fb3bc02f08e_145"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90ZXh0cmVnaW9uOmUzYWI0ZDY1YTQ3ZDRiMzY5OTI4ZGI5ZDJkNGQxODc5XzUxOA_11ff65ef-950a-42c7-8116-7b4ddf8a4f2c" continuedAt="i3fe9a7d15c2842a5b293a201441b4b14" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i3fe9a7d15c2842a5b293a201441b4b14"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90ZXh0cmVnaW9uOmUzYWI0ZDY1YTQ3ZDRiMzY5OTI4ZGI5ZDJkNGQxODc5XzUxNg_4abe7061-88d1-48c0-9b3d-c2c94dda6a3e" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of investments, which were measured at fair value on a recurring basis.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.464%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.398%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Leveling</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id63f24106d73460cb43b5496689583ba_I20221231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzQtMS0xLTEtMTM5MDYy_8e99137c-95b2-424c-8d29-bebfcaa957d1">262.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea0e6362bc9a41baa6232f3d791b1b30_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzQtMy0xLTEtMTM5MDYy_abdbc3b3-6fc5-492e-8bbb-e620d80fa445">262.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b718dc4ea4045ddb88690b0606e023f_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzQtNS0xLTEtMTM5MDYy_a494a4c2-cc88-4301-a190-340ed48e50d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8286a497677b4b46a9e257151dfe0240_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzQtNy0xLTEtMTM5MDYy_b1955d96-f54d-4c64-8a0d-0c674f8b8fc7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e2f6bb95ef942549f5717766447bf89_I20211231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzQtOS0xLTEtMTM5MDYy_7084492f-de04-47f1-9bfb-f7c30ce99654">340.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b0d1aff1c264abba7252395e73cacd2_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzQtMTEtMS0xLTEzOTA2Mg_ebdaee5a-915e-45b4-9d1c-697e647b56ce">340.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9258781d2d9a48c3abc627b4e38a38f6_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzQtMTMtMS0xLTEzOTA2Mg_b2aca89e-29e0-4871-9057-41b0b03a943b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icacc4e9a05c844698340e3f6ee1020e9_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzQtMTUtMS0xLTEzOTA2Mg_671bdc7a-63df-4372-a426-f511590a631d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3469d1c34084c0caf63fea3b7ad7ad0_I20221231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzYtMS0xLTEtMTM5MDYy_74419944-012d-465f-b6d8-a030ad178d46">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55208f6888cb4f1aa1161cb859460aa3_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzYtMy0xLTEtMTM5MDYy_03ea3df9-d271-43fa-9072-56038bc79e78">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ef2bfe4b974f9dbf50fa97b715887d_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzYtNS0xLTEtMTM5MDYy_a70bd651-175b-468a-8703-3a512a7dbdce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb0138cfa605465396a47f3dd519480e_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzYtNy0xLTEtMTM5MDYy_c27eefdd-a469-4770-bfdb-a09520efc0e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8f1b78aab9747879b7bf25dd9a9712c_I20211231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzYtOS0xLTEtMTM5MDYy_085ae7c4-3991-4467-a997-37824c29b259">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic12ec9940933424ea6839c2a0d9170e3_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzYtMTEtMS0xLTEzOTA2Mg_970f1536-f742-4ac3-a6c8-5176b913c657">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e86195663524f63a9bd0a9f18bf1cbf_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzYtMTMtMS0xLTEzOTA2Mg_2ed7fa9d-cbf4-4fa4-8a6f-9d837f6c5946">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5eb4267dd8494bd9b9dcaabe2416461d_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzYtMTUtMS0xLTEzOTA2Mg_b9215266-c18a-4b24-8841-848115b56cf6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654c80e71bff4d869218415b7e3dc0a0_I20221231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzgtMS0xLTEtMTM5MDYy_cb86ea86-a3b7-424d-816c-dde5e03967d7">156.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i007cfabe3a8849bab803ba60c015eab2_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzgtMy0xLTEtMTM5MDYy_c095358d-3eb8-41d0-bf8a-02e7390b175b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a9b7472fc7b4972acb2ac9f7cef302d_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzgtNS0xLTEtMTM5MDYy_4b3a86a4-cb8c-41d3-8970-ae1fca97316b">156.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibeb578648cbe47d9949ee6e34fe0ad99_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzgtNy0xLTEtMTM5MDYy_96c91fd8-38e3-4ac0-acbd-b9dc76a48360">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae37ac3f84054636b37554762cc34e63_I20211231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzgtOS0xLTEtMTM5MDYy_483e7e53-a21b-46f9-8e64-23ddde8cd975">204.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46d509c4cb348eeba80e5d4d37e4475_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzgtMTEtMS0xLTEzOTA2Mg_c3d1d65f-f788-4c7e-832d-df0a3563f61a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i439770d7fd6f4f859128c5157c9235a1_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzgtMTMtMS0xLTEzOTA2Mg_522c9a94-839f-4b7e-995f-49b394c3081f">204.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2b42a9d8bc44f1ea40843385e1e20d1_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzgtMTUtMS0xLTEzOTA2Mg_c3706799-58b2-4b4a-953e-1929f9121488">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10967d72424a4f7791a64e8d6c259d64_I20221231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzktMS0xLTEtMTM5MDYy_f7d6cc71-1903-4346-bdf7-7d03c535fba9">548.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia49862c3506f4b74acff88c95716b232_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzktMy0xLTEtMTM5MDYy_6c7b185c-58b2-41d0-bda5-79d1052349f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c8a28f6dfe4ed090fe32a6157f5e6c_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzktNS0xLTEtMTM5MDYy_563c6684-10dc-4e6b-a676-1d882d0328b9">548.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i592eaf87071c432cb1c6e78bf7a7e092_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzktNy0xLTEtMTM5MDYy_82064331-3359-4147-a5e3-935eff3cf4e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4474116f1b674daca505b919ccc95074_I20211231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzktOS0xLTEtMTM5MDYy_b4e15e90-7afd-4a72-a466-b651c3188daa">485.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i699cec09a8334f4c8b6ac965045cb456_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzktMTEtMS0xLTEzOTA2Mg_3fcc6a17-4e05-4d51-b70a-bdb1831fbec4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddb56fada71460eba444fd3d97f4b69_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzktMTMtMS0xLTEzOTA2Mg_8be82e11-f0a8-4b64-8331-04f92924cb7b">485.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57d06337718492f9cfef217012538ee_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzktMTUtMS0xLTEzOTA2Mg_3e0c36c1-0961-44e7-96e2-c1b6d901a96b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fd315b303184968b952d7bb6d9c6472_I20221231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEwLTEtMS0xLTEzOTA2Mg_17e91672-40e9-4844-851b-ce11867b64ca">321.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e1a8fc8f38c4c8aa7c1dae7f202b3b4_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEwLTMtMS0xLTEzOTA2Mg_da2f748a-7dca-46a9-81bc-bb1aef97c424">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idec09e5a03864099989354c76b828527_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEwLTUtMS0xLTEzOTA2Mg_21d3b865-8dbd-404f-ae71-eb01ba74160c">321.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31b04184eff74bf4b5192930aacadfec_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEwLTctMS0xLTEzOTA2Mg_9c7866ad-615f-4958-a972-27cb2bb65349">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26120348d6074f35b090ebbda6b3fcf0_I20211231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEwLTktMS0xLTEzOTA2Mg_b9161e6c-7c49-4616-9a5b-3c4ffcd93d98">240.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc55062153d94ad7b8d61e6d19057c50_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEwLTExLTEtMS0xMzkwNjI_77b9ac72-c6a9-4d89-bda6-689dba0c73c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if47e96c65cb74988b1f42acee047add6_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEwLTEzLTEtMS0xMzkwNjI_aea05c42-f1ab-458f-85f5-4e3e0324964c">240.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d61b3503a4e475e8484e3f0377b2a11_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEwLTE1LTEtMS0xMzkwNjI_956ea3bb-1f5a-4434-acf5-e2a110760d52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities&#8211;biotechnology industry</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22fe030fdf4397978434417c7b8788_I20221231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEyLTEtMS0xLTEzOTA2Mg_3bb6d315-22ef-4008-a795-7c8b50e208e9">102.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23f85f7c13a54d018aba01edd3e7dbf6_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEyLTMtMS0xLTEzOTA2Mg_c76368b2-2bbe-4eed-8ace-c1da7e4a2d9b">102.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69926a6399c34cf885a190c0d20df7f3_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEyLTUtMS0xLTEzOTA2Mg_adb2a83c-768f-4273-9a4c-9d26d9499917">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5a5bad1ec804fe58946f735c8b3b59a_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEyLTctMS0xLTEzOTA2Mg_69caa9fa-907e-4b69-8ecb-1686e1773f3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3416e3592d234d7aa0dc1a6d0c4492e2_I20211231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEyLTktMS0xLTEzOTA2Mg_693dd4d3-a5b7-4f35-bb25-eb463811b5bd">63.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if164f03cdc61491492728ca7e7517143_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEyLTExLTEtMS0xMzkwNjI_f5a6ecab-4927-4508-8eb4-92995554aed9">52.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a0f1b836d0749b486fff5c035616613_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEyLTEzLTEtMS0xMzkwNjI_57ecc8fa-8af8-4e5f-8d64-22e3d7a5ad92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19826127b8b3400a9e18b46be425bc61_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEyLTE1LTEtMS0xMzkwNjI_a687a052-1681-4572-9f36-d87a088e9d63">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ce1cf497c004f079441d676651e2808_I20221231" decimals="-5" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEzLTEtMS0xLTEzOTA2Mg_6579b7f7-75bd-4072-9d51-70a3ae6053c5">1,398.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8373d29f581740ec8093f00de6a55275_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEzLTMtMS0xLTEzOTA2Mg_305e6549-ddd6-4c34-8a5e-ffc86bfb8de9">372.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id96df92d50994507814aa00688b39486_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEzLTUtMS0xLTEzOTA2Mg_22c03f64-4fdc-4993-a33b-51ee5b2d8eb1">1,025.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedb24ff2ca7b44618a98e55d5e02fb8a_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEzLTctMS0xLTEzOTA2Mg_564cb860-2741-4757-ad69-3b2e35ff0f24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i170c112de5b842e4b59047014a54dcc0_I20211231" decimals="-5" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEzLTktMS0xLTEzOTA2Mg_04d05b68-ef8d-4366-9064-6104f41dc4f6">1,338.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fc84fce9b6f4f4494703d493708167e_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEzLTExLTEtMS0xMzkwNjI_c09accd6-5222-4aed-aa20-667c7b693f95">396.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i607d3acd1b9a45c49ba0983930259c41_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEzLTEzLTEtMS0xMzkwNjI_d3898901-32b3-411c-a208-1111f7fb5bac">931.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i738cf7daafb54a76adcadab34123ba8f_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEzLTE1LTEtMS0xMzkwNjI_c5ce3e0c-e7ad-45ae-b125-76628e84f38f">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90ZXh0cmVnaW9uOmUzYWI0ZDY1YTQ3ZDRiMzY5OTI4ZGI5ZDJkNGQxODc5XzUxNw_a04b2491-418f-4399-9660-4caf752f4eda" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of equity security investments, which were measured at fair value on a recurring basis using significant unobservable inputs (Level 3):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19826127b8b3400a9e18b46be425bc61_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo0MDEyZjNmMmU3MWU0ZDgxOWZhMDJlZDI2YjUxYzk1MC90YWJsZXJhbmdlOjQwMTJmM2YyZTcxZTRkODE5ZmEwMmVkMjZiNTFjOTUwXzItMS0xLTEtMTM5MDYy_93d57a4d-0d53-47ad-90be-7b9d0f3735a8">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e243caf058841239f5b24d4011ad3df_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo0MDEyZjNmMmU3MWU0ZDgxOWZhMDJlZDI2YjUxYzk1MC90YWJsZXJhbmdlOjQwMTJmM2YyZTcxZTRkODE5ZmEwMmVkMjZiNTFjOTUwXzItMy0xLTEtMTM5MDYy_0a100269-5e1b-4c64-b41e-81a065573b23">38.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i202b3b88d9ac4d138f5675ec9220d37e_I20191231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo0MDEyZjNmMmU3MWU0ZDgxOWZhMDJlZDI2YjUxYzk1MC90YWJsZXJhbmdlOjQwMTJmM2YyZTcxZTRkODE5ZmEwMmVkMjZiNTFjOTUwXzItNS0xLTEtMTM5MDYy_b40b979f-0e4a-4322-8659-de7cd3381255">55.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4971e09f913f4c90bd8fd83e1d0fcd54_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsToAcquireRestrictedInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo0MDEyZjNmMmU3MWU0ZDgxOWZhMDJlZDI2YjUxYzk1MC90YWJsZXJhbmdlOjQwMTJmM2YyZTcxZTRkODE5ZmEwMmVkMjZiNTFjOTUwXzMtMS0xLTEtMTM5MDYy_a3c63265-b691-4b25-8c84-3adcb747d291">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3f57bcb850140d7aa4beb063512caf3_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireRestrictedInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo0MDEyZjNmMmU3MWU0ZDgxOWZhMDJlZDI2YjUxYzk1MC90YWJsZXJhbmdlOjQwMTJmM2YyZTcxZTRkODE5ZmEwMmVkMjZiNTFjOTUwXzMtMy0xLTEtMTM5MDYy_eb88e077-7a65-4e44-9b6f-4d580e0dbf74">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd3d786e58da41c8ab668363ea9b72d4_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireRestrictedInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo0MDEyZjNmMmU3MWU0ZDgxOWZhMDJlZDI2YjUxYzk1MC90YWJsZXJhbmdlOjQwMTJmM2YyZTcxZTRkODE5ZmEwMmVkMjZiNTFjOTUwXzMtNS0xLTEtMTM5MDYy_fb0c6d44-c2c6-43bd-a2a8-914d54aac91a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain (loss) included in earnings </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie68e2d5dfa5744d28e808e7184b1ac64_D20220101-20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo0MDEyZjNmMmU3MWU0ZDgxOWZhMDJlZDI2YjUxYzk1MC90YWJsZXJhbmdlOjQwMTJmM2YyZTcxZTRkODE5ZmEwMmVkMjZiNTFjOTUwXzQtMS0xLTEtMTM5MDYy_4fb7ee57-aa3a-455a-ab33-732c8125b183">20.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1910f568982940418f0b3f4ef8742b36_D20210101-20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo0MDEyZjNmMmU3MWU0ZDgxOWZhMDJlZDI2YjUxYzk1MC90YWJsZXJhbmdlOjQwMTJmM2YyZTcxZTRkODE5ZmEwMmVkMjZiNTFjOTUwXzQtMy0xLTEtMTM5MDYy_cf6b3a97-f1e9-4c5d-94a1-c7920f636a9f">20.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea06eb619bca46279cd1e26fd668574c_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo0MDEyZjNmMmU3MWU0ZDgxOWZhMDJlZDI2YjUxYzk1MC90YWJsZXJhbmdlOjQwMTJmM2YyZTcxZTRkODE5ZmEwMmVkMjZiNTFjOTUwXzQtNS0xLTEtMTM5MDYy_6ec954c2-0123-4bda-b132-d1596a7afa1a">17.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfers out of Level 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie68e2d5dfa5744d28e808e7184b1ac64_D20220101-20221231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo0MDEyZjNmMmU3MWU0ZDgxOWZhMDJlZDI2YjUxYzk1MC90YWJsZXJhbmdlOjQwMTJmM2YyZTcxZTRkODE5ZmEwMmVkMjZiNTFjOTUwXzUtMS0xLTEtMTM5MDYy_9e5b11df-914c-440f-a757-a5dc7780919d">31.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1910f568982940418f0b3f4ef8742b36_D20210101-20211231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo0MDEyZjNmMmU3MWU0ZDgxOWZhMDJlZDI2YjUxYzk1MC90YWJsZXJhbmdlOjQwMTJmM2YyZTcxZTRkODE5ZmEwMmVkMjZiNTFjOTUwXzUtMy0xLTEtMTM5MDYy_2e99cfb6-0f2e-41d3-a8b8-0ed6d755f1eb">52.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea06eb619bca46279cd1e26fd668574c_D20200101-20201231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo0MDEyZjNmMmU3MWU0ZDgxOWZhMDJlZDI2YjUxYzk1MC90YWJsZXJhbmdlOjQwMTJmM2YyZTcxZTRkODE5ZmEwMmVkMjZiNTFjOTUwXzUtNS0xLTEtMTM5MDYy_920c6e39-a72b-44de-a9a4-a38f8a6d4887">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5a5bad1ec804fe58946f735c8b3b59a_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRestricted" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo0MDEyZjNmMmU3MWU0ZDgxOWZhMDJlZDI2YjUxYzk1MC90YWJsZXJhbmdlOjQwMTJmM2YyZTcxZTRkODE5ZmEwMmVkMjZiNTFjOTUwXzYtMS0xLTEtMTM5MDYy_11ad9bfc-3b24-4db6-a8aa-e1fe689c1341">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19826127b8b3400a9e18b46be425bc61_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo0MDEyZjNmMmU3MWU0ZDgxOWZhMDJlZDI2YjUxYzk1MC90YWJsZXJhbmdlOjQwMTJmM2YyZTcxZTRkODE5ZmEwMmVkMjZiNTFjOTUwXzYtMy0xLTEtMTM5MDYy_28cd8ce1-70aa-45f9-be21-b27bd04d92ca">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e243caf058841239f5b24d4011ad3df_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo0MDEyZjNmMmU3MWU0ZDgxOWZhMDJlZDI2YjUxYzk1MC90YWJsZXJhbmdlOjQwMTJmM2YyZTcxZTRkODE5ZmEwMmVkMjZiNTFjOTUwXzYtNS0xLTEtMTM5MDYy_22af6d1b-1c1b-4a65-84f6-af35cf4d5bb2">38.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Unrealized gains and losses on equity security investments which were measured at fair value on a recurring basis using significant unobservable inputs (Level 3) and are included in other income (expense), net.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Certain of our equity security investments were transferred from Level 3 to Level 1 during 2022 and 2021 as the associated holding period restriction expired.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><div id="id795223301944418ba8c3fb3bc02f08e_148"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzgxMDM_a0f8eab5-0588-4d1f-9af5-c872d472a318" continuedAt="i88c8e2c16a1f4beebbc899d80cb339d3" escape="true">Convertible Senior Notes</ix:nonNumeric></span></div><ix:continuation id="i88c8e2c16a1f4beebbc899d80cb339d3" continuedAt="ic1a90139cb704bc6b57ad21646466d18"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;2, 2017, we completed a private placement of $<ix:nonFraction unitRef="usd" contextRef="i4b5b4f7eab2446ce84ea30524cbd6aa0_I20170502" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzMjEyOA_cb3505f0-7d11-4ef3-a1c9-16525e9b2922">517.5</ix:nonFraction> million in aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i4b5b4f7eab2446ce84ea30524cbd6aa0_I20170502" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzMjE2NQ_8d782fd5-97a8-4b26-8dc2-09f8a81a0d3b">2.25</ix:nonFraction>% fixed-rate convertible senior notes due May&#160;15, 2024, or the 2024 Notes, and entered into the 2017 Indenture with respect to the 2024 Notes. Interest on the 2024 Notes is due semi-annually on May 15 and November 15 of each year.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with authoritative guidance in effect at the time of issuance, we were required to separately account for the liability and equity components of the 2024 Notes. The initial carrying value of the liability component of $<ix:nonFraction unitRef="usd" contextRef="i4b5b4f7eab2446ce84ea30524cbd6aa0_I20170502" decimals="-5" name="nbix:CarryingAmountOfLiabilityComponentUponIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzMjU2Mw_3f198dd8-5f67-4aeb-818f-2be3a39c0aa9">368.3</ix:nonFraction> million was calculated using a <ix:nonFraction unitRef="number" contextRef="i35bad398da4e4adb94afe6a3edc6fbd6_D20170502-20170502" decimals="3" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzMjU5MA_550cf0c8-aad8-41f4-9f02-db8d40895899">7.50</ix:nonFraction>% assumed borrowing rate, which reflected the market interest rate for a similar non-convertible instrument at the date of issuance. The equity component of $<ix:nonFraction unitRef="usd" contextRef="i4b5b4f7eab2446ce84ea30524cbd6aa0_I20170502" decimals="-5" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzMjc0OQ_e0f62ac0-5e24-4e88-87a1-caca9d625b9e">149.2</ix:nonFraction> million, which was treated as a discount on the liability component and amortized over the <ix:nonNumeric contextRef="i35bad398da4e4adb94afe6a3edc6fbd6_D20170502-20170502" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzQzOTgwNDY1Mzc5NTU_c5566527-47cf-423e-94f4-a570d03b39ec">seven-year</ix:nonNumeric> term of the 2024 Notes using the effective interest rate method, was determined by deducting the fair value of the liability component from the par value of the 2024 Notes and recorded as an increase to additional paid-in capital on the issuance date. In addition, we allocated transaction costs of $<ix:nonFraction unitRef="usd" contextRef="i4b5b4f7eab2446ce84ea30524cbd6aa0_I20170502" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzMzEzMA_bccd779f-0ba5-4152-9fb8-b1803fbb903c">14.7</ix:nonFraction> million related to the issuance of the 2024 Notes to the liability and equity components based on their relative values on the issuance date. Transaction costs attributable to the liability component were being amortized over the <ix:nonNumeric contextRef="i35bad398da4e4adb94afe6a3edc6fbd6_D20170502-20170502" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzQzOTgwNDY1Mzc5NTY_3e2c317b-4b59-4670-af0f-a3d7844d44b3">seven-year</ix:nonNumeric> term of the 2024 Notes using the effective interest rate method, while transaction costs attributable to the equity component were recorded as a reduction to additional paid-in capital on the issuance date.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2020, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $<ix:nonFraction unitRef="usd" contextRef="id330e3069fc840d18f4175221a90fd47_I20201231" decimals="-5" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzMzY5NQ_d186da92-296f-4fc3-9574-0c38f145d67d">136.2</ix:nonFraction> million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $<ix:nonFraction unitRef="usd" contextRef="i48eccd3ba1b3454495acdad169d5d6f5_D20201001-20201231" decimals="-5" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzMzc3NA_6abc82f0-ecc8-40c3-867d-013a996e998f">186.9</ix:nonFraction> million in cash. We accounted for the partial repurchase of the 2024 Notes as a debt extinguishment. As a result, we attributed $<ix:nonFraction unitRef="usd" contextRef="i48eccd3ba1b3454495acdad169d5d6f5_D20201001-20201231" decimals="-5" name="nbix:FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzMzg5MQ_d55db1b4-e213-40e7-9149-ad6d7eb4422c">130.7</ix:nonFraction> million of the aggregate repurchase price to the liability component based on the fair value of the liability component immediately before extinguishment. The fair value of the liability component was calculated at settlement using a discounted cash flow analysis with a discount rate of <ix:nonFraction unitRef="number" contextRef="i629ba4e4ef664986a91d0ae915e45857_I20201231" decimals="4" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNDE3NQ_b1e2526a-8a7f-4901-8f3f-f0043cc5a0df">3.37</ix:nonFraction>%, which was the market rate for similar notes that have no conversion rights. The difference of $<ix:nonFraction unitRef="usd" contextRef="i48eccd3ba1b3454495acdad169d5d6f5_D20201001-20201231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNDI3NA_14d1683f-8dc4-4368-b490-15b26d5028fd">56.3</ix:nonFraction> million between the fair value of the aggregate consideration remitted to certain holders of the 2024 Notes and the fair value of the liability component was attributed to the reacquisition of the equity component and recorded as a reduction to additional paid-in capital. The carrying amount of the liability of $<ix:nonFraction unitRef="usd" contextRef="i48eccd3ba1b3454495acdad169d5d6f5_D20201001-20201231" decimals="-5" name="nbix:CarryingAmountOfLiabilityComponentAtSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNDU3Ng_7a75810a-bd62-43e3-8834-372d84d16def">112.4</ix:nonFraction> million at settlement was recognized as a reduction to the 2024 Notes and resulted in an $<ix:nonFraction unitRef="usd" contextRef="ibb0ec417ca564717bb097aa83567533a_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNDY1NA_115addce-cb6e-44a3-860e-b12309049fe5">18.4</ix:nonFraction> million loss on extinguishment, which we recognized in 2020.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, we adopted <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNDc2NA_b11908b6-457c-4872-91a0-7e1b27137ced">ASU 2020-06</span> using the modified retrospective transition method, which allowed for a cumulative-effect adjustment in the period of adoption and did not require restatement of prior period amounts. Under this transition method, the cumulative effect of the accounting change increased the carrying amount of the 2024 Notes by $<ix:nonFraction unitRef="usd" contextRef="i7b26f825c6434881a754e7e6c53ed556_I20211231" decimals="-5" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNTA3Mw_ab6805cc-c8e2-4d42-a97f-fd70c8b37e80">42.2</ix:nonFraction> million, reduced deferred tax liabilities by $<ix:nonFraction unitRef="usd" contextRef="i7b26f825c6434881a754e7e6c53ed556_I20211231" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNTExNA_b1a7c797-e094-4508-8b50-c99e7fa1d9e0">9.9</ix:nonFraction> million, reduced additional paid-in capital by $<ix:nonFraction unitRef="usd" contextRef="i7b26f825c6434881a754e7e6c53ed556_I20211231" decimals="-5" sign="-" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNTE1Nw_2e77ce7d-d0e0-4cfd-b7f4-f2955414de9a">106.8</ix:nonFraction> million, and reduced the accumulated deficit by $<ix:nonFraction unitRef="usd" contextRef="i7b26f825c6434881a754e7e6c53ed556_I20211231" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNTIwMQ_fd21ee6f-67bc-4df7-b9cc-b168c633a8ba">74.5</ix:nonFraction> million.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2022, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $<ix:nonFraction unitRef="usd" contextRef="i601493722ddc4060955049e1e99ec96e_I20220630" decimals="-5" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNTM1MA_93d23992-35da-4d57-9b3f-4f3a9409e015">210.8</ix:nonFraction> million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $<ix:nonFraction unitRef="usd" contextRef="iaee95a0d57144ecaa3a678d3909bf7b2_D20220401-20220630" decimals="-5" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNTQzNg_d114252f-b043-440d-bd48-3c9babf48e23">279.0</ix:nonFraction> million in cash. We accounted for the partial repurchase of the 2024 Notes as a debt extinguishment, which resulted in the recognition of a $<ix:nonFraction unitRef="usd" contextRef="i9bf8e6cfdf3742479b08b59beb60be53_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNTU3Mg_f9056ffc-9bf1-4aa3-92d0-74017fc36e2b">70.0</ix:nonFraction> million loss on extinguishment in 2022.</span></div><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzQzOTgwNDY1Mzc5NTc_0a786499-e622-4420-a0e3-51b03fb2f1bb" continuedAt="id095275a41b44b4eac4fb23d4a93b54e" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the 2024 Notes as of December&#160;31, 2022.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.846%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unamortized Debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48dd18e80c3e4426a4bf9c87e59b2aa4_I20221231" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90YWJsZTpjOTJlMDg0MTViY2U0MGE3YmNmYTQ3MzJkNGNmNzY3MC90YWJsZXJhbmdlOmM5MmUwODQxNWJjZTQwYTdiY2ZhNDczMmQ0Y2Y3NjcwXzItMS0xLTEtMTQwMTY4_8b64d1da-2f31-495a-ab89-262d5f519764">170.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48dd18e80c3e4426a4bf9c87e59b2aa4_I20221231" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90YWJsZTpjOTJlMDg0MTViY2U0MGE3YmNmYTQ3MzJkNGNmNzY3MC90YWJsZXJhbmdlOmM5MmUwODQxNWJjZTQwYTdiY2ZhNDczMmQ0Y2Y3NjcwXzItMy0xLTEtMTQwMTY4_16a09ccc-e2b8-49ea-95ff-57ccabe298aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48dd18e80c3e4426a4bf9c87e59b2aa4_I20221231" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90YWJsZTpjOTJlMDg0MTViY2U0MGE3YmNmYTQ3MzJkNGNmNzY3MC90YWJsZXJhbmdlOmM5MmUwODQxNWJjZTQwYTdiY2ZhNDczMmQ0Y2Y3NjcwXzItNS0xLTEtMTQwMTY4_117bfdda-334f-4fd6-bbb1-8a63f2a2b48a">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48dd18e80c3e4426a4bf9c87e59b2aa4_I20221231" decimals="-5" name="us-gaap:ConvertibleDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90YWJsZTpjOTJlMDg0MTViY2U0MGE3YmNmYTQ3MzJkNGNmNzY3MC90YWJsZXJhbmdlOmM5MmUwODQxNWJjZTQwYTdiY2ZhNDczMmQ0Y2Y3NjcwXzItNy0xLTEtMTQwMTY4_82456780-8282-4e1b-b7c7-9bfe9d3d2662">169.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48dd18e80c3e4426a4bf9c87e59b2aa4_I20221231" decimals="-5" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90YWJsZTpjOTJlMDg0MTViY2U0MGE3YmNmYTQ3MzJkNGNmNzY3MC90YWJsZXJhbmdlOmM5MmUwODQxNWJjZTQwYTdiY2ZhNDczMmQ0Y2Y3NjcwXzItOS0xLTEtMTQwMTY4_59c223db-aca7-443e-bb40-9f294b72341c">268.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the 2024 Notes as of December&#160;31, 2021.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.846%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unamortized Debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5ecf9e10df34a7a853f2e59470d0f7f_I20211231" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90YWJsZTpkOTcwMzUwMTQ2MjY0NzY4ODhhNzkyMDUzZGJjYjZjZC90YWJsZXJhbmdlOmQ5NzAzNTAxNDYyNjQ3Njg4OGE3OTIwNTNkYmNiNmNkXzItMS0xLTEtMTQwMTY4_da253e66-90bb-4b23-8e3a-284e52dcde1f">381.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5ecf9e10df34a7a853f2e59470d0f7f_I20211231" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90YWJsZTpkOTcwMzUwMTQ2MjY0NzY4ODhhNzkyMDUzZGJjYjZjZC90YWJsZXJhbmdlOmQ5NzAzNTAxNDYyNjQ3Njg4OGE3OTIwNTNkYmNiNmNkXzItMy0xLTEtMTQwMTY4_75726d90-e479-4e5a-8f19-da852aa05ca7">43.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5ecf9e10df34a7a853f2e59470d0f7f_I20211231" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90YWJsZTpkOTcwMzUwMTQ2MjY0NzY4ODhhNzkyMDUzZGJjYjZjZC90YWJsZXJhbmdlOmQ5NzAzNTAxNDYyNjQ3Njg4OGE3OTIwNTNkYmNiNmNkXzItNS0xLTEtMTQwMTY4_bbc30dc3-81aa-4b83-80d6-9bb76817e2c6">2.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5ecf9e10df34a7a853f2e59470d0f7f_I20211231" decimals="-5" name="us-gaap:ConvertibleDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90YWJsZTpkOTcwMzUwMTQ2MjY0NzY4ODhhNzkyMDUzZGJjYjZjZC90YWJsZXJhbmdlOmQ5NzAzNTAxNDYyNjQ3Njg4OGE3OTIwNTNkYmNiNmNkXzItNy0xLTEtMTQwMTY4_081ed243-f4c2-452b-ac48-aa411fb7dbe8">335.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5ecf9e10df34a7a853f2e59470d0f7f_I20211231" decimals="-5" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90YWJsZTpkOTcwMzUwMTQ2MjY0NzY4ODhhNzkyMDUzZGJjYjZjZC90YWJsZXJhbmdlOmQ5NzAzNTAxNDYyNjQ3Njg4OGE3OTIwNTNkYmNiNmNkXzItOS0xLTEtMTQwMTY4_285bb8c5-fdfd-41f8-8123-941de090c166">464.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic1a90139cb704bc6b57ad21646466d18" continuedAt="iba659ad98f654096a17de3ba29c68b2a"><ix:continuation id="id095275a41b44b4eac4fb23d4a93b54e"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the interest expense of the 2024 Notes.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Coupon interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="nbix:DebtInstrumentCouponInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90YWJsZTpkODRhMjcxMTZkMDI0OWNhODFlMWUzM2Q1ODIwN2IxNS90YWJsZXJhbmdlOmQ4NGEyNzExNmQwMjQ5Y2E4MWUxZTMzZDU4MjA3YjE1XzItNS0xLTEtMTQwMTY4_66fe81aa-a032-4f39-9df2-eb3030f7ce29">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="nbix:DebtInstrumentCouponInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90YWJsZTpkODRhMjcxMTZkMDI0OWNhODFlMWUzM2Q1ODIwN2IxNS90YWJsZXJhbmdlOmQ4NGEyNzExNmQwMjQ5Y2E4MWUxZTMzZDU4MjA3YjE1XzItNy0xLTEtMTQwMTY4_5912d272-0274-4187-a280-9deb0c530076">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="nbix:DebtInstrumentCouponInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90YWJsZTpkODRhMjcxMTZkMDI0OWNhODFlMWUzM2Q1ODIwN2IxNS90YWJsZXJhbmdlOmQ4NGEyNzExNmQwMjQ5Y2E4MWUxZTMzZDU4MjA3YjE1XzItNS0xLTEtMTQwMjEz_1d6fe18d-caf5-4a69-b12f-458c5a2120b2">11.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90YWJsZTpkODRhMjcxMTZkMDI0OWNhODFlMWUzM2Q1ODIwN2IxNS90YWJsZXJhbmdlOmQ4NGEyNzExNmQwMjQ5Y2E4MWUxZTMzZDU4MjA3YjE1XzMtNS0xLTEtMTQwMTY4_9289fd6c-bf3f-4b1c-bb55-b5d2a8b4190b">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90YWJsZTpkODRhMjcxMTZkMDI0OWNhODFlMWUzM2Q1ODIwN2IxNS90YWJsZXJhbmdlOmQ4NGEyNzExNmQwMjQ5Y2E4MWUxZTMzZDU4MjA3YjE1XzMtNy0xLTEtMTQwMTY4_93fac2a5-eaf7-4337-a820-ba11783b468a">17.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90YWJsZTpkODRhMjcxMTZkMDI0OWNhODFlMWUzM2Q1ODIwN2IxNS90YWJsZXJhbmdlOmQ4NGEyNzExNmQwMjQ5Y2E4MWUxZTMzZDU4MjA3YjE1XzMtNS0xLTEtMTQwMjEz_a2152edf-eaf5-4067-b4f4-a11c073fc4df">21.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90YWJsZTpkODRhMjcxMTZkMDI0OWNhODFlMWUzM2Q1ODIwN2IxNS90YWJsZXJhbmdlOmQ4NGEyNzExNmQwMjQ5Y2E4MWUxZTMzZDU4MjA3YjE1XzQtNS0xLTEtMTQwMTY4_6e8541c0-40b7-4e4c-92b0-84f3177d7f7f">7.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90YWJsZTpkODRhMjcxMTZkMDI0OWNhODFlMWUzM2Q1ODIwN2IxNS90YWJsZXJhbmdlOmQ4NGEyNzExNmQwMjQ5Y2E4MWUxZTMzZDU4MjA3YjE1XzQtNy0xLTEtMTQwMTY4_442bda04-5473-4cfd-ac15-993885e92b6a">25.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90YWJsZTpkODRhMjcxMTZkMDI0OWNhODFlMWUzM2Q1ODIwN2IxNS90YWJsZXJhbmdlOmQ4NGEyNzExNmQwMjQ5Y2E4MWUxZTMzZDU4MjA3YjE1XzQtNS0xLTEtMTQwMjEz_f3a788dc-5a38-4ad1-8397-c5d5c7fdd9f2">32.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we entered into the First Supplemental Indenture to the 2017 Indenture, pursuant to which we irrevocably elected to settle the principal amount of the 2024 Notes in cash upon conversion and to settle any conversion premium, calculated based on the per share volume-weighted average price for each of the <ix:nonFraction unitRef="d" contextRef="i17f7971a67b44e4798fe7f7d49131fe4_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNjEzNw_da7e4504-89f7-4e85-a332-4c07fd8820b2">30</ix:nonFraction> consecutive trading days during the observation period (as more fully described in the 2017 Indenture), in either cash or shares of our common stock.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial conversion rate for the 2024 Notes, which is subject to adjustment in some events (as provided for in the 2017 Indenture), is 13.1711 shares of common stock per $<ix:nonFraction unitRef="usd" contextRef="if30740e0928241cb97cfb0ed6563a982_I20170502" decimals="INF" name="nbix:PrincipalAmountOnConversionRate" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNjQzNQ_cb39c6e4-cb99-4087-bc48-8f8b8d074ee0">1,000</ix:nonFraction> principal amount and equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i4b5b4f7eab2446ce84ea30524cbd6aa0_I20170502" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNjUxOQ_1c176d83-077a-4e2e-b017-759316a8ae8c">75.92</ix:nonFraction> per share, reflecting a conversion premium of approximately <ix:nonFraction unitRef="number" contextRef="i4b5b4f7eab2446ce84ea30524cbd6aa0_I20170502" decimals="3" name="nbix:DebtInstrumentConvertibleConversionPremium" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNjU4Mw_47b779b9-dfe1-44a5-9c33-f0ade1817a80">42.5</ix:nonFraction>% above the closing price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i4b5b4f7eab2446ce84ea30524cbd6aa0_I20170502" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNjYxNA_0d810886-dc26-4564-a466-741d3f7c9860">53.28</ix:nonFraction> per share of our common stock on April&#160;26, 2017.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may redeem for cash all or part of the 2024 Notes if the last reported sale price (as defined in the 2017 Indenture) of our common stock has been at least <ix:nonFraction unitRef="number" contextRef="i17f7971a67b44e4798fe7f7d49131fe4_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNjc5Ng_48c122a8-408a-43d7-a460-0b86c4190741">130</ix:nonFraction>% of the conversion price then in effect (equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="ibfcb863f462042bbaf5db27efbc920d6_D20220101-20221231" decimals="2" name="us-gaap:DebtInstrumentConvertibleStockPriceTrigger" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNjg0OQ_ded4fd99-a5ad-45a3-9608-ef4e849100ae">98.70</ix:nonFraction> as of December&#160;31, 2022) for at least <ix:nonFraction unitRef="d" contextRef="i17f7971a67b44e4798fe7f7d49131fe4_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNjg3Nw_fb99f8fe-2b8e-41e1-a787-b4c85460c13b">20</ix:nonFraction> trading days (whether or not consecutive) during any <ix:nonFraction unitRef="d" contextRef="i17f7971a67b44e4798fe7f7d49131fe4_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNjkzNA_da7e4504-89f7-4e85-a332-4c07fd8820b2">30</ix:nonFraction> consecutive trading-day period ending on, and including, the trading day immediately before the date which we provide notice of redemption.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes may convert the 2024 Notes at any time prior to the close of business on the business day immediately preceding May&#160;15, 2024, only under the following circumstances:</span></div><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">during any calendar quarter (and only during such calendar quarter), if the last reported sale price of our common stock for at least&#160;<ix:nonFraction unitRef="d" contextRef="i17f7971a67b44e4798fe7f7d49131fe4_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNzM4MQ_fb99f8fe-2b8e-41e1-a787-b4c85460c13b">20</ix:nonFraction>&#160;trading days (whether or not consecutive) during a period of&#160;<ix:nonFraction unitRef="d" contextRef="i17f7971a67b44e4798fe7f7d49131fe4_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNzQ0Ng_da7e4504-89f7-4e85-a332-4c07fd8820b2">30</ix:nonFraction>&#160;consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than&#160;<ix:nonFraction unitRef="number" contextRef="i17f7971a67b44e4798fe7f7d49131fe4_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNzU2OA_48c122a8-408a-43d7-a460-0b86c4190741">130</ix:nonFraction>%&#160;of the conversion price (equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="ibfcb863f462042bbaf5db27efbc920d6_D20220101-20221231" decimals="2" name="us-gaap:DebtInstrumentConvertibleStockPriceTrigger" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNzYwNg_ded4fd99-a5ad-45a3-9608-ef4e849100ae">98.70</ix:nonFraction> as of December&#160;31, 2022) on each applicable trading day;</span></div><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">during the&#160;<ix:nonFraction unitRef="d" contextRef="i134fefee8f064cab9634e36d3fc21cfa_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNzY2NA_4d141455-2198-4c7e-b55c-ed83048a322f">five</ix:nonFraction> business-day period immediately after any&#160;<ix:nonFraction unitRef="d" contextRef="i134fefee8f064cab9634e36d3fc21cfa_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNzcxMA_4d141455-2198-4c7e-b55c-ed83048a322f">five</ix:nonFraction>&#160;consecutive trading-day period (the measurement period) in which the trading price (as defined in the 2017 Indenture) per&#160;$<ix:nonFraction unitRef="usd" contextRef="if30740e0928241cb97cfb0ed6563a982_I20170502" decimals="INF" name="nbix:PrincipalAmountOnConversionRate" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNzgyNQ_cb39c6e4-cb99-4087-bc48-8f8b8d074ee0">1,000</ix:nonFraction>&#160;principal amount of the 2024 Notes for each trading day of the measurement period was less than&#160;<ix:nonFraction unitRef="number" contextRef="i134fefee8f064cab9634e36d3fc21cfa_D20170502-20170502" decimals="INF" name="nbix:MinimumPercentageOfTradingPriceToLastReportedSalePrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNzkxOA_47104114-51d2-436d-b208-024ecebb32e8">98</ix:nonFraction>% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day;</span></div><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.03pt">upon the occurrence of specified corporate events, including a merger or a sale of all or substantially all of our assets; or</span></div><div style="margin-bottom:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.57pt">if we call the 2024 Notes for redemption, until the close of business on the business day immediately preceding the redemption date.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after January&#160;15, 2024, until the close of business on the scheduled trading day immediately preceding May&#160;15, 2024, holders of the 2024 Notes may convert the 2024 Notes at any time.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the conditional conversion feature described under (i) above was triggered as of December 31, 2022, holders of the 2024 Notes may convert the 2024 Notes at any time during the period beginning on January 1, 2023, and ending at the close of business on March 31, 2023. Accordingly, the 2024 Notes have been classified as a current liability as of December 31, 2022. The future conditional convertibility of the 2024 Notes will be monitored at each quarterly reporting date and analyzed dependent upon market prices of our common stock during the prescribed measurement periods.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, holders will receive the principal amount of their 2024 Notes in cash and any excess conversion value, calculated based on the per share volume-weighted average price for each of the <ix:nonFraction unitRef="d" contextRef="i17f7971a67b44e4798fe7f7d49131fe4_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzOTE5NA_da7e4504-89f7-4e85-a332-4c07fd8820b2">30</ix:nonFraction> consecutive trading days during the observation period (as more fully described in the 2017 Indenture), in either cash or shares of our common stock.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iba659ad98f654096a17de3ba29c68b2a"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we undergo a fundamental change (as defined in the 2017 Indenture), subject to certain conditions, holders of the 2024 Notes may require us to repurchase for cash all or part of their 2024 Notes at a repurchase price equal to <ix:nonFraction unitRef="number" contextRef="i35bad398da4e4adb94afe6a3edc6fbd6_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzOTU0MQ_c962eaef-1be6-4367-822d-6f09ced073a9">100</ix:nonFraction>% of the principal amount of the 2024 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, if a make-whole fundamental change (as defined in the 2017 Indenture) occurs prior to January&#160;15, 2024, we would, in certain circumstances, increase the conversion rate for a holder who elects to convert their notes in connection with the make-whole fundamental change.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes are our general unsecured obligations that rank senior in right of payment to all of our indebtedness that is expressly subordinated in right of payment to the 2024 Notes, and equal in right of payment to our unsecured indebtedness. The 2024 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by us. The 2017 Indenture contains customary events of default with respect to the 2024 Notes, including that upon certain events of default, <ix:nonFraction unitRef="number" contextRef="i35bad398da4e4adb94afe6a3edc6fbd6_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTg0MDQ5Ng_c962eaef-1be6-4367-822d-6f09ced073a9">100</ix:nonFraction>% of the principal and accrued and unpaid interest on the 2024 Notes will automatically become due and payable.</span></div></ix:continuation><div id="id795223301944418ba8c3fb3bc02f08e_1717"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGV4dHJlZ2lvbjpiYWVkYzViZjNkODQ0NmUzYWFkZWEyNDY5YzEyMzRlOF8yMTk5MDIzMjU4ODc5_bd3e1444-b713-4e36-b28b-5a09ef1ab643" continuedAt="i0f5c112e4ae844c48d2d3b5d6ca50c44" escape="true">Goodwill and Intangible Assets</ix:nonNumeric></span></div><ix:continuation id="i0f5c112e4ae844c48d2d3b5d6ca50c44"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Diurnal in November 2022, we recognized goodwill of $<ix:nonFraction unitRef="usd" contextRef="i5a8688d19b0c4b7f9f790a262226d2ea_I20221101" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGV4dHJlZ2lvbjpiYWVkYzViZjNkODQ0NmUzYWFkZWEyNDY5YzEyMzRlOF8xNjQ5MjY3NDQ3MzU2_733ab158-c072-4ccc-aacd-c25672892219">5.2</ix:nonFraction>&#160;million for the excess consideration transferred over the net assets acquired, reflecting the expected revenue and cost synergies of the combined company and assembled workforce.</span></div><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGV4dHJlZ2lvbjpiYWVkYzViZjNkODQ0NmUzYWFkZWEyNDY5YzEyMzRlOF8yMTk5MDIzMjU4ODgy_c1394c7c-4d94-4eaf-ab34-e9427fb197aa" escape="true"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the carrying amount of goodwill.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGFibGU6OTg2N2M3ZjBlMDM1NDc0MGExNzMzOTQ0YzI5NTU4MGIvdGFibGVyYW5nZTo5ODY3YzdmMGUwMzU0NzQwYTE3MzM5NDRjMjk1NTgwYl8xLTEtMS0xLTE0NDcwOQ_f4374835-7c7d-44e7-9ed8-69e6d5a5db9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill recognized in connection with business combination</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGFibGU6OTg2N2M3ZjBlMDM1NDc0MGExNzMzOTQ0YzI5NTU4MGIvdGFibGVyYW5nZTo5ODY3YzdmMGUwMzU0NzQwYTE3MzM5NDRjMjk1NTgwYl8yLTEtMS0xLTE0NDcwOQ_29f972a9-c5dc-40e2-8472-c781427b2f66">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGFibGU6OTg2N2M3ZjBlMDM1NDc0MGExNzMzOTQ0YzI5NTU4MGIvdGFibGVyYW5nZTo5ODY3YzdmMGUwMzU0NzQwYTE3MzM5NDRjMjk1NTgwYl8zLTEtMS0xLTE1MDk1Mg_a8fb2645-c8d4-4f9b-860b-c1bf94fb7bd8">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGFibGU6OTg2N2M3ZjBlMDM1NDc0MGExNzMzOTQ0YzI5NTU4MGIvdGFibGVyYW5nZTo5ODY3YzdmMGUwMzU0NzQwYTE3MzM5NDRjMjk1NTgwYl8zLTEtMS0xLTE0NDcwOQ_e2ae4248-5416-4172-ab50-2c6f4e740c22">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGV4dHJlZ2lvbjpiYWVkYzViZjNkODQ0NmUzYWFkZWEyNDY5YzEyMzRlOF8yMTk5MDIzMjU4ODg1_33cd858d-c0f3-4263-9c83-211d63c6adb6" escape="true"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGV4dHJlZ2lvbjpiYWVkYzViZjNkODQ0NmUzYWFkZWEyNDY5YzEyMzRlOF8yMTk5MDIzMjU4ODg1_77f7964c-21b8-4c48-8baa-61ad951fe163" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information relating to our recognized intangible assets as of December&#160;31, 2022.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.861%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net <br/>Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Developed product rights</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i18d39a0874004a4dbfac9a59054c0309_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGFibGU6NDE3ZDg0N2ZmNTU5NGZhZmEwNjc0OTllOGNlMmExNGIvdGFibGVyYW5nZTo0MTdkODQ3ZmY1NTk0ZmFmYTA2NzQ5OWU4Y2UyYTE0Yl8xLTEtMS0xLTE2Mjk5Nw_338ae044-1b49-4f36-aecf-c901d1c94c95">10</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6282ace541846298e168b3652f98351_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGFibGU6NDE3ZDg0N2ZmNTU5NGZhZmEwNjc0OTllOGNlMmExNGIvdGFibGVyYW5nZTo0MTdkODQ3ZmY1NTk0ZmFmYTA2NzQ5OWU4Y2UyYTE0Yl8xLTMtMS0xLTE0NDczNQ_e867784b-e8ac-4bfa-b83e-9f843033da81">34.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6282ace541846298e168b3652f98351_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGFibGU6NDE3ZDg0N2ZmNTU5NGZhZmEwNjc0OTllOGNlMmExNGIvdGFibGVyYW5nZTo0MTdkODQ3ZmY1NTk0ZmFmYTA2NzQ5OWU4Y2UyYTE0Yl8xLTUtMS0xLTE0NDczNQ_c73598d6-7179-46b2-a3f1-f05130a58b69">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6282ace541846298e168b3652f98351_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGFibGU6NDE3ZDg0N2ZmNTU5NGZhZmEwNjc0OTllOGNlMmExNGIvdGFibGVyYW5nZTo0MTdkODQ3ZmY1NTk0ZmFmYTA2NzQ5OWU4Y2UyYTE0Yl8xLTctMS0xLTE0NDczNQ_54338056-d99a-404c-81a6-ee467bf7b84c">33.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfdc712fb9f342aca6ae054a16698cef_I20221231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGFibGU6NDE3ZDg0N2ZmNTU5NGZhZmEwNjc0OTllOGNlMmExNGIvdGFibGVyYW5nZTo0MTdkODQ3ZmY1NTk0ZmFmYTA2NzQ5OWU4Y2UyYTE0Yl8yLTEtMS0xLTE1MDk1NA_97cf99bd-e89c-475b-b4e2-21b248449373">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfdc712fb9f342aca6ae054a16698cef_I20221231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGFibGU6NDE3ZDg0N2ZmNTU5NGZhZmEwNjc0OTllOGNlMmExNGIvdGFibGVyYW5nZTo0MTdkODQ3ZmY1NTk0ZmFmYTA2NzQ5OWU4Y2UyYTE0Yl80LTctMS0xLTE0NDczNQ_b19899d0-f77a-46a9-984d-bd5efb684f68">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGFibGU6NDE3ZDg0N2ZmNTU5NGZhZmEwNjc0OTllOGNlMmExNGIvdGFibGVyYW5nZTo0MTdkODQ3ZmY1NTk0ZmFmYTA2NzQ5OWU4Y2UyYTE0Yl8zLTctMS0xLTE3MzA0Ng_0064d339-dd55-4850-8256-fcf07f300c79">37.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGV4dHJlZ2lvbjpiYWVkYzViZjNkODQ0NmUzYWFkZWEyNDY5YzEyMzRlOF8yMTk5MDIzMjYyMTAz_4f8b1b92-fed7-4af1-98ce-7e1d369749e0" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the estimated annual amortization expense for our finite-lived intangible assets. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGFibGU6ZGMzNjQ2OTE5YzUyNDE5NWI0MjhlM2Q1YmQ0MmI5ZWYvdGFibGVyYW5nZTpkYzM2NDY5MTljNTI0MTk1YjQyOGUzZDViZDQyYjllZl8xLTEtMS0xLTE3MDU3Ng_a1a5a602-bc26-4811-b423-be5f5adb872d">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2024</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGFibGU6ZGMzNjQ2OTE5YzUyNDE5NWI0MjhlM2Q1YmQ0MmI5ZWYvdGFibGVyYW5nZTpkYzM2NDY5MTljNTI0MTk1YjQyOGUzZDViZDQyYjllZl8yLTEtMS0xLTE3MDU3Ng_3253dacf-fb87-476f-b1ad-503e82b264ef">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2025</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGFibGU6ZGMzNjQ2OTE5YzUyNDE5NWI0MjhlM2Q1YmQ0MmI5ZWYvdGFibGVyYW5nZTpkYzM2NDY5MTljNTI0MTk1YjQyOGUzZDViZDQyYjllZl8zLTEtMS0xLTE3MDU3Ng_6c4efba5-00cc-4ccd-957b-03d5c69fb371">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2026</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGFibGU6ZGMzNjQ2OTE5YzUyNDE5NWI0MjhlM2Q1YmQ0MmI5ZWYvdGFibGVyYW5nZTpkYzM2NDY5MTljNTI0MTk1YjQyOGUzZDViZDQyYjllZl80LTEtMS0xLTE3MDU3Ng_28aa28ad-dc8b-4c0d-bf5d-010413f1f791">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2027</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGFibGU6ZGMzNjQ2OTE5YzUyNDE5NWI0MjhlM2Q1YmQ0MmI5ZWYvdGFibGVyYW5nZTpkYzM2NDY5MTljNTI0MTk1YjQyOGUzZDViZDQyYjllZl81LTEtMS0xLTE3MDU3Ng_e8ad3682-325e-4d5c-b86e-7df37cb241f1">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGFibGU6ZGMzNjQ2OTE5YzUyNDE5NWI0MjhlM2Q1YmQ0MmI5ZWYvdGFibGVyYW5nZTpkYzM2NDY5MTljNTI0MTk1YjQyOGUzZDViZDQyYjllZl82LTEtMS0xLTE3MDU3Ng_d1b60230-25c3-4646-b783-e09d4fa01e93">16.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="id795223301944418ba8c3fb3bc02f08e_154"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90ZXh0cmVnaW9uOmVhMzc2ZTcwMzkyYjQyMTk4OTAyOWNjNTNmZmY0NjJhXzQ1MA_2fcef701-45e4-4c8e-9dfd-813a147cad3b" continuedAt="i9f851c0aaa79418a88b99eafe90741ae" escape="true">Other Balance Sheet Details</ix:nonNumeric></span></div><ix:continuation id="i9f851c0aaa79418a88b99eafe90741ae" continuedAt="id319258590bb41038809b673c98106b8"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90ZXh0cmVnaW9uOmVhMzc2ZTcwMzkyYjQyMTk4OTAyOWNjNTNmZmY0NjJhXzQ1MQ_facdb9ea-faf8-4fb5-b99d-e71a594c99a0" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTpkZGMzYWU0MGU2YWI0NWQ2YjhmMDUyODI2MDA4ZTJhYy90YWJsZXJhbmdlOmRkYzNhZTQwZTZhYjQ1ZDZiOGYwNTI4MjYwMDhlMmFjXzItMS0xLTEtMTM5MDYy_cadae040-3a2c-4a4b-a01b-87c4b4e1b55d">12.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTpkZGMzYWU0MGU2YWI0NWQ2YjhmMDUyODI2MDA4ZTJhYy90YWJsZXJhbmdlOmRkYzNhZTQwZTZhYjQ1ZDZiOGYwNTI4MjYwMDhlMmFjXzItMy0xLTEtMTM5MDYy_bc0a01f9-0ace-49b4-9af7-eb2e5e184ca9">11.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTpkZGMzYWU0MGU2YWI0NWQ2YjhmMDUyODI2MDA4ZTJhYy90YWJsZXJhbmdlOmRkYzNhZTQwZTZhYjQ1ZDZiOGYwNTI4MjYwMDhlMmFjXzMtMS0xLTEtMTM5MDYy_4e2ddbad-66e6-42e3-8d1b-b4ed3646b6c0">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTpkZGMzYWU0MGU2YWI0NWQ2YjhmMDUyODI2MDA4ZTJhYy90YWJsZXJhbmdlOmRkYzNhZTQwZTZhYjQ1ZDZiOGYwNTI4MjYwMDhlMmFjXzMtMy0xLTEtMTM5MDYy_1bed4afb-6813-4814-8130-1ebfd186267d">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTpkZGMzYWU0MGU2YWI0NWQ2YjhmMDUyODI2MDA4ZTJhYy90YWJsZXJhbmdlOmRkYzNhZTQwZTZhYjQ1ZDZiOGYwNTI4MjYwMDhlMmFjXzQtMS0xLTEtMTM5MDYy_1a9b1ef9-1698-4657-8800-f2e6428588ae">17.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTpkZGMzYWU0MGU2YWI0NWQ2YjhmMDUyODI2MDA4ZTJhYy90YWJsZXJhbmdlOmRkYzNhZTQwZTZhYjQ1ZDZiOGYwNTI4MjYwMDhlMmFjXzQtMy0xLTEtMTM5MDYy_70c0b199-ef0e-45b1-85c9-e25f57f52558">15.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTpkZGMzYWU0MGU2YWI0NWQ2YjhmMDUyODI2MDA4ZTJhYy90YWJsZXJhbmdlOmRkYzNhZTQwZTZhYjQ1ZDZiOGYwNTI4MjYwMDhlMmFjXzUtMS0xLTEtMTM5MDYy_9291c246-270a-4753-b36d-0b4024b21ada">35.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTpkZGMzYWU0MGU2YWI0NWQ2YjhmMDUyODI2MDA4ZTJhYy90YWJsZXJhbmdlOmRkYzNhZTQwZTZhYjQ1ZDZiOGYwNTI4MjYwMDhlMmFjXzUtMy0xLTEtMTM5MDYy_68e14d65-c09b-4af0-ac19-9701ff7d8d84">30.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id319258590bb41038809b673c98106b8"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90ZXh0cmVnaW9uOmVhMzc2ZTcwMzkyYjQyMTk4OTAyOWNjNTNmZmY0NjJhXzQ1Mg_77f9d426-0617-4b2d-b007-aa4f50bb8e69" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tenant improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib36cc15a97d94e96a193bf977c9bcc64_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo4NjYyOTE4MDkzNzI0OTk0YTBiNDFkNDQ2NWQyOWJjMi90YWJsZXJhbmdlOjg2NjI5MTgwOTM3MjQ5OTRhMGI0MWQ0NDY1ZDI5YmMyXzItMS0xLTEtMTM5MDYy_a47d423b-9fe8-49f3-abd3-23bf870f4540">37.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfcd3b4d7074f90897906a633ffcd5c_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo4NjYyOTE4MDkzNzI0OTk0YTBiNDFkNDQ2NWQyOWJjMi90YWJsZXJhbmdlOjg2NjI5MTgwOTM3MjQ5OTRhMGI0MWQ0NDY1ZDI5YmMyXzItMy0xLTEtMTM5MDYy_622d32fa-648f-48f0-9c27-8d403eb4c941">34.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Scientific equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad805873aae044c699ba94c98221a05f_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo4NjYyOTE4MDkzNzI0OTk0YTBiNDFkNDQ2NWQyOWJjMi90YWJsZXJhbmdlOjg2NjI5MTgwOTM3MjQ5OTRhMGI0MWQ0NDY1ZDI5YmMyXzMtMS0xLTEtMTM5MDYy_3431c9a5-e193-4c8b-91d8-2681fe85f924">58.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a4a256d6b68420ca9418a64a947bc8b_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo4NjYyOTE4MDkzNzI0OTk0YTBiNDFkNDQ2NWQyOWJjMi90YWJsZXJhbmdlOjg2NjI5MTgwOTM3MjQ5OTRhMGI0MWQ0NDY1ZDI5YmMyXzMtMy0xLTEtMTM5MDYy_10149c70-5ca6-4240-a98d-c54aebdef42b">51.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5947e62d00f451eb3a24072ec5328d8_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo4NjYyOTE4MDkzNzI0OTk0YTBiNDFkNDQ2NWQyOWJjMi90YWJsZXJhbmdlOjg2NjI5MTgwOTM3MjQ5OTRhMGI0MWQ0NDY1ZDI5YmMyXzQtMS0xLTEtMTM5MDYy_1da52e3f-be8b-4814-9812-282ac0ef50c7">21.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d163cbc8c3d4cef88df04d4844d353c_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo4NjYyOTE4MDkzNzI0OTk0YTBiNDFkNDQ2NWQyOWJjMi90YWJsZXJhbmdlOjg2NjI5MTgwOTM3MjQ5OTRhMGI0MWQ0NDY1ZDI5YmMyXzQtMy0xLTEtMTM5MDYy_27a94bc6-8aa5-43e0-b0ac-f2a43a5226d9">18.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ae1d4d52be44bc3bc2ba9cfc000d178_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo4NjYyOTE4MDkzNzI0OTk0YTBiNDFkNDQ2NWQyOWJjMi90YWJsZXJhbmdlOjg2NjI5MTgwOTM3MjQ5OTRhMGI0MWQ0NDY1ZDI5YmMyXzUtMS0xLTEtMTM5MDYy_f03a73af-579b-4bfe-8b14-fa233318ae85">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f931f023a9b4e74be1c9df8a59da030_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo4NjYyOTE4MDkzNzI0OTk0YTBiNDFkNDQ2NWQyOWJjMi90YWJsZXJhbmdlOjg2NjI5MTgwOTM3MjQ5OTRhMGI0MWQ0NDY1ZDI5YmMyXzUtMy0xLTEtMTM5MDYy_f794b868-a99d-4a05-a8e8-939a8c6e40eb">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo4NjYyOTE4MDkzNzI0OTk0YTBiNDFkNDQ2NWQyOWJjMi90YWJsZXJhbmdlOjg2NjI5MTgwOTM3MjQ5OTRhMGI0MWQ0NDY1ZDI5YmMyXzYtMS0xLTEtMTM5MDYy_7fcf210e-80bf-493b-a778-ccfe2732dc9a">124.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo4NjYyOTE4MDkzNzI0OTk0YTBiNDFkNDQ2NWQyOWJjMi90YWJsZXJhbmdlOjg2NjI5MTgwOTM3MjQ5OTRhMGI0MWQ0NDY1ZDI5YmMyXzYtMy0xLTEtMTM5MDYy_5f48ed2a-e3da-4828-bfa2-41ee116e97fd">110.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo4NjYyOTE4MDkzNzI0OTk0YTBiNDFkNDQ2NWQyOWJjMi90YWJsZXJhbmdlOjg2NjI5MTgwOTM3MjQ5OTRhMGI0MWQ0NDY1ZDI5YmMyXzctMS0xLTEtMTM5MDYy_ccbf0e33-7933-45e7-a766-8c475cf924be">66.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo4NjYyOTE4MDkzNzI0OTk0YTBiNDFkNDQ2NWQyOWJjMi90YWJsZXJhbmdlOjg2NjI5MTgwOTM3MjQ5OTRhMGI0MWQ0NDY1ZDI5YmMyXzctMy0xLTEtMTM5MDYy_b8e2bd5e-0ea5-4685-8a99-905037664d78">51.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo4NjYyOTE4MDkzNzI0OTk0YTBiNDFkNDQ2NWQyOWJjMi90YWJsZXJhbmdlOjg2NjI5MTgwOTM3MjQ5OTRhMGI0MWQ0NDY1ZDI5YmMyXzgtMS0xLTEtMTM5MDYy_5ba6f99f-97af-4d83-8c0f-1fbba70bcdc1">58.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo4NjYyOTE4MDkzNzI0OTk0YTBiNDFkNDQ2NWQyOWJjMi90YWJsZXJhbmdlOjg2NjI5MTgwOTM3MjQ5OTRhMGI0MWQ0NDY1ZDI5YmMyXzgtMy0xLTEtMTM5MDYy_875d1c32-15a5-47ba-8357-76a1a869a5cf">58.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90ZXh0cmVnaW9uOmVhMzc2ZTcwMzkyYjQyMTk4OTAyOWNjNTNmZmY0NjJhXzQ1Mw_d62c5184-82dd-4d91-a5a5-9fdbc47b0a06" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued employee related costs </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo3YzNlMGM0Y2RiODM0MzFhYTY3YzU1NzVhNDhmMmVkYS90YWJsZXJhbmdlOjdjM2UwYzRjZGI4MzQzMWFhNjdjNTU3NWE0OGYyZWRhXzItMS0xLTEtMTM5MDYy_937b5427-1fff-4942-9f78-d837ca25ca24">72.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo3YzNlMGM0Y2RiODM0MzFhYTY3YzU1NzVhNDhmMmVkYS90YWJsZXJhbmdlOjdjM2UwYzRjZGI4MzQzMWFhNjdjNTU3NWE0OGYyZWRhXzItMy0xLTEtMTM5MDYy_614f5056-9734-4ab4-ae93-1298ae658822">50.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="nbix:RevenueRelatedReservesForDiscountsAndAllowances" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo3YzNlMGM0Y2RiODM0MzFhYTY3YzU1NzVhNDhmMmVkYS90YWJsZXJhbmdlOjdjM2UwYzRjZGI4MzQzMWFhNjdjNTU3NWE0OGYyZWRhXzMtMS0xLTEtMTM5MDYy_cea543df-c7c5-4c5c-8847-e37d78ff0ad6">131.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="nbix:RevenueRelatedReservesForDiscountsAndAllowances" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo3YzNlMGM0Y2RiODM0MzFhYTY3YzU1NzVhNDhmMmVkYS90YWJsZXJhbmdlOjdjM2UwYzRjZGI4MzQzMWFhNjdjNTU3NWE0OGYyZWRhXzMtMy0xLTEtMTM5MDYy_2622191d-b7a2-4c73-aa39-d7a647dbb7c2">62.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="nbix:AccruedResearchAndDevelopmentExpenseCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo3YzNlMGM0Y2RiODM0MzFhYTY3YzU1NzVhNDhmMmVkYS90YWJsZXJhbmdlOjdjM2UwYzRjZGI4MzQzMWFhNjdjNTU3NWE0OGYyZWRhXzQtMS0xLTEtMTM5MDYy_e635b0c9-9bd1-4da2-92ec-781ae326f404">39.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="nbix:AccruedResearchAndDevelopmentExpenseCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo3YzNlMGM0Y2RiODM0MzFhYTY3YzU1NzVhNDhmMmVkYS90YWJsZXJhbmdlOjdjM2UwYzRjZGI4MzQzMWFhNjdjNTU3NWE0OGYyZWRhXzQtMy0xLTEtMTM5MDYy_3c32a768-9fc8-4205-93f7-2a4718afbda7">32.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current branded prescription drug fee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="nbix:AccruedBrandedPrescriptionDrugFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo3YzNlMGM0Y2RiODM0MzFhYTY3YzU1NzVhNDhmMmVkYS90YWJsZXJhbmdlOjdjM2UwYzRjZGI4MzQzMWFhNjdjNTU3NWE0OGYyZWRhXzUtMS0xLTEtMTM5MDYy_608e8e39-e2db-4f76-b95f-01a2144bfcce">27.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="nbix:AccruedBrandedPrescriptionDrugFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo3YzNlMGM0Y2RiODM0MzFhYTY3YzU1NzVhNDhmMmVkYS90YWJsZXJhbmdlOjdjM2UwYzRjZGI4MzQzMWFhNjdjNTU3NWE0OGYyZWRhXzUtMy0xLTEtMTM5MDYy_61002a5e-2494-46ee-8670-42987f7e157a">28.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo3YzNlMGM0Y2RiODM0MzFhYTY3YzU1NzVhNDhmMmVkYS90YWJsZXJhbmdlOjdjM2UwYzRjZGI4MzQzMWFhNjdjNTU3NWE0OGYyZWRhXzYtMS0xLTEtMTM5MDYy_751d7fb1-2b0d-4643-9208-39b7957d2a59">76.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo3YzNlMGM0Y2RiODM0MzFhYTY3YzU1NzVhNDhmMmVkYS90YWJsZXJhbmdlOjdjM2UwYzRjZGI4MzQzMWFhNjdjNTU3NWE0OGYyZWRhXzYtMy0xLTEtMTM5MDYy_bc8a684b-bcda-417d-ad7a-ca4edadbae1f">51.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo3YzNlMGM0Y2RiODM0MzFhYTY3YzU1NzVhNDhmMmVkYS90YWJsZXJhbmdlOjdjM2UwYzRjZGI4MzQzMWFhNjdjNTU3NWE0OGYyZWRhXzctMS0xLTEtMTM5MDYy_d634183b-48e6-4a1d-bf3a-434812bf59c3">347.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo3YzNlMGM0Y2RiODM0MzFhYTY3YzU1NzVhNDhmMmVkYS90YWJsZXJhbmdlOjdjM2UwYzRjZGI4MzQzMWFhNjdjNTU3NWE0OGYyZWRhXzctMy0xLTEtMTM5MDYy_660f0f3a-524d-4af2-a9d4-b81ad8d2caac">225.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90ZXh0cmVnaW9uOmVhMzc2ZTcwMzkyYjQyMTk4OTAyOWNjNTNmZmY0NjJhXzQ1NA_140d3a8f-5cb8-4124-a13e-7b317a951a02" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTpjZjFjNzRmMDE4Mzg0OGZkOGEzOWE2Nzg0MjQ2MjIyNy90YWJsZXJhbmdlOmNmMWM3NGYwMTgzODQ4ZmQ4YTM5YTY3ODQyNDYyMjI3XzItMS0xLTEtMTM5MDYy_76ef77e0-00dc-4d6e-94fc-810c85f2143d">262.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTpjZjFjNzRmMDE4Mzg0OGZkOGEzOWE2Nzg0MjQ2MjIyNy90YWJsZXJhbmdlOmNmMWM3NGYwMTgzODQ4ZmQ4YTM5YTY3ODQyNDYyMjI3XzItMy0xLTEtMTM5MDYy_7bc5cf76-6247-4cec-a4b2-6d03ba4f742d">340.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTpjZjFjNzRmMDE4Mzg0OGZkOGEzOWE2Nzg0MjQ2MjIyNy90YWJsZXJhbmdlOmNmMWM3NGYwMTgzODQ4ZmQ4YTM5YTY3ODQyNDYyMjI3XzMtMS0xLTEtMTM5MDYy_7bd54788-16c0-4f02-9f40-137653c6312d">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTpjZjFjNzRmMDE4Mzg0OGZkOGEzOWE2Nzg0MjQ2MjIyNy90YWJsZXJhbmdlOmNmMWM3NGYwMTgzODQ4ZmQ4YTM5YTY3ODQyNDYyMjI3XzMtMy0xLTEtMTM5MDYy_1fe5c994-b01d-403c-848c-eee206861dc9">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTpjZjFjNzRmMDE4Mzg0OGZkOGEzOWE2Nzg0MjQ2MjIyNy90YWJsZXJhbmdlOmNmMWM3NGYwMTgzODQ4ZmQ4YTM5YTY3ODQyNDYyMjI3XzQtMS0xLTEtMTM5MDYy_c5dc2fd8-67b7-43fa-b71e-9653c617303b">270.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTpjZjFjNzRmMDE4Mzg0OGZkOGEzOWE2Nzg0MjQ2MjIyNy90YWJsZXJhbmdlOmNmMWM3NGYwMTgzODQ4ZmQ4YTM5YTY3ODQyNDYyMjI3XzQtMy0xLTEtMTM5MDYy_f7733321-b5b1-495b-a94c-5e8e26e52d98">344.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="id795223301944418ba8c3fb3bc02f08e_157"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90ZXh0cmVnaW9uOjUwZDA3ZDllZmQwODRhOGI5Y2Y3ODVlOGM5NzY5NjJjXzIyOQ_17db00f6-13d3-4bd8-9002-45378996cf14" continuedAt="i5b7bf2ff573b4f5a957a18e561d5acf5" escape="true">Earnings Per Share</ix:nonNumeric></span></div><ix:continuation id="i5b7bf2ff573b4f5a957a18e561d5acf5"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90ZXh0cmVnaW9uOjUwZDA3ZDllZmQwODRhOGI5Y2Y3ODVlOGM5NzY5NjJjXzIzMA_2179e199-8143-4835-970b-39b05ab85c65" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share were calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income - basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzItMS0xLTEtMTM5MDYy_01d2327e-a89a-4b12-ac91-cf26ba488aed"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzItMS0xLTEtMTM5MDYy_37687ad4-20a3-482a-84e6-88937936dfe0">154.5</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzItMy0xLTEtMTM5MDYy_7d128a5e-ec04-4289-a7e6-496a797f8bec"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzItMy0xLTEtMTM5MDYy_bddeea5e-049b-4718-a368-ae47228b7630">89.6</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzItNS0xLTEtMTM5MDYy_4e1a998b-3c66-4aa2-9852-51324126baaa"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzItNS0xLTEtMTM5MDYy_7f2a1f1c-5213-4357-876f-c5f774b0ce63">407.3</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzQtMS0xLTEtMTM5MDYy_149bc02b-8215-476b-9f16-fabec7450561">95.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzQtMy0xLTEtMTM5MDYy_59dadf71-deed-40d5-b517-c065fabdc17b">94.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzQtNS0xLTEtMTM5MDYy_2e1dc6ef-0a22-4e5b-9d1c-5668f94d8c9b">93.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzUtMS0xLTEtMTQ0NzU0_720485e1-9f07-4b44-8568-20b6f63ca5b8">3.1</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzUtMy0xLTEtMTQ0NzU0_761bfcd5-f67b-4e17-afc2-fe13c5d859cf">3.3</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzUtNS0xLTEtMTQ0NzU0_d4c04b12-1464-4bf9-9e07-115e1e4f10f8">4.7</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzEwLTEtMS0xLTEzOTA2Mg_a4c020e0-c1ff-48d3-a501-d8eaf9d8ac61">98.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzEwLTMtMS0xLTEzOTA2Mg_5fddf87c-75a7-47e8-84de-6ae254a16034">97.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzEwLTUtMS0xLTEzOTA2Mg_b3ea9868-7e6f-41a1-b934-b0854c79d32e">97.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per share:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzEyLTEtMS0xLTEzOTA2Mg_e98f0c22-5615-458d-83c6-63c5c6673ac7">1.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzEyLTMtMS0xLTEzOTA2Mg_5e93c517-354a-4ac7-917c-dd34e0714650">0.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzEyLTUtMS0xLTEzOTA2Mg_5df6e98a-bc3b-4f31-aa99-b84205c0a424">4.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzEzLTEtMS0xLTEzOTA2Mg_3fa1522a-0f35-483f-81cb-42d9c5c47ea6">1.56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzEzLTMtMS0xLTEzOTA2Mg_17659869-c428-4aaf-96f4-71d2819b991f">0.92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzEzLTUtMS0xLTEzOTA2Mg_43c099b1-7aa2-48eb-9bda-c19b65deaccb">4.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares which have been excluded from diluted per share amounts because their effect would have been anti-dilutive were <ix:nonFraction unitRef="shares" contextRef="ic7d26b322bb24bff8ec6e47dcf836515_D20220101-20221231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90ZXh0cmVnaW9uOjUwZDA3ZDllZmQwODRhOGI5Y2Y3ODVlOGM5NzY5NjJjXzE5NQ_6fd227d8-631e-4458-af5c-b0d07ea0d73d">4.6</ix:nonFraction> million for 2022, <ix:nonFraction unitRef="shares" contextRef="idaf8254dea124bfb9e7456439c9c6107_D20210101-20211231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90ZXh0cmVnaW9uOjUwZDA3ZDllZmQwODRhOGI5Y2Y3ODVlOGM5NzY5NjJjXzIwNg_3b1d9e83-62df-4767-b904-ac42d8c28ab5">4.1</ix:nonFraction> million for 2021 and <ix:nonFraction unitRef="shares" contextRef="if2bedeff3c8c43e6a805d773f9fd4669_D20200101-20201231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90ZXh0cmVnaW9uOjUwZDA3ZDllZmQwODRhOGI5Y2Y3ODVlOGM5NzY5NjJjXzIyMA_42473040-5354-4a86-bbc8-268387297691">2.5</ix:nonFraction> million for 2020.</span></div></ix:continuation><div id="id795223301944418ba8c3fb3bc02f08e_160"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzUxNjQ_04a0f3cd-59f6-4d02-a387-7f950fb94356" continuedAt="i3b96c18df2784e5cbaddb045647c2b2a" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><div style="margin-bottom:3pt"><ix:continuation id="i3b96c18df2784e5cbaddb045647c2b2a" continuedAt="ia90c8e1f346945f7950c363ee499da3e"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Equity Incentive Plan.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, our stockholders approved an amendment and restatement of the 2020 Equity Incentive Plan (as so amended and restated, the Amended 2020 Plan). The Amended 2020 Plan provides for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards, and other awards. As of December 31, 2022, <ix:nonFraction unitRef="shares" contextRef="i25f7e10858b24f7fae2103c935cfd949_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzEwOTk1MTE2NDQwNTQ_bd5910c4-8f6b-490f-b962-a48e0e201c74">7.9</ix:nonFraction>&#160;million shares of common stock remain available for future grant under the Amended 2020 Plan.</span></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia90c8e1f346945f7950c363ee499da3e" continuedAt="i180d38157f1b4df7ba0cfb0b9bb6bbd9"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Amended 2020 Plan, the number of shares of common stock available for issuance will be: (i) reduced by (a) <ix:nonFraction unitRef="shares" contextRef="i213982ce809548e292c18f6215fa9e6b_D20220518-20221231" decimals="0" name="nbix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzU0OTc1NTg0MDYwNw_c695a531-3695-4cbe-bfd3-5f6f9bb66ab6">one</ix:nonFraction> share for each share issued pursuant to an appreciation award (as defined in the Amended 2020 Plan) granted under the Amended 2020 Plan and (b) <ix:nonFraction unitRef="shares" contextRef="i213982ce809548e292c18f6215fa9e6b_D20220518-20221231" decimals="2" name="nbix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzU0OTc1NTg0MDYyNg_fe441992-bcc8-43ee-95d2-00c2cc6b29d1">2.13</ix:nonFraction> shares for each share issued pursuant to a full value award (as defined in the Amended 2020 Plan) granted under the Amended 2020 Plan on or after May 18, 2022; and (ii) increased by (a) <ix:nonFraction unitRef="shares" contextRef="i213982ce809548e292c18f6215fa9e6b_D20220518-20221231" decimals="0" name="nbix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzU0OTc1NTg0MDYxOA_22eb330c-a405-431e-a909-2269c1e2fbda">one</ix:nonFraction> share for each share subject to an appreciation award that becomes available again for issuance under the terms of the Amended 2020 Plan and (b) <ix:nonFraction unitRef="shares" contextRef="i213982ce809548e292c18f6215fa9e6b_D20220518-20221231" decimals="2" name="nbix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzU0OTc1NTg0MDYzNA_bbc5a0c9-e4ff-40fd-9a1a-f1bb75797e7e">2.13</ix:nonFraction> shares for each share subject to a full value award that becomes available again for issuance under the terms of the Amended 2020 Plan on or after May 18, 2022.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2011 Equity Incentive Plan.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2011, we adopted the 2011 Equity Incentive Plan, or the 2011 Plan. The 2011 Plan was a stockholder-approved plan pursuant to which outstanding awards have been made, but from which <ix:nonFraction unitRef="shares" contextRef="id479e592bc6b4c9fb00c946120287b70_I20110531" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzE2NDkyNjc0ODgxMjI_f0452b47-5315-4ddd-a17a-dc5f6e080411">no</ix:nonFraction> further awards can or will be made.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Employee Stock Purchase Plan.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, our stockholders approved an amendment and restatement of the 2018 Employee Stock Purchase Plan (as so amended and restated, the Amended 2018 ESPP). As of December 31, 2022, <ix:nonFraction unitRef="shares" contextRef="i695a8fab0f384006baa1447f58213de8_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzEwOTk1MTE2NDY0MTA_f54bbdcb-e52b-456f-9aa8-ab45e1b667ca">0.6</ix:nonFraction>&#160;million shares of common stock remain available for future issuance under the Amended 2018 ESPP.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzUxNjU_0e55e018-4305-4b2c-a418-b4be1761c2ee" continuedAt="if7050137c07547668ac2c7edb34694b7" escape="true">The effect of stock-based compensation expense on our consolidated statements of income and comprehensive income by line-item follows:</ix:nonNumeric></span></div><ix:continuation id="if7050137c07547668ac2c7edb34694b7"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdd80fdaea2455ba085c93bafcf958a_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTphMjc4YzI0ZTEzNmQ0MTQ4YTllZjFlNDQwMmYzY2VmNS90YWJsZXJhbmdlOmEyNzhjMjRlMTM2ZDQxNDhhOWVmMWU0NDAyZjNjZWY1XzItMS0xLTEtMTM5MDYy_e72e4c82-26f5-4e13-ad54-1eb9cf8aa054">115.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56babcc72eb54154a6b2bbf854d97490_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTphMjc4YzI0ZTEzNmQ0MTQ4YTllZjFlNDQwMmYzY2VmNS90YWJsZXJhbmdlOmEyNzhjMjRlMTM2ZDQxNDhhOWVmMWU0NDAyZjNjZWY1XzItMy0xLTEtMTM5MDYy_26e5575a-9411-4f40-b8ad-472c03f24587">85.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8089736b115438bae00a39b3e804807_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTphMjc4YzI0ZTEzNmQ0MTQ4YTllZjFlNDQwMmYzY2VmNS90YWJsZXJhbmdlOmEyNzhjMjRlMTM2ZDQxNDhhOWVmMWU0NDAyZjNjZWY1XzItNS0xLTEtMTM5MDYy_eca0e3f8-2d25-43a4-a41b-6f276ee5bfbe">66.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8bb02545f4e412b99ba7d4bcfab2fbd_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTphMjc4YzI0ZTEzNmQ0MTQ4YTllZjFlNDQwMmYzY2VmNS90YWJsZXJhbmdlOmEyNzhjMjRlMTM2ZDQxNDhhOWVmMWU0NDAyZjNjZWY1XzMtMS0xLTEtMTM5MDYy_7982255d-767e-468a-a554-4b98ce61903c">57.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3dd11bd409d4809a79dea85436f4401_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTphMjc4YzI0ZTEzNmQ0MTQ4YTllZjFlNDQwMmYzY2VmNS90YWJsZXJhbmdlOmEyNzhjMjRlMTM2ZDQxNDhhOWVmMWU0NDAyZjNjZWY1XzMtMy0xLTEtMTM5MDYy_031d762d-c74e-403d-be91-5496e481102e">48.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i901a3c0cc12a478b90f47154a36d3711_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTphMjc4YzI0ZTEzNmQ0MTQ4YTllZjFlNDQwMmYzY2VmNS90YWJsZXJhbmdlOmEyNzhjMjRlMTM2ZDQxNDhhOWVmMWU0NDAyZjNjZWY1XzMtNS0xLTEtMTM5MDYy_4cd0f42a-d189-498d-b90f-89b286b7b3f7">33.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTphMjc4YzI0ZTEzNmQ0MTQ4YTllZjFlNDQwMmYzY2VmNS90YWJsZXJhbmdlOmEyNzhjMjRlMTM2ZDQxNDhhOWVmMWU0NDAyZjNjZWY1XzQtMS0xLTEtMTM5MDYy_031a7949-f457-41bd-ae74-0f07e032d3e4">173.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTphMjc4YzI0ZTEzNmQ0MTQ4YTllZjFlNDQwMmYzY2VmNS90YWJsZXJhbmdlOmEyNzhjMjRlMTM2ZDQxNDhhOWVmMWU0NDAyZjNjZWY1XzQtMy0xLTEtMTM5MDYy_56bba6cf-9692-4a19-bc52-54072bba6d0b">134.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTphMjc4YzI0ZTEzNmQ0MTQ4YTllZjFlNDQwMmYzY2VmNS90YWJsZXJhbmdlOmEyNzhjMjRlMTM2ZDQxNDhhOWVmMWU0NDAyZjNjZWY1XzQtNS0xLTEtMTM5MDYy_ba1d7298-40a3-4c7c-8251-41475928aa70">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense by award-type follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6946e8304b548468ab27182f7a4d25b_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo1ZDhhN2MzNzIzZjk0YmIzYmQ1MWQ3ODg0OGMxZDMyZi90YWJsZXJhbmdlOjVkOGE3YzM3MjNmOTRiYjNiZDUxZDc4ODQ4YzFkMzJmXzItMS0xLTEtMTM5MDYy_0da70f11-4f3a-4002-beb6-76d8922621a2">62.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7178f777b084a969408727f29c9743f_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo1ZDhhN2MzNzIzZjk0YmIzYmQ1MWQ3ODg0OGMxZDMyZi90YWJsZXJhbmdlOjVkOGE3YzM3MjNmOTRiYjNiZDUxZDc4ODQ4YzFkMzJmXzItMy0xLTEtMTM5MDYy_187cb670-9196-4e17-8044-97ee09d3957e">60.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85732a5f6db74d908155c57c3c4f6f54_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo1ZDhhN2MzNzIzZjk0YmIzYmQ1MWQ3ODg0OGMxZDMyZi90YWJsZXJhbmdlOjVkOGE3YzM3MjNmOTRiYjNiZDUxZDc4ODQ4YzFkMzJmXzItNS0xLTEtMTM5MDYy_2c9fa85b-a3c5-488c-85aa-806deaca34a4">47.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic76478c478fb48838837717f4d08aac5_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo1ZDhhN2MzNzIzZjk0YmIzYmQ1MWQ3ODg0OGMxZDMyZi90YWJsZXJhbmdlOjVkOGE3YzM3MjNmOTRiYjNiZDUxZDc4ODQ4YzFkMzJmXzMtMS0xLTEtMTM5MDYy_7ab67484-42f9-44fe-a44d-11e9229b4e7e">86.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45d277e0630f42518902ef7c75a787b7_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo1ZDhhN2MzNzIzZjk0YmIzYmQ1MWQ3ODg0OGMxZDMyZi90YWJsZXJhbmdlOjVkOGE3YzM3MjNmOTRiYjNiZDUxZDc4ODQ4YzFkMzJmXzMtMy0xLTEtMTM5MDYy_da8d4bb0-f363-4d3f-8254-17990056125d">62.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb26118589cd4a7f9365abf100167588_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo1ZDhhN2MzNzIzZjk0YmIzYmQ1MWQ3ODg0OGMxZDMyZi90YWJsZXJhbmdlOjVkOGE3YzM3MjNmOTRiYjNiZDUxZDc4ODQ4YzFkMzJmXzMtNS0xLTEtMTM5MDYy_e40979b9-3bda-4fed-8ca7-f227b8155bbb">44.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PRSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dac2801c32400a82446d8538afc4cf_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo1ZDhhN2MzNzIzZjk0YmIzYmQ1MWQ3ODg0OGMxZDMyZi90YWJsZXJhbmdlOjVkOGE3YzM3MjNmOTRiYjNiZDUxZDc4ODQ4YzFkMzJmXzQtMS0xLTEtMTM5MDYy_d94f4112-6142-406d-bb6e-7c9ba9616b9c">20.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2383f1847c08462b992435e6a74d3b13_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo1ZDhhN2MzNzIzZjk0YmIzYmQ1MWQ3ODg0OGMxZDMyZi90YWJsZXJhbmdlOjVkOGE3YzM3MjNmOTRiYjNiZDUxZDc4ODQ4YzFkMzJmXzQtMy0xLTEtMTM5MDYy_1b57222d-5bcc-4555-be96-46a7b31d65a3">7.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4445191c2fc34a93a6035559db9ca75f_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo1ZDhhN2MzNzIzZjk0YmIzYmQ1MWQ3ODg0OGMxZDMyZi90YWJsZXJhbmdlOjVkOGE3YzM3MjNmOTRiYjNiZDUxZDc4ODQ4YzFkMzJmXzQtNS0xLTEtMTM5MDYy_a3d6d3c0-a8b0-458f-9a99-18acc4e82663">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fab03eca0a475d8e8c0d679f6b27b8_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo1ZDhhN2MzNzIzZjk0YmIzYmQ1MWQ3ODg0OGMxZDMyZi90YWJsZXJhbmdlOjVkOGE3YzM3MjNmOTRiYjNiZDUxZDc4ODQ4YzFkMzJmXzUtMS0xLTEtMTM5MDYy_e1912d40-b0c7-45dd-acdd-d0e7e7a20ac5">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d5d3961550840ffb667ec48e12d4486_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo1ZDhhN2MzNzIzZjk0YmIzYmQ1MWQ3ODg0OGMxZDMyZi90YWJsZXJhbmdlOjVkOGE3YzM3MjNmOTRiYjNiZDUxZDc4ODQ4YzFkMzJmXzUtMy0xLTEtMTM5MDYy_1f7847c4-5875-4e87-b6ed-494068a02355">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9983074f75e943bf8e1b6ffe1be8dfaa_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo1ZDhhN2MzNzIzZjk0YmIzYmQ1MWQ3ODg0OGMxZDMyZi90YWJsZXJhbmdlOjVkOGE3YzM3MjNmOTRiYjNiZDUxZDc4ODQ4YzFkMzJmXzUtNS0xLTEtMTM5MDYy_5492f774-6f01-4656-b1c9-b660174c5093">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo1ZDhhN2MzNzIzZjk0YmIzYmQ1MWQ3ODg0OGMxZDMyZi90YWJsZXJhbmdlOjVkOGE3YzM3MjNmOTRiYjNiZDUxZDc4ODQ4YzFkMzJmXzYtMS0xLTEtMTM5MDYy_0b970afa-3ca8-4f13-b3b0-a7273bb4cff4">173.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo1ZDhhN2MzNzIzZjk0YmIzYmQ1MWQ3ODg0OGMxZDMyZi90YWJsZXJhbmdlOjVkOGE3YzM3MjNmOTRiYjNiZDUxZDc4ODQ4YzFkMzJmXzYtMy0xLTEtMTM5MDYy_e420b048-fdc3-4e4f-99b1-53e25682dffb">134.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo1ZDhhN2MzNzIzZjk0YmIzYmQ1MWQ3ODg0OGMxZDMyZi90YWJsZXJhbmdlOjVkOGE3YzM3MjNmOTRiYjNiZDUxZDc4ODQ4YzFkMzJmXzYtNS0xLTEtMTM5MDYy_a33a46a5-75aa-4a93-8dae-63b95a6b3c04">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, unrecognized stock-based compensation expense by award-type and the weighted-average period over which such expense is expected to be recognized, as applicable, was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.726%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.729%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrecognized Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Recognition Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0960363045f4c3fa3cbebd5f5dd1c92_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTpmYTU0ZTY1ZWQ2MGI0NTY1OTk0YjhmNmFjNGMxY2Q0Yi90YWJsZXJhbmdlOmZhNTRlNjVlZDYwYjQ1NjU5OTRiOGY2YWM0YzFjZDRiXzEtMS0xLTEtMTM5MDYy_2ccb153f-825a-4759-b44c-cfe23451f92f">106.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic6946e8304b548468ab27182f7a4d25b_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTpmYTU0ZTY1ZWQ2MGI0NTY1OTk0YjhmNmFjNGMxY2Q0Yi90YWJsZXJhbmdlOmZhNTRlNjVlZDYwYjQ1NjU5OTRiOGY2YWM0YzFjZDRiXzEtMy0xLTEtMTM5MDYy_9bc885ea-b4db-4465-9726-de77f40e7ebc">2.5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSUs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab54417bdda84f5da649889184df892f_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTpmYTU0ZTY1ZWQ2MGI0NTY1OTk0YjhmNmFjNGMxY2Q0Yi90YWJsZXJhbmdlOmZhNTRlNjVlZDYwYjQ1NjU5OTRiOGY2YWM0YzFjZDRiXzItMS0xLTEtMTM5MDYy_cf50e1bb-82ca-4525-82b9-21bd6c2ddec9">151.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic76478c478fb48838837717f4d08aac5_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTpmYTU0ZTY1ZWQ2MGI0NTY1OTk0YjhmNmFjNGMxY2Q0Yi90YWJsZXJhbmdlOmZhNTRlNjVlZDYwYjQ1NjU5OTRiOGY2YWM0YzFjZDRiXzItMy0xLTEtMTM5MDYy_ae30aaa3-310d-48b6-89ad-541625035985">2.3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PRSUs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3f2d647e6d24e838c79ec0e84ee0b98_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTpmYTU0ZTY1ZWQ2MGI0NTY1OTk0YjhmNmFjNGMxY2Q0Yi90YWJsZXJhbmdlOmZhNTRlNjVlZDYwYjQ1NjU5OTRiOGY2YWM0YzFjZDRiXzMtMS0xLTEtMTcwNzc2_cd91ed90-6ddc-48df-b709-678e73f2080b">33.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:continuation><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Typically, stock options have a <ix:nonNumeric contextRef="ic6946e8304b548468ab27182f7a4d25b_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzUxNjM_7afd24f5-e3f7-4768-9fb5-e4e8f1c321e3">10-year</ix:nonNumeric> term and vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzIwMTc_50d14189-4f30-4d95-85d1-8b0107a221f2">three</span> to <ix:nonNumeric contextRef="i67cf3f5a803b4310944b01aeae80d081_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzUxNjY_29eb77e6-62f0-48dc-bb15-bb23441ddd0d">four-year</ix:nonNumeric> period. The exercise price of stock options granted is equal to the closing price of our common stock on the date of grant. We estimate the fair value of stock options using the Black-Scholes option-pricing model on the date of grant. The Black-Scholes option-pricing model incorporates various and highly sensitive assumptions including expected volatility, term and interest rates. The weighted-average grant-date fair values of stock options granted were $<ix:nonFraction unitRef="usdPerShare" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzI0ODk_326bc7e1-268c-4864-81cd-9b66f1b69aa9">32.05</ix:nonFraction> for 2022, $<ix:nonFraction unitRef="usdPerShare" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzI1MDA_2007f4f7-2d32-412e-bee2-31f450b1d00b">45.02</ix:nonFraction> for 2021 and $<ix:nonFraction unitRef="usdPerShare" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzI1MTQ_2052b63e-6b50-47df-836e-9705ed2e21f6">45.67</ix:nonFraction> for 2020.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i180d38157f1b4df7ba0cfb0b9bb6bbd9" continuedAt="i20c4f5c8ae5d4d34b4817a5d01d263fc"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzUxNjc_303cb28d-b169-45bc-b003-f23cfe365374" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option granted was estimated on the date of grant using the Black-Scholes option-pricing valuation model with the following weighted-average assumptions: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic6946e8304b548468ab27182f7a4d25b_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZToyNmRhYzkxZTM4OWI0Nzc4YWM4YTE3Y2YyNjQ2YzQyNi90YWJsZXJhbmdlOjI2ZGFjOTFlMzg5YjQ3NzhhYzhhMTdjZjI2NDZjNDI2XzItMS0xLTEtMTM5MDYy_0b767148-7482-45e9-aef8-5fb3f00766cb">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic7178f777b084a969408727f29c9743f_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZToyNmRhYzkxZTM4OWI0Nzc4YWM4YTE3Y2YyNjQ2YzQyNi90YWJsZXJhbmdlOjI2ZGFjOTFlMzg5YjQ3NzhhYzhhMTdjZjI2NDZjNDI2XzItMy0xLTEtMTM5MDYy_f07ed641-2807-45f1-9747-6df1d9343323">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i85732a5f6db74d908155c57c3c4f6f54_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZToyNmRhYzkxZTM4OWI0Nzc4YWM4YTE3Y2YyNjQ2YzQyNi90YWJsZXJhbmdlOjI2ZGFjOTFlMzg5YjQ3NzhhYzhhMTdjZjI2NDZjNDI2XzItNS0xLTEtMTM5MDYy_09af2844-768f-4062-a725-4fcf4e159756">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic6946e8304b548468ab27182f7a4d25b_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZToyNmRhYzkxZTM4OWI0Nzc4YWM4YTE3Y2YyNjQ2YzQyNi90YWJsZXJhbmdlOjI2ZGFjOTFlMzg5YjQ3NzhhYzhhMTdjZjI2NDZjNDI2XzMtMS0xLTEtMTM5MDYy_101cc0bc-4bb6-4258-8e82-6146cf72fd1e">42.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic7178f777b084a969408727f29c9743f_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZToyNmRhYzkxZTM4OWI0Nzc4YWM4YTE3Y2YyNjQ2YzQyNi90YWJsZXJhbmdlOjI2ZGFjOTFlMzg5YjQ3NzhhYzhhMTdjZjI2NDZjNDI2XzMtMy0xLTEtMTM5MDYy_29d86b7e-ae20-46b7-b3c9-162307bd3150">45.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i85732a5f6db74d908155c57c3c4f6f54_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZToyNmRhYzkxZTM4OWI0Nzc4YWM4YTE3Y2YyNjQ2YzQyNi90YWJsZXJhbmdlOjI2ZGFjOTFlMzg5YjQ3NzhhYzhhMTdjZjI2NDZjNDI2XzMtNS0xLTEtMTM5MDYy_bb39473d-403e-4f73-9eb4-3696bc270db1">48.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic6946e8304b548468ab27182f7a4d25b_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZToyNmRhYzkxZTM4OWI0Nzc4YWM4YTE3Y2YyNjQ2YzQyNi90YWJsZXJhbmdlOjI2ZGFjOTFlMzg5YjQ3NzhhYzhhMTdjZjI2NDZjNDI2XzQtMS0xLTEtMTM5MDYy_da9adb43-6666-4344-a925-3fffa393cba7">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic7178f777b084a969408727f29c9743f_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZToyNmRhYzkxZTM4OWI0Nzc4YWM4YTE3Y2YyNjQ2YzQyNi90YWJsZXJhbmdlOjI2ZGFjOTFlMzg5YjQ3NzhhYzhhMTdjZjI2NDZjNDI2XzQtMy0xLTEtMTM5MDYy_95b9a9af-14a8-4fd2-a181-921063cf7d8d">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i85732a5f6db74d908155c57c3c4f6f54_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZToyNmRhYzkxZTM4OWI0Nzc4YWM4YTE3Y2YyNjQ2YzQyNi90YWJsZXJhbmdlOjI2ZGFjOTFlMzg5YjQ3NzhhYzhhMTdjZjI2NDZjNDI2XzQtNS0xLTEtMTM5MDYy_d434d44e-e525-4877-91d5-7dfdfd1f6341">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected option term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic6946e8304b548468ab27182f7a4d25b_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZToyNmRhYzkxZTM4OWI0Nzc4YWM4YTE3Y2YyNjQ2YzQyNi90YWJsZXJhbmdlOjI2ZGFjOTFlMzg5YjQ3NzhhYzhhMTdjZjI2NDZjNDI2XzUtMS0xLTEtMTM5MDYy_42eb8dff-cc6c-48f4-adb7-199119ed95e0">5.0</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic7178f777b084a969408727f29c9743f_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZToyNmRhYzkxZTM4OWI0Nzc4YWM4YTE3Y2YyNjQ2YzQyNi90YWJsZXJhbmdlOjI2ZGFjOTFlMzg5YjQ3NzhhYzhhMTdjZjI2NDZjNDI2XzUtMy0xLTEtMTM5MDYy_1c40f486-6471-4a70-8ad0-05dabae69511">5.2</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i85732a5f6db74d908155c57c3c4f6f54_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZToyNmRhYzkxZTM4OWI0Nzc4YWM4YTE3Y2YyNjQ2YzQyNi90YWJsZXJhbmdlOjI2ZGFjOTFlMzg5YjQ3NzhhYzhhMTdjZjI2NDZjNDI2XzUtNS0xLTEtMTM5MDYy_fc0810df-372c-4263-9a4c-9ec01e2536f3">5.3</ix:nonNumeric> years</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average valuation assumptions were determined as follows:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The expected volatility of common stock is estimated based on the historical volatility of our common stock over the most recent period commensurate with the estimated expected term of our stock options.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The expected option term is estimated based on historical experience as well as the status of the employee. For example, directors and officers have a longer expected option term than all other employees. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The risk-free interest rate for periods within the contractual life of a stock option is based upon observed interest rates appropriate for the expected term of our employee stock options. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have not historically declared or paid dividends and do not intend to do so in the foreseeable future. </span></div><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzUxNjg_aaab0fa8-54ef-44e8-b7cb-2e86c846705e" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents summary of activity related to stock options.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTowZjY2YTZhYTgzNDA0NzM3YmFmMzQwMDc1YWEyMTk2NS90YWJsZXJhbmdlOjBmNjZhNmFhODM0MDQ3MzdiYWYzNDAwNzVhYTIxOTY1XzEtMS0xLTEtMTM5MDYy_7dda68f5-e6d3-4e84-b2be-e130cdcaaa07">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTowZjY2YTZhYTgzNDA0NzM3YmFmMzQwMDc1YWEyMTk2NS90YWJsZXJhbmdlOjBmNjZhNmFhODM0MDQ3MzdiYWYzNDAwNzVhYTIxOTY1XzEtMy0xLTEtMTM5MDYy_ba1af229-42ec-4e4a-bea3-34de787eab17">76.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTowZjY2YTZhYTgzNDA0NzM3YmFmMzQwMDc1YWEyMTk2NS90YWJsZXJhbmdlOjBmNjZhNmFhODM0MDQ3MzdiYWYzNDAwNzVhYTIxOTY1XzItMS0xLTEtMTM5MDYy_42f8698b-7f31-4582-aad2-a3c556b7d26b">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTowZjY2YTZhYTgzNDA0NzM3YmFmMzQwMDc1YWEyMTk2NS90YWJsZXJhbmdlOjBmNjZhNmFhODM0MDQ3MzdiYWYzNDAwNzVhYTIxOTY1XzItMy0xLTEtMTM5MDYy_a8a3f958-a784-4343-8592-bee92dccf773">81.27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTowZjY2YTZhYTgzNDA0NzM3YmFmMzQwMDc1YWEyMTk2NS90YWJsZXJhbmdlOjBmNjZhNmFhODM0MDQ3MzdiYWYzNDAwNzVhYTIxOTY1XzMtMS0xLTEtMTM5MDYy_7aac8826-afa9-4e6f-8167-e591863164b4">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTowZjY2YTZhYTgzNDA0NzM3YmFmMzQwMDc1YWEyMTk2NS90YWJsZXJhbmdlOjBmNjZhNmFhODM0MDQ3MzdiYWYzNDAwNzVhYTIxOTY1XzMtMy0xLTEtMTM5MDYy_518ebb70-e352-4920-aced-b90f49561a90">52.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTowZjY2YTZhYTgzNDA0NzM3YmFmMzQwMDc1YWEyMTk2NS90YWJsZXJhbmdlOjBmNjZhNmFhODM0MDQ3MzdiYWYzNDAwNzVhYTIxOTY1XzQtMS0xLTEtMTM5MDYy_e8c4ecc7-2037-4ed2-9deb-70736685bc11">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTowZjY2YTZhYTgzNDA0NzM3YmFmMzQwMDc1YWEyMTk2NS90YWJsZXJhbmdlOjBmNjZhNmFhODM0MDQ3MzdiYWYzNDAwNzVhYTIxOTY1XzQtMy0xLTEtMTM5MDYy_0b564828-f5e2-433e-a73b-5e7f3133cc5d">96.28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTowZjY2YTZhYTgzNDA0NzM3YmFmMzQwMDc1YWEyMTk2NS90YWJsZXJhbmdlOjBmNjZhNmFhODM0MDQ3MzdiYWYzNDAwNzVhYTIxOTY1XzUtMS0xLTEtMTM5MDYy_249e2646-5cda-400f-8318-13e8c50868a9">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTowZjY2YTZhYTgzNDA0NzM3YmFmMzQwMDc1YWEyMTk2NS90YWJsZXJhbmdlOjBmNjZhNmFhODM0MDQ3MzdiYWYzNDAwNzVhYTIxOTY1XzUtMy0xLTEtMTM5MDYy_0d7946f8-e3a6-45f1-aa53-07f851bb6583">79.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTowZjY2YTZhYTgzNDA0NzM3YmFmMzQwMDc1YWEyMTk2NS90YWJsZXJhbmdlOjBmNjZhNmFhODM0MDQ3MzdiYWYzNDAwNzVhYTIxOTY1XzUtNS0xLTEtMTM5MDYy_0e1e03ea-8c5a-43e5-9eab-57e71614f241">6.5</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTowZjY2YTZhYTgzNDA0NzM3YmFmMzQwMDc1YWEyMTk2NS90YWJsZXJhbmdlOjBmNjZhNmFhODM0MDQ3MzdiYWYzNDAwNzVhYTIxOTY1XzUtNy0xLTEtMTM5MDYy_5e0ee085-99f7-40d8-b5ef-6e0e09c0094b">362.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTowZjY2YTZhYTgzNDA0NzM3YmFmMzQwMDc1YWEyMTk2NS90YWJsZXJhbmdlOjBmNjZhNmFhODM0MDQ3MzdiYWYzNDAwNzVhYTIxOTY1XzYtMS0xLTEtMTM5MDYy_90b2e7aa-cc57-417b-9c14-fea182499bee">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTowZjY2YTZhYTgzNDA0NzM3YmFmMzQwMDc1YWEyMTk2NS90YWJsZXJhbmdlOjBmNjZhNmFhODM0MDQ3MzdiYWYzNDAwNzVhYTIxOTY1XzYtMy0xLTEtMTM5MDYy_95593107-5c4a-4629-887d-5da031b2f7e7">72.27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTowZjY2YTZhYTgzNDA0NzM3YmFmMzQwMDc1YWEyMTk2NS90YWJsZXJhbmdlOjBmNjZhNmFhODM0MDQ3MzdiYWYzNDAwNzVhYTIxOTY1XzYtNS0xLTEtMTM5MDYy_cdd05805-1e69-415d-86ff-f58e015ab8db">5.4</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTowZjY2YTZhYTgzNDA0NzM3YmFmMzQwMDc1YWEyMTk2NS90YWJsZXJhbmdlOjBmNjZhNmFhODM0MDQ3MzdiYWYzNDAwNzVhYTIxOTY1XzYtNy0xLTEtMTM5MDYy_994aa284-6840-4e2a-8a03-55fb91d7c465">281.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of stock options exercised was $<ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzU0OTc1NTg0ODI3Mw_badab349-632a-4467-8cc2-6ab5f26463fa">39.7</ix:nonFraction> million for 2022, $<ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzU0OTc1NTg0ODI4Ng_7c7e3639-5896-4f33-8aba-bfd9bdcff7fb">58.0</ix:nonFraction> million for 2021 and $<ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzU0OTc1NTg0ODMwMg_b95a032b-a76f-46a4-a9a4-b3c5a1bbadbd">40.2</ix:nonFraction> million for 2020. Cash received from stock option exercises was $<ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzU0OTc1NTg0ODM2MQ_b94f1682-a5fd-4b06-9510-f92bf7fb9f6e">37.0</ix:nonFraction> million for 2022, $<ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzU0OTc1NTg0ODM3NA_e02a014c-81ee-4ef9-9eb8-bff89bc45c92">20.7</ix:nonFraction> million for 2021 and $<ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzU0OTc1NTg0ODM5MA_e7f7eee4-1327-4cb6-b743-9f3050539021">23.5</ix:nonFraction> million for 2020.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs typically vest over a <ix:nonNumeric contextRef="ic76478c478fb48838837717f4d08aac5_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzUxNjk_14db9a30-70a6-4a42-91e6-00ea769f269d">four-year</ix:nonNumeric> period and may be subject to a deferred delivery arrangement at the election of eligible employees. The fair value of RSUs is based on the closing sale price of our common stock on the date of issuance. The total fair value of RSUs that vested was $<ix:nonFraction unitRef="usd" contextRef="ic76478c478fb48838837717f4d08aac5_D20220101-20221231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzU0OTc1NTg0NjczNg_1f20d709-43d8-49ac-9c77-e1daf8c34b01">72.4</ix:nonFraction> million for 2022, $<ix:nonFraction unitRef="usd" contextRef="i45d277e0630f42518902ef7c75a787b7_D20210101-20211231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzU0OTc1NTg0Njc0OQ_1efbbdac-bc91-4477-a2bf-3e3bcfc05539">64.3</ix:nonFraction> million for 2021 and $<ix:nonFraction unitRef="usd" contextRef="ibb26118589cd4a7f9365abf100167588_D20200101-20201231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzU0OTc1NTg0Njc2NQ_e5f9b3e8-544c-4efd-a109-777178e49ee2">49.7</ix:nonFraction> million for 2020.</span></div><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzUxNzA_2f90c4e1-c925-4389-a52b-e09fb44fec45" continuedAt="i7fdb4bd5b9dd4014a0627900ce0fb1c2" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of activity related to RSUs.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant Date <br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i60b1905034ee4ddfb0d307e7deb147c0_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTpjOTNkZjg1OThlYTU0NDhlYWU5NDRhYWRjMmI1ZWMwNS90YWJsZXJhbmdlOmM5M2RmODU5OGVhNTQ0OGVhZTk0NGFhZGMyYjVlYzA1XzEtMS0xLTEtMTM5MDYy_5de8a9fb-3c3e-4383-a78d-a51895b39393">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i60b1905034ee4ddfb0d307e7deb147c0_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTpjOTNkZjg1OThlYTU0NDhlYWU5NDRhYWRjMmI1ZWMwNS90YWJsZXJhbmdlOmM5M2RmODU5OGVhNTQ0OGVhZTk0NGFhZGMyYjVlYzA1XzEtMy0xLTEtMTM5MDYy_73998a98-75c1-4a65-acb9-c09e5afff5ff">99.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic76478c478fb48838837717f4d08aac5_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTpjOTNkZjg1OThlYTU0NDhlYWU5NDRhYWRjMmI1ZWMwNS90YWJsZXJhbmdlOmM5M2RmODU5OGVhNTQ0OGVhZTk0NGFhZGMyYjVlYzA1XzItMS0xLTEtMTM5MDYy_7d69c15a-f39d-42a3-926c-730cfa42b1ee">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic76478c478fb48838837717f4d08aac5_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTpjOTNkZjg1OThlYTU0NDhlYWU5NDRhYWRjMmI1ZWMwNS90YWJsZXJhbmdlOmM5M2RmODU5OGVhNTQ0OGVhZTk0NGFhZGMyYjVlYzA1XzItMy0xLTEtMTM5MDYy_bd3ca249-1f11-4f34-8bb3-2e967ea4bfee">83.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic76478c478fb48838837717f4d08aac5_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTpjOTNkZjg1OThlYTU0NDhlYWU5NDRhYWRjMmI1ZWMwNS90YWJsZXJhbmdlOmM5M2RmODU5OGVhNTQ0OGVhZTk0NGFhZGMyYjVlYzA1XzMtMS0xLTEtMTM5MDYy_0b0f4e12-9a58-4b27-8e5e-c1700ad41512">0.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic76478c478fb48838837717f4d08aac5_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTpjOTNkZjg1OThlYTU0NDhlYWU5NDRhYWRjMmI1ZWMwNS90YWJsZXJhbmdlOmM5M2RmODU5OGVhNTQ0OGVhZTk0NGFhZGMyYjVlYzA1XzMtMy0xLTEtMTM5MDYy_d7a9c079-ecba-488e-917d-2745de60b765">96.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic76478c478fb48838837717f4d08aac5_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTpjOTNkZjg1OThlYTU0NDhlYWU5NDRhYWRjMmI1ZWMwNS90YWJsZXJhbmdlOmM5M2RmODU5OGVhNTQ0OGVhZTk0NGFhZGMyYjVlYzA1XzQtMS0xLTEtMTM5MDYy_71c887e7-a631-4940-9548-ed27277ceb2f">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic76478c478fb48838837717f4d08aac5_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTpjOTNkZjg1OThlYTU0NDhlYWU5NDRhYWRjMmI1ZWMwNS90YWJsZXJhbmdlOmM5M2RmODU5OGVhNTQ0OGVhZTk0NGFhZGMyYjVlYzA1XzQtMy0xLTEtMTM5MDYy_7dbb0f79-ca07-41b1-9fea-0477129a707a">94.05</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab54417bdda84f5da649889184df892f_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTpjOTNkZjg1OThlYTU0NDhlYWU5NDRhYWRjMmI1ZWMwNS90YWJsZXJhbmdlOmM5M2RmODU5OGVhNTQ0OGVhZTk0NGFhZGMyYjVlYzA1XzUtMS0xLTEtMTM5MDYy_35513344-8017-4f52-8903-73a4e26e8f0b">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iab54417bdda84f5da649889184df892f_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTpjOTNkZjg1OThlYTU0NDhlYWU5NDRhYWRjMmI1ZWMwNS90YWJsZXJhbmdlOmM5M2RmODU5OGVhNTQ0OGVhZTk0NGFhZGMyYjVlYzA1XzUtMy0xLTEtMTM5MDYy_180b9f2c-7e34-4987-a52a-551a632f857f">92.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic76478c478fb48838837717f4d08aac5_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTpjOTNkZjg1OThlYTU0NDhlYWU5NDRhYWRjMmI1ZWMwNS90YWJsZXJhbmdlOmM5M2RmODU5OGVhNTQ0OGVhZTk0NGFhZGMyYjVlYzA1XzUtNS0xLTEtMTM5MDYy_d715bede-6224-4511-b627-82f609bc639c">1.3</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab54417bdda84f5da649889184df892f_I20221231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTpjOTNkZjg1OThlYTU0NDhlYWU5NDRhYWRjMmI1ZWMwNS90YWJsZXJhbmdlOmM5M2RmODU5OGVhNTQ0OGVhZTk0NGFhZGMyYjVlYzA1XzUtNy0xLTEtMTM5MDYy_3bc4460e-6192-4f2b-bc56-8512d5994343">276.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-Based Restricted Stock Units. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PRSUs vest based on the achievement of certain predefined Company-specific performance criteria. Any unvested PRSUs will expire if it is determined the related performance criteria has not been met during the applicable <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzU0OTc1NTg0OTAyMA_025ee6ff-3e68-4066-aa62-f80b858bd74f">three</span> to <ix:nonNumeric contextRef="ic887499617c2453682a9ed77390375fe_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzE2NDkyNjc0NzcyNzM_aa5a5a15-c1dc-438f-8383-029616d91b6d">four-year</ix:nonNumeric> performance period. The fair value of PRSUs is estimated based on the closing sale price of our common stock on the date of grant. The fair value of PRSUs that vested during 2020 was $<ix:nonFraction unitRef="usd" contextRef="i4445191c2fc34a93a6035559db9ca75f_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzU0OTc1NTgzNTIyOQ_13eefbfe-f925-4a58-91fc-314234236ca4">13.5</ix:nonFraction>&#160;million. <ix:nonFraction unitRef="usd" contextRef="i2383f1847c08462b992435e6a74d3b13_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzU0OTc1NTgzNTU4NQ_331ca298-d3c2-407e-8bd1-fec8d38f8bad"><ix:nonFraction unitRef="usd" contextRef="i87dac2801c32400a82446d8538afc4cf_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzU0OTc1NTgzNTU4NQ_9d55b973-faae-4df8-981a-b9439290df7b">No</ix:nonFraction></ix:nonFraction> PRSUs vested during 2021 or 2022.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i20c4f5c8ae5d4d34b4817a5d01d263fc"><ix:continuation id="i7fdb4bd5b9dd4014a0627900ce0fb1c2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of activity related to PRSUs.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>PRSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant Date <br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i229630d0b4d149969094372fd9771fee_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo4YTM0ZjlhODBhMzk0MDg1ODk5ZjNjNTU2OGUwMzc0Ny90YWJsZXJhbmdlOjhhMzRmOWE4MGEzOTQwODU4OTlmM2M1NTY4ZTAzNzQ3XzEtMS0xLTEtMTM5MDYy_55cfe178-99e3-4880-b366-239e080834d3">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i229630d0b4d149969094372fd9771fee_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo4YTM0ZjlhODBhMzk0MDg1ODk5ZjNjNTU2OGUwMzc0Ny90YWJsZXJhbmdlOjhhMzRmOWE4MGEzOTQwODU4OTlmM2M1NTY4ZTAzNzQ3XzEtMy0xLTEtMTM5MDYy_9c09b06b-eaa4-4725-a591-8de29f80a277">109.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i87dac2801c32400a82446d8538afc4cf_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo4YTM0ZjlhODBhMzk0MDg1ODk5ZjNjNTU2OGUwMzc0Ny90YWJsZXJhbmdlOjhhMzRmOWE4MGEzOTQwODU4OTlmM2M1NTY4ZTAzNzQ3XzItMS0xLTEtMTM5MDYy_8e939bba-0977-484a-9d3c-c05920143ca8">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i87dac2801c32400a82446d8538afc4cf_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo4YTM0ZjlhODBhMzk0MDg1ODk5ZjNjNTU2OGUwMzc0Ny90YWJsZXJhbmdlOjhhMzRmOWE4MGEzOTQwODU4OTlmM2M1NTY4ZTAzNzQ3XzItMy0xLTEtMTM5MDYy_6bfbab6a-defc-47a4-a639-bebe6ec61a1b">80.04</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i87dac2801c32400a82446d8538afc4cf_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo4YTM0ZjlhODBhMzk0MDg1ODk5ZjNjNTU2OGUwMzc0Ny90YWJsZXJhbmdlOjhhMzRmOWE4MGEzOTQwODU4OTlmM2M1NTY4ZTAzNzQ3XzMtMS0xLTEtMTM5MDYy_fc906344-f496-4d2f-9605-bcf40cd44a30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i87dac2801c32400a82446d8538afc4cf_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo4YTM0ZjlhODBhMzk0MDg1ODk5ZjNjNTU2OGUwMzc0Ny90YWJsZXJhbmdlOjhhMzRmOWE4MGEzOTQwODU4OTlmM2M1NTY4ZTAzNzQ3XzMtMy0xLTEtMTM5MDYy_4924dc16-36b7-4e49-8465-4d42279c4ec6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i87dac2801c32400a82446d8538afc4cf_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo4YTM0ZjlhODBhMzk0MDg1ODk5ZjNjNTU2OGUwMzc0Ny90YWJsZXJhbmdlOjhhMzRmOWE4MGEzOTQwODU4OTlmM2M1NTY4ZTAzNzQ3XzQtMS0xLTEtMTM5MDYy_aee3fa83-d00b-43f5-8094-47a251ae08ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i87dac2801c32400a82446d8538afc4cf_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo4YTM0ZjlhODBhMzk0MDg1ODk5ZjNjNTU2OGUwMzc0Ny90YWJsZXJhbmdlOjhhMzRmOWE4MGEzOTQwODU4OTlmM2M1NTY4ZTAzNzQ3XzQtMy0xLTEtMTM5MDYy_02e387be-7f39-4c09-9bc1-ba0ad5b7dc95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if3f2d647e6d24e838c79ec0e84ee0b98_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo4YTM0ZjlhODBhMzk0MDg1ODk5ZjNjNTU2OGUwMzc0Ny90YWJsZXJhbmdlOjhhMzRmOWE4MGEzOTQwODU4OTlmM2M1NTY4ZTAzNzQ3XzUtMS0xLTEtMTM5MDYy_05fd0e15-96dd-4cfd-aa98-9147c3387200">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if3f2d647e6d24e838c79ec0e84ee0b98_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo4YTM0ZjlhODBhMzk0MDg1ODk5ZjNjNTU2OGUwMzc0Ny90YWJsZXJhbmdlOjhhMzRmOWE4MGEzOTQwODU4OTlmM2M1NTY4ZTAzNzQ3XzUtMy0xLTEtMTM5MDYy_ca6cce5f-9b46-406c-8d10-ef3cf54ae4ad">101.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i87dac2801c32400a82446d8538afc4cf_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo4YTM0ZjlhODBhMzk0MDg1ODk5ZjNjNTU2OGUwMzc0Ny90YWJsZXJhbmdlOjhhMzRmOWE4MGEzOTQwODU4OTlmM2M1NTY4ZTAzNzQ3XzUtNS0xLTEtMTM5MDYy_48e4397a-dff5-47b8-99eb-d6577e60cc31">0.8</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3f2d647e6d24e838c79ec0e84ee0b98_I20221231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo4YTM0ZjlhODBhMzk0MDg1ODk5ZjNjNTU2OGUwMzc0Ny90YWJsZXJhbmdlOjhhMzRmOWE4MGEzOTQwODU4OTlmM2M1NTY4ZTAzNzQ3XzUtNy0xLTEtMTM5MDYy_64c8d5ed-a73d-47fb-b3dd-94bf24ef0ceb">60.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Amended 2018 ESPP, eligible employees may purchase shares of our common stock at a discount semi-annually based on a percentage of their annual compensation. The discounted purchase price is equal to the lower of <ix:nonFraction unitRef="number" contextRef="ibf71df6caa1445c7a59724087fa5d3fa_D20220101-20221231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzQ5OTU_65473d91-462f-4226-a6f2-6acd83297113">85</ix:nonFraction>% of (i) the market value per share of the common stock on the first day of the offering period or (ii) the market value per share of common stock on the purchase date.</span></div></ix:continuation><div id="id795223301944418ba8c3fb3bc02f08e_163"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90ZXh0cmVnaW9uOjA1ZTFlOWYxMzA1OTQwY2I4YmQ1ODQ1YmQ5NGE0MzExXzM3NTQ_061df3e1-7abf-498d-a64a-61c8ab8e77fa" continuedAt="i41035c47a94348c4a37dbb2d939ea17c" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i41035c47a94348c4a37dbb2d939ea17c" continuedAt="ie37ce54d278e4842bed0e359b1595456"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90ZXh0cmVnaW9uOjA1ZTFlOWYxMzA1OTQwY2I4YmQ1ODQ1YmQ5NGE0MzExXzIxOTkwMjMyNjQ0MDk_f2f9f5ab-efa7-4862-ae57-c2ace642e558" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents income before the provision for income taxes from continuing domestic and foreign operations.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTpmNzFiNjY0YjRjYzI0ZWFmOWMwOThlYTEzYmYwODQ1Mi90YWJsZXJhbmdlOmY3MWI2NjRiNGNjMjRlYWY5YzA5OGVhMTNiZjA4NDUyXzItMS0xLTEtMTcxNDk0_7accda6c-60a5-41f8-a3cb-6244c666cc7b">218.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTpmNzFiNjY0YjRjYzI0ZWFmOWMwOThlYTEzYmYwODQ1Mi90YWJsZXJhbmdlOmY3MWI2NjRiNGNjMjRlYWY5YzA5OGVhMTNiZjA4NDUyXzItMy0xLTEtMTcxNTAx_8308f1b5-6d56-4cb9-be6a-6e58f381a86d">101.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTpmNzFiNjY0YjRjYzI0ZWFmOWMwOThlYTEzYmYwODQ1Mi90YWJsZXJhbmdlOmY3MWI2NjRiNGNjMjRlYWY5YzA5OGVhMTNiZjA4NDUyXzItNS0xLTEtMTcxNTA4_2b15f596-d7d6-4bd5-b8da-e97ba66446dc">106.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTpmNzFiNjY0YjRjYzI0ZWFmOWMwOThlYTEzYmYwODQ1Mi90YWJsZXJhbmdlOmY3MWI2NjRiNGNjMjRlYWY5YzA5OGVhMTNiZjA4NDUyXzMtMS0xLTEtMTcxNDk0_5c3deba2-4225-456c-a966-b9a27c6c663d">4.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTpmNzFiNjY0YjRjYzI0ZWFmOWMwOThlYTEzYmYwODQ1Mi90YWJsZXJhbmdlOmY3MWI2NjRiNGNjMjRlYWY5YzA5OGVhMTNiZjA4NDUyXzMtMy0xLTEtMTcxNTAx_95bf4914-9f24-44c7-9c04-6ffed27564bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTpmNzFiNjY0YjRjYzI0ZWFmOWMwOThlYTEzYmYwODQ1Mi90YWJsZXJhbmdlOmY3MWI2NjRiNGNjMjRlYWY5YzA5OGVhMTNiZjA4NDUyXzMtNS0xLTEtMTcxNTA4_9de62087-57c2-46a0-965b-4b52f691e013">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTpmNzFiNjY0YjRjYzI0ZWFmOWMwOThlYTEzYmYwODQ1Mi90YWJsZXJhbmdlOmY3MWI2NjRiNGNjMjRlYWY5YzA5OGVhMTNiZjA4NDUyXzQtMS0xLTEtMTcxNDk0_0aca913b-d31d-4c98-910a-c3d6e8e2f274">213.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTpmNzFiNjY0YjRjYzI0ZWFmOWMwOThlYTEzYmYwODQ1Mi90YWJsZXJhbmdlOmY3MWI2NjRiNGNjMjRlYWY5YzA5OGVhMTNiZjA4NDUyXzQtMy0xLTEtMTcxNTAx_7ef46d9c-1b63-4f12-947f-ee75db003fc3">101.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTpmNzFiNjY0YjRjYzI0ZWFmOWMwOThlYTEzYmYwODQ1Mi90YWJsZXJhbmdlOmY3MWI2NjRiNGNjMjRlYWY5YzA5OGVhMTNiZjA4NDUyXzQtNS0xLTEtMTcxNTA4_9ae68501-1b72-4652-a434-d03d6407a446">106.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90ZXh0cmVnaW9uOjA1ZTFlOWYxMzA1OTQwY2I4YmQ1ODQ1YmQ5NGE0MzExXzM3NTU_6367ed5e-6abd-4af8-92d0-ee580ff93bd5" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of the provision for (benefit from) income taxes for continuing operations.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzMtMS0xLTEtMTM5MDYy_617696ab-b17f-4fff-a931-90eab2eed5eb">17.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzMtMy0xLTEtMTM5MDYy_ab61aa94-cf51-4f6a-a44a-3b7db89262ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzMtNS0xLTEtMTM5MDYy_13fab059-920d-493c-8afd-75138f99d64c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzQtMS0xLTEtMTM5MDYy_a4543e8d-73ef-49a4-a326-c7eaa533cfd8">20.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzQtMy0xLTEtMTM5MDYy_37cd82c6-6edf-4410-a9e1-5d7b753a7377">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzQtNS0xLTEtMTM5MDYy_e4b1dfd4-25c3-400c-bc92-8e3bac3d573d">10.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzUtMS0xLTEtMTM5MDYy_c7f05460-3aa1-4f91-b6c3-de5cd3b333e3">37.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzUtMy0xLTEtMTM5MDYy_1a2ff063-82bc-47b9-9d5a-383dbbdaa97c">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzUtNS0xLTEtMTM5MDYy_21eb59e1-72a5-44d9-a3a2-385c6fadd3a2">10.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzctMS0xLTEtMTM5MDYy_104d0c54-c018-4f74-8610-27ab0e4fc5ad">27.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzctMy0xLTEtMTM5MDYy_9194b92c-db6c-44a0-89d9-63777208dbd6">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzctNS0xLTEtMTM5MDYy_bc5fc2c7-718a-410a-b340-a88f9eb05374">287.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzgtMS0xLTEtMTM5MDYy_ccc3c6ca-d919-495e-adf3-8ba7458e1dc8">5.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzgtMy0xLTEtMTM5MDYy_b349592c-06d3-4081-b598-5ca317534d7a">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzgtNS0xLTEtMTM5MDYy_dd3604f5-d9a9-4504-94e2-0b6565b9e53f">23.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzktMS0xLTEtMTM5MDYy_ac29b239-4f5b-4d04-81bb-c38e766ba1d8">22.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzktMy0xLTEtMTM5MDYy_7ac1d302-7407-4549-ab42-f39e4f3b13e6">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzktNS0xLTEtMTM5MDYy_26b5e5df-359b-42b1-bef2-2056b1b94ee8">310.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzEwLTEtMS0xLTEzOTA2Mg_ef4af46e-1e9d-4f5b-a9cd-ab2563c7e202">59.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzEwLTMtMS0xLTEzOTA2Mg_6daca9bf-789c-4f33-b6a7-221af56006f1">11.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzEwLTUtMS0xLTEzOTA2Mg_e816c29d-59b0-4383-9def-c732616bc96b">300.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie37ce54d278e4842bed0e359b1595456" continuedAt="i529ecbd218864b7182bb871854b5d9a5"><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90ZXh0cmVnaW9uOjA1ZTFlOWYxMzA1OTQwY2I4YmQ1ODQ1YmQ5NGE0MzExXzM3NTY_91fa09d2-e266-4f87-ad6a-41e3505324a1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for (benefit from) income taxes on earnings subject to income taxes differs from the statutory federal rate due to the following: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal income taxes at <ix:nonFraction unitRef="number" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzItMC0xLTEtMTM5MDYyL3RleHRyZWdpb246MzEzN2EzYWU2Y2Y5NDdkMTk3Y2VmNGIyNTI4NGZmNGJfMjg_27c82d69-1296-42d4-86ff-abc232eaad2c"><ix:nonFraction unitRef="number" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzItMC0xLTEtMTM5MDYyL3RleHRyZWdpb246MzEzN2EzYWU2Y2Y5NDdkMTk3Y2VmNGIyNTI4NGZmNGJfMjg_80f75563-8c3f-4229-b601-cc5d2532f483"><ix:nonFraction unitRef="number" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzItMC0xLTEtMTM5MDYyL3RleHRyZWdpb246MzEzN2EzYWU2Y2Y5NDdkMTk3Y2VmNGIyNTI4NGZmNGJfMjg_b789158a-55c6-42ac-a103-f2d69e4a933b">21</ix:nonFraction></ix:nonFraction></ix:nonFraction>%</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzItMS0xLTEtMTM5MDYy_6a8191b6-f39c-464a-9999-3a17143fac52">44.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzItMy0xLTEtMTM5MDYy_9b1fade0-6c9c-4560-9509-89f9c0593937">21.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzItNS0xLTEtMTM5MDYy_2146b277-4ab0-42f1-b4b1-c2b1769f69cf">22.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State income tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzMtMS0xLTEtMTM5MDYy_c2a0ef77-24fb-429a-ba25-46b7ed43b61d">11.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzMtMy0xLTEtMTM5MDYy_d00ef1b9-959a-4015-8942-f50a9725856a">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzMtNS0xLTEtMTM5MDYy_d27cacf8-716f-4023-9876-573455d4476a">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Branded prescription drug fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="nbix:IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzUtMS0xLTEtMTM5MDYy_5c418079-4ad3-40cc-bd9f-5401da8447cf">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="nbix:IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzUtMy0xLTEtMTM5MDYy_cff1e71c-b2c2-4f41-85c0-0cd12741ba48">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="nbix:IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzUtNS0xLTEtMTM5MDYy_1f30b0dd-0329-4d2e-b790-3b0a2e7dd71c">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="nbix:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzUtMS0xLTEtMTcyMTI3_bad41ff3-f622-4043-ac37-560adc5c6be7">12.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="nbix:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzUtMy0xLTEtMTcyMTM0_ba5cf874-f571-40e1-a15d-b49a763e68ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="nbix:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzUtNS0xLTEtMTcyMTQx_1c906a46-81f1-4f3e-a031-e9be3b2d0cc5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzYtMS0xLTEtMTM5MDYy_480ba12a-0f7a-4d33-99fb-2acf99a30279">2.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzYtMy0xLTEtMTM5MDYy_07e6b66a-7c1a-4f2e-9da3-5ae746117d21">11.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzYtNS0xLTEtMTM5MDYy_f08f8086-aae4-4309-a6e8-3f71d5d850db">6.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Officer compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="nbix:IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzctMS0xLTEtMTM5MDYy_8b745ad9-6a11-4047-8ad1-f9b3dff41a3e">9.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="nbix:IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzctMy0xLTEtMTM5MDYy_bed38923-14ef-4c8b-87d0-fae6596e90e6">7.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="nbix:IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzctNS0xLTEtMTM5MDYy_86434135-4b90-4be5-b1d7-f3066b17cbb4">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzgtMS0xLTEtMTM5MDYy_2846ed06-ba7d-455c-8774-44bda577b4d6">1.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzgtMy0xLTEtMTM5MDYy_2d8bde20-97c1-485a-a840-b3b79e92f6c5">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzgtNS0xLTEtMTM5MDYy_a10133b9-42fc-4cf6-a6a4-6eeb88e1798e">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired tax attributes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="nbix:IncomeTaxReconciliationExpirationOfTaxCredits" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzktMS0xLTEtMTM5MDYy_e30c9d35-4aa0-47a8-b748-96be00f0cf61">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="nbix:IncomeTaxReconciliationExpirationOfTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzktMy0xLTEtMTM5MDYy_7ee7fb1f-a415-4477-a5dd-965851292b22">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="nbix:IncomeTaxReconciliationExpirationOfTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzktNS0xLTEtMTM5MDYy_61c71cf8-2c7f-4b64-af0b-cd3df98d4836">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzEwLTEtMS0xLTEzOTA2Mg_3a1ad8bf-ffc2-4c4f-9222-2ec64d6f0abe">29.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzEwLTMtMS0xLTEzOTA2Mg_e5fc4655-7900-41eb-a717-44e6d2e0ae72">22.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzEwLTUtMS0xLTEzOTA2Mg_82c48d87-7d34-4d6c-8bad-3b69fcb9b735">39.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzExLTEtMS0xLTEzOTA2Mg_3cd4d803-8ea1-4d39-8733-0af2cc5f4f86">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzExLTMtMS0xLTEzOTA2Mg_4c956464-311d-4f5e-a8d0-2f7c91d3d761">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzExLTUtMS0xLTEzOTA2Mg_bdc68d23-0315-4223-b4ef-751c1a6d59dd">296.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzEyLTEtMS0xLTEzOTA2Mg_2bb7d480-ef2f-4466-a354-67294de5ee56">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzEyLTMtMS0xLTEzOTA2Mg_ed109126-3466-4a46-8d68-998260bdc29b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzEyLTUtMS0xLTEzOTA2Mg_35ce6bd6-7f6b-4194-b55f-474118dc49db">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzEzLTEtMS0xLTEzOTA2Mg_89c51617-ee50-4001-a4bf-26c1cc423335">59.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzEzLTMtMS0xLTEzOTA2Mg_62d718ec-2b65-4d65-b399-1c55d8ee90ad">11.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzEzLTUtMS0xLTEzOTA2Mg_4d2879bd-18b3-4b05-bf4d-0dcc84d50b71">300.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90ZXh0cmVnaW9uOjA1ZTFlOWYxMzA1OTQwY2I4YmQ1ODQ1YmQ5NGE0MzExXzM3NTc_b3af6882-e8a0-4c76-a56c-9f64cea40db4" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the significant components of our deferred tax assets. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzMtMS0xLTEtMTM5MDYy_3e965711-701a-4102-8036-47b63afd2221">27.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzMtMy0xLTEtMTM5MDYy_96e5feee-bfd3-4eae-8c73-174d354b5fd8">90.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzQtMS0xLTEtMTM5MDYy_6a3abba9-5ad8-42b7-b384-95a558319ba6">108.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzQtMy0xLTEtMTM5MDYy_027f756c-5f28-4a67-8f67-7170768d9f7a">129.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="nbix:DeferredTaxAssetsCapitalizedResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzUtMS0xLTEtMTM5MDYy_c62ac4da-3a8c-49d4-b208-c37259503484">91.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="nbix:DeferredTaxAssetsCapitalizedResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzUtMy0xLTEtMTM5MDYy_00bf90bf-b49a-4c21-a472-507dcb6e391f">17.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzYtMS0xLTEtMTM5MDYy_bdc494bf-0db5-4e2b-9969-4cfb66bdf657">45.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzYtMy0xLTEtMTM5MDYy_ee38725b-ca04-4db2-a18f-705fe2811dbd">38.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="nbix:DeferredTaxAssetsOperatingLeasesAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzctMS0xLTEtMTM5MDYy_4c26e0ec-7a7c-4161-a669-31d5748ce02b">26.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="nbix:DeferredTaxAssetsOperatingLeasesAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzctMy0xLTEtMTM5MDYy_1a14ecad-749e-4f7a-9422-726ee2de22a5">29.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzgtMS0xLTEtMTM5MDYy_6400f06a-cd85-4660-8fb7-08fc34f75017">80.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzgtMy0xLTEtMTM5MDYy_f3af938d-bf63-4a3c-ab05-fa27ee2b883c">86.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzktMS0xLTEtMTM5MDYy_9547b9aa-1a30-4a79-b99d-eefda27e88b1">24.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzktMy0xLTEtMTM5MDYy_87041893-ada3-4601-b630-c855ed509d1b">21.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzEwLTEtMS0xLTEzOTA2Mg_313f45ae-00cc-4fab-b4ee-766868979899">405.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzEwLTMtMS0xLTEzOTA2Mg_2138134d-3011-45a0-a47e-0cd35b310c13">413.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="nbix:DeferredTaxLiabilitiesConvertibleSeniorNotes" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzEyLTEtMS0xLTEzOTA2Mg_f83b9ea8-55f1-49bc-8e6a-9acb10955d0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="nbix:DeferredTaxLiabilitiesConvertibleSeniorNotes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzEyLTMtMS0xLTEzOTA2Mg_eb351b06-e931-4e9d-95d0-9ea0757430d4">9.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="nbix:DeferredTaxLiabilitiesOperatingLeasesLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzEzLTEtMS0xLTEzOTA2Mg_f101c689-2ad3-4e5d-8fb1-3e1983517f6d">21.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="nbix:DeferredTaxLiabilitiesOperatingLeasesLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzEzLTMtMS0xLTEzOTA2Mg_5ae28b31-078e-4828-b646-88a9f3094c6f">23.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzE0LTEtMS0xLTEzOTA2Mg_88fd71c7-5c0a-470a-b0bf-b7f45cfee534">11.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzE0LTMtMS0xLTEzOTA2Mg_eb8be0c4-5e8e-4402-a5ac-43accef425e5">10.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzE1LTEtMS0xLTEzOTA2Mg_73098579-2948-4d41-bf8f-2b39cb1e4010">32.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzE1LTMtMS0xLTEzOTA2Mg_86892ab9-41c9-4e39-935c-3ee1a8bced28">43.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net of deferred tax assets and liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="nbix:DeferredTaxAssetsLiabilitiesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzE2LTEtMS0xLTEzOTA2Mg_d1a86425-9ae5-4ad9-be0b-af03ebbdff05">372.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="nbix:DeferredTaxAssetsLiabilitiesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzE2LTMtMS0xLTEzOTA2Mg_8c6206e3-96ea-4969-bde3-a2c367ea155d">369.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzE3LTEtMS0xLTEzOTA2Mg_74508b56-294d-4fef-aed1-764fcbf16434">67.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzE3LTMtMS0xLTEzOTA2Mg_981b69fb-1bbf-4796-9259-f48f441853fa">54.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzE4LTEtMS0xLTEzOTA2Mg_3564549e-4e35-4c20-8bb5-1788c9a9481b">305.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzE4LTMtMS0xLTEzOTA2Mg_2a1db7a9-9fe4-4416-bd97-d3870aeacce6">315.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, our deferred tax assets were primarily the result of net operating loss carry forwards, capitalized research costs, acquired intangible assets and tax credit carryforwards. As of December 31, 2022 and 2021, we recorded a valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90ZXh0cmVnaW9uOjA1ZTFlOWYxMzA1OTQwY2I4YmQ1ODQ1YmQ5NGE0MzExXzYyNw_74508b56-294d-4fef-aed1-764fcbf16434">67.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90ZXh0cmVnaW9uOjA1ZTFlOWYxMzA1OTQwY2I4YmQ1ODQ1YmQ5NGE0MzExXzYzNA_981b69fb-1bbf-4796-9259-f48f441853fa">54.8</ix:nonFraction> million, respectively, against our gross deferred tax asset balance.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of each reporting date, management considers new evidence, both positive and negative, that could affect its assessment of the future realizability of our deferred tax assets. As of December&#160;31, 2022, management determined there was sufficient positive evidence to conclude that it is more likely than not deferred tax assets of $<ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90ZXh0cmVnaW9uOjA1ZTFlOWYxMzA1OTQwY2I4YmQ1ODQ1YmQ5NGE0MzExXzEwMzA_3564549e-4e35-4c20-8bb5-1788c9a9481b">305.9</ix:nonFraction> million are realizable. The recorded valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90ZXh0cmVnaW9uOjA1ZTFlOWYxMzA1OTQwY2I4YmQ1ODQ1YmQ5NGE0MzExXzEwODU_74508b56-294d-4fef-aed1-764fcbf16434">67.0</ix:nonFraction> million consisted primarily of state and foreign net operating loss carryforwards and state credit carryforwards for which management cannot conclude it is more likely than not to be realized.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i529ecbd218864b7182bb871854b5d9a5"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had state and foreign income tax net operating loss carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i216211ef6a3c4bf293c5a051308c8517_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90ZXh0cmVnaW9uOjA1ZTFlOWYxMzA1OTQwY2I4YmQ1ODQ1YmQ5NGE0MzExXzU0OTc1NTgxOTU3NA_39645a37-4c67-44fc-8d16-22d30b827c0a">324.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i71608a5505e146ccaf00cf18ac3af453_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90ZXh0cmVnaW9uOjA1ZTFlOWYxMzA1OTQwY2I4YmQ1ODQ1YmQ5NGE0MzExXzU0OTc1NTgxOTU4Mg_7ca0a8df-9591-4eed-aad3-9573d6b5a26d">60.1</ix:nonFraction> million, respectively. We had <ix:nonFraction unitRef="usd" contextRef="iec21f5b659784393b128ecb098d076d0_I20221231" decimals="INF" name="us-gaap:OperatingLossCarryforwards" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90ZXh0cmVnaW9uOjA1ZTFlOWYxMzA1OTQwY2I4YmQ1ODQ1YmQ5NGE0MzExXzU0OTc1NTgxOTU5MA_7b3c6b24-d6e9-4251-9bd4-33797c7532cb">no</ix:nonFraction> federal income tax operating loss carryforwards as of December&#160;31, 2022. California net operating losses will begin to expire in 2031 unless previously utilized and the net operating losses related to other states will begin to expire in 2026. Foreign net operating losses will carry forward indefinitely unless previously utilized.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we had federal and state R&amp;D tax credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="iec21f5b659784393b128ecb098d076d0_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90ZXh0cmVnaW9uOjA1ZTFlOWYxMzA1OTQwY2I4YmQ1ODQ1YmQ5NGE0MzExXzE2Nzc_3ffed27d-7ae2-469f-97ed-db538a35fad7">98.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i216211ef6a3c4bf293c5a051308c8517_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90ZXh0cmVnaW9uOjA1ZTFlOWYxMzA1OTQwY2I4YmQ1ODQ1YmQ5NGE0MzExXzE2ODQ_a5e4eee3-a155-4aa7-b11b-efcc923ca07d">72.5</ix:nonFraction> million, respectively. Federal R&amp;D tax credits will begin to expire in 2037 unless previously utilized. California R&amp;D tax credits carry forward indefinitely, while R&amp;D tax credits related to other states will begin to expire in 2033 unless previously utilized.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the future utilization of our net operating loss and R&amp;D tax credit carryforwards to offset future taxable income may be subject to an annual limitation, pursuant to Internal Revenue Code Sections 382 and 383, as a result of ownership changes that could occur in the future. No ownership changes have occurred through December&#160;31, 2022.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize interest and penalties related to income tax matters in income tax expense. As of December&#160;31, 2022, we had accruals for interest and penalties related to income tax matters of $<ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:IncomeTaxExaminationInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90ZXh0cmVnaW9uOjA1ZTFlOWYxMzA1OTQwY2I4YmQ1ODQ1YmQ5NGE0MzExXzU0OTc1NTgyMjY4Mg_efbb0a12-22ab-4e98-af87-fbcd57fc3e62">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:IncomeTaxExaminationPenaltiesAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90ZXh0cmVnaW9uOjA1ZTFlOWYxMzA1OTQwY2I4YmQ1ODQ1YmQ5NGE0MzExXzU0OTc1NTgyMjcwMQ_e05c5abe-7fb1-4482-a8e2-96190c7b8dcb">0.4</ix:nonFraction> million, respectively. Interest and penalties related to income tax matters were not material for 2021 or 2020.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to taxation in the United States and various state and foreign jurisdictions. Tax years for 2002 for federal, inception for California, 2015 to 2019 for other significant state jurisdictions, and 2019 and forward for foreign are subject to examination by tax authorities due to the carryforward of unutilized net operating losses and R&amp;D tax credits.</span></div><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90ZXh0cmVnaW9uOjA1ZTFlOWYxMzA1OTQwY2I4YmQ1ODQ1YmQ5NGE0MzExXzM3NTg_0190ea75-2180-45d1-be6b-d2a479df0a11" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of activity related to unrecognized tax benefits.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2ODRlYTI1Y2Q0NTg0MDdkYWRjM2I4ZGM2MTMwYzYxMS90YWJsZXJhbmdlOjY4NGVhMjVjZDQ1ODQwN2RhZGMzYjhkYzYxMzBjNjExXzItMS0xLTEtMTM5MDYy_e8d45611-6fea-4193-ab11-45e993891201">64.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a88ab4de251408db4aa98552134a56a_I20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2ODRlYTI1Y2Q0NTg0MDdkYWRjM2I4ZGM2MTMwYzYxMS90YWJsZXJhbmdlOjY4NGVhMjVjZDQ1ODQwN2RhZGMzYjhkYzYxMzBjNjExXzItMy0xLTEtMTM5MDYy_ab185d22-a40c-4108-9526-ad0091b030e2">60.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9e7a539304246b48b58f35e4a888e14_I20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2ODRlYTI1Y2Q0NTg0MDdkYWRjM2I4ZGM2MTMwYzYxMS90YWJsZXJhbmdlOjY4NGVhMjVjZDQ1ODQwN2RhZGMzYjhkYzYxMzBjNjExXzItNS0xLTEtMTM5MDYy_243ce682-39c5-4849-9234-31faed19e31a">63.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase (decrease) related to prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2ODRlYTI1Y2Q0NTg0MDdkYWRjM2I4ZGM2MTMwYzYxMS90YWJsZXJhbmdlOjY4NGVhMjVjZDQ1ODQwN2RhZGMzYjhkYzYxMzBjNjExXzMtMS0xLTEtMTM5MDYy_4f02e5d6-81b8-458b-8127-37c66d51ac59">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2ODRlYTI1Y2Q0NTg0MDdkYWRjM2I4ZGM2MTMwYzYxMS90YWJsZXJhbmdlOjY4NGVhMjVjZDQ1ODQwN2RhZGMzYjhkYzYxMzBjNjExXzMtMy0xLTEtMTM5MDYy_9de93aa2-5abe-40e3-9517-80d16f8dee1a">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2ODRlYTI1Y2Q0NTg0MDdkYWRjM2I4ZGM2MTMwYzYxMS90YWJsZXJhbmdlOjY4NGVhMjVjZDQ1ODQwN2RhZGMzYjhkYzYxMzBjNjExXzMtNS0xLTEtMTM5MDYy_d8f173ff-204e-45bd-90e5-7decfdc44c90">5.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase related to current year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2ODRlYTI1Y2Q0NTg0MDdkYWRjM2I4ZGM2MTMwYzYxMS90YWJsZXJhbmdlOjY4NGVhMjVjZDQ1ODQwN2RhZGMzYjhkYzYxMzBjNjExXzQtMS0xLTEtMTM5MDYy_b34b1ed1-8ef3-48ef-974e-ec24e933bfe2">15.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2ODRlYTI1Y2Q0NTg0MDdkYWRjM2I4ZGM2MTMwYzYxMS90YWJsZXJhbmdlOjY4NGVhMjVjZDQ1ODQwN2RhZGMzYjhkYzYxMzBjNjExXzQtMy0xLTEtMTM5MDYy_e2f9d5a3-783d-4650-859f-4a2123a0fa83">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2ODRlYTI1Y2Q0NTg0MDdkYWRjM2I4ZGM2MTMwYzYxMS90YWJsZXJhbmdlOjY4NGVhMjVjZDQ1ODQwN2RhZGMzYjhkYzYxMzBjNjExXzQtNS0xLTEtMTM5MDYy_0d03a4f1-fc4f-48fe-8e8d-15d3308c70fe">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements related to prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2ODRlYTI1Y2Q0NTg0MDdkYWRjM2I4ZGM2MTMwYzYxMS90YWJsZXJhbmdlOjY4NGVhMjVjZDQ1ODQwN2RhZGMzYjhkYzYxMzBjNjExXzUtMS0xLTEtMTM5MDYy_a95cc886-5d89-413f-8480-4059922eb35c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2ODRlYTI1Y2Q0NTg0MDdkYWRjM2I4ZGM2MTMwYzYxMS90YWJsZXJhbmdlOjY4NGVhMjVjZDQ1ODQwN2RhZGMzYjhkYzYxMzBjNjExXzUtMy0xLTEtMTM5MDYy_30d7a163-a91c-449a-aacd-01d9a45153e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2ODRlYTI1Y2Q0NTg0MDdkYWRjM2I4ZGM2MTMwYzYxMS90YWJsZXJhbmdlOjY4NGVhMjVjZDQ1ODQwN2RhZGMzYjhkYzYxMzBjNjExXzUtNS0xLTEtMTM5MDYy_f087fea1-b422-4aa5-87d8-bab8a32c293a">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expiration of the statute of limitations for the assessment of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2ODRlYTI1Y2Q0NTg0MDdkYWRjM2I4ZGM2MTMwYzYxMS90YWJsZXJhbmdlOjY4NGVhMjVjZDQ1ODQwN2RhZGMzYjhkYzYxMzBjNjExXzYtMS0xLTEtMTM5MDYy_11fdb366-1aac-48fa-aa55-9950c6034ae0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2ODRlYTI1Y2Q0NTg0MDdkYWRjM2I4ZGM2MTMwYzYxMS90YWJsZXJhbmdlOjY4NGVhMjVjZDQ1ODQwN2RhZGMzYjhkYzYxMzBjNjExXzYtMy0xLTEtMTM5MDYy_93ff0208-a080-4ca9-93d1-850676f466af">1.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2ODRlYTI1Y2Q0NTg0MDdkYWRjM2I4ZGM2MTMwYzYxMS90YWJsZXJhbmdlOjY4NGVhMjVjZDQ1ODQwN2RhZGMzYjhkYzYxMzBjNjExXzYtNS0xLTEtMTM5MDYy_875c35e4-f566-40a9-9c28-ba20f82b2df8">1.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2ODRlYTI1Y2Q0NTg0MDdkYWRjM2I4ZGM2MTMwYzYxMS90YWJsZXJhbmdlOjY4NGVhMjVjZDQ1ODQwN2RhZGMzYjhkYzYxMzBjNjExXzctMS0xLTEtMTM5MDYy_0d9bd7cd-7293-4970-bea7-f8cc88c22b5b">84.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2ODRlYTI1Y2Q0NTg0MDdkYWRjM2I4ZGM2MTMwYzYxMS90YWJsZXJhbmdlOjY4NGVhMjVjZDQ1ODQwN2RhZGMzYjhkYzYxMzBjNjExXzctMy0xLTEtMTM5MDYy_3d171912-9bb4-4998-b0ed-8e8e8d28748f">64.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a88ab4de251408db4aa98552134a56a_I20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2ODRlYTI1Y2Q0NTg0MDdkYWRjM2I4ZGM2MTMwYzYxMS90YWJsZXJhbmdlOjY4NGVhMjVjZDQ1ODQwN2RhZGMzYjhkYzYxMzBjNjExXzctNS0xLTEtMTM5MDYy_818be51b-dcb6-4fe5-b9b8-9023df2964f5">60.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had $<ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90ZXh0cmVnaW9uOjA1ZTFlOWYxMzA1OTQwY2I4YmQ1ODQ1YmQ5NGE0MzExXzM1MTk_54b2e6e4-2cd5-4b98-be10-73f714f89c38">74.8</ix:nonFraction> million of unrecognized tax benefits that, if recognized and realized, would affect the effective tax rate, subject to changes in the valuation allowance. We do not expect a significant change in our unrecognized tax benefits in the next 12 months.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><div id="id795223301944418ba8c3fb3bc02f08e_166"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90ZXh0cmVnaW9uOjU1NzA4M2I5OTQyZTQ5ZGNiMzRhNmEyZjc1ZjExNGFjXzIyNTE_c9a938ee-5637-4f23-8a2c-c8ccd077f283" continuedAt="icc6c881858b547d3b2a4de058b6bb201" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="icc6c881858b547d3b2a4de058b6bb201"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating leases that have commenced have terms that expire beginning 2024 through 2031 and consist of office space and research and development laboratories, including our corporate headquarters. Certain of these lease agreements contain clauses for renewal at our option. As we were not reasonably certain to exercise any of these renewal options at commencement of the associated leases, no such options were recognized as part of our operating lease right-of-use, or ROU, assets or operating lease liabilities.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;8, 2022, we entered into a lease agreement for a four-building campus facility to be constructed in San Diego, California, pursuant to which we also secured a <ix:nonNumeric contextRef="i3cd52a694c0b4753b93edf35c2915881_D20220208-20220208" name="nbix:LesseeOperatingLeaseOptionTermToConstructFifthBuilding" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90ZXh0cmVnaW9uOjU1NzA4M2I5OTQyZTQ5ZGNiMzRhNmEyZjc1ZjExNGFjXzcxNDY4MjU1ODI4MDc_ad5b2987-4e87-41d0-9996-c38d637a6b92">six-year</ix:nonNumeric> option for the construction of a fifth building and an option to purchase the entire campus facility, which will consist of office space and research and development laboratories, in the future. Upon completion of construction, we expect to utilize the campus facility as our new corporate headquarters. This lease has not commenced for accounting purposes. Under the terms of the lease, on a building-by-building basis, base rent will be subject to a <ix:nonNumeric contextRef="i3cd52a694c0b4753b93edf35c2915881_D20220208-20220208" name="nbix:RentAbatementPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90ZXh0cmVnaW9uOjU1NzA4M2I5OTQyZTQ5ZGNiMzRhNmEyZjc1ZjExNGFjXzcxNDY4MjU1ODI4MDg_17d67139-0105-4e25-89cc-b232829be315">10-month</ix:nonNumeric> rent abatement period following the respective lease commencement date, which dates will be determined in the future based upon achievement of substantial completion of construction with respect to each such building in the condition suitable for the installation of our furniture, fixtures, and equipment, and on which date we will record a lease liability, corresponding right-of-use asset, and begin lease expense recognition with respect to each such building. After the rent abatement period, monthly base rent will be $<ix:nonFraction unitRef="usd" contextRef="if8d41d8e8ddc41f1ba3f1ca687d9551d_I20220208" decimals="0" name="nbix:LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90ZXh0cmVnaW9uOjU1NzA4M2I5OTQyZTQ5ZGNiMzRhNmEyZjc1ZjExNGFjXzE2ODE_c986d85c-038e-48d7-bc25-ae4773fdeee8">6</ix:nonFraction> per square foot, subject to annual escalations of <ix:nonFraction unitRef="number" contextRef="if8d41d8e8ddc41f1ba3f1ca687d9551d_I20220208" decimals="INF" name="nbix:AnnualRentEscalationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90ZXh0cmVnaW9uOjU1NzA4M2I5OTQyZTQ5ZGNiMzRhNmEyZjc1ZjExNGFjXzE3MzQ_82c77f81-d5e9-4e02-8042-998e18a9d5f1">3</ix:nonFraction>% during the initial <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90ZXh0cmVnaW9uOjU1NzA4M2I5OTQyZTQ5ZGNiMzRhNmEyZjc1ZjExNGFjXzcxNDY4MjU1ODI4MDk_9da6dfa7-7ad5-4e15-990b-61663bd419f1">13.6-year</span> lease term, which term we have the option to renew for <ix:nonFraction unitRef="renewaloption" contextRef="if8d41d8e8ddc41f1ba3f1ca687d9551d_I20220208" decimals="INF" name="nbix:NumberOfRenewalOptions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90ZXh0cmVnaW9uOjU1NzA4M2I5OTQyZTQ5ZGNiMzRhNmEyZjc1ZjExNGFjXzE4MTk_baa9c2b7-fb22-44d5-a855-4d560ea88ed5">two</ix:nonFraction> additional terms of <ix:nonNumeric contextRef="if8d41d8e8ddc41f1ba3f1ca687d9551d_I20220208" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90ZXh0cmVnaW9uOjU1NzA4M2I5OTQyZTQ5ZGNiMzRhNmEyZjc1ZjExNGFjXzE4NDI_d4d24688-e19f-4781-b825-2e7edc26af33">five years</ix:nonNumeric> each.</span></div><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90ZXh0cmVnaW9uOjU1NzA4M2I5OTQyZTQ5ZGNiMzRhNmEyZjc1ZjExNGFjXzIyNTI_87aaa0ea-db95-4af6-ac1a-6786ec215317" escape="true"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present supplemental operating lease information.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpkMzJmNDI4MWQ1M2Y0MzIwYTYxMjE4OTE1MWI5MTk4OS90YWJsZXJhbmdlOmQzMmY0MjgxZDUzZjQzMjBhNjEyMTg5MTUxYjkxOTg5XzItMS0xLTEtMTM5MDYy_2deebd46-1e2c-4019-9b3a-ba7e396468a6">16.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpkMzJmNDI4MWQ1M2Y0MzIwYTYxMjE4OTE1MWI5MTk4OS90YWJsZXJhbmdlOmQzMmY0MjgxZDUzZjQzMjBhNjEyMTg5MTUxYjkxOTg5XzItMy0xLTEtMTM5MDYy_1ecfddcc-55c5-4330-84a0-fb14e1009123">15.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpkMzJmNDI4MWQ1M2Y0MzIwYTYxMjE4OTE1MWI5MTk4OS90YWJsZXJhbmdlOmQzMmY0MjgxZDUzZjQzMjBhNjEyMTg5MTUxYjkxOTg5XzItNS0xLTEtMTM5MDYy_9ce3b2a6-f8df-497c-9008-bf3a48326866">10.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpkMzJmNDI4MWQ1M2Y0MzIwYTYxMjE4OTE1MWI5MTk4OS90YWJsZXJhbmdlOmQzMmY0MjgxZDUzZjQzMjBhNjEyMTg5MTUxYjkxOTg5XzMtMS0xLTEtMTM5MDYy_58a87548-d1e8-4db6-a582-8bac9dab64cc">16.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpkMzJmNDI4MWQ1M2Y0MzIwYTYxMjE4OTE1MWI5MTk4OS90YWJsZXJhbmdlOmQzMmY0MjgxZDUzZjQzMjBhNjEyMTg5MTUxYjkxOTg5XzMtMy0xLTEtMTM5MDYy_5c1dd0f1-1067-4783-b7c1-427ea60800e5">12.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpkMzJmNDI4MWQ1M2Y0MzIwYTYxMjE4OTE1MWI5MTk4OS90YWJsZXJhbmdlOmQzMmY0MjgxZDUzZjQzMjBhNjEyMTg5MTUxYjkxOTg5XzMtNS0xLTEtMTM5MDYy_51342715-41d7-40db-b3f2-3882bb549522">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpkMzJmNDI4MWQ1M2Y0MzIwYTYxMjE4OTE1MWI5MTk4OS90YWJsZXJhbmdlOmQzMmY0MjgxZDUzZjQzMjBhNjEyMTg5MTUxYjkxOTg5XzctMy0xLTEtMTM5MDYy_78057c3c-49d7-4b6d-a1d4-a25d1aaeab07">7.9</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpkMzJmNDI4MWQ1M2Y0MzIwYTYxMjE4OTE1MWI5MTk4OS90YWJsZXJhbmdlOmQzMmY0MjgxZDUzZjQzMjBhNjEyMTg5MTUxYjkxOTg5XzctNS0xLTEtMTM5MDYy_3e257c0d-12a0-4c1a-9f1e-677e8f169434">8.8</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpkMzJmNDI4MWQ1M2Y0MzIwYTYxMjE4OTE1MWI5MTk4OS90YWJsZXJhbmdlOmQzMmY0MjgxZDUzZjQzMjBhNjEyMTg5MTUxYjkxOTg5XzgtMy0xLTEtMTM5MDYy_3561e0d9-17a0-4bd3-b169-c45ed74d9b4e">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpkMzJmNDI4MWQ1M2Y0MzIwYTYxMjE4OTE1MWI5MTk4OS90YWJsZXJhbmdlOmQzMmY0MjgxZDUzZjQzMjBhNjEyMTg5MTUxYjkxOTg5XzgtNS0xLTEtMTM5MDYy_5b1866ae-051c-453a-be09-b97afbdf4f81">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash related to letters of credit issued in lieu of cash security deposits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bcdc018b3641e5b570fb899c943e20_I20221231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpkMzJmNDI4MWQ1M2Y0MzIwYTYxMjE4OTE1MWI5MTk4OS90YWJsZXJhbmdlOmQzMmY0MjgxZDUzZjQzMjBhNjEyMTg5MTUxYjkxOTg5XzktMy0xLTEtMTM5MDYy_9ed0f313-e1c3-4c9d-859b-b77965a5478a">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5576346c88f84a9aa3ea6be5a075ead3_I20211231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpkMzJmNDI4MWQ1M2Y0MzIwYTYxMjE4OTE1MWI5MTk4OS90YWJsZXJhbmdlOmQzMmY0MjgxZDUzZjQzMjBhNjEyMTg5MTUxYjkxOTg5XzktNS0xLTEtMTM5MDYy_a792adfe-67e1-437f-963c-7118e3a88b20">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90ZXh0cmVnaW9uOjU1NzA4M2I5OTQyZTQ5ZGNiMzRhNmEyZjc1ZjExNGFjXzIyNTA_a1b9a962-7551-450b-b635-c074272dceed" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximate future minimum lease payments under operating leases were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpmYjg1MmU0NGUwYmY0ZDA3YTVmNjZhM2QxM2VkNmYxMC90YWJsZXJhbmdlOmZiODUyZTQ0ZTBiZjRkMDdhNWY2NmEzZDEzZWQ2ZjEwXzEtMS0xLTEtMTM5MDYy_9b0ff4f0-0ee0-4ca5-b944-7ab9c50445e5">17.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpmYjg1MmU0NGUwYmY0ZDA3YTVmNjZhM2QxM2VkNmYxMC90YWJsZXJhbmdlOmZiODUyZTQ0ZTBiZjRkMDdhNWY2NmEzZDEzZWQ2ZjEwXzItMS0xLTEtMTM5MDYy_54d2f171-9828-4542-9518-faf5980ceac3">17.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpmYjg1MmU0NGUwYmY0ZDA3YTVmNjZhM2QxM2VkNmYxMC90YWJsZXJhbmdlOmZiODUyZTQ0ZTBiZjRkMDdhNWY2NmEzZDEzZWQ2ZjEwXzMtMS0xLTEtMTM5MDYy_9a1c4bb6-d060-46eb-ab20-723921198d02">15.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpmYjg1MmU0NGUwYmY0ZDA3YTVmNjZhM2QxM2VkNmYxMC90YWJsZXJhbmdlOmZiODUyZTQ0ZTBiZjRkMDdhNWY2NmEzZDEzZWQ2ZjEwXzQtMS0xLTEtMTM5MDYy_ab4b74bd-3fca-4b4a-bf69-674afa0a89eb">15.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2027</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpmYjg1MmU0NGUwYmY0ZDA3YTVmNjZhM2QxM2VkNmYxMC90YWJsZXJhbmdlOmZiODUyZTQ0ZTBiZjRkMDdhNWY2NmEzZDEzZWQ2ZjEwXzUtMS0xLTEtMTM5MDYy_0cff1927-05cf-4348-a3fd-569a2087be5b">16.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpmYjg1MmU0NGUwYmY0ZDA3YTVmNjZhM2QxM2VkNmYxMC90YWJsZXJhbmdlOmZiODUyZTQ0ZTBiZjRkMDdhNWY2NmEzZDEzZWQ2ZjEwXzYtMS0xLTEtMTM5MDYy_13018f2a-8647-452a-bdb9-3bf901599520">54.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpmYjg1MmU0NGUwYmY0ZDA3YTVmNjZhM2QxM2VkNmYxMC90YWJsZXJhbmdlOmZiODUyZTQ0ZTBiZjRkMDdhNWY2NmEzZDEzZWQ2ZjEwXzctMS0xLTEtMTM5MDYy_94c5c4e3-de56-40f4-9a6b-7878928eadad">137.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accreted interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpmYjg1MmU0NGUwYmY0ZDA3YTVmNjZhM2QxM2VkNmYxMC90YWJsZXJhbmdlOmZiODUyZTQ0ZTBiZjRkMDdhNWY2NmEzZDEzZWQ2ZjEwXzgtMS0xLTEtMTM5MDYy_fb3934bd-aa61-4c53-b97a-325247d9da9a">26.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpmYjg1MmU0NGUwYmY0ZDA3YTVmNjZhM2QxM2VkNmYxMC90YWJsZXJhbmdlOmZiODUyZTQ0ZTBiZjRkMDdhNWY2NmEzZDEzZWQ2ZjEwXzktMS0xLTEtMTM5MDYy_e1a926fa-3190-49c9-9131-d254b86a2eb2">110.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpmYjg1MmU0NGUwYmY0ZDA3YTVmNjZhM2QxM2VkNmYxMC90YWJsZXJhbmdlOmZiODUyZTQ0ZTBiZjRkMDdhNWY2NmEzZDEzZWQ2ZjEwXzEwLTAtMS0xLTEzOTA2Mg_85571070-dcc5-4354-8358-dbaa0e075ba0">Less current operating lease liabilities included in other current liabilities</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpmYjg1MmU0NGUwYmY0ZDA3YTVmNjZhM2QxM2VkNmYxMC90YWJsZXJhbmdlOmZiODUyZTQ0ZTBiZjRkMDdhNWY2NmEzZDEzZWQ2ZjEwXzEwLTEtMS0xLTEzOTA2Mg_29d8c9ea-cfbc-4ddf-bf35-edb4fdb22664">17.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpmYjg1MmU0NGUwYmY0ZDA3YTVmNjZhM2QxM2VkNmYxMC90YWJsZXJhbmdlOmZiODUyZTQ0ZTBiZjRkMDdhNWY2NmEzZDEzZWQ2ZjEwXzExLTEtMS0xLTEzOTA2Mg_a04adfcb-4996-4728-8bbd-4a3a8c3da9d4">93.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Amounts presented in the table above exclude $<ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90ZXh0cmVnaW9uOjU1NzA4M2I5OTQyZTQ5ZGNiMzRhNmEyZjc1ZjExNGFjXzIwODM_33f06b5b-d025-4db5-abc5-1d0ea5615ff4">17.2</ix:nonFraction> million for 2024, $<ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90ZXh0cmVnaW9uOjU1NzA4M2I5OTQyZTQ5ZGNiMzRhNmEyZjc1ZjExNGFjXzIwOTY_fbd790a7-2a16-49ad-8a0b-b44428264f56">33.3</ix:nonFraction> million for 2025, $<ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90ZXh0cmVnaW9uOjU1NzA4M2I5OTQyZTQ5ZGNiMzRhNmEyZjc1ZjExNGFjXzIxMDk_390e71fd-35a3-46c6-950b-1b035136c8d3">41.9</ix:nonFraction> million for 2026, and $<ix:nonFraction unitRef="usd" contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231" decimals="-5" name="nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90ZXh0cmVnaW9uOjU1NzA4M2I5OTQyZTQ5ZGNiMzRhNmEyZjc1ZjExNGFjXzIxMjY_f7b9c3c7-91d2-42cf-b45f-13d9657feefc">479.7</ix:nonFraction> million thereafter of approximate non-cancelable future minimum lease payments under operating leases that have not yet commenced.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><div id="id795223301944418ba8c3fb3bc02f08e_169"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjkvZnJhZzo4NTlmNzQzOGJiZmQ0OWZjODkzMmYwMWQyZTIyYzJmNC90ZXh0cmVnaW9uOjg1OWY3NDM4YmJmZDQ5ZmM4OTMyZjAxZDJlMjJjMmY0XzMzMQ_e65c118f-1b10-484c-964c-030b4898e5d3" continuedAt="i2261ba75a49b41328e4f8151b1ab0321" escape="true">Retirement Plan</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2261ba75a49b41328e4f8151b1ab0321">We have a 401(k) defined contribution savings plan, or the 401(k)&#160;Plan. The 401(k) Plan is for the benefit of all qualifying employees and permits voluntary contributions by employees up to <ix:nonFraction unitRef="number" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjkvZnJhZzo4NTlmNzQzOGJiZmQ0OWZjODkzMmYwMWQyZTIyYzJmNC90ZXh0cmVnaW9uOjg1OWY3NDM4YmJmZDQ5ZmM4OTMyZjAxZDJlMjJjMmY0XzIxNQ_e1341f5b-c437-40c1-b90b-3f1053160cd2">60</ix:nonFraction>% of base salary limited by the IRS-imposed maximum. Employer contributions were $<ix:nonFraction unitRef="usd" contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjkvZnJhZzo4NTlmNzQzOGJiZmQ0OWZjODkzMmYwMWQyZTIyYzJmNC90ZXh0cmVnaW9uOjg1OWY3NDM4YmJmZDQ5ZmM4OTMyZjAxZDJlMjJjMmY0XzI5Nw_90626ca7-39b6-4de2-ac46-86f97f36d76a">10.3</ix:nonFraction> million for 2022, $<ix:nonFraction unitRef="usd" contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjkvZnJhZzo4NTlmNzQzOGJiZmQ0OWZjODkzMmYwMWQyZTIyYzJmNC90ZXh0cmVnaW9uOjg1OWY3NDM4YmJmZDQ5ZmM4OTMyZjAxZDJlMjJjMmY0XzMwOA_dee9d593-680b-4adf-8fbe-f65e2ca8aa94">8.1</ix:nonFraction> million for 2021 and $<ix:nonFraction unitRef="usd" contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjkvZnJhZzo4NTlmNzQzOGJiZmQ0OWZjODkzMmYwMWQyZTIyYzJmNC90ZXh0cmVnaW9uOjg1OWY3NDM4YmJmZDQ5ZmM4OTMyZjAxZDJlMjJjMmY0XzMyMg_6a97908f-8c99-4a48-98ef-8c6883fdbab4">6.7</ix:nonFraction> million for 2020.</ix:continuation></span></div><div id="id795223301944418ba8c3fb3bc02f08e_1746"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzQ2L2ZyYWc6MDFjZDZmOTlhYjgzNGJjZTljMjIxMGUyOWEzMGNmYzkvdGV4dHJlZ2lvbjowMWNkNmY5OWFiODM0YmNlOWMyMjEwZTI5YTMwY2ZjOV8yMTk5MDIzMjYxNjQ5_0ad1a5a0-f176-4d4f-b4a5-f492565ea948" continuedAt="i6dc9507eeaf34a19bfe8a37a5a67961b" escape="true">Legal Proceedings</ix:nonNumeric></span></div><ix:continuation id="i6dc9507eeaf34a19bfe8a37a5a67961b"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021 and 2022, we received notices from (i) Teva Pharmaceuticals Development, Inc., (ii) Lupin Limited, (iii) Crystal Pharmaceutical (Suzhou) Co. Ltd., (iv) Sandoz Inc. and (v) Zydus Pharmaceuticals (USA) Inc. that each company had filed an abbreviated new drug application, or ANDA, with the FDA seeking approval of a generic version of INGREZZA. These companies represented that their respective ANDAs each contained a Paragraph IV Patent Certification alleging that certain of our patents covering INGREZZA are invalid and/or will not be infringed by the manufacture, use or sale of the medicine for which the ANDA was submitted.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We filed suit in the United States District Court for the District of Delaware during 2021 and 2022, against (i) Teva Pharmaceuticals, Inc., Teva Pharmaceuticals Development, Inc., Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd. (entity dismissed), (ii) Lupin Limited, Lupin Pharmaceuticals, Inc., Lupin Inc. and Lupin Atlantis Holdings S.A., (iii) Crystal Pharmaceutical (Suzhou) Co., Ltd., Crystal Pharmatech Co., Ltd., (iv) Sandoz Inc., Sandoz International GmbH (entity dismissed) and Sandoz AG (entity dismissed) and (v) Zydus Pharmaceuticals (USA) Inc., Zydus Worldwide DMCC, Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited d/b/a Zydus Cadila) and Zydus Healthcare (USA) LLC (entity dismissed). Sandoz Inc. has been joined in the cases against Crystal Pharmaceutical (Suzhou) Co., Ltd. and Crystal Pharmatech Co., Ltd. These cases have been consolidated in the United States District Court for the District of Delaware and the trial is currently scheduled for January 2, 2024.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also filed suit in the United States District Court for the District of New Jersey during 2021 and 2022 against Zydus Pharmaceuticals (USA) Inc., Zydus Worldwide DMCC, Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited d/b/a Zydus Cadila) and Zydus Healthcare (USA) LLC and these cases were dismissed in favor of continued prosecution of the Delaware proceedings against the same entities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may also become subject to other legal proceedings or claims arising in the ordinary course of our business. We currently believe that none of the claims or actions pending against us is likely to have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Given the unpredictability inherent in litigation, however, we cannot predict the outcome of these matters.</span></div></ix:continuation><div id="id795223301944418ba8c3fb3bc02f08e_1739"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzM5L2ZyYWc6OTIxM2U5YmM5M2JkNDM5Yzk1YjhiYTlmMjFhYzJkOTAvdGV4dHJlZ2lvbjo5MjEzZTliYzkzYmQ0MzljOTViOGJhOWYyMWFjMmQ5MF8yMTk5MDIzMjU3OTAy_edf3c711-8287-4c14-b8e8-be84b682ced8" continuedAt="idc40678b1b90464399d5dad2927d7a43" escape="true">Subsequent Events</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><ix:continuation id="idc40678b1b90464399d5dad2927d7a43"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2023, we entered into a new strategic collaboration with Voyager, under which we agreed to pay Voyager $<ix:nonFraction unitRef="usd" contextRef="iced58b51ca3c40e3942fff0f7f450577_I20230108" decimals="-6" name="nbix:UpfrontPaymentsMade" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzM5L2ZyYWc6OTIxM2U5YmM5M2JkNDM5Yzk1YjhiYTlmMjFhYzJkOTAvdGV4dHJlZ2lvbjo5MjEzZTliYzkzYmQ0MzljOTViOGJhOWYyMWFjMmQ5MF81NDk3NTU4MTYxMTc_d5a978d1-cc22-445d-a8d5-eb4c590b1d9e">175</ix:nonFraction>&#160;million upfront, including a $<ix:nonFraction unitRef="usd" contextRef="iced58b51ca3c40e3942fff0f7f450577_I20230108" decimals="-6" name="nbix:BusinessAcquisitionEquityInvestmentToAcquireTheWorldwideRights" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzM5L2ZyYWc6OTIxM2U5YmM5M2JkNDM5Yzk1YjhiYTlmMjFhYzJkOTAvdGV4dHJlZ2lvbjo5MjEzZTliYzkzYmQ0MzljOTViOGJhOWYyMWFjMmQ5MF81NDk3NTU4MTYxMzE_a163e08e-ef53-4cbf-88d5-39f75182d087">39</ix:nonFraction>&#160;million equity investment, to acquire the worldwide rights to Voyager&#8217;s GBA1 gene therapy program for Parkinson&#8217;s disease and other GBA1-mediated diseases and three gene therapy programs directed to rare central nervous system targets, each enabled by Voyager&#8217;s next-generation TRACER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> capsids. The effectiveness of the collaboration agreement and the closing of the sale and issuance of Voyager common stock are expected to be completed prior to the end of the first quarter of 2023 and are subject to certain conditions including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and other customary closing conditions.</span></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><div id="id795223301944418ba8c3fb3bc02f08e_172"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;9. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Changes and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="id795223301944418ba8c3fb3bc02f08e_175"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;9A. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Controls and Procedures</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the timelines specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by SEC Rule&#160;13a-15(b), we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the year covered by this report. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><div id="id795223301944418ba8c3fb3bc02f08e_178"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal control over financial reporting refers to the process designed by, or under the supervision of, our Chief Executive Officer and Chief Financial Officer, and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles, and includes those policies and procedures that:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">&#160;&#160;&#160;&#160;Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">&#160;&#160;&#160;&#160;Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorization of our management and directors;&#160;and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">&#160;&#160;&#160;&#160;Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal control over financial reporting cannot provide absolute assurance of achieving financial reporting objectives because of its inherent limitations. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper management override. Because of such limitations, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk. Management is responsible for establishing and maintaining adequate internal control over financial reporting for the company.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has used the framework set forth in the report entitled Internal Control-Integrated Framework (2013&#160;framework)&#160;published by the Committee of Sponsoring Organizations of the Treadway Commission (2013&#160;framework), known as COSO, to evaluate the effectiveness of our internal control over financial reporting. Based on this assessment, management has concluded that our internal control over financial reporting was effective as of December&#160;31, 2022. Ernst&#160;&amp; Young, LLP, our independent registered public accounting firm, has issued an attestation report on our internal control over financial reporting as of December&#160;31, 2022, which is included herein.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no change in our internal control over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><div id="id795223301944418ba8c3fb3bc02f08e_181"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Neurocrine Biosciences, Inc.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Neurocrine Biosciences, Inc.&#8217;s internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), (the COSO criteria). In our opinion, Neurocrine Biosciences, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on the COSO criteria. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2022 and 2021, the related consolidated statements of income and comprehensive income, stockholders&#8216; equity, and cash flows, for each of the three years in the period ended December 31, 2022, and the related notes and our report dated February&#160;9, 2023 expressed an unqualified opinion thereon. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:6pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:32.051%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Ernst &amp; Young LLP</span></div></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;9, 2023</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><div id="id795223301944418ba8c3fb3bc02f08e_184"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;9B. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Other Information</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="id795223301944418ba8c3fb3bc02f08e_1733"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;9C. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><div id="id795223301944418ba8c3fb3bc02f08e_187"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART&#160;III</span></div><div id="id795223301944418ba8c3fb3bc02f08e_190"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;10. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Directors, Executive Officers and Corporate Governance</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item will be contained in our Definitive Proxy Statement for our 2023 Annual Meeting of Stockholders, to be filed pursuant to Regulation&#160;14A with the SEC within 120&#160;days of December&#160;31, 2022. Such information is incorporated herein by reference.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a code of ethics that applies to our Chief Executive Officer, Chief Financial Officer, and to all of our other officers, directors, employees and agents. The code of ethics is available at the Corporate Governance section of the Investors page on our website at www.neurocrine.com. We intend to disclose future amendments to, or waivers from, certain provisions of our code of ethics on the above website within four business days following the date of such amendment or waiver. Information found on, or accessible through, our website is not part of, and is not incorporated into, this Annual Report on Form 10-K.</span></div><div id="id795223301944418ba8c3fb3bc02f08e_193"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;11. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Executive Compensation</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item will be contained in our Definitive Proxy Statement for our 2023 Annual Meeting of Stockholders, to be filed pursuant to Regulation&#160;14A with the SEC within 120&#160;days of December&#160;31, 2022. Such information is incorporated herein by reference.</span></div><div id="id795223301944418ba8c3fb3bc02f08e_196"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;12. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item will be contained in our Definitive Proxy Statement for our 2023 Annual Meeting of Stockholders, to be filed pursuant to Regulation&#160;14A with the SEC within 120&#160;days of December&#160;31, 2022. Such information is incorporated herein by reference.</span></div><div id="id795223301944418ba8c3fb3bc02f08e_199"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;13. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item will be contained in our Definitive Proxy Statement for our 2023 Annual Meeting of Stockholders, to be filed pursuant to Regulation&#160;14A with the SEC within 120&#160;days of December&#160;31, 2022. Such information is incorporated herein by reference.</span></div><div id="id795223301944418ba8c3fb3bc02f08e_202"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;14. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Principal Accounting Fees and Services</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item will be contained in our Definitive Proxy Statement for our 2023 Annual Meeting of Stockholders, to be filed pursuant to Regulation&#160;14A with the SEC within 120&#160;days of December&#160;31, 2022. Such information is incorporated herein by reference.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><div id="id795223301944418ba8c3fb3bc02f08e_205"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART IV</span></div><div id="id795223301944418ba8c3fb3bc02f08e_208"></div><div style="-sec-extract:summary;margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 15. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Exhibits, Financial Statement Schedules</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)&#160;Documents filed as part of this report.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. List of Financial Statements. The following are included in Item&#160;8 of this report:</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Balance Sheets as of December&#160;31, 2022 and 2021</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Income and Comprehensive Income for the years ended December&#160;31, 2022, 2021 and 2020</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity for the years ended December&#160;31, 2022, 2021 and 2020</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Cash Flows for the years ended December&#160;31, 2022, 2021 and 2020</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. List of all Financial Statement schedules. All schedules are omitted because they are not applicable, or the required information is shown in the Financial Statements or notes thereto.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. List of Exhibits required by Item&#160;601 of Regulation&#160;S-K. See part (b)&#160;below.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b) Exhibits. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits are filed as part of, or incorporated by reference into, this report:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000156459018026844/nbix-ex31_91.htm">Certificate of Incorporation, as amended</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 3.1 of the Company&#8217;s Quarterly Report on Form 10-Q filed on November 5, 2018</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000091447521000036/nbix-20210331exhibit3_2.htm">Bylaws</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 3.2 of the Company's Quarterly Report on Form 10-Q filed on May 5, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/0000898430-96-002108.txt">Form of Common Stock Certificate</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to the Company&#8217;s Registration Statement on Form S-1 (Registration No. 333-03172)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312517154199/d390610dex41.htm">Indenture, dated as of May&#160;2, 2017, by and between the Company and U.S. Bank National Association, as Trustee</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 4.1 of the Company&#8217;s Current Report on Form 8-K filed on May 2, 2017</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000091447522000013/nbix-20211231exhibit43.htm">First Supplemental Indenture, dated as of December 22, 2021, by and between the Company and U.S. Bank National Association, as Trustee</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Incorporated by reference to Exhibit 4.3 of the Company&#8217;s Annual Report on Form 10-K filed on February 11, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312517154199/d390610dex991.htm">Form of Note representing the Company&#8217;s 2.25% Convertible Notes due 2024</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 99.1 of the Company&#8217;s Current Report on Form 8-K filed on May 2, 2017</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000156459020003773/nbix-ex44_74.htm">Description of Common Stock of the Company</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 4.4 of the Company&#8217;s Annual Report on Form 10-K filed on February 7, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="q4-2022xexhibit211.htm">Subsidiaries of the Company</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="q4-2022xexhibit231.htm">Consent of Independent Registered Public Accounting Firm</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="q4-2022xexhibit311.htm">Certification of Chief Executive Officer pursuant to Rules&#160;13a-14 and 15d-14 promulgated under the Securities Exchange Act of 1934</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="q4-2022xexhibit312.htm">Certification of Chief Financial Officer pursuant to Rules&#160;13a-14 and 15d-14 promulgated under the Securities Exchange Act of 1934</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32***</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="q4-2022xexhibit32.htm">Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18&#160;U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Instance Document. &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibit 101)</span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Collaboration and License Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000091447521000036/nbix-20210331exhibit101.htm">Collaboration Agreement dated June 15, 2010, by and between Abbott International Luxembourg S.a.r.l. and the Company as amended on August&#160;31, 2011</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.1 of the Company's Quarterly Report on Form 10-Q filed on May 5, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000091447521000036/nbix-20210331exhibit102.htm">First Amendment to Collaboration and License Agreement Dated August 31, 2011 between the Company and Abbott International Luxemburg S.a.r.l.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.2 of the Company's Quarterly Report on Form 10-Q filed on May 5, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000091447521000036/nbix-20210331exhibit103.htm">Collaboration and License Agreement dated March&#160;31, 2015 between Mitsubishi Tanabe Pharma Corporation and the Company</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.3 of the Company's Quarterly Report on Form 10-Q filed on May 5, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000156459019002328/nbix-ex105_822.htm">Collaboration and License Agreement dated January 28, 2019 between Voyager Therapeutics, Inc. and the Company</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.5 of the Company&#8217;s Annual Report on Form 10-K filed on February 7, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000156459019002328/nbix-ex106_401.htm">Stock Purchase Agreement dated January 28, 2019 between Voyager Therapeutics, Inc. and the Company</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.6 of the Company&#8217;s Annual Report on Form 10-K filed on February 7, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000156459019002328/nbix-ex107_400.htm">Investor Agreement dated January 28, 2019 between Voyager Therapeutics, Inc. and the Company</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.7 of the Company&#8217;s Annual Report on Form 10-K filed on February 7, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000156459019026602/nbix-ex101_71.htm">Amendment No. 1 to Collaboration and License Agreement dated June 14, 2019 between Voyager Therapeutics, Inc. and the Company</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Quarterly Report on Form 10-Q filed on July 29, 2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.8**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000091447520000018/nbix-20200630exhibit103.htm">Exclusive License Agreement dated June 12, 2020 between Takeda Pharmaceutical Company Limited and the Company</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.3 of the Company&#8217;s Quarterly Report on Form 10-Q filed on August 3, 2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.9**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000091447522000013/nbix-20211231exhibit1010.htm">Collaboration and License Agreement dated November 22, 2021 between Heptares Therapeutics Limited and the Company</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.10 of the Company&#8217;s Annual Report on Form 10-K filed on February 11, 2022</span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Equity Plans and Related Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312517181670/d363882dex991.htm">Neurocrine Biosciences, Inc. 2011 Equity Incentive Plan, as amended</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 99.1 of the Company&#8217;s Current Report on Form 8-K filed on May 30, 2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312515209053/d934906dex991.htm">Form of Stock Option Grant Notice and Option Agreement for use under the Neurocrine Biosciences, Inc. 2011 Equity Incentive Plan, and Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement for use under the Neurocrine Biosciences, Inc. 2011 Equity Incentive Plan</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 99.1 of the Company&#8217;s Current Report on Form 8-K filed on June 1, 2015</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312518042794/d520757dex1017.htm">Neurocrine Biosciences, Inc. Inducement Plan, as amended</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.17 of the Company&#8217;s Annual Report on Form 10-K filed on February 13, 2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312515268390/d938011dex101.htm">Form of Stock Option Grant Notice and Option Agreement for use under the Neurocrine Biosciences, Inc. Inducement Plan, and Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement for use under the Neurocrine Biosciences, Inc. Inducement Plan</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Quarterly Report on Form 10-Q filed on July 29, 2015</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000091447522000044/q2-2022xexhibit103.htm">Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan, as amended and restated</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.3 of the Company&#8217;s Quarterly Report on Form 10-Q filed on August 4, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000091447522000044/q2-2022xexhibit102.htm">Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan, as amended and restated</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.2 of the Company&#8217;s Quarterly Report on Form 10-Q filed on August 4, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000914475/000091447522000013/nbix-20211231exhibit1017.htm">Form of Stock Option Grant Notice and Option Agreement for use under the Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan, and Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement for use under the Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.17 of the Company&#8217;s Annual Report on Form 10-K filed on February 11, 2022</span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Agreements with Officers and Directors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000093639207000628/a32155exv10w3.htm">Amended and Restated Employment Agreement effective August&#160;1, 2007 between the Company and Kevin C. Gorman,&#160;Ph.D.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.3 of the Company&#8217;s Quarterly Report on Form 10-Q filed on August 3, 2007</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312511030707/dex1032.htm">Form of Amendment to Employment Agreement for executive officers, effective as of December 15, 2010</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.32 of the Company&#8217;s Annual Report on Form 10-K filed on February 11, 2008</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312517043838/d324435dex103.htm">Employment Agreement dated May 26, 2015 between the Company and Eric Benevich</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.3 of the Company&#8217;s Annual Report on Form 10-K filed on February 14, 2017</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312518042794/d520757dex1026.htm">Employment Agreement effective November&#160;29, 2017 between the Company and Matthew C. Abernethy</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.26 of the Company&#8217;s Annual Report on Form 10-K filed on February 13, 2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312517329460/d466738dex101.htm">Form of Indemnity Agreement entered into between the Company and its officers and directors</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Quarterly Report on Form 10-Q filed on November 1, 2017</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.22</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000156459019026602/nbix-ex102_72.htm">Employment Agreement dated January 8, 2018 between the Company and Eiry W. Roberts, M.D.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.2 of the Company&#8217;s Quarterly Report on Form 10-Q filed on July 29, 2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.23</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000091447522000044/q2-2022xexhibit101.htm">Employment Agreement dated November 29, 2021 between the Company and Jude Onyia</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Quarterly Report on Form 10-Q filed on August 4, 2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Agreements Related to Real Property</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312512015472/d284170dex992.htm">Amended and Restated Lease dated November 1, 2011 between the Company and Kilroy Realty, L.P.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 99.2 of the Company&#8217;s Current Report on Form 8-K filed on January 18, 2012</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.25</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312517247437/d253292dex101.htm">First Amendment to Amended and Restated Lease between the Company and Kilroy Realty, L.P., dated June&#160;5, 2017</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Quarterly Report on Form 10-Q filed on August 3, 2017</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312517329460/d466738dex103.htm">Second Amendment to Amended and Restated Lease between the Company and Kilroy Realty, L.P., dated October&#160;12, 2017</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.3 of the Company&#8217;s Quarterly Report on Form 10-Q filed on November 1, 2017</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.27</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000156459019039803/nbix-ex101_32.htm">Third Amendment to Amended and Restated Lease between the Company and Kilroy Realty, L.P. dated August 7, 2019</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Quarterly Report on Form 10-Q filed on November 4, 2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.28</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000091447522000022/gemdale-neurocrinexcomme.htm">Commercial Lease dated February 8, 2022, by and between the Company and Gemdale Aperture Phase I, LLC</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Quarterly Report on Form 10-Q filed on May 4, 2022</span></td></tr></table></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management contract or compensatory plan or arrangement.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Confidential treatment has been granted with respect to certain portions of the exhibit.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain information in this exhibit has been omitted pursuant to Item 601 of Regulation S-K.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">These certifications are being furnished solely to accompany this annual report pursuant to 18&#160;U.S.C. Section&#160;1350 and are not being filed for purposes of Section&#160;18 of the Securities Exchange Act of 1934 and are not to be incorporated by reference into any filing of Neurocrine Biosciences, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Except as specifically noted above, the Company&#8217;s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K have a Commission File Number of 000-22705.</span></td></tr></table></div><div style="margin-bottom:6pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c)&#160;Financial Statement Schedules. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item&#160;15(a)(2) above.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><div id="id795223301944418ba8c3fb3bc02f08e_211"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.971%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NEUROCRINE BIOSCIENCES, INC.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Kevin C. Gorman</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevin C. Gorman</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 9, 2023</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Matthew C. Abernethy</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew C. Abernethy</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 9, 2023</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><div id="id795223301944418ba8c3fb3bc02f08e_214"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Kevin C. Gorman and Matthew C. Abernethy, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution for him or her, and in his or her name in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power of authority to do and perform each and every act and thing requisite and necessary to be done therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and any of them, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the Registrant and in the capacities indicated as of February&#160;9, 2023:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Kevin C. Gorman</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chief Executive Officer and Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kevin C. Gorman, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">/ Matthew C. Abernethy</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Matthew C. Abernethy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">William H. Rastetter</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chairman of the Board of Directors</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">William H. Rastetter, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Gary A. Lyons</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gary A. Lyons</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Johanna Mercier</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johanna Mercier</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">George J. Morrow</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">George J. Morrow</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Leslie V. Norwalk</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leslie V. Norwalk</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Richard F. Pops</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Richard F. Pops</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Shalini Sharp</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shalini Sharp</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Stephen A. Sherwin</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stephen A. Sherwin, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>q4-2022xexhibit211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i5076fbec08d7450ea57a2ffb6063d09b_1"></div><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NEUROCRINE BIOSCIENCES INC. SUBSIDIARIES</font></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.102%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Subsidiary</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Jurisdiction</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neurocrine Continental, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware, USA</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neurocrine Europe, Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neurocrine Therapeutics, Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neurocrine UK Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">England and Wales</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diurnal Group Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">England and Wales</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diurnal Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">England and Wales</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diurnal Europe B.V.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Netherlands</font></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>q4-2022xexhibit231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i0d4a4fbc458b4d72901cd8da876ed3ac_1"></div><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Registration Statements (Form S-8 Nos. 333-175889, 333-190178, 333-197916, and 333-212871) pertaining to the 2011 Equity Incentive Plan of Neurocrine Biosciences, Inc.,</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Registration Statements (Form S-8 Nos. 333-199837, and 333-216067) pertaining to the Inducement Plan of Neurocrine Biosciences, Inc.,  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Registration Statements (Form S-8 Nos. 333-205933 and 333-223020) pertaining to the 2011 Equity Incentive Plan and Inducement Plan of Neurocrine Biosciences, Inc.,</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) Registration Statements (Form S-8 No. 333-226971) pertaining to the 2011 Equity Incentive Plan and 2018 Employee Stock Purchase Plan of Neurocrine Biosciences, Inc.,</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) Registration Statements (Form S-8 No. 333-234501) pertaining to the 2011 Equity Incentive Plan of Neurocrine Biosciences, Inc.,</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6) Registration Statements (Form S-8 No. 333-240301) pertaining to the 2020 Equity Incentive Plan of Neurocrine Biosciences, Inc., and</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)  Registration Statements (Form S-8 No. 333-266530) pertaining to the 2020 Equity Incentive Plan and 2018 Employee Stock Purchase Plan of Neurocrine Biosciences, Inc.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our reports dated February&#160;9, 2023 with respect to the consolidated financial statements of Neurocrine Biosciences, Inc., and the effectiveness of internal control over financial reporting of Neurocrine Biosciences, Inc., included in this Annual Report (Form 10-K) of Neurocrine Biosciences, Inc. for the year ended December&#160;31, 2022.</font></div><div style="margin-top:12pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:32.051%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Ernst &#38; Young LLP</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;9, 2023</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>q4-2022xexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i5534600a516944c9a025b205b8a45255_1"></div><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Kevin C. Gorman, Chief Executive Officer of Neurocrine Biosciences, Inc., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this annual report on Form 10-K of Neurocrine Biosciences, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this annual report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this annual report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent function)&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal controls over financial reporting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; February&#160;9, 2023</font></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:147.75pt"><tr><td style="width:1.0pt"></td><td style="width:145.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Kevin C. Gorman</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevin C. Gorman</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>q4-2022xexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="if03bece4c14640e3afc095d080e699e0_1"></div><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Matthew C. Abernethy, Chief Financial Officer of Neurocrine Biosciences, Inc., certify that&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this annual report on Form 10-K of Neurocrine Biosciences, Inc.&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this annual report based on such evaluation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent function)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal controls over financial reporting.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; February&#160;9, 2023</font></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:147.75pt"><tr><td style="width:1.0pt"></td><td style="width:145.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Matthew C. Abernethy</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew C. Abernethy</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>6
<FILENAME>q4-2022xexhibit32.htm
<DESCRIPTION>EX-32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ic90086bdcb2a4d59a2c56c6d64a3d76e_1"></div><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32</font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATIONS OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report on Form 10-K of Neurocrine Biosciences, Inc. (the &#8220;Company&#8221;) for the year ended December&#160;31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Kevin C. Gorman, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of Section&#160;13(a) or 15(d), of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">That information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.011%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;9, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Kevin C. Gorman</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevin C. Gorman</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report on Form 10-K of Neurocrine Biosciences, Inc. (the &#8220;Company&#8221;) for the year ended December&#160;31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Matthew C. Abernethy, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of Section&#160;13(a) or 15(d), of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">That information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.010%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;9, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Matthew C. Abernethy</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew C. Abernethy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>nbix-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:218564f8-ce6a-495b-ab09-3ced376fc2a9,g:579af41c-0e49-45b3-bd8f-934603ccb3b3-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nbix="http://www.neurocrine.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.neurocrine.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.neurocrine.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.neurocrine.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.neurocrine.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsIncomeandComprehensiveIncome" roleURI="http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome">
        <link:definition>0000005 - Statement - Consolidated Statements Income and Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000006 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000007 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPolicies" roleURI="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPolicies">
        <link:definition>0000008 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreements" roleURI="http://www.neurocrine.com/role/CollaborationandLicenseAgreements">
        <link:definition>0000009 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiurnalAcquisition" roleURI="http://www.neurocrine.com/role/DiurnalAcquisition">
        <link:definition>0000010 - Disclosure - Diurnal Acquisition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSecurities" roleURI="http://www.neurocrine.com/role/DebtSecurities">
        <link:definition>0000011 - Disclosure - Debt Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.neurocrine.com/role/FairValueMeasurements">
        <link:definition>0000012 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotes" roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotes">
        <link:definition>0000013 - Disclosure - Convertible Senior Notes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://www.neurocrine.com/role/GoodwillandIntangibleAssets">
        <link:definition>0000014 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetDetails" roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetails">
        <link:definition>0000015 - Disclosure - Other Balance Sheet Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.neurocrine.com/role/EarningsPerShare">
        <link:definition>0000016 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.neurocrine.com/role/ShareBasedCompensation">
        <link:definition>0000017 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.neurocrine.com/role/IncomeTaxes">
        <link:definition>0000018 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.neurocrine.com/role/Leases">
        <link:definition>0000019 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementPlan" roleURI="http://www.neurocrine.com/role/RetirementPlan">
        <link:definition>0000020 - Disclosure - Retirement Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedings" roleURI="http://www.neurocrine.com/role/LegalProceedings">
        <link:definition>0000021 - Disclosure - Legal Proceedings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.neurocrine.com/role/SubsequentEvents">
        <link:definition>0000022 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000023 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiurnalAcquisitionTables" roleURI="http://www.neurocrine.com/role/DiurnalAcquisitionTables">
        <link:definition>0000024 - Disclosure - Diurnal Acquisition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSecuritiesTables" roleURI="http://www.neurocrine.com/role/DebtSecuritiesTables">
        <link:definition>0000025 - Disclosure - Debt Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.neurocrine.com/role/FairValueMeasurementsTables">
        <link:definition>0000026 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotesTables" roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesTables">
        <link:definition>0000027 - Disclosure - Convertible Senior Notes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://www.neurocrine.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>0000028 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetDetailsTables" roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsTables">
        <link:definition>0000029 - Disclosure - Other Balance Sheet Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.neurocrine.com/role/EarningsPerShareTables">
        <link:definition>0000030 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.neurocrine.com/role/ShareBasedCompensationTables">
        <link:definition>0000031 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.neurocrine.com/role/IncomeTaxesTables">
        <link:definition>0000032 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.neurocrine.com/role/LeasesTables">
        <link:definition>0000033 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>0000034 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsAdditionalInformationDetails" roleURI="http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails">
        <link:definition>0000035 - Disclosure - Collaboration and License Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiurnalAcquisitionAdditionalInformationDetails" roleURI="http://www.neurocrine.com/role/DiurnalAcquisitionAdditionalInformationDetails">
        <link:definition>0000036 - Disclosure - Diurnal Acquisition - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiurnalAcquisitionEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedattheDateofAcquisitionDetails" roleURI="http://www.neurocrine.com/role/DiurnalAcquisitionEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedattheDateofAcquisitionDetails">
        <link:definition>0000037 - Disclosure - Diurnal Acquisition - Estimated Fair Values of the Assets Acquired and Liabilities Assumed at the Date of Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails" roleURI="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails">
        <link:definition>0000038 - Disclosure - Debt Securities - Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSecuritiesAdditionalInformationDetails" roleURI="http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetails">
        <link:definition>0000039 - Disclosure - Debt Securities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails" roleURI="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails">
        <link:definition>0000040 - Disclosure - Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Debt securities in Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" roleURI="http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>0000041 - Disclosure - Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails" roleURI="http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>0000042 - Disclosure - Fair Value Measurements - Reconciliation of Equity Securities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotesAdditionalInformationDetails" roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails">
        <link:definition>0000043 - Disclosure - Convertible Senior Notes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotes2024NotesDetails" roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails">
        <link:definition>0000044 - Disclosure - Convertible Senior Notes - 2024 Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotesInterestExpenseDetails" roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails">
        <link:definition>0000045 - Disclosure - Convertible Senior Notes - Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsAdditionalInformationDetails" roleURI="http://www.neurocrine.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails">
        <link:definition>0000046 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails" roleURI="http://www.neurocrine.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails">
        <link:definition>0000047 - Disclosure - Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails" roleURI="http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails">
        <link:definition>0000048 - Disclosure - Goodwill and Intangible Assets - Intangible Assets Amortized Over Estimated Useful Lives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsEstimatedAnnualAmortizationExpenseforFiniteLivedIntangibleAssetsDetails" roleURI="http://www.neurocrine.com/role/GoodwillandIntangibleAssetsEstimatedAnnualAmortizationExpenseforFiniteLivedIntangibleAssetsDetails">
        <link:definition>0000049 - Disclosure - Goodwill and Intangible Assets - Estimated Annual Amortization Expense for Finite-Lived Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetDetailsInventoriesDetails" roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails">
        <link:definition>0000050 - Disclosure - Other Balance Sheet Details - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetDetailsPropertyandEquipmentDetails" roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails">
        <link:definition>0000051 - Disclosure - Other Balance Sheet Details - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails" roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails">
        <link:definition>0000052 - Disclosure - Other Balance Sheet Details - Accounts Payable and Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>0000053 - Disclosure - Other Balance Sheet Details - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareScheduleofNetIncomeLossPerShareDetails" roleURI="http://www.neurocrine.com/role/EarningsPerShareScheduleofNetIncomeLossPerShareDetails">
        <link:definition>0000054 - Disclosure - Earnings Per Share - Schedule of Net Income (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails" roleURI="http://www.neurocrine.com/role/EarningsPerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails">
        <link:definition>0000055 - Disclosure - Earnings Per Share - Schedule of Anti-Dilutive Shares Excluded from Diluted Per Share Amounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationAdditionalInformationDetails" roleURI="http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails">
        <link:definition>0000056 - Disclosure - Share-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails" roleURI="http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails">
        <link:definition>0000057 - Disclosure - Share-Based Compensation - Compensation Cost Related to Share-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails" roleURI="http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails">
        <link:definition>0000058 - Disclosure - Share-Based Compensation - Schedule of Share-based Compensation Expense by Award-type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails" roleURI="http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails">
        <link:definition>0000059 - Disclosure - Share-Based Compensation - Schedule of Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails" roleURI="http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails">
        <link:definition>0000060 - Disclosure - Share-Based Compensation - Weighted-Average Assumptions for Stock Option Grants using Black-Scholes Option-Pricing Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails" roleURI="http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails">
        <link:definition>0000061 - Disclosure - Share-Based Compensation - Summary of Activity Related to Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails" roleURI="http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails">
        <link:definition>0000062 - Disclosure - Share-Based Compensation - Summary and Changes in Restricted Stock Units Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeBeforetheProvisionforIncomeTaxesfromContinuingDomesticandForeignOperationsDetails" roleURI="http://www.neurocrine.com/role/IncomeTaxesIncomeBeforetheProvisionforIncomeTaxesfromContinuingDomesticandForeignOperationsDetails">
        <link:definition>0000063 - Disclosure - Income Taxes - Income Before the Provision for Income Taxes from Continuing Domestic and Foreign Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsoftheProvisionforBenefitfromIncomeTaxesforContinuingOperationsDetails" roleURI="http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforBenefitfromIncomeTaxesforContinuingOperationsDetails">
        <link:definition>0000064 - Disclosure - Income Taxes - Components of the Provision for (Benefit from) Income Taxes for Continuing Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails" roleURI="http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails">
        <link:definition>0000065 - Disclosure - Income Taxes - Provision for Income Taxes on Earnings Subject to Income Taxes Differs from Statutory Federal Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofDeferredTaxAssetsDetails" roleURI="http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails">
        <link:definition>0000066 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>0000067 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" roleURI="http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails">
        <link:definition>0000068 - Disclosure - Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeInformationDetails" roleURI="http://www.neurocrine.com/role/LeasesNarrativeInformationDetails">
        <link:definition>0000069 - Disclosure - Leases - Narrative Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalInformationDetails" roleURI="http://www.neurocrine.com/role/LeasesSupplementalInformationDetails">
        <link:definition>0000070 - Disclosure - Leases - Supplemental Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails" roleURI="http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails">
        <link:definition>0000071 - Disclosure - Leases - Summary of Future Minimum Lease Payments Under Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails_1" roleURI="http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails_1">
        <link:definition>0000071 - Disclosure - Leases - Summary of Future Minimum Lease Payments Under Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementPlanAdditionalInformationDetails" roleURI="http://www.neurocrine.com/role/RetirementPlanAdditionalInformationDetails">
        <link:definition>0000072 - Disclosure - Retirement Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.neurocrine.com/role/SubsequentEventsDetails">
        <link:definition>0000073 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="nbix_OrganizationAndBusinesDescriptionPolicyPolicyTextBlock" abstract="false" name="OrganizationAndBusinesDescriptionPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nbix_IncomeTaxesTable" abstract="true" name="IncomeTaxesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment" abstract="false" name="DeferredTaxAssetsCapitalizedResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_RentAbatementPeriod" abstract="false" name="RentAbatementPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes" abstract="false" name="DeferredTaxLiabilitiesConvertibleSeniorNotes" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember" abstract="true" name="SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nbix_InvestmentIncomeAndOtherNet" abstract="false" name="InvestmentIncomeAndOtherNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nbix_ESPPPurchasePeriod" abstract="false" name="ESPPPurchasePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbix_Amended2020EquityIncentivePlanMember" abstract="true" name="Amended2020EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_DeferredTaxAssetsLiabilitiesGross" abstract="false" name="DeferredTaxAssetsLiabilitiesGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_BIALPortelaCaSAMember" abstract="true" name="BIALPortelaCaSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" abstract="false" name="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_DebtInstrumentConversionAxis" abstract="true" name="DebtInstrumentConversionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="nbix_AuditorInformationAbstract" abstract="true" name="AuditorInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment" abstract="false" name="FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nbix_DebtInstrumentCouponInterest" abstract="false" name="DebtInstrumentCouponInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_IdorsiaPharmaceuticalsLtdMember" abstract="true" name="IdorsiaPharmaceuticalsLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_CarryingAmountOfLiabilityComponentUponIssuance" abstract="false" name="CarryingAmountOfLiabilityComponentUponIssuance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_HeptaresTherapeuticsLimitedMember" abstract="true" name="HeptaresTherapeuticsLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_ConversionPeriodOneMember" abstract="true" name="ConversionPeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_SaleOfStockNumberOfSharesSoldInTransaction" abstract="false" name="SaleOfStockNumberOfSharesSoldInTransaction" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nbix_RevenueRelatedReservesForDiscountsAndAllowances" abstract="false" name="RevenueRelatedReservesForDiscountsAndAllowances" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_DiurnalGroupPlcMember" abstract="true" name="DiurnalGroupPlcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_ScientificEquipmentMember" abstract="true" name="ScientificEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_CashAndMoneyMarketFundMember" abstract="true" name="CashAndMoneyMarketFundMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_OtherBalanceSheetDetailsAbstract" abstract="true" name="OtherBalanceSheetDetailsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive" abstract="false" name="NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_MitsubishiTanabePharmaCorporationMember" abstract="true" name="MitsubishiTanabePharmaCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_PrincipalAmountOnConversionRate" abstract="false" name="PrincipalAmountOnConversionRate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding" abstract="false" name="LesseeOperatingLeaseOptionTermToConstructFifthBuilding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" abstract="false" name="MinimumPercentageOfTradingPriceToLastReportedSalePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nbix_DebtInstrumentConvertibleConversionPremium" abstract="false" name="DebtInstrumentConvertibleConversionPremium" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" abstract="false" name="DebtSecuritiesAvailableForSalePositionNumberOfPositions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nbix_EarningsPerShareBasicAndDilutedEPSAbstract" abstract="true" name="EarningsPerShareBasicAndDilutedEPSAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo" abstract="false" name="NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" abstract="false" name="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_IncomeTaxesLineItems" abstract="true" name="IncomeTaxesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbix_UpfrontPaymentsMade" abstract="false" name="UpfrontPaymentsMade" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_PatentTerm" abstract="false" name="PatentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbix_ConversionPeriodTwoMember" abstract="true" name="ConversionPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_LargestFourCustomersMember" abstract="true" name="LargestFourCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember" abstract="true" name="StockOptionsRestrictedStockAndConvertibleSeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_DebtSecuritiesAvailableForSaleFairValueCurrent" abstract="false" name="DebtSecuritiesAvailableForSaleFairValueCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_Amended2018EmployeeStockPurchasePlanMember" abstract="true" name="Amended2018EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_AccruedBrandedPrescriptionDrugFee" abstract="false" name="AccruedBrandedPrescriptionDrugFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndOtherAccruedExpenses" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndOtherAccruedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_DeferredTaxAssetsOperatingLeasesAssets" abstract="false" name="DeferredTaxAssetsOperatingLeasesAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbix_TakedaPharmaceuticalCompanyLimitedMember" abstract="true" name="TakedaPharmaceuticalCompanyLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_DebtInstrumentConversionDomain" abstract="true" name="DebtInstrumentConversionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" abstract="false" name="SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nbix_XenonPharmaceuticalsIncMember" abstract="true" name="XenonPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot" abstract="false" name="LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" abstract="false" name="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_IncomeTaxReconciliationExpirationOfTaxCredits" abstract="false" name="IncomeTaxReconciliationExpirationOfTaxCredits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_AnnualRentEscalationPercentage" abstract="false" name="AnnualRentEscalationPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent" abstract="false" name="DebtSecuritiesAvailableForSaleFairValueNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_MilestonePayment" abstract="false" name="MilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee" abstract="false" name="IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_PerformanceBasedRestrictedStockUnitMember" abstract="true" name="PerformanceBasedRestrictedStockUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_TwoThousandAndElevenEquityIncentivePlanMember" abstract="true" name="TwoThousandAndElevenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities" abstract="false" name="DeferredTaxLiabilitiesOperatingLeasesLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_AbbVieIncMember" abstract="true" name="AbbVieIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_PotentialMilestonePayments" abstract="false" name="PotentialMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour" abstract="false" name="NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" abstract="true" name="OrganizationAndSummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsAcquiredInProcessResearchAndDevelopment" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsAcquiredInProcessResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree" abstract="false" name="NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_NumberOfRenewalOptions" abstract="false" name="NumberOfRenewalOptions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nbix_BusinessAcquisitionEquityInvestmentToAcquireTheWorldwideRights" abstract="false" name="BusinessAcquisitionEquityInvestmentToAcquireTheWorldwideRights" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_CarryingAmountOfLiabilityComponentAtSettlement" abstract="false" name="CarryingAmountOfLiabilityComponentAtSettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_CollaborationRevenueMember" abstract="true" name="CollaborationRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_VoyagerTherapeuticsMember" abstract="true" name="VoyagerTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_AccruedResearchAndDevelopmentExpenseCurrent" abstract="false" name="AccruedResearchAndDevelopmentExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" abstract="false" name="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost" abstract="false" name="IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_PotentialMilestonePaymentReceipts" abstract="false" name="PotentialMilestonePaymentReceipts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>nbix-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:218564f8-ce6a-495b-ab09-3ced376fc2a9,g:579af41c-0e49-45b3-bd8f-934603ccb3b3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nbix-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_46816bdd-04d4-497f-b605-177579780c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8e2a9c40-462a-4063-83de-05ecb213fbca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_46816bdd-04d4-497f-b605-177579780c3e" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8e2a9c40-462a-4063-83de-05ecb213fbca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_1336dd47-013d-4ec7-8d5e-b6dd696f44b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_46816bdd-04d4-497f-b605-177579780c3e" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_1336dd47-013d-4ec7-8d5e-b6dd696f44b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_efd5bb86-2b68-474d-94d9-216e9b589274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_46816bdd-04d4-497f-b605-177579780c3e" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_efd5bb86-2b68-474d-94d9-216e9b589274" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cc8f1f64-38d3-4ad8-a3e2-8d4e109d79f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_0cbae163-5c42-4421-a61d-e9465f442f65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cc8f1f64-38d3-4ad8-a3e2-8d4e109d79f5" xlink:to="loc_us-gaap_PreferredStockValue_0cbae163-5c42-4421-a61d-e9465f442f65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f91b45e0-d1d9-41dc-8d3c-dfe699d63094" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cc8f1f64-38d3-4ad8-a3e2-8d4e109d79f5" xlink:to="loc_us-gaap_CommonStockValue_f91b45e0-d1d9-41dc-8d3c-dfe699d63094" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_dd96950a-cbc9-4f66-b871-7b8e3a7405c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cc8f1f64-38d3-4ad8-a3e2-8d4e109d79f5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_dd96950a-cbc9-4f66-b871-7b8e3a7405c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e82478ec-7b96-4a65-b1e6-21b87abda78a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cc8f1f64-38d3-4ad8-a3e2-8d4e109d79f5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e82478ec-7b96-4a65-b1e6-21b87abda78a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_23d4f3a1-f57c-4eae-8dce-21cb0be6c11d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cc8f1f64-38d3-4ad8-a3e2-8d4e109d79f5" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_23d4f3a1-f57c-4eae-8dce-21cb0be6c11d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6e62cc9d-5713-4673-b028-6aa904155c46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b4253a15-3345-4cc7-bc07-29055d7ec092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6e62cc9d-5713-4673-b028-6aa904155c46" xlink:to="loc_us-gaap_LiabilitiesCurrent_b4253a15-3345-4cc7-bc07-29055d7ec092" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_5bad11af-a4af-4a98-9188-a47d8820302a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6e62cc9d-5713-4673-b028-6aa904155c46" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_5bad11af-a4af-4a98-9188-a47d8820302a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5f79aa0d-62e7-460d-b63f-67ce443139e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6e62cc9d-5713-4673-b028-6aa904155c46" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5f79aa0d-62e7-460d-b63f-67ce443139e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_0c68a3b5-d720-44b1-b6b9-c9af019dda58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6e62cc9d-5713-4673-b028-6aa904155c46" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_0c68a3b5-d720-44b1-b6b9-c9af019dda58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_98de8bd4-8f5b-40a1-bd7b-fde0b4cf309b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7a17db67-bcf8-4748-9302-c4ec7ca08cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_98de8bd4-8f5b-40a1-bd7b-fde0b4cf309b" xlink:to="loc_us-gaap_Liabilities_7a17db67-bcf8-4748-9302-c4ec7ca08cf7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_35d50d77-cccb-4c1b-bca2-1d13f9bbc741" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_98de8bd4-8f5b-40a1-bd7b-fde0b4cf309b" xlink:to="loc_us-gaap_StockholdersEquity_35d50d77-cccb-4c1b-bca2-1d13f9bbc741" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e7db927a-45e9-48e5-bafe-7f0d5781d44b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_43c945e6-44f0-46dd-9987-fa51722889dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e7db927a-45e9-48e5-bafe-7f0d5781d44b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_43c945e6-44f0-46dd-9987-fa51722889dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_bda05913-6975-4b47-9176-460b089b906e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e7db927a-45e9-48e5-bafe-7f0d5781d44b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_bda05913-6975-4b47-9176-460b089b906e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_fb9b7615-6e5f-4c64-84f1-926fece8b1aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e7db927a-45e9-48e5-bafe-7f0d5781d44b" xlink:to="loc_us-gaap_InventoryNet_fb9b7615-6e5f-4c64-84f1-926fece8b1aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_f3354249-3ae3-46ce-ae89-27344d771ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e7db927a-45e9-48e5-bafe-7f0d5781d44b" xlink:to="loc_us-gaap_OtherAssetsCurrent_f3354249-3ae3-46ce-ae89-27344d771ac6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5281e4d4-88e5-43a1-a602-790296c05dce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e7db927a-45e9-48e5-bafe-7f0d5781d44b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5281e4d4-88e5-43a1-a602-790296c05dce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ad5d441d-2c62-41ba-9d25-0d92da2c2350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d5d6fc0b-782c-4932-8124-0630e4fe3787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ad5d441d-2c62-41ba-9d25-0d92da2c2350" xlink:to="loc_us-gaap_AssetsCurrent_d5d6fc0b-782c-4932-8124-0630e4fe3787" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_85051ef6-5393-4cda-a17f-365f824d7fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ad5d441d-2c62-41ba-9d25-0d92da2c2350" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_85051ef6-5393-4cda-a17f-365f824d7fe6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_7aa2a0d2-590b-4604-b125-b3d0d0964f20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ad5d441d-2c62-41ba-9d25-0d92da2c2350" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_7aa2a0d2-590b-4604-b125-b3d0d0964f20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_fc5bced3-382a-4571-93bf-8aecb8e94d87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ad5d441d-2c62-41ba-9d25-0d92da2c2350" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_fc5bced3-382a-4571-93bf-8aecb8e94d87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRestricted_2ac6c62f-2f16-49ca-b362-83ba211e59aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiRestricted"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ad5d441d-2c62-41ba-9d25-0d92da2c2350" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRestricted_2ac6c62f-2f16-49ca-b362-83ba211e59aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_bce4318a-5c74-48b8-b671-92eb4a0b41bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ad5d441d-2c62-41ba-9d25-0d92da2c2350" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_bce4318a-5c74-48b8-b671-92eb4a0b41bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_98d02c14-3293-43cc-b948-c320cf532fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ad5d441d-2c62-41ba-9d25-0d92da2c2350" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_98d02c14-3293-43cc-b948-c320cf532fd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_77ff6dce-ebd5-4dc1-b67f-72d8be62a53c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ad5d441d-2c62-41ba-9d25-0d92da2c2350" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_77ff6dce-ebd5-4dc1-b67f-72d8be62a53c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome" xlink:type="simple" xlink:href="nbix-20221231.xsd#ConsolidatedStatementsIncomeandComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_73a1c377-f4aa-4da1-8691-1367fc9f4519" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3be5cdac-1162-436d-b184-def4072d47e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_73a1c377-f4aa-4da1-8691-1367fc9f4519" xlink:to="loc_us-gaap_NetIncomeLoss_3be5cdac-1162-436d-b184-def4072d47e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_fa34f7ab-bc8e-4f43-b6af-efbc946fae1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_73a1c377-f4aa-4da1-8691-1367fc9f4519" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_fa34f7ab-bc8e-4f43-b6af-efbc946fae1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_ee96bd23-dd0e-4190-ac68-c5e8dbe79bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_73a1c377-f4aa-4da1-8691-1367fc9f4519" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_ee96bd23-dd0e-4190-ac68-c5e8dbe79bc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_3483e131-7969-4f8d-95a6-7c75dec4f35e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_02dec57a-d761-415d-b6ff-7fda9a3a57c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3483e131-7969-4f8d-95a6-7c75dec4f35e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_02dec57a-d761-415d-b6ff-7fda9a3a57c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_4e065d9c-ed00-4540-97ae-05626ff1a64a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3483e131-7969-4f8d-95a6-7c75dec4f35e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_4e065d9c-ed00-4540-97ae-05626ff1a64a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_21affe0e-8dd1-4a90-aadc-eef8511fbfd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3483e131-7969-4f8d-95a6-7c75dec4f35e" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_21affe0e-8dd1-4a90-aadc-eef8511fbfd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f6fd0b9a-58b6-459d-ad34-2bbf65ba56b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3483e131-7969-4f8d-95a6-7c75dec4f35e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f6fd0b9a-58b6-459d-ad34-2bbf65ba56b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_4a6c9055-4c34-4fa1-a620-71b0e1a0fa97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_99d1d8ca-35e7-4980-8f15-81daabff199d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_4a6c9055-4c34-4fa1-a620-71b0e1a0fa97" xlink:to="loc_us-gaap_InterestExpense_99d1d8ca-35e7-4980-8f15-81daabff199d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d1f63207-b44e-4ac9-bdb4-38fedd3ce8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_4a6c9055-4c34-4fa1-a620-71b0e1a0fa97" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d1f63207-b44e-4ac9-bdb4-38fedd3ce8cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fff37ad1-aa7d-40aa-a7a8-8ef918384984" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_4a6c9055-4c34-4fa1-a620-71b0e1a0fa97" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fff37ad1-aa7d-40aa-a7a8-8ef918384984" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_InvestmentIncomeAndOtherNet_25e8f3d2-2ba9-4bb0-b2e9-c4a56493d9e9" xlink:href="nbix-20221231.xsd#nbix_InvestmentIncomeAndOtherNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_4a6c9055-4c34-4fa1-a620-71b0e1a0fa97" xlink:to="loc_nbix_InvestmentIncomeAndOtherNet_25e8f3d2-2ba9-4bb0-b2e9-c4a56493d9e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bbfb0d5e-15d9-46f5-855e-861cd125e671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_23e6f7f6-d706-4635-81d5-4d16f79fc5b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_bbfb0d5e-15d9-46f5-855e-861cd125e671" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_23e6f7f6-d706-4635-81d5-4d16f79fc5b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_e2d4be91-c6ac-4c49-be06-8c9b480580fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_bbfb0d5e-15d9-46f5-855e-861cd125e671" xlink:to="loc_us-gaap_CostsAndExpenses_e2d4be91-c6ac-4c49-be06-8c9b480580fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_37d1c9c9-279d-43ab-9650-2f671bb8f525" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1f845ce3-d3e5-4630-9aa7-0e3df2fd0b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_37d1c9c9-279d-43ab-9650-2f671bb8f525" xlink:to="loc_us-gaap_OperatingIncomeLoss_1f845ce3-d3e5-4630-9aa7-0e3df2fd0b4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_b4797ece-c87d-4886-a468-c9f0c89ff7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_37d1c9c9-279d-43ab-9650-2f671bb8f525" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_b4797ece-c87d-4886-a468-c9f0c89ff7cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_afd08fe9-6e96-4615-ba5a-bb2bcafab41c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_79a064a9-a1bc-4cca-af99-9084882bc057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_afd08fe9-6e96-4615-ba5a-bb2bcafab41c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_79a064a9-a1bc-4cca-af99-9084882bc057" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1dbc689d-f32f-4dea-819e-a281680f9518" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_afd08fe9-6e96-4615-ba5a-bb2bcafab41c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1dbc689d-f32f-4dea-819e-a281680f9518" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="nbix-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d3e58853-2765-4d18-a103-a1e3a58ae92c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9709d58d-9d7c-420a-81e1-d5f93eff2920" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d3e58853-2765-4d18-a103-a1e3a58ae92c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9709d58d-9d7c-420a-81e1-d5f93eff2920" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_3789d923-5cc1-447a-88d2-3ad96454a2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d3e58853-2765-4d18-a103-a1e3a58ae92c" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_3789d923-5cc1-447a-88d2-3ad96454a2f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_191c9f86-6534-477b-b51f-901bb83830e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_50c6f52a-7715-4792-b83c-b1a776422c33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_191c9f86-6534-477b-b51f-901bb83830e7" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_50c6f52a-7715-4792-b83c-b1a776422c33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_f177a37f-6f83-4b97-a5c3-8e8bfd287ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_191c9f86-6534-477b-b51f-901bb83830e7" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_f177a37f-6f83-4b97-a5c3-8e8bfd287ec9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_79fb05dc-62d2-4cd3-871e-37b04d2635ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_191c9f86-6534-477b-b51f-901bb83830e7" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_79fb05dc-62d2-4cd3-871e-37b04d2635ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8f8704b6-7752-4fae-99ec-042688a240fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_191c9f86-6534-477b-b51f-901bb83830e7" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8f8704b6-7752-4fae-99ec-042688a240fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_27c4157d-5d84-4f8b-be65-6a75aeef1a51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_191c9f86-6534-477b-b51f-901bb83830e7" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_27c4157d-5d84-4f8b-be65-6a75aeef1a51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f6ce270a-2a2e-437c-bef9-8fa8087ba619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_93ce5534-51e8-4bf8-bdcc-444c6243f50c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f6ce270a-2a2e-437c-bef9-8fa8087ba619" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_93ce5534-51e8-4bf8-bdcc-444c6243f50c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c931d0ee-9f1d-4a97-8ab1-533c3a534010" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f6ce270a-2a2e-437c-bef9-8fa8087ba619" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c931d0ee-9f1d-4a97-8ab1-533c3a534010" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_64bf86e6-0fdc-403a-a2e7-78f9ed9d19a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f6ce270a-2a2e-437c-bef9-8fa8087ba619" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_64bf86e6-0fdc-403a-a2e7-78f9ed9d19a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_838a967b-adfc-46bc-8201-089001d2c325" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f6ce270a-2a2e-437c-bef9-8fa8087ba619" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_838a967b-adfc-46bc-8201-089001d2c325" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20e09830-f7e7-4b66-bba0-e6f5bbf6dc1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e932f250-8489-435c-8b6c-a135c199d4fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20e09830-f7e7-4b66-bba0-e6f5bbf6dc1b" xlink:to="loc_us-gaap_NetIncomeLoss_e932f250-8489-435c-8b6c-a135c199d4fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_685d452e-5472-4bfa-9001-35ffaab80cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20e09830-f7e7-4b66-bba0-e6f5bbf6dc1b" xlink:to="loc_us-gaap_ShareBasedCompensation_685d452e-5472-4bfa-9001-35ffaab80cb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_1f0eed0d-4601-4e15-a4c1-d34f03f28a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20e09830-f7e7-4b66-bba0-e6f5bbf6dc1b" xlink:to="loc_us-gaap_Depreciation_1f0eed0d-4601-4e15-a4c1-d34f03f28a0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_bccd270a-411d-4e4e-aead-19619c8f6fba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20e09830-f7e7-4b66-bba0-e6f5bbf6dc1b" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_bccd270a-411d-4e4e-aead-19619c8f6fba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_a6b0a63f-1c99-49d4-a9e6-3e5ed70b2577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20e09830-f7e7-4b66-bba0-e6f5bbf6dc1b" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_a6b0a63f-1c99-49d4-a9e6-3e5ed70b2577" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_75d12775-39d2-4b5b-8796-f89769c567ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20e09830-f7e7-4b66-bba0-e6f5bbf6dc1b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_75d12775-39d2-4b5b-8796-f89769c567ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_80de3128-6613-4faa-9852-0c83e32d5242" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20e09830-f7e7-4b66-bba0-e6f5bbf6dc1b" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_80de3128-6613-4faa-9852-0c83e32d5242" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a2498430-7a36-4e57-9a8c-702fd4d10b68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20e09830-f7e7-4b66-bba0-e6f5bbf6dc1b" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a2498430-7a36-4e57-9a8c-702fd4d10b68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_5dde9ea4-296c-4383-9c15-3b48b6f0253c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20e09830-f7e7-4b66-bba0-e6f5bbf6dc1b" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_5dde9ea4-296c-4383-9c15-3b48b6f0253c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_eef7ce86-8d44-4db2-bb53-0005f68e9794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20e09830-f7e7-4b66-bba0-e6f5bbf6dc1b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_eef7ce86-8d44-4db2-bb53-0005f68e9794" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_20538ef7-ea62-4fcc-934b-76a7251bca5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20e09830-f7e7-4b66-bba0-e6f5bbf6dc1b" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_20538ef7-ea62-4fcc-934b-76a7251bca5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ccd01d6c-0b04-4522-a2c6-1f7ed78de026" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20e09830-f7e7-4b66-bba0-e6f5bbf6dc1b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ccd01d6c-0b04-4522-a2c6-1f7ed78de026" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet_f8afc102-3ff2-4b0a-ad35-a713701ff6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20e09830-f7e7-4b66-bba0-e6f5bbf6dc1b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet_f8afc102-3ff2-4b0a-ad35-a713701ff6f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_a92e1dc6-0652-47ed-a8c4-a060d6a51a69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_20e09830-f7e7-4b66-bba0-e6f5bbf6dc1b" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_a92e1dc6-0652-47ed-a8c4-a060d6a51a69" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DiurnalAcquisitionEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedattheDateofAcquisitionDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#DiurnalAcquisitionEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedattheDateofAcquisitionDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/DiurnalAcquisitionEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedattheDateofAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_dcf83129-b2dd-44ec-9258-9c06e9087f11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_4f7f6c50-d82d-40d9-9754-894b8456b770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_dcf83129-b2dd-44ec-9258-9c06e9087f11" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_4f7f6c50-d82d-40d9-9754-894b8456b770" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_21660960-921c-4d6f-ab76-0f363a3e3ede" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_dcf83129-b2dd-44ec-9258-9c06e9087f11" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_21660960-921c-4d6f-ab76-0f363a3e3ede" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_bcb088e4-1b09-4131-a891-438387934ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_dcf83129-b2dd-44ec-9258-9c06e9087f11" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_bcb088e4-1b09-4131-a891-438387934ec3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndOtherAccruedExpenses_807a5c98-c741-4ded-9e73-cd0b3ad81c41" xlink:href="nbix-20221231.xsd#nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndOtherAccruedExpenses"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_dcf83129-b2dd-44ec-9258-9c06e9087f11" xlink:to="loc_nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndOtherAccruedExpenses_807a5c98-c741-4ded-9e73-cd0b3ad81c41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsAcquiredInProcessResearchAndDevelopment_525a7414-4fda-4987-99e5-4d48a62bb467" xlink:href="nbix-20221231.xsd#nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsAcquiredInProcessResearchAndDevelopment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_dcf83129-b2dd-44ec-9258-9c06e9087f11" xlink:to="loc_nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsAcquiredInProcessResearchAndDevelopment_525a7414-4fda-4987-99e5-4d48a62bb467" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_e3677111-834d-4e23-8f46-aab82692ec9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_b0a44ae0-a551-4ebd-8ab5-c5d33cab3b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_e3677111-834d-4e23-8f46-aab82692ec9f" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_b0a44ae0-a551-4ebd-8ab5-c5d33cab3b59" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_6a1d4eec-cafd-4bfa-899f-b37353037481" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_f6d47b03-658e-43bb-ac09-e046419a2d8c" xlink:href="nbix-20221231.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_6a1d4eec-cafd-4bfa-899f-b37353037481" xlink:to="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_f6d47b03-658e-43bb-ac09-e046419a2d8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_f236e6ce-c02b-43eb-8eb3-63d95e5153de" xlink:href="nbix-20221231.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_6a1d4eec-cafd-4bfa-899f-b37353037481" xlink:to="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_f236e6ce-c02b-43eb-8eb3-63d95e5153de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent_eed16636-d1c7-4670-93ed-450e2b301065" xlink:href="nbix-20221231.xsd#nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_6a1d4eec-cafd-4bfa-899f-b37353037481" xlink:to="loc_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent_eed16636-d1c7-4670-93ed-450e2b301065" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_69dc70ca-4264-47b6-a29e-c2518d0e4dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_d80271f6-3866-4ce5-87d0-47c5666b9262" xlink:href="nbix-20221231.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_69dc70ca-4264-47b6-a29e-c2518d0e4dd9" xlink:to="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_d80271f6-3866-4ce5-87d0-47c5666b9262" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_60253913-9b64-4ee3-9093-03702ec338c9" xlink:href="nbix-20221231.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_69dc70ca-4264-47b6-a29e-c2518d0e4dd9" xlink:to="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_60253913-9b64-4ee3-9093-03702ec338c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent_581af1cc-f025-4876-8e35-caa47bcbbbf1" xlink:href="nbix-20221231.xsd#nbix_DebtSecuritiesAvailableForSaleFairValueCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_69dc70ca-4264-47b6-a29e-c2518d0e4dd9" xlink:to="loc_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent_581af1cc-f025-4876-8e35-caa47bcbbbf1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_a0fcf3f3-fab2-44b6-8479-15f8fb9a8cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_3fbb2cf4-879b-4998-8d27-90e99381c1d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_a0fcf3f3-fab2-44b6-8479-15f8fb9a8cf4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_3fbb2cf4-879b-4998-8d27-90e99381c1d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_19d60e24-2dcc-48f6-af95-40cd25f9a857" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_a0fcf3f3-fab2-44b6-8479-15f8fb9a8cf4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_19d60e24-2dcc-48f6-af95-40cd25f9a857" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_21ab0cb8-4701-4cd5-9706-8401e0fd879c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_4b0d0208-60e1-423f-84a7-888178d51294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_21ab0cb8-4701-4cd5-9706-8401e0fd879c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_4b0d0208-60e1-423f-84a7-888178d51294" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_c09f0fbb-7531-4b9a-9294-c69f99cf7731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_21ab0cb8-4701-4cd5-9706-8401e0fd879c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_c09f0fbb-7531-4b9a-9294-c69f99cf7731" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#ConvertibleSeniorNotesInterestExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f709e6e1-13ee-4e60-a2f1-d8a6bd9a09df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentCouponInterest_cd8a34fd-fa70-42c3-ad64-ff2b2cd3f2b2" xlink:href="nbix-20221231.xsd#nbix_DebtInstrumentCouponInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpense_f709e6e1-13ee-4e60-a2f1-d8a6bd9a09df" xlink:to="loc_nbix_DebtInstrumentCouponInterest_cd8a34fd-fa70-42c3-ad64-ff2b2cd3f2b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_90c0a077-f9c6-42eb-89f7-793bfe7f03af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpense_f709e6e1-13ee-4e60-a2f1-d8a6bd9a09df" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_90c0a077-f9c6-42eb-89f7-793bfe7f03af" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c846b783-6858-40b6-bcd4-f3e12bd733f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_40b022f5-de36-474a-8e6e-3c2218c2bddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c846b783-6858-40b6-bcd4-f3e12bd733f6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_40b022f5-de36-474a-8e6e-3c2218c2bddd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_d8f60cdb-227b-43ef-879e-1fe86d41a089" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c846b783-6858-40b6-bcd4-f3e12bd733f6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_d8f60cdb-227b-43ef-879e-1fe86d41a089" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_95071d71-ff8d-4675-bef1-fec52db3a4e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3d29ada1-8dde-4ac2-a06d-316b9315fe1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_95071d71-ff8d-4675-bef1-fec52db3a4e4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3d29ada1-8dde-4ac2-a06d-316b9315fe1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f3ed922d-2097-457d-b29b-846a1aec537f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_95071d71-ff8d-4675-bef1-fec52db3a4e4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f3ed922d-2097-457d-b29b-846a1aec537f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#OtherBalanceSheetDetailsInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_c8c0d9a2-a013-4e3e-8f47-ce74e3227c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_6529b96e-2673-4790-a5bc-650a54651da3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_c8c0d9a2-a013-4e3e-8f47-ce74e3227c0d" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_6529b96e-2673-4790-a5bc-650a54651da3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_04b902c5-b1c1-4eb0-a1d3-c80abfba39d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_c8c0d9a2-a013-4e3e-8f47-ce74e3227c0d" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_04b902c5-b1c1-4eb0-a1d3-c80abfba39d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7448abb4-0e62-4b53-93d2-eece4a0688e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_c8c0d9a2-a013-4e3e-8f47-ce74e3227c0d" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7448abb4-0e62-4b53-93d2-eece4a0688e5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#OtherBalanceSheetDetailsPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_bd671888-ad22-44e0-8644-3fde749a6062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_f5dc7b65-6130-4081-8022-216804843aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_bd671888-ad22-44e0-8644-3fde749a6062" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_f5dc7b65-6130-4081-8022-216804843aa4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_93323cc6-b362-44dc-9f28-dda0f582350c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_bd671888-ad22-44e0-8644-3fde749a6062" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_93323cc6-b362-44dc-9f28-dda0f582350c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c96d8017-f3c2-443e-8692-25e30f19f245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_57ba36be-f3fe-4bba-a8cf-79094a82e134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c96d8017-f3c2-443e-8692-25e30f19f245" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_57ba36be-f3fe-4bba-a8cf-79094a82e134" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_RevenueRelatedReservesForDiscountsAndAllowances_a1df9d1b-cf6c-4650-b8e7-fe04f518dbee" xlink:href="nbix-20221231.xsd#nbix_RevenueRelatedReservesForDiscountsAndAllowances"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c96d8017-f3c2-443e-8692-25e30f19f245" xlink:to="loc_nbix_RevenueRelatedReservesForDiscountsAndAllowances_a1df9d1b-cf6c-4650-b8e7-fe04f518dbee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AccruedResearchAndDevelopmentExpenseCurrent_0e910c36-5ec8-4245-a4d9-ecb35849d56b" xlink:href="nbix-20221231.xsd#nbix_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c96d8017-f3c2-443e-8692-25e30f19f245" xlink:to="loc_nbix_AccruedResearchAndDevelopmentExpenseCurrent_0e910c36-5ec8-4245-a4d9-ecb35849d56b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AccruedBrandedPrescriptionDrugFee_bdcafa96-988e-4f3c-8737-c4824a531dc8" xlink:href="nbix-20221231.xsd#nbix_AccruedBrandedPrescriptionDrugFee"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c96d8017-f3c2-443e-8692-25e30f19f245" xlink:to="loc_nbix_AccruedBrandedPrescriptionDrugFee_bdcafa96-988e-4f3c-8737-c4824a531dc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_f5b03d43-1077-4c57-8421-fc9ca9ed6220" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c96d8017-f3c2-443e-8692-25e30f19f245" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_f5b03d43-1077-4c57-8421-fc9ca9ed6220" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_80802803-ead6-4e84-9197-49a22ceaf1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ca17899c-6228-478d-8267-01746380764a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents_80802803-ead6-4e84-9197-49a22ceaf1e4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ca17899c-6228-478d-8267-01746380764a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_6625314c-25cc-4e73-bf88-5645829ab4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents_80802803-ead6-4e84-9197-49a22ceaf1e4" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_6625314c-25cc-4e73-bf88-5645829ab4dc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/EarningsPerShareScheduleofNetIncomeLossPerShareDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#EarningsPerShareScheduleofNetIncomeLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/EarningsPerShareScheduleofNetIncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ef36828d-864e-44b5-8fa4-5c5e13325839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7dbb4324-27de-4c5f-b61a-d923c81482ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ef36828d-864e-44b5-8fa4-5c5e13325839" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7dbb4324-27de-4c5f-b61a-d923c81482ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_e6d61c68-325c-493c-9671-db801437b3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ef36828d-864e-44b5-8fa4-5c5e13325839" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_e6d61c68-325c-493c-9671-db801437b3f6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesIncomeBeforetheProvisionforIncomeTaxesfromContinuingDomesticandForeignOperationsDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#IncomeTaxesIncomeBeforetheProvisionforIncomeTaxesfromContinuingDomesticandForeignOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesIncomeBeforetheProvisionforIncomeTaxesfromContinuingDomesticandForeignOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_593cd9f1-1f35-49c5-bd6e-1a9f18f204de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_cd8e4f8f-e163-4e93-ac84-985b346f46e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_593cd9f1-1f35-49c5-bd6e-1a9f18f204de" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_cd8e4f8f-e163-4e93-ac84-985b346f46e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_42e071e3-fcf5-4e5b-b1a4-f4fc0283b83f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_593cd9f1-1f35-49c5-bd6e-1a9f18f204de" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_42e071e3-fcf5-4e5b-b1a4-f4fc0283b83f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforBenefitfromIncomeTaxesforContinuingOperationsDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#IncomeTaxesComponentsoftheProvisionforBenefitfromIncomeTaxesforContinuingOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforBenefitfromIncomeTaxesforContinuingOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_94dedb3e-2352-4382-ac2a-4056620f8b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_9fc4fb7e-afa4-4373-b71d-2a01096aeaf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_94dedb3e-2352-4382-ac2a-4056620f8b3e" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_9fc4fb7e-afa4-4373-b71d-2a01096aeaf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_0a6f24fe-1f14-4aed-9e7f-406aa1ced91d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_94dedb3e-2352-4382-ac2a-4056620f8b3e" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_0a6f24fe-1f14-4aed-9e7f-406aa1ced91d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5c7f27ea-d85e-4b5c-a655-d00591e73724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_0a2c2e06-efa1-4fc5-b0f0-3dae1500da27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5c7f27ea-d85e-4b5c-a655-d00591e73724" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_0a2c2e06-efa1-4fc5-b0f0-3dae1500da27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_a81f334d-68ba-49fc-820e-c060cb91cbf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5c7f27ea-d85e-4b5c-a655-d00591e73724" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_a81f334d-68ba-49fc-820e-c060cb91cbf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_21d563d2-d0ff-4b85-a1db-41f45dab00f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e75dd589-2d90-43cd-90d3-6fe0cec2b56f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_21d563d2-d0ff-4b85-a1db-41f45dab00f5" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e75dd589-2d90-43cd-90d3-6fe0cec2b56f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_dccd6a78-82e7-40b1-ab56-87a7dd97f009" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_21d563d2-d0ff-4b85-a1db-41f45dab00f5" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_dccd6a78-82e7-40b1-ab56-87a7dd97f009" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_899071f0-d7ff-43f6-a2fe-ba9d85ef87d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_37b2d639-61e6-47a7-86ac-977f427ce43b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_899071f0-d7ff-43f6-a2fe-ba9d85ef87d6" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_37b2d639-61e6-47a7-86ac-977f427ce43b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_876fdf53-09d9-478f-bd49-59bc7ba78dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_899071f0-d7ff-43f6-a2fe-ba9d85ef87d6" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_876fdf53-09d9-478f-bd49-59bc7ba78dd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee_6bf579ce-0b8f-497e-b39f-9b2e6da7298d" xlink:href="nbix-20221231.xsd#nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_899071f0-d7ff-43f6-a2fe-ba9d85ef87d6" xlink:to="loc_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee_6bf579ce-0b8f-497e-b39f-9b2e6da7298d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_232d1dbd-7313-4bbc-afd7-9465e111df00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_899071f0-d7ff-43f6-a2fe-ba9d85ef87d6" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_232d1dbd-7313-4bbc-afd7-9465e111df00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost_f9376686-6db9-4a31-a832-e31715ab1baa" xlink:href="nbix-20221231.xsd#nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_899071f0-d7ff-43f6-a2fe-ba9d85ef87d6" xlink:to="loc_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost_f9376686-6db9-4a31-a832-e31715ab1baa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_243fbea1-d766-45be-8a8f-56b95478cf1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_899071f0-d7ff-43f6-a2fe-ba9d85ef87d6" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_243fbea1-d766-45be-8a8f-56b95478cf1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxReconciliationExpirationOfTaxCredits_c4b28222-2b53-44b9-9b61-b2907ee85a12" xlink:href="nbix-20221231.xsd#nbix_IncomeTaxReconciliationExpirationOfTaxCredits"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_899071f0-d7ff-43f6-a2fe-ba9d85ef87d6" xlink:to="loc_nbix_IncomeTaxReconciliationExpirationOfTaxCredits_c4b28222-2b53-44b9-9b61-b2907ee85a12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_eee0450e-3566-4a34-b840-0237a70d2d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_899071f0-d7ff-43f6-a2fe-ba9d85ef87d6" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_eee0450e-3566-4a34-b840-0237a70d2d1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_8f42c8d6-054e-4897-babe-55e1082cef2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_899071f0-d7ff-43f6-a2fe-ba9d85ef87d6" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_8f42c8d6-054e-4897-babe-55e1082cef2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_d01c92db-add5-4c0e-a5a2-ad331cf68f03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_899071f0-d7ff-43f6-a2fe-ba9d85ef87d6" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_d01c92db-add5-4c0e-a5a2-ad331cf68f03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes_176deb35-8ab7-4795-b949-1117e04bfbd9" xlink:href="nbix-20221231.xsd#nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_899071f0-d7ff-43f6-a2fe-ba9d85ef87d6" xlink:to="loc_nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes_176deb35-8ab7-4795-b949-1117e04bfbd9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#IncomeTaxesComponentsofDeferredTaxAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_09edfeb5-272f-4a1e-a788-822d2dfd810f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_4059d621-a35b-4d72-91bf-f33b66689da5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_09edfeb5-272f-4a1e-a788-822d2dfd810f" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_4059d621-a35b-4d72-91bf-f33b66689da5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxAssetsLiabilitiesGross_c5175ff5-685a-485f-8be5-fbc248e19bfa" xlink:href="nbix-20221231.xsd#nbix_DeferredTaxAssetsLiabilitiesGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_09edfeb5-272f-4a1e-a788-822d2dfd810f" xlink:to="loc_nbix_DeferredTaxAssetsLiabilitiesGross_c5175ff5-685a-485f-8be5-fbc248e19bfa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_8e0fcc24-6386-4cdf-8cfb-c1dabfcfe4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_c27cb132-8e7e-485a-8bae-abd56246de97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_8e0fcc24-6386-4cdf-8cfb-c1dabfcfe4b8" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_c27cb132-8e7e-485a-8bae-abd56246de97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities_8a4e013e-0a85-4be8-a601-290bc657ecad" xlink:href="nbix-20221231.xsd#nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_8e0fcc24-6386-4cdf-8cfb-c1dabfcfe4b8" xlink:to="loc_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities_8a4e013e-0a85-4be8-a601-290bc657ecad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes_2dcfcfa7-5e07-4a00-8e19-6368ee564c68" xlink:href="nbix-20221231.xsd#nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_8e0fcc24-6386-4cdf-8cfb-c1dabfcfe4b8" xlink:to="loc_nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes_2dcfcfa7-5e07-4a00-8e19-6368ee564c68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxAssetsLiabilitiesGross_c03b751e-aa6a-4d7e-8578-96d62218aa6c" xlink:href="nbix-20221231.xsd#nbix_DeferredTaxAssetsLiabilitiesGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_cfa70ac9-c314-43ff-bd3e-04d1d199bdd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nbix_DeferredTaxAssetsLiabilitiesGross_c03b751e-aa6a-4d7e-8578-96d62218aa6c" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_cfa70ac9-c314-43ff-bd3e-04d1d199bdd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_08d4b07c-d338-4941-9357-f307ed769c43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nbix_DeferredTaxAssetsLiabilitiesGross_c03b751e-aa6a-4d7e-8578-96d62218aa6c" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_08d4b07c-d338-4941-9357-f307ed769c43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_364359d1-05e0-4632-a473-3791690a8c38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_58ae46a8-4af3-4d1c-a515-02f547f14ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_364359d1-05e0-4632-a473-3791690a8c38" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_58ae46a8-4af3-4d1c-a515-02f547f14ab5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_3787f5d4-7041-477d-a5da-b14053484cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_364359d1-05e0-4632-a473-3791690a8c38" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_3787f5d4-7041-477d-a5da-b14053484cdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_1399b5f1-6f0c-4dec-9bc7-85e1de42de77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_364359d1-05e0-4632-a473-3791690a8c38" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_1399b5f1-6f0c-4dec-9bc7-85e1de42de77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxAssetsOperatingLeasesAssets_fd9d14b1-6eed-4af0-8cc0-c73ecb5690e7" xlink:href="nbix-20221231.xsd#nbix_DeferredTaxAssetsOperatingLeasesAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_364359d1-05e0-4632-a473-3791690a8c38" xlink:to="loc_nbix_DeferredTaxAssetsOperatingLeasesAssets_fd9d14b1-6eed-4af0-8cc0-c73ecb5690e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_9206437b-1d0d-451f-b906-d3c79dd15f02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_364359d1-05e0-4632-a473-3791690a8c38" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_9206437b-1d0d-451f-b906-d3c79dd15f02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_a30e249c-8c1a-42a7-b734-5224e6eecdb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_364359d1-05e0-4632-a473-3791690a8c38" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_a30e249c-8c1a-42a7-b734-5224e6eecdb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment_e23f1236-cb26-4d66-8ba2-2ef9389d7d20" xlink:href="nbix-20221231.xsd#nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_364359d1-05e0-4632-a473-3791690a8c38" xlink:to="loc_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment_e23f1236-cb26-4d66-8ba2-2ef9389d7d20" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0a0b4781-fdab-4ee9-8b28-2991076ea4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_27575c3f-da0b-4b81-8634-1a5f828f9dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_0a0b4781-fdab-4ee9-8b28-2991076ea4a6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_27575c3f-da0b-4b81-8634-1a5f828f9dd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b5dab314-82b8-48e5-a82d-6a8c20f41dde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_0a0b4781-fdab-4ee9-8b28-2991076ea4a6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b5dab314-82b8-48e5-a82d-6a8c20f41dde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ae4da4dc-6fa6-4eff-aa65-be933c8fe038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7bbc0183-29a2-4237-9244-34aea2183453" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ae4da4dc-6fa6-4eff-aa65-be933c8fe038" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7bbc0183-29a2-4237-9244-34aea2183453" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c6164a3c-6b11-48e9-92a1-8dd2201328b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ae4da4dc-6fa6-4eff-aa65-be933c8fe038" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c6164a3c-6b11-48e9-92a1-8dd2201328b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e82f0e3e-b2ae-45c5-9077-663d9e6f8f01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ae4da4dc-6fa6-4eff-aa65-be933c8fe038" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e82f0e3e-b2ae-45c5-9077-663d9e6f8f01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e3bd844e-f628-43e0-b248-7d481c6fc2c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ae4da4dc-6fa6-4eff-aa65-be933c8fe038" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e3bd844e-f628-43e0-b248-7d481c6fc2c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f15fc4f9-efae-493f-84c2-246080d0dd11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ae4da4dc-6fa6-4eff-aa65-be933c8fe038" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f15fc4f9-efae-493f-84c2-246080d0dd11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_c22b07fe-0807-4aa4-a3bd-6dd8c7c46485" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ae4da4dc-6fa6-4eff-aa65-be933c8fe038" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_c22b07fe-0807-4aa4-a3bd-6dd8c7c46485" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="nbix-20221231.xsd#LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9c9e061c-88b5-4b5b-a59c-ec766bb4b3b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_69ed8752-1fbd-45d5-a74c-b8715efef57b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9c9e061c-88b5-4b5b-a59c-ec766bb4b3b5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_69ed8752-1fbd-45d5-a74c-b8715efef57b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_4476530f-a3ed-4cb5-8226-b19f79fd6b37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9c9e061c-88b5-4b5b-a59c-ec766bb4b3b5" xlink:to="loc_us-gaap_OperatingLeaseLiability_4476530f-a3ed-4cb5-8226-b19f79fd6b37" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>nbix-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:218564f8-ce6a-495b-ab09-3ced376fc2a9,g:579af41c-0e49-45b3-bd8f-934603ccb3b3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome" xlink:type="simple" xlink:href="nbix-20221231.xsd#ConsolidatedStatementsIncomeandComprehensiveIncome"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome" xlink:type="extended" id="i6b9b7a237698477c91f595715f4fbcd1_ConsolidatedStatementsIncomeandComprehensiveIncome">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b957fe5d-0d3a-4afb-a03a-b241273ffe3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_ef801057-f321-42d4-ab6c-bb289c24401e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b957fe5d-0d3a-4afb-a03a-b241273ffe3b" xlink:to="loc_us-gaap_RevenuesAbstract_ef801057-f321-42d4-ab6c-bb289c24401e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_71e927fc-da3d-40cf-869a-619075f3e55c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_ef801057-f321-42d4-ab6c-bb289c24401e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_71e927fc-da3d-40cf-869a-619075f3e55c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_5e581b89-69fc-4ca4-bd5f-aa226e828ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b957fe5d-0d3a-4afb-a03a-b241273ffe3b" xlink:to="loc_us-gaap_OperatingExpensesAbstract_5e581b89-69fc-4ca4-bd5f-aa226e828ed6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_2db18781-2bd3-44d8-9a65-5636363791be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5e581b89-69fc-4ca4-bd5f-aa226e828ed6" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_2db18781-2bd3-44d8-9a65-5636363791be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_cdf4805e-30c9-4a1a-9d5c-aff5792bd45a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5e581b89-69fc-4ca4-bd5f-aa226e828ed6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_cdf4805e-30c9-4a1a-9d5c-aff5792bd45a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_a28c0051-3fc5-46ec-9f20-54cf47528a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5e581b89-69fc-4ca4-bd5f-aa226e828ed6" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_a28c0051-3fc5-46ec-9f20-54cf47528a4c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e152d143-4680-4d18-98f5-1f188c93f9b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5e581b89-69fc-4ca4-bd5f-aa226e828ed6" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e152d143-4680-4d18-98f5-1f188c93f9b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_38ec8462-af9d-4ade-b344-3ee0551f72c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5e581b89-69fc-4ca4-bd5f-aa226e828ed6" xlink:to="loc_us-gaap_CostsAndExpenses_38ec8462-af9d-4ade-b344-3ee0551f72c6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b1b2ca7e-5410-47dc-872c-83c98faa9b76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b957fe5d-0d3a-4afb-a03a-b241273ffe3b" xlink:to="loc_us-gaap_OperatingIncomeLoss_b1b2ca7e-5410-47dc-872c-83c98faa9b76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1a09db29-e143-4f04-897e-7e3a4b504630" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b957fe5d-0d3a-4afb-a03a-b241273ffe3b" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1a09db29-e143-4f04-897e-7e3a4b504630" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_7277d66f-93a3-4d45-bf83-b8d14163afd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1a09db29-e143-4f04-897e-7e3a4b504630" xlink:to="loc_us-gaap_InterestExpense_7277d66f-93a3-4d45-bf83-b8d14163afd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_5f7a23c3-14ba-4051-b04e-e459aa3ab74d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1a09db29-e143-4f04-897e-7e3a4b504630" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_5f7a23c3-14ba-4051-b04e-e459aa3ab74d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5d840516-b173-4f03-96a8-98aca0a3b624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1a09db29-e143-4f04-897e-7e3a4b504630" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5d840516-b173-4f03-96a8-98aca0a3b624" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_InvestmentIncomeAndOtherNet_7f084553-50d1-4094-a334-fb7cfb959ccd" xlink:href="nbix-20221231.xsd#nbix_InvestmentIncomeAndOtherNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1a09db29-e143-4f04-897e-7e3a4b504630" xlink:to="loc_nbix_InvestmentIncomeAndOtherNet_7f084553-50d1-4094-a334-fb7cfb959ccd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d858a5bb-dd61-4549-aa32-171175c679c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1a09db29-e143-4f04-897e-7e3a4b504630" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_d858a5bb-dd61-4549-aa32-171175c679c4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bd7a2469-749e-4ea9-93ff-2888cb6f5310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b957fe5d-0d3a-4afb-a03a-b241273ffe3b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bd7a2469-749e-4ea9-93ff-2888cb6f5310" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_78b43164-9592-4f89-aa35-59b6c96d520f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b957fe5d-0d3a-4afb-a03a-b241273ffe3b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_78b43164-9592-4f89-aa35-59b6c96d520f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7e20e9bb-08db-4b11-8f9d-1970ef5b835b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b957fe5d-0d3a-4afb-a03a-b241273ffe3b" xlink:to="loc_us-gaap_NetIncomeLoss_7e20e9bb-08db-4b11-8f9d-1970ef5b835b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_f70fa1b4-17db-449d-bbb6-63c65ab23fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b957fe5d-0d3a-4afb-a03a-b241273ffe3b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_f70fa1b4-17db-449d-bbb6-63c65ab23fc5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_f7c56ae2-f761-43da-a069-889bddc48bad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b957fe5d-0d3a-4afb-a03a-b241273ffe3b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_f7c56ae2-f761-43da-a069-889bddc48bad" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b304f1d3-b81d-4eac-8a85-7ee46b6decd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b957fe5d-0d3a-4afb-a03a-b241273ffe3b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_b304f1d3-b81d-4eac-8a85-7ee46b6decd6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_cc6fd776-2b12-43d6-8fe0-355e636ef984" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b957fe5d-0d3a-4afb-a03a-b241273ffe3b" xlink:to="loc_us-gaap_EarningsPerShareBasic_cc6fd776-2b12-43d6-8fe0-355e636ef984" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3a912ee9-bf2e-409f-8f2e-5282c310f469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b957fe5d-0d3a-4afb-a03a-b241273ffe3b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3a912ee9-bf2e-409f-8f2e-5282c310f469" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c7ea1029-26bd-4b7a-aef4-f9c774d68cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b957fe5d-0d3a-4afb-a03a-b241273ffe3b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c7ea1029-26bd-4b7a-aef4-f9c774d68cbf" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_feff7f5d-6ba7-41c9-aef5-09ad6daa743e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b957fe5d-0d3a-4afb-a03a-b241273ffe3b" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_feff7f5d-6ba7-41c9-aef5-09ad6daa743e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f59e56a7-4dfa-460d-b70b-db29763ab688" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b957fe5d-0d3a-4afb-a03a-b241273ffe3b" xlink:to="loc_us-gaap_StatementTable_f59e56a7-4dfa-460d-b70b-db29763ab688" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b6c33f1b-01fc-4e8b-b23c-0c65a5ec93ac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f59e56a7-4dfa-460d-b70b-db29763ab688" xlink:to="loc_srt_ProductOrServiceAxis_b6c33f1b-01fc-4e8b-b23c-0c65a5ec93ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b6c33f1b-01fc-4e8b-b23c-0c65a5ec93ac_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b6c33f1b-01fc-4e8b-b23c-0c65a5ec93ac" xlink:to="loc_srt_ProductsAndServicesDomain_b6c33f1b-01fc-4e8b-b23c-0c65a5ec93ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_62d90ddf-293d-46b6-819f-2c834ad6861e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b6c33f1b-01fc-4e8b-b23c-0c65a5ec93ac" xlink:to="loc_srt_ProductsAndServicesDomain_62d90ddf-293d-46b6-819f-2c834ad6861e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_9b0d10ad-242e-4e23-976a-a34064f3a439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_62d90ddf-293d-46b6-819f-2c834ad6861e" xlink:to="loc_us-gaap_ProductMember_9b0d10ad-242e-4e23-976a-a34064f3a439" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CollaborationRevenueMember_6d2b2813-2950-4349-8aba-5ae853f19536" xlink:href="nbix-20221231.xsd#nbix_CollaborationRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_62d90ddf-293d-46b6-819f-2c834ad6861e" xlink:to="loc_nbix_CollaborationRevenueMember_6d2b2813-2950-4349-8aba-5ae853f19536" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="nbix-20221231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i5339aaad99bf46cabdfbd327a148e6b4_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_93486757-f237-4e22-9680-9e8785d2dff5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8e67a80-41b3-4721-a158-8a405e06f4af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_93486757-f237-4e22-9680-9e8785d2dff5" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8e67a80-41b3-4721-a158-8a405e06f4af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_e067ef10-48dc-4475-96f5-8c10e0504af9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8e67a80-41b3-4721-a158-8a405e06f4af" xlink:to="loc_us-gaap_SharesOutstanding_e067ef10-48dc-4475-96f5-8c10e0504af9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2a01ff76-b3a7-4c3a-905b-6368cd75d3a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8e67a80-41b3-4721-a158-8a405e06f4af" xlink:to="loc_us-gaap_StockholdersEquity_2a01ff76-b3a7-4c3a-905b-6368cd75d3a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e7dfdbc8-3a2c-45f9-a973-edcf1c92bf34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8e67a80-41b3-4721-a158-8a405e06f4af" xlink:to="loc_us-gaap_NetIncomeLoss_e7dfdbc8-3a2c-45f9-a973-edcf1c92bf34" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4e9dbd9a-c4ea-486b-bdcd-3b50a158a3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8e67a80-41b3-4721-a158-8a405e06f4af" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4e9dbd9a-c4ea-486b-bdcd-3b50a158a3dc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_7c2e7684-42b8-48a2-b375-c0912419935e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8e67a80-41b3-4721-a158-8a405e06f4af" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_7c2e7684-42b8-48a2-b375-c0912419935e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fb079de9-c08b-4049-a279-0ab53cd7958d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8e67a80-41b3-4721-a158-8a405e06f4af" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fb079de9-c08b-4049-a279-0ab53cd7958d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_a4873851-15d2-4208-a4f1-6ebf3a7f481a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8e67a80-41b3-4721-a158-8a405e06f4af" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_a4873851-15d2-4208-a4f1-6ebf3a7f481a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0226eb52-75f3-48f7-bbc6-36ae3ec4f67b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8e67a80-41b3-4721-a158-8a405e06f4af" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0226eb52-75f3-48f7-bbc6-36ae3ec4f67b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_369a1a47-7acb-473a-8bb6-d5f9b5d65c95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8e67a80-41b3-4721-a158-8a405e06f4af" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_369a1a47-7acb-473a-8bb6-d5f9b5d65c95" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_f09fe8ed-0e58-4383-9ca0-fa9066658c84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c02e0acd-3449-4397-aa58-b9f3200818d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2bdc662a-18c1-481d-8d8e-d8612e5c4d07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_93486757-f237-4e22-9680-9e8785d2dff5" xlink:to="loc_us-gaap_StatementTable_2bdc662a-18c1-481d-8d8e-d8612e5c4d07" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6a1f3438-c881-40ff-9d72-d19a563f3358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2bdc662a-18c1-481d-8d8e-d8612e5c4d07" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6a1f3438-c881-40ff-9d72-d19a563f3358" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6a1f3438-c881-40ff-9d72-d19a563f3358_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6a1f3438-c881-40ff-9d72-d19a563f3358" xlink:to="loc_us-gaap_EquityComponentDomain_6a1f3438-c881-40ff-9d72-d19a563f3358_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_903034ef-4a2e-4f8d-a706-993893053047" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6a1f3438-c881-40ff-9d72-d19a563f3358" xlink:to="loc_us-gaap_EquityComponentDomain_903034ef-4a2e-4f8d-a706-993893053047" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_976b120c-c66d-4b87-b4b4-4cce72a35747" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_903034ef-4a2e-4f8d-a706-993893053047" xlink:to="loc_us-gaap_CommonStockMember_976b120c-c66d-4b87-b4b4-4cce72a35747" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e1c444aa-26fd-4318-bf7f-95e2a3c64257" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_903034ef-4a2e-4f8d-a706-993893053047" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e1c444aa-26fd-4318-bf7f-95e2a3c64257" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_976747a1-5ebe-480f-87b7-a49b3a4f45e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_903034ef-4a2e-4f8d-a706-993893053047" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_976747a1-5ebe-480f-87b7-a49b3a4f45e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_80096f60-5df8-4a20-9250-dbe1d009b38a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_903034ef-4a2e-4f8d-a706-993893053047" xlink:to="loc_us-gaap_RetainedEarningsMember_80096f60-5df8-4a20-9250-dbe1d009b38a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c885c7e6-f78f-4960-8586-60843c3fc1a7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2bdc662a-18c1-481d-8d8e-d8612e5c4d07" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c885c7e6-f78f-4960-8586-60843c3fc1a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c885c7e6-f78f-4960-8586-60843c3fc1a7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c885c7e6-f78f-4960-8586-60843c3fc1a7" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c885c7e6-f78f-4960-8586-60843c3fc1a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3b1a950f-5043-4b94-8935-2e210ada5c56" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c885c7e6-f78f-4960-8586-60843c3fc1a7" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3b1a950f-5043-4b94-8935-2e210ada5c56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_d5be8c37-fa9b-432b-b7a5-82d50b3b8c29" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3b1a950f-5043-4b94-8935-2e210ada5c56" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_d5be8c37-fa9b-432b-b7a5-82d50b3b8c29" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" id="if207ba08d3eb4a288e64851c43d3c953_OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f82cd718-9616-4113-a626-3e44ef056274" xlink:href="nbix-20221231.xsd#nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_aac8f30f-3d97-4b38-832b-643f07f4356f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f82cd718-9616-4113-a626-3e44ef056274" xlink:to="loc_us-gaap_NumberOfOperatingSegments_aac8f30f-3d97-4b38-832b-643f07f4356f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_3f435bfa-1bd1-450c-98d0-8f7a994e0b74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f82cd718-9616-4113-a626-3e44ef056274" xlink:to="loc_us-gaap_NumberOfReportableSegments_3f435bfa-1bd1-450c-98d0-8f7a994e0b74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff_655bfabb-c47c-4621-85a0-091a8bafb903" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f82cd718-9616-4113-a626-3e44ef056274" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff_655bfabb-c47c-4621-85a0-091a8bafb903" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_4a3ccff0-375b-4d4b-a178-b244c4c2af0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f82cd718-9616-4113-a626-3e44ef056274" xlink:to="loc_us-gaap_InterestReceivableCurrent_4a3ccff0-375b-4d4b-a178-b244c4c2af0c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff_28683ca7-eba4-43d2-aa8f-1c27b5403df9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f82cd718-9616-4113-a626-3e44ef056274" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff_28683ca7-eba4-43d2-aa8f-1c27b5403df9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2de744e2-1547-4d6f-b694-1365744c602c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f82cd718-9616-4113-a626-3e44ef056274" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2de744e2-1547-4d6f-b694-1365744c602c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_af700e1c-98aa-4266-bd90-e227d2c287c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f82cd718-9616-4113-a626-3e44ef056274" xlink:to="loc_us-gaap_Depreciation_af700e1c-98aa-4266-bd90-e227d2c287c8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_4ea72fb4-0ddf-4007-a64f-32be1177246d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f82cd718-9616-4113-a626-3e44ef056274" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_4ea72fb4-0ddf-4007-a64f-32be1177246d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_272e4b0f-6122-4cd1-a992-79c2e3407c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f82cd718-9616-4113-a626-3e44ef056274" xlink:to="loc_us-gaap_AdvertisingExpense_272e4b0f-6122-4cd1-a992-79c2e3407c5d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_882dd55b-77b8-4152-a5c0-1d1994a09a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f82cd718-9616-4113-a626-3e44ef056274" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_882dd55b-77b8-4152-a5c0-1d1994a09a5c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ESPPPurchasePeriod_bbe176f2-c842-4e7e-9353-8bce17901f12" xlink:href="nbix-20221231.xsd#nbix_ESPPPurchasePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f82cd718-9616-4113-a626-3e44ef056274" xlink:to="loc_nbix_ESPPPurchasePeriod_bbe176f2-c842-4e7e-9353-8bce17901f12" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_cebb7610-fbd7-4882-a22d-be4d39738ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f82cd718-9616-4113-a626-3e44ef056274" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_cebb7610-fbd7-4882-a22d-be4d39738ef7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_669ed098-29e4-443d-94c1-db4fa7e33d84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f82cd718-9616-4113-a626-3e44ef056274" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_669ed098-29e4-443d-94c1-db4fa7e33d84" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_bd88e5db-f22d-4031-9036-a3042d019511" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f82cd718-9616-4113-a626-3e44ef056274" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_bd88e5db-f22d-4031-9036-a3042d019511" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_dbab798f-02ce-4c10-99dc-e7c9e02ec6b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f82cd718-9616-4113-a626-3e44ef056274" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_dbab798f-02ce-4c10-99dc-e7c9e02ec6b5" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_23e8b191-9312-43cd-a5c5-8ee5401fc022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f82cd718-9616-4113-a626-3e44ef056274" xlink:to="loc_us-gaap_AdditionalPaidInCapital_23e8b191-9312-43cd-a5c5-8ee5401fc022" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2f1b0d85-9e3c-4269-89ad-5cdc498bc307" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f82cd718-9616-4113-a626-3e44ef056274" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2f1b0d85-9e3c-4269-89ad-5cdc498bc307" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_e53b27b8-eaee-4b72-bf68-0b1b2ef94b3c" xlink:href="nbix-20221231.xsd#nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f82cd718-9616-4113-a626-3e44ef056274" xlink:to="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_e53b27b8-eaee-4b72-bf68-0b1b2ef94b3c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a1eae3d6-d161-46e8-93ad-cf9b5f2d943b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_e53b27b8-eaee-4b72-bf68-0b1b2ef94b3c" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a1eae3d6-d161-46e8-93ad-cf9b5f2d943b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a1eae3d6-d161-46e8-93ad-cf9b5f2d943b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a1eae3d6-d161-46e8-93ad-cf9b5f2d943b" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a1eae3d6-d161-46e8-93ad-cf9b5f2d943b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_80f3bd1d-7dc8-452c-a983-a127a4255d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a1eae3d6-d161-46e8-93ad-cf9b5f2d943b" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_80f3bd1d-7dc8-452c-a983-a127a4255d3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember_254df914-23c3-4cda-b7e3-8cec19653691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_80f3bd1d-7dc8-452c-a983-a127a4255d3c" xlink:to="loc_us-gaap_SalesRevenueProductLineMember_254df914-23c3-4cda-b7e3-8cec19653691" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_cc0d4296-2a3b-4c81-914f-9b75eed27ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_80f3bd1d-7dc8-452c-a983-a127a4255d3c" xlink:to="loc_us-gaap_AccountsReceivableMember_cc0d4296-2a3b-4c81-914f-9b75eed27ce6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_243294bc-bc0f-4930-ae27-4fd471e4fa27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_e53b27b8-eaee-4b72-bf68-0b1b2ef94b3c" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_243294bc-bc0f-4930-ae27-4fd471e4fa27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_243294bc-bc0f-4930-ae27-4fd471e4fa27_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_243294bc-bc0f-4930-ae27-4fd471e4fa27" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_243294bc-bc0f-4930-ae27-4fd471e4fa27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_677a618e-a331-4f16-9004-e63ee26f757f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_243294bc-bc0f-4930-ae27-4fd471e4fa27" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_677a618e-a331-4f16-9004-e63ee26f757f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_5e8e6163-20ef-4bf4-bad9-7bf709ed81b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_677a618e-a331-4f16-9004-e63ee26f757f" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_5e8e6163-20ef-4bf4-bad9-7bf709ed81b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_9afc1b66-ba1d-49f4-82c0-87caea0a6efd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_e53b27b8-eaee-4b72-bf68-0b1b2ef94b3c" xlink:to="loc_srt_MajorCustomersAxis_9afc1b66-ba1d-49f4-82c0-87caea0a6efd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_9afc1b66-ba1d-49f4-82c0-87caea0a6efd_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_9afc1b66-ba1d-49f4-82c0-87caea0a6efd" xlink:to="loc_srt_NameOfMajorCustomerDomain_9afc1b66-ba1d-49f4-82c0-87caea0a6efd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_4a3c3eb8-b743-4855-ac59-6687d457c9a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_9afc1b66-ba1d-49f4-82c0-87caea0a6efd" xlink:to="loc_srt_NameOfMajorCustomerDomain_4a3c3eb8-b743-4855-ac59-6687d457c9a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LargestFourCustomersMember_978cd781-5c11-4098-8901-fa9b1a9a1513" xlink:href="nbix-20221231.xsd#nbix_LargestFourCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_4a3c3eb8-b743-4855-ac59-6687d457c9a4" xlink:to="loc_nbix_LargestFourCustomersMember_978cd781-5c11-4098-8901-fa9b1a9a1513" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8638ecfd-e1a5-4a20-a88d-1804eaaa687b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_e53b27b8-eaee-4b72-bf68-0b1b2ef94b3c" xlink:to="loc_srt_RangeAxis_8638ecfd-e1a5-4a20-a88d-1804eaaa687b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8638ecfd-e1a5-4a20-a88d-1804eaaa687b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8638ecfd-e1a5-4a20-a88d-1804eaaa687b" xlink:to="loc_srt_RangeMember_8638ecfd-e1a5-4a20-a88d-1804eaaa687b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_208bc679-a255-47f5-a003-5c9875dd6cd8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8638ecfd-e1a5-4a20-a88d-1804eaaa687b" xlink:to="loc_srt_RangeMember_208bc679-a255-47f5-a003-5c9875dd6cd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_934bfd42-06ee-429b-afa2-4220a2b29525" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_208bc679-a255-47f5-a003-5c9875dd6cd8" xlink:to="loc_srt_MinimumMember_934bfd42-06ee-429b-afa2-4220a2b29525" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5ad12da5-4a69-4a3a-8c1d-c8410890f1e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_208bc679-a255-47f5-a003-5c9875dd6cd8" xlink:to="loc_srt_MaximumMember_5ad12da5-4a69-4a3a-8c1d-c8410890f1e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_397b9f37-3e06-4863-a004-54394654f374" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_e53b27b8-eaee-4b72-bf68-0b1b2ef94b3c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_397b9f37-3e06-4863-a004-54394654f374" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_397b9f37-3e06-4863-a004-54394654f374_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_397b9f37-3e06-4863-a004-54394654f374" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_397b9f37-3e06-4863-a004-54394654f374_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_eb9e6ea7-5031-4896-9af3-af14a7927e79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_397b9f37-3e06-4863-a004-54394654f374" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_eb9e6ea7-5031-4896-9af3-af14a7927e79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_e284b0f8-9644-4089-84b9-a24c4019456a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_eb9e6ea7-5031-4896-9af3-af14a7927e79" xlink:to="loc_us-gaap_EmployeeStockMember_e284b0f8-9644-4089-84b9-a24c4019456a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8ea0cd55-e8d7-43d3-93b1-a64f4a650a05" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_e53b27b8-eaee-4b72-bf68-0b1b2ef94b3c" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8ea0cd55-e8d7-43d3-93b1-a64f4a650a05" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_8ea0cd55-e8d7-43d3-93b1-a64f4a650a05_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8ea0cd55-e8d7-43d3-93b1-a64f4a650a05" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_8ea0cd55-e8d7-43d3-93b1-a64f4a650a05_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7293f16c-621c-49ac-aa36-66905ebc1a2b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8ea0cd55-e8d7-43d3-93b1-a64f4a650a05" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7293f16c-621c-49ac-aa36-66905ebc1a2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_eb75fd75-2286-499e-aef3-d81d75d5c277" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7293f16c-621c-49ac-aa36-66905ebc1a2b" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_eb75fd75-2286-499e-aef3-d81d75d5c277" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_0c24a072-0dc3-4d55-abae-72d6f68191c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_e53b27b8-eaee-4b72-bf68-0b1b2ef94b3c" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_0c24a072-0dc3-4d55-abae-72d6f68191c5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_0c24a072-0dc3-4d55-abae-72d6f68191c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_0c24a072-0dc3-4d55-abae-72d6f68191c5" xlink:to="loc_us-gaap_TypeOfAdoptionMember_0c24a072-0dc3-4d55-abae-72d6f68191c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_79c81dc9-14d7-4885-98fd-064eac5452af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_0c24a072-0dc3-4d55-abae-72d6f68191c5" xlink:to="loc_us-gaap_TypeOfAdoptionMember_79c81dc9-14d7-4885-98fd-064eac5452af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_aa004d14-4d9f-4efd-910d-15abf9db5d91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_79c81dc9-14d7-4885-98fd-064eac5452af" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_aa004d14-4d9f-4efd-910d-15abf9db5d91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_449e2099-5a01-46f9-b493-0284ae473be2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_e53b27b8-eaee-4b72-bf68-0b1b2ef94b3c" xlink:to="loc_us-gaap_DebtInstrumentAxis_449e2099-5a01-46f9-b493-0284ae473be2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_449e2099-5a01-46f9-b493-0284ae473be2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_449e2099-5a01-46f9-b493-0284ae473be2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_449e2099-5a01-46f9-b493-0284ae473be2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b4b8a53a-304c-4635-8d9f-715a5770b3bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_449e2099-5a01-46f9-b493-0284ae473be2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b4b8a53a-304c-4635-8d9f-715a5770b3bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_d965044b-faf0-4c98-a710-b19cc903933a" xlink:href="nbix-20221231.xsd#nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b4b8a53a-304c-4635-8d9f-715a5770b3bb" xlink:to="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_d965044b-faf0-4c98-a710-b19cc903933a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#CollaborationandLicenseAgreementsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="extended" id="i438149889cc74fd49fda2a17fb28c5d1_CollaborationandLicenseAgreementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d305027-323b-4b37-98dd-be7ce86f4495" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePayments_765178fe-dda9-47c1-a096-d5f3c0bf4b4f" xlink:href="nbix-20221231.xsd#nbix_PotentialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d305027-323b-4b37-98dd-be7ce86f4495" xlink:to="loc_nbix_PotentialMilestonePayments_765178fe-dda9-47c1-a096-d5f3c0bf4b4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_8d537767-7702-4655-b8e5-74b505c90e42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d305027-323b-4b37-98dd-be7ce86f4495" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_8d537767-7702-4655-b8e5-74b505c90e42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ddd628f5-e592-4944-a81d-a11a3e292334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d305027-323b-4b37-98dd-be7ce86f4495" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ddd628f5-e592-4944-a81d-a11a3e292334" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_UpfrontPaymentsMade_af59b76d-94a4-490a-b2da-a343dc113627" xlink:href="nbix-20221231.xsd#nbix_UpfrontPaymentsMade"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d305027-323b-4b37-98dd-be7ce86f4495" xlink:to="loc_nbix_UpfrontPaymentsMade_af59b76d-94a4-490a-b2da-a343dc113627" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SaleOfStockNumberOfSharesSoldInTransaction_87651c54-78bf-42f4-bf66-cf19f4c015b6" xlink:href="nbix-20221231.xsd#nbix_SaleOfStockNumberOfSharesSoldInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d305027-323b-4b37-98dd-be7ce86f4495" xlink:to="loc_nbix_SaleOfStockNumberOfSharesSoldInTransaction_87651c54-78bf-42f4-bf66-cf19f4c015b6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_9f9e5838-7b27-4aec-bf76-bdb0ca5d6981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d305027-323b-4b37-98dd-be7ce86f4495" xlink:to="loc_us-gaap_SharePrice_9f9e5838-7b27-4aec-bf76-bdb0ca5d6981" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_ed18d292-d613-4b83-a3c0-ec429dc32a19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d305027-323b-4b37-98dd-be7ce86f4495" xlink:to="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_ed18d292-d613-4b83-a3c0-ec429dc32a19" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MilestonePayment_f2951936-f827-4c1b-97ed-b4f23ce2a36f" xlink:href="nbix-20221231.xsd#nbix_MilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d305027-323b-4b37-98dd-be7ce86f4495" xlink:to="loc_nbix_MilestonePayment_f2951936-f827-4c1b-97ed-b4f23ce2a36f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_cc06ae4b-d35f-4219-8c8b-1089a92abcdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d305027-323b-4b37-98dd-be7ce86f4495" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_cc06ae4b-d35f-4219-8c8b-1089a92abcdd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eb0eb513-ff97-4793-a46b-ae2c3d7d3d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d305027-323b-4b37-98dd-be7ce86f4495" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eb0eb513-ff97-4793-a46b-ae2c3d7d3d6b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePaymentReceipts_e78316e5-30e6-4d09-a844-d545b295a52f" xlink:href="nbix-20221231.xsd#nbix_PotentialMilestonePaymentReceipts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d305027-323b-4b37-98dd-be7ce86f4495" xlink:to="loc_nbix_PotentialMilestonePaymentReceipts_e78316e5-30e6-4d09-a844-d545b295a52f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PatentTerm_87fd52ee-68e4-4715-a486-c449abb725c0" xlink:href="nbix-20221231.xsd#nbix_PatentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d305027-323b-4b37-98dd-be7ce86f4495" xlink:to="loc_nbix_PatentTerm_87fd52ee-68e4-4715-a486-c449abb725c0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_816cf7b9-8f96-4ced-9073-78f2ab053d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d305027-323b-4b37-98dd-be7ce86f4495" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_816cf7b9-8f96-4ced-9073-78f2ab053d7c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_92664fcc-62b0-419f-b73c-85c062bac89f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_816cf7b9-8f96-4ced-9073-78f2ab053d7c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_92664fcc-62b0-419f-b73c-85c062bac89f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_92664fcc-62b0-419f-b73c-85c062bac89f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_92664fcc-62b0-419f-b73c-85c062bac89f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_92664fcc-62b0-419f-b73c-85c062bac89f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_27cd5efb-97a7-43e1-85df-61b506ae5b00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_92664fcc-62b0-419f-b73c-85c062bac89f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_27cd5efb-97a7-43e1-85df-61b506ae5b00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_73874fe1-4f9e-40ce-b603-ae05bfd35027" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_27cd5efb-97a7-43e1-85df-61b506ae5b00" xlink:to="loc_us-gaap_CollaborativeArrangementMember_73874fe1-4f9e-40ce-b603-ae05bfd35027" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d3705300-36d7-4d49-8f67-82220ac9b74c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_816cf7b9-8f96-4ced-9073-78f2ab053d7c" xlink:to="loc_srt_CounterpartyNameAxis_d3705300-36d7-4d49-8f67-82220ac9b74c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d3705300-36d7-4d49-8f67-82220ac9b74c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d3705300-36d7-4d49-8f67-82220ac9b74c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d3705300-36d7-4d49-8f67-82220ac9b74c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f2c9d4a4-f1f1-40ce-b39e-5b644fa090ab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d3705300-36d7-4d49-8f67-82220ac9b74c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f2c9d4a4-f1f1-40ce-b39e-5b644fa090ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_HeptaresTherapeuticsLimitedMember_2140e680-fc4e-45a6-9586-e1ea7e9f613f" xlink:href="nbix-20221231.xsd#nbix_HeptaresTherapeuticsLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f2c9d4a4-f1f1-40ce-b39e-5b644fa090ab" xlink:to="loc_nbix_HeptaresTherapeuticsLimitedMember_2140e680-fc4e-45a6-9586-e1ea7e9f613f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember_a0e7486d-0f5b-4ad3-853f-e4e35e4f9bb2" xlink:href="nbix-20221231.xsd#nbix_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f2c9d4a4-f1f1-40ce-b39e-5b644fa090ab" xlink:to="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember_a0e7486d-0f5b-4ad3-853f-e4e35e4f9bb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IdorsiaPharmaceuticalsLtdMember_2f273359-95c0-4122-8ec9-b6507c71b111" xlink:href="nbix-20221231.xsd#nbix_IdorsiaPharmaceuticalsLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f2c9d4a4-f1f1-40ce-b39e-5b644fa090ab" xlink:to="loc_nbix_IdorsiaPharmaceuticalsLtdMember_2f273359-95c0-4122-8ec9-b6507c71b111" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_XenonPharmaceuticalsIncMember_6e96012e-57e4-4b4c-9608-d235fae6dd14" xlink:href="nbix-20221231.xsd#nbix_XenonPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f2c9d4a4-f1f1-40ce-b39e-5b644fa090ab" xlink:to="loc_nbix_XenonPharmaceuticalsIncMember_6e96012e-57e4-4b4c-9608-d235fae6dd14" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_VoyagerTherapeuticsMember_eb88eceb-4c1f-4aa1-8905-5a93c2d0e053" xlink:href="nbix-20221231.xsd#nbix_VoyagerTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f2c9d4a4-f1f1-40ce-b39e-5b644fa090ab" xlink:to="loc_nbix_VoyagerTherapeuticsMember_eb88eceb-4c1f-4aa1-8905-5a93c2d0e053" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BIALPortelaCaSAMember_43845a5c-bc66-4ac9-a349-1ec08333e5e6" xlink:href="nbix-20221231.xsd#nbix_BIALPortelaCaSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f2c9d4a4-f1f1-40ce-b39e-5b644fa090ab" xlink:to="loc_nbix_BIALPortelaCaSAMember_43845a5c-bc66-4ac9-a349-1ec08333e5e6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MitsubishiTanabePharmaCorporationMember_7047fca4-8e34-44a7-8618-768168a08938" xlink:href="nbix-20221231.xsd#nbix_MitsubishiTanabePharmaCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f2c9d4a4-f1f1-40ce-b39e-5b644fa090ab" xlink:to="loc_nbix_MitsubishiTanabePharmaCorporationMember_7047fca4-8e34-44a7-8618-768168a08938" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AbbVieIncMember_566e1869-12b5-4e5a-a2e9-d6b80fb0672f" xlink:href="nbix-20221231.xsd#nbix_AbbVieIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f2c9d4a4-f1f1-40ce-b39e-5b644fa090ab" xlink:to="loc_nbix_AbbVieIncMember_566e1869-12b5-4e5a-a2e9-d6b80fb0672f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_30d0f4d2-62e2-41fd-b914-91c41d93d1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_816cf7b9-8f96-4ced-9073-78f2ab053d7c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_30d0f4d2-62e2-41fd-b914-91c41d93d1d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_30d0f4d2-62e2-41fd-b914-91c41d93d1d0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_30d0f4d2-62e2-41fd-b914-91c41d93d1d0" xlink:to="loc_us-gaap_EquityComponentDomain_30d0f4d2-62e2-41fd-b914-91c41d93d1d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cba7f0bd-ea6e-4558-ba68-7a79784cc27c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_30d0f4d2-62e2-41fd-b914-91c41d93d1d0" xlink:to="loc_us-gaap_EquityComponentDomain_cba7f0bd-ea6e-4558-ba68-7a79784cc27c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_837ad5fc-3f6b-46bf-a561-09fdd7a48862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cba7f0bd-ea6e-4558-ba68-7a79784cc27c" xlink:to="loc_us-gaap_CommonStockMember_837ad5fc-3f6b-46bf-a561-09fdd7a48862" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a63a95d0-ce49-487b-a4a7-46352a109eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_816cf7b9-8f96-4ced-9073-78f2ab053d7c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a63a95d0-ce49-487b-a4a7-46352a109eb8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a63a95d0-ce49-487b-a4a7-46352a109eb8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a63a95d0-ce49-487b-a4a7-46352a109eb8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a63a95d0-ce49-487b-a4a7-46352a109eb8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a0bed962-05ed-4e3b-8440-3c8fd9c54e27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a63a95d0-ce49-487b-a4a7-46352a109eb8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a0bed962-05ed-4e3b-8440-3c8fd9c54e27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_426c9f8c-21ca-47aa-bd3f-e0b4b00067d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a0bed962-05ed-4e3b-8440-3c8fd9c54e27" xlink:to="loc_us-gaap_PatentsMember_426c9f8c-21ca-47aa-bd3f-e0b4b00067d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9e0421bc-3b07-46df-b747-6f80142ea738" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_816cf7b9-8f96-4ced-9073-78f2ab053d7c" xlink:to="loc_srt_ProductOrServiceAxis_9e0421bc-3b07-46df-b747-6f80142ea738" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9e0421bc-3b07-46df-b747-6f80142ea738_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9e0421bc-3b07-46df-b747-6f80142ea738" xlink:to="loc_srt_ProductsAndServicesDomain_9e0421bc-3b07-46df-b747-6f80142ea738_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b65397e8-f351-4171-be9d-e8aa0c0883c9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9e0421bc-3b07-46df-b747-6f80142ea738" xlink:to="loc_srt_ProductsAndServicesDomain_b65397e8-f351-4171-be9d-e8aa0c0883c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_04a2e68d-3f19-4010-a4c0-af377dec8182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b65397e8-f351-4171-be9d-e8aa0c0883c9" xlink:to="loc_us-gaap_RoyaltyMember_04a2e68d-3f19-4010-a4c0-af377dec8182" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_133bb277-ef68-438f-8a63-e067def5f095" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_816cf7b9-8f96-4ced-9073-78f2ab053d7c" xlink:to="loc_srt_RangeAxis_133bb277-ef68-438f-8a63-e067def5f095" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_133bb277-ef68-438f-8a63-e067def5f095_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_133bb277-ef68-438f-8a63-e067def5f095" xlink:to="loc_srt_RangeMember_133bb277-ef68-438f-8a63-e067def5f095_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f10dea28-eaae-40bd-ac13-b921f2f6d4e0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_133bb277-ef68-438f-8a63-e067def5f095" xlink:to="loc_srt_RangeMember_f10dea28-eaae-40bd-ac13-b921f2f6d4e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_96be46a1-ac66-403d-bd88-3db2e96ad817" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f10dea28-eaae-40bd-ac13-b921f2f6d4e0" xlink:to="loc_srt_MinimumMember_96be46a1-ac66-403d-bd88-3db2e96ad817" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DiurnalAcquisitionAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#DiurnalAcquisitionAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/DiurnalAcquisitionAdditionalInformationDetails" xlink:type="extended" id="id7a6faac9a4b4365bb3df9016810b7b5_DiurnalAcquisitionAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_ab27ef4d-289a-4485-80c2-46d24a7a9155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_675f2332-87ec-410e-be39-432a418687a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ab27ef4d-289a-4485-80c2-46d24a7a9155" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_675f2332-87ec-410e-be39-432a418687a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_a1841bb5-4b69-492b-8437-c1131162d558" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ab27ef4d-289a-4485-80c2-46d24a7a9155" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_a1841bb5-4b69-492b-8437-c1131162d558" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_90c34127-9cc6-485b-8929-1ac51c211965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ab27ef4d-289a-4485-80c2-46d24a7a9155" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_90c34127-9cc6-485b-8929-1ac51c211965" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7b9a803f-6a9a-434f-9e18-375fd5c994d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_90c34127-9cc6-485b-8929-1ac51c211965" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7b9a803f-6a9a-434f-9e18-375fd5c994d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7b9a803f-6a9a-434f-9e18-375fd5c994d0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7b9a803f-6a9a-434f-9e18-375fd5c994d0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7b9a803f-6a9a-434f-9e18-375fd5c994d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bd222f71-c829-40d2-aa13-d1724f3e8616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7b9a803f-6a9a-434f-9e18-375fd5c994d0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bd222f71-c829-40d2-aa13-d1724f3e8616" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DiurnalGroupPlcMember_ea4e6095-12c7-4935-8d99-12c78d644401" xlink:href="nbix-20221231.xsd#nbix_DiurnalGroupPlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bd222f71-c829-40d2-aa13-d1724f3e8616" xlink:to="loc_nbix_DiurnalGroupPlcMember_ea4e6095-12c7-4935-8d99-12c78d644401" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DiurnalAcquisitionEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedattheDateofAcquisitionDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#DiurnalAcquisitionEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedattheDateofAcquisitionDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/DiurnalAcquisitionEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedattheDateofAcquisitionDetails" xlink:type="extended" id="if35b8dcb362b43bfbaa9c1364c545229_DiurnalAcquisitionEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedattheDateofAcquisitionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8395fd13-5dd3-4957-88b2-3377e32c458e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_bc51e704-2c20-45e0-a47b-24a30a21fc12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8395fd13-5dd3-4957-88b2-3377e32c458e" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_bc51e704-2c20-45e0-a47b-24a30a21fc12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_7433c457-e252-4e0a-9a2c-68b038e87619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_bc51e704-2c20-45e0-a47b-24a30a21fc12" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_7433c457-e252-4e0a-9a2c-68b038e87619" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_6dc8ae9b-23fd-4865-8111-af8d5db92380" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_bc51e704-2c20-45e0-a47b-24a30a21fc12" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_6dc8ae9b-23fd-4865-8111-af8d5db92380" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_2e51a7ea-e8d5-42dd-a2fa-c461b9836232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8395fd13-5dd3-4957-88b2-3377e32c458e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_2e51a7ea-e8d5-42dd-a2fa-c461b9836232" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_36ce8195-b5db-4c0b-af6b-b1ea24e5b82a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_2e51a7ea-e8d5-42dd-a2fa-c461b9836232" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_36ce8195-b5db-4c0b-af6b-b1ea24e5b82a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_ad219bf1-5aaa-4dfe-ad68-65d466f4b7e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_2e51a7ea-e8d5-42dd-a2fa-c461b9836232" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_ad219bf1-5aaa-4dfe-ad68-65d466f4b7e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsAcquiredInProcessResearchAndDevelopment_9b1d220f-1279-4539-ab79-bec1ec13efff" xlink:href="nbix-20221231.xsd#nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsAcquiredInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_2e51a7ea-e8d5-42dd-a2fa-c461b9836232" xlink:to="loc_nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsAcquiredInProcessResearchAndDevelopment_9b1d220f-1279-4539-ab79-bec1ec13efff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_cdf1f815-5544-491c-99f9-d2b7287825fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_2e51a7ea-e8d5-42dd-a2fa-c461b9836232" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_cdf1f815-5544-491c-99f9-d2b7287825fa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndOtherAccruedExpenses_b950411a-5909-465a-b5bb-596e9237be14" xlink:href="nbix-20221231.xsd#nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndOtherAccruedExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_2e51a7ea-e8d5-42dd-a2fa-c461b9836232" xlink:to="loc_nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndOtherAccruedExpenses_b950411a-5909-465a-b5bb-596e9237be14" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_01709769-fa4b-4132-b586-ac14c6b4dfed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_2e51a7ea-e8d5-42dd-a2fa-c461b9836232" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_01709769-fa4b-4132-b586-ac14c6b4dfed" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_39c0f1d7-5e9e-4cdb-88e4-f10fc7b974f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_2e51a7ea-e8d5-42dd-a2fa-c461b9836232" xlink:to="loc_us-gaap_Goodwill_39c0f1d7-5e9e-4cdb-88e4-f10fc7b974f9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_96eedf44-d6f1-4b64-9318-93de79084574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8395fd13-5dd3-4957-88b2-3377e32c458e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_96eedf44-d6f1-4b64-9318-93de79084574" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_791fa360-4f8d-479d-b182-454bf2d7ab52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_96eedf44-d6f1-4b64-9318-93de79084574" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_791fa360-4f8d-479d-b182-454bf2d7ab52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_791fa360-4f8d-479d-b182-454bf2d7ab52_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_791fa360-4f8d-479d-b182-454bf2d7ab52" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_791fa360-4f8d-479d-b182-454bf2d7ab52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_75195277-4e1a-4098-a2ba-94143f1d822f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_791fa360-4f8d-479d-b182-454bf2d7ab52" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_75195277-4e1a-4098-a2ba-94143f1d822f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DiurnalGroupPlcMember_f4c031e3-deab-4dfb-95d3-911b85251b14" xlink:href="nbix-20221231.xsd#nbix_DiurnalGroupPlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_75195277-4e1a-4098-a2ba-94143f1d822f" xlink:to="loc_nbix_DiurnalGroupPlcMember_f4c031e3-deab-4dfb-95d3-911b85251b14" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails" xlink:type="extended" id="ie943562e88964f4f9a4853afa9e7a337_DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5f1912cb-069d-4962-8bb3-1796365ea2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_fa8fd0c1-aafb-42bd-84d0-09f04e178616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5f1912cb-069d-4962-8bb3-1796365ea2ca" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_fa8fd0c1-aafb-42bd-84d0-09f04e178616" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_a6d6359f-2a41-4b71-a23d-6e39efd76671" xlink:href="nbix-20221231.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5f1912cb-069d-4962-8bb3-1796365ea2ca" xlink:to="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_a6d6359f-2a41-4b71-a23d-6e39efd76671" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_0f6f634d-ecad-4d6c-834d-66e53b5fc3da" xlink:href="nbix-20221231.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5f1912cb-069d-4962-8bb3-1796365ea2ca" xlink:to="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_0f6f634d-ecad-4d6c-834d-66e53b5fc3da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent_b969f71a-0433-4a16-aab9-82d50e64f0e1" xlink:href="nbix-20221231.xsd#nbix_DebtSecuritiesAvailableForSaleFairValueCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5f1912cb-069d-4962-8bb3-1796365ea2ca" xlink:to="loc_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent_b969f71a-0433-4a16-aab9-82d50e64f0e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_3482c030-7c92-420f-be02-b2080eaf6b93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5f1912cb-069d-4962-8bb3-1796365ea2ca" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_3482c030-7c92-420f-be02-b2080eaf6b93" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_422b6ea1-dc96-4de1-a1bf-07e0825bed5a" xlink:href="nbix-20221231.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5f1912cb-069d-4962-8bb3-1796365ea2ca" xlink:to="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_422b6ea1-dc96-4de1-a1bf-07e0825bed5a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_9c48cfdb-b4da-4703-b5ec-5f58e6163e3f" xlink:href="nbix-20221231.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5f1912cb-069d-4962-8bb3-1796365ea2ca" xlink:to="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_9c48cfdb-b4da-4703-b5ec-5f58e6163e3f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent_5ff8fb6c-78de-421b-81f6-671bcb6628d0" xlink:href="nbix-20221231.xsd#nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5f1912cb-069d-4962-8bb3-1796365ea2ca" xlink:to="loc_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent_5ff8fb6c-78de-421b-81f6-671bcb6628d0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f02316ce-896b-49b7-8e8f-331f5fea5ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5f1912cb-069d-4962-8bb3-1796365ea2ca" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f02316ce-896b-49b7-8e8f-331f5fea5ab1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4253b350-40e9-4969-9e38-e175b440221e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f02316ce-896b-49b7-8e8f-331f5fea5ab1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4253b350-40e9-4969-9e38-e175b440221e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4253b350-40e9-4969-9e38-e175b440221e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4253b350-40e9-4969-9e38-e175b440221e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4253b350-40e9-4969-9e38-e175b440221e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_86f80138-a138-4001-9ff7-0f3c745ee546" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4253b350-40e9-4969-9e38-e175b440221e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_86f80138-a138-4001-9ff7-0f3c745ee546" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_90befb73-f9a2-4436-bb52-a3757612ed50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_86f80138-a138-4001-9ff7-0f3c745ee546" xlink:to="loc_us-gaap_CommercialPaperMember_90befb73-f9a2-4436-bb52-a3757612ed50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9be40bbf-a551-424d-94be-43ea78ff0e03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_86f80138-a138-4001-9ff7-0f3c745ee546" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9be40bbf-a551-424d-94be-43ea78ff0e03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_bf1bded8-30ab-4066-8f5c-91bded82e129" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_86f80138-a138-4001-9ff7-0f3c745ee546" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_bf1bded8-30ab-4066-8f5c-91bded82e129" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails" xlink:type="extended" id="i05d96b61f09a4a56910a81eb474df557_DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7063bb18-c064-4e1d-a804-b9b8efa59127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_c0c0f891-f497-4136-bf8d-47a27db36c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7063bb18-c064-4e1d-a804-b9b8efa59127" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_c0c0f891-f497-4136-bf8d-47a27db36c3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_f75c7e66-e958-4016-afec-4e0cb91b9de6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7063bb18-c064-4e1d-a804-b9b8efa59127" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_f75c7e66-e958-4016-afec-4e0cb91b9de6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_353b2cf0-34b9-4b39-b6d0-91e73fcbd4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7063bb18-c064-4e1d-a804-b9b8efa59127" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_353b2cf0-34b9-4b39-b6d0-91e73fcbd4d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_19827738-bb1c-4f60-bfc9-26fb58919b76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7063bb18-c064-4e1d-a804-b9b8efa59127" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_19827738-bb1c-4f60-bfc9-26fb58919b76" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_c649566e-5885-491e-8788-3ebbb2b801e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7063bb18-c064-4e1d-a804-b9b8efa59127" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_c649566e-5885-491e-8788-3ebbb2b801e3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_946bbe7c-361e-420d-8419-f77b876d9a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7063bb18-c064-4e1d-a804-b9b8efa59127" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_946bbe7c-361e-420d-8419-f77b876d9a0c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f92761c7-e78b-4c0d-88ec-e3a8de8e1f60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7063bb18-c064-4e1d-a804-b9b8efa59127" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f92761c7-e78b-4c0d-88ec-e3a8de8e1f60" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ec4de54a-01a6-463c-a39d-cf56a748a770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f92761c7-e78b-4c0d-88ec-e3a8de8e1f60" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ec4de54a-01a6-463c-a39d-cf56a748a770" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ec4de54a-01a6-463c-a39d-cf56a748a770_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ec4de54a-01a6-463c-a39d-cf56a748a770" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ec4de54a-01a6-463c-a39d-cf56a748a770_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_36f5f463-2736-4c19-a5a7-ea204c833e70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ec4de54a-01a6-463c-a39d-cf56a748a770" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_36f5f463-2736-4c19-a5a7-ea204c833e70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_963605f0-3ff1-419e-9646-93460b26f810" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_36f5f463-2736-4c19-a5a7-ea204c833e70" xlink:to="loc_us-gaap_CommercialPaperMember_963605f0-3ff1-419e-9646-93460b26f810" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_1ec0d9e9-2642-4509-9f1a-2735b03a183f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_36f5f463-2736-4c19-a5a7-ea204c833e70" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_1ec0d9e9-2642-4509-9f1a-2735b03a183f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_03ebc4e8-2031-4cd1-a23b-4f14f87165e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_36f5f463-2736-4c19-a5a7-ea204c833e70" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_03ebc4e8-2031-4cd1-a23b-4f14f87165e8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended" id="ib7924a5bb7c34a77bd0df284486d98ff_FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3cbce0c1-7808-4bcc-ba25-f385ceb4dc17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_9769a20a-fd16-490a-910f-162e05f372f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3cbce0c1-7808-4bcc-ba25-f385ceb4dc17" xlink:to="loc_us-gaap_Investments_9769a20a-fd16-490a-910f-162e05f372f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_e21127c3-9aea-4184-8db0-68686d19055b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3cbce0c1-7808-4bcc-ba25-f385ceb4dc17" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_e21127c3-9aea-4184-8db0-68686d19055b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a887fbe9-5dec-43d2-a4ad-1c0296ecc8eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3cbce0c1-7808-4bcc-ba25-f385ceb4dc17" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a887fbe9-5dec-43d2-a4ad-1c0296ecc8eb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_86a2113b-da0b-4851-b878-37c62ff29985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a887fbe9-5dec-43d2-a4ad-1c0296ecc8eb" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_86a2113b-da0b-4851-b878-37c62ff29985" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_86a2113b-da0b-4851-b878-37c62ff29985_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_86a2113b-da0b-4851-b878-37c62ff29985" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_86a2113b-da0b-4851-b878-37c62ff29985_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e5a57f08-25de-49f9-9e5d-3a22d3138f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_86a2113b-da0b-4851-b878-37c62ff29985" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e5a57f08-25de-49f9-9e5d-3a22d3138f1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_e1d65479-c17b-4157-b6b4-7e45d928beb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e5a57f08-25de-49f9-9e5d-3a22d3138f1a" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_e1d65479-c17b-4157-b6b4-7e45d928beb8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_fb2be3f3-0fd1-48f6-8915-fd7192115959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e5a57f08-25de-49f9-9e5d-3a22d3138f1a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_fb2be3f3-0fd1-48f6-8915-fd7192115959" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e2f7445b-241a-4c7a-a60f-3032a69b63e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e5a57f08-25de-49f9-9e5d-3a22d3138f1a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e2f7445b-241a-4c7a-a60f-3032a69b63e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_ae4853a2-06f7-4caf-91ed-2cb3e6cdab17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a887fbe9-5dec-43d2-a4ad-1c0296ecc8eb" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_ae4853a2-06f7-4caf-91ed-2cb3e6cdab17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ae4853a2-06f7-4caf-91ed-2cb3e6cdab17_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_ae4853a2-06f7-4caf-91ed-2cb3e6cdab17" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ae4853a2-06f7-4caf-91ed-2cb3e6cdab17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a2a36db7-13bd-475a-9065-b7269c3940d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_ae4853a2-06f7-4caf-91ed-2cb3e6cdab17" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a2a36db7-13bd-475a-9065-b7269c3940d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CashAndMoneyMarketFundMember_edb88434-2414-41cc-aa8a-b6893c387391" xlink:href="nbix-20221231.xsd#nbix_CashAndMoneyMarketFundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a2a36db7-13bd-475a-9065-b7269c3940d2" xlink:to="loc_nbix_CashAndMoneyMarketFundMember_edb88434-2414-41cc-aa8a-b6893c387391" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_b512d931-09cc-4278-9e95-01231687e13f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a2a36db7-13bd-475a-9065-b7269c3940d2" xlink:to="loc_us-gaap_CertificatesOfDepositMember_b512d931-09cc-4278-9e95-01231687e13f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_67bcb4c0-707c-453a-b47d-dc06a534d18e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a2a36db7-13bd-475a-9065-b7269c3940d2" xlink:to="loc_us-gaap_CommercialPaperMember_67bcb4c0-707c-453a-b47d-dc06a534d18e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7d0aeea8-bf84-40d8-8155-682ba5deeb6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a887fbe9-5dec-43d2-a4ad-1c0296ecc8eb" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7d0aeea8-bf84-40d8-8155-682ba5deeb6d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7d0aeea8-bf84-40d8-8155-682ba5deeb6d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7d0aeea8-bf84-40d8-8155-682ba5deeb6d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7d0aeea8-bf84-40d8-8155-682ba5deeb6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c1bbd9d3-0ac7-4b20-b730-721695410770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7d0aeea8-bf84-40d8-8155-682ba5deeb6d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c1bbd9d3-0ac7-4b20-b730-721695410770" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_73de1720-5f17-4a18-be70-145c1b02bd70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c1bbd9d3-0ac7-4b20-b730-721695410770" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_73de1720-5f17-4a18-be70-145c1b02bd70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_f42a2caa-02da-4a6f-bed4-f97679c10e14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c1bbd9d3-0ac7-4b20-b730-721695410770" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_f42a2caa-02da-4a6f-bed4-f97679c10e14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_01bf01d5-f33f-4e2e-88a5-eaf9143a6bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c1bbd9d3-0ac7-4b20-b730-721695410770" xlink:to="loc_us-gaap_EquitySecuritiesMember_01bf01d5-f33f-4e2e-88a5-eaf9143a6bd1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_beb014bf-bbc3-4f8c-9a7f-3464a281e2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a887fbe9-5dec-43d2-a4ad-1c0296ecc8eb" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_beb014bf-bbc3-4f8c-9a7f-3464a281e2fe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_beb014bf-bbc3-4f8c-9a7f-3464a281e2fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_beb014bf-bbc3-4f8c-9a7f-3464a281e2fe" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_beb014bf-bbc3-4f8c-9a7f-3464a281e2fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d509aaeb-a5c9-4940-95eb-d0254b0ac15f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_beb014bf-bbc3-4f8c-9a7f-3464a281e2fe" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d509aaeb-a5c9-4940-95eb-d0254b0ac15f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_b9f61289-185c-4647-8619-51675260aa4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_d509aaeb-a5c9-4940-95eb-d0254b0ac15f" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_b9f61289-185c-4647-8619-51675260aa4b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended" id="i419c9b7d2c9b4baea8e23f75543cb6bb_FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3d3e2002-03f0-4f6f-bf87-bb57226868d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_ab04ad0c-9d77-4a2a-bda0-e9d9f6fd412b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3d3e2002-03f0-4f6f-bf87-bb57226868d0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_ab04ad0c-9d77-4a2a-bda0-e9d9f6fd412b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRestricted_da2fafad-ce5e-4452-8ca7-3004849b9326" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiRestricted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_ab04ad0c-9d77-4a2a-bda0-e9d9f6fd412b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRestricted_da2fafad-ce5e-4452-8ca7-3004849b9326" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_8322474f-f0e9-4ecf-a8a1-f7aa37fe49d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_ab04ad0c-9d77-4a2a-bda0-e9d9f6fd412b" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_8322474f-f0e9-4ecf-a8a1-f7aa37fe49d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_55bea072-288d-456b-9450-daee9f023dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_ab04ad0c-9d77-4a2a-bda0-e9d9f6fd412b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_55bea072-288d-456b-9450-daee9f023dfc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_0e1d6fd6-5142-4861-a0a6-07e939f13e66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_ab04ad0c-9d77-4a2a-bda0-e9d9f6fd412b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_0e1d6fd6-5142-4861-a0a6-07e939f13e66" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRestricted_b8c834cb-9f7f-46a1-93ea-a7330f9d7f66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiRestricted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_381ad033-0a8a-4942-9156-be3354c1a2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3d3e2002-03f0-4f6f-bf87-bb57226868d0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_381ad033-0a8a-4942-9156-be3354c1a2ee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8171ef10-73c2-4c5c-a377-e9338d667a12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_381ad033-0a8a-4942-9156-be3354c1a2ee" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8171ef10-73c2-4c5c-a377-e9338d667a12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8171ef10-73c2-4c5c-a377-e9338d667a12_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8171ef10-73c2-4c5c-a377-e9338d667a12" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8171ef10-73c2-4c5c-a377-e9338d667a12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b984a51e-1f86-4169-9af6-4607ec3c515f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8171ef10-73c2-4c5c-a377-e9338d667a12" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b984a51e-1f86-4169-9af6-4607ec3c515f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_18316c9e-aab9-4c98-97c7-1a62ca0d0955" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b984a51e-1f86-4169-9af6-4607ec3c515f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_18316c9e-aab9-4c98-97c7-1a62ca0d0955" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_38c156c4-3cea-4999-b131-be181c688045" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_381ad033-0a8a-4942-9156-be3354c1a2ee" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_38c156c4-3cea-4999-b131-be181c688045" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_38c156c4-3cea-4999-b131-be181c688045_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_38c156c4-3cea-4999-b131-be181c688045" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_38c156c4-3cea-4999-b131-be181c688045_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e3240a9c-bbc3-4667-93fa-4ad2e80f359c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_38c156c4-3cea-4999-b131-be181c688045" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e3240a9c-bbc3-4667-93fa-4ad2e80f359c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_d96db0aa-845a-4d06-89a2-2caa55cc7b44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e3240a9c-bbc3-4667-93fa-4ad2e80f359c" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_d96db0aa-845a-4d06-89a2-2caa55cc7b44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c9bb5bbb-7305-4b16-955b-04297a8e0a48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_381ad033-0a8a-4942-9156-be3354c1a2ee" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c9bb5bbb-7305-4b16-955b-04297a8e0a48" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c9bb5bbb-7305-4b16-955b-04297a8e0a48_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c9bb5bbb-7305-4b16-955b-04297a8e0a48" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c9bb5bbb-7305-4b16-955b-04297a8e0a48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27723aaa-2967-4876-8b60-ef66f26ead7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c9bb5bbb-7305-4b16-955b-04297a8e0a48" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27723aaa-2967-4876-8b60-ef66f26ead7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_517662b3-435e-436b-9bec-25b69138720d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27723aaa-2967-4876-8b60-ef66f26ead7e" xlink:to="loc_us-gaap_EquitySecuritiesMember_517662b3-435e-436b-9bec-25b69138720d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAxis_45dc2f37-103c-46f3-8890-e02a83eaab95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollateralAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_381ad033-0a8a-4942-9156-be3354c1a2ee" xlink:to="loc_us-gaap_CollateralAxis_45dc2f37-103c-46f3-8890-e02a83eaab95" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralDomain_45dc2f37-103c-46f3-8890-e02a83eaab95_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollateralDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CollateralAxis_45dc2f37-103c-46f3-8890-e02a83eaab95" xlink:to="loc_us-gaap_CollateralDomain_45dc2f37-103c-46f3-8890-e02a83eaab95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralDomain_e2157f3a-ea5e-4ac1-a8eb-0d53642085bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollateralDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CollateralAxis_45dc2f37-103c-46f3-8890-e02a83eaab95" xlink:to="loc_us-gaap_CollateralDomain_e2157f3a-ea5e-4ac1-a8eb-0d53642085bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_b2d31b86-2808-4120-9d63-318709a8d070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollateralDomain_e2157f3a-ea5e-4ac1-a8eb-0d53642085bf" xlink:to="loc_us-gaap_EquitySecuritiesMember_b2d31b86-2808-4120-9d63-318709a8d070" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#ConvertibleSeniorNotesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" xlink:type="extended" id="ie8680590c4d84b7e8f2a513772a66274_ConvertibleSeniorNotesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_fe742f61-8b8e-43ab-9e3b-a2221f6d80bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_fe742f61-8b8e-43ab-9e3b-a2221f6d80bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4aa9c346-0c7a-4839-a5bb-dd590f4428a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4aa9c346-0c7a-4839-a5bb-dd590f4428a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CarryingAmountOfLiabilityComponentUponIssuance_4dd99d11-90ac-4067-a014-1454c4c56012" xlink:href="nbix-20221231.xsd#nbix_CarryingAmountOfLiabilityComponentUponIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_nbix_CarryingAmountOfLiabilityComponentUponIssuance_4dd99d11-90ac-4067-a014-1454c4c56012" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_aa2bd5b9-c950-48d4-8a1e-430390c77c22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_aa2bd5b9-c950-48d4-8a1e-430390c77c22" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_bdfab860-8280-4c8d-84d2-762e6b5c6bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_bdfab860-8280-4c8d-84d2-762e6b5c6bd4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_a02102d1-14a5-47cf-99bc-b6ca2f1b198d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_DebtInstrumentTerm_a02102d1-14a5-47cf-99bc-b6ca2f1b198d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_1bcd6b49-6aff-46e8-9722-bfc7a7d3d08e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_1bcd6b49-6aff-46e8-9722-bfc7a7d3d08e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_695f33a6-5778-4cad-9e83-cc74009d1e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_695f33a6-5778-4cad-9e83-cc74009d1e0d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_e9c031a0-ac42-4cee-8f1e-9ba2af3ca1fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_RepaymentsOfDebt_e9c031a0-ac42-4cee-8f1e-9ba2af3ca1fb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment_d704cb92-6171-42a4-b625-d970e39f0a83" xlink:href="nbix-20221231.xsd#nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment_d704cb92-6171-42a4-b625-d970e39f0a83" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput_721dfa8b-d4d4-44e3-b51f-7cc063e47a41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_DebtInstrumentMeasurementInput_721dfa8b-d4d4-44e3-b51f-7cc063e47a41" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_bbb12658-8161-4b0d-b34f-1fe02bf06bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_bbb12658-8161-4b0d-b34f-1fe02bf06bc6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CarryingAmountOfLiabilityComponentAtSettlement_dc7e4aaa-5eb9-46b5-b4d5-8a213dd7a626" xlink:href="nbix-20221231.xsd#nbix_CarryingAmountOfLiabilityComponentAtSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_nbix_CarryingAmountOfLiabilityComponentAtSettlement_dc7e4aaa-5eb9-46b5-b4d5-8a213dd7a626" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6457377a-8212-4f69-90e3-c357c46e72d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6457377a-8212-4f69-90e3-c357c46e72d0" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_6acc14f0-167d-49e9-a8f5-f6aaff190bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_6acc14f0-167d-49e9-a8f5-f6aaff190bb2" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_bd52bcec-4f13-40ca-b640-815f5dde446f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_bd52bcec-4f13-40ca-b640-815f5dde446f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_60962b8f-981f-473d-81c7-e6d5662764d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_60962b8f-981f-473d-81c7-e6d5662764d5" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_810ed1f0-0ca0-4e90-aeed-c177192c9289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_AdditionalPaidInCapital_810ed1f0-0ca0-4e90-aeed-c177192c9289" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bb78fb25-c4dc-4749-b38a-d0e4e7ed8a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bb78fb25-c4dc-4749-b38a-d0e4e7ed8a5b" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_86ebf9f5-3ba2-4fd2-9b2f-b72c88e83a81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_86ebf9f5-3ba2-4fd2-9b2f-b72c88e83a81" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PrincipalAmountOnConversionRate_7cc25e0f-6006-4130-bf53-679b15ff51bf" xlink:href="nbix-20221231.xsd#nbix_PrincipalAmountOnConversionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_nbix_PrincipalAmountOnConversionRate_7cc25e0f-6006-4130-bf53-679b15ff51bf" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_1368fc72-2637-4d62-af6d-4bc9769f7b04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_1368fc72-2637-4d62-af6d-4bc9769f7b04" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_9cf10776-09f5-42a2-b378-cd84abca59e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_9cf10776-09f5-42a2-b378-cd84abca59e9" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConvertibleConversionPremium_e67ca0c3-ea1c-4eac-b3d4-9e3590f7c38d" xlink:href="nbix-20221231.xsd#nbix_DebtInstrumentConvertibleConversionPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_nbix_DebtInstrumentConvertibleConversionPremium_e67ca0c3-ea1c-4eac-b3d4-9e3590f7c38d" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_33ba06aa-6ffd-420f-b0d0-b8897d7a54e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_SharePrice_33ba06aa-6ffd-420f-b0d0-b8897d7a54e8" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_32b41fb9-1d74-4029-82c3-351a9ece96a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_32b41fb9-1d74-4029-82c3-351a9ece96a8" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleStockPriceTrigger_bb1ebe2b-e0bc-4150-8d20-01bffe62cdbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleStockPriceTrigger_bb1ebe2b-e0bc-4150-8d20-01bffe62cdbb" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_e7e23221-b57f-4a6a-b08e-33cd8742a5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_e7e23221-b57f-4a6a-b08e-33cd8742a5bc" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_6826791b-1384-4f74-b802-46224f6cbd2e" xlink:href="nbix-20221231.xsd#nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_6826791b-1384-4f74-b802-46224f6cbd2e" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_9f0563aa-c778-4ffb-b31b-15f6a77360d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_9f0563aa-c778-4ffb-b31b-15f6a77360d4" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8935f029-b107-4d82-b398-d61eec3fa044" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_DebtInstrumentTable_8935f029-b107-4d82-b398-d61eec3fa044" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d6540153-acd8-4ea0-b288-f6e3bdb7c56c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8935f029-b107-4d82-b398-d61eec3fa044" xlink:to="loc_us-gaap_DebtInstrumentAxis_d6540153-acd8-4ea0-b288-f6e3bdb7c56c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d6540153-acd8-4ea0-b288-f6e3bdb7c56c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_d6540153-acd8-4ea0-b288-f6e3bdb7c56c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d6540153-acd8-4ea0-b288-f6e3bdb7c56c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d4d3458b-f52f-4923-b222-61b739052738" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_d6540153-acd8-4ea0-b288-f6e3bdb7c56c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d4d3458b-f52f-4923-b222-61b739052738" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_dc6308c7-dfe3-411c-8adf-cdc291af3f43" xlink:href="nbix-20221231.xsd#nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d3458b-f52f-4923-b222-61b739052738" xlink:to="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_dc6308c7-dfe3-411c-8adf-cdc291af3f43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_a1aa7c0a-cdc7-45d4-97e9-001930ae9775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8935f029-b107-4d82-b398-d61eec3fa044" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_a1aa7c0a-cdc7-45d4-97e9-001930ae9775" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_a1aa7c0a-cdc7-45d4-97e9-001930ae9775_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_a1aa7c0a-cdc7-45d4-97e9-001930ae9775" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_a1aa7c0a-cdc7-45d4-97e9-001930ae9775_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_d7c9379e-3853-48f0-bf42-4e1673fda140" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_a1aa7c0a-cdc7-45d4-97e9-001930ae9775" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_d7c9379e-3853-48f0-bf42-4e1673fda140" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_a853fffa-f552-4b7e-8f0f-0106c74a1cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d7c9379e-3853-48f0-bf42-4e1673fda140" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_a853fffa-f552-4b7e-8f0f-0106c74a1cff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConversionAxis_812e6314-6e0f-4c9c-9e94-68a00ef73664" xlink:href="nbix-20221231.xsd#nbix_DebtInstrumentConversionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8935f029-b107-4d82-b398-d61eec3fa044" xlink:to="loc_nbix_DebtInstrumentConversionAxis_812e6314-6e0f-4c9c-9e94-68a00ef73664" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConversionDomain_812e6314-6e0f-4c9c-9e94-68a00ef73664_default" xlink:href="nbix-20221231.xsd#nbix_DebtInstrumentConversionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nbix_DebtInstrumentConversionAxis_812e6314-6e0f-4c9c-9e94-68a00ef73664" xlink:to="loc_nbix_DebtInstrumentConversionDomain_812e6314-6e0f-4c9c-9e94-68a00ef73664_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConversionDomain_191bdbdb-0009-48d0-a43d-ed2beefa412b" xlink:href="nbix-20221231.xsd#nbix_DebtInstrumentConversionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nbix_DebtInstrumentConversionAxis_812e6314-6e0f-4c9c-9e94-68a00ef73664" xlink:to="loc_nbix_DebtInstrumentConversionDomain_191bdbdb-0009-48d0-a43d-ed2beefa412b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ConversionPeriodOneMember_f03117fc-2b4f-4f16-a828-91f845eb634e" xlink:href="nbix-20221231.xsd#nbix_ConversionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_DebtInstrumentConversionDomain_191bdbdb-0009-48d0-a43d-ed2beefa412b" xlink:to="loc_nbix_ConversionPeriodOneMember_f03117fc-2b4f-4f16-a828-91f845eb634e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ConversionPeriodTwoMember_543d7e6c-62a5-4b13-96e8-6205ed8ddea5" xlink:href="nbix-20221231.xsd#nbix_ConversionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_DebtInstrumentConversionDomain_191bdbdb-0009-48d0-a43d-ed2beefa412b" xlink:to="loc_nbix_ConversionPeriodTwoMember_543d7e6c-62a5-4b13-96e8-6205ed8ddea5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8c1af456-0ee2-4bc2-bb39-04593e139f63" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8935f029-b107-4d82-b398-d61eec3fa044" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8c1af456-0ee2-4bc2-bb39-04593e139f63" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_8c1af456-0ee2-4bc2-bb39-04593e139f63_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8c1af456-0ee2-4bc2-bb39-04593e139f63" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_8c1af456-0ee2-4bc2-bb39-04593e139f63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e46c6a95-36a7-486f-871f-cc3cdc388316" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8c1af456-0ee2-4bc2-bb39-04593e139f63" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e46c6a95-36a7-486f-871f-cc3cdc388316" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_c542fc8f-c640-4657-8782-d8cf1ed65875" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e46c6a95-36a7-486f-871f-cc3cdc388316" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_c542fc8f-c640-4657-8782-d8cf1ed65875" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_c235d3e8-9167-40c2-9d4d-560d3456f391" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8935f029-b107-4d82-b398-d61eec3fa044" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_c235d3e8-9167-40c2-9d4d-560d3456f391" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_c235d3e8-9167-40c2-9d4d-560d3456f391_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_c235d3e8-9167-40c2-9d4d-560d3456f391" xlink:to="loc_us-gaap_TypeOfAdoptionMember_c235d3e8-9167-40c2-9d4d-560d3456f391_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_d39a23a6-8070-48fa-8e20-4926d39baabb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_c235d3e8-9167-40c2-9d4d-560d3456f391" xlink:to="loc_us-gaap_TypeOfAdoptionMember_d39a23a6-8070-48fa-8e20-4926d39baabb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_cbb619a0-700a-4710-b830-666fcd0c095f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_d39a23a6-8070-48fa-8e20-4926d39baabb" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_cbb619a0-700a-4710-b830-666fcd0c095f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#ConvertibleSeniorNotes2024NotesDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails" xlink:type="extended" id="i9fa8839eb13745dba3b778ad7f209722_ConvertibleSeniorNotes2024NotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d54ec616-3ee5-4211-b4a1-f581abf55604" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_9a062014-cab0-4652-8d71-a6011a5f8931" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d54ec616-3ee5-4211-b4a1-f581abf55604" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_9a062014-cab0-4652-8d71-a6011a5f8931" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_44d5cc26-7c8a-4b17-84b1-0476aeecdf97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d54ec616-3ee5-4211-b4a1-f581abf55604" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_44d5cc26-7c8a-4b17-84b1-0476aeecdf97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_de803317-4d9a-43c4-8b55-44058e7aa7c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d54ec616-3ee5-4211-b4a1-f581abf55604" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_de803317-4d9a-43c4-8b55-44058e7aa7c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_50d3d1b6-6eb1-4a12-b129-56ecd9d776bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d54ec616-3ee5-4211-b4a1-f581abf55604" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_50d3d1b6-6eb1-4a12-b129-56ecd9d776bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_3e7b2fc3-0a8c-411f-8cc6-0472e75f88be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d54ec616-3ee5-4211-b4a1-f581abf55604" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_3e7b2fc3-0a8c-411f-8cc6-0472e75f88be" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_49d4eb16-f39e-459a-a456-3c27ea7d5a86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d54ec616-3ee5-4211-b4a1-f581abf55604" xlink:to="loc_us-gaap_DebtInstrumentFairValue_49d4eb16-f39e-459a-a456-3c27ea7d5a86" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_53e99afd-3abd-4611-b65a-77b6481759f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d54ec616-3ee5-4211-b4a1-f581abf55604" xlink:to="loc_us-gaap_DebtInstrumentTable_53e99afd-3abd-4611-b65a-77b6481759f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_86cd88ec-f3c9-4bb7-bbe9-7d2867483650" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_53e99afd-3abd-4611-b65a-77b6481759f3" xlink:to="loc_us-gaap_DebtInstrumentAxis_86cd88ec-f3c9-4bb7-bbe9-7d2867483650" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_86cd88ec-f3c9-4bb7-bbe9-7d2867483650_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_86cd88ec-f3c9-4bb7-bbe9-7d2867483650" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_86cd88ec-f3c9-4bb7-bbe9-7d2867483650_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0f45de70-4c89-4978-8f6e-b05323532911" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_86cd88ec-f3c9-4bb7-bbe9-7d2867483650" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0f45de70-4c89-4978-8f6e-b05323532911" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_ae6295d2-4bc4-4453-aa4b-5a9c00f2268f" xlink:href="nbix-20221231.xsd#nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0f45de70-4c89-4978-8f6e-b05323532911" xlink:to="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_ae6295d2-4bc4-4453-aa4b-5a9c00f2268f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#GoodwillandIntangibleAssetsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails" xlink:type="extended" id="i064a42c68d284815b82ff58ca72278e7_GoodwillandIntangibleAssetsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_91445d8f-63d1-4a1b-af69-a6c4a4251cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2282e8a8-8b5f-45b2-a5da-657dcd3af593" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_91445d8f-63d1-4a1b-af69-a6c4a4251cbe" xlink:to="loc_us-gaap_Goodwill_2282e8a8-8b5f-45b2-a5da-657dcd3af593" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_9802bc5d-736f-46c0-951b-1f486e03195c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_91445d8f-63d1-4a1b-af69-a6c4a4251cbe" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_9802bc5d-736f-46c0-951b-1f486e03195c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0e8c1915-24f6-4dff-8aab-efaf2bdd636b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_9802bc5d-736f-46c0-951b-1f486e03195c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0e8c1915-24f6-4dff-8aab-efaf2bdd636b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0e8c1915-24f6-4dff-8aab-efaf2bdd636b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0e8c1915-24f6-4dff-8aab-efaf2bdd636b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0e8c1915-24f6-4dff-8aab-efaf2bdd636b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_874b3107-10a0-4955-b501-ea1167205902" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0e8c1915-24f6-4dff-8aab-efaf2bdd636b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_874b3107-10a0-4955-b501-ea1167205902" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DiurnalGroupPlcMember_c314a1c6-b12a-4303-8519-7b91bf896da0" xlink:href="nbix-20221231.xsd#nbix_DiurnalGroupPlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_874b3107-10a0-4955-b501-ea1167205902" xlink:to="loc_nbix_DiurnalGroupPlcMember_c314a1c6-b12a-4303-8519-7b91bf896da0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails" xlink:type="extended" id="iaa16fbccc69941989dc2c78b0eead13e_GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_4945d3b4-2475-43f7-81cc-91ccdb212f36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_c7cb5d6b-5868-4efb-a1cf-b4b1b471981b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_4945d3b4-2475-43f7-81cc-91ccdb212f36" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_c7cb5d6b-5868-4efb-a1cf-b4b1b471981b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_078defab-8d65-4454-b71f-81a0ba7ae642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_4945d3b4-2475-43f7-81cc-91ccdb212f36" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_078defab-8d65-4454-b71f-81a0ba7ae642" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ae02cb1b-02fd-4728-9a54-35ca607707aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_4945d3b4-2475-43f7-81cc-91ccdb212f36" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ae02cb1b-02fd-4728-9a54-35ca607707aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_42f5f7d4-18d5-4942-b0f2-559f467b7448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_4945d3b4-2475-43f7-81cc-91ccdb212f36" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_42f5f7d4-18d5-4942-b0f2-559f467b7448" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1c892a34-3fab-4eb0-a1b1-6e9c5542b427" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_4945d3b4-2475-43f7-81cc-91ccdb212f36" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1c892a34-3fab-4eb0-a1b1-6e9c5542b427" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_fbbbed1c-be8a-4469-b720-5c566ef4b7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_4945d3b4-2475-43f7-81cc-91ccdb212f36" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_fbbbed1c-be8a-4469-b720-5c566ef4b7b3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_18fe34ae-7a24-413c-a612-ffb86798a1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_4945d3b4-2475-43f7-81cc-91ccdb212f36" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_18fe34ae-7a24-413c-a612-ffb86798a1fc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1674c58d-6fce-41e7-a513-dc25403efab8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_18fe34ae-7a24-413c-a612-ffb86798a1fc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1674c58d-6fce-41e7-a513-dc25403efab8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1674c58d-6fce-41e7-a513-dc25403efab8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1674c58d-6fce-41e7-a513-dc25403efab8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1674c58d-6fce-41e7-a513-dc25403efab8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a7c32c1f-2639-4142-8340-e5edeba193c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1674c58d-6fce-41e7-a513-dc25403efab8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a7c32c1f-2639-4142-8340-e5edeba193c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_9a99c1a9-7f2f-4857-b379-3277205a4e91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a7c32c1f-2639-4142-8340-e5edeba193c5" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_9a99c1a9-7f2f-4857-b379-3277205a4e91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_74669db9-2998-40a8-aba9-b40cfd8b401d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_18fe34ae-7a24-413c-a612-ffb86798a1fc" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_74669db9-2998-40a8-aba9-b40cfd8b401d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_74669db9-2998-40a8-aba9-b40cfd8b401d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_74669db9-2998-40a8-aba9-b40cfd8b401d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_74669db9-2998-40a8-aba9-b40cfd8b401d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8366eeaf-d06b-425e-a699-1f10255a560c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_74669db9-2998-40a8-aba9-b40cfd8b401d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8366eeaf-d06b-425e-a699-1f10255a560c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_61f38d9a-6cee-4b08-9b9b-cc2f9ae623d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8366eeaf-d06b-425e-a699-1f10255a560c" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_61f38d9a-6cee-4b08-9b9b-cc2f9ae623d6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#OtherBalanceSheetDetailsPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails" xlink:type="extended" id="i1baf843279e14a11a104ef862a915d05_OtherBalanceSheetDetailsPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7d1c4711-60a8-4e1f-bf88-18c73871e827" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_f8e79860-3ed5-41db-9fac-952b9797a6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7d1c4711-60a8-4e1f-bf88-18c73871e827" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_f8e79860-3ed5-41db-9fac-952b9797a6cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ab66d249-6737-49a3-9090-f3c79f51d3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7d1c4711-60a8-4e1f-bf88-18c73871e827" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ab66d249-6737-49a3-9090-f3c79f51d3c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e1611bd7-0a0f-4e16-a616-5fbf8d48d5d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7d1c4711-60a8-4e1f-bf88-18c73871e827" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e1611bd7-0a0f-4e16-a616-5fbf8d48d5d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5f0b6827-2820-4cc3-bd4f-5afa95130fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7d1c4711-60a8-4e1f-bf88-18c73871e827" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5f0b6827-2820-4cc3-bd4f-5afa95130fbd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_20ff6a83-949f-4285-874e-a4f44a90ee02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5f0b6827-2820-4cc3-bd4f-5afa95130fbd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_20ff6a83-949f-4285-874e-a4f44a90ee02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_20ff6a83-949f-4285-874e-a4f44a90ee02_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_20ff6a83-949f-4285-874e-a4f44a90ee02" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_20ff6a83-949f-4285-874e-a4f44a90ee02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_05e505ad-a3b3-4015-b94d-dd3ed819e5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_20ff6a83-949f-4285-874e-a4f44a90ee02" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_05e505ad-a3b3-4015-b94d-dd3ed819e5ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_ff5171f2-0163-4e8a-bf3e-b015b8f6baa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_05e505ad-a3b3-4015-b94d-dd3ed819e5ea" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_ff5171f2-0163-4e8a-bf3e-b015b8f6baa5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ScientificEquipmentMember_6b4588cd-e8a7-4602-a7e5-e3b43b9d3450" xlink:href="nbix-20221231.xsd#nbix_ScientificEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_05e505ad-a3b3-4015-b94d-dd3ed819e5ea" xlink:to="loc_nbix_ScientificEquipmentMember_6b4588cd-e8a7-4602-a7e5-e3b43b9d3450" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_2139e897-985d-49a8-88ea-8ccff9bb45e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_05e505ad-a3b3-4015-b94d-dd3ed819e5ea" xlink:to="loc_us-gaap_ComputerEquipmentMember_2139e897-985d-49a8-88ea-8ccff9bb45e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_66ceb525-75b7-4703-af73-4e7cc2c4ad85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_05e505ad-a3b3-4015-b94d-dd3ed819e5ea" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_66ceb525-75b7-4703-af73-4e7cc2c4ad85" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/EarningsPerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#EarningsPerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/EarningsPerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails" xlink:type="extended" id="i85d7389d317948fc9f760e40deb6f9aa_EarningsPerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7ea1b8cd-96d0-4171-a41f-7246e810fc0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2bf05275-ea9a-4be6-b3ca-dc509f12db72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7ea1b8cd-96d0-4171-a41f-7246e810fc0f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2bf05275-ea9a-4be6-b3ca-dc509f12db72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f9c9515e-f543-4277-9cf2-3c4d19150adf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7ea1b8cd-96d0-4171-a41f-7246e810fc0f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f9c9515e-f543-4277-9cf2-3c4d19150adf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ec7379cc-58c0-4931-ad05-d6c7b366f210" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f9c9515e-f543-4277-9cf2-3c4d19150adf" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ec7379cc-58c0-4931-ad05-d6c7b366f210" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ec7379cc-58c0-4931-ad05-d6c7b366f210_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ec7379cc-58c0-4931-ad05-d6c7b366f210" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ec7379cc-58c0-4931-ad05-d6c7b366f210_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3237e8e0-d2a2-4e58-8e60-e70f3996a276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ec7379cc-58c0-4931-ad05-d6c7b366f210" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3237e8e0-d2a2-4e58-8e60-e70f3996a276" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember_9ce17ba3-db39-462f-a24d-abf4d565d33c" xlink:href="nbix-20221231.xsd#nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3237e8e0-d2a2-4e58-8e60-e70f3996a276" xlink:to="loc_nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember_9ce17ba3-db39-462f-a24d-abf4d565d33c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#ShareBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="extended" id="ied24edbdd2764e819aef349b235c9a21_ShareBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_551dba91-ddf0-4544-b033-831fa2136a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8765bc5a-54f7-4723-bf18-47c364464a05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_551dba91-ddf0-4544-b033-831fa2136a3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8765bc5a-54f7-4723-bf18-47c364464a05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward_fef1daeb-cebd-4bb0-b035-770b681d082f" xlink:href="nbix-20221231.xsd#nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_551dba91-ddf0-4544-b033-831fa2136a3f" xlink:to="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward_fef1daeb-cebd-4bb0-b035-770b681d082f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted_e75d8d00-892e-4980-958d-acaa3465c2e4" xlink:href="nbix-20221231.xsd#nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_551dba91-ddf0-4544-b033-831fa2136a3f" xlink:to="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted_e75d8d00-892e-4980-958d-acaa3465c2e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward_bca17736-fb6a-41b0-8b27-6659b35b0bb7" xlink:href="nbix-20221231.xsd#nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_551dba91-ddf0-4544-b033-831fa2136a3f" xlink:to="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward_bca17736-fb6a-41b0-8b27-6659b35b0bb7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward_70ffc681-ef15-4521-b6da-bee03a3c69fc" xlink:href="nbix-20221231.xsd#nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_551dba91-ddf0-4544-b033-831fa2136a3f" xlink:to="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward_70ffc681-ef15-4521-b6da-bee03a3c69fc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_defc022c-edbd-4c61-84c2-4e19e1d89e86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_551dba91-ddf0-4544-b033-831fa2136a3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_defc022c-edbd-4c61-84c2-4e19e1d89e86" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e49d827d-b1c4-4360-9824-dd189e2dfb1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_551dba91-ddf0-4544-b033-831fa2136a3f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e49d827d-b1c4-4360-9824-dd189e2dfb1d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_00ce9756-91c5-4c4d-ad29-01c630d8fd2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_551dba91-ddf0-4544-b033-831fa2136a3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_00ce9756-91c5-4c4d-ad29-01c630d8fd2d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f6b76520-e515-4120-8b29-6df456ac96de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_551dba91-ddf0-4544-b033-831fa2136a3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f6b76520-e515-4120-8b29-6df456ac96de" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_dd7d24e2-9aff-48c1-bf4f-c4f677320c97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_551dba91-ddf0-4544-b033-831fa2136a3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_dd7d24e2-9aff-48c1-bf4f-c4f677320c97" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_b8300866-089e-4e4e-9970-6a9b65296727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_551dba91-ddf0-4544-b033-831fa2136a3f" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_b8300866-089e-4e4e-9970-6a9b65296727" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_e1168fff-157e-4c31-a352-bbb61d14c116" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_551dba91-ddf0-4544-b033-831fa2136a3f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_e1168fff-157e-4c31-a352-bbb61d14c116" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_39503482-f5ed-43ec-9020-dfe8feadb09a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_551dba91-ddf0-4544-b033-831fa2136a3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_39503482-f5ed-43ec-9020-dfe8feadb09a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_ca8c4efb-d546-4068-8c8a-ac1ace909cea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_551dba91-ddf0-4544-b033-831fa2136a3f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_ca8c4efb-d546-4068-8c8a-ac1ace909cea" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_78e198c4-ed68-44bd-9bce-332e6bcd4277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_551dba91-ddf0-4544-b033-831fa2136a3f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_78e198c4-ed68-44bd-9bce-332e6bcd4277" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9ebadb8f-dd30-46ac-a4df-781987a4a19e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_78e198c4-ed68-44bd-9bce-332e6bcd4277" xlink:to="loc_us-gaap_PlanNameAxis_9ebadb8f-dd30-46ac-a4df-781987a4a19e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9ebadb8f-dd30-46ac-a4df-781987a4a19e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_9ebadb8f-dd30-46ac-a4df-781987a4a19e" xlink:to="loc_us-gaap_PlanNameDomain_9ebadb8f-dd30-46ac-a4df-781987a4a19e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_bcf70e1c-fa8c-477f-bdd2-0bd250843f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_9ebadb8f-dd30-46ac-a4df-781987a4a19e" xlink:to="loc_us-gaap_PlanNameDomain_bcf70e1c-fa8c-477f-bdd2-0bd250843f1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_Amended2020EquityIncentivePlanMember_a09d9c02-ec93-4a20-97c1-41657cc87c42" xlink:href="nbix-20221231.xsd#nbix_Amended2020EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_bcf70e1c-fa8c-477f-bdd2-0bd250843f1a" xlink:to="loc_nbix_Amended2020EquityIncentivePlanMember_a09d9c02-ec93-4a20-97c1-41657cc87c42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TwoThousandAndElevenEquityIncentivePlanMember_aaf2885b-a277-40eb-9bcd-7b165c211119" xlink:href="nbix-20221231.xsd#nbix_TwoThousandAndElevenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_bcf70e1c-fa8c-477f-bdd2-0bd250843f1a" xlink:to="loc_nbix_TwoThousandAndElevenEquityIncentivePlanMember_aaf2885b-a277-40eb-9bcd-7b165c211119" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_Amended2018EmployeeStockPurchasePlanMember_c5b11552-6b2f-4b29-86ba-2b9580063d3e" xlink:href="nbix-20221231.xsd#nbix_Amended2018EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_bcf70e1c-fa8c-477f-bdd2-0bd250843f1a" xlink:to="loc_nbix_Amended2018EmployeeStockPurchasePlanMember_c5b11552-6b2f-4b29-86ba-2b9580063d3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_052402ab-32d5-4d1e-8e19-b8ddcb815a93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_78e198c4-ed68-44bd-9bce-332e6bcd4277" xlink:to="loc_us-gaap_AwardTypeAxis_052402ab-32d5-4d1e-8e19-b8ddcb815a93" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_052402ab-32d5-4d1e-8e19-b8ddcb815a93_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_052402ab-32d5-4d1e-8e19-b8ddcb815a93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_052402ab-32d5-4d1e-8e19-b8ddcb815a93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_382b52ca-d606-469f-8f53-91d36c5eacba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_052402ab-32d5-4d1e-8e19-b8ddcb815a93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_382b52ca-d606-469f-8f53-91d36c5eacba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_d31f69a8-949e-4a95-9d2a-49ad6866623f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_382b52ca-d606-469f-8f53-91d36c5eacba" xlink:to="loc_us-gaap_EmployeeStockMember_d31f69a8-949e-4a95-9d2a-49ad6866623f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1833f850-c6d3-4770-8436-d82936dafbc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_382b52ca-d606-469f-8f53-91d36c5eacba" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1833f850-c6d3-4770-8436-d82936dafbc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ff24656e-f30e-4199-9296-603fa0f742f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_382b52ca-d606-469f-8f53-91d36c5eacba" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ff24656e-f30e-4199-9296-603fa0f742f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PerformanceBasedRestrictedStockUnitMember_0cee8ac5-4b18-4219-8ff5-d36540119612" xlink:href="nbix-20221231.xsd#nbix_PerformanceBasedRestrictedStockUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_382b52ca-d606-469f-8f53-91d36c5eacba" xlink:to="loc_nbix_PerformanceBasedRestrictedStockUnitMember_0cee8ac5-4b18-4219-8ff5-d36540119612" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4bf015fd-86e7-4ce9-b15a-1719a1383358" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_78e198c4-ed68-44bd-9bce-332e6bcd4277" xlink:to="loc_srt_RangeAxis_4bf015fd-86e7-4ce9-b15a-1719a1383358" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4bf015fd-86e7-4ce9-b15a-1719a1383358_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4bf015fd-86e7-4ce9-b15a-1719a1383358" xlink:to="loc_srt_RangeMember_4bf015fd-86e7-4ce9-b15a-1719a1383358_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f8a705eb-9e64-4c14-b46a-9dac8cc80131" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4bf015fd-86e7-4ce9-b15a-1719a1383358" xlink:to="loc_srt_RangeMember_f8a705eb-9e64-4c14-b46a-9dac8cc80131" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d0d83028-abcd-4192-b490-a7f39461bb6e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f8a705eb-9e64-4c14-b46a-9dac8cc80131" xlink:to="loc_srt_MinimumMember_d0d83028-abcd-4192-b490-a7f39461bb6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f417d092-27da-433f-b40d-7d8b403c5bd6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f8a705eb-9e64-4c14-b46a-9dac8cc80131" xlink:to="loc_srt_MaximumMember_f417d092-27da-433f-b40d-7d8b403c5bd6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails" xlink:type="extended" id="i81ebf3ff2a6b4c09a4f3f871410727b4_ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e19d9c94-49cf-4180-8879-8ab0687b4858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_fe488fc4-239f-481e-8cd7-b61fefd485b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e19d9c94-49cf-4180-8879-8ab0687b4858" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_fe488fc4-239f-481e-8cd7-b61fefd485b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1d44c120-60c5-4bd1-b34c-795629f21f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e19d9c94-49cf-4180-8879-8ab0687b4858" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1d44c120-60c5-4bd1-b34c-795629f21f1c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c845f987-0359-4990-8272-1b05f35259c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1d44c120-60c5-4bd1-b34c-795629f21f1c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c845f987-0359-4990-8272-1b05f35259c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c845f987-0359-4990-8272-1b05f35259c1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c845f987-0359-4990-8272-1b05f35259c1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c845f987-0359-4990-8272-1b05f35259c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_02cba898-f47d-4de0-95f3-47140383a761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c845f987-0359-4990-8272-1b05f35259c1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_02cba898-f47d-4de0-95f3-47140383a761" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_206a31f5-409a-48c1-ab88-9f3774b7d146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_02cba898-f47d-4de0-95f3-47140383a761" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_206a31f5-409a-48c1-ab88-9f3774b7d146" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_958c23fb-5e4a-4d50-9160-828ddac79564" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_02cba898-f47d-4de0-95f3-47140383a761" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_958c23fb-5e4a-4d50-9160-828ddac79564" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails" xlink:type="extended" id="ic3b405b88eab43d08570bb18d7ccc9a8_ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8d71ec32-534e-4f81-b91f-c4dc4e746c26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_15ff0622-6a88-4efd-977b-7d5ad820dd1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8d71ec32-534e-4f81-b91f-c4dc4e746c26" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_15ff0622-6a88-4efd-977b-7d5ad820dd1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8b19ffb5-2bc1-41a2-848c-fb1a19d88c63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8d71ec32-534e-4f81-b91f-c4dc4e746c26" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8b19ffb5-2bc1-41a2-848c-fb1a19d88c63" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ac423140-d7a1-4bef-8401-662194d2ceda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8b19ffb5-2bc1-41a2-848c-fb1a19d88c63" xlink:to="loc_us-gaap_AwardTypeAxis_ac423140-d7a1-4bef-8401-662194d2ceda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac423140-d7a1-4bef-8401-662194d2ceda_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ac423140-d7a1-4bef-8401-662194d2ceda" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac423140-d7a1-4bef-8401-662194d2ceda_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d52eb159-d488-479d-8f58-8df815373eba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ac423140-d7a1-4bef-8401-662194d2ceda" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d52eb159-d488-479d-8f58-8df815373eba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5402343f-8a4b-4f37-a99f-acb77765a13e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d52eb159-d488-479d-8f58-8df815373eba" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5402343f-8a4b-4f37-a99f-acb77765a13e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d4dcb103-4cc3-47f7-bb29-3df95c195d14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d52eb159-d488-479d-8f58-8df815373eba" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d4dcb103-4cc3-47f7-bb29-3df95c195d14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PerformanceBasedRestrictedStockUnitMember_7c166ed0-9273-4316-9f2e-2a66fa91ff6b" xlink:href="nbix-20221231.xsd#nbix_PerformanceBasedRestrictedStockUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d52eb159-d488-479d-8f58-8df815373eba" xlink:to="loc_nbix_PerformanceBasedRestrictedStockUnitMember_7c166ed0-9273-4316-9f2e-2a66fa91ff6b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_b2d9a00b-6cbf-493e-b802-4493303f9809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d52eb159-d488-479d-8f58-8df815373eba" xlink:to="loc_us-gaap_EmployeeStockMember_b2d9a00b-6cbf-493e-b802-4493303f9809" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails" xlink:type="extended" id="ie16781fbc78545cfa992c48ceec4d6a6_ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5d345085-285e-443f-9688-eadef3a0d057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_71c7c6ab-e9aa-43cb-a7ae-e3e0b4403e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5d345085-285e-443f-9688-eadef3a0d057" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_71c7c6ab-e9aa-43cb-a7ae-e3e0b4403e5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_07f52dde-bc44-40ba-a224-85985896d8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5d345085-285e-443f-9688-eadef3a0d057" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_07f52dde-bc44-40ba-a224-85985896d8cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2f510f0b-703d-4ba8-bfc0-9fe069eb64a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5d345085-285e-443f-9688-eadef3a0d057" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2f510f0b-703d-4ba8-bfc0-9fe069eb64a0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_af890217-927b-4a87-9335-75f9c3d01307" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2f510f0b-703d-4ba8-bfc0-9fe069eb64a0" xlink:to="loc_us-gaap_AwardTypeAxis_af890217-927b-4a87-9335-75f9c3d01307" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af890217-927b-4a87-9335-75f9c3d01307_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_af890217-927b-4a87-9335-75f9c3d01307" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af890217-927b-4a87-9335-75f9c3d01307_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6d363347-1314-480c-92e3-18d1d013eb08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_af890217-927b-4a87-9335-75f9c3d01307" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6d363347-1314-480c-92e3-18d1d013eb08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_40c63dfe-f1eb-4611-94f0-1d9722879601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6d363347-1314-480c-92e3-18d1d013eb08" xlink:to="loc_us-gaap_EmployeeStockOptionMember_40c63dfe-f1eb-4611-94f0-1d9722879601" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d0c7769e-0e84-4978-acf1-191c3e07c4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6d363347-1314-480c-92e3-18d1d013eb08" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d0c7769e-0e84-4978-acf1-191c3e07c4dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PerformanceBasedRestrictedStockUnitMember_7d2dedd9-32c6-4740-8844-6a75afecd900" xlink:href="nbix-20221231.xsd#nbix_PerformanceBasedRestrictedStockUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6d363347-1314-480c-92e3-18d1d013eb08" xlink:to="loc_nbix_PerformanceBasedRestrictedStockUnitMember_7d2dedd9-32c6-4740-8844-6a75afecd900" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails" xlink:type="extended" id="ib893e8743cd94d449b433b855d4c046b_ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f2e7f497-4336-4b79-962f-c4624dd8c6e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d8749aa6-44df-47f1-868f-86e07d9a531f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f2e7f497-4336-4b79-962f-c4624dd8c6e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d8749aa6-44df-47f1-868f-86e07d9a531f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_87836619-df7c-4bd1-9374-deb0bb3387d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f2e7f497-4336-4b79-962f-c4624dd8c6e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_87836619-df7c-4bd1-9374-deb0bb3387d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_fe1ec004-9b08-4c29-a04f-bfc46e0ea152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f2e7f497-4336-4b79-962f-c4624dd8c6e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_fe1ec004-9b08-4c29-a04f-bfc46e0ea152" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_54036329-4f4d-4ce4-a4a4-2a374fc36e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f2e7f497-4336-4b79-962f-c4624dd8c6e7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_54036329-4f4d-4ce4-a4a4-2a374fc36e1b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c67c590f-5cf3-4385-bbd6-a0bda9ffcaa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f2e7f497-4336-4b79-962f-c4624dd8c6e7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c67c590f-5cf3-4385-bbd6-a0bda9ffcaa4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_66b899f9-5632-4251-98f4-b944f29dad0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c67c590f-5cf3-4385-bbd6-a0bda9ffcaa4" xlink:to="loc_us-gaap_AwardTypeAxis_66b899f9-5632-4251-98f4-b944f29dad0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66b899f9-5632-4251-98f4-b944f29dad0c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_66b899f9-5632-4251-98f4-b944f29dad0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66b899f9-5632-4251-98f4-b944f29dad0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_27ea4233-d691-46aa-90e9-91390ddc56d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_66b899f9-5632-4251-98f4-b944f29dad0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_27ea4233-d691-46aa-90e9-91390ddc56d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e5536643-fd0e-4a0b-97d1-dfafee0b5605" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_27ea4233-d691-46aa-90e9-91390ddc56d7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e5536643-fd0e-4a0b-97d1-dfafee0b5605" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails" xlink:type="extended" id="i63f4a211e72c4cee9fc055258e9db550_ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b91d550-ea00-41c8-a21c-8c5bc22e899b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d5d9472e-0622-42e8-9ab3-8c1609a5a7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b91d550-ea00-41c8-a21c-8c5bc22e899b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d5d9472e-0622-42e8-9ab3-8c1609a5a7b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_794176be-5914-4d47-95a1-03ecb12ac982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d5d9472e-0622-42e8-9ab3-8c1609a5a7b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_794176be-5914-4d47-95a1-03ecb12ac982" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_51be5f7d-0c7f-4a72-bb6a-2e91693c28ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d5d9472e-0622-42e8-9ab3-8c1609a5a7b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_51be5f7d-0c7f-4a72-bb6a-2e91693c28ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f512e87d-db19-4202-80d5-a0e78f898c25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d5d9472e-0622-42e8-9ab3-8c1609a5a7b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f512e87d-db19-4202-80d5-a0e78f898c25" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0945a435-080a-45cf-8b78-25133802523e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d5d9472e-0622-42e8-9ab3-8c1609a5a7b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0945a435-080a-45cf-8b78-25133802523e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_967de6d4-42c1-4fb9-9724-8ccc6b9b0d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_43b8d1c9-5bc7-4f2d-880d-e952ff35f446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b91d550-ea00-41c8-a21c-8c5bc22e899b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_43b8d1c9-5bc7-4f2d-880d-e952ff35f446" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6df49321-dfc3-40ae-a436-39e28382dab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_43b8d1c9-5bc7-4f2d-880d-e952ff35f446" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6df49321-dfc3-40ae-a436-39e28382dab4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1941a043-425e-4a42-9e7b-24b7a573c0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_43b8d1c9-5bc7-4f2d-880d-e952ff35f446" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1941a043-425e-4a42-9e7b-24b7a573c0ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ed9c6fe2-7b80-40dc-89d5-603cca908b10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_43b8d1c9-5bc7-4f2d-880d-e952ff35f446" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ed9c6fe2-7b80-40dc-89d5-603cca908b10" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1dad7e5e-a4e7-4d53-910c-fb705871c50c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_43b8d1c9-5bc7-4f2d-880d-e952ff35f446" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1dad7e5e-a4e7-4d53-910c-fb705871c50c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3755c706-e1e5-4724-b1f6-207ffcf73611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_b8f47a97-a348-4d62-8fbc-4620fdf90571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b91d550-ea00-41c8-a21c-8c5bc22e899b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_b8f47a97-a348-4d62-8fbc-4620fdf90571" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_03453af6-b0bd-4c26-9167-ba6e494eb4db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_b8f47a97-a348-4d62-8fbc-4620fdf90571" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_03453af6-b0bd-4c26-9167-ba6e494eb4db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_27ff6d4c-2d98-407a-9264-ca40d62c09b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_b8f47a97-a348-4d62-8fbc-4620fdf90571" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_27ff6d4c-2d98-407a-9264-ca40d62c09b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0e06c957-9672-4eef-b6e1-48b69d72fc21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b91d550-ea00-41c8-a21c-8c5bc22e899b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0e06c957-9672-4eef-b6e1-48b69d72fc21" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6b8e1ab9-9276-4eb5-831a-8c651942b40c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0e06c957-9672-4eef-b6e1-48b69d72fc21" xlink:to="loc_us-gaap_AwardTypeAxis_6b8e1ab9-9276-4eb5-831a-8c651942b40c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b8e1ab9-9276-4eb5-831a-8c651942b40c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6b8e1ab9-9276-4eb5-831a-8c651942b40c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b8e1ab9-9276-4eb5-831a-8c651942b40c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_efef2a19-9a9d-460b-b00b-fd1cf7d9f8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6b8e1ab9-9276-4eb5-831a-8c651942b40c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_efef2a19-9a9d-460b-b00b-fd1cf7d9f8ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b9ad2346-6ff9-4bb9-9b7b-28fea03ad515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_efef2a19-9a9d-460b-b00b-fd1cf7d9f8ff" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b9ad2346-6ff9-4bb9-9b7b-28fea03ad515" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PerformanceBasedRestrictedStockUnitMember_7b17b7ab-045b-42f1-b8cd-e8d8a1f31d8a" xlink:href="nbix-20221231.xsd#nbix_PerformanceBasedRestrictedStockUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_efef2a19-9a9d-460b-b00b-fd1cf7d9f8ff" xlink:to="loc_nbix_PerformanceBasedRestrictedStockUnitMember_7b17b7ab-045b-42f1-b8cd-e8d8a1f31d8a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended" id="i8c35bba38417403eb133ed3a57804a2e_IncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxesLineItems_1504b3ca-1ba0-4b93-8629-1a738b57248f" xlink:href="nbix-20221231.xsd#nbix_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_0505a608-10fd-4b7b-9bff-a3255d2b1d07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_IncomeTaxesLineItems_1504b3ca-1ba0-4b93-8629-1a738b57248f" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_0505a608-10fd-4b7b-9bff-a3255d2b1d07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_bf1f1fbb-8f9d-4884-b3b8-6b34528c309e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_IncomeTaxesLineItems_1504b3ca-1ba0-4b93-8629-1a738b57248f" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_bf1f1fbb-8f9d-4884-b3b8-6b34528c309e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_d17afab6-b6a2-4227-a162-1efc16e03a49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_IncomeTaxesLineItems_1504b3ca-1ba0-4b93-8629-1a738b57248f" xlink:to="loc_us-gaap_OperatingLossCarryforwards_d17afab6-b6a2-4227-a162-1efc16e03a49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_a54a50b0-064f-42e8-a0a2-0b8fc38521f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_IncomeTaxesLineItems_1504b3ca-1ba0-4b93-8629-1a738b57248f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_a54a50b0-064f-42e8-a0a2-0b8fc38521f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationInterestAccrued_f07dc7f8-eab9-46a0-ac28-4b68b44f850e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_IncomeTaxesLineItems_1504b3ca-1ba0-4b93-8629-1a738b57248f" xlink:to="loc_us-gaap_IncomeTaxExaminationInterestAccrued_f07dc7f8-eab9-46a0-ac28-4b68b44f850e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAccrued_a0f2338d-3735-4e38-bf1d-4defb811204a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_IncomeTaxesLineItems_1504b3ca-1ba0-4b93-8629-1a738b57248f" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAccrued_a0f2338d-3735-4e38-bf1d-4defb811204a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_de19e6bf-7a90-4c8b-9b84-af65e319489c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_IncomeTaxesLineItems_1504b3ca-1ba0-4b93-8629-1a738b57248f" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_de19e6bf-7a90-4c8b-9b84-af65e319489c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxesTable_357117be-fa7b-4cec-8a98-dad6e45ec502" xlink:href="nbix-20221231.xsd#nbix_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nbix_IncomeTaxesLineItems_1504b3ca-1ba0-4b93-8629-1a738b57248f" xlink:to="loc_nbix_IncomeTaxesTable_357117be-fa7b-4cec-8a98-dad6e45ec502" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_931ff5d3-9e5e-400d-a4fc-6320ab717847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbix_IncomeTaxesTable_357117be-fa7b-4cec-8a98-dad6e45ec502" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_931ff5d3-9e5e-400d-a4fc-6320ab717847" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_931ff5d3-9e5e-400d-a4fc-6320ab717847_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_931ff5d3-9e5e-400d-a4fc-6320ab717847" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_931ff5d3-9e5e-400d-a4fc-6320ab717847_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_c48acc26-7320-4e7e-85eb-4d64bd2c6ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_931ff5d3-9e5e-400d-a4fc-6320ab717847" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_c48acc26-7320-4e7e-85eb-4d64bd2c6ff8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_e0b8ba1b-9f83-458c-bd3b-73732c2a8772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c48acc26-7320-4e7e-85eb-4d64bd2c6ff8" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_e0b8ba1b-9f83-458c-bd3b-73732c2a8772" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_fda7a951-4405-47fa-8416-ffab2579c598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c48acc26-7320-4e7e-85eb-4d64bd2c6ff8" xlink:to="loc_us-gaap_ForeignCountryMember_fda7a951-4405-47fa-8416-ffab2579c598" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_2ae8b7d2-d407-436a-93d3-dbd8820362bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c48acc26-7320-4e7e-85eb-4d64bd2c6ff8" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_2ae8b7d2-d407-436a-93d3-dbd8820362bf" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesSupplementalInformationDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#LeasesSupplementalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/LeasesSupplementalInformationDetails" xlink:type="extended" id="i2a6c8ca310854b5c8d8ad7800ac18efb_LeasesSupplementalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_ce4c07c2-f0ab-444c-9835-f4f460cdd9df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_c142f1f0-3c0d-4254-98a9-ec73cbddf2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ce4c07c2-f0ab-444c-9835-f4f460cdd9df" xlink:to="loc_us-gaap_OperatingLeaseCost_c142f1f0-3c0d-4254-98a9-ec73cbddf2eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_eb5460f6-92ab-4644-89cb-d9e6338569f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ce4c07c2-f0ab-444c-9835-f4f460cdd9df" xlink:to="loc_us-gaap_OperatingLeasePayments_eb5460f6-92ab-4644-89cb-d9e6338569f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c827e8d1-1231-4def-8833-56af8ce88002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ce4c07c2-f0ab-444c-9835-f4f460cdd9df" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c827e8d1-1231-4def-8833-56af8ce88002" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_eccd1989-81ba-4e46-97df-3240b0182f27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ce4c07c2-f0ab-444c-9835-f4f460cdd9df" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_eccd1989-81ba-4e46-97df-3240b0182f27" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_f50a2c52-b378-4aa3-a5df-781d6c549472" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ce4c07c2-f0ab-444c-9835-f4f460cdd9df" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_f50a2c52-b378-4aa3-a5df-781d6c549472" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_917ebb57-d32b-486b-9f7a-7134937a94ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ce4c07c2-f0ab-444c-9835-f4f460cdd9df" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_917ebb57-d32b-486b-9f7a-7134937a94ae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_dfec4952-a871-428c-939a-1113d3ed2850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_917ebb57-d32b-486b-9f7a-7134937a94ae" xlink:to="loc_us-gaap_CreditFacilityAxis_dfec4952-a871-428c-939a-1113d3ed2850" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_dfec4952-a871-428c-939a-1113d3ed2850_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_dfec4952-a871-428c-939a-1113d3ed2850" xlink:to="loc_us-gaap_CreditFacilityDomain_dfec4952-a871-428c-939a-1113d3ed2850_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_d5045ae1-05b5-4ebd-a3e2-f7bb6791f082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_dfec4952-a871-428c-939a-1113d3ed2850" xlink:to="loc_us-gaap_CreditFacilityDomain_d5045ae1-05b5-4ebd-a3e2-f7bb6791f082" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_22d92369-38f5-4cca-944c-2b31f0a76577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_d5045ae1-05b5-4ebd-a3e2-f7bb6791f082" xlink:to="loc_us-gaap_LetterOfCreditMember_22d92369-38f5-4cca-944c-2b31f0a76577" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/SubsequentEventsDetails" xlink:type="extended" id="i7008cc09ee3f4378950c41e3ca571f31_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_4c9d027b-631e-4633-9411-df1d5ee6b9dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_UpfrontPaymentsMade_c880b387-abb3-427d-ab87-3a4cab07ab3a" xlink:href="nbix-20221231.xsd#nbix_UpfrontPaymentsMade"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_4c9d027b-631e-4633-9411-df1d5ee6b9dd" xlink:to="loc_nbix_UpfrontPaymentsMade_c880b387-abb3-427d-ab87-3a4cab07ab3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BusinessAcquisitionEquityInvestmentToAcquireTheWorldwideRights_76195111-645d-4902-ab7a-285f806627fb" xlink:href="nbix-20221231.xsd#nbix_BusinessAcquisitionEquityInvestmentToAcquireTheWorldwideRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_4c9d027b-631e-4633-9411-df1d5ee6b9dd" xlink:to="loc_nbix_BusinessAcquisitionEquityInvestmentToAcquireTheWorldwideRights_76195111-645d-4902-ab7a-285f806627fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_70f931d6-2e70-4590-82bb-e9ed74eb5f39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_4c9d027b-631e-4633-9411-df1d5ee6b9dd" xlink:to="loc_us-gaap_SubsequentEventTable_70f931d6-2e70-4590-82bb-e9ed74eb5f39" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_888127ae-4f0d-4253-8ff7-d61f6426008b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_70f931d6-2e70-4590-82bb-e9ed74eb5f39" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_888127ae-4f0d-4253-8ff7-d61f6426008b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_888127ae-4f0d-4253-8ff7-d61f6426008b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_888127ae-4f0d-4253-8ff7-d61f6426008b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_888127ae-4f0d-4253-8ff7-d61f6426008b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_401be2f0-4570-443f-9552-c680642a4a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_888127ae-4f0d-4253-8ff7-d61f6426008b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_401be2f0-4570-443f-9552-c680642a4a2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_238519d7-b698-4576-b459-4dd7ab57c817" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_401be2f0-4570-443f-9552-c680642a4a2e" xlink:to="loc_us-gaap_SubsequentEventMember_238519d7-b698-4576-b459-4dd7ab57c817" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b9b78731-ce9e-47fb-b548-0aaf3526f035" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_70f931d6-2e70-4590-82bb-e9ed74eb5f39" xlink:to="loc_srt_CounterpartyNameAxis_b9b78731-ce9e-47fb-b548-0aaf3526f035" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b9b78731-ce9e-47fb-b548-0aaf3526f035_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_b9b78731-ce9e-47fb-b548-0aaf3526f035" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b9b78731-ce9e-47fb-b548-0aaf3526f035_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ca2fbd3f-42c2-4486-8ef7-15369f10d85c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_b9b78731-ce9e-47fb-b548-0aaf3526f035" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ca2fbd3f-42c2-4486-8ef7-15369f10d85c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_VoyagerTherapeuticsMember_06209bef-eaa0-4b45-a6bd-547f73b80cac" xlink:href="nbix-20221231.xsd#nbix_VoyagerTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ca2fbd3f-42c2-4486-8ef7-15369f10d85c" xlink:to="loc_nbix_VoyagerTherapeuticsMember_06209bef-eaa0-4b45-a6bd-547f73b80cac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5468ef47-4f30-47de-aae2-299ab4f7a155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_70f931d6-2e70-4590-82bb-e9ed74eb5f39" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5468ef47-4f30-47de-aae2-299ab4f7a155" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5468ef47-4f30-47de-aae2-299ab4f7a155_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5468ef47-4f30-47de-aae2-299ab4f7a155" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5468ef47-4f30-47de-aae2-299ab4f7a155_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d0849ced-ecf2-4d04-9104-205dbd9bb0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5468ef47-4f30-47de-aae2-299ab4f7a155" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d0849ced-ecf2-4d04-9104-205dbd9bb0fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_87cb64c4-c2ed-4505-89c2-2077e5427790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d0849ced-ecf2-4d04-9104-205dbd9bb0fd" xlink:to="loc_us-gaap_CollaborativeArrangementMember_87cb64c4-c2ed-4505-89c2-2077e5427790" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>nbix-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:218564f8-ce6a-495b-ab09-3ced376fc2a9,g:579af41c-0e49-45b3-bd8f-934603ccb3b3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_nbix_DebtInstrumentConversionDomain_c891e686-1119-44f6-b5af-d131e5391b01_terseLabel_en-US" xlink:label="lab_nbix_DebtInstrumentConversionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion [Domain]</link:label>
    <link:label id="lab_nbix_DebtInstrumentConversionDomain_label_en-US" xlink:label="lab_nbix_DebtInstrumentConversionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion [Domain]</link:label>
    <link:label id="lab_nbix_DebtInstrumentConversionDomain_documentation_en-US" xlink:label="lab_nbix_DebtInstrumentConversionDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConversionDomain" xlink:href="nbix-20221231.xsd#nbix_DebtInstrumentConversionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DebtInstrumentConversionDomain" xlink:to="lab_nbix_DebtInstrumentConversionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_6f439952-4c77-4c64-83b9-4d7ea8216255_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_d611810d-985b-4013-8443-783ef8d9de3a_terseLabel_en-US" xlink:label="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_label_en-US" xlink:label="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Reconciliation Of Cash Cash Equivalents And Restricted Cash [Table Text Block]</link:label>
    <link:label id="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_documentation_en-US" xlink:label="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of reconciliation of cash cash equivalents and restricted cash.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:href="nbix-20221231.xsd#nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:to="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1acac705-172d-40f0-9901-46da53e173ce_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_79d0745c-d92d-4e34-a5c9-9ef3065d6fac_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_873b15d3-3ae8-4ff7-8f40-d3ee55ffde57_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_256c69f2-6b33-4236-974c-f87740ac9888_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted_9843c6ce-1a8d-4da7-97ac-dc5f42b7fded_terseLabel_en-US" xlink:label="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares reduced pursuant to any full value award granted (in shares)</link:label>
    <link:label id="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted_label_en-US" xlink:label="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Reduced Pursuant To Award Granted</link:label>
    <link:label id="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted_documentation_en-US" xlink:label="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Reduced Pursuant To Award Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted" xlink:href="nbix-20221231.xsd#nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted" xlink:to="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_5b32456d-31b1-45cc-a4ae-fe7a0947b80e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized losses and fair value available-for-sale investments in unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_9c702301-3fbd-4fcb-9cf3-7584394bf915_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_3d53c466-27a6-4a04-86fe-4fef26095a98_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_af255845-640a-4151-a7da-2b0292e2bd27_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_9840d13f-e6b3-4131-9712-fb9738304a69_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_3c9d1de3-a8a5-4c42-9353-9486e850f906_terseLabel_en-US" xlink:label="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum percentage of common stock price trigger</link:label>
    <link:label id="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_label_en-US" xlink:label="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Percentage Of Trading Price To Last Reported Sale Price</link:label>
    <link:label id="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_documentation_en-US" xlink:label="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The minimum percentage of the product of the common stock trading price multiplied by the conversion rate during the measurement period as compared to the principal note amount that triggers a conversion option on the notes, if it falls below this percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:href="nbix-20221231.xsd#nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:to="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_cf904b6e-3e7b-45f3-939d-30955ff15045_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations and Asset Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_e23468b5-c556-41f8-89bb-b21730f28324_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold consecutive common stock trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_73431cca-b555-4529-8454-6ea5359ff1c4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_5a243b8f-cc0f-4c22-93b7-0c6af7588cb5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Information Relating to our Recognized Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_afb58286-3580-4c6d-901b-578e2a4887b1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_UpfrontPaymentsMade_afe77a71-6a60-4dfe-9596-eab52f3eb915_terseLabel_en-US" xlink:label="lab_nbix_UpfrontPaymentsMade" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payments made</link:label>
    <link:label id="lab_nbix_UpfrontPaymentsMade_label_en-US" xlink:label="lab_nbix_UpfrontPaymentsMade" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payments Made</link:label>
    <link:label id="lab_nbix_UpfrontPaymentsMade_documentation_en-US" xlink:label="lab_nbix_UpfrontPaymentsMade" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payments made under a collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_UpfrontPaymentsMade" xlink:href="nbix-20221231.xsd#nbix_UpfrontPaymentsMade"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_UpfrontPaymentsMade" xlink:to="lab_nbix_UpfrontPaymentsMade" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_3aa842ad-5706-4375-8962-20d407f421e3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_b4d62d84-1b69-47c3-960d-53a5ec0fa513_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_InvestmentIncomeAndOtherNet_e5460143-c757-4d66-9ea8-cdb9c0a4327f_terseLabel_en-US" xlink:label="lab_nbix_InvestmentIncomeAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income and other, net</link:label>
    <link:label id="lab_nbix_InvestmentIncomeAndOtherNet_label_en-US" xlink:label="lab_nbix_InvestmentIncomeAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income And Other Net</link:label>
    <link:label id="lab_nbix_InvestmentIncomeAndOtherNet_documentation_en-US" xlink:label="lab_nbix_InvestmentIncomeAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income and other net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_InvestmentIncomeAndOtherNet" xlink:href="nbix-20221231.xsd#nbix_InvestmentIncomeAndOtherNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_InvestmentIncomeAndOtherNet" xlink:to="lab_nbix_InvestmentIncomeAndOtherNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_6c62164a-6bd8-4d7b-8fc0-f0353c4f56dd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_3ff80d1e-4890-47aa-b4d0-e825ed1fd43d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_72d207c2-dc8c-451c-ac81-c064bab74ad5_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c4d3c793-a13d-42b0-a39b-2b68e5c44b82_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRestricted_12f2d5f6-8be8-47c1-9b7b-a84a2022f692_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRestricted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRestricted_b5f02799-5986-4270-ac37-4eb6b2d4dfeb_periodStartLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRestricted" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRestricted_d6c851d5-7652-44e2-9152-2c4a79da1a27_periodEndLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRestricted" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at ending of period</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRestricted_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRestricted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Restricted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRestricted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiRestricted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRestricted" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRestricted" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_f97a4755-6173-4c27-a558-a7d605b26aed_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_874895fc-4f5e-4bc9-acab-a32889297ec9_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_b094f1e9-3a22-468b-88c3-94bd61dfd186_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0ba9cd2d-fd64-458b-abc2-6d4f66ea8f95_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_6672609c-2028-4e34-885a-2d7dd19b3208_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_cb3fe403-d23b-42fd-a07f-38a883500177_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_572710a5-556c-4fac-abeb-f92442b32d32_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2e70f173-83fb-46bc-81e0-0bf0d87c4e2b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_d20a9bc9-f484-4b3d-be0f-ad177c24bcd3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_af5c8b94-7059-4e4f-9068-478c5b7a1c78_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_60a90810-50d9-4a84-adf2-3816f3f87aa2_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration of the statute of limitations for the assessment of taxes</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_b4bad756-bb26-48f6-b4dc-50e2444030c2_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_921f6d2e-831a-4dd2-a812-ae58d0af2536_negatedTerseLabel_en-US" xlink:label="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss, current</link:label>
    <link:label id="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_label_en-US" xlink:label="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current</link:label>
    <link:label id="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_documentation_en-US" xlink:label="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:href="nbix-20221231.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:to="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_9325394c-743b-424b-81e3-5395f0abfaa2_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate repurchase price paid in cash</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_428fa3fc-aa9d-4c68-ad4e-3957cec26f1d_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_d5be1c47-0e04-43be-8e10-2490d549668b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_6db8445d-33f9-4b68-b793-2501af15f18c_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_8fd2e3f3-d454-421e-a7f6-4ed216ae7d2f_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_8d0f5b07-f8a3-4082-8c5d-fe10486353b2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_a89f6afa-cab3-4572-a2db-22b3ab55626e_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cd27d2d3-5a06-43c1-ac89-af68832cdaf2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_32d739cc-4783-4b4e-bd3e-edb791d49b32_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive shares excluded from diluted per share amounts (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_e5c9c1e0-8715-433a-84a7-ad219fac2c82_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_0e274e47-5aa7-450e-a2f8-c27f5f587d25_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_60b741b9-3f16-44c1-918f-f6bb17873145_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_e67a17ae-d028-4b52-8436-a42d5aae5aec_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_f47e9bde-43c5-4d68-8ce6-830ef967be06_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_568624e8-1a26-4b41-9faa-ebe0653645b1_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_e6c0f0eb-7036-4af7-a7b3-910e889e95f3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_39415173-02a8-4df8-b729-034c87d774ba_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets on recurring basis</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireRestrictedInvestments_1857ad6c-3d81-486f-bf54-2a91c9b5cbe7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of equity securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireRestrictedInvestments_b94d9be7-c113-4281-937a-369ea89e3030_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireRestrictedInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Restricted Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_02a0cf08-2e59-4e7d-8193-70bc429e198d_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase related to current year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_14a02c4a-0daf-42e8-a9a2-61e1d6378828_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_CashAndMoneyMarketFundMember_69c363b3-f046-4593-95d3-930f3446f498_terseLabel_en-US" xlink:label="lab_nbix_CashAndMoneyMarketFundMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and money market funds</link:label>
    <link:label id="lab_nbix_CashAndMoneyMarketFundMember_label_en-US" xlink:label="lab_nbix_CashAndMoneyMarketFundMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Money Market Fund [Member]</link:label>
    <link:label id="lab_nbix_CashAndMoneyMarketFundMember_documentation_en-US" xlink:label="lab_nbix_CashAndMoneyMarketFundMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency on hand as well as demand deposits with banks or financial institutions, and funds that invest in short-term money-market instruments, for example, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CashAndMoneyMarketFundMember" xlink:href="nbix-20221231.xsd#nbix_CashAndMoneyMarketFundMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_CashAndMoneyMarketFundMember" xlink:to="lab_nbix_CashAndMoneyMarketFundMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_29e4ebaa-5ad3-4d80-bcf0-6fe9a2899adf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_89e225d2-1b10-4412-a929-466d45269969_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_BusinessAcquisitionEquityInvestmentToAcquireTheWorldwideRights_c243b0de-b9d4-4abd-a269-c4caeae9bd47_terseLabel_en-US" xlink:label="lab_nbix_BusinessAcquisitionEquityInvestmentToAcquireTheWorldwideRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investment to acquire the worldwide rights</link:label>
    <link:label id="lab_nbix_BusinessAcquisitionEquityInvestmentToAcquireTheWorldwideRights_label_en-US" xlink:label="lab_nbix_BusinessAcquisitionEquityInvestmentToAcquireTheWorldwideRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Investment To Acquire The Worldwide Rights</link:label>
    <link:label id="lab_nbix_BusinessAcquisitionEquityInvestmentToAcquireTheWorldwideRights_documentation_en-US" xlink:label="lab_nbix_BusinessAcquisitionEquityInvestmentToAcquireTheWorldwideRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Investment To Acquire The Worldwide Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BusinessAcquisitionEquityInvestmentToAcquireTheWorldwideRights" xlink:href="nbix-20221231.xsd#nbix_BusinessAcquisitionEquityInvestmentToAcquireTheWorldwideRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_BusinessAcquisitionEquityInvestmentToAcquireTheWorldwideRights" xlink:to="lab_nbix_BusinessAcquisitionEquityInvestmentToAcquireTheWorldwideRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleStockPriceTrigger_928cdbbe-0479-4cf4-8edb-2d9e74983f62_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock price trigger (in USD per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_9d70f9a6-5eda-44e4-8b24-f7180b7c045f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_PrincipalAmountOnConversionRate_44a706d3-4481-4438-b910-e88d71b2e91b_terseLabel_en-US" xlink:label="lab_nbix_PrincipalAmountOnConversionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount on conversion rate</link:label>
    <link:label id="lab_nbix_PrincipalAmountOnConversionRate_label_en-US" xlink:label="lab_nbix_PrincipalAmountOnConversionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Amount On Conversion Rate</link:label>
    <link:label id="lab_nbix_PrincipalAmountOnConversionRate_documentation_en-US" xlink:label="lab_nbix_PrincipalAmountOnConversionRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount on conversion rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PrincipalAmountOnConversionRate" xlink:href="nbix-20221231.xsd#nbix_PrincipalAmountOnConversionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_PrincipalAmountOnConversionRate" xlink:to="lab_nbix_PrincipalAmountOnConversionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_58d3681d-9377-44a0-b346-f25b7852baa2_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosure:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_f596b4d5-849a-4259-99fb-31d9c7abdb76_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_6e92b1fe-5268-43e3-a0c7-672c1c57c990_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_f14f879c-b42d-4e99-93ba-e239c2712009_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_41e6f5ac-326c-4f90-8306-51416be59c64_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_b6ecad37-ce32-4740-afe6-f560602048ea_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_8ab563d1-0faa-4df0-95ca-0ac7d31a86a9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_40596658-c95c-4d2b-99d9-65cdea30b7c5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_46ebe344-cb80-4006-9c09-986885d5ce28_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfers out of Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_140e7562-2855-4e21-9db5-c27c66dcf714_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_7f0577d6-a1d6-412a-aca6-eb66ab224c1e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_NumberOfRenewalOptions_fe1d3316-f0d9-4550-b7db-5e83899ca415_terseLabel_en-US" xlink:label="lab_nbix_NumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of lease renewal options</link:label>
    <link:label id="lab_nbix_NumberOfRenewalOptions_label_en-US" xlink:label="lab_nbix_NumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Renewal Options</link:label>
    <link:label id="lab_nbix_NumberOfRenewalOptions_documentation_en-US" xlink:label="lab_nbix_NumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of renewal options under the terms of the lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NumberOfRenewalOptions" xlink:href="nbix-20221231.xsd#nbix_NumberOfRenewalOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_NumberOfRenewalOptions" xlink:to="lab_nbix_NumberOfRenewalOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_CarryingAmountOfLiabilityComponentUponIssuance_d289e6da-9b11-4b33-8483-a8fa1d0639de_terseLabel_en-US" xlink:label="lab_nbix_CarryingAmountOfLiabilityComponentUponIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount of the liability component upon issuance</link:label>
    <link:label id="lab_nbix_CarryingAmountOfLiabilityComponentUponIssuance_label_en-US" xlink:label="lab_nbix_CarryingAmountOfLiabilityComponentUponIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount Of Liability Component Upon Issuance</link:label>
    <link:label id="lab_nbix_CarryingAmountOfLiabilityComponentUponIssuance_documentation_en-US" xlink:label="lab_nbix_CarryingAmountOfLiabilityComponentUponIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The carrying amount of the liability component upon issuance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CarryingAmountOfLiabilityComponentUponIssuance" xlink:href="nbix-20221231.xsd#nbix_CarryingAmountOfLiabilityComponentUponIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_CarryingAmountOfLiabilityComponentUponIssuance" xlink:to="lab_nbix_CarryingAmountOfLiabilityComponentUponIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_7a22e411-5fac-4260-bbe1-77eb5146a87e_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_1d29ff20-03e9-44eb-85af-9ed0e000809b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements related to prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_caea58a6-9c30-487b-8e95-e07dee4117aa_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_OtherBalanceSheetDetailsAbstract_087d443c-9f55-4037-ae95-48424967da8a_terseLabel_en-US" xlink:label="lab_nbix_OtherBalanceSheetDetailsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Balance Sheet Details [Abstract]</link:label>
    <link:label id="lab_nbix_OtherBalanceSheetDetailsAbstract_label_en-US" xlink:label="lab_nbix_OtherBalanceSheetDetailsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Balance Sheet Details [Abstract]</link:label>
    <link:label id="lab_nbix_OtherBalanceSheetDetailsAbstract_documentation_en-US" xlink:label="lab_nbix_OtherBalanceSheetDetailsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other balance sheet details.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OtherBalanceSheetDetailsAbstract" xlink:href="nbix-20221231.xsd#nbix_OtherBalanceSheetDetailsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract" xlink:to="lab_nbix_OtherBalanceSheetDetailsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_ded965bf-9457-4efe-a7ee-22e5fa473c99_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less current operating lease liabilities included in other current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_50b6d5d9-c445-470c-ab30-eb129868d281_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_dc5f7a5f-b023-465d-a24e-30d63684bb55_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_08b68a65-eb0f-423e-bb7a-139671c17047_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_fa9a5068-d490-4c47-9ffa-05872c964f2f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, maximum employee contribution percentage</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2fd9b617-b285-42ae-85a6-75cad1d59f00_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAccrued_a81cbd16-d82d-4b35-b6f7-a1b91027d470_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Penalties accrued</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAccrued_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Penalties Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAccrued" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_f57a0dfa-749d-415b-91fc-68a6b39f5ec5_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_5c73daad-24a4-42e8-8775-126e45bf4f36_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_AccruedResearchAndDevelopmentExpenseCurrent_829d46df-2391-45d1-af63-4153ea4443bd_terseLabel_en-US" xlink:label="lab_nbix_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued development costs</link:label>
    <link:label id="lab_nbix_AccruedResearchAndDevelopmentExpenseCurrent_label_en-US" xlink:label="lab_nbix_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Expense Current</link:label>
    <link:label id="lab_nbix_AccruedResearchAndDevelopmentExpenseCurrent_documentation_en-US" xlink:label="lab_nbix_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development expense current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AccruedResearchAndDevelopmentExpenseCurrent" xlink:href="nbix-20221231.xsd#nbix_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="lab_nbix_AccruedResearchAndDevelopmentExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_4b32c986-ce12-4df1-bf75-6c5ce73da459_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_242287fa-6eb8-4f8f-895d-a4d884095d0a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57041c24-dae4-44b4-8292-f62a5004ee67_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fb2eafa8-7204-4d81-b1fa-ca4c6b419c0f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_cdedd3a7-b07e-4ff8-99ab-b254617223df_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_bfe4bab0-a00b-424d-9a98-9f497b7695d4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intrinsic value vested in period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_07f9c70a-c5d5-42b3-b9a7-f03c54bd1648_verboseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_33b5c391-3eb5-41ab-b0cf-c53d815b790a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_5c876c75-4063-4cdb-aca0-ab5e83c3453c_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost, current</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollateralAxis_81d6553e-8681-498f-870d-208595570225_terseLabel_en-US" xlink:label="lab_us-gaap_CollateralAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral Held [Axis]</link:label>
    <link:label id="lab_us-gaap_CollateralAxis_label_en-US" xlink:label="lab_us-gaap_CollateralAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral Held [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollateralAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollateralAxis" xlink:to="lab_us-gaap_CollateralAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_696f9252-da52-4fea-8a58-96a46885901c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_6346181f-a59b-4f63-a0a5-01da655c3024_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e30c9154-cac9-4674-b1b2-c8d86c2651d0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_edfb77d6-b6d8-4178-ab42-bec476841cf6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_1099e38e-1f82-4d02-8035-001b76f6ef6e_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e86abd7e-f542-40de-a59b-49d1314ac788_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_16256112-38a0-4cbf-95c4-4a9572f2026a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7ef1e408-462e-4920-a38e-405dc195e6fb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_da1c3aaa-01e1-4bc7-99db-a54d82e2d499_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0262d82e-8743-453b-9cab-994e25bb6ce6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_MilestonePayment_740c7e81-4fa3-4286-a876-84067dac0693_terseLabel_en-US" xlink:label="lab_nbix_MilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment</link:label>
    <link:label id="lab_nbix_MilestonePayment_label_en-US" xlink:label="lab_nbix_MilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment</link:label>
    <link:label id="lab_nbix_MilestonePayment_documentation_en-US" xlink:label="lab_nbix_MilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments made for milestones under a collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MilestonePayment" xlink:href="nbix-20221231.xsd#nbix_MilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_MilestonePayment" xlink:to="lab_nbix_MilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d79a9c94-5c42-478d-80ca-dad3d56ed2f6_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance, Unvested (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_10b35ebd-1982-442e-aede-34c284536ae0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance, Unvested (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_701e4c2e-e3fa-4674-837a-b639efdbeeaf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_861cf2e0-7f9e-4c22-af93-ed5eb14ded14_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_1d26f629-4839-4c08-8750-57999d441c3f_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_3a57c6c8-a73b-498d-90ca-0a2c8a02b90f_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_85268536-637f-4dd2-bc9e-c4994afe4eba_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Decrease) related to prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8a8fd879-1eeb-4014-8a3b-c7d23f000f79_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_23035b4c-ac47-4c39-bf11-0a7516d8a099_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed product rights</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_6b196a2f-9fe4-49f9-9449-48728bd37cce_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_ae2657cc-3c28-4b02-90ba-5e699e612b93_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_c903abbf-5ba0-421d-8fa2-9f133e039357_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_PatentTerm_9ff53b74-a5ec-4e71-8d3b-df45fe4eb6e3_terseLabel_en-US" xlink:label="lab_nbix_PatentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent term</link:label>
    <link:label id="lab_nbix_PatentTerm_label_en-US" xlink:label="lab_nbix_PatentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent term</link:label>
    <link:label id="lab_nbix_PatentTerm_documentation_en-US" xlink:label="lab_nbix_PatentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of the patent, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PatentTerm" xlink:href="nbix-20221231.xsd#nbix_PatentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_PatentTerm" xlink:to="lab_nbix_PatentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_632dc4e0-c10a-480c-9dcd-0ead33c185a4_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest receivables</link:label>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivableCurrent" xlink:to="lab_us-gaap_InterestReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities_fba0c4bc-16f4-4ae9-af4f-a2c181056615_negatedTerseLabel_en-US" xlink:label="lab_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities_label_en-US" xlink:label="lab_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities Operating Leases Liabilities</link:label>
    <link:label id="lab_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities_documentation_en-US" xlink:label="lab_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities operating leases liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities" xlink:href="nbix-20221231.xsd#nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities" xlink:to="lab_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate202006Member_94518211-2aff-4788-b88d-6dfd01e32235_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2020-06</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate202006Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2020-06 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_62445a0f-bb8e-4085-8c1e-bfe7df0de062_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_8de2194e-9672-43be-a14f-86b676804c07_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_dd8f5dec-910c-4490-89c7-09e311c4a51a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_e29d55de-e54d-444d-9cee-331095e759a6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_84c3305c-de81-4170-b7d1-4fab33e9b2e6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_4927061a-7ced-4f7e-8f42-cf2d61836b48_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_CarryingAmountOfLiabilityComponentAtSettlement_2a0ce987-0296-4e3d-a9d4-f5d289739244_terseLabel_en-US" xlink:label="lab_nbix_CarryingAmountOfLiabilityComponentAtSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount of the liability component at settlement</link:label>
    <link:label id="lab_nbix_CarryingAmountOfLiabilityComponentAtSettlement_label_en-US" xlink:label="lab_nbix_CarryingAmountOfLiabilityComponentAtSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount Of Liability Component At Settlement</link:label>
    <link:label id="lab_nbix_CarryingAmountOfLiabilityComponentAtSettlement_documentation_en-US" xlink:label="lab_nbix_CarryingAmountOfLiabilityComponentAtSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount of the liability component at settlement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CarryingAmountOfLiabilityComponentAtSettlement" xlink:href="nbix-20221231.xsd#nbix_CarryingAmountOfLiabilityComponentAtSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_CarryingAmountOfLiabilityComponentAtSettlement" xlink:to="lab_nbix_CarryingAmountOfLiabilityComponentAtSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_0cf09340-ddd0-416e-8d06-f8314fe408d0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5a72e402-35ab-4fd3-9a2a-9f8768a6ec03_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_254609bf-b150-44b9-95aa-02933a7ea12b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_f38600ae-21a4-49fa-aab4-8b4000dd9e0e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_5c832ac5-fec6-48e1-a244-89eac11f055d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued employee related costs</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_83b5d3d2-cdd1-4f7d-b549-f96477e6bb36_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before provision for (benefit from) income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_8773e3c7-c278-4f4c-8b76-1ca104aa998a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_07b07797-9bf7-4f6a-ab95-f25102650e36_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_8a040501-72cd-46ba-b201-b9779e5e3383_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_AccruedBrandedPrescriptionDrugFee_a0c4626c-36e1-42bf-b4b4-f747c340776a_terseLabel_en-US" xlink:label="lab_nbix_AccruedBrandedPrescriptionDrugFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current branded prescription drug fee</link:label>
    <link:label id="lab_nbix_AccruedBrandedPrescriptionDrugFee_label_en-US" xlink:label="lab_nbix_AccruedBrandedPrescriptionDrugFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Branded Prescription Drug Fee</link:label>
    <link:label id="lab_nbix_AccruedBrandedPrescriptionDrugFee_documentation_en-US" xlink:label="lab_nbix_AccruedBrandedPrescriptionDrugFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Branded Prescription Drug Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AccruedBrandedPrescriptionDrugFee" xlink:href="nbix-20221231.xsd#nbix_AccruedBrandedPrescriptionDrugFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_AccruedBrandedPrescriptionDrugFee" xlink:to="lab_nbix_AccruedBrandedPrescriptionDrugFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_49acfe9f-9d64-4c91-88d3-6180b0d08dc6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_2fd19f33-c562-4366-b566-c27a605f6547_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_fadeea7f-8bf4-4e9c-b123-723a28b0583e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_566dc9f3-882f-41d7-b39e-0144f1f257f0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_85ae7808-beb6-4ba5-9afc-488671bd3468_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_e66c1280-cee3-48ce-a34e-f4b3e2f204fc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average assumptions for stock option grants using black-scholes option-pricing model</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost_35992568-2946-4a34-91b9-c9ed128c4c39_terseLabel_en-US" xlink:label="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Officer compensation</link:label>
    <link:label id="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost_label_en-US" xlink:label="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Nondeductible Expense Officer Compensation Cost</link:label>
    <link:label id="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost_documentation_en-US" xlink:label="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax reconciliation nondeductible expense officer compensation cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost" xlink:href="nbix-20221231.xsd#nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost" xlink:to="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_e642f1f0-70a0-4e2d-a3c2-3a14058fc27f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_5544b9a0-c453-4c42-9a58-be9593f79e72_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Balance Sheet Details</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_788eb1ec-507d-4557-a046-14dfc86a9b2c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of the Provision for (Benefit from) Income Taxes for Continuing Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4d7d7bc6-11e7-4c0e-a351-56c297b17c59_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a2cdb535-a98b-46ae-a780-f8ff035f5d23_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Recognition Period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_40c73a4a-bc2b-4e18-ae62-a34cd4711ff2_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_a94df5dc-302c-4741-bf3a-74470de9bde1_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of convertible senior notes</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_f19d898b-6e78-4de7-8418-333d794bd84f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of convertible senior notes</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_8305a24a-1338-466a-b41d-c13f105074f9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Information Relating to our Recognized Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_78da6fe0-ab20-4e22-8435-08b2c85fe8cf_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_99ea59fb-fc83-4bee-8144-0220c02da8ea_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_4d9297ec-f49a-4ec4-bfdb-69f53501f922_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_d92ab953-9b07-4fea-9d88-e32b368b7d59_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_64e6bfe1-5468-4167-b838-bb6eaa92aee7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount repurchased</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchased Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_e748783f-9cab-4932-b472-8acf24011309_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5c9e20cf-174c-4f93-9702-767729431ad2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_e4db6135-d668-4a4d-ae66-5fb206cb75f1_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentsMember_0f57ac67-2c3a-4179-885f-b07063a877cb_terseLabel_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents</link:label>
    <link:label id="lab_us-gaap_PatentsMember_label_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_71fac468-845b-4d92-babf-c0513566231a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_726b56b0-b78f-48c9-8535-a72ac5634514_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet_57495adf-3402-4070-808f-001998cd34cf_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets and liabilities, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Current Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot_2d65250c-b0a0-4025-a2b2-361e1c07f64b_terseLabel_en-US" xlink:label="lab_nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly base rent per square foot</link:label>
    <link:label id="lab_nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot_label_en-US" xlink:label="lab_nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Monthly Base Rent Per Square Foot</link:label>
    <link:label id="lab_nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot_documentation_en-US" xlink:label="lab_nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Monthly Base Rent Per Square Foot</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot" xlink:href="nbix-20221231.xsd#nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot" xlink:to="lab_nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_48de12b7-b0c3-4203-91d7-0a58496d09b5_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_a6c2d3fc-fbde-4e68-a43e-e1648fd8749c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_dba90513-0baa-4779-8a9e-1c967412322d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_e2a01996-37b9-4d99-bcd0-20b77137e7e4_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_32e0bf2c-e55e-4f0f-8c06-5c5fa261dca1_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_48376d33-3c02-478f-8cfc-f328033fff73_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_e65ce6d4-75a2-4bd9-ac14-7f24726c37cd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_0215f811-83ba-4875-87cc-b5e2475ea516_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_387fac11-7827-4291-9459-d5b6ea900bef_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_fe99a492-16bb-48c3-9993-d79af45015ec_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_499c2f07-a17e-4d62-8cbb-4a917a4ab4fe_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_b1089e8f-51e9-4d9e-8ac8-38db71423055_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_ddce3987-10a4-4e53-b060-0dd7b0120805_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_af3218ff-b1b0-41d7-af74-efaebdf78fcd_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized Debt, Issuance Costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e71b068d-1a5f-4936-ad14-236c05c597ea_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_c9a0f449-1e3c-4333-af37-743523d7755b_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_e42f6772-c762-4f1d-8af6-ce4d2f96be76_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_e3713bbe-7f83-492d-8ab2-c049beae656c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_d9bb32bc-2368-4890-99cf-e26803fd41a5_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_f316f414-5cf4-428e-83bf-6ef8707c1837_verboseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market price of common stock (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_ff494998-33f3-4679-8dc9-f23355fa7f84_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carry forward, net</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_EarningsPerShareBasicAndDilutedEPSAbstract_f068dc45-d336-49b5-84c2-c1613da46f93_terseLabel_en-US" xlink:label="lab_nbix_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share:</link:label>
    <link:label id="lab_nbix_EarningsPerShareBasicAndDilutedEPSAbstract_label_en-US" xlink:label="lab_nbix_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted EPS [Abstract]</link:label>
    <link:label id="lab_nbix_EarningsPerShareBasicAndDilutedEPSAbstract_documentation_en-US" xlink:label="lab_nbix_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted EPS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:href="nbix-20221231.xsd#nbix_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:to="lab_nbix_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_512e5dfb-43ae-450b-9821-decc72c9aa12_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_6b58067c-13c2-4e86-934e-4149add29477_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1f871229-e79c-4007-841f-40b1ff1e61ea_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree_39703a7a-6a58-4073-b853-2842a076b5e8_terseLabel_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cancelable future minimum lease payments under operating leases not yet commenced for 2025</link:label>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree_label_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Three</link:label>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree_documentation_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree" xlink:href="nbix-20221231.xsd#nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree" xlink:to="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_feae92cc-ef72-48a8-8b2f-272b3b4181e1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_a5e06dd0-1937-4ecb-b0cc-44beeeed45cb_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase related to prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_130ee142-f9a7-4414-9cb8-ccc83a36f0be_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Term, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_1b7eaed3-8271-4c21-984c-b58482b027b3_totalLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_11e9b899-3fe3-4453-964a-ac04546aa358_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_d823c355-ad5c-4972-b056-0f6dabd24746_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_316ef2e7-e01c-4f08-bee3-97d28c7cb871_terseLabel_en-US" xlink:label="lab_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Convertible senior notes due 2024</link:label>
    <link:label id="lab_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_label_en-US" xlink:label="lab_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes Two Point Two Five Percent Due In May Two Thousand Twenty Four [Member]</link:label>
    <link:label id="lab_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_documentation_en-US" xlink:label="lab_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information related to the 2.25% Convertible Senior Notes Due in May 2024.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember" xlink:href="nbix-20221231.xsd#nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember" xlink:to="lab_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_44860570-1ce9-476c-9ace-c70a6cba1f47_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_5095b9fe-1110-43b7-9b5b-bf2a551b947a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_1534afe2-8602-41b9-96c3-cfae5dbf9984_terseLabel_en-US" xlink:label="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain, current</link:label>
    <link:label id="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_label_en-US" xlink:label="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current</link:label>
    <link:label id="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_documentation_en-US" xlink:label="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:href="nbix-20221231.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:to="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_d58cf8e4-f52c-4cc7-aa8d-396506f8def7_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_5ae5836b-597a-4fa6-832a-cc45d1e6f96e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diurnal Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_d0d75843-7fd3-4613-ab8c-0de4907ca772_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_ecb01461-7787-4e9e-aa5d-c6428fb60f7f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_d06a5030-ac48-4a4b-b0c8-243522cf52d8_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_b0590c9f-6f05-4b09-a6b2-1bcb92b095e1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember_197771d0-03ef-4285-81f0-c9e9174c6c00_terseLabel_en-US" xlink:label="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda</link:label>
    <link:label id="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember_label_en-US" xlink:label="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Pharmaceutical Company Limited [Member]</link:label>
    <link:label id="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember_documentation_en-US" xlink:label="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Pharmaceutical Company Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:href="nbix-20221231.xsd#nbix_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:to="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_386ff20b-3c57-4273-bd85-f67c6a809d63_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_35b97548-dd4e-4d2a-b9e8-5cb7d2899af3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_f51d9eb8-6640-4966-a985-8c0453c9afa0_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_9d6486d0-e0c1-4802-aae1-cdc2f970accb_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_b1993d4c-69e5-49d5-9267-83ed2451cd58_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12 Months or Longer, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_60106ede-98c1-41a0-b0d8-1bd4f6b51581_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_04d43cf7-ff88-4f2f-b589-7609b9f248d0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the Carrying Amount of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_b1fbe4ff-fe65-44ad-8878-ba43f93ff4cf_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_bf8c3cd2-e72a-4ab7-9d83-d6c97b1e459c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share, basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_82958365-6d81-44bc-9f3e-e88e658f87d7_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_SaleOfStockNumberOfSharesSoldInTransaction_72800f30-8ddb-4487-8470-61978121ca44_terseLabel_en-US" xlink:label="lab_nbix_SaleOfStockNumberOfSharesSoldInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock (in shares)</link:label>
    <link:label id="lab_nbix_SaleOfStockNumberOfSharesSoldInTransaction_label_en-US" xlink:label="lab_nbix_SaleOfStockNumberOfSharesSoldInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Sold in Transaction</link:label>
    <link:label id="lab_nbix_SaleOfStockNumberOfSharesSoldInTransaction_documentation_en-US" xlink:label="lab_nbix_SaleOfStockNumberOfSharesSoldInTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of shares sold by the collaboration partner per stock transaction.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SaleOfStockNumberOfSharesSoldInTransaction" xlink:href="nbix-20221231.xsd#nbix_SaleOfStockNumberOfSharesSoldInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_SaleOfStockNumberOfSharesSoldInTransaction" xlink:to="lab_nbix_SaleOfStockNumberOfSharesSoldInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_6cceefe4-3cfc-4ef1-b938-e0b8f9a1f01d_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_c87a9d02-289f-415b-9001-7271a33a50a4_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent" xlink:to="lab_us-gaap_ConvertibleDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b5b770bb-7eca-4d6b-9fde-47bf16aefd3c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_ffa12664-0e85-4bfa-bfda-e66f850bb6fd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, award requisite service period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_7ef211d4-24f5-4c4f-8580-6282e0a685a2_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of PRSUs vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_a2f2c8af-0ab8-4674-8128-f63bc5af07e8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_725d48c4-832d-4ba0-a895-e0bea118e17f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_a6feef94-b494-4404-91bf-fe1f8cdf1fcb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of convertible senior notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_0bf490de-6897-4eb3-804e-af5e2ba6e296_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bd96e3e9-8ba3-44dc-9a56-1cbcec973b38_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_c3ecceb7-6d95-47c9-be46-ea4ce6072581_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_15e53988-a680-4c36-80d9-9c7287567c4a_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_a981db79-2dd6-44c2-8ee8-20916c9ea9b8_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_37eabfe0-b431-4397-a9f3-dc16c34ba7ca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_610c574b-50a2-4b01-9a50-ac7f834cceea_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_6a23cfd9-2a76-42da-926a-b311c206d0bc_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a7f715f7-29fb-45eb-bf65-0b3e7951c0f4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DebtInstrumentCouponInterest_d859d58b-1c5f-4501-b5de-f73699a5f212_terseLabel_en-US" xlink:label="lab_nbix_DebtInstrumentCouponInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coupon interest</link:label>
    <link:label id="lab_nbix_DebtInstrumentCouponInterest_label_en-US" xlink:label="lab_nbix_DebtInstrumentCouponInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Coupon Interest</link:label>
    <link:label id="lab_nbix_DebtInstrumentCouponInterest_documentation_en-US" xlink:label="lab_nbix_DebtInstrumentCouponInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Coupon Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentCouponInterest" xlink:href="nbix-20221231.xsd#nbix_DebtInstrumentCouponInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DebtInstrumentCouponInterest" xlink:to="lab_nbix_DebtInstrumentCouponInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6e7aaa25-317d-4bbd-8324-b81f4318da6a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_81c1d245-a9ea-48f4-8ecb-49e4e592d74b_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities of government-sponsored entities</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_22f7c393-fe53-4350-ae93-bd5d6925048e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_5f62da7b-0285-4237-87d0-01e5e8d7a75f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_97e15f77-6ddd-4e31-8755-bb1c8f5f5bd3_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_e4ebd3b9-368f-4cba-b2a6-88378ba03941_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_b53c9ab5-5ec3-4270-8797-eb4f7281f45a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff_e5cee179-aac8-46e5-acf5-07664fc757a2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest receivables write-off threshold period</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accrued Interest, Threshold Period, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_b6c4cfbe-07ce-4064-bafe-de28ac9d88f9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances of common stock under stock plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_3695be47-df61-46c4-9225-cc1e96a70039_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_b3dffc98-73b0-4142-b644-d853ee70ea02_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of supplemental operating lease information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0fb15c26-4530-4747-85a7-adb24832b67e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for future grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_547fbb8a-1ccb-4667-abed-f954161e3704_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_b19fcf3b-2a94-4b55-a250-732b5e14615a_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_b4f531ea-8922-4bfe-b8bd-cf723587d262_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_2c455211-72f5-4c30-b438-f2049f93934e_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_058884aa-442f-4765-ace8-1a439a02447b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Released (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_2a09fd79-8d3f-438e-b8f6-7618b5318cbb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_500efbaa-dc5b-446e-a966-6da63f895f07_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_5c0a6fa5-30a5-4880-ba68-dd9d1c1ccec3_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_c15f7c28-749c-4500-b7ef-50ce77f1196a_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_4844f7a8-5540-45db-a110-04fb2247e140_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total identifiable net assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_5661050f-4685-4931-b4f3-f5f2157c789a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized amounts of identifiable assets acquired and liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_b09fc56d-6e73-4489-b2ac-2c6550eee738_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_cf1eb3d2-7d00-4085-a33b-933fc8e9aa76_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_74ab5189-e2e0-4670-8b61-100054322246_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_0a391d11-8ada-48ea-b17a-87d4c67f659f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2404a076-5039-4376-bbb5-f3ca1d90482d_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credit carry forwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_ccd826d0-23dc-4635-bfb2-226ae29d538f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, employer contribution amount</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_644103ee-586a-4cea-82ff-5fd6a50132eb_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_1758351c-4244-4df1-92e2-23cb33ad8e74_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Asset Acquired Other than Through Business Combination, Written-off</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:to="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_6d46b25f-fb1b-4bc7-a67b-06dd7a7838fc_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward_6d60cda1-716f-4f61-b9b5-56d96ac06f9d_terseLabel_en-US" xlink:label="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares reduced pursuant to appreciation award (in shares)</link:label>
    <link:label id="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward_label_en-US" xlink:label="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Reduced Pursuant To Appreciation Award</link:label>
    <link:label id="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward_documentation_en-US" xlink:label="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Reduced Pursuant To Appreciation Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward" xlink:href="nbix-20221231.xsd#nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward" xlink:to="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_33cd64d7-33cb-44ac-bd93-07d241086fc8_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2a42264d-6caa-49d4-93ca-af0aa3145f1b_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_fefeebc0-b0b0-424d-b091-9fae8de2a08a_terseLabel_en-US" xlink:label="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:href="nbix-20221231.xsd#nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_b411c46d-a766-44e0-b2ea-331b308259e1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_f99b855a-3844-40ea-93a4-4e33a7bf7e94_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_de9c34bb-3d2f-4c62-95d7-82af75755ecb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_PotentialMilestonePaymentReceipts_228254a9-7abc-4801-8aa4-42aeae2139b2_terseLabel_en-US" xlink:label="lab_nbix_PotentialMilestonePaymentReceipts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payment receipts</link:label>
    <link:label id="lab_nbix_PotentialMilestonePaymentReceipts_label_en-US" xlink:label="lab_nbix_PotentialMilestonePaymentReceipts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payment Receipts</link:label>
    <link:label id="lab_nbix_PotentialMilestonePaymentReceipts_documentation_en-US" xlink:label="lab_nbix_PotentialMilestonePaymentReceipts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential later stage milestone payments and royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePaymentReceipts" xlink:href="nbix-20221231.xsd#nbix_PotentialMilestonePaymentReceipts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_PotentialMilestonePaymentReceipts" xlink:to="lab_nbix_PotentialMilestonePaymentReceipts" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour_85b4321a-74c3-4e2f-87a6-fba8d0b67fce_terseLabel_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cancelable future minimum lease payments under operating leases not yet commenced for 2026</link:label>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour_label_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Four</link:label>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour_documentation_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour" xlink:href="nbix-20221231.xsd#nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour" xlink:to="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_9bd0f794-9aeb-4638-a3ae-23c2474f9b56_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurements recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_126ce6f0-c157-4c0d-8d10-0bb2e9784c31_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_cebe24d2-87ce-4327-a99c-f4024c6b9960_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less Than 12 Months, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_bd18f52b-e36b-42de-8198-04e20626a00c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6723f98c-469c-46c5-a81f-104ddb000e1b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_b3bf0649-9b15-4963-89a7-36d47ea24dba_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_27b42395-cd4c-471b-8a71-7982d396cc29_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e023f743-5283-4f0e-9d43-9a35c25ca493_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance, Unvested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_44dc9763-14a0-4b3d-8464-9eb9e60b394d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance, Unvested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent_a80c08b1-1be9-45ca-90ad-b0f02d02b8e1_terseLabel_en-US" xlink:label="lab_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, current</link:label>
    <link:label id="lab_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent_label_en-US" xlink:label="lab_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Current</link:label>
    <link:label id="lab_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent_documentation_en-US" xlink:label="lab_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent" xlink:href="nbix-20221231.xsd#nbix_DebtSecuritiesAvailableForSaleFairValueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent" xlink:to="lab_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_LargestFourCustomersMember_d44c2406-acc4-4b1f-9ebc-7a9517c86415_terseLabel_en-US" xlink:label="lab_nbix_LargestFourCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Largest four customers</link:label>
    <link:label id="lab_nbix_LargestFourCustomersMember_label_en-US" xlink:label="lab_nbix_LargestFourCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Largest Four Customers [Member]</link:label>
    <link:label id="lab_nbix_LargestFourCustomersMember_documentation_en-US" xlink:label="lab_nbix_LargestFourCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Largest Four Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LargestFourCustomersMember" xlink:href="nbix-20221231.xsd#nbix_LargestFourCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_LargestFourCustomersMember" xlink:to="lab_nbix_LargestFourCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_f4731c6e-1878-4959-9ed9-8bcbd99da1a7_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other expense, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_233b30a2-78fd-41e0-8ca1-31833c2b8e14_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_50bb30c4-d24e-4ec9-bc43-e22be5a93c29_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_242e9cdb-6fa5-4dce-bee7-44a2a8dc10da_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_1ebb6ee1-da3f-4708-a134-6d069287952c_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current taxes</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_6eca84a5-662d-4d5a-9ff3-a09351e68d8a_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_2e505425-e9cc-487d-934f-efb2bee95911_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8ff3abf1-0d68-4c7f-99b7-66142a9bdab7_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_AbbVieIncMember_af00ba40-88df-47b0-8786-11c8d382c0ba_terseLabel_en-US" xlink:label="lab_nbix_AbbVieIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbbVie Inc.</link:label>
    <link:label id="lab_nbix_AbbVieIncMember_label_en-US" xlink:label="lab_nbix_AbbVieIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbbVie Inc. [Member]</link:label>
    <link:label id="lab_nbix_AbbVieIncMember_documentation_en-US" xlink:label="lab_nbix_AbbVieIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbbVie Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AbbVieIncMember" xlink:href="nbix-20221231.xsd#nbix_AbbVieIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_AbbVieIncMember" xlink:to="lab_nbix_AbbVieIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent_733c50ba-08ed-491e-a296-b030a65d4f75_verboseLabel_en-US" xlink:label="lab_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, noncurrent</link:label>
    <link:label id="lab_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent_label_en-US" xlink:label="lab_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Noncurrent</link:label>
    <link:label id="lab_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent_documentation_en-US" xlink:label="lab_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent" xlink:href="nbix-20221231.xsd#nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent" xlink:to="lab_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_2332a06e-d97d-44c6-9f18-f15b7bae1afc_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DebtInstrumentConvertibleConversionPremium_47e994a3-32d6-4b3e-8e3c-8b53eec65a4c_terseLabel_en-US" xlink:label="lab_nbix_DebtInstrumentConvertibleConversionPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion premium</link:label>
    <link:label id="lab_nbix_DebtInstrumentConvertibleConversionPremium_label_en-US" xlink:label="lab_nbix_DebtInstrumentConvertibleConversionPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Convertible Conversion Premium</link:label>
    <link:label id="lab_nbix_DebtInstrumentConvertibleConversionPremium_documentation_en-US" xlink:label="lab_nbix_DebtInstrumentConvertibleConversionPremium" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of excess of the price paid for the convertible note over the closing stock price on the closing date of the convertible note.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConvertibleConversionPremium" xlink:href="nbix-20221231.xsd#nbix_DebtInstrumentConvertibleConversionPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DebtInstrumentConvertibleConversionPremium" xlink:to="lab_nbix_DebtInstrumentConvertibleConversionPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_9a9d479f-fcb7-4069-bde8-afba90e5e1e9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_ecbc7a31-a8b3-47e1-b3f3-96530289177a_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_45c30112-69d7-4e74-b4ef-60d827180286_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign tax authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_057bb618-deb9-46dd-96d0-db923ebb6fab_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_078b0180-360c-4716-b207-cc1836604317_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary and changes in stock options outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_ae99be9f-1ac9-4b32-b862-96869fda4921_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_34a4d4bd-7e3c-4cdc-b00a-c4b32d34c790_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fe85adfc-0149-45a8-a6e4-d69155bc4fb4_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted and Issued Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_9aeb1a2c-15e2-412d-9e48-b059adca5cc6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized Debt, Discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_0a98a880-b06b-40f3-8202-adbb126e7377_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DebtInstrumentConversionAxis_2f6f539e-2d65-4d50-a982-58c174af8e32_terseLabel_en-US" xlink:label="lab_nbix_DebtInstrumentConversionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion [Axis]</link:label>
    <link:label id="lab_nbix_DebtInstrumentConversionAxis_label_en-US" xlink:label="lab_nbix_DebtInstrumentConversionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion [Axis]</link:label>
    <link:label id="lab_nbix_DebtInstrumentConversionAxis_documentation_en-US" xlink:label="lab_nbix_DebtInstrumentConversionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConversionAxis" xlink:href="nbix-20221231.xsd#nbix_DebtInstrumentConversionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DebtInstrumentConversionAxis" xlink:to="lab_nbix_DebtInstrumentConversionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_47efb8ea-f1be-4132-a76b-e5a2239026ae_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_5933aeb0-c674-4cd6-be7e-8d14253ec959_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_4bee7bca-5e65-4f12-8848-45c025f961a8_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, at beginning period</link:label>
    <link:label id="lab_us-gaap_Goodwill_676bb52a-ec35-4afd-aacc-10869f15ea37_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, at ending period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_TwoThousandAndElevenEquityIncentivePlanMember_1c10dd39-c462-4bf3-a89f-2a69cb414db2_terseLabel_en-US" xlink:label="lab_nbix_TwoThousandAndElevenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2011 Equity Incentive Plan</link:label>
    <link:label id="lab_nbix_TwoThousandAndElevenEquityIncentivePlanMember_label_en-US" xlink:label="lab_nbix_TwoThousandAndElevenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Eleven Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_nbix_TwoThousandAndElevenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_nbix_TwoThousandAndElevenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Eleven Equity Incentive Plan [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TwoThousandAndElevenEquityIncentivePlanMember" xlink:href="nbix-20221231.xsd#nbix_TwoThousandAndElevenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_TwoThousandAndElevenEquityIncentivePlanMember" xlink:to="lab_nbix_TwoThousandAndElevenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_78990c2a-3a9c-43d0-8ac4-af04bc3c0432_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fbf7e392-5ddc-434e-b450-10243fe585ce_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_81ba40a2-26c3-4f56-8bad-9787bec59c0b_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_32d5226c-11cf-4173-b056-b8c160ddf893_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for (benefit from) income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_0fc969ed-6c10-4442-b91f-f15dc45234e2_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for (benefit from) income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_095b94ac-3974-4373-b291-970166c9b926_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_8d07aedb-f2fc-4841-b40d-cddfbeadf9ab_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_68db0318-d736-4418-99ad-b7d70a93684c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_995d7c39-c331-45a9-93ed-615a4d08f76a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_db17444c-f63b-4b9a-a596-34eef11810a7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_64084434-ce0f-4e66-8e8b-3c68f199426b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_650d4190-61a1-48cc-9fb8-42ae7c106402_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_d223a101-3935-4f81-96d2-d1f0746a54f3_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_76cefdad-4cf4-481d-87ec-17aad5306aa6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_e0527362-8665-41b9-ad0e-7f92639f6fec_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c27fb17d-d096-4bbd-bd55-647da5da84c9_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_4d93c295-c3a9-44d5-865c-38aa74fb9d66_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_ddae87e5-a595-47de-b715-79dbe8c946f4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_1646c954-6048-4ff2-81ab-872229dfe552_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_3d333e38-4271-4570-96e3-150254f5b659_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_c606196d-64d7-43c7-abf4-a7ce5ea0163c_negatedLabel_en-US" xlink:label="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss, noncurrent</link:label>
    <link:label id="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_label_en-US" xlink:label="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Noncurrent</link:label>
    <link:label id="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_documentation_en-US" xlink:label="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:href="nbix-20221231.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:to="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8ae8d1cd-39d7-465a-9011-ccb7114e1660_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options exercised in period intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_ac72d62c-ab4c-498a-a44b-edd864eac220_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenues</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a43763da-17f4-4539-99b4-ee43ff70b141_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_dbe467b0-f6c1-497c-81a1-0dc663e0682d_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_e58a8c8a-a502-478f-919b-8e0a2d673b08_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_09134e20-e488-4b26-9d88-953de9419094_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3cd48882-4cc5-4dc8-a0b3-85cc097ca6b7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2bca5c64-8545-4c03-b489-20ddd81ad17e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected option term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_HeptaresTherapeuticsLimitedMember_08a55315-46d2-4d35-bc95-9ba8f2555d5d_terseLabel_en-US" xlink:label="lab_nbix_HeptaresTherapeuticsLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Heptares</link:label>
    <link:label id="lab_nbix_HeptaresTherapeuticsLimitedMember_label_en-US" xlink:label="lab_nbix_HeptaresTherapeuticsLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Heptares Therapeutics Limited [Member]</link:label>
    <link:label id="lab_nbix_HeptaresTherapeuticsLimitedMember_documentation_en-US" xlink:label="lab_nbix_HeptaresTherapeuticsLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Heptares Therapeutics Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_HeptaresTherapeuticsLimitedMember" xlink:href="nbix-20221231.xsd#nbix_HeptaresTherapeuticsLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_HeptaresTherapeuticsLimitedMember" xlink:to="lab_nbix_HeptaresTherapeuticsLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f44bd4ea-c023-4b82-a3d0-a74dd9f3b7de_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_98bb47f6-0f41-4add-baa4-d6ed9ef5dce2_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_f60b397a-2c7c-4d7f-9162-30ad97d1754f_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_eb7d4fc3-e055-405f-98de-a023f8bbbcfa_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e1ca846f-febd-47bc-8af1-5a4aa7534a21_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_cc5fd153-cd81-4966-9c2a-864d376895d1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost, gross unrealized gain (loss) positions and estimated fair value for available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_3f81db9b-88ae-4925-be38-1654406e37e0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_e6e2bb6a-2887-4860-86c8-886603506123_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_860845f6-2e86-4b8d-8081-5bd0584203c8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction cost related to issuance of convertible senior note</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_e7efc838-e801-4ae6-991b-ca9fa840e5a8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_09d8e90e-9d56-4708-8da6-9263b53557cf_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Investments_ef2dab67-fda4-4ed6-abda-343ddbc21c0b_verboseLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_Investments_label_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Investments" xlink:to="lab_us-gaap_Investments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_c8cf7d14-397f-475c-9c67-d737748a1641_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 220.0 million shares authorized; 96.5 million and 94.9 million shares issued and outstanding, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_4b2fe032-32f6-400f-af3c-0c3303668edc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_91b710f4-7bd1-458e-a698-36ecc9b69400_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_3f781e9f-2de2-4b6c-baf5-32bb1611491d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1f7b9832-07c1-4e86-a96b-31e68752293c_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_6a984efc-9daf-4458-8084-a5ccade603a5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_590e632d-2055-4b04-849e-3b2436079a87_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7ba88fd7-a309-4d68-ab63-e984dd40d3ee_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1ed8f6d8-0b32-4512-9d8b-2ca9e2df0bab_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_e1d8873f-093a-4435-a620-ec9a33314db2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_CollaborationRevenueMember_0795feac-3b45-4829-9a7f-05a69365ea0a_terseLabel_en-US" xlink:label="lab_nbix_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_nbix_CollaborationRevenueMember_label_en-US" xlink:label="lab_nbix_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Revenue [Member]</link:label>
    <link:label id="lab_nbix_CollaborationRevenueMember_documentation_en-US" xlink:label="lab_nbix_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CollaborationRevenueMember" xlink:href="nbix-20221231.xsd#nbix_CollaborationRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_CollaborationRevenueMember" xlink:to="lab_nbix_CollaborationRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9a13c23b-de06-4d76-a35e-17cdd529aff1_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceedings</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_f22e47e0-c4e9-48aa-ab5f-f4143575e439_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_7afb7296-6409-4541-bd17-b8eda46efe65_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received from stock option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_7ff478f9-c38c-45cd-9b15-db36d31fbeeb_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income - basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_1c249884-6f1c-4d6d-956a-4398e59c26a3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_e226ff4e-9d42-41f2-97e6-cfde4c2c8ff8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_25a22612-05c9-43c1-996c-0a26f7378082_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Term, Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentMeasurementInput_c490d0c0-4e60-4b47-acf7-cc224836591d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMeasurementInput_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMeasurementInput" xlink:to="lab_us-gaap_DebtInstrumentMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_dbe5a25a-bd45-445c-bc04-e8fef7b1e3ff_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash capital expenditures</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_4fc7b8ef-e9f2-4b09-bd5f-18b25e6d8127_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_1e930a44-5f32-4183-9a0c-a8c959da9f4f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition related costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_27b17ddc-d049-4505-918f-6ed204ff3fa0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, weighted average remaining contractual term (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_75a9afff-b5c2-4c67-b248-50b0bad8785b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_688a7eca-75ef-4c2b-8f93-1a23cc8a81ee_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of debt securities available-for-sale in an unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_a032717e-2422-4a62-9f4e-c2e070548fbb_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_78ae3b37-7385-4ae7-9312-9754c892fec6_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6241d2d6-114f-4543-b9d2-03d065ede835_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful Life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_6489dd62-e26c-4188-bce2-f1d7d9b9b499_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_6a14d08f-0e44-49ed-8ec8-f634470cdb7f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_7dfca0b5-65e6-40a1-b8ec-d4d70c5e8c09_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_a436bfae-0130-4a49-b82d-62c158395869_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal tax authority</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1d0e7ebc-c1e1-40e6-9a47-29d1a59551ed_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_b3ef7d30-0fab-4cbf-8c2d-8db3f7d06092_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_a80611f8-74c7-4abc-82b7-f7f4e5c4b88f_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill recognized in connection with business combination</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_83163e16-65fa-43ed-b872-4139ef1d8576_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_AuditorInformationAbstract_label_en-US" xlink:label="lab_nbix_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:label id="lab_nbix_AuditorInformationAbstract_documentation_en-US" xlink:label="lab_nbix_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AuditorInformationAbstract" xlink:href="nbix-20221231.xsd#nbix_AuditorInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_AuditorInformationAbstract" xlink:to="lab_nbix_AuditorInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_193bd4ec-296c-4e64-ad06-a29205dd094a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_365d6720-37ba-463f-a670-0f28e138aca4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_d9659d27-3bb7-4dd0-91ff-08fd4fcea43b_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Intangible Assets and Other Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0ac9d5f9-f329-4a61-a70a-6248eb5a5f26_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Term and Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_ead56bd0-06fa-4cc6-8682-99b87160adc2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounted purchase price percentage of common stock authorized for issuance</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_fed3ab72-df95-4586-8fda-9597ed743fd5_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal income taxes, rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding_3b34ccdd-e40e-4ec0-ae4f-7521bab88bc7_terseLabel_en-US" xlink:label="lab_nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee option term for construction of fifth building</link:label>
    <link:label id="lab_nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding_label_en-US" xlink:label="lab_nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Option Term To Construct Fifth Building</link:label>
    <link:label id="lab_nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding_documentation_en-US" xlink:label="lab_nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of term of lessee's option for the construction of a fifth building under operating lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding" xlink:href="nbix-20221231.xsd#nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding" xlink:to="lab_nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_165284c9-0ea5-4f8b-b69e-5d9c7d936b97_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_d116c7c3-2dcb-4855-bf5f-105e982b0e0c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_BIALPortelaCaSAMember_c1a068f6-7feb-4005-bcea-2a5fda98ca8c_terseLabel_en-US" xlink:label="lab_nbix_BIALPortelaCaSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIAL &#8211; Portela &amp; Ca, S.A.</link:label>
    <link:label id="lab_nbix_BIALPortelaCaSAMember_label_en-US" xlink:label="lab_nbix_BIALPortelaCaSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIAL &#8211; Portela &amp; Ca, S.A. [Member]</link:label>
    <link:label id="lab_nbix_BIALPortelaCaSAMember_documentation_en-US" xlink:label="lab_nbix_BIALPortelaCaSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIAL &#8211; Portela &amp; Ca, S.A.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BIALPortelaCaSAMember" xlink:href="nbix-20221231.xsd#nbix_BIALPortelaCaSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_BIALPortelaCaSAMember" xlink:to="lab_nbix_BIALPortelaCaSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_f4588584-cbf5-485a-9581-3bad97ad6d69_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_70c9cc01-35fa-4309-95d7-0d743d714c39_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Fair Values of the Assets Acquired and Liabilities Assumed at the Date of Acquisition</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_RentAbatementPeriod_21d522c3-56a9-4a3a-a908-7353c8571fae_terseLabel_en-US" xlink:label="lab_nbix_RentAbatementPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent abatement period</link:label>
    <link:label id="lab_nbix_RentAbatementPeriod_label_en-US" xlink:label="lab_nbix_RentAbatementPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent Abatement Period</link:label>
    <link:label id="lab_nbix_RentAbatementPeriod_documentation_en-US" xlink:label="lab_nbix_RentAbatementPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent Abatement Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_RentAbatementPeriod" xlink:href="nbix-20221231.xsd#nbix_RentAbatementPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_RentAbatementPeriod" xlink:to="lab_nbix_RentAbatementPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo_3d412caa-bd52-4a8f-b687-9cd2fb6a1029_terseLabel_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cancelable future minimum lease payments under operating leases not yet commenced for 2024</link:label>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo_label_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Two</link:label>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo_documentation_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo" xlink:href="nbix-20221231.xsd#nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo" xlink:to="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ad6cf07b-32f8-4621-964b-786772c7a131_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance, Outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6c9876e1-0707-41d9-88c9-3ae2c5f6ab80_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance, Outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_22f1015b-5bb7-4f3f-a9d7-b05c3986468e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_PerformanceBasedRestrictedStockUnitMember_a341048c-5ec4-4778-a894-558062b1c5c4_terseLabel_en-US" xlink:label="lab_nbix_PerformanceBasedRestrictedStockUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PRSUs</link:label>
    <link:label id="lab_nbix_PerformanceBasedRestrictedStockUnitMember_label_en-US" xlink:label="lab_nbix_PerformanceBasedRestrictedStockUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Restricted Stock Unit [Member]</link:label>
    <link:label id="lab_nbix_PerformanceBasedRestrictedStockUnitMember_documentation_en-US" xlink:label="lab_nbix_PerformanceBasedRestrictedStockUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units which are awarded to employees after certain performance targets are met.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PerformanceBasedRestrictedStockUnitMember" xlink:href="nbix-20221231.xsd#nbix_PerformanceBasedRestrictedStockUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_PerformanceBasedRestrictedStockUnitMember" xlink:to="lab_nbix_PerformanceBasedRestrictedStockUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_e9e5c32c-a7d0-44b4-9f4a-6fdc40257bf1_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_345f8b03-749e-4a3b-96e4-7c8d60d7ae6b_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_681d558e-4003-4fe6-a9ef-9bb24b8a8e40_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c65e838e-9fcf-4a3e-939d-2958e1b03cb1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_6c63ce75-716d-4ec1-b373-255e1220d1ef_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_822261a5-86c9-4687-a004-5b76ed35bd07_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_74c1136b-f12a-4a11-993c-6933098aa8de_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Annual Amortization Expense for our Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_62e37a24-f1c5-45d0-9688-545d736c923d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f8516593-759c-4d52-a2bc-3305ce284f2c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility of common stock</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7957b0cd-6524-468f-a8e7-cbbd8ea3bc7a_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff_0e98a43f-063c-4f9d-96c3-0ccee99570bb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest receivables write-off</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accrued Interest Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a445747e-f9f3-4a92-8da0-88bce17612b6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (loss) gain on debt securities available-for-sale, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_63b83000-2f90-4911-844f-dd2b0822b614_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_ESPPPurchasePeriod_a05f5651-fc89-4acf-97c8-71ae047ac8df_terseLabel_en-US" xlink:label="lab_nbix_ESPPPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP purchase period</link:label>
    <link:label id="lab_nbix_ESPPPurchasePeriod_label_en-US" xlink:label="lab_nbix_ESPPPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP Purchase Period</link:label>
    <link:label id="lab_nbix_ESPPPurchasePeriod_documentation_en-US" xlink:label="lab_nbix_ESPPPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP Purchase Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ESPPPurchasePeriod" xlink:href="nbix-20221231.xsd#nbix_ESPPPurchasePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_ESPPPurchasePeriod" xlink:to="lab_nbix_ESPPPurchasePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_6d7116cd-c4fd-418f-988d-9975416d4137_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_183a1143-c3df-4091-ad96-e0d7c92b4eb8_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3330c46d-cc1e-4217-8a3f-667f1a3f30f6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_77e50da1-7b43-48e7-a56e-df024fada0ee_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_af15c0ad-3b18-41be-978e-7ae2a070f8ca_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash related to letters of credit issued in lieu of cash security deposits</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_65ea09fe-21fa-4e09-8aee-0d5b10913ae7_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_9c3e6394-9315-49ba-b8aa-48b5783ffc8d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_6e4af7be-c3c2-4b97-bb57-0fdc93de6795_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_a0cb69af-5e50-40c6-8713-38bf21a7df1a_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_8caa5ff4-6d7f-4f06-a8ca-d79738216171_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_971113d1-3cf6-4c6f-8408-69b1ce5c79e7_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_0d2f3cf9-6ab4-4b56-a63c-957c6ca2ff30_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_6ea42430-2cbc-431e-a20e-fd47624ea88e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_ee715b78-1333-41df-8065-4cd865f58517_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_IncomeTaxReconciliationExpirationOfTaxCredits_0f883586-6d49-4f37-b6a4-3164a3d2fef2_terseLabel_en-US" xlink:label="lab_nbix_IncomeTaxReconciliationExpirationOfTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired tax attributes</link:label>
    <link:label id="lab_nbix_IncomeTaxReconciliationExpirationOfTaxCredits_label_en-US" xlink:label="lab_nbix_IncomeTaxReconciliationExpirationOfTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Expiration Of Tax Credits</link:label>
    <link:label id="lab_nbix_IncomeTaxReconciliationExpirationOfTaxCredits_documentation_en-US" xlink:label="lab_nbix_IncomeTaxReconciliationExpirationOfTaxCredits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax reconciliation, expiration of tax credits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxReconciliationExpirationOfTaxCredits" xlink:href="nbix-20221231.xsd#nbix_IncomeTaxReconciliationExpirationOfTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_IncomeTaxReconciliationExpirationOfTaxCredits" xlink:to="lab_nbix_IncomeTaxReconciliationExpirationOfTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_f15f9197-1e72-468b-be81-a8aa40eaffd8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments measured at fair value on recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4094b0f9-0c0a-4f0a-b258-32f26841687c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_f2161f89-f0a9-408c-93ef-cd99b42c59c2_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenues</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_a6bd7bbb-861a-400f-ab29-47397c35dbc3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold common stock trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_bf36c301-21f6-48f1-8791-0c8fd3c9a3f4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_be5d6ab8-cbaa-4e05-9c43-de997bb08d6b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Stock Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes_1e304822-eaad-4baa-bd98-44c13e8a0155_terseLabel_en-US" xlink:label="lab_nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of convertible senior notes</link:label>
    <link:label id="lab_nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes_label_en-US" xlink:label="lab_nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Loss On Extinguishment Of Convertible Senior Notes</link:label>
    <link:label id="lab_nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes_documentation_en-US" xlink:label="lab_nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Loss On Extinguishment Of Convertible Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes" xlink:href="nbix-20221231.xsd#nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes" xlink:to="lab_nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_5ef4a9c1-7e54-45c6-b9e7-3cc988af9132_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_50a2824f-3d5b-489e-b3b5-cc80c927e43f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_MitsubishiTanabePharmaCorporationMember_e1d230d7-28ac-4ce5-91f9-5b8314b62830_terseLabel_en-US" xlink:label="lab_nbix_MitsubishiTanabePharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MTPC</link:label>
    <link:label id="lab_nbix_MitsubishiTanabePharmaCorporationMember_label_en-US" xlink:label="lab_nbix_MitsubishiTanabePharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mitsubishi Tanabe Pharma Corporation [Member]</link:label>
    <link:label id="lab_nbix_MitsubishiTanabePharmaCorporationMember_documentation_en-US" xlink:label="lab_nbix_MitsubishiTanabePharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information related to the Mitsubishi Tanabe Pharma Corporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MitsubishiTanabePharmaCorporationMember" xlink:href="nbix-20221231.xsd#nbix_MitsubishiTanabePharmaCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_MitsubishiTanabePharmaCorporationMember" xlink:to="lab_nbix_MitsubishiTanabePharmaCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_23138ee6-1973-47e4-9798-8cc1ec513224_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_c9861908-270a-44ad-adfd-8b46fca4eca1_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_PotentialMilestonePayments_0b4582b6-223f-4541-a4bc-15b991f49b1d_terseLabel_en-US" xlink:label="lab_nbix_PotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payments</link:label>
    <link:label id="lab_nbix_PotentialMilestonePayments_label_en-US" xlink:label="lab_nbix_PotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payments</link:label>
    <link:label id="lab_nbix_PotentialMilestonePayments_documentation_en-US" xlink:label="lab_nbix_PotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of potential milestone payments to be paid under a license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePayments" xlink:href="nbix-20221231.xsd#nbix_PotentialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_PotentialMilestonePayments" xlink:to="lab_nbix_PotentialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_2e1742e6-b4b5-4045-b176-c8fd694eadfa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Activity related to unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_acfc6d70-c9f6-4744-b754-3097b70ae670_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_37c5d53a-438b-4ffa-a163-85436444272f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_d7d0c996-4520-48cf-8892-80d015b0576c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_ea771548-a95b-4a39-8c20-82f96f940eb8_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less Than 12 Months, Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions_eaf1befc-1964-4d07-b510-6eb2fd8694ef_terseLabel_en-US" xlink:label="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities available for sale position number of positions</link:label>
    <link:label id="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions_label_en-US" xlink:label="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities Available For Sale Position Number Of Positions</link:label>
    <link:label id="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions_documentation_en-US" xlink:label="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities available for sale position number of positions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" xlink:href="nbix-20221231.xsd#nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" xlink:to="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_e38973d7-e73c-4497-b64b-5fafec51bd24_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances of common stock under stock plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_ac492ef8-f9af-45e8-9683-6ebd87c7d33e_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_98e54caa-47a9-49b5-9047-81511eb504d1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_a432481c-b31f-4d10-8c2f-a06c30e1e4e4_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d362b4cd-91d5-4b77-9351-7d28ec805422_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_513c50c5-9aba-4e88-961b-ff7183aec325_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_5eefe7c4-f080-4612-b3f1-6310ae8e8085_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12 Months or Longer, Unrealized Loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7ed04baf-38df-429c-96ad-ea378732373b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_33a275fe-e045-4273-8188-f624b5032a51_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee_319efc9b-6105-422f-9295-5d3ed3441402_terseLabel_en-US" xlink:label="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Branded prescription drug fee</link:label>
    <link:label id="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee_label_en-US" xlink:label="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Nondeductible Expense Branded Prescription Drug Fee</link:label>
    <link:label id="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee_documentation_en-US" xlink:label="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax reconciliation nondeductible expense branded prescription drug fee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee" xlink:href="nbix-20221231.xsd#nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee" xlink:to="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bb4ec0c2-dae2-4a56-876d-c92141bc1512_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes_9529dfdd-38ae-4a87-889d-acc3e9235780_negatedTerseLabel_en-US" xlink:label="lab_nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes_label_en-US" xlink:label="lab_nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities Convertible Senior Notes</link:label>
    <link:label id="lab_nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes_documentation_en-US" xlink:label="lab_nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities convertible senior notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes" xlink:href="nbix-20221231.xsd#nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes" xlink:to="lab_nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0a6712b0-19d6-4c19-9e55-95bb95c4beab_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DiurnalGroupPlcMember_1738c674-f9d6-48e5-bd4f-a8cabff716cc_terseLabel_en-US" xlink:label="lab_nbix_DiurnalGroupPlcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diurnal Group Plc</link:label>
    <link:label id="lab_nbix_DiurnalGroupPlcMember_label_en-US" xlink:label="lab_nbix_DiurnalGroupPlcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diurnal Group Plc [Member]</link:label>
    <link:label id="lab_nbix_DiurnalGroupPlcMember_documentation_en-US" xlink:label="lab_nbix_DiurnalGroupPlcMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diurnal Group Plc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DiurnalGroupPlcMember" xlink:href="nbix-20221231.xsd#nbix_DiurnalGroupPlcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DiurnalGroupPlcMember" xlink:to="lab_nbix_DiurnalGroupPlcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_aedd4762-fa0b-4056-a6b0-873357d36efc_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_8126c777-677c-4af2-9dda-e01a197b7ccb_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_0a3e477c-77a4-48b4-8e3a-e824f09a7780_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_5b3bc497-0df4-4eb4-9d0c-4bba8d1d7681_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_30aed0b4-5d9e-42db-9580-e760bc3aaba0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold percentage of common stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_bea5f024-97ca-4107-941a-ab47df5959c4_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities cost</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_AnnualRentEscalationPercentage_06b0d608-ec83-42cb-99ea-2176cf2689e5_terseLabel_en-US" xlink:label="lab_nbix_AnnualRentEscalationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual rent escalation percentage</link:label>
    <link:label id="lab_nbix_AnnualRentEscalationPercentage_label_en-US" xlink:label="lab_nbix_AnnualRentEscalationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Rent Escalation Percentage</link:label>
    <link:label id="lab_nbix_AnnualRentEscalationPercentage_documentation_en-US" xlink:label="lab_nbix_AnnualRentEscalationPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Rent Escalation Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AnnualRentEscalationPercentage" xlink:href="nbix-20221231.xsd#nbix_AnnualRentEscalationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_AnnualRentEscalationPercentage" xlink:to="lab_nbix_AnnualRentEscalationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract_e1b7304a-42c0-40c7-b854-77919fb4385d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_71e2d28f-fe0a-4e32-acf7-166b7f7ba869_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueProductLineMember_5ea40b24-a4e4-47df-9e8a-d6d13c983e54_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueProductLineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Product and Service Benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueProductLineMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueProductLineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Product and Service Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueProductLineMember" xlink:to="lab_us-gaap_SalesRevenueProductLineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_fbd58ec2-7c13-4ff2-8ce1-8da16fcd89f8_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_fb247947-3aaf-43b2-a846-4d2f83f9b044_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances of common stock under benefit plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_79c78a64-c6f9-4949-bae0-718eb141865f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c2ad2123-2248-4618-8afd-3fbe1d73a51d_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_2199867f-1f30-4c9d-8fb2-37f141ac38ef_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_56fc4fc2-29b1-4b11-bfee-004ef4b5a3fe_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount of the equity component upon issuance</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Carrying Amount of Equity Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_dae823a1-5998-4568-bff8-80cdf17c0c11_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_e1de5384-186b-408c-96f0-4872decd80d2_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e17e62f9-c2a4-4955-bd08-2033b32656fc_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance, Outstanding (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ae57be44-10ab-49d9-90ab-81bd902a0f96_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance, Outstanding (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment_999e461d-6686-4d75-85dd-d67ebf3159ef_terseLabel_en-US" xlink:label="lab_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized research and development</link:label>
    <link:label id="lab_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment_label_en-US" xlink:label="lab_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Capitalized Research And Development</link:label>
    <link:label id="lab_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment_documentation_en-US" xlink:label="lab_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development costs capitalized.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:href="nbix-20221231.xsd#nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:to="lab_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_8c137140-0cd5-4f62-869b-472a21e28b06_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_8c6596dd-152e-47ea-97c3-366d46342b92_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 5.0 million shares authorized; no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_39f871b1-9e71-4c00-9f74-211aeddfc123_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_dcde94b7-9366-43e8-8539-a5b1632d1c54_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_e521c79c-26f8-4052-a53c-6f4f0922c924_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward_6f49cde1-252c-4129-99a3-ea5e6bef45d9_terseLabel_en-US" xlink:label="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares increased returning shares subject to any full value award (in shares)</link:label>
    <link:label id="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward_label_en-US" xlink:label="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Increased By Returning Shares Subject To An Award</link:label>
    <link:label id="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward_documentation_en-US" xlink:label="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Increased By Returning Shares Subject To An Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward" xlink:href="nbix-20221231.xsd#nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward" xlink:to="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7ab3250d-b5ba-4d59-acf7-4e551bd33e1d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of equity securities measured at fair value on recurring basis using significant unobservable inputs</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_48f67bf4-7fc5-45e9-82f4-6e1deffdc3cb_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_c11dacba-834a-4ef1-ba4d-77327b425562_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_1ffb6b09-9686-4d3a-9877-273475dcc91a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_8b983622-ad54-4f1f-a3c4-6a992086ba19_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_b6778a79-9908-4f26-a4b4-d178f318e914_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_11628322-872b-4887-bd5b-c731432432b0_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_8bf53d63-c22f-4d2f-aae9-439819c42c1b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_716bb500-4b6a-457b-9a44-e701bd018d58_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_70b45439-29b1-4b62-afd4-397be04665b7_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_3bfe63c1-26e5-4ff1-91dc-b6eb56fb3ae8_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_f05fa45d-5bc6-4408-b21f-f1278ee077bd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_ca4aa4e2-c849-4d38-bd3f-ef1dbdb795d6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of deferred tax assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_c7338057-a447-4708-a2dc-cf8527f36e2e_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive_f535959d-7f6a-4568-ac8a-fbf1607d551d_terseLabel_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cancelable future minimum lease payments under operating leases not yet commenced for thereafter</link:label>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive_label_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Five</link:label>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive_documentation_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive" xlink:href="nbix-20221231.xsd#nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive" xlink:to="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_Amended2020EquityIncentivePlanMember_80001c10-1fb9-4c12-a4b7-c51b7d2b544d_terseLabel_en-US" xlink:label="lab_nbix_Amended2020EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended 2020 Equity Incentive Plan</link:label>
    <link:label id="lab_nbix_Amended2020EquityIncentivePlanMember_label_en-US" xlink:label="lab_nbix_Amended2020EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended 2020 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_nbix_Amended2020EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_nbix_Amended2020EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended 2020 Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_Amended2020EquityIncentivePlanMember" xlink:href="nbix-20221231.xsd#nbix_Amended2020EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_Amended2020EquityIncentivePlanMember" xlink:to="lab_nbix_Amended2020EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_bf95a88d-0b97-4275-b0a6-51f040ae3b52_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_5922aa8c-599f-4518-a600-e20c56567706_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_IncomeTaxesTable_9afc9e75-f92f-410c-9666-b601786f4552_terseLabel_en-US" xlink:label="lab_nbix_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_nbix_IncomeTaxesTable_label_en-US" xlink:label="lab_nbix_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_nbix_IncomeTaxesTable_documentation_en-US" xlink:label="lab_nbix_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxesTable" xlink:href="nbix-20221231.xsd#nbix_IncomeTaxesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_IncomeTaxesTable" xlink:to="lab_nbix_IncomeTaxesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_80a80fde-f052-4db1-81f5-5f9760d049f9_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_a1e3a203-54c3-46ec-9bd0-dfbcce62c0c4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_d3d2d16c-ecb0-4c79-904c-e248cd222ff6_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_3adbb233-2618-4ee1-a37c-3c0084e08b23_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income Before the Provision for Income Taxes from Continuing Domestic and Foreign Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_Amended2018EmployeeStockPurchasePlanMember_d66e53b6-f32f-4e77-a503-e38a7f542e2e_terseLabel_en-US" xlink:label="lab_nbix_Amended2018EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended 2018 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_nbix_Amended2018EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_nbix_Amended2018EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended 2018 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_nbix_Amended2018EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_nbix_Amended2018EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended 2018 Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_Amended2018EmployeeStockPurchasePlanMember" xlink:href="nbix-20221231.xsd#nbix_Amended2018EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_Amended2018EmployeeStockPurchasePlanMember" xlink:to="lab_nbix_Amended2018EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_683a4528-5568-4569-b73e-db276b68dfe7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of business, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_33055294-2e29-45f4-96e7-8fbcdce336d7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity component of repurchased convertible senior notes, net</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_db674632-bc08-4c20-90c8-49a821ff6a31_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity component of repurchased convertible senior notes</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_13e5b263-738d-4d99-af8d-1eaab9f43600_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_85e4b09d-f073-4380-a46a-02b36a8fb7a5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_9b7d0eed-47e6-4fd0-9e11-f9c043b9ac65_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_cf0fdc06-ac49-456c-99f4-b8ea79389513_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accreted interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_7b1af1f3-22b6-4865-9412-c1b48653ad34_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income - diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_613e671b-1369-4159-a0e3-757dd86e2007_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_0b7acf94-b233-4be1-b158-d0b6dfb9ff8f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share, diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_87e4c253-1f3b-4471-a410-cb5887e4b800_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_37535912-fb2e-4000-9f34-b2e0829aa1b8_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_3e4057e5-ccd5-4c50-a291-c2e1da0cd4c4_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_5810f5b9-c3e7-4548-8d5c-4cd7b18d5301_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e4cbc0bf-7e94-41f3-bf6e-854d347e5755_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_02663919-997b-440d-815a-01a30bbf978b_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost, noncurrent</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8afb1387-b0ef-4ed8-b388-be8fb9ffb39f_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollateralDomain_e53ad4f0-54ee-4430-a28a-bdc7bbcbf477_terseLabel_en-US" xlink:label="lab_us-gaap_CollateralDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral Held [Domain]</link:label>
    <link:label id="lab_us-gaap_CollateralDomain_label_en-US" xlink:label="lab_us-gaap_CollateralDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral Held [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollateralDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollateralDomain" xlink:to="lab_us-gaap_CollateralDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_OrganizationAndBusinesDescriptionPolicyPolicyTextBlock_224bb6f0-5cb8-4d7c-85a8-8a2578ffafec_terseLabel_en-US" xlink:label="lab_nbix_OrganizationAndBusinesDescriptionPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Business</link:label>
    <link:label id="lab_nbix_OrganizationAndBusinesDescriptionPolicyPolicyTextBlock_label_en-US" xlink:label="lab_nbix_OrganizationAndBusinesDescriptionPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Busines Description Policy [Policy Text Block]</link:label>
    <link:label id="lab_nbix_OrganizationAndBusinesDescriptionPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_nbix_OrganizationAndBusinesDescriptionPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description Policy [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OrganizationAndBusinesDescriptionPolicyPolicyTextBlock" xlink:href="nbix-20221231.xsd#nbix_OrganizationAndBusinesDescriptionPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_OrganizationAndBusinesDescriptionPolicyPolicyTextBlock" xlink:to="lab_nbix_OrganizationAndBusinesDescriptionPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndOtherAccruedExpenses_2efb3d66-428a-4ff2-a6c6-b680114ae681_negatedTerseLabel_en-US" xlink:label="lab_nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndOtherAccruedExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other accrued expenses</link:label>
    <link:label id="lab_nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndOtherAccruedExpenses_label_en-US" xlink:label="lab_nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndOtherAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accounts Payable And Other Accrued Expenses</link:label>
    <link:label id="lab_nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndOtherAccruedExpenses_documentation_en-US" xlink:label="lab_nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndOtherAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accounts Payable And Other Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndOtherAccruedExpenses" xlink:href="nbix-20221231.xsd#nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndOtherAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndOtherAccruedExpenses" xlink:to="lab_nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndOtherAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_cf02b3ca-a7a5-47dc-8517-4e16a7113d4a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_e1124e05-2f5f-4ea1-9f79-3e1548d54ed9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_afedfa94-d53f-4eff-b922-11ef85864366_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_16fe04cb-b905-4c04-9174-453118d0ab52_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_VoyagerTherapeuticsMember_09396ae0-afe5-4db0-beb0-39a37564f12a_terseLabel_en-US" xlink:label="lab_nbix_VoyagerTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voyager</link:label>
    <link:label id="lab_nbix_VoyagerTherapeuticsMember_label_en-US" xlink:label="lab_nbix_VoyagerTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voyager Therapeutics [Member]</link:label>
    <link:label id="lab_nbix_VoyagerTherapeuticsMember_documentation_en-US" xlink:label="lab_nbix_VoyagerTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voyager therapeutics.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_VoyagerTherapeuticsMember" xlink:href="nbix-20221231.xsd#nbix_VoyagerTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_VoyagerTherapeuticsMember" xlink:to="lab_nbix_VoyagerTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_44616bd1-20e2-4115-824d-61118d32b362_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6131dbda-ef95-49af-ad4f-1b349b20910f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_7db4c9f3-6be9-46a3-9fc1-d15a58f48114_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at January 1</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_fd98637e-9d9b-4e1d-bf6b-27e3ab5f02de_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December 31</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_689c0ca3-7e27-40e1-a606-a5dd92f93410_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities purchase date fair value amount</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI and without Readily Determinable Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:to="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_RevenueRelatedReservesForDiscountsAndAllowances_80b4bbd5-e6df-47d4-b00d-e2cae797db69_terseLabel_en-US" xlink:label="lab_nbix_RevenueRelatedReservesForDiscountsAndAllowances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue-related reserves for discounts and allowances</link:label>
    <link:label id="lab_nbix_RevenueRelatedReservesForDiscountsAndAllowances_label_en-US" xlink:label="lab_nbix_RevenueRelatedReservesForDiscountsAndAllowances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Related Reserves For Discounts And Allowances</link:label>
    <link:label id="lab_nbix_RevenueRelatedReservesForDiscountsAndAllowances_documentation_en-US" xlink:label="lab_nbix_RevenueRelatedReservesForDiscountsAndAllowances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue-related reserves for discounts and allowances.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_RevenueRelatedReservesForDiscountsAndAllowances" xlink:href="nbix-20221231.xsd#nbix_RevenueRelatedReservesForDiscountsAndAllowances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_RevenueRelatedReservesForDiscountsAndAllowances" xlink:to="lab_nbix_RevenueRelatedReservesForDiscountsAndAllowances" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_300ba01a-9a7e-44e2-b20a-5f31236f7380_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities&#8211;biotechnology industry</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_8ba3fdcd-53b8-4e91-9642-f8f0d2cd4af3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary and changes in restricted stock units outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_ConversionPeriodOneMember_7e37f09f-9688-4ae6-8617-96cdcc641657_terseLabel_en-US" xlink:label="lab_nbix_ConversionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period One</link:label>
    <link:label id="lab_nbix_ConversionPeriodOneMember_label_en-US" xlink:label="lab_nbix_ConversionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period One [Member]</link:label>
    <link:label id="lab_nbix_ConversionPeriodOneMember_documentation_en-US" xlink:label="lab_nbix_ConversionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ConversionPeriodOneMember" xlink:href="nbix-20221231.xsd#nbix_ConversionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_ConversionPeriodOneMember" xlink:to="lab_nbix_ConversionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_116848e8-d123-4495-b16c-881ed71e444a_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would affect effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_cab49f84-13c0-4210-a25e-492b1bd883e4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationInterestAccrued_9d9e8869-0196-4d17-a7c3-59393bf4e7d4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest accrued</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationInterestAccrued_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationInterestAccrued" xlink:to="lab_us-gaap_IncomeTaxExaminationInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_d51c8e42-8974-4e6c-a153-301da9706f89_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual term of stock options</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_c1c33d2d-cd90-4915-9ee2-8943e0c4e668_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_be7a9b2d-94e4-4d22-85d0-c6b8b5ad9d24_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_6b5f9784-caf3-4d0a-ad77-3c65fc714d14_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_29e3adbb-179f-45f1-959a-6fed068811b0_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_8732373c-9516-478d-a8be-f667bc492e8d_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_5b650ad6-d479-4ae0-9e6b-aee9cfac1aea_negatedLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_4f589c3d-f932-4442-93f2-f67ea241a8c2_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) included in earnings</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward_840cdf69-716b-486a-a0d2-934ab136e6e3_terseLabel_en-US" xlink:label="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares increased by returning shares subject to appreciation award (in shares)</link:label>
    <link:label id="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward_label_en-US" xlink:label="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Increased By Returning Shares Subject To Appreciation Award</link:label>
    <link:label id="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward_documentation_en-US" xlink:label="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Increased By Returning Shares Subject To Appreciation Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward" xlink:href="nbix-20221231.xsd#nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward" xlink:to="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_ad6669e2-76e7-46fb-ae3f-aa9b7a8459e3_terseLabel_en-US" xlink:label="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain, noncurrent</link:label>
    <link:label id="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_label_en-US" xlink:label="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Noncurrent</link:label>
    <link:label id="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_documentation_en-US" xlink:label="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:href="nbix-20221231.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:to="lab_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_954467a6-603f-4653-bde5-f497b1788626_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of minimum lease payments for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_590958d1-add2-42ac-9d73-c11cc84b2ce8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in tax rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_ddd709fd-cf2d-437e-a4e6-81514e14203b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_06265648-7aa5-4b24-b10b-11c59e8085ce_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_ScientificEquipmentMember_5d616d0b-1dc4-4906-8f8e-7a539c9e508f_terseLabel_en-US" xlink:label="lab_nbix_ScientificEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scientific equipment</link:label>
    <link:label id="lab_nbix_ScientificEquipmentMember_label_en-US" xlink:label="lab_nbix_ScientificEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scientific Equipment [Member]</link:label>
    <link:label id="lab_nbix_ScientificEquipmentMember_documentation_en-US" xlink:label="lab_nbix_ScientificEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scientific equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ScientificEquipmentMember" xlink:href="nbix-20221231.xsd#nbix_ScientificEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_ScientificEquipmentMember" xlink:to="lab_nbix_ScientificEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_f6a36b30-a6bd-43f2-b877-7b2c0751d6af_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_05fb65f4-7e43-493d-9324-e73bebbb9c94_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_2d42f6db-8937-46d0-b5f8-84f6601914ea_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_bce6f6ac-ac56-4dfa-8275-38d7f0d059a0_totalLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Total</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_69ed702d-43c8-44dd-902c-498cff9bf0bd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_e296c94f-df71-4021-9b43-75f90774c6d0_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_bfa4b473-e9e7-45ec-98ac-d047019339a1_terseLabel_en-US" xlink:label="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:href="nbix-20221231.xsd#nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2762d275-13ec-4079-8c9a-19748065a959_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and maturities of debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4fbdbaaf-0bcd-4bc5-ac74-63aa14f8776e_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_IncomeTaxesLineItems_cd400c06-cefd-419d-b842-c4508a69f219_terseLabel_en-US" xlink:label="lab_nbix_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_nbix_IncomeTaxesLineItems_label_en-US" xlink:label="lab_nbix_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_nbix_IncomeTaxesLineItems_documentation_en-US" xlink:label="lab_nbix_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxesLineItems" xlink:href="nbix-20221231.xsd#nbix_IncomeTaxesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_IncomeTaxesLineItems" xlink:to="lab_nbix_IncomeTaxesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_95eb74a1-a702-4411-8144-1744dd31fc67_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes net of discounts and deferred financing costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_4677ea67-0638-450e-aa22-e1fe3128b18f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5dd597f4-cb2c-4696-8885-3380f34264e6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Released (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_b5f7bcc2-aab5-4174-a70b-f24a1976d021_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3f669bed-2bba-42e1-ab83-97472cdcce63_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common stock authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_IdorsiaPharmaceuticalsLtdMember_e9c0e922-b934-4a8a-a5fc-de149b079ca1_terseLabel_en-US" xlink:label="lab_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Idorsia</link:label>
    <link:label id="lab_nbix_IdorsiaPharmaceuticalsLtdMember_label_en-US" xlink:label="lab_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Idorsia Pharmaceuticals Ltd [Member]</link:label>
    <link:label id="lab_nbix_IdorsiaPharmaceuticalsLtdMember_documentation_en-US" xlink:label="lab_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Idorsia Pharmaceuticals Ltd</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:href="nbix-20221231.xsd#nbix_IdorsiaPharmaceuticalsLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:to="lab_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_be4b648b-4831-4c58-8948-11e1c0fe3c6e_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_0c0afc53-87ab-4e79-b908-4b33a255652e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_9b3fd9bc-718c-4e5e-b807-d0ed230e10c2_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ba44b385-7ffa-4f90-ac3f-641ec2bf5e33_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_27e2ada5-2dde-40e3-8323-61ddb519a052_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed borrowing rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_5c5d87b1-53f3-48c0-a0a6-ddce09a3387b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for (benefit from) income taxes on earnings subject to income taxes differs from statutory federal rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1aaa3c23-5075-4230-b924-78a9b06e5932_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in cash and cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_035c0a08-773c-4ed5-9ecc-d4eeb1bc267b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income tax, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment_9e6f6be6-ec83-4c68-b08d-b761c87b02d6_terseLabel_en-US" xlink:label="lab_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of the liability component immediately before extinguishment</link:label>
    <link:label id="lab_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment_label_en-US" xlink:label="lab_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Liability Component Immediately Before Extinguishment</link:label>
    <link:label id="lab_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment_documentation_en-US" xlink:label="lab_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of the liability component immediately before extinguishment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment" xlink:href="nbix-20221231.xsd#nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment" xlink:to="lab_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_d1bd352e-3648-430c-af38-32a2349ca2d8_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_f2dcd89c-2fd9-46c5-8155-401a81ec4a9b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_39ccd4fb-b567-4a9c-afbd-df25b570607a_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_d59bf411-ef07-4cca-bb0a-e513e10420c8_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_c5f4e31c-13f6-47e2-ba11-ba5eb8060ebc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_9be42c81-31ac-4487-ac72-38c01064c28a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6a8de02c-189c-43f3-8e6c-fe2c5a83685f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0abba643-add8-4bd7-a1b6-2d365d0c04ec_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DeferredTaxAssetsLiabilitiesGross_5a725402-2849-4a5b-a81d-d26cc9249aad_totalLabel_en-US" xlink:label="lab_nbix_DeferredTaxAssetsLiabilitiesGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net of deferred tax assets and liabilities</link:label>
    <link:label id="lab_nbix_DeferredTaxAssetsLiabilitiesGross_label_en-US" xlink:label="lab_nbix_DeferredTaxAssetsLiabilitiesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Liabilities Gross</link:label>
    <link:label id="lab_nbix_DeferredTaxAssetsLiabilitiesGross_documentation_en-US" xlink:label="lab_nbix_DeferredTaxAssetsLiabilitiesGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets (liabilities) gross.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxAssetsLiabilitiesGross" xlink:href="nbix-20221231.xsd#nbix_DeferredTaxAssetsLiabilitiesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DeferredTaxAssetsLiabilitiesGross" xlink:to="lab_nbix_DeferredTaxAssetsLiabilitiesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7b5a6977-db1b-44a1-b6d7-d365154ec5b8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_beec7b8c-482f-4223-85c2-73aa5bfb0d89_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_63064ee6-ab77-430f-b45f-7aa04fa4d55f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_aa429856-2d5b-4f35-9508-365896313b61_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_bb827110-d6b2-4aca-b9d6-eaf6e89fd078_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_ec7ba105-591d-4e06-ba69-886f99c329ca_terseLabel_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for Credit Losses</link:label>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Loss, Financial Instrument [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:to="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_86ce9d5f-2827-4b25-b055-25f36305eba4_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_XenonPharmaceuticalsIncMember_4addbc36-d3bf-4991-8910-8778662b7d7a_terseLabel_en-US" xlink:label="lab_nbix_XenonPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xenon</link:label>
    <link:label id="lab_nbix_XenonPharmaceuticalsIncMember_label_en-US" xlink:label="lab_nbix_XenonPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xenon Pharmaceuticals Inc [Member]</link:label>
    <link:label id="lab_nbix_XenonPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_nbix_XenonPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xenon Pharmaceuticals Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_XenonPharmaceuticalsIncMember" xlink:href="nbix-20221231.xsd#nbix_XenonPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_XenonPharmaceuticalsIncMember" xlink:to="lab_nbix_XenonPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_ConversionPeriodTwoMember_21f7871f-af67-4c47-807d-c7740066cffa_terseLabel_en-US" xlink:label="lab_nbix_ConversionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period Two</link:label>
    <link:label id="lab_nbix_ConversionPeriodTwoMember_label_en-US" xlink:label="lab_nbix_ConversionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period Two [Member]</link:label>
    <link:label id="lab_nbix_ConversionPeriodTwoMember_documentation_en-US" xlink:label="lab_nbix_ConversionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ConversionPeriodTwoMember" xlink:href="nbix-20221231.xsd#nbix_ConversionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_ConversionPeriodTwoMember" xlink:to="lab_nbix_ConversionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_5526316c-c750-4a66-8837-c768189e27ac_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_85d70312-bba0-4792-b610-7c510aee1ca8_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DeferredTaxAssetsOperatingLeasesAssets_34c3a632-ad15-498d-a388-db732c8714d8_terseLabel_en-US" xlink:label="lab_nbix_DeferredTaxAssetsOperatingLeasesAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_nbix_DeferredTaxAssetsOperatingLeasesAssets_label_en-US" xlink:label="lab_nbix_DeferredTaxAssetsOperatingLeasesAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Operating Leases Assets</link:label>
    <link:label id="lab_nbix_DeferredTaxAssetsOperatingLeasesAssets_documentation_en-US" xlink:label="lab_nbix_DeferredTaxAssetsOperatingLeasesAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets operating leases assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxAssetsOperatingLeasesAssets" xlink:href="nbix-20221231.xsd#nbix_DeferredTaxAssetsOperatingLeasesAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DeferredTaxAssetsOperatingLeasesAssets" xlink:to="lab_nbix_DeferredTaxAssetsOperatingLeasesAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_92d5d96e-ae24-4b96-8b6f-0bcbd96f8c42_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_9dbde2f6-9ddf-4fe1-bfb2-08e3e3638bf4_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_8b287aa7-6f53-4f5e-b011-3ea7b6dded82_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsAcquiredInProcessResearchAndDevelopment_62147677-ac89-48ae-855f-c916b0e55dea_terseLabel_en-US" xlink:label="lab_nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsAcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsAcquiredInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsAcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Acquired In-Process Research And Development</link:label>
    <link:label id="lab_nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsAcquiredInProcessResearchAndDevelopment_documentation_en-US" xlink:label="lab_nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsAcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Acquired In-Process Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsAcquiredInProcessResearchAndDevelopment" xlink:href="nbix-20221231.xsd#nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsAcquiredInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsAcquiredInProcessResearchAndDevelopment" xlink:to="lab_nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsAcquiredInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_7b6d9b44-083e-462b-8ef1-86c499a22d97_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_50fbfa5b-3ddd-41ba-bae2-4636b7b63f18_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal income taxes at 21%</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_532a73c3-2675-4800-82b0-e93264afd798_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5f92179a-fa3c-447b-af83-8be373b5734f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_98fb673a-78fd-45a2-a1d3-44f3f9729e21_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_aaffe35e-eb51-42b9-bae4-2e32969fc78c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_fa7a38dc-060b-4885-ae6f-ca1a109b8733_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember_fc98caff-488b-47af-bdf1-9cd6d372a07a_terseLabel_en-US" xlink:label="lab_nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options restricted stock and convertible senior notes</link:label>
    <link:label id="lab_nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember_label_en-US" xlink:label="lab_nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Restricted Stock And Convertible Senior Notes [Member]</link:label>
    <link:label id="lab_nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember_documentation_en-US" xlink:label="lab_nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, restricted stock and convertible senior notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember" xlink:href="nbix-20221231.xsd#nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember" xlink:to="lab_nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c31f68f3-b365-4448-8e13-ea8b0b0461f3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair values of stock options granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_13814068-68a4-4d89-853c-73e773a2def6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7ce4ac9c-bf36-46cf-94fe-398c592884c9_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_5ecce59c-9002-4451-a923-7063cb4edfc3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_f180c116-8d3f-421e-898d-0900e8d34912_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1c7c8980-b1e9-4326-a5d6-c8012de4f2d1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Income Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_a7fe141d-b538-4d1d-9464-b7b50a3ed91d_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets acquired through operating leases</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_afadabc1-2250-4206-a609-8902e6bf745c_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_fe6b4757-4fc5-4dde-a3e7-aa320a67091e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>nbix-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:218564f8-ce6a-495b-ab09-3ced376fc2a9,g:579af41c-0e49-45b3-bd8f-934603ccb3b3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.neurocrine.com/role/CoverPage" xlink:type="simple" xlink:href="nbix-20221231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_14480a6f-8a65-4c98-aef3-09f6361c5f62" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_414a30eb-353f-40b9-961e-46793ebf7935" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_14480a6f-8a65-4c98-aef3-09f6361c5f62" xlink:to="loc_dei_DocumentType_414a30eb-353f-40b9-961e-46793ebf7935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_2f46f500-1c47-4f86-8f35-7c84a87fc9df" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_14480a6f-8a65-4c98-aef3-09f6361c5f62" xlink:to="loc_dei_DocumentAnnualReport_2f46f500-1c47-4f86-8f35-7c84a87fc9df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_228a617b-7973-4200-8839-446c1e893e90" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_14480a6f-8a65-4c98-aef3-09f6361c5f62" xlink:to="loc_dei_DocumentPeriodEndDate_228a617b-7973-4200-8839-446c1e893e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_318c181f-cdf3-496b-823b-38b20eba46dd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_14480a6f-8a65-4c98-aef3-09f6361c5f62" xlink:to="loc_dei_CurrentFiscalYearEndDate_318c181f-cdf3-496b-823b-38b20eba46dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_221282fb-ab7b-4edf-bd8f-6137e11e4d6a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_14480a6f-8a65-4c98-aef3-09f6361c5f62" xlink:to="loc_dei_DocumentTransitionReport_221282fb-ab7b-4edf-bd8f-6137e11e4d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_8cfeac18-2ebb-4b89-a6fb-3aec80ad999a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_14480a6f-8a65-4c98-aef3-09f6361c5f62" xlink:to="loc_dei_EntityFileNumber_8cfeac18-2ebb-4b89-a6fb-3aec80ad999a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_ea4fbf92-f8a8-4edd-b42b-bac86a4c6424" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_14480a6f-8a65-4c98-aef3-09f6361c5f62" xlink:to="loc_dei_EntityRegistrantName_ea4fbf92-f8a8-4edd-b42b-bac86a4c6424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_8f2338b3-f052-4def-88ab-1c1ed6300059" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_14480a6f-8a65-4c98-aef3-09f6361c5f62" xlink:to="loc_dei_EntityIncorporationStateCountryCode_8f2338b3-f052-4def-88ab-1c1ed6300059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_7cb69cb9-e06d-40a9-87a3-8f7b3681019d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_14480a6f-8a65-4c98-aef3-09f6361c5f62" xlink:to="loc_dei_EntityTaxIdentificationNumber_7cb69cb9-e06d-40a9-87a3-8f7b3681019d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_a3a36ae5-726b-4581-851b-372a8c8d7af6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_14480a6f-8a65-4c98-aef3-09f6361c5f62" xlink:to="loc_dei_EntityAddressAddressLine1_a3a36ae5-726b-4581-851b-372a8c8d7af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_d0526e16-c4aa-475f-93c4-f63c77a0f506" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_14480a6f-8a65-4c98-aef3-09f6361c5f62" xlink:to="loc_dei_EntityAddressCityOrTown_d0526e16-c4aa-475f-93c4-f63c77a0f506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_85075f99-c2d8-4e0e-891d-090f800ce929" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_14480a6f-8a65-4c98-aef3-09f6361c5f62" xlink:to="loc_dei_EntityAddressStateOrProvince_85075f99-c2d8-4e0e-891d-090f800ce929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_5ecfaed5-eb68-4399-8825-3e3a7b345e13" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_14480a6f-8a65-4c98-aef3-09f6361c5f62" xlink:to="loc_dei_EntityAddressPostalZipCode_5ecfaed5-eb68-4399-8825-3e3a7b345e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_4cae9856-00ae-475d-9e99-4505e5cb7b96" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_14480a6f-8a65-4c98-aef3-09f6361c5f62" xlink:to="loc_dei_CityAreaCode_4cae9856-00ae-475d-9e99-4505e5cb7b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_fe01148e-48e8-42e6-b535-53a4524a6fc8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_14480a6f-8a65-4c98-aef3-09f6361c5f62" xlink:to="loc_dei_LocalPhoneNumber_fe01148e-48e8-42e6-b535-53a4524a6fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_a87b1a23-91fe-4e6a-b4af-332bf0637f07" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_14480a6f-8a65-4c98-aef3-09f6361c5f62" xlink:to="loc_dei_Security12bTitle_a87b1a23-91fe-4e6a-b4af-332bf0637f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d3cbbe02-0423-429d-ab9a-72f7d252b59e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_14480a6f-8a65-4c98-aef3-09f6361c5f62" xlink:to="loc_dei_TradingSymbol_d3cbbe02-0423-429d-ab9a-72f7d252b59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_95bec92b-cf4b-4643-b177-c7495faa4be0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_14480a6f-8a65-4c98-aef3-09f6361c5f62" xlink:to="loc_dei_SecurityExchangeName_95bec92b-cf4b-4643-b177-c7495faa4be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_c28ca670-e985-45ed-a996-ee594c224385" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_14480a6f-8a65-4c98-aef3-09f6361c5f62" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_c28ca670-e985-45ed-a996-ee594c224385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_e96dafd6-48b2-4970-96d7-bb4eab3aa3ac" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_14480a6f-8a65-4c98-aef3-09f6361c5f62" xlink:to="loc_dei_EntityVoluntaryFilers_e96dafd6-48b2-4970-96d7-bb4eab3aa3ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_9663f9a9-2ea5-4b7a-b2cd-d8cce5739cb9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_14480a6f-8a65-4c98-aef3-09f6361c5f62" xlink:to="loc_dei_EntityCurrentReportingStatus_9663f9a9-2ea5-4b7a-b2cd-d8cce5739cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_5549103a-7d2b-4c0d-9ab3-94bb410adb74" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_14480a6f-8a65-4c98-aef3-09f6361c5f62" xlink:to="loc_dei_EntityInteractiveDataCurrent_5549103a-7d2b-4c0d-9ab3-94bb410adb74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_303f8c24-a0a3-4dc3-be88-7d1ad983882c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_14480a6f-8a65-4c98-aef3-09f6361c5f62" xlink:to="loc_dei_EntityFilerCategory_303f8c24-a0a3-4dc3-be88-7d1ad983882c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_65e1f819-0b58-409b-826a-329aca96fce4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_14480a6f-8a65-4c98-aef3-09f6361c5f62" xlink:to="loc_dei_EntitySmallBusiness_65e1f819-0b58-409b-826a-329aca96fce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_e607374c-e04b-4e41-a4b9-b168cf5a542a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_14480a6f-8a65-4c98-aef3-09f6361c5f62" xlink:to="loc_dei_EntityEmergingGrowthCompany_e607374c-e04b-4e41-a4b9-b168cf5a542a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_dc587209-ffe5-4f8e-b8b2-f6e7ba8c8012" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_14480a6f-8a65-4c98-aef3-09f6361c5f62" xlink:to="loc_dei_IcfrAuditorAttestationFlag_dc587209-ffe5-4f8e-b8b2-f6e7ba8c8012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_eb3785c2-b4f7-4f47-8162-86a48f190a6b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_14480a6f-8a65-4c98-aef3-09f6361c5f62" xlink:to="loc_dei_EntityShellCompany_eb3785c2-b4f7-4f47-8162-86a48f190a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_a7dad85e-355d-4049-96a2-569c76f353d6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_14480a6f-8a65-4c98-aef3-09f6361c5f62" xlink:to="loc_dei_EntityPublicFloat_a7dad85e-355d-4049-96a2-569c76f353d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_89064fd1-004c-43fc-b431-d3107636d2cc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_14480a6f-8a65-4c98-aef3-09f6361c5f62" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_89064fd1-004c-43fc-b431-d3107636d2cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_fd4389da-dc3f-432b-b5b6-c78f51c1b9df" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_14480a6f-8a65-4c98-aef3-09f6361c5f62" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_fd4389da-dc3f-432b-b5b6-c78f51c1b9df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_aedbf7e5-0042-4623-acb1-d74a7370405a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_14480a6f-8a65-4c98-aef3-09f6361c5f62" xlink:to="loc_dei_AmendmentFlag_aedbf7e5-0042-4623-acb1-d74a7370405a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_4f260ef5-7d55-4637-83e9-cfbb9bcffd93" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_14480a6f-8a65-4c98-aef3-09f6361c5f62" xlink:to="loc_dei_DocumentFiscalYearFocus_4f260ef5-7d55-4637-83e9-cfbb9bcffd93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_ce880474-8364-4992-8b12-6a5022e6d509" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_14480a6f-8a65-4c98-aef3-09f6361c5f62" xlink:to="loc_dei_DocumentFiscalPeriodFocus_ce880474-8364-4992-8b12-6a5022e6d509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_cd942fc0-ce0e-4ee1-b31a-df661a2371e2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_14480a6f-8a65-4c98-aef3-09f6361c5f62" xlink:to="loc_dei_EntityCentralIndexKey_cd942fc0-ce0e-4ee1-b31a-df661a2371e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/AuditInformation" xlink:type="simple" xlink:href="nbix-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AuditorInformationAbstract_a0f77663-af32-4489-91ca-5a2b59656107" xlink:href="nbix-20221231.xsd#nbix_AuditorInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_7ffe0588-3887-4d40-802a-667f5a31d5bd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_AuditorInformationAbstract_a0f77663-af32-4489-91ca-5a2b59656107" xlink:to="loc_dei_AuditorFirmId_7ffe0588-3887-4d40-802a-667f5a31d5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_7b2870e1-6e11-469e-bf8a-93d9c31f91b6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_AuditorInformationAbstract_a0f77663-af32-4489-91ca-5a2b59656107" xlink:to="loc_dei_AuditorName_7b2870e1-6e11-469e-bf8a-93d9c31f91b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_cc16e05a-4c64-47e6-8fa6-a1562fc9e8b6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_AuditorInformationAbstract_a0f77663-af32-4489-91ca-5a2b59656107" xlink:to="loc_dei_AuditorLocation_cc16e05a-4c64-47e6-8fa6-a1562fc9e8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nbix-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_809c1eec-380e-4ce6-a0a3-c980834d96a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_b86a8681-73d3-4c52-95af-a0ccb1874d34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_809c1eec-380e-4ce6-a0a3-c980834d96a7" xlink:to="loc_us-gaap_AssetsAbstract_b86a8681-73d3-4c52-95af-a0ccb1874d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_e1bd0871-7527-4660-8a64-6c6f2bc1a4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b86a8681-73d3-4c52-95af-a0ccb1874d34" xlink:to="loc_us-gaap_AssetsCurrentAbstract_e1bd0871-7527-4660-8a64-6c6f2bc1a4ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_246b147e-cbbb-4a97-b725-0a1c3c1bbc25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e1bd0871-7527-4660-8a64-6c6f2bc1a4ee" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_246b147e-cbbb-4a97-b725-0a1c3c1bbc25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8512ce95-3b22-4eba-8491-f66dba5975eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e1bd0871-7527-4660-8a64-6c6f2bc1a4ee" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8512ce95-3b22-4eba-8491-f66dba5975eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_abbb616a-b3ad-4e6c-9082-1a7a688675f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e1bd0871-7527-4660-8a64-6c6f2bc1a4ee" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_abbb616a-b3ad-4e6c-9082-1a7a688675f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_71f2688a-e683-4e6f-8eae-b8de18b3ce6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e1bd0871-7527-4660-8a64-6c6f2bc1a4ee" xlink:to="loc_us-gaap_InventoryNet_71f2688a-e683-4e6f-8eae-b8de18b3ce6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_c021dff5-d89b-4151-9550-5d73e45d6684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e1bd0871-7527-4660-8a64-6c6f2bc1a4ee" xlink:to="loc_us-gaap_OtherAssetsCurrent_c021dff5-d89b-4151-9550-5d73e45d6684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_629c50c8-2ab3-4d8e-b049-2aaf29ea9ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e1bd0871-7527-4660-8a64-6c6f2bc1a4ee" xlink:to="loc_us-gaap_AssetsCurrent_629c50c8-2ab3-4d8e-b049-2aaf29ea9ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_f45e8ef5-acec-4171-be36-bd21df95329d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b86a8681-73d3-4c52-95af-a0ccb1874d34" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_f45e8ef5-acec-4171-be36-bd21df95329d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_f8bf252c-6452-4225-abdd-0b79963e79bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b86a8681-73d3-4c52-95af-a0ccb1874d34" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_f8bf252c-6452-4225-abdd-0b79963e79bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_998ddadc-85a8-41c6-8279-179ff7f1c541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b86a8681-73d3-4c52-95af-a0ccb1874d34" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_998ddadc-85a8-41c6-8279-179ff7f1c541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRestricted_d3c3ad1a-8864-4d56-aa80-dea03fe05a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiRestricted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b86a8681-73d3-4c52-95af-a0ccb1874d34" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRestricted_d3c3ad1a-8864-4d56-aa80-dea03fe05a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_25ea478d-9728-47f7-aee6-6df68c946eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b86a8681-73d3-4c52-95af-a0ccb1874d34" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_25ea478d-9728-47f7-aee6-6df68c946eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d4892167-2af0-44c2-8436-1b3cb8da430d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b86a8681-73d3-4c52-95af-a0ccb1874d34" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d4892167-2af0-44c2-8436-1b3cb8da430d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7b1b72ee-3dd0-4f68-a033-dbda45f5a979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b86a8681-73d3-4c52-95af-a0ccb1874d34" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7b1b72ee-3dd0-4f68-a033-dbda45f5a979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_131b9575-bf8f-47ac-a52e-ac0004d904b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b86a8681-73d3-4c52-95af-a0ccb1874d34" xlink:to="loc_us-gaap_Assets_131b9575-bf8f-47ac-a52e-ac0004d904b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c7aec301-6ebc-48d7-8521-9bd2b3a4b9f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_809c1eec-380e-4ce6-a0a3-c980834d96a7" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c7aec301-6ebc-48d7-8521-9bd2b3a4b9f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_b8614bfa-8ab5-4a47-b344-d8a660e4523d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c7aec301-6ebc-48d7-8521-9bd2b3a4b9f6" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_b8614bfa-8ab5-4a47-b344-d8a660e4523d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c0ccb94b-a304-4826-85db-72c4bdf82a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b8614bfa-8ab5-4a47-b344-d8a660e4523d" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c0ccb94b-a304-4826-85db-72c4bdf82a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_a09654a5-000c-441f-bccf-aa2010ffb280" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b8614bfa-8ab5-4a47-b344-d8a660e4523d" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_a09654a5-000c-441f-bccf-aa2010ffb280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_5956d6f2-c74d-42a3-b9e6-e28d75c73daa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b8614bfa-8ab5-4a47-b344-d8a660e4523d" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_5956d6f2-c74d-42a3-b9e6-e28d75c73daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_780c6330-25ff-470c-9eca-3127284db0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b8614bfa-8ab5-4a47-b344-d8a660e4523d" xlink:to="loc_us-gaap_LiabilitiesCurrent_780c6330-25ff-470c-9eca-3127284db0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_435555b3-2957-40a4-b173-ccae2669675c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c7aec301-6ebc-48d7-8521-9bd2b3a4b9f6" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_435555b3-2957-40a4-b173-ccae2669675c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_be91818a-b177-487f-8727-a7a68832a341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c7aec301-6ebc-48d7-8521-9bd2b3a4b9f6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_be91818a-b177-487f-8727-a7a68832a341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_536b49c5-dc2e-42ab-98f9-5055f0620efe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c7aec301-6ebc-48d7-8521-9bd2b3a4b9f6" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_536b49c5-dc2e-42ab-98f9-5055f0620efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a4f1b88f-7e43-4bfa-8d7a-7efb30a1032e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c7aec301-6ebc-48d7-8521-9bd2b3a4b9f6" xlink:to="loc_us-gaap_Liabilities_a4f1b88f-7e43-4bfa-8d7a-7efb30a1032e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_900500e9-2968-4fad-ae0a-2cbca98a594c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c7aec301-6ebc-48d7-8521-9bd2b3a4b9f6" xlink:to="loc_us-gaap_StockholdersEquityAbstract_900500e9-2968-4fad-ae0a-2cbca98a594c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_1b2c8b09-836a-40af-92f7-8a409f433deb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_900500e9-2968-4fad-ae0a-2cbca98a594c" xlink:to="loc_us-gaap_PreferredStockValue_1b2c8b09-836a-40af-92f7-8a409f433deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_66a37774-d5c9-43af-8065-5df25fe0dc6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_900500e9-2968-4fad-ae0a-2cbca98a594c" xlink:to="loc_us-gaap_CommonStockValue_66a37774-d5c9-43af-8065-5df25fe0dc6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b4f5bd70-a388-462e-92dd-1724ee7fee21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_900500e9-2968-4fad-ae0a-2cbca98a594c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b4f5bd70-a388-462e-92dd-1724ee7fee21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_41e101f4-a790-4bd0-8f22-64946c4a515c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_900500e9-2968-4fad-ae0a-2cbca98a594c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_41e101f4-a790-4bd0-8f22-64946c4a515c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_74366390-c545-4458-9c5f-92f09060e503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_900500e9-2968-4fad-ae0a-2cbca98a594c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_74366390-c545-4458-9c5f-92f09060e503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8853811e-ec2e-458c-8a1f-6d2408606b97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_900500e9-2968-4fad-ae0a-2cbca98a594c" xlink:to="loc_us-gaap_StockholdersEquity_8853811e-ec2e-458c-8a1f-6d2408606b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f585f4a2-d95c-4848-b770-8b9909166127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c7aec301-6ebc-48d7-8521-9bd2b3a4b9f6" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_f585f4a2-d95c-4848-b770-8b9909166127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="nbix-20221231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c203e9d0-b238-4326-b352-7b3a876c77c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_608c291a-03fa-4998-a670-50bb306d4824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c203e9d0-b238-4326-b352-7b3a876c77c5" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_608c291a-03fa-4998-a670-50bb306d4824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_5fac4331-caff-4329-b15b-3a18cb5b8446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c203e9d0-b238-4326-b352-7b3a876c77c5" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_5fac4331-caff-4329-b15b-3a18cb5b8446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_79c4a081-65d1-4081-bf6c-2a58cf3e175a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c203e9d0-b238-4326-b352-7b3a876c77c5" xlink:to="loc_us-gaap_PreferredStockSharesIssued_79c4a081-65d1-4081-bf6c-2a58cf3e175a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_811efd53-1f3c-4884-a8bb-e676cc0819ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c203e9d0-b238-4326-b352-7b3a876c77c5" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_811efd53-1f3c-4884-a8bb-e676cc0819ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f8e685b0-6a34-4a12-ac51-9e686806838a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c203e9d0-b238-4326-b352-7b3a876c77c5" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f8e685b0-6a34-4a12-ac51-9e686806838a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_40cb24ac-f2fe-4466-97a4-243fb4fbab55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c203e9d0-b238-4326-b352-7b3a876c77c5" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_40cb24ac-f2fe-4466-97a4-243fb4fbab55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ac518c2d-a332-4232-b245-d11f7f734e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c203e9d0-b238-4326-b352-7b3a876c77c5" xlink:to="loc_us-gaap_CommonStockSharesIssued_ac518c2d-a332-4232-b245-d11f7f734e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_428c702c-da8b-40ea-bfad-918916b82083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c203e9d0-b238-4326-b352-7b3a876c77c5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_428c702c-da8b-40ea-bfad-918916b82083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome" xlink:type="simple" xlink:href="nbix-20221231.xsd#ConsolidatedStatementsIncomeandComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_7c0f8ef2-a649-4f3b-9217-5dea4cb027ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f59e56a7-4dfa-460d-b70b-db29763ab688" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7c0f8ef2-a649-4f3b-9217-5dea4cb027ee" xlink:to="loc_us-gaap_StatementTable_f59e56a7-4dfa-460d-b70b-db29763ab688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b6c33f1b-01fc-4e8b-b23c-0c65a5ec93ac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f59e56a7-4dfa-460d-b70b-db29763ab688" xlink:to="loc_srt_ProductOrServiceAxis_b6c33f1b-01fc-4e8b-b23c-0c65a5ec93ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_62d90ddf-293d-46b6-819f-2c834ad6861e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b6c33f1b-01fc-4e8b-b23c-0c65a5ec93ac" xlink:to="loc_srt_ProductsAndServicesDomain_62d90ddf-293d-46b6-819f-2c834ad6861e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_9b0d10ad-242e-4e23-976a-a34064f3a439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_62d90ddf-293d-46b6-819f-2c834ad6861e" xlink:to="loc_us-gaap_ProductMember_9b0d10ad-242e-4e23-976a-a34064f3a439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CollaborationRevenueMember_6d2b2813-2950-4349-8aba-5ae853f19536" xlink:href="nbix-20221231.xsd#nbix_CollaborationRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_62d90ddf-293d-46b6-819f-2c834ad6861e" xlink:to="loc_nbix_CollaborationRevenueMember_6d2b2813-2950-4349-8aba-5ae853f19536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b957fe5d-0d3a-4afb-a03a-b241273ffe3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f59e56a7-4dfa-460d-b70b-db29763ab688" xlink:to="loc_us-gaap_StatementLineItems_b957fe5d-0d3a-4afb-a03a-b241273ffe3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_ef801057-f321-42d4-ab6c-bb289c24401e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b957fe5d-0d3a-4afb-a03a-b241273ffe3b" xlink:to="loc_us-gaap_RevenuesAbstract_ef801057-f321-42d4-ab6c-bb289c24401e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_71e927fc-da3d-40cf-869a-619075f3e55c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_ef801057-f321-42d4-ab6c-bb289c24401e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_71e927fc-da3d-40cf-869a-619075f3e55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_5e581b89-69fc-4ca4-bd5f-aa226e828ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b957fe5d-0d3a-4afb-a03a-b241273ffe3b" xlink:to="loc_us-gaap_OperatingExpensesAbstract_5e581b89-69fc-4ca4-bd5f-aa226e828ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_2db18781-2bd3-44d8-9a65-5636363791be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5e581b89-69fc-4ca4-bd5f-aa226e828ed6" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_2db18781-2bd3-44d8-9a65-5636363791be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_cdf4805e-30c9-4a1a-9d5c-aff5792bd45a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5e581b89-69fc-4ca4-bd5f-aa226e828ed6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_cdf4805e-30c9-4a1a-9d5c-aff5792bd45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_a28c0051-3fc5-46ec-9f20-54cf47528a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5e581b89-69fc-4ca4-bd5f-aa226e828ed6" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_a28c0051-3fc5-46ec-9f20-54cf47528a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e152d143-4680-4d18-98f5-1f188c93f9b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5e581b89-69fc-4ca4-bd5f-aa226e828ed6" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e152d143-4680-4d18-98f5-1f188c93f9b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_38ec8462-af9d-4ade-b344-3ee0551f72c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5e581b89-69fc-4ca4-bd5f-aa226e828ed6" xlink:to="loc_us-gaap_CostsAndExpenses_38ec8462-af9d-4ade-b344-3ee0551f72c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b1b2ca7e-5410-47dc-872c-83c98faa9b76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b957fe5d-0d3a-4afb-a03a-b241273ffe3b" xlink:to="loc_us-gaap_OperatingIncomeLoss_b1b2ca7e-5410-47dc-872c-83c98faa9b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1a09db29-e143-4f04-897e-7e3a4b504630" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b957fe5d-0d3a-4afb-a03a-b241273ffe3b" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1a09db29-e143-4f04-897e-7e3a4b504630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_7277d66f-93a3-4d45-bf83-b8d14163afd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1a09db29-e143-4f04-897e-7e3a4b504630" xlink:to="loc_us-gaap_InterestExpense_7277d66f-93a3-4d45-bf83-b8d14163afd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_5f7a23c3-14ba-4051-b04e-e459aa3ab74d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1a09db29-e143-4f04-897e-7e3a4b504630" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_5f7a23c3-14ba-4051-b04e-e459aa3ab74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5d840516-b173-4f03-96a8-98aca0a3b624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1a09db29-e143-4f04-897e-7e3a4b504630" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5d840516-b173-4f03-96a8-98aca0a3b624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_InvestmentIncomeAndOtherNet_7f084553-50d1-4094-a334-fb7cfb959ccd" xlink:href="nbix-20221231.xsd#nbix_InvestmentIncomeAndOtherNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1a09db29-e143-4f04-897e-7e3a4b504630" xlink:to="loc_nbix_InvestmentIncomeAndOtherNet_7f084553-50d1-4094-a334-fb7cfb959ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d858a5bb-dd61-4549-aa32-171175c679c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1a09db29-e143-4f04-897e-7e3a4b504630" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_d858a5bb-dd61-4549-aa32-171175c679c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bd7a2469-749e-4ea9-93ff-2888cb6f5310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b957fe5d-0d3a-4afb-a03a-b241273ffe3b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bd7a2469-749e-4ea9-93ff-2888cb6f5310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_78b43164-9592-4f89-aa35-59b6c96d520f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b957fe5d-0d3a-4afb-a03a-b241273ffe3b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_78b43164-9592-4f89-aa35-59b6c96d520f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7e20e9bb-08db-4b11-8f9d-1970ef5b835b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b957fe5d-0d3a-4afb-a03a-b241273ffe3b" xlink:to="loc_us-gaap_NetIncomeLoss_7e20e9bb-08db-4b11-8f9d-1970ef5b835b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_f70fa1b4-17db-449d-bbb6-63c65ab23fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b957fe5d-0d3a-4afb-a03a-b241273ffe3b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_f70fa1b4-17db-449d-bbb6-63c65ab23fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_f7c56ae2-f761-43da-a069-889bddc48bad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b957fe5d-0d3a-4afb-a03a-b241273ffe3b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_f7c56ae2-f761-43da-a069-889bddc48bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b304f1d3-b81d-4eac-8a85-7ee46b6decd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b957fe5d-0d3a-4afb-a03a-b241273ffe3b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_b304f1d3-b81d-4eac-8a85-7ee46b6decd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_cc6fd776-2b12-43d6-8fe0-355e636ef984" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b957fe5d-0d3a-4afb-a03a-b241273ffe3b" xlink:to="loc_us-gaap_EarningsPerShareBasic_cc6fd776-2b12-43d6-8fe0-355e636ef984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3a912ee9-bf2e-409f-8f2e-5282c310f469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b957fe5d-0d3a-4afb-a03a-b241273ffe3b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3a912ee9-bf2e-409f-8f2e-5282c310f469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c7ea1029-26bd-4b7a-aef4-f9c774d68cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b957fe5d-0d3a-4afb-a03a-b241273ffe3b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c7ea1029-26bd-4b7a-aef4-f9c774d68cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_feff7f5d-6ba7-41c9-aef5-09ad6daa743e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b957fe5d-0d3a-4afb-a03a-b241273ffe3b" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_feff7f5d-6ba7-41c9-aef5-09ad6daa743e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="nbix-20221231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_7f857109-a556-4da2-9bea-3e34e75d8b34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2bdc662a-18c1-481d-8d8e-d8612e5c4d07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_7f857109-a556-4da2-9bea-3e34e75d8b34" xlink:to="loc_us-gaap_StatementTable_2bdc662a-18c1-481d-8d8e-d8612e5c4d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6a1f3438-c881-40ff-9d72-d19a563f3358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2bdc662a-18c1-481d-8d8e-d8612e5c4d07" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6a1f3438-c881-40ff-9d72-d19a563f3358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_903034ef-4a2e-4f8d-a706-993893053047" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6a1f3438-c881-40ff-9d72-d19a563f3358" xlink:to="loc_us-gaap_EquityComponentDomain_903034ef-4a2e-4f8d-a706-993893053047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_976b120c-c66d-4b87-b4b4-4cce72a35747" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_903034ef-4a2e-4f8d-a706-993893053047" xlink:to="loc_us-gaap_CommonStockMember_976b120c-c66d-4b87-b4b4-4cce72a35747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e1c444aa-26fd-4318-bf7f-95e2a3c64257" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_903034ef-4a2e-4f8d-a706-993893053047" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e1c444aa-26fd-4318-bf7f-95e2a3c64257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_976747a1-5ebe-480f-87b7-a49b3a4f45e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_903034ef-4a2e-4f8d-a706-993893053047" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_976747a1-5ebe-480f-87b7-a49b3a4f45e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_80096f60-5df8-4a20-9250-dbe1d009b38a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_903034ef-4a2e-4f8d-a706-993893053047" xlink:to="loc_us-gaap_RetainedEarningsMember_80096f60-5df8-4a20-9250-dbe1d009b38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c885c7e6-f78f-4960-8586-60843c3fc1a7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2bdc662a-18c1-481d-8d8e-d8612e5c4d07" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c885c7e6-f78f-4960-8586-60843c3fc1a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3b1a950f-5043-4b94-8935-2e210ada5c56" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c885c7e6-f78f-4960-8586-60843c3fc1a7" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3b1a950f-5043-4b94-8935-2e210ada5c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_d5be8c37-fa9b-432b-b7a5-82d50b3b8c29" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3b1a950f-5043-4b94-8935-2e210ada5c56" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_d5be8c37-fa9b-432b-b7a5-82d50b3b8c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_93486757-f237-4e22-9680-9e8785d2dff5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2bdc662a-18c1-481d-8d8e-d8612e5c4d07" xlink:to="loc_us-gaap_StatementLineItems_93486757-f237-4e22-9680-9e8785d2dff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8e67a80-41b3-4721-a158-8a405e06f4af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_93486757-f237-4e22-9680-9e8785d2dff5" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8e67a80-41b3-4721-a158-8a405e06f4af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_e067ef10-48dc-4475-96f5-8c10e0504af9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8e67a80-41b3-4721-a158-8a405e06f4af" xlink:to="loc_us-gaap_SharesOutstanding_e067ef10-48dc-4475-96f5-8c10e0504af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2a01ff76-b3a7-4c3a-905b-6368cd75d3a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8e67a80-41b3-4721-a158-8a405e06f4af" xlink:to="loc_us-gaap_StockholdersEquity_2a01ff76-b3a7-4c3a-905b-6368cd75d3a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e7dfdbc8-3a2c-45f9-a973-edcf1c92bf34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8e67a80-41b3-4721-a158-8a405e06f4af" xlink:to="loc_us-gaap_NetIncomeLoss_e7dfdbc8-3a2c-45f9-a973-edcf1c92bf34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4e9dbd9a-c4ea-486b-bdcd-3b50a158a3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8e67a80-41b3-4721-a158-8a405e06f4af" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4e9dbd9a-c4ea-486b-bdcd-3b50a158a3dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_7c2e7684-42b8-48a2-b375-c0912419935e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8e67a80-41b3-4721-a158-8a405e06f4af" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_7c2e7684-42b8-48a2-b375-c0912419935e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fb079de9-c08b-4049-a279-0ab53cd7958d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8e67a80-41b3-4721-a158-8a405e06f4af" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fb079de9-c08b-4049-a279-0ab53cd7958d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_a4873851-15d2-4208-a4f1-6ebf3a7f481a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8e67a80-41b3-4721-a158-8a405e06f4af" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_a4873851-15d2-4208-a4f1-6ebf3a7f481a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0226eb52-75f3-48f7-bbc6-36ae3ec4f67b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8e67a80-41b3-4721-a158-8a405e06f4af" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0226eb52-75f3-48f7-bbc6-36ae3ec4f67b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_369a1a47-7acb-473a-8bb6-d5f9b5d65c95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8e67a80-41b3-4721-a158-8a405e06f4af" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_369a1a47-7acb-473a-8bb6-d5f9b5d65c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_f09fe8ed-0e58-4383-9ca0-fa9066658c84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8e67a80-41b3-4721-a158-8a405e06f4af" xlink:to="loc_us-gaap_SharesOutstanding_f09fe8ed-0e58-4383-9ca0-fa9066658c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c02e0acd-3449-4397-aa58-b9f3200818d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d8e67a80-41b3-4721-a158-8a405e06f4af" xlink:to="loc_us-gaap_StockholdersEquity_c02e0acd-3449-4397-aa58-b9f3200818d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="nbix-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_96ffae6f-d309-4e81-8bce-ca45bde4bdc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fd6b00ab-3ca7-4f95-a031-c7b40b0fa8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_96ffae6f-d309-4e81-8bce-ca45bde4bdc2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fd6b00ab-3ca7-4f95-a031-c7b40b0fa8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ac115c03-055b-4f1f-9722-f8096197d8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fd6b00ab-3ca7-4f95-a031-c7b40b0fa8bd" xlink:to="loc_us-gaap_NetIncomeLoss_ac115c03-055b-4f1f-9722-f8096197d8ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_15acb9cb-d197-47ce-b219-2555127956b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fd6b00ab-3ca7-4f95-a031-c7b40b0fa8bd" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_15acb9cb-d197-47ce-b219-2555127956b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ea4ef116-1b72-40e1-91e5-985f8ea35fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_15acb9cb-d197-47ce-b219-2555127956b1" xlink:to="loc_us-gaap_ShareBasedCompensation_ea4ef116-1b72-40e1-91e5-985f8ea35fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_84f9aa7e-b507-4da1-b76a-ce8bc341d78e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_15acb9cb-d197-47ce-b219-2555127956b1" xlink:to="loc_us-gaap_Depreciation_84f9aa7e-b507-4da1-b76a-ce8bc341d78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_c5cbe164-5f12-49c8-a960-ea6e287f432f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_15acb9cb-d197-47ce-b219-2555127956b1" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_c5cbe164-5f12-49c8-a960-ea6e287f432f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_f777f869-eaef-48f5-8962-095c5f008113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_15acb9cb-d197-47ce-b219-2555127956b1" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_f777f869-eaef-48f5-8962-095c5f008113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_0cfa6f1e-22fc-40e3-b048-c0689da90101" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_15acb9cb-d197-47ce-b219-2555127956b1" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_0cfa6f1e-22fc-40e3-b048-c0689da90101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_bae5485c-7108-4159-a094-13275d11856f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_15acb9cb-d197-47ce-b219-2555127956b1" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_bae5485c-7108-4159-a094-13275d11856f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_a6c65785-1df5-4018-92f0-1945ee83e633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_15acb9cb-d197-47ce-b219-2555127956b1" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_a6c65785-1df5-4018-92f0-1945ee83e633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0a818cd3-69e8-4f23-96dd-1513ac26d7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_15acb9cb-d197-47ce-b219-2555127956b1" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0a818cd3-69e8-4f23-96dd-1513ac26d7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_9a14d9e1-8a88-4f6d-9f52-456efa5938d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_15acb9cb-d197-47ce-b219-2555127956b1" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_9a14d9e1-8a88-4f6d-9f52-456efa5938d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5919305c-e4a2-49f1-82e0-9deba9d92184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_15acb9cb-d197-47ce-b219-2555127956b1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5919305c-e4a2-49f1-82e0-9deba9d92184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ee7cfaa1-7dbd-4a48-8b1d-15475aacd8be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5919305c-e4a2-49f1-82e0-9deba9d92184" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ee7cfaa1-7dbd-4a48-8b1d-15475aacd8be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_2ee33ce2-7cb2-4c73-a182-53a94e2d40f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5919305c-e4a2-49f1-82e0-9deba9d92184" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_2ee33ce2-7cb2-4c73-a182-53a94e2d40f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_544195ec-17a1-4672-a4f0-bb9e65dffb7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5919305c-e4a2-49f1-82e0-9deba9d92184" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_544195ec-17a1-4672-a4f0-bb9e65dffb7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet_6eec94b4-3346-4536-b314-1baac3fbde0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5919305c-e4a2-49f1-82e0-9deba9d92184" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet_6eec94b4-3346-4536-b314-1baac3fbde0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_787bfdaf-be73-4546-b6c5-4830a9a27208" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fd6b00ab-3ca7-4f95-a031-c7b40b0fa8bd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_787bfdaf-be73-4546-b6c5-4830a9a27208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0202239a-b453-4bf3-94e1-b7de32cc62f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_96ffae6f-d309-4e81-8bce-ca45bde4bdc2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0202239a-b453-4bf3-94e1-b7de32cc62f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_5ef70899-b94c-43c9-b739-a6d3d6141dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0202239a-b453-4bf3-94e1-b7de32cc62f8" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_5ef70899-b94c-43c9-b739-a6d3d6141dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_3c901755-b2a2-41c1-99bd-c1f9bace178a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0202239a-b453-4bf3-94e1-b7de32cc62f8" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_3c901755-b2a2-41c1-99bd-c1f9bace178a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_cc168262-7473-462b-8626-ca487e15063e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0202239a-b453-4bf3-94e1-b7de32cc62f8" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_cc168262-7473-462b-8626-ca487e15063e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_6ea23046-62e8-417b-ac43-47e8422c4ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0202239a-b453-4bf3-94e1-b7de32cc62f8" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_6ea23046-62e8-417b-ac43-47e8422c4ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_79792fd2-1cf9-4920-97c5-13927b8dbacc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0202239a-b453-4bf3-94e1-b7de32cc62f8" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_79792fd2-1cf9-4920-97c5-13927b8dbacc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b1c8fc24-ae0a-4fd8-91b6-28685d25e963" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0202239a-b453-4bf3-94e1-b7de32cc62f8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b1c8fc24-ae0a-4fd8-91b6-28685d25e963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9304bf38-01a2-4466-9396-e479ed2dc945" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_96ffae6f-d309-4e81-8bce-ca45bde4bdc2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9304bf38-01a2-4466-9396-e479ed2dc945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3710c1a7-0094-48a1-8a73-cd7beeaaf144" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9304bf38-01a2-4466-9396-e479ed2dc945" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3710c1a7-0094-48a1-8a73-cd7beeaaf144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_a51d462b-dae9-422b-9197-3288ce09e49e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9304bf38-01a2-4466-9396-e479ed2dc945" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_a51d462b-dae9-422b-9197-3288ce09e49e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c9a3f6ec-8818-43fe-a09f-6d090e5dfb4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9304bf38-01a2-4466-9396-e479ed2dc945" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c9a3f6ec-8818-43fe-a09f-6d090e5dfb4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e204f739-4c7d-44d6-b590-13d9decdae3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_96ffae6f-d309-4e81-8bce-ca45bde4bdc2" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e204f739-4c7d-44d6-b590-13d9decdae3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_feff7d08-6fc3-41a5-8c70-34a4cacdcb08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_96ffae6f-d309-4e81-8bce-ca45bde4bdc2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_feff7d08-6fc3-41a5-8c70-34a4cacdcb08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_52ca5157-a573-457f-8421-52ffecacfb06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_96ffae6f-d309-4e81-8bce-ca45bde4bdc2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_52ca5157-a573-457f-8421-52ffecacfb06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_63460913-db02-4b88-9273-c62505e8c652" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_96ffae6f-d309-4e81-8bce-ca45bde4bdc2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_63460913-db02-4b88-9273-c62505e8c652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_0c767348-445a-4591-8ead-e8210e25d1a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_96ffae6f-d309-4e81-8bce-ca45bde4bdc2" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_0c767348-445a-4591-8ead-e8210e25d1a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_bac331dd-95e8-4558-9c40-3d5e4a91d26a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_0c767348-445a-4591-8ead-e8210e25d1a9" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_bac331dd-95e8-4558-9c40-3d5e4a91d26a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_ab65e8b5-fd34-4258-8c4f-6abef51ec073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_0c767348-445a-4591-8ead-e8210e25d1a9" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_ab65e8b5-fd34-4258-8c4f-6abef51ec073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_aa948bde-4b0d-4b53-ba01-31ccc42bf6c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_0c767348-445a-4591-8ead-e8210e25d1a9" xlink:to="loc_us-gaap_InterestPaidNet_aa948bde-4b0d-4b53-ba01-31ccc42bf6c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_683774cf-eb4f-4f45-a507-a73e50b51caf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_0c767348-445a-4591-8ead-e8210e25d1a9" xlink:to="loc_us-gaap_IncomeTaxesPaid_683774cf-eb4f-4f45-a507-a73e50b51caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="nbix-20221231.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a7363df4-ef00-4ec4-8bae-1b46ca08a363" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_6052a976-2570-41bf-bd61-9b82d041c5b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a7363df4-ef00-4ec4-8bae-1b46ca08a363" xlink:to="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_6052a976-2570-41bf-bd61-9b82d041c5b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CollaborationandLicenseAgreements" xlink:type="simple" xlink:href="nbix-20221231.xsd#CollaborationandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CollaborationandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_2aa2f5cc-e765-4260-b1bd-ba2e83cccfeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_ef12fee5-2dd0-472a-b303-b93f054edb12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_2aa2f5cc-e765-4260-b1bd-ba2e83cccfeb" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_ef12fee5-2dd0-472a-b303-b93f054edb12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DiurnalAcquisition" xlink:type="simple" xlink:href="nbix-20221231.xsd#DiurnalAcquisition"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/DiurnalAcquisition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_de3caca0-679e-419d-a01d-5ca2b68ffed8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_9ed819c3-517e-4376-9620-4b4df55269df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_de3caca0-679e-419d-a01d-5ca2b68ffed8" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_9ed819c3-517e-4376-9620-4b4df55269df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecurities" xlink:type="simple" xlink:href="nbix-20221231.xsd#DebtSecurities"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/DebtSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9032d913-0f2b-46e8-9570-bb0ca01811b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_21c9a792-ed38-47e2-ad8a-d3d5da0cafe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9032d913-0f2b-46e8-9570-bb0ca01811b6" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_21c9a792-ed38-47e2-ad8a-d3d5da0cafe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="nbix-20221231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a6b11f03-de7b-45fe-b01c-535afe548aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_1c677e81-2e4c-4b9e-bad9-e685a832b248" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a6b11f03-de7b-45fe-b01c-535afe548aa4" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_1c677e81-2e4c-4b9e-bad9-e685a832b248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotes" xlink:type="simple" xlink:href="nbix-20221231.xsd#ConvertibleSeniorNotes"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5770beba-7c17-47ef-8bf2-d03019e6b11e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_83f58a4d-1c96-4a24-b153-b27b232d221d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5770beba-7c17-47ef-8bf2-d03019e6b11e" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_83f58a4d-1c96-4a24-b153-b27b232d221d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="nbix-20221231.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fddb530a-3a38-4bed-9f34-d161067a288a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_ad3cbf0b-06fd-416f-8f83-43a8b82adbb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fddb530a-3a38-4bed-9f34-d161067a288a" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_ad3cbf0b-06fd-416f-8f83-43a8b82adbb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#OtherBalanceSheetDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OtherBalanceSheetDetailsAbstract_344280d5-bc5f-48c4-9258-e46e9bb440bc" xlink:href="nbix-20221231.xsd#nbix_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_83e2770c-bb58-4377-9310-b23448de7d60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_344280d5-bc5f-48c4-9258-e46e9bb440bc" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_83e2770c-bb58-4377-9310-b23448de7d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/EarningsPerShare" xlink:type="simple" xlink:href="nbix-20221231.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e2ae84a1-7a63-42e1-b6b5-83c2220f3c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_be583230-83bc-4850-ad1f-1fb657e6f168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e2ae84a1-7a63-42e1-b6b5-83c2220f3c9c" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_be583230-83bc-4850-ad1f-1fb657e6f168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="nbix-20221231.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e0de0b42-d62e-41a1-aa22-ca2261cba4b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_41a7a054-caf1-49d5-9bd5-fc045513b262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e0de0b42-d62e-41a1-aa22-ca2261cba4b2" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_41a7a054-caf1-49d5-9bd5-fc045513b262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxes" xlink:type="simple" xlink:href="nbix-20221231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_179024f8-5108-4bc8-9e08-8619ecc11a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_fb4ade67-795c-4878-a75d-51c1c2e95f08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_179024f8-5108-4bc8-9e08-8619ecc11a3d" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_fb4ade67-795c-4878-a75d-51c1c2e95f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/Leases" xlink:type="simple" xlink:href="nbix-20221231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_7ad0090b-0e1d-4ffd-9a3f-58c493c64abc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_46ec2cd7-86ae-45e6-819d-c8be91c07e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7ad0090b-0e1d-4ffd-9a3f-58c493c64abc" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_46ec2cd7-86ae-45e6-819d-c8be91c07e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/RetirementPlan" xlink:type="simple" xlink:href="nbix-20221231.xsd#RetirementPlan"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/RetirementPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_82beded5-29fd-4a3e-8e61-88c525e4ee5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_fb6530ed-0e2e-41e4-b251-aade62b6775f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_82beded5-29fd-4a3e-8e61-88c525e4ee5f" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_fb6530ed-0e2e-41e4-b251-aade62b6775f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LegalProceedings" xlink:type="simple" xlink:href="nbix-20221231.xsd#LegalProceedings"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LegalProceedings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4669c7e4-690c-4b05-8830-87fa89c3973a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1c5b8662-5627-4135-a76b-a2900655f3cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4669c7e4-690c-4b05-8830-87fa89c3973a" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1c5b8662-5627-4135-a76b-a2900655f3cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/SubsequentEvents" xlink:type="simple" xlink:href="nbix-20221231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_ec5aaed3-0ce3-4691-ba6c-9a7d7183d543" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_e2e3d311-2d5b-4b9a-b30c-8f020b2251d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_ec5aaed3-0ce3-4691-ba6c-9a7d7183d543" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_e2e3d311-2d5b-4b9a-b30c-8f020b2251d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="nbix-20221231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2f3c9970-b8d9-4559-a8c8-242090544be8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OrganizationAndBusinesDescriptionPolicyPolicyTextBlock_a4a6433e-2ace-4474-aee1-dcc27f773c9e" xlink:href="nbix-20221231.xsd#nbix_OrganizationAndBusinesDescriptionPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2f3c9970-b8d9-4559-a8c8-242090544be8" xlink:to="loc_nbix_OrganizationAndBusinesDescriptionPolicyPolicyTextBlock_a4a6433e-2ace-4474-aee1-dcc27f773c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_f7500fbf-bd29-4b17-b92a-09d95388ae06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2f3c9970-b8d9-4559-a8c8-242090544be8" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_f7500fbf-bd29-4b17-b92a-09d95388ae06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_426f9bc0-ecc5-4daa-a3f8-ff324ec43fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2f3c9970-b8d9-4559-a8c8-242090544be8" xlink:to="loc_us-gaap_UseOfEstimates_426f9bc0-ecc5-4daa-a3f8-ff324ec43fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_8ff0148d-cac5-4110-8c79-100af58c3caa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2f3c9970-b8d9-4559-a8c8-242090544be8" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_8ff0148d-cac5-4110-8c79-100af58c3caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_7c790750-59e2-4511-b2b3-634219d88791" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2f3c9970-b8d9-4559-a8c8-242090544be8" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_7c790750-59e2-4511-b2b3-634219d88791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_12aba376-da06-4e4b-b484-9b0c8e00322a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2f3c9970-b8d9-4559-a8c8-242090544be8" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_12aba376-da06-4e4b-b484-9b0c8e00322a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_bc4caea8-fefd-4346-8418-61604647aa6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2f3c9970-b8d9-4559-a8c8-242090544be8" xlink:to="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_bc4caea8-fefd-4346-8418-61604647aa6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_9cf1d9d1-c59d-4c95-b524-60409c97dd87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2f3c9970-b8d9-4559-a8c8-242090544be8" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_9cf1d9d1-c59d-4c95-b524-60409c97dd87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_0be4ab3e-71ba-4e52-b708-1efd8a6feb31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2f3c9970-b8d9-4559-a8c8-242090544be8" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_0be4ab3e-71ba-4e52-b708-1efd8a6feb31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_759254ee-ed51-4a0f-9d8b-00be6539b495" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2f3c9970-b8d9-4559-a8c8-242090544be8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_759254ee-ed51-4a0f-9d8b-00be6539b495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_de7d625a-a5be-4583-ac2f-b3212e505904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2f3c9970-b8d9-4559-a8c8-242090544be8" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_de7d625a-a5be-4583-ac2f-b3212e505904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_42f71d1f-0eb3-4972-ae6c-b988161ca71f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2f3c9970-b8d9-4559-a8c8-242090544be8" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_42f71d1f-0eb3-4972-ae6c-b988161ca71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_b8d8accd-fd1c-4b1e-9ca8-ee5e14018afe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2f3c9970-b8d9-4559-a8c8-242090544be8" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_b8d8accd-fd1c-4b1e-9ca8-ee5e14018afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_29ae974d-5a34-4423-a7dd-91541214ef13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2f3c9970-b8d9-4559-a8c8-242090544be8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_29ae974d-5a34-4423-a7dd-91541214ef13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_1c50fc6d-3480-491f-82f8-fa0e6cd485e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2f3c9970-b8d9-4559-a8c8-242090544be8" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_1c50fc6d-3480-491f-82f8-fa0e6cd485e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_5c299800-5380-4ad6-9402-85673da373f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2f3c9970-b8d9-4559-a8c8-242090544be8" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_5c299800-5380-4ad6-9402-85673da373f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_9271cb67-1854-4464-84d2-27d1fd09a24c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2f3c9970-b8d9-4559-a8c8-242090544be8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_9271cb67-1854-4464-84d2-27d1fd09a24c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_f504a24d-9be6-45a2-bee4-e3915a0bac39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2f3c9970-b8d9-4559-a8c8-242090544be8" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_f504a24d-9be6-45a2-bee4-e3915a0bac39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_f8555918-a999-4ca1-8bf8-b87359d3a6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2f3c9970-b8d9-4559-a8c8-242090544be8" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_f8555918-a999-4ca1-8bf8-b87359d3a6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_92caea7e-8205-4769-9ca5-209d622c2aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2f3c9970-b8d9-4559-a8c8-242090544be8" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_92caea7e-8205-4769-9ca5-209d622c2aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_a3614911-1cd0-4d89-9b6f-c9f940e7b7b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2f3c9970-b8d9-4559-a8c8-242090544be8" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_a3614911-1cd0-4d89-9b6f-c9f940e7b7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_871efd13-9c9a-4393-b3b4-4fdf5f7df207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2f3c9970-b8d9-4559-a8c8-242090544be8" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_871efd13-9c9a-4393-b3b4-4fdf5f7df207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DiurnalAcquisitionTables" xlink:type="simple" xlink:href="nbix-20221231.xsd#DiurnalAcquisitionTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/DiurnalAcquisitionTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_e377202c-84c8-4ca6-8bd3-117b6bf9dad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_996bea58-e615-48e0-9ded-7aa48a02d525" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_e377202c-84c8-4ca6-8bd3-117b6bf9dad4" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_996bea58-e615-48e0-9ded-7aa48a02d525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesTables" xlink:type="simple" xlink:href="nbix-20221231.xsd#DebtSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_712cda8c-c630-473d-928b-f28832322ece" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_70eb6f7b-dea7-4eab-834a-82569dbd5412" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_712cda8c-c630-473d-928b-f28832322ece" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_70eb6f7b-dea7-4eab-834a-82569dbd5412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_377257af-d191-4bda-9a57-0e0aa96fbf2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_712cda8c-c630-473d-928b-f28832322ece" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_377257af-d191-4bda-9a57-0e0aa96fbf2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="nbix-20221231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_76740474-6674-408c-a3ae-abb1db9e9042" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_bd588044-556e-495b-87e5-7b8cad1f49d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_76740474-6674-408c-a3ae-abb1db9e9042" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_bd588044-556e-495b-87e5-7b8cad1f49d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2bffb4ae-df65-4074-881e-d2cf55e40501" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_76740474-6674-408c-a3ae-abb1db9e9042" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2bffb4ae-df65-4074-881e-d2cf55e40501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesTables" xlink:type="simple" xlink:href="nbix-20221231.xsd#ConvertibleSeniorNotesTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_78185358-52ed-4dd5-acf7-76f5f2b6f1b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_053e7c83-f022-457d-992d-9e6ad768fb35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_78185358-52ed-4dd5-acf7-76f5f2b6f1b5" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_053e7c83-f022-457d-992d-9e6ad768fb35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="nbix-20221231.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ba9e97c1-3766-4a01-8af5-401494c22fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_df7fb109-0e48-47aa-9399-67d6eecb0383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ba9e97c1-3766-4a01-8af5-401494c22fa8" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_df7fb109-0e48-47aa-9399-67d6eecb0383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_7ff7c1ac-a0c0-4fd0-abdf-5416044ef2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ba9e97c1-3766-4a01-8af5-401494c22fa8" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_7ff7c1ac-a0c0-4fd0-abdf-5416044ef2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_2f0cb303-8dbe-48e5-9d27-ccc5ffeb334e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ba9e97c1-3766-4a01-8af5-401494c22fa8" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_2f0cb303-8dbe-48e5-9d27-ccc5ffeb334e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_b6179b6f-42c3-4c6d-a34f-0a85787259d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ba9e97c1-3766-4a01-8af5-401494c22fa8" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_b6179b6f-42c3-4c6d-a34f-0a85787259d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsTables" xlink:type="simple" xlink:href="nbix-20221231.xsd#OtherBalanceSheetDetailsTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetailsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OtherBalanceSheetDetailsAbstract_8e99d56c-517c-4953-aa77-d5306be4d7fb" xlink:href="nbix-20221231.xsd#nbix_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_005a3948-18b8-49a7-a712-4bbadf06fc68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_8e99d56c-517c-4953-aa77-d5306be4d7fb" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_005a3948-18b8-49a7-a712-4bbadf06fc68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_0b5d4523-85e4-49a6-8bd8-c098b6e79b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_8e99d56c-517c-4953-aa77-d5306be4d7fb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_0b5d4523-85e4-49a6-8bd8-c098b6e79b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_f1efbc2e-3631-49bf-99ec-0db8d5c0e027" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_8e99d56c-517c-4953-aa77-d5306be4d7fb" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_f1efbc2e-3631-49bf-99ec-0db8d5c0e027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_00837350-61fd-40f0-8ced-a20a24c4d8b7" xlink:href="nbix-20221231.xsd#nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_8e99d56c-517c-4953-aa77-d5306be4d7fb" xlink:to="loc_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_00837350-61fd-40f0-8ced-a20a24c4d8b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="nbix-20221231.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c5928748-ba11-4abe-91bf-8d5f98423acc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e2e61e26-40c5-4276-8f97-c106a4380886" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c5928748-ba11-4abe-91bf-8d5f98423acc" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e2e61e26-40c5-4276-8f97-c106a4380886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="nbix-20221231.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_925fff2e-9ffc-4fed-b360-1c046c11d831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8d701096-83f1-4004-b731-35ebfb79c4de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_925fff2e-9ffc-4fed-b360-1c046c11d831" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8d701096-83f1-4004-b731-35ebfb79c4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a4a66998-386d-4baa-a79a-773953cc0b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_925fff2e-9ffc-4fed-b360-1c046c11d831" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a4a66998-386d-4baa-a79a-773953cc0b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_46f391c4-dbc9-4fb6-8301-cf29f5b5ec38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_925fff2e-9ffc-4fed-b360-1c046c11d831" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_46f391c4-dbc9-4fb6-8301-cf29f5b5ec38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_c5222ffb-507e-4c4d-8ac1-9a536494ca82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_925fff2e-9ffc-4fed-b360-1c046c11d831" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_c5222ffb-507e-4c4d-8ac1-9a536494ca82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="nbix-20221231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ef17b120-91d7-4616-8e83-98260f06d979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_9b80b0b8-5bbb-489b-8ec0-253b2a78141d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ef17b120-91d7-4616-8e83-98260f06d979" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_9b80b0b8-5bbb-489b-8ec0-253b2a78141d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_50007ee3-4d29-4fbc-8a62-b677d576713f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ef17b120-91d7-4616-8e83-98260f06d979" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_50007ee3-4d29-4fbc-8a62-b677d576713f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_a23d7b56-dac4-484a-a382-88e33d8b9cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ef17b120-91d7-4616-8e83-98260f06d979" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_a23d7b56-dac4-484a-a382-88e33d8b9cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_a2427839-d663-4242-ab07-101837c780b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ef17b120-91d7-4616-8e83-98260f06d979" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_a2427839-d663-4242-ab07-101837c780b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_1815c21a-81a8-413d-9e4e-70e03f0b2f79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ef17b120-91d7-4616-8e83-98260f06d979" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_1815c21a-81a8-413d-9e4e-70e03f0b2f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesTables" xlink:type="simple" xlink:href="nbix-20221231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d554c5cb-ee5a-4dbe-94ca-561179871fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_f7aa2ea6-7f5f-4700-92da-6f0a6786ffdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d554c5cb-ee5a-4dbe-94ca-561179871fe5" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_f7aa2ea6-7f5f-4700-92da-6f0a6786ffdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_73523163-07b7-43fd-8a1a-3ec969674b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d554c5cb-ee5a-4dbe-94ca-561179871fe5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_73523163-07b7-43fd-8a1a-3ec969674b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7b4a564e-30a4-4ad9-8a99-923d6080a983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_e53b27b8-eaee-4b72-bf68-0b1b2ef94b3c" xlink:href="nbix-20221231.xsd#nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7b4a564e-30a4-4ad9-8a99-923d6080a983" xlink:to="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_e53b27b8-eaee-4b72-bf68-0b1b2ef94b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a1eae3d6-d161-46e8-93ad-cf9b5f2d943b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_e53b27b8-eaee-4b72-bf68-0b1b2ef94b3c" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a1eae3d6-d161-46e8-93ad-cf9b5f2d943b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_80f3bd1d-7dc8-452c-a983-a127a4255d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a1eae3d6-d161-46e8-93ad-cf9b5f2d943b" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_80f3bd1d-7dc8-452c-a983-a127a4255d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember_254df914-23c3-4cda-b7e3-8cec19653691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_80f3bd1d-7dc8-452c-a983-a127a4255d3c" xlink:to="loc_us-gaap_SalesRevenueProductLineMember_254df914-23c3-4cda-b7e3-8cec19653691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_cc0d4296-2a3b-4c81-914f-9b75eed27ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_80f3bd1d-7dc8-452c-a983-a127a4255d3c" xlink:to="loc_us-gaap_AccountsReceivableMember_cc0d4296-2a3b-4c81-914f-9b75eed27ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_243294bc-bc0f-4930-ae27-4fd471e4fa27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_e53b27b8-eaee-4b72-bf68-0b1b2ef94b3c" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_243294bc-bc0f-4930-ae27-4fd471e4fa27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_677a618e-a331-4f16-9004-e63ee26f757f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_243294bc-bc0f-4930-ae27-4fd471e4fa27" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_677a618e-a331-4f16-9004-e63ee26f757f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_5e8e6163-20ef-4bf4-bad9-7bf709ed81b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_677a618e-a331-4f16-9004-e63ee26f757f" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_5e8e6163-20ef-4bf4-bad9-7bf709ed81b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_9afc1b66-ba1d-49f4-82c0-87caea0a6efd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_e53b27b8-eaee-4b72-bf68-0b1b2ef94b3c" xlink:to="loc_srt_MajorCustomersAxis_9afc1b66-ba1d-49f4-82c0-87caea0a6efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_4a3c3eb8-b743-4855-ac59-6687d457c9a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_9afc1b66-ba1d-49f4-82c0-87caea0a6efd" xlink:to="loc_srt_NameOfMajorCustomerDomain_4a3c3eb8-b743-4855-ac59-6687d457c9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LargestFourCustomersMember_978cd781-5c11-4098-8901-fa9b1a9a1513" xlink:href="nbix-20221231.xsd#nbix_LargestFourCustomersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_4a3c3eb8-b743-4855-ac59-6687d457c9a4" xlink:to="loc_nbix_LargestFourCustomersMember_978cd781-5c11-4098-8901-fa9b1a9a1513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8638ecfd-e1a5-4a20-a88d-1804eaaa687b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_e53b27b8-eaee-4b72-bf68-0b1b2ef94b3c" xlink:to="loc_srt_RangeAxis_8638ecfd-e1a5-4a20-a88d-1804eaaa687b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_208bc679-a255-47f5-a003-5c9875dd6cd8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8638ecfd-e1a5-4a20-a88d-1804eaaa687b" xlink:to="loc_srt_RangeMember_208bc679-a255-47f5-a003-5c9875dd6cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_934bfd42-06ee-429b-afa2-4220a2b29525" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_208bc679-a255-47f5-a003-5c9875dd6cd8" xlink:to="loc_srt_MinimumMember_934bfd42-06ee-429b-afa2-4220a2b29525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5ad12da5-4a69-4a3a-8c1d-c8410890f1e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_208bc679-a255-47f5-a003-5c9875dd6cd8" xlink:to="loc_srt_MaximumMember_5ad12da5-4a69-4a3a-8c1d-c8410890f1e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_397b9f37-3e06-4863-a004-54394654f374" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_e53b27b8-eaee-4b72-bf68-0b1b2ef94b3c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_397b9f37-3e06-4863-a004-54394654f374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_eb9e6ea7-5031-4896-9af3-af14a7927e79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_397b9f37-3e06-4863-a004-54394654f374" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_eb9e6ea7-5031-4896-9af3-af14a7927e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_e284b0f8-9644-4089-84b9-a24c4019456a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_eb9e6ea7-5031-4896-9af3-af14a7927e79" xlink:to="loc_us-gaap_EmployeeStockMember_e284b0f8-9644-4089-84b9-a24c4019456a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8ea0cd55-e8d7-43d3-93b1-a64f4a650a05" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_e53b27b8-eaee-4b72-bf68-0b1b2ef94b3c" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8ea0cd55-e8d7-43d3-93b1-a64f4a650a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7293f16c-621c-49ac-aa36-66905ebc1a2b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8ea0cd55-e8d7-43d3-93b1-a64f4a650a05" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7293f16c-621c-49ac-aa36-66905ebc1a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_eb75fd75-2286-499e-aef3-d81d75d5c277" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7293f16c-621c-49ac-aa36-66905ebc1a2b" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_eb75fd75-2286-499e-aef3-d81d75d5c277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_0c24a072-0dc3-4d55-abae-72d6f68191c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_e53b27b8-eaee-4b72-bf68-0b1b2ef94b3c" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_0c24a072-0dc3-4d55-abae-72d6f68191c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_79c81dc9-14d7-4885-98fd-064eac5452af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_0c24a072-0dc3-4d55-abae-72d6f68191c5" xlink:to="loc_us-gaap_TypeOfAdoptionMember_79c81dc9-14d7-4885-98fd-064eac5452af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_aa004d14-4d9f-4efd-910d-15abf9db5d91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_79c81dc9-14d7-4885-98fd-064eac5452af" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_aa004d14-4d9f-4efd-910d-15abf9db5d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_449e2099-5a01-46f9-b493-0284ae473be2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_e53b27b8-eaee-4b72-bf68-0b1b2ef94b3c" xlink:to="loc_us-gaap_DebtInstrumentAxis_449e2099-5a01-46f9-b493-0284ae473be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b4b8a53a-304c-4635-8d9f-715a5770b3bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_449e2099-5a01-46f9-b493-0284ae473be2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b4b8a53a-304c-4635-8d9f-715a5770b3bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_d965044b-faf0-4c98-a710-b19cc903933a" xlink:href="nbix-20221231.xsd#nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b4b8a53a-304c-4635-8d9f-715a5770b3bb" xlink:to="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_d965044b-faf0-4c98-a710-b19cc903933a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f82cd718-9616-4113-a626-3e44ef056274" xlink:href="nbix-20221231.xsd#nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_e53b27b8-eaee-4b72-bf68-0b1b2ef94b3c" xlink:to="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f82cd718-9616-4113-a626-3e44ef056274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_aac8f30f-3d97-4b38-832b-643f07f4356f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f82cd718-9616-4113-a626-3e44ef056274" xlink:to="loc_us-gaap_NumberOfOperatingSegments_aac8f30f-3d97-4b38-832b-643f07f4356f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_3f435bfa-1bd1-450c-98d0-8f7a994e0b74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f82cd718-9616-4113-a626-3e44ef056274" xlink:to="loc_us-gaap_NumberOfReportableSegments_3f435bfa-1bd1-450c-98d0-8f7a994e0b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff_655bfabb-c47c-4621-85a0-091a8bafb903" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f82cd718-9616-4113-a626-3e44ef056274" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff_655bfabb-c47c-4621-85a0-091a8bafb903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_4a3ccff0-375b-4d4b-a178-b244c4c2af0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f82cd718-9616-4113-a626-3e44ef056274" xlink:to="loc_us-gaap_InterestReceivableCurrent_4a3ccff0-375b-4d4b-a178-b244c4c2af0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff_28683ca7-eba4-43d2-aa8f-1c27b5403df9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f82cd718-9616-4113-a626-3e44ef056274" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff_28683ca7-eba4-43d2-aa8f-1c27b5403df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2de744e2-1547-4d6f-b694-1365744c602c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f82cd718-9616-4113-a626-3e44ef056274" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2de744e2-1547-4d6f-b694-1365744c602c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_af700e1c-98aa-4266-bd90-e227d2c287c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f82cd718-9616-4113-a626-3e44ef056274" xlink:to="loc_us-gaap_Depreciation_af700e1c-98aa-4266-bd90-e227d2c287c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_4ea72fb4-0ddf-4007-a64f-32be1177246d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f82cd718-9616-4113-a626-3e44ef056274" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_4ea72fb4-0ddf-4007-a64f-32be1177246d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_272e4b0f-6122-4cd1-a992-79c2e3407c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f82cd718-9616-4113-a626-3e44ef056274" xlink:to="loc_us-gaap_AdvertisingExpense_272e4b0f-6122-4cd1-a992-79c2e3407c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_882dd55b-77b8-4152-a5c0-1d1994a09a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f82cd718-9616-4113-a626-3e44ef056274" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_882dd55b-77b8-4152-a5c0-1d1994a09a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ESPPPurchasePeriod_bbe176f2-c842-4e7e-9353-8bce17901f12" xlink:href="nbix-20221231.xsd#nbix_ESPPPurchasePeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f82cd718-9616-4113-a626-3e44ef056274" xlink:to="loc_nbix_ESPPPurchasePeriod_bbe176f2-c842-4e7e-9353-8bce17901f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_cebb7610-fbd7-4882-a22d-be4d39738ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f82cd718-9616-4113-a626-3e44ef056274" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_cebb7610-fbd7-4882-a22d-be4d39738ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_669ed098-29e4-443d-94c1-db4fa7e33d84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f82cd718-9616-4113-a626-3e44ef056274" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_669ed098-29e4-443d-94c1-db4fa7e33d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_bd88e5db-f22d-4031-9036-a3042d019511" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f82cd718-9616-4113-a626-3e44ef056274" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_bd88e5db-f22d-4031-9036-a3042d019511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_dbab798f-02ce-4c10-99dc-e7c9e02ec6b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f82cd718-9616-4113-a626-3e44ef056274" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_dbab798f-02ce-4c10-99dc-e7c9e02ec6b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_23e8b191-9312-43cd-a5c5-8ee5401fc022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f82cd718-9616-4113-a626-3e44ef056274" xlink:to="loc_us-gaap_AdditionalPaidInCapital_23e8b191-9312-43cd-a5c5-8ee5401fc022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2f1b0d85-9e3c-4269-89ad-5cdc498bc307" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f82cd718-9616-4113-a626-3e44ef056274" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2f1b0d85-9e3c-4269-89ad-5cdc498bc307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#CollaborationandLicenseAgreementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_db2bd65d-4898-4616-8a3e-00f8ca3930a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_816cf7b9-8f96-4ced-9073-78f2ab053d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_db2bd65d-4898-4616-8a3e-00f8ca3930a2" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_816cf7b9-8f96-4ced-9073-78f2ab053d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_92664fcc-62b0-419f-b73c-85c062bac89f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_816cf7b9-8f96-4ced-9073-78f2ab053d7c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_92664fcc-62b0-419f-b73c-85c062bac89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_27cd5efb-97a7-43e1-85df-61b506ae5b00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_92664fcc-62b0-419f-b73c-85c062bac89f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_27cd5efb-97a7-43e1-85df-61b506ae5b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_73874fe1-4f9e-40ce-b603-ae05bfd35027" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_27cd5efb-97a7-43e1-85df-61b506ae5b00" xlink:to="loc_us-gaap_CollaborativeArrangementMember_73874fe1-4f9e-40ce-b603-ae05bfd35027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d3705300-36d7-4d49-8f67-82220ac9b74c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_816cf7b9-8f96-4ced-9073-78f2ab053d7c" xlink:to="loc_srt_CounterpartyNameAxis_d3705300-36d7-4d49-8f67-82220ac9b74c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f2c9d4a4-f1f1-40ce-b39e-5b644fa090ab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d3705300-36d7-4d49-8f67-82220ac9b74c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f2c9d4a4-f1f1-40ce-b39e-5b644fa090ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_HeptaresTherapeuticsLimitedMember_2140e680-fc4e-45a6-9586-e1ea7e9f613f" xlink:href="nbix-20221231.xsd#nbix_HeptaresTherapeuticsLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f2c9d4a4-f1f1-40ce-b39e-5b644fa090ab" xlink:to="loc_nbix_HeptaresTherapeuticsLimitedMember_2140e680-fc4e-45a6-9586-e1ea7e9f613f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember_a0e7486d-0f5b-4ad3-853f-e4e35e4f9bb2" xlink:href="nbix-20221231.xsd#nbix_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f2c9d4a4-f1f1-40ce-b39e-5b644fa090ab" xlink:to="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember_a0e7486d-0f5b-4ad3-853f-e4e35e4f9bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IdorsiaPharmaceuticalsLtdMember_2f273359-95c0-4122-8ec9-b6507c71b111" xlink:href="nbix-20221231.xsd#nbix_IdorsiaPharmaceuticalsLtdMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f2c9d4a4-f1f1-40ce-b39e-5b644fa090ab" xlink:to="loc_nbix_IdorsiaPharmaceuticalsLtdMember_2f273359-95c0-4122-8ec9-b6507c71b111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_XenonPharmaceuticalsIncMember_6e96012e-57e4-4b4c-9608-d235fae6dd14" xlink:href="nbix-20221231.xsd#nbix_XenonPharmaceuticalsIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f2c9d4a4-f1f1-40ce-b39e-5b644fa090ab" xlink:to="loc_nbix_XenonPharmaceuticalsIncMember_6e96012e-57e4-4b4c-9608-d235fae6dd14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_VoyagerTherapeuticsMember_eb88eceb-4c1f-4aa1-8905-5a93c2d0e053" xlink:href="nbix-20221231.xsd#nbix_VoyagerTherapeuticsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f2c9d4a4-f1f1-40ce-b39e-5b644fa090ab" xlink:to="loc_nbix_VoyagerTherapeuticsMember_eb88eceb-4c1f-4aa1-8905-5a93c2d0e053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BIALPortelaCaSAMember_43845a5c-bc66-4ac9-a349-1ec08333e5e6" xlink:href="nbix-20221231.xsd#nbix_BIALPortelaCaSAMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f2c9d4a4-f1f1-40ce-b39e-5b644fa090ab" xlink:to="loc_nbix_BIALPortelaCaSAMember_43845a5c-bc66-4ac9-a349-1ec08333e5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MitsubishiTanabePharmaCorporationMember_7047fca4-8e34-44a7-8618-768168a08938" xlink:href="nbix-20221231.xsd#nbix_MitsubishiTanabePharmaCorporationMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f2c9d4a4-f1f1-40ce-b39e-5b644fa090ab" xlink:to="loc_nbix_MitsubishiTanabePharmaCorporationMember_7047fca4-8e34-44a7-8618-768168a08938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AbbVieIncMember_566e1869-12b5-4e5a-a2e9-d6b80fb0672f" xlink:href="nbix-20221231.xsd#nbix_AbbVieIncMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f2c9d4a4-f1f1-40ce-b39e-5b644fa090ab" xlink:to="loc_nbix_AbbVieIncMember_566e1869-12b5-4e5a-a2e9-d6b80fb0672f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_30d0f4d2-62e2-41fd-b914-91c41d93d1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_816cf7b9-8f96-4ced-9073-78f2ab053d7c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_30d0f4d2-62e2-41fd-b914-91c41d93d1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cba7f0bd-ea6e-4558-ba68-7a79784cc27c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_30d0f4d2-62e2-41fd-b914-91c41d93d1d0" xlink:to="loc_us-gaap_EquityComponentDomain_cba7f0bd-ea6e-4558-ba68-7a79784cc27c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_837ad5fc-3f6b-46bf-a561-09fdd7a48862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cba7f0bd-ea6e-4558-ba68-7a79784cc27c" xlink:to="loc_us-gaap_CommonStockMember_837ad5fc-3f6b-46bf-a561-09fdd7a48862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a63a95d0-ce49-487b-a4a7-46352a109eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_816cf7b9-8f96-4ced-9073-78f2ab053d7c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a63a95d0-ce49-487b-a4a7-46352a109eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a0bed962-05ed-4e3b-8440-3c8fd9c54e27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a63a95d0-ce49-487b-a4a7-46352a109eb8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a0bed962-05ed-4e3b-8440-3c8fd9c54e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_426c9f8c-21ca-47aa-bd3f-e0b4b00067d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a0bed962-05ed-4e3b-8440-3c8fd9c54e27" xlink:to="loc_us-gaap_PatentsMember_426c9f8c-21ca-47aa-bd3f-e0b4b00067d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9e0421bc-3b07-46df-b747-6f80142ea738" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_816cf7b9-8f96-4ced-9073-78f2ab053d7c" xlink:to="loc_srt_ProductOrServiceAxis_9e0421bc-3b07-46df-b747-6f80142ea738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b65397e8-f351-4171-be9d-e8aa0c0883c9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9e0421bc-3b07-46df-b747-6f80142ea738" xlink:to="loc_srt_ProductsAndServicesDomain_b65397e8-f351-4171-be9d-e8aa0c0883c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_04a2e68d-3f19-4010-a4c0-af377dec8182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b65397e8-f351-4171-be9d-e8aa0c0883c9" xlink:to="loc_us-gaap_RoyaltyMember_04a2e68d-3f19-4010-a4c0-af377dec8182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_133bb277-ef68-438f-8a63-e067def5f095" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_816cf7b9-8f96-4ced-9073-78f2ab053d7c" xlink:to="loc_srt_RangeAxis_133bb277-ef68-438f-8a63-e067def5f095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f10dea28-eaae-40bd-ac13-b921f2f6d4e0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_133bb277-ef68-438f-8a63-e067def5f095" xlink:to="loc_srt_RangeMember_f10dea28-eaae-40bd-ac13-b921f2f6d4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_96be46a1-ac66-403d-bd88-3db2e96ad817" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f10dea28-eaae-40bd-ac13-b921f2f6d4e0" xlink:to="loc_srt_MinimumMember_96be46a1-ac66-403d-bd88-3db2e96ad817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d305027-323b-4b37-98dd-be7ce86f4495" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_816cf7b9-8f96-4ced-9073-78f2ab053d7c" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d305027-323b-4b37-98dd-be7ce86f4495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePayments_765178fe-dda9-47c1-a096-d5f3c0bf4b4f" xlink:href="nbix-20221231.xsd#nbix_PotentialMilestonePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d305027-323b-4b37-98dd-be7ce86f4495" xlink:to="loc_nbix_PotentialMilestonePayments_765178fe-dda9-47c1-a096-d5f3c0bf4b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_8d537767-7702-4655-b8e5-74b505c90e42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d305027-323b-4b37-98dd-be7ce86f4495" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_8d537767-7702-4655-b8e5-74b505c90e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ddd628f5-e592-4944-a81d-a11a3e292334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d305027-323b-4b37-98dd-be7ce86f4495" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ddd628f5-e592-4944-a81d-a11a3e292334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_UpfrontPaymentsMade_af59b76d-94a4-490a-b2da-a343dc113627" xlink:href="nbix-20221231.xsd#nbix_UpfrontPaymentsMade"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d305027-323b-4b37-98dd-be7ce86f4495" xlink:to="loc_nbix_UpfrontPaymentsMade_af59b76d-94a4-490a-b2da-a343dc113627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SaleOfStockNumberOfSharesSoldInTransaction_87651c54-78bf-42f4-bf66-cf19f4c015b6" xlink:href="nbix-20221231.xsd#nbix_SaleOfStockNumberOfSharesSoldInTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d305027-323b-4b37-98dd-be7ce86f4495" xlink:to="loc_nbix_SaleOfStockNumberOfSharesSoldInTransaction_87651c54-78bf-42f4-bf66-cf19f4c015b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_9f9e5838-7b27-4aec-bf76-bdb0ca5d6981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d305027-323b-4b37-98dd-be7ce86f4495" xlink:to="loc_us-gaap_SharePrice_9f9e5838-7b27-4aec-bf76-bdb0ca5d6981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_ed18d292-d613-4b83-a3c0-ec429dc32a19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d305027-323b-4b37-98dd-be7ce86f4495" xlink:to="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_ed18d292-d613-4b83-a3c0-ec429dc32a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MilestonePayment_f2951936-f827-4c1b-97ed-b4f23ce2a36f" xlink:href="nbix-20221231.xsd#nbix_MilestonePayment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d305027-323b-4b37-98dd-be7ce86f4495" xlink:to="loc_nbix_MilestonePayment_f2951936-f827-4c1b-97ed-b4f23ce2a36f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_cc06ae4b-d35f-4219-8c8b-1089a92abcdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d305027-323b-4b37-98dd-be7ce86f4495" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_cc06ae4b-d35f-4219-8c8b-1089a92abcdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eb0eb513-ff97-4793-a46b-ae2c3d7d3d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d305027-323b-4b37-98dd-be7ce86f4495" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eb0eb513-ff97-4793-a46b-ae2c3d7d3d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePaymentReceipts_e78316e5-30e6-4d09-a844-d545b295a52f" xlink:href="nbix-20221231.xsd#nbix_PotentialMilestonePaymentReceipts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d305027-323b-4b37-98dd-be7ce86f4495" xlink:to="loc_nbix_PotentialMilestonePaymentReceipts_e78316e5-30e6-4d09-a844-d545b295a52f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PatentTerm_87fd52ee-68e4-4715-a486-c449abb725c0" xlink:href="nbix-20221231.xsd#nbix_PatentTerm"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d305027-323b-4b37-98dd-be7ce86f4495" xlink:to="loc_nbix_PatentTerm_87fd52ee-68e4-4715-a486-c449abb725c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DiurnalAcquisitionAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#DiurnalAcquisitionAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/DiurnalAcquisitionAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_8408d3f8-26df-4412-ba05-b9cc845ccec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_90c34127-9cc6-485b-8929-1ac51c211965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_8408d3f8-26df-4412-ba05-b9cc845ccec9" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_90c34127-9cc6-485b-8929-1ac51c211965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7b9a803f-6a9a-434f-9e18-375fd5c994d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_90c34127-9cc6-485b-8929-1ac51c211965" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7b9a803f-6a9a-434f-9e18-375fd5c994d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bd222f71-c829-40d2-aa13-d1724f3e8616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7b9a803f-6a9a-434f-9e18-375fd5c994d0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bd222f71-c829-40d2-aa13-d1724f3e8616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DiurnalGroupPlcMember_ea4e6095-12c7-4935-8d99-12c78d644401" xlink:href="nbix-20221231.xsd#nbix_DiurnalGroupPlcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bd222f71-c829-40d2-aa13-d1724f3e8616" xlink:to="loc_nbix_DiurnalGroupPlcMember_ea4e6095-12c7-4935-8d99-12c78d644401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_ab27ef4d-289a-4485-80c2-46d24a7a9155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_90c34127-9cc6-485b-8929-1ac51c211965" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_ab27ef4d-289a-4485-80c2-46d24a7a9155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_675f2332-87ec-410e-be39-432a418687a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ab27ef4d-289a-4485-80c2-46d24a7a9155" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_675f2332-87ec-410e-be39-432a418687a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_a1841bb5-4b69-492b-8437-c1131162d558" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ab27ef4d-289a-4485-80c2-46d24a7a9155" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_a1841bb5-4b69-492b-8437-c1131162d558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DiurnalAcquisitionEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedattheDateofAcquisitionDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#DiurnalAcquisitionEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedattheDateofAcquisitionDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/DiurnalAcquisitionEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedattheDateofAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0ea52583-e6c8-4294-9deb-361e197677b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_96eedf44-d6f1-4b64-9318-93de79084574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0ea52583-e6c8-4294-9deb-361e197677b1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_96eedf44-d6f1-4b64-9318-93de79084574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_791fa360-4f8d-479d-b182-454bf2d7ab52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_96eedf44-d6f1-4b64-9318-93de79084574" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_791fa360-4f8d-479d-b182-454bf2d7ab52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_75195277-4e1a-4098-a2ba-94143f1d822f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_791fa360-4f8d-479d-b182-454bf2d7ab52" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_75195277-4e1a-4098-a2ba-94143f1d822f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DiurnalGroupPlcMember_f4c031e3-deab-4dfb-95d3-911b85251b14" xlink:href="nbix-20221231.xsd#nbix_DiurnalGroupPlcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_75195277-4e1a-4098-a2ba-94143f1d822f" xlink:to="loc_nbix_DiurnalGroupPlcMember_f4c031e3-deab-4dfb-95d3-911b85251b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8395fd13-5dd3-4957-88b2-3377e32c458e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_96eedf44-d6f1-4b64-9318-93de79084574" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_8395fd13-5dd3-4957-88b2-3377e32c458e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_bc51e704-2c20-45e0-a47b-24a30a21fc12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8395fd13-5dd3-4957-88b2-3377e32c458e" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_bc51e704-2c20-45e0-a47b-24a30a21fc12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_7433c457-e252-4e0a-9a2c-68b038e87619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_bc51e704-2c20-45e0-a47b-24a30a21fc12" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_7433c457-e252-4e0a-9a2c-68b038e87619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_6dc8ae9b-23fd-4865-8111-af8d5db92380" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_bc51e704-2c20-45e0-a47b-24a30a21fc12" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_6dc8ae9b-23fd-4865-8111-af8d5db92380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_2e51a7ea-e8d5-42dd-a2fa-c461b9836232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8395fd13-5dd3-4957-88b2-3377e32c458e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_2e51a7ea-e8d5-42dd-a2fa-c461b9836232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_36ce8195-b5db-4c0b-af6b-b1ea24e5b82a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_2e51a7ea-e8d5-42dd-a2fa-c461b9836232" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_36ce8195-b5db-4c0b-af6b-b1ea24e5b82a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_ad219bf1-5aaa-4dfe-ad68-65d466f4b7e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_2e51a7ea-e8d5-42dd-a2fa-c461b9836232" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_ad219bf1-5aaa-4dfe-ad68-65d466f4b7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsAcquiredInProcessResearchAndDevelopment_9b1d220f-1279-4539-ab79-bec1ec13efff" xlink:href="nbix-20221231.xsd#nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsAcquiredInProcessResearchAndDevelopment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_2e51a7ea-e8d5-42dd-a2fa-c461b9836232" xlink:to="loc_nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsAcquiredInProcessResearchAndDevelopment_9b1d220f-1279-4539-ab79-bec1ec13efff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_cdf1f815-5544-491c-99f9-d2b7287825fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_2e51a7ea-e8d5-42dd-a2fa-c461b9836232" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_cdf1f815-5544-491c-99f9-d2b7287825fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndOtherAccruedExpenses_b950411a-5909-465a-b5bb-596e9237be14" xlink:href="nbix-20221231.xsd#nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndOtherAccruedExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_2e51a7ea-e8d5-42dd-a2fa-c461b9836232" xlink:to="loc_nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndOtherAccruedExpenses_b950411a-5909-465a-b5bb-596e9237be14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_01709769-fa4b-4132-b586-ac14c6b4dfed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_2e51a7ea-e8d5-42dd-a2fa-c461b9836232" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_01709769-fa4b-4132-b586-ac14c6b4dfed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_39c0f1d7-5e9e-4cdb-88e4-f10fc7b974f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_2e51a7ea-e8d5-42dd-a2fa-c461b9836232" xlink:to="loc_us-gaap_Goodwill_39c0f1d7-5e9e-4cdb-88e4-f10fc7b974f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6d390605-3a8d-4f45-80ea-732528b0e1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f02316ce-896b-49b7-8e8f-331f5fea5ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6d390605-3a8d-4f45-80ea-732528b0e1ee" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f02316ce-896b-49b7-8e8f-331f5fea5ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4253b350-40e9-4969-9e38-e175b440221e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f02316ce-896b-49b7-8e8f-331f5fea5ab1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4253b350-40e9-4969-9e38-e175b440221e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_86f80138-a138-4001-9ff7-0f3c745ee546" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4253b350-40e9-4969-9e38-e175b440221e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_86f80138-a138-4001-9ff7-0f3c745ee546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_90befb73-f9a2-4436-bb52-a3757612ed50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_86f80138-a138-4001-9ff7-0f3c745ee546" xlink:to="loc_us-gaap_CommercialPaperMember_90befb73-f9a2-4436-bb52-a3757612ed50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9be40bbf-a551-424d-94be-43ea78ff0e03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_86f80138-a138-4001-9ff7-0f3c745ee546" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9be40bbf-a551-424d-94be-43ea78ff0e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_bf1bded8-30ab-4066-8f5c-91bded82e129" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_86f80138-a138-4001-9ff7-0f3c745ee546" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_bf1bded8-30ab-4066-8f5c-91bded82e129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5f1912cb-069d-4962-8bb3-1796365ea2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f02316ce-896b-49b7-8e8f-331f5fea5ab1" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5f1912cb-069d-4962-8bb3-1796365ea2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_fa8fd0c1-aafb-42bd-84d0-09f04e178616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5f1912cb-069d-4962-8bb3-1796365ea2ca" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_fa8fd0c1-aafb-42bd-84d0-09f04e178616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_a6d6359f-2a41-4b71-a23d-6e39efd76671" xlink:href="nbix-20221231.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5f1912cb-069d-4962-8bb3-1796365ea2ca" xlink:to="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_a6d6359f-2a41-4b71-a23d-6e39efd76671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_0f6f634d-ecad-4d6c-834d-66e53b5fc3da" xlink:href="nbix-20221231.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5f1912cb-069d-4962-8bb3-1796365ea2ca" xlink:to="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_0f6f634d-ecad-4d6c-834d-66e53b5fc3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent_b969f71a-0433-4a16-aab9-82d50e64f0e1" xlink:href="nbix-20221231.xsd#nbix_DebtSecuritiesAvailableForSaleFairValueCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5f1912cb-069d-4962-8bb3-1796365ea2ca" xlink:to="loc_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent_b969f71a-0433-4a16-aab9-82d50e64f0e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_3482c030-7c92-420f-be02-b2080eaf6b93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5f1912cb-069d-4962-8bb3-1796365ea2ca" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_3482c030-7c92-420f-be02-b2080eaf6b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_422b6ea1-dc96-4de1-a1bf-07e0825bed5a" xlink:href="nbix-20221231.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5f1912cb-069d-4962-8bb3-1796365ea2ca" xlink:to="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_422b6ea1-dc96-4de1-a1bf-07e0825bed5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_9c48cfdb-b4da-4703-b5ec-5f58e6163e3f" xlink:href="nbix-20221231.xsd#nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5f1912cb-069d-4962-8bb3-1796365ea2ca" xlink:to="loc_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_9c48cfdb-b4da-4703-b5ec-5f58e6163e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent_5ff8fb6c-78de-421b-81f6-671bcb6628d0" xlink:href="nbix-20221231.xsd#nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5f1912cb-069d-4962-8bb3-1796365ea2ca" xlink:to="loc_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent_5ff8fb6c-78de-421b-81f6-671bcb6628d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#DebtSecuritiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b4103039-4fa9-43dd-95fc-6b4bc8cfa861" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions_7d9d053f-0fe1-426a-8c44-a9c189af0b18" xlink:href="nbix-20221231.xsd#nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b4103039-4fa9-43dd-95fc-6b4bc8cfa861" xlink:to="loc_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions_7d9d053f-0fe1-426a-8c44-a9c189af0b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_a2e69722-b2b3-4015-9560-32ce15730a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b4103039-4fa9-43dd-95fc-6b4bc8cfa861" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_a2e69722-b2b3-4015-9560-32ce15730a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c0b7241b-47aa-499a-9fa0-965de70af676" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f92761c7-e78b-4c0d-88ec-e3a8de8e1f60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c0b7241b-47aa-499a-9fa0-965de70af676" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f92761c7-e78b-4c0d-88ec-e3a8de8e1f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ec4de54a-01a6-463c-a39d-cf56a748a770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f92761c7-e78b-4c0d-88ec-e3a8de8e1f60" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ec4de54a-01a6-463c-a39d-cf56a748a770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_36f5f463-2736-4c19-a5a7-ea204c833e70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ec4de54a-01a6-463c-a39d-cf56a748a770" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_36f5f463-2736-4c19-a5a7-ea204c833e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_963605f0-3ff1-419e-9646-93460b26f810" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_36f5f463-2736-4c19-a5a7-ea204c833e70" xlink:to="loc_us-gaap_CommercialPaperMember_963605f0-3ff1-419e-9646-93460b26f810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_1ec0d9e9-2642-4509-9f1a-2735b03a183f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_36f5f463-2736-4c19-a5a7-ea204c833e70" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_1ec0d9e9-2642-4509-9f1a-2735b03a183f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_03ebc4e8-2031-4cd1-a23b-4f14f87165e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_36f5f463-2736-4c19-a5a7-ea204c833e70" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_03ebc4e8-2031-4cd1-a23b-4f14f87165e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7063bb18-c064-4e1d-a804-b9b8efa59127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f92761c7-e78b-4c0d-88ec-e3a8de8e1f60" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7063bb18-c064-4e1d-a804-b9b8efa59127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_c0c0f891-f497-4136-bf8d-47a27db36c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7063bb18-c064-4e1d-a804-b9b8efa59127" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_c0c0f891-f497-4136-bf8d-47a27db36c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_f75c7e66-e958-4016-afec-4e0cb91b9de6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7063bb18-c064-4e1d-a804-b9b8efa59127" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_f75c7e66-e958-4016-afec-4e0cb91b9de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_353b2cf0-34b9-4b39-b6d0-91e73fcbd4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7063bb18-c064-4e1d-a804-b9b8efa59127" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_353b2cf0-34b9-4b39-b6d0-91e73fcbd4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_19827738-bb1c-4f60-bfc9-26fb58919b76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7063bb18-c064-4e1d-a804-b9b8efa59127" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_19827738-bb1c-4f60-bfc9-26fb58919b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_c649566e-5885-491e-8788-3ebbb2b801e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7063bb18-c064-4e1d-a804-b9b8efa59127" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_c649566e-5885-491e-8788-3ebbb2b801e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_946bbe7c-361e-420d-8419-f77b876d9a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7063bb18-c064-4e1d-a804-b9b8efa59127" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_946bbe7c-361e-420d-8419-f77b876d9a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9f3a38e2-d7e7-4f4f-a2b5-6efcbcfc868e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a887fbe9-5dec-43d2-a4ad-1c0296ecc8eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9f3a38e2-d7e7-4f4f-a2b5-6efcbcfc868e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a887fbe9-5dec-43d2-a4ad-1c0296ecc8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_86a2113b-da0b-4851-b878-37c62ff29985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a887fbe9-5dec-43d2-a4ad-1c0296ecc8eb" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_86a2113b-da0b-4851-b878-37c62ff29985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e5a57f08-25de-49f9-9e5d-3a22d3138f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_86a2113b-da0b-4851-b878-37c62ff29985" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e5a57f08-25de-49f9-9e5d-3a22d3138f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_e1d65479-c17b-4157-b6b4-7e45d928beb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e5a57f08-25de-49f9-9e5d-3a22d3138f1a" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_e1d65479-c17b-4157-b6b4-7e45d928beb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_fb2be3f3-0fd1-48f6-8915-fd7192115959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e5a57f08-25de-49f9-9e5d-3a22d3138f1a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_fb2be3f3-0fd1-48f6-8915-fd7192115959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e2f7445b-241a-4c7a-a60f-3032a69b63e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e5a57f08-25de-49f9-9e5d-3a22d3138f1a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e2f7445b-241a-4c7a-a60f-3032a69b63e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_ae4853a2-06f7-4caf-91ed-2cb3e6cdab17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a887fbe9-5dec-43d2-a4ad-1c0296ecc8eb" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_ae4853a2-06f7-4caf-91ed-2cb3e6cdab17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a2a36db7-13bd-475a-9065-b7269c3940d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_ae4853a2-06f7-4caf-91ed-2cb3e6cdab17" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a2a36db7-13bd-475a-9065-b7269c3940d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CashAndMoneyMarketFundMember_edb88434-2414-41cc-aa8a-b6893c387391" xlink:href="nbix-20221231.xsd#nbix_CashAndMoneyMarketFundMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a2a36db7-13bd-475a-9065-b7269c3940d2" xlink:to="loc_nbix_CashAndMoneyMarketFundMember_edb88434-2414-41cc-aa8a-b6893c387391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_b512d931-09cc-4278-9e95-01231687e13f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a2a36db7-13bd-475a-9065-b7269c3940d2" xlink:to="loc_us-gaap_CertificatesOfDepositMember_b512d931-09cc-4278-9e95-01231687e13f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_67bcb4c0-707c-453a-b47d-dc06a534d18e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a2a36db7-13bd-475a-9065-b7269c3940d2" xlink:to="loc_us-gaap_CommercialPaperMember_67bcb4c0-707c-453a-b47d-dc06a534d18e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7d0aeea8-bf84-40d8-8155-682ba5deeb6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a887fbe9-5dec-43d2-a4ad-1c0296ecc8eb" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7d0aeea8-bf84-40d8-8155-682ba5deeb6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c1bbd9d3-0ac7-4b20-b730-721695410770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7d0aeea8-bf84-40d8-8155-682ba5deeb6d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c1bbd9d3-0ac7-4b20-b730-721695410770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_73de1720-5f17-4a18-be70-145c1b02bd70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c1bbd9d3-0ac7-4b20-b730-721695410770" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_73de1720-5f17-4a18-be70-145c1b02bd70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_f42a2caa-02da-4a6f-bed4-f97679c10e14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c1bbd9d3-0ac7-4b20-b730-721695410770" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_f42a2caa-02da-4a6f-bed4-f97679c10e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_01bf01d5-f33f-4e2e-88a5-eaf9143a6bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c1bbd9d3-0ac7-4b20-b730-721695410770" xlink:to="loc_us-gaap_EquitySecuritiesMember_01bf01d5-f33f-4e2e-88a5-eaf9143a6bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_beb014bf-bbc3-4f8c-9a7f-3464a281e2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a887fbe9-5dec-43d2-a4ad-1c0296ecc8eb" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_beb014bf-bbc3-4f8c-9a7f-3464a281e2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d509aaeb-a5c9-4940-95eb-d0254b0ac15f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_beb014bf-bbc3-4f8c-9a7f-3464a281e2fe" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d509aaeb-a5c9-4940-95eb-d0254b0ac15f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_b9f61289-185c-4647-8619-51675260aa4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_d509aaeb-a5c9-4940-95eb-d0254b0ac15f" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_b9f61289-185c-4647-8619-51675260aa4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3cbce0c1-7808-4bcc-ba25-f385ceb4dc17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a887fbe9-5dec-43d2-a4ad-1c0296ecc8eb" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3cbce0c1-7808-4bcc-ba25-f385ceb4dc17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_9769a20a-fd16-490a-910f-162e05f372f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3cbce0c1-7808-4bcc-ba25-f385ceb4dc17" xlink:to="loc_us-gaap_Investments_9769a20a-fd16-490a-910f-162e05f372f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_e21127c3-9aea-4184-8db0-68686d19055b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3cbce0c1-7808-4bcc-ba25-f385ceb4dc17" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_e21127c3-9aea-4184-8db0-68686d19055b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b579c71e-35fb-41f2-b3ff-17220a45c910" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_381ad033-0a8a-4942-9156-be3354c1a2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b579c71e-35fb-41f2-b3ff-17220a45c910" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_381ad033-0a8a-4942-9156-be3354c1a2ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8171ef10-73c2-4c5c-a377-e9338d667a12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_381ad033-0a8a-4942-9156-be3354c1a2ee" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8171ef10-73c2-4c5c-a377-e9338d667a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b984a51e-1f86-4169-9af6-4607ec3c515f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8171ef10-73c2-4c5c-a377-e9338d667a12" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b984a51e-1f86-4169-9af6-4607ec3c515f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_18316c9e-aab9-4c98-97c7-1a62ca0d0955" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b984a51e-1f86-4169-9af6-4607ec3c515f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_18316c9e-aab9-4c98-97c7-1a62ca0d0955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_38c156c4-3cea-4999-b131-be181c688045" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_381ad033-0a8a-4942-9156-be3354c1a2ee" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_38c156c4-3cea-4999-b131-be181c688045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e3240a9c-bbc3-4667-93fa-4ad2e80f359c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_38c156c4-3cea-4999-b131-be181c688045" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e3240a9c-bbc3-4667-93fa-4ad2e80f359c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_d96db0aa-845a-4d06-89a2-2caa55cc7b44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e3240a9c-bbc3-4667-93fa-4ad2e80f359c" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_d96db0aa-845a-4d06-89a2-2caa55cc7b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c9bb5bbb-7305-4b16-955b-04297a8e0a48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_381ad033-0a8a-4942-9156-be3354c1a2ee" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c9bb5bbb-7305-4b16-955b-04297a8e0a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27723aaa-2967-4876-8b60-ef66f26ead7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c9bb5bbb-7305-4b16-955b-04297a8e0a48" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27723aaa-2967-4876-8b60-ef66f26ead7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_517662b3-435e-436b-9bec-25b69138720d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27723aaa-2967-4876-8b60-ef66f26ead7e" xlink:to="loc_us-gaap_EquitySecuritiesMember_517662b3-435e-436b-9bec-25b69138720d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAxis_45dc2f37-103c-46f3-8890-e02a83eaab95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollateralAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_381ad033-0a8a-4942-9156-be3354c1a2ee" xlink:to="loc_us-gaap_CollateralAxis_45dc2f37-103c-46f3-8890-e02a83eaab95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralDomain_e2157f3a-ea5e-4ac1-a8eb-0d53642085bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollateralDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollateralAxis_45dc2f37-103c-46f3-8890-e02a83eaab95" xlink:to="loc_us-gaap_CollateralDomain_e2157f3a-ea5e-4ac1-a8eb-0d53642085bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_b2d31b86-2808-4120-9d63-318709a8d070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollateralDomain_e2157f3a-ea5e-4ac1-a8eb-0d53642085bf" xlink:to="loc_us-gaap_EquitySecuritiesMember_b2d31b86-2808-4120-9d63-318709a8d070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3d3e2002-03f0-4f6f-bf87-bb57226868d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_381ad033-0a8a-4942-9156-be3354c1a2ee" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3d3e2002-03f0-4f6f-bf87-bb57226868d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_ab04ad0c-9d77-4a2a-bda0-e9d9f6fd412b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3d3e2002-03f0-4f6f-bf87-bb57226868d0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_ab04ad0c-9d77-4a2a-bda0-e9d9f6fd412b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRestricted_da2fafad-ce5e-4452-8ca7-3004849b9326" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiRestricted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_ab04ad0c-9d77-4a2a-bda0-e9d9f6fd412b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRestricted_da2fafad-ce5e-4452-8ca7-3004849b9326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_8322474f-f0e9-4ecf-a8a1-f7aa37fe49d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_ab04ad0c-9d77-4a2a-bda0-e9d9f6fd412b" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_8322474f-f0e9-4ecf-a8a1-f7aa37fe49d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_55bea072-288d-456b-9450-daee9f023dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_ab04ad0c-9d77-4a2a-bda0-e9d9f6fd412b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_55bea072-288d-456b-9450-daee9f023dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_0e1d6fd6-5142-4861-a0a6-07e939f13e66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_ab04ad0c-9d77-4a2a-bda0-e9d9f6fd412b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_0e1d6fd6-5142-4861-a0a6-07e939f13e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRestricted_b8c834cb-9f7f-46a1-93ea-a7330f9d7f66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiRestricted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_ab04ad0c-9d77-4a2a-bda0-e9d9f6fd412b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRestricted_b8c834cb-9f7f-46a1-93ea-a7330f9d7f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#ConvertibleSeniorNotesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_de9876ed-4370-4306-8887-1e9a8906e3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8935f029-b107-4d82-b398-d61eec3fa044" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_de9876ed-4370-4306-8887-1e9a8906e3dc" xlink:to="loc_us-gaap_DebtInstrumentTable_8935f029-b107-4d82-b398-d61eec3fa044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d6540153-acd8-4ea0-b288-f6e3bdb7c56c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8935f029-b107-4d82-b398-d61eec3fa044" xlink:to="loc_us-gaap_DebtInstrumentAxis_d6540153-acd8-4ea0-b288-f6e3bdb7c56c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d4d3458b-f52f-4923-b222-61b739052738" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_d6540153-acd8-4ea0-b288-f6e3bdb7c56c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d4d3458b-f52f-4923-b222-61b739052738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_dc6308c7-dfe3-411c-8adf-cdc291af3f43" xlink:href="nbix-20221231.xsd#nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d3458b-f52f-4923-b222-61b739052738" xlink:to="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_dc6308c7-dfe3-411c-8adf-cdc291af3f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_a1aa7c0a-cdc7-45d4-97e9-001930ae9775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8935f029-b107-4d82-b398-d61eec3fa044" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_a1aa7c0a-cdc7-45d4-97e9-001930ae9775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_d7c9379e-3853-48f0-bf42-4e1673fda140" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_a1aa7c0a-cdc7-45d4-97e9-001930ae9775" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_d7c9379e-3853-48f0-bf42-4e1673fda140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_a853fffa-f552-4b7e-8f0f-0106c74a1cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d7c9379e-3853-48f0-bf42-4e1673fda140" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_a853fffa-f552-4b7e-8f0f-0106c74a1cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConversionAxis_812e6314-6e0f-4c9c-9e94-68a00ef73664" xlink:href="nbix-20221231.xsd#nbix_DebtInstrumentConversionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8935f029-b107-4d82-b398-d61eec3fa044" xlink:to="loc_nbix_DebtInstrumentConversionAxis_812e6314-6e0f-4c9c-9e94-68a00ef73664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConversionDomain_191bdbdb-0009-48d0-a43d-ed2beefa412b" xlink:href="nbix-20221231.xsd#nbix_DebtInstrumentConversionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_DebtInstrumentConversionAxis_812e6314-6e0f-4c9c-9e94-68a00ef73664" xlink:to="loc_nbix_DebtInstrumentConversionDomain_191bdbdb-0009-48d0-a43d-ed2beefa412b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ConversionPeriodOneMember_f03117fc-2b4f-4f16-a828-91f845eb634e" xlink:href="nbix-20221231.xsd#nbix_ConversionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_DebtInstrumentConversionDomain_191bdbdb-0009-48d0-a43d-ed2beefa412b" xlink:to="loc_nbix_ConversionPeriodOneMember_f03117fc-2b4f-4f16-a828-91f845eb634e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ConversionPeriodTwoMember_543d7e6c-62a5-4b13-96e8-6205ed8ddea5" xlink:href="nbix-20221231.xsd#nbix_ConversionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_DebtInstrumentConversionDomain_191bdbdb-0009-48d0-a43d-ed2beefa412b" xlink:to="loc_nbix_ConversionPeriodTwoMember_543d7e6c-62a5-4b13-96e8-6205ed8ddea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8c1af456-0ee2-4bc2-bb39-04593e139f63" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8935f029-b107-4d82-b398-d61eec3fa044" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8c1af456-0ee2-4bc2-bb39-04593e139f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e46c6a95-36a7-486f-871f-cc3cdc388316" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8c1af456-0ee2-4bc2-bb39-04593e139f63" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e46c6a95-36a7-486f-871f-cc3cdc388316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_c542fc8f-c640-4657-8782-d8cf1ed65875" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e46c6a95-36a7-486f-871f-cc3cdc388316" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_c542fc8f-c640-4657-8782-d8cf1ed65875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_c235d3e8-9167-40c2-9d4d-560d3456f391" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8935f029-b107-4d82-b398-d61eec3fa044" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_c235d3e8-9167-40c2-9d4d-560d3456f391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_d39a23a6-8070-48fa-8e20-4926d39baabb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_c235d3e8-9167-40c2-9d4d-560d3456f391" xlink:to="loc_us-gaap_TypeOfAdoptionMember_d39a23a6-8070-48fa-8e20-4926d39baabb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_cbb619a0-700a-4710-b830-666fcd0c095f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_d39a23a6-8070-48fa-8e20-4926d39baabb" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_cbb619a0-700a-4710-b830-666fcd0c095f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8935f029-b107-4d82-b398-d61eec3fa044" xlink:to="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_fe742f61-8b8e-43ab-9e3b-a2221f6d80bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_fe742f61-8b8e-43ab-9e3b-a2221f6d80bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4aa9c346-0c7a-4839-a5bb-dd590f4428a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4aa9c346-0c7a-4839-a5bb-dd590f4428a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CarryingAmountOfLiabilityComponentUponIssuance_4dd99d11-90ac-4067-a014-1454c4c56012" xlink:href="nbix-20221231.xsd#nbix_CarryingAmountOfLiabilityComponentUponIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_nbix_CarryingAmountOfLiabilityComponentUponIssuance_4dd99d11-90ac-4067-a014-1454c4c56012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_aa2bd5b9-c950-48d4-8a1e-430390c77c22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_aa2bd5b9-c950-48d4-8a1e-430390c77c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_bdfab860-8280-4c8d-84d2-762e6b5c6bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_bdfab860-8280-4c8d-84d2-762e6b5c6bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_a02102d1-14a5-47cf-99bc-b6ca2f1b198d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_DebtInstrumentTerm_a02102d1-14a5-47cf-99bc-b6ca2f1b198d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_1bcd6b49-6aff-46e8-9722-bfc7a7d3d08e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_1bcd6b49-6aff-46e8-9722-bfc7a7d3d08e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_695f33a6-5778-4cad-9e83-cc74009d1e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_695f33a6-5778-4cad-9e83-cc74009d1e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_e9c031a0-ac42-4cee-8f1e-9ba2af3ca1fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_RepaymentsOfDebt_e9c031a0-ac42-4cee-8f1e-9ba2af3ca1fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment_d704cb92-6171-42a4-b625-d970e39f0a83" xlink:href="nbix-20221231.xsd#nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment_d704cb92-6171-42a4-b625-d970e39f0a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput_721dfa8b-d4d4-44e3-b51f-7cc063e47a41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMeasurementInput"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_DebtInstrumentMeasurementInput_721dfa8b-d4d4-44e3-b51f-7cc063e47a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_bbb12658-8161-4b0d-b34f-1fe02bf06bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_bbb12658-8161-4b0d-b34f-1fe02bf06bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CarryingAmountOfLiabilityComponentAtSettlement_dc7e4aaa-5eb9-46b5-b4d5-8a213dd7a626" xlink:href="nbix-20221231.xsd#nbix_CarryingAmountOfLiabilityComponentAtSettlement"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_nbix_CarryingAmountOfLiabilityComponentAtSettlement_dc7e4aaa-5eb9-46b5-b4d5-8a213dd7a626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6457377a-8212-4f69-90e3-c357c46e72d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6457377a-8212-4f69-90e3-c357c46e72d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_6acc14f0-167d-49e9-a8f5-f6aaff190bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_6acc14f0-167d-49e9-a8f5-f6aaff190bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_bd52bcec-4f13-40ca-b640-815f5dde446f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_bd52bcec-4f13-40ca-b640-815f5dde446f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_60962b8f-981f-473d-81c7-e6d5662764d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_60962b8f-981f-473d-81c7-e6d5662764d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_810ed1f0-0ca0-4e90-aeed-c177192c9289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_AdditionalPaidInCapital_810ed1f0-0ca0-4e90-aeed-c177192c9289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bb78fb25-c4dc-4749-b38a-d0e4e7ed8a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bb78fb25-c4dc-4749-b38a-d0e4e7ed8a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_86ebf9f5-3ba2-4fd2-9b2f-b72c88e83a81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_86ebf9f5-3ba2-4fd2-9b2f-b72c88e83a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PrincipalAmountOnConversionRate_7cc25e0f-6006-4130-bf53-679b15ff51bf" xlink:href="nbix-20221231.xsd#nbix_PrincipalAmountOnConversionRate"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_nbix_PrincipalAmountOnConversionRate_7cc25e0f-6006-4130-bf53-679b15ff51bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_1368fc72-2637-4d62-af6d-4bc9769f7b04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_1368fc72-2637-4d62-af6d-4bc9769f7b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_9cf10776-09f5-42a2-b378-cd84abca59e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_9cf10776-09f5-42a2-b378-cd84abca59e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConvertibleConversionPremium_e67ca0c3-ea1c-4eac-b3d4-9e3590f7c38d" xlink:href="nbix-20221231.xsd#nbix_DebtInstrumentConvertibleConversionPremium"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_nbix_DebtInstrumentConvertibleConversionPremium_e67ca0c3-ea1c-4eac-b3d4-9e3590f7c38d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_33ba06aa-6ffd-420f-b0d0-b8897d7a54e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_SharePrice_33ba06aa-6ffd-420f-b0d0-b8897d7a54e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_32b41fb9-1d74-4029-82c3-351a9ece96a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_32b41fb9-1d74-4029-82c3-351a9ece96a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleStockPriceTrigger_bb1ebe2b-e0bc-4150-8d20-01bffe62cdbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleStockPriceTrigger"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleStockPriceTrigger_bb1ebe2b-e0bc-4150-8d20-01bffe62cdbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_e7e23221-b57f-4a6a-b08e-33cd8742a5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_e7e23221-b57f-4a6a-b08e-33cd8742a5bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_6826791b-1384-4f74-b802-46224f6cbd2e" xlink:href="nbix-20221231.xsd#nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_6826791b-1384-4f74-b802-46224f6cbd2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_9f0563aa-c778-4ffb-b31b-15f6a77360d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11b685e5-3eeb-4d79-84f5-c600ccba20d3" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_9f0563aa-c778-4ffb-b31b-15f6a77360d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#ConvertibleSeniorNotes2024NotesDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5a7f21cf-3931-4991-9a95-9791f512e66b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_53e99afd-3abd-4611-b65a-77b6481759f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5a7f21cf-3931-4991-9a95-9791f512e66b" xlink:to="loc_us-gaap_DebtInstrumentTable_53e99afd-3abd-4611-b65a-77b6481759f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_86cd88ec-f3c9-4bb7-bbe9-7d2867483650" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_53e99afd-3abd-4611-b65a-77b6481759f3" xlink:to="loc_us-gaap_DebtInstrumentAxis_86cd88ec-f3c9-4bb7-bbe9-7d2867483650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0f45de70-4c89-4978-8f6e-b05323532911" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_86cd88ec-f3c9-4bb7-bbe9-7d2867483650" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0f45de70-4c89-4978-8f6e-b05323532911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_ae6295d2-4bc4-4453-aa4b-5a9c00f2268f" xlink:href="nbix-20221231.xsd#nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0f45de70-4c89-4978-8f6e-b05323532911" xlink:to="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_ae6295d2-4bc4-4453-aa4b-5a9c00f2268f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d54ec616-3ee5-4211-b4a1-f581abf55604" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_53e99afd-3abd-4611-b65a-77b6481759f3" xlink:to="loc_us-gaap_DebtInstrumentLineItems_d54ec616-3ee5-4211-b4a1-f581abf55604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_9a062014-cab0-4652-8d71-a6011a5f8931" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d54ec616-3ee5-4211-b4a1-f581abf55604" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_9a062014-cab0-4652-8d71-a6011a5f8931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_44d5cc26-7c8a-4b17-84b1-0476aeecdf97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d54ec616-3ee5-4211-b4a1-f581abf55604" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_44d5cc26-7c8a-4b17-84b1-0476aeecdf97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_de803317-4d9a-43c4-8b55-44058e7aa7c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d54ec616-3ee5-4211-b4a1-f581abf55604" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_de803317-4d9a-43c4-8b55-44058e7aa7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_50d3d1b6-6eb1-4a12-b129-56ecd9d776bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d54ec616-3ee5-4211-b4a1-f581abf55604" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_50d3d1b6-6eb1-4a12-b129-56ecd9d776bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_3e7b2fc3-0a8c-411f-8cc6-0472e75f88be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d54ec616-3ee5-4211-b4a1-f581abf55604" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_3e7b2fc3-0a8c-411f-8cc6-0472e75f88be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_49d4eb16-f39e-459a-a456-3c27ea7d5a86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d54ec616-3ee5-4211-b4a1-f581abf55604" xlink:to="loc_us-gaap_DebtInstrumentFairValue_49d4eb16-f39e-459a-a456-3c27ea7d5a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#ConvertibleSeniorNotesInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7d604b31-240a-4064-8530-8b45b0018267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentCouponInterest_7e2c8433-36a5-4d61-83b8-a00f49793cf6" xlink:href="nbix-20221231.xsd#nbix_DebtInstrumentCouponInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7d604b31-240a-4064-8530-8b45b0018267" xlink:to="loc_nbix_DebtInstrumentCouponInterest_7e2c8433-36a5-4d61-83b8-a00f49793cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_4071833d-ccc3-412e-9d8a-a1e33eba4afd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7d604b31-240a-4064-8530-8b45b0018267" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_4071833d-ccc3-412e-9d8a-a1e33eba4afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_a224db9e-78a1-4471-9536-5aa6dd73d22b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7d604b31-240a-4064-8530-8b45b0018267" xlink:to="loc_us-gaap_InterestExpense_a224db9e-78a1-4471-9536-5aa6dd73d22b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#GoodwillandIntangibleAssetsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_def1fa01-2738-4d52-8c80-903955de4b19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_9802bc5d-736f-46c0-951b-1f486e03195c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_def1fa01-2738-4d52-8c80-903955de4b19" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_9802bc5d-736f-46c0-951b-1f486e03195c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0e8c1915-24f6-4dff-8aab-efaf2bdd636b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_9802bc5d-736f-46c0-951b-1f486e03195c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0e8c1915-24f6-4dff-8aab-efaf2bdd636b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_874b3107-10a0-4955-b501-ea1167205902" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0e8c1915-24f6-4dff-8aab-efaf2bdd636b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_874b3107-10a0-4955-b501-ea1167205902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DiurnalGroupPlcMember_c314a1c6-b12a-4303-8519-7b91bf896da0" xlink:href="nbix-20221231.xsd#nbix_DiurnalGroupPlcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_874b3107-10a0-4955-b501-ea1167205902" xlink:to="loc_nbix_DiurnalGroupPlcMember_c314a1c6-b12a-4303-8519-7b91bf896da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_91445d8f-63d1-4a1b-af69-a6c4a4251cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_9802bc5d-736f-46c0-951b-1f486e03195c" xlink:to="loc_us-gaap_GoodwillLineItems_91445d8f-63d1-4a1b-af69-a6c4a4251cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2282e8a8-8b5f-45b2-a5da-657dcd3af593" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_91445d8f-63d1-4a1b-af69-a6c4a4251cbe" xlink:to="loc_us-gaap_Goodwill_2282e8a8-8b5f-45b2-a5da-657dcd3af593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d48e9355-d6fa-49cb-b515-19d918b4c34a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_77edaafd-2924-4915-96fd-2d83d9982881" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d48e9355-d6fa-49cb-b515-19d918b4c34a" xlink:to="loc_us-gaap_GoodwillRollForward_77edaafd-2924-4915-96fd-2d83d9982881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_188ac7ac-a4a3-4da1-9fff-3e88476db73a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_77edaafd-2924-4915-96fd-2d83d9982881" xlink:to="loc_us-gaap_Goodwill_188ac7ac-a4a3-4da1-9fff-3e88476db73a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_a0f59f66-aff6-4280-81e1-2f83c2fc3f78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_77edaafd-2924-4915-96fd-2d83d9982881" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_a0f59f66-aff6-4280-81e1-2f83c2fc3f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_e1e6d924-293c-427c-89a3-b6f714458ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_77edaafd-2924-4915-96fd-2d83d9982881" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_e1e6d924-293c-427c-89a3-b6f714458ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_332f0550-0d69-4b80-9514-1148fea428e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_77edaafd-2924-4915-96fd-2d83d9982881" xlink:to="loc_us-gaap_Goodwill_332f0550-0d69-4b80-9514-1148fea428e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f734fea7-359b-4e14-b7c2-a147945fd5d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_18fe34ae-7a24-413c-a612-ffb86798a1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f734fea7-359b-4e14-b7c2-a147945fd5d8" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_18fe34ae-7a24-413c-a612-ffb86798a1fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1674c58d-6fce-41e7-a513-dc25403efab8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_18fe34ae-7a24-413c-a612-ffb86798a1fc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1674c58d-6fce-41e7-a513-dc25403efab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a7c32c1f-2639-4142-8340-e5edeba193c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1674c58d-6fce-41e7-a513-dc25403efab8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a7c32c1f-2639-4142-8340-e5edeba193c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_9a99c1a9-7f2f-4857-b379-3277205a4e91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a7c32c1f-2639-4142-8340-e5edeba193c5" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_9a99c1a9-7f2f-4857-b379-3277205a4e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_74669db9-2998-40a8-aba9-b40cfd8b401d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_18fe34ae-7a24-413c-a612-ffb86798a1fc" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_74669db9-2998-40a8-aba9-b40cfd8b401d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8366eeaf-d06b-425e-a699-1f10255a560c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_74669db9-2998-40a8-aba9-b40cfd8b401d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8366eeaf-d06b-425e-a699-1f10255a560c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_61f38d9a-6cee-4b08-9b9b-cc2f9ae623d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8366eeaf-d06b-425e-a699-1f10255a560c" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_61f38d9a-6cee-4b08-9b9b-cc2f9ae623d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_4945d3b4-2475-43f7-81cc-91ccdb212f36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_18fe34ae-7a24-413c-a612-ffb86798a1fc" xlink:to="loc_us-gaap_GoodwillLineItems_4945d3b4-2475-43f7-81cc-91ccdb212f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_c7cb5d6b-5868-4efb-a1cf-b4b1b471981b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_4945d3b4-2475-43f7-81cc-91ccdb212f36" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_c7cb5d6b-5868-4efb-a1cf-b4b1b471981b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_078defab-8d65-4454-b71f-81a0ba7ae642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_4945d3b4-2475-43f7-81cc-91ccdb212f36" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_078defab-8d65-4454-b71f-81a0ba7ae642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ae02cb1b-02fd-4728-9a54-35ca607707aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_4945d3b4-2475-43f7-81cc-91ccdb212f36" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ae02cb1b-02fd-4728-9a54-35ca607707aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_42f5f7d4-18d5-4942-b0f2-559f467b7448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_4945d3b4-2475-43f7-81cc-91ccdb212f36" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_42f5f7d4-18d5-4942-b0f2-559f467b7448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1c892a34-3fab-4eb0-a1b1-6e9c5542b427" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_4945d3b4-2475-43f7-81cc-91ccdb212f36" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1c892a34-3fab-4eb0-a1b1-6e9c5542b427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_fbbbed1c-be8a-4469-b720-5c566ef4b7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_4945d3b4-2475-43f7-81cc-91ccdb212f36" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_fbbbed1c-be8a-4469-b720-5c566ef4b7b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/GoodwillandIntangibleAssetsEstimatedAnnualAmortizationExpenseforFiniteLivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#GoodwillandIntangibleAssetsEstimatedAnnualAmortizationExpenseforFiniteLivedIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/GoodwillandIntangibleAssetsEstimatedAnnualAmortizationExpenseforFiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_86674589-fb5e-40bf-a35f-2e08778c3469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_8234292d-8944-4cbd-89ec-c160acc3a39f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_86674589-fb5e-40bf-a35f-2e08778c3469" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_8234292d-8944-4cbd-89ec-c160acc3a39f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_6783ff5d-68c1-455a-a695-b73c7da5ca7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_86674589-fb5e-40bf-a35f-2e08778c3469" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_6783ff5d-68c1-455a-a695-b73c7da5ca7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_eca07e8f-7514-40fc-92cf-52ebc758f859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_86674589-fb5e-40bf-a35f-2e08778c3469" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_eca07e8f-7514-40fc-92cf-52ebc758f859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_cde58791-2481-4235-bfa0-5e3c69907c46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_86674589-fb5e-40bf-a35f-2e08778c3469" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_cde58791-2481-4235-bfa0-5e3c69907c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_18af9532-4f78-42b8-8963-fa1a9b534bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_86674589-fb5e-40bf-a35f-2e08778c3469" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_18af9532-4f78-42b8-8963-fa1a9b534bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_01afcf0d-79bf-4d55-9671-e7a95b70f5c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_86674589-fb5e-40bf-a35f-2e08778c3469" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_01afcf0d-79bf-4d55-9671-e7a95b70f5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#OtherBalanceSheetDetailsInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OtherBalanceSheetDetailsAbstract_8d409baf-b731-4d82-90bd-cef9c6c25e8d" xlink:href="nbix-20221231.xsd#nbix_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_3a551e00-9f63-45d7-b3f3-05dde2f421a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_8d409baf-b731-4d82-90bd-cef9c6c25e8d" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_3a551e00-9f63-45d7-b3f3-05dde2f421a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_167dcbae-6c8a-4ba7-8af0-5ace3a1b7810" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_8d409baf-b731-4d82-90bd-cef9c6c25e8d" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_167dcbae-6c8a-4ba7-8af0-5ace3a1b7810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_bfdb0d33-c65f-4575-9c16-424466206995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_8d409baf-b731-4d82-90bd-cef9c6c25e8d" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_bfdb0d33-c65f-4575-9c16-424466206995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7635760a-6789-44aa-ab11-adf46e57aa26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_8d409baf-b731-4d82-90bd-cef9c6c25e8d" xlink:to="loc_us-gaap_InventoryNet_7635760a-6789-44aa-ab11-adf46e57aa26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#OtherBalanceSheetDetailsPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b4e94d77-f0a8-4f79-9db6-df3e264d44a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5f0b6827-2820-4cc3-bd4f-5afa95130fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b4e94d77-f0a8-4f79-9db6-df3e264d44a7" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5f0b6827-2820-4cc3-bd4f-5afa95130fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_20ff6a83-949f-4285-874e-a4f44a90ee02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5f0b6827-2820-4cc3-bd4f-5afa95130fbd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_20ff6a83-949f-4285-874e-a4f44a90ee02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_05e505ad-a3b3-4015-b94d-dd3ed819e5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_20ff6a83-949f-4285-874e-a4f44a90ee02" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_05e505ad-a3b3-4015-b94d-dd3ed819e5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_ff5171f2-0163-4e8a-bf3e-b015b8f6baa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_05e505ad-a3b3-4015-b94d-dd3ed819e5ea" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_ff5171f2-0163-4e8a-bf3e-b015b8f6baa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ScientificEquipmentMember_6b4588cd-e8a7-4602-a7e5-e3b43b9d3450" xlink:href="nbix-20221231.xsd#nbix_ScientificEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_05e505ad-a3b3-4015-b94d-dd3ed819e5ea" xlink:to="loc_nbix_ScientificEquipmentMember_6b4588cd-e8a7-4602-a7e5-e3b43b9d3450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_2139e897-985d-49a8-88ea-8ccff9bb45e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_05e505ad-a3b3-4015-b94d-dd3ed819e5ea" xlink:to="loc_us-gaap_ComputerEquipmentMember_2139e897-985d-49a8-88ea-8ccff9bb45e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_66ceb525-75b7-4703-af73-4e7cc2c4ad85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_05e505ad-a3b3-4015-b94d-dd3ed819e5ea" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_66ceb525-75b7-4703-af73-4e7cc2c4ad85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7d1c4711-60a8-4e1f-bf88-18c73871e827" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5f0b6827-2820-4cc3-bd4f-5afa95130fbd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7d1c4711-60a8-4e1f-bf88-18c73871e827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_f8e79860-3ed5-41db-9fac-952b9797a6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7d1c4711-60a8-4e1f-bf88-18c73871e827" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_f8e79860-3ed5-41db-9fac-952b9797a6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ab66d249-6737-49a3-9090-f3c79f51d3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7d1c4711-60a8-4e1f-bf88-18c73871e827" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ab66d249-6737-49a3-9090-f3c79f51d3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e1611bd7-0a0f-4e16-a616-5fbf8d48d5d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7d1c4711-60a8-4e1f-bf88-18c73871e827" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e1611bd7-0a0f-4e16-a616-5fbf8d48d5d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OtherBalanceSheetDetailsAbstract_d7484504-1ed6-467b-a8c2-94f3cd9f72f0" xlink:href="nbix-20221231.xsd#nbix_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1bd2b634-1ba3-47b8-8c46-df5e0d32fd03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_d7484504-1ed6-467b-a8c2-94f3cd9f72f0" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1bd2b634-1ba3-47b8-8c46-df5e0d32fd03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_RevenueRelatedReservesForDiscountsAndAllowances_e4c55db9-89f2-476e-827a-e0140c872f63" xlink:href="nbix-20221231.xsd#nbix_RevenueRelatedReservesForDiscountsAndAllowances"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_d7484504-1ed6-467b-a8c2-94f3cd9f72f0" xlink:to="loc_nbix_RevenueRelatedReservesForDiscountsAndAllowances_e4c55db9-89f2-476e-827a-e0140c872f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AccruedResearchAndDevelopmentExpenseCurrent_34e45817-0cc0-40b7-8369-f4d2e3c2f159" xlink:href="nbix-20221231.xsd#nbix_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_d7484504-1ed6-467b-a8c2-94f3cd9f72f0" xlink:to="loc_nbix_AccruedResearchAndDevelopmentExpenseCurrent_34e45817-0cc0-40b7-8369-f4d2e3c2f159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AccruedBrandedPrescriptionDrugFee_ddc1d3c7-7ea3-417b-82d1-357231c748f5" xlink:href="nbix-20221231.xsd#nbix_AccruedBrandedPrescriptionDrugFee"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_d7484504-1ed6-467b-a8c2-94f3cd9f72f0" xlink:to="loc_nbix_AccruedBrandedPrescriptionDrugFee_ddc1d3c7-7ea3-417b-82d1-357231c748f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_c016eda6-48e1-4e65-8d69-e3f5017b3337" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_d7484504-1ed6-467b-a8c2-94f3cd9f72f0" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_c016eda6-48e1-4e65-8d69-e3f5017b3337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_43755624-ab14-4fc4-bb43-4d16f9f5bad2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_d7484504-1ed6-467b-a8c2-94f3cd9f72f0" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_43755624-ab14-4fc4-bb43-4d16f9f5bad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OtherBalanceSheetDetailsAbstract_bbd2ffa0-bbaf-40db-b257-5f0246be36bb" xlink:href="nbix-20221231.xsd#nbix_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ecc19feb-0899-4d34-ba94-64ef645b8bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_bbd2ffa0-bbaf-40db-b257-5f0246be36bb" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ecc19feb-0899-4d34-ba94-64ef645b8bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_4dd30096-a15d-4e69-89fb-7ed03cfe33d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_bbd2ffa0-bbaf-40db-b257-5f0246be36bb" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_4dd30096-a15d-4e69-89fb-7ed03cfe33d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_eb33a24f-7229-4448-a0be-ebcb7f4f8576" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_bbd2ffa0-bbaf-40db-b257-5f0246be36bb" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_eb33a24f-7229-4448-a0be-ebcb7f4f8576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/EarningsPerShareScheduleofNetIncomeLossPerShareDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#EarningsPerShareScheduleofNetIncomeLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/EarningsPerShareScheduleofNetIncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d32fb644-4869-4428-8c78-ace2305258bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_31fbad8d-10b9-4e05-ae90-f219742b0b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d32fb644-4869-4428-8c78-ace2305258bb" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_31fbad8d-10b9-4e05-ae90-f219742b0b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_cf8b3204-9bd5-49b6-86ab-691e4331867b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d32fb644-4869-4428-8c78-ace2305258bb" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_cf8b3204-9bd5-49b6-86ab-691e4331867b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9d60441c-e021-49f0-b335-3fb00649a4a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d32fb644-4869-4428-8c78-ace2305258bb" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9d60441c-e021-49f0-b335-3fb00649a4a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_22462654-bbf9-4927-8351-5f91caed7bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9d60441c-e021-49f0-b335-3fb00649a4a1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_22462654-bbf9-4927-8351-5f91caed7bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_99062a5c-bdd6-46b1-b961-1cb58bac9cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9d60441c-e021-49f0-b335-3fb00649a4a1" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_99062a5c-bdd6-46b1-b961-1cb58bac9cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f0986bdc-5915-49c3-9fa2-db8a318a0889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9d60441c-e021-49f0-b335-3fb00649a4a1" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f0986bdc-5915-49c3-9fa2-db8a318a0889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_EarningsPerShareBasicAndDilutedEPSAbstract_d437953d-da48-4e5f-9dcd-e9f0eb8a397b" xlink:href="nbix-20221231.xsd#nbix_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d32fb644-4869-4428-8c78-ace2305258bb" xlink:to="loc_nbix_EarningsPerShareBasicAndDilutedEPSAbstract_d437953d-da48-4e5f-9dcd-e9f0eb8a397b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_fe1d77f0-a46f-40d2-8621-30cfec0a3ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_EarningsPerShareBasicAndDilutedEPSAbstract_d437953d-da48-4e5f-9dcd-e9f0eb8a397b" xlink:to="loc_us-gaap_EarningsPerShareBasic_fe1d77f0-a46f-40d2-8621-30cfec0a3ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2a864d97-ac90-4cd0-a829-57473b2025d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_EarningsPerShareBasicAndDilutedEPSAbstract_d437953d-da48-4e5f-9dcd-e9f0eb8a397b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2a864d97-ac90-4cd0-a829-57473b2025d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/EarningsPerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#EarningsPerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/EarningsPerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_61f36514-cf6b-4795-bee1-56fdbfa92fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f9c9515e-f543-4277-9cf2-3c4d19150adf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_61f36514-cf6b-4795-bee1-56fdbfa92fe5" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f9c9515e-f543-4277-9cf2-3c4d19150adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ec7379cc-58c0-4931-ad05-d6c7b366f210" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f9c9515e-f543-4277-9cf2-3c4d19150adf" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ec7379cc-58c0-4931-ad05-d6c7b366f210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3237e8e0-d2a2-4e58-8e60-e70f3996a276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ec7379cc-58c0-4931-ad05-d6c7b366f210" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3237e8e0-d2a2-4e58-8e60-e70f3996a276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember_9ce17ba3-db39-462f-a24d-abf4d565d33c" xlink:href="nbix-20221231.xsd#nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3237e8e0-d2a2-4e58-8e60-e70f3996a276" xlink:to="loc_nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember_9ce17ba3-db39-462f-a24d-abf4d565d33c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7ea1b8cd-96d0-4171-a41f-7246e810fc0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f9c9515e-f543-4277-9cf2-3c4d19150adf" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7ea1b8cd-96d0-4171-a41f-7246e810fc0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2bf05275-ea9a-4be6-b3ca-dc509f12db72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7ea1b8cd-96d0-4171-a41f-7246e810fc0f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2bf05275-ea9a-4be6-b3ca-dc509f12db72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#ShareBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fca1ba63-4ad6-4de0-89a5-85402fe34163" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_78e198c4-ed68-44bd-9bce-332e6bcd4277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fca1ba63-4ad6-4de0-89a5-85402fe34163" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_78e198c4-ed68-44bd-9bce-332e6bcd4277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9ebadb8f-dd30-46ac-a4df-781987a4a19e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_78e198c4-ed68-44bd-9bce-332e6bcd4277" xlink:to="loc_us-gaap_PlanNameAxis_9ebadb8f-dd30-46ac-a4df-781987a4a19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_bcf70e1c-fa8c-477f-bdd2-0bd250843f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_9ebadb8f-dd30-46ac-a4df-781987a4a19e" xlink:to="loc_us-gaap_PlanNameDomain_bcf70e1c-fa8c-477f-bdd2-0bd250843f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_Amended2020EquityIncentivePlanMember_a09d9c02-ec93-4a20-97c1-41657cc87c42" xlink:href="nbix-20221231.xsd#nbix_Amended2020EquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_bcf70e1c-fa8c-477f-bdd2-0bd250843f1a" xlink:to="loc_nbix_Amended2020EquityIncentivePlanMember_a09d9c02-ec93-4a20-97c1-41657cc87c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TwoThousandAndElevenEquityIncentivePlanMember_aaf2885b-a277-40eb-9bcd-7b165c211119" xlink:href="nbix-20221231.xsd#nbix_TwoThousandAndElevenEquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_bcf70e1c-fa8c-477f-bdd2-0bd250843f1a" xlink:to="loc_nbix_TwoThousandAndElevenEquityIncentivePlanMember_aaf2885b-a277-40eb-9bcd-7b165c211119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_Amended2018EmployeeStockPurchasePlanMember_c5b11552-6b2f-4b29-86ba-2b9580063d3e" xlink:href="nbix-20221231.xsd#nbix_Amended2018EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_bcf70e1c-fa8c-477f-bdd2-0bd250843f1a" xlink:to="loc_nbix_Amended2018EmployeeStockPurchasePlanMember_c5b11552-6b2f-4b29-86ba-2b9580063d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_052402ab-32d5-4d1e-8e19-b8ddcb815a93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_78e198c4-ed68-44bd-9bce-332e6bcd4277" xlink:to="loc_us-gaap_AwardTypeAxis_052402ab-32d5-4d1e-8e19-b8ddcb815a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_382b52ca-d606-469f-8f53-91d36c5eacba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_052402ab-32d5-4d1e-8e19-b8ddcb815a93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_382b52ca-d606-469f-8f53-91d36c5eacba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_d31f69a8-949e-4a95-9d2a-49ad6866623f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_382b52ca-d606-469f-8f53-91d36c5eacba" xlink:to="loc_us-gaap_EmployeeStockMember_d31f69a8-949e-4a95-9d2a-49ad6866623f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1833f850-c6d3-4770-8436-d82936dafbc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_382b52ca-d606-469f-8f53-91d36c5eacba" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1833f850-c6d3-4770-8436-d82936dafbc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ff24656e-f30e-4199-9296-603fa0f742f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_382b52ca-d606-469f-8f53-91d36c5eacba" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ff24656e-f30e-4199-9296-603fa0f742f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PerformanceBasedRestrictedStockUnitMember_0cee8ac5-4b18-4219-8ff5-d36540119612" xlink:href="nbix-20221231.xsd#nbix_PerformanceBasedRestrictedStockUnitMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_382b52ca-d606-469f-8f53-91d36c5eacba" xlink:to="loc_nbix_PerformanceBasedRestrictedStockUnitMember_0cee8ac5-4b18-4219-8ff5-d36540119612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4bf015fd-86e7-4ce9-b15a-1719a1383358" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_78e198c4-ed68-44bd-9bce-332e6bcd4277" xlink:to="loc_srt_RangeAxis_4bf015fd-86e7-4ce9-b15a-1719a1383358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f8a705eb-9e64-4c14-b46a-9dac8cc80131" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4bf015fd-86e7-4ce9-b15a-1719a1383358" xlink:to="loc_srt_RangeMember_f8a705eb-9e64-4c14-b46a-9dac8cc80131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d0d83028-abcd-4192-b490-a7f39461bb6e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f8a705eb-9e64-4c14-b46a-9dac8cc80131" xlink:to="loc_srt_MinimumMember_d0d83028-abcd-4192-b490-a7f39461bb6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f417d092-27da-433f-b40d-7d8b403c5bd6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f8a705eb-9e64-4c14-b46a-9dac8cc80131" xlink:to="loc_srt_MaximumMember_f417d092-27da-433f-b40d-7d8b403c5bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_551dba91-ddf0-4544-b033-831fa2136a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_78e198c4-ed68-44bd-9bce-332e6bcd4277" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_551dba91-ddf0-4544-b033-831fa2136a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8765bc5a-54f7-4723-bf18-47c364464a05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_551dba91-ddf0-4544-b033-831fa2136a3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8765bc5a-54f7-4723-bf18-47c364464a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward_fef1daeb-cebd-4bb0-b035-770b681d082f" xlink:href="nbix-20221231.xsd#nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_551dba91-ddf0-4544-b033-831fa2136a3f" xlink:to="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward_fef1daeb-cebd-4bb0-b035-770b681d082f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted_e75d8d00-892e-4980-958d-acaa3465c2e4" xlink:href="nbix-20221231.xsd#nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_551dba91-ddf0-4544-b033-831fa2136a3f" xlink:to="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted_e75d8d00-892e-4980-958d-acaa3465c2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward_bca17736-fb6a-41b0-8b27-6659b35b0bb7" xlink:href="nbix-20221231.xsd#nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_551dba91-ddf0-4544-b033-831fa2136a3f" xlink:to="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward_bca17736-fb6a-41b0-8b27-6659b35b0bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward_70ffc681-ef15-4521-b6da-bee03a3c69fc" xlink:href="nbix-20221231.xsd#nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_551dba91-ddf0-4544-b033-831fa2136a3f" xlink:to="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward_70ffc681-ef15-4521-b6da-bee03a3c69fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_defc022c-edbd-4c61-84c2-4e19e1d89e86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_551dba91-ddf0-4544-b033-831fa2136a3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_defc022c-edbd-4c61-84c2-4e19e1d89e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e49d827d-b1c4-4360-9824-dd189e2dfb1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_551dba91-ddf0-4544-b033-831fa2136a3f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e49d827d-b1c4-4360-9824-dd189e2dfb1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_00ce9756-91c5-4c4d-ad29-01c630d8fd2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_551dba91-ddf0-4544-b033-831fa2136a3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_00ce9756-91c5-4c4d-ad29-01c630d8fd2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f6b76520-e515-4120-8b29-6df456ac96de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_551dba91-ddf0-4544-b033-831fa2136a3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f6b76520-e515-4120-8b29-6df456ac96de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_dd7d24e2-9aff-48c1-bf4f-c4f677320c97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_551dba91-ddf0-4544-b033-831fa2136a3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_dd7d24e2-9aff-48c1-bf4f-c4f677320c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_b8300866-089e-4e4e-9970-6a9b65296727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_551dba91-ddf0-4544-b033-831fa2136a3f" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_b8300866-089e-4e4e-9970-6a9b65296727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_e1168fff-157e-4c31-a352-bbb61d14c116" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_551dba91-ddf0-4544-b033-831fa2136a3f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_e1168fff-157e-4c31-a352-bbb61d14c116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_39503482-f5ed-43ec-9020-dfe8feadb09a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_551dba91-ddf0-4544-b033-831fa2136a3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_39503482-f5ed-43ec-9020-dfe8feadb09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_ca8c4efb-d546-4068-8c8a-ac1ace909cea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_551dba91-ddf0-4544-b033-831fa2136a3f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_ca8c4efb-d546-4068-8c8a-ac1ace909cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_04758c43-e30f-4584-8833-c4ae1079a79e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1d44c120-60c5-4bd1-b34c-795629f21f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_04758c43-e30f-4584-8833-c4ae1079a79e" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1d44c120-60c5-4bd1-b34c-795629f21f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c845f987-0359-4990-8272-1b05f35259c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1d44c120-60c5-4bd1-b34c-795629f21f1c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c845f987-0359-4990-8272-1b05f35259c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_02cba898-f47d-4de0-95f3-47140383a761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c845f987-0359-4990-8272-1b05f35259c1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_02cba898-f47d-4de0-95f3-47140383a761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_206a31f5-409a-48c1-ab88-9f3774b7d146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_02cba898-f47d-4de0-95f3-47140383a761" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_206a31f5-409a-48c1-ab88-9f3774b7d146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_958c23fb-5e4a-4d50-9160-828ddac79564" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_02cba898-f47d-4de0-95f3-47140383a761" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_958c23fb-5e4a-4d50-9160-828ddac79564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e19d9c94-49cf-4180-8879-8ab0687b4858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1d44c120-60c5-4bd1-b34c-795629f21f1c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e19d9c94-49cf-4180-8879-8ab0687b4858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_fe488fc4-239f-481e-8cd7-b61fefd485b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e19d9c94-49cf-4180-8879-8ab0687b4858" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_fe488fc4-239f-481e-8cd7-b61fefd485b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cdecc3a4-4194-454a-b7d8-507142ca9289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8b19ffb5-2bc1-41a2-848c-fb1a19d88c63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cdecc3a4-4194-454a-b7d8-507142ca9289" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8b19ffb5-2bc1-41a2-848c-fb1a19d88c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ac423140-d7a1-4bef-8401-662194d2ceda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8b19ffb5-2bc1-41a2-848c-fb1a19d88c63" xlink:to="loc_us-gaap_AwardTypeAxis_ac423140-d7a1-4bef-8401-662194d2ceda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d52eb159-d488-479d-8f58-8df815373eba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ac423140-d7a1-4bef-8401-662194d2ceda" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d52eb159-d488-479d-8f58-8df815373eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5402343f-8a4b-4f37-a99f-acb77765a13e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d52eb159-d488-479d-8f58-8df815373eba" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5402343f-8a4b-4f37-a99f-acb77765a13e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d4dcb103-4cc3-47f7-bb29-3df95c195d14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d52eb159-d488-479d-8f58-8df815373eba" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d4dcb103-4cc3-47f7-bb29-3df95c195d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PerformanceBasedRestrictedStockUnitMember_7c166ed0-9273-4316-9f2e-2a66fa91ff6b" xlink:href="nbix-20221231.xsd#nbix_PerformanceBasedRestrictedStockUnitMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d52eb159-d488-479d-8f58-8df815373eba" xlink:to="loc_nbix_PerformanceBasedRestrictedStockUnitMember_7c166ed0-9273-4316-9f2e-2a66fa91ff6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_b2d9a00b-6cbf-493e-b802-4493303f9809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d52eb159-d488-479d-8f58-8df815373eba" xlink:to="loc_us-gaap_EmployeeStockMember_b2d9a00b-6cbf-493e-b802-4493303f9809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8d71ec32-534e-4f81-b91f-c4dc4e746c26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8b19ffb5-2bc1-41a2-848c-fb1a19d88c63" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8d71ec32-534e-4f81-b91f-c4dc4e746c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_15ff0622-6a88-4efd-977b-7d5ad820dd1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8d71ec32-534e-4f81-b91f-c4dc4e746c26" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_15ff0622-6a88-4efd-977b-7d5ad820dd1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dfdde192-372e-45a2-894d-63980a935a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2f510f0b-703d-4ba8-bfc0-9fe069eb64a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dfdde192-372e-45a2-894d-63980a935a0e" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2f510f0b-703d-4ba8-bfc0-9fe069eb64a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_af890217-927b-4a87-9335-75f9c3d01307" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2f510f0b-703d-4ba8-bfc0-9fe069eb64a0" xlink:to="loc_us-gaap_AwardTypeAxis_af890217-927b-4a87-9335-75f9c3d01307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6d363347-1314-480c-92e3-18d1d013eb08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_af890217-927b-4a87-9335-75f9c3d01307" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6d363347-1314-480c-92e3-18d1d013eb08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_40c63dfe-f1eb-4611-94f0-1d9722879601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6d363347-1314-480c-92e3-18d1d013eb08" xlink:to="loc_us-gaap_EmployeeStockOptionMember_40c63dfe-f1eb-4611-94f0-1d9722879601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d0c7769e-0e84-4978-acf1-191c3e07c4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6d363347-1314-480c-92e3-18d1d013eb08" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d0c7769e-0e84-4978-acf1-191c3e07c4dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PerformanceBasedRestrictedStockUnitMember_7d2dedd9-32c6-4740-8844-6a75afecd900" xlink:href="nbix-20221231.xsd#nbix_PerformanceBasedRestrictedStockUnitMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6d363347-1314-480c-92e3-18d1d013eb08" xlink:to="loc_nbix_PerformanceBasedRestrictedStockUnitMember_7d2dedd9-32c6-4740-8844-6a75afecd900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5d345085-285e-443f-9688-eadef3a0d057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2f510f0b-703d-4ba8-bfc0-9fe069eb64a0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5d345085-285e-443f-9688-eadef3a0d057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_71c7c6ab-e9aa-43cb-a7ae-e3e0b4403e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5d345085-285e-443f-9688-eadef3a0d057" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_71c7c6ab-e9aa-43cb-a7ae-e3e0b4403e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_07f52dde-bc44-40ba-a224-85985896d8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5d345085-285e-443f-9688-eadef3a0d057" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_07f52dde-bc44-40ba-a224-85985896d8cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_94db0321-89e4-4144-b7a5-7fcc6a04c77e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c67c590f-5cf3-4385-bbd6-a0bda9ffcaa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_94db0321-89e4-4144-b7a5-7fcc6a04c77e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c67c590f-5cf3-4385-bbd6-a0bda9ffcaa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_66b899f9-5632-4251-98f4-b944f29dad0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c67c590f-5cf3-4385-bbd6-a0bda9ffcaa4" xlink:to="loc_us-gaap_AwardTypeAxis_66b899f9-5632-4251-98f4-b944f29dad0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_27ea4233-d691-46aa-90e9-91390ddc56d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_66b899f9-5632-4251-98f4-b944f29dad0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_27ea4233-d691-46aa-90e9-91390ddc56d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e5536643-fd0e-4a0b-97d1-dfafee0b5605" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_27ea4233-d691-46aa-90e9-91390ddc56d7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e5536643-fd0e-4a0b-97d1-dfafee0b5605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f2e7f497-4336-4b79-962f-c4624dd8c6e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c67c590f-5cf3-4385-bbd6-a0bda9ffcaa4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f2e7f497-4336-4b79-962f-c4624dd8c6e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d8749aa6-44df-47f1-868f-86e07d9a531f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f2e7f497-4336-4b79-962f-c4624dd8c6e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d8749aa6-44df-47f1-868f-86e07d9a531f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_87836619-df7c-4bd1-9374-deb0bb3387d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f2e7f497-4336-4b79-962f-c4624dd8c6e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_87836619-df7c-4bd1-9374-deb0bb3387d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_fe1ec004-9b08-4c29-a04f-bfc46e0ea152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f2e7f497-4336-4b79-962f-c4624dd8c6e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_fe1ec004-9b08-4c29-a04f-bfc46e0ea152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_54036329-4f4d-4ce4-a4a4-2a374fc36e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f2e7f497-4336-4b79-962f-c4624dd8c6e7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_54036329-4f4d-4ce4-a4a4-2a374fc36e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8927b659-9447-48a0-ae23-a9b465227699" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dd4a443a-5341-4e11-b1a4-2a2b465ab633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8927b659-9447-48a0-ae23-a9b465227699" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dd4a443a-5341-4e11-b1a4-2a2b465ab633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_aab8784b-1b3d-430c-a778-5cbc31d14d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dd4a443a-5341-4e11-b1a4-2a2b465ab633" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_aab8784b-1b3d-430c-a778-5cbc31d14d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_551d4694-7608-4b1f-9cf4-5a1c5c1251ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dd4a443a-5341-4e11-b1a4-2a2b465ab633" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_551d4694-7608-4b1f-9cf4-5a1c5c1251ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0ac4eb68-687e-4538-9a94-28889c75f1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dd4a443a-5341-4e11-b1a4-2a2b465ab633" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0ac4eb68-687e-4538-9a94-28889c75f1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c67f45cb-b3a1-4dcc-91b9-0e6a277f6096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dd4a443a-5341-4e11-b1a4-2a2b465ab633" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c67f45cb-b3a1-4dcc-91b9-0e6a277f6096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_be71c33d-ca4d-4df8-a22c-ce13f46d1311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dd4a443a-5341-4e11-b1a4-2a2b465ab633" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_be71c33d-ca4d-4df8-a22c-ce13f46d1311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_4354a10e-03fe-4907-8466-63684e63b446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8927b659-9447-48a0-ae23-a9b465227699" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_4354a10e-03fe-4907-8466-63684e63b446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2ebeab2c-6176-4d37-87bc-df19a2b649b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8927b659-9447-48a0-ae23-a9b465227699" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2ebeab2c-6176-4d37-87bc-df19a2b649b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_459d7c3c-5e17-44a9-9594-552cc8659ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2ebeab2c-6176-4d37-87bc-df19a2b649b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_459d7c3c-5e17-44a9-9594-552cc8659ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6302bc93-9d7b-4e09-b8db-7310cdc34887" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2ebeab2c-6176-4d37-87bc-df19a2b649b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6302bc93-9d7b-4e09-b8db-7310cdc34887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4ab35a0b-6767-442f-bb0e-0b1d61eb7bef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2ebeab2c-6176-4d37-87bc-df19a2b649b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4ab35a0b-6767-442f-bb0e-0b1d61eb7bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_63ffcfb1-1496-4de1-b30c-08754e23b543" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2ebeab2c-6176-4d37-87bc-df19a2b649b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_63ffcfb1-1496-4de1-b30c-08754e23b543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7418776b-8758-4f4f-ac93-e7938849d855" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2ebeab2c-6176-4d37-87bc-df19a2b649b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7418776b-8758-4f4f-ac93-e7938849d855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_13abc4b1-5907-4739-a076-d2a0d4bb13d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8927b659-9447-48a0-ae23-a9b465227699" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_13abc4b1-5907-4739-a076-d2a0d4bb13d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b9fc1024-8422-4ada-9e26-5b0d55759da5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8927b659-9447-48a0-ae23-a9b465227699" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b9fc1024-8422-4ada-9e26-5b0d55759da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_8880efcb-2c28-4d0e-81bb-c5f67e8b7580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b9fc1024-8422-4ada-9e26-5b0d55759da5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_8880efcb-2c28-4d0e-81bb-c5f67e8b7580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_83f5d95c-67c7-4ade-8962-237e369cac34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b9fc1024-8422-4ada-9e26-5b0d55759da5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_83f5d95c-67c7-4ade-8962-237e369cac34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_e8e94fca-ff16-4428-9be4-609649c5787b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b9fc1024-8422-4ada-9e26-5b0d55759da5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_e8e94fca-ff16-4428-9be4-609649c5787b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_5e212127-815e-46b6-9563-ec1972e901e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b9fc1024-8422-4ada-9e26-5b0d55759da5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_5e212127-815e-46b6-9563-ec1972e901e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_71c0c257-945a-4128-96ce-d6547b01ddfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0e06c957-9672-4eef-b6e1-48b69d72fc21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_71c0c257-945a-4128-96ce-d6547b01ddfb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0e06c957-9672-4eef-b6e1-48b69d72fc21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6b8e1ab9-9276-4eb5-831a-8c651942b40c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0e06c957-9672-4eef-b6e1-48b69d72fc21" xlink:to="loc_us-gaap_AwardTypeAxis_6b8e1ab9-9276-4eb5-831a-8c651942b40c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_efef2a19-9a9d-460b-b00b-fd1cf7d9f8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6b8e1ab9-9276-4eb5-831a-8c651942b40c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_efef2a19-9a9d-460b-b00b-fd1cf7d9f8ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b9ad2346-6ff9-4bb9-9b7b-28fea03ad515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_efef2a19-9a9d-460b-b00b-fd1cf7d9f8ff" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b9ad2346-6ff9-4bb9-9b7b-28fea03ad515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PerformanceBasedRestrictedStockUnitMember_7b17b7ab-045b-42f1-b8cd-e8d8a1f31d8a" xlink:href="nbix-20221231.xsd#nbix_PerformanceBasedRestrictedStockUnitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_efef2a19-9a9d-460b-b00b-fd1cf7d9f8ff" xlink:to="loc_nbix_PerformanceBasedRestrictedStockUnitMember_7b17b7ab-045b-42f1-b8cd-e8d8a1f31d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b91d550-ea00-41c8-a21c-8c5bc22e899b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0e06c957-9672-4eef-b6e1-48b69d72fc21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b91d550-ea00-41c8-a21c-8c5bc22e899b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d5d9472e-0622-42e8-9ab3-8c1609a5a7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b91d550-ea00-41c8-a21c-8c5bc22e899b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d5d9472e-0622-42e8-9ab3-8c1609a5a7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_794176be-5914-4d47-95a1-03ecb12ac982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d5d9472e-0622-42e8-9ab3-8c1609a5a7b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_794176be-5914-4d47-95a1-03ecb12ac982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_51be5f7d-0c7f-4a72-bb6a-2e91693c28ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d5d9472e-0622-42e8-9ab3-8c1609a5a7b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_51be5f7d-0c7f-4a72-bb6a-2e91693c28ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f512e87d-db19-4202-80d5-a0e78f898c25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d5d9472e-0622-42e8-9ab3-8c1609a5a7b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f512e87d-db19-4202-80d5-a0e78f898c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0945a435-080a-45cf-8b78-25133802523e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d5d9472e-0622-42e8-9ab3-8c1609a5a7b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0945a435-080a-45cf-8b78-25133802523e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_967de6d4-42c1-4fb9-9724-8ccc6b9b0d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d5d9472e-0622-42e8-9ab3-8c1609a5a7b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_967de6d4-42c1-4fb9-9724-8ccc6b9b0d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_43b8d1c9-5bc7-4f2d-880d-e952ff35f446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b91d550-ea00-41c8-a21c-8c5bc22e899b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_43b8d1c9-5bc7-4f2d-880d-e952ff35f446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6df49321-dfc3-40ae-a436-39e28382dab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_43b8d1c9-5bc7-4f2d-880d-e952ff35f446" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6df49321-dfc3-40ae-a436-39e28382dab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1941a043-425e-4a42-9e7b-24b7a573c0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_43b8d1c9-5bc7-4f2d-880d-e952ff35f446" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1941a043-425e-4a42-9e7b-24b7a573c0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ed9c6fe2-7b80-40dc-89d5-603cca908b10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_43b8d1c9-5bc7-4f2d-880d-e952ff35f446" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ed9c6fe2-7b80-40dc-89d5-603cca908b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1dad7e5e-a4e7-4d53-910c-fb705871c50c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_43b8d1c9-5bc7-4f2d-880d-e952ff35f446" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1dad7e5e-a4e7-4d53-910c-fb705871c50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3755c706-e1e5-4724-b1f6-207ffcf73611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_43b8d1c9-5bc7-4f2d-880d-e952ff35f446" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3755c706-e1e5-4724-b1f6-207ffcf73611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_b8f47a97-a348-4d62-8fbc-4620fdf90571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7b91d550-ea00-41c8-a21c-8c5bc22e899b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_b8f47a97-a348-4d62-8fbc-4620fdf90571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_03453af6-b0bd-4c26-9167-ba6e494eb4db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_b8f47a97-a348-4d62-8fbc-4620fdf90571" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_03453af6-b0bd-4c26-9167-ba6e494eb4db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_27ff6d4c-2d98-407a-9264-ca40d62c09b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_b8f47a97-a348-4d62-8fbc-4620fdf90571" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_27ff6d4c-2d98-407a-9264-ca40d62c09b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesIncomeBeforetheProvisionforIncomeTaxesfromContinuingDomesticandForeignOperationsDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#IncomeTaxesIncomeBeforetheProvisionforIncomeTaxesfromContinuingDomesticandForeignOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesIncomeBeforetheProvisionforIncomeTaxesfromContinuingDomesticandForeignOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_bef00250-81d5-4ca2-819a-5e6c7f774c11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_f77ca110-8d59-4218-b754-2628540d2504" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bef00250-81d5-4ca2-819a-5e6c7f774c11" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_f77ca110-8d59-4218-b754-2628540d2504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_685d0063-6edb-467a-84e4-c8b122d3df98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bef00250-81d5-4ca2-819a-5e6c7f774c11" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_685d0063-6edb-467a-84e4-c8b122d3df98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_84650c8e-0c5a-4c5c-bdc3-3484d21a7c54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bef00250-81d5-4ca2-819a-5e6c7f774c11" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_84650c8e-0c5a-4c5c-bdc3-3484d21a7c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforBenefitfromIncomeTaxesforContinuingOperationsDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#IncomeTaxesComponentsoftheProvisionforBenefitfromIncomeTaxesforContinuingOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforBenefitfromIncomeTaxesforContinuingOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2d2c916d-59b0-4e58-8a95-694e3ab19534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_d04f817b-b7b7-4b3a-aa84-74c67fa5ae64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2d2c916d-59b0-4e58-8a95-694e3ab19534" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_d04f817b-b7b7-4b3a-aa84-74c67fa5ae64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_2a8e1f9b-2c48-4f31-ae30-69510be1076d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_d04f817b-b7b7-4b3a-aa84-74c67fa5ae64" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_2a8e1f9b-2c48-4f31-ae30-69510be1076d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_39195ab0-3d5d-4c66-8df6-531e08e9b12e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_d04f817b-b7b7-4b3a-aa84-74c67fa5ae64" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_39195ab0-3d5d-4c66-8df6-531e08e9b12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_be44de2d-c2f1-4d70-b75e-96463135da0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_d04f817b-b7b7-4b3a-aa84-74c67fa5ae64" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_be44de2d-c2f1-4d70-b75e-96463135da0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_9c29d22a-af17-4a7a-8435-fa613d6c9ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2d2c916d-59b0-4e58-8a95-694e3ab19534" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_9c29d22a-af17-4a7a-8435-fa613d6c9ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2bc488ca-e60b-4fc5-a7b3-b12b14b44266" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_9c29d22a-af17-4a7a-8435-fa613d6c9ecc" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2bc488ca-e60b-4fc5-a7b3-b12b14b44266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_32dc7edb-efe2-4ce6-8679-fa722f7a0e29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_9c29d22a-af17-4a7a-8435-fa613d6c9ecc" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_32dc7edb-efe2-4ce6-8679-fa722f7a0e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_06ac1cbb-6516-4912-b467-6548a3b41827" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_9c29d22a-af17-4a7a-8435-fa613d6c9ecc" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_06ac1cbb-6516-4912-b467-6548a3b41827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9a2c302b-1441-41fa-a11d-a14baaa39294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2d2c916d-59b0-4e58-8a95-694e3ab19534" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9a2c302b-1441-41fa-a11d-a14baaa39294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9c0becb4-5248-40a2-832d-32c336b14376" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_08b7729d-e9ad-45de-9f14-46f8fca81360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9c0becb4-5248-40a2-832d-32c336b14376" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_08b7729d-e9ad-45de-9f14-46f8fca81360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_6571d505-b5dc-4316-89bc-9f5b91ba20d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9c0becb4-5248-40a2-832d-32c336b14376" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_6571d505-b5dc-4316-89bc-9f5b91ba20d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_845fc3ae-9ce0-4a27-b3b6-be1055938b31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9c0becb4-5248-40a2-832d-32c336b14376" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_845fc3ae-9ce0-4a27-b3b6-be1055938b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee_0c324952-fcaf-48a9-a0e6-2ccc5212f615" xlink:href="nbix-20221231.xsd#nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9c0becb4-5248-40a2-832d-32c336b14376" xlink:to="loc_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee_0c324952-fcaf-48a9-a0e6-2ccc5212f615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes_6e19eb6b-d205-46e6-90e0-92be0c0dd2ae" xlink:href="nbix-20221231.xsd#nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9c0becb4-5248-40a2-832d-32c336b14376" xlink:to="loc_nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes_6e19eb6b-d205-46e6-90e0-92be0c0dd2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_85c1e35a-8193-41ee-8da4-b025dbdd8f87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9c0becb4-5248-40a2-832d-32c336b14376" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_85c1e35a-8193-41ee-8da4-b025dbdd8f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost_8e0f7188-244a-4f0a-8a52-60626b331030" xlink:href="nbix-20221231.xsd#nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9c0becb4-5248-40a2-832d-32c336b14376" xlink:to="loc_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost_8e0f7188-244a-4f0a-8a52-60626b331030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_85312964-6af5-4941-8e4e-77e3129fd778" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9c0becb4-5248-40a2-832d-32c336b14376" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_85312964-6af5-4941-8e4e-77e3129fd778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxReconciliationExpirationOfTaxCredits_b4a7a370-605a-4155-87c8-5908686954e3" xlink:href="nbix-20221231.xsd#nbix_IncomeTaxReconciliationExpirationOfTaxCredits"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9c0becb4-5248-40a2-832d-32c336b14376" xlink:to="loc_nbix_IncomeTaxReconciliationExpirationOfTaxCredits_b4a7a370-605a-4155-87c8-5908686954e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_9294d4cc-06bb-42a0-ba2d-c812cc185235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9c0becb4-5248-40a2-832d-32c336b14376" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_9294d4cc-06bb-42a0-ba2d-c812cc185235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_d5b5672f-a162-4cc9-80d8-798b20b2a2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9c0becb4-5248-40a2-832d-32c336b14376" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_d5b5672f-a162-4cc9-80d8-798b20b2a2ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_68b7e95b-cc35-4736-8f25-91c5b616e410" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9c0becb4-5248-40a2-832d-32c336b14376" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_68b7e95b-cc35-4736-8f25-91c5b616e410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3b37a64f-5d44-4653-b017-7489e14abf57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9c0becb4-5248-40a2-832d-32c336b14376" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3b37a64f-5d44-4653-b017-7489e14abf57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#IncomeTaxesComponentsofDeferredTaxAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5e8e10b1-6576-4b37-9861-474532eb9fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_38282477-2a64-4941-b056-f0609af63687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5e8e10b1-6576-4b37-9861-474532eb9fa5" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_38282477-2a64-4941-b056-f0609af63687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_39e8ceef-be86-4173-a8b7-fd540f8f3313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_38282477-2a64-4941-b056-f0609af63687" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_39e8ceef-be86-4173-a8b7-fd540f8f3313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_31d0f1f1-2a47-4ea4-a86a-8406c5b0683d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_38282477-2a64-4941-b056-f0609af63687" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_31d0f1f1-2a47-4ea4-a86a-8406c5b0683d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment_a5d86bad-e60f-4519-b294-70294bc51ed7" xlink:href="nbix-20221231.xsd#nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_38282477-2a64-4941-b056-f0609af63687" xlink:to="loc_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment_a5d86bad-e60f-4519-b294-70294bc51ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_d6d6d194-9031-4449-b65c-c69501fe00b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_38282477-2a64-4941-b056-f0609af63687" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_d6d6d194-9031-4449-b65c-c69501fe00b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxAssetsOperatingLeasesAssets_f36d8d53-db93-4acd-8e88-78bc02110cbd" xlink:href="nbix-20221231.xsd#nbix_DeferredTaxAssetsOperatingLeasesAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_38282477-2a64-4941-b056-f0609af63687" xlink:to="loc_nbix_DeferredTaxAssetsOperatingLeasesAssets_f36d8d53-db93-4acd-8e88-78bc02110cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_c5726aba-ea3b-4ce3-bb79-d47629692922" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_38282477-2a64-4941-b056-f0609af63687" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_c5726aba-ea3b-4ce3-bb79-d47629692922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_ab83730d-12cc-4e1d-9edc-d8a2edcc5127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_38282477-2a64-4941-b056-f0609af63687" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_ab83730d-12cc-4e1d-9edc-d8a2edcc5127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_074b6bc7-1911-48f0-b5f6-78efdf776704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_38282477-2a64-4941-b056-f0609af63687" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_074b6bc7-1911-48f0-b5f6-78efdf776704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_5fcafaf6-ba05-46ec-b50c-dbd117573d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5e8e10b1-6576-4b37-9861-474532eb9fa5" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_5fcafaf6-ba05-46ec-b50c-dbd117573d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes_b75e360a-d370-4760-8af4-00648def274e" xlink:href="nbix-20221231.xsd#nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_5fcafaf6-ba05-46ec-b50c-dbd117573d7e" xlink:to="loc_nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes_b75e360a-d370-4760-8af4-00648def274e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities_c63a6baf-264b-4f87-b77e-f5c7b713fdb4" xlink:href="nbix-20221231.xsd#nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_5fcafaf6-ba05-46ec-b50c-dbd117573d7e" xlink:to="loc_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities_c63a6baf-264b-4f87-b77e-f5c7b713fdb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_7973a49e-511f-4f14-a264-0577cd85a766" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_5fcafaf6-ba05-46ec-b50c-dbd117573d7e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_7973a49e-511f-4f14-a264-0577cd85a766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_83475601-8c1a-4b44-8922-45ddfa442c59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_5fcafaf6-ba05-46ec-b50c-dbd117573d7e" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_83475601-8c1a-4b44-8922-45ddfa442c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxAssetsLiabilitiesGross_393cc068-402a-4e8b-921b-e5eaa89ee703" xlink:href="nbix-20221231.xsd#nbix_DeferredTaxAssetsLiabilitiesGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5e8e10b1-6576-4b37-9861-474532eb9fa5" xlink:to="loc_nbix_DeferredTaxAssetsLiabilitiesGross_393cc068-402a-4e8b-921b-e5eaa89ee703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b6f92376-0d4f-4827-9d42-b8a2a84e2d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5e8e10b1-6576-4b37-9861-474532eb9fa5" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b6f92376-0d4f-4827-9d42-b8a2a84e2d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_e721301b-d417-418a-a79d-4d45d22b8e19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5e8e10b1-6576-4b37-9861-474532eb9fa5" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_e721301b-d417-418a-a79d-4d45d22b8e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c1a641ca-48b0-4643-b798-b47fbe22e9c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxesTable_357117be-fa7b-4cec-8a98-dad6e45ec502" xlink:href="nbix-20221231.xsd#nbix_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c1a641ca-48b0-4643-b798-b47fbe22e9c3" xlink:to="loc_nbix_IncomeTaxesTable_357117be-fa7b-4cec-8a98-dad6e45ec502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_931ff5d3-9e5e-400d-a4fc-6320ab717847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_IncomeTaxesTable_357117be-fa7b-4cec-8a98-dad6e45ec502" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_931ff5d3-9e5e-400d-a4fc-6320ab717847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_c48acc26-7320-4e7e-85eb-4d64bd2c6ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_931ff5d3-9e5e-400d-a4fc-6320ab717847" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_c48acc26-7320-4e7e-85eb-4d64bd2c6ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_e0b8ba1b-9f83-458c-bd3b-73732c2a8772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c48acc26-7320-4e7e-85eb-4d64bd2c6ff8" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_e0b8ba1b-9f83-458c-bd3b-73732c2a8772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_fda7a951-4405-47fa-8416-ffab2579c598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c48acc26-7320-4e7e-85eb-4d64bd2c6ff8" xlink:to="loc_us-gaap_ForeignCountryMember_fda7a951-4405-47fa-8416-ffab2579c598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_2ae8b7d2-d407-436a-93d3-dbd8820362bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c48acc26-7320-4e7e-85eb-4d64bd2c6ff8" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_2ae8b7d2-d407-436a-93d3-dbd8820362bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxesLineItems_1504b3ca-1ba0-4b93-8629-1a738b57248f" xlink:href="nbix-20221231.xsd#nbix_IncomeTaxesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_IncomeTaxesTable_357117be-fa7b-4cec-8a98-dad6e45ec502" xlink:to="loc_nbix_IncomeTaxesLineItems_1504b3ca-1ba0-4b93-8629-1a738b57248f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_0505a608-10fd-4b7b-9bff-a3255d2b1d07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_IncomeTaxesLineItems_1504b3ca-1ba0-4b93-8629-1a738b57248f" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_0505a608-10fd-4b7b-9bff-a3255d2b1d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_bf1f1fbb-8f9d-4884-b3b8-6b34528c309e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_IncomeTaxesLineItems_1504b3ca-1ba0-4b93-8629-1a738b57248f" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_bf1f1fbb-8f9d-4884-b3b8-6b34528c309e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_d17afab6-b6a2-4227-a162-1efc16e03a49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_IncomeTaxesLineItems_1504b3ca-1ba0-4b93-8629-1a738b57248f" xlink:to="loc_us-gaap_OperatingLossCarryforwards_d17afab6-b6a2-4227-a162-1efc16e03a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_a54a50b0-064f-42e8-a0a2-0b8fc38521f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_IncomeTaxesLineItems_1504b3ca-1ba0-4b93-8629-1a738b57248f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_a54a50b0-064f-42e8-a0a2-0b8fc38521f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationInterestAccrued_f07dc7f8-eab9-46a0-ac28-4b68b44f850e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationInterestAccrued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_IncomeTaxesLineItems_1504b3ca-1ba0-4b93-8629-1a738b57248f" xlink:to="loc_us-gaap_IncomeTaxExaminationInterestAccrued_f07dc7f8-eab9-46a0-ac28-4b68b44f850e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAccrued_a0f2338d-3735-4e38-bf1d-4defb811204a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAccrued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_IncomeTaxesLineItems_1504b3ca-1ba0-4b93-8629-1a738b57248f" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAccrued_a0f2338d-3735-4e38-bf1d-4defb811204a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_de19e6bf-7a90-4c8b-9b84-af65e319489c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_IncomeTaxesLineItems_1504b3ca-1ba0-4b93-8629-1a738b57248f" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_de19e6bf-7a90-4c8b-9b84-af65e319489c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8b9589ef-9a95-4344-93c5-dd07969de5f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_504d7412-410a-4ea6-87e7-33e51fb63ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8b9589ef-9a95-4344-93c5-dd07969de5f0" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_504d7412-410a-4ea6-87e7-33e51fb63ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_ea6ff868-069e-4989-a30b-13f7811eee56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_504d7412-410a-4ea6-87e7-33e51fb63ecd" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_ea6ff868-069e-4989-a30b-13f7811eee56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_39a7d7d4-1223-4bd1-959b-eb45804723d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_504d7412-410a-4ea6-87e7-33e51fb63ecd" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_39a7d7d4-1223-4bd1-959b-eb45804723d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_8d5e2e5f-bb4a-42da-bb21-e724218333aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_504d7412-410a-4ea6-87e7-33e51fb63ecd" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_8d5e2e5f-bb4a-42da-bb21-e724218333aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_038b6753-94eb-4455-bb0d-252c87eeb585" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_504d7412-410a-4ea6-87e7-33e51fb63ecd" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_038b6753-94eb-4455-bb0d-252c87eeb585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_f243ac42-e1ad-49ff-8997-4fcaeb2a6379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_504d7412-410a-4ea6-87e7-33e51fb63ecd" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_f243ac42-e1ad-49ff-8997-4fcaeb2a6379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_c5fb61d6-1fa0-42cc-9c27-4701476eae0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_504d7412-410a-4ea6-87e7-33e51fb63ecd" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_c5fb61d6-1fa0-42cc-9c27-4701476eae0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_a78687e9-3bb4-406a-9ba2-2fa9edb049d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_504d7412-410a-4ea6-87e7-33e51fb63ecd" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_a78687e9-3bb4-406a-9ba2-2fa9edb049d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesNarrativeInformationDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#LeasesNarrativeInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LeasesNarrativeInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c6d75770-37cf-4378-9634-73d4cc4a56a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding_8b9d5dec-18b4-4e5b-9644-3872d75002f1" xlink:href="nbix-20221231.xsd#nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c6d75770-37cf-4378-9634-73d4cc4a56a2" xlink:to="loc_nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding_8b9d5dec-18b4-4e5b-9644-3872d75002f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_RentAbatementPeriod_7ee065a9-77fc-45a8-ad0d-d25cffe8d87e" xlink:href="nbix-20221231.xsd#nbix_RentAbatementPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c6d75770-37cf-4378-9634-73d4cc4a56a2" xlink:to="loc_nbix_RentAbatementPeriod_7ee065a9-77fc-45a8-ad0d-d25cffe8d87e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot_2856fb19-ea52-4352-a72b-8312c70f00e2" xlink:href="nbix-20221231.xsd#nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c6d75770-37cf-4378-9634-73d4cc4a56a2" xlink:to="loc_nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot_2856fb19-ea52-4352-a72b-8312c70f00e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AnnualRentEscalationPercentage_53afe6d8-4ba4-4d1d-bf8b-7f6602279825" xlink:href="nbix-20221231.xsd#nbix_AnnualRentEscalationPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c6d75770-37cf-4378-9634-73d4cc4a56a2" xlink:to="loc_nbix_AnnualRentEscalationPercentage_53afe6d8-4ba4-4d1d-bf8b-7f6602279825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_161f3040-c653-4b6a-9f11-f002cdd0aea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c6d75770-37cf-4378-9634-73d4cc4a56a2" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_161f3040-c653-4b6a-9f11-f002cdd0aea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NumberOfRenewalOptions_0c8580ee-7a99-46fa-a8d6-aad65e0c761f" xlink:href="nbix-20221231.xsd#nbix_NumberOfRenewalOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c6d75770-37cf-4378-9634-73d4cc4a56a2" xlink:to="loc_nbix_NumberOfRenewalOptions_0c8580ee-7a99-46fa-a8d6-aad65e0c761f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_f7b85fea-9b57-4d9b-bc17-ad1d8c6ba95e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c6d75770-37cf-4378-9634-73d4cc4a56a2" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_f7b85fea-9b57-4d9b-bc17-ad1d8c6ba95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesSupplementalInformationDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#LeasesSupplementalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LeasesSupplementalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_553c4042-cca7-4f56-95f9-79893f89e2f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_917ebb57-d32b-486b-9f7a-7134937a94ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_553c4042-cca7-4f56-95f9-79893f89e2f6" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_917ebb57-d32b-486b-9f7a-7134937a94ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_dfec4952-a871-428c-939a-1113d3ed2850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_917ebb57-d32b-486b-9f7a-7134937a94ae" xlink:to="loc_us-gaap_CreditFacilityAxis_dfec4952-a871-428c-939a-1113d3ed2850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_d5045ae1-05b5-4ebd-a3e2-f7bb6791f082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_dfec4952-a871-428c-939a-1113d3ed2850" xlink:to="loc_us-gaap_CreditFacilityDomain_d5045ae1-05b5-4ebd-a3e2-f7bb6791f082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_22d92369-38f5-4cca-944c-2b31f0a76577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_d5045ae1-05b5-4ebd-a3e2-f7bb6791f082" xlink:to="loc_us-gaap_LetterOfCreditMember_22d92369-38f5-4cca-944c-2b31f0a76577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_ce4c07c2-f0ab-444c-9835-f4f460cdd9df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_917ebb57-d32b-486b-9f7a-7134937a94ae" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_ce4c07c2-f0ab-444c-9835-f4f460cdd9df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_c142f1f0-3c0d-4254-98a9-ec73cbddf2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ce4c07c2-f0ab-444c-9835-f4f460cdd9df" xlink:to="loc_us-gaap_OperatingLeaseCost_c142f1f0-3c0d-4254-98a9-ec73cbddf2eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_eb5460f6-92ab-4644-89cb-d9e6338569f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ce4c07c2-f0ab-444c-9835-f4f460cdd9df" xlink:to="loc_us-gaap_OperatingLeasePayments_eb5460f6-92ab-4644-89cb-d9e6338569f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c827e8d1-1231-4def-8833-56af8ce88002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ce4c07c2-f0ab-444c-9835-f4f460cdd9df" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c827e8d1-1231-4def-8833-56af8ce88002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_eccd1989-81ba-4e46-97df-3240b0182f27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ce4c07c2-f0ab-444c-9835-f4f460cdd9df" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_eccd1989-81ba-4e46-97df-3240b0182f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_f50a2c52-b378-4aa3-a5df-781d6c549472" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_ce4c07c2-f0ab-444c-9835-f4f460cdd9df" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_f50a2c52-b378-4aa3-a5df-781d6c549472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b1b0fe0c-60c8-4d39-b0a8-03d9c26712bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_75e0cd21-7d15-458e-8abb-92be10952d22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b1b0fe0c-60c8-4d39-b0a8-03d9c26712bd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_75e0cd21-7d15-458e-8abb-92be10952d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9fd16af6-eb92-439b-96f4-5c7c5af6b008" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b1b0fe0c-60c8-4d39-b0a8-03d9c26712bd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9fd16af6-eb92-439b-96f4-5c7c5af6b008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_bcaa4223-b6ac-4d9d-9766-57c424f6026b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b1b0fe0c-60c8-4d39-b0a8-03d9c26712bd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_bcaa4223-b6ac-4d9d-9766-57c424f6026b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7f0792e8-7e22-4991-938c-1a174d6d222f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b1b0fe0c-60c8-4d39-b0a8-03d9c26712bd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7f0792e8-7e22-4991-938c-1a174d6d222f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6a4eb07a-49fd-44ba-b274-5faf9d262a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b1b0fe0c-60c8-4d39-b0a8-03d9c26712bd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6a4eb07a-49fd-44ba-b274-5faf9d262a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2fc2a5b4-e7a9-4606-9d2e-325d7bae170c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b1b0fe0c-60c8-4d39-b0a8-03d9c26712bd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2fc2a5b4-e7a9-4606-9d2e-325d7bae170c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_75e8a94f-03d6-4f6e-b7a0-f382e75d34cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b1b0fe0c-60c8-4d39-b0a8-03d9c26712bd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_75e8a94f-03d6-4f6e-b7a0-f382e75d34cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e4374383-239a-4a94-9d48-1c71de16853b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b1b0fe0c-60c8-4d39-b0a8-03d9c26712bd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e4374383-239a-4a94-9d48-1c71de16853b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_816a1ca8-1244-4b10-957a-fc64d37f4df5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b1b0fe0c-60c8-4d39-b0a8-03d9c26712bd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_816a1ca8-1244-4b10-957a-fc64d37f4df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_685327fc-4d2e-4626-86e9-9d1f63e14f17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b1b0fe0c-60c8-4d39-b0a8-03d9c26712bd" xlink:to="loc_us-gaap_OperatingLeaseLiability_685327fc-4d2e-4626-86e9-9d1f63e14f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c56ceb37-921b-44d2-a755-3f0b57803f70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b1b0fe0c-60c8-4d39-b0a8-03d9c26712bd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c56ceb37-921b-44d2-a755-3f0b57803f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ee43e522-aa64-43a0-8b4f-ab16540fff50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b1b0fe0c-60c8-4d39-b0a8-03d9c26712bd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ee43e522-aa64-43a0-8b4f-ab16540fff50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo_0bb248cf-54d2-4fe4-a856-dcb5bc1797c4" xlink:href="nbix-20221231.xsd#nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b1b0fe0c-60c8-4d39-b0a8-03d9c26712bd" xlink:to="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo_0bb248cf-54d2-4fe4-a856-dcb5bc1797c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree_5ab88ed6-a993-4174-8d66-b5b644e9c0e4" xlink:href="nbix-20221231.xsd#nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b1b0fe0c-60c8-4d39-b0a8-03d9c26712bd" xlink:to="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree_5ab88ed6-a993-4174-8d66-b5b644e9c0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour_5c79211a-ad36-4489-9bab-3c77782d640d" xlink:href="nbix-20221231.xsd#nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b1b0fe0c-60c8-4d39-b0a8-03d9c26712bd" xlink:to="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour_5c79211a-ad36-4489-9bab-3c77782d640d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive_1f61a357-e7da-4abb-aa6c-a4edb833aa97" xlink:href="nbix-20221231.xsd#nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b1b0fe0c-60c8-4d39-b0a8-03d9c26712bd" xlink:to="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive_1f61a357-e7da-4abb-aa6c-a4edb833aa97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="nbix-20221231.xsd#LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/RetirementPlanAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#RetirementPlanAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/RetirementPlanAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_7f42c4d5-1959-44b0-8044-5b6e6727a0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_87d77b88-c4a4-466f-bd2c-79dde450e454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_7f42c4d5-1959-44b0-8044-5b6e6727a0a7" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_87d77b88-c4a4-466f-bd2c-79dde450e454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_b5b3751f-adfa-4dd7-a03a-7739e451436a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_7f42c4d5-1959-44b0-8044-5b6e6727a0a7" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_b5b3751f-adfa-4dd7-a03a-7739e451436a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="nbix-20221231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_9b5c8d00-8d99-4412-8334-c7a68eb6b9db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_70f931d6-2e70-4590-82bb-e9ed74eb5f39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_9b5c8d00-8d99-4412-8334-c7a68eb6b9db" xlink:to="loc_us-gaap_SubsequentEventTable_70f931d6-2e70-4590-82bb-e9ed74eb5f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_888127ae-4f0d-4253-8ff7-d61f6426008b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_70f931d6-2e70-4590-82bb-e9ed74eb5f39" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_888127ae-4f0d-4253-8ff7-d61f6426008b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_401be2f0-4570-443f-9552-c680642a4a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_888127ae-4f0d-4253-8ff7-d61f6426008b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_401be2f0-4570-443f-9552-c680642a4a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_238519d7-b698-4576-b459-4dd7ab57c817" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_401be2f0-4570-443f-9552-c680642a4a2e" xlink:to="loc_us-gaap_SubsequentEventMember_238519d7-b698-4576-b459-4dd7ab57c817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b9b78731-ce9e-47fb-b548-0aaf3526f035" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_70f931d6-2e70-4590-82bb-e9ed74eb5f39" xlink:to="loc_srt_CounterpartyNameAxis_b9b78731-ce9e-47fb-b548-0aaf3526f035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ca2fbd3f-42c2-4486-8ef7-15369f10d85c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_b9b78731-ce9e-47fb-b548-0aaf3526f035" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ca2fbd3f-42c2-4486-8ef7-15369f10d85c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_VoyagerTherapeuticsMember_06209bef-eaa0-4b45-a6bd-547f73b80cac" xlink:href="nbix-20221231.xsd#nbix_VoyagerTherapeuticsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ca2fbd3f-42c2-4486-8ef7-15369f10d85c" xlink:to="loc_nbix_VoyagerTherapeuticsMember_06209bef-eaa0-4b45-a6bd-547f73b80cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5468ef47-4f30-47de-aae2-299ab4f7a155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_70f931d6-2e70-4590-82bb-e9ed74eb5f39" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5468ef47-4f30-47de-aae2-299ab4f7a155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d0849ced-ecf2-4d04-9104-205dbd9bb0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5468ef47-4f30-47de-aae2-299ab4f7a155" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d0849ced-ecf2-4d04-9104-205dbd9bb0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_87cb64c4-c2ed-4505-89c2-2077e5427790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d0849ced-ecf2-4d04-9104-205dbd9bb0fd" xlink:to="loc_us-gaap_CollaborativeArrangementMember_87cb64c4-c2ed-4505-89c2-2077e5427790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_4c9d027b-631e-4633-9411-df1d5ee6b9dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_70f931d6-2e70-4590-82bb-e9ed74eb5f39" xlink:to="loc_us-gaap_SubsequentEventLineItems_4c9d027b-631e-4633-9411-df1d5ee6b9dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_UpfrontPaymentsMade_c880b387-abb3-427d-ab87-3a4cab07ab3a" xlink:href="nbix-20221231.xsd#nbix_UpfrontPaymentsMade"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_4c9d027b-631e-4633-9411-df1d5ee6b9dd" xlink:to="loc_nbix_UpfrontPaymentsMade_c880b387-abb3-427d-ab87-3a4cab07ab3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BusinessAcquisitionEquityInvestmentToAcquireTheWorldwideRights_76195111-645d-4902-ab7a-285f806627fb" xlink:href="nbix-20221231.xsd#nbix_BusinessAcquisitionEquityInvestmentToAcquireTheWorldwideRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_4c9d027b-631e-4633-9411-df1d5ee6b9dd" xlink:to="loc_nbix_BusinessAcquisitionEquityInvestmentToAcquireTheWorldwideRights_76195111-645d-4902-ab7a-285f806627fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>nbix-20221231_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nbix-20221231_g1.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ;2"64# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **KW[7"V<S6BHUR%/EB3.TMVSBOA;XK_MO?%?X8^,+[1KCP_P"&52%R(WEM
M+DEU'?(N!FJ47+8^ER3A_&<05)4L%R\T5>S=ON/O&BOS=_X>1_$S_H!^$_\
MP$N?_DBE_P"'D7Q+_P"@'X4_\!+G_P"2*?*S[#_B&G$'\L/_  )'Z0T5^;X_
MX*0_$L_\P/PI_P" ES_\D4O_  \@^)?_ $ _"G_@)<__ "12Y6'_ !#/B#^6
M'_@2/T?HK\X1_P %(/B7_P! /PI_X"7/_P D4O\ P\>^)?\ T _"G_@)<_\
MR14C_P"(9\0?RP_\"1^CM%?G(O\ P4<^)1_Y@GA7_P !+G_Y(K['_9[^-UO\
M;/!J:F?)AU&(B.Y@A!50^.=H+$X_&E<\'.>#<WR+#_6L7!<E[73O;U/5****
M9\.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% &+I?_(QZY_VP_P#0#6U6+I?_ ",>N?\
M;#_T UM4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHHHH *_(#_@KW?W=KXVTT07<\*^6ORQR%0>?:OU_K\>O^"P7_([:=_US7^=
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M[_H7+W_ORW^%'_#/?C[_ *%R]_[\M_A0!Q']O:G_ -!&[_[_ +?XT?V]J?\
MT$;O_O\ M_C7;_\ #/?C[_H7+W_ORW^%!_9\\??]"Y>_]^6_PH _4/\ X)!W
M=Q=>"]2,]S-<'S&_UKENWO7Z05^>O_!*'P/KW@WPCJ,6M:?)8LTC;1(A4GCW
MK]"J "OP)_X*,ZI?6_[1FJK%>W$:Y?"K*P ^;V-?OM7X8_\ !0+X/>,/$G[0
M.IW>GZ)=75L[/MDCB8C[WTH ^,_[>U/_ *"-W_W_ &_QH_M[4_\ H(W?_?\
M;_&NW_X9[\??]"Y>_P#?EO\ "C_AGOQ]_P!"Y>_]^6_PH XC^WM3_P"@C=_]
M_P!O\:/[>U/_ *"-W_W_ &_QKM_^&>_'W_0N7O\ WY;_  H_X9[\??\ 0N7O
M_?EO\* .(_M[4_\ H(W?_?\ ;_&C^WM3_P"@C=_]_P!O\:[@?L]^/F.!X<OL
M_P#7%O\ "N:\5> =<\%2)'K-C)9.PR%E4J?UH S/[>U/_H(W?_?]O\:^D/V
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/3Z22,QR%6&"#14L^U/KK]B'X^/X<UX>#M9N,Z5>C;$\I^6+ Z?C5O\ ;9^
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M#(-?M61YG',\*IOXUH_7O\S^2N)LEEDF/E22]R6L7Y=OD.HHHKZ$^2"BBB@
MHHHH **** "OB;_@J_\ \FWW'_7S'7VS7Q-_P5?_ .3;[C_KYCH _#!OO&O4
M?V6_^3BOAU_V&[;_ -#%>7-]XUZC^RW_ ,G%?#K_ +#=M_Z&* /Z5Z*** ,K
MQ3_R+>I?]<'_ )5_.)^U-_R7+Q5_U]M_.OZ._%/_ "+>I?\ 7!_Y5_.)^U-_
MR7+Q5_U]M_.@#R>BA?O"OK;Q)^R%-K'[+=G\4- MY+FZBN!#=11\A8PN2V*
M/F;P3XPU'P'XFL=:TNX>VNK657#(>H!!(K^@_P#8]_:4TS]HKX7Z?J,4JKJD
M,02X@S\PQQDU_.G7T3^Q7^T[J/[.?Q4L+MKAO[!NI52]B+'&S/4#M0!_0_16
M%X)\9:=X^\,:?KFERK-9WD2RIM.<9&<&MV@ K\>O^"P7_([:=_US7^=?L+7X
M]?\ !8+_ )';3O\ KFO\Z /S<K].O^"+/_(X>+O^O,?^A5^8M?IU_P $6?\
MD</%W_7F/_0J /UNHHHH \S_ &B?BI;_  @^%&NZ_)<"VNHK9_LS'O(!Q7\Z
M/Q6^(NJ_%+QQJFOZM=/=7%U,SAF/0$]J_5C_ (*_?%G^R_!.G>$HI?+EDE$K
MA3R0RU^/- !7OG[)_P"R9XB_::\7I9V,;V^E0D//=[<KM!Y%>,^$_#=YXO\
M$-CI%A&9;JZD"(JC)ZU_1+^R/\ ])^ ?PAT?2;&W1;N>%+BXE*C?O902,^E
M''_!G_@GS\*OA3I5NK:##J.J* 9+J3/S,.^*^C-*\/Z=HEJEM96<-O"@P%1
M*T:* (_)C_YYK_WR*/L\7_/-/^^14E% '.>)?AWX=\71LFK:5;W:L,'<@R:\
M/\;?L _"/Q9J>GZC%X>AL+ZSN5N%DC)Y93D5])T4 4M'TR+1=+MK&'B*! B_
M05=HHH \N_:<_P"2%>,_^P;/_P"@&OYJ*_I7_:<_Y(5XS_[!L_\ Z :_FHH
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M1PC_ &% JQ110 50N-#T^ZD,DUG#(_\ >9 35^B@#,_X1G2O^@?;_P#?I?\
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MU=8UZ-EUO5/WL^_KU./TKZ-ID4*01K'&@1%& JC %/H **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&N>GM7RY7](?[5'P"TGX_P#PMU/1;^W1[E8C)!(1R"H) !^M?SN>/?!U_P"
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MOZ D18U55 55& !V%?B7_P $C?\ DN4W /W>WL:_;:@ HHHH **** "BBB@
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M$]"L='TNW6UT^RB$,$*]%4=!0!I4444 ?D%_P6<_Y'SPO_UZM_.OS4K]*_\
M@LY_R/GA?_KU;^=?FI0!]B_\$R_BMX=^$WQFO-3\1W?V2S:T*!_?-?J^?V[?
MA$/^9@'_ 'R/\:_G<61HSE6*GV.*?]IF_P">K_\ ?1H _H?_ .&[OA%_T, _
M[Y'^-'_#=WPB_P"A@'_?(_QK^>#[3-_SU?\ [Z-'VF;_ )ZO_P!]&@#^A_\
MX;N^$7_0P#_OD?XTJ_MV?"-W51KXRQP/E'^-?SO_ &F;_GJ__?1J>QFEDO8%
M,LF"X_B/K0!_4+X5\5:?XRT>'4]+F\^TF 9']0:V*\%_8G&/@'X>Y)_<)U.?
MX17O5 !1110 4444 -DD6&-I)&"(H+,S'  '4U^1O_!4#]N!O$5_=?##P??L
M+" F/4YH6.R7."!D=:^@/^"DG[:R_![PG/X-\*WRKXEOT*22QG)C0Y#+CZ&O
MQ0NKJ6^N9+B>1I9I&+,['))- $5?27[$G[+.K?M%?$RR46S#1+*42W$[#"_*
M0<9KR/X/?"O5OC#XZTWPYI%N\\MS*J.R#.Q2<9-?T'_LM_L^Z5^SQ\,['0K*
MW1+Z1%>\E Y>0"@#TWPKX9L?!^@6>DZ; EM:6T818XQ@<#DUK444 %%%% !1
M110 5'//':PO+*ZQQ(-S.QP /6I*^!/^"E/[:MO\)/#<O@GPW>*_B.^CQ+Y;
M<QQL"#F@#P+_ (*9?MT2^(-5N?AQX,O-ME 3'?W43$$L", $=:_-!F+L68Y8
MG))[U-?7T^I7<MU<RM-/*Q9Y'.22:[WX$_!?6OCG\0-.\.:1;R.LTJK/,HR(
ME)ZF@#V;]@W]D74?VC/B):7=["\7ABPD$D\^.'92#L^AK]ZO#'AO3_"&@V>D
M:7;1VEC:QB..&,84 5P'[.?P*T;X _#C3_#VEVZ),L:FZE4<R28P37J= !11
M10 4444 1SS+;PR2N=J(I8D^@%?A#_P4W^.$GQ0^.5WHT4OG:=HSE864Y&2.
M<5^O?[77Q>MO@K\#]>UZX8*7B:VC.<89U(!K^<W7M9NO$&L7>H7LS7%S<2,[
M2-U.30!0K]??^"0_P(;0?"NH>--1MP9[QU>TD8<A"N.*_*CX:^$9?'7CK1=#
MBC:3[;=)"VT=%)P37]'_ , ?AW;_  M^$_A[P];J MI;*AP,=J .^NK>.\MY
M(94#QR*596'!!K^>G]O3X)M\$OV@-9L%#>1J#-?H2.!O8G K^ANOSW_X*V?
ME/&/PSM?%NF67F:O92CSYE&3Y*@DT ?B_7ZS_P#!(?\ :!&H:9?> +^;+VJ^
M9"TC<G<W05^3%>M?LM_%6;X1?&;P[K8N#!9K<J+GG *>] '])U%8?@GQ+;^,
M/"NEZQ:N)(;R!)E(.>HS6Y0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!BZ7_ ,C'KG_;#_T UM5BZ7_R,>N?]L/_ $ UM4 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7_?IO\*/^&,_BA_T+UU_WZ;_  K^BO\ LNS_ .?:+_OD4?V79_\ /M%_WR*
M/YU/^&,_BA_T+UU_WZ;_  J6T_8W^*,=W"1X?N1\P.?);U^E?T3?V79_\^T7
M_?(H_LNS_P"?:+_OD4 >2?LE^&]0\)_!?0].U.(PW<4**Z,,8(6O9J:D:QJ%
M50H]!3J "BBB@ KYM_;,_:[T3]FGP3=;Y/-\07,16UA4@E6(X)'I7L'Q8^*6
MB_!_P7J'B/7+E(+6UC+8)Y8]L"OY]/VLOVB-2_:*^*FH:]=2L+)6\JWAW?*%
M4D _E0!Y[\3/B-J_Q3\8:AXAUFX>>[NY6DPS$A,GH/:L/1=&O/$&J6VG6$#W
M-Y<.$CBC&2Q/M5( L0 ,DU^H?_!+7]BW^TKB'XG>++#$"$/ID4R?>/0D@]*
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M9_.O$?VHOVL/AK%\*M<T^W\26-]>30LBQ6\ZL<X/O0!^">J_\A2\_P"NS_\
MH1K>^%O_ "4GPO\ ]A*W_P#1@KGM0D$U_<R+]UI68?B370_"W_DI/A?_ +"5
MO_Z,% ']+_P^_P"1*T?_ *]UKH:Y[X??\B5H_P#U[K70T >7?M.?\D*\9_\
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M&,L>YKT;_A<7@O\ Z&33_P#O^M '9T5QG_"XO!?_ $,FG_\ ?]:/^%Q>"_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8NE_\C'KG_;#_P!
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !7S?\ MG?')/AKX%?2;&8?VMJ:M$I0_-%WS7N'CSQA9> _"M]K5_*(
M8+="=S' W8X'YU^0OQC^)5_\4O'&H:U>RL_F/A%S\H4<# K6G'F=S]5X X;_
M +9QWUJNOW-+5^;Z+]6<9=W4EY<233.9)'8LS'J23DFH:**Z#^NR:"%IY510
M69C@!1DU^CG[(/PAM/A+X$N?&FNQ+#?20M*)'P"(MN<5\X?L=? V3XC>-(=3
MO;9O[,L7$FYA\KD'I7KG[<GQP@TS3X/ >@W"HBA3,T!^Z!P5-82U=C\@XKQE
M;.\;3X9P+^+6K+M'L?.G[2WQBN/B]\0[R[$QDTRV=H[-<\*G%>1T@.<TM(_4
ML%@Z.7X:GA:"M""LOZ\Q5KUO]G/X07/Q8\>65F8F_LZ-PUQ,!POH*\U\/:+<
MZ_JUM96L;233.J*%&>I K],/AGX9TG]F/X+RZQJ**M\T(:7H&9NU9L^0XOSZ
M63X-4,-KB*WNP777K_D<Y^UQ\7+7X3?#R'P=HDBI?7$(@D6/@HFWK7YX^<T\
MS2.Q9F.26.370_$SQY??$3QA?ZO>RM(TKD)D]%R<5S</:N6ML=G"^0QR'+U1
MEK4E[TWW;_R+L-:=C;O=3)&B%V8X"KU-9D-?3O[(/P8;QMXFCUF]B#:=:-N4
MD<,P->).FZDU!=3T<VS*CE.#GC*[]V*^]]$>_?LO_#"U^%G@&;Q/JZJEW-%Y
MZO)P47;]VOE;XY?%*Y^)WC:[O#(?L*,5@BSPH[XKW+]L3XSI%"G@S1I1' F/
M/\HXP0>G%?(<9+-DUY^95E&*PU/9;^I^;\)Y=7Q56IQ!CU^]J_"OY8_\'^MR
MY#U%7(>U4X>M;?A_2Y=8U*WMH8VE>1PH"]>HKXFM=Z(_19M13E+9'IOP'^&$
MOQ!\5VT<D1:PB<-.2.,5]'_M'?$B'P%X1A\,:5*$N9(Q$RJ>D>,5O>$])TWX
M!?"I[VXV)>>5O.[[SD\X_6OBWQEXJN?&'B"[U&YD:0RN2FX]%SP*]7%R628#
MV,?XU7?R1^-X9/BW.'BYK_9J#M%?S2[F6K;B35J&JD=6X><5^38@_5)&C86S
MW5PD4:[F8@!?6OM;]G[X;IX1\.K>3Q_Z9= .=PY6O%_V;/AE_P ))J@U:Z3=
M9V[?+D?Q"OL)$6-0J@*HX %?IO!.1V_X4ZZ_P_YGX3QWGO-+^S*#V^+_ "'4
M445^PGXN%%%% !1110 5\3?\%7_^3;[C_KY2OMFODG_@I-\._$'Q*^ LVE^'
M-/FU&^-PC"&%<M@4 ?@:WWC7J/[+?_)Q7PZ_[#=M_P"ABM]?V+?C"W)\%:D/
M^V5>A_L\_LC_ !6\-_';P'J-_P"#]0M[&VU:"6:9H\*BJP))H _?6BBB@#*\
M4_\ (MZE_P!<'_E7\XG[4W_)<O%7_7VW\Z_H_P#$4+W&@W\4:[G>%E4#N<5^
M$/[1'[(_Q6\1?&#Q'?V'A&_NK2>Y9HY4CX(H ^1E^\*_?/\ X)D_\FT6/_7R
MW_H(K\??^&*_C#V\%:CG_KG7[/\ _!/OP+K?P]^ %GI6OV4EA?K.S&&48(&!
M0!],4444 %,FB6>)XW&Y'4J1Z@T^B@#\6O\ @IY^QZWPS\6-XY\-V3#1=1?]
M]#"G$;8R6_.OS\K^G_XE_#W2_B?X.U'P_JUO'/;7<1C^=0=N>XK\,/CQ^P#\
M2?!GQ+U*QT#PY=ZMI,DKR6\]O&2JIG@4 ?)]?IU_P19_Y'#Q;_UYC_T*OC;_
M (8K^,/_ $)6H_\ ?JOT%_X)._ WQK\*/$_B6X\4Z'=:3%<6H2,SKC)W=* /
MTRHHHH *\=_:<_9M\/\ [27P^N]!U6%([S;NMKS;EXV&2!],U[%10!_-_P#M
M$?LK^,?V>O%=UINK:?-+9J_[JZC4L&7L>*\792IP1@^AK^H;QC\/] \>Z;)9
M:YIEO?0R#!,D8+#Z'%?!GQU_X)(>%O%'VJ_\&W/]E7\S%MLC$J,^U 'XV5)#
M<2VS[HI&C;U4D5]B?$#_ ()=_%3P2KO;QKK*CI]FA;)_6O%M2_9%^+^FW30M
MX"U>3:<;HX<@_K0!YFOB;55L_L@OYQ;;M_E[SC/K6;)(TCEW8LS')8G)->J?
M\,J_%S_HG^M?]^/_ *]6=/\ V1_B]J%TL*^ M8CW?Q/#@#]: /(:ZCX6_P#)
M2/"__82M_P#T8*^C_ O_  30^+'C+9YMBVD[O^?F(\?K7UO^S[_P2*MO#>K6
M.K>-]36^FM)EN(X[<L@W*<C([\T ?HS\/O\ D2M&_P"O=:Z&JFEZ?%I.G6]G
M",10H$7Z"K= 'EW[3G_)"O&?_8-G_P#0#7\U%?TQ_M":/>>(/@WXKL+"!KB\
MGT^9(HD'+,4( %?@5#^Q?\898PQ\$:DO)X,5 'C.G_\ ']!_OC^=?TA_LG_\
MD!\&_P#8/B_]!%?A5:?L6_&%+R _\(7J(&\9/E=*_>3]FO0;[PS\%O"VFZE
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MT'\8?V&?B?I/Q(UV#1_"E]>:;]JD,$L4?RE,\8KC?^&*_C#_ -"5J/\ W[H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDY):';2P6(KTI5J4&XQW:Z'NE%%%9G$)436L+')B4GZ5-10!#]C@_P">*?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7COQMM]MY938^\A7]:]BKSCXS6)N/#\4XZPRY/TYKR\SI^UPLXGL91
M4]GCJ;[Z'BU%%%?GA^MA1112 *DMUW7$8_VA4=36?_'U%]:YL5)QH5&NS_(F
M6S.P_A I)9!#&TAZ*"32G[J_2L;QI<?9?">JR@[2+=\'\*_DO!T5BJ].D_M2
M2^]V/%A'VDE'NSY7UV^.J:Y?W3=7E8_D<?TK/IS9DD9S]XG)IM?Z%4::H0C3
MCTLON1^ZPCR04>V@4445L,**** #M[]J]&T&X^U:3;MW P:\Y_B_"NV\$R;M
M/D3^Z_\ 2J/-S"-Z7H="/NFOIK]G&Z\WP3)%_P \YB/Y5\R,?F_"OHS]F>0M
MX?U!>PFK2)^6\5QYLMOV:/9DI],7[U/H9^+!1112 **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^M55[L=O-_\  /Q[CW/_ *EA_P"SJ#]^>_E'_@FG1117ZF?SB%%%% !1110
M4444 %%%% !7@G[9_BH>&_@W>A7VR32*@YQQS7O=?&'_  4,\1)_8-CI*O\
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M_P#D8]<_[8?^@&MJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *C\OK4E)1<1Y-\:/#^8X=3B!W+\DGT[&O
M*!7TYK^CQZWIMS:29Q*I&?2OG#6--DTC49K24;6C./PKXC.,,X5?:QV9^C</
M8Q5*+H3>L=BG124M?/'U[5@HZ$&BD/3/I1OHR3L-/D$MG&W4XQ6)\1;<W'@K
M5E')$#-^0JYX?N-T+1=U.:M:W:B^TB\MSTDB9>/I7\S8JB\ISY*6G)-/Y73/
M+@W1K*79H^.=NW/UI:ENHWCO)D<;2LC*1]#Q45?W7&2E%2CU_5'[=%W2:"BB
MBF,**** #M78^"8\6T[=F;^E<?\ PDUW?A2W,.DH3U<[JH\['RM1]380;G5>
M['%?9_PXTG^Q_!NEVS##B%2WU-?*'@30SXB\6:;9<D/*"V/[HK[2MX5AC5%X
M50%%6MC\.XRQ"O2PR]62>U+24M!^:!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@\5BX4*6'46W9/0^>?V+O^2P6?\ US;^8K](?BQ_R3_5?^N)_D:_-_\ 8O\
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M25K6/ELZSY9M2A2C3Y>4_(O]I;_DK6K?]=F_G7Z&?L@_\D/\/_\ 7!:_//\
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MOL;,AG>-N"Q!!!K[ _:.^+4'PF^'.H7X=3J$D96WA)Y<G@U^8G@#POJ'Q?\
MB5!:@/+)>W.^5NNT%C7/@Z:UJRV1XW"> BG/,J_PPV]>K^1]2?L"_!N1KZ;Q
MG?18$8,,2N.N1P:^[*YSX?\ @^U\"^$]/TBVB2/[/$J.4'WF ZUT=<=:HZLW
M(^2S;'RS+%SKO;9>A\U_MY?\DAB_Z^#_ .@U\C?L1?\ )<K+_KB_\J^N?V\O
M^20Q?]?!_P#0:^1OV(O^2Y67_7%_Y5Z%'_=I'WN3?\D]7_[>/U!U7_D&3_\
M7,_RK\C/BM_R5N^_Z^O_ &8U^N>J_P#(,G_ZYG^5?D9\5O\ DK=]_P!?7_LQ
MJ,#\4CBX+_BUO0_4'X&?\DPT+_KW6NF\7_\ (M:A_P!<6_E7,_ S_DF&A?\
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M'M)A+#I\,<B]&5>:XGC%9I1/D)\6TW2G2IX=1YE;1F%\1?A[:?$OP'<:'>#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=6)G&5&*3/H\_P 50K930ITYIR5M/D>DZC_QXS_[A_E7Y'_&G_DKNH?]??\
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M_C2>[U>U,$/RX.TC=UYYKBJ8>C&+:EJ?(X[),JH8:=6CB.:26BTU/2_V\O\
MDD,7_7P?_0:^1OV(O^2Y67_7%_Y5]N?M<> =4^(GPXCT[2H_,N!-N(P3QBOG
M+]E?]G?Q;X%^*]IJVJ6ABMDB92=I'6KHSBL/*+>IUY3BJ%/(JU*<TI/FT/O+
M5?\ D&3_ /7,_P J_(SXK?\ )6[[_KZ_]F-?KMJ$336,R+]YD('Y5^<7Q"_9
ME\::I\2+F^M[(O;27&\/M/3=FHP4HQD[LX^$<31P]6JZTE&ZZGW1\#/^28:%
M_P!>ZUTWB_\ Y%K4/^N+?RK(^$^BW'A_P'I-A=+MGAA"L/>MSQ):O>Z'>P1C
M+R1E17#+X[GQE:2>*E);<WZGXYZA_P E/G_["+_^C#7ZW_#2,S?#'1HQU:SV
M_GFOSQN?V5_',_CN>]%B?L_VYI VT\J7)S7Z._#[39M'\%Z/97 Q-# $8>]>
MAC)QDH\K/O>+,50Q%*@J,U*W;T/RO_:8\$WW@?XI:E%<Q%$D;S$)'7.37UE^
MR/\ M0:!<>#[?0-?OXK&_MB(H5D;[R@8!KU;]H?]G/3OC5I)9<0ZK&/W<I.,
MGMDU\'>*OV4?'O@[576"RENECY66V#?S%:QG3Q--0F[-'IT<7@.(,OAA<5/D
MG'^KGZ777Q3\+6<#32ZQ;J@ZG=7*Q?M,> KKQ%;:):ZW;W%_.X18U/.37YTV
M_P (_B9J8,0LM49<X.XR8KTOX-_LA^-[GQ78ZM>!;,VTHES-D'CZUD\-2@FY
M3/*J</99A:<IU<5=I:6MN?H_&XDC5AT89%?-O[<WCY?#/POETC=B34EX]>#7
MT1ID#Z?I5O%.X+PQ ._;@<FOS4_;>^)'_"8?$B73+>;S;;3V*K@Y%<^%I\]5
M>1X7#>"^MYC'^6.OW;'+?LC>!YO&GQCTJ9$,D>G2I=2#M@,>M?J_7R!_P3]^
M%XT3PQ=^+)8VCN+[= %<8.T'(-?8%5C)\U2RZ&_%6,6*S!PB](:?YA2,H92#
MT-+17"?&GY*?M5>&[GP[\8-:,\;)'<3M)&V/O+FOJ+]CG]I7PU8?#^S\*ZW>
MQZ?=V0*Q-*?];DUZQ^TI^S;I_P ;='$T&VVUNW'[J7H&'7!KX(\0_LO^//">
MH2!=-GG$;?+- K?S%>U&5/$4E"3LT?KV'Q& S[+H83$3Y)QM]ZZGZ6:M\</!
M>BQ&2ZURWC4+O))[5H^'O'6B_$;PU?7F@WL=_;B-D+Q],E3Q7Y?6_P #?B/K
MVU'TZ_=3\O[W>17W3^Q[\-=;^&O@F\L=8C"--('"XQVKDK4*=.-U*[/F,TR;
M!9?AO:4J_/.ZT/SM^,.FSZ/\0]5M[J-HW$K'!'8YK]%_V</CUX6\0_#W3+-M
M0AMKNSA6%HF;GY0!FN _:P_9.N/'EW-XD\/A1>XS)#_>^@KY'C^!_P 0M NC
M#!I=_"['&8@ZY_*NU^SQ5-)NS1]=4E@>(\!3A.JH2C^#L?HI\3OVBO!'ACP_
MJ$,VLP27+PLBPAN22"*_+'[<NI>+7N$&%ENBX^A8U]"_#S]C/QIX_NC/KDKV
M<"_\_#L'_6J?B3]CWQ5HGCHVVF6C2Z?$RE9L$Y]:*/L:-XJ5V7E*RO*'4H4Z
M_-)K5]/D?H3\*?\ DGVA?]>D?\J_-7]LO_DN&N_]=C_2OTU^'NFS:/X-TFSG
M&V:&W1&'N!7YD_MF?\EOU[_KL:YL'_%9\YPFT\TJM=G^9],_L9_&KP?X9^$=
MIHVI:Q#:ZBEQ*[0N><%LBO<M:_:(\"Z3IT]R^NVYV*2%SU/I7YD^#?@=XP\4
M>'HM<T:RFGM9'9 T0;.0>>E67^"7C^\D:W?2K^0YP0RN16\\-2G-R<CV\9P_
MEV*Q52M/$6;;;6FY2^.7CY?B-\2M4U*!P]I+*?)QZ5^B'[&>ASZ/\%]/$X*M
M([,%([5\R_!']A_6M:U"VU+Q(!:V<;!FA;(<_G7Z Z#H=KX<TFWT^S01P0J%
M51]*QQ56'*J<.AY'$V9866'IY?A7=1_0XOQ+\?/!?@_71I&KZS!9WQY$3GDU
ML6OQ4\+7EJMQ%K%NT3#(;=7Q9^U!^SCXQ\4>/+G7=.@-S"Q.U5!+8SD5XC-\
M(_B9IH6'[%JB+T"J9,4HX:E.*?-J8X7A_+\70A4CB>636J=CW?\ ;A^/&B>*
M]-M- T*_BNWCD)F9.>,=*YC_ ()_^'Y+_P")<NHF%C!#"P,G;..E<9X'_9%\
M<^--:CCN[22QB<@M+<!A^.37Z#_ _P""^E_!OPO'IUFBO=, 9IL<EL<X-:59
MTZ-+V4'=GIYEB\#E.6/+L+/GE+]>I\X_\%&+67^S] FVGR_G&ZO$/V*?B=HW
MPS^)5S<:U<+;07=O]G5V. &+5]X_M#_!F+XR^"9M/#;+V-28&)P :_.'Q!^S
M1XX\.W\D3:1<3"-R%EB1L'!Z]*K#RA4H^SD[&N0XG"8S*I9?6GRO5/T>NA^D
M.N?M+?#W0;4SW/B&V"XR.>M?!G[77QXTKXQ:U9KI<?[BSW 2YR'S6?X3_96\
M?^,[R".:UFM86/W[C<,?G7H7Q"_8.UCP_P"';.73)1?:ASYVTEA3IPH4)I\U
MV7@,)D^3XJ,_;\U3IV1Z;_P3Q_Y%/4/^NK_S%>V_M1?\D9UG_@/]:\^_8K^&
M>N?#OPW>1:U;FWEDD8A2".M>K?'SPU>>+OACJ>F6"[[F;;M7&?6N*K)/$7OI
M<^0S*M3GGCJQE>/,M3\O?@#_ ,EL\-_]?O\ 0U^NMU:?;]"DM_\ GK#M_,5^
M<_PA_9@\:^'?BEH>I7=D4M;>Z\QVVGIS_C7Z26JF.WB4]0H!K3&24I)Q9Z/%
MV)HU\12E1DI673U/R"^.6@W7@_XN:PES R(EV98VQ@, 1R/RK[S_ &=?VH/"
M?B?PC8:;?:C%9:I @1H9&YXX%:'[27[+MA\9K,7MD5M=:A'R/T5OK7PUK'[,
MWQ \(ZE*(=/N9?+.!-;AOYBNGFIXJFE)V:/=C6R_B/!4Z5>IR5(?\,?IMJ'Q
M8\*Z;;F>XUBW2,<9W5S?AW]H_P %>+/&UMX8T?5H;[4)@WRQGH0,D5^<UO\
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MW<_(*DW4FYOKJ%%%%(@**** "BBB@ HHHH **** "BBB@#%TO_D8]<_[8?\
MH!K:K%TO_D8]<_[8?^@&MJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBD/2@ 9@.IK&UK0X=<MS'*N&'*OZ5JOC'WA6
M-X@\7Z3X7@,NHWD4 [)N&X_A7)B\'0QU&6'Q$>:$MTS6C[5U%[&_-TL>7ZIH
M\^DWAAE5E&>&QU%4I9([=2\LBHG]YCBLOX@?':'5K>:TTBRRQX2ZE['Z5\G>
M.M8\5-=2/JFIW$T#D[2C?(.>E?SGB/">O+'2^KXA1H/:^K]/D?LV2Y/C,RBO
MK#5-^>[/I_6OB=X8T)3]JU>UW#^!7!;\JXC4OVF?#EFS+:VMQ=$=&5, U\Q[
MG9L[RY/.6.:3C/'3VK[3!^%.3X=)XB<JGX+\+'Z+1X/P<%>K)R_ ^@)_VIE;
M)CT7/H6EY_E54?M2W.[YM&7;[2X_I7A%%?10\/.&H*WU;_R:7^9Z<>&<KBM:
M5_FSZ%M?VIK;=_I&BR(OJDA8_P JZ'2?VD/#&I2;+D3V.?XIDX_G7RS0<=Z\
M_$^&?#U:+5.FX>:DW^;:.:KPKEU3X$X^C_S/N32?&6@ZU&IL=6M9]W.V.0$U
M?NK6&\3#A3GHRU\'0RR6[!DE>-NQ0D$5VWA?XR>)_"K(%OWOX!_RRN#GCTKX
M/&^%6,PDU6R?$^\ME+1_>K(^>Q?"%6G[V#JJ7D]#ZB:SFTBY$L>7CS\U<[\8
M/"X\4>%?MUJGF75K\ZA1EBO<5C^#_P!HC1==V0:LITVY;CYN8\_7M7IUFL$T
M?F6DJ3V\P_Y9L&7GN*^*QN)S7)<;1Q68T7#$T7I+I-=F_0^2J1Q>75XSK1<9
M1?R9\>>M%=I\4O![^$_$DI1"+*Y)>/C@9ZBN+K^K,NQU',\+3Q>'?NS5U_7D
M?K.'KPQ5*-:GLQ,C&>U=-X-TIKBY-TR%@I"H,=37/6MN]U/'%&"6<^G:OJOX
M!?"+[0T&K:A 190@&&-EQYC>M>DD>'GN:4LJPCJ5'OLNK.[^!_PW_P"$<TW^
MU[Z+9?W ^17&"BUL^-OCIX2\"S?9[[4EEN_XH+?#NOU&:TOBQX@D\*_#O5]1
MMSLFA@*QE>Q(P*_.RYO)M1N'NKAVEGF8NSMU))S7S.=9T\L<*<(WD_R/R7(<
MB?%-6KCL;4<8)VT[]O0_0WP'\9O"OCXF/3=3076?^/68A9/RKNA(K=#FOR_T
MG6+G0-0M[ZRF,%S"X97!QWK]'_A_KS^*/".E:I(NR2Y@61E]S59-G#S&,H5(
MVDOR/,XIX:CD,X3HRO3EWW3.BW"EI ,4M?4'P84444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !29%(U)D+UH =D4;AZTW\:./
M6F3<=D49IO:CM18=QV:-P]:9N'J*-X/3F@!]%-8C]*5?NB@!U)2TQVVT@'T4
MQ6'K3J!BT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%<=\5?BEI7P@\*_P!OZS;WES9^>EOY=BB/)N;.#AF48X/>J_PB^,&C
M?&CP_=:QHEM?6MM;W)M734(T1RP56R CL,8<=_6A>]>W0'[MK]3N:*** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4<D,<V-Z*V.F14E% !1110 4R2))EVNH<>A%/HH 15"J !@#H!2T44 %%%%
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M%SK@F&68&6+H57+EWOU]#ZVHI@ .,&G!0#2/RD=1110,**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBOB+QM\,?VB[SQCKEQI-YXA72I;Z9[01>
M)4C01%R4VKYXVC;CC Q4WUL5;2YZW^W%_P D//\ V$[?^3UD?L#_ /)*=:_[
M#,G_ *)AKYP^*O@7XT>'?"OVOQY<ZS+H7GHFV^UQ;N/S3G;^[$S<]><<57^$
M7@GXP>)/#]U<?#ZXU>'2$N3',NGZRMFGG;5)RAE3)VE><>G/%53]WG\_PV(J
M>]R>7_!/TPHKX4T7X6_M*0ZQ8R7=[XC-JL\;2AO$Z,-@8;LC[1R,9XK[KJK:
M7"^M@HHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!\^_MQ?\D//_83M_P"3UD?L#_\ )*=:_P"PS)_Z)AK7_;B_Y(>?^PG;
M_P GK(_8'_Y)3K7_ &&9/_1,-.C_ ,O?Z_E)K;T_Z_F/IFBBBD4%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 8NE_\C'KG_;#_ - -;58NE_\ (QZY_P!L/_0#6U0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 444P,>: 'UD>(/$5EX:TZ:]O9ECBC7/)Y/M4NL:Y!H>GSWMW(L4$*Y9F
M_E7R=\2/B)=^.M49BVVRC)$,*]"/4T]CZ')LHJ9K5[06[_0?\1OB??\ CV[9
M=[6^G*?W< .-WN:XH,5XZTG.[.30HV\"I;/VW"X>CA*2HT(VBOZU _-UP:
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M,_M#_"=OA[XF-[:0E=&OF+1XZ(W]VLY1ZH_<^#N)98RV78UWFOAE?>W1EO\
M9Q^,DO@778='OY#_ &/>.%RW2)CT/TK[=M9UN%21&W(PR&'0^]?EY\R\J<'J
MI]*^W?V7_B8?&G@X:?=2AM2TW]T^>K)V/ZTUM8X..LCC"V:4(VOI-+\&>W44
MP,3GTI>:9^-CJ*J:E?#3[&XN6&5@C:5ACLHR?Y5X@_[8/A..1D-M=EE8J<(?
M\*'H>E@\MQF8<WU6DY\N]CWJBO/?AG\9-+^*37HTN*6/[)C?YJXSG/3\JS?B
M%^T/X:^'\SVLLWVZ_4?\>]N=QS[D=*"EE>.EB?JBI/VBZ6U/5**^0]7_ &S=
M:DD8:=H]O"G9ILM_A6?9_ME>+(Y,W.G6$L>?NI&5/YYJ>9'U$."<YE#GY$O)
MO4^S**^?O _[76A:]-';:S"=(F<A5D<Y3/U[5[K9:E!J%ND]M/'<0N,K)&P*
MGZ&FG<^5QV6XO+9\F+IN+_#[RY146YN^#S7&?$SXJZ=\+K&WN]3CDDCF;8HB
M&3FF<F'H5<54C1H1YI/9([BBO I/VQ/":J2+>[Z=T/\ A7LOAOQ GB71[+4[
M<;;>ZC610PYP1FA:G=C,JQN7I/%TG!/:YKTVEYI*H\D\C_:D_P"2/ZG_ +R?
MS%?"=?=G[4G_ "1_4_\ >3^8KX3K*6Z/Z$X _P"17+_&_P HGWE^S%_R232_
MJW]*]9KR;]F+_DDFE_5OZ5ZS5GXIG/\ R,<1_B?YA116'XP\40^#]!NM5N5+
M6]NNY@HR:#RJ<)5)J$%=O1&Y17@2_MB>%&ZVMXK#J-A_PKTOX9_$S3_BAI,N
MHZ:CI!&^PB08.:#UL5D^88&G[7$T7&/=G9444AH/&%HIA8XJ.:8HI(QG^5.P
MKHGHKS[QM\;O"_@/Y-0U&-[C_GA"0[?D*\@\1?MG1QR,NCZ*TZCH\S;?TQ18
M^AP609GF"4J%%M=]E^)]04G/UKXOO/VQ_%\S'[-9:="O;S(RW_LU5[;]L/QO
M$P,T&ER+W"P%3_Z%4<R/H8\#9PX\UHK_ +>_X!]L4M?)^A_MI7.]5U71D*YY
MD@;'Z5ZOX._:4\(>+IE@-ZNG7#=$O"$!/L35'B8SAO-<#%SJT7RKJM4>LT56
MMKQ+N(21.LB-R'4Y%2J['.1BG8^8)**;NHW4ACJ*;N-123^6A<D!1R3V%,5T
M3T5Y9XT_:,\(^"YGMY+T7UTO'E6OS\^A(Z5Y+KG[:%QYC+I6B+L[/._]*EZ'
MTF"X=S3'I2HT7;N]#ZL4D]J*^*[K]L+QI*3]GM=-C_WH2W_LU.L_VQ/&<.#<
M6NFS#N$A*?\ LU":9[_^HN<<O-:/W_\  /M.BOESP_\ MH1R,JZOHQC7O);M
MNQ^&*]?\$_'3PIXZ98['4HH;H_\ +O<$(_X U5NQ\[C<@S/+TY5Z+LNJU1Z)
M14*S;E!!!!Z8IZN><T'SUT/HIFXGI1N-%@N/HIC$YIKR,HSD8]:+!>Q+17">
M,OC1X5\#J5U#58&NNUM P>3_ +Y'->1>(OVS+*!F32-(DN".CS':/RQ2/>P>
M1YECU>A1;7>UD?2]#'%?&-]^V-XPD;-M8:? #T$D1?\ ]F%5;?\ ;#\;1MF:
M#3)%_P!FW(_]FJ>9'TD>!<XE'FM'_P "_P" ?;%+7R5HW[:.H*Z#4M%AD3NT
M+[3^7->K^"_VFO"/BR:.VENAI=T_ 6Z.U<^F35'BXSAK-<#%SJT7RKJM3UZB
MJT%XEU"LL3J\;#*NO(-3*QIV/E[CZ*8S'M7'?$+XGZ9\.=+6ZU!_,ED.V&WC
MYDE;L *+&U*E.O-4J2O)[([.EKP&/XD?%#Q1']KTS3-+T6R;F,:D<R$>XR*F
M_P"%W>*_ UQ$/&V@J-.<A?[2T\$Q@GN1S@?C18]QY'B?AC*,I?RJ6O\ E^)[
MQ16;H^M6^N65O>6DJS6TZ[XY%.016E2/GVG%N+W05\]>(/VWO OAO7M1TFYT
MGQ"]S8W$EM(T5M 4+(Q4E29@<9'<"OH6O)M6_95^%NN:I=ZC>^%_.O+N9YYI
M/[0NEW.Q)8X$H R2>@Q4ZW\AZ6\SYR_:._:F\*?%_P"')T#1M/UFVO/MD5QY
ME]#$D>U0V1E96.>1VJC^S)^TQX7^"_@G4='UNPU>ZN;C4&ND;3X8G0*8XUP2
M\BG.4/;TKL/VJO@!X"^&_P *SK'AS0?[.U'[=##YWVRXE^1@V1M>1AV':L[]
MD7X%^!_BA\/]4U+Q-HG]IWL.IO;QR_:YXL1B*-@,1NHZL><9YJJ?V^7Y_A_P
M"*GV.;Y?C_P3TC3_ -NSP%J-];6D>D>(UDGD6)2UM;X!8@#/[_IS7T;7D-K^
MR7\*+*ZAN(?"NR:%UD1O[1NSA@<@X,OK7KU5I;S#6_D%%%%2,**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH BN?^/>7
M_</\JP:WKG_CWE_W#_*L&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .CHHHH
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M+.L>OV.;_P! -?FC=DK=3'_IHP_6OTO\4_\ (KZP?^G.;_T U^:%[_Q\3?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'\.^+M)U"-BC13J2?8\8_6O?_P!M30D6ZT+5PN&8- Q'?&6%?,<3>6X<_>#
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MBD'H>Q]"#P1V(-;-JI'VD?Z9E9P?(_Z1YA^UI_R0O7/^NEO_ .CDKC/V&?\
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MJXG]NO\ Y%+PQ_U_2?\ HNNV_9#_ .2':3_U\7'_ *-:BEM4^7Z#J?\ +O\
MKN>SUYO^T-XZ_P"%?_"G6;Z.3R[VY3[%:XZ^9(",CZ+N;_@->D5\8_MI>,Y/
M$'C;2/"-D3*M@@DEC3G=<2XVK]0N/^^S64TY6@NNAI#W7S/IJ>'>&[C5OAYJ
M?AGQ?%&4C:X:>V;M)Y3A9%/L<X/L:_3'0M:M?$6BV.J63^9:7D"3Q-ZJP!'\
MZ^<OCE\%UTW]F[1;6WCW7_AB)+B0J/O!O^/C\-QW?\!K3_8O\?C7_ =UX;N)
M,W>BR9B!/)@D)(_)MP_$5T7YN:'\K_#^OR9SZKEGW_K^O4^B****S- HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .CHHHH
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MZ=H,+MP&CM9BP/L#*1^E5X_A3\7/V@O$$%_XEBNK*V7Y1=:I%]GCA0\GRX<
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M#CUW#Z"N./B7XT?"'_CXN/$6F6T/RC[:C7%J/92X:/\ *OT(BE2>))(V#QN
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M\BN7^-_E$^\OV8O^22:7]6_I7K->3?LQ?\DDTOZM_2O6:L_%,Y_Y&.(_Q/\
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M+_(^"='U:\T/4(KW3[E[2YC.1(AP17V)^S[\>U\>6ZZ-K<B1:U&/E?.!,/\
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MO^$T74-8.J?V@=2\DS1>1YA<OC'E;MN3TW9]Z]@I4_=HQ@]U_D@EK5E);/\
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M)'E:6Z96ED9CDEBJJ#Q@=.@%.E[J][=*R_KT_$*GO/39N[_K^M#J:YOXE?\
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M $-/_E/NO_C5'_#5OPL_Z&G_ ,I]U_\ &JY+_AAWP)_T%O$7_@3!_P#&:/\
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MKO\ URI,QRS_ 'ZC_BC^:/SY'W5K[/\ V.?^2=W?_7R?ZU\8#[JU]G_L<_\
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MR]1GN*T1_-V/J0K8RK5CLY/[FSR'XP?M#Z5\/89K"PD6]UO&%13E8R>[5/\
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M^9MH5=WLO7]*]O\ #/[)7BO6&4Z@\6E19YW'+?@,5[S\//V:_"_@Y5GN+?\
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MK4/ ?B'2Y-EWHEW;L.SQUGJ?<UL-P]G"]M/V<F^MTG\]F?11_;53;QH#;O\
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M KJZK8_"<;)3Q564=G)_FPHHHH.,**** "BBB@ HHHH **** "BBB@ HHHH
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M_//_ ,>/^-']GV__ #S_ /'C_C0!BT5M?V?;_P#//_QX_P"-']GV_P#SS_\
M'C_C0!BT5M?V?;_\\_\ QX_XT?V?;_\ //\ \>/^- &+16U_9]O_ ,\__'C_
M (T?V?;_ ///_P >/^- &+16U_9]O_SS_P#'C_C1_9]O_P \_P#QX_XT 8M%
M;7]GV_\ SS_\>/\ C1_9]O\ \\__ !X_XT 8M%;7]GV__//_ ,>/^-']GV__
M #S_ /'C_C0!BT5M?V?;_P#//_QX_P"-']GV_P#SS_\ 'C_C0!BT5M?V?;_\
M\_\ QX_XT?V?;_\ //\ \>/^- &+16U_9]O_ ,\__'C_ (T?V?;_ ///_P >
M/^- &+16U_9]O_SS_P#'C_C1_9]O_P \_P#QX_XT 8M%;7]GV_\ SS_\>/\
MC1_9]O\ \\__ !X_XT 8M%;7]GV__//_ ,>/^-']GV__ #S_ /'C_C0!BT5M
M?V?;_P#//_QX_P"-']GV_P#SS_\ 'C_C0!BT5M?V?;_\\_\ QX_XT?V?;_\
M//\ \>/^- &+16U_9]O_ ,\__'C_ (T?V?;_ ///_P >/^- &+16U_9]O_SS
M_P#'C_C1_9]O_P \_P#QX_XT 8M%;7]GV_\ SS_\>/\ C1_9]O\ \\__ !X_
MXT 8M%;7]GV__//_ ,>/^-']GV__ #S_ /'C_C0!BT5M?V?;_P#//_QX_P"-
M']GV_P#SS_\ 'C_C0!BT5M?V?;_\\_\ QX_XT?V?;_\ //\ \>/^- &+16U_
M9]O_ ,\__'C_ (T?V?;_ ///_P >/^- &+16U_9]O_SS_P#'C_C1_9]O_P \
M_P#QX_XT 8M%;7]GV_\ SS_\>/\ C1_9]O\ \\__ !X_XT 8M%;7]GV__//_
M ,>/^-']GV__ #S_ /'C_C0!BT5M?V?;_P#//_QX_P"-']GV_P#SS_\ 'C_C
M0!BT5M?V?;_\\_\ QX_XT?V?;_\ //\ \>/^- &+16U_9]O_ ,\__'C_ (T?
MV?;_ ///_P >/^- &+16U_9]O_SS_P#'C_C1_9]O_P \_P#QX_XT 8M%;7]G
MV_\ SS_\>/\ C1_9]O\ \\__ !X_XT 8M%;7]GV__//_ ,>/^-']GV__ #S_
M /'C_C0!BT5M?V?;_P#//_QX_P"-']GV_P#SS_\ 'C_C0!BT5M?V?;_\\_\
MQX_XT?V?;_\ //\ \>/^- &+16U_9]O_ ,\__'C_ (T?V?;_ ///_P >/^-
M&+16U_9]O_SS_P#'C_C1_9]O_P \_P#QX_XT 8M%;7]GV_\ SS_\>/\ C1_9
M]O\ \\__ !X_XT 8M%;7]GV__//_ ,>/^-']GV__ #S_ /'C_C0!BT5M?V?;
M_P#//_QX_P"-']GV_P#SS_\ 'C_C0!BT5M?V?;_\\_\ QX_XT?V?;_\ //\
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MA_ZAG_D2C_BH?^H9_P"1*VJ* ,7_ (J'_J&?^1*/^*A_ZAG_ )$K:HH Q?\
MBH?^H9_Y$H_XJ'_J&?\ D2MJB@#%_P"*A_ZAG_D2C_BH?^H9_P"1*VJ* ,7_
M (J'_J&?^1*/^*A_ZAG_ )$K:HH Q?\ BH?^H9_Y$H_XJ'_J&?\ D2MJB@#%
M_P"*A_ZAG_D2C_BH?^H9_P"1*VJ* ,7_ (J'_J&?^1*/^*A_ZAG_ )$K:HH
MQ?\ BH?^H9_Y$H_XJ'_J&?\ D2MJB@#%_P"*A_ZAG_D2C_BH?^H9_P"1*VJ*
M ,7_ (J'_J&?^1*/^*A_ZAG_ )$K:HH Q?\ BH?^H9_Y$H_XJ'_J&?\ D2MJ
MB@#%_P"*A_ZAG_D2C_BH?^H9_P"1*VJ* ,7_ (J'_J&?^1*/^*A_ZAG_ )$K
M:HH Q?\ BH?^H9_Y$H_XJ'_J&?\ D2MJB@#%_P"*A_ZAG_D2C_BH?^H9_P"1
M*VJ* ,7_ (J'_J&?^1*/^*A_ZAG_ )$K:HH Q?\ BH?^H9_Y$H_XJ'_J&?\
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MA_ZAG_D2C_BH?^H9_P"1*VJ* ,7_ (J'_J&?^1*/^*A_ZAG_ )$K:HH Q?\
MBH?^H9_Y$H_XJ'_J&?\ D2MJB@#%_P"*A_ZAG_D2C_BH?^H9_P"1*VJ* ,7_
M (J'_J&?^1*/^*A_ZAG_ )$K:HH Q?\ BH?^H9_Y$H_XJ'_J&?\ D2MJB@#%
M_P"*A_ZAG_D2C_BH?^H9_P"1*VJ* ,7_ (J'_J&?^1*/^*A_ZAG_ )$K:HH
MQ?\ BH?^H9_Y$H_XJ'_J&?\ D2MJB@#%_P"*A_ZAG_D2C_BH?^H9_P"1*VJ*
M ,7_ (J'_J&?^1*/^*A_ZAG_ )$K:HH Q?\ BH?^H9_Y$H_XJ'_J&?\ D2MJ
MB@#%_P"*A_ZAG_D2C_BH?^H9_P"1*VJ* ,7_ (J'_J&?^1*V5SM&>O?%+10
M4444 %%%% !1110!BZ7_ ,C'KG_;#_T UM5BZ7_R,>N?]L/_ $ UM4 %%%%
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M>W8] S\TVP\7:-JDGEVNI6\S_P!U7%4!K4C=#1N'7.1ZTC<J3[4@/B3XD?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG\#)EN?6[?>-?)/Q\\*?\([XRDN8DVVM]^\'^]W_ %S7ULWWC]*\Q^/W@_\
MX23P8]W"N;K3SYJ8')'0C]:SB]31ZHX#P?\ %0Z7\&=1@DFS?VH-M <\_,,*
M?PQ7+_ 3PT_B3QQ%<RIO@L_W[L?[QZ?K7FOG,L1CW-L8@E<\$U]7_L_^%1X?
M\%I=/&/M5\_F,Q'.W P/TK:7NHSCN>IT4C4M<YJ-_B/TKXF^*W_)0-:_ZZ_T
M%?;/\1^E?$WQ6_Y*!K7_ %U_H*VI]29'UG\,?^1!T3_KU3^0K5\2:9_;6B7V
MG>88C=0M%O';(Q65\,?^1!T3_KU3^0KHY#\_MBLI;CZ'B7AG]G-O#NN66I#5
MS/\ 9WWF,H.?TKV].]<QXT^(.D>!;$S7\X\TKF.W7[S?A7A&N?M+Z]?7#KIE
ME':0YPH?YF/OTH^(GX3V[XP?\D[UC_KD?Y5\N?"?_D?M%_ZZUIZY\8_%/B#2
MY[&\D4VTJXD BK,^%*[?B!HN#QYU;15DR>;4^PO$G_(OZE_UP?\ E7Q#X:C6
M;7M-C<95IE!'XU]O>)/^0!J7_7!_Y5\2>%?^1DTO_KNO\ZF&S*D?=$"A88@.
M %4#\JDF_P!4_P#NFFP*##&2/X1_*G3?ZI_]TUD6?#7C+_D<=7_Z^F_F:^P/
MAE_R(>B?]>R_UKX_\9?\CEJ__7TW\S7V!\,_^1#T3_KV7^M;3^%$1/D[XK_\
ME"U[_KK_ .RBOJ/X,_\ ).='_P"N=?+OQ8_Y*'KW_77_ -E%?47P9_Y)SH__
M %SISV0T>;?M8?\ 'OX:_P"ND_\ )*J?LL_\A#6O^N:_S%6_VL/^/?PS_P!=
M)_Y)7#_!?XEZ;\.[G47U".:07"@+Y2YZ4E\-B?M'UHOWFKS']HO_ ))W)_U\
M1_UK-'[37AH $V]YSZ1__7KC?BO\;-&\<>$Y--L8;E)S(K@RI@8&:B*=[E.2
M,_\ 9E_Y'6?_ *]S_6O<OC)_R3+7_P#K@/\ T-:\-_9GS_PG-QZ?9S_6O<OC
M)_R3+Q!_UP'_ *&M5+XD*.Q\M?"W_D?M$_Z^5K[67[M?%/PM_P"1^T3_ *^5
MK[7_ (:=3<:/*?V@_"\^O>"WN+9/,FLI/-55Z[>A_F:\$^%'CAO _BR*\8G[
M)+^ZG7_9/\5?9<UO%<0R1R#?'(-K#U!KY(^,7PVG\%Z]+<V\!;2KEBT;*.$)
M_A-3'56):]ZY]9V=]!J5I%<6THEAE4,DBG@U*UO'(V7C5FQC+*#7S)\#_BVW
MARZBT/5)2VG2G;#*Q_U1]/I7T[#(LT2R(P9&&0P[BHLXZ&@Y46-<*H4>@&*4
M&EJ-^",9Q[4@)*1N*Y#Q5\4/#W@^;R-1OMMQ_P \H_F8?6K_ (6\;:1XRMS-
MI=T+@+]Y>C+^%.S$;VZC=7*>*OB5X?\ !\@BU&]V3G_EE&-S?E3?"WQ,\/>,
M)_)TZ]#W'>*3Y6_*BS"YUNZ@-6%XE\7Z5X1MA-J=VMNI^ZO\1_"L+0_C)X5U
MZ\%O!J/ES$X59AMS2U"YWM)4:_,H.>.HP:EH&%%%%2!Q'Q%\+^(/$'V630=8
M_LN: DLK#A_KQ7%+\(/%'BJ]MF\6:\MU8P.'^S1# 8CUXKVRDP.N*=Q$-G;I
M9V\<,2>7%&H5%'8"IZ**8PHHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGC#HP=&&0RG((^M25R_PQ8MX T(MDL;1"2>IXZUU%3L,**** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !6!X_\ %7_"#> _$GB3[+]M_L?3;G4/LOF>7YWE
M1-)LW8.W.W&<'&>AK?K@OC]_R0CXC_\ 8MZE_P"DLE:THJ52,7LVB)MJ+:/D
M7_AZ?_U3'_RO_P#W+4EO_P %2O/GCC_X5EMWL%S_ &_TR?\ KVKX$JQI_P#Q
M_6W_ %T7^8K]-_L7 ?\ /O\ &7^9\K]>Q'\WX+_(_>53E0:6FI]U?I3J_+3Z
MT**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M12,P522< <DF@#F?B1\1]"^$_@Z_\3>([L6FFV:Y..7E<_=C1?XG8\ ?B< $
MU^2/[0O[1WB7]H3Q0;S5)&LM$MW;^S]'B<^5;K_>/]^0CJY^@P,"NQ_;1_:,
MF^-WQ#ETS2[G=X.T.5H;%8S\MS(.'N#ZYY"^B^A8U\ZU^D9/ED<+!5JJ]]_@
MO\^_W'R^-Q;K2Y(/W5^(45H>'] U'Q5K5EI&D6<M_J=[*L%O;0C+R.QP /\
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MC["C6C6@IQ"BBBN,W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ K@OC]_P D(^(__8MZE_Z2R5WM<%\?O^2$?$?_ +%O4O\
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M (]+1N X_P!N0<Y_N$#^)A7V/4%C8V^F65O9VD*6]K;QK%%#&,*B* %4#L
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &+I?_ ",>N?\
M;#_T UM5BZ7_ ,C'KG_;#_T UM4 %%%% !1110 4444 %%%% !1110 4444
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M ,]/_'3_ (4 6:*K?VA;_P#/3_QT_P"%']H6_P#ST_\ '3_A0!9HJM_:%O\
M\]/_ !T_X4?VA;_\]/\ QT_X4 6:*K?VA;_\]/\ QT_X4?VA;_\ /3_QT_X4
M 6:*K?VA;_\ /3_QT_X4?VA;_P#/3_QT_P"% %FBJW]H6_\ ST_\=/\ A1_:
M%O\ \]/_ !T_X4 6:*K?VA;_ //3_P =/^%']H6__/3_ ,=/^% %FBJW]H6_
M_/3_ ,=/^%']H6__ #T_\=/^% %FBJW]H6__ #T_\=/^%']H6_\ ST_\=/\
MA0!9HJM_:%O_ ,]/_'3_ (4?VA;_ //3_P =/^% %FBJW]H6_P#ST_\ '3_A
M1_:%O_ST_P#'3_A0!9HJM_:%O_ST_P#'3_A1_:%O_P ]/_'3_A0!9HJM_:%O
M_P ]/_'3_A1_:%O_ ,]/_'3_ (4 6:*K?VA;_P#/3_QT_P"%']H6_P#ST_\
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M_AZ?_P!4Q_\ *_\ _<M?!%%>+_8N _Y]_C+_ #._Z_B?YOP7^1][_P##T_\
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M,5^P5)<L)271'Q,5>21^V5O!':V\4,2+'%&H1$48"@#  J2BBOQ8^["BBB@
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MG\9^GZH]WHHHK\[/I@HHHH *_"+Q%_R,&I_]?4O_ *&:_=VOPB\1?\C!J?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%:/S/S:_X=A^/?\ H:O#GYW'_P ;H_X=A^/?^AJ\.?G<?_&Z_26BL_[=QO\
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M6VEPM]SSFR[^H5!EF_ &E>VX]]C?HKP'4/VU_A_9W#1PVVMWR \2V]K&%/\
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MQWIOV_0-5M]4M@<,T+?,A/9E/S*?8@&JL]R;]#<HHHI#"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** -ZV_X]XO]P?RJ6HK;_CWB_W!_*I: "BBB@ HHHH **** "BBB@ HHHH
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M -&BO0R__>Z7^)?F<V)_@S]&?E'7L?['O_)R_@'_ *_F_P#13UXY7L?['O\
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M>ME^6PR]R<)-\UM_(XL3BI8FW,K6"OV?_9A_Y-Y^'G_8$MO_ $6*_&"OV?\
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MVU1^;WP1\ Z=\3/BE::!JLEQ%97"SN[6KJLF51F&"01U'I7U#_PQ'X"_Y_\
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MO/L;VYTZ6-N_,<.0?0@Y!'J#3IM5*].HOGZW7]?>#3IPJ0?;0_0>OS\^&O\
MR=1:_P#8>N?_ $.2OT#K\_/AK_R=1:_]AZY_]#DJ:7^\0_KJBY_P)_UT9^@=
M%%%(1YA^TS)''\#?%9D'!@C ^IE0#]:\2_8/CD_M#Q@XSY0BME/INS)C^M=9
M^VOXZM]+\#V?AB.0&^U.=9I(P>5AC.<GZOMQ_NFK?[%?A&71/AQ>ZS.A1]8N
MMT>X8S%&"JG\6+T4=ZDOE_7X_<%7X81[N_\ 7W?B?/O[4.\?M :YYVT+OML>
MFWR8_6OT#M\?9XL=-H_E7QC^V[X,ET_QEI?B6)#]EU"W%M*XZ":/.,_52/\
MODU])_ OQ];?$3X9Z/J$4BM=0PK:W<>>4F0 -GZ\,/9J*7\'E_E?]?UYA5_B
MJ7=?Y?U\COZ*** /GO\ ;<>-?A/IZO\ ZQM6BV<_],Y<_I_.F_L0K(OPKU)G
M^XVK2;/^_46?UKSW]MWQ];ZIK6D>%;242G3PUU=[3D+(X 13[A<G_@8KWO\
M9O\ !LO@GX0:'9W*&.\N5:]G1A@JTAW 'W"[1^%%'X:DNC_X'^3"KO"/5?\
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MDAEN["V6&5[=B8RPSRI(!Q]0*ZFBBJE)R;D^HDN561Y=^TY_R0OQ5_URB_\
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M]OI:+?W X,I/[I3_ .S?AQ[UP?B[Q]?^*9&BR;6P!^6W0_>]V/<_I7+U[E#
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M+7Y\?=!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEAO0?.OY"=P9@>0F>23][H.#FOM*BBJ;T45LB4M6WNSX#^-G_)TEU_V$[/\
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M+GC/PBJ)I/B74;6%?NP&<R1#_@#97]*^5K\*]</5^37ZK_(^FH\2]*]/[O\
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M8B<+0?73_ASBCC*$ZSP\97FNAW=%%%<)VA1110 4444 %%%% !1110 4444
M%%%% !7Y=_\ !23_ ).&M_\ L!VW_HR:OU$KSCX@?LZ_#KXI:ZNL^*O#%OJ^
MIK"MN+B2:5#Y:DD+A7 X+'MWKULLQD,%B/:U$VK-:''BZ,L13Y(GXL45^P7_
M  Q;\%?^A#L__ FX_P#CE'_#%OP5_P"A#L__  )N/_CE?6_ZQX;^27X?YGC?
MV75_F7X_Y'X^T5^P7_#%OP5_Z$.S_P# FX_^.5+:_L;_  8LY"Z> M/8D8_>
MRS2#\F<BE_K'AOY)?A_F']EU?YE^/^1^/%;OA/P+XB\>:@MCX<T/4-;NR?\
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MVF>&$K I]&E;"+^+"OM3X ?\$Y;?2YX-:^)]Q'?S(P>/0+*0F$$=/.D'W_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$J5:.%A\,%^+_P D>!P]AW&C+$S^*;_!?YL****^-/K0HHHH **** "BBB@
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M6E%?I7>? [X?W_\ K?!VCK_UQM$B_P#0 *P+O]EGX87>2?#(B8C :&\N%Q^
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M'1U/0@C@BO@GXD?LI^,/A_I\^I0^1KVF0KOEEL=WFQKW9HR,X'JI.!R<5G?
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MOAZE.5*;A-6:T9]G"<:D5.#NF%<'XV^.7@CX?RRP:OKUNM[']ZSM\S3 ^A5
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX>_$^X^P0B#2]4C%[!&OW8V)(D0>@# D#L& K]!:^5?V[-.5K'PA?A<,DES
MS>H(C8#_ ,=/YU]/P[7E2QT8)Z233^ZZ/G,^HQJ8)S>\;/\ &QVO['GC)_$G
MPK_LVXE,ESHUPUL-QR?)8;X_P&64>RUV?[07_)%_%W_7DW_H0KP+]A74GCUK
MQ9I^?DEMX)\>Z,Z_^SU[[^T%_P D7\7?]>3?^A"GCJ*HYSRQV<HO[[/\PP55
MULIYGNHR7W71\8_LO_\ )=O"O_72?_TGEK]$*_._]E__ )+MX5_ZZ3_^D\M?
MHA73Q1_OD/\ "OS9S<-_[K/_ !?HCX6_;)\9/KWQ171HY2UIHMNL6P'Y?.D
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M]Z/_ ,EI^!\OAZ].MG2JT'[LO_D=?Q/H?XW?\D@\8_\ 8+G_ /0#7P5\$/\
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M=CPW]GOX>1?$KXGZ;IMVGF:;;AKR\3^]&F/E/LS%5/L37Z,0PI;Q)%$BQQH
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M*_VI!N&>#C'%:U% &+_:FK_] 3_R;3_"C^U-7_Z G_DVG^%;5% &+_:FK_\
M0$_\FT_PH_M35_\ H"?^3:?X5M44 8O]J:O_ - 3_P FT_PH_M35_P#H"?\
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M_P"@)_Y-I_A6U10!B_VIJ_\ T!/_ ";3_"C^U-7_ .@)_P"3:?X5M44 8O\
M:FK_ /0$_P#)M/\ "C^U-7_Z G_DVG^%;5% &+_:FK_] 3_R;3_"C^U-7_Z
MG_DVG^%;5% &+_:FK_\ 0$_\FT_PH_M35_\ H"?^3:?X5M44 8O]J:O_ - 3
M_P FT_PH_M35_P#H"?\ DVG^%;5% &+_ &IJ_P#T!/\ R;3_  H_M35_^@)_
MY-I_A6U10!B_VIJ__0$_\FT_PH_M35_^@)_Y-I_A6U10!B_VIJ__ $!/_)M/
M\*/[4U?_ * G_DVG^%;5% &+_:FK_P#0$_\ )M/\*/[4U?\ Z G_ )-I_A6U
M10!B_P!J:O\ ] 3_ ,FT_P */[4U?_H"?^3:?X5M44 8O]J:O_T!/_)M/\*/
M[4U?_H"?^3:?X5M44 8O]J:O_P! 3_R;3_"C^U-7_P"@)_Y-I_A6U10!B_VI
MJ_\ T!/_ ";3_"C^U-7_ .@)_P"3:?X5M44 8O\ :FK_ /0$_P#)M/\ "C^U
M-7_Z G_DVG^%;5% &+_:FK_] 3_R;3_"C^U-7_Z G_DVG^%;5% &+_:FK_\
M0$_\FT_PH_M35_\ H"?^3:?X5M44 8O]J:O_ - 3_P FT_PH_M35_P#H"?\
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M_P"@)_Y-I_A6U10!B_VIJ_\ T!/_ ";3_"C^U-7_ .@)_P"3:?X5M44 8O\
M:FK_ /0$_P#)M/\ "C^U-7_Z G_DVG^%;5% &+_:FK_] 3_R;3_"C^U-7_Z
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MO_I)\AG6F88=^G_I1^E-?&O[<ZM_PF'AIL_*;&0 >_F?_JK[*KY._;LTL_\
M%(:BH^7_ $FW<_\ ?ME_]FKP>'Y*.8T[];_DSVL\BY8"=NEOS1M?L,_\B5XC
M_P"P@O\ Z+%?2]?*?[">J(UIXMTTG$BO;W"CU!#J?RPOYU]65EGD7',:M_+\
MD:Y-)2P%.WG^;"BBBO"/:/CW]NH_\5!X4'?[+-_Z&M=)^PNK?\(SXI;/RF\B
M '_ #_B*X7]M[5$NOB/H]BAR;7359_9GD<X_)0?QKU+]B72S:_"_4KQA@W>J
M/M]U6.,#]=U??XC]WP_!/K;_ -*N?#4/?SV;72_Y6(OVX?\ DF>B_P#873_T
M3+7EG[$/_)5]6_[ DO\ Z/@KU/\ ;A_Y)GHO_873_P!$RUY9^Q#_ ,E7U;_L
M"2_^CX*K"?\ (@J?/\Q8K_D=T_E^1]O4445^?'W05\R?MT$?\(IX8&>?MLG_
M * *^FZ^1_VZ]81KSPEI2M\\<=Q=2+GLQ15/_CCU[V11<LQI6Z7_ "9XF=24
M<!4OY?FC(_8;5O\ A.O$+9^4:: 1[F5<?R-?1O[07_)%_%W_ %Y-_P"A"O#_
M -A31SGQ;JK*<?Z/:QMV/WV<?^@?G7N'[07_ "1?Q=_UY-_Z$*]'-)*6=*W1
MP_0X,MBXY0[]5+]3XQ_9?_Y+MX5_ZZ3_ /I/+7Z(5^=_[+__ "7;PK_UTG_]
M)Y:_1"JXH_WR'^%?FR>&_P#=9_XOT1^7_P 2$,?Q$\4JW#+JMT#_ -_FK]%O
MA2RR?"WP<RC"MHUF0/;R$KX$^/FD'0_C)XNMBFS=?O< 8[2XD'Z/7V]^SKK"
M:Y\%?"DR'/E6GV5AZ&)C'_[+^M>AQ!^\P&'JK;3\4<&1>YC:]-[Z_@ST>BBB
MOSX^["BBB@#Y+_:X^.5]::E)X'T*Z:VC2,'4[B%L.Y89$((Z#:06QUW8[$'R
M?X*_L]:U\87DNUF72M"A?9)?R(6+MQE(UR-Q /)R /TKC?B9J$NJ?$;Q/=S,
M6DEU.X8Y]/,; _ 8%?H1\$]'BT'X2>$K6%50'389GV8P7D42.>.N68\U^E8J
MK_8F74X8=6E+KYVU?^1^>X:E_;&/G+$/W8]/GHO\SSS1_P!C'P#I\:B\?5-4
MDXW--<A%/T"*,#\3]:Z:Q_9?^&6GX*>%XY6&,M/=3R9Q[,^/TKU.BOAYYGC:
MGQ5I?>U^1]E#+L'#X:4?N1\:_MC> O#O@FR\)#0=&L]*\][H2FVC"F0*(MNX
M]3C)Z^M7/V$_^0OXO_ZX6W_H4E:7[=W_ !Y^"_\ KI>?RAK-_83_ .0OXO\
M^N%M_P"A25]ESRJ</.4W=^?^,^2Y8PSU1BK+_P"T/H?XW?\ )(/&/_8+G_\
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M1^YE>(F]O>_])/A<X]_,J$%OI_Z4?HC7Y.M]XU^L5?DZWWC2X3_Y?_\ ;O\
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M%X2;5GJG_7X,^W;&^@U*QM[RUD6:VN(UEBD7HR, 01]014]<E\(_^24>"_\
ML"67_HA*ZVO@*L?9U)071L^YIRYX1D^J"BBBLC0**** "BBB@ HHHH ****
M"BBB@#%TO_D8]<_[8?\ H!K:K%TO_D8]<_[8?^@&MJ@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#*O\
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MI&01T-+7YMW&H?$GX.W LI;K7O#0#?+#YLB0.1W49V/]1FK?_#2'Q*\GRO\
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M][=/S/8R_&SQT93E3Y5T\SF/BAJ']D_#?Q5>9VF'2[EU/^UY38_7%?G1\-+
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M44 %%%% !1110!BZ7_R,>N?]L/\ T UM5BZ7_P C'KG_ &P_] -;5 !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(3CF
M@#,\2:[#X=TF>\F91M'R*Q^\W85E>"?'EKXNMR/E@O%^]#G]17EOQ0\7'Q!J
MYM8'S96YP,=&/K7*:7J=QH]]'=VKF.6,YX[^U>A'#IPUW/2AA>:G=[GU-6/X
MH\36GA;37N[EN>B1CJQK(T7XC:=J'AN34IY5BD@7]]$3SN]AWKQ+Q=XLNO%V
MJ/<3$K #B*'/ %30PTJDO>V1\EFV8++X\B^-[+]3W+P'XYB\96<K;/*N8F^:
M,=E[&NJKY?\ "?B*;POK4%Y%DIG;(F<!@>.?I7TQI]]#J=E#=0-OAE7<K"EB
MJ'L97CLS/*,P^NTN6H_?COY^98HHHKB/?"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "O@#]K3PS_PCOQFU*9$V0ZG#%?)Z9(V/_X^C'\:^_Z\3_:2
M^ ^H?&*'19]&N+&TU&Q:1':^=T5XF .,JK'(9>./XC7T.1XR&#QBE4=HM-/\
M_P!#PLZPLL7A7&FKR337Y#_V1_%'_"1?!NRMG;=/I4\EDV>NW.]/_'7 _P"
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MUMH;:/\ NPH$'Y"K%%4Y2:LV2HQ3ND%%%%24%0W5G!?0F*Y@CN(CUCE0,I_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBBB@#%TO_D8]<_[8?^@&MJL72_\ D8]<_P"V'_H!K:H **** "BBB@ HHHH
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MJM10!9_M"X_YZ?\ CH_PH_M"X_YZ?^.C_"JU% %G^T+C_GI_XZ/\*/[0N/\
MGI_XZ/\ "JU% %G^T+C_ )Z?^.C_  H_M"X_YZ?^.C_"JU% %G^T+C_GI_XZ
M/\*/[0N/^>G_ (Z/\*K44 6?[0N/^>G_ (Z/\*/[0N/^>G_CH_PJM10!9_M"
MX_YZ?^.C_"C^T+C_ )Z?^.C_  JM10!9_M"X_P">G_CH_P */[0N/^>G_CH_
MPJM10!9_M"X_YZ?^.C_"C^T+C_GI_P".C_"JU% %G^T+C_GI_P".C_"C^T+C
M_GI_XZ/\*K44 6?[0N/^>G_CH_PH_M"X_P">G_CH_P *K44 6?[0N/\ GI_X
MZ/\ "C^T+C_GI_XZ/\*K44 6?[0N/^>G_CH_PH_M"X_YZ?\ CH_PJM10!9_M
M"X_YZ?\ CH_PH_M"X_YZ?^.C_"JU% %G^T+C_GI_XZ/\*/[0N/\ GI_XZ/\
M"JU% %G^T+C_ )Z?^.C_  H_M"X_YZ?^.C_"JU% %G^T+C_GI_XZ/\*/[0N/
M^>G_ (Z/\*K44 6?[0N/^>G_ (Z/\*/[0N/^>G_CH_PJM10!9_M"X_YZ?^.C
M_"C^T+C_ )Z?^.C_  JM10!9_M"X_P">G_CH_P */[0N/^>G_CH_PJM10!9_
MM"X_YZ?^.C_"C^T+C_GI_P".C_"JU% %G^T+C_GI_P".C_"C^T+C_GI_XZ/\
M*K44 6?[0N/^>G_CH_PH_M"X_P">G_CH_P *K44 6?[0N/\ GI_XZ/\ "C^T
M+C_GI_XZ/\*K44 6?[0N/^>G_CH_PH_M"X_YZ?\ CH_PJM10!9_M"X_YZ?\
MCH_PH_M"X_YZ?^.C_"JU% %G^T+C_GI_XZ/\*/[0N/\ GI_XZ/\ "JU% %G^
MT+C_ )Z?^.C_  H_M"X_YZ?^.C_"JU% %G^T+C_GI_XZ/\*/[0N/^>G_ (Z/
M\*K44 6?[0N/^>G_ (Z/\*/[0N/^>G_CH_PJM10!9_M"X_YZ?^.C_"C^T+C_
M )Z?^.C_  JM10!9_M"X_P">G_CH_P */[0N/^>G_CH_PJM10!9_M"X_YZ?^
M.C_"C^T+C_GI_P".C_"JU% %G^T+C_GI_P".C_"C^T+C_GI_XZ/\*K44 6?[
M0N/^>G_CH_PH_M"X_P">G_CH_P *K44 6?[0N/\ GI_XZ/\ "C^T+C_GI_XZ
M/\*K44 6?[0N/^>G_CH_PH_M"X_YZ?\ CH_PJM10!9_M"X_YZ?\ CH_PH_M"
MX_YZ?^.C_"JU% %G^T+C_GI_XZ/\*/[0N/\ GI_XZ/\ "JU% %G^T+C_ )Z?
M^.C_  H_M"X_YZ?^.C_"JU% %G^T+C_GI_XZ/\*/[0N/^>G_ (Z/\*K44 6?
M[0N/^>G_ (Z/\*/[0N/^>G_CH_PJM10!T=%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!BZ7_ ,C'KG_;#_T UM5BZ7_R,>N?]L/_ $ UM4 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!%<_P#'O+_N'^58-;US_P >\O\ N'^5
M8- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 ='1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 8NE_\ (QZY_P!L/_0#6U6+I?\ R,>N?]L/_0#6U0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7A'[7'@EO$'@./5[>)
M?-TMS-*P'S,AXQ],FO=ZIZQI<&M:7<V-U&LL$Z%&5NAS0>IE>.EEN-I8J/V7
M^'7\#\P**Z;XC^#+CP%XQU'1YU;;#(?+D;HZGG(_.N9K(_K.C6AB*<:M-WC)
M77S"D/(-+10;GT#X-U#^T_#=G-_=7R_R&*Y3XT+_ ,2G3V_Z;X_2I_A#JWVK
M1YK CYK9MV[UW&KGQ6TTW_AGS1_RZMYI_+%?58":<X29_('B)@9T\%F&'A':
M[7I=2_+4\3HHHK[ _BL**** "NX^$<?F>(K@YQM@S^M</7HWP?MC]IO+C'&W
M9FN?$.U*1Z66QYL73]3U.WB-Q<11*,M(X4#ZU]3Z' ;71K&%AAHX44CZ"OG;
MX?Z4VL>++&$#/EMYQ_X"<U]+U\1F$M8Q/Z X;HVC4J]] HHHKR3[,**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8X^K$8& .,M9/DAO^1II%<TMC1A^(GQ._:%^)#6_AO5=2T2V;I!87DL%O9P
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MU;2[N5[>W'F2S:#>N=JCJ60A68>ORD8ZU]XA@P!!R#T-+2=U\.A2_O:GS?\
MLT_M+77C^_7PQXH:,ZT4+6E\BA!<[1ED91P' !.1@$ \ CGZ0KY>D_91U_3?
MC(/%6B:CI5AI$6IK?0V^^3S53<&9-H3:,G<,9Z&OJ&JOS14MF3;EDXK5!111
M4E'YUR>,OB3XH^(E[H6A^*?$$]Y/?3Q6UJFKRQ+PS' +2!0 !ZCI79_\*O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKZDTG]FSX::+.)K?PG:2..@NI);A?^^9&8?I7HUK:06-M';VT,=O;QKM2*)
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MTYX[BUW'/EK)N#(/;*@X]S51M.ZZHF5X6?1GB_[2UP=6_:"UN*1LHLUO;CV
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M0CP]_O7/_I1)79?$[X;:5\5/"L^B:J&1&(DAN(_OP2#.'7\R".X)KC?V3_\
MDA'A[_>N?_2B2I?'G[3'A+X>>+I/#FIP:G)?QF,.UO AC4.%(.YG'&&].QK2
MLE*HXOJ11;C%R72_YGR_XB_9S^)_PJU1[[05N[^*,_N]0T"5A*5]#&I$@/J
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MV/[;?CFZOK>%]*\/!9)%0E;:?."0/^>U?;5%%%]+%=;A1112&%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 ='1110 4444 %%%% !1110
M4444 %%%% !1110 4444 8NE_P#(QZY_VP_] -;58NE_\C'KG_;#_P! -;5
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1)A(Q Y\E\*X_ [#^!K#_8E^(']I^&M2\)W,F9]-?[3:ACR87/S ?[K\_P#
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M:PI5*GP1;..OC,-AOX]11]6D>A45X[_PU9\/_M'E?VDW3._ V_GFM[2?V@?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 17/\ Q[R_[A_E6#6]
M<_\ 'O+_ +A_E6#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '1T444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% &+I?_ ",>N?\ ;#_T UM5BZ7_ ,C'
MKG_;#_T UM4 %%%% !1110 4444 %%%% !1110 4444 %%%% !534M+M=6M7
M@NX5FC88.X<CZ>E6Z*:;6J)E%25I+0\A\5?!,AI+C1)..,6LA_/YC7F6I:+?
MZ/,\5W:R1,IP6VG;^=?5=5-2L[*\MV%]%%+"HR?- (KT:6-G'26I\QB\AH5K
MSHOD?X?\ ^40V>AS6)K]CHMQ#MOX8S_US&&_,5Z)\1)O#]U<20:%$\3*<&9"
M A^@KS&?PG/-(6^TJQ/=LFO?HR4DI/0_-\=3=.3I12GY]#@]4\*V-Q.38[K6
M/T8ELUE3>$)T_P!5()?J,5Z,_A2Z4X#*WTH7PK=LV"RJ/6O35>RW/E)Y=SN_
M);T/,#X7U$?\LE_[[%*OA:_/WHU4?[PKU9/!TO\ %<)^ -7[?PK:Q8+EG;Z\
M4/%"CD[EO=?,\HM_!,T^,RG/HJYKI]%^%(F9?M3%MQ&W;U/MBO1(;2&U7]W$
MJ?[HKUSX5_#IIG36-3CP@YAA8=?<UPXC'.G&Y]!EW#L,355-*_?LC2^"_P )
MM-\ Z.+Q;91J%PNXLZ_,B_W:^./C#XPN/&WQ U2^F=VB63RXHV.0@7@X';I7
MZ+'D$5^?GQZ^'MWX#\?7J-;R+I]VQFMIL9#CJWTP37QE:I.M)SF]6?V+X9X?
M!X"O/#024N7W?O\ >^>QYQ7N/[)_C6ZT/Q\ND%VDL=07RQ%NX5\_>_(5X=FO
MH;]DGX<7>I^)G\2W4+QV%H-L+,,;I<@_E@U@MS]?XEGAX937^L;-:>O2WS/L
M6BBN-^*7Q0TGX5>&9=5U.3+X(@ME/SS-Z"MX0E4DH05VS^4:]>EA:4JU:7+&
M.K;-OQ-XLTKP?I4^HZO>Q6=M"I<EV&3CLHZD_2ODOXH?MK7]Y)/8^#;=;.)6
M^749@&+CO\A'%>'?%/XMZY\5M:>\U.=EM5;]S:*3LC'T]:S? OP[U[XC:M'8
M:)8R73E@)) ,)&O=B?05]MA<IHX>'M<5J_P1^"9QQICLSK?5,I3C%Z)KXI?Y
M?+7S(/$/CO7_ !1?2W6I:M=3R2'++YK!/P7.!6+!:S7C$0PR7#=_+0L?TK[6
M^'O[$^B:/&L_B:];5+P'(2W.V+Z$$<U[;HOPI\(^'HU6P\/V%N5'WUA&X^Y-
M.IG6&H^[1C?\$9X7@/-,=^]QM10;[OF?]?,_,?\ X1W5<9_LJ]Q_U[O_ (54
MN+2:S8">"2!NWF(5/ZU^L']@Z=MQ]B@QZ;!6%K7PI\(^((V6_P##]A<$C[[0
MKN'N#7/'B"-_>IZ>IZ=7PWJ*/[K$IOS7_!9^:>@^-M=\-7D-SIVK74#Q'*J)
MF*?BN<&OH;X8_MJZIITD=GXP@74(&8 WL("-&O\ N@?-7<?$+]B?1=8C:?PQ
M>MI=X3DQW!W1?0 #BODOQU\.M>^'.K/8ZY8R6K[B(Y"/ED _B!]#7HQG@<T7
M+;7[F?,5</Q!PC-5%)J'=:P?JO\ .WD?IIX5\8Z/XUTN'4-'OHKRWD4,-C#<
MN?[PZ@_6MJOR]^&?Q4USX6:TE_I%PPCW9EM6)\N4>A%?H9\)OBMI/Q:\,1:I
MIL@6=0%NK5C\\#^A^O6OELPRV>#?-'6'?_,_7^&^*J&>1]C47)673H_-?Y=#
MMJ***\4^["BBB@ HHHH **** "N,^,7A&X\=_#?7-#M&"7%U#A"?4$-C]*[.
MBKIS=.:G'=:G/B*,,31G0J?#)-/T>A^4>H^#];TJ_EL[C2;Q+B-BI40,<GVX
MYK[B_9$^'.I>!O ]Q=:I&UO<:DZR"W;JBC./S!KVZ?2+*ZN%GEM89)EZ2,@)
MJW7N8W-IXNE[+EMW/@,BX,HY+C'C'5<VKJ*M:U^_R%HHHKP#]'"BBB@ HHHH
M **** "BBB@ KXR_;J_Y#FA_[K?RK[-KXR_;J_Y#FA_[K?RKVLG_ -\C\SX/
MC?\ Y$E7UC^9S?[$_P#R52[_ .O(_P#H0K[QKX._8G_Y*I=_]>1_]"%?>-:Y
MW_O;]$<G /\ R)E_BE^@4445X!^CA1110 4444 %%%% !1110 4444 %%%%
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M]9*L?%#X@-KET^G6$C+91'#NO&]J\\KW,+A>5<\]S\_SC-G6;P]!^ZMWW_X
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MSK.\/D=&-;$)M2=M#[BHKY4^%_[44VC_  BU3Q#XLNDU+5%U!K:SM8P$:3Y
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MG03JR7;1??\ Y(_3K</6BORE/C?Q"QY\0ZGG_K\D_P :DC\=>)(^5\0ZH/\
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MJTNZCG@\0:B7C.X"2Y=E_$$U[O\ #C]M;6]/O([?Q9;QZC9MA?/MT$;1CU(
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJU#_ (_KG_KJW_H1K]%?V7?^2+:%_P!M/_0C7VV>_P"[1]?T/P/P]_Y&M7_
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MG(R5SR%'I@&OK\=BJ>!BZEKSE_7W'XIP]D^*XBJ1PKFU1IZOROV\V>4_#O\
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MNMF5/BI;Z-8?"OX>Z-X?N_/BEUBT-FV<N1N;+?F:^B;.-X;.".0[I%158^I
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M_P"*A_ZAG_D2C_BH?^H9_P"1*VJ* ,7_ (J'_J&?^1*/^*A_ZAG_ )$K:HH
MQ?\ BH?^H9_Y$H_XJ'_J&?\ D2MJB@#%_P"*A_ZAG_D2C_BH?^H9_P"1*VJ*
M ,7_ (J'_J&?^1*/^*A_ZAG_ )$K:HH Q?\ BH?^H9_Y$H_XJ'_J&?\ D2MJ
MB@#%_P"*A_ZAG_D2C_BH?^H9_P"1*VJ* ,7_ (J'_J&?^1*/^*A_ZAG_ )$K
M:HH Q?\ BH?^H9_Y$H_XJ'_J&?\ D2MJB@#%_P"*A_ZAG_D2C_BH?^H9_P"1
M*VJ* ,7_ (J'_J&?^1*/^*A_ZAG_ )$K:HH Q?\ BH?^H9_Y$H_XJ'_J&?\
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MA_ZAG_D2C_BH?^H9_P"1*VJ* ,7_ (J'_J&?^1*/^*A_ZAG_ )$K:HH Q?\
MBH?^H9_Y$H_XJ'_J&?\ D2MJB@#%_P"*A_ZAG_D2C_BH?^H9_P"1*VJ* ,7_
M (J'_J&?^1*/^*A_ZAG_ )$K:HH Q?\ BH?^H9_Y$H_XJ'_J&?\ D2MJB@#%
M_P"*A_ZAG_D2C_BH?^H9_P"1*VJ* ,7_ (J'_J&?^1*/^*A_ZAG_ )$K:HH
MQ?\ BH?^H9_Y$H_XJ'_J&?\ D2MJB@#%_P"*A_ZAG_D2C_BH?^H9_P"1*VJ*
M ,7_ (J'_J&?^1*/^*A_ZAG_ )$K:HH Q?\ BH?^H9_Y$H_XJ'_J&?\ D2MJ
MB@#%_P"*A_ZAG_D2C_BH?^H9_P"1*VJ* ,7_ (J'_J&?^1*/^*A_ZAG_ )$K
M:HH Q?\ BH?^H9_Y$H_XJ'_J&?\ D2MJB@#%_P"*A_ZAG_D2C_BH?^H9_P"1
M*VJ* ,7_ (J'_J&?^1*/^*A_ZAG_ )$K:HH Q?\ BH?^H9_Y$H_XJ'_J&?\
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MOK'\SA?V1?#5IXA^+EM+=#<=/C^U1#MN!QS^=?H/7P=^Q/\ \E4N_P#KR/\
MZ$*^\:VSR3>*L^B1P^'].,<HYDM7)W_ ****^?/TH**** /*OVFM#36O@[KK
M.H;[)$;E<CH5!Y_6OSHTV8V^H6DP.#'*CY^A!K],?CM_R1WQA_V#9O\ T&OS
M)M?]9#]17W&0MNA.+[_H?S[XB04,QHS6[C^39^J7@&[-_P""=$N"=QEM(W)/
MNHK?KE_A?_R3KPW_ ->$/_H(KJ*^,JZ5)+S9^[X1N6'IM_RK\C\J?'O_ "._
MB#_K_G_]#-?:_P"Q;I\%K\*99HT EFO7+OW/"U\4>/O^1W\0?]?\_P#Z&:^W
M_P!C7_DD(_Z_)/Y+7V^;_P"XQ^1^ <$I//YM]I?F>[T445\&?T4%%%% !7P[
M^W)I;0?$32KQ8]L,MB%+@=6#M_2ON*OD/]NS[VA?7_&O;R>7+C(^=SX+CBFJ
MF25&^CB_Q. _8MD*_&F-.S6$_P"@%??=? '[%_\ R6Z#_KPN/Y"OO^M<\_WO
MY+]3A\/_ /D3O_'+\D>2?M2?\D;US_KD:_/30;=+O6M/@E&Z*2=$8>H) -?H
M7^U)_P D;US_ *Y&OSX\,_\ (Q:5_P!?,?\ Z$*]G)/]UEZ_H?#<?*^;T4_Y
M5^;/U+\(V<.G^%]*MK=!'#%;1JJCL HK7K.\._\ (!T__K@G\A6C7Q$OB9^_
M44E2BEV04445)L%1W$"75O+#(-T<BE&'J",&I**!;Z,_+KXN:*GA_P")GB2P
MB7;#%>R",?[.>*^KOV%]3EO? >N6\ARMK>JB<]BF:^<?VD8UC^,&O;1C,S$_
M7)KWS]@S_D7/%'_7VG_H%?>9B^?+5)]H_H?SKPS'V'%,J<=KS7YGU31117P9
M_184444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !114<D\<*[I)%1?5F %)M)78]]B2BLJ?Q5HUKD2
MZM91GT:X0'\LU2E^(7AR'[VKVY_W26_D*\ZIF6!I?Q*\%ZR2_4Z(X6O/X:;?
MR9T5%<JWQ1\+KP=63\(I#_[+2?\ "T_"W_067_OS)_\ $UR_V[E/_073_P#
MX_YFOU#%_P#/F7_@+_R.KHKF8_B5X9DZ:O"/]Y6'\Q5R'QIH%Q]S6++/HTZJ
M?U-;PS;+ZFD,1!^DH_YD2PF(C\5.2^3-JBJ]OJ-K>#,%S#,/^F<@;^53UZ49
MQFKQ=T<K3B[-"T4458@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#%TO\ Y&/7/^V'_H!K:K%TO_D8]<_[8?\
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M%<EQ'Q8=+TNOR9^4GBWP[)X3\1W^DRN))+65HRP[X.,U]B?L*_\ )/\ 6O\
ML('_ -!6OE7XP7$=U\3/$+Q.'3[7(NX=,AC7U5^PK_R3_6O^P@?_ $%:^KS6
M3E@+O=V/QO@^G&EQ&Z<-ESI'TQ7QE^W5_P AS0_]UOY5]FU\9?MU?\AS0_\
M=;^5?-Y/_OD?F?JG&_\ R)*OK'\SF_V)_P#DJEW_ ->1_P#0A7WC7P=^Q/\
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M?]=.>?[U\E^IY?A]_P B=_XY?DCR3]J3_DC>N?\ 7(U^?'AG_D8M*_Z^8_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^)-<U17X9F_%V:YQ>-6IR0?V8Z+Y]7\V?>8/)\)@[.,;R[O5_P#  DGKS10
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MES1[K]>QO4445]L>&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT&*6N7$5GB*LJK5KGJY7@5EN#IX.,N905KA1117.>H%5=44MIEVH&287 '_
M35JBFA27,FC\M+[X>^)&O+@C1[H@R,?]6?4U]]_LV:?<Z7\']%MKN%H)TW[H
MW&"/F->G>6G]U?RI0 . ,"O:QN9RQE-4W&UF?!Y#PG3R+$RQ,*KDY*UK6ZI]
M_(6JFK:3::YI\]C?0)<VLZE)(I!D$&K=%>*FT[H^[E%23C)73/CCXK_L77<%
MU/?^#91/ Y+#3Y3\X)]&.!BOGGQ!\,_%'ABZ>WU'1;J&5.&54+_J*_4VFF-6
MZJ#^%?0X?.Z])<M1<WYGYEF7 .7XR;J8>3I-]%JONZ?>?DQ_8=__ - V[_\
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M%5KI<]I%''*^TLHYZ_6O=*;5A)W"BBBD,**** "BBB@ HHHH **** "BBB@
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M )&/7/\ MA_Z :VJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!'9:B@<\!9OW9/L,T[,5T==7R3^T3_R4!_\ KG_6OK:ODG]HG_DH#_\ 7/\
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M9\M3N?\ +K6%HOQP\(:]="WMM1*2$X'G1F,?F:=F*Z/"_P!H_P#Y'H_]<_\
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MZAN()&BFB<.DBG!4@Y!%?;WAK4FUKP[I>H.-KW5K',P]"R@_UKX;K[6^'_\
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M\Q/X3U?X?_LVP:MH\-]KMS+&9TWI!;G:R9_O5QWQ4^$-W\-IHK^UG:?3F?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP6R7]?B?F]:M4Q$W4JRNV%%%%=AB%%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH Q=+_Y&/7/^V'_ * :VJQ=+_Y&/7/^V'_H!K:H **** "BBB@
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MS7JE>5_M+?\ ),9?^ON'^9K*.YH]CS_]EC_D8=;_ .N"?S-<]^T3_P E ?\
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MVIO^1QTG_KR/_H9J8;A+8]<^ _\ R3#2?^!_^A&O0:\^^ __ "3#2?\ @?\
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MI6<]RH['R7^TA_R/DW_7,?\ H(KWOP;_ ,DIM_\ KP/_ *!7@G[2'_(^3?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXU_\,OR9\DT445^OG\_GT?\ LQ?\BWJ__7TO_H KV>O&/V8O^1;U?_KZ7_T
M5[/7Y3F_^_5/7]$?NF0_\BVCZ?JPHHHKR#WPHHHH ***R?$7BC3_  O9FXOY
MPF?N1KR[GT _R*PKUZ6&IRK5Y*,5NWHD:4Z<ZLE""NV:DDBQ1L[L$11DLQP
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MLR^%9M-T:]U>9#&;PB-0PQE5.0?UKS[]I"SEM_'R/(N%FAWH?49JU\1/V3Z
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M JC)/2OF7X)^++'P;XTBO-28Q6S0M$S@9VD^U$?A82W1]D5\Q?M3?\CCI/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K*\2>&=/\
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MZZ]F!]*^XR_,Z6/5EI);K_(_-,VR6ME<N9^]![/]'V,6BBBO9/G0K[6^'_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HJ-;B)FP)$)] PJ2@ HHHH **** "BBB@
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MKTGX'?\ (P77_7 _S%>;5Z3\#O\ D8+K_K@?YBOS_A+_ )'N%_Q?HSZ'./\
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MW5<'\$?^2=Z?]6KO*E[E+8****0PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@!KNL:,[D*JC)8] *I6^O:;>3+%!?V
MTTK?=1)5)/T&:A\5$CPOK!!P?L<W_H!KY*^!US-)\3O#ZM,[*6?()_V#5J-U
M<ENS/LJBBBH*"BBB@ JI>:M9:>P6YNX;=CR!)(%/ZU;KYJ_:>GEB\26 21D'
MD#[IQW-5%7=A-V1](6UU#>0K+!*DT3='C8$'\:EKSSX"2-)\,=*9V+-M;DG_
M &C7H=)Z.P+8****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQMSSCK7K?B#P;I?B'P]-H\]LD=HX^41J!Y;=F7W%>:?LQ?\ (MZO_P!?2_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M16_7Y74IRI2<)JS1^XTJD*T%4INZ>J"O"OVH_P#CS\/?[\W\DKW6O"OVH_\
MCS\/?[\W\DKULF_W^G\_R9X/$7_(KK?+_P!*1\_4445^IGX>?8'P7_Y)AH/_
M %R?_P!&-76ZE_R#[K_KDW\C7)?!?_DF&@_]<G_]&-76ZE_R#[K_ *Y-_(U^
M08K_ 'NI_B?YG] 8'_<*7^"/Y(^&+O\ X^I?]XU#4UW_ ,?4O^\:AK]?6Q^
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M"6%=+"SKR^V]/1?\&Y0U[_D!ZC_U[2?^@FOEB7_6/]37U/KW_(#U'_KVD_\
M037RQ+_K'^IK^4_$_P#CX7TE^:/WSA;X*OJOU&UZ3\#O^1@NO^N!_F*\VKTG
MX'?\C!=?]<#_ #%?G_"7_(]PO^+]&?0YQ_N%7T/;Z***_L _' HHHH ****
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MVJ/^0UHO_7NW_H9KDOV>_P#DHEE]#_(UUO[5'_(:T7_KW;_T,UM]HS^R>D_
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M_P"ABNYTW_D'6O\ UR7^0KAOCY_R2W6/HG_H8K*.Z*>QYA^RW_R&M4_ZX?\
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M^T>]5Y-K/P#M=7\8?VZU\ROYR3>7S_">E>LT5"=B[7.*\<?"71?B!-!+J;7
M>%=J^3)MK=\->'[+P;H=KI=J["UMUVH9FR<>YJEX^\=6/@'09-0O&W.?EAA'
MWI&]!7SI9:MX[^-&KW"V=R]O:9Y4$B"+_9SUJDFUY";29[7\<;J&3X<Z@J31
ML=R\!P3UKRS]E;_D9M:_Z]4_]"K#\7?!7Q-X5T*?4M0U&VGMXR-T:2,2<_6M
MS]E?_D:-:_Z]4_\ 0JO:+L1]HS_VFO\ D=+7_K@?YU[O\)0%\!:9@8^2O"/V
MFO\ D=+7_K@?YU[Q\)?^1"TO_<J7\*''XF:WC3_D5=3_ .N)KYA^ '_)2U_Z
MYO\ ^A5]/>-/^15U/_KB:^8?@!_R4M?^N;_^A4X[,<MT=I^TYX-=FM/$%M S
M+CR[J0?P@ !:T/V>_BA#=6$?AO49=EU%Q:LQX9>R#WZU[/K&D6NO:;/8WD2S
M6\R[65OYU\??$3P+J/PO\3 Q,ZVI??:72_7@$^M$?>5F)Z.Y]F,BOPRAA[BN
M4^*"A/ >JA0 /+[?6L+X,_%2+QYI0M;MECU>V7$B9_U@_O"M[XI?\B+JO_7/
M^M1LR]T>!_LR_P#(]7?_ %[?^S5]45\K_LR_\CU=_P#7M_[-7U13GN3'8^2O
MVE/^2FS_ /7G%_(U[_\ "W_DD^A_]>(_K7@'[2G_ "4V?_KSB_D:]_\ A;_R
M2?0_^O$?UJI?"A+XF?-OPM_Y*I#_ -?+_P#H=?2_Q>_Y)WK'_7,?^A"OFCX6
M_P#)5(?^OE__ $.OI?XO?\D[UC_KF/\ T(42W01V9X9^R_\ \C[?_P#7B?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J&\O(M/LY[F9ML,*&1V]
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% &+I?_(QZY_VP_\ 0#6U6+I?_(QZY_VP_P#0#6U0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 5\I_M,?\E"'_7FG]:^K*^4_VF/^2A#_ *\T_K6D-R);'O/P;_Y)?X<_
MZ]1_,UN>+O\ D5=8_P"O27_T UA_!O\ Y)?X<_Z]1_,UN>+O^15UC_KTE_\
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MTK]GO_DE^F?5_P#T(UH_A1"^(T_C/_R3;6?^N:_^A"O#_P!F/_D?KS_KS/\
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M -?(WP+_ .2H>'O]Y_\ T U]<^+/^16UC_KSF_\ 0#7R-\"_^2H>'O\ >?\
M] -:QV9G+='V5<3+;P22M]U%+&OB]6G\:_$_,[;WDOL'=W17Z?E7V5J4!NM/
MN(5ZNA4?E7Q?X8O%T?XD0R2#A;\QG\7Q1#J$NA]JVUO'9V\<,*!(HU"JJ] !
M7SK^U3_R&-#_ .N#?^A5]' A@".17S)^T_JUO>>*--M(7#R6T#++C^$ELX_*
MIAN.6QZ9^SA_R2VR_P"N\O\ Z%7F_P"U%_R,NG_]>X_F:](_9P_Y);9?]=Y?
M_0J\W_:B_P"1ET__ *]Q_,U2^(3^$]3^ /\ R3#2?]UO_0C6)^TQ_P B7%_U
MT_PK;^ /_),-)_W6_P#0C6/^TM"[^!1(!\D<@W'ZD4OM#^R8W[+L,<N@ZGOC
M1SYY^\H/I7N'V.W_ .>$?_? KP;]EK4H?L^J:?N'G[O.V_[.0*]_J9;CCL0B
MS@4Y$$8/^X*FHHJ2CR']IK_D04_Z^4_G6'^RS_QXZK]1_.M[]IE&/P]#@9 N
M8P?SKFOV6+R-O[8M<_O5"N1[$FM/L&?VCZ!JC)KFFPW'D/J%JD^<>6TRAL^F
M,U>KXY\5727GQD22%]Z&_A4$>H;%3%<Q3=CI/VFM=EO/&%OI8;-O;PK*O/\
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M_%OT'ZUZW117P.)Q57%U'4JN[/U+!X*A@:2HT(V7XOS84445RG<4=<!;1-0
M&2;>0?\ CIKY7D_UC?4U]:LH=2K#*D8(/>OG_P >_#F^\/ZA-<6L+W.FN2R2
M(,F,?W6QTQZU^*^)&5XG%4Z&,HQ<HPNI6Z7M9^FA]OPUBJ5*4Z,W9RM8XBO2
M_@:K-KUVP'"P')_$5P%GH][J%PL%M:RSRL<!8U)->]?#7P2WA'3'>YP;^XP9
M .=@'1<]Z^"X'RK$XO-J6)C!^SIN[?39V7JV>_GN+I4<'*DW[TM$CLJ***_J
M<_*0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,72_\ D8]<
M_P"V'_H!K:K%TO\ Y&/7/^V'_H!K:H **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^6/VE+6>
M;X@*T<+NOV-!E1GUKZGJO<:=:73[YK6&9\8W21AC^HJHNSN)JZ.5^#J-'\,?
M#JNI5A:C(/7J:W/%JEO"VK@#)-I+@?\  #6G'$D,:I&BQHO 51@#\*<RAU*L
M RG@@C@TNH=#Y)_9_LYXOB%9,\+HN#RP]C7O7QB^'Y\>^&6BMPHO[<^9"W][
M&?E_&NTATVTMW#Q6L,3_ -Y(P#^@JS5.5W<2CI8^,/#/BSQ'\']8G'V>2#<<
M36EP"$DQT-;7C#X]:_XZT\Z7#;1V$4O$BVI):0>G-?5-YHUAJ!)N;*WN&/!:
M2)6/YD57M?"^D6?^ITRT0YSGR5S^>*?,M[$\K[GBGP!^$]WI]Z=?UFV,+!<6
M\$HPP/7=]:Z/]I*&2;P.!&C.?,'"CW%>M@8& ,"HY[:&Z39-$DR_W9%##]:G
MFUN5RZ6/!_V7;>6!=5\R-H\CC<,=Q7OM0V]G;VF?(@CASU\M N?RJ:DW=W&E
M8\*_:!^%-YKLZ^(-(MS<7"KMN84&790, @?SKS#P=\8O$7PZ7[%L%S;)P+2Z
MR GTQS7V'6==>&M)O,^=IMK(3SDPKG\\52EI9DN.MT?-&K?M'>*/$$:P6%K#
MITO]ZU)9C^=>V?!?4-=U'P;')XA6X_M RN=]PNTLA/RXKJ[?PWI5HH$.FVB8
MZ$0KG\\5HJ H  P!P *&U:R0TGU/$?VE?!]UJVFV6K65O)<R6Y\N58USM3DY
M/XUY-X+^,6O>!=,DTNSC2>(_<27.8S[5]C21K(A1U#JW!5AD&J/_  C^E[MW
M]FV>[U\A,_RIJ6EF)QUNCR[5-5U'Q%\";^[U ,]Y*,X(YQN7%>?_ +,]K-#X
M\O&DA=%^QD98?[0KZ<^RP>3Y/DQ^3_SSVC;^5,M]/M;5R\-M#"Y&-T<84_I2
MYM&AV+%?)_[0=I/-\3'9(7=?(CY4<=:^L*K3:;:7$F^6UAE?^\\8)_,BE%V8
M-7,;X>J4\%:.K#!$ R#]37RIX?L[A?BDC&"0+_:+'=MX_P!97V6B+&H5%"J.
MBJ, 5772[)9/,%G;A\YW")<Y]<XIJ5K@XW.7^,2-)\-M<5%+,81@#_>%>%_L
MUVD\/Q$F:2%T7[&XRPQW%?4<D231E)$61&ZJPR#44&GVMK)OAMH87QC='&%/
MZ"DI65@:N[EBOE7]HZTGF^(D;1PNZ_94Y4>]?555Y].M+J3?-:PROTW21AC^
MHHB[,&KHX_P'I*:M\*;#3KA2L=Q:-$X/H217R]XA\/:U\,?$[N(Y+0PR$V]P
MH^4KGC!^E?:\<:0H$C540=%48 J&ZTZTOL"YM8;@#IYL8;^8IJ5@<;GR_P#\
M-">+M>TZ/2["T07K#:+JWRTK?ATKGO''PWU+PMHNGWEZCS7]\#),.24.>AKZ
MZM=!TRS8/!I]K"X.0R0J#^>*LW%G;W8 G@CF Z>8@;^=/FMLA<O<XOX*QM'\
M/=/5U*MEN#7S=\4+.XD^*&M,L$C*;TD$#CJ*^R(H8X$"1HL:#HJC J"32[*:
M0R/9P.Y.2S1*2?QQ24K.XW&ZL+IO&GVH_P"F2_R%0:]HUOX@TBZT^ZC66&9"
MI5NF>Q_.KX&!@# I:@H^,->\*^(OA1XD%Q&LT/D/NAO(Q\C#ZUUEQ^U!K]QI
MIMH["UAN&7;]I5F+ ^N.F:^G;FSM[Q=MQ!'.O]V1 P_6LZ/PCHL<QE72K0/_
M -<5_P *TYD]T1ROH?+7PY^&NL?$/Q,NH7\<JV+2^=<74H_UC9SQ^-?3WB^W
M6'P;J4,285;9E55'M6U!;Q6L8CAB2)!T6-0H_(4YE612K*&4]01D5+E=C2L?
M(OP4LYX_B?:L\+HO[SDCCK7UY5:+3;.WD\R*T@C?^\L:@_GBK-$GS E8^=?V
MHK:6?5M',<32 0'.T9_B->A_L_Q-'\,-.21"K;Y,JP_VC7H%Q8VUV09[>*8C
MIYB!L?G3X8([>,1Q1K$@Z*B@#\A1S:6"VMSY?^-GPEU'1=>N-:TRW>ZT^Y?S
M7\L9:)R<G/M5#PQ^T/XC\+6?V.>*+5 GRK]J)!4>G%?6,D:RH4=5=#P589!K
M+N/">C73 R:7:$^ODJ/Z57-I9BY>Q\RZI\=O&GBR94TE#9/T$5D"V[\Z^EO!
M<E]-X4TI]35TU!K=3.L@PP?'.?>KMOHFG694P6%M"5Z%(5!_E5VI;3V&D,EB
M2>-HY%#(PPRGN*^/?BAX#U'P!XKFNHXY/L;S?:(+E1\H.<XS[5]BU!=65O?1
M[+F".X3^[*@8?K1&7*#5SYEC_:.\3:KI*Z79V$;ZC(@C%U%DR9_O =,UR'C[
MX?ZCX7L]'GNTDFOM0B>:X&,[&W<#\C7U]:>&]*L6W6^G6L3YSN6%0?SQ5NXL
M;>[QY]O%-CIYB!L?G5<R6R%ROJ<G\+5>Z^'NGQ7()W1>60W]W&,5\[_$KX<Z
MQ\//%$FHZ?#(+#S?-MKB$9$7L?0U]<1Q)"@2-%C0=%48%)/;Q749CFB29/[L
MBAA^1I*5F-QNCY@LOVH->M--6VDT^UN)U7;]H=F#'W(Z9KF]"\->(_B]XJ6[
MG2297<&6YD!V*@.=N:^KW\'Z))-YITJTWYS_ *E?\*TK:SM[-2MO!' OI&@4
M?I3YDMD+E[F-J7@VQO\ P?+X>5/)LV@\A0H^Z/:ODO6/#?B3X4^(C*J2VKPL
M?)NXA\CK[&OM.H+JQM[U0MQ;Q3J.@E0,/UJ8RL-QN?,MK^U)KUO9I#)IEG<2
M*,&9F8,?? XJSX$^(WCGQ=XXTUB;F32VN%,\429C1.^3Z5] #PAHBS>:-*L]
M_7_4KC\L5HVMC;661;V\4 /7RD"_RJN9=$+E?<9JMG_:6EW=IG'GPO%GTW*1
M_6OBW4-/U?X7^+C(L4EK<6<I\B9EP&7ID>Q%?;E5;K2[.^;=<VD%PW3,L:L?
MU%*,K#:N>)_"OXQ:]X\\816MU D%FL.6\K)#'/4YKB?CC\.;[POXFDUFQ@8Z
M;.WF+)&,^4_4EO3GI7U%:Z5963;K>SMX&]8HE4_H*FN+>*ZC,<T231GJDBA@
M?P-'-9W0N734^7-%_:/\0VNC1Z8EE#>W87RTN&+;SV!QTS7/^,?!.O0Z,GB+
M6Q+)J.H2AMC#YPI_O#M7UG!X7TBVF:6/3+1)&.=PA7_"KT]G!=*%FACF4=!(
M@8?K3YDMD'*^IYM^SG$\/PQM5D1D;SY>&'^U7.?M+>#;K5+&RU>RMY+AX3LF
M$8SM3DY_.O;H;>*UCV0Q)$G]U%"C\A3I(UE0HZAT/!5AD&IYM;CMI8^._!OQ
MDU[P/I,FE6<:3QG_ %:R9S']*^A+/29?B=\+OLVK$_:+I-V6&,,.5_#-=E_P
MC^E[MW]FV>[U\A,_RJ]'&D*!(T5%'15&!3<NP)=SXJN--\3_  GUXR%9K*YC
M.!.B_)(/8]Q7<1_M3ZZELL1TJR>3;CS2[Y)]<5]+W6GVM]@7-M#< =/-C#?S
MK/C\(:)%*9%TJSW?]<5/]*?,GNA<K6S/"?A?X^\;^+/'EG+<M=3:/EC-&B#R
MUR.,FOHZH;:SM[-2MO!' #U$:!?Y5-4MW*2L8GC/PS#XN\-WFF3*I\U#Y9;H
MKX^4_G7R2(O$WP=\2.X26VEC.WS-OR3+]>XK[1JM=:;:7W_'S:PW';][&&_F
M*<96$U<^8]8_:9\0:QIS6EM96]C-(-OGPLQ8?3-2?!'X5ZAKOB*+7=6MF33X
M6,H,P(:23.0R_C7T5!X2T6WD+QZ7:!CW\E3_ $K4CC2% D:*B#HJC %/FTLD
M+E[GD7[0GP[N?%&DPZGIL)GO+3)DC099U]!]*\<\ ?&35_AO%-8B!+NWS_J)
MR1Y9]L5]A5F3>%](GF6633+1I <[C"O^%)2TLP<=;H^:KZ#Q1\9OM>M:G$UK
MI-E$[PQ*#MSC^'UZ<UI?LNV\T/BC5FDB>,&V7[PQ_%7TC':00P^2D,:0_P#/
M-4 7\J;;Z?:VC%H+:&%CP3'&%/Z4<VE@Y=;GS!^TP<>-K3_K@?YUD:!J7BOX
M30P:I9(TNE7@#,I!,3D#N>W7M6M^TU_R.EK_ -<#_.O<_A?:07GP_P!+2XAC
MG39]V1 P_(U=[11-KMGSIXW^.&N_$&R&G&&.QMI.'AMB6\WV.:])_9V^&EWH
M\LOB#4H6MYI$\N")Q@[3U)KV.'POH]O,TD>F6BNQR2(5_P *TU4*H & .@%0
MY:612CK=G@O[07PJO-5NQXATF!KF4KMN88QEL <$#^=<3X2_: U[P3I::5/9
MQ7R0C;']H+*R*.B\5]8$!@01D5G3>&])N&#2:9:.P.<F!<_RH4M+,.7JCY*O
M)/$WQP\41R?9W;<=B[0?*@4]>?2OIN/P+;VO@$^'X55/]'VG;T:3')_$UTEK
MI]K8Y^S6T-OGKY487^0JQ0Y7V&HV/AT?VW\,?$VY@]G?6S_>Q\K_ $]17H-Y
M\?/%GC>Q_L?2],C@NIOD::U+,^.AX/K7TG?:'I^J9-W96]P?[TD8)_/%)8Z#
MIVFX-K8V\##HT<2@_GBGS+L+E?<^._'W@"]\'O:PSK)<7D\?G2D#."1G'UKZ
MA^%<#-\+M!A8%&-F%(/;K757&GVMTVZ:VAF;UDC#']:ECC2&-4C1411@*HP!
M^%)RNAJ-F?$.N:?K'@/Q5/)(DEE=Q3M)')C@Y;((KW'X%^.];^(%[K-MK,S3
MVRVZA,J,9.037LUUI=E?-NN;."X;UEB5C^HI;73K2QS]FM8;?=U\J,+G\A3<
MKH2C8^1OB!\-=9^'/B)[NSBE-BLGF6UW$,[/8GUK:T;]ISQ#I-BEO<6=MJ+K
MQYT[,&/UQ7U)<6\5U'Y<T23)_=D4,/R-9DGA'19I1(VE698?],5_PHYD]T'*
M^A\U0_%_QWXPUJ Z<LR0M(NZUM$W+MSSUYKW?XH>!_\ A8'@]K-?DNX\30[O
M[X'0_G75VVEV=FVZWM((#ZQQ*O\ (5:J7+L-+N?&WAGQ7XD^#&LW"/:,@8XF
MM;@$))C@-6AXR^-'B'XEVBZ5!:+;02'$D-KEC+['-?5UUI-C?,6N;.WN&Z9E
MB5C^HJ.WT#3+,@PZ?:Q,.C)"H/YXJN9;V%RO:YYM\!_AI/X-TF6^U%-FH77(
M0]8U]#7K%%%0W?4I:!1112&%%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!BZ7_R,>N?]L/_
M $ UM5BZ7_R,>N?]L/\ T UM4 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 51US5$T/1[W4)%+1VL32LH[@#-7JY[XA_\ (BZ__P!>4O\
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M/5$US1[/4(U*QW,2RJI[ C-?*7[1'_)3+_\ ZXQ_^@5]-?#W_D1=!_Z\XO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#]<8__ $"OIKX>_P#(BZ#_ -><7_H(KYE_:(_Y*9?_ /7&/_T"OIKX>_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'^UC\0?VIM)^(5QX]N[&ZDT6>QCL_L5FMN%$JSE\[>O^K6ON&OR[_P""&_\
MR+_Q?_Z^M+_] NJ^_P#XL?M#?#KX&R:>GCOQ78^&FU ,;47A8>:%QNQ@'ID4
M >BT5Y3\3/VI/A=\(? .E^,O%/BZST_0M6A6?39%#2RWR,H8&&)07<893D#
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MA']?W@0X_"O5/@M^W'\%?CYJ46E^$_&MJ^MR?<TK48GL[ESZ(LH D/\ N%J
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M=X+\96UWK.TM_9-Y&]I=$ 9.V.0+OP.I3<!0![?1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%5<<X(4%0!Z?>_BC_@DC\ M;\-R:?INFZMH6H>61%JEOJ#R2!\<,ROE6&>H
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MQ;U+_P!)9*_(;_@L=HT'A_\ :TTC5+()#<W_ (=M+J8K]XRI-/&'/_ 40?\
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MJ_#GXNZ!;^&_^"L<EI:Q"&W?Q=8W*J!@9E2*1C^+,U 'ZH?MU?\ )H/Q7_[
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M_P!.H((/-:M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUS_KSE_]!-5_AI_R(&@?]><?\JF^(#B/P1KK,< 6<O\ Z":QZFO0^8_V>_\
MDIVG_P#7.3_T&OKROD/]GHY^)VGG_IE)_P"@5]>5<]R8['E'[3'_ "3-O^OV
M'^M>$?#+X6S?$^XU"*&^CL39JK$R1[]V[/Y=*]W_ &F/^29M_P!?L/\ 6N*_
M91_Y"7B/_KG#_,TT[1N)_$1?\,GWO_0?MO\ P'/^-7M%_9AOM*UBPO3KT#K;
M3I,4$!&[:<XZU]!T5/.Q\J/(/VEO^1*A_P"NG^%8O[+/_(+U;_KM_05M?M+?
M\B7%_P!=#_2L7]EG_D%ZM_UV_H*:^$7VCK/CI\1)?!/AU;>S;9J%\"L;?W5Z
M,1[\UY3\&O@_'X_6?6M<>62RWE5P^'D<=235C]J.^>?Q%IMN00L$3;??.*]=
M^!\"6_P\L @P&RQ^I I_#'0-Y&)\0OA;X;T7P%K-S:V"I/;VS-')U(([UY;^
MS/\ \CW_ -L'_P#0:]^^+'_)-_$/_7H]> _LS_\ (]#_ *X/_P"@T+X6#W1J
M_M1?\AZP_P"N0_K7JGP'_P"29Z3_ +G]37E?[47_ "'K#_KD/ZUZI\!_^29Z
M3_N?U-#^$%\1V>O?\@/4?^O:3_T$U\A?!_\ Y*UH7_7PW_H)KZ]\0'&@ZD3T
M^S2?^@FOD'X.L&^+&@D'(-PV/^^32CLPENCV#]J+_D5['_KNO]:7]E__ )%N
M]_ZZ?U-)^U%_R*]C_P!=U_K2_LO_ /(MWO\ UT_J:?V ^T>UM]TU\6_$W_DI
MVJ?]=U_E7VDWW37Q;\3?^2G:I_UW7^5%/<)GO?QA_P"2$R?]>]M_-:\V_9>_
MY'?4?^O/_P!FKTGXP_\ )"9/^O>V_FM>;?LO?\COJ/\ UY_^S4U\+!_$CW'X
MM?\ (@ZM_P!<C_(UX/\ LS?\CC+_ -<OZ&O>/BU_R(.K?]<C_(UX/^S-_P C
MC+_UR_H:F/PL'\2/JBOCGXV>(+?Q'X^O9;3#P18C$@'+$#!S^(KZ=^)GBC_A
M$?!NHW\<J1W:QD6X?^)^PKY\^!W@5?'6I:S?7R;XO*>,EN@DD!(8?0T1TU'+
M70[7]E_Q1%)I=]H++ME@<SA\_>W'I^&*]WKXR\%ZM)\./B8JL[>3;7+6TH/1
MQG:":^RXY%DC5U.589!%*:U"+T,WQ1_R+6K?]>DO_H!KY.^!O_)4]'_WG_\
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MKWW_ &'KG_T%*^\*^6?^"=7[/?C#]FOX%W7A;QK!:6^K2:K-=JMG<B=/+8*
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MX[^,>IRW?C&?2;B/1-+U&_#S27C1L(FF<96*-&.0@[@=!U .W_X(;_\ (O\
MQ?\ ^OK2_P#T"ZK&_P""X'_(0^%W_7*\_FE>_?\ !,7]DWX@?LKZ3\0K?QY;
M6%O)K4]C):?8;M;@$1+.'W8''^L7]:S?^"FG['_Q%_:EO/ \G@2UT^X328[A
M;K[=>+!@N5VXR.>AH ^D/V.?^33_ (/?]BGIG_I-'7@O_!7#X3WGQ&_9;?6-
M/A>XN?"NH1ZH\<8R?(*M'*WT57W'_=KZ8_9W\%:G\-_@+\//"FM)''J^BZ#9
M:?>)"X=!-%"B.%8=1D'FNZU+3;76-/N;"^MX[JSNHFAF@E7<DB,,,I'<$$T
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M_P""9?QK_9W^(,GBWX":W=:I8QNSVOV.[%OJ-NI.?*=3A95_0XY%8GB#X?\
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MD[&96],G&1D;CZF@#[ _X+)?\FL6/_8>M_\ T%ZZ/_@D?_R9AH?_ &%=0_\
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M:N;&QDD66ZBN+S[3J5V <^5D$K$O;KP#P*_6OPYX=TSPCH.GZ)HUE#IVE:?
MEM:VD"X2*-1A5'X"@#\4/CK_ ,I;M(_['W0__2BVK]P:_,GXH?L#_%GQ7^WY
M8?%JPLM*;P?#XJTS5GE?4%6;[/!-"TA\O&<X1N.]?IM0!\E_\%2_^3,/&/\
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M [#.*GT']@']IO\ :Q\:6&K?&K7+O1M,A.)+G6;A);B)"1N6"WC.U20/]D9
MS0!]9_\ !'FYU6X_9#*ZB\S6T/B&\CT_S.@M]D)(7_9\TS?B37W#7)_"GX8:
M!\&?AYH?@OPQ:_9-$T>W$$",<NW)+.Y[LS%F)]6-=90 4444 %%%% !1110
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MK>GS65["L]M*-KHPR#7CFI?LOZ3-=,]G>RP0$Y"2$L1^-)-6LQM.]T8_Q/\
MCE%XJTQM$\*Q7$\LX)FF\LAE4=<#N,=:\V^#2&/XJ^'U/43,/_'37T1X=^$F
MB_#_ $74KBU1IKYK60&XE.2/D/W?2OGKX/\ _)6M"_Z^&_\ 035*UG8EWNKG
MNG[2&ARZIX%$\*EGM9ED?'9.<FO//V;_ !U8Z%J%[I>H7"VZ705H'D(" C).
M3VS7TK>6<.H6LMM<1K+!*I1T89!![5\\^-/V:+E;R6YT"X5H'8L+5Q\R_0^E
M3%JUF4T[W1[CJ7C+1--L9;J;4[41(N?EE4D_09YKY%21_'GQ.BDCC9A>7B[@
MHR0F<9^E=)%^S]XQO&2*X4)%GJ[A@/?&:]H^%OP9LOA]F[FE%YJ;+M,V,*H]
M *>D1:R&_'2R-O\ "#4+:(%A$D2#'H& KQK]G77;'0O&ET]_<);1SV_EH\C!
M5W9SR37U'K6DP:YI=Q8W*!X9D*D'^=?-.N?LTZY:WSKI\T=W:DY1CP0/0Y-*
M+5K,))WNCVGXE:I9ZM\/=8DLKJ&[18R"T+A@.#Z5XC^S-_R.,O\ UR_H:]*\
M'_"74=#^'.K:)-/']JON00.%X(Y_.JGPC^#.J> =;EO;JZBF5H]JJJXYP:-$
MF@U;3.6_:<\7?:]2L]"B;=%!^^D(/1\XQ^1KUCX->$V\)>![*"95%U,OFR,O
M?/(_0UY])\!=6UOQY_;.LWD5Q:2W'FS0JN,KZ"O>(8UAB2-!A$4*!["E)JUD
M-7O=GS#^TIX6?2?%%OK$,2QVUVH3*_\ /1>237L'P/\ %@\4^!;7.XSV?^CS
M,W=@,Y_6K_Q4\!CQ_P"%Y+&-UBNT.Z"1AD*>,_I7+?!OX8Z[\/-2NA=WZ3:=
M,F?)08_>9'S?E3NG$+69Z?K%HU_I-[;)P\T+QC/J5(KXV\-ZD_PZ^)44]U'N
M-A<M%(OK_#G]:^U:\I^*GP-M?&\YU'3Y5L=2Q\Y*Y23\!W]Z47;1A)'?VOB[
M1;RV6>+5+1HR,Y\Y>/KS7SA^T=XRL_$VO6>GV#K<)8JV9HVW*Y<#@'VQ5+_A
M0'C*W+111_NCUVR  _AFNU^'W[-[6-]#?Z_.L@C;>MI&,<CU/0U2M'6XM7H-
M\9^#YKCX!Z5,W^LL(UNBG?# #'ZUA?LV>,8-%U>]TJ[GCMK>Y7S@\C!07& !
MS7TI<Z=;7=B]G+"C6SIL,97Y<>F*^</&'[-NJVFI/-H4JW-LS;DC8X:/\30F
MFK,&FM4>S_$#XA:3X3\-WEQ)>1O.T92**)PSEF& <#M7R5X7OI9?&=A=S_/,
M\^]R>Y->O^"?V>=2NM4M[[Q/=%X8&#"V+;F;'09]*M:C^S_J4WCJ;5K6Y@@L
M3<F6.!4QM7T%-6B)W>IT?[1W/PRC/_3S#_(UY#\"_B)!X%\02P7PVV-_M5Y>
M\;#[I^F37K_[2"[/AHBGJ+J(?H:\D^$/PWL_B-I&O02N8;R$1_9YNRDYSD=^
ME*-N74<MSZ=D\7:)' 9CJUEY>/O>>N/YU\?>*M3;QY\1[BY@!S>W*Q)@>GRC
M^5=/=_L\^+89#;QJMQ;J>&#@*??&:]-^%/P&3PG>1ZKJ\JW5\HS%$H^6,^I]
M30K1U!WD8_[0FCWUGX-\.3P23PBQ3RIVB=E'W5 SCWS5K]G7Q_9R:'/I&I:A
MMOHY"\?VE\!DX  8GDY[5[)K6BVGB#2Y["]B$MM,NUE/\Z^=/$G[->KZ;?-+
MH=T+B#.8U/#I[$GK2335F-IIW1Z=\:O&NFZ7X'OH5N;>XN;C$*PJX9OF!&<>
MU>;_ ++6DRR:MJE\01#'&JANS'G(JAI7[.7B76+Y3JMTMK&/O22'>Q'H,&OH
M;P?X0L/!>BQ:?81[47EG/5F[DT7459"U;NSY,^*$WV7XM:],PX6]W?H*^KM!
M\8:+?:-:31ZI:[?*7.Z905X'!YXKSOXO? UO%UZVKZ1(L-\P_>Q,.)3Z^QKS
M+3?V??&$TWDR(+*%CAGW@CZX!IZ26X:IFA^T!\0(/&&H1:9IBFXLM-8O)<Q\
MJ6/'Y>]=9^RO_P @/6/^OG_V45I2? *'3O %[I%A,K:I=;?-NF'!P0< 5M_!
M?X<7OP[TV_M[V=)VGF\Q2@Q@8Q0VN6R!)WN>&_M$9_X69?\ _7&/_P! KZ#^
M&_BS1IO!VAVRZG:BX6VCC,+2J'W!>1C-<_\ &#X+GQY.FI:?.MO?HN'5AD2>
ME>?^"OV?_$&F^)K*\NS'## ^\G@Y_6C22#5,X_XR:;=Z#\3-3G=#&)I1-;L?
MXEP.:^D/A_\ $O1?$GANSE-]!;7"QB-X9I K9 QG!I_Q(^%]A\1--CCG/D7L
M(Q#<#JOL?45X/??LY^*=/NV%H4NE!XF0A<_F:-)+4-8L^D[WQIH6GPO)/JUF
MH09*^<I/Y9K%UZ^B\?\ PUOKO1I)&%U;.8",HQ89'X=*\*T_]G#Q/JMP!?3Q
MVBGK))A_Y&OH/X>^#!X%\.Q:8+EKG9_$>GX#M4NRV*5V?-?P7\;2>$_&Z0ZK
M=S?99-T,S2RE@CC@=3ZU]27GBC2+2Q>ZDU*U$ !._P Y2#QVYKRKXF?L]Q>(
M[^74]%FCL[B3YI("ORN?4>AKSQ/@#XSN MM*=ML#T:0%1[XS5.TM25>.A@6-
MTWBOXN6MU90O(DM^C[57.%!P6/M7V8J[5 ]!BO-OA5\&K7X>EKR:;[9JCKM,
MJC"J#U %>E5,FGL5%6$/ )KP+PU8P_$;XQ:Q/J_[ZULQMBLV8[00!S7OU>->
M)/A3XAL_'=QK_AC4(K3[8-LB,O$? !/7FE$)&3X%L[73_CAJMO:*L4*QD!%Z
M X-2_!G_ )*UXP_'_P!"%:_@KX.ZEX6\>C6IM0%W$\9,I.<L[ Y_#-:W@'X;
MWOA7QOKVL7$Z207^=B*.1R#_ $JFUJ2DSF=#_P"3G-9_Z]!_Z *I_!O_ )*Y
MXS_Z[-_Z$:[;3?AY>V?Q@O\ Q4TZ&SN(/*6+'S [0/Z5RVN?!WQ!I?C*YUKP
MOJ0MQ>,6E63)P3U/7D<T7069FZ8ZM^T=?@,"0V#CMTKW;5+T:;IMU=E=P@B:
M4KZ[03_2O*_"7P9OO#?C>#6YM0%[(T>;J1@<O)GJ,]!BO6+RU2^M9K>49CF0
MQMCT(P:4K%1.6\">.8/B'X5N-2BA\@!Y(6C)R>!UKPGP/F/1?B-%#_QZ?8IB
M,'C=Q752?!WQ=X7OKV'PWJXCTV[)^0Y&P$_7K7>?#WX3VG@_PO>:;=.+V:^S
M]JDQ@-D<@>U/1;"U9E?LV,#\,;, @D.^1Z<UQOPMY^)7Q& Y^63_ -"-6?\
MA3OC'PI=74/AW6=NGW#$B/D>6#^-=S\+?A2O@:WO;F]NC?:K?C$\W.-IYQSW
M]Z=UJQ6>B.8_9<(_X1O7,'_E^/\ *L[PT0W[2%X5.1Y##(_W#4MW\&_$_A36
M+J?PGJWDV5TQ8VY)&TGN>>374_"WX2R^$;ZXUC5KS[=J\_\ 'SA,YR*3:U86
M>B-_XM_\DYUW_KA_[,*Y'X2?\D7?_KA)_6O0/'&AR^)?">I:9 XCEN8MBLW0
M'(/]*P_ _@>[\-_#]M#GF62X,;)O48'.?\:GH5U.&_9O_P"/'Q#_ -=3_,U1
M^$W_ ".WC_\ ZYR?SKNOA-\.KWP+;ZK'=SI,;I]R[1C'7_&H_A]\-;SPMXK\
M0ZE=3QS6^HY"H!T!.>:JZU%;8Q?V;9HX_#.LLSJJI=$L2<!>O6LG]GV19?'W
MCAT8.C3Y#*<@C>>16E;_  #>QU"[>R\1S6FBW+EKBUB<C<#U!.<5D?LX6267
MB[QC#!EK:&01(Y.<@,0.>]/2S%KH>_T445D:!1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY_LVFZ=;27=U/L9O+BC4N[84$G"@G !/'% %^OC3_@J%^T)XX_9T^$'A37/
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MPK?$6-S;>29=_E_ZZ--V?+?[N<8YQD4 >I4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% &+I?_(QZY_VP_P#0#6U6+I?_ ",>N?\ ;#_T UM4
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MLE9'[*?_ ":[\'O^Q.T?_P!(H:UOC]_R0GXC_P#8MZE_Z2R4 ?EO_P $1_\
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M,?\ 8!7_ -&O0!][?LX_L(_"/X ZGHWQ'\/0ZE::U'I6Z2>\OR\*K)$#(2I
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** ,72_P#D8]<_[8?^@&MJL72_^1CUS_MA_P"@&MJ@
M HHHH **** "BBB@ HHHH **** "BBB@ HHKG* .CHKG** .CHKG** .CHKG
M** .CHKG** .CHKG** .CHKG** .CHKG** .CHKG** .CHKG** .CHKG** .
MCHKG** .CHKG** .CHKG** .CHKG** .CHKG** .CHKG** .CHKG** .CHKG
M** .CHKG** .CHKG** .CHKG** .CHKG** .CHKG** .CHKG** .CHKG** .
MCHKG** .CHKG** .CHKG** .CHKG** .CHKG** .CHKG** .CHKG** .CHKG
M** .CHKG** .CHKG** .CHKG** .CHKG** .CHKG** .CHKG** .CHKG** .
MCHKG** .CHKG** .CHKG** .CHKG** .CHKG** .CHKG** .CHKG** .CHKG
M** .CHKG** .CHKG** .CHKG** .CHKG** .CHKG** .CHKG** .CHKG** .
MCHKG** .CHKG** .CHKG** .CHKG** .CHKG** .CHKG** .CHKG** .CHK-
MT?\ Y;?A_6M*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$1R.NUT56#="=P[&O>/'WCS0_ACX-U?Q3XDOX]-T32K=KFYN)2!A5'0>K$X
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M# [L@8ZT ?*__!;W_DIWPS_[ ]S_ .CA7Z9_LT_\FX_"K_L5-*_](XJ^4_\
M@H]^P[X]_:P\9>#]5\'W6E06^DV$UM.NH3M&Q9I PQA3D8K[&^#WA2\\!_"3
MP1X:U!HWO]&T.QTZX:$Y0R0VZ1L5/<94XH _'']G;_E+9;_]C/JW_I-<U^WM
M?G!\)_\ @GO\2/!/[=4/Q@OKO1G\,+K5]?F.*Y8W'ES0S(GR[<9S(N1GUK]'
MZ /@;_@LQ_R;'H__ &'H?_0'KM?^"37_ "91X6_Z_P#4/_2IZZ/_ (*$?LU^
M*/VHO@WI_A;PG-8P:C!JD=XS7\IC38JL#@@'GFNB_88^!?B#]G+]G71? WB>
M2TEU>SNKN:1K&0O$5DF9UP2!S@B@#\J/VA[2\_8Y_P""DEQXJFMI!I0\0Q^)
M[?8,">SN)#)*J>P+31_5*_<'PMXHTGQMX<T[7M"OX=3T?48%N;6\MVW)+&PR
M"#_3J#D&O"/VT/V+_#G[7W@FWM;N<:+XKTO<VDZTJ;O+W8W12C^*-L#CJ" 1
MW!_.S0_V0?VU_P!GI[G0O FK:@-%9V*?V+JZ-:MSRZQ2'Y"?]T&@#[4_X*G?
M'K1_A9^S+KGA8WL9\3^+T73[*R5@9!!O4SS,O9 @*9_O..N#7S__ ,$-?^0;
M\9?^NND?^@WE>.^//^"?_P 2-%^$'Q%^,WQY\1S7.LZ;IA>RL9;\W=S+.SI'
M&TTI)"HI?A%/7 X'7V;_ ((;V\BZ+\8IRI$3W&E(K=B56[)'_CP_.@#]1Z**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#%TO_ )&/7/\ MA_Z
M :VJQ=+_ .1CUS_MA_Z :VJ "BBB@ HHHH **** "BBB@ HHHH **** "N<K
MHZYR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** -'1_^6WX?UK2K-T?_EM^']:T
MJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#%TO\
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M;CQ5\?M?T>T>..YO]<DMHGF)"!FEP"Q )QD]@:[_ /X8=\=_]!;P[_X$S_\
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M1NHD6SU>UPE[8[L[&/1U]4;!QZ8([<TDI*\1.\7:1Z/139/]6WT-? ?[)O\
MR7S2_P#KG=?^BGJ(OFFX>5_S_P ARTCS>:7WGW]15'7O^0'J/_7M)_Z":_-#
MX9_#?4_BKXG70M)GM+>[:%Y@]Z[+'M7&1E58YY]*%>4G%?UO_D4U:*D^O_ _
MS/T]HKX>_P"&'?'?_06\._\ @3/_ /&:H:C^S!\5O $;7^D3+=/"-Q;0[YUE
M '.0"$8GV7)IW2W)UZ'WA17Q_P# C]JW5+76K?PWXZF-Q;R/Y$6J3+MF@?.
MLO\ >7/&X\COGM]@53C9)K8E/6W4*S=:\3:/X;C635M5L=+C;HU[<I"#^+$5
MXA^U1\>+SX;6=MX?T"40ZY?QF62ZP";:') *@_Q,0<'L 3UP:\9\"_LJ^,OB
MG9Q^(M=U==+COAYJRWV^XNI5/1RI(X/;+9]NE9QO*[6R+E:-K[L^PK'XF>#]
M3G6"S\5Z'=S,<".#4878_@&KI>O(KX^U;]A#48;5FTSQ?;7ESCB.ZL6@0_\
M E=S^E</X)^)_C;]F[QL-!U[[1)I<+A;G2YGWIY9_P"6D![<<C'!Z'VN-F^6
M]F2[I7L??-%5].U"WU;3[:]M)!-:W,:S12+T9& (/Y&K%#TT8)W5T%%%%(84
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!HZ/\ \MOP_K6E6;H__+;\/ZUI4 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!BZ7_P C'KG_ &P_] -;58NE
M_P#(QZY_VP_] -;5 !1110 4444 %%%% !1110 4444 %%%% !7.5T=<Y0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %?$'[<7_ "5+2/\ L$1_^CI:^WZ^(/VXO^2I:1_V"(__ $=+6,_B
MAZ_HS6'PR]/U1]>_#G_DGOA?_L%VO_HE:Z*N=^'/_)/?"_\ V"[7_P!$K715
MU5/CEZG-3^"/H<W\2O\ DG7BC_L%W7_HIJ^1?V'O^2G:O_V"G_\ 1L=?77Q*
M_P"2=>*/^P7=?^BFKY%_8>_Y*=J__8*?_P!&QUE2_C2_P_\ R1=7^%'U_5'V
M]1113&?GYX0_Y.N@_P"QDE_]&M7Z!U^?GA#_ ).N@_[&27_T:U?H'13_ -WA
M_71#J?QY_P!=6%?"'[:/_)9%_P"P;!_Z$]?=]?"'[:/_ "61?^P;!_Z$]9RW
MCZ_HS2'PR]/U1]J>!_\ D2O#_P#V#[?_ -%K6W7PII7Q*_:#M]+LXK"TU\V,
M<*+;F/PXCKY84!<-Y!R,8YSS5K_A:'[1W_/GXB_\)I/_ )'K>;YI-G/!<L4C
M[AHKX?7XG_M'9&;/Q%C_ +%I/_D>OM?37EDT^U><$3M$IDW#!W8&<CMS2Y=.
M8J^MCX*_:I_Y. U/Z6O_ **2OON#_4Q_[H_E7P!^UE(8?CQJ[J,LL=LPS[1)
M72K^VM\0455&AZ#@#'_'I<?_ !ZLZ4E[%+S951/VE_)'V[7F?[24UA#\$_%/
M]H%/+:V"Q!^\Q8>7CWW8_*OFF3]M_P >89?[*\/QMTR+:?(_.:L^^TGXR?M)
M369OK.Y_LG(E@>>+[)9(#_&,@;^.XW'GBB47-<J'&2@U)G5_L)QW!\3>*9%#
M?919Q*Y[;RYV_C@-7NW[3G_)"_%7_7*+_P!')6C\%?A'9?![PBNF02_:[^=O
M.O;S;CS9,8P!V4#@#ZGO6=^TY_R0OQ5_URB_]')1B&N2RZ"HI\Z;ZL\?_8/_
M -3XQ_WK7^4M>@_MC_\ )%+K_K]M_P#T(UY]^P?_ *GQC_O6O\I:]!_;'_Y(
MI=?]?MO_ .A&KQ'3_MW]":&\OG^1\M^&_@_+XR^!^J>*M,C:35-(U&19X5Y,
MMMY4;$@>J$D_0MZ"O=?V//C0=8T__A!]7GS>V:%]-D<\R0CK%]5ZC_9S_=K3
M_8?4/\+]95@&4ZM("#T/[F*O%OV@/AK?? WXDVGB'P^6M-+NI_M5A+'TMI@<
MM%]!U [J<=C5R:IU.5_"TOOLOZ^_N3%.I"ZW3?W7_K^D?>M?!GQZ_P"3J)O^
MO[3_ /T7#7U]\(/B99?%;P39ZU;;8[G'E7ELIYAF ^9?H>H]B*^0?CU_R=1-
M_P!?VG_^BX:F"<<333_K5%7YJ4VNQ]YU^>O@'_DZ.S_[&.7_ -&O7Z%5^9NH
MWVLZ;\8M2NO#RS/K<6L7#6BV\ FD,GFMC:A!W'VP:B+Y:T7_ %NBY*]&2]/R
M9^F5%?#W_"T/VCO^?/Q%_P"$TG_R/1_PM#]H[_GS\1?^$TG_ ,CTR3[AHKY.
M^$/C[XWZM\1M$M/$]KK2:#+*PNFNM"6",+L8C,@A7;SCN*^L:KET3%?6P444
M5(S\_;K_ ).U/_8TC_T>*_0*OS?^)%UJ=C\?M?N=%61M7BUR1[188O-<RB7*
M;4P=QSCC!S7?_P#"T/VCO^?/Q%_X32?_ "/4TG^X@OZV0ZB_?2?];L^X:*^'
MO^%H?M'?\^?B+_PFD_\ D>OHK]G'7O&_B'P=?W'CN*]BU5+YDA%]8BT?R?+0
MC"A%R-Q;G'KZ5HE=-]B&[-+N:G[0G_)%?%__ %XM_,5X#^PC_P AGQ=_U[V_
M_H3U[]^T)_R17Q?_ ->+?S%> _L(_P#(9\7?]>]O_P"A/2I?Q)>G^953^''U
M_P CV#]K3_DA>N?]=+?_ -')7GW["7_(M^*_^ON'_P! :O0?VM/^2%ZY_P!=
M+?\ ]')7R%\)O%GQ.\.66H)X!@U*6VED5KK[!I2W@#@';DF-]IQGCBHINSJ+
M^NA=17C#Y_J?H]7F7[2EU86OP3\4?V@R!)+<1PAL9:8L/+ ]]V#^!KYK_P"%
MG_M'?\^?B+_PFD_^1Z\Q\=^*?&.OZQ:+\0)]:>.-PWV:Z0P%5_B,:,H56QWV
MTI1YER]PC+E?-V/>_P!A'3;M?^$MORK"Q?[/ &SPT@WL?R!'_?5>F?M??\D.
MU7_KYMO_ $:M;7[/OB+P3K'@.WM/!(:"TL_EGM+@ 7*2-R6E]2V/O#(.,#I@
M8O[7W_)#M5_Z^;;_ -&K5XCHNUOS1.'W;[W_ ".,_85_Y$[Q-_U_I_Z+%?3=
M?G/\)/CWXE^$.F7]EH>GZ=>0W<PFD:]AE=@P7&!LD7C%=T_[;GC^/!?1O#Z#
M_:M;@?\ M:M*DE)W79?D9Q5E]Y]O5^>'[1SVMY\?-=&C;6<W,*'R>]P$0/CW
MWYS[YKJ9/VEOBY\3O-TSP_9+%,R_O!H-@[R*IXR68N4'^UQCUKM_@#^ROJNE
M^(K;Q3XV58I;>3S[;33())&ESD22L"1P><9)SUQC!B$7[2,WHD7*5H.*U;/J
M=[A;+3VGN6V)#%OD8]@!DFOS\\)V<W[0W[0*OJ!9K6_NWN9UR?DMHQD1@]OE
M55_&ON'XK7+V?PQ\6S)NWII5T5V#D'RFYKY'_8A@23XJ:E(PRT>E2;?;,D8I
M4_>K7?17_/\ R%+W**2ZNWY?YGV[:VL-C;16]O$D$$*"...-<*B@8  [ "I:
M**![&5XI\,Z?XR\/WVC:I MQ8WD9CD0CD>C#T(."#V(%?!WPEU:]^"?[0$6F
MW$I6%+YM)O/[LD;/M#8^NUA]*_0:OSX_:?C73?V@-;EM_O[[:;"]0WE1G\\\
M_C2IOEKQ\_Z_S')<U*2[?U_D?H+)_JV^AKX#_9-_Y+YI?_7.Z_\ 13U]\1N9
M+16/5DR?RKX'_9-_Y+YI?_7.Z_\ 13TJ?\9^G^9,GS4;KNC[PU[_ ) >H_\
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MT?:9O^>K_P#?1H WZ*P/M,W_ #U?_OHT?:9O^>K_ /?1H WZ*P/M,W_/5_\
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MH WZ*P/M,W_/5_\ OHT?:9O^>K_]]&@#?HK ^TS?\]7_ .^C1]IF_P">K_\
M?1H WZ*P/M,W_/5_^^C1]IF_YZO_ -]&@#?HK ^TS?\ /5_^^C1]IF_YZO\
M]]&@#?HK ^TS?\]7_P"^C1]IF_YZO_WT: -^BL#[3-_SU?\ [Z-'VF;_ )ZO
M_P!]&@#?HK ^TS?\]7_[Z-'VF;_GJ_\ WT: -^BL#[3-_P ]7_[Z-'VF;_GJ
M_P#WT: -^BL#[3-_SU?_ +Z-'VF;_GJ__?1H WZ*P/M,W_/5_P#OHT?:9O\
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M .^C1]IF_P">K_\ ?1H WZ*P/M,W_/5_^^C1]IF_YZO_ -]&@#?HK ^TS?\
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M$\9/K7O=%*RO<=W:Q\\?\,.^!/\ H+>(O_ F#_XS1_PP[X$_Z"WB+_P)@_\
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M-2M]4T%(+RWCN(UDN)PP5U# '$)&<'UK.#YH\WG8N2Y78^[J*^'O^&'?'?\
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MB:O/9W-VU[)<![)W9-K*@ RRJ<_*>U?,G[;'_)6[3_L%Q?\ H<E*;Y6DNO\
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MV0K;R/;;U^HK,_89CN%\ Z\[AA;-J7[O/3<(EW8_\=KR:/X4_%S]H+Q!!?\
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M"0<.OX,&'X5YW^U]_P D.U7_ *^;;_T:M95HN.C[K\S6C+FU79_DSC/V%?\
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MEZ,NG\<?4^1?V'O^2G:O_P!@I_\ T;'7TI^TA_R0_P 6_P#7JO\ Z,2OFO\
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M>/\ C5FB@"M_9]O_ ,\__'C_ (T?V?;_ ///_P >/^-6:* *W]GV_P#SS_\
M'C_C1_9]O_SS_P#'C_C5FB@"M_9]O_SS_P#'C_C1_9]O_P \_P#QX_XU9HH
MK?V?;_\ //\ \>/^-']GV_\ SS_\>/\ C5FB@"M_9]O_ ,\__'C_ (T?V?;_
M ///_P >/^-6:* *W]GV_P#SS_\ 'C_C1_9]O_SS_P#'C_C5FB@"M_9]O_SS
M_P#'C_C1_9]O_P \_P#QX_XU9HH K?V?;_\ //\ \>/^-']GV_\ SS_\>/\
MC5FB@"M_9]O_ ,\__'C_ (T?V?;_ ///_P >/^-6:* *W]GV_P#SS_\ 'C_C
M1_9]O_SS_P#'C_C5FB@"M_9]O_SS_P#'C_C1_9]O_P \_P#QX_XU9HH K?V?
M;_\ //\ \>/^-']GV_\ SS_\>/\ C5FB@"M_9]O_ ,\__'C_ (T?V?;_ ///
M_P >/^-6:* *W]GV_P#SS_\ 'C_C1_9]O_SS_P#'C_C5FB@"M_9]O_SS_P#'
MC_C1_9]O_P \_P#QX_XU9HH K?V?;_\ //\ \>/^-']GV_\ SS_\>/\ C5FB
M@"M_9]O_ ,\__'C_ (T?V?;_ ///_P >/^-6:* *W]GV_P#SS_\ 'C_C1_9]
MO_SS_P#'C_C5FB@"M_9]O_SS_P#'C_C1_9]O_P \_P#QX_XU9HH K?V?;_\
M//\ \>/^-']GV_\ SS_\>/\ C5FB@"M_9]O_ ,\__'C_ (T?V?;_ ///_P >
M/^-6:* *W]GV_P#SS_\ 'C_C1_9]O_SS_P#'C_C5FB@"M_9]O_SS_P#'C_C1
M_9]O_P \_P#QX_XU9HH K?V?;_\ //\ \>/^-']GV_\ SS_\>/\ C5FB@"M_
M9]O_ ,\__'C_ (T?V?;_ ///_P >/^-6:* *W]GV_P#SS_\ 'C_C1_9]O_SS
M_P#'C_C5FB@"M_9]O_SS_P#'C_C1_9]O_P \_P#QX_XU9HH K?V?;_\ //\
M\>/^-']GV_\ SS_\>/\ C5FB@"M_9]O_ ,\__'C_ (T?V?;_ ///_P >/^-6
M:* *W]GV_P#SS_\ 'C_C1_9]O_SS_P#'C_C5FB@"M_9]O_SS_P#'C_C1_9]O
M_P \_P#QX_XU9HH K?V?;_\ //\ \>/^-']GV_\ SS_\>/\ C5FB@"M_9]O_
M ,\__'C_ (T?V?;_ ///_P >/^-6:* *W]GV_P#SS_\ 'C_C1_9]O_SS_P#'
MC_C5FB@"M_9]O_SS_P#'C_C1_9]O_P \_P#QX_XU9HH K?V?;_\ //\ \>/^
M-']GV_\ SS_\>/\ C5FB@"M_9]O_ ,\__'C_ (T?V?;_ ///_P >/^-6:* *
MW]GV_P#SS_\ 'C_C1_9]O_SS_P#'C_C5FB@"M_9]O_SS_P#'C_C1_9]O_P \
M_P#QX_XU9HH K?V?;_\ //\ \>/^-']GV_\ SS_\>/\ C5FB@"M_9]O_ ,\_
M_'C_ (T?V?;_ ///_P >/^-6:* *W]GV_P#SS_\ 'C_C1_9]O_SS_P#'C_C5
MFB@"M_9]O_SS_P#'C_C1_9]O_P \_P#QX_XU9HH K?V?;_\ //\ \>/^-']G
MV_\ SS_\>/\ C5FB@"M_9]O_ ,\__'C_ (T?V?;_ ///_P >/^-6:* *W]GV
M_P#SS_\ 'C_C1_9]O_SS_P#'C_C5FB@"M_9]O_SS_P#'C_C1_9]O_P \_P#Q
MX_XU9HH K?V?;_\ //\ \>/^-']GV_\ SS_\>/\ C5FB@"M_9]O_ ,\__'C_
M (T?V?;_ ///_P >/^-6:* *W]GV_P#SS_\ 'C_C1_9]O_SS_P#'C_C5FB@"
MM_9]O_SS_P#'C_C1_9]O_P \_P#QX_XU9HH K?V?;_\ //\ \>/^-']GV_\
MSS_\>/\ C5FB@"M_9]O_ ,\__'C_ (T?V?;_ ///_P >/^-6:* *W]GV_P#S
MS_\ 'C_C1_9]O_SS_P#'C_C5FB@"M_9]O_SS_P#'C_C1_9]O_P \_P#QX_XU
M9HH K?V?;_\ //\ \>/^-']GV_\ SS_\>/\ C5FB@"M_9]O_ ,\__'C_ (T?
MV?;_ ///_P >/^-6:* (H;>.WSY:[<]>2:EHHH **** "BBB@ HHHH ****
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M=UA+G 7GHA/!'\)YXYK[<KXN_;$^#W_"/ZTOC32X,:?J+[+Y$'$5P>C^P?\
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M** "BBB@ HHHH **** "BBB@ HHHH Q=+_Y&/7/^V'_H!K:K%TO_ )&/7/\
MMA_Z :VJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@"EJW_'NO\ O_T-9-:VK?\ 'NO^_P#T-9- !1110 4444 %%%%
M!1110 4444 %%%% !1110!Y!\1OV8?#/Q0\53:]K&J:VEU(B1B&VGB6)%48
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M?_&:^AZ*226P[MGSQ_PP[X$_Z"WB+_P)@_\ C-'_  P[X$_Z"WB+_P "8/\
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MY2P([=P:W**EJZLREIJCSKX2_ O0?@T^IMHMWJ-T=0$8E^WR1OC9NQMV(O\
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M1P+;A+&:)$VJ6(.&C8Y^8]Z]7HH?O.[!>ZFD0:?9IIMC;6D19H[>-8E+=2%
M S[\5/113;<G=B2LK(YSX@> =)^)?A>YT+68W:TF(820D+)$X/#H2" 1]#P2
M*Y+X4_L\^'/@_K%YJ6C7NJ7,]U;_ &=UOI8W4+N#9&V-3G*CO7J%%)>Z[H;U
M5F%<YXX^'GA_XCZ3_9_B#38[^!<F-CE9(F/=''*GZ=>^:Z.BDTGN--K8^7];
M_83T:XN"VD^*;VPB/2.[M4N2/Q5DIFB_L):5;W2MJOBR[OH >8[2S6W8_P#
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M HHHH **** *6K?\>Z_[_P#0UDUK:M_Q[K_O_P!#630 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG53C:CG@$MPIX'XUI^'-3N-:\/Z;J%U8R:9<W5M'-+939WP,R@F-L@'*DXY
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@".:%)U"NNX9SUJ+^S[?_GG_ ./'_&K-% %;^S[?_GG_ ./'_&C^S[?_
M )Y_^/'_ !JS10!6_L^W_P">?_CQ_P :/[/M_P#GG_X\?\:LT4 5O[/M_P#G
MG_X\?\:/[/M_^>?_ (\?\:LT4 5O[/M_^>?_ (\?\:/[/M_^>?\ X\?\:LT4
M 5O[/M_^>?\ X\?\:/[/M_\ GG_X\?\ &K-% %;^S[?_ )Y_^/'_ !H_L^W_
M .>?_CQ_QJS10!6_L^W_ .>?_CQ_QH_L^W_YY_\ CQ_QJS10!6_L^W_YY_\
MCQ_QH_L^W_YY_P#CQ_QJS10!6_L^W_YY_P#CQ_QH_L^W_P">?_CQ_P :LT4
M5O[/M_\ GG_X\?\ &C^S[?\ YY_^/'_&K-% %;^S[?\ YY_^/'_&C^S[?_GG
M_P"/'_&K-% %;^S[?_GG_P"/'_&C^S[?_GG_ ./'_&K-% %;^S[?_GG_ ./'
M_&C^S[?_ )Y_^/'_ !JS10!6_L^W_P">?_CQ_P :/[/M_P#GG_X\?\:LT4 5
MO[/M_P#GG_X\?\:/[/M_^>?_ (\?\:LT4 5O[/M_^>?_ (\?\:/[/M_^>?\
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M_P">?_CQ_P :LT4 5O[/M_\ GG_X\?\ &C^S[?\ YY_^/'_&K-% %;^S[?\
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MQ_QH_L^W_P">?_CQ_P :LT4 5O[/M_\ GG_X\?\ &C^S[?\ YY_^/'_&K-%
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M44 %%%% !1110!BZ7_R,>N?]L/\ T UM5BZ7_P C'KG_ &P_] -;5 !1110
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M&&125=">^".#W&#WKR35_P!EWPEHNAW.JZA\1/&EOI<$)FEN9-8C,8CQG/\
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M5/7_ "/G[QQ\5O&_C3XJ7GP]^&K6.GRZ9&)-3UR^C\P0$X^55(([@?=))ST
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MN,UK_$:-6_;,^&:L-X&F3'YN>0MQ@TU[TH)]W]W*]/7_ ( I>[&<ET5_G?\
MK\3IV\2>-/@AX%\3>(_B+XCL_%<<"1_V?#9VJVS&1B1L8J@X+%>>< $^U<KH
ML?[0GCCP['XIMO$>BZ MU&+FTT V2,&C(RH9V1F4L,?Q'KSM[;O[:>F7.H_
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MWLDDS&>5+NT;,N1@]2>>@Z5V?P'^,FI^.KS7/"_BNPCTSQEH+[+N.#_53)G
MD7DXYQGG'S C@X':?"OQ)IWBCX<^'M1TR>.:T:QA7Y"/W;*@#(?0J001[5XA
M\';R'QA^UI\1_$.DL)]'@LDLS<1$&.20>4O!'!R8G(/M5M*-9TEM9_AM]YG=
MRI*H]]/QZ?UV,CX6_$;XR?&*/7-+T;6=/TY=-U"03Z]?6D;.J$XC@BC5-I("
ML26&>1R._7_#'XF>//#_ ,9)/AM\0+JRUJXN+1KRQU6SA$1< $X(55&,*_\
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M*]%;]1/W;-:Z2?W6L=G?+^T!X)T"3Q1?Z[HWB*.WB:XO/#Z6J1M'&!EA'(J
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M) =>00RD@@," 1D'I61\*/A-HGP=\-R:+H;7,T,L[7$L]ZZO-(Y ')55&
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MO\.]?\%VE]JC:+K+2M+YLL1DA\Q0K",B, # 'W@U>FT4/5-/J"T::Z'G.H?
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M*HHJKDA1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!BZ7_R,>N?]L/_ $ UM5BZ7_R,>N?]L/\ T UM4 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%8=YXVT:P\6V'AF>\*:W?P/<V]KY,AWQIG<V\+M&,="0:/(#<HKG/'7Q
M"\/_  TT5=6\2:A_9NGM,L F\F27YR"0,(K'HI[8XJ?P;XUT7X@:!!K?A^^7
M4-,F9E2=8W3)4E2"K@,#D=Q0M;VZ ]+7ZFY16=XB\0:?X4T.]UC5KE;/3K.,
MS3SLI8(HZG !)^@&:R? 7Q*\-_$[29]3\,ZC_:5C!,;>27R)(MKA0Q&)%4GA
MASC'-+OY!V\SIZ*YGP5\2/#GQ$T6XU?0-26^TZWE:&6X:*2$(Z@%@1(JG !!
MSTK2\.^)]*\7:<;_ $:^AU*Q\QXA<6[;HV93AMK=",CJ.*K4#4HHHI %%%%
M!17.Z7\0M UKQ=JOABRO_.US2T62\M?)D7RE;&#O*A3]X=">M=%1TN'6P45S
M6M_$;P]X=\5:/X;U'4/L^M:MG[%:^1(WFXZ_,JE5Z?Q$5TM'2X=;!117-?\
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M6X:UFD\F2+;*H!*X=5)X8<CCFC_AP.DHHHH **** "BBN;U_XB^'O"_B31=
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@"*ZMTN[>6"3=LE0HVUBIP1@X(Y!]Z^%_$W@_6-)\77UYHM[XO'@
M3P[=IH<]RSYU&))B/-6VRF[RP?+ '7#C'#&ONVBDE[W-_7]6NOF._NV_K^MO
MN/EW]KCP]9^%?V<=!TC3VN'L;2_MHXFNV9I2OER8W$@'//3 QTP*M_LGSR>!
M_%GC7X<W+,$MI$U;3U8]89%7./P,7XDU>_;I_P"2,VG_ &%X/_0)*SOBD/\
MA6_Q8^%?Q 3]U8WL,>B:F_;:R?(S?0,Q_P"V8JJ3O*;?VI6^^*M^*7WDU%[L
M5V5_N>OX7.D_:JOIM=TWPO\ #ZQD*WGBK4XXI=IY6VC(:1C[9VG\#6'^PW$E
MK\-O$T:+^[CUV90I]!%%Q6MX1'_"R/VG/%/B GS-,\(VBZ/:'M]H?)E(]Q\Z
MGZBLO]B/_DG?BK_L/7'_ **BK%-QIS:W<6_Q27X*_P QU-9179I?A)O_ "^1
M!H?Q:'B#]G_Q)JO@_P"&UM81M=7%A<:9IEQ'$B*8,O=,5B4' (R,9.!S5?\
M8O\ &.KP_#^'2KSPW)9^&[2.YNE\1O= Q2,)<M'Y>W(P"W.[^'IS5/\ 99_Y
M-K\=_P#7?4/_ $F6NK_91ALKK]F>"#49EM]/E-['<2NX0+&SL&)8\#@GFM]8
M^T:_EC_7WZ_\ ):N*?\ -+\_\M/^"-B_:BUOQ,US=^"OA?K/BG0H7:,:GY_V
M<2E3SL7RVW?3.?4"N_\ A5\:M(^+'AO4-1T^VN+&]TUC%>Z;> ++#( 3@D=0
M<'!]CD"O$O"?A'XQ?"'1TC^'>J:%\0O!9DDDLX3(A(4L=V&W+SG/"R,,YX[5
MW?P5^*VG^.)O&&E7/@^'P;XQM(VFU.WCB53<D@_O&8*&)RW\6?O @G-9R=H2
MY=TOF-:R5]K_ ".R^!OQ:_X71X,EU_\ LK^Q]EY):?9_M'GYVA3NW;%Z[NF.
MU0K\8L_'1OAS_9'33_MW]I?:?;.SR]GZ[OPK@OV&V'_"F;H9Y&L7&?\ OB.J
M4;JW[=$H!!*Z!@X/0[ <?J*V:7/&/=?^VM_F1?W9/L__ &ZWY'*_\+,B^&G[
M47Q(F72KW7M4OX;:UL=,T]"TD\FR-CS@[0 "2<'Z5Z;X7_:9>3QE8^&/&_@[
M4/ FHZ@0MC)=3":"=B<!=^Q<$D@< C)P2*P?AC9V<W[8'Q.GE56O8;.#R"W5
M598@Y'_CH_&G?MR1P+\+]'N@=NI0:Q";1U^^&*/D+^0/X"LH>[3I7UO9?>[&
MLUS5*B6G_#7.Q^(?CW1]!^-'@30+SPG8ZMJ6J!_LVM3E/.L<$YV9C)Y]F7K4
M?Q$_:"_X1?QD?"/AKPMJ'C7Q+'$L]Q:V;^7';H<$;Y-K8."#TQ\PYR<5POQ;
M:63]I?X,-.-L[0L9!Z-SG]:L>.OAOXF3XN:SXO\ A3XMTC^WY84BU?0[J9';
M@  $8;&=@X;;@@X;G%4E[L;]Y;>6W_!9%TVVNT?Q.L\ _M&?\)!XVB\'^*?"
MFH>"?$5PADM8+R02Q3@ G"OM7G@XXP<$9SQ7EGQ"\>6WPZ_;"FU:XLKS4I&T
M5+>WL;"(R37$S@!$4>_]._2M[1?C1KVE?$3PWI/Q<^'5AIFK74OV?3-?MXTD
M$;L0,*Q+X!)7)5^,C(J1[>*X_;J5I(U=HM"WH6&=K;,9'O@G\Z:5W!K^]_Z2
M_P ;"O927I^:_ U[?]J:^T/Q%IFG^.OA]JG@NRU*016VH37 GCW$@#<-BXQD
M9P21GI73?&KQYI'@_P 5?#ZSU+PG9>(Y]6U,6UK=713=I[[XAYL>Z-CG+ \%
M?NCGTX[]NA%_X4_828'F1ZQ 4;NOR2=*J_M/<^./@B3_ -!Q/_1EO4Q?,X_X
MTOR?ZBJ>ZGYQ;^ZY]*5E:IX3T/6[@7&HZ-I]_.%V"6ZM4D;:.V6!..36K104
M?*4WA;1?^&VH--_LBP_L[^QM_P!C^S)Y.[RB<[,8SGVKZ7TWPKH>@SM<Z?H^
MGZ=-M*M-;6L<3;>I!*@<<#\J^?)O^3[8/^P)_P"TFKZ%\4:A8:3X;U6]U5MN
MF6]K+)<D$@^6%);&.<XSTJ;\M-/U_P#2F.W-4:]/R1XS<?M07NOZM?6WP_\
M &J>-[.QD,,VI1S"V@+CLC%&W?C@]\8KH_A#\?K7XG:YJ7AZ_P!"OO"WB?3T
M\V?3+[D[,@95L*3C<O51]X$9KRWX4^)_B#K7AK9\)O F@^%O!;SRFVN-<NII
MGD;=AGX?=U'H0,8!.*I?"FU\36?[8&IQ>+]1L=3UT:*3--IZ;85!$95 -H/"
MXZC-:Q7O*+[/??17(D]&UW_6W]>9WNK?M4)IOC;Q-X3M_"-_J^N:;<I;6-II
MTIE>^R"7=AL_=*H R<M]X>]6?!O[2TVH>/+/PCXP\&:AX)U:_P"+(W$WGQ3'
MG W;%ZD8! (SQQ7,_!&VB?\ :H^+L[1J9H]BHY'*AF&0/KM'Y5-^U,JQ_$OX
M+SJ )AKH3?CG:98.*B'_ "Z;^W;\=/\ @CGHZEOLWM\E<]+^+?QLTKX3C3K2
M2RO-;U[4VV6.D:>FZ:8YQD^@R<="2>@/.//=0_:HUWPA+:W'C7X6:QX:T69P
MAU%;D7 0GIN7RU /MNSP< TWXR>,K2Q^->B6'A3P;'XJ^)D-F3#=75R\<%E"
M0W5=P4G#,><8W#DDXKA/VC8_C%>?"C4KSQC=>&-,T(20B33=*61II6,B[1N<
M-C!YX;M4*34>9]_EO;U_X)IRWER^7S_K]#MOVT]1MKCX3^&;^.57M)-<M9UE
M7H4,4K!ORYJS??M5ZM'9R:[9?"_7;WP8AS_;9D\MFB'641;#\O?)8#U(KF?V
MCXX)OV;OAG'<G%L]UI:RG_9-J^?TKZC2SMH]/6U6*,6:Q>4(@!L\O&-N.F,5
M;7)[2W23_*.YG&7-R-]8K\WL87A;XB:#XP\%P^*]/OD_L5X6G>>;Y/)"YWA_
M[I7!S]/2O(D_:EUCQ)-=7'@CX8ZUXKT*W<H=4\[[.LA'7RU\MMWTSGD9 KQ'
MPK>7MI^RG\5X-/9CI<>M+% PZ")I(@^.>A7;GZFO3OA7H?QR3X<>'/\ A'-9
M\$0Z&UC$]I'*DYD"%<_/B(C=DG//7-'Q-M;:?BK_ -?,?PI)[W?X.Q[+\)?C
M)HWQ=TR[EL(KC3]2L9/)OM+O4V3VS\\$=QD'!]CD \5WM>!?"+X._$#PS\8=
M8\:^*M0\/S+JMF8+F+1VE&^0%-K[&C4=$Y.>Y]:]]JGLF);M'R[H.CV&N?MN
M^-K?4;&VU"!='C<174*R*&$=J,X8$9Y/YU[AXB^%?@?5-$O;;4?#6CQV31-Y
MLHLXHS&N#EPX *D#G<#Q7S7KW@74/B#^V)XRTW3O$^I>$YX]-AG-]I<C)*RB
M*W&PE64[3N!Z_P (KOKC]DF_UR,VOB'XJ^+M;TQO]99RW+;7_P"^W<?^.UE%
M<U""\OU95[5)/T_])1P7[.]Y=R?LU_%>S,LD^D6<=\EC(_3!MF+ >WW3]6-6
M?@)\=-6T3X2Z)H7A3P#JOC.[TY)?MTT+_9X(6:5W"!RC;FVD' '?O7M_BKP3
MH_P[^ /BK0M"M!9Z?;Z+>[5R69F,+EF9CR6)ZG^E9'[(=M%;_ 'PT8HU0RF>
M1RH^\WG.,GWP!^5:7YISUV4?PNB7I&%UNY?HS;^#/QPTWXQ6FHI%87.BZUID
M@BOM+O/OPDD@$' R,@CD @@Y'3/->)/VE9/^$LU#P[X'\&ZEXZO]-?R[Z:UE
M$%O"V2"OF%6R<@CD $@X)KF?A&T=E^U;\722(8%MXY7[#_EF2Q_,G\36+\-?
M&GB;6KC7?^%*> M)TWPY)?N;C5]>NI7^TS8&7"^9N'!!VC<!GL3BDGS*,EU5
M_P!/N*:Y'*+Z.W]>9Z5\-?VC%\8>-6\'^(O"VH>#/$K1M+#:7C^8DR@9.UMJ
MG. 2/EP0#SVJEX^_:<'@?XFWW@N+PK=:SJ"6L<MD+.<F2[F?:1%L\L[  6);
M)X7IS7E]O:>-+3]KKP /'.IZ7J&JO9SO&FDH5B@B,4^%^90Q.0QR<_6NJL[2
M*X_;JOY)%W-!HBR1^S&)%S^3'\Z:7-R>=[_+F_R(;Y7)=DG][1T^O?M$ZUX1
M^&=QXJ\0> +K1;F'4H]/_LVZO@"ZLN?-5_*Y4=/N\X//%9.L_M7:G:Z?)KVF
M?#/6M1\&QD$ZY++Y 9,X,BQE#E/1B1[XJ3]N'_DB/_<3M_Y/7HOBRS@@^!>K
MVT<2+;Q^'946,#Y0HMB ,5G*5J<ZG\O^5_Z]311]^$._^9PUU^U%)KT*R_#_
M ,#ZOXYACA66[GA/V>*W9E#>5NV-ND /*@?0FNV^#/QDTSXS>';C4+*UGTV\
MLYOL][87/+P28SU[@\\X'0\"N4_8XMXX?V?] >- C2RW+N1_$WGNN3^"@?A7
M*?LVW4&F_$;XYRSOY%E;ZN\DAY"HHDN"3QZ 5K.T)RAV3?W-?AJ91;E!27>W
MY_Y'1ZS^TU/?>)-1T;P'X(U+QT^FR>5>7EO*+>V1P2-H<JV>AZXS@XR.:U/A
M7^T-%X\\67/A/6_#6H>#_%$,1F%A>G>LB#&2K;5.<'/W<$<@FO,/A7XO\8:S
M8ZBOP9\!:+H7A&2]D/\ :&O74LC3RX +XW[AP!P-P'3.<U1\*VOBZS_;&\/I
MXUU+3M2UIM)F;.EH5ABC,<NU!E5)/4Y(SS2@M4I=5Z=+_P!7Z%2V;71_K;^K
M=3Z\KYG_ &D=6U#XA?%+PA\)+&\ELM/U+%YJLD)PSQ L=A]@L;-CH25]*^F*
M^8?B9,/!O[9'@77;XB+3=3L38I.W"K(1)'C)]Y$_[ZJ4E*I!/O\ HVOQ*;M"
M<ENE^J_0]QT#X3>#?#.CIIFG^&=+BM%38RO:H[2#&,NS ES[DFO/O#_[/]W\
M/_C6/%/@Z\M-(\+WD&S4M%^?#MS_ *M0-J@':PYX.X 8.*]NKA_$GQA\/^%_
MB#H?@RZ^U2ZUJZ[H%MX@Z(,D#S.<KG#'.,84U2;YT^I-O<:Z'/\ Q3_:#L/A
M_P"(+7PSI6C7OB[Q9<*'72=.ZQJ1D%VP=N1S@ \<G QG$T']IYK?Q59:!X\\
M&ZCX"N=08)9W-W,)K:1B< &3:N.2!D9 )YQ7-_L^)'>?M&_&2[O<-JD5TL4)
M?EA#YC@XXZ82+]*V/VW+:TD^",TTX7[3#?V[6K'[P<D@X_X"6_*H4N6$)RUY
MK?CV]/S+Y>:<H+2U_P %<Z/XS_M"6OP9\2>'M-O='EU"VU6.5VN()L21%, *
ML>P[RQ( ^9>M0:/\<?$TWAOQ1K&N_#?4/#<.CZ>U_#]LN\B[P"1'GRQL; YX
M..]>9?%.%]6^*W[/0U$>;-)%%)-N[R#R6.<_[0KW;XZ?\D;\:?\ 8)N/_19H
MG>G2E+JG)?<.%IU8QMHU%_?N>7Z7^UEJOB[3H+CPC\-=4\3/' LFH&WN=L-K
M(1GRE?RCYC =L ^@->D?![XTZ/\ &+2[N6R@GTW5+"3RK[2[P8EMVYQ]02",
M\=#D"LS]ENRLK+X#^$_L2(JS6[2RLO\ %*7;>3[YX_"O++=I=*_:R^)/]AC;
MO\-R3W BZ"?RXBIX_BW8_,UI4M3G*/D_P5_NZ?<90O.*EZ?BTOOU.V\1_M.%
M_%E[X=\"^#]0\>WM@Q2\FLY1#;Q,#@CS-K9Y!'( R.":V/A?^T+8^//$EQX7
MUC1+[P?XLA4R?V7J//F*!G,;X7<<<X*CCD9&<<K^P[;VL?P7:XA"F[GU*<W+
M_P 18;0 3_NX_.LS]I%([7X]?!F[L=JZO)?F*0K]XP^;%@'V^:3\S3Y>6<*;
MUYK?BK@Y<T936EK_ (?Y_F=)XX_:>/@_XFZGX)M_"5WK6IPPQ-8K9W!+WDKJ
MK;-GEG8 K,2V3PO3GC?MOCD=$^'.H^+/'/AN\\&"SN#;#3YI!/+.V!M\OY5W
M9)('0?*3G S7GOAZSBNOVY_$LLBY>WT19(SZ,8X$S^3&NL_:E\2^%M!\)Z3#
MXA\//XJOKJ^4:7I2SO$'G QN8H<X&[&,')8#'.1DK^SB^LO_ )*VGF::.;71
M?_(W^XPKC]IWQA!I?]M?\*;US_A']OF_;6NL2>5C/F&+RB0,<YSCWKJ?$7Q@
M_P"$N^!\_BGP?H5QXB2^BDMWLFE6"6W7:RR,YPP^3'0=<CFN5U2Y_: \1>'[
MU[F#PCX.L1 [R;B\UPD>TY'5TSCZ5G?LH_\ )K^L_P"_?_\ HL4IZPJ+LKCA
MI*#[NW_#%3]B7Q5KC>"[?0F\+3+H"O<SKX@^T@QO)N'[KR]N0>3SN[=*]%^
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MP_J-EK*12:3/;O'=K,^Q/**G=ELC:,9YR,=:^8/VE[#PYI7PX^&MGX3DM9-
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M5XF4JR,,J5(P01Z5I-:RDN[2^7<SIRO&"?9-_/\ X8X6\^,&D3?"._\ 'VB
M:QI]O9O=+!O\IF*#F-C@[&!X/!_&O-M/_:JU?Q5I,%[X1^&>K^)E6%7O9(9]
MD$$I4,T22>6?-9<X.%'/:O+OA*QC_9T^-MM;MNTJ&>Y%I@Y4#R^<?@$KZ#_9
M=MHK7X"^$!%&L8>V:1MHQEC(Y)/OFIW;:VM%_>FS39)=;R7W6-'X,_&C2_C-
MHMY=6=I<:9J%A+Y%]IUU]^!SG'/<'!YP#D'(%>AU\W?L] 6_[0GQI@C 2)KU
M'*@?Q>9(<_\ CQ_.OI&C>,9=TF+:4H]G8****0PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** ,72_P#D8]<_[8?^@&MJL72_
M^1CUS_MA_P"@&MJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH \I_:2^%.K?&+X?P:'HUQ96UVE]
M'<E[YW2/:JN",JK'/S#M5WXP?"F7XF?"2;PO'-!#J:1PO:W$I81I-'C!) )
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M  ,Y]CHJKN]^I-E:W0\2^)7P'UJ\\>#QW\/=?B\->*9(Q#=QW,9:VO%P!E\
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MTWP>\&WOP^^&>@>'=1EMYKW3X/*EDM69HR=S'Y2P!QSW KLJ*=VVV^MOPO\
MYA:R2[7_ !M_D>2?"_X2ZQX*^*_Q \3WUS8RV'B"99+6.WD<RH S']X"@ ZC
MH37K=%%+HH]E8?5R[A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% &+I?_(QZY_VP_\ 0#6U6+I?_(QZY_VP_P#0#6U0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 445\M>"?VB/BK\3I-7T_P +>%M#NM0TR[D6XN[DR16RP](T
MP9<F1BK\YQ@#CO2ZV'TN>W^(OBUH_AGXC>'_  7=6U])JFMQM);S0QH8$ W9
MWDN&'W3T4UVU>):I\8?%F@_%3X<^$=1T[2X'UZR\[4U0.[P3 /E8G#XP"H'(
M;OS2?$GXZ>(+?X@#P%\/- @\0>)HHA/>3WKE;6T4@'#89<G!7/S#&0!DG KH
MNK;?X?Y=Q=7T5D_O_K8]NKB?'?Q9TCX>^(O"VC:C;7LUUXBN3:VCVJ(R(P9!
MF0LX(&9!T!Z&O#?'G[2GQ.^%ZV&E^)O".DV>L7ET@@OX#)+8SP<B0*!)N612
M4ZL>"?E'!,W[8FN#PSXX^$NK&VEO/L6H33_9X!EY=KVYVK[GI^-3?WH=F[?Y
MAK[R6Z3?YV_(^HJRO%/BC3/!?A^]UO6+D6>FV:;YIBI;:,@#@ DDD@<>M>!>
M*?C+\:? ^D'Q3K7@31(_#,;*\]G#<NUY!&2 -[!RN>1R$..X%._:8\7:UXP_
M9]AUKPU;V,GA;5+-;C4I+W<+F)"\1C$8#8W;LAL@].*F;<8.2_X8J*3FHOJ>
M^^&?$%KXK\.Z;K5D)!9ZA;QW4/FKM?8ZAER,G!P:TZ^?OA%X\\3> O@/_P )
M!XTLM-30-,TBUDTG^RRQGGBV *)=S$!CF,< #DU2L_BG\=M<T!/$^F>!O#XT
M.:(74%E+<.UY)"1N!!$@&2.@V@^U:U+1E)+9?AZF5-N44WN_ZT/HZD)P":XG
MX._%"V^+W@>U\06]G)I[N[0SVDAW&*1>H#8&X8((.!UKMF.%)J9WC>Y2=SB_
MA7\6-(^+VCW^I:/;7MM!9WCV4BWR(C%U56)&UV&,,.^?:NUKPGX7_';7_&WP
M?\<^*[ZTTV+4="DO$MHK>*01.(H!(N\%R3DGG!''I7/>#?CK\6OBMX9M=0\'
M^#M%80IMO+_4I'C@FG')C@C\P-@# R6(SGI1ULNR?WK?^O0?^;7W/;^O4^EZ
M*\C^!'QLO?B=-KNB>(-'70O%6A2B*]M8V+1MDD;ER21@@@C)[$$YX]<IM6L^
MXK[KL%<-:?&#1KSXL7GP^2VOAK-K:B[>=HT^SE"JM@-OW9PX_A]:[FOF;0?^
M3ZO$/_8%7_T5#2CK44?)_@KC?PM^GYI'TS17B?Q ^./B'_A84O@/X>>'K?7O
M$-M")[VZOY=EK:J0#@X().&7^(=0 ">F /CM\1?AYXPT/2_B7X7TFWTK6;A;
M6WU+196VQR$@?,&=R<9&0=O&2,XQ1'WK6Z[>82]V]^A]%T5X?\>OCYJ?P>\9
M>%-/MM+AU6PU2.<S0+&[7+R+@1I$0P W,P!RK=:Y[7/C5\8_A[8Q>(_%G@32
M3X7W*;F/39V-W:HQP"Y\QESS_=QG@E<TDTU?H-II\O4^D:*\^\9?&S0/"/PK
M3QWN>^TRXBC>TBBP'G=_N)['KGTVGKC%>;_\+$_: O\ 1UUVR\"^'8].DC%Q
M'I\T[M>&,C(_Y:J-V.V ?;/%#T;3Z;^0EJDUUV/HFBO*/ OQP'Q"^"^K>,[&
MQ6RU#3[>Y\VSF8R(D\49?&1@E3\I['G'O7GO@CX\_%GXL>&;:]\(>#]&=X5*
M7VH:C(\=M)-DGRX4\P-PI7+%B,D]*;TDX]K?B"V3]?P/IFBO(/@7\;M0^)&H
M:]X=\2:,FA>+-#<+=V\+EHG!)&Y<DXP>V2.00>>/7Z=MGW%?==@HKQ7XC?'#
M7K;X@_\ "!> /#\/B#Q-' +F[FO9=EM:(0"-V""3AE/4?> &2>.<N/CO\2/A
MKXHT6T^)7A;2(=%U:Y6TBU+1)7Q&Y(^\&=\XST.WC."<4H^]:W7;S'+W;^1]
M&T5XG\>_CQJ?P>\5>$;.UTV'4['5?/%Q"(W:X=EVB-(B& !9F Y#=:YCQ5\:
M/C1\/],'B;Q#X%T-/#*.IN+:UN6:[MT8@#>X<KGD#(0C)YQ2337-TO8;33MU
M/I.D)P":X#Q9\:M"\*?"F+QY+YD^G7%O%-:VZX$DSR %(_8\\^F#UQ7F=G\7
M?C4NBCQ5??#[2F\,%/M#6%O.XU%;?&=XRY!('.-@)]!1*ZYEV_!B6J3778]7
M^%?Q8TCXO:/?ZEH]M>VT%G>/92+?(B,7558D;788PP[Y]J[6OF[]A6=;KX;^
M(YD!"2:[,XSUP8HC7TC5R7+;T7Y(F+YK^K_-A17SY>?'WQI\0/%FIZ/\*?#5
MAJMCI4GDW6M:Q(RV[/Z(%93U!QR2>N .:TO /QYU^/Q]#X%^)'AZ'PYX@ND+
MV-U9R%K6[Z_*N2V"<''S'D8.#P9C[UK==O,J7NWOTW\CTF_^)&A:?X\TSP=)
M<N^OW\+W$=O'&2$C56;>S= #M( Y.>V.:H>*/BWH_A+Q]X<\(WEM?2:EKP8V
MTL$:&%,$YWDN".G8&OF7Q9??$U?VLK"6VT_P^WB9;"9=.AD:3[,]I^^VM)\^
M?,V[NA SCBMS]HWQ)?\ A7XV?"?6+G36U+5;>T9FT^Q_Y;7!.WRT)SP7.,\\
M>M$'S.FWLWK^/^7WCDN7G2Z+_+_/[CZUHKYK\5?&SXQ?#.RA\1>+/!&B#PP9
M56>+3[EFNK<,< ,V]ESVR%QGCC->L>.OC)H7@3X:Q>,[II)[&YACDLX$P)+A
MI%W(@]"1R?0 T/2/-VT$M6DNIWE%?.\?Q*^/EUI8U^+X?:&NDL/.72WG?[>8
ML9_YZ ;L=MN?]GM78Z;\=K;Q;\$=;\<Z#;K%>Z=:SM)87H+>1<1IN,;[2"1T
M.1C((Z'@*7NIM]-QQ]YI+KL>KT5\U_#WXV?%_P"*FCZ=K'A[PEH7]E*ZP7EQ
M>2/&9I-W[QH5\WA5!_BW9(./0?2=6XM;DII["T5XS\4OC1XATKQ]:> _ F@6
M^N>)Y;;[9-)?R^7;VT>3U&5+'O\ >'4=2>,;2OC?X_\ !WCO0_#WQ*\+Z=:6
MVN2^19ZIH<CM$LF0,,K,QZE<\C&<\U,?>M;J.7NWOT/?Z*\G^,7QNF\!ZMI?
MACPWH[>)?&FK#=:Z>'VI$G/[R0^G!XR.%)) %<9JGQJ^*WPO6WU7XA>#=)D\
M,,ZI<7F@2L9+3<< NK2-G] 3QNY%)-,;5M.IZK\4/BUI'PEM=)N-7MKZY34[
MQ;*$64:,5<@D%MSK@<=LGVKMJ^9OVP]2MM8\)_#J^LYEN+2ZUN":&5.CHR$J
M1]0:]-^-'QHB^%<&F6-CILFO^*-8D\G3M*A;!<Y +,<'"@D?4^G)#V3OO>WX
M+_,-[6VM?\7_ )'IE%?.FK?%WXT?#VP&O>+_  -HMUX=BPUVNC7#?:;9"?O-
MF1P<>PQZD=:]*\5_&WP[X7^%:>/#*UYI5Q"CVD<>!).[_=C&>ASG/IM;TH=D
MN82NW8]!K'\6^+-+\#>';W7-:NOL>F6:AIIMI;&2%   )))(''K7@Q^+GQSE
M\/MXKC\ :*GA_P O[2-/DFD-^8,9W??'..?N9_V:POC]\3M5^*G[.8U_PU:V
M(\+W:*NLK>,WVNUE6>(*D>" ?GZD@Y4@\9J)WBG;?3Y?U^94+2DD]G^/H?3W
MA[7+?Q-H.G:O:"1;6^MX[F(2@!MCJ&&1DX.#6A7D_P"S=<^,I_A[IR^*+72[
M>P2QM1I+:<7+R0>7UEW,?FQLZ8')KUBMJD5&32,J<G**;.7^)'Q$TKX6>$;O
MQ%K/G-96[(GE6RJTLC,P4*H8@$\YZC@&H_AC\3-'^+7A.'Q!H@N$M'D>%H;I
M566-U."K!68 XP>">"*\6_:"NF^)GQH\ _#2V8R6D,XU;5%4Y 1<D _\ #_]
M_!4/P;N/^%2_M'>-/A_,?*TO6V_M72U/W=Q!<JO_  $LO_;*HI^]OUO;Y6_/
M7[BY^[MTM?YW_+3[SZ;HKSGXW?%Y?A'X=LKB#36UC6-2NELK"Q5]@DE;NS8X
M X^I(''4>:^(/B_\:OASIB^(/%?@G0;GP_&R_:H]*N'^T0*Q !),CCJ0,@$?
M2E=#LSUWXK_%;2?@]X9CUS6;>]N;22Y2U"6*(\FY@Q!PS*,?*>]=A'()8T<=
M& (S[UX[\<?CA?> _A)I'C+PU;VMT=1GMQ&FI1.5$<D;/RJNI## [^M:GQD^
M-7_"K]/T2VLM*?7?$VN2"#3]-C?8';@%F/. "RC'?/4<D/:Z>][?@M"=W&VS
M3?\ P3U&BOF[Q-\6/CE\/=);Q#XB\&>&[G0K?#W<6GW#B>%"0.6,C#OU"L/P
MKM?B5\;)]"^ R_$'PY;V\TD\5O-##J",R 2.JD,%93D9(X/44GI'F^7WE).3
M45U/7**^=;?XO?&7QIH:>(?"'@?2!H31!X?[4F;[3> #YGC02+M!(. V>,<F
MO1?@7\7X?C-X+.KBR.FW]M.UI>69;<(Y% .0< X((//3D<XS5\KNUV)NM'W/
M1:**^9/#/[1?Q&\>:YXD\.^&?"FEZAK&F:C-%]LF9X;2WME<JADS)N>1B&X4
MKTS@\XCK8JVG-T/INBOF?2?VG/&MEXAU+P1KW@B&X^("LJV%KIDI6UGW#=N=
MF9MJ!?FW;CD9'RUI6'QS^(7@OXB>'_#WQ)\-:39V.O2BWL[_ $:1R$D)  ;<
M[9Y901\O7(STJE[S2778EOE3OT/H:BO+?C1\:I/AK<:+HNCZ0WB#Q7K<ACL=
M/#[$X(&]V],GVZ'D 9KS[Q1\8/C9\,]-&O\ BOP;X=NO#T3+]J_LJ=Q-"K$
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,"7R YW,/]X9[^V-FX6ZZ_GT^7XZFEUSI]-/Z?\ 6QP7QZY_8X^'P_V=-_\
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#%TO_D8]<_[8?\
MH!K:K%TO_D8]<_[8?^@&MJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X[QY\'_!OQ-:)_$N@V
M^IS1#:DY+Q2A?[OF(5;'MG'-=C12LGN.[1Q/@7X*^"/AK</<>'/#UMI]TP*F
MY+/-, >H#R,S 'T!KMJ**J[9(4444AA1110 4444 %%%% !1110 4444 %%%
M% '-Z_\ #KP]XH\2:+K^IZ?]IU;1F+V-QYTB>2202=JL%;D#[P-=)111TL&[
MNPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH Q=+_Y&/7/^V'_ * :VJQ=+_Y&/7/^V'_H!K:H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGF"V1^ZA!*H(!SV7Z"KWP'^)7BV/Q]X@^&OCN:/4=9TF/S[;5(T"_:(OEX;
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#(@(Z;E!7\:=X=_MK]I+XY>'O&?]A7NA^"?#:[[674$V274F=P*CH<MMS@D
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M,#(SRPK+3VD+OJ__ $EC=_9U+*^GZHWO$VO_ +3%UH=W%#X:\.6KO&1YVFR
MW"C')3S)RN?P)]*WOV.]4\--\.;C1]&BO+76+"Y)UBWU  3_ &AN"_'\/R;1
MW&W!YY-*;]N3X?>6PM+37+VYQB.WCLU#.W8<O3/V5?!NOC7/&OC[Q!ILFB2>
M);KS+;3Y5*NJ%V<L5/(&6 &0"<$]Q6L+WEII;?\ )?UZD3M9=[[?F4_V8/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 8NE_P#(QZY_VP_] -;58NE_\C'KG_;#_P! -;5 !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7%:OX)O]=^*.A>(;FYMX](T.VF^RVT88S27$PV.SGH%5 , 9)).
M<8KM:*.J8=+!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 8NE_\ (QZY_P!L/_0#6U6+I?\ R,>N?]L/_0#6U0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!BZ7_R,>N?]L/_ $ UM5BZ7_R,>N?]L/\ T UM4 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 8NE_\ (QZY_P!L/_0#6U6+I?\ R,>N?]L/_0#6U0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!BZ7_R,>N?]L/_ $ UM5BZ7_R,>N?]L/\ T UM4 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 8NE_\ (QZY_P!L/_0#6U6+I?\ R,>N?]L/_0#6U0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!BZ7_R,>N?]L/_ $ UM5BZ7_R,>N?]L/\ T UM4 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 ,6%$D=U15=\;F Y;'3)[T^BB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
(* "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>nbix-20221231_g2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nbix-20221231_g2.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" @0#$ # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N5^+%Y<:?\+?&5U:3
MRVMW!HUY+#/"Y1XW6!RK*PY!! ((Z8KJJY'XP#=\)?&P_P"H'??^D[T >2?#
M']EKX7^(OAKX4U74/#'VB_OM)M;FXF_M"Z7?(\*LS864 9))P !73?\ #(/P
MD_Z%/_RI7?\ \=KKO@F<_!OP-_V [+_T0E=K0!XY_P ,@_"3_H4__*E=_P#Q
MVC_AD'X2?]"G_P"5*[_^.U['10!XY_PR#\)/^A3_ /*E=_\ QVC_ (9!^$G_
M $*?_E2N_P#X[7L=% 'CG_#(/PD_Z%/_ ,J5W_\ ':/^&0?A)_T*?_E2N_\
MX[7L=% 'CG_#(/PD_P"A3_\ *E=__':/^&0?A)_T*?\ Y4KO_P".U['10!XY
M_P ,@_"3_H4__*E=_P#QVC_AD'X2?]"G_P"5*[_^.U['10!XY_PR#\)/^A3_
M /*E=_\ QVC_ (9!^$G_ $*?_E2N_P#X[7L=% 'CG_#(/PD_Z%/_ ,J5W_\
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M $*?_E2N_P#X[7L=% 'CG_#(/PD_Z%/_ ,J5W_\ ':/^&0?A)_T*?_E2N_\
MX[7L=% 'CG_#(/PD_P"A3_\ *E=__':/^&0?A)_T*?\ Y4KO_P".U['10!XY
M_P ,@_"3_H4__*E=_P#QVC_AD'X2?]"G_P"5*[_^.U['10!XY_PR#\)/^A3_
M /*E=_\ QVC_ (9!^$G_ $*?_E2N_P#X[7L=% 'CG_#(/PD_Z%/_ ,J5W_\
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MG_Y4KO\ ^.UQ'Q2^"_@_X.CPCKO@W39]!U:3Q'8V3W5OJ%RS&&1B)$^:0C#
M8/J,CH37TU7CG[3G_(N^#?\ L;--_P#0VH ]CHHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *Y/XM#=\*?&8_Z@M[_ .B'KK*Y7XK#=\+O
M& _Z@UY_Z(>@"E\#CGX,^!_^P+9_^B5KMZX7X%'/P7\#_P#8&M?_ $4M=U0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %>.?#'_ ).(^-?_ '!/_21Z]CKQSX8_\G$?&O\ [@G_ *2/
M0!['1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 >.?M??\F[^+/\ MT_]*X:]CKQS]K[_ )-W\6?]
MNG_I7#7L= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 >.?LX_\?'Q3'_4\:E_*.O8Z\<_9S_X^
M_BH/^IVU'^4=>QT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7CG[3G_(N^#?\ L;--_P#0VKV.O'/V
MG/\ D7?!O_8V:;_Z&U 'L=%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M247'<_:*BOSV_91_X*W:#\9O&FF>#/'WAM/!VM:G*EM8ZG97!FL9YV.%C=6
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M 4444 %%%% !7CG[3'[S2? -J/\ 677C+3(4)Z!BSG)]N*]CKQS]I'_FEO\
MV/>E_P#M6@#V.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^&&D_L_>&/&'C'PAI/C+Q1XGLTU.237K1+R&VAD&Z&***0%%PA4EL;B6/.
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M3S;:XO8894R1N5I%!&1R.">E?O3_ ,.N/V8O^B9_^5_5/_DFNUJ7LTV]+O\
M2_Z'$I1]K)):V7W:V_4_'?\ :4_;4^*'[5364'C34[6+1K*3SK?1=)@\BT27
M!'F$$LSM@D NS8!.,9.?M[_@C_\ LFZ[H^M7?QI\3V$NFV4ED]EX?@N4*27
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M!'M(WYP$;.,9YS73_P#!&&W,W[56MR X\KPK=,1ZYN;4?UKIP:M5G9W=I?\
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MQBG)6WO]Z_+6Q_/+^QEX\^$7P[^,4>J?&?PO)XI\+FU>*&+R!<Q6UP63;-+
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M4^^-GQV\&WOA:_NM&\,Z+?H8;V'P[9R0O=1'K&TDLDC!3T(4KD9!R"17V_\
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M;WP3^TA+X'ENF&B^+K*5/L['Y!=P(TL<@]#L65??</05>_X<J?&__H:?A_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "L'QZ-W@;Q$/^H;<_P#HIJWJQ/' W>"_$ ]=
M/N/_ $6U '*?LZG/P.\%_P#8-C_K7HU>;_LXG=\#/!?_ &#T_F:](H ****
M"BBB@ HHHH **** "BBB@ HHHH _.[_@ME_R;WX'_P"QH7_TDN*\$_X(D?\
M);OB!_V+J_\ I3'7ZU>-OAQX2^)FGP6'B_POHOBNQ@E\^*UUO3X;R*.3!7>J
MRJP#8)&1S@FL_P $?!CX??#.^N+WP?X%\->%+RXC\F:XT/2+>SDE3(.QFB12
M5R <'C(IX?\ <SG-];_C'E)KKVT(Q72WX2N=E1112*"OYU?V^?\ D\CXL_\
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MN-0C1@<AECN))$4@]"%R.U>M^./A)X&^)OV+_A,/!GA[Q9]B#"U_MS2H+SR
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M%X:LED1P<AE819!!&<BO3ZZ.;]W&'9O\;?Y&<ES5I5>]OS?^84445F4%%%%
M!1110 4444 %%%% !1110 5XY\,?^3B/C7_W!/\ TD>O8Z\<^&/_ "<1\:_^
MX)_Z2/0!['1110 4444 %%%% !1110 4444 %%%% !6;XF_Y%O5?^O27_P!
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MG_7QIO\ Z#<5^CWCCX6^#/B=#:0^,?".@^+(K1F>WCUS3(;U868 ,4$JMM)
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M/']G7P%JBZAI7PMTJ6Y4Y7^U9[C44!]0ES)(N??%?1$<:0QK'&JI&H"JJC
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8WC,;O!^NC
M_IPG_P#1;5LUD^+AN\*:T/6RF_\ 1;4 <5^S:<_ KP9_UX+_ .A-7I=>9?LT
M'/P(\&_]>7_L[5Z;0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %>.?#'_DXCXU_]P3_ -)'KV.O'/AC
M_P G$?&O_N"?^DCT >QT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'CG[7W_ ";OXL_[=/\ TKAK
MV.O'/VOO^3=_%G_;I_Z5PU['0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'CG[/_\ R,7Q8'_4
MV7/_ * E>QUXY\ /^1F^+(_ZFNX_] 2O8Z "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQS]I'_ )I;
M_P!CWI?_ +5KV.O'/VB_W][\*[5>)&\;:?,">FU!(2/KSQ0!['1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5E^*1N\,ZN/\ ISF_] -:
ME9OB0;O#NJ#_ *=9?_0#0!P7[,AS\!O!O_7F?_1C5Z?7EO[,!S\!?!W_ %ZM
M_P"C7KU*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *\<^&/_)Q'QK_ .X)_P"DCU['7CGPQ_Y.(^-?
M_<$_])'H ]CHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** /'/VOO^3=_%G_;I_P"E<->QUXY^U]_R
M;OXL_P"W3_TKAKV.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** /'/@%_R-/Q:'_4TS?^@)7L=>
M.? /_D;/BT/^IHE_]%K7L= !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5XY^T!_R,7PG_[&RV_] >O8
MZ\<_: _Y&+X3_P#8V6W_ * ] 'L=%%% !37=8T9W8*BC)9C@ >M> ?&;]KS0
M?AW<S:3H,*>(M<C+)*5?%M;.#@AV'+,#U5?Q(-?'OQ ^-7C'XF73R:WK,[VS
M9"V-NQBMT![!!P?JV3[UW4L'4J:O1'VN5\*8W,(JK4_=P?5[OT7^=C]"O$'Q
MP\ ^%YI8=2\6Z7#/$VV2&.<2R(<XP53)!^HXKG)OVL/A3!(4;Q6I8?W+"Z8?
MF(L5^<%%=ZP%/JV?;4^!L"E^\JS;\K+]&?HY_P -;?"C_H:__*==_P#QJC_A
MK;X4?]#7_P"4Z[_^-5^<=%/ZA2[O^OD:_P"H^7?\_)_?'_Y$_1S_ (:V^%'_
M $-?_E.N_P#XU1_PUM\*/^AK_P#*==__ !JOSCHH^H4N[_KY!_J/EW_/R?WQ
M_P#D3]'/^&MOA1_T-?\ Y3KO_P"-4?\ #6WPH_Z&O_RG7?\ \:K\XZ*/J%+N
M_P"OD'^H^7?\_)_?'_Y$_1S_ (:V^%'_ $-?_E.N_P#XU1_PUM\*/^AK_P#*
M==__ !JOSCHH^H4N[_KY!_J/EW_/R?WQ_P#D3]'/^&MOA1_T-?\ Y3KO_P"-
M4?\ #6WPH_Z&O_RG7?\ \:K\XZ*/J%+N_P"OD'^H^7?\_)_?'_Y$_1S_ (:V
M^%'_ $-?_E.N_P#XU1_PUM\*/^AK_P#*==__ !JOSCHH^H4N[_KY!_J/EW_/
MR?WQ_P#D3]'/^&MOA1_T-?\ Y3KO_P"-4?\ #6WPH_Z&O_RG7?\ \:K\XZ*/
MJ%+N_P"OD'^H^7?\_)_?'_Y$_1S_ (:V^%'_ $-?_E.N_P#XU1_PUM\*/^AK
M_P#*==__ !JOSCHH^H4N[_KY!_J/EW_/R?WQ_P#D3]'/^&MOA1_T-?\ Y3KO
M_P"-4?\ #6WPH_Z&O_RG7?\ \:K\XZ*/J%+N_P"OD'^H^7?\_)_?'_Y$_1S_
M (:V^%'_ $-?_E.N_P#XU1_PUM\*/^AK_P#*==__ !JOSCHH^H4N[_KY!_J/
MEW_/R?WQ_P#D3]'/^&MOA1_T-?\ Y3KO_P"-4?\ #6WPH_Z&O_RG7?\ \:K\
MXZ*/J%+N_P"OD'^H^7?\_)_?'_Y$_1S_ (:V^%'_ $-?_E.N_P#XU1_PUM\*
M/^AK_P#*==__ !JOSCHH^H4N[_KY!_J/EW_/R?WQ_P#D3]'/^&MOA1_T-?\
MY3KO_P"-4?\ #6WPH_Z&O_RG7?\ \:K\XZ*/J%+N_P"OD'^H^7?\_)_?'_Y$
M_1S_ (:V^%'_ $-?_E.N_P#XU1_PUM\*/^AK_P#*==__ !JOSCHH^H4N[_KY
M!_J/EW_/R?WQ_P#D3]'/^&MOA1_T-?\ Y3KO_P"-4?\ #6WPH_Z&O_RG7?\
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M !JOSCHH^H4N[_KY!_J/EW_/R?WQ_P#D3]'/^&MOA1_T-?\ Y3KO_P"-4?\
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M/^AK_P#*==__ !JOSCHH^H4N[_KY!_J/EW_/R?WQ_P#D3]'/^&MOA1_T-?\
MY3KO_P"-4?\ #6WPH_Z&O_RG7?\ \:K\XZ*/J%+N_P"OD'^H^7?\_)_?'_Y$
M_1S_ (:V^%'_ $-?_E.N_P#XU1_PUM\*/^AK_P#*==__ !JOSCHH^H4N[_KY
M!_J/EW_/R?WQ_P#D3]'/^&MOA1_T-?\ Y3KO_P"-4?\ #6WPH_Z&O_RG7?\
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M !JOSCHH^H4N[_KY!_J/EW_/R?WQ_P#D3]'/^&MOA1_T-?\ Y3KO_P"-4?\
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M/^AK_P#*==__ !JOSCHH^H4N[_KY!_J/EW_/R?WQ_P#D3]'/^&MOA1_T-?\
MY3KO_P"-4?\ #6WPH_Z&O_RG7?\ \:K\XZ*/J%+N_P"OD'^H^7?\_)_?'_Y$
M_1S_ (:V^%'_ $-?_E.N_P#XU1_PUM\*/^AK_P#*==__ !JOSCHH^H4N[_KY
M!_J/EW_/R?WQ_P#D3]'/^&MOA1_T-?\ Y3KO_P"-4?\ #6WPH_Z&O_RG7?\
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M[O\ KY!_J/EW_/R?WQ_^1/T<_P"&MOA1_P!#7_Y3KO\ ^-4?\-;?"C_H:_\
MRG7?_P :K\XZ*/J%+N_Z^0?ZCY=_S\G]\?\ Y$_1S_AK;X4?]#7_ .4Z[_\
MC5'_  UM\*/^AK_\IUW_ /&J_..BCZA2[O\ KY!_J/EW_/R?WQ_^1/T<_P"&
MMOA1_P!#7_Y3KO\ ^-4?\-;?"C_H:_\ RG7?_P :K\XZ*/J%+N_Z^0?ZCY=_
MS\G]\?\ Y$_1S_AK;X4?]#7_ .4Z[_\ C5'_  UM\*/^AK_\IUW_ /&J_..B
MCZA2[O\ KY!_J/EW_/R?WQ_^1/T<_P"&MOA1_P!#7_Y3KO\ ^-4?\-;?"C_H
M:_\ RG7?_P :K\XZ*/J%+N_Z^0?ZCY=_S\G]\?\ Y$_1S_AK;X4?]#7_ .4Z
M[_\ C5'_  UM\*/^AK_\IUW_ /&J_..BCZA2[O\ KY!_J/EW_/R?WQ_^1/T<
M_P"&MOA1_P!#7_Y3KO\ ^-4?\-;?"C_H:_\ RG7?_P :K\XZ*/J%+N_Z^0?Z
MCY=_S\G]\?\ Y$_1S_AK;X4?]#7_ .4Z[_\ C5'_  UM\*/^AK_\IUW_ /&J
M_..BCZA2[O\ KY!_J/EW_/R?WQ_^1/T<_P"&MOA1_P!#7_Y3KO\ ^-4?\-;?
M"C_H:_\ RG7?_P :K\XZ*/J%+N_Z^0?ZCY=_S\G]\?\ Y$_1S_AK;X4?]#7_
M .4Z[_\ C5'_  UM\*/^AK_\IUW_ /&J_..BCZA2[O\ KY!_J/EW_/R?WQ_^
M1/T<_P"&MOA1_P!#7_Y3KO\ ^-4?\-;?"C_H:_\ RG7?_P :K\XZ*/J%+N_Z
M^0?ZCY=_S\G]\?\ Y$_1S_AK;X4?]#7_ .4Z[_\ C5'_  UM\*/^AK_\IUW_
M /&J_..BCZA2[O\ KY!_J/EW_/R?WQ_^1/T<_P"&MOA1_P!#7_Y3KO\ ^-4?
M\-;?"C_H:_\ RG7?_P :K\XZ*/J%+N_Z^0?ZCY=_S\G]\?\ Y$_1S_AK;X4?
M]#7_ .4Z[_\ C5'_  UM\*/^AK_\IUW_ /&J_..BCZA2[O\ KY!_J/EW_/R?
MWQ_^1/T<_P"&MOA1_P!#7_Y3KO\ ^-4?\-;?"C_H:_\ RG7?_P :K\XZ*/J%
M+N_Z^0?ZCY=_S\G]\?\ Y$_1S_AK;X4?]#7_ .4Z[_\ C5'_  UM\*/^AK_\
MIUW_ /&J_..BCZA2[O\ KY!_J/EW_/R?WQ_^1/T<_P"&MOA1_P!#7_Y3KO\
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M?ZCY=_S\G]\?_D3]'/\ AK;X4?\ 0U_^4Z[_ /C5'_#6WPH_Z&O_ ,IUW_\
M&J_..BCZA2[O^OD'^H^7?\_)_?'_ .1/T<_X:V^%'_0U_P#E.N__ (U1_P -
M;?"C_H:__*==_P#QJOSCHH^H4N[_ *^0?ZCY=_S\G]\?_D3]'/\ AK;X4?\
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M (U1_P -;?"C_H:__*==_P#QJOSCHH^H4N[_ *^0?ZCY=_S\G]\?_D3]'/\
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MPUM\*/\ H:__ "G7?_QJC_AK;X4?]#7_ .4Z[_\ C5?G'16GU"EW?]?([O\
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MO_RG7?\ \:H_X:V^%'_0U_\ E.N__C5?G'11]0I=W_7R#_4?+O\ GY/[X_\
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M ,B?HY_PUM\*/^AK_P#*==__ !JC_AK;X4?]#7_Y3KO_ .-5^<=%'U"EW?\
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MV^%'_0U_^4Z[_P#C5'_#6WPH_P"AK_\ *==__&J_..BCZA2[O^OD'^H^7?\
M/R?WQ_\ D3]'/^&MOA1_T-?_ )3KO_XU1_PUM\*/^AK_ /*==_\ QJOSCHH^
MH4N[_KY!_J/EW_/R?WQ_^1/T<_X:V^%'_0U_^4Z[_P#C5'_#6WPH_P"AK_\
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M^4Z[_P#C5'_#6WPH_P"AK_\ *==__&J_..BCZA2[O^OD'^H^7?\ /R?WQ_\
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M"R.#_5+4E1P?ZE:DK&C_  X^B/,RK_D7X?\ P1_])04445L>J%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1I
M_KI/P_E4E1I_KI/P_E6-3XH>OZ,\C&_Q\+_C?_INH24445L>N%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% $=Q_J6_P ]ZDJ.X_U+?Y[U)6*_BR]%^IY%/_D95O\ !3_]*JA1116QZX44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 1Q_>D^M25'']Z3ZU)6-'X/O\ S/(RK_=5ZR_]+D%%%%;'KA11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@3V(X/]2M25';_ZE:DK&C_"CZ(\K*?^1=A_\$/_ $E!1116QZP4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M&G^ND_#^525&G^ND_#^58U/BAZ_HSR,;_'PO^-_^FZA)1116QZX4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MMV:'%>?#/2-3V*;BQU)8PY'(CDC?<!]2B?E4_P"PG_R2/5?^PU-_Z(@KQ/\
M:$NOC-HGA^WTSX@:O:WVC7L_[H6RVH$DB<Y&Q%DP,]<8Y&>HKVK]A.16^$NK
M(#\RZU*2/K!#_A5QBX82HKI^GJB<;AY87AF--U(S7/HXNZM=^2ZW/&/VX_\
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M/HDG^OYLX,#47$'$"Q:7[NFDU\MO_)FW\CQZBBBO;/UP**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 1V_^J%25';_ .J%25C1_A1]
M$>1E'_(NP_\ @C^2"BBBMCUPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ J-/]=)^'\JDJ-/\ 72?A_*L:GQ0]
M?T9Y&-_CX7_&_P#TW4)****V/7"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@".X_U+?Y[U)4=Q_J6_P ]
MZDK%?Q9>B_4\BG_R,JW^"G_Z55"BBBMCUPHHHH **** "BBB@ HHHH ****
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M1[:E_,OO#^U\N_Z"8?\ @<?\SR"BO7_^&2?BO_T*G_E1M/\ X[1_PR3\5_\
MH5/_ "HVG_QVCVU+^9?>']KY=_T$P_\  X_YGD%%>O\ _#)/Q7_Z%3_RHVG_
M ,=H_P"&2?BO_P!"I_Y4;3_X[1[:E_,OO#^U\N_Z"8?^!Q_S/(**]?\ ^&2?
MBO\ ]"I_Y4;3_P".T?\ #)/Q7_Z%3_RHVG_QVCVU+^9?>']KY=_T$P_\#C_F
M>045Z_\ \,D_%?\ Z%3_ ,J-I_\ ':/^&2?BO_T*G_E1M/\ X[1[:E_,OO#^
MU\N_Z"8?^!Q_S/(**]?_ .&2?BO_ -"I_P"5&T_^.T?\,D_%?_H5/_*C:?\
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M2_F7WA_:^7?]!,/_  ./^9Y!17K_ /PR3\5_^A4_\J-I_P#':/\ ADGXK_\
M0J?^5&T_^.T>VI?S+[P_M?+O^@F'_@<?\SR"BO7_ /ADGXK_ /0J?^5&T_\
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M7_Z%3_RHVG_QVK]M2_F7WG;_ &OEO_03#_P./^9Y!17K_P#PR3\5_P#H5/\
MRHVG_P =H_X9)^*__0J?^5&T_P#CM'MJ7\R^\/[7R[_H)A_X''_,\@HKU_\
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MX@?] #_R=M__ (Y1_P ,\_$#_H ?^3MO_P#'*/;4OYE]X?VOEW_03#_P./\
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MQ _Z '_D[;__ !RC_AGGX@?] #_R=M__ (Y1[:E_,OO#^U\N_P"@F'_@<?\
M,\ZHKT7_ (9Y^('_ $ /_)VW_P#CE'_#//Q _P"@!_Y.V_\ \<H]M2_F7WA_
M:^7?]!,/_ X_YGG5%>B_\,\_$#_H ?\ D[;_ /QRC_AGGX@?] #_ ,G;?_XY
M1[:E_,OO#^U\N_Z"8?\ @<?\SSJBO1?^&>?B!_T /_)VW_\ CE'_  SS\0/^
M@!_Y.V__ ,<H]M2_F7WA_:^7?]!,/_ X_P"9YU17HO\ PSS\0/\ H ?^3MO_
M /'*/^&>?B!_T /_ "=M_P#XY1[:E_,OO#^U\N_Z"8?^!Q_S/.J*]%_X9Y^(
M'_0 _P#)VW_^.4?\,\_$#_H ?^3MO_\ '*/;4OYE]X?VOEW_ $$P_P# X_YG
MG5%>B_\ #//Q _Z '_D[;_\ QRC_ (9Y^('_ $ /_)VW_P#CE'MJ7\R^\/[7
MR[_H)A_X''_,\ZHKT7_AGGX@?] #_P G;?\ ^.4?\,\_$#_H ?\ D[;_ /QR
MCVU+^9?>']KY=_T$P_\  X_YGG5%>B_\,\_$#_H ?^3MO_\ '*/^&>?B!_T
M/_)VW_\ CE'MJ7\R^\/[7R[_ *"8?^!Q_P SSJBO1?\ AGGX@?\ 0 _\G;?_
M ..4?\,\_$#_ * '_D[;_P#QRCVU+^9?>']KY=_T$P_\#C_F>=45Z+_PSS\0
M/^@!_P"3MO\ _'*/^&>?B!_T /\ R=M__CE'MJ7\R^\/[7R[_H)A_P"!Q_S/
M.J*]%_X9Y^('_0 _\G;?_P".4?\ #//Q _Z '_D[;_\ QRCVU+^9?>']KY=_
MT$P_\#C_ )GG5%>B_P##//Q _P"@!_Y.V_\ \<H_X9Y^('_0 _\ )VW_ /CE
M'MJ7\R^\/[7R[_H)A_X''_,\ZHKT7_AGGX@?] #_ ,G;?_XY1_PSS\0/^@!_
MY.V__P <H]M2_F7WA_:^7?\ 03#_ ,#C_F>=45Z+_P ,\_$#_H ?^3MO_P#'
M*/\ AGGX@?\ 0 _\G;?_ ..4>VI?S+[P_M?+O^@F'_@<?\SSJBO1?^&>?B!_
MT /_ "=M_P#XY1_PSS\0/^@!_P"3MO\ _'*/;4OYE]X?VOEW_03#_P #C_F>
M=45Z+_PSS\0/^@!_Y.V__P <H_X9Y^('_0 _\G;?_P".4>VI?S+[P_M?+O\
MH)A_X''_ #/.J*]%_P"&>?B!_P! #_R=M_\ XY1_PSS\0/\ H ?^3MO_ /'*
M/;4OYE]X?VOEW_03#_P./^9YU17HO_#//Q _Z '_ ).V_P#\<H_X9Y^('_0
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M,\_$#_H ?^3MO_\ '*/;4OYE]X?VOEW_ $$P_P# X_YGG5%>B_\ #//Q _Z
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MGGX@?] #_P G;?\ ^.4>VI?S+[P_M?+O^@F'_@<?\SSJBO1?^&>?B!_T /\
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M_#)/Q7_Z%3_RHVG_ ,=H]M2_F7WA_:^7?]!,/_ X_P"9Y!17K_\ PR3\5_\
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M*_\ T*G_ )4;3_X[1_PR3\5_^A4_\J-I_P#':/;4OYE]X?VOEW_03#_P./\
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M-KJ52_7I=?>CR"BO7_\ ADGXK_\ 0J?^5&T_^.T?\,D_%?\ Z%3_ ,J-I_\
M':U]M2_F7WGI_P!KY=_T$P_\#C_F>045Z_\ \,D_%?\ Z%3_ ,J-I_\ ':/^
M&2?BO_T*G_E1M/\ X[1[:E_,OO#^U\N_Z"8?^!Q_S/(**]?_ .&2?BO_ -"I
M_P"5&T_^.T?\,D_%?_H5/_*C:?\ QVCVU+^9?>']KY=_T$P_\#C_ )GD%%>O
M_P##)/Q7_P"A4_\ *C:?_':/^&2?BO\ ]"I_Y4;3_P".T>VI?S+[P_M?+O\
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M4_\ *C:?_':/;4OYE]X?VOEW_03#_P #C_F>045Z_P#\,D_%?_H5/_*C:?\
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MT?\ #)/Q7_Z%3_RHVG_QVCVU+^9?>']KY=_T$P_\#C_F>045Z_\ \,D_%?\
MZ%3_ ,J-I_\ ':/^&2?BO_T*G_E1M/\ X[1[:E_,OO#^U\N_Z"8?^!Q_S/'(
M_OR?6I*]#T+]G?XA>(-8UO3;#P_]HO=)F6"]C^VVZ^4[+N49,@#<?W2:W/\
MADGXK_\ 0J?^5&T_^.UE2K4U'62Z]?,\S+<TP%/#\L\1!/FG]J/\\K=3R"BO
M7_\ ADGXK_\ 0J?^5&T_^.T?\,D_%?\ Z%3_ ,J-I_\ ':U]M2_F7WGI_P!K
MY=_T$P_\#C_F>045Z_\ \,D_%?\ Z%3_ ,J-I_\ ':/^&2?BO_T*G_E1M/\
MX[1[:E_,OO#^U\N_Z"8?^!Q_S/(**]?_ .&2?BO_ -"I_P"5&T_^.T?\,D_%
M?_H5/_*C:?\ QVCVU+^9?>']KY=_T$P_\#C_ )GD%%>O_P##)/Q7_P"A4_\
M*C:?_':/^&2?BO\ ]"I_Y4;3_P".T>VI?S+[P_M?+O\ H)A_X''_ #/(**]?
M_P"&2?BO_P!"I_Y4;3_X[1_PR3\5_P#H5/\ RHVG_P =H]M2_F7WA_:^7?\
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M&2?BO_T*G_E1M/\ X[1_PR3\5_\ H5/_ "HVG_QVCVU+^9?>']KY=_T$P_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU'_"9?\ 3G_Y%_\ K4<K#ZO5['345S/_  F7_3G_ .1?_K4?\)E_TY_^1?\
MZU'*P^KU>QTU%<S_ ,)E_P!.?_D7_P"M1_PF7_3G_P"1?_K4<K#ZO5['345S
M/_"9?].?_D7_ .M1_P )E_TY_P#D7_ZU'*P^KU>QTU%<S_PF7_3G_P"1?_K4
M?\)E_P!.?_D7_P"M1RL/J]7L=-17,_\ "9?].?\ Y%_^M1_PF7_3G_Y%_P#K
M4<K#ZO5['345S/\ PF7_ $Y_^1?_ *U'_"9?].?_ )%_^M1RL/J]7L=-17,_
M\)E_TY_^1?\ ZU'_  F7_3G_ .1?_K4<K#ZO5['345S/_"9?].?_ )%_^M1_
MPF7_ $Y_^1?_ *U'*P^KU>QTU%<S_P )E_TY_P#D7_ZU'_"9?].?_D7_ .M1
MRL/J]7L=-17,_P#"9?\ 3G_Y%_\ K4?\)E_TY_\ D7_ZU'*P^KU>QTU%<S_P
MF7_3G_Y%_P#K4?\ "9?].?\ Y%_^M1RL/J]7L=-17,_\)E_TY_\ D7_ZU'_"
M9?\ 3G_Y%_\ K4<K#ZO5['345S/_  F7_3G_ .1?_K4?\)E_TY_^1?\ ZU'*
MP^KU>QTU%<S_ ,)E_P!.?_D7_P"M1_PF7_3G_P"1?_K4<K#ZO5['345S/_"9
M?].?_D7_ .M1_P )E_TY_P#D7_ZU'*P^KU>QTU%<S_PF7_3G_P"1?_K4?\)E
M_P!.?_D7_P"M1RL/J]7L=-17,_\ "9?].?\ Y%_^M2_\)EZV?_D7_P"M1RL/
MJ]7L=+16%;^+K61@)8Y(O?[PK7M[N&\3=#(LB]]IZ5+36YE*G.'Q(FHHHI&8
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!XY^RE_R2IQZ:M?C_ ,CM7L=>.?LJ_P#),;H>FLWX_P#([5['0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %>.?#'_DXCXU_]P3_ -)'KV.O'/AC_P G$?&O_N"?^DCT >QT444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% 'CG[7W_ ";OXL_[=/\ TKAKV.O'/VOO^3=_%G_;I_Z5PU['
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% 'CGP<_Y*]\8Q_P!1*S_])Z]CKQSX._\ )8OC(/\
MJ(V7_I.:]CH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "O'/B__ ,EF^#7_ %_W_P#Z3"O8Z\<^+_\
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MUT:;L^6_3.,<]J],JVFMPC)2UB[A1112*"BBB@ HHHH **** "BBB@ HHHH
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MQ5U.017>Z7?#4+&.8?>(PP]&[UA*-M4>3B*/LWS1V+=%%%9G&%%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% 'CG[*_\ R3?4!Z:YJ _\C&O8Z\<_
M99X^'VK#^[K^H#_R+7L= !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5XY\,?^3B/C7_ -P3_P!)'KV.
MO'/AC_R<1\:_^X)_Z2/0!['1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 >.?M??\F[^+/^W3_P!*
MX:]CKQS]K[_DW?Q9_P!NG_I7#7L= !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MUI^I:HQQ'8SQRVD\O&3Y<<Z(S\ GY0:]?K\$/VJO@5<?LI?':?PYIFL7%U!
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MO',0. 61USC@LK'BOH[Q=J=MHOA/6M0O'6.TM+*:>9W. J+&S,3[8!K\[_\
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M*.5C^KR.HHKE_P"VKS_GM_XZO^%-;6[WG]]_XXO^%'*Q_5Y]SJJ*Y)M=OO\
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M7[K\?\CW:BO"?^%F>)/^@E_Y B_^)IC?$[Q+_P!!+_R!%_\ $T_8R'_8]?\
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MO(/[#Q/\T?O?^1])45\V-\7O%O\ T%O_ "6A_P#B*9_PN#Q=_P!!;_R6A_\
MB*/J\A_V%B?YH_>_\CZ6HKYG;XP^+_\ H+_^2T/_ ,12-\8O%_\ T%__ "6A
M_P#B*?U>?<?]@XG^:/WO_(^F:*^9/^%Q>+_^@O\ ^2T/_P 12?\ "Y/&'_07
M_P#):'_XBCZO/N/^P,5_-'[W_D?3E%?,#?&;QCS_ ,3C_P E8?\ XBD_X7-X
MQ_Z#'_DK#_\ $4?5Y]Q_ZOXK^:/WO_(^H**^7F^,_C+_ *#'_DK#_P#$4QOC
M3XRY_P")S_Y*P_\ Q%'U:?</]7\5_-'[W_D?4E%?+/\ PNKQG_T&?_)6'_XB
MD/QJ\9_]!G_R5A_^(H^K3[C_ -7L5_-'[W_D?4]%?*K?&SQI_P!!G_R5@_\
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MJ-3NOZ^0?ZG8_P#GA]\O_D3[ZHKX$;]J#XF_]#-_Y(6O_P :IO\ PU%\3O\
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MUI3A%J.OWV>OXI'P_P#M5?\ )\GC'_L9X_\ T*.OTM_X*;?\F=^+O^OJP_\
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MO??3Y_>>"_\ !83_ )++X)_[ +?^E$E?<G[! "_L@_#3 Q_H$A_\F):^1_\
M@JI\(_'7Q$^+'@^\\*^"_$/B:T@T4Q2W&CZ5/=QQOY[G:S1H0#@@X/K7V3^Q
M/X?U7PK^RS\/=)UO3+S1]5M;)TGL=0@>">)O/D.'1P&4X(/([UEA-,/43_G_
M %F=%9/^T$^G)^D#\X_^"M/_ "=%8?\ 8MVG_HZXK[=TCXVI^SS_ ,$]O!WC
M?[&NH75EX9TZ*TM7)"R3R(B1AB.=H+9..< U\I_\%//@S\0/'W[1MEJ?ACP+
MXE\1Z:N@6L)O-)TBXNH1()9R4WQH1N (.,YY%?6K_L]WOQF_8'\-?#?44F\/
MZ\WAVP$:7\3Q/:WD*(RK*A&Y1N7:PQD GC(K*'.L)54=^;YVO*]OEL6E_MM_
M[ORO:-OQW/B7X(:7\>O^"A?B+Q$^I?%B]T#P_IHC6]6&62. >;OV1QVD+(C\
M(V2Y!QCDFN4_;:_8U\/_ +)_AOP8]EXHOO$>N:U-<K<M<QQPQ[(UC.Y(AN8<
MOR2[=JH>#?A+^U5^ROXXOAX-\*^*M.U&X7[/-<Z-IG]IV5R@/RDD))$?4%AE
M<GIDUUOQJ_9!_:/^('@&;XH_$)]4\3>*S<PVL'AJUA-Y>I;-NW2"* %(E#;3
MY:+_ !,6VD<E11<(NFK+2[^?Z_@OO.6',^958MRUMVV_3\=+=C[4_P""7,/V
M?]D71Y&88EU*^D], 2E?_9:^2?\ @HM^V\OQ4U*X^&G@6^+>$+&;;JFHPMQJ
M<Z-]Q".L*$=>CL,] ">[^$VE_%30?^"<?Q \&6G@SQCH7C&TU#R;6S_L>ZBN
MKJTN)8C)Y*E-S#:9@VP<#DXS7QGX7^ _QR\'>(=/UO2_A3XRCU&PF6XMWN/"
M5Q<HLB\JQCE@9&P>?F4\@&M,1^\JJ,OA2C^2_+\_0(3E2PJ4%J^;\W^?Y'WU
M_P $Y?V'?^$%L[+XI^/M.9/$MPOF:+I5TF#81$?Z^13TE8'Y0?N Y^\?E^Z?
M''_(E>(/^P?<?^BVK\H/^&AOV[_^@5XY_P#" B_^0J^S/V0/%WQC^(7P&\<S
M?%^SUE/$HN+BWL8=4T1=.F> VR%0D2Q1[P7+C.#SQGBC$OVM"HHJR47I^'WZ
MG3@90I5(02=V]6?GG_P31_Y/"\'_ /7"^_\ 262OI3_@LM_R#_A3_P!==2_E
M;5Y%_P $]_@9\2/!?[57A75O$/P^\5:#I4,-X);[4]%N;>!"UM(%#.Z!1DD
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MT6ZM6LI[&= T4L++L:-AW!7BOC:V_P""/O[/UOXN;67B\37%@9#(- DU4"R
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M3[)!_P \8_\ O@5-10%V0_8X/^>$?_? H^QV_P#SPC_[X%344!S/N0_8[?\
MYX1_]\"D^PV__/O%_P!\"IZ*!\S[D'V&V_Y]XO\ O@4?8;;_ )]XO^^!4]%
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M  %C_P *UJ*.9]P]K4_F?WF3_P (EH?_ $!=/_\  6/_  H_X1'0O^@+I_\
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M-+N'UBM_._O9@?\ "O\ PO\ ]"UI'_@!%_\ $TG_  K[PM_T+6C_ /@!%_\
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M11SR[A];Q'_/R7WLY+_A47@7_H2O#O\ X*H/_B*/^%0^!/\ H2O#O_@J@_\
MB*ZVBCGEW'];Q'_/R7WLY'_A4/@3_H2O#O\ X*H/_B*^3?VR_AC:>$/$.BZS
MHVDVNF:/>6_V9X[&!(HEG0EN550 65ASWVGTK[@KE?B9\/-.^*/@Z]\/ZEF.
M.8;X;A1EH)1]R0#O@]NX)'>MZ-9TYJ4GH>UD^<5<!C85JTVX;/5O1_Y;GY=-
M36KI/'GP_P!=^'&O2Z5KUA)9SHQ$<A4^5.H/WXVQAE]QTZ'!R*YMJ^EBU)71
M_0M.I"M%5*;NGLT1MUIK4YNM.M[::\N(;>WB>>XF<1QQ1J69V)P% '))/:F;
M[*[.K^$/@^?QU\2?#^CPQR/'+>1M<,BL=D*L#(QP.,*#STR1R*_4BO /V5?@
M'+\+]'GUW7857Q)J2*JPD FSAZ[,_P!]C@M_NJ.QS[_7SV,K*I.T=D?@G%>:
M4\QQBA1=X4U9/N^K7Y?(****X#XD\<^$O_)<OC./^GK3/_24U['7CGPG_P"2
M[?&@?]/&E_\ I*U>QT %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7CGQ._Y.(^"G_<;_P#21*]CKQSX
MG?\ )Q'P4_[C?_I(E 'L=%%% !1110 4444 %)UX-+10!R&OZ"UF[7$"YMSR
M5'\'_P!:L.O2F 8$$9!X(-8>H^%8;EC);MY#'JN/E_#TK6,^C/1HXE6Y9G(T
M5I7'AV_MV/[GS!_>C.?_ *]5_P"R[S_GTG_[]G_"M;H[E.+V95HJS_9=Y_SZ
M3_\ ?MO\*/[+O/\ GTG_ ._;?X47*YH]RM15G^R[S_GTG_[]M_A1_9=Y_P ^
MD_\ W[;_  HN'-'N5J*L_P!EWG_/I/\ ]^V_PH_LN\_Y])_^_;?X47#FCW*U
M%6?[+O/^?2?_ +]M_A1_9=Y_SZ3_ /?MO\*+AS1[E:BK/]EWG_/I/_W[;_"C
M^R[S_GTG_P"_;?X47#FCW*U%6?[+O/\ GTG_ ._;?X4?V7>?\^D__?MO\*+A
MS1[E:BK/]EWG_/I/_P!^V_PH_LN\_P"?2?\ []M_A1<.:/<K459_LN\_Y])_
M^_;?X4?V7>?\^D__ '[;_"BX<T>Y6HJS_9=Y_P ^D_\ W[;_  H_LN\_Y])_
M^_;?X47#FCW*U%6?[+O/^?2?_OVW^%']EWG_ #Z3_P#?MO\ "BX<T>Y6HJS_
M &7>?\^D_P#W[;_"C^R[S_GTG_[]M_A1<.:/<K459_LN\_Y])_\ OVW^%']E
MWG_/I/\ ]^V_PHN'-'N5J*L_V7>?\^D__?MO\*/[+O/^?2?_ +]M_A1<.:/<
MK459_LN\_P"?2?\ []M_A1_9=Y_SZ3_]^V_PHN'-'N5J*L_V7>?\^D__ '[;
M_"C^R[S_ )])_P#OVW^%%PYH]RM15G^R[S_GTG_[]M_A1_9=Y_SZ3_\ ?MO\
M*+AS1[E:BK/]EWG_ #Z3_P#?MO\ "C^R[S_GTG_[]M_A1<.:/<K459_LN\_Y
M])_^_;?X4?V7>?\ /I/_ -^V_P *+AS1[E:BK/\ 9=Y_SZ3_ /?MO\*/[+O/
M^?2?_OVW^%%PYH]RM15G^R[S_GTG_P"_;?X4?V7>?\^D_P#W[;_"BX<T>Y6H
MJS_9=Y_SZ3_]^V_PH_LN\_Y])_\ OVW^%%PYH]RM15G^R[S_ )])_P#OVW^%
M']EWG_/I/_W[;_"BX<T>Y6HJS_9=Y_SZ3_\ ?MO\*/[+O/\ GTG_ ._;?X47
M#FCW*U%6?[+O/^?2?_OVW^%+_9=Y_P ^D_\ W[/^%%Q<T>Y5HK2M_#M_<'_4
M^6/60X_^O6[I_A6"WP]P?/?^[T4?XU+DD93KPAU,S0-!-XPGN%(MQT4_Q_\
MUJZ^DZ<"EK%RYCR:E1U'=A1114F04444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "O'/AC_ ,G$?&O_ +@G_I(]>QUXY\,?^3B/C7_W!/\ TD>@#V.BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /'/A9_R<!\:A_TTT?_ -)&KV.O'/A;_P G!_&H?[6C?^DC5['0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %>.?$[_DXCX*?]QO\ ])$KV.O'/'W[S]I7X5JWS+'9:JZ
M\A6,2@D>AQQ0!['1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M44R97DAD6-_*D92%DQG:<<''>LC^R]7_ .@Y_P"2B?XT ;5%8O\ 9>K_ /0<
M_P#)1/\ &C^R]7_Z#G_DHG^- &U16+_9>K_]!S_R43_&C^R]7_Z#G_DHG^-
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M7J__ $'/_)1/\:/[+U?_ *#G_DHG^- &U16+_9>K_P#0<_\ )1/\:/[+U?\
MZ#G_ )*)_C0!M45B_P!EZO\ ]!S_ ,E$_P :/[+U?_H.?^2B?XT ;5%8O]EZ
MO_T'/_)1/\:/[+U?_H.?^2B?XT ;5%8O]EZO_P!!S_R43_&C^R]7_P"@Y_Y*
M)_C0!M45B_V7J_\ T'/_ "43_&C^R]7_ .@Y_P"2B?XT ;5%8O\ 9>K_ /0<
M_P#)1/\ &C^R]7_Z#G_DHG^- &U16+_9>K_]!S_R43_&C^R]7_Z#G_DHG^-
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M_P"X)_Z2/0!['1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 >.?M??\F[^+/^W3_TKAKV.O'/VOO^
M3=_%G_;I_P"E<->QT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!XY\+_\ DX?XUCWT7_TD>O8Z
M\<^&/_)Q/QJ_[@G_ *2/7L= !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5XYX[_ .3E_A?_ ->&J?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 >.?LX\7'Q4'_4\:D?TCKV.O'/V=>+[XJC_J
M==0/Z1U['0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %>.?#'_DXCXU_P#<$_\ 21Z]CKQSX8_\G$?&
MO_N"?^DCT >QT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% 'CG[7W_)N_BS_MT_\ 2N&O8Z\<_:^_
MY-W\6?\ ;I_Z5PU['0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !116-XA\9:!X11&UO6]/T@2 E/MUTD)?'7:&(S^%-)O
M1%PA*I+E@KOR-FBN)L_C;X OIS##XRT0R XP]]&F3QP"Q&>HZ?TKLX9H[B%)
M8G66*10R.A!5@1D$$=13<7'=&E2A5H_Q8./JFA]%%%28!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'CGPS_Y.*^-'
M^[HO_I*]>QUXY\-?^3C/C+_N:-_Z2M7L= !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-<2+C#HH*JF!'TYP/:ZCHGU_+R+?Q-+;\PHHHH **** "BOD/_@HY^TIXP^
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MGC5OBL/^IRO3_P".QU['7CG[/?&N?%<?]3?=G\U2O8Z "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ
MSX8_\G$?&O\ [@G_ *2/7L=>.?#'_DXCXU_]P3_TD>@#V.BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]VL3#'W0H_0'^M=M7%^*8C'JS-CAU4CCVQ_2M(;G9A?XGR,BBBBMSUPHHHH
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MCC33IU55&  (FP *BM&5'"U.;XG%_+K?Y_EZA@8.KB(SUY4]//I^'YGY,_\
M!/?XY_$CQI^U5X5TGQ#\0?%6O:5-#>&6QU/6KFX@<K;2%2R.Y4X(!&1P17T#
M_P %9/B9XP^'-C\-&\)^*]<\+M=R:@+@Z+J,UH9MHM]N_P MEW8W-C/3)]:^
M1_\ @FC_ ,GA>#_^N%]_Z2R5]*?\%EO^0?\ "G_KKJ7\K:JQ6E*C;^M9$8%M
MQK7\_P#TD\K^$NM_M*?MG?#/3_ OA;Q%=6'A_04E36?$NKZK.KZC/+*\BQS7
M #RN%C95$:@@!<MU0#Q#Q[X-^+O[#'Q6ALVUN?0=;,:7EOJ.BW;M:WT>[K\P
M'F+N!#)(O;D8(S^DW_!*FSAMOV4;>6- LEQK-Y)*PZLP**#^2@?A7SO_ ,%D
M%'_";_#5L#<=.O 3W_UL?^-+$7HU82AO*U_G'F_X"\B*=/VN&E4F]5M_X%;_
M (/J?>OP/^-UM\1_V=?#_P 2]8,>G13:4U[J3 $1Q-"&$[#/\(:-R/;%?EG\
M0OCI\8?V_?C*WA#PA<WEEH-P\@LM"@N#;VT-JIYGNV4X<XP26R 3M0<@'Z<^
M&4\]O_P2'U-[9F63^Q]44E.NTWTP?\-I/X5\0?L?Q_&]O'6KO\"=O_"2KIQ%
MYDV.?LID3.!=_+]\)]WG\*NM&,L=.FTW&*O9?]O?E;Y*Y4JLUA::OJ]&^KM9
M?>[_ #=CM_B1^S1\?/V%;.R\9V?B%+33VG2.74O"NH3-#%(3\B7$;HFY6(Q\
MRLAZ'J ?TH_8E_::/[4'P?\ [5U."&W\3:7-]@U:&$8CD?:&695[*ZGIV8,.
M@%?&/Q'^&_[>OQ;\&ZAX5\6::-6T&_V?:+0S:!%OV.KK\\;*PPRJ>".E>R_\
M$T?V;OBC^S[J_CP>/?#IT&PU2"T^R_Z?;7(DDC:7=Q#*^,!QUQUJJ+;YX3VZ
M>7]:K[A)<E2,J2:77^OZZ]SRWQ]^SEXO_;._:;\9:;J/@NW^%'ASPQ:2K!<1
MZ;#'/>SNK"W>6=%_?[V4.=K,J(I4$,2Q]T_X)KVOBC1_ NN^&_%GPXMO#5UX
M>O7T^'Q%!I\-J=1*,4DC?:%:5T9<>< 0PZG<"3]FT4J2]E'E7:S\W>]_T_K7
MME14I^T;UO?Y6V_K_ABBBBJ.@**** "BBB@ HHHH *U?#+E=8B']X,/T)_I6
M56OX6C\S5D;&=B,WZ8_K4RV,:O\ #D=I1117,>$%%%% !1110 G3DU^9G_!/
M'_B\W[<W[0?Q9D_TBUMY9;"RF[;)K@K%CZ0VJC_@5?>'[1/CT?"_X#^/_%8<
M1RZ5HEW<0ECUE$3",?BY4?C7RE_P1Q\ GPW^R_J'B.9/](\2ZW/<+(1RT,(6
M%>>_SK+^=%'^-.?\L/\ TMV_)/\ I!6_@QC_ #27_DJO^)]XU^8W_!2K&G_M
MM?LSW^FA5UIKVU0LO#%5U"+RP3Z9>3OW-?IK<7$5G;RSSR)#!$I>221@JHH&
M223T '>OS&^&[/\ MW?\%()_B+IZM<_#'X9I'#8WQ7]U=31ES#M/<O,TDP/]
MR-<XR**>N*HO^5\S]$G_ )Z=PJ:8>K_>5EYMM:'7_P#!1:-_ _[6'[+GQ B7
MRT36QIMS-T^3[1 0I/\ NRS?K7VM\;/BUHWP+^%?B3QSKSXT_1K1I_+W -/)
MTCB7/\3N54>[5\C_ /!8KP]-=?LV>'_$EKN6Y\.^);6Y$B]45TDCS_WV8ZY7
M]HCQ)+^W3^T1\.?@3H-R[^"-'MK?Q3XSNH"0K!HT=(,^NR15'^U/G_EF:SII
MSI/#TW9\[^2DE)OY:_@NI<W&%55JBNN1?/EDTE\[I?B=?_P3X^&>OV?@7QS^
MT9XRLGU+XB>/UGU*U@9?GCL5R\,4>>5$A5<#^XL/I7R_^S/\+?"W_!1_6O$>
MM_&WXQZX/&_]H2"P\&Z=?0VOV:WV@[H(YTD!3DKMC4%=F6)+9K]'_P!I+]IO
MP7^QQX!T+6/$FD:M<:+<WB:1:6V@6T+F$B)V7*R2QJ$"QD<$]N*\E^/O_!-/
MX0_M$R2>+M!-QX$\5Z@!?1ZUH1!@GD8!EEEMR=K$D[B8S&Q)R6-:/EYW*,;P
M244OY;:_>UO\[;D+FY4IRM.3<F^_1_)/;\3D?@3^S'\;?V1_VE-)T;P?K6J^
M//@!J<!%^NL:A;AM)8A]I6)I Q=6"$M"@#JY!7*@CE_V_67XM_MP?LX?"H,'
MM;6X&M7\9^Z8VF#-D>T=G)_WU6W^P/\ &3XG^%_V@OB!^SE\3]>;QG=>%[0W
MEAKDCM+*(U:+Y&D;YG5DGC8;\LI#+DC '@7Q$^$_BS]MK_@I%\1].\->(&\.
M:%X<B72-3UF%OWEO9K$+>:&(#DO(YG7&0,%\G'!I.3JX=Q?-O--]4KVOZ.WG
M;O9":2IU^;W?LNW1NRT]5?RZ:'N/Q\_: \:_MI?$*_\ @3^S[=FV\,6Y\KQ=
M\0(]WV>.(DAH877JIPR_*<RD$+B,,Y]=\1?"?P7^P?\ L5?$)/!ULMO=6NA7
M#3ZO<8^U7]Z\9BBDD;_KHZA5'"YP!US\[?LMZ/%^P[_P4#\3?!7[5<_\(1XV
ML(KG0Y+U]S-*J%XBS8 SD7,7 Y(2O4O^"PGC=_#_ .RS:^'K<EKKQ-KEK9>6
MOWFCCW3G [_-'&/^!5SU8KZLE3U=2R;ZW;Y;?)]/F]3>FV\3[ZLJ>J72UN:_
MFVM+_):$?_!/FRA^ /\ P3KNO&MX@MY+BVU3Q/-N&,A%98_S2"/'UKYF_P""
M=OP+^)_[07PF\0Z</&6H?#KX7WFLRW6J:CH?R:MKUT416A68G]W#& ,D AF=
M@0W.SZ:_;AN(_P!GK_@FK;^#H)!!=2:9I?AF/U=L(9OS2*;\S7T'^QI\.T^%
M?[+GPU\/" 6\\>C075T@&#]HG7SI<^^^1J[9<LZ^(GO%<L%^+_)+Y^FO'!N-
M&C'9RO-_E^;?HKGY^^*O@K)_P3V_;-^"=A\+_%_B#5-+\;7T=KJND:M<([31
MM<1PN9/+1$<$3%E)3*M&3D]OK#]OC]J;Q+\';/PI\._AG EW\5?'5R+/3&95
M?[%$6"&;:W&XLP5=WRC#L<[<'QOQ0/\ A=W_  6%T#3U/G:;\.]$6>5>JB18
MFD!]B);N'_OBN%_:T^#^A?M$_P#!470/A_XZU34]*T#4/#D26<VFRQQ3%DBG
ME54:1'7F17SE3GD=:YHN52E0A+7FE)_]NJ[2O_VZ_O\ ,WERTZE6:Z1C_P"!
M.UVUY<R;]-=CTS3_ /@D3IGC338]:^*/Q;\:>)/B'*GF3:I:7D9@AE/(5?/C
MDD=5/?>F<=%Z#9_8'^*GCOP=\<OB7^S=\0?$4WC*Z\(1_;=(URY+-.]KNC!1
MV8DD;9X64,25RZY("XSKC_@B[\"[.WEGG\7>/88(E+R22:E8JJ*!DDDV?  K
M?_X)\_L\?L]>$O%'B/Q[\$?&WBCQF\$#Z#>S:PFRUC+/'*1&3:0;V_=H<JS
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M4?V?:_\ /M#_ -^Q3YEV#VU/^4Y4^(+_ /Y[_P#CB_X4UO$.H?\ /Q_XXO\
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MQ7JO_/U_Y#3_  KN/[(L?^?*W_[]+_A1_9%A_P ^5O\ ]^E_PHYH]A_6*/\
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M[#^MX?\ Y]?@CS0^.M<_Y_?_ "$G_P 336\=:X/^7[_R#'_\37IO]@:9_P!
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M79D?_"S/$G_02_\ ($7_ ,33&^)WB7_H)?\ D"+_ .)KV7_A%M%_Z!%A_P"
MR?X4?\(KHO\ T![#_P !4_PJO:0_E-?K^$_Y\K[D>+_\+0\3?]!/_P @1?\
MQ-(?BAXF_P"@G_Y B_\ B:]H_P"$4T3_ * ^G_\ @*G^%'_"*:)_T!]/_P#
M5/\ "CVD/Y1_7\)_SX7W(\4/Q2\3_P#03_\ )>+_ .)IK?%/Q1_T$_\ R7B_
M^)KVS_A$]#_Z VG_ /@+'_A1_P (GH?_ $!M/_\  6/_  H]I#^4?]H8/_GP
MON1XDWQ4\4?]!3_R7B_^)IK?%7Q3_P!!3_R7B_\ B:]O_P"$1T/_ * NG_\
M@+'_ (4?\(CH7_0%T_\ \!8_\*?M(?RC_M#!_P#/A?<CPYOBMXJ_Z"G_ )+Q
M?_$TS_A;'BK_ *"O_DO%_P#$5[G_ ,(CH7_0%T[_ ,!(_P#"C_A#]!_Z FG?
M^ D?^%/VL/Y2O[1P7_/A?<CPH_%KQ7_T%?\ R7B_^(II^+7BS_H*_P#DO%_\
M17NW_"'Z#_T!--_\!(_\*/\ A#M _P"@'IO_ ("1_P"%'M8?RC_M+!?] Z^Y
M'@[?%SQ9_P!!7_R6A_\ B*1OB[XM_P"@M_Y+0_\ Q%>\_P#"&Z!_T ]-_P#
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M_P")I^VI_P I7]JY?_T#+[H_Y'SBWQN\:_\ 0:_\E8/_ (BHV^.'C;_H-?\
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M_A?_ *%K2/\ P B_^)H]M2_D'_:^7?\ 0*ONC_D?,+?'CQUS_P 3S_R4@_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'.I^UC\</B;^UCX?L?B#J?A%_#_PWT:Y_L^P,)9X1<3 EB96"F9CY6"RJ%7
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M'T=)%]5-?8'P>^#?A+X#^!+#PAX+TF/2=&M 3M4[I)I#]Z65SR[MCDGV P
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MYV/H       !W]%%:2DY/FEN9QBHJR.*^,7P?\+_ !W^'NJ^#/&%@-0T74$
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH \<^!?'CWXNC_J80?_ "$M>QUXY\#^/B)\7Q_U'D/_ )!%>QT %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7CGPQ_Y.(^-?\ W!/_ $D>O8Z\<^&/_)Q'QK_[@G_I(] 'L=%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!XY^U]_R;OXL_[=/_ $KAKV.O'/VOO^3=_%G_ &Z?^E<->QT
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!XYX#_ .3EOBG_ ->6E?\ HIJ]CKQSP)_R<O\ %#_K
MPTO_ -%M7L= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5XWXH_Y.F\$_\ 8!O?_0A7LE>-^*/^3IO!
M/_8!O?\ T(4 >R4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,
MF\SR9/)V^;M.S?G;NQQG';-9'_%0_P#4,_\ (E;5% &+_P 5#_U#/_(E'_%0
M_P#4,_\ (E;5% &+_P 5#_U#/_(E'_%0_P#4,_\ (E;5% &+_P 5#_U#/_(E
M'_%0_P#4,_\ (E;5% &+_P 5#_U#/_(E'_%0_P#4,_\ (E;5% &+_P 5#_U#
M/_(E'_%0_P#4,_\ (E;5% &+_P 5#_U#/_(E'_%0_P#4,_\ (E;5% &+_P 5
M#_U#/_(E'_%0_P#4,_\ (E;5% &+_P 5#_U#/_(E'_%0_P#4,_\ (E;5% &+
M_P 5#_U#/_(E'_%0_P#4,_\ (E;5% &+_P 5#_U#/_(E'_%0_P#4,_\ (E;5
M% &+_P 5#_U#/_(E'_%0_P#4,_\ (E;5% &+_P 5#_U#/_(E'_%0_P#4,_\
M(E;5% &+_P 5#_U#/_(E'_%0_P#4,_\ (E;5% &+_P 5#_U#/_(E'_%0_P#4
M,_\ (E;5% &+_P 5#_U#/_(E'_%0_P#4,_\ (E;5% &+_P 5#_U#/_(E'_%0
M_P#4,_\ (E;5% &+_P 5#_U#/_(E'_%0_P#4,_\ (E;5% &+_P 5#_U#/_(E
M'_%0_P#4,_\ (E;5% &+_P 5#_U#/_(E'_%0_P#4,_\ (E;5% &+_P 5#_U#
M/_(E'_%0_P#4,_\ (E;5% &+_P 5#_U#/_(E'_%0_P#4,_\ (E;5% &+_P 5
M#_U#/_(E'_%0_P#4,_\ (E;5% &+_P 5#_U#/_(E'_%0_P#4,_\ (E;5% &+
M_P 5#_U#/_(E'_%0_P#4,_\ (E;5% &+_P 5#_U#/_(E'_%0_P#4,_\ (E;5
M% &+_P 5#_U#/_(E'_%0_P#4,_\ (E;5% &+_P 5#_U#/_(E'_%0_P#4,_\
M(E;5% &+_P 5#_U#/_(E'_%0_P#4,_\ (E;5% &+_P 5#_U#/_(E'_%0_P#4
M,_\ (E;5% &+_P 5#_U#/_(E'_%0_P#4,_\ (E;5% &+_P 5#_U#/_(E'_%0
M_P#4,_\ (E;5% &+_P 5#_U#/_(E'_%0_P#4,_\ (E;5% &+_P 5#_U#/_(E
M'_%0_P#4,_\ (E;5% &+_P 5#_U#/_(E'_%0_P#4,_\ (E;5% &+_P 5#_U#
M/_(E'_%0_P#4,_\ (E;5% &+_P 5#_U#/_(E'_%0_P#4,_\ (E;5% &+_P 5
M#_U#/_(E'_%0_P#4,_\ (E;5% &+_P 5#_U#/_(E'_%0_P#4,_\ (E;5% &+
M_P 5#_U#/_(E'_%0_P#4,_\ (E;5% &+_P 5#_U#/_(E'_%0_P#4,_\ (E;5
M% &+_P 5#_U#/_(E'_%0_P#4,_\ (E;5% &+_P 5#_U#/_(E'_%0_P#4,_\
M(E;5% &+_P 5#_U#/_(E'_%0_P#4,_\ (E;5% &+_P 5#_U#/_(E'_%0_P#4
M,_\ (E;5% &+_P 5#_U#/_(E'_%0_P#4,_\ (E;5% &+_P 5#_U#/_(E'_%0
M_P#4,_\ (E;5% &+_P 5#_U#/_(E'_%0_P#4,_\ (E;5% &+_P 5#_U#/_(E
M'_%0_P#4,_\ (E;5% &+_P 5#_U#/_(E'_%0_P#4,_\ (E;5% &+_P 5#_U#
M/_(E'_%0_P#4,_\ (E;5% &+_P 5#_U#/_(E'_%0_P#4,_\ (E;5% &+_P 5
M#_U#/_(E'_%0_P#4,_\ (E;5% &+_P 5#_U#/_(E'_%0_P#4,_\ (E;5% &+
M_P 5#_U#/_(E'_%0_P#4,_\ (E;5% &+_P 5#_U#/_(E'_%0_P#4,_\ (E;5
M% &+_P 5#_U#/_(E'_%0_P#4,_\ (E;5% &+_P 5#_U#/_(E36?]L_:$^U?8
M?(YW>3OW=.,9XZXK4HH \<^"7'Q*^, _ZC<1_P#((KV.O'/@KQ\4?C"/^HQ;
MG\X*]CH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB_V7J_\ T'/_ "43_&C^R]7_ .@Y_P"2B?XUM44 8O\ 9>K_ /0<_P#)1/\
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MR]7_ .@Y_P"2B?XUM44 8O\ 9>K_ /0<_P#)1/\ &C^R]7_Z#G_DHG^-;5%
M&+_9>K_]!S_R43_&C^R]7_Z#G_DHG^-;5% &+_9>K_\ 0<_\E$_QH_LO5_\
MH.?^2B?XUM44 8O]EZO_ -!S_P E$_QH_LO5_P#H.?\ DHG^-;5% &+_ &7J
M_P#T'/\ R43_ !H_LO5_^@Y_Y*)_C6U10!B_V7J__0<_\E$_QH_LO5_^@Y_Y
M*)_C6U10!B_V7J__ $'/_)1/\:/[+U?_ *#G_DHG^-;5% &+_9>K_P#0<_\
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M_P"3F_B1_P!@S3?_ $%J]CKQSP9_R<Y\1O\ L%:;_P"@M7L= !1110 4444
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MYH45^>O_  4D_:J^*7P#^)GA;2? ?BC^PM/O=)-U<0_V?:W&^3SG7=F:)R.
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M3IW\FKV.O'/"'_)T'Q _[ ^G_P#LU>QT %%%% !1110 4444 %%%% !1110
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MJ]I<Z5'?M-J!E\P,TDB%1L<#&$'YU]S5^/'_  5Z_P"3DM#_ .Q<@_\ 1\]
MT?<W["/[6&O_ +5WA?Q5JFOZ-INCRZ3>16T2::9-KJZ%B6WL><CM7U#7YV_\
M$:?^2<_$;_L*VW_HEJ_1*@ HHHH$%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7CFJ?\G9Z)_P!BG/\ ^E(K
MV.O'-4_Y.ST3_L4Y_P#TI% 'L=%%% !1110 4444 %<MXQF)FMXL\*I;'U./
MZ5U-<CXP7_B80MZQ8_4_XU<-SJPW\1&%11170>R%%%% !1110 4444 %%%%
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MUNPE*3Q,'65M-/Q_X/Y:61^7W[=__)X'Q)_[",?_ *(BK]S_  __ ,@'3?\
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M!T=??E?Y:1=_DV_FR*<HT:]=M>[%K3SO)6^Y?<CRWQE_PFW[<WC+XG?%&_\
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MM$K-QVY)K6*YH.5K6=O6ZNFOQN92?+-1O>ZOZ6=FG^%C<K\POVI--M/VA/\
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M7P-_9.^,'QR_:.T_XZ_M(166CRZ'L;0O"-G(DB0LA+1%@KN$1&)DP79V?&[
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M$5X#^T?^WQ\(OV8-2_LCQ1JUUJ?B3:LC:%H4 N;J-&&0TFYECCR,$!W#$$$
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M^T&Y<NKHKA'DB8A3\K$!D90RE@/F'->"_P#!:JU:'X<_"S5T4;[/Q!+&&(.
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M1Z$%1[!6TE*"5.?16_5:]=]'VL8Q<9-SCU_X9^FVOG<****@L**** "BBB@
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M>Y7L*7\_Y'8_VM8_\_EO_P!_5_QH_M>Q_P"?VW_[^K_C7%MX7U,]+;_R(O\
MC4?_  BNJ?\ /K_Y$3_&CECW*^KT?Y_R.W_MBP_Y_K;_ +^K_C2?VUI__/\
M6W_?Y?\ &N%;PEJW/^B?^1$_QIC>$-7_ .?3_P B)_C1RQ[E?5J'_/S\CO?[
M:T[_ )_[7_O\O^-)_;FF_P#00M?^_P O^-< W@[6/^?3_P BI_C4;>"]9_Y\
M_P#R*G_Q5/DCW*^JT/\ GY^1Z'_;NF_]!"U_[_K_ (TG]O:9_P!!&T_[_K_C
M7G3>"=:Y_P!"_P#(J?\ Q51_\(/K?_/E_P"14_\ BJ.2/<?U7#_\_?R/2?\
MA(-+_P"@E:?]_P!?\:3_ (2'2_\ H)6?_?\ 3_&O-&\"ZYS_ *#_ .18_P#X
MJHV\!Z[S_H/_ )&C_P#BJ?)'N7]3PW_/U?>CT[_A(M*_Z"=G_P"!"?XT?\))
MI/\ T%++_P "$_QKRYO .O?\^'_D:/\ ^*J-OA[K_/\ H'_D:/\ ^*HY(]Q_
M4\-_S]7WH]4_X232/^@K9?\ @0G^-'_"3:1_T%;'_P "$_QKRAOAWX@_Z!__
M )&C_P#BJ8WPZ\0\_P#$O_\ (T?_ ,53]G#^8I8+"_\ /Y?>CUG_ (2;1_\
MH+6/_@2G^-)_PE&C?]!>Q_\  E/\:\C/PW\1?] [_P CQ_\ Q51O\-?$9Z:=
M_P"1X_\ XJCV</YBOJ.%_P"?R^]'L'_"4Z+_ -!>P_\  E/\:3_A*]$_Z#&G
M_P#@4G^->.GX9^)/^@;_ .1XO_BJB;X8>)O^@;_Y'B_^*I^SA_,5]0PG_/\
M7WH]G_X2S1/^@SI__@4G^-)_PENA_P#09T__ ,"H_P#&O%F^%WB<_P#,,_\
M)B+_ .*IC?"SQ1S_ ,2S_P F(O\ XJG[.'\Q7]GX/_G^OO1[9_PEVA?]!K3_
M /P*C_QI/^$PT'_H-Z=_X%Q_XUXBWPJ\4_\ 0+_\F(O_ (JHV^$_BH_\PO\
M\F(O_BZ/9P_F*678/_G^OO1[C_PF&@_]!O3?_ N/_&C_ (3+0/\ H.:;_P"!
M<?\ C7A3?"7Q7S_Q*O\ R8B_^+IC?"/Q9_T"O_)F'_XNG[*'\Q7]FX+_ *"%
M]Z/=_P#A,_#_ /T'=-_\#(_\:/\ A-/#W_0>TS_P,C_^*KP5OA#XM(_Y!/\
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M7E37G8Y+V:?F?!<;4X2RZ-1[J2M\T[_UY'O5%%%>"?AX4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'CG[7W_)N_BS_MT_\
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M2-X6T#0+^3388;.WB,DK1G:\CNZEB2P. , #''4GVK_@C3_R3GXC?]A6V_\
M1+5\!?M=_P#)TGQ7_P"QFO\ _P!'M0'4^_\ X5^%_C_\1_V4YOBH_P >M8L]
M:FL+K4K+2ULK=H#'"7 1WVYW-Y9Y PN1P:^4/A;_ ,%'/CAX9\;Z1<ZMXOE\
M2:2;F-+O3=0MX62:(L P#*@96QG!!ZXZ]*_1#]EW_E'/H_\ V*VI?SN*_$_1
M_P#D,6/_ %W3_P!"% '[X?MB?&_4_@+^SMXA\::%#%+J\8A@LC<+N2.2:14#
MLO?:&)QT) K\Q?@?^U1^T/\ 'OXS>&O!<7Q8O]*DUR\\I[I;6#;"@5G=@@0
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MADC9,H2B@,I5CU&05'/-?I)7XO?\$G_^3L(O^P)>?^TZ_:&@&%%%% @HHHH
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M.\!^(/"6J37%OINM64MA<2V;*LRQR*58H65@&P>,@CVKQC]F_P#89\!_LO\
MB[4/$7A75O$6H7M]9&QDCUBY@DC$9=7R!'!&=V4'4D=>*BG!>U;G\-OQL_\
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M\9/C5\0OVH_&6FOI2>)]]EX<LYOO"URJEQ_LJD442M_%B0XQC.9^Q/CXO?\
M!1#]HOXE-F6VTAFT2UDZK@RB%"#_ -<[(_\ ?5?HQ#;Q6UO'!#&L,$:A$CC4
M*JJ!@  = !7GOP;_ &>/A]^S_!K47@+P_P#V&NM7(N]09KVXNGN)0" Q::1R
M/O'@$#DUK%J%2+BO=C%Q2];;_B_5]C.7-.$E+XI24G\NB_!>A\6? M3\9/\
M@K+\6?%A(N--\%::VF6[]1',%CMMH_$71_.L3XH>+K;]D;_@J9)\0O&R26?@
M;QUHZVD6L^4S16S>5#&V2 <[)($W <A95:ONWX7?L\?#[X,>(O%6N^#O#_\
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MN:>X\ >"-/T&]G4I)?;I+FZ*'&4$\S/(%.!\H;''2MZM**:H3^&"2TZVZ/\
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M^/7P-^&OPE\&>%(_C%\/U&BZ/:V!'_"46/WHXE5C_K>Y!/XUV/\ PUC\$/\
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M_P!*X:]CKQS]K[_DW?Q9_P!NG_I7#7L= !1110 4444 %%%% !1110 4444
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M=1DDGL *_33_ (+%744?P.\&V[2*)Y/$ =(\\L%MY=Q ]!N'YB@#Y8_X)/\
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MZ_\ X1"S_P">L_\ WTO^%'_"(6?_ #UG_P"^E_PHYT'UJF<A177_ /"(6?\
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M.@^M4SD**Z__ (1"S_YZS_\ ?2_X4?\ "(6?_/6?_OI?\*.=!]:IG(45U_\
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M:,?_ "6:O8Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KQSX8_\G$?&O\ [@G_ *2/7L=>.?#'_DXC
MXU_]P3_TD>@#V.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *IZIH]AKEHUKJ5E;ZA:M]Z&ZB65#P1RK CH2/Q-7**!J3B[I
MZG#_ /"C_A]]H,__  AFB[R0<?8H]O!)^[C'?TKK-)T>PT&QCLM,L;;3K./[
MEO:1+%&OT50 *N453E*6[-ZF(K5E:I-R7FVPHHHJ3G"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /'/VOO^3=_%G_;
MI_Z5PU['7CG[7W_)N_BS_MT_]*X:]CH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#QSPS_ ,G3
M>,_^P!9?^AFO8Z\<\-_\G4>,?^Q?L_\ T8:]CH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "N6^*'P[TSXM?#_7?!^LR7$6EZQ;-:W#VCA)0I(.5)!
M/'<&NIHH ^//!?\ P2U^$7@7QAH?B33]1\4/?Z1>PW]NL]]"T9DB<.H8"$$C
M*C/(KZ/^+WP?\*_'3P1=>%/&.F_VEI%PZR[5<QR12+G;(CCE6&3SZ$@Y!(KM
M** /B_2O^"4OPF\/ZM#J>C^(O&VDW]N^^"YL]5CBEB/JKK""#^-&N?\ !*?X
M5>)M4GU/6/$_CC5M1N#NFO+[58III#C&6=H23QZU]H44 >.?LV_LL^$?V6]'
MUK3?"5UJEU;ZM<)<3G5)TE8,BE0%VHN!@^]<;\<O^"?/PD^/GC"X\5:U::GI
M6O707[5=:/="(7)4!0SHRLN[  R "<<YKZ5HH ^/;/\ X)A_#S3_  W<^'K7
MQM\0;;0+IM\^E0ZVBVLK>K1"+:3P.H[5=^&W_!,3X+?#?Q9I_B%+?6=>O+"9
M;BWAUB\62!9%.58HB+NP0#AB1ZBOK6B@#S[X[?!/0?VA/AS>>"_$D][;Z5=3
M1322:?(L<N8W#J 65AC(YXKQ+X0_\$VOA=\%OB/HGC70M1\23:MI$C2P1WEY
M$\1+(R'<!$">&/0BOJZB@#S;X[?L\^"?VCO"L.@^-=.>\M[>7S[6XMY3%/;2
M8P61QZC@@@@\9' KY_\ #O\ P2T^&/@[5DU3P_XL\=Z%J* JEWIVL1P2JIZ@
M.D(.#7V310!\6W/_  2>^#^I:I+J&I:UXRU.ZFD,L\MUJ<3/,Q.26;R=Q)[G
M.:^J_AK\-?#GPB\%Z;X3\*::FE:'IZ%(;=&+'))9F9B268DDDDY)-=/10!\6
MZI_P2<^#>KZG>7\^I^*Q/=3/.^R_A #,Q8X_<],FOJW1?A[HVC_#NR\$M;G4
M- MM-323!>X<S6ZQB/:_ !RHYX'6NEHH ^+]5_X),_!#4-0EN;:7Q-ID;MN6
MVM=20QQ^REXF;'U8U?\ $W_!,3X<^-/LG_"0^,_B!KOV./RK;^TM;2X\E./E
M3?$=HX' ]*^P:* /FKX!?L"?#C]G+Q\OB_PO>Z]/JBVLEILU&ZBDBV/C)PL2
MG/RCO7TK110 4444 %%%% !1110 4444 %%%% !1110 4444 %>.?\WA?]R)
M_P"Y"O8Z\<_YO"_[D3_W(4 >QT444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% 'CGP[X_:0^+WO;Z0?_)=J]CKQSX?\?M)?%@>MKI)_
M\@-7L= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5XY\,?^3B/C7_W!/_21Z]CKQSX8_P#)Q'QK_P"X
M)_Z2/0!['1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 >.?M??\F[^+/^W3_TKAKV.O'/VOO^3=_%
MG_;I_P"E<->QT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!XYX=_Y.I\7>_AVS_P#1AKV.O'/#
M_P#R=5XK_P"Q<M/_ $::]CH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "O'/^;PO^Y$_P#<A7L=>.?\
MWA?]R)_[D* /8Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0G_PK:HH Q?^$PTC_G[_ /(3_P"%'_"8:1_S]_\ D)_\*VJ* ,7_ (3#2/\
MG[_\A/\ X4?\)AI'_/W_ .0G_P *VJ* ,7_A,-(_Y^__ "$_^%'_  F&D?\
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MMJB@#%_X3#2/^?O_ ,A/_A1_PF&D?\_?_D)_\*VJ* ,7_A,-(_Y^_P#R$_\
MA1_PF&D?\_?_ )"?_"MJB@#%_P"$PTC_ )^__(3_ .%'_"8:1_S]_P#D)_\
M"MJB@#%_X3#2/^?O_P A/_A1_P )AI'_ #]_^0G_ ,*VJ* ,7_A,-(_Y^_\
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MI'_/W_Y"?_"MJB@#%_X3#2/^?O\ \A/_ (4?\)AI'_/W_P"0G_PK:HH Q?\
MA,-(_P"?O_R$_P#A1_PF&D?\_?\ Y"?_  K:HH Q?^$PTC_G[_\ (3_X4?\
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M/AC_ ,G$?&O_ +@G_I(] 'L=%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!XY^U]_R;OXL_[=/_2N
M&O8Z\<_:^_Y-W\6?]NG_ *5PU['0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'CF@_\G6>*?\
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M"?\ PK:HH Q?^$PTC_G[_P#(3_X4?\)AI'_/W_Y"?_"MJB@#%_X3#2/^?O\
M\A/_ (4?\)AI'_/W_P"0G_PK:HH Q?\ A,-(_P"?O_R$_P#A1_PF&D?\_?\
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M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
MQSP5Q^TW\2??3--/_CC5['7CG@WC]I[XA^^DZ<?T:O8Z "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQQG$<5PB,YP"?E!KVJOC+]K#_@F[\-/BA\/]1U#P#X7T[P)X^TV!KG2KGP_
MME#/(@++#+%& GS$8#@!E.#D@%3=_P""8_[2VL_M#? :>U\4W#7GBOPK=#2[
MR[E.9;J(H&AED_VR-R$]28R3R35QM-22T<;/Y-VNOGT,Y7ARM[2T^>]G\C[
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MWW/8:*^)_A[_ ,%>/@)XZ\00:5=R>(O!_GL(X[[Q!81);;B0 &>&:78.?O,
MHZD@5]J6]Q'=01S0R+-#(H=)(V#*RD9!!'4$57*[7Z"YE>Q)1114C"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#QSPCQ^U!X^'KHVGG_ -"KV.O'
M/"O'[4?CD>NAV)_\>->QT %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !7CGPQ_Y.(^-?_<$_])'KV.O'
M/AC_ ,G$?&O_ +@G_I(] 'L=%%% !1110 4444 %%%% !1110 4444 %%%%
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MKV.O'/VOO^3=_%G_ &Z?^E<->QT %%%% !1110 4444 %%%% !1110 4444
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ME$C<0&&?O$#@U^MW[&?Q<^'OQ6^"NE_\*ZTW_A'M+T9183Z"YS)8R 9PS?\
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M&]EV_KIUOKHK(F5\8TEI37X_U]UM%U9IT444ST0HHHH **** "BBB@ HHHH
M*U/#6?[9@QZ-G_ODUEUN>$8#)J$DO\,:?J?\FIEL8UG:G(Z^BBBN8\(****
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MTNNJ^\F5_:<K=[)6?6S;T_"_S11US5[?P_HNH:I=N([6RMY+F5B< (BEF/Y
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M3_"HF\%^(?\ H ZG_P" <G_Q-?6%%'UA]BEGU5?81\EMX*\1<_\ $AU/_P
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M]K[_ )-W\6?]NG_I7#7L= !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 >.:;_R=IK/_ &*4/_I4
M:]CKQS3_ /D[;5_^Q0A_]*C7L= !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5XYI?\ R=GK?_8IP?\
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M:6-F&.#NCSCM7U1^Q9_P3C7X&>)(/''C^^LM:\56P/\ 9^GV.Y[6P8C!E+L
M9),' X"KR1N."/N:BM(?NW=;]SB^JT[Z[=NA\A?\%'OA7\5OC9\/?#GA+X;Z
M VM6,EZ]YJY6_MK4 1J!"A\Z1-P+.S<9P8U]J_/;_AVY^T9_T3O_ ,K>G?\
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M_DAPK7 *Y10V" <L<C-?KA15U(JI)2?3;^OZW?<%1BJ?LEHGK_7]=NQ^'/\
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M5")?9DM[L("2$\^%DDV@D_+NQR>*]7HHE[SO+44?=T1YC\'?V9_A=\ (95\
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M4O#<0@G)5)HF615) R P!P,UZ514V5E'HMO+T*N[N75[GA4/[#?P,M?AK?>
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M1(<.&'RXZ$UTWC[X?>'/BEX3O_#/BS1K77M!OE"W%C>)N1\'(/J&! (8$$$
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M %%%% !1110 5XY\,?\ DXCXU_\ <$_])'KV.O'/AC_R<1\:_P#N"?\ I(]
M'L=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!X%^TE^SF_Q,4>(/#RQQ^)(4V2PR/L6]0#Y1DG"N.@)P"#@D8!'Q#K6C7WA_
M4KBPU*TELKR!BDD,RE64@X/ZBOU;K!\4> _#OC6(1Z[HECJH4 *]S K.@!SA
M6ZK^![GUKT*&+=)<LE='W>3<4U<NIK#XB//!;=UY>:_JY^6+4P(TC!$4LS'
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:J'(?\(A>?\ /6#_ +Z;_"C_ (1"\_YZP?\ ?3?X5U]%'.P^M5#D/^$0O/\
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M)'O:/>I7<APPR.H/K61_PC7_ %%=3_\  C_ZU28FU16+_P (U_U%=3_\"/\
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M4?\ "-?]174__ C_ .M0!M45B_\ "-?]174__ C_ .M1_P (U_U%=3_\"/\
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M/_P(_P#K4 ;5%8O_  C7_45U/_P(_P#K4?\ "-?]174__ C_ .M0!M45B_\
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MU_U%=3_\"/\ ZU'_  C7_45U/_P(_P#K4 ;5%8O_  C7_45U/_P(_P#K4?\
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MB_\ "-?]174__ C_ .M1_P (U_U%=3_\"/\ ZU &U16+_P (U_U%=3_\"/\
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M4?\ "-?]174__ C_ .M0!M45B_\ "-?]174__ C_ .M1_P (U_U%=3_\"/\
MZU &U16+_P (U_U%=3_\"/\ ZU'_  C7_45U/_P(_P#K4 ;5%8O_  C7_45U
M/_P(_P#K4?\ "-?]174__ C_ .M0!M45B_\ "-?]174__ C_ .M4UGH?V.X2
M;^T+Z?;G]W--N4\8Y&* /,-)X_:QU\>OA6W/_DP:]CKQS3./VM-:]_"4)_\
M)DU['0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %>.?#'_DXCXU_P#<$_\ 21Z]CKQSX8_\G$?&O_N"
M?^DCT >QT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#QRPX_:VU7W\'Q'_R;->QUXY9\?M<WX]?
M!D9_\G*]CH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "O'/AC_R<1\:_P#N"?\ I(]>QUXY\,?^3B/C
M7_W!/_21Z /8Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#QS]K[_DW?Q9_VZ?\ I7#7L=>.?M??
M\F[^+/\ MT_]*X:]CH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;U8Y--HHK0[ HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH \<M^/VO+H>O@E3_ .3M>QUXY'Q^U]*/7P.#
M_P"3]>QT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !7CGPQ_P"3B/C7_P!P3_TD>O8Z\<^&/_)Q'QK_
M .X)_P"DCT >QT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% 'CG[7W_)N_BS_ +=/_2N&O8Z\<_:^
M_P"3=_%G_;I_Z5PU['0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% 'CB?\ )W\G_8C#_P!+Z]CK
MQQ?^3P&_[$7_ -R%>QT %%%% !1110 4444 %%%% !1110 4444 %%%% ";1
MNW8&[UQS2T44 %)M Z#%+10 4F >HI:* "DI:* $VCT%)M7^Z/RIU% K(2BE
MHH&)CVI:** $P/2EHHH *0C/!&:6B@!@C1>0B@_2GT44""DZTM% Q.G2EHHH
M 3:,YQS2T44 %%%% !1110 4444 %%%% !1110 5XYX0_P!(_:@^($B\+;Z/
MI\+YZEFRPQ[8KV.O'/ G_)R_Q0_Z\-+_ /134 >QT444 %%%% !1110 5SWB
MZ\\NWBME.#(=S#V'3]?Y5T-<5XHD,FKNN?N*J_IG^M7!79U8:/-4]#)HHHKH
M/9"BBB@ HHHH **** "BBB@ HHHH *\;_;&U[4_#'[,/Q$U71M1N])U2UTQI
M+>]L9VAFA;>OS(ZD,I]P:]DKPS]N+_DTOXG?]@EO_0UKDQ;:PU1K^5_D:4_C
MCZGY9?LT_MR?$'X7_%_1=6\7^-?$GBKPK*_V74['5M4N+Q%@<@&5$D=@'0@,
M"!D@%?XC7[<:;J5KK&GVM_8W$=W9742SP3PL&22-@"K*1U!!!_&OYTO#'PWU
MOQAX5\4Z_I5O]JM/#<,-SJ")DND,CE/, [JK8SZ YZ X_2[_ ()6_M/?\)5X
M8F^$GB"[W:KH\;7&B22MS-:9^>')ZF,G(']QL#A*[:;]I#DZK5>G7_/[SP</
M5=.?O/26GS_X.WW'AO\ P46^.'Q&\$?M2Z]I/ASQ_P"*- TJ.SLV2QTO6;FV
M@4M"I8A$<*"3R>.:_4'6M0NHO@E?WR7,R7R^'I)UN5D(D$@MBP<-G.[/.>N:
M_(C_ (*??\G>>(O^O&Q_]$+7ZWZ]_P D"U'_ +%F3_TE->8F_P"SZTNNO_MY
MZM/_ )&,8]++_P!M/Q3^''Q6_:%^+?C+3_"GA/XD>.=5U_4-_P!FM/\ A*KB
M'S-B-(WSR3JHPJ,>2.GK7N)_9[_;N4$_VKXY_P#"_B_^3:\,_8I^)'AWX2?M
M+^#_ !7XLU'^RM T\W7VF[\B2;R]]K+&OR1JS'+.HX!Z^E?JLW_!23]G15)'
MQ#+'T&B:CS_Y+UWN,.2+OJ]_O/+HVFWSRM\S\_/"?[:'[0O[+/Q(&A?$*\U;
M68;60?;]!\3-YTLD9_BBN#EQQG:RLR'T85^P7@SQ9IWCSPCHWB32)3-I>K6<
M5[;2,,$QR(&7(['!Y%?C/^UU\31^VY^TKIL?PQT'4-45+*+2;,?9]LUWMDD=
MIF7^",>9U?&%7+;>@_7OX)^ )/A7\(?!WA":=;JXT72[>REF3[KR(@#D>V[.
M/:G1<IT.::UOIYK7_@>ESHI^[B)0IRO&WXZ?\'UL?D)H_P"T!\49/VO+31G^
M)/BY](;QPMH=/;7;HVYA^W[?*\OS-NS;\NW&,<5^V-?@AHG_ ">M9?\ 90%_
M].-?O?4877!4F]_^!$TIM_6:R_K>05\R?MR_M?I^RSX)L8])M8-1\9:V733[
M>YR8H(U WSR $%@"5 7(R3UP#7TW7Y&_\%?(+U?C[X7EE$GV%_#L:P,?N;A<
M3;P/?E<_45C7DTHQ3M=V_!O]#LD^6G.:W2_5+]3D_#NI?ME_'_0[KQ_X>UOQ
MKJ&CHS_OM+U9=/ADV?>$-LDD?FX((_=HW((ZY%>T_L3_ /!1'Q9>?$*Q^''Q
M<N3J']H7 LK+6KB%8+FUN<[5AN   RLWR[B-RL?F)!^7[&_8EUC2M9_94^&L
MFD2Q2V\&D16TPBQ\DZ?+,I'9MX;/USWK\A_VT-6TZ/\ :Z^(FH>&IHT@AU@/
M'-:G %PB)YK COYP<Y]<UT2:P^)5%ZPUO\FM5]^GZGE.,_JRQ,9>\[>FJ;_2
MW^1^RW[2GQXTS]G'X1ZMXTU&#[;+!M@LK'?L-U<OD1QY[#@L3SA58X-?EEI/
MQR_:O_;&\4:BG@K6-< M!YLEGX9NUTFTLT8_*IFWIDG!P))&8X/7!K]-_'WP
M7\)_M;?!_P )P>-(;U[*:"VU>-;*Y:!EF>#J2.#Q(PP0>M:/[.W[-OA/]F/P
MIJ/A_P )2ZA<6E]>F^FFU25)9MY1$VAD1/E 3@$=2>>:3HN-6:JO;;^OO.N4
MI5X4W3=HO5]_ZV/R\TG]K+]I/]D+XB0Z'\0;W5=56/9-<Z)XHG%Y]IA;C=%=
M9=AT8!D=E# Y#8(K]<OAC\1-*^+'P_T'Q?HCLVEZQ:I=0A\;TR/F1L?Q*P*G
MW!K\N?\ @KA\2-#\5?%SPOX:TN>.ZU#PY8S+J,L1!$<DS(RPDC^)53<1V\SU
MS7VW^Q5X)UOPC^Q5X3TJ598=8NM+NKR"/=L>,W$DLL(!.-IQ(A]B:5*HYX:=
M1J[B]//?\[:&<(NGB_81EHUUZ;?E>W_#&U^U)^U]X,_9C\,7#ZA>0ZEXMFA+
M:=X>@D!GE8@A7D _U<6>K'K@A0QXK\\OV&_VA_B;\2/VQ/"=MXB\>^(]3TS4
MI[^:XTJ?5;A[(DVL[A1 7*!58 JN,#:,=*]1^$O_  2OU:[FO/%OQJ\1_P!H
M7)C>[?1M/N7FEGDV[O\ 2;HX.<YR$SGM(*^:_P#@G'_R>5\/_K>_^D4]5AD_
MK-IO6S]%H_\ (RQ52I*FG;EC?YNUO\S]R"<#)X%?DU^T9^WE\5/C1\7[CP!\
M&;N\TS2?MC:=9?V*H^W:I(IP9?-ZQIE25V%<+RQ]/UCDC6:-XW4.C JRGH0>
MHKR?1?V;_A)\+/$TGCW0_!&F:!K.GVLQ^UZ:C0A(RA\S$2L(\E01G;GFLIQ7
M,I3=H*]_Z_KOT/1J1G.')2^)O^OZ^74_+;Q%\5/VM?V/]?TJ\\9:[XCA2^.^
M&#Q#J*ZQ9W04@M'N,D@4X(R%97 .1CK7ZF?LP_'W3_VDOA#I7C*RMOL%S(S6
MU_8[MWV>Y3&]0>ZG(93UVL,\YK\R_P!M3]L>#]LR;PEX)\ ^%=52T@O?M$8O
MHT-[=7+*8T1(XV<*H#-_$<DCIMY_03]A/]GS4_V<O@/:Z%KK*/$&I7;ZKJ$$
M;AUMY'1%$08<$JD: D<;LXR,&MZ/-*$W/9?"_N_2_P"&U]?/B^6O&-*5U;7^
MON_'L?+/_!5;X]^+O OQ$\%>&_"'B[7/##Q:9+?7@T749K3SO-EV1[_+9=V!
M"V,]-Q]:^8+*]_:^U*S@N[2?XVW5I<1K+#/"^L/'(C#*LK#@@@@@CKFKO_!1
MKQ>GBW]K_P 6(\A:STH6NF*4P2%2)6<#GJ'>2OINQ_X+ ^'M%NK/2K'X7:@W
MAVU1+>.Z?5XTN!$H"@^0(BN<#IYF/>N/#VE2YW+5MV]+M_DU8K$R3Q$DW9))
M?.R_6]R?_@G/_P +\_X7;J__  M'_A9'_"/_ -A3>3_PE_\ :'V7[1Y\&W;]
MH^7S-N_&.<;O>ND_X*!?M\:Y\%?$@^'GP[>WM_$:P)/J>L31+,;+>-R11(V5
M\PKAB6! ## R<CZK^ ?[1G@G]I#PFVN^#K]Y?(94O-/ND$=U9N1D+(F2.><,
MI*G!P3@UY?\ %K_@G;\*/C)X]U#QCK3:];:WJ$ZSW4EE?J$E95"@%9(W &%
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M; ,K*<@@]"#6)-X\\,VWB^W\*3>(M)B\4W$!NH=#>^B%[+",YD6 MO*?*WS
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MA@TC1QH%#.0 "QQDD  DG@5*VE?2SM^&OI;L5=:6ZHZ2BN#O/CY\,=.\2?\
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M]? Y'_D_7L= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P!\BMZ?/STY5?BA3O+U:Y5^#_!]3"IR\M54_AE.T?1.\OQ7]7(O%G_%YO\
M@L1X<T\'S]/^'VAB:5.JK((7E!^OF7</_?-<[^V'\:X_VDOVI3\ +CXE:?\
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MJ!&!>TN0H$L$@ZAE;(YZC!&00:I_M)_M$>%_V9_A=JGB[Q)>PI+'$ZZ=IQD
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M+QM=?"O_ ()6V.NW4Q@O[?X>P0P.W!66:W6*#\09$KPO]L7Q++^WM^TQX.^
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M<8KW>BJ32O=$M-VLPHHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7_\ W\3_ .(IO_"F-$_Y^M0_[^)_\13O2[%<^5_RO\?\S);XY;?^8)_Y-_\
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M_P#]JIK?M18_YEG_ ,G_ /[56_\ \,V>&?\ G^U;_O\ 1?\ QNFG]FGPP?\
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M.\MO^Q);_P!+J]CH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNQIS/EY>A\ ?\.X?C?\ ]'H?$#_OB^_^65>M?LS_ +(GQ$^!_P 09_$7B_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ KQSP)_R<O\4/\ KPTO_P!%-7L=>.?#O_2?VD/B])]W[-!H\&.N
M[=;L^?;'2@#V.BBB@ HHHH **** "BBB@ HHHH JW&EVETQ,MO&S'JV,'\ZK
M?\(WIW_/O_X^W^-:=%.[+52:V9F?\(WIW_/O_P"/M_C1_P (WIW_ #[_ /C[
M?XUIT4<S[C]I/^9F9_PC>G?\^_\ X^W^-'_"-Z=_S[_^/M_C6G11S/N'M)_S
M,S/^$;T[_GW_ /'V_P :/^$;T[_GW_\ 'V_QK3HHYGW#VD_YF9G_  C>G?\
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MO3O^??\ \?;_ !K3HHYGW#VD_P"9F9_PC>G?\^__ (^W^-'_  C>G?\ /O\
M^/M_C6G11S/N'M)_S,S/^$;T[_GW_P#'V_QH_P"$;T[_ )]__'V_QK3HHYGW
M#VD_YF9G_"-Z=_S[_P#C[?XT?\(WIW_/O_X^W^-:=%',^X>TG_,S,_X1O3O^
M??\ \?;_ !H_X1O3O^??_P ?;_&M.BCF?</:3_F9F?\ "-Z=_P ^_P#X^W^-
M'_"-Z=_S[_\ C[?XUIT4<S[A[2?\S,S_ (1O3O\ GW_\?;_&C_A&]._Y]_\
MQ]O\:TZ*.9]P]I/^9F9_PC>G?\^__C[?XT?\(WIW_/O_ ./M_C6G11S/N'M)
M_P S,S_A&]._Y]__ !]O\:/^$;T[_GW_ /'V_P :TZ*.9]P]I/\ F9F?\(WI
MW_/O_P"/M_C1_P (WIW_ #[_ /C[?XUIT4<S[A[2?\S*MOI=I:G,5O&I_O8R
M?S-6J**1#;>X4444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /'-7X_:QT ^OA6X'_DP*]CKQS6^/VKO#1]?#%R/
M_(XKV.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *\<^&/_ "<1\:_^X)_Z2/7L=>.?#'_DXCXU_P#<
M$_\ 21Z /8Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#QS]K[_DW?Q9_P!NG_I7#7L=>.?M??\
M)N_BS_MT_P#2N&O8Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH \<O/^3N-._[$V3_ -+*]CKQ
MR^_Y.WTS_L3Y?_2L5['0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %>.?#'_DXCXU_]P3_TD>O8Z\<^
M&/\ R<1\:_\ N"?^DCT >QT444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'CFO<?M6>%3Z^&[H?^117L=>.>(N/VJ/"'OX>O!_Y$%>
MQT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7CGPQ_Y.(^-?_<$_P#21Z]CKQSX8_\ )Q'QK_[@G_I(
M] 'L=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!XY^U]_P F[^+/^W3_ -*X:]CKQS]K[_DW?Q9_
MVZ?^E<->QT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!XYJ'_)VVD_]BA-_P"E0KV.O'-2_P"3
MM-&_[%&;_P!*A7L= !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC_P/B_\ BJ^)J*R_U\Q/_/B/WLT_U+P__/Y_<C[9_P"%@>%_^ADTC_P/B_\
MBJ/^%@>%_P#H9-(_\#XO_BJ^)J*/]?,3_P ^(_>P_P!2\/\ \_G]R/MG_A8'
MA?\ Z&32/_ ^+_XJC_A8'A?_ *&32/\ P/B_^*KXFHH_U\Q/_/B/WL/]2\/_
M ,_G]R/MG_A8'A?_ *&32/\ P/B_^*H_X6!X7_Z&32/_  /B_P#BJ^)J*/\
M7S$_\^(_>P_U+P__ #^?W(^V?^%@>%_^ADTC_P #XO\ XJC_ (6!X7_Z&32/
M_ ^+_P"*KXFHH_U\Q/\ SXC][#_4O#_\_G]R/MG_ (6!X7_Z&32/_ ^+_P"*
MH_X6!X7_ .ADTC_P/B_^*KXFHH_U\Q/_ #XC][#_ %+P_P#S^?W(^V?^%@>%
M_P#H9-(_\#XO_BJ/^%@>%_\ H9-(_P# ^+_XJOB:BC_7S$_\^(_>P_U+P_\
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M%@>%_P#H9-(_\#XO_BJ^)J*/]?,3_P ^(_>P_P!2\/\ \_G]R/MG_A8'A?\
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M/WL/]2\/_P _G]R/MG_A8'A?_H9-(_\  ^+_ .*H_P"%@>%_^ADTC_P/B_\
MBJ^)J*/]?,3_ ,^(_>P_U+P__/Y_<C[9_P"%@>%_^ADTC_P/B_\ BJ/^%@>%
M_P#H9-(_\#XO_BJ^)J*/]?,3_P ^(_>P_P!2\/\ \_G]R/MG_A8'A?\ Z&32
M/_ ^+_XJC_A8'A?_ *&32/\ P/B_^*KXFHH_U\Q/_/B/WL/]2\/_ ,_G]R/M
MG_A8'A?_ *&32/\ P/B_^*H_X6!X7_Z&32/_  /B_P#BJ^)J*/\ 7S$_\^(_
M>P_U+P__ #^?W(^V?^%@>%_^ADTC_P #XO\ XJC_ (6!X7_Z&32/_ ^+_P"*
MKXFHH_U\Q/\ SXC][#_4O#_\_G]R/MG_ (6!X7_Z&32/_ ^+_P"*H_X6!X7_
M .ADTC_P/B_^*KXFHH_U\Q/_ #XC][#_ %+P_P#S^?W(^V?^%@>%_P#H9-(_
M\#XO_BJ/^%@>%_\ H9-(_P# ^+_XJOB:BC_7S$_\^(_>P_U+P_\ S^?W(^V?
M^%@>%_\ H9-(_P# ^+_XJC_A8'A?_H9-(_\  ^+_ .*KXFHH_P!?,3_SXC][
M#_4O#_\ /Y_<C[9_X6!X7_Z&32/_  /B_P#BJ/\ A8'A?_H9-(_\#XO_ (JO
MB:BC_7S$_P#/B/WL/]2\/_S^?W(^V?\ A8'A?_H9-(_\#XO_ (JC_A8'A?\
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M^%@>%_\ H9-(_P# ^+_XJOB:BC_7S$_\^(_>P_U+P_\ S^?W(^V?^%@>%_\
MH9-(_P# ^+_XJC_A8'A?_H9-(_\  ^+_ .*KXFHH_P!?,3_SXC][#_4O#_\
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MW(^V?^%@>%_^ADTC_P #XO\ XJC_ (6!X7_Z&32/_ ^+_P"*KXFHH_U\Q/\
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M *&32/\ P/B_^*KXFHH_U\Q/_/B/WL/]2\/_ ,_G]R/MG_A8'A?_ *&32/\
MP/B_^*H_X6!X7_Z&32/_  /B_P#BJ^)J*/\ 7S$_\^(_>P_U+P__ #^?W(^V
M?^%@>%_^ADTC_P #XO\ XJC_ (6!X7_Z&32/_ ^+_P"*KXFHH_U\Q/\ SXC]
M[#_4O#_\_G]R/MG_ (6!X7_Z&32/_ ^+_P"*H_X6!X7_ .ADTC_P/B_^*KXF
MHH_U\Q/_ #XC][#_ %+P_P#S^?W(^V?^%@>%_P#H9-(_\#XO_BJ/^%@>%_\
MH9-(_P# ^+_XJOB:BC_7S$_\^(_>P_U+P_\ S^?W(^V?^%@>%_\ H9-(_P#
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MC_P/B_\ BJ^)J*/]?,3_ ,^(_>P_U+P__/Y_<C[9_P"%@>%_^ADTC_P/B_\
MBJ/^%@>%_P#H9-(_\#XO_BJ^)J*/]?,3_P ^(_>P_P!2\/\ \_G]R/MG_A8'
MA?\ Z&32/_ ^+_XJC_A8'A?_ *&32/\ P/B_^*KXFHH_U\Q/_/B/WL/]2\/_
M ,_G]R/MG_A8'A?_ *&32/\ P/B_^*H_X6!X7_Z&32/_  /B_P#BJ^)J*/\
M7S$_\^(_>P_U+P__ #^?W(^V?^%@>%_^ADTC_P #XO\ XJC_ (6!X7_Z&32/
M_ ^+_P"*KXFHH_U\Q/\ SXC][#_4O#_\_G]R/MG_ (6!X7_Z&32/_ ^+_P"*
MH_X6!X7_ .ADTC_P/B_^*KXFHH_U\Q/_ #XC][#_ %+P_P#S^?W(^V?^%@>%
M_P#H9-(_\#XO_BJ/^%@>%_\ H9-(_P# ^+_XJOB:BC_7S$_\^(_>P_U+P_\
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M%@>%_P#H9-(_\#XO_BJ^)J*/]?,3_P ^(_>P_P!2\/\ \_G]R/MG_A8'A?\
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MTC_P/B_^*KR3X;^,-!M_C]\8[J76]-BMKG^QO(F>[C"2[;5@VUB<-@\''2O
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MADTC_P #XO\ XJOB:BC_ %\Q/_/B/WL/]2\/_P _G]R/MG_A8'A?_H9-(_\
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M_P#BJ/\ A8'A?_H9-(_\#XO_ (JOB:BC_7S$_P#/B/WL/]2\/_S^?W(^V?\
MA8'A?_H9-(_\#XO_ (JC_A8'A?\ Z&32/_ ^+_XJOB:BC_7S$_\ /B/WL/\
M4O#_ //Y_<C[9_X6!X7_ .ADTC_P/B_^*H_X6!X7_P"ADTC_ ,#XO_BJ^)J*
M/]?,3_SXC][#_4O#_P#/Y_<C[9_X6!X7_P"ADTC_ ,#XO_BJ/^%@>%_^ADTC
M_P #XO\ XJOB:BC_ %\Q/_/B/WL/]2\/_P _G]R/MG_A8'A?_H9-(_\  ^+_
M .*H_P"%@>%_^ADTC_P/B_\ BJ^)J*/]?,3_ ,^(_>P_U+P__/Y_<C[9_P"%
M@>%_^ADTC_P/B_\ BJ/^%@>%_P#H9-(_\#XO_BJ^)J*/]?,3_P ^(_>P_P!2
M\/\ \_G]R/MG_A8'A?\ Z&32/_ ^+_XJC_A8'A?_ *&32/\ P/B_^*KXFHH_
MU\Q/_/B/WL/]2\/_ ,_G]R/MG_A8'A?_ *&32/\ P/B_^*H_X6!X7_Z&32/_
M  /B_P#BJ^)J*/\ 7S$_\^(_>P_U+P__ #^?W(^V?^%@>%_^ADTC_P #XO\
MXJC_ (6!X7_Z&32/_ ^+_P"*KXFHH_U\Q/\ SXC][#_4O#_\_G]R/MG_ (6!
MX7_Z&32/_ ^+_P"*H_X6!X7_ .ADTC_P/B_^*KXFHH_U\Q/_ #XC][#_ %+P
M_P#S^?W(^V?^%@>%_P#H9-(_\#XO_BJ/^%@>%_\ H9-(_P# ^+_XJOB:BC_7
MS$_\^(_>P_U+P_\ S^?W(^V?^%@>%_\ H9-(_P# ^+_XJC_A8'A?_H9-(_\
M ^+_ .*KXFHH_P!?,3_SXC][#_4O#_\ /Y_<CW[]J_QAH.J? 'Q3:V6MZ;>7
M,GV79#;W<;NV+J$G"@Y/ )_"O6_^%@>%_P#H9-(_\#XO_BJ^ ?B-_P B9J/_
M &S_ /1BUTM=D^-<1'"PQ'L5>4I+=_94'_[<<D>$:$L3.A[5VC&+V7VG)?\
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MQ-11_KYB?^?$?O8?ZEX?_G\_N1]L_P#"P/"__0R:1_X'Q?\ Q5'_  L#PO\
M]#)I'_@?%_\ %5\344?Z^8G_ )\1^]A_J7A_^?S^Y'VS_P + \+_ /0R:1_X
M'Q?_ !5'_"P/"_\ T,FD?^!\7_Q5?$U%'^OF)_Y\1^]A_J7A_P#G\_N1]L_\
M+ \+_P#0R:1_X'Q?_%4?\+ \+_\ 0R:1_P"!\7_Q5?$U%'^OF)_Y\1^]A_J7
MA_\ G\_N1]L_\+ \+_\ 0R:1_P"!\7_Q5'_"P/"__0R:1_X'Q?\ Q5?$U%'^
MOF)_Y\1^]A_J7A_^?S^Y'VS_ ,+ \+_]#)I'_@?%_P#%4?\ "P/"_P#T,FD?
M^!\7_P 57Q-11_KYB?\ GQ'[V'^I>'_Y_/[D?;/_  L#PO\ ]#)I'_@?%_\
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M44?Z^8G_ )\1^]A_J7A_^?S^Y'VS_P + \+_ /0R:1_X'Q?_ !5'_"P/"_\
MT,FD?^!\7_Q5?$U%'^OF)_Y\1^]A_J7A_P#G\_N1]L_\+ \+_P#0R:1_X'Q?
M_%4?\+ \+_\ 0R:1_P"!\7_Q5?$U%'^OF)_Y\1^]A_J7A_\ G\_N1]L_\+ \
M+_\ 0R:1_P"!\7_Q5'_"P/"__0R:1_X'Q?\ Q5?$U%'^OF)_Y\1^]A_J7A_^
M?S^Y'VS_ ,+ \+_]#)I'_@?%_P#%4?\ "P/"_P#T,FD?^!\7_P 57Q-11_KY
MB?\ GQ'[V'^I>'_Y_/[D?;/_  L#PO\ ]#)I'_@?%_\ %4?\+ \+_P#0R:1_
MX'Q?_%5\344?Z^8G_GQ'[V'^I>'_ .?S^Y'VS_PL#PO_ -#)I'_@?%_\51_P
ML#PO_P!#)I'_ ('Q?_%5\344?Z^8G_GQ'[V'^I>'_P"?S^Y'VS_PL#PO_P!#
M)I'_ ('Q?_%4?\+ \+_]#)I'_@?%_P#%5\344?Z^8G_GQ'[V'^I>'_Y_/[D>
M_:EXPT%OVI=&O1K>FFS7PM-$UP+N/RP_V@$*6SC..U>M_P#"P/"__0R:1_X'
MQ?\ Q5? -Q_R4*T_[![_ /H==+79B>-<105-JBGS13W?=K]#DP_"-"LZB=5^
M[)K9=E_F?;/_  L#PO\ ]#)I'_@?%_\ %4?\+ \+_P#0R:1_X'Q?_%5\345Q
M_P"OF)_Y\1^]G7_J7A_^?S^Y'VS_ ,+ \+_]#)I'_@?%_P#%4?\ "P/"_P#T
M,FD?^!\7_P 57Q-11_KYB?\ GQ'[V'^I>'_Y_/[D?;/_  L#PO\ ]#)I'_@?
M%_\ %4?\+ \+_P#0R:1_X'Q?_%5\344?Z^8G_GQ'[V'^I>'_ .?S^Y'VS_PL
M#PO_ -#)I'_@?%_\51_PL#PO_P!#)I'_ ('Q?_%5\344?Z^8G_GQ'[V'^I>'
M_P"?S^Y'VS_PL#PO_P!#)I'_ ('Q?_%4?\+ \+_]#)I'_@?%_P#%5\344?Z^
M8G_GQ'[V'^I>'_Y_/[D?;/\ PL#PO_T,FD?^!\7_ ,51_P + \+_ /0R:1_X
M'Q?_ !5?$U%'^OF)_P"?$?O8?ZEX?_G\_N1]L_\ "P/"_P#T,FD?^!\7_P 5
M1_PL#PO_ -#)I'_@?%_\57Q-11_KYB?^?$?O8?ZEX?\ Y_/[D?;/_"P/"_\
MT,FD?^!\7_Q5'_"P/"__ $,FD?\ @?%_\57Q-11_KYB?^?$?O8?ZEX?_ )_/
M[D?;/_"P/"__ $,FD?\ @?%_\51_PL#PO_T,FD?^!\7_ ,57Q-11_KYB?^?$
M?O8?ZEX?_G\_N1]L_P#"P/"__0R:1_X'Q?\ Q5'_  L#PO\ ]#)I'_@?%_\
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MDG /2M84:E1.4(MI=D92JTZ;2G))OS.KHHHK(U"BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YK4?^1\TC_KVF_I7
M2US6I?\ (]:-_P!>\W\A72UZ^/\ X6&_P?\ M\SR\%_$Q'^/_P!MB%%%%>0>
MH%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %<UH7_(Y^*/^W7_ -%FNEKFM"_Y'/Q1_P!NO_HLUZ^!_@8O_ O_
M $Y3/+QG\;#?XW_Z;J'2T445Y!Z@4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 <U\1O\ D3-1_P"V?_HQ
M:Z6N:^(W_(F:C_VS_P#1BUTM>O5_Y%M'_'4_])I'ET_^1A5_P4__ $JH%%%%
M>0>H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% '-7/_)0K/\ Z\'_ /0ZZ6N:NO\ DH-E_P!>#_\ H==+
M7KYA\.'_ ,"_.1Y>!^*O_C?Y1"BBBO(/4"BBB@ HHHH **** "BBB@ HHHH
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MCAS%9M3=>+4*:ZO]/3J]CHS3/L-E<E2DG*;Z+]?ZN?HE\?O^2'^/?^P'>?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS?\ (]^+?^P;'_Z-%?J>6MKA7$M?S/\ ]M/S?-_^2BPOI'_TJ1X=\=OA3??
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M644LY=><ZKKJ6R5UIT2Y;M->>QT819I4RE4J<*?L7%ZMZZWNWK:Z?EHSB_\
M@G;XIFL_B!XC\/EF-M?:>+L+G@21.%!Q[K*WY"J__!13_DJOAW_L"K_Z/EKW
M']G+X,?"3PKXPEU_P!XUNO$6I1VC12VLFH6\P6)ROS-&D2L.0.3QFO#_ /@H
MHC#XI>'&*G:=& #8X)$\N1^H_.C"XJCC.*(UJ,6KQ=[JSND^C\K&D\-5PG#=
M:E5:=I*UG=6<H]O.Y[=_P3__ .2%W'_88N/_ $7%5C]O;_D@C_\ 84MO_9ZH
M_P#!/N\BF^"=_ C RPZS-O7/(S'$147_  4&UR"Q^#NG::TJ"ZOM5C*1$_,R
M(CEF ] 2G/N/6OGJD)2XJLE_R\3_ %_(]K!R4>&FW_S[G_[<CQ7_ ()X_P#)
M7M;_ .P+)_Z.AKV#_@HE_P DD\/_ /8<3_TGFKQ__@GC_P E>UO_ + LG_HZ
M&O8/^"B7_))/#_\ V'$_])YJ]W,O^2KH?]N_DSQ,K_Y)S$?]O?DCYS_8S^$N
ME?%7XJ2KKMLM[I.DVAO)+5_N32;E5%;U7)+$=]N#D$U^@^A?"'P5X6\0QZYH
MOA?2]&U..![83:?;+;CRV*E@50!2?E')&1SSR:^0?^"<7_(T^-/^O.W_ /0W
MK[MKP^,,9B/[3E14VHJ*5D]-5=_?<]?A/"4?J'M903DY-WMKI:WW;GY)_M"^
M,+GQU\:/%FISR%U6_DM8%)R%AB8QH!Z<+GZDU^F?P5^&^G?"OX<:-H>GVZ0R
M+ DMW*H^:>X909'8]2<\#T  Z"OR_P#C=X?F\*_&#QAILZ%&AU2=D![QNY=#
M^*LI_&OU3^&GC&R\?^ M"U_3Y5FM[VUC<[3G8^,.A]U8$'W%>QQ9S0RO!QH?
MPK?+X5R_A<\[AWEEF^+E6_B7?_I6OZ'B_P"W)\-]/\5?!^[\1?9E&LZ"T<T-
MPH <PLZI)&3W7#;L>J^YKYU_8$\87&B_&2;1/-(L]:L9%>+/!DB'F(WU"B0?
M\"KZ>_;8\96GA?X#ZO8RS*M[K+QV5M%GYG^=7<X] BGGU(]:^5OV#?#,^M?'
M2+4EC8VVD6,T\DF. SKY2CZG>3_P$T9*Y2X9Q2Q'P+FY;^B:M_V]^(9XE'/<
M(Z/QMQOZ<UM?E?Y6&?MW^)Y];^.UQIS.QMM(LH+>-.P+KYK''J=X'_ 17KW[
M+OQX^#_PC^$VG:;J'B%+'Q!<L]QJ6-.NG8R%CM!=8B"%3:!@D=?4UXI^W%HL
M^E_M":O<2KB+4+6VN86]5$8C/_CT;5Z?\!?V/_AS\8/A=H_B2;6O$"7\P:.\
MAM;JW"13*Q#* 820,8(R3PPKU,1' ?ZO86.,E*--J/P6WLWKH]+W^9Y\98S_
M %@KRPL8RJ*]N;:VBTU6MOPN87[9_P 5/AC\6M%T/4?"FKQZCXDL[@PRD65Q
M"S6K*QP6DC4':X7 SD;FQU-=G_P3E\433:;XQ\.R,3!;RP7T*YZ%PR/_ .@)
M3/'O[)?P*^%\FGQ^*/&WB+1VU N+837$+;]N-Q^6V. -PY.!S7J_[-/PD^&G
M@2]UC5?A]XMN/$QN(DM[I7OX+A8AN++D1QJ5)P?O=LUX^,QF7QR&6#PWM)1^
MS*4=+\RZV2[K\#TJ&$Q]3.:>+Q')&:W49:VLUM=O;\CY3_;T_P"2^S?]@VV_
M]FKZ5_8.\'V&B_!.#7(K=!J.L74SSW! WE(Y#&B9_NC:3CU8U\U?MZ?\E]F_
M[!MM_P"S5]:?L4_\FW^%_P#?N_\ TJEK7-YRAPMAE%[N*?I:3_-(G 0C+B:L
MY+:[7X+]3S7_ (*+Z%:R>!_"VLF%/ML.HM9B;'S>6\3.5]QF,'_]=<E_P3AG
M9?$'CB$?<:UM7/U#R ?^A&N__P""B7_))/#_ /V'$_\ 2>:O//\ @G%_R-'C
M3_KSM_\ T-ZG"R<N$:J?1O\ ]*3#'+EXFHM=;?DT8?\ P4,\03WWQ7T72&8_
M9;#2EE1>V^61]Q_)$'X5[9^P/X!L-%^$K>)A C:KK5S*&N"OS+#&Y18P?3<K
M-[Y'H*\._P""A.C3V?Q@TK464_9KS28UC?L6CDD##\ R_G7O_P"P;XIM=9^!
ML6E1R@W>CWLT,T6?F59',JMCT.]AGU4^E/'N4>$Z'L=KKFMVN[_^36##J,N*
M*GMM^G_@*M_Y*=9^UIX#L?''P.\2-<0*]YI5L^HVDVT%XWC&Y@#_ +2AE/U]
MJ^"?V5/^3A?!/_7X?_1;U^@_[3WBNT\(_ GQ?<74RQ/=6,EA;J2,O+,I10!W
M/)/T4GM7Y\?LJ?\ )PO@G_K\/_HMZTX7E4>2XM2^%<UO_ =?T(XH5-9CA6OB
MTOZ<VGZGUG_P4&\8W&B?"W2=#MY#'_;5]^_P?O11+N*_]]F,_A7DW_!/WX;Z
M=XF\8ZYXGU&V2Z;0TB2S6095)I"W[S']Y50X]-V>H%>F?\%$O#LM]\//#6LQ
MQLZ:?J#0R,/X5E3J?;=&H_$5PW_!.OQE9:?X@\5>&KB98KO4(H;JU5CCS/*W
MAU'J0'!QZ ^E9X'FAPE5EAOBN[V_Q)/_ ,E_ O,K3XDP\:_P65K^DK?^3'W+
M?6-OJ=G/:7<$=S:SH8Y89E#(ZD8*D'@@BOR7^.W@F'X7?&3Q)H6G%X;6RNQ)
M:?,=R1NJR( >ORA@,^U?K<S!023@#DDU^3G[2GC"T\>?'#Q9J^GRB>QDNA!!
M*N"KK$BQ[@1U!*$@^A%<7 DJOURK%?!RZ]KW5OPN=W&4:7U&FY?%S:>EG?Y;
M?@?>'B;XH7<_[(%QXQ\[9J5UX>3=,G59Y%6(L/<.Q-?#?[*_@RQ\>?'7PSIF
MIP)<V"R274T$@RL@BC9PI'<%E7([C-?:/BCX>WEG^Q+-X;>)EO[7P['/+"/O
M"1-L[K^:D5\<?LB^);7PO^T%X5N;V18;>>22S,CG 5I8F1/S8J/QKV,C4(8#
M,GA?BO.UNW*^6WXV/#SISE4RWZSM:/-?UCS?AN?J88U:,H5!0C!7'&/2O [;
M]A_X61:O=W\^GW]X;B=YUMWO6BBAW,3MC$00A1G !)( '->_5\L^(/V^O#/A
MGQMK6AW7AV_NK33[I[5+^PGCD\[8VTL$;;@9!Q\QK\ZRF&:5)3CECE>VO*[:
M=.J/T',Y9=3A"68)<M[*ZOK;Y]O0[#]M5!'^S9XD1<[5DLP,DD_\?,7<U\)?
MLW_#>T^*WQBT+0-25GTMF>XNT5BI>.-"Y7(Y&X@+D<X/%?<G[86H#5_V6M9O
MA!-;"Z6QG$-P )(]UQ$=K $@,,X.">:^6_V"?^2])_V"[G^:5^@<.U:F%X?Q
M=2#M*+G\GR1/A.(84\3G.#@]8R4/N<Y?H?=>G_!#P!H^K:9JFG>$-(TW4=-<
MR6US96JP.K%2N6* ;^&/WL\\]1FOD?\ X*.?\C=X-_Z\9_\ T8M?>%?!_P#P
M4<_Y&[P;_P!>,_\ Z,6OE^%:U6MG-%U9.5E+=W^RSZCB*C3HY175.*7P[*WV
MHGI'_!.[_DD.O?\ 8<D_])X*\1_X*#?\EPT__L!P?^CIZ]N_X)W?\DAU[_L.
M2?\ I/!7B/\ P4&_Y+AI_P#V X/_ $=/7U.!_P"2MK>C_)'S6(_Y):G\O_2F
M>Z?\$_\ P;8Z7\)[OQ"+=#J>J7TD;7!4;Q#'A50'TW;C]3["J_\ P4.T*UNO
MA7HFK-"GVVSU584FQ\PCDBD++GT)13_P$5U/["__ ";UI?\ U^77_HPUD?\
M!0/_ )(;9_\ 8:M__14U>![:<N*N9O7VEOEM;[CVL/2@N&W&VGLY/YZO\SQS
M_@G1=.OQ$\4VX^Y)I2R'GNLR@?\ H1J[_P %%?&4]QXI\,>%DD9;2VM&U&2,
M'AI)'9%)^@C;'^^:S/\ @G5_R5#Q+_V!S_Z/CJ7_ (**>'9;7XA>&M<VG[/>
MZ:;7=VWQ2,Q'Y2BOJ:D:;XNCS[\NGKRO]#YG#2J?ZL5N3^;\+Q/1?^"??PVT
M^Q\#ZAXTGMHY=6OKI[2WG89:*!  0OIN?=G'7:*^FO''@O2OB%X5U'P_K-LM
MU87L1C=6 )0XX=3V93@@]B*^>?\ @G[XSL]6^%-[X=$JC4=)OI)&AS\QAEPR
MOCTW;Q^'N*^E==UNR\-Z+?:KJ,ZVUA90O//,YP%11DG]*_/^(9XC^V:SDWS*
M7N][?9L?;\.QH_V524$K-._K=WO^7H?D1H.K7_PH^)UK>0R%+[0M3PS*<;C'
M(5=?H0"#[$U^FG[2<RW'[/OC65#E'TMV!]C@U^8JP77Q+^)!CM(F^UZ]JI\N
M,<D--+Q^6[]*_3G]I"W6U_9Y\:0I]V/2F0?08%?=<5)?6LO<_P")?7[X_K<^
M2X9VQL:?P6T_\FM^'Z'P/^QS_P G(>#O]^Y_])9J^I/^"@WC&XT3X6Z3H=O(
M8_[:OOW^#]Z*)=Q7_OLQG\*^6_V.?^3D/!W^_<_^DLU?2_\ P42\.RWWP\\-
M:S'&SII^H-#(P_A65.I]MT:C\16^<*$N)L$JFW*OOO.WXV,,E<UD6,<-]?NY
M5?\  \S_ ."?OPWT[Q-XQUSQ/J-LETVAI$EFL@RJ32%OWF/[RJAQZ;L]0*^^
M+ZQM]3LY[2[@CN;6=#'+#,H9'4C!4@\$$5\-?\$Z_&5EI_B#Q5X:N)EBN]0B
MANK56./,\K>'4>I <''H#Z5]ULP4$DX Y)-?%\82J_VO-3V2CR^EEM\[_,^H
MX2C3_LQ.'Q-RYO6^G_DMC\D?CMX)A^%WQD\2:%IQ>&ULKL26GS'<D;JLB 'K
M\H8#/M7WGXU^)5YJ'[&UUXL\PC4;WP_&LDL9P1+*%B=AZ89F-?"_[2GC"T\>
M?'#Q9J^GRB>QDNA!!*N"KK$BQ[@1U!*$@^A%?;_B3X<WT'[%$GACRF74;?P]
M'-)"OWO,3;.Z?7*D5]AGG++"9;+%_'S0O?>UES?I<^=R:\<SQT<+\%IVMWYO
M=M^-CXM_97\#67Q"^.7AS3-2@6YTZ-Y+N>&09601(7"L.X+!00>HR*_57RT\
MOR]J[,;=N.,>F*_*G]EGQS9?#WXY>&]4U*=;;3I'DM)YG.%C65&0,Q[ ,5))
MZ 9K]53*BQF0NHC W%\\8]<^E>'QU[7Z[2O\'+IVO=W^>WX'H<%>S^K5K?'S
M?A96_'F/RO\ VKO =C\._CCK^G:9 MKIL_EWL$$8PL8D0,RJ.P#[L < 8':O
MNK]CD9_9Q\(@C(V7'_I1+7PI^U5\0+'XD?&[7=3TN9;G3(?+L[>=#E95C4*6
M![@MNP>XP:^[/V.?^3<O"/\ NW'_ *42UZG$GM?]7<+[?X[PO??X);^?<X<E
M]E_K%B/8_#:>VWQ1V\KGP/\ M(?#U_A7\:->TNW0P6;S_;K KP!#(=RA<?W3
MN7_@%?HY\+/BE:>+O@GI/C6\F5(UTXSWSYX22)2)O_'D:O!_^"A7PY_M/PGH
MOC2VBS/IDOV*[8 9,,ARA/\ NOQ_VTKYR\%_'>7PS^SKXR\!&1Q=:C=Q?8R,
MG;#)_P ? ]AB-1_VU-:5,/+B;)L-4CK4A)1E^$9/[K281K1X?SJMS?PZD7)?
MC)?BG%>IR5E;ZE\=OC,D9W?;O$FK%G/WO*61\L?HB9_!:_6O2=+MM$TNSTZS
MC$-I:0I!#&O1450JC\@*^#?^">_P[_MCQUK'B^YBS;Z/!]FMF8<>?*#DCW5
MP_[:"OOVO!XTQ<98JG@:7PTEMYO_ "5OQ/4X2P\G2JX^KK*H]_);OYN_W!11
M17YT??A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME1;^'?BQ^TYXEANY8-4\1SM^[%_<IY5G;KQG#8$:#OM7D^A-?H)^SS\"=/\
M@3X+_LZ*1;S6+PB;4;Y1@2N!PJYY"+D@?4GOBO4Z*PS;B.MF5%86G!4J2^RO
MUVT79)%9;D%+ UGBJLW4J]W_ $]?.^QX1^U=^SLWQQ\,6UUI+10^*-*#&U,I
MVI<1M@M"S=N0"I/ .1P"2/A;2?$'Q6_9MU2[AMCJWA*:8[)8KBV#03$'&X+(
MK1O[.,\=#@U^L%%7E7$E3+\.\'7I*K2[/_AFK7UU0\SR"GCZRQ5*HZ=5=5_2
MUZ7OL?E#'H_Q3_::\50WDEOJ?B:]?$(OI(O+M8%'."P CC7J<#&2>A)K]%/V
M?_@S9_ _X?V^AQ2K=:A,_P!IU"[4<2S$ ';_ +*@!1],]2:]*HJ,WXBJYG1C
MA:=-4J2^RO\ AEHNR2#+,AIX"L\55J.I5?5_T]?.^Q^?W[:WPS\8>*OC;+?:
M)X4US6+$Z?;H+FPTZ:>/<-V1N12,CTKZ>_9$T'4_#7P!\.:=J^G7>E:A$]T9
M+6]@:&5,W,A&48 C((/3H:]CHKGQ>>5,7EM++9024&M>KLFOU.FAD].AF$\P
M4VW*^G36W^1\U?MX>$]<\8?"_0[70=&U#6[J/6$E>#3K62X=4\B8;BJ D#)
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M\'Y[A1117(=@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% '-:U_R.OAS_<N?_0!72US6
MM_\ (Z>&O]VY_P#18KI:]?'?P,+_ ('_ .G*AY>#_C8G_&O_ $W ****\@]0
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *YK0O^1S\4?]NO\ Z+-=+7-:%_R.?BC_ +=?_19KU\#_  ,7_@7_
M *<IGEXS^-AO\;_]-U#I:***\@]0**** "BBB@ HHHH **** "BBB@ HHHH
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MOT?RU\C]:RWBS#5XJ&,]R??[+_5?/3S/ :*[G4_@GXRTN1@VC27* 9$EJZR
M\=@#G]*QF^'OBE6*GPWJV0<<6,I'_H-?$U,NQM)\M2C)/_"_\C["GC\)45X5
M8OYHY^BM_P#X5_XI_P"A:U?_ , )?_B:/^%?^*?^A:U?_P  )?\ XFLOJ>)_
MY]2^YFGUK#_\_%]Z,"BM_P#X5_XI_P"A:U?_ , )?_B:/^%?^*?^A:U?_P
M)?\ XFCZGB?^?4ON8?6L/_S\7WHP**W_ /A7_BG_ *%K5_\ P E_^)H_X5_X
MI_Z%K5__   E_P#B:/J>)_Y]2^YA]:P__/Q?>C HK?\ ^%?^*?\ H6M7_P#
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M^)H_X5_XI_Z%K5__   E_P#B:/J>)_Y]2^YA]:P__/Q?>C HK?\ ^%?^*?\
MH6M7_P# "7_XFC_A7_BG_H6M7_\  "7_ .)H^IXG_GU+[F'UK#_\_%]Z,"BM
M_P#X5_XI_P"A:U?_ , )?_B:/^%?^*?^A:U?_P  )?\ XFCZGB?^?4ON8?6L
M/_S\7WHP**W_ /A7_BG_ *%K5_\ P E_^)H_X5_XI_Z%K5__   E_P#B:/J>
M)_Y]2^YA]:P__/Q?>C HK?\ ^%?^*?\ H6M7_P# "7_XFC_A7_BG_H6M7_\
M "7_ .)H^IXG_GU+[F'UK#_\_%]Z,"BM_P#X5_XI_P"A:U?_ , )?_B:/^%?
M^*?^A:U?_P  )?\ XFCZGB?^?4ON8?6L/_S\7WHP**W_ /A7_BG_ *%K5_\
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M5_\ P E_^)H_X5_XI_Z%K5__   E_P#B:/J>)_Y]2^YA]:P__/Q?>C HK?\
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M/^%?^*?^A:U?_P  )?\ XFO*^IXG_GU+[F>E]:P__/Q?>C HK?\ ^%?^*?\
MH6M7_P# "7_XFC_A7_BG_H6M7_\  "7_ .)H^IXG_GU+[F'UK#_\_%]Z,"BM
M_P#X5_XI_P"A:U?_ , )?_B:/^%?^*?^A:U?_P  )?\ XFCZGB?^?4ON8?6L
M/_S\7WHP**W_ /A7_BG_ *%K5_\ P E_^)H_X5_XI_Z%K5__   E_P#B:/J>
M)_Y]2^YA]:P__/Q?>C HK?\ ^%?^*?\ H6M7_P# "7_XFC_A7_BG_H6M7_\
M "7_ .)H^IXG_GU+[F'UK#_\_%]Z,"BM_P#X5_XI_P"A:U?_ , )?_B:/^%?
M^*?^A:U?_P  )?\ XFCZGB?^?4ON8?6L/_S\7WHP**W_ /A7_BG_ *%K5_\
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M5_\ P E_^)H_X5_XI_Z%K5__   E_P#B:/J>)_Y]2^YA]:P__/Q?>C HK?\
M^%?^*?\ H6M7_P# "7_XFC_A7_BG_H6M7_\  "7_ .)H^IXG_GU+[F'UK#_\
M_%]Z,"BM_P#X5_XI_P"A:U?_ , )?_B:/^%?^*?^A:U?_P  )?\ XFCZGB?^
M?4ON8?6L/_S\7WHP**W_ /A7_BG_ *%K5_\ P E_^)H_X5_XI_Z%K5__   E
M_P#B:/J>)_Y]2^YA]:P__/Q?>C HK?\ ^%?^*?\ H6M7_P# "7_XFC_A7_BG
M_H6M7_\  "7_ .)H^IXG_GU+[F'UK#_\_%]Z,"BM_P#X5_XI_P"A:U?_ , )
M?_B:/^%?^*?^A:U?_P  )?\ XFCZGB?^?4ON8?6L/_S\7WHP**W_ /A7_BG_
M *%K5_\ P E_^)H_X5_XI_Z%K5__   E_P#B:/J>)_Y]2^YA]:P__/Q?>C H
MK?\ ^%?^*?\ H6M7_P# "7_XFC_A7_BG_H6M7_\  "7_ .)H^IXG_GU+[F'U
MK#_\_%]Z,"BM_P#X5_XI_P"A:U?_ , )?_B:/^%?^*?^A:U?_P  )?\ XFCZ
MGB?^?4ON8?6L/_S\7WHP**W_ /A7_BG_ *%K5_\ P E_^)H_X5_XI_Z%K5__
M   E_P#B:/J>)_Y]2^YA]:P__/Q?>C HK?\ ^%?^*?\ H6M7_P# "7_XFC_A
M7_BG_H6M7_\  "7_ .)H^IXG_GU+[F'UK#_\_%]Z,"BM_P#X5_XI_P"A:U?_
M , )?_B:/^%?^*?^A:U?_P  )?\ XFCZGB?^?4ON8?6L/_S\7WHP**W_ /A7
M_BG_ *%K5_\ P E_^)H_X5_XI_Z%K5__   E_P#B:/J>)_Y]2^YA]:P__/Q?
M>C HK?\ ^%?^*?\ H6M7_P# "7_XFC_A7_BG_H6M7_\  "7_ .)H^IXG_GU+
M[F'UK#_\_%]Z,"BM_P#X5_XI_P"A:U?_ , )?_B:/^%?^*?^A:U?_P  )?\
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M_GU+[F'UK#_\_%]Z,"BM_P#X5_XI_P"A:U?_ , )?_B:/^%?^*?^A:U?_P
M)?\ XFCZGB?^?4ON8?6L/_S\7WHP**W_ /A7_BG_ *%K5_\ P E_^)H_X5_X
MI_Z%K5__   E_P#B:/J>)_Y]2^YA]:P__/Q?>C HK?\ ^%?^*?\ H6M7_P#
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M^)H_X5_XI_Z%K5__   E_P#B:/J>)_Y]2^YA]:P__/Q?>C HK?\ ^%?^*?\
MH6M7_P# "7_XFC_A7_BG_H6M7_\  "7_ .)H^IXG_GU+[F'UK#_\_%]Z,"BM
M_P#X5_XI_P"A:U?_ , )?_B:/^%?^*?^A:U?_P  )?\ XFCZGB?^?4ON8?6L
M/_S\7WHP**W_ /A7_BG_ *%K5_\ P E_^)H_X5_XI_Z%K5__   E_P#B:/J>
M)_Y]2^YA]:P__/Q?>C HK?\ ^%?^*?\ H6M7_P# "7_XFC_A7_BG_H6M7_\
M "7_ .)H^IXG_GU+[F'UK#_\_%]Z,"BM_P#X5_XI_P"A:U?_ , )?_B:/^%?
M^*?^A:U?_P  )?\ XFCZGB?^?4ON8?6L/_S\7WHP**W_ /A7_BG_ *%K5_\
MP E_^)H_X5_XI_Z%K5__   E_P#B:/J>)_Y]2^YA]:P__/Q?>CSO7/\ D<_#
M'TNO_18KI:H^)/!^O6WCSP?;3:)J45S<&\$$+VD@>7;$"VT$9; Y..E=;_PK
M_P 4_P#0M:O_ . $O_Q->KC<+B'0PMJ;T@^C_P"?E0\S"8F@JV)O-:S75?\
M/N!@45O_ /"O_%/_ $+6K_\ @!+_ /$T?\*_\4_]"UJ__@!+_P#$UY7U/$_\
M^I?<ST_K6'_Y^+[T8%%;_P#PK_Q3_P!"UJ__ ( 2_P#Q-'_"O_%/_0M:O_X
M2_\ Q-'U/$_\^I?<P^M8?_GXOO1@45O_ /"O_%/_ $+6K_\ @!+_ /$T?\*_
M\4_]"UJ__@!+_P#$T?4\3_SZE]S#ZUA_^?B^]&!16_\ \*_\4_\ 0M:O_P"
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M /$T?\*_\4_]"UJ__@!+_P#$T?4\3_SZE]S#ZUA_^?B^]&!16_\ \*_\4_\
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MO_%/_0M:O_X 2_\ Q-'U/$_\^I?<P^M8?_GXOO1@45O_ /"O_%/_ $+6K_\
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M6K_^ $O_ ,31]3Q/_/J7W,/K6'_Y^+[T8%<UH7_(Y^*/^W7_ -%FO1/^%?\
MBG_H6M7_ / "7_XFN2\-^#]>N/'WC"UBT34I;FV^Q^?"EI(7BW1$KN4#*Y'(
MSUKU<%A<0J&*3IO6"Z/_ )^4SS,7B:#K89J:TF^J_P"?<R]16_\ \*_\4_\
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M /$T?\*_\4_]"UJ__@!+_P#$T?4\3_SZE]S#ZUA_^?B^]&!16_\ \*_\4_\
M0M:O_P" $O\ \31_PK_Q3_T+6K_^ $O_ ,31]3Q/_/J7W,/K6'_Y^+[T8%%;
M_P#PK_Q3_P!"UJ__ ( 2_P#Q-'_"O_%/_0M:O_X 2_\ Q-'U/$_\^I?<P^M8
M?_GXOO1@45O_ /"O_%/_ $+6K_\ @!+_ /$T?\*_\4_]"UJ__@!+_P#$T?4\
M3_SZE]S#ZUA_^?B^]&!16_\ \*_\4_\ 0M:O_P" $O\ \31_PK_Q3_T+6K_^
M $O_ ,31]3Q/_/J7W,/K6'_Y^+[T8%%;_P#PK_Q3_P!"UJ__ ( 2_P#Q-'_"
MO_%/_0M:O_X 2_\ Q-'U/$_\^I?<P^M8?_GXOO1@45O_ /"O_%/_ $+6K_\
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MK_\ @!+_ /$T?\*_\4_]"UJ__@!+_P#$T?4\3_SZE]S#ZUA_^?B^]&!16_\
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M\^I?<P^M8?\ Y^+[T8%%;_\ PK_Q3_T+6K_^ $O_ ,31_P *_P#%/_0M:O\
M^ $O_P 31]3Q/_/J7W,/K6'_ .?B^]&!16__ ,*_\4_]"UJ__@!+_P#$T?\
M"O\ Q3_T+6K_ /@!+_\ $T?4\3_SZE]S#ZUA_P#GXOO1@45O_P#"O_%/_0M:
MO_X 2_\ Q-'_  K_ ,4_]"UJ_P#X 2__ !-'U/$_\^I?<P^M8?\ Y^+[T8%%
M;_\ PK_Q3_T+6K_^ $O_ ,31_P *_P#%/_0M:O\ ^ $O_P 31]3Q/_/J7W,/
MK6'_ .?B^]&!16__ ,*_\4_]"UJ__@!+_P#$T?\ "O\ Q3_T+6K_ /@!+_\
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M\^I?<P^M8?\ Y^+[T8%%;_\ PK_Q3_T+6K_^ $O_ ,31_P *_P#%/_0M:O\
M^ $O_P 31]3Q/_/J7W,/K6'_ .?B^]&!16__ ,*_\4_]"UJ__@!+_P#$T?\
M"O\ Q3_T+6K_ /@!+_\ $T?4\3_SZE]S#ZUA_P#GXOO1@45O_P#"O_%/_0M:
MO_X 2_\ Q-'_  K_ ,4_]"UJ_P#X 2__ !-'U/$_\^I?<P^M8?\ Y^+[T8%%
M;_\ PK_Q3_T+6K_^ $O_ ,31_P *_P#%/_0M:O\ ^ $O_P 31]3Q/_/J7W,/
MK6'_ .?B^]&!16__ ,*_\4_]"UJ__@!+_P#$T?\ "O\ Q3_T+6K_ /@!+_\
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M\^I?<P^M8?\ Y^+[T8%%;_\ PK_Q3_T+6K_^ $O_ ,31_P *_P#%/_0M:O\
M^ $O_P 31]3Q/_/J7W,/K6'_ .?B^]&!16__ ,*_\4_]"UJ__@!+_P#$T?\
M"O\ Q3_T+6K_ /@!+_\ $T?4\3_SZE]S#ZUA_P#GXOO1@45O_P#"O_%/_0M:
MO_X 2_\ Q-'_  K_ ,4_]"UJ_P#X 2__ !-'U/$_\^I?<P^M8?\ Y^+[T8%%
M;_\ PK_Q3_T+6K_^ $O_ ,31_P *_P#%/_0M:O\ ^ $O_P 31]3Q/_/J7W,/
MK6'_ .?B^]&!16__ ,*_\4_]"UJ__@!+_P#$T?\ "O\ Q3_T+6K_ /@!+_\
M$T?4\3_SZE]S#ZUA_P#GXOO1YW??\C[I?_7I+_,5TM4=2\'Z]%\2M&LWT34D
MNY;*9TMVM)!(Z@C)"XR0*ZW_ (5_XI_Z%K5__ "7_P")KU<=A<0Z>'M3?P=G
M_-(\S!XF@IU[S7Q]U_+$P**W_P#A7_BG_H6M7_\  "7_ .)H_P"%?^*?^A:U
M?_P E_\ B:\KZGB?^?4ON9Z?UK#_ //Q?>C HK?_ .%?^*?^A:U?_P  )?\
MXFC_ (5_XI_Z%K5__ "7_P")H^IXG_GU+[F'UK#_ //Q?>C HK?_ .%?^*?^
MA:U?_P  )?\ XFC_ (5_XI_Z%K5__ "7_P")H^IXG_GU+[F'UK#_ //Q?>C
MHK?_ .%?^*?^A:U?_P  )?\ XFC_ (5_XI_Z%K5__ "7_P")H^IXG_GU+[F'
MUK#_ //Q?>C HK?_ .%?^*?^A:U?_P  )?\ XFC_ (5_XI_Z%K5__ "7_P")
MH^IXG_GU+[F'UK#_ //Q?>C HK?_ .%?^*?^A:U?_P  )?\ XFC_ (5_XI_Z
M%K5__ "7_P")H^IXG_GU+[F'UK#_ //Q?>C HK?_ .%?^*?^A:U?_P  )?\
MXFC_ (5_XI_Z%K5__ "7_P")H^IXG_GU+[F'UK#_ //Q?>C HK?_ .%?^*?^
MA:U?_P  )?\ XFC_ (5_XI_Z%K5__ "7_P")H^IXG_GU+[F'UK#_ //Q?>C
MHK?_ .%?^*?^A:U?_P  )?\ XFC_ (5_XI_Z%K5__ "7_P")H^IXG_GU+[F'
MUK#_ //Q?>C HK?_ .%?^*?^A:U?_P  )?\ XFC_ (5_XI_Z%K5__ "7_P")
MH^IXG_GU+[F'UK#_ //Q?>C HK?_ .%?^*?^A:U?_P  )?\ XFC_ (5_XI_Z
M%K5__ "7_P")H^IXG_GU+[F'UK#_ //Q?>C HK?_ .%?^*?^A:U?_P  )?\
MXFC_ (5_XI_Z%K5__ "7_P")H^IXG_GU+[F'UK#_ //Q?>C HK?_ .%?^*?^
MA:U?_P  )?\ XFC_ (5_XI_Z%K5__ "7_P")H^IXG_GU+[F'UK#_ //Q?>C
MHK?_ .%?^*?^A:U?_P  )?\ XFC_ (5_XI_Z%K5__ "7_P")H^IXG_GU+[F'
MUK#_ //Q?>C HK?_ .%?^*?^A:U?_P  )?\ XFC_ (5_XI_Z%K5__ "7_P")
MH^IXG_GU+[F'UK#_ //Q?>C HK?_ .%?^*?^A:U?_P  )?\ XFC_ (5_XI_Z
M%K5__ "7_P")H^IXG_GU+[F'UK#_ //Q?>C HK?_ .%?^*?^A:U?_P  )?\
MXFC_ (5_XI_Z%K5__ "7_P")H^IXG_GU+[F'UK#_ //Q?>C HK?_ .%?^*?^
MA:U?_P  )?\ XFC_ (5_XI_Z%K5__ "7_P")H^IXG_GU+[F'UK#_ //Q?>C
MHK?_ .%?^*?^A:U?_P  )?\ XFC_ (5_XI_Z%K5__ "7_P")H^IXG_GU+[F'
MUK#_ //Q?>C HK?_ .%?^*?^A:U?_P  )?\ XFC_ (5_XI_Z%K5__ "7_P")
MH^IXG_GU+[F'UK#_ //Q?>C HK?_ .%?^*?^A:U?_P  )?\ XFC_ (5_XI_Z
M%K5__ "7_P")H^IXG_GU+[F'UK#_ //Q?>C HK?_ .%?^*?^A:U?_P  )?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7CGPQ_Y.(^-?\ W!/_ $D>O8Z\<^&/_)Q'QK_[@G_I(] 'L=%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!XY^U]_R;OXL_[=/_ $KAKV.O'/VOO^3=_%G_ &Z?^E<-
M>QT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!XYXK_ .3HO G_ &!+_P#F*]CKQSQ;_P G0^ O
M^P-?_P#LM>QT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'CGQ:X^.7P
M8/\ T]:F/_)85['7CGQ=X^-?P9/_ $^ZB/SMA7L= !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5XY\,
M?^3B/C7_ -P3_P!)'KV.O'/AC_R<1\:_^X)_Z2/0!['1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M >.?M??\F[^+/^W3_P!*X:]CKQS]K[_DW?Q9_P!NG_I7#7L= !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'CGQ@X^,GP:/_40
MOA_Y+BO8Z\<^,G'Q>^#A_P"HG>#_ ,EZ]CH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O'/AC_ ,G$
M?&O_ +@G_I(]>QUXY\,?^3B/C7_W!/\ TD>@#V.BBB@ HHHH **** "BBB@
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M::AHVIZS>6B6&GMHTTLL<4);?,6,D<9W,5C P.BGGFKK8:%*$W4EI:Z\]/\
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M?VE/^"9'BG]G#X=2^/\ 0_&L7BJVTEDFOTBL&L+BU7<H66/$LF\*Q&3E2!R
M><?8O_!,7]J?6OCU\.-6\->+;U]2\4>%C$HU"8YEO+20,(VD/\3J492W4C:3
MDDDW[&$H2G2E?EW1/MIQE&-2-E+9_P!?UMW/M.218HV=V"(HRS,< #U-< W[
M0_PJ75O[+;XF>#AJ?F>5]B.OVGG;\XV[/,W9SVQ7Y;?\%'OVH_%7Q>^-%_\
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M?\'^NJ[DTZZE"4YZ<N_]?UL^Q^D$G[0'POAUHZ/)\2/"*:L'\HV#:[:B??\
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MKX5W4'B)D;QGX<>.VU&9%"B[C<'RKC:.%9MKA@.-RDC ( ET(RINI2E=+?\
MKYK[RO;2C-0JJU]CZMKGO&'Q$\*_#NTBNO%7B;1_#-K*VV.;6+^*T1V] TC
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M"-IR/W,6QO\ KI)OZBI2=2I[-.UE=OLO\V]$4VJ<.=J^MDN[_P DM6>@Z?\
MM5?MK?$RUBU[P)^SIH>E^&YUWPP^)+O;=,O]X>;=6S$$=#Y6#D$9KT#]G/\
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M;\/?!NI_%B]UOP/H7AW2HEO;OP7IT,=S+# "-RR/)"2Y4'YC'<<X.WTKZZ^
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MRPKY;_9D^-_Q6U#]E?XA?'3XI:V);6YM+W5_#NAK96\,=A9PI(T>&2-7?>V
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M]%YGZ1_!OQX?BE\)?!GC!DCBDUW1[749(X<[$>6)795R2< DCDGI78U\L_\
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MPUX_\4:_)?6^MZVNZ"&V@:..0L##,&)\N<#*$?/GCK6K7LJM3G^Q'7UDTO\
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M#JDB!@K>XS@^XII<T7)/9V?D#=FDUOL=+1114C"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH \<^,W'Q7^#I_P"HM=#_ ,@5['7CGQJX^*'P>/\
MU&)Q_P"0*]CH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?*I .3@C&GA<33DW?1I^5[/Y;?*Z\P;GBJ%2"5M4UYVO_G\[/R,X?L,?MG,
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MB@VKN/F&VD"X'?DBOCK_ ((NZA9S?LP^(;2%XS>6_B>=KB-?O#=;V^PGZA2
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MA'<5[K7YO?%3X7^./VV/V\-&TWQ-X.\0Z)\$_ 1=UN-8TR>UMM5=&4R&-I$
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MGCS0-:L=5EO+6"+6-2L)X8-3V2W7FS032JOFJS%6R.H93WK&\3?"/X[?L/\
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MJWPNL/#FE6>AVYU8S1OJ:B QR.D4L$9C4!%[O]_&>.?EKX7^'/VC/^";&O\
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M /ZU3_V!;_WY?S'^%)_PC]O_ 'Y?S'^%3RXKO^0[X;M^9!_PDO\ T[?^/_\
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M "+_ /6JU_PB=I_STG_[Z'^%)_PB-G_STG_[Z7_"ERX[^;\O\A\V#[?F5?\
MA,_^G/\ \B__ %J3_A-/^G/_ ,B__8U;_P"$0L_^>L__ 'TO^%)_PA]E_P ]
M9_\ OI?\*7+C_P"9?A_D/FP7;\_\RI_PFW_3E_Y%_P#L:3_A./\ IR_\B_\
MV-6_^$-LO^>MQ_WTO^%)_P (99?\];C_ +Z7_"ERX_\ F7X?Y#YL#_+^?^94
M/CC'_+E_Y%_^QH_X3K_IR_\ (O\ ]C5O_A"[$_\ +6X_[Z7_ .)I/^$*L?\
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M/VF3_P C_'_,S/\ A<7_ %"/_)G_ .PH_P"%R?\ 4(_\F?\ ["M+_A4FC_\
M/S??]_$_^(H_X5'H_P#S\WW_ '\3_P"(I>SSS^=?^2_Y#]ID_P#(_P#R;_,S
M#\9,?\PC_P F?_L*3_A<W_4'_P#)G_["M3_A4>CG_EYOO^_B?_$4G_"H='_Y
M^;[_ +^)_P#$4O9YY_.O_)?\A^TR;^1_^3?YF9_PN;_J#_\ DU_]A2?\+H_Z
M@_\ Y-?_ &%:?_"H='_Y^;[_ +^)_P#$4?\ "G]&_P"?F^_[^)_\12]GGO\
M.O\ R7_(?M,F_D?_ )-_F97_  NG_J#?^37_ -A2?\+K_P"H-_Y-?_85J_\
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M^_D?_P 11[+B+_GXO_)?\BO:9#_(_P#R;_,R#\>O^H%_Y-__ &ND_P"%^?\
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M\_NJ_P#?V+_XW2]CQ5_S]C_Y)_\ (A[7AK_GV_\ R;_Y(PO^&F/^I<_\GO\
M[72?\-,_]2W_ .3W_P!KK=_X9S\-_P#/]JO_ ']B_P#C=)_PSCX:_P"?[5?^
M_L7_ ,;I>QXK_P"?L?\ R3_Y$KVW#/\ S[?_ )-_\D8?_#37_4M_^3W_ -KI
M/^&F_P#J6_\ R?\ _M=;O_#./AK_ )_M5_[^Q?\ QND_X9P\-?\ /]JW_?Z+
M_P"-TO8\6?\ /V/_ ))_\B/VW#/_ #[?_DW_ ,D87_#3G_4M?^3_ /\ :Z;_
M ,-/?]2U_P"3_P#]JK>_X9O\,_\ /]JW_?Z+_P"-TG_#-OAG_G^U;_O]%_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]N[]IW6K$^'])_9-\0:=XLD3R$U:]^U'3DFQCS,-;HFS//,^/]HUZS_P3_\
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M<6L(P6ZN!CGG[THHHC[M-4ULFW]["7O5/:>27W!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!XY\=./'G
MPB/_ %,./_(35['7CGQWX\;?",_]3(H_\A-7L= !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5XY\,?^
M3B/C7_W!/_21Z]CKQSX8_P#)Q'QK_P"X)_Z2/0!['1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >
M.?M??\F[^+/^W3_TKAKV.O'/VOO^3=_%G_;I_P"E<->QT %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !5#7M%M_$6C7FFW:[K>ZB
M,;>HST(]P<$?2K]%1.$:D7":NGHRHRE3DIQ=FCXF\7>%KWP;KUUI5\O[V(Y6
M0#Y9$/W77V(_(Y'45BU]J>,/ ^D>.-/-KJEN&('[NXC $T7^ZQ!QTZ=#Z5X)
MXC_9R\1:?,[:4\&JV^3L7S!%*!GC(;"]/0]C[9_"LXX3Q>#JN>$BZE-[6U:\
MFMWZH_9\JXFPN*IJ.*DH3ZWT3\T^GHSR2F_XUW$?P5\:S/L70I0<X^:6-1TS
MU+8KN/"7[,]Y/*LOB*]2V@&#]FLVWR-[%B,+^&:^?P^0YGBIJ$*$EYM-+[W8
M]S$9UEV&ASSK1?DG=_<CBO@_\/9O'7B:%I8F_LBT8274I'RMCD1CL2QQD>F3
MZ5]=1QI#&L<:JB* JJHP !T %4="T&P\-:7#I^FVR6MK$,*B#J>Y)[D]R>36
MA7[ED.2PR7#>SO><M9/]%Y(_&\ZS:>;8CGM:$=$OU?FPHHHKZ8^>"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \<\??\G*?
M"K_KSU7_ -$K7L=>.?$#_DY/X4?]>FK?^B5KV.@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\<_9__
M .1B^+'_ &-ES_Z E>QUXY^S=_S5+_L>]4_]I4 >QT444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% 'CGQZX\8?"0_]3/&/_(;5['7C
MGQ^X\4?"4_\ 4U0C_P <>O8Z "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQSX8_P#)Q'QK_P"X)_Z2
M/7L=>.?#'_DXCXU_]P3_ -)'H ]CHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /'/VOO^3=_%G_;
MI_Z5PU['7CG[7W_)N_BS_MT_]*X:]CH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#QSXA?\G)?
M"7_KUU;_ -$+7L=>.?$3_DY#X1?]>^K_ /I.M>QT %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7CG[-
MW_-4O^Q[U3_VE7L=>.?LW?\ -4O^Q[U3_P!I4 >QT444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 ,F5Y(9%C?RI&4A9,9VG'!QWK(_LO5_^@Y_Y
M*)_C6U10!B_V7J__ $'/_)1/\:/[+U?_ *#G_DHG^-;5% &+_9>K_P#0<_\
M)1/\:/[+U?\ Z#G_ )*)_C6U10!B_P!EZO\ ]!S_ ,E$_P :/[+U?_H.?^2B
M?XUM44 8O]EZO_T'/_)1/\:/[+U?_H.?^2B?XUM44 8O]EZO_P!!S_R43_&C
M^R]7_P"@Y_Y*)_C6U10!B_V7J_\ T'/_ "43_&C^R]7_ .@Y_P"2B?XUM44
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MB_V7J_\ T'/_ "43_&C^R]7_ .@Y_P"2B?XUM44 8O\ 9>K_ /0<_P#)1/\
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MR]7_ .@Y_P"2B?XUM44 8O\ 9>K_ /0<_P#)1/\ &C^R]7_Z#G_DHG^-;5%
M&+_9>K_]!S_R43_&C^R]7_Z#G_DHG^-;5% &+_9>K_\ 0<_\E$_QH_LO5_\
MH.?^2B?XUM44 8O]EZO_ -!S_P E$_QH_LO5_P#H.?\ DHG^-;5% &+_ &7J
M_P#T'/\ R43_ !H_LO5_^@Y_Y*)_C6U10!B_V7J__0<_\E$_QH_LO5_^@Y_Y
M*)_C6U10!B_V7J__ $'/_)1/\:/[+U?_ *#G_DHG^-;5% &+_9>K_P#0<_\
M)1/\:/[+U?\ Z#G_ )*)_C6U10!B_P!EZO\ ]!S_ ,E$_P :/[+U?_H.?^2B
M?XUM44 8O]EZO_T'/_)1/\:/[+U?_H.?^2B?XUM44 8O]EZO_P!!S_R43_&C
M^R]7_P"@Y_Y*)_C6U10!B_V7J_\ T'/_ "43_&C^R]7_ .@Y_P"2B?XUM44
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MB_V7J_\ T'/_ "43_&C^R]7_ .@Y_P"2B?XUM44 8O\ 9>K_ /0<_P#)1/\
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M^(W_ "<?\(/^N&L?^DZU['7CGQ(_Y..^#O\ URUC_P!)EKV.@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *\<_9N_YJE_V/>J?^TJ]CKQS]F[_FJ7_8]ZI_[2H ]CHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** /'/VA^-5^%)_ZG*R'_CL
ME>QUXY^T5Q??"H_]3KIX_22O8Z "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQSX8_\G$?&O_N"?^DC
MU['7CGPQ_P"3B/C7_P!P3_TD>@#V.BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \<_:^_P"3=_%G
M_;I_Z5PU['7CG[7W_)N_BS_MT_\ 2N&O8Z "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \<^)7_
M "<9\&O^N>L_^DJU['7CGQ,_Y.+^#'^[K7_I*E>QT %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7CG[
M-W_-4O\ L>]4_P#:5>QUXY^S=_S5+_L>]4_]I4 >QT444 %%%% !1110 444
MA.!D\"@!&=8U+,0JCJ363=:[U6!?^!M_A534M0:\?:N1$O0>ON:I5Y5;%-OE
MAL>E2PZ2O,EENYIOORLWX\5%117 VWN=J26P4444AA1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 2Q7D\)RDK+^/%:5I
MKAW!;@#']]>WX5D45K"M.GLS*5.$]T=<DBR*&4[E/((IU<YINH-9R!6.82>1
MZ>XKHE8,H(.0>17LT:RJJ_4\JK3=-VZ"T445N8A1110 4444 %? G[6W[8'Q
M!\8?&B']G?\ 9Y1&\;2G9K/B,[2NG#&YT1B"J;%.7D()7.U!OZ?;?Q"\3CP3
MX!\2>(6 8:3IMS?D'H?*B9\?^.U\!?\ !&WP6NL>$/B/\6=7/VWQ1X@UM[&2
M]DP7V*JSRD>F^2;)]=B^E3"*JU7%_#%<S\[NR7I?<J4G3IJ2WD[+RTNWZVV-
M73_^"/\ X<\66L6I?%'XL^.?%_B]US/J5O>1J@;K@?:(YI"!ZEAG&<#I7&0^
M(OB3_P $T/C[X/\ #/B/QGJ7C_X&>+IQ9VT^KN7FTMMRJ<$D[#'O1B%(1U+$
M*&''Z=USGC;X;^$OB58V]GXO\+:+XJL[:7SX+?6]/AO(XI,$;U616"M@D9'.
M#6D9.,XR6U]5T:ZK_)[W,W%2BXO?H^J?1_YK:QT0((R.17!7?[0'PNL/$)T"
MY^)'A&VUT2>3_9<VNVJW._.-OE&3=G/;&:^-?VYOB?XT^.'QZ\-?LK_#/56T
M'^TX5NO%.KV^=T-L5+F([2"$$0WLN1O+QID D'M[7_@D=^SU#X)_L671=6N-
M8,'EGQ(VK3B[$F/]8(PWD9SV,1'UK.+<H^TMIK;N[:/Y7T\RVE%J#>NC?97V
M_P S[05@R@@Y!Y!%<_J/Q$\*:/XMT_PK?^)]&LO$^HQ^;9:+<:A%'>W*?-\T
M<);>X^1^5!^ZWH:^(/\ @F'XT\5>$_%WQ:^ ?B?59-<@^']]Y>E7DI)*P>;)
M&R#))"?*CJN3MWL.E>-?&#3/&?[27_!5+5/#_@779/#<GAW2UTNY\0VZAIM-
MLQ!_I3Q$_=E+7,D2L.0S@Y&,B])3IQIZJ:NO2U[_ 'V3^_4GX8U'/1P=OG=?
M?IJC],M9^-7P]\.^)HO#FK>//#.F>(965(])O-8MX;MV;[H$3.')/;CFNSK\
MX/VO/^"=_P "?A'^RSXV\56&EZE%XKTBR%S%XBO=7N)KBYN3(JCS49_*)D9L
M'$8^]Q@UZ+\&?VC]1^"/_!,GPS\2_%S-JFKV&CM#8Q7#DM=N;AX;)&/4@KY6
M3UV@FH<HQISDWK&WSO>UO/3\45RR<X12TE?\+7OY:_(^M?&WQ-\'_#6V@N/%
MWBO0_"MO.VV*76]1ALTD/HID903]*;J'Q0\&Z3X/3Q;?>+="LO"KA2NN7&I0
MQV+!CM7$Y;8<D@#GDFO@C]EW]@_3?VEO#$?QI_:,GU+QOXF\71_;;/2Y;Z:U
M@LK1B3#CRG5AE3N5 P158#:3DU\\_MR_LZZA^SCXU\/_  B^'VM7J_#/XG:A
M;74.@7DQG^QWT4RQ$(S?-M_?QG).XX 8G8#5\LXSC1E\<FEY)]4_E?YZ"YH2
MC*I%^[%7]5W7SM\M3]G-.U&TUC3[:^L+J&]L;J)9H+FWD$D<L; %71@<,I!!
M!'!!KD?%OQP^'/@'5$TSQ/X_\+^'-2< K9ZMK-M:S,#T(21P?TKY4_X**?M)
M:E^SG\,O!OPT\!ZG;Z#XK\4[--M]4FG6!-+L8PD;3>8W$9)95#G&T!VR"H->
M9?#?]D?]B31?"Z)XZ^*_A'X@>*[D>=?ZW>>/([?=.PRYC2&Y4;=V2-^]CGDF
ME=2<I0^%.WF_3TZ^>@*\8Q4_B:OZ?UT\M3])K#4+75;*"\LKF&\M)T$D5Q;R
M!XY%/1E8<$>XK&\7?$3PKX %@?%'B;1_#8U";[/9_P!KW\5K]IE_YYQ^8PWM
MR/E&3S7YV?L(>*K#X,_MG>-?@?X&\;0^._A+?:>VK:/<6]_'>QVLP6-V"RQG
M9G#R(VWJ50G!S5+_ (*@:MXE^(G[6'P(^&G@AXV\46C#4[7SE#Q17$LZB.61
M2""L8M6<Y!^7/!Z4;RI*'_+QKU6]_GH_+8%HJG,_@7RV5OS5^JU/T4\:?%[P
M+\-[BV@\6^-?#OA:>Y&8(M:U6"S:7_=$CJ6_"NGL[VWU*SANK2>.ZM9D$D4\
M+ATD4C(96'!!'<5\8ZK_ ,$Q_@W)X(US5OB'/KGC?QI-9RW6H^,]4U>X2X\X
M1DM*D:N(PJX^575\  $G%<Y_P1IUS6M4_9DURUU&YEN-)T[Q%/;Z7YQ/[N,P
MPR.B^B[W9OJS54$I<\6]8I/3:S=OZT%-\JC);2;6N^USVGXB?!GX1?&#]J;P
MEXFU;QX)_B+X%@6:U\(6NL6>(U5C*)IK4H9Q_K$;=N48"?C\X?M:?M;:1XT_
M:C^#/P^\,?%?1K/X;M=1ZEXJU+3M:MUL9E28M]GN+E7P!LA8&,L WFKD'BF?
ML%V4/QL_;,_:8^)UTK7%C]H?0K256*AH9)64;6&"#Y5K%R""-U>4? G]CKX1
M?%S]OKXP>$D\)A_A=X.M?LT6E)J5Y@7@,41)F$WFGYUN3@OCCIBLZ%W*@EV=
M2W2^[3]?=?FRZUK5V^C4+_<E;\5Y*^[/UG\/^(=*\6:-::OHFIV>LZ3>)YMM
M?Z?.D\$R?WDD0E6'N#7(:S^T)\+?#NN/HNK?$KPAIFL(_EMI]YKUK#<*Q_A,
M;2!@?;%>2_M+?L]^/?$GP-\._"GX)ZSH_P /O#$(CL=2N[R\N5N(=-C4*(;=
ME1V8D9W%W4D+@MAV(\H/_!/']CSP+X36P\375B;Z*#$VNZMXL>UG+=#*569(
M1SVV8[<TVU>37PIZ=W^B_P Q):13W?W+^OR]3[LM[B*ZACFAD2:&10R21L&5
M@>A!'45^=/\ P4S9OBE^T;^SC\(8CYT-_JPU"_M_^F3S1QAB/0)'<?K1_P $
MD/$5[;:]\;? >F^(;CQ'\/?#6K1KH%Q/()5$;RW*[XV'&V1(D<A?ESE@!N.4
MT7_B\W_!8S5;DCSK#X>Z"8XVZJ'$"H1]1+>/_P!\5I&*^L4+:KX_DH\WYV_,
MB3:HUD]U[OS;2_)L_1I5"J !@#@"EHJ*ZNH;&UFN;F5(+>%&DDED;:J*!DL3
MV  K-M)79271'S!_P40_:<_X9O\ @->#2+C;XV\2EM*T2*,YE1F&);@#K^[4
M\'^^T8[U\7?L!?#K5OV6_P!O.T\">()G74?$7@M9YXI"/EN)(HKIX_<HT4J9
M_P!DUW7P3MYO^"A/[=&J_%34(I)OA3\.76WT*"8'R[F=6)A.#P2S!IV[@"%3
MQ6U^V(P^&G_!3C]G?QJ3Y=OK$46DR-T^8S2P,?\ OF[3\JK#IQJ4I/XJK:](
MN,E'[W[S\@KN].I%;4U?UDI1;^ZW+]Y^D-<QXV^*/@SX:QV\GB[Q=H7A6.X)
M$+:WJ4-F)2.H4R,N?PKBOVKOCS;?LU_ ?Q/X[EB2YO+*$0Z?:N>)[N1@D2G_
M &0QW-C^%6KX[_95_P""?^C?M!>#X_C#^T3+J7CKQ;XQ0:A!97%_-;1VML_,
M1/DLC9*X(0$(BE5"\5$;S<N7:-KOS>R]>I4K12ON]EZ=?0]?_P""GOQ0L]!_
M8D\1W&EZA!<Q^)I+33+.ZM95DCF2202.48$A@8HY.1V-=?\ L4Z3H_P(_8F^
M'<OB#4;+P_IR:0FJWU]J=PEM#"UTYFS)(Y"KS,J\GT%?G#^W7\ =2^"OQ)\%
M_ OPAJ]Y-\-/%FJV^L:/HU[*9WTV]DD:UDC1S\QC.\,,Y/S<Y();[#_X*S>(
MHOA_^QO8>$-.4J-9U.QT>&&/KY,(,V /K @_&E&7+1G4AKSSBEWTT:?I*7S&
MX\U:%*6T8MOYZIKUBOD?7OB#XQ^ ?">@Z9KFN>./#>C:+JB++8:EJ&K6\%M=
MHRAE:*1W"N"I!!4G(.:Z2/6+";24U2.^MI-,DA%PEZLJF%HB-P</G:5(YSG&
M*^,_A+_P3M\)>./"NB>)_CS97'C3QS-96P73WO[BVL-#MT0"&QMXH9%!2-<!
MMQ;<VX]R3\\?%GXG>'OVW/VH/$'@#Q?\4]+^&7P'\#R?9C:3:O;Z>VM7$;["
M4\U@K_.K8.&"(BD -)FM9KEJ>RC\6OHDMVWU?IUVON90ES4_:OX;+U;>UO+S
M?3>VQ^DWAGX[?#7QKK?]C>'OB%X5U[5^?^)?IFMVUS<<=?W:.6X^E=S7Y<?'
M?]E_]B^W^$NN7WPW^(GA/PWXYTFSDO\ 2[W3_':7,MQ<1(72,QR7#YW,H \L
M*P)&/0_6/_!/KXW:S\:OV3O#7B?Q5<FYUBS^T6%[?2=;CR'*K*WJQ3;N/=@3
MWI+E<9/K&S?H^HY7BX]I72[W6MON/==)^(OA37_$>J^'],\3Z-J.O:2,ZAI=
MIJ$4MU9C./WT2L6CZ_Q 5G:#\:/A]XJ\22^'M%\=^&=8U^+<)-*L-8MY[I-O
MWLQ(Y88[\<5^4G[%_P &_$G[9WQ<^-/B*]\2:GX>^%VN:R\^N+I<@AN=89I9
M9(;(2X)6)4DS(!U!08Y!7>_X*/?LH?#']E'P?\//%_PETR\\)>,3X@2"!K?4
MKFX,NV-I!(!,[E75TCP4P/G.0>,*%[4W45N;ETZIRMT^>V[\BY*\JD*;ORWU
MZ:?UZ'ZWUQGC+XU?#SX<WR6?BSQYX9\+WDB[DM]9UBWM)&'J%D=2163\7M/^
M)'B#X*ZC8?#V^TC2/B!?6<<,&H:M)(EO:.P ED!2.0[U!;;\I&[&>!7R5\/?
M^";?P \%^$XYOC3J]KXS\>7A\_5]6U/Q+/:Q_:6&YUCVRQ,RYR=TF6;ECC.
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M_P#@J%I/BOQ-X.O/ ]QX2TB227P[J$CR369AC:-0Y>*-@WG7(?!08R.M>O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[KX[^/7_  3?T'XF?$JZ^(_@#QUKOP@\>7A+7>I:"6,4['[\A1)(G5VXW%9
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M-^K?Y62MV0G[U64[65DE\E^=V[]PHHHJ"PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M**2@!:*3(]:-P]: /'?VD_\ 4_#(_P!WQSI9_62O8Z\;_:58?8_AR<_=\;:6
M?UDKV/</44 +13=R^H_.C>O]X?G2 =13?,7^\/SH\Q/[R_G1=#'44WS$_O+^
M=)YR?WU_.BZ"S'T4SSD_OK^='G1_WU_,47068^BF>='_ ,]%_,4GGQ_\]%_[
MZ%%T%F245']HB_YZ)_WT*/M$7_/1/^^A1S+N%F245']HB_YZI_WT*/M,7_/5
M/^^A2YEW"S[$E%1?:H?^>J?]]"C[5#_SUC_[Z%',NX<K[$M%1?:H?^>T?_?0
MI/M<'_/:/_OH4<R[CY7V)J*A^V0?\]H_^^Q1]L@_Y[1_]]BCFCW#E?8FHJ'[
M9;_\]X_^^Q1]LM_^>\?_ 'V*.:/<.678FHJ#[;;_ //>+_OL4?;K?_GXB_[[
M%'-'N'++L3T5!]NMO^?B+_OL4?;K;_GXB_[[%+GCW#EEV)Z*K_;[;_GXA_[[
M%']H6O\ S\P_]]BCGCW#EEV+%%5_[0M?^?F'_OX*/[0M?^?F'_OX*.>/<?++
ML6**K_VC:?\ /S#_ -_!_C2?VE:?\_4/_?P?XT<\>X<DNQ9HJM_:5I_S]0_]
M_!_C1_:5I_S]0_\ ?P?XT>TAW#DEV+-%5O[2M/\ GZA_[^#_ !H_M.S_ .?N
M#_OXO^-'M(=PY)=BS157^U+/_G[@_P"_B_XT?VI9?\_<'_?U?\:7M(=T')+L
M6J*J_P!J67_/Y;_]_5_QH_M6R_Y_+?\ [^K_ (T>TAW0<D^Q:HJI_:UC_P _
MEO\ ]_5_QH_M:Q_Y_+?_ +^K_C1[2'\R#V<^Q;HJI_:UC_S^6_\ W]7_ !H_
MM>Q_Y_;?_OZO^-'M(?S(?LY]F6Z*I_VQ8?\ /[;_ /?U?\:/[8L/^?VW_P"_
MJ_XT>TA_,@]G/LRY15/^V+#_ )_K;_OZO^-']LZ?_P _UM_W^7_&CVL/YD'L
MY_RLN453_MG3_P#G^MO^_P O^-)_;6G_ //];?\ ?Y?\:7M:?\R^\/9S_E9=
MKQSX8_\ )Q'QK_[@G_I(]>K?VUI__/\ VO\ W^7_ !KQ_P"&>J64?[0GQHD:
M[@6.3^Q=C&50&Q:/G!SS3]I#^9![.?9GMM%4O[<T[_G_ +7_ +_+_C2?VYIW
M_00M?^_R_P"-+VM/^9?>'LY_RLO451_MS3?^@A:_]_E_QH_MS3?^@A:_]_E_
MQH]K3_F7WA[.?\K^XO451_MW3?\ H(6O_?\ 7_&C^WM-_P"@C:_]_P!?\:/;
M4_YE]X_95/Y7]Q>HJA_;VF?]!&T_[_K_ (T?V]IG_01M/^_Z_P"-'MJ?\R^\
M/95/Y7]Q?HJA_;^F?]!*T_[_ *_XT?V_IG_02M/^_P"O^-+VU/\ F7WA[*I_
M*_N+]%9__"0:7_T$K/\ [_I_C1_PD&E_]!*S_P"_Z?XT>VI_S+[P]E4_E?W&
MA16?_P )!I?_ $$K/_O^G^-'_"0Z5_T$[/\ [_I_C1[:E_,OO#V53^5_<:%%
M9W_"1:5_T$[/_P "$_QH_P"$BTK_ *"=G_X$)_C1[:E_,OO#V-3^5_<:-%9W
M_"1Z3_T%+/\ \"$_QH_X2/2?^@I9_P#@0G^-'MJ7\R^\/8U/Y7]QHT5G?\))
MI/\ T%++_P "$_QI/^$DTG_H*67_ ($)_C1[>E_,OO'[&I_*_N-*BLW_ (23
M2/\ H*V7_@0G^-'_  DND?\ 05LO_ A/\:7MZ7\Z^]![&K_*_N-*BLW_ (2;
M1_\ H*V/_@0G^-)_PDVC_P#05L?_  )3_&CV]+^=?>@]C5_E?W&G169_PDVC
M_P#06L?_  )3_&C_ (2?1_\ H+6/_@2G^-'MZ7\Z^]![&K_*_N-.BLS_ (2?
M1_\ H+6/_@2G^-'_  E&C?\ 06L?_ E/\:/;TOYU]Z#V-7^5_<:=%9?_  E&
MC?\ 07L?_ E/\:/^$IT7_H+V'_@2G^-'UBC_ #K[T'L:O\K^XU**R_\ A*=%
M_P"@O8?^!*?XT?\ "5:+_P!!>P_\"4_QH^L4?YU]Z'["K_(_N9J45E_\)5HO
M_08L/_ E/\:3_A*M$_Z#%A_X%)_C2^L4?YU]Z#V%7^1_<S5HK*_X2O1/^@QI
M_P#X%)_C1_PEFB?]!G3_ /P*3_&CZQ1_G7WH/85?Y']S-6BLK_A+-#_Z#.G_
M /@4G^-)_P )9H?_ $&=/_\  J/_ !H^L4?YU]Z#V%7^1_<S6HK)_P"$MT/_
M *#.G_\ @5'_ (T?\);H?_09T_\ \"H_\:/K%'^=?>@]A6_D?W,UJ*R?^$NT
M+_H-:?\ ^!4?^-)_PEVA?]!K3O\ P*C_ ,:/K-'^=?>@^KUOY']S->BLC_A+
M]"_Z#6G?^!<?^-'_  F&@_\ 0;T[_P "X_\ &CZS0_G7WH/J];^1_<S7HK(_
MX3#0?^@WIW_@7'_C1_PF&@_]!O3O_ N/_&E]9H?SK[T/ZO6_D?W,UZ*Q_P#A
M,-!_Z#>F_P#@7'_C1_PF.@?]!S3?_ N/_&CZS0_G7WH/J];^1_<S8HK'_P"$
MRT#_ *#FF_\ @7'_ (T?\)EH'_0<TW_P+C_QH^LT/YU]Z#ZO6_D?W,V**QO^
M$S\/_P#0=TW_ ,"X_P#&C_A,_#__ $'=-_\  R/_ !H^M4/^?B^]!]7K?R/[
MF>:_M??\F[^+/^W3_P!*X:]CKPG]K+Q/H^H?L_\ BJWM=6L;FX?[+MBAN4=C
MB[A)P <] ?RKUW_A-/#_ /T'=-_\#(_\:?UBC:_.K>J%["M>W(_N9LT5C?\
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M$^(6HOJOC1[33YM4GDACB99GO(G,96-57Y P3('.W/.:YY4ZD:$)-V7,M/\
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M\)?^NNI_RM:] _X)"_#72='^ ^J^,_L<+Z[K.JS6YO"@,B6\2HJQANH&\NQ
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MM?<[?=V+E[LW3>]D_O"BBB@ HHHH **** "BBB@ HKXO_:L_:P^(UM\<-&^
MGP*TO3[SXA:A;"[U#6=4&^WTJ%E+ [3\NX+ARS!@ 5 1F; \]^'O[1_[1?[.
M_P"T]X+^%G[0&HZ'XTTGQJPBT_6]'@CC,,K-L7:8X8<@/M5E>/.'#!L#!*?[
MUQ2^TVEYM=ON85/W:;?17?DGW^\_1*BBB@ HHK\\/^"@7[:'Q&\'_$ZW^&?P
M0U5+'7]$TJZU_P 2Z@MG!=>1#% TPA(FC=5(C7>3@$EX@",D5$IJ-EW_ $U;
M]$M67&+E?R_X9?>]#]#Z*\*_8?\ B_J_QU_9?\$>,?$%ZNHZ_>0S1:A=+$D7
MF313R1EMB*JKD(#@ #FO=:WJ0=.;@^AC"2G%20445\*_%[]I;XD3?\%(/A_\
M&O!OB3^S?"?V:"XUZR2QMIC,0LMQ*#))&SIF%8U^5EQNR.>:SC[U2-/K)V_"
M]WY:%OW82J=(J_Z?J?=5%%% !117Q5\!_P!HCXA?%W_@H!\7/!Z>(/,^%OA"
MU:"+2TL[? NU:&+)F$?FG+BX;!?'&,8'!'WJBIK>S?W;A+W8.H]DTOFW9'VK
M1110 4444 %%%% '.?$;PQ>^-O /B+P_INM7'AO4-4L)K.#6+0,9K)W0JLR;
M64[E)R,,#D=17S9^SM_P3]M/A+\24^(WC[XAZ[\8?'EK$;?3M5U_>%LHR",H
MLDLK%\,P!+X 8X4'FOK:BB/NRYUO_7^82]Z/(]OZ_P @KYS?]D'[;^V@GQ^U
M'Q8+W[+IO]GV'AW^S=OV7]R8B_VCSCN^_*<>6/\ 6=>,GZ,HH6DE);J_XJS_
M  ;!ZQ<7L_\ ._YH**** "BBOEGQ;^U3XAO/VY/"_P !O#&GV<>FPV1U;Q%J
M\I,DPC$+R+!&OW4S^YRQW$B7 VD9(M9*"W?Z*[^Y+^F#TBY/9?\ #+[VTCZF
MHHHH ^<OB3^R"?B9^UIX"^,]_P"+?+L?"-J(+?PS_9N\22#SF$OVCSAM.^56
MQY9_U8&>>/HVBBA>[%06VK^;U82]Z7.][)?);!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %-QTIU% #-IQ3=I]*EHI
M6'<\9_:64KIG@ XZ>,],/_CSUZ_Y;<\5Y'^TU_R!? I]/&&F'_QYZ]CI<J'<
MKM&WI2&%^./UJS12Y$/F94\A^/E_6D-O)_=_45<HI>S0^=E+[/)S\OZBF&UE
M_N_J*T**7LT/VC,\VLO]W]12?9)>?D_45HT4O91#VC,S['-_<_44W[%-_<_4
M5JT4O8Q'[61D_89_[GZBD:QG_N?J*UZ*7L(C]M(Q_P"SY_\ GG^HI/[/N.?W
M?ZBMFBE]7B/V\C$_LZXY_=_^/#_&D.FW/_//_P >'^-;E%+ZM#N/ZQ(P?[,N
M?^>?_CP_QIITNZX_=?\ CP_QKH**7U:'=C^L3['/?V5=?\\O_'A_C2?V3=<_
MNO\ QX?XUT5%+ZK#NQ_69]D<Y_9-WS^Z_P#'A_C2-I%W_P \O_'A_C7244OJ
MD.[']:GV1S+:/=_\\?\ QX?XTAT:\X_<_P#CR_XUT]%+ZG3[L?UJ?9'+?V+>
M?\\?_'E_QI/[%O?^>/\ X\O^-=512^I4^[#ZW/LCD_[#O>?W/_CZ_P"-!T.^
M_P">'_CZ_P"-=912^HT^[_KY#^N5.R.1.A7W_/#_ ,?7_&D.@WW_ #P_\?7_
M !KKZ*7U&GW?]?(?UVIV1QW]@7^?]1_X^O\ C3?^$?O_ /GW_P#'U_QKLZ*7
MU"EW?]?(?UZIV7]?,XO_ (1W4/\ GW_\?7_&D_X1W4/^??\ \?7_ !KM:*7]
MGTN[_#_(?UZIV7]?,XK_ (1W4.?]'_\ 'U_QIO\ PCFH\_Z/_P"/K_C7;T4O
M[.I=W^'^0_K]7LOZ^9PW_"-ZC_S[_P#CZ_XTG_"-:E_S[?\ D1?\:[JBE_9M
M'N_P_P A_P!H5>R_KYG!_P#",ZEQ_HW_ )$7_&D_X1C4_P#GV[_\]%_QKO:*
M7]F4>[_#_(?]H5>R_'_,X!O"^I\_Z-_Y$7_&D_X1?5.?]&_\B+_C7H%%+^RZ
M/=_A_D']HU>R_'_,\_/A;5/^?7_R(O\ C3?^$5U3_GU_\B)_C7H5%+^RZ/=_
MA_D/^TJW9?C_ )GG9\*:KQ_HO_D1/\:1O">J_P#/K_Y$3_&O1:*7]E4.[_#_
M "'_ &G6[+\?\SSG_A$]5_Y]?_(B?XTT^$=6_P"?3_R(G^->D44O[)H=W^'^
M0_[3K=E^/^9YM_PB.K?\^G_D1/\ &D;PAJY_Y=/_ "(G^->E44O[(H=W^'^0
M_P"U*W9?C_F>9GP?J_\ SZ?^14_QKR[P#X:U*?XW?%:!+;=+!_9/F+O7C=;,
M1WKZ=KQSX8_\G$?&O_N"?^DCU4<JHQ4DF]5;IW3[>1,LRK2<6TM/7LUW\S4_
MX0W6./\ 0_\ R*G^--_X0O6>/]#_ /(J?_%5ZC16?]CX?^9_A_D:?VM7[+\?
M\SR[_A"]9_Y\^_\ SU3_ .*I/^$+UGG_ $/_ ,BI_P#%5ZE12_L7#_S/\/\
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MH/\ Y&C_ /BJ]@HI?V#AOYI?>O\ (?\ ;6(_EC^/^9XZ? .O<?Z!_P"1H_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 >.?M.?\B_X+/IXMTT_P#C[5['7CG[3W_(L>$3_=\5::?_ !]J
M]CH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "O'/AC_ ,G$?&O_ +@G_I(]>QUXY\,?^3B/C7_W!/\
MTD>@#V.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPZ,N]>0>XXKV.O&_V5_^2=:G_P!A[4/_ $<: /9**** "BBB@ HHHH ****
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M>PI_RA[:IW,W^P;?^_)^8_PH_L&W_OR?F/\ "M*BCV%/^4/;5.YF_P!@V_\
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MXN4D]97_ /)KW_/0\>^//P5OO'W[+WB7X8>%+N#2KRZT-=*L))\B(!%551B
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MM,T32X!;:;IMK%9VL(.=D4:!$7\ !6C115RDY-R>[(C%12BMD%%%%2,****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH \<_:@_P"11\+GT\3Z<?\ R(:]CKQS]J+_ )$OPZ?3Q+IQ_P#(AKV.@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY7/_ +GH_L7'_P#/O\8_YA_K5D__ #__ /)9?_(GVU17Q+_P\H_ZIU_Y7/\
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MC'_,/]:LG_Y__P#DLO\ Y$^VJ*^)?^'E'_5.O_*Y_P#<]'_#RC_JG7_E<_\
MN>C^Q<?_ ,^_QC_F'^M63_\ /_\ \EE_\B?;5%?$O_#RC_JG7_E<_P#N>C_A
MY1_U3K_RN?\ W/1_8N/_ .??XQ_S#_6K)_\ G_\ ^2R_^1/MJBOB7_AY1_U3
MK_RN?_<]'_#RC_JG7_E<_P#N>C^Q<?\ \^_QC_F'^M63_P#/_P#\EE_\B?;5
M%?$O_#RC_JG7_E<_^YZ/^'E'_5.O_*Y_]ST?V+C_ /GW^,?\P_UJR?\ Y_\
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M^)?^'E'_ %3K_P KG_W/1_P\H_ZIU_Y7/_N>C^Q<?_S[_&/^8?ZU9/\ \_\
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M_P __P#R67_R)]M45\2_\/*/^J=?^5S_ .YZ/^'E'_5.O_*Y_P#<]']BX_\
MY]_C'_,/]:LG_P"?_P#Y++_Y$^VJ*^)?^'E'_5.O_*Y_]ST?\/*/^J=?^5S_
M .YZ/[%Q_P#S[_&/^8?ZU9/_ ,__ /R67_R)]M45\2_\/*/^J=?^5S_[GH_X
M>4?]4Z_\KG_W/1_8N/\ ^??XQ_S#_6K)_P#G_P#^2R_^1/MJBOB7_AY1_P!4
MZ_\ *Y_]ST?\/*/^J=?^5S_[GH_L7'_\^_QC_F'^M63_ //_ /\ )9?_ ")]
MM45\2_\ #RC_ *IU_P"5S_[GH_X>4?\ 5.O_ "N?_<]']BX__GW^,?\ ,/\
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M)_\ G_\ ^2R_^1/MJBOB7_AY1_U3K_RN?_<]'_#RC_JG7_E<_P#N>C^Q<?\
M\^_QC_F'^M63_P#/_P#\EE_\B?;5%?$O_#RC_JG7_E<_^YZ/^'E'_5.O_*Y_
M]ST?V+C_ /GW^,?\P_UJR?\ Y_\ _DLO_D3[:HKXE_X>4?\ 5.O_ "N?_<]'
M_#RC_JG7_E<_^YZ/[%Q__/O\8_YA_K5D_P#S_P#_ "67_P B?;5%?$O_  \H
M_P"J=?\ E<_^YZ/^'E'_ %3K_P KG_W/1_8N/_Y]_C'_ ##_ %JR?_G_ /\
MDLO_ )$^VJ*^)?\ AY1_U3K_ ,KG_P!ST?\ #RC_ *IU_P"5S_[GH_L7'_\
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M_P"5S_[GH_X>4?\ 5.O_ "N?_<]']BX__GW^,?\ ,/\ 6K)_^?\ _P"2R_\
MD3[:HKXE_P"'E'_5.O\ RN?_ '/1_P /*/\ JG7_ )7/_N>C^Q<?_P ^_P 8
M_P"8?ZU9/_S_ /\ R67_ ,B?;5%?$O\ P\H_ZIU_Y7/_ +GH_P"'E'_5.O\
MRN?_ '/1_8N/_P"??XQ_S#_6K)_^?_\ Y++_ .1/MJBOB7_AY1_U3K_RN?\
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M ")]M45\2_\ #RC_ *IU_P"5S_[GH_X>4?\ 5.O_ "N?_<]']BX__GW^,?\
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MW^,?\P_UJR?_ )__ /DLO_D3[:HKXE_X>4?]4Z_\KG_W/1_P\H_ZIU_Y7/\
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MYZ/[%Q__ #[_ !C_ )A_K5D__/\ _P#)9?\ R)]M45\2_P##RC_JG7_E<_\
MN>C_ (>4?]4Z_P#*Y_\ <]']BX__ )]_C'_,/]:LG_Y__P#DLO\ Y$^VJ*^)
M?^'E'_5.O_*Y_P#<]'_#RC_JG7_E<_\ N>C^Q<?_ ,^_QC_F'^M63_\ /_\
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M'_\ /O\ &/\ F'^M63_\_P#_ ,EE_P#(GVU17Q+_ ,/*/^J=?^5S_P"YZ/\
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M/T&HKXE_X>4?]4Z_\KG_ -ST?\/*/^J=?^5S_P"YZO\ L7'_ //O\8_YF/\
MK5D__/\ _P#)9?\ R)]M45\2_P##RC_JG7_E<_\ N>C_ (>4?]4Z_P#*Y_\
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M'E'_ %3K_P KG_W/1_8N/_Y]_C'_ ##_ %JR?_G_ /\ DLO_ )$^VJ*^)?\
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M^_QC_F'^M63_ //_ /\ )9?_ ")]M45\2_\ #RC_ *IU_P"5S_[GH_X>4?\
M5.O_ "N?_<]']BX__GW^,?\ ,/\ 6K)_^?\ _P"2R_\ D3[:HKXE_P"'E'_5
M.O\ RN?_ '/1_P /*/\ JG7_ )7/_N>C^Q<?_P ^_P 8_P"8?ZU9/_S_ /\
MR67_ ,B?;5%?$O\ P\H_ZIU_Y7/_ +GH_P"'E'_5.O\ RN?_ '/1_8N/_P"?
M?XQ_S#_6K)_^?_\ Y++_ .1/MJBOB7_AY1_U3K_RN?\ W/1_P\H_ZIU_Y7/_
M +GH_L7'_P#/O\8_YA_K5D__ #__ /)9?_(GVU17Q+_P\H_ZIU_Y7/\ [GH_
MX>4?]4Z_\KG_ -ST?V+C_P#GW^,?\P_UJR?_ )__ /DLO_D3[:HKXE_X>4?]
M4Z_\KG_W/1_P\H_ZIU_Y7/\ [GH_L7'_ //O\8_YA_K5D_\ S_\ _)9?_(GV
MU17Q+_P\H_ZIU_Y7/_N>C_AY1_U3K_RN?_<]']BX_P#Y]_C'_,/]:LG_ .?_
M /Y++_Y$^VJ*^)?^'E'_ %3K_P KG_W/1_P\H_ZIU_Y7/_N>C^Q<?_S[_&/^
M8?ZU9/\ \_\ _P EE_\ (GVU17Q+_P /*/\ JG7_ )7/_N>C_AY1_P!4Z_\
M*Y_]ST?V+C_^??XQ_P P_P!:LG_Y_P#_ )++_P"1/MJBOB7_ (>4?]4Z_P#*
MY_\ <]'_  \H_P"J=?\ E<_^YZ/[%Q__ #[_ !C_ )A_K5D__/\ _P#)9?\
MR)]M45\2_P##RC_JG7_E<_\ N>C_ (>4?]4Z_P#*Y_\ <]']BX__ )]_C'_,
M/]:LG_Y__P#DLO\ Y$]W_:^_Y-W\6?\ ;I_Z5PU['7Y\_%7]M[_A;W@'5/"7
M_"%_V3_:'E?Z9_:OG>7Y<J2_<\E<YV8ZCKGVKK/^'E'_ %3K_P KG_W/4+*,
M:YN"IZJSW76]NODS9\2Y5&FJSK>ZVTO=ENK-]/-'VU17Q+_P\H_ZIU_Y7/\
M[GH_X>4?]4Z_\KG_ -SU?]BX_P#Y]_C'_,Q_UJR?_G__ .2R_P#D3[:HKXE_
MX>4?]4Z_\KG_ -ST?\/*/^J=?^5S_P"YZ/[%Q_\ S[_&/^8?ZU9/_P __P#R
M67_R)]M45\2_\/*/^J=?^5S_ .YZ/^'E'_5.O_*Y_P#<]']BX_\ Y]_C'_,/
M]:LG_P"?_P#Y++_Y$^VJ*^)?^'E'_5.O_*Y_]ST?\/*/^J=?^5S_ .YZ/[%Q
M_P#S[_&/^8?ZU9/_ ,__ /R67_R)]M45\2_\/*/^J=?^5S_[GH_X>4?]4Z_\
MKG_W/1_8N/\ ^??XQ_S#_6K)_P#G_P#^2R_^1/MJBOB7_AY1_P!4Z_\ *Y_]
MST?\/*/^J=?^5S_[GH_L7'_\^_QC_F'^M63_ //_ /\ )9?_ ")]M45\2_\
M#RC_ *IU_P"5S_[GH_X>4?\ 5.O_ "N?_<]']BX__GW^,?\ ,/\ 6K)_^?\
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MH_ZIU_Y7/_N>C^Q<?_S[_&/^8?ZU9/\ \_\ _P EE_\ (GVU17Q+_P /*/\
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MO_#RC_JG7_E<_P#N>C_AY1_U3K_RN?\ W/1_8N/_ .??XQ_S#_6K)_\ G_\
M^2R_^1/MJBOB7_AY1_U3K_RN?_<]'_#RC_JG7_E<_P#N>C^Q<?\ \^_QC_F'
M^M63_P#/_P#\EE_\B?;5%?$O_#RC_JG7_E<_^YZ/^'E'_5.O_*Y_]ST?V+C_
M /GW^,?\P_UJR?\ Y_\ _DLO_D3[:HKXE_X>4?\ 5.O_ "N?_<]'_#RC_JG7
M_E<_^YZ/[%Q__/O\8_YA_K5D_P#S_P#_ "67_P B?;5%?$O_  \H_P"J=?\
ME<_^YZ/^'E'_ %3K_P KG_W/1_8N/_Y]_C'_ ##_ %JR?_G_ /\ DLO_ )$^
MVJ*^)?\ AY1_U3K_ ,KG_P!ST?\ #RC_ *IU_P"5S_[GH_L7'_\ /O\ &/\
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MM45\2_\ #RC_ *IU_P"5S_[GH_X>4?\ 5.O_ "N?_<]']BX__GW^,?\ ,/\
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M)_\ G_\ ^2R_^1/MJBOB7_AY1_U3K_RN?_<]'_#RC_JG7_E<_P#N>C^Q<?\
M\^_QC_F'^M63_P#/_P#\EE_\B?;5%?$O_#RC_JG7_E<_^YZ/^'E'_5.O_*Y_
M]ST?V+C_ /GW^,?\P_UJR?\ Y_\ _DLO_D3[:HKXE_X>4?\ 5.O_ "N?_<]'
M_#RC_JG7_E<_^YZ/[%Q__/O\8_YA_K5D_P#S_P#_ "67_P B?;5%?$O_  \H
M_P"J=?\ E<_^YZ/^'E'_ %3K_P KG_W/1_8N/_Y]_C'_ ##_ %JR?_G_ /\
MDLO_ )$^VJ*^)?\ AY1_U3K_ ,KG_P!ST?\ #RC_ *IU_P"5S_[GH_L7'_\
M/O\ &/\ F'^M63_\_P#_ ,EE_P#(GVU17Q+_ ,/*/^J=?^5S_P"YZGL_^"DE
MM),!=?#^6&'NT.KB1NOH85[9[T?V+C_^??XK_,:XJR=Z>W_\EE_\B?:=%?,_
MA?\ ;^^&^M-LU6'5O#SY4%[BV\Z/D<D&(LW!_P!GN/?'OWA?QIH'C>Q^V^']
M9L=9ML*6DLKA9=F>@8 Y4\'@X/!KSZV$KX?^+!K^NY[.%S+!X[_=JJD^R>OW
M;FU1117(>D%>-_LK_P#).M3_ .P]J'_HXU[)7C?[*_\ R3K4_P#L/:A_Z.-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!:T[_CX;_<;^55:M:;_P ?!_W&_E56
MN*G_ +S4](_^W'K5O]PH?XI_^V!1117:>2%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %6KC_CQM/^!_SJK5JX
M_P"/&T_X'_.N+$?Q*/\ B?\ Z1(];!?P,5_@7_IRF5:***[3R0HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH M:9_Q_1?C_(U5JUIG_']%^/\ (U5KBA_O=3_#'\YGK5/^1=1_QU/_ $FD
M%%%%=IY(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 6K7_CUNO]T?SJK5JU_X];K_ '1_.JM<5#^+6]5_
MZ3$];&?[MA?\+_\ 2YA1117:>2%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !6IX:\5:QX-U:+5-"U.ZTG4(ONW%G*8WQW4D=
M0>X/![UET4FE)6:T*C*4&I1=FC[_ /V>?VXK/QE>6OAWQW'%I>M3R>7;ZI"
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MS[\%_P#A>WCB;P[_ &Q_8?EV4EY]I^R_:,[61=NW>G7?USVZ5[!\4_V"-2\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !5JX_X\;3_@?\ZJU:N/^/&T
M_P"!_P ZXL1_$H_XG_Z1(];!?P,5_@7_ *<IE6BBBNT\D**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** +6
MF?\ ']%^/\C56K6F?\?T7X_R-5:XH?[W4_PQ_.9ZU3_D74?\=3_TFD%%%%=I
MY(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNCMX>U>-8+R2)2SP,I)24*.6 W,"!SALC)&#^C.FZSX/^+7A]S:7.D>*]'E
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** /?/V'-0:R_:*T.%93&+RVNX
M&4?Q@0-)M/XQ@_\  :^U/V3?^2,V7_7_ 'W_ *4R5\5_L.:6VH?M%:'.N<6-
MM=W#8]# T7/'K(/3^E?:G[)O_)&;+_K_ +[_ -*9*_.>(;?6U;^5?FS]QX)Y
MO[-E?^=_E$^#OVLO!/\ P@OQY\3VZ1^7:W\W]IP<Y&V;YVQP, /O&.V,5Y!7
MZ(?MY?"+_A+_ (?P>+["'?JGA_/VC:/FDM&/S?78V&]@7K\[Z^ORK%+%86,N
MJT?R/S/B+ 2R_,:D;>[+WEZ/_)Z!1117KGS04444 %%%% 'TU_P3Z_Y+C>_]
M@6?_ -&PU[3_ ,%%O^26^&_^PR/_ $1+7R3^S[\:/^%$^.)O$7]C_P!N>992
M6?V;[5]GQN9&W;MC]-G3'?K7:_M%_M8?\+^\+:;HW_"+?V%]CO?M?G?VA]HW
M_(R;=OE)C[V<Y[5\QC,'7JYE2KPC>*M=W7=_,^_R_-,'0R*O@JD[5)-V5GUM
MUM;\3RKX5_$?4?A/X[TKQ-IA+2V<G[V#=A9XCP\;>Q&?H<'M7ZW>$/%>F^./
M#.FZ]I$XN=.OX5FAD'7!Z@^A!R".Q!%?C)7T!^SS^UUJ?P)\/WVASZ+_ ,))
MIDLHGMH6O?LYMF.=X!\M\JW!QQ@@GN:VSC+GC::G27OQ_%=OU^\Y^&,\CE=:
M5+$.U*?SL^^G?9_+L?0?_!1;_DEOAO\ [#(_]$2UC_\ !.SQ];3>'_$7@V:4
M+>P7']I6Z,>7C=51\?[K*N?]\5XM^T7^UA_PO[PMINC?\(M_87V.]^U^=_:'
MVC?\C)MV^4F/O9SGM7BW@_QAJ_@'Q)9:[H5X]AJ=F^^*9,'M@@@\$$$@@\$&
MN?"9;4EET\+67+)OU[6V]#IS#/:$,\AF.%?/!))Z-7T:>Z7?3S/L[]MS]G/Q
M)XS\16GC3PMI\NLG[*MK?6-J-TZ["2LB)U<$':0,D8'!R<>>?L^?L3ZIX_%_
M?>/;75_"VF)&%M(@JP74LN>24D5BJ  ]5!)88/!KT?P5_P %&-'DTU$\7>&+
MZ"_4 --HS)+'*<<MLD9"G/;<WUJSXK_X*,>'(=-?_A&O"^J7=^PPG]JF.").
M/O'RW<MSVXSZBN&F\VP]#ZI"GML_Z=CVJZX<QN*_M&K7WU<==7:VUK_=NSPG
M]J3]G7P_\!/['73?$MUJ=YJ+.1I]U @>.)>LA=2.Y  V\\\\8KZ%_P""=.I0
MR_"_Q)8*X-Q!JYF=,\A7AC"G'UC;\J^'_B#\0-;^)_BJ\\0^(+O[7J%R>PPD
M2#[L:+_"H'0?B<DDGH_@;\<=;^!7BMM6TI$O+2X017NGS,52X0'(Y'W6'.&P
M<9/!!(KVJV#Q%?+W0JSO4?YWO;]+GRN%S3!X/.8XO#T^2BM+=;-6OOWUMVT\
MSZ:_;L^!_BKQAXJT?Q7X=T>ZUR!;(6-S!81---&RR.RMY:Y8@^8>0.-O/45K
M?L/_ +/GB7X>ZEJOB[Q18OI$MW:?8[.QGP)MC,KN[K_!]Q0%//7('&=&W_X*
M*>!&L5:?P[XBCO-N6BCC@>,-Z!S*"1[[?PKQ[5OV]/$&J?$G2M;.BK'X:TQI
M6BT*&[,;3LT;('EFV')&XD +@>YYKQ*-/,Y85X+V=E9ZO[[;]=K_ /#GU>*Q
M&0PS".:^V<I-KW5M?1<STOHM6MV^^Q[=_P %"?\ DBNF_P#8:A_]%2UX]_P3
MG_Y*5XG_ .P0/_1R5RW[0G[7G_"^/!5MX?\ ^$3_ +#\F]2\^T?VE]HSM1UV
M[?*3^_USVZ5Q_P"SG\>O^% ^)=4U?^PO[>^VVGV7R?M?V?9\ZMNSY;Y^[C&!
MUKNPF!Q%/+:F'G'WG>RNNR\['D9IFV#Q&>8?&4IWIQY;NSTLVWI:_P"!]0_\
M%&O^2>^%?^PHW_HEJ^!*]^_:,_:K_P"&@/#NE:7_ ,(O_8/V&Z-SYO\ :'VG
M?E"NW'E)CKG.37@-=^3X:KA<-[.LK.[[?H>+Q+CL/F&/=?#2YHV2O9K\TC]6
M/V6?B+:_$;X*^'KB*827VG6Z:=>QY^9)8E"Y/^\H5A_O5\@_M+?LG>+_  _X
M^U;6O#&B7GB#P_J=PUU&NG1&::W=V+-&T:C=@,3@@$8QDYKQ[X1_&;Q-\%?$
M3:KX=NE42J$N;.X!>"Y4<@.N1R.<,"",GGDY^P/#?_!1CPK/8*=?\+ZQ8WO1
METUHKF,^X+O&1],?B:\FK@\7@,7+$X2/-&6Z]=;?Y?B?2T,SRS.,NA@<RG[.
M<+6EZ*U_NW3^7EE?L6_LR^(?"'B9O&_BW3WTF2&!HM.L+CB?<XPTKK_!A25"
MMS\Q.!@9U_\ @H)\3[33/!6G^![>97U+4YDN[J-2"8[>,Y7=Z%G Q_N-6-X^
M_P""BUD=/>'P7X:NC>.I N];*(L1]?+C9M_XL/QKXQ\3^)]5\9:]>ZUK5[+J
M.IWC^9-<3'YF/3Z  8  X   XJJ&#Q6-Q<<7C(\JCLO3;\=3/&9IEV59;++<
MLESRG?FEZJS[:M:*VRZWW^UO^";_ /R+_CC_ *^K7_T"2O1/VQ_@'J/QF\(Z
M=>Z!&L_B#1G=HK5F"_:(G WH"2 &!52,\<$=Z\[_ .";_P#R+_CC_KZM?_0)
M*[/]J#]HC7/@'\0O"<UE;QZGI%]9S?;=-F;9YA5UVNCX)1AD\X((/(/!'FXY
M5GG+6'^/2WR@G;YK0]K*)8:/"R>,3]G[R=M]:K2?R;3^74^8/@;^RCXW\7?$
M#3AKOAV_T'0K&Y26^N-3@:#>BL"4C# %RV,97(&<D^OWK\>O'EO\-_A'XEUJ
M658IDM'@M5)Y>=P4C4?\"(/T!/:O$V_X**> _L19?#WB(W>W(B,5N(]V.F_S
M<X]]OX5\H_'S]H[Q#\>M5@-[&NEZ):,6M-)@D+HC$8+NV!O?'&<  = ,G/74
MPV.S6O!8F')"/]/YNWHOSXJ&/RGAW"5'@*OM*L]OE>U]-$KW[O\ +J?V6_V;
M_#_Q\AU=]2\2W.FW>G2('T^U@4N\3#B0.Q/<,,;>,#GFNO\ C7^QIXC^%MYI
MVM?#&36M:MXXSYYAE!OH)03\R")5)4@CA02"#G@U\Y_#SXB:[\+?%%KK_AZ\
M-G?P?*01F.9#]Z.1?XE..GL",$ C[+\(_P#!1C09M/0>*/"VI6E\H 9M(>.>
M-SCE@)&0KSGC+8]37IXZ.8TZZK89\T/Y=/Z?<\#*)9)B,(\-CE[.KTGKWNNZ
M3Z;6MYC/V3;KX]R>,K>'Q8FM#P=''(+H^)(BLV[:=GEM*/-)W8]5QGVKT#]N
MW5;*Q_9_O[6Y=1<WMY;16JGJ760.Q'_ %?\ .N3UK_@HOX,AL9&TGPSKU[>8
M^2*]\FWC)]W620C_ +Y-?(7QJ^.?B/XY>(EU'6Y$@M+?<MGIUOGR;93UQGEF
M.!ECUQV& /*IX'$XS&0Q%6DJ<8V>G6SO]_GV/H<1FV RW+*N#H8AUYS36NMN
M96WZ)+6VNIQ.AZS=>'=:L-5L9/*O;&>.YAD_NNC!E/Y@5^N>EW6C_&SX4V\T
ML?G:/XBTT>;&#@A9$PRY[,IR/8BOQ^K])/V"3K'_  HI1J*[; :A/_9NX<F'
M@M^'F>9^M>CQ!14L/&LG9Q?Y_P!)_>>-P7B90QL\*U>-2.ORZ_<VOFCT#]HC
MQ['\)_@KKVIVS"WN5MOL5@JX&)I!L3 _V02WT4U^3=?97_!1+XA&ZUGP[X+M
MY/W=K&=2NU'3S'RD0^H4.?\ @8KXUIY!A_9X9UI;S?X+1?J_F1QEC57QT<-#
MX:2M\WJ_PLOD?J3^R!X^M?'7P+T"..56O='B&F740ZH8QA"?JFP_GZ5\J?M2
M?LN^,=-^)FL:]X<T&]U_0]8N&O%.FPM/+#+(2TB/&H+?>R0V,8(YSFO'?@]\
M:/$?P3\2'5M G4QR@)=V-P"8+E!T# '@C)PPY&3V)!^P]#_X*+^#IK"-M8\,
MZY97N/GCL?)N(P?9F>,_^.UR5L)B\#C)8K"1YHRW7KJ_QV9Z.'S++<XRR& S
M&?LYT[6?HK)WUZ;I[[KR3]DO]E6WT/PGJ>H_$7PO87>H:G(GV:PU2VCF>UB4
M'YCN!V,Q;D=<*N>>!X'^VCH/@?PC\2K70O!VD6^ES6MKOU+[*[%#*Y!1-I)"
ME4 / '^LYZ5ZO\2/^"B,5QI<MKX&\/W%M>2H5&H:P4'DGU6)"P8^A+8!QD'I
M7QAJFJ7>M:E=:A?W$EW>W4C333RMN>1V.2Q/J375@:&-JXIXO%>ZND;^5MNR
M\^NIP9QC,JP^7QRW )3?6;6JUOO;=OMHEH?KU\'_ /DD_@S_ + UG_Z)2ORE
M^*W_ "5+QC_V&;S_ -'O7TQX/_X*$?\ ")^$]%T3_A ?M7]G6<-IY_\ ;.SS
M/+0+NV_9SC.,XR:^4O%FN?\ "4>*=8UGR/LW]HWLUWY._?Y?F.7V[L#.,XS@
M4LMP5?#XRM5J1M&5[:KN+/LTP>-R[#4*$[RA:ZLU;W;=5;?L?>/_  3K_P"2
M4>(?^PTW_HB*O(/^"B'_ "5[0_\ L"Q_^CI:YO\ 9U_:R_X4%X3U'1?^$5_M
MW[7>F\\_^T?L^S*(FW;Y3Y^YG.>_2N0_:(^.7_"^_%]CKG]B?V%]ELEL_L_V
MO[1NP[MNW;$Q]_&,=NM$<%76;/$N/N=[K^6VVYK5S;!RX<6 4_WNFEG_ #WW
MM;;S/LS]@'_D@\G_ &%[C_T&.OF[]OC_ )+X<]/[+MOYO2_ #]L3_A1G@-O#
M?_"(_P!MYNY+K[5_:7V?[X4;=ODOTV]<]Z\V^/GQA_X7CX^/B7^R/[%_T6.V
M^R_:?M'W-WS;MB]=W3':BE@L1'-7B7'W.]UV[7N98C-,'4X>IX&,_P!ZNEG_
M #-[VM^)^JOA2&UA\):/%IGEK9+90K;>7]SR_+&S&.V,5^;WQ#^#/QT\<?$*
M[T_7=)US7[LW#F.\<LUAM).&CD)\J-<=%R".F >*Z[]GS]MZX^&GARU\->*]
M,N-9TFS7R[2\LW7[3#&.D95B ZCH/F! &.>,>F^+/^"B_AJ'29/^$9\,ZM=Z
MFPPG]K>5!"A_O'RW<MC^[QGU%>;1PN.R_$SE2I*?-LW_ %IYGT&(S#*,YR^E
M#$5W2Y=XKTU5K._E_P .CZ)^#'@6?X:?"WPWX9NIDN+K3[4)-)'RID)+,%X&
M0"Q ]A7YE_M'6KV?Q]\<1R<,=6ED_!CN'Z$5[/\ #_\ X*#>(/#>FWL/B/P^
MOBB]N+N2X2Z6_P#LBQ1L!B)4\I_E4@X.>A_$^%?&_P")EI\7_B%>^*;;1#H#
MWD<8GMOM7V@-(J[=X;8F,J%XQU!.>:[\KP>+PN/G7KQNI7U36[:?KWZ'D9YF
MN6XS**6$P<K.#C:+3ORQ3BM;6VL]S]:)(OMFBM$ASYUOM4CW7%?D5XI^$'C3
MP1I<VHZ_X:U#1[&.Y%F9[R$QJTI#$!,_?&%/S+D<=:^I/@_^W]I^@>$;'2/&
MNBZC=WEC"L":AI?ER&X51@%T=DVM@#)!.3DX%<U^TY^UWX8^-'P_'AK1-#U2
M%S=1W/VO4?*C\LIGHJ,^[()'48SWKCR_#XW+\3*"IWC)J[\DWK]S/0SG&93G
M.!IU95^6=.,FH]7)I:/3NEJ>^_L(?\F^V7_7_=?^A"OEG]N[_DX*]_Z\+;_T
M$UH? ?\ ;,_X4G\/H/#'_"'_ -L^7<2S_:O[3\C.\YQL\ENGUKRSX\?%O_A=
MGQ G\3_V5_8WF6\4'V7[3Y^-@QG?L7K]*[</@<1#-)XB4?<=];K_ #N>3B\U
MP=7A^G@H3O45KJSZ/O:WXGGE?:7_  3M^(_E7GB#P/<R?+*!J=DI_O#"2K^(
M\LX]FKXMKU/]EXZROQ[\&G0UW7GVT>9D?+]GP1.3[>7O_2O<QU&.(PU2G+M^
M6I\KD^*G@L?1K05[-*W=/1K[GIYGZDV?A73;'Q-J6OPP!-3U""&WN)?[R1%R
MGX_O#^0]*_.C]N+XB?\ ":_&JYTR"7?I_A^(6* $%3,?FF;Z[B%/_7.OT,^(
MGC"W^'_@77?$=US%IMI)<;<XWL!\JCW+8'XU^/&J:E<ZUJ=WJ%Y(9KN[F>>:
M0]6=F+,?Q)-?&\/T'5KRKR^RK+U?^2_,_3^-,7'#X2&#IZ.H[OT6OXNS^15H
MHHK] /Q@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH M:;_ ,?B_0_RJK5K3?\ C\3Z'^1JK7%#_>JG^&/YR/6J_P#(
MOH_XZGY4PHHHKM/)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "K5Q_P >-I_P/^=5:M7'_'C:?\#_ )UQ8C^)
M1_Q/_P!(D>M@OX&*_P "_P#3E,JT445VGDA1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH M:9_P ?T7X_R-5:M:9_Q_1?C_(U5KBA_O=3_#'\YGK5/^1=1_QU/_2:
M04445VGDA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!:L_P#CWNO]S^M5:M6?^HNO]S^M5:XJ'\:MZK_T
ME'K8O_=<-_AE_P"ER"BBBNT\D**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBMOPCX)U[Q]JR:9X>TFZU>^;_EE:QEMH_O,>
MBCW) I2DHKFD[(N$)5)*$%=OHC$K[I_8L_9ANM!N+?X@^++017319TG3IT^>
M+=C_ $AQV;;D*#T#$\'&-3]G7]B&U\&W5IXC\>>3J6L1'S+?2(SOM[9@059V
MZ2.,=/NC_:X(^MJ^&S;.(U(O#X9Z/=_HO\S]:X;X8G1G'&XY6:UC'MYO]%]X
M5XY^R3^\^!>C70_U=U<WLR ]0INI1@^_%>QUXY^R#_R;OX3_ .WO_P!*YJ^,
M/U,]CHHHH *XCX@?!7P1\4873Q)X<LK^9L?Z8J>5<C P,3)A\=.,X.!D&NWH
MJX5)TY<T'9^1E5HTZ\'3JQ4D^C5T?*?B+_@G?X(U"9Y-(UW6-(# 8BD,=Q&I
MQCC*ANN#RWK[8Y.3_@FPID8I\1"J9^4-HF2![G[0,U]L45ZL<XQT%95/P3_-
M'SM3AG**CO*@ODY+\FCXE_X=K_\ 51?_ "A__=%'_#M?_JHO_E#_ /NBOMJB
MK_MK'_\ /S\(_P"1E_JKD_\ SX_\FE_\D?$O_#M?_JHO_E#_ /NBC_AVO_U4
M7_RA_P#W17VU11_;6/\ ^?GX1_R#_57)_P#GQ_Y-+_Y(^)?^':__ %47_P H
M?_W11_P[7_ZJ+_Y0_P#[HK[:HH_MK'_\_/PC_D'^JN3_ //C_P FE_\ )'Q+
M_P .U_\ JHO_ )0__NBC_AVO_P!5%_\ *'_]T5]M44?VUC_^?GX1_P @_P!5
M<G_Y\?\ DTO_ )(^)?\ AVO_ -5%_P#*'_\ =%'_  [7_P"JB_\ E#_^Z*^V
MJ*/[:Q__ #\_"/\ D'^JN3_\^/\ R:7_ ,D?$O\ P[7_ .JB_P#E#_\ NBC_
M (=K_P#51?\ RA__ '17VU11_;6/_P"?GX1_R#_57)_^?'_DTO\ Y(^)?^':
M_P#U47_RA_\ W11_P[7_ .JB_P#E#_\ NBOMJBC^VL?_ ,_/PC_D'^JN3_\
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MH_MK'_\ /S\(_P"0?ZJY/_SX_P#)I?\ R1\2_P##M?\ ZJ+_ .4/_P"Z*/\
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MT4?\.U_^JB_^4/\ ^Z*^VJ*/[:Q__/S\(_Y!_JKD_P#SX_\ )I?_ "1\2_\
M#M?_ *J+_P"4/_[HH_X=K_\ 51?_ "A__=%?;5%']M8__GY^$?\ (/\ 57)_
M^?'_ )-+_P"2/B7_ (=K_P#51?\ RA__ '11_P .U_\ JHO_ )0__NBOMJBC
M^VL?_P _/PC_ )!_JKD__/C_ ,FE_P#)'Q+_ ,.U_P#JHO\ Y0__ +HH_P"'
M:_\ U47_ ,H?_P!T5]M44?VUC_\ GY^$?\@_U5R?_GQ_Y-+_ .2/B7_AVO\
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M_P#S\_"/^0?ZJY/_ ,^/_)I?_)'Q+_P[7_ZJ+_Y0_P#[HH_X=K_]5%_\H?\
M]T5]M44?VUC_ /GY^$?\@_U5R?\ Y\?^32_^2/B7_AVO_P!5%_\ *'_]T4?\
M.U_^JB_^4/\ ^Z*^VJ*/[:Q__/S\(_Y!_JKD_P#SX_\ )I?_ "1\2_\ #M?_
M *J+_P"4/_[HH_X=K_\ 51?_ "A__=%?;5%']M8__GY^$?\ (/\ 57)_^?'_
M )-+_P"2/B7_ (=K_P#51?\ RA__ '11_P .U_\ JHO_ )0__NBOMJBC^VL?
M_P _/PC_ )!_JKD__/C_ ,FE_P#)'Q+_ ,.U_P#JHO\ Y0__ +HH_P"':_\
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M7_ZJ+_Y0_P#[HK[:HH_MK'_\_/PC_D'^JN3_ //C_P FE_\ )'Q+_P .U_\
MJHO_ )0__NBC_AVO_P!5%_\ *'_]T5]M44?VUC_^?GX1_P @_P!5<G_Y\?\
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M)_\ GQ_Y-+_Y(^)?^':__51?_*'_ /=%'_#M?_JHO_E#_P#NBOMJBC^VL?\
M\_/PC_D'^JN3_P#/C_R:7_R1\2_\.U_^JB_^4/\ ^Z*/^':__51?_*'_ /=%
M?;5%']M8_P#Y^?A'_(/]5<G_ .?'_DTO_DCXE_X=K_\ 51?_ "A__=%'_#M?
M_JHO_E#_ /NBOMJBC^VL?_S\_"/^0?ZJY/\ \^/_ ":7_P D?$O_  [7_P"J
MB_\ E#_^Z*/^':__ %47_P H?_W17VU11_;6/_Y^?A'_ "#_ %5R?_GQ_P"3
M2_\ DCXE_P"':_\ U47_ ,H?_P!T4?\ #M?_ *J+_P"4/_[HK[:HH_MK'_\
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M"/\ D'^JN3_\^/\ R:7_ ,D?$O\ P[7_ .JB_P#E#_\ NBC_ (=K_P#51?\
MRA__ '17VU11_;6/_P"?GX1_R#_57)_^?'_DTO\ Y(^)?^':_P#U47_RA_\
MW11_P[7_ .JB_P#E#_\ NBOMJBC^VL?_ ,_/PC_D'^JN3_\ /C_R:7_R1\2_
M\.U_^JB_^4/_ .Z*/^':_P#U47_RA_\ W17VU11_;6/_ .?GX1_R#_57)_\
MGQ_Y-+_Y(^)?^':__51?_*'_ /=%'_#M?_JHO_E#_P#NBOMJBC^VL?\ \_/P
MC_D'^JN3_P#/C_R:7_R1\2_\.U_^JB_^4/\ ^Z*/^':__51?_*'_ /=%?;5%
M']M8_P#Y^?A'_(/]5<G_ .?'_DTO_DCXE_X=K_\ 51?_ "A__=%'_#M?_JHO
M_E#_ /NBOMJBC^VL?_S\_"/^0?ZJY/\ \^/_ ":7_P D?$O_  [7_P"JB_\
ME#_^Z*/^':__ %47_P H?_W17VU11_;6/_Y^?A'_ "#_ %5R?_GQ_P"32_\
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MT4?\.U_^JB_^4/\ ^Z*^VJ*/[:Q__/S\(_Y!_JKD_P#SX_\ )I?_ "1\2_\
M#M?_ *J+_P"4/_[HH_X=K_\ 51?_ "A__=%?;5%']M8__GY^$?\ (/\ 57)_
M^?'_ )-+_P"2/B7_ (=K_P#51?\ RA__ '11_P .U_\ JHO_ )0__NBOMJBC
M^VL?_P _/PC_ )!_JKD__/C_ ,FE_P#)'Q+_ ,.U_P#JHO\ Y0__ +HH_P"'
M:_\ U47_ ,H?_P!T5]M44?VUC_\ GY^$?\@_U5R?_GQ_Y-+_ .2/B7_AVO\
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M_P#S\_"/^0?ZJY/_ ,^/_)I?_)'Q+_P[7_ZJ+_Y0_P#[HH_X=K_]5%_\H?\
M]T5]M44?VUC_ /GY^$?\@_U5R?\ Y\?^32_^2/B7_AVO_P!5%_\ *'_]T4?\
M.U_^JB_^4/\ ^Z*^VJ*/[:Q__/S\(_Y!_JKD_P#SX_\ )I?_ "1\2_\ #M?_
M *J+_P"4/_[HH_X=K_\ 51?_ "A__=%?;5%']M8__GY^$?\ (/\ 57)_^?'_
M )-+_P"2/B7_ (=K_P#51?\ RA__ '11_P .U_\ JHO_ )0__NBOMJBC^VL?
M_P _/PC_ )!_JKD__/C_ ,FE_P#)'Q+_ ,.U_P#JHO\ Y0__ +HH_P"':_\
MU47_ ,H?_P!T5]M44?VUC_\ GY^$?\@_U5R?_GQ_Y-+_ .2/B7_AVO\ ]5%_
M\H?_ -T4?\.U_P#JHO\ Y0__ +HK[:HH_MK'_P#/S\(_Y!_JKD__ #X_\FE_
M\D?$O_#M?_JHO_E#_P#NBC_AVO\ ]5%_\H?_ -T5]M44?VUC_P#GY^$?\@_U
M5R?_ )\?^32_^2/B7_AVO_U47_RA_P#W11_P[7_ZJ+_Y0_\ [HK[:HH_MK'_
M //S\(_Y!_JKD_\ SX_\FE_\D?$O_#M?_JHO_E#_ /NBC_AVO_U47_RA_P#W
M17VU11_;6/\ ^?GX1_R#_57)_P#GQ_Y-+_Y(^)?^':__ %47_P H?_W11_P[
M7_ZJ+_Y0_P#[HK[:HH_MK'_\_/PC_D'^JN3_ //C_P FE_\ )'Q+_P .U_\
MJHO_ )0__NBC_AVO_P!5%_\ *'_]T5]M44?VUC_^?GX1_P @_P!5<G_Y\?\
MDTO_ )(^)?\ AVO_ -5%_P#*'_\ =%'_  [7_P"JB_\ E#_^Z*^VJ*/[:Q__
M #\_"/\ D'^JN3_\^/\ R:7_ ,D?GS\5?V(?^%0^ =4\7?\ ":?VM_9WE?Z'
M_97D^9YDJ1??\YL8WYZ'ICWKK/\ AVO_ -5%_P#*'_\ =%>[_M??\F[^+/\
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M7_AVO_U47_RA_P#W11_P[7_ZJ+_Y0_\ [HK[:HH_MK'_ //S\(_Y!_JKD_\
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M %47_P H?_W17VU11_;6/_Y^?A'_ "#_ %5R?_GQ_P"32_\ DCXE_P"':_\
MU47_ ,H?_P!T4?\ #M?_ *J+_P"4/_[HK[:HH_MK'_\ /S\(_P"0?ZJY/_SX
M_P#)I?\ R1\2_P##M?\ ZJ+_ .4/_P"Z*/\ AVO_ -5%_P#*'_\ =%?;5%']
MM8__ )^?A'_(/]5<G_Y\?^32_P#DCXE_X=K_ /51?_*'_P#=%'_#M?\ ZJ+_
M .4/_P"Z*^VJ*/[:Q_\ S\_"/^0?ZJY/_P ^/_)I?_)'Q+_P[7_ZJ+_Y0_\
M[HH_X=K_ /51?_*'_P#=%?;5%']M8_\ Y^?A'_(/]5<G_P"?'_DTO_DCXE_X
M=K_]5%_\H?\ ]T4?\.U_^JB_^4/_ .Z*^VJ*/[:Q_P#S\_"/^0?ZJY/_ ,^/
M_)I?_)'Q+_P[7_ZJ+_Y0_P#[HH_X=K_]5%_\H?\ ]T5]M44?VUC_ /GY^$?\
M@_U5R?\ Y\?^32_^2/B7_AVO_P!5%_\ *'_]T4?\.U_^JB_^4/\ ^Z*^VJ*/
M[:Q__/S\(_Y!_JKD_P#SX_\ )I?_ "1\2_\ #M?_ *J+_P"4/_[HH_X=K_\
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M]%-7L=1'-\;%N2J:O?1>G8VGPUE52,82HZ1V]Z75W[]V?$O_  [7_P"JB_\
ME#_^Z*/^':__ %47_P H?_W17VU15_VUC_\ GY^$?\C'_57)_P#GQ_Y-+_Y(
M^)?^':__ %47_P H?_W11_P[7_ZJ+_Y0_P#[HK[:HH_MK'_\_/PC_D'^JN3_
M //C_P FE_\ )'Q+_P .U_\ JHO_ )0__NBC_AVO_P!5%_\ *'_]T5]M44?V
MUC_^?GX1_P @_P!5<G_Y\?\ DTO_ )(^)?\ AVO_ -5%_P#*'_\ =%'_  [7
M_P"JB_\ E#_^Z*^VJ*/[:Q__ #\_"/\ D'^JN3_\^/\ R:7_ ,D?$O\ P[7_
M .JB_P#E#_\ NBC_ (=K_P#51?\ RA__ '17VU11_;6/_P"?GX1_R#_57)_^
M?'_DTO\ Y(^)?^':_P#U47_RA_\ W11_P[7_ .JB_P#E#_\ NBOMJBC^VL?_
M ,_/PC_D'^JN3_\ /C_R:7_R1\2_\.U_^JB_^4/_ .Z*/^':_P#U47_RA_\
MW17VU11_;6/_ .?GX1_R#_57)_\ GQ_Y-+_Y(^)?^':__51?_*'_ /=%'_#M
M?_JHO_E#_P#NBOMJBC^VL?\ \_/PC_D'^JN3_P#/C_R:7_R1\2_\.U_^JB_^
M4/\ ^Z*/^':__51?_*'_ /=%?;5%']M8_P#Y^?A'_(/]5<G_ .?'_DTO_DCX
ME_X=K_\ 51?_ "A__=%'_#M?_JHO_E#_ /NBOMJBC^VL?_S\_"/^0?ZJY/\
M\^/_ ":7_P D?$O_  [7_P"JB_\ E#_^Z*/^':__ %47_P H?_W17VU11_;6
M/_Y^?A'_ "#_ %5R?_GQ_P"32_\ DCXE_P"':_\ U47_ ,H?_P!T4?\ #M?_
M *J+_P"4/_[HK[:HH_MK'_\ /S\(_P"0?ZJY/_SX_P#)I?\ R1\2_P##M?\
MZJ+_ .4/_P"Z*/\ AVO_ -5%_P#*'_\ =%?;5%']M8__ )^?A'_(/]5<G_Y\
M?^32_P#DCXE_X=K_ /51?_*'_P#=%'_#M?\ ZJ+_ .4/_P"Z*^VJ*/[:Q_\
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M_GY^$?\ (/\ 57)_^?'_ )-+_P"2/B7_ (=K_P#51?\ RA__ '11_P .U_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /(?VM!N_9[\7?[EO_Z4
MQ5ZQ9G=:PGU1?Y5Y5^U@,_L^^+_^N4'_ *415ZGIYW:?;'_IDO\ (4 6****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "O'/AC_ ,G$?&O_ +@G_I(]>QUXY\,?^3B/C7_W!/\ TD>@#V.B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH \<_:^_Y-W\6?]NG_I7#7L=>.?M??\F[^+/^W3_TKAKV
M.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MAV9Z%17GO_"5:I_S]?\ D-/\*/\ A*M4_P"?K_R&G^%'L)!];AV9Z%17GO\
MPE6J?\_7_D-/\*/^$JU3_GZ_\AI_A1["0?6X=F>A45Y[_P )5JG_ #]?^0T_
MPH_X2K5/^?K_ ,AI_A1["0?6X=F>A45Y[_PE6J?\_7_D-/\ "C_A*M4_Y^O_
M "&G^%'L)!];AV9Z%17GO_"5:I_S]?\ D-/\*/\ A*M4_P"?K_R&G^%'L)!]
M;AV9Z%17GO\ PE6J?\_7_D-/\*/^$JU3_GZ_\AI_A1["0?6X=F>A45Y[_P )
M5JG_ #]?^0T_PH_X2K5/^?K_ ,AI_A1["0?6X=F>A45Y[_PE6J?\_7_D-/\
M"C_A*M4_Y^O_ "&G^%'L)!];AV9Z%17GO_"5:I_S]?\ D-/\*/\ A*M4_P"?
MK_R&G^%'L)!];AV9Z%17GO\ PE6J?\_7_D-/\*/^$JU3_GZ_\AI_A1["0?6X
M=F>A45Y[_P )5JG_ #]?^0T_PH_X2K5/^?K_ ,AI_A1["0?6X=F>A45Y[_PE
M6J?\_7_D-/\ "C_A*M4_Y^O_ "&G^%'L)!];AV9Z%17GO_"5:I_S]?\ D-/\
M*/\ A*M4_P"?K_R&G^%'L)!];AV9Z%17GO\ PE6J?\_7_D-/\*!XJU3_ )^<
M_P#;-?\ "CV$@^MP[,]"HKA[?QK>QL/-CCF7OQM/Y_\ UJZ'2_$UIJ<@C!:&
M8]$?O]#42IRB:PKPGHF:]%%%9'0%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 >3?M6#/[/_B__ *XP_P#H^.O3M*.=
M+LS_ -,4_P#017FG[5 S\ ?&'_7O'_Z.CKTG13NT:P/_ $[Q_P#H(H NT444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %>.?#'_ ).(^-?_ '!/_21Z]CKQSX8_\G$?&O\ [@G_ *2/0!['
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 >.?M??\F[^+/\ MT_]*X:]CKQS]K[_ )-W\6?]NG_I
M7#7L= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 >.?'C_D=/A&?^IE7_T6U>QUXY\>O^1P^$A_
MZF:/_P!%M7L= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5XY^R#_R;OX3_ .WO_P!*YJ]=O;C['9SS
M[=_E1L^W.,X&<5Y1^R9;_9?V>_"*;MV8[A\XQ]ZYE;'ZT >NT444 %%%% !1
M110 445D>)M4;3-.)C.V:0[$;T]3^7\Z:7,[(F4E%.3,GQ-XF.YK2S? '$DJ
MG]!_C7*445Z48J*LCPZE1U'=A1115&04444 %%%% !1110 4444 %%%% !11
M10 4444 %%?&7[4?_!1;_AFOXL7/@K_A7W_"1^3:PW7V[^VOLN?,7.W9]G?I
MZ[N:^@O&GQF_X1']GV\^)_\ 8_VO[/H::U_97VG9NW1*_E>;L./O8W;>W2LE
M5@Z<JJ?NQW^5_P#)FKI3C.--K66WX?YH]+HKY,_9#_;R_P"&JO'6K>'/^$&_
MX1?[!IQO_M/]K_:]^)$39M\B/'W\YR>G2OK.MK:*71_\-^AF_=DXO=?\.%%%
M%(04444 %%%% !1110 4444 %%%% !1110 45\-?#_\ X*;?\)U\=M,^''_"
MMOL/VW63I/\ :?\ ;OF;,2%/,\K[,,],[=WXU]RU-.2JTU5AK%[?@_U1=2$J
M4W3GHU_P?\@HHHJB HHHH **** "BL'Q?X^\,?#ZQAO?%/B/2?#5G/)Y,5QK
M%]%:1R28)V*TC %L G YP#6Y'(LL:NC!T895E.00>XH&.HHHH$%%%% !1110
M 4444 =7X9\3'<EG=MD'Y8Y3_(UUM>3UZ%X9U/\ M+34W',T7R/_ $/Y5QUH
M6]Y'J8:LY>Y(UJ***YCO"BBB@#DOBQ\3-%^#?PW\0^-?$,_D:3HMH]U-R SD
M#Y8USU9V*J!W+"OA[]BO_@HA\2OV@OC]8^"O'/ACP[X?T?6-'N-4TI]/M[B.
MYD"-\A+23NK*527H@R5!&!6-^WCXNU;]K#]I'P;^R[X,NW33+>X34?%E[!RL
M( W[6/3]U$=V#P9)(QU6J?Q\\-Z=\ /^"E'[-=WHULFF>'Y](MO#MO$G"JH:
M>U"^^%GBHP_OU(-[3;C%?]NR][_P*UO),*_NTY*.\%S/[U:/W7OZH_3.BJFK
MZM9:!I-[J>HW,5EI]G"]Q<7,S!4BC12S.Q/0  DGVK\\;+]J#]I+]M;Q3KB_
MLY0Z/X!^'NCW!ME\6>(X%>2]D SMP\4P&00VQ(B5!&YQN J;WERQ5WOZ+N_Z
MUZ%6M'F>BV^9]H_M'_%:3X'_  )\;^.H([>:\T33);FUBNP3%)<8VPJX4@E3
M(R @$'!X(KB/V*?CCXR_:%_9UTWX@^+],TJTU;4I[K[-::-#)!"T,4AC3B65
MSN+(_.X#!'%? /[<G[27Q<\,_ 36_@?\;-+L1XXOKNQN;+Q%H:XL=7TY'9Y'
MX "R++$BD;4R&^XN,M]>>,O$VH_L<_\ !->QN](G73?$>B>&;*VM9O*1_+OY
MS&I?8X*L1)*S88$''(-*ZC2JU6[K2*M\VVO._NZ[,+.52E22LW=N_P DD_+K
M?L>M?LP^)_C9XJ\-:U=_&[PCHG@S5TO_ "]-L-&E67?;;%/F2,MS.NXL2, K
M]T\<BO9Z^<?A[\8/%'A;]A&R^)_CK5?[7\41>$Y=?N+M[>&#S)'B::%/+C54
M'#1I@+SCGDUF_P#!.?XE?$/XQ?LVV?C3XD:^WB#5M6U&Z:TF-E;VOEVL;")5
MVPQHI^>.0Y(SSUZ5T2B_:5*>S@E?[[??HV8J5X0J=)MV^Z_W:V1]045\6?MY
M?M$?$'X>?%KX(?#CX::]_86K^+]5\O4)EL[>Y;[.98HE&)HW"C+R-D 'Y.M'
M_!3S]J#Q9^S;\/?!*^"/$'_".Z_K>L,DM[]C@NF%G%&?-Q',C*?FDBZ#/'49
MK!27(JG1RY?GHG\E?\&;<KY^3KR\WRU_'3\C[3HKX/U+Q=^V7^T5H</B7X8)
MX<^$/A*2,2Z8GB<)+K&J0[<K-(AMYHXMXP0FU,9ZL,-7:_\ !/#]J[Q7^T7X
M9\8Z#\0+2V@\<^"[]+'4+BTC$:7"MYBAF53M#AX95.W"G ( K11;<HO1K6W6
MUTOU5^JZF;DK*2U3Z_U_PSZ,^NZ*^(_C_P#MG?$#Q#\;IO@?^SIH%AXA\:V:
M,=;U_4_FL]*Q@,!R%W(67<S;@&.P([' \L^(GQF_;+_8MCTWQK\5=6\+_%'P
M%-=);:A#I,$<36FX\?.EM R,W(5B)$S@'DC.<9*24GHGLWL^GW7TOLRY1<6X
MK5K==5U_+H?HQXN\46'@GPKK/B+5':+3=)LYKZZ=0"1%$A=R,D<X4UY1^R3^
MT5<?M2?#>_\ ':Z ?#NB3:K/9Z3;S2^9/+;Q!5\V4CY0S/O&U<A=N-S=:^7_
M /@II\1/B9J7[.NF>.?A_P",=*TKX1:]H\4&IZ?-$K7^J?;2OEK'N@;8HB.3
MME0X+]<"NI_X)M?!;X[?"GP=H#>-/%^AR_"RXT+[9H_ABP@7[7;3W+I.&GD-
MLC9"O+D>:XRWH!6E*+;J\^G+IKT:NW?U2T]=;$5))1I\FM]?5:+3T;U]#WNY
M\5?'"3]IVVT.V\'Z)#\$4LO,N/$D\JM?R7'E,=D:+<[E7S"B_-">%;GD&O:J
M^'_V(?V@?B=^TEXT^/FHW_B;S_"&EW\FG^%H8[&U1;8L\Y1@ZQAI"J+#_K"P
M.[G-=!_P3-_:&\:_M!?!_P 3W/Q#U?\ MGQ5HNORV$DYM(;8B'RHV12D2(O#
M&09QGCK4T_>BEVBI:[VD]/FKKY6ZE3]V3_Q<OE=+];/SO?H?8%%?(O\ P4&_
M:<\4_!O0?"7@?X83@?%?QIJ,=KI82"*=K>$.H>39(K)\S%8QN&,%S_#6A^T9
M^U==_L?_  G\':/JSS?$WXP:W#'96-E# D+:A=859)VCA0!8][ *B+N8E5'\
M3"5*\7)=^5>;\O39^?S*Y7S*/E?T7GZ]#ZJHK\]O[#_X*'>(+#_A+4\3^!]
M+)]H7P3Y$!DX&?)W-;R8)][D8S]X5[I^Q%^UM/\ M/>$]>LO$>C)X;^(?A2[
M_L_7]*C!$:R98"1 Q)4%DD4J22K(>2,&M%%NZZK6WEL9N5K/H^I]*UYI^T1X
M@^)OAGX87M[\(?#&G^+?''GPI:Z=JDR16_EEQYKN6FASA,X <')'!Y%>ET5G
M)<RM>Q:=F?G#X]_:@_;O^&/@[5O%7B;X,?#[2] TF W-Y>-=))Y48ZG:FJ%F
MZCA02?2J'PI_:\_;B^-W@BR\7^"_@YX!UCP[>M(EO>F3[/YAC<H^$EU-&X96
M&2.W%>L?\%=/'H\(_L@ZAI:2%)_$FJVFFJ%/)56-P_X8@Q_P*O=?V0? 9^&?
M[,/PS\.O%Y-Q;:';2W$>.DTJ^;+_ ./R-54_?C4D_LM+[TV_T%4]QPCUDF_D
MFE^9C?LJ^*_V@?%ECXAF^._@WP[X,GADA32;;0I!(TRD.97D9;J<8!V #Y3]
M[KQCWFOEO_@H[^T'XA_9S_9REU[PCJJZ-XIO]4M=.L+PV\4_E[BTDAV2JRG]
MW$XY4XW>N*\WTSQ=^UC^TU8Z'KWPRUS0OAE\/ (HHM:\06D<FJZ]$ !)?+;M
M;2)&CX9HXR(\Y!S@C#C+VK=E:S2?W+7\?GK9:.R<?9I<SW3?XVM_7S=]_NRB
MOB;]H3]L_P =M\74^!O[/WAZ#QK\1;6('6=:U(#['IH &[< 43>-P+,2%4L$
M"NQVCSGQMXO_ &Y_V7=!F^(?C/7?!WQ0\):>1+JNCZ?!'');6^?F?<EM PP.
M-P,FW.2I -0I)KG;M'OT?GZ>>Q?*[\J7O=NOIVOY'Z/T5POP?^,.@_&CX2Z#
M\0M&D:'1=6L_M>+@@-;[<B5'/3*,KJ>WRFOBQ/VGOVC/VR/%GB*V_9O@T'P;
M\/=%NC9+XR\11AWO9EY.Q6CE !!#!1$Q (+,"P47)2C-T[:K?RZ:_/[^A$6I
M052^C/T-JGK&K6V@Z1?:G>R>59V4#W,TG]U$4LQ_(&OSLN/VF?VF?V./B1X-
MTG]H";P]X_\ !GBB]%FFO:'$D4MLY90=NR*')0,&*O%\PSM?(./0_P#@J=K7
MQ<\*?!.ZUWP1XMTKPYX'ALYK#Q+97$:O>ZB+IXX(XX=T#[0 [Y(DC.&/7 K*
MLW&GS0>]UZ/S^]?>:TDI5>27D_5>7W/[M3V3]D/]IQ_VL/!_B'QC9^'Y/#WA
MNWU9]-TI+J0/<W*1QHSS28^523(!L7.-I^9L\>\5^?\ _P $Q?@O\=OASX/\
M*ZAX@\7Z&/@_J6D/J>G^&;2!3?+/<E9(WF<VJMC:S,<3-U48QTXCPE^WA\8O
M%G[5GQ=\&>#K:3QZ+:XN-,\*>&39V\%E:M'.(WO;JZ5%D$,8C8X:3YS,JC&0
M5Z:D5&JJ,5K9OYQLG?S;^7>QSTVY4W5EM?\ !ZKY);]?4_3>BOS#^)W[2W[5
M?[%_Q$\(:Y\:=<\+^+O 7B*[:&?3]!M4"V:*5,BH_D12B15;<NXR*=I!.>:]
M&U_QY^V/^T=I<WB_X20^'OA1X&96GT:#Q D<FK:O;[<I*RR0S)'OZJK"/&1\
MS##'#F7+SK9;^7K^G?H:V][E>G;S]/U[=3[VHKY-_P""<O[57B7]J3X2ZS=>
M,K:UC\3>']1_LZYNK./RX[I3&&60H#A7^\"%^7@$ 9P.!^*7[9GQ4^,GQCUK
MX3_LQZ!I^HW&AL8=;\;:N UG9R9*D1Y^7"L"-S!RY5]L9"[C<TXS4%JVKZ=K
M7OZ:BC[T7)Z).SOWO:WK<^\**_-WQA\9/VQ/V+X;'QE\7K_PS\5OAX]S'!J;
M:+#'#/8J[!059;>W(8DX!977. 2NX&OO"?XI:)+\(9OB+8W2S^'O[$;78;@C
M :W$!F#$=OE[5,I*-.56]U'?RTO^0XIRJ*G;5[>?3\SLJ*_+G]E#]LC]IK]H
MGP#JN@>$+.R\4^-?[0DDO/%_B*V@LM)T*T9%$,*K!&IGF9A(W*L0"N589V]3
MX3_:._:1_9J_:@\"?#GX]ZWH'C;0O'$J6UGJ&CV\<?V>1Y/*4HR0PL<2,@99
M$/#94UHH-SC3ZRV\VU>W]:>=B)22C*:U4=_+6U_U[^1][?$_XA:7\)OAWXC\
M9ZT)FTK0K&6_N$MP#(Z1J6VH"0"QQ@ D<D<UQ/[*_P <+W]H[X.V'Q!N=$7P
M]::M=7/V"Q\TRR+;1RM$K2-@ LQ1FX  ! YQD_'7_!7_ %KXN^&? Z3Z9XMT
MK3?A)K*6^C7F@+&K:A>WA>68ON,!*QA8D'RS#.T@KSS[3^P'\%_CK\&_"L.E
M_$WQAH>J>#(-)MXO#^@Z1 @DL2QWOYS_ &6)RP! Y=\DL3V-11_><\GTT^>K
M?S>EO)ZV*K?N^1+KK\M%^#;OZ:7/KFBBOBW]J;]MSQ;X?^+5I\$_@1X:M_&G
MQ0F4/?37(+VNF*5#88;E&\*0S,[!$!7.XG ERU44KM]"DM')NR1]I45^;WCC
MQ!^WI^SGX:N?B%XD\1>#?B-X=TY/M&I:'96D>^V@'+N=EM Y"CJ4=\=2" 37
MU+X/^,^M_M3?LIMXR^$%Y9^'/%^L63PV3ZP0\6FWJOLD$F(I VPABN8R&&TD
M 'BG\$I+6VZ6_E]_?8G[48O2^SZ?U^)Y?^UQ^VIX[^&OQJ\-_!OX.>";#QI\
M0]6M1>N-4D;R(D.\JFU9(^=L;.6:155<=<\>R_LN^,OC+XR\(ZK/\:_!>E^"
M?$5M>^1;VNDS"6*>'8K>;D32@?,Q7AS]TU^6WP'\"_M._'3]JSXE>*O"OQ%\
M-1_$SPDW]D:IXFU&W3[+*,M;A;>,63I@BW;!\I#@$]2:_9GP?9:MIOA/1;37
M]075M=@LH8K^_1%1;FX" 22!550 S;C@* ,]!TJJ<;4E)N[E^3=U;Y)+SOMU
M%4?[UP2LE^:2O?YO3T^1KU\._$[_ (*$>*_$?Q4UGX:_L\_#&;XG^(-'D:#4
M-9N93'IUM*I*LO!4%=P9=[R1@LI"[AS7V_-'YT+H&*%E*[EZC(ZBOR>_9#^.
MFF?\$[_BA\0OA-\:M-OM#&JZH-0L_%,=LTT,\>"B2-M!=HF !5D#;69PP!!Q
ME'WJO))V5F_5Z:7Z66OGT-'[M-S2N[I>BUUMZV7E>YZOK'[7G[9/P=L9?$7Q
M,_9YT2^\+6RE[IO#5WF:%!RSLT=S=;5 !)+)@=R*^OOV=?VB/"7[3GPUM?&?
MA":;[(\C6]U972A;BSG4 M%( 2,X((()!# BNM\%^/O"_P 4/#R:OX6UW3?$
MVC3@J+K3;E+B(^JDJ3@^JGD=Q7F'P'_9E\ _L@:7XVO_  [J6I6^DZM,=5U#
M^UKF-K>S$8=B8PD:!$56(YSPJ\\5K?EYE45DEH_\_*UV96YN5T]7?^K>=['N
M-%?G=:_M1?M'?MG>)M>B_9QLM$\$?#W2;@VJ>,O$D0:2\E7G"J\<H&05;8(6
M*@C<P+!:M?##]JCX[_ ']HSPQ\(?VCAH_B&T\6.L6D>+-(B2)6F<A$ V1QJR
M>850J8T=2ZMDKC*A%S<8VLY;)]>J^_I>PYM14I;J.]NG_#>1[_\ MW?M+ZI^
MRK\!I_&.@VNFWNOS:A;Z?8V^JQR26[LY+/N5'1CB-'(PPYQ]*]?^%>M:WXD^
M&?A35_$L%K:^(-0TJVN]0M[)&2&*>2)7=$#,S!0Q(&6)XZU^>7_!8[QS8-KW
MP6\$:DTK:3-J4FKZG';IOE\E6CA7:HZL5>? [FO1?%U]^V_\5]-;Q+X!A\+?
M!_PY%$9=.\,ZL(Y]8N80H*"?S()8TD8#[F8MN=K<C-9TY+V4YO5<V_9123^]
MW\]"ZD?WD(K3W=?-MZ?<OEJC[QKQ7XK^*OCAIWQF\!:3\/\ P?HFI_#NZ=6\
M3Z_JDJ^=9IYF&6!!<QL6\L$Y\N099?0BN)_X)\?M3ZU^U3\&KW5O$]C;V?B;
M1-1;2[Y[-"D-P0BNLH4D[20V& .,J2, @#B_@I^T-\0_BQ_P4(^*O@N'7P_P
MM\'V;1#2TL[?'VM?)B.9O+\W/F?:#C?CY<8QQ6W*U7C#=V<O)I*^OWKS,W+]
MU*3TUY?--NWWZ,^U**^(_B/\+/VZ=7\?>(;WP?\ &'P+H?A6>_F?2M-N+6.2
M2WM2Y\I'9M,<E@N,Y9N<\FOE2]_:$_;,;]HZ#X*Z#\8=&\8>+ ZQ7MSH6BV,
MEE8L.9?-E>R0XB7!<A>"=O+?+6<'[1QBEJ^G]=NO0TFN12=]%U/V'HKP+]I3
M]IS2_P!COX(V&N>+;M_%'B=X8[&RM8U6"35KT1C>Y"C;$F078@84$  DJ#\T
M:(W_  4$^,6BQ>,].UWP=\-+&ZC$]MX7O;.-9WC(RN1);SLA8=GD0C/(6GUD
MEJEN^G]?B3]F+>C>RZ_U^!^BE%?('[$_[9'B;XQ^+?%?PK^*WA^'PO\ %?PL
M"]S#;+LANX5959PI9L,I9"=I*L'5EXX'"_MX?MF^,?@/^TG\)?!_A.^O#IMR
MBW^N:-IEA;W5SJB/<!(K:,RHS(S^5(H*%3^\SV%-_%3C_/L]UUU_ %=QF[?!
MNOZ]3[YHK\\OBIKG[>VC:'>?$VTG\':1HEE$;Z7X?Z?''>7<5NN699'>',CA
M>6\J<$X.T9P*^G?V./VF+/\ :L^".G>,X[---U2.9[#5;&-B4@ND"EMA/.QE
M9'&>0&P<D9IQBY*7>.ZZKS].@I-1:[/9GGWQ0_:R\7>'_P!N?X>_ SPQINBW
M6D:M8K?:U>7L$TEU N)W81,DJJI\N$'+*W+BOK&OR'T?XU:U??\ !3CXM>(_
M!WA*Z^('C"""?0/#NDQ,([>.6+R;=[B>9B!%"BQ2Y.1DR 9&[(]&^.7Q8_;9
M_98TR#XH^-?$7@?Q#X.^VQPW?AG2;9?+MA(<*I=H(Y@,_*&69R"1G(S6=.2]
MA3E+3FUN_-Z+Y*WWEU(M5IQ7V;*WHM7\W?[C],J*\>^*'QRC\/\ [*6N_%?3
M,VC?\(LVM6"SA24EDMP\"L#D$[W08Z&OCSX'_'W]JC]J;X+Z):?#+4]'L]5M
M(W.O?$;Q1:10137;2,RV=I!';LA\N,HKR&(@G(R,9:VI1G.FUK&U_G?\K?BD
MKMD1<90C4OI*]OP_S_-[)L_22BOC'XX?M:>+OV7_  /X"^'!"?%_]HCQ!:HH
MM[>!8[<RL2#,\<*1_N]V510J%EC+,5P37!7VB_\ !0W2=-D\8MXH\$7WE)]J
M;P/#;P-*1C)A#?9QDCIQ<Y/9C4MI<SO[J=K]--[=[=2DGHNK5[===K]C]"Z*
M\$_8Q_:GL_VL?A&/$G]G_P!C>(-/N6T[6=,!)6"Y50VY">=C*P(SR.5.=N3\
MO_%C]O#XA^#_ -O;7?AWX8M;[QAHMC81V&F^#=/M;9?[0U5X4?=+<LGF11IY
MC,S!L 1<@ DU4DXU%2W;UT]+_CHEYM$Q?-!SV2WOIUM^'7R3/T;HK\U/CQ\0
MOVYO@/X3N/BWXA\1>!!X6L987O?">E6RS+;I(ZH%=GA$A&YE4E+@GG(XYK[<
M\!_'*P\:?LYZ;\6'@_L^PN?#YUR>!VR(-L)>1,]PI5AGOBHE)1IRJO:._EI<
MI)RG&FE\6WGLOU1B?#CQ5\<-8^//C;3O%_@_1-!^$]DC+X>U6&59+^_?>@5G
MVW+[5*^8V&B0\J.H.?:J^/?^";GQN^(GQH^ _B+Q]\4O$:ZG&VK3QV,KVEO:
MQV]I#&A<_NHTR-Y?ELGY.M>96G[2W[2G[9OB+7F_9U@T'P+\.=)NFLX?%OB.
M(/+?2+C.U7CE !!#;1"=H(W/D[:MQ<'&E:[44WZ/6[Z7UM^1*:ES5+Z-M+U6
MEEUZ7_,_0^BOSFM_VG/VD_V1OBUX)\,?M!/H'COPIXNO%LK?Q#H4:1202%T0
MXV10@[-ZL5:(%@?E;((K]&:=O=4D[K;YH+^]RM:[_)_\,PHHHJ1A1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'E?[4
M8S\ _&/_ %[)_P"C4KT7P^=V@Z:?^G:/_P!!%>>?M/C=\!?&/_7JO_HU*] \
M-G=X=TH_].L7_H H TJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "O'/AC_R<1\:_^X)_Z2/7L=>.?#'_
M ).(^-?_ '!/_21Z /8Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MTDNS_P GT"BBBO,/>"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH \<^/?_(V_"4_]31%_P"BVKV.O'/C[_R-7PE/_4TP_P#H
MMZ]CH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** *6M?\@>__ .N$G_H)KS7]E?\ Y(#X/_ZX2_\ H^2O
M2M:_Y ]__P!<)/\ T$UYK^RO_P D!\'_ /7"7_T?)0!ZO1110 4444 %%%%
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M.P?-P"1]1C\A2P\G4<X/HM']Q>(I*%-58JVNJ_ \2_X*C?\ )V&I?]@JR_\
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MVC^/5?UY>9]-R?\ !8S2AK!C3X77C:5OP+IM:03[/7RO(*Y]O,_&OK[]GO\
M:>\#?M+>'Y]1\)7LJ7=H0+W2;Y!'=VI/W2R@D%3@X921VSD$#Y.TKQY^P7IO
MP^B\)R/HU["+;R)-4N/#5\=1D;',GVD6WF*Q//RL .@ '%?(O[)7CVW^$?[8
MWAU_#>J2W_AR\UIM$6Y*M']LLIY?*C=U8 CK')@@$%1P,5=*5ZRHMWOL_/\
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M/LC0%FPDS,<#HI/:KG4]G*$XJ_(XV797MT\MR:</:<T9O62=_-M?U;MT&?\
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M?,@@A6&+?M0P3*7+WCL,IQUR"!7Z=_!WX6Z-\$_ACX<\$:!%Y>EZ+:+;1L0
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M^ 9O@3\)UN$GU,ZP[F\N61@0"CK')+C[RKY:)N&6<D+CZ*_:Z\ WGPQ_8/\
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M]I;]JOX"> =,^%.H_LVZOXN\0:-;KIFF^)+5IGL#$BA83*T43QN%  +>='D
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MOE!?\!G%_P#!*#PO#\-OV+YO%=_^Z&M:A?:U-(_!$,0\D$^V(&;_ (%7+?\
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M=_\ KTATS/\ RT_\=_\ KT_=%[X[^TXO[K_D/\::=6A'\+_D/\:0Z7_TU_\
M'?\ Z],.CY_Y;?\ CO\ ]>G[HO?'_P!L0_W9/R'^-']M0?W9/R'^-1_V+_TV
M_P#'?_KTG]A_]-O_ !S_ .O1[@OWA)_;<']R3\A_C3?[>M_[DGY#_&H_[!_Z
M;_\ CG_UZ:?#_P#TW_\ '/\ Z]/W!7J]B7_A(+?^Y+^0_P :3_A(K;^Y+^0_
MQJ'_ (1W_IX_\<_^O2?\(W_T\?\ CG_UZ?N"O5[$W_"1VP_@E_(?XTG_  DM
MK_SSF_(?XU"?#.?^7G_R'_\ 7IO_  B__3S_ .0__KT?NQ7K=B;_ (2BU_YY
MS?\ ?(_QI/\ A*;0?\LYO^^1_C4!\*Y_Y>O_ "'_ /7I#X3S_P O7_D/_P"O
M3_=BO7[$_P#PE5I_SSF_[Y'^-)_PEMG_ ,\Y_P#OD?XU ?".?^7O_P A_P#U
MZ;_PA_\ T]_^0O\ Z].U(5Z_8L'Q?9C_ )93_P#?*_XTG_"8V7_/*?\ [Y7_
M !JLW@W/_+Y_Y"_^O2?\(5_T^?\ D+_[*BU+N3?$=BS_ ,)E9?\ /*X_[Y7_
M !IO_":V(_Y97'_?*_\ Q55_^$)_Z??_ "%_]E33X&S_ ,OO_D+_ .RIVI=Q
M7Q/;\BS_ ,)O8_\ /*X_[Y7_ .*II\=6 _Y8W'_?*_\ Q55O^$#_ .G[_P @
M_P#V5-/@'/\ R_\ _D'_ .RIVH]Q7Q/;\BU_PG=A_P \;G_OE?\ XJC_ (3S
M3_\ GC<_]\K_ /%54_X5_P#]/_\ Y!_^RI/^%>_]/_\ Y!_^RIVH]Q<V*[?D
M6CX_T\?\L;K_ +Y7_P"*I/\ A86G?\\;K_OA?_BJIGX=Y_YB'_D'_P"RI/\
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M_P#9TT_ [/\ S&O_ "4_^SHY<)W_ #%S9C_*OP_S-/\ X75HG_/KJ'_?M/\
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M ,DO_ME/EP7?\_\ (GGS7^5?A_F;'_#07AW_ )\M3_[]1_\ QRD_X:$\._\
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M^9O_ /*9_P#;J?)EG\S_ !_R%[3/_P"1?^2_YG2?\->^#O\ H&ZY_P!^(?\
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M?_#!G_4\_P#E(_\ M])_PP7_ -3S_P"4C_[?3Y,H_G?X_P"0O:\2_P#/M?\
MDO\ \D=7_P -R>!/^@3XB_\  :#_ ./TG_#<_@/_ *!/B+_P&M__ (_7)G]@
M?/\ S/7_ )2/_M]-_P"&!?\ J>O_ "D?_;Z/9Y/_ #O_ ,F_R%[;B;_GVO\
MR7_Y(ZW_ (;H\!_] CQ'_P" UO\ _'Z3_ANKP%_T"/$?_@-;_P#Q^N2_X8#_
M .I[_P#*/_\ ;Z;_ ,,!?]3W_P"4?_[?3]GD_P#._P#R;_(7MN)O^?:_\E_^
M2.N/[=G@(?\ ,(\1_P#@-;__ !^F_P##=_@'_H$>)/\ P&M__C]<D?V ,_\
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M=[)C&\@$-$YXRR[@<9VY))TK1M6C6BN9<L4UZ+_@O\ HU(N$Z4G:\FT_5_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO_H#U['7CG[0?_(<^%!_ZF^T_P#07KV.@ HHHH **** "BBB@ HHHH ****
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M_P#OIO\ XFC_ (0B^_YZV_\ WTW_ ,31[2'</8U/Y3GJ*Z'_ (0B^_YZV_\
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MZ'_A"+[_ )ZV_P#WTW_Q-'_"$7W_ #UM_P#OIO\ XFCVD.X>QJ?RG/45T/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#SG]HH9^!WC7_L&R?TKJ/ 1W>!?#A_ZAMM_Z*6N:_:&&?@AXU_[
M!DO\JZ/X>G=X!\-'_J&6W_HI: .@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\<^&/_ "<1\:_^X)_Z
M2/7L=>.?#'_DXCXU_P#<$_\ 21Z /8Z*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#QS]K[_DW?Q9
M_P!NG_I7#7L=>.?M??\ )N_BS_MT_P#2N&O8Z "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \<_
M:%_Y#/PH/_4X6?\ Z"]>QUXU^T5(L6I?"MW8(B^,;,EF. !MDY->L?VUI_\
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M^-']M:?_ ,_]K_W^7_&@"[15+^VM/_Y_[7_O\O\ C1_;6G_\_P#:_P#?Y?\
M&@"[15+^VM/_ .?^U_[_ "_XT?VUI_\ S_VO_?Y?\: +M%4O[:T__G_M?^_R
M_P"-']M:?_S_ -K_ -_E_P : *_BJX:T\+ZQ.@!>*SF<!NF0A/-<+^S+;K;?
M ?P:BDD&S+\^K2,Q_4UV'BR[@O/!FOM!-',HL9P3&P8#]VWI7)_LV_\ )"O!
MG_7@O_H34 >ET444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,FA
M2XADBD&Z.12K+G&01@UD?\(?I'_/I_Y%?_&MJB@#%_X0_2/^?3_R*_\ C1_P
MA^D?\^G_ )%?_&MJB@#%_P"$/TC_ )]/_(K_ .-'_"'Z1_SZ?^17_P :VJ*
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MA^D?\^G_ )%?_&MJB@#%_P"$/TC_ )]/_(K_ .-'_"'Z1_SZ?^17_P :VJ*
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MA^D?\^G_ )%?_&MJB@#%_P"$/TC_ )]/_(K_ .-'_"'Z1_SZ?^17_P :VJ*
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MA^D?\^G_ )%?_&MJB@#%_P"$/TC_ )]/_(K_ .-'_"'Z1_SZ?^17_P :VJ*
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MA^D?\^G_ )%?_&MJB@#%_P"$/TC_ )]/_(K_ .-'_"'Z1_SZ?^17_P :VJ*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH \<_:^_Y-W\6?]NG_I7#7L=>
M.?M??\F[^+/^W3_TKAKV.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /&OVC$634/A6KJ'1O&5
MBI5AD$%9.#7K']BZ?_SX6O\ WY7_  KRG]HK_C_^%1_ZG6P_E)7L= %+^Q=/
M_P"?"U_[\K_A1_8NG_\ /A:_]^5_PJ[10!2_L73_ /GPM?\ ORO^%']BZ?\
M\^%K_P!^5_PJ[10!2_L73_\ GPM?^_*_X4?V+I__ #X6O_?E?\*NT4 4O[%T
M_P#Y\+7_ +\K_A1_8NG_ //A:_\ ?E?\*NT4 4O[%T__ )\+7_ORO^%']BZ?
M_P ^%K_WY7_"KM% %+^Q=/\ ^?"U_P"_*_X4?V+I_P#SX6O_ 'Y7_"KM% %+
M^Q=/_P"?"U_[\K_A1_8NG_\ /A:_]^5_PJ[10!2_L73_ /GPM?\ ORO^%']B
MZ?\ \^%K_P!^5_PJ[10!2_L73_\ GPM?^_*_X4?V+I__ #X6O_?E?\*NT4 4
MO[%T_P#Y\+7_ +\K_A1_8NG_ //A:_\ ?E?\*NT4 4O[%T__ )\+7_ORO^%'
M]BZ?_P ^%K_WY7_"KM% %+^Q=/\ ^?"U_P"_*_X4?V+I_P#SX6O_ 'Y7_"KM
M% %+^Q=/_P"?"U_[\K_A1_8NG_\ /A:_]^5_PJ[10!2_L73_ /GPM?\ ORO^
M%']BZ?\ \^%K_P!^5_PJ[10!2_L73_\ GPM?^_*_X4?V+I__ #X6O_?E?\*N
MT4 4O[%T_P#Y\+7_ +\K_A1_8NG_ //A:_\ ?E?\*NT4 4O[%T__ )\+7_OR
MO^%']BZ?_P ^%K_WY7_"KM% %+^Q=/\ ^?"U_P"_*_X4?V+I_P#SX6O_ 'Y7
M_"KM% %+^Q=/_P"?"U_[\K_A1_8NG_\ /A:_]^5_PJ[10!2_L73_ /GPM?\
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MVO8_\_MO_P!_5_QHL^P<T>Y;HJI_:]C_ ,_MO_W]7_&C^U['_G]M_P#OZO\
MC19]@YH]RW153^U['_G]M_\ OZO^-']KV/\ S^V__?U?\:+/L'-'N6Z*J?VO
M8_\ /[;_ /?U?\:/[7L?^?VW_P"_J_XT6?8.:/<MT4R.:.;F-U<?[)!I](H*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** .#^/(S\%O&__ &"+G_T6:U?A<=WPS\(G_J$6?_HE*S/CH,_!CQQ_
MV!KK_P!%-6A\*3N^%W@X_P#4&L__ $0E '54444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>.?#'_DXCXU
M_P#<$_\ 21Z]CKQSX8_\G$?&O_N"?^DCT >QT444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'CG[7W
M_)N_BS_MT_\ 2N&O8Z\<_:^_Y-W\6?\ ;I_Z5PU['0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M 'CG[1G_ !^?"L_]3MI_\I*]CKQS]HW_ (^/A6?^IWTW^4E>QT %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?&O_ +@G_I(]>QUXY\,?^3B/C7_W!/\ TD>@#V.BBB@ HHHH **** "BBB@
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M'7CG[7W_ ";OXL_[=/\ TKAKV.@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /'/VCO];\+#_U/
M.F?^U:]CKQS]I#[WPM/_ %/6E_\ M6O8Z "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;DMM'BY^]YLH,@_[]))7)B)-4I<KU>B]7HOQ.J@E*I&^V[]%J_P/FC_@G?\
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MP^,6ER>-;OX]3> /$[1F>Q\">'_/@TZU'WDMY;F.5?,;H&=HY!G."5Q7>?\
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M;XB>*^?^*GUG_P &$O\ \55?V5/^9$_ZQ4O^?;_ ^YZ*^%&^(WBS_H9]9_\
M!A+_ /%5')\1_%O_ $-&M?\ @PF_^*I_V3/^=$_ZR4O^?;^]'W?7CGPQ_P"3
MB/C7_P!P3_TD>OFYOB1XN_Z&G6O_  83?_%5RVB>./$=KXT\47<.OZI#=W7V
M7[1/'>R*\VV,A=[!LM@<#/2HEE<XN*YEJ[?@W^AK#B"E.,Y>S?NJ_P"*7ZGZ
M.T5\!-\3/%^?^1JUO_P8S?\ Q51-\3/&'_0UZY_X,9O_ (JMO['J?SHYO]9J
M/_/M_>C] J*_/=OB=XQY_P"*LUS_ ,&4W_Q5,;XH>,O^AMUW_P &4W_Q5/\
ML:I_.A?ZT4?^?;^]'Z%T5^=\GQ1\9_\ 0W:[_P"#*;_XJHF^*7C3_H;M>_\
M!G-_\53_ +%J?SHG_6FC_P ^G]Z/T5HK\YF^*GC7/_(WZ]_X,Y__ (JHF^*O
MC7_H<-?_ /!G/_\ %4_[$J?SHG_6NC_SZ?WH_1ZBOS<;XK>-L?\ (XZ__P"#
M2?\ ^*J)OBQXW_Z'+Q!_X-)__BZ?]AU/YT3_ *V4/^?3^]'Z445^:;?%GQQ_
MT.7B#_P:3_\ Q=1/\6_'/_0Y^(?_  :S_P#Q=/\ L.I_.B?];J'_ #Z?WH_3
M&BOS);XN>.O^AT\0_P#@UG_^+J-OB]X[_P"AU\1?^#6?_P"+JO[!J?SHG_6^
MA_SZ?WH_3JBOR_;XO^//^AV\1?\ @VG_ /BZC;XP>/>?^*V\1_\ @VN/_BZ?
M]@U?YT3_ *X4/^?3^]'ZB45^6S?&+Q[C_D=_$?\ X-KC_P"+J(_&3Q]S_P 5
MQXD_\&UQ_P#%T_[ J_\ /Q$_ZY4/^?+^]'ZG45^5S?&3Q_\ ]#SXD_\ !O<?
M_%U"_P 9OB!_T//B7_P;W'_Q=/\ U?J_\_$+_7/#_P#/E_>C]5ZY[XA^+(_
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M:^)O_)-_%G_8)N__ $2]8WP#_P"2*^"/^P3;_P#H K9^)O\ R3?Q9_V";O\
M]$O6-\ _^2*^"/\ L$V__H H [ZBBB@ HHHH **** "N!\7Q^7KDK?WU5OTQ
M_2N^KEO'%B7A@NE&=GR,?8]/US^=;47:1RXF/-3]#D****[SQ@HHHH ****
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MO):ZBHQ[7BEKVMJ_P,6Q_9-_:P\3Z>C^*_VJWT6[8$RPZ!H:.BY'.'4VY_\
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MV_9%T_X%V5]-IUGI$$3:9JSH))([N,LWGNO ;>SR;E&.)&QCBOGCP/9_M^?
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M?9_&L$*0GCT\R6(_@*_0+POX=L?!_AO2M"TN!;;3=,M8K.VA08"1QH$4 >P
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MS@H+H%%%%9F@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#FOB;_R
M3?Q9_P!@F[_]$O6-\ _^2*^"/^P3;_\ H K9^)O_ "3?Q9_V";O_ -$O6-\
M_P#DBO@C_L$V_P#Z * .^HHHH **** "BBB@ J.>%+B%XI%W(XP14E% 'FNL
M:5)I-XT39*'E'Q]X?XU1KU"]L8-0@,4\8=#T]1[@]JXW4_"%U9Y>W_TJ+T48
M<?AW_"NZ%52T>YY-;#RB[QU1@T4K(T;%64JP[$8-)6YQ!1110 4444 %%%%
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M#'<02*4>*50RNIZ@@\$5+11N!Q>@?!/X=^%=675=$\!>&-'U-3D7NGZ-;P3
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M_)Q'QK_[@G_I(] 'L=%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ9_VZ?\ I7#7L=>.?M??\F[^+/\ MT_]*X:]CH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#QS
M]I;_ (\/AV?3QKI?\Y*]CKQS]I?_ )!OP^/IXSTS_P!">O8Z "BBB@ HHHH
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MCV*G]D6/_/E;_P#?I?\ "C^R+'_GRM_^_2_X5;HHYGW#ECV*G]D6/_/E;_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% '-_$H;OASXJ'_4*NO_1+UB? $Y^"?@G_
M +!5O_Z *W?B*-WP^\3C_J%W7_HIJY_]GPY^"/@G_L%P_P#H- 'H5%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7CGPQ_Y.(^-?\ W!/_ $D>O8Z\<^&/_)Q'QK_[@G_I(] 'L=%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!XY^U]_R;OXL_[=/_ $KAKV.O'/VOO^3=_%G_ &Z?^E<->QT
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M+_U"M3_\!_\ Z]'_  DO_4*U/_P'_P#KT ;5%8O_  DO_4*U/_P'_P#KT?\
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MB_\ "2_]0K4__ ?_ .O1_P )+_U"M3_\!_\ Z] &U16+_P )+_U"M3_\!_\
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MT?\ "2_]0K4__ ?_ .O0!M45B_\ "2_]0K4__ ?_ .O1_P )+_U"M3_\!_\
MZ] &U16+_P )+_U"M3_\!_\ Z]'_  DO_4*U/_P'_P#KT ;5%8O_  DO_4*U
M/_P'_P#KT?\ "2_]0K4__ ?_ .O0!M45B_\ "2_]0K4__ ?_ .O1_P )+_U"
MM3_\!_\ Z] &U16+_P )+_U"M3_\!_\ Z]'_  DO_4*U/_P'_P#KT ;5%8O_
M  DO_4*U/_P'_P#KT?\ "2_]0K4__ ?_ .O0!M45B_\ "2_]0K4__ ?_ .O1
M_P )+_U"M3_\!_\ Z] &U16+_P )+_U"M3_\!_\ Z]'_  DO_4*U/_P'_P#K
MT ;5%8O_  DO_4*U/_P'_P#KT?\ "2_]0K4__ ?_ .O0!M45B_\ "2_]0K4_
M_ ?_ .O1_P )+_U"M3_\!_\ Z] &U16+_P )+_U"M3_\!_\ Z]'_  DO_4*U
M/_P'_P#KT ;5%8O_  DO_4*U/_P'_P#KT?\ "2_]0K4__ ?_ .O0!M45B_\
M"2_]0K4__ ?_ .O1_P )+_U"M3_\!_\ Z] &U16+_P )+_U"M3_\!_\ Z]'_
M  DO_4*U/_P'_P#KT ;5%8O_  DO_4*U/_P'_P#KT?\ "2_]0K4__ ?_ .O0
M!M45B_\ "2_]0K4__ ?_ .O1_P )+_U"M3_\!_\ Z] &U16+_P )+_U"M3_\
M!_\ Z]'_  DO_4*U/_P'_P#KT ;5%8O_  DO_4*U/_P'_P#KT?\ "2_]0K4_
M_ ?_ .O0!M45B_\ "2_]0K4__ ?_ .O1_P )+_U"M3_\!_\ Z] &U16+_P )
M+_U"M3_\!_\ Z]'_  DO_4*U/_P'_P#KT ;5%8O_  DO_4*U/_P'_P#KT?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M\<_::_Y ?@<_]3?IG_H3U['7CG[3G_(O^"CZ>+M-_P#0VKV.@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH XWXS?\D?\=?\ 8!OO_2=Z/@S_ ,D?\"_]@&Q_])TH^,W_ "1_QU_V ;[_
M -)WH^#/_)'_  +_ -@&Q_\ 2=* .RHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** ,7QL-W@S7Q_U#[C_ -%M7(?LWG/P+\%_]@]?
MYFNQ\9#=X1UP?].,_P#Z+:N,_9K.?@3X,_Z\1_Z$U 'I=%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7C
MGPQ_Y.(^-?\ W!/_ $D>O8Z\<^&/_)Q'QK_[@G_I(] 'L=%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!XY^U]_R;OXL_[=/_ $KAKV.O'/VOO^3=_%G_ &Z?^E<->QT %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!XY^TY_P BYX-/IXLTT_\ C[5['7CG[3W_ "+/A ^GBO3?_0VK
MV.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH XWXS?\ )'_'7_8!OO\ TG>CX,_\D?\  O\ V ;'_P!)
MTH^,W_)'_'7_ & ;[_TG>CX,_P#)'_ O_8!L?_2=* .RHHHH **** "BBB@
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M .*KGJ*/9P[![:I_,=#_ ,)O??\ /*W_ .^6_P#BJ/\ A-[[_GE;_P#?+?\
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M-[[_ )Y6_P#WRW_Q5<]11[.'8/;5/YCH?^$WOO\ GE;_ /?+?_%4?\)O??\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5XY\,?^3B/C7_W!/\ TD>O8Z\<^&/_ "<1\:_^X)_Z2/0!['1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 >.?M??\ )N_BS_MT_P#2N&O8Z\<_:^_Y-W\6?]NG_I7#7L=
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MW[3WQW_X9O\ A'?>-_[#_P"$B^RW$$'V'[7]EW>8X7/F;'QC.<;>:Y#]CO\
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M_@208F$:=*E**UEO]TO\CZWHHHK8Y!DLJ01O)(ZQQH"S.QP% ZDGL*^(+?\
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M/V<1%"W'WL'=BB,7'V%%Z.SF^NOQ:=VTU;T";3=:KNKJ"]-M>R33N>U^+?\
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M]9^*'Q[L/"<-YI_@":]AU32-+O  ]HDDLZHI"LRJWEA%."?]6.3BOI7X]?\
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M27CC7OA+I%CX%^&'B^Q0K?/=12V5];KCDQI/-,SC&#NCB; 96!&0:_515"J
M!@#@"OSF_P""K'P]U/X;ZQ\/_P!H[P2K6/B?PSJ$5GJ%S$.'B))@:3!&5W;X
MF_O+,%/ JZDXNHG5^&3L_GL_/7==3.G"2I\L/B2T[:=/+39GK7P1_9]T3_@G
M?^SW\0O&FI:F_BSQ<UC-J^M:M*"OVF2-&:."/)+;=['YF)9F<L<<*/S]_9'_
M &Q/@W\,_%GB?XD_&3PYXF\=_%C6M1>YCU2#3[6YM[*(@8\GSKA"LA.1D+\J
M*JJ0,Y_3KXIW'_#6W[#NOW?@]?/N/%WA=KFQMPPR9]@?R"?[WF*8SZ&O!O\
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MOQ*U*6;3/$&I_N[)[J&:26:!YCPAVW:'+$+QC.<"O=/V]/VS/#WCKP"?@O\
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M<JL>;"PI4M;Q5K=9-:OUYM^IO"T<7.<W:TG\HIZ?+EZ?\,:7_!'7Q9J7B/\
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M #Y;K\9_@9U9*<,147PRER_*Z3?W1?WGZ;4R6188WD=@J*"S,>@ ZFGUY/\
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MQ#F7QY?:9=^*/$%U,<RM=>2TD<!;OLR%//+LY[UG"?+0IXB6OLX??.-XI?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MAS^RQ<>27X'?FWA;BOJW]H</UUBJ+U5OBM^3_!^1]]T5S_@WQYH/Q TF+4M
MU.#4;60 AH6SCZBN@KZ6,E)<T7='XC6HU,/4=*M%QDMTU9KY!1115&(4444
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MO@'\+OCIX\77]1^"%MXHTW0_/\N>33]=6Q4]2L3S%X5F=589P.^=HR*^E/\
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MI$+'Y&'&>G.*SC.=3"VCT=M.SOK^&_FM=$:SIPCB8SF]U>S[JVGXZKR\R/\
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MC[1[".&#\"*_1Z>%+F&2&0$QR*48 D'!&#R.E>?_  5_9]\ ?L[Z#?Z+\/M
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M "!+_P#$T>RJ?RO[@^LT?YU]Z.JHKE/^%I>&/^@G_P"2\O\ \32?\+4\+?\
M04_\EY?_ (FCV-3^5_<+ZS0_G7WHZRBN1_X6QX5'_,4_\EY?_B*3_A;7A3_H
M*_\ DO+_ /$4_8U?Y7]P?6J'_/Q?>CKZ*X[_ (6YX2_Z"W_DM-_\12?\+@\(
M_P#06_\ ):;_ .(H]C5_E?W"^M8?_GXOO1V5%<9_PN'PA_T%_P#R6F_^(IO_
M  N3P>/^8Q_Y+3?_ !%'L*O\C^YA];P__/R/WH[6BN)_X7-X._Z#'_DK-_\
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M,/\ Y)7'_P ;I_5:_P#S[?W,C^T,'_S^C_X$O\STJBO,_P#AI#X<_P#0Q?\
MDC<__&Z3_AI/X<?]#%_Y(W/_ ,;I_5<1_P ^W]S#^T,'_P _H_\ @2_S/3:*
M\Q/[2WPW'7Q'_P"2-S_\;I/^&F/AM_T,G_DC<_\ QNCZKB/^?;^YB_M#!_\
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M\8K\([O6_B#>2?8XQYUO<70PXB ))-.AF2K5O8RIN.E];;>?8SS7@EY;EO\
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M]M30/BL+?1]?:/1?$1 50YQ'.?\ 9/K7S;^VI^R_#\+]0/BSP^NW0KV7;);
M?ZF0YX'^SQ7RC%-)!(LD3M'(IRK*<$?C7RM/%8O)J[I2U2Z='Z'[[C,CX?\
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MS_P4$\??&7XA^-]4\0:;ISZ\TMBVBW$,3N\[RRNKF6*0$*AB QC[U?1FM?\
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M@P>7'XB_X3^%[H28XD,9N/()SU'E@>F*[_\ X)._&+7_ !_\(?%7A'Q!J_\
MPD+^"=5&G6.K>9YOG6C*?+4/DEU4H^T_W64=!6L4I<T>J5_)JZ7X-K?OY&4I
M./*^C=O-.S?Z/^F?<M>&?MQ>/Q\,_P!DWXG:V)3#.='EL8'7J);C$"$?1I0?
MPKW.OS\_X+->.9-*^ /A7P?:L3>>)==0F%>LD,"%B,=_WCP_I7+7BYP]FOM-
M+[W;]3KH/EJ*3^S=_<K_ *'CG['G_!*WX>?'3]GGPMX[\9ZYXMT[6=:6:<6V
MDW=K% L(F=(B!);NV2JAOO?Q5UWQA_X)W^)/V3/!.H_$?]GKXG>+K+4] B:_
MO='U"XCD%Y!'\SX\M$1]J@MY<D;!L'H< _H/\&_ \?PS^$O@WPG$H5=%TBUL
M#MZ%HXE5C^)!/XUJ>.Y[:U\#^(9KW:+./3KAYMW38(F+9_#-=&,G[+VDZ+MR
MWM\MCFPD?:\BJ*_-:_S/)/V*?VDE_:F^ ND>,;B"&TUR*1]/U>VM\^7'=1XW
M% 22%961P"3@/C)QFLF^^"WPB^)'[8%A\1U\=?VM\3O"-C]E_P"$7L]8M)([
M.,+(F^:U5#,A!N"<E@,E?I7S=_P10\^T^!/Q#N[A]FG#7P4+= RVT9D/Y%/R
MJQ_P2KA;XD?$W]H+XPS9D&O:\;6TD8<B,R23NOTVR0#_ (#71-+ZSHK6CS>C
M:25O5R?R]#&#?U=WUO+E]5=W^Y(^]_&7Q"\+?#K3TO\ Q7XET?PQ8NVQ;K6;
M^*TB9O0-(P!-1>"_B9X0^)-K-<^$?%>B>*;>$[99M%U&&\1#Z,8V8 _6OR4O
MKKX8^.OV]/BG9?M;W6I6R0WC67ANWN[B>WTV*V$K>2'DA*O&AB,;JP*H2TC.
M<D&OHGQ!_P $Z++PWX]\!?%+]E/Q'IGA=K6=9KN&\UJYN=.OK7(/[J55F9PX
MRK*S%""",$<\]+WXPG+:5MNE^_Z]C>K[DIPCO'\?3]#]!ZX+5?C]\,-!\0'0
MM2^(_A'3M<5Q&=,NM=M8KD.>B^4T@;/MBOD/]OSXR>-O'WQ:\&_LQ_"_47T?
M7/%*+<:]JT#$/;6C;CY88$%5V1R2/C!90B@X8@]/H7_!(W]GS3O!*Z/J&CZK
MJ^M&$I)XBDU6>*Y\PCF1(D80C!Z QL.F=W4S%N474M[MVEW=M[>CTUW^14K1
M:A?6U_)7VOZ[Z;'VA'(LL:NC!T895E.01ZBL2^\>>&=+\5Z?X7O/$6DVGB74
M8VFLM&GOHDO+F-0Q9XX2V]U 5LE00-I]*^$/^";OB+Q-\*/C=\7/V<-<UB;7
MM(\(N;S1;B8Y,,/F*K*/[JNLL+[!PK;\=37 ?%ZP\8_M#?\ !4G6/"O@W6)?
M#R:)X>CTC4/$%L,SZ;9-&LER]N<_+,QN#"K<X,A/;(OXI4_9ZJ:<ETTL]7Z/
M1_>1\*J<^C@[/UNMN^CNON/T?L?BWX&U3QC)X2L_&?AZ[\5Q;O,T*#58'ODV
MC+9@#[Q@<GCBI?&WQ1\&?#6.WD\7>+M"\*QW!(A;6]2ALQ*1U"F1ES^%?+7C
MCX3?!C_@F[\(?%?Q7\&>$_+\5P:<-,M[R^U"XN9;V>5U"*PDD*J"X5W\M5^5
M&^E>5_LJ_P#!/_1OV@O!\?QA_:)EU+QUXM\8H-0@LKB_FMH[6V?F(GR61LE<
M$("$12JA>*2]ZZC]G=]+N]DOEKJ-^ZKRZ[+K9;M_/0]?_P""GOQ0L]!_8D\1
MW&EZA!<Q^)I+33+.ZM95DCF2202.48$A@8HY.1V->@_L#^ Q\.?V0?ACI9C,
M<\^E+J4RL,'?<LUP<^X\T#\*_,_]NOX ZE\%?B3X+^!?A#5[R;X:>+-5M]8T
M?1KV4SOIM[)(UK)&CGYC&=X89R?FYR02WV/_ ,%&/VD-3^ O@;P3\)O .KVW
MAKQ-XJV6"ZS<7"VZ:3IZ;83*920(MQ('F?P*DA&" 0J<DJ4YPU=2:2[^ZK-/
MT;?XLJ<6ZD(2T4(MOMKL_G%6MWTZGUEXK^.7PW\!ZLNE>)OB#X6\.ZHP!%EJ
MVM6UK,0>GR2.&_2NQL[VWU*TANK2>.ZMIE#QS0N'1U/(*L."#ZBOS:^'W[(W
M[#VA^%8[?QE\5/"/COQ/,OF7NN7GCR.W9YF&7:..&Y50N[)&_>?4FH_^"?OC
M"V^$O[7GQ#^!/@_QG'X[^%7V%M8T.]AOH[R.WD A=E26,[#Q,R/MX+1@X!S6
MD8WE[-O6S=^FFMC.3?+SK;3UU=K_ 'GZ):YX\\,^&-:TC1]8\1:3I.K:Q(8M
M-L+Z^BAGOG&,K#&S!I"-R\*#U'K5"?XN>!K7QG%X0F\9^'H?%DQVQZ#)JL"W
M[G:6P("^\_*">!T&:_/+]LRZ\9_%C_@I!\,O G@"^CT[6=%T1R-3DC\P:6;A
M9C/=!<_?2'RV3/\ &$]:^N/@E^PK\(?@/XFL_%FA:'=7_C>&*1)?$VKZC<7-
MU</(,2RLK/Y0=\G+*@/S'U-12]^"J2T3<OP;2_+5_=>S*J>[-PCJ[)_>K_TO
M\T?0-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI/\ R%-!_P# B?\ ^,U&?V,?&O\ T%- _P# B?\ ^,U]FT4_[7Q7=?<+_5O
M=G]Y\7M^Q?XV(_Y"F@?^!$__ ,9IC?L5^-S_ ,Q7P_\ ^!$__P 9K[3HH_M?
M%=U]PO\ 5G+^S^\^*3^Q1XX_Z"OA_P#\")__ (S4;?L2>.6_YBOA[_P(G_\
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M\LI?#%><4M?4_)'X?_"WQ-\3=6CL/#^F37LI(#.J_*GN37ZG?LP?"GQ/\)/
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MF/U%5O\ A"+[_GK;_P#?3?\ Q-=O16OMIG,\-3['$?\ "$7W_/6W_P"^F_\
MB:/^$(OO^>MO_P!]-_\ $UV]%/VTQ?5:9Q'_  A%]_SUM_\ OIO_ (FC_A"+
M[_GK;_\ ?3?_ !-=O11[:8?5:9Q'_"$7W_/6W_[Z;_XFC_A"+[_GK;_]]-_\
M37;T4>VF'U6F<1_PA%]_SUM_^^F_^)H_X0B^_P">MO\ ]]-_\37;T4>VF'U6
MF<1_PA%]_P ];?\ [Z;_ .)H_P"$(OO^>MO_ -]-_P#$UV]%'MIA]5IG$?\
M"$7W_/6W_P"^F_\ B:/^$(OO^>MO_P!]-_\ $UV]%'MIA]5IG$?\(1??\];?
M_OIO_B:/^$(OO^>MO_WTW_Q-=O11[:8?5:9Q'_"$7W_/6W_[Z;_XFC_A"+[_
M )ZV_P#WTW_Q-=O11[:8?5:9Q'_"$7W_ #UM_P#OIO\ XFC_ (0B^_YZV_\
MWTW_ ,37;T4>VF'U6F<1_P (1??\];?_ +Z;_P")H_X0B^_YZV__ 'TW_P 3
M7;T4>VF'U6F<1_PA%]_SUM_^^F_^)H_X0B^_YZV__?3?_$UV]%'MIA]5IG$?
M\(1??\];?_OIO_B:/^$(OO\ GK;_ /?3?_$UV]%'MIA]5IG$?\(1??\ /6W_
M .^F_P#B:/\ A"+[_GK;_P#?3?\ Q-=O11[:8?5:9Q'_  A%]_SUM_\ OIO_
M (FC_A"+[_GK;_\ ?3?_ !-=O11[:8?5:9Q'_"$7W_/6W_[Z;_XFC_A"+[_G
MK;_]]-_\37;T4>VF'U6F<1_PA%]_SUM_^^F_^)H_X0B^_P">MO\ ]]-_\37;
MT4>VF'U6F<1_PA%]_P ];?\ [Z;_ .)H_P"$(OO^>MO_ -]-_P#$UV]%'MIA
M]5IG$?\ "$7W_/6W_P"^F_\ B:/^$(OO^>MO_P!]-_\ $UV]%'MIA]5IG$?\
M(1??\];?_OIO_B:/^$(OO^>MO_WTW_Q-=O11[:8?5:9Q'_"$7W_/6W_[Z;_X
MFC_A"+[_ )ZV_P#WTW_Q-=O11[:8?5:9Q'_"$7W_ #UM_P#OIO\ XFC_ (0B
M^_YZV_\ WTW_ ,37;T4>VF'U6F<1_P (1??\];?_ +Z;_P")H_X0B^_YZV__
M 'TW_P 37;T4>VF'U6F<1_PA%]_SUM_^^F_^)H_X0B^_YZV__?3?_$UV]%'M
MIA]5IG$?\(1??\];?_OIO_B:!X'ON\UOC_>;_"NWHH]M,/JM,Y&W\"MD&>Z
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M>?M+?LU?L4?LKZ'I=]XM^&M]J%]JER+:PT31=:U">_N2>KI$]Z@V+P"Q/5E
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MOX-_ 7X9_&C_ (*%?M!^#_C'HAUC4Y-0N-0T2UGU"YM2R><7.TPR(6/DR0L
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[0O^O"#_ -%K7&_M)?\ )"O&?_7@W_H2UV7@O_D3M"_Z\(/_ $6M &S1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !7SG\?/V0?^%]?'OX6_$*_\6?8=+\"SK=)X?\ [-\W[7*)EE+&;SEV
M9,<8QL;[OOQ]&44+W9QJ+>+NO4'K&4'LU9^@4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %>.?LA_\F^^&1Z/>#_R;FKV.O'/V1O^2">'QZ37@_\ )J6@
M#V.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#QS]JK_DFED?36[ _^1A7L=>.?M5?
M\DQM3Z:S8?\ H]:]CH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M *AG_D2@#:HK%_XJ'_J&?^1*/^*A_P"H9_Y$H VJ*Q?^*A_ZAG_D2C_BH?\
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MY(CI@]+R]'_DS)0!['1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5XY\,?^3B/C7_ -P3_P!)'KV.O'/A
MC_R<1\:_^X)_Z2/0!['1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 >.?M??\F[^+/^W3_P!*X:]C
MKQS]K[_DW?Q9_P!NG_I7#7L= !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >.?M6?\ )+8#_P!1
MBP_]'K7L=>.?M6_\DJ0_]1:P_P#1ZU['0 4444 %%%% !1110 4444 %%%%
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M /?+?_%4>QF'UJF=O17$?\)O??\ /*W_ .^6_P#BJ/\ A-[[_GE;_P#?+?\
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M'D@#-7_A?\2M$^,'@;3/%_AN2>?0M2$CV=Q<0M"TT:R,@D"-\P5MI(R <$9
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O'/AC_R<1\:_P#N"?\
MI(]>QUXY\,?^3B/C7_W!/_21Z /8Z*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#QS]K[_DW?Q9_V
MZ?\ I7#7L=>.?M??\F[^+/\ MT_]*X:]CH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MRJ-O" MM>->.1G!KU#]I;]JKP%^RKX1AUOQK>S&:[8QV&DV"+)>7K#&[RT+
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[JI8C>\*J.%/4CI7-_\ !.C_ ),U\"_2_P#_ $MGK\S/V'?^3S/ /_83N/\
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MV-J3*/\ EHNYX'/U7S%S_L**^FO^"=OQ=_X6K^S-H45S-YFJ^'&.BW63R5C
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MN_9')2C1YGJ^5+YMFA_P]L^#?VKR?[$\9>7G'G_V?;;/KC[3NQ^%?2GP9_:
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M>BHJEB?R%8UU\-O"-]XTM?%]SX6T6X\6VD?DV^O2Z="U_#'AAL2<KYBKAW&
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M+S0OA!X)Q'X9MM13:]_.C%E<#E21)^\=E) *1IEB"1D_MA:]8? ?_@I)\/\
MXJ?$K1+G4_AS)I<=O9WJP^?':SHDJE@G=HI'67:.<-N7)&*_3NWMXK.WC@@B
M2""-0B1QJ%55'   Z"L_Q+X5T7QIH\^D^(-'L-=TJ?\ UMCJ5JEQ!)CIN1P5
M/XBG\'L_9;0;>O5M--OS=_EH+X^?VGVDEIT2M9+R5NN^MSXM^+G_  5,^'=[
MX7NM&^"PU?XE_$#48)(M-L]/T>ZC2WDVG][+YL:,RH,MA%;.WDJ,L.8_X(OZ
M=%;_ +/_ ([\27,HDO-0\2R+<S,P+%8K:)@6/UE<\^N>]?<7@[X3^!_AW#<0
M^%/!OA_PS%<#;-'H^EP6BRCT81H,_C4WA'X9>#_A_H]WI/A?PGH?AO2KQVDN
M;'2--AM8)F*A2SI&H5B5 !)'0 4XVA[1K>4;+RUO]P2][D3V3O\ @U]^I\%_
M\$JX7^(_Q2_:$^+\X\Q==UW[+:2MU"-)+.ZCVVO!^0KH/V&0OQ._;2_:=^)S
M)OA@U&/P[93=08XW9&P?]VUA/XU]L^"_A[X5^&VERZ9X1\,Z/X6TV64SR6>B
MV$5G"\A 4N4C506(51G&<*/2E\(_#_PM\/X;R'POX:TCPW#>SFYNH](L(K59
MYB,&1Q&HW,0!\QYIQM3E%QVC#E7SM=_.S^\4[U%.^\I\S^5[+\ON/&OV_P#Q
MX/AW^Q[\3M260QSW.EMID)!P=]RRV_'T$A/X5F?\$X/ I\ _L9_#FV=-EQJ-
MI)JTO&"WVB5I4)_[9L@_"O??%W@GP[\0-%?1_%.@:7XETEW61K#5[..Z@9E.
M58QR*5)!Z''%:.FZ;9Z+IUKI^GVD%A86L2P6]K;1K'%#&H 5$50 J@   < "
MII^[SWWE;[E?3[W^0Y^]R+I&[^;LOR7XGYV::!\9O^"QE].1YUA\/=!VJ>JA
MQ %_,2WK?]\5[E_P4[\>'P)^QEXX\N3R[G6/(T>+G[WG2J)!_P!^EDKZ'T3X
M;^$O#/B35/$.C^%M%TK7]5R=0U6QT^&&ZO,G<?-E50TG//S$\T_QI\/?"WQ(
MTN/3/%WAK1_%.FQRB=+/6K"*\A60 @.$D5@& 9AG&<$^M93@Y8>%'MOYWE>7
MWIV-8SY:\JOW?)67XZGSK\!_V?VNO^"=>C?#)2+"]\0>$)EDD<?ZNXO8GE);
MZ--S["OFG]AW]MKPE^RG\/;[X)_'%;_P%XA\)WUPD$LVGSW$<T<DC2E2(4=@
MP9V(;&QD92&-?IY;V\5G;Q001)#!$H2..-0JHH&  !T ':N8\;?"?P1\3/L_
M_"7^#?#_ (K^SY\G^V]+@O/+SUV^:C8_"NFI4<JTZD=I[KYMKYJ[.>$4J,*<
MMXZW\[6?WGQ,W[9'Q%_;$^-.B>$/V;Y=0\,^!M+N/.\2^.K_ $N"17AS_JXH
MYXW"DKG:"!(S'D*J,3+_ ,%B/$UW)\&_ ?P^TV0OJ7BSQ'%&L/>9(EQC_O[+
M#^E?=^@^'=*\*Z5!IFBZ99Z/IL VQ6=A;I!#&/140 #\!69XG^&_A'QMJ>DZ
MEXB\+:+K^HZ3)YVG7>J:=#<RV3[E;?"[J3&V44Y4@Y4>@K.4824(-72:;ON[
M-/Y;?+7J:1E*+E/JTTNRNFOGOK]Q8\$^&;?P3X,T'P]:*%M=)L(+&)1TVQ1J
M@_1:_/[]D@#XT?\ !2_X^?$5OWUCX:C;1;1CR%?>MLI7ZI:S'_@=?HY7.>$?
MAMX1^'\NHR>%_"VB^&Y-2D$UZ^D:=#:FZD&2'E,:C>WS-RV3R?6KYFZ_MI:N
MTE\Y6U^ZYGRI4?8Q[Q^Z.MOR/SF_:Z^+GAOP%_P5"^%^L?$6ZFT7P7X7T1;A
M+QK26=3*ZW)60+&K,P\TQKE0<%/QK])/!_BW2O'OA72/$FAW+7FC:M:QWME<
M-$\1EAD4,C[' 9<J0<, >>E4/&WPN\&?$N.VC\7^$="\51VK%H$UO38;P1$]
M2@E5MI/M706-C;:78V]E96\5I9V\:Q0V\"!(XD48554<     <#%13]VE[-]
M&W][;=_/9>B+G[U3VB[)?<K+]3EOB[\4=$^"WPU\0^-O$,X@TG1K1[F09 :5
MAPD29ZN[%54=RPK\_?\ @GS\ XOVH/$OCO\ :*^,GA_3O$[>)KR2VT?2]:LT
MN[5(U8!Y%CD!4JFU88SC($;^N:_1?QAX'\.?$+1FTCQ3X?TOQ+I+.LC6&L64
M=W 77[K&.12N1V..*N:#H&E^%='M-)T73;32-*LXQ%;6-A L$$"#HJ(H"J/8
M"E#W9RF]7:R\K[OU>P3;E%06BO=^=ME\MSSG_AD[X(?]$;^'_P#X2]C_ /&J
M^'_V4]*LO@C_ ,%4OC#X#TVSM])T35M-EGLK"UB6&&//V>ZC6-% 555'E  &
M !Q7Z:US+?#'P<WC9?&3>$]#/B]4\L>(#IL/V\)MV;?M&WS,;?EQNZ<=*J'N
M554\I+[U84_>IN'FG]SO_7R/S[\>?M'>-?V+_P!O#Q/J'Q1OO%.J?!OQ9#C2
M'^TS75E8[O+;=#"S;%,;*Z.B /M8, 00&9^W!^W-\"_V@?@3J7P_\$FZ^)/C
M'6Y88-(M+;1;F-[2YWKME4S1(V[&Y0(PQ;=MZ$FOT=U[P[I7BK2Y],UK3+/6
M--G&V6SO[=)X9!Z,C@@_B*YSP7\%_A[\.+R2\\)>!/#/A>[D78]QHNCV]G(R
M^A:-%)%9*"E2C1G\*TTWMOOW\]S7FY:CJPW?W7_KIL?$WQD^#7QL^'/_  3;
M\ :)X-UCQ!IGCSPHD%[JEOX=OI8;PVQ$IDMU:%@9!%YJ94$@B(XS@5U7PA_X
M*R_ [6_AQI,_C;Q!>>%O%,5LD5_IMQI=U<[YE4!VCDAC=2K,"1N*GGD"ON*N
M"\0? #X7^+M;?6=<^&_A'6M7<[FU#4-"M9[AB.YD>,L3^-;2G*4YR>TW?T?E
MY&,8QC"$5]A6]5YGPA^P'H?_  MC]M+XJ_'+P9X<N?"GPJOK62QLEF@$"WUP
M[0EV5!\OWH9)&VGY6=0>2:YWP7\2U_X)S_MJ?%6V^).GWT'P^^(UXVIV'B.V
MMFEC0^=)*IPHRP3[1(CJN6!"G:017ZD6MK!8VL5M;0QV]O$H2.&)0J(HX  '
M 'M5#Q-X4T3QII$NE>(='T_7M+FQYECJ=JEQ ^.F4<%3^5*[I\BI[1CRZ]4]
M=?GJNWXE?&I^T^TT].C6W_![GP'^TM_P4N\/?$;PE/\ #K]GB/5O'GCSQ/$U
MA!=V6FSPI9HX*R.JRHCM)M)P0NU>6+?+@^E_!G]B6[^&W[!GB?X2R2P#QCXH
MTN\FU"96S&M_-%A(]P/*IMC3(X.TGO7T]X)^%G@OX:1SQ^$/"&@^%4N.9ET3
M3(+,28Z;A&JY_&NHJ)0BZ<X+>:LWY=E^8U*7/"3VB[I>?=_D?F/^PW^WE\/?
MV=?@LGPG^,4VI>!O%?A"ZN;;R;K3+B;SU>9Y0N(D8HZERI#@ @*03DX[/X$_
M%+XB?MP?M66_Q#T&]\4>#/@+X2C,-O9_;);6+7;D%L>;&C!)/F(+*=P58U4\
MN:^U/&7P:\ ?$34(+[Q7X&\-^)[V!0L5SK.D6]W)& <@*TB$@?2NJL;&VTRS
MAM+.WBM+6%!'%! @1(U' 55'  ]!6W.Y35:IK)?=>UK^OEM?T,W!*+IPTB_O
MM>]O^#O8_.O3?^+S?\%C+Z<CSK#X>Z#L4]5#B +CZB6];_OBN?\ VWM6M/@E
M_P %#_A;\5_B)H5SJ_PT33H[6&Y6'SX[:Y3S^=AX+QO+'-MZD<KDKBOT7T3X
M:^$?#/B35/$6D>%M%TKQ!JF?M^K6.G0PW5WD[CYLJJ&DY /S$\BM'Q%X9T?Q
MAH\^DZ]I-CK>EW Q-8ZC;)<02#T9'!4_B*QCS0C1Y=X7;[-OFOZ;_*QI*TY5
M.;:5EYI*UOR]-3XS^*'_  50^&EQX=ETKX.C5OB;\0-1C>'2],T_1[J-8YBI
M(>7S8T9E7EB$#$XQ\HRPXG_@BSIOVCX1?$CQ+=2&?5M3\2>3<S2',C>7 CY;
MODM.Y_$U]T^#/A+X&^'"SCPEX,\/^%Q<#;,-%TN"T\P>C>6BY_&K/@OX<>$O
MAM9W-IX1\+Z+X6M+F7SYX-%T^&S263 &]EC50S8 &3SQ6D.6#F]W)6]-4_T_
MJQ,KR45V=_71K]?S/S._9'_:)\#^!_VY_C_J/Q&U*?0O%/B37UT30[633[B=
MY?\ 2Y(_*_=(VP_);#+X'OQ7IG_!2_PKXH^'/Q3^$?[1/A[29=<T_P $W AU
MBUA!)C@$N]7. =J,&E0OT4E,]:^V=4^#_@/7/%EOXIU+P3X<U#Q/;,CP:U=:
M3;RWL3(<H5F9"ZE3T(/%=:Z+(K(ZAE88*L,@CTK.*<845'XJ=K=M/+SN[^I<
MK2G5;7NU-UZ_\,ON/BSQ!_P5T_9_TWP3_;&F:IJVMZX\(>/PY%I<T5R)".$>
M5U$(P>K*[=#C=P#W7[$FM?'/Q]H.O>._C%>MIECKL_F^'O"#6$$#Z9:EF8-(
MZQK*Q(*J!(2<+N/+<>Q:/\"/AIX=\0G7]*^'GA33-=+F0ZI9Z);17.X]6\U4
M#9]\UW-:*RO*VK^Y>GGYO8S=VE&^B^]_UV6_4_*SPC\6+;_@GW^WE\6H?B39
MWMGX'^(-PVI66O16S2JH,KS(^U02ZJ9I8W"@L&"G&#5K]O3_ (*%:3\7/@CX
MB\*_!F'4M>T">.*+Q'XN:RFM;6U@D<*MLGFJK&24\'('R;L;OF*?I9XP\!^&
M?B'I8TWQ5X=TGQ-IP<2"SUBQBNX=PZ-LD4C/OBLNZ^#/P_OO!\7A.Y\"^&KC
MPK#()H]#ETBW:Q209PX@*; W)Y SS6'(Y48TI:\MEZJ_7Y??Z:&_/:K*JMY:
MOR=NG]:>IY;^P#X#'P[_ &/OACIIC\N>YTM=3F!&#ON6:?GW D _"OH.H+*R
MM]-LX+2T@BM;2WC6*&"% D<:*,*JJ.     .F*GKJK3]I4E-=6<M*+IP47N@
MHHHK(U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$LT/_H,Z?_X%1_XT?\)=H7_0:T__ ,"H_P#&CDEV#VD/YD:U%9'_  F&@_\
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MG\K^X7UBC_.OO1TU%<Q_PM'P9_T-VA?^#*'_ .*I/^%I>"_^ANT'_P &</\
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M#O\ X-H/_BZ3_A<'@/\ Z';PY_X-K?\ ^+H]C5_E?W!]:H?\_%]Z.OHKD/\
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MZ].OW]SZ"HHHKX@_60HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /'/VOO\ DW?Q9_VZ?^E<->QUXY^U]_R;OXL_[=/_ $KA
MKV.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** /'/VLO^2,WA]+^Q_]*$KV.O'/VM/^2+7Y]+ZR
M_P#2F.O8Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#RC]JC_D@/C#_ *X1?^CXZ]*T7_D#V'_7"/\
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M]5PZG)&,,/45T$-Q%=01S0R)+#(H=)$8%64C(((Z@BOG;]GX?L^_$SXR>/\
MXE?# ?VMX]1_[,\0ZQ_Q,%&6('EJMQB+_EW7F)<80<X/(OCY7M9OS\OE=ZL3
M?NW7=>G_  ]MCZ-HKR[XQ?M0?"OX ^6OC[QOIGA^YD42)8NS3W;(20'$$2M(
M5R#\VW''6LSX/_MB?!KX]:H=,\#>/M.UC5,$KI\J2VES( ,DI%.B.X Y)4'%
M$?>^'4<O=^+0]DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P"?+_R*G_Q5,;P)KAZ6/_D:/_XJO7**?UJ?9$_4*7=_U\CQYO .O'_EQ_\
M(T?_ ,53&^'^O\_Z!_Y&C_\ BJ]DHI_6I]D+^SZ7=_A_D>+-\//$'/\ Q+__
M "-'_P#%5&WPY\0\_P#$O_\ (\?_ ,57MM%/ZW4[(C^S:/=_A_D>'M\-_$9Z
M:=_Y'C_^*J)OAIXD_P"@=_Y'B_\ BJ]UHI_7*G9"_LNCW?X?Y'@[?#/Q+S_Q
M+?\ R/%_\543?"_Q,?\ F&?^1XO_ (JO?:*?UVIV1/\ 95'N_P /\CY_;X6^
M)^?^)9_Y,1?_ !51-\*_%//_ !*__)B+_P"*KZ%HI_7JG9?U\Q?V30[O\/\
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M /)N#_XNHS\!O'7_ $ __)N#_P"+KZ]HI_VI6[+\?\R?]7\+_-+[U_D?'S?
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M?_)ZV_\ CE,;]FSXC_\ 0N_^3UM_\<K[EHI_VQB/Y5^/^9/^K.#_ )I?>O\
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M8_V?_%Y9@H\F$9)QR9XP!^=>FZ2C1Z59(ZE'6% 588(.T<4 6Z*** "BBB@
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M_$T?\(1??\];?_OIO_B:/:0[A[&I_*<]170_\(1??\];?_OIO_B:/^$(OO\
MGK;_ /?3?_$T>TAW#V-3^4YZBNA_X0B^_P">MO\ ]]-_\31_PA%]_P ];?\
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MOC9IEOX_\9>,KF6[MH=>B%Q;6]L&**WD-E"6*G:""%0(% YSR=]\+_&6F_\
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M^1P/[">/B_\ MZ_M'_%)U,MOI\QT6RE/(*&;RU(_[9V:_P#??O7UA\7/A3\
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MBOLO]M[]J?0/V:?@OK=T^I6[>,=2M)+70]*60-/-.ZE1+LSGRX\[F;IP!G+
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MWZW_ %ZVZ6/U^3.Q=WWL<TZBBLBPHHHH&%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %>.?LN_\B;XD'IXFU$?^1!7L=>.?LP?
M\BIXJ'IXIU(?^1!0!['1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8XYO$Z@_9-/5E>.P)R"Q920\F.F.%R<9."/J:BBOD,3BJN+J.K5=W^7H?I>
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH \<_:^_Y-W\6?]NG_ *5PU['7CG[7
MW_)N_BS_ +=/_2N&O8Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7;NP?NYRHYH\7_L]^'/%W[/S?!YKS5-*\+-I4&C"?3I8TNUMX@@ #/&R994
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M)PN>G/TG151DXVL]B6E*]^H4444AA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5XY^S%_P BWXP'IXKU(?\ CZU['7CG
M[,G_ " ?&X]/%VI#_P ?6@#V.BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'CG[7W_
M ";OXL_[=/\ TKAKV.O'/VOO^3=_%G_;I_Z5PU['0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 ,FA2XADBD&Z.12K+G&01@UD?\(?I'_/I_
MY%?_ !K:HH Q?^$/TC_GT_\ (K_XT?\ "'Z1_P ^G_D5_P#&MJB@#%_X0_2/
M^?3_ ,BO_C1_PA^D?\^G_D5_\:VJ* ,7_A#](_Y]/_(K_P"-'_"'Z1_SZ?\
MD5_\:VJ* ,7_ (0_2/\ GT_\BO\ XT?\(?I'_/I_Y%?_ !K:HH Q?^$/TC_G
MT_\ (K_XT?\ "'Z1_P ^G_D5_P#&MJB@#%_X0_2/^?3_ ,BO_C1_PA^D?\^G
M_D5_\:VJ* ,7_A#](_Y]/_(K_P"-'_"'Z1_SZ?\ D5_\:VJ* ,7_ (0_2/\
MGT_\BO\ XT?\(?I'_/I_Y%?_ !K:HH Q?^$/TC_GT_\ (K_XT?\ "'Z1_P ^
MG_D5_P#&MJB@#%_X0_2/^?3_ ,BO_C1_PA^D?\^G_D5_\:VJ* ,7_A#](_Y]
M/_(K_P"-'_"'Z1_SZ?\ D5_\:VJ* ,7_ (0_2/\ GT_\BO\ XT?\(?I'_/I_
MY%?_ !K:HH Q?^$/TC_GT_\ (K_XT?\ "'Z1_P ^G_D5_P#&MJB@#%_X0_2/
M^?3_ ,BO_C1_PA^D?\^G_D5_\:VJ* ,7_A#](_Y]/_(K_P"-'_"'Z1_SZ?\
MD5_\:VJ* ,7_ (0_2/\ GT_\BO\ XT?\(?I'_/I_Y%?_ !K:HH Q?^$/TC_G
MT_\ (K_XT?\ "'Z1_P ^G_D5_P#&MJB@#%_X0_2/^?3_ ,BO_C1_PA^D?\^G
M_D5_\:VJ* ,7_A#](_Y]/_(K_P"-'_"'Z1_SZ?\ D5_\:VJ* ,7_ (0_2/\
MGT_\BO\ XT?\(?I'_/I_Y%?_ !K:HH Q?^$/TC_GT_\ (K_XT?\ "'Z1_P ^
MG_D5_P#&MJB@#%_X0_2/^?3_ ,BO_C1_PA^D?\^G_D5_\:VJ* ,7_A#](_Y]
M/_(K_P"-'_"'Z1_SZ?\ D5_\:VJ* ,7_ (0_2/\ GT_\BO\ XT?\(?I'_/I_
MY%?_ !K:HH Q?^$/TC_GT_\ (K_XT?\ "'Z1_P ^G_D5_P#&MJB@#%_X0_2/
M^?3_ ,BO_C1_PA^D?\^G_D5_\:VJ* ,7_A#](_Y]/_(K_P"-'_"'Z1_SZ?\
MD5_\:VJ* ,7_ (0_2/\ GT_\BO\ XT?\(?I'_/I_Y%?_ !K:HH Q?^$/TC_G
MT_\ (K_XT?\ "'Z1_P ^G_D5_P#&MJB@#%_X0_2/^?3_ ,BO_C1_PA^D?\^G
M_D5_\:VJ* ,7_A#](_Y]/_(K_P"-'_"'Z1_SZ?\ D5_\:VJ* ,7_ (0_2/\
MGT_\BO\ XT?\(?I'_/I_Y%?_ !K:HH Q?^$/TC_GT_\ (K_XT?\ "'Z1_P ^
MG_D5_P#&MJB@#%_X0_2/^?3_ ,BO_C1_PA^D?\^G_D5_\:VJ* ,7_A#](_Y]
M/_(K_P"-'_"'Z1_SZ?\ D5_\:VJ* ,7_ (0_2/\ GT_\BO\ XT?\(?I'_/I_
MY%?_ !K:HH Q?^$/TC_GT_\ (K_XT?\ "'Z1_P ^G_D5_P#&MJB@#%_X0_2/
M^?3_ ,BO_C1_PA^D?\^G_D5_\:VJ* ,7_A#](_Y]/_(K_P"-'_"'Z1_SZ?\
MD5_\:VJ* ,7_ (0_2/\ GT_\BO\ XT?\(?I'_/I_Y%?_ !K:HH Q?^$/TC_G
MT_\ (K_XT?\ "'Z1_P ^G_D5_P#&MJB@#%_X0_2/^?3_ ,BO_C1_PA^D?\^G
M_D5_\:VJ* ,7_A#](_Y]/_(K_P"-'_"'Z1_SZ?\ D5_\:VJ* ,7_ (0_2/\
MGT_\BO\ XT?\(?I'_/I_Y%?_ !K:HH Q?^$/TC_GT_\ (K_XT?\ "'Z1_P ^
MG_D5_P#&MJB@#%_X0_2/^?3_ ,BO_C1_PA^D?\^G_D5_\:VJ* ,7_A#](_Y]
M/_(K_P"-'_"'Z1_SZ?\ D5_\:VJ* ,7_ (0_2/\ GT_\BO\ XT?\(?I'_/I_
MY%?_ !K:HH Q?^$/TC_GT_\ (K_XT?\ "'Z1_P ^G_D5_P#&MJB@#%_X0_2/
M^?3_ ,BO_C1_PA^D?\^G_D5_\:VJ* ,7_A#](_Y]/_(K_P"-'_"'Z1_SZ?\
MD5_\:VJ* ,7_ (0_2/\ GT_\BO\ XT?\(?I'_/I_Y%?_ !K:HH Q?^$/TC_G
MT_\ (K_XT?\ "'Z1_P ^G_D5_P#&MJB@#%_X0_2/^?3_ ,BO_C1_PA^D?\^G
M_D5_\:VJ* ,7_A#](_Y]/_(K_P"-'_"'Z1_SZ?\ D5_\:VJ* ,7_ (0_2/\
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M]P3_ -)'H ]CHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_D5_\:VJ* ,7_A#](_Y]/_(K_P"-'_"'Z1_SZ?\ D5_\:VJ* ,7_ (0_2/\
MGT_\BO\ XT?\(?I'_/I_Y%?_ !K:HH Q?^$/TC_GT_\ (K_XT?\ "'Z1_P ^
MG_D5_P#&MJB@#%_X0_2/^?3_ ,BO_C1_PA^D?\^G_D5_\:VJ* ,7_A#](_Y]
M/_(K_P"-'_"'Z1_SZ?\ D5_\:VJ* ,7_ (0_2/\ GT_\BO\ XT?\(?I'_/I_
MY%?_ !K:HH Q?^$/TC_GT_\ (K_XT?\ "'Z1_P ^G_D5_P#&MJB@#%_X0_2/
M^?3_ ,BO_C1_PA^D?\^G_D5_\:VJ* ,7_A#](_Y]/_(K_P"-'_"'Z1_SZ?\
MD5_\:VJ* ,7_ (0_2/\ GT_\BO\ XT?\(?I'_/I_Y%?_ !K:HH Q?^$/TC_G
MT_\ (K_XT?\ "'Z1_P ^G_D5_P#&MJB@#%_X0_2/^?3_ ,BO_C1_PA^D?\^G
M_D5_\:VJ* ,7_A#](_Y]/_(K_P"-'_"'Z1_SZ?\ D5_\:VJ* ,7_ (0_2/\
MGT_\BO\ XT?\(?I'_/I_Y%?_ !K:HH Q?^$/TC_GT_\ (K_XT?\ "'Z1_P ^
MG_D5_P#&MJB@#%_X0_2/^?3_ ,BO_C1_PA^D?\^G_D5_\:VJ* ,7_A#](_Y]
M/_(K_P"-'_"'Z1_SZ?\ D5_\:VJ* ,7_ (0_2/\ GT_\BO\ XT?\(?I'_/I_
MY%?_ !K:HH Q?^$/TC_GT_\ (K_XT?\ "'Z1_P ^G_D5_P#&MJB@#%_X0_2/
M^?3_ ,BO_C1_PA^D?\^G_D5_\:VJ* ,7_A#](_Y]/_(K_P"-'_"'Z1_SZ?\
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M/^^5_P#BJ/\ A-['_GE<?]\K_P#%5Q%%'L8!]:J';_\ ";V/_/*X_P"^5_\
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M?_BJ/^$WL?\ GE<?]\K_ /%5Q%%'L8!]:J';_P#";V/_ #RN/^^5_P#BJ/\
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M_BJ/^$WL?^>5Q_WRO_Q5<111[& ?6JAV_P#PF]C_ ,\KC_OE?_BJ/^$WL?\
MGE<?]\K_ /%5Q%%'L8!]:J';_P#";V/_ #RN/^^5_P#BJ/\ A-['_GE<?]\K
M_P#%5Q%%'L8!]:J';_\ ";V/_/*X_P"^5_\ BJ/^$WL?^>5Q_P!\K_\ %5Q%
M%'L8!]:J';_\)O8_\\KC_OE?_BJ/^$WL?^>5Q_WRO_Q5<111[& ?6JAV_P#P
MF]C_ ,\KC_OE?_BJ/^$WL?\ GE<?]\K_ /%5Q%%'L8!]:J';_P#";V/_ #RN
M/^^5_P#BJ/\ A-['_GE<?]\K_P#%5Q%%'L8!]:J';_\ ";V/_/*X_P"^5_\
MBJ/^$WL?^>5Q_P!\K_\ %5Q%%'L8!]:J'H$'BS39FP9C&?\ IHI'ZUK1R),@
M>-E=&Y#*<@UY35JPU2ZTU]UO*R#NO53]142H+[+-88M_;1Z=165HGB"'6$VX
M\NX49:,_S'J*U:Y&G%V9Z,9*2N@HHHI%!1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %>.?LU_\ 'K\21Z>-]4'ZQU['7CG[
M-OW/B>/3QUJ@_P#15 'L=%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !7CGPQ_Y.(^-?\ W!/_ $D>O8Z\
M<^&/_)Q'QK_[@G_I(] 'L=%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!XY^U]_R;OXL_[=/_ $KA
MKV.O'/VOO^3=_%G_ &Z?^E<->QT %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!XY^U[_P F\>*S
MZ&T_]*X:]CKQW]KS_DW?Q;_VZ?\ I7#7L*\J* %HHHH **** "BBB@ HHHH
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MP4@41][X=0E[OQ:'KM%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"_;G^)G[2/AV'P]XB?2=)T)95FEL=%MGB2=U^Z9#(\C$*>0 0,\X) Q^C/\
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MJ\':K)^Q+\ -9OXI6N])M+2TN]XRR>=9(1N/UA ^I%<]23JX5RGO&<5ZZO\
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M^;_''QPUG]LKXO>'6^*7BS2_!FBQ_P"C)<06DOV2PC8@N40%V+,0,L[8X&6
M%?M7\,?".A> _AWX=\/^&6630-/L8H;*5)!()8PH(DW#ABV=V1UW9KX$_P""
MO7@?PW8Z3X(\4065M:^)[N\FM)YXE5)+J!8PV7QRVQMH!/3?CO7LW_!+CQ1J
MWB3]EV&#5)))H=)U:YL+&21LG[.%CD"@^BM(ZCT  Z"GA6G&I22LXN[\]O\
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MJ;NSGV@.DL>=P.X-AB,,.02#FO"/^"I_Q)^&>D_LS^(?#/BFYT_4/%>H"/\
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MV5/^9$_ZQ4O^?;_ ^YZ*^%&^(WBS_H9]9_\ !A+_ /%5')\1_%O_ $-&M?\
M@PF_^*I_V3/^=$_ZR4O^?;^]'W?7CGPQ_P"3B/C7_P!P3_TD>OFYOB1XN_Z&
MG6O_  83?_%5R'A_QSXDM?'GBZZA\0:I%=7/V3SYDO95>7;$0NY@V6P.!GI3
M_LBI_.B?]9:/_/M_>C](Z*^ F^)GB_/_ "-6M_\ @QF_^*J)OB9XP_Z&O7/_
M  8S?_%57]CU/YT3_K-1_P"?;^]'Z!45^>[?$[QCS_Q5FN?^#*;_ .*IC?%#
MQE_T-NN_^#*;_P"*I_V-4_G0O]:*/_/M_>C]"Z*_.^3XH^,_^ANUW_P93?\
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M5/\ KN?6E%%%?G!^Y!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MNV*%6(&]\A2<=@3QD5]'_MP?LUWGQN\(V>M>'85E\5:&K^7;Y -Y >6B!/\
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M&$72,91*$V[, G=G&*_8:BBLZ,/8THTET_R2_0WKU77J.HU:_P#P?\S\G/\
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MB7O1Y7L$?=ES+<^'?#7_  1W^ 6@^(%U&[?Q5X@ME;=_9>I:I&MM[ F&*.3
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M)QM;I_E;\FR914KW6_\ PX4445(PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQS]
MGWC7OBP/^INNC_XXE>QUXY^S_P >)/BR/^IKN#_XXE 'L=%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBB@#QS]K[_DW?Q9_VZ?^E<->QUXY^U]_R;OXL_[=/_2N&O8Z "BBB@ HHHH
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MZ'!]J] KTL+BZ&.HQKX:7-![-'GXG"UL'5=#$1Y9+=!11176<H4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ KQSX!\>*_BT/\ J:9C^<:5['7CGP&X
M\9?%L?\ 4S.?_(:T >QT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MSDJ2#TQ7ME%=D\QQ=2/+*H['ETLCRVC/VD*$;^E_S"BBBO./<"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /'/VOO^
M3=_%G_;I_P"E<->QUXY^U]_R;OXL_P"W3_TKAKV.@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB*,EF. !ZFJG]M:?_P _]K_W^7_&@"[15+^VM/\ ^?\ M?\ O\O^-']M:?\
M\_\ :_\ ?Y?\: +M%4O[:T__ )_[7_O\O^-']M:?_P _]K_W^7_&@"[15+^V
MM/\ ^?\ M?\ O\O^-']M:?\ \_\ :_\ ?Y?\: +M%4O[:T__ )_[7_O\O^-'
M]M:?_P _]K_W^7_&@"[15+^VM/\ ^?\ M?\ O\O^-']M:?\ \_\ :_\ ?Y?\
M: +M%4O[:T__ )_[7_O\O^-']M:?_P _]K_W^7_&@"[15+^VM/\ ^?\ M?\
MO\O^-']M:?\ \_\ :_\ ?Y?\: +M%4O[:T__ )_[7_O\O^-']M:?_P _]K_W
M^7_&@"[15+^VM/\ ^?\ M?\ O\O^-']M:?\ \_\ :_\ ?Y?\: +M%4O[:T__
M )_[7_O\O^-']M:?_P _]K_W^7_&@"[15+^VM/\ ^?\ M?\ O\O^-']M:?\
M\_\ :_\ ?Y?\: +M%4O[:T__ )_[7_O\O^-']M:?_P _]K_W^7_&@"[15+^V
MM/\ ^?\ M?\ O\O^-']M:?\ \_\ :_\ ?Y?\: +M%4O[:T__ )_[7_O\O^-'
M]M:?_P _]K_W^7_&@"[15+^VM/\ ^?\ M?\ O\O^-']M:?\ \_\ :_\ ?Y?\
M: +M%4O[:T__ )_[7_O\O^-']M:?_P _]K_W^7_&@"[15+^VM/\ ^?\ M?\
MO\O^-']M:?\ \_\ :_\ ?Y?\: +M%4O[:T__ )_[7_O\O^-']M:?_P _]K_W
M^7_&@"[15+^VM/\ ^?\ M?\ O\O^-']M:?\ \_\ :_\ ?Y?\: +M%4O[:T__
M )_[7_O\O^-']M:?_P _]K_W^7_&@"[15+^VM/\ ^?\ M?\ O\O^-']M:?\
M\_\ :_\ ?Y?\: +M%4O[:T__ )_[7_O\O^-']M:?_P _]K_W^7_&@"[15+^V
MM/\ ^?\ M?\ O\O^-']M:?\ \_\ :_\ ?Y?\: +M%4O[:T__ )_[7_O\O^-'
M]M:?_P _]K_W^7_&@"[15+^VM/\ ^?\ M?\ O\O^-']M:?\ \_\ :_\ ?Y?\
M: +M%4O[:T__ )_[7_O\O^-']M:?_P _]K_W^7_&@"[15+^VM/\ ^?\ M?\
MO\O^-']M:?\ \_\ :_\ ?Y?\: +M%4O[:T__ )_[7_O\O^-']M:?_P _]K_W
M^7_&@"[15+^VM/\ ^?\ M?\ O\O^-']M:?\ \_\ :_\ ?Y?\: +M%4O[:T__
M )_[7_O\O^-']M:?_P _]K_W^7_&@"[15+^VM/\ ^?\ M?\ O\O^-']M:?\
M\_\ :_\ ?Y?\: +M%4O[:T__ )_[7_O\O^-']M:?_P _]K_W^7_&@"[15+^V
MM/\ ^?\ M?\ O\O^-']M:?\ \_\ :_\ ?Y?\: +M%4O[:T__ )_[7_O\O^-'
M]M:?_P _]K_W^7_&@"[15+^VM/\ ^?\ M?\ O\O^-']M:?\ \_\ :_\ ?Y?\
M: +M%4O[:T__ )_[7_O\O^-']M:?_P _]K_W^7_&@"[15+^VM/\ ^?\ M?\
MO\O^-']M:?\ \_\ :_\ ?Y?\: +M%4O[:T__ )_[7_O\O^-']M:?_P _]K_W
M^7_&@"[15+^VM/\ ^?\ M?\ O\O^-']M:?\ \_\ :_\ ?Y?\: +M%4O[:T__
M )_[7_O\O^-']M:?_P _]K_W^7_&@"[15+^VM/\ ^?\ M?\ O\O^-']M:?\
M\_\ :_\ ?Y?\: +M%4O[:T__ )_[7_O\O^-']M:?_P _]K_W^7_&@"[15+^V
MM/\ ^?\ M?\ O\O^-']M:?\ \_\ :_\ ?Y?\: +M%4O[:T__ )_[7_O\O^-'
M]M:?_P _]K_W^7_&@"[15+^VM/\ ^?\ M?\ O\O^-']M:?\ \_\ :_\ ?Y?\
M: +M%4O[:T__ )_[7_O\O^-']M:?_P _]K_W^7_&@"[15+^VM/\ ^?\ M?\
MO\O^-']M:?\ \_\ :_\ ?Y?\: +M%4O[:T__ )_[7_O\O^-']M:?_P _]K_W
M^7_&@"[15+^VM/\ ^?\ M?\ O\O^-']M:?\ \_\ :_\ ?Y?\: +M%4O[:T__
M )_[7_O\O^-']M:?_P _]K_W^7_&@"[15+^VM/\ ^?\ M?\ O\O^-']M:?\
M\_\ :_\ ?Y?\: +M%4O[:T__ )_[7_O\O^-']M:?_P _]K_W^7_&@"[15+^V
MM/\ ^?\ M?\ O\O^-']M:?\ \_\ :_\ ?Y?\: +M%4O[:T__ )_[7_O\O^-'
M]M:?_P _]K_W^7_&@"[15+^VM/\ ^?\ M?\ O\O^-']M:?\ \_\ :_\ ?Y?\
M: +M%4O[:T__ )_[7_O\O^-']M:?_P _]K_W^7_&@"[15+^VM/\ ^?\ M?\
MO\O^-/AU2RN)!'%=P2R-T5)5)/X9H M5XY\">/''Q<'_ %,9/_D):]CKQSX&
M\?$#XO#_ *F '_R$* /8Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "O'/AC_ ,G$?&O_ +@G_I(]>QUX
MY\,?^3B/C7_W!/\ TD>@#V.BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %>.?#'_ ).(^-?_ '!/_21Z]CKQSX8_\G$?&O\ [@G_ *2/0!['1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 >.?M??\F[^+/\ MT_]*X:]CKQS]K[_ )-W\6?]NG_I7#7L
M= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHH Q?^$:_P"HKJ?_ ($?_6H_X1K_ *BNI_\ @1_]:MJB@#%_X1K_ *BNI_\
M@1_]:C_A&O\ J*ZG_P"!'_UJVJ* ,7_A&O\ J*ZG_P"!'_UJ/^$:_P"HKJ?_
M ($?_6K:HH Q?^$:_P"HKJ?_ ($?_6H_X1K_ *BNI_\ @1_]:MJB@#%_X1K_
M *BNI_\ @1_]:C_A&O\ J*ZG_P"!'_UJVJ* ,7_A&O\ J*ZG_P"!'_UJ/^$:
M_P"HKJ?_ ($?_6K:HH Q?^$:_P"HKJ?_ ($?_6H_X1K_ *BNI_\ @1_]:MJB
M@#%_X1K_ *BNI_\ @1_]:C_A&O\ J*ZG_P"!'_UJVJ* ,7_A&O\ J*ZG_P"!
M'_UJ/^$:_P"HKJ?_ ($?_6K:HH Q?^$:_P"HKJ?_ ($?_6H_X1K_ *BNI_\
M@1_]:MJB@#%_X1K_ *BNI_\ @1_]:C_A&O\ J*ZG_P"!'_UJVJ* ,7_A&O\
MJ*ZG_P"!'_UJ/^$:_P"HKJ?_ ($?_6K:HH Q?^$:_P"HKJ?_ ($?_6H_X1K_
M *BNI_\ @1_]:MJB@#%_X1K_ *BNI_\ @1_]:C_A&O\ J*ZG_P"!'_UJVJ*
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M//\ IQ_\C?\ V-'_  GG_3C_ .1O_L:Y.BCV4.P?6*O<ZS_A//\ IQ_\C?\
MV-'_  GG_3C_ .1O_L:Y.BCV4.P?6*O<ZS_A//\ IQ_\C?\ V-'_  GG_3C_
M .1O_L:Y.BCV4.P?6*O<ZS_A//\ IQ_\C?\ V-'_  GG_3C_ .1O_L:Y.BCV
M4.P?6*O<ZS_A//\ IQ_\C?\ V-'_  GG_3C_ .1O_L:Y.BCV4.P?6*O<ZS_A
M//\ IQ_\C?\ V-'_  GG_3C_ .1O_L:Y.BCV4.P?6*O<ZS_A//\ IQ_\C?\
MV-'_  GG_3C_ .1O_L:Y.BCV4.P?6*O<ZS_A//\ IQ_\C?\ V-'_  GG_3C_
M .1O_L:Y.BCV4.P?6*O<ZS_A//\ IQ_\C?\ V-'_  GG_3C_ .1O_L:Y.BCV
M4.P?6*O<ZS_A//\ IQ_\C?\ V-'_  GG_3C_ .1O_L:Y.BCV4.P?6*O<ZS_A
M//\ IQ_\C?\ V-'_  GG_3C_ .1O_L:Y.BCV4.P?6*O<ZS_A//\ IQ_\C?\
MV-'_  GG_3C_ .1O_L:Y.BCV4.P?6*O<ZS_A//\ IQ_\C?\ V-'_  GG_3C_
M .1O_L:Y.BCV4.P?6*O<ZS_A//\ IQ_\C?\ V-'_  GG_3C_ .1O_L:Y.BCV
M4.P?6*O<ZS_A//\ IQ_\C?\ V-'_  GG_3C_ .1O_L:Y.BCV4.P?6*O<ZS_A
M//\ IQ_\C?\ V-'_  GG_3C_ .1O_L:Y.BCV4.P?6*O<ZS_A//\ IQ_\C?\
MV-'_  GG_3C_ .1O_L:Y.BCV4.P?6*O<ZS_A//\ IQ_\C?\ V-'_  GG_3C_
M .1O_L:Y.BCV4.P?6*O<ZS_A//\ IQ_\C?\ V-'_  GG_3C_ .1O_L:Y.BCV
M4.P?6*O<ZS_A//\ IQ_\C?\ V-'_  GG_3C_ .1O_L:Y.BCV4.P?6*O<ZS_A
M//\ IQ_\C?\ V-'_  GG_3C_ .1O_L:Y.BCV4.P?6*O<ZS_A//\ IQ_\C?\
MV-'_  GG_3C_ .1O_L:Y.BCV4.P?6*O<[&'QU V/-M9$]=C!O\*V=/UJSU/B
M"8%_[C<-^5>:T*Q5@0<$<@BI=&+V-(XJ:^+4]8HKC]!\6-&4M[YMR'A9V/(_
MWO\ &NPKDE%P=F>C3J1J*\0HHHJ#4**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7CGPQ_Y.(^-?_<$_])'H ]CHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /'/VOO^3=_%G_;I_P"E
M<->QUXY^U]_R;OXL_P"W3_TKAKV.@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /+/VH?\ D@?C
M'_KU3_T:E>A>'?\ D7],_P"O6+_T 5Y]^T__ ,D%\8_]>J_^C4KT#PW_ ,B[
MI7_7K%_Z * -*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHJE>ZUI^FJS75];VX49/FRJO\S2;2W*C&4W:*NR[17FNN?M'?#KP\
M[)>>*+19%_@CRY_05Q.H?MK_  ^MY&CM6U#4&'3R;23!_';7)/&8>G\51?>?
M18?AO.<4KT<)-K_"[?>SZ HKYV3]LK2[I2;+PEK5T.Q\LK_-:L+^U?,R[AX
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MNM^-G_)&?'G_ & ;_P#])WK\J_\ @E-_R=)+_P!@"[_]#AJH5'+$.D]K7_\
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M:W42SPR;2NY& 93@C(R".M)J>J6>BZ?<W^HW<%A8VT9EGNKF18XHD R69F(
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MX_\ &FGQKX>'77M,'_;Y'_\ %4<DNPO:T_YE]YM45AGQUX;'7Q!I8_[?8O\
MXJFGQ]X9'7Q'I(_[?HO_ (JG[.?9B]M3_F7WF]17/GXA>%AU\2Z./^W^+_XJ
MFGXC>$QU\3Z,/^XA%_\ %4>SG_*Q>WI?SK[T=%17-GXE>$1U\5:*/^XC#_\
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MU]5_P#]8****_+C^@PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFX36Z:LPHHHK4X0HHHH **** "BBB@ HHHH **** "BBB@#QS]IS_D7?!O\
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M(_\ KRL?_2=*XL4N5THK:[_)G=@I.4JCD[^[^L3]A/AO_P D[\+_ /8*M?\
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MVY8#/)KX[_X*/0I\4OVL?V<?@U9QK]C%TE[=6L8P@ADG1.@Z;8K:;\#75_\
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M^Y2_IGU#\.?V ?@/\._!%OX<'PXT'Q"5BV3ZKKUA%>7MPY&&D,KJ2A)YQ'M
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M*,*JJ.     .F*=.RHNVJD[KRLK.WD]->KN*HG[97T:5G\W=7]-?2Y-7YE_
MW_B^'_!77XD^*3F?3O!=I<6MN_54DB2.RP/JS3M^!K]'O%OB*V\(>%=9UV]8
M)9Z7937LS'H$C0NQ_)37Y[?\$:_#MSK7AWXL_$W45W7WB/75MC(PY)0--(1[
M%KD?]\U-'7$.7\D6_P#P+W5^I572AR]922^2]Y_DC]'Z_.'_ (+9:E WP?\
MASHRX?4KSQ"\\,0Y=D2W=&P.OWIH_P Q7Z#>+/&&A^ _#]WKGB/5[+0M'M$W
MSWVH3K#%&/=F('T'<U^;?@^TOO\ @I+^VCI_Q!6PN8O@?\.91'IT]U&474KA
M'$@ ![O)L=AVCC16PS5')[:I&GTNG)]DG?\ '9=[Z%\WLH2J>327=O2WZO\
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M8_?-&'E/_?;-7J5=M>T)NG':.GW:''2DZD54EJY:_?K_ %]X4445SFX4444
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M?\%_)'Z2T445^/G],A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5XY\,?^3B/C7_ -P3_P!)'KV.O'/AC_R<1\:_^X)_Z2/0!['1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 >.?M??\F[^+/^W3_P!*X:]CKQS]K[_DW?Q9_P!NG_I7
M#7L= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 >8_M,?\ )!_&7_7E_P"SK7<^$_\ D5M&_P"O
M*'_T 5P_[2W/P)\9_P#7E_[.M=MX1Y\)Z*?^G*#_ -%K0!KT444 %%%% !11
M10 4444 %%%% !1110 445GZ_K]AX7TFYU/4[J.SLK==\DTAP *3:2NRX0E4
MDH05V]D79ID@C:21UCC499F. !ZU\G?M#_MT:-X!^TZ+X1V:QK2Y1KC.8H3_
M (UX-^T]^VGJ?Q%GN/#_ (2EDTW0%)22=>)+C'OZ5\I*)+B; W22.<>I)KX?
M,L^=W2PGW_Y']3\%>$\>6.8<0+S5/_Y/_+[SI_''Q$\2_%'7&OM<U"XU*ZD;
MY(R20N>@45];_LO_ +#+ZBEIXF\>PF.W8"2WTMNK#J"_M72?L9?LCV^DVMIX
MV\66RSWL@$EE:2#(C'4.??FOM=5"J% P!P *O*\G=2V*QFK>R?YLYN//$:.$
M3R/AVT(1TE..G_;L+;>;^[N?-/Q@_:P\.? '7+?PIIFARW?V>/$D=K'A(?1?
M>O/I/^"DVEQ-A_#5TA]& ']:^O/$%IHFG6-YJVHV=JR6\;32S2QJ3A1GJ17Y
M:>/+RZ_:8^/GV#1[=8[*:Y^SPFV0!4BW??-=.9UL7@Y+V=5>\[*-CQ.!\KX>
MXBI5/KN"DE1CS5*KJ/5[[66_KL?22?\ !2#3Y%W+X7O67U5<C^=>T?L\_M$R
M_'AM1EBT&XTNSLRH\Z=<!\CMS53Q1XB^'/[+WPYTRSU>UM&FBA54MTC5I9Y
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MS?QEP#C^%*CJK]YAV])KIY271^>S/0****]P_+ HHHH **** "BBB@ HHHH
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MH@HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH \T_:4_Y(3XS_P"O$_\ H2UV?@[_ )%'0_\ KQ@_]%K7&_M)?\D+\9_]
M>#?^A"NQ\%_\B?H7_7A!_P"BUH V:*** "BBB@ HHHH **** "BBB@ HHHH
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M  BNJ?\ /K_Y$3_&O0J*/;R#ZI#NSSW_ (175/\ GU_\B)_C1_PBNJ?\^O\
MY$3_ !KT*BCV\@^J0[L\]_X175/^?7_R(G^-'_"*ZI_SZ_\ D1/\:]"HH]O(
M/JD.[//?^$5U3_GU_P#(B?XT?\(KJG_/K_Y$3_&O0J*/;R#ZI#NSSW_A%=4_
MY]?_ "(G^-'_  BNJ?\ /K_Y$3_&O0J*/;R#ZI#NSSW_ (175/\ GU_\B)_C
M1_PBNJ?\^O\ Y$3_ !KT*BCV\@^J0[L\]_X175/^?7_R(G^-'_"*ZI_SZ_\
MD1/\:]"HH]O(/JD.[//?^$5U3_GU_P#(B?XT?\(KJG_/K_Y$3_&O0J*/;R#Z
MI#NSSW_A%=4_Y]?_ "(G^-'_  BNJ?\ /K_Y$3_&O0J*/;R#ZI#NSSW_ (17
M5/\ GU_\B)_C1_PBNJ?\^O\ Y$3_ !KT*BCV\@^J0[L\]_X175/^?7_R(G^-
M'_"*ZI_SZ_\ D1/\:]"HH]O(/JD.[//?^$5U3_GU_P#(B?XT?\(KJG_/K_Y$
M3_&O0J*/;R#ZI#NSSW_A%=4_Y]?_ "(G^-'_  BNJ?\ /K_Y$3_&O0J*/;R#
MZI#NSSW_ (175/\ GU_\B)_C1_PBNJ?\^O\ Y$3_ !KT*BCV\@^J0[L\]_X1
M75/^?7_R(G^-'_"*ZI_SZ_\ D1/\:]"HH]O(/JD.[//?^$5U3_GU_P#(B?XT
M?\(KJG_/K_Y$3_&O0J*/;R#ZI#NSSW_A%=4_Y]?_ "(G^-'_  BNJ?\ /K_Y
M$3_&O0J*/;R#ZI#NSSW_ (175/\ GU_\B)_C1_PBNJ?\^O\ Y$3_ !KT*BCV
M\@^J0[LX*'P?J,C#<L<0]6<'^5;.G^"X(&5[J0SL.=BC"Y_K7245+JR9I'#T
MXZVN-5%C4*JA5'  & *=116)TA1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7CGPPX_:(^-8_[ I_\E'KV.O'/AIQ^
MT9\9AZIHI_\ )5Z /8Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "O'/AC_R<1\:_^X)_Z2/7L=>.?#'_
M ).(^-?_ '!/_21Z /8Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#QS]K[_ )-W\6?]NG_I7#7L
M=>.?M??\F[^+/^W3_P!*X:]CH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S;]I#_DA?C3_L'M
M_,5U_@GGP9H/_8/M_P#T6M<C^T=_R0SQI_V#W_F*ZWP/_P B5X?_ .P?;_\
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M_0V?^4V[_P#C5>QT4 >.?\-??"3_ *&S_P IMW_\:H_X:^^$G_0V?^4V[_\
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M/_*;=_\ QJC_ (:^^$G_ $-G_E-N_P#XU7L=% 'CG_#7WPD_Z&S_ ,IMW_\
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MW_\ &J]CHH \<_X:^^$G_0V?^4V[_P#C5'_#7WPD_P"AL_\ *;=__&J]CHH
M\<_X:^^$G_0V?^4V[_\ C5'_  U]\)/^AL_\IMW_ /&J]CHH \<_X:^^$G_0
MV?\ E-N__C5'_#7WPD_Z&S_RFW?_ ,:KV.B@#QS_ (:^^$G_ $-G_E-N_P#X
MU1_PU]\)/^AL_P#*;=__ !JO8Z* /'/^&OOA)_T-G_E-N_\ XU1_PU]\)/\
MH;/_ "FW?_QJO8Z* /'/^&OOA)_T-G_E-N__ (U1_P -??"3_H;/_*;=_P#Q
MJO8Z* /'/^&OOA)_T-G_ )3;O_XU1_PU]\)/^AL_\IMW_P#&J]CHH \<_P"&
MOOA)_P!#9_Y3;O\ ^-4?\-??"3_H;/\ RFW?_P :KV.B@#QS_AK[X2?]#9_Y
M3;O_ .-4?\-??"3_ *&S_P IMW_\:KV.B@#QS_AK[X2?]#9_Y3;O_P"-4?\
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M *&S_P IMW_\:H_X:^^$G_0V?^4V[_\ C5>QT4 >.?\ #7WPD_Z&S_RFW?\
M\:H_X:^^$G_0V?\ E-N__C5>QT4 >.?\-??"3_H;/_*;=_\ QJC_ (:^^$G_
M $-G_E-N_P#XU7L=% 'CG_#7WPD_Z&S_ ,IMW_\ &J/^&OOA)_T-G_E-N_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_.K]IK3_ !S\6/\
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MG<SV-M:QR,IE=(QAF;:N5;@DL2#\NV(2O2HPOJU)_)3DOF]4O^&-:BM.<O\
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M\2>(!H6K6&F,T5M<PO)#&<QYVC*RMD  $A3U&:[']IB ?L[_ +>7P@^,4/\
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MCQ9XZ^+O[87[3'Q"^%OP_P#B#)\)? ?@(1VVJ:MIMOYFI7]RY(PC;E9%#)(
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M!4@C(((ZBOD+P_8W_P -_P!B/XOW&E_'6X^,6I6UEJUY;>+K/4FEFL9!:@K
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MME?G.[:/E]0><^!_LP_M#>(_AO\ \$L?&_B1;V:[UCPA<WFBZ7<S'>8-[PI
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M6=]H]Q +F'4+:=)+>6$C<)%D!*E2.=P.,5\;_P#!2+5+OXC1_"WX":).PO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(K?\#->8_&?2OB-^Q[^UMKGQN\,>$=4^(OPX\9VD5MXATS2%:6[TZ6,*/-5
M#\HV%@2-OSNK%,JQ^_J*4G[ZG3TY59=?=M:WW?/J$=8RC4UYG=^M[W7;7\-#
MX;?_ (*X?"W6+5;3PEX/\=>*?%DRLMOX=MM)43F7'".5D; S@$H'(ST-=?\
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M>&[[Q=+;>#G^VZ+I:AKJXL_.O#.8E_B=%&\+_$4 [YK]'Z^4/B%\#_&VN?\
M!1+X:?$ZRT7S_ ^C^&)]/OM4^U0+Y,[?:]J>47$C9\V/E5(^;KP<7'^)3MTY
MG=_X):/RZ6\][L3_ (56_5*R_P"WXO3SZ_+;0\8_:&_;'@_;&^'M[\&_@/X9
M\0>(O$?B;R[/5;^]T][6UT6WW@R^>[?=;"[3_#@G#%L*>K_;[^"E]X3_ ."=
MNG^"?#=E<ZTOA-=+27[+"7D:& !))MH!.,G<?09)X%?==%9RBG&T=&W%W_PN
MZ7HM=/-ZE1DXS4GLDU]^_P ]ONV/@']IK]HCP9^TA_P37^)&N>"KNXN;33TT
M[3[N.[MVADAG6YM'9"#UP''()!YP34?Q]^#/C#QI^RS^SA\1OA]ILFN>+OAO
M9Z7K4.CPY,EY!]GMVE1%'+-F&,[1R1N !. ?T"HK9RUE*.C<HR7DXW_!M_=I
MYF<5RQC!ZI*2]5))?DCX8\0?\%3O"&M^#[O2O!'A+QAJ/Q;N('M[3P@VBN;B
MUO"I ,N,@HK8)VY8@?=&3CZ>_9TM?B):_!OPW_PM?48=2\>RP&;4W@@BB6)G
M8LL6(@$)12JDJ,$@XKTFBDFDGIJ[?*W;MOKUV%9Z:Z+^M?ZL?/W[?W_)FOQ8
M_P"P,W_H:5\N?LR_\%/O@A\*_P!G[P!X0UV[UQ-9T71X+*[6#3#)&)$7#;6W
M<CWK])**RC%QE*5][?AS?_)%NS45VO\ C;_(^-="_P""LGP#\1:WI^E6=YX@
M:\OKB.UA#Z2RJ7=@JY.[@9(K$_:0_P"4F7[-'_8-U+_T5/7W+16BLITZG6+;
M]=&OUN2[N$X=)*WIK<^7?^"FW_)CWQ,_ZY67_I=;UY+^T!\%?%_Q%_8__9]\
M:?#^Q;5_&/P]M=(UZUTM,E[N-;:%G1!GYG!2-@HY(5@,D@'[\HJ8WC&23U<H
MR3[.-[&G,GRIK1*2]5))/\OQ/AK5O^"J7@W4O"5QIOAKP=XQN_BU+"]O;^"F
MT:1KF&\VD 2$<&-6QG +8_@'0<U\?/@+\>?B!^S)\*/'FM-#XF^.G@+5AXCD
MTV"VAC:2(NK_ &94B"JTB". D+]XJX7<=N?T*HI_WHZ2NFGVL[JR]=^K6ER(
MZ63U5FO6ZL[OTV^\^(5_X*O_  X7P\MM-X2\91_$?;Y+>!QI#F[^U8QY8;@;
M-W&?O8YV9^6NKUKQ;\3_ !Y^P/\ $[Q!\6/#VF^%/$=_X:U2:'1M/BEC:VMC
M;-Y8G$CN1*?F)7(P"H(!R!]9UYW^T5X4U7QU\!?B'X<T.U^W:SJV@7ME9VWF
M)'YLTD#JB[G(5<D@98@#N:RKZT:EEJT_Z2_X+-L/[M:G=Z)K^F_^&/A3]D'_
M (*!Z#\"_P!FGP9X?^+7A[Q%HC6UBRZ!JMIIS7-KK=J'81K$ZG E7F,JV -J
MDD9P/5OV-_!?B_XJ_M#?$3]I'QCX:O?!]IKUG'HWAG1M339=+8H4S-(AY7=Y
M,9&>NY\97:3[?^QC\._$/PG_ &8/ 'A+Q5I_]E>(=+LGAO+/SHYO*8S2,!OC
M9D/# \$]:]JKMJM*O.:U>J3]=&_5K2^VKLD<-&[H1CM=)M>EG;T3Z>6K/AO_
M ()=?ZCX_?\ 90[[^0J/XZ?\I5OV>O\ L7M1_P#1-[7W117-3_=ND_Y%;U]Q
MP_6_X>9TO6-6/\]_E>7-_P  _+WQSXA\-?LU?\% /B%XY^/G@Z]UOPOX@A@/
MA;Q1-IOV^TL0JH-BJ00K@*5^4%UVYQB0FN<_;Y_:/N_C]\-O">K>"O >NV'P
MD\,>(+2^N_%6L67V*&[F)9(DMHV^9HP&?<^."5! XW?K+113_=QIQWY&K>=G
M?7N_/3SOL*=IN;?VTT_FK:=OQ\CX1_;TNHK[]I+]CRYA=989O%$DB.ARK*9+
M(@@]Q@U#^T%I?BK]E/\ ;'_X:'TKPMJGC/P!XBT9=(\46^BQ&:[T\QA LXCZ
M;<0Q$$D#Y7!*[E)^]**J+<(I0W4I/Y2233^7]:#;YM)?RJ/W2<K_ 'O;78_.
M?]H;]M"V_;$^&^H?"+]G_P -^(/%NN^)UCL]0U6;3WMK+2K9G!E\Z1^A(7;D
MX4!B0Q.%-+_@H-X+U'X$_LO_ +.7AGPXXU'6O"_B?2[:R=OE%Q=0VTNT\D8#
M2#N1C-?I+7RG_P % /@CXU^-WA[X76W@K1?[:GT7QE9ZK?K]J@@\FU1) \F9
M77=@L/E7+<]*2LG%1T;E!M^DE]R5V_Q9$K\LF];1DDO5?F[)?D<3XF_X*>Z'
M'X9G\/:3\/O&3_&R2%K9/ LND2>=;WA4C<[#[T(;D,H+%<?*,\<)J/[(?Q&^
M'?\ P3!\3>"=,@GN/B)K-P-?UG3;%]\TVZ6-I;92I.]A#&H*KG<591G(S^CM
M%3**E&2V<K7[63O9+M??5WV-(R<91[1U^=K7;\DW;M>Y^=G[._[<GP0^'/PO
MT+PIX,^%_B*/XB6=G'9W/@_0_#A;4)KM$"R,\H'S L"2[G?@Y*YXJ?\ X)EZ
MAXBM_CW^TOIWCC2X_#_C2]U6TUF]TD3+(83,UQ(RJ5R&5?-C&X'^(5^AE%;^
MT;J2J2WDFOO:>GS76_E8QY;4U2CLFG]U]_DW_P $_./]D;XM:)\ ?VN/CC\.
M/'4.HZ%XD\;^,C=:"LUFYAO(WEG*,).@#!U(8\'/7/%=Q^R;_P I"/VK/][3
M?_0#7W)16-/W90F]7&+CZJR2^ZWS\BZBY^=+12DI?.[;^^_R\SX7_P""B_\
MR6S]D[_L?(?_ $?:U[/^WA\%V^.7[,'C#1+2(R:W80?VQI10?.+JWS(JKZ%U
M#Q_\#KZ!KYB_:LOOVD=8U63P9\(O"N@R>&==TW[-<^,-0OUAFTJ20NDI$?FA
MV(38RLJ-@GH<5E-2]BZ4/B<FT^S:C;TLXWN=$)+VD9RVBDGYJ[OZWYK6/)_^
M";LVL_'WQ9XU_:&\5P,NH7]G9>%M*$G.R*VAC-TZ''W9)@#QW#BOO6N!^ WP
M?TOX"?"'POX"TAO-M-%M%A:X*[3<3$EI92.Q>1G;';=BN^KMK2BY6ALM%^K^
M;N_F<5&+4;RW?_#)?)67R/F__@H9\,'^*7[)?CBVM$)U71H%UZP=!\Z2VI\T
M[?\ :,8D4?[U>+?\$[M+N?VBO!'QJ^*7B^S5+GXD7G]C/&?F'V."U$.%)'(S
M*RGU*5]\T5RQBDJB>JFK>E[7?S22^1T2DWR-:.+O_DOD]?4_)W_@FWX9\2^/
M/VBK/2_%,8?3_@7I5_HEIDY_TRXO)UW'T.SS5X[1+7OO[2'_ "DR_9H_[!NI
M?^BIZ^Y:*UYGS4IO5PNWYMJ5WY7<KD.*M54593T7DM++Y6/SP_:5^)&F_LV?
M\%'O"7Q0\<6NI6?@6[\'-I*:Q:V;SQ+<>9,2AV]QE<@9/S@XQS6_\>=4MM<_
MX*._LMZE9R>;9WFCW]Q#)_>1X)F4_B"*^\**BFN1TV]>1MKY\VGWRW\AS]Y5
M$M.=)/U7*K_='8^7?^"FW_)CWQ,_ZY67_I=;UZW^S;_R;O\ ##_L6--_])8Z
M]'HJH/DC./\ ,T_N37ZCE[W)_=YOQY?_ )'\3EOBE\.]+^+GPY\2>#-:#?V9
MKEC+8SM']Y ZD!U_VE.&'N!7PC\$_P!H[Q1^P+H*_";X\>$]=D\+Z+,\.@>/
MM&LVNK&>T+L567!^7;V )< A2@P&/Z+T5"O&3DNNC^6WS5W][!VE%)]-OU^3
MT^Y'YW_'#]LC5OVQO"-_\*?V<O"?B#79O$ %AJ?C"]LFM-.T^U;_ %O[QN02
MNY26"D G:&8@5T_[47[(_B_2_P!G#X2GP#<W/B[QS\);VWU:!;IWDFU4H5>8
M*"Q)8NBLJ9SM4JO.!7W313V7N:.Z=_..WR7;S87O).6JLU;REO\ -GP])_P5
M<\!R>&S9VO@KQG-\4"OD#P+_ &3)]J%UC[A;ILW=P-^.=F>*R/@;\"O%GPA_
M8:^/&N>/H/L7C3QQIVM^(-0L>]KYEI)MC8 G#Y+L1VW@'D&OOBBE.*G":ZR5
MO1>2]4NO0JG)TZD);J+3\VUW?HWT/F/_ ()I_P#)DGPR_P"O>Z_]*YJ\V_9I
M_P"4EG[3W_7EIG_HF&ON6BMYU.;$O$6W4M/\7^1S*G:@J-^L7?T=S\XO@-\6
M]$_9Q_;T^.WA?Q_%J&B7_P 0]?L6\.S/9NT%YNDF"$.!@!C<(-WW<A@2",5V
MWP#_ .4IG[0__8 L/_1=I7W/16=)^S]FWJXQ<?5<JBOFOQ\C:K^]=3ISM2^:
M:?XV^7F?#'_!.+_DKW[5?_8]2?\ HVYI_P"U5_RD2_97_P!W4_\ T6:^Y**2
MTG1G_P ^^7Y\L>7Y7W%)<T:L?Y^;Y<TN;\-C\^OVCO$6H?LH_MZ:9\<M<\.Z
MMJOPTUOPT-#U+5=+MC/_ &=*'',@' 'R1'DC<&?;DKBO)OV_/VGX_P!J+X4^
M'Y/A_P"&M:D^'.B^(K.ZO_%VJVAM+:YN6W10P6RO\TA'F2%S@;=J_P!X9_5Z
MBBG^[Y+Z\LKK_P "YK/YWM^-]G4G?F:T<E9_^ \OY;_H?%_[='PQ\;:9X\^%
M'QY^'VAS>*]7\ 3R)J7A^U#-<7=C*!O,0 )+ &12 "?W@.#M(K!\9_\ !43P
MGXT\%WF@_"SPGXN\2_%'4K>2TM?#IT=UDL+AE*[[@@D;4)SA-V<8)49(^[J*
MCD3@Z3^%MOSUWU\]_78<9<LHS7Q))>6FVGD? ,'[%?BSPQ_P3#U_X5I#]K\?
M7T1UR>QA</NNA<1S_9E.<,WEQ+'D'!;H<&G_  7_ ."D'AG2OA3X9\"OX(\9
M:A\8-)TZ#1W\&6ND.)Y;F&)8]^XX"1DJ"2V&49^4XY^^Z*UE)RE.^TK:+I96
M5GKTTZF:BHQBEO&^K_O6;O\ -7Z'YZ?\$U=+\:'X5_M$6*SVVB?$)O%E^GG%
M5F@M=1, Y(Y5D67Z@@5GZ+^W!X'B\#IX%_:]\ W:_$+2FEBG76/"\=U:ZD0[
M;);8*A4$C W* A(!5B#Q^C=%1;9=+15O\*M==OQZ=B^[ZW;^]WL^_P"'XGP9
M_P $U/ACJ>A^-_C!X\TOPCJOP\^&'BB[MSX;\.ZL&CF*(7+3>4Q)52&&.2/F
M(!(4&OO.BBK;TC%;))=]O,A+64GNW<_-_2_$GCC_ ()N_&;XA'6?!.O>.O@G
MXOU)]<MM;T&'[1-I4C9W)(I(48!1/G9 0BLI/S+74>-/^"GWA/XK>$]6\*_!
M[P'XQ^(/C+5K*2UM[--*VV]NTBE-T[!V8*N[)PNTXP64<C[XHK'D4J:I3UBE
M;L[;6^[0UYG&;J0T=[^5_3U/SQ\9? 75/V</^"2_BWP=KLB/KPL?MVH1Q,&2
M&::[B<Q!AP=@VJ2."02.*D^!O_!2#P[\*?@/X*T#XI>%O%6D>,;;0[-=-M[7
M33/'K]OY2_9YK60$*2Z;-P8C:Q(R2,#Z=_;2^'/B'XM?LO\ C[PEX4T_^U?$
M.J6<<5I9^='#YK":-B-\C*@X4GDCI75_L\^%=4\"_ 7X<^'-<M?L6LZ3X>L+
M&]MO,23RIH[=$=-R$JV&4C*D@XX-:J4IRK2>E^33T4MO31==]>A'+&$*<5JU
MS_CR;^NO;;0^>OV$?A?XRG\4?%7XX_$'0Y?"^O\ Q$O(WL=#N@1/96$0/EB0
M$ JQ!488 XC!(&[ \&_8U_Y1A_'O_KIX@_\ 2*.OU HJ917).G'1."@O))IW
M\]M?-W-*<W&2F]7SJ;\]&K?C^!^>7PO_ &6]-_:,_P""8?@#0M-@@TOQ7:VL
MNL:)J4($31Z@L\I!9UYQ(!L9NO(;JHK;^&OC:\_X* ?L7^//A9XBD72OBSHL
M']D:O:WGR.+V!PUO<..RN\.U\#AA(!QC/WE155;595;[3UMV?1I^FGR78QHI
MT8TK/WH=>ZZI_/7RU[GY[? W_@H-HW[/?PRT;X;_ !Y\,^)O _C;PO9IIB!M
M+>:'4XH1Y<3PNO#$JH!/W">5<@\>Z_LO_'/XD?M(:UXMUK7_  !%X.^$K*(/
M#\>M6DD>JZD& W/*K.8S%MW=%P=X 9MK$_2E%4YN<G.IJW]VN[M_2$H\B4:>
MB7WZ=+_TSRK_ (9/^" Y'P;^'_\ X2]C_P#&J^,?VVK.T^%_[:OP_P#BA\3?
M!=[XS^"MGHGV!%@LQ=VFEW0:0;I(3\G!>-@&QN'*[C'BOTCHK/7FC)?9=_P:
M_)FFCC*+ZJWXI_I\S\R/VQ/VJK+]HS]F+Q?X5^"/@37-5\)PVT=]KGBB72_L
M&F65I!(DS)$7P9)=R+E0!A=Q&<'%W]L;6+?7_P#@E!\-[ZV='BDM/#X.QMP#
M+$%9<^H8$'W!K]*J*+>ZXKK*$OG%_D_PWUN.,FI1D^BDO_ DOQT^>FUC,T'_
M )%K3O\ KTC_ /0!7YO?L+?"#_A?7_!.[XJ^ EF2VN-9U[4([::7.Q+A4MI(
M6;'\(D1,^V:_32BG)*;JM_;5O35._P" J;=*$(K>+3^Y-?J?GM\$?^"@6E?L
M^?#/1OA?\:/"7BKP[\1O"]G'I4.GV^F-<?VPD0\N%K=@<,655&2=I/(8YXJ?
M\$]_%7B#XB?M>?M(:]XO\/3>&M6U:#3;B71+U?WMK ZOY$<H_O>3Y>X$ Y)R
M <BOT4HJN9RJ^VJ:R::?_;V[_KY6(<4J?LH:*Z?W=/Z_$\J_X9.^"'_1&_A_
M_P"$O8__ !JD_:=^%L7Q6_9Q\>^"X+>,->Z+-'9PJ@"K-&N^  =@'1.G3%>K
M45C5A[2G*G>US6G+V<XSML?FM_P2MN-5^-?Q"\8_%K7XG,NC>'])\%6#R-N/
M[F!/M!^K-%&__;4UZ]_P4\TBXT'X7^"/BSIMN9M4^&_BBRUC"\,UNTBI(F>P
M9_)S["OLNBMJTG5Y7'1II_._,W\W=_,SI15.Z>J::^5N5+Y*R/E;_@FGX)N/
M#7[+.D:]J2_\3OQG?77B:^D/5VN)#Y9)]XTC/XU\N/XL\*_LK_MS?%OQ1^T+
MX1O-3LO$ETESX4\6W&E_;[:V@!8B./(.&"&*/* LOE8P V3^IE%$G^]52"LD
MK)=EHK+T22O_ )@KNFZ<];N[?G=O[FV]#\H/VU?VC+_XV3_"/Q7H'@;6]"^#
MOAGQ=93/XFUZT%DM]<,X*F",G=Y"QI)^\Q@EL$ @9_0?]J;X/P?'_P#9\\:>
M"]J2W&I:>SV#GD+=1XD@;/IYBI^!->L45E."E2E275MWZZI+[U;3Y=KEQDXU
M(U.R2MTT;?ZZ_P!(_-3_ ()NS>(_VCOC+?\ Q9\9VTBOX#\-67@G31<<DW2Q
M_P"DRG/1^&)]KC':O3?VW/A[XV\ ?'KX9_M'> _#5UXR?PM"^EZ]H>GH7N9+
M)_,'F1H 2V!-*#@$J=A(VAB/MZBMISE*49K1QU^;OS7\G=Z=G8SC%14H/:2M
M\DDE]R2U[J_D?#/BC_@JEX/\0^&WT[X2^$_%'C7XF7<9CL_#DFBRC[+.>]UM
M;)53U$9.<8RH^8?77PIO/&&H?#O0KKQ_::;I_C">V$NHV>D!_LUO(Q)\M2SL
M25! )W$$@D<8KK**5U9Z:O\ K3^F/6Z[+^M3@_CW_P D,^(G_8NZA_Z325^<
MO["O_!1;X/?L_P#[-/AKP1XMNM9BUVPFNWF6TTXS1XDN))%PV[GY6%?JM16<
M4XRG)?:27W-O]2Y-2A&/\K;^])?H?FU\;OVIO%'[>_A-OA-\!/ _B)='UV9;
M?7/&6NV?V:QMK56#,JN&88; SN(8J"JHQ;(]E_:T_9;O)_\ @G_<_"GP':S:
MI>^';&R:RMHT'G7IMI$>7"CK(X$C8'5C@=:^P**4X1E3<%U:;?FMODNWF[A&
M34U-ZVNK>3W^;[^2/A/X>_\ !2SP]K'P^TCPIHO@;Q=K'QEALH].?P;#I;*Z
M7B1A"TDIPL< <9+-\RKR5&#7+?\ !.2PU'2OV.OCQ9:N%75K;Q#KD-X(R"HF
M6QA$F"."-P/2OT5HJJW[Z-6^]2+B_*[3NONU773705)^RY$MH-/[DUK]_P#P
M]SY&_P""5/\ R9'X)_Z^=0_]+)JY/P]_REZ\4?\ 9/X__0X*^Y:*UJ3]I65;
MM?\ &+C^MS.,>6G*'?\ ^24OTL?"_P"PG_R=]^U__P!C#9_^AWE+^W'_ ,GD
M?LB?]A^Z_P#0[6ON>BH@^25%_P#/OE^?*K?*YI5_>>V_Z><WRNOQ/@C]H*VU
MW]D7]LD_M"VGA;5/%/P[\3:,-(\4?V-%YUQITB! LY3CY-L,7)('#@D$KGR+
M]OW]MK3/VC/V;M:T7X6:!KNJ^$H[BUF\0>*[VQ:ULK=1,GE6\9<@O*TICR .
M%!(R,E?K+]HCP3^T#X=^+VF?$KX-ZO;>*-+33_L&I_#S7-0>"TG(8D3P981K
M(00"Q*XV#[P8K7EOQ#^%7[2/[:_]D>$OB9X3T'X._#*WOX;[5;6WU5-3U'4A
M&21&C1,R*N?7;@X;YL;3C&#J0C2>R?I9<U_FNJ2UZ&CG[.;J=6O6[Y;?)]'?
M3JC[-^%R-'\,_"*.I5ETBS!5A@@^2G%>6_MN?L_W_P"TI^SSK_A#1KM;/7U:
M._TUI'*1O/$21&Y[!U+)GL6![5[I;6\=G;Q00H(X8D"(B]%4# 'Y5+6V(M6E
M)[7=_36Z^XPP]Z$(KLK?A8^ ? G_  4\M/A7X?T_PO\ M > /%W@;QII\(M9
M[L:;YEI?-& IF0EE;+$$_*&3N'(-<_XD\5:Y_P %(?C5\)Y_"/@77O#/PL\%
M:JNNWOBSQ%:BW:\=70B&W4,P8'RP/E9C\^6"A?F_1ZBJYN::J35VG?RNM;V]
M=;;"Y>6#IPT35N[MM;[M#X6^+'_*6[X-_P#8F77_ +?US&OZEK_[ ?[77Q$\
M?ZEX3U;Q#\&OB.8[V]U;0[7SY-*O%+,3*H/"[Y)3SC<L@*EF1E/Z(45$;Q4.
M7>*DO52DY-?BOFKFLVJCES;2Y?DXI)/\/Q^9\0WW_!0K5?C=XLT'PK^S7X.N
MO&5Y<7B+JOB+Q#ID\.D:=;$'<S,KHP8=?FP#MPH<L,0_MF> _''PL_:+^'/[
M27@OPU=>-(-!LFT?Q)HNEQEKEK1O,'FQH,LV!-)G&=I1"?EW$?<E%&W*X;IW
MOZJUO2U]/,GXKQELU;\;W];VU\CX9\5?\%3O"OB?P\VE_!KPGXF\=?$N\399
MZ#+HTH2TE.!FZVMG:O.1&3G&-RCYA7_X*/77BRZ_X)XRW/C>WTZR\72W.F2Z
MC;:3N^S03&=28T+,Q.W(!.3D@D<5]W5\T?\ !1#X/^+OCI^S#K/A+P/I']M^
M(+B^LYHK/[3#;[D28,YWRNBC '<UC6OR+E6O-%^EI+;\WN:4_CNWI9_BNOZ;
M'E^B_P#!3;0O!?@?3M#\=^!O%UC\7H;2*#_A%+?3&D;4YRH"RVTH)5HI#\P;
MDX)P'P,]O_P3U^"?BSX=^"_&?C?X@6']D^-_B)K<NO7NFL,/9Q,6:.)QGALR
M2-M/(# 'D$5]-^%;*;3?"^CVERGEW%O9PQ2)D':RH 1D<'D=JU:[:C4:DVM6
M[KRM>^B\[+]#EIINE".R5G;K>UOPN_U"BBBL#8**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ KR[X]_M,?#O]FGP_;ZMX^U^/2EN
MV9+.SBC::ZNV49(CB4$D#(RQPHW#)&17J-?G-^V%KUO\!OV^/AW\8?B-H%]K
MOPOCT;^S;6_@MS<1:5?;I3O*=-XW!Q_$025!,>*AOWHQO:[W^3?XVLO-E+X9
M2M>RV^:_+=^2/1=-_P""LWP<DOK1-<T'QWX/TVZ/[G6-<T)5M'[@@Q2R.1CG
MA#Q7V#X9\3Z3XT\/V&N:#J-MJ^CW\2SVM]9R"2*9#T96'!KQ;0?VG/V>_P!I
MCPW=>&K;QWX9\066M1-:2:+JDPMI[A6&"HM[@)(3Z87MD5E? CX,M^PK^S?X
MNL)_%,_C+2=$6_U^U,UG]F-M"L/F-  )'R-R,V>.7;BKE)4X3E45DE=/OW7Z
MW%&+J2C&#NV[6_)_?I8Z/X^?MD?"S]F^Z@T[Q;KSR^(KE ]MX?TF!KN_F!.%
M_=KPFX]"Y4'!P37F6B_\%/?A/)X@LM)\6Z+XV^&+7Q M;SQIH1M+>7) R'22
M3"Y/+, HZDBN+_X);_#:'Q7X&USX^^+(X]:^(?C;5;N3^U;E=\EM;)(8_+B)
MSL!=7Z?PJB]%%?7OQ@^$_AWXW?#K6_!GBBQBO=*U.W:(^8@9H7P=DT9/W70X
M8$="*)1G27O*\K7:V^5^Z[OKT%&4:C:3LKM7]-+V[>7;J6_'7Q#TKP#\-]<\
M;W1DU#1-)TV759#IVR5YH(XS(3%E@K$J.,L <CFN+_9I_:>\%_M5> Y?%/@Q
M[R&"WN6M+K3]3C2.[MI!R/,1'=<,I#*0Q!!]00/+_$/P3G_9X_X)]^/_  %+
MXHO/%T>E>%=42"_OH1$ZQM!(PB503A%)(4$G P,X KX8_9[36?V'_"WP?^/V
ME_:K[X9>.+)=+\:V*;I/LDPGD6.X ^@W+[K(F1YBBK7)[64;^[[J3\Y<UK^M
MK>K1+YO91=O>]YM=U'EO;S]Z_HK;GZH?'SXW:'^SK\*]8\?>)+34+W1]+,(F
M@TN..2X;S)5B7:KNBGYG&<L.,_2M*R^*WAR;X4V?Q%O[P:'X7N-*BUE[G4RL
M9M[=XQ(/,P2 P# 8!// S7SK_P %,M7LO$'[!?C/4]-NHK[3[Q--N+:Y@8-'
M+&]Y RNI'4$$$'WK!^//PD\2_&K_ ()F^'/#GA/$NL+X;T6^6T:58Q=1PQ0R
M/'N; !P-PR1DJ!FL9.4:-6=M8RBO2Z=[^FYK%1E.DD])*3];6M;UN71_P58^
M#[2F\&A>/#X1%Q]F/C$>'S_9(;.,[_,\SKV\O=[5]:^%/%>C^.O#>F^(- U&
M#5M%U&!;FTO;9MT<L;#(8'^G4'@U\%6?_!2C]GJ/]F6/PS-:W*ZRFA?V.W@$
M:1+S*(O*, <)Y'EEN^[.WG;GY:]Q_P""<_PC\5?!7]E7PWX?\8#R-6EGN+];
M'S!)]CBF?>D65R,]7(!."Y%='*DZD>D;6???3]=.GR.?F=H/9RO==O/]#T7]
MI+]I+PG^RU\.QXP\7QZA<V,EW'8PV>E1QR7,\KY("+(Z*<*K,<L.%/7I70_!
MOXMZ!\=?AGH/CKPP\S:+K$'G0I<JJS1$,5>.0*S .K*RD D9'!-?('QLN!^T
MM_P44^'7PSC O/"WPUM'\2ZY']Z-KM@IB1AT)&;?\)'IO_!/G5I?@A\;OC-^
MS?JDK)%HNI/KOAQ)&)W6,NTE5SZ*]NV!W>3WK*C[Z?-O*[CZ1:3^_5KR1K5]
MQKEZ64O65VON]U/S9]ZU!?7B:?97%U(&:."-I6"]2%!)Q[\5/6;XF_Y%O5?^
MO27_ - -8UI.%.4ENDS6E%2J1B^K1\6:1_P5T^&7B"T^U:7\-_BIJ5KN*>=9
MZ%:RIN'4;ENR,\BNS^%__!3;X,?$CQC;^%;V37O 6NW,BPV]KXPT];,2NWW5
MWH\B(3VWE<D@#DXKC_\ @CM_R:"?^QBO?_08:]G_ &VO@%H/Q^_9]\6:;J6G
MPSZSIVGW&H:/?%/WUK=1QEUVMU"L5VL.X/L*Z,0UAO>EJDDWTT:3?W'/A[XC
M1:-MI?)M:GI_Q6^).F?!_P"&_B+QKK,%W<Z5H5F]]<PV**\[H@R0@9E4GZL!
M[U\F6'_!6CX=:I9Q7=E\,/BQ>6LHW1SV_A^V=''J&%U@BN4\&_%;4_C!_P $
MA_$^K:U<27FKV7AV_P!*N+F4EGE\ABB,Q/5C&$R>YR:]'_8F_:0^$GA3]E'X
M8Z1K?Q1\%Z/JUGI$<5S8:AXAM()X7#-\KQO(&4^Q%*47&K4A?1<MO._-K]R0
MHSYH0=M^:_E;ET_%_<+X1_X*:^"O&'BK1M!M_AA\5+*?5+R&RCN;[P_!'!$T
MCA \C"Y)5 6R3@X /%>A?M/?MJ>#?V4]8\+:7XFT+Q-KM[XC69K*+PY9PW#9
MB*!E8231G),BX"@YP>E=]X9_:(^%/C37+71O#WQ-\':[K%T2+?3],U^TN+B8
MA2Q"1I(6; !/ Z FOC[]O_7M,\+_ +97[*.K:SJ-II.E6>IW4US?7TZPP0()
M;;+N[$*JCU)Q0O>J4J>W-*S?E;]+%2?+3J5-^6-TOG^IU?\ P]8\"?\ 1)_B
M]_X3D'_R57L?[./[77A_]IC4M;L]%\(>,O#$FDQ132/XJTR.T28.6 $925]Q
M&WG.,9%=!_PUC\$/^BR?#_\ \*BQ_P#CM=CX(^)7A'XF6-Q>^#_%.B^*[.WD
M\F:XT/48;R.*3 .QFB9@&P0<'G!IKS0/R9TE%%?)_P 3OVL/C9X+\?ZYH?A[
M]E[7/&&BV-R8;77;?71!'>H /WBI]F;:#SQN/2L^97Y2[.USZPHKXG_X;7_:
M%_Z,Z\1?^%(O_P AU]GZ;<RWFFVMQ/;M:3RQ)));L<F)B 2I.!G!X_"KL[7)
MOK8?>7D&GVDUU=31VUM C22S3,%2- ,EF)X  !))KX^\3?\ !53X-:5KUWIG
MA[3O&'Q"%H2L][X3T83VZ$'!^:62,L/1E!4]02*]9_;8\%^)OB)^RO\ $?P]
MX/6:3Q!>Z81!!;_ZRX575Y85'<R1JZ =]V*^<_V*?VZ/@)X/^#/A'X=ZKJ<7
MPT\3:):)8:CINLVCVL;7: ">8S;?+!>3<Q\QE;).1Q41O*4E?:VG5WOKZ*WJ
M7+W81E;=OY6M^=_P/H[]GG]L7X6_M/+<P^"==9]8M(_-NM$U&$VU["F0"Q0\
M.H) +(6 ) )&17J?C#QEH7P_\-WWB#Q+JUIH>B6,?F7-]?2B.*-<X&2>Y)
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M\;>*;+5+_2H[J&S,.D11R3[Y"0IQ)(BXXY^;\*])LKI+ZS@N8PPCFC610W4
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MK_Y,^I:QO&7C#1_A]X5U7Q+XAODTW1-+MWN[R[D5F$42C+-A02>.P!)KXO\
M%G[3_P"UA\-/#;?$CQ3\%?"__"NX0;J]T33]1E;7-/M.OF2OO,9*CD[8SCG<
M$ )&K^V?\5?$?Q>_8;O?&7PI70]0\%Z[HL]QK<NM>8MU!9E,,L C;:)U<,K!
MMP!4UE6E*G2E46Z_!]+^7^3+IJ,JD8O9_CWM_78^F]'^,?A_7_@V/B;IXN[K
MPR^DR:U%B(+/+;K&TF0C$88JO 8CJ,XJO\!?C9H?[1'PJT7Q_P"&[74++1M6
M\[R(-4CCCN%\J9XFW*CNH^:,D88\$=.E?,O[%7C#XO>$OV.7USQ/I_A-?#6C
M>#DOO"3:=]H:YF6*"1\7H9\9^6/_ %>WJWM7=?!G]LA-3_8ELOCQ\2HK+32L
M-U+=VVBQ.D;M'=R0110I)(QWN50<OC<W8=.FHHTY5;O2-OE=R^]NWRMYF5/F
MJ4Z;MK)M>NB?Z[GU#17POHW[27[7GQ#\)K\0_"?P7\(VG@J:,7EEH6K7\S:U
M?6V,[XV$B("PY4-&"1C ;(S]&_LN_M&Z)^U%\)[+QGH]K+IDWG/9:CI5PVZ2
MQNTQOB+8&X896#8&589 .0)Y7JGNMUU7];>NC#F6C6SV?0]/UC5(M%TF^U&=
M7>"T@>XD6, L512Q R1S@>M?$^D_\%<OAGKUF+O3/AM\5-1M2Q43VFA6TJ9'
M4;ENR,U]B_$#_D0_$G_8-N?_ $4U?"/_  2W^/7PR^'W[)NFZ1XI^(OA/PUJ
MR:K>R-8:QKEK:3A6<%6,<D@;![''-94[RJ5(MZ1BG][:+G[L8-+=M?<KG;+_
M ,%6/ C,!_PJ?XN\_P#4N0?_ "57VC9W*WEI#<*K(LJ+(%<88 C.#[UYSIO[
M3WP<UK4;73]/^+7@:^O[J58+>UMO$EG)+-(Q"JB*LI+,20 !R2:\M_;;_:RU
M7]E$_#6_M-,M=4TC7-::RU6.2WDFN?LZH&(M@LB#S3G W;ADCBKE)1BKK=I?
M>TOS8DFV[=$W]VOZ'T]17PM\1/VFOVM/AOX5N/B3JWP9\(6W@"S7[7>Z"-4D
MEUJTM1R7DE5_+X')VQL5[J,''T4G[4/@R/\ 9I@^-UW+-:>$Y-)75#&P4S@M
M\HMP,X,GF?NP,X+=Z3:C!SEI;?R_JS!>])0CK?;S_JZ^\]?HKX6\/_M+?M;_
M !3\*CXA>"/@UX1LO!$T8NK#1]<OY6UC4;?KOB99$1=PY7>@SD8W @GUOX7_
M +<?@?QU^S1JWQAU>.?PU9Z#YEOKFDSGS)[.\3:#;KPN\N70)P,[P"%.0'+W
M5)RTY=UU7R_#UT!>\THZWT7FSZ.HKX>\/_M$?M=?%C0%\<^!?@]X-TSP7<H+
MG3=*\2:A+_:VH6YY5T994C3<.1YBCJ"-PP3[I^RY^T]IW[2GA'5[AM&N?"OB
M[P]>-INO^&[Y]TMA<KGC=@;D.UL,0#E6&.*'>*DY:-:M=;?U]W45UHUJGUZ?
MU^?0]MHK\\/@;^W9^T!^TUX;>P^''PX\+W?BC3[J8:SKNK&>VT2SCW$00HGG
M&629E!+;7PN1\N#D>S?LW?M>>)_&'Q6U3X._&'P=!X#^*5C:_;K=+&8R6&J6
M_=X"68@@<XW/D*_(*LHJ,7*R7577FK7_ *_R'/\ =MI]'9^3O8]3\#_M(>&O
M'_QP\=_"O3['5H?$/@V*":_N;J&);242JK+Y3+(7) <9W(O?K7JU?E_I?Q5\
M9?#_ /X*0?M!:3\//!#>./&>OP6$-G!-<K;V5FD=O TEQ<R$Y"+N48&"Q( (
M)&?:?#O[7OQD^$_QR\'?#W]H'P-X;TVR\9W'V/1?$?A"XE-M]H)51&Z2N[$[
MW13]PC>" PZ32_>4Z3^U-?>]=%_7XDS]R=5/:+^Y66_X_P##'VO17SO^U-^U
M;=? W6O"/@KPAX4E\=_$WQ?*\>D:&MP((E1?O332'[JCGT!"N2RA2:\6^(W[
M47[5?[.&BIXT^*/PQ\"ZSX!ADC746\)7T\=W9*[A%+&65P?F8#Y4*YZLN<U,
M9*2OTO:_2_\ 7XZ&CBT[==[=;'TW^T=^TAX:_9A\%Z;XF\4V.K7]A?ZI#I,4
M>CPQ22B:1796822(-N(VR02>1Q7JBMO4,.A&:^"/^"J7B2R\8_LH?#C7M-<R
MZ=JGBK2KVV=A@M%);7#H2.QPPKW[]JC]JS3OV9_#?A^&WT2Y\7^-_$MP+'0/
M#-D^V2\E^4%F;!VH"Z#@$DLH ZD:6<8OF7O<[C;Y1T];MDZ2<.1Z./-^,E?T
MLCWNBOAKQ+^TE^UM\&_#Q\<_$/X/>#]3\$VZ>?J=AX8U"7^U--@_B>0M+(C[
M1R=BD<$DJ,D>F?'C]KQ/#?[&5W\<OAI_9^M))#:S6*:M$[1?O+F.&1)4C=&#
MH6=2 W#+WJ)/EBY/HTGY7V'%.<E!==O,^F:*^'=-_:=_:B^+OAM?'7PJ^$?A
MD^!/*62TC\374D6IZTH^_+;(LRK$A(.T29R,$%LXKW+]EW]JK0OVE/A=>^*%
ML9O#&J:+/)9Z_HU\W[S3;B-=S@D@$IC)#$ \$$ J15-<O-S:<NK]._I^74A2
MORVZ[>O;^OD>X45\/^&OVL_V@?VEO[3USX"?#GPK;> ;.ZEM+;7O'=U,'U1D
M(!:*&%T*#/KN';<""!VO[,?[6GC3XE_$3QC\)OB9X)M/!?Q4\-V(OS%97)FL
M;V%BH#I\S%0/,B_C;(?J""*2NUMK:]NMK7V]->Y3LGOI>U^B=[?GH>W:/\</
M"'B#XO:U\,]-U%KSQ;HM@NH:E;1PL$M8W*!%9R "S"13M7.!UQQG&7]H_P -
M-^T<WP5^PZK_ ,)2NC?VY]L\F+[#Y&[;MW^9OWY[;,>]?GU\#=1_:,7_ (*#
M?%*6#2_A\WCB2PL!XGA=KO[!'9XML&T_>;_-V;/ODC.:[#XZ?$[7/A;_ ,%2
M$O/"_A"Z\<^*-2\$Q:9I>BVTRP+).[LV^65N(XU6-V9NV.PR0+X:+_GO?[I-
M6^Y?B3+XJJ7V>7[GRWO][^5C]*Z*^%?$7[87Q\_9R\7^%Y/CU\/?"<?@/Q%?
M1Z<FM>#[J9GT^9\D"82R/O(4$D *"%8JQ(VUZE^T!^TQXI^!7[1GPA\/W=AI
M,OPR\;3MI=SJ3P2_;+2^SMC D$GEA&,D7!0G"R<\<-+F<4OM/E^?;\OO0V[<
MU^BO\NZ^Y_<SZ8HKR7]JKXXI^SG\!/%GCP);SW^G6P33[>Z#&.:[D8)"C!2"
M5WL"0"#M!Y'6NH^#>L^*?$?PK\*ZMXVM;&Q\5:AI\-WJ%IIT3QP02R*'\M5=
MW8;00IRQR03[4H^\I-=+?C?_ "_+N-^[:_6_X6_S.RHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M02#N5@?2OJ3X&_ OPA^SO\/;+P;X*TXV&DV[&5Y)7\R>YF;&^:5_XG; ]
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MD&K>*_CY^T5\-/@3\/\ 3;/7M1TE3XGU&PU"0I9R2*"8TN""I""-7S@@GSU
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M\;/[K9SVJG^TU^Q_H'[15]H?B*WUW5/ OQ"T#(TGQ9H;[;F!3G]VXR-Z9).
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MA@R,_@/R%._X*5@?\)S^S&<<_P#"P+49_P"VD->Y_#3]F3_A7?[2WQ/^+?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X7X@? _P3\4O%'A#Q%X
MGT7^T]8\(W;7VBW/VJ>'[),2A+[8W57YB3APPXZ<FNZHH6C4EN@Z-=PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MA;[X(>"M2^+VG?%"YT7S/'6GV#:9;:K]JG'EV[;\IY0?RS_K'Y*$\]>!7=44
M;._]=OR#=6_KO^>H4444 %%%% !7"_$;X(>"OBUK?A/5_%>B_P!JZCX5OUU/
M1IOM4\/V6Y#(P?$;J'YC3APPXZ=:[JBCJGU6OS **** "BBB@ HHHH ****
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M<4,:C"HBC@  =!5ZBBJ;;=V2E9604444AA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-P*_*JDL6*\8R1A=J%*27.TH67=V5E\GW[:G5)7K58M\MW/7LFWKK_78W_\
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MO!_[1LFB?$^&-Y[?QG_PEH-U-=8)!F (!0MU"[6Q_%Z]%^V?\-[U_@K^S/\
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MJ_$KQ!I_PFT[X-6FLZ)>7L?AW3HXD#H455N'6.&(!G51C*YVA#GG ]P_8?\
M^30_A%_V+EI_Z *)I>UJW5G:'W^_?T=_FMM-1QE[M-1>GO\ W7C;U7X/<\*_
MX)W^./$/A.Z^.OPN\5>(;[Q)I_PSUDPZ??:A(9;A;,^< A8_P@0;@N?EW$#
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M!3M7S9"2^<]V90_E[><BOU7K7XJ<):]5KOHW]Z[/Y=#/X:DH^CTVU7X/NO\
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M'.[TKX7^"9_V,/\ @H!X4^%/@_7]7N?AEXZT2YO5T'4KHSQV-Q&DS[H\]/\
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M5.;DQ*>RI_)>\MNGK;R-*/+SX=]>=>K]V6_Z7\SI=)_:$UC]G#_@E#\/-?\
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MP PN",J3EC[3^S+\*_BS\"IOBCX%\5:E=^*/A?9Q&;P?KVJWL<][Y;1G?;N
MQ<*N0!E5&48J & 'FW[$/[9'@#X6_!/3_A;\5M:B^'7COP.)=-O=.UY&M_,C
M61FC>-B-K':P&T'<2,@$$$^G_ ?]J?7_ -ISQ=\4;K0=$M5^"^CVC6NC^(Y;
M>:&ZU*[\L>9M#M@QCYS]P$ QYY)%/$\JC4C0^#DE;M:VC]>W5MV'A^9N#K?%
MS+UO?5+RW\K:^9Y'_P $\KKQG9_\$W]3D^'=C%J/C?[7J2:1!/)'&GVAG"JY
M,A"87.[#'!VX[URL?[*?[/T/@^"^_:3^,8U'XO7-L+C5IM1\:1"ZTV=AN,,$
M(=LB,G'*N"1D  @#B_@]JGC+1?\ @COXGN_ \EW!JL>IW7VB:PR)X[,W*"X9
M".1B/=DCHNX]J[?X&^*/V#_AU\#] UJZM?"^KZTME";VWUW3CJ6KR7FP>8OD
M2(Y!+@@; (^X..:VJVE.<NR@O/X>B[=WNVDNAC1NJ<5W<_3XNOGV71-L[S_@
MEI\3M0\4Z=\7?!Z^+K_QQX1\*:TL/AS6-3=WGDLI/-" EP&"[8E8*0,;C@ <
M#D/^"?/_ "CS^,O_ %]Z]_Z0I5W_ ():ZX^K?%;]I>6Y\/3^$KF\UFUU%="N
MK?[/)913-=.D1CXVE5*C&,#(JE_P3Y_Y1Y_&7_K[U[_TA2L,1_!KM]:$?_;3
MLP]E4C%;*LONM,[#]B_]G_P7^TA_P3K^&7ACQWI\VI:/;WM[?QPP74ENPF6]
MNT4[D(.,2-QTYKQ']L+]C_X#?#.ZT+X9_##P3>Z]\:/%KB+2['^V;F1-/A).
MZ[G!? 4 -C=Q\K,?E0@][\ _VIM+_9-_X)=^ _%%S;_VAK=Y+J-CHVGD';/=
M&]N2"Y'W8U +-SR!@<D5I_L7^-O@U\+H]6^)7Q-^,_A'7OC3XN_?ZM?S:O#)
M_9\1P5LXB#@!0%#;?E^557Y47/7B8QGBJO1)Z]V^B7RW?1>;1R4Y.-*/5N]N
MRU>K^>RZORN>P>'OV>_&_P"RK^Q3?>!/@WCQ!\2&C,JWD\T4*&\F9!/.GG$(
MH1 =BM_<7.23GY\U7]D_]E[1_"0E^-/QL.I_%/[,LFK:S<^,TDU"WNMH+K%#
MN8D*V0 R.3BO2_\ @H9\:C\1_P!B_P 1ZQ\'/%,'B'2H=4M[+Q!?^';GS3#9
M%294+(> 2T.[_88YX)KD/ ?C3]@SX7_"_2=3T72/#'BC4V@C^SZ==:6=4URZ
MNBHQ'Y4J,R2,_'\* G@@8KF<G.52<M[I>>VEET6OJWIT-5%4XTX1V=WY;Z\S
M[]>RU?4UO^"?=PO[4W[,/Q'^'GC[7=0\>>%+'7Y=)M-2NYY4NKJP CEBW2$^
M8.1N&3D!MO0 5Q7_  2L_9K\!W&L>,OB#)IMP?%'A+Q=?Z3I-S]KDV16_D!-
MK)G:YVROR03S[5V__!(W4I[OP[\:HK_2WT'5?^$RDN;G29$\MK-I$_U10X*E
M2K+@@?=JG_P3!^)GA;PSJGQ8^'FK:Y::;XVO/'>H3VVAW3^7<3H$ 8HI^]CR
M9,@<C;SC(K2/-[=/[3I7\[_N^V[LY?>S-V]BX]%-KRM[_P"&B^Y#/V1?&]O\
M-/B5^W%XMNXFGMM#\0W.I21+U<1-?/M'N=N/QJA^SG^R>G[<G@2+XR_'[Q%K
MGB2Z\133RZ1X=M+][73]+MED:-?+1>0<H2,$#&"VYB33OV7_  &?BEXT_;M\
M'I*L$FNZY=Z<DKC*HTK7R*Q]@2#6Q^PW^UUX)^"WPFM_@U\7=5C^'/CSP1+<
M6,]KKBF&*XB\UI$>.3&P\.!C.6 #+D'-1#E<8\VZIT[?^ ^\UY_#Z(VK<RJ3
MY=O:3O\ ?[M_+XO5V+'P=N?$_P"QK^V1H?P*N/%.J^+OA=XTTV2\\/?VY-YU
MSI4\:R$PK)Q\G[HC: %^=" "&W<#I/PAU3X\?\%$?VA_!TGBK5O#/@F1-.O=
M>BT*X^SW6H[+:)(;8RX)6(F61G Z[0/0CK/!?BZ+]M;_ (*#>%_B!X)M[FZ^
M&'PSTR:W;Q!-;-%%>WLJ2#9%O )YE4X(! C)XW+GJ/V:?^4EG[3W_7EIG_HF
M&G1O*=/VJNW&IOV3]V_R2WZ6,J[4(S]D].:GMW?Q6_X'6YYO\2O@K9_L ?M'
M_!/6OA3K.LZ;X2\::^FA:[X=O+]Y[60.T:!PIY)VR.V6R0R#! )%?I;7PU_P
M4K_Y'C]F/_LH%K_Z,BK[EI4Y.5)I])-+TY8.WWMV*E%*::6\4_G>2O\ <D?G
M_P#\%8TUF23X!)X<O#I_B!_&*)IUV$#F"X/EB)\$$':VTX/I7JGA[]B?P%^S
MQX7\=^+-!O?$&H^)K[PO?VFI7^K:F]Q]OD:,N]Q(AX\PE>HX 8\<YKAO^"E?
M_(\?LQ_]E M?_1D5?7/Q<_Y)3XT_[ M[_P"B'KBJ^[A,1);WFO\ RG#_ #_J
MR.FG[V(I)[6C_P"ER_K_ (=GY[? [X]7W[./_!)'3_%NCE1X@:YO-/TMG4,$
MN)KZ51)@\'8NY\'@E #UKT7X?_\ !,?0->\$V'BGQOXY\8WGQDU""._F\86N
ML2)/87+*&"P>J(2%^;).#@ID >.^ ?@KJ_QR_P""/>FZ/X>MI+W7M-O;K5[.
MSB4L]PT-],7C4#JQC:3:.[8'>OI3X7?\%*_@AJ/P9T[7/$/BZ#P]KEC9QPZE
MX?N89/ML=RJ /'%$%S*"PX9<C!&[:00/3K6]I6<OB3C;OR\O3_MZ][:[''"_
M+34=GS7[<W-U^6U]-SS3_@E_8>)=)^)_[3%AXQU#^UO%%IK]O;ZAJ&P)]JF0
MW2F7   W8W?C7CW_  3L_9)LOVDOA'XCN/'_ (DUR?P#9^(;F&R\(Z;>FTM9
MKG9$9;BX*8:0X,:H"1MVL?XL5[!_P2_\97GQ$^*'[37B:_TVXT>ZU7Q!!=MI
M]W&4FM@S71$3J>C*, ^X-=)_P1^_Y-G\0_\ 8VWW_HJ"E"+<GSK54H??[I<I
M)1FH/1U7]UIF!^S=X;U#]E7]O+6/@9HGB/5M6^&NL^&?[=T[2M4N#/\ V=*'
MQA">%'R2C@#<"F[)7->3VG[$?PFUS_@I!XD^&UYHEW)X2C\+#75M1J$RO]K:
M2+<_F!MV/G;Y<XYKWC6O^4OF@?\ 9/&_]&SUS7BKXE>&/@W_ ,%7M7UKQOK5
MKX8TC4/ L5O;7VHMY<,DA>,A=YX&?*D&3@97'4@5E3DW/#R;U]]7ZZ*I;\4K
M>:0/15HK;W']_)?\W][,#]M3Q5H.M?MCZ#\/?C=XMU_P=\#SX?2XL8=-EEAL
M]3O3( 1<O&I)48*DD?)M7E0Y8][\%?V7='\#_%GPIXS_ &8OBM8W/PX69H_%
M7AE]?;4;.>,A0#"J!P)<%C^\(*D+@X+"M?\ :,_:*\,^$_VAK?X=?'WP;X<N
M?@SK.F+=Z!XDU'3'O%^V_*'61CN5,9<;D4%=T;$@,<?+OQ,\(_!30?VB?A)_
MPR/JEQ)\1+C78GU&W\-WMQ=Z?'8$@RO*[E@%Q]Y%?:$W[E'RT8?>'G)ZKSD_
MB7EM_A29->W++LHK3_MU?"^E_P#TJZ/UWKX6_P""@'_)SO[(7_8V3?\ HVRK
M[IKX1_X*<O<>!_%'[/OQ5GM+BY\-^#/%8EU9[>(N88I'@8.<=.(& SU9E'<4
M0DH5Z,Y:)3C^9I9RA42W<)_^DL^A_P!M#_DTKXO_ /8KZA_Z(:OD?Q]_RA7L
MO^Q?T[_TX0UV_P"V!^W!\+?&W[./C#PM\/O$$?CWQ/XET.YAM]-T6&25X+<Q
MDSW$YVXA6*+>Y#X;Y>G4CB/'W_*%>R_[%_3O_3A#7/43]G5=NL/SF:T+?6</
MZR_.!T?PQ_X)\^'/VA?@OX6\8?%OQ5XH\0^,M:T>UN[6XM]2,-OHD;Q*T,-I
M" 44(FP'<&W,">,UI_L$>/O%6N?L_P#QC\%>+M<N?$=_X$U;4M#@U&\D:29X
M$B8*K.Q)8!EDQDG ('0"OJ+]FW_DW?X8?]BQIO\ Z2QU\A_L'_\ (/\ VO/^
MQQU7^4]=&8>Y+$TX_#RST])12?KJ]>M]3EPCYHX>;WYH_C&3MZ:+0Y7]EWXZ
M3_LX_P#!*"?QS8Q13ZM9W5[!I\<PRAN9KTQ1LP[A2VXCN%(KD/ 'PI_9D^)7
M@NQ\4_&[]H+_ (2GXHZQ;)>7>HR>*5@;29G&_P JW3HOEEL88%<KPJCY:T_@
MA\&]6^.W_!(&\\+Z!"UUKHO;N_LK9?O3R07QE\I?]IE5E'N177?L]_&C]CC7
M?A'I8\?>"_ASX/\ &VBVB6>NZ7KWA:UCN?M,2[)&4-"3*692V%RP)PP!K2=N
M>HY;I0MWMRZM?/?KL*G=0@H[-SOZ\VB?RV^9UO[ ?Q\U+4/''Q2^#C^.!\4[
M#PHBZAX7\427 GEO+)\#RI) ?G*,\:Y)R"6' "@?-GP#T_X%_M+3^(;[]IWX
MC:M;_%X:G<PRZ5XBUA]+M=,0/A$M2V(UP<C86X*XV8&6^P_V/_B-X*^+%]\0
M?$'PA^!V@>!M T]7T_1_&$.GP6/]NR#G9Y4<".L095+9<XRO ;(7QKPS\:/V
M<OVE=(UG3OVG_"?A+P/\7-*O)K35X+JWFTV9EC<B(QW0;S&PN 5,I.5) VD5
MGO).6LN17OH]_B7G:W-I?KI<T7PR2=ES]-5ML_*][:VOIK;3Z0_9+^#?Q ^!
M>B^,=)U'Q[#\1? DDHN/!LEQ=O<WMO!M;]U+(5"E3^[ ",5R&("[L#X1^ >G
M_ O]I:?Q#??M._$;5K?XO#4[F&72O$6L/I=KIB!\(EJ6Q&N#D;"W!7&S RWK
M/_!.[3QI7QV^-\?P4O=2U/X&P6:KHSZT9?LDNJ[4($98*V!^]!.-Q3RRQ/RD
MR^&?C1^SE^TKI&LZ=^T_X3\)>!_BYI5Y-::O!=6\VFS,L;D1&.Z#>8V%P"IE
M)RI(&TBA^]*,WJW!:/1I7M?UT5_)IZ7#:,H[6ETV>E[>FNGFFM3Z7_8]^"_C
MKX(6?BG1M9^(,7Q ^'DURD_A&XGNY+J^M;;# QRR%0I7'EX"$KE6("[L#Z,K
M\XO^":^FV.F_M%?&*'X37^L7_P"SY##$FGS:EYA@?4#Y9;R2X!.T><"<;BGE
M;L_*3^CM:RNXPD^J6^_;7SZ^>Y$=)3CV?3;OI]_R>A^=>D^%]5_X*,?M$?%"
MQ\7>)=9TCX-> -2_L2U\,Z/<FV75+I78/)<,/O#,;'ID!T"E?F+9OQO^&-Q_
MP3.UWP?\2OA;XAUH?#:^UF+2_$G@O4KQKJT\N12?-ASRK8C?#'+!MO)4E:N?
M!7XE:1^P?^U%\7O!'Q2D?PYX7\<ZPWB+PWXDE@8V4H=W+1,Z@[2!(JDGA3&<
MX#*35_;6^-'A[]MO5?!/P&^#U]_PF5W=:Y!J6N:QIL3/9Z=:1JREC*1M./,W
M$KD?*%SN;%8T=J'L^O+?\.?F]-;WV^XUG9RK*MLN:WDM>3E_#U9B?MX?LT_#
M[7OVR/@;<S:=<2_\+)UB2+Q"RWD@^TQQK;1Q[,']W\AQ\N,UT/\ P4F^&L7P
MT^$/[/7@GX?L=(&F^+[>RT5[AS-]GDVMY3,7SNVN0?FSTYS71?\ !0?6M-^'
M?[1W[*7B76KA=,\,Z3K=P+K495/DVZAK7[Q XX!/T!]#3_\ @HMXJT?QQHO[
M->NZ!J5MK&C7WQ L9;6^LY!)%,F<;E8<$9!H@H^PIQ6WM4OES1M^%[?@95'+
MVDIRW]E?YVG?\E?Y7(_C9_P3=\+:+\)?$GCBV\:^,;SXO:-IL^KIXTNM8D-Q
M/<PQ-)M('"1DJ0 N&48^8XYT]-_;/\1^%?\ @F/I'QAOI$U'QK)9_P!F07%T
MH(FO!=/:K.X'#$!#(1W*GIFOJ[X]_P#)#/B)_P!B[J'_ *325^?W@/X,:S\=
M?^".6C>'_#MNU[KULUUJ=G:1@EKAH=3G9HU'=F3>%'=L"LJDI>RK);+V?R3<
MU*UMM%T['5&,>:C-ZMN2UZZ)J_S,3P1\'_V7O'O@^S\1_&/]H3_A*/BGJENE
MW>:RWBM8GTR=AN\JW7D 1D[?F##*\*HPH]M_8#^/6H^)-8^*_P (M2\<+\2[
M+P?BXT#Q89Q/+?:?("-KR9.\H2@W$DY<KG"BN6^!7QP_8P\2?"?3KKQMX,^&
M_@_Q=I=HEOK>D:UX5M8[E+F-=LA0& F4,RDC;EN<, <BO7/V.OB!X#^+2>/_
M !%\./@CH_P[\(VI?3M/\5V5A;V4FO(,EL11P(RHI52<LPR0/O!@N]:T?:QC
M\/++1;>37Z=6F]SEI\SC3<OBYEJ]_-?=OT6C/DS_ ()Z?L>Z)^U%\#=2U#XC
M:OKMSX>TG6+JQT#1]/O3:P6DI"2378VCYY2SA06R $(P1C'O?P?T&#]F_P#X
M*3>+O!=J6@\-_$3PQ;ZK8+*Y8O=6PVL"Q^\Y"7+DGD[ZU/\ @D'_ ,FFW'_8
MRW__ *#%3O\ @I(9OA9J'P=^/-C;2SS>!/$2PZBL&-SV%R-LJ\]SLV#GK+6E
M64:%6G+:+44_^WHI7_\  FG\AI.M&JNMY-?]NS;_ !2M\SYL^/GQ"UE?^"@@
M^,MO*!X/\ >+=(\#S2X. LT,WVHYZ84M,#_OK7TI^V,G_"Z/VK_V??@U%^_T
MVVOI/&>N1 97R+<$0AO9BLR?\#%>5>$O@C>?$3_@EC\0=8U"W+>*/&%Q?^/7
M*@L[3)/YL>WO\T4 Q_UT/K73?\$V=<U+]HSXI_$'X\Z[;-%*NF:;X2T\2<[#
M%;QO=E3Z-($?_MH:FC%Q<:,MZ5IOU<5_[E6VUO(*TE)2JQVJ)P7HG:_SIO?N
MO0Z#X"Y_X>E?M$8&3_8%AC_OW:5\V?"./X,_M(>-O',G[5?C_5-.^)EMK=U;
M0:!KVK2:9IVF6ZD!5MV.(U(;<NTN/N@[3DL?I#X&^=_P]#_:-^S[//\ ^$>L
M?+\S.W=Y5IC..V:X[0_C?\!?VA)O$WAK]JSP?X1\$_%71;^6RNEN[>6Q:6W0
MCRFBO=WF8P>GF#(PRC#5C3_AT>O[M[_XWJO/OY=C2;_>5O\ ''_TA:/R?YI'
MT'^R#\$?&'P)NO%UE+\1HO'GPBNC%<>$S=7SW=Y91@?.K2;0GEX( ",5^0,
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MMQB&36M*@O&B'HID1L?A71:/HVG^']-M].TNQMM-T^W79#:6<*Q11J.RHH
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M;Q%JB@!;[5M%MKJ< = 'D0MQ]:[>BC=W8+31$%E96^FVD-K:016MK"H2.&%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBN4^(WQ2\,?"72;#4_%6HMIEE?:A!I=O(MK-.7N9FVQ1[8D8C<>,D #N1
M1V_K?8/,ZNBBO/OC5\?? ?[._AFU\0?$'7?^$?TBZNELH;C['<7.Z8JSA=L,
M;L/E1CDC''6DVEN-)O8]!HKF?AM\2?#?Q>\$Z7XN\(:HFL^'=31GM+U(WC$@
M5RC?(ZJRD,K A@#Q4GQ"^(/A_P"%?@S5?%GBK4DTCP_I<7GWEX\;R"-,@?=0
M%F))  4$DD8%.7[N_/I84??MRZW.BHK@OA-\=O _QR\#S>,/!&M_VWX<BFE@
M>]^R3V^'C +C9*BOP&'.W!SQ3_A9\</!'QI\!GQKX/UZ/5/"X>6-M1E@EM44
MQ?ZS<)D1@%]2,>]-W5T^BO\ )[/T$FG9KJ[?-;KU.ZHK$\&^-="^(?AVVU[P
MUJMMK>BW+2+!?V;[X9MCM&Q1NC#<K#<.#C()'-;=#36C&%%%%( HHKB?"/QH
M\&^.O'GBWP9H>L?;O$OA1H4UFQ^RS1_93*"8QO= CY /W&;'?%&[LMPV5WL=
MM117"Z[\;_!7AKXK>'OAMJ6M?9O&OB"WDN]-TS[+.WGQ1J[.WFJAC7 C?AF!
MXXZBC=I+=_\ #_EJ'1OHCNJ*** "BN%T_P"-_@K5?B]J?POM=:\WQUIM@NIW
M6E?99QY=L2@#^:4\L_ZU. Y/S=.#7=4=$^C_ .&_,-G9_P!=0HKA?B!\</!/
MPM\4>$/#OB?6O[,UCQ==M8Z+;?99Y?M<P* INC1E3F5.7*CGKP:[JC=<RV#9
MV?\ 7]6845X;\8OVV_@M\ O&'_"+>//&?]A:[]G2Z^R?V5>W'[I\A6WPPNO.
MT\9SQ7#_ /#T;]F+_HIG_E U3_Y&I)J6J&TUN?55%>.?!']K[X2?M&:YJ&D?
M#OQ;_P )#J.GVXN[F'^S;NV\N(L%W9FB0'YB!@$GFO8ZIIJS?4E23NET"BBB
MD,**** "BBN)^)WQH\&_!N/0)/&&L?V.FO:G%H^G'[+-/Y]W)G9'^Z1MN<'Y
MFPH[FCR#S.VHHHH **** "BBOGOXE?M_? 7X0^-]4\(>+?'?]D^(M+=4N[/^
MQ[^;RF9%=1OC@9#E74\$]:5U>P[.USZ$HKYCT3_@I;^S5X@U*&QM?BC:133-
MM5K[3+ZTB'^]++ J*/<D5[SXB^(GAOPMX!OO&VH:M /"ME8MJ<VJ6VZYB^S*
MF\RKY08NNWD;0<]LTW[L>9["6KY5N='17/\ @'QYH7Q0\&Z3XK\,WW]IZ!JL
M N;.[\F2+S8R2 VR159>AX(!KH*;3B[,2:DKK8****0PHHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^_"/P'\+_A06F;1I/&FHW=U/.C2N6F B<N,L2?G5AS\I9<&I5Y3:[)?BWO\
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M#\JX_P#X)PV-O8_L4_"];>%81)932OM&-SM<REF/N334;J:3^&UN^O-O_P"
M]+;[F'-I3DU\5[]M.7;K?WNMSM_V8?VEO#?[4WPU'BWP];7>FO!<O8ZAI=^
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M3P*\V_X+ V]BO[+^E:BY6+6['Q+9OI<RG$JRE9-P0]?N@GC^Z#VK(_:&T_\
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M'XY4T:\9732X 5(@<@@[.#7SC^QE_P GR?M;?]A*P_\ :]?7/Q<_Y)3XT_[
MM[_Z(>N#%3=3 *H]W33_ /)3JH14,9*"V4_\CY%_X)8?#OPKXA_8W\-WNJ^&
M='U.]>_OPUQ>6$4LC 7#@ LRDG K(_X+!:38Z)^R;X9L=.LK>PLHO%MH([:U
MB6.-,V]T3A5  Y)/XUW'_!)G_DRGPQ_V$-0_]*7KD/\ @LRN[]EK0%!VD^+;
M09';_1KJO1K756G97UI_G$SP/VO2I^4C[ L_A#X$-G 3X*\.G]VO_,*@]/\
M<KX1\<>#/#OP8_X*J_"BU^&%E:Z%+XATJ;_A(M&TE%AM_+*3Y=HT&U=RQJY
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MR]TQ#!5W*5'S9QQ7I_\ P3S1;;]H;]K>VB'EVZ>-"5C7A03/=YP*F_X)=_\
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M".&UA2"(^%M-D*(,#<]NCN?J68D^Y-?'/[*]Q?Z/X:_;ICT/?#=6>LZM+8)
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M ,%#-7\!^(M(LOCA\%/$/P?T;5Y5@L_$,UZFHV*R-G G=8T\HX!)'S,!DD
MD>8?\%B/''B4_"71_#]IX->]\&7%Y9Z@WC&/4$\I+G,X6U$&W<VY '\P-CG&
M*^D?^"AFGZ5J/[&?Q275TB:"'2_/A,V/EN%D0PD?[7F;0/KCO7Q_^UA>7]]_
MP2;^#<^I.TEVS:+EG))*B&0(3GOL"THOGG%;.,Z?_DTM/FFK]GIYHUI7C/\
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M$XCA\LQG!)(5Y& Z @8 ^[**25FWWW^6WYO[P;NDNQ\9_L[_ +#_ (L_9_\
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M(O'2WVDW%MXIO]9=[>]GNY 0'MH(XVC6$!8%$;2#:%..@%?:]%%5?W5'HO\
M-O\ 4FWO.75_Y6_0\;_:@_9=\,?M3>!8=#UR:XTG5=/F^V:1KUA@76G7 Z.A
M[J<#<N1G (((5AX;9_"?]MSPKI;>']*^+OP^\0Z<@$5OX@U[3YTU1$  !*+"
M\;,/5RY/<FOM:BI2M>VS*;O:_38^:OV7_P!C.'X(>*]=^(/C#Q5=?$?XK:\N
MV^\1WT0C6&,XS% F3L7A1G/1%"A%&VN=^,W['GC2V^-%Y\8O@/XXL_ WC?4X
M5@UK2M7MS-I>KA<8:3 8HV%&2$8DC(*'<6^MZ*;U<6M.716Z+MZ/JNHEHI)Z
MWWOU??\ R['Q9I?[&OQ5^-?Q*\.^+/VC_'NBZ_I?ANY%YI?@WPE;R1Z:9Q@K
M)*\BHS<CE2K$]-P7*GT3XM?LW^)?'G[8'P@^*NGWVDP^'O!]I=P7]K<S2K=R
MM*DBJ8E6,H0"XSN=>_6OH^BFM'!K[+;7JU9O[A6NI)_:5GZ;GA?[<_\ R9_\
M6_\ L7KG_P!!KY3_ &7_ (+_ +2_AO\ 9O\  \GP@^*/AI/"WB#2(;_[#XPL
MG>XT6:5=TGV1TC<.I8LP60!03C!R2?O3XK?#?3/C!\-_$7@K69[NVTK7;-[&
MYFL75)T1Q@E"RLH/U4CVIWPK^'.F_"'X<^'/!6CSW5SI6A64=A;37SJ\[QH,
M N555+?10/:LXQM*;?7E_#FO^:*D[\J[7_'EM^3/+_V5?V4K#]G'P_X@EU#6
MY_&?C7Q3=&^\0^(KZ,*UY*=V$5<G$8WN<$DDLQ[@#QNS_8Y^,_[.OBO7;C]G
M'X@>'=/\&ZW=/>R^#?&EM*]K92L,%H)(D=\<  87@*&+[0:^WJ*MZRYEII;3
MMV]-!+9IZZWU[]_4^5/V??V._$?AOXO7'QD^,?C6/X@_$][8V=D;.W\G3])A
M((*0+@$G#, =J8#OD$L6K;^&/[-WB;P7^VA\5?B[>WVDR^&_%6F6ME96MO-*
M;R-XU@#&53&$ _=-C:[=1QZ?2%%4I<LE)=$TO1[DM<T91?5IOY--?D?./[9/
M[*-[^TAIOA+6/#'B;_A#_B!X.OCJ.AZM)'YD(<E24D Y +1QD-AL;3\K D5Y
M[??LW_M+_'+0I?"OQD^+/AO1O!LT7E7]GX L7%WJJ8^Y+/-&GE*3C<$4AAE2
M,&OM"BLN56<>CUMY]S3F=T^JT^6_ZGS/^R;^S'XC^#_[*M]\(O&VH:9<RS?V
MA;)>Z)/+,GV:YW')\V.,JX,C_* 1P#GDUA?L:?L\_&K]G/1;KX?^)_$?A#7_
M (965M=KHTFGI/'J:S2S>8#*K1A AWRD@.Q!8 $CI]:T5I)\SDW]I)/SLK+Y
MJ[U\R5HDET;:\F]SY4_95_8WN?AG^RQX@^$'Q-;2=>M]:OKR6Z72)Y7A,$RH
M%P[QQLKJ4R"!P0"#7!^%OV9/VK/@3H;^"?A=\7?".J^!(0T>F3>+[&7^T=+B
M))"1[(I%?:#QO.WCA5'%?<]%$GS2YGV2]4E9 M%;S;^;=V?/O[*/[)=O^SG'
MXDUS6/$=UXW^(GBJ<7.N>)+Q/+,Q!)$<:9.U 6)ZY)] %44OV)_V;_$O[-WA
MWQ]8>)K[2;Z;7_%%UK=JVDS2R*D,BH%5_,C3#_*<@9'O7T?11]KF7;E\K73M
M_P"2H5M+>=_G9K]3YM\;?LV^)O$G[<G@#XS6M]I,?A?P_P"'YM)NK2::47KR
MO]IPR((RA7]^G)<'@\=,_25%%%_=4>BO^+;_ #8Y>])S>[M^"27X(^,_^"B'
MAF\\(WGPI^/&F6\ES+\-]>CEU6.%27;3)W19VP.NW 'L)&)X%>X_M%> KK]H
M;]FWQ7X8\*7^G_:/$^E*FGWUW*PM6#E75V9%8[2O.0IZBO3->T'3_%&AZAH^
MK6<6H:7J$#VMU:SKN2:)U*LC#N""17-?!WX5Z?\ !7X>Z5X,TC4M4U/2-+#1
M63ZO,DTT,)8E(0ZHN40':N02% !)Q67(I4IT9;-M_>K27X)KU?D5S.-2%6.Z
MT^YW3_%I_*W4X+P5^SO+#^Q[IWP8\53VEQ<?\(Q_8-Y<6+,\(D,13S(RRJQ"
MMA@2H/ XK@/V ?V0O$?[+?AGQ/+XXUC3_$'B[69K:#[9IL\LT<=A;0B.VA#2
MQHWRY<8Q@ *,\5]845OS/GG4ZRT?WW,^5<D:?2.WW6_0^</V?_V;_$OPI_:.
M^.7Q U:^TFXT;QS=VT^FP64TK7$2Q^9N$RM&JJ?G&-K-WKW/QSH<_B;P3X@T
M>U>..YU#3[BTB>8D('DB9%+$ G&2,X!K<HK"5.,J*H/X5'E^5K&JDXU'56[=
M_F>"?L/_  #\0?LT_L\Z/X#\3WFFW^KV=U=3R3:3+));E99F=0&DC1LX(S\O
M7UK"_;^_9G\4?M5?!G2O"7A._P!(T_4K778-3>769I8H3$D4R$ QQR'=F1<#
M&, \U],45O*3E*,WNK/_ ,!M;\B*?[J_+UO^-[_F1V\9AMXD/)50IQ["I***
MG<F,5%**Z'SY^U3^R!I/[2!T+7M/UZ\\#?$7PZ_F:-XKTQ<S0<Y\N105+IGD
M ,"I)P<%@WE\GPP_;BGTT:"WQ:^',5EGRV\21:;+_:AC_O>5]G\D-CTQ_O9Y
MK[3HJ%%)-=.W3^GU[FC;;3Z]SP;]E+]D?0?V7]$U>2/5;OQ9XSU^;[5KGBC4
MA_I%[)DG !+%4W,S8+,26)+'C'D7[6VFG]H3]J[X*_!RS!N-,\/W!\;^)BHR
ML4$1"6Z-[NV],=<2*:^UJ\]^&_P/T#X9^+/&OBBSGOM5\1^+KX7NI:IJDB23
M;57;%;QE$4+#&O"K@GGDL>:TYFZD)/:.OS7PKT3U^5NIGRKDE%;RT^_=^MM/
MG?H>A5\W_MR?LW>)OVF/ OA#1?"]]I-A=:/XEMM8G?5YI8T:&-)%94,<;DOE
MQ@$ =>:^D**2TDI=FG]SNBGK&47U37R:L_S,SQ1IDNM>&=7TZ!D2>[M)K>-I
M"0H9T*@G /&3Z5\C_#7]@N]'["=Q\!/'FL6*:G-//<IJNAM)/#;S&X,T+@2)
M&S8. RD#(+ $=:^RZ*SY%[W]Y)/Y.Z_$KF?N_P!UW^]6_(^)/!WP'_;&TGPS
M9^!;OXR^"]-\+V<2V</B2QTR6YUL6RC:J[)(TCW;0!N+%AUW$\UT7['_ .Q7
MJW[,'CSXM0W6K6OB7P'XL6U-FUY=23:BS(L@F^U(8EC)<S/\RL<X&1SQ]<T5
MK>[DY:N2:?G?O]Q%M%%:)-->5CX8\*_LE?M#_LTW&J:'\"/B1X3NOA[>74MW
M:Z%XXMIR^F,YR5BDB1RX^I4'KMR23ZI^R]^RCK/PE\<>+?B9\0_& \<_%+Q7
M''!?:A;VPM[6U@0+B&% !D?(GS$+PB@*.2WTG12BW'7K:U^MNU_P[V"24K]F
M[VZ7W_/7U"OD/XJ_L?\ C[P_\:]6^+OP!\;Z=X/\4:ZBIKN@Z_;M+I6IL,8D
M8HK,C<9.%)R20R[FS]>45%O>4EHU^NZ]'V*OHXO9GR%\-_V1_B/XP^-.A?%3
M]H+QKI'BG6?#0<Z!X<\-VSQZ982-C]]N=5=VX!Y7.54[B% #/BA^QUX]\,_&
MC6/BS^S[XXT_P9XCUX+_ &]X?UVW:72M3<'/FL55F1CR3A"<LQ#+N;/V!15?
MR\NEK[>>_K?K?]$+O?6]M_+;TMTM^K/C/PG^QO\ $OXH?%SP[\0_VB_'FE>)
MY/#$_P!IT3PGX8MWCTNWF!5A*S2*K.0R@X*DDJN7VC:>]^+7[-_B7QY^V!\(
M/BMI]]I,/A[P?:7<%_;7,TJW<K2I(JF)1&4(!<9W.O?K7T?136C@UIRMM>K3
M3?G>XGJI)_:5GZ'SE^WE^SEXE_:B^"$/@[PK?:5I^IIJ]M?F;6)98X?+C#AA
MF..1MWS#'RXZ\UZS\6O!=]X\^#?C'PGI\MO#J.LZ%>:7;RW+,L*RRV[QJ7*J
M2%!89(!..QKM**AQ4J<J;VDVW\TE^21JJDHSA46\=OOO^9\AV?[(?C&W_P""
M>+_ =M2T,^+VL'M1>B>;[!N-X9P=_E>9C:<?ZOK[<U]"?!+P/?\ PV^"W@?P
MAJ<MO/J6AZ%9Z9<RVC,T+RPP)&Q0LJDJ2IP2 <=A7<45I4DZCJ.7V[-_*_\
MFS&,5&,8+:-[?.W^2/F_]@_]F_Q-^R]\']5\*>*K[2=0U&ZURYU-)='FEDB$
M4B1*H)DCC.[*'(QCIS1\,?V;O$W@O]M#XJ_%V]OM)E\-^*M,M;*RM;>:4WD;
MQK &,JF,(!^Z;&UVZCCT^D**?,^=5.J7+\K6_(J7OJ2?VG=^O-S?F?&_C_\
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MX!!0[L#"U;]F?]I/X]>'I_"_QE^+'AS1_",L)CO-.\ 63K/JO'"S3S1J8UW
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MWYK[#HHULUW;?S9-EIY)+Y(^0_C_ /LC_$7XV:/\+_'%GXRTGPG\=_!<6_\
MM.QA>32KB1L&1 &7>J;AP2C95G5E.[(P?%7[+/[1G[1/A.^\-_&7XK^'=*\.
M/ P.C> [*1%U&8*3$;FXF175 X5F1%(8#L<$?;5%2XIQ<>CN[=$WNU_7F4I-
M-2ZJROULNY\Q?"?]E?Q#I?[#<GP*\9ZMIT6JRZ7?:4=4T:26Y@199)'BD D2
M-CMWKE< ?+P>:R/V?_@'\<? OP)\5?"OQWK_ (,U?1$\/2Z+X9NM(-PD\>Z.
M5!]JW0J-H#1X*AB-ISN/-?6E%55_?.;G]M6?X_CJQ4_W2@H_9=U^'X:(^8?@
MK^QS%I/[%%A\"/B8UCJP,-U%=SZ/*[1JTEW)/%)"\D:-O0LC E<;EZ$=?./#
MO[.O[7WPJ\-IX$\%?&3P;J7@VVC6VT[5_$&G2C5K"W' 1$$4D;;1P-[MT &T
M  ?<M%5.3J3E-_:W[,45RQ45TO;RON>"?LN_LFZ7^S1X)UZSCUBX\4^+_$DS
M7NN^)+]=LM]<$-CC+%4!=C@ECEV))S5#]A']G7Q)^S!\#Y?!OBF]TN_U-M7N
MM0$VCRRR0^7($"C,D:-N^4Y^7'3FOHJBCF:<I=TE\EM^0G%-)/H[_.S7ZL^<
M%_9P\2K^W<_QJ^W:5_PBS>%?[#^Q^=+]N\_>&W;/+V;,=]^?:OH^BBH7NQ45
MLK_BV_S975R[V_!)?DCYPU#]F_Q+=_MW:9\:DOM)'A:U\*MH;V;32_;C.7D;
M<$\O9LPXYWYZ\5L_MM? G7_VDOV=?$'@'PS=Z;8ZQJ$]I+%/JTLD=N!%<1R-
MN:-';.$.,*><=*]VHJ914H*#V7^?-^8XOEDYK=_Y<OY(^/\ ]KKX7> ?%7PZ
M^$O@#QCXZ7X?_$6.>WC\'^(+:&60)J,"1(RAPH 5F,>-S(20A'*XKRSX^?"[
M]I"X^ ?B^/XV_&/PK8?#[2-(N)KI_"MJT>HZXZ(3#!,\D2)'YD@12(_O;MN#
MG-?9_P <O@!X&_:,\&GPSX\T5=6TY9//@D61HI[:4 @212*05."1Z$<$$<5X
M)I/_  2^^%<>HV$OB;Q)X]^(&F6#![70_%/B SV,)'3$<<<9P!Q@M@C@@T24
MJO.I:<S;\M5O;O\ @]+CARTE3Y5=15O/1[7[?BM;;G)_L[_ _7_B1_P2ITKX
M?:?):V&M^(M&NFM)-29XX5$]Y)-&SE5=@I1@<A3U'%?5OP!\ ZA\*_@CX%\'
M:M-;7&IZ%HUKIUS+9LS0O)'&JL4+*K%<CC*@^U=O8V-MI=C;V=G;Q6EI;QK%
M#;P($CC11A551P    !TQ4]=%6?/5J5%]IK\+V_]*9C3BXPC&6ZO][M?\CYM
M_9;_ &;?$WP1^+7QT\4:[?:3=Z?XZ\0?VMIL>GS2O+#%YD[;9@\:A6Q*O"EA
MP>?7C/@/^R[\8OV=?CMXJN?#WB?PGJGP@\4Z]/K>HV-_'.FK0F0.=L6V,H2"
M4&6?#!,X4DU]BT5DO=<7_*E'Y*VGX(TE[_-?[3O\W?;[V?$TG[(/QH^!/Q$\
M4Z[^SOX]\-Z=X:\3WSZE>^$?&-K*;2WN&^\\,D2.W4G  3 "@[MHQV/P"_9-
M\9:+\:KKXT?&7QK9^,OB(VGG2["UT>U\C3M+MR22L9(5G."P!*KC>^=Q.1]4
M440]Q)+HK+R5K?EIZ:!/W[WZZOS=[_GKZA7S@O[.'B5?V[G^-7V[2O\ A%F\
M*_V']C\Z7[=Y^\-NV>7LV8[[\^U?1]%+[2EU5_Q37Y,'JG'O;\&G^:/G#]G_
M /9O\2_"G]H[XY?$#5K[2;C1O'-W;3Z;!932M<1+'YFX3*T:JI^<8VLW>F?M
M0?LV^)OC7\8O@3XLT.^TFUT[P)K<FI:G%J$TJ331L]NP$(2-@S8A;ABHY'/I
M])44X?N_9\O_ "[M;Y;#D^9S;^W>_P U9_@%?,G[6O[)FN_&CQ3X/^(OPZ\7
M)X'^*7A'S$T[4KB'S;:XB?.8I1AL#+-SM88=P5.<CZ;HJ6M4^JU0T[)KH]&?
M$'A7]C3XR_%7XO\ A'QQ^T7\1-#\0V7@^Y%[H_ASPO;LEJUP"K"21FBB/WD1
MB-K$XQE1D'T/]K_]DW7OCEKW@KQY\/\ Q;'X,^)G@V5WTR^NHO,MID;!,<@
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MEG>W2Y\6^ /V ;V?]A)_@+XZUJQAU?[5/>PZMHADN(;>8W!EA<"1(V<#.&7
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M@2#PS=1-97/B2STZ9M9EMF!5@8S$L89E."5<-WWYYK[?HHE:5[K1[KH]+?\
M#]^HHWBE;=;/JNO_  W8\.T3X!ZO\$_V6S\-/@WK,.D>)-/L&BTK6M8573[4
M\GF23RCRY!\S,YQL8#(&.*[SX+Z7XXT3X7^'['XD:Q9>(/'$,#+JFI:<@2WG
MDWL0R 1Q@#:5'W%Z'CO7:T54I.4I2EJW;\+_ .>OHNQ*BHI)=+_C;?OM^+[A
M1114E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
K%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>nbix-20221231_g3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nbix-20221231_g3.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_#6WPB_Z#D/_ ']_^M1_PUM\(O\ H.0_]_?_ *U 'I]%>8?\-;?"+_H.0_\
M?W_ZU'_#6WPB_P"@Y#_W]_\ K4 >GT5YA_PUM\(O^@Y#_P!_?_K4?\-;?"+_
M *#D/_?W_P"M0!Z?17F'_#6WPB_Z#D/_ ']_^M1_PUM\(O\ H.0_]_?_ *U
M'I]%>8?\-;?"+_H.0_\ ?W_ZU'_#6WPB_P"@Y#_W]_\ K4 >GT5YA_PUM\(O
M^@Y#_P!_?_K4?\-;?"+_ *#D/_?W_P"M0!Z?17F'_#6WPB_Z#D/_ ']_^M1_
MPUM\(O\ H.0_]_?_ *U 'I]%>8?\-;?"+_H.0_\ ?W_ZU'_#6WPB_P"@Y#_W
M]_\ K4 >GT5YA_PUM\(O^@Y#_P!_?_K4?\-;?"+_ *#D/_?W_P"M0!Z?17F'
M_#6WPB_Z#D/_ ']_^M1_PUM\(O\ H.0_]_?_ *U 'I]%>8?\-;?"+_H.0_\
M?W_ZU'_#6WPB_P"@Y#_W]_\ K4 >GT5YA_PUM\(O^@Y#_P!_?_K4?\-;?"+_
M *#D/_?W_P"M0!Z?17F'_#6WPB_Z#D/_ ']_^M1_PUM\(O\ H.0_]_?_ *U
M'I]%>8?\-;?"+_H.0_\ ?W_ZU'_#6WPB_P"@Y#_W]_\ K4 >GT5YA_PUM\(O
M^@Y#_P!_?_K4?\-;?"+_ *#D/_?W_P"M0!Z?17F'_#6WPB_Z#D/_ ']_^M1_
MPUM\(O\ H.0_]_?_ *U 'I]%>8?\-;?"+_H.0_\ ?W_ZU'_#6WPB_P"@Y#_W
M]_\ K4 >GT5YA_PUM\(O^@Y#_P!_?_K4?\-;?"+_ *#D/_?W_P"M0!Z?17F'
M_#6WPB_Z#D/_ ']_^M1_PUM\(O\ H.0_]_?_ *U 'I]%>8?\-;?"+_H.0_\
M?W_ZU'_#6WPB_P"@Y#_W]_\ K4 >GT5YA_PUM\(O^@Y#_P!_?_K4?\-;?"+_
M *#D/_?W_P"M0!Z?17F'_#6WPB_Z#D/_ ']_^M1_PUM\(O\ H.0_]_?_ *U
M'I]%>8?\-;?"+_H.0_\ ?W_ZU'_#6WPB_P"@Y#_W]_\ K4 >GT5YA_PUM\(O
M^@Y#_P!_?_K4?\-;?"+_ *#D/_?W_P"M0!Z?17F'_#6WPB_Z#D/_ ']_^M1_
MPUM\(O\ H.0_]_?_ *U 'I]%>8?\-;?"+_H.0_\ ?W_ZU'_#6WPB_P"@Y#_W
M]_\ K4 >GT5YA_PUM\(O^@Y#_P!_?_K4?\-;?"+_ *#D/_?W_P"M0!Z?17F'
M_#6WPB_Z#D/_ ']_^M1_PUM\(O\ H.0_]_?_ *U 'I]%>8?\-;?"+_H.0_\
M?W_ZU'_#6WPB_P"@Y#_W]_\ K4 >GT5YA_PUM\(O^@Y#_P!_?_K4?\-;?"+_
M *#D/_?W_P"M0!Z?17F'_#6WPB_Z#D/_ ']_^M1_PUM\(O\ H.0_]_?_ *U
M'I]%>8?\-;?"+_H.0_\ ?W_ZU'_#6WPB_P"@Y#_W]_\ K4 >GT5YA_PUM\(O
M^@Y#_P!_?_K4?\-;?"+_ *#D/_?W_P"M0!Z?17F'_#6WPB_Z#D/_ ']_^M1_
MPUM\(O\ H.0_]_?_ *U 'I]%>8?\-;?"+_H.0_\ ?W_ZU'_#6WPB_P"@Y#_W
M]_\ K4 >GT5YA_PUM\(O^@Y#_P!_?_K4?\-;?"+_ *#D/_?W_P"M0!Z?17F'
M_#6WPB_Z#D/_ ']_^M1_PUM\(O\ H.0_]_?_ *U 'I]%>8?\-;?"+_H.0_\
M?W_ZU'_#6WPB_P"@Y#_W]_\ K4 >GT5YA_PUM\(O^@Y#_P!_?_K4?\-;?"+_
M *#D/_?W_P"M0!Z?17F'_#6WPB_Z#D/_ ']_^M1_PUM\(O\ H.0_]_?_ *U
M'I]%>8?\-;?"+_H.0_\ ?W_ZU'_#6WPB_P"@Y#_W]_\ K4 >GT5YA_PUM\(O
M^@Y#_P!_?_K4?\-;?"+_ *#D/_?W_P"M0!Z?17F'_#6WPB_Z#D/_ ']_^M1_
MPUM\(O\ H.0_]_?_ *U 'I]%>8?\-;?"+_H.0_\ ?W_ZU'_#6WPB_P"@Y#_W
M]_\ K4 >GT5YA_PUM\(O^@Y#_P!_?_K4?\-;?"+_ *#D/_?W_P"M0!Z?17F'
M_#6WPB_Z#D/_ ']_^M1_PUM\(O\ H.0_]_?_ *U 'I]%>8?\-;?"+_H.0_\
M?W_ZU'_#6WPB_P"@Y#_W]_\ K4 >GT5YA_PUM\(O^@Y#_P!_?_K4?\-;?"+_
M *#D/_?W_P"M0!Z?17F'_#6WPB_Z#D/_ ']_^M1_PUM\(O\ H.0_]_?_ *U
M'I]%>8?\-;?"+_H.0_\ ?W_ZU'_#6WPB_P"@Y#_W]_\ K4 >GT5YA_PUM\(O
M^@Y#_P!_?_K4?\-;?"+_ *#D/_?W_P"M0!Z?17F'_#6WPB_Z#D/_ ']_^M1_
MPUM\(O\ H.0_]_?_ *U 'I]%>8?\-;?"+_H.0_\ ?W_ZU'_#6WPB_P"@Y#_W
M]_\ K4 >GT5YA_PUM\(O^@Y#_P!_?_K4?\-;?"+_ *#D/_?W_P"M0!Z?17F'
M_#6WPB_Z#D/_ ']_^M1_PUM\(O\ H.0_]_?_ *U 'I]%>8?\-;?"+_H.0_\
M?W_ZU'_#6WPB_P"@Y#_W]_\ K4 >GT5YA_PUM\(O^@Y#_P!_?_K4?\-;?"+_
M *#D/_?W_P"M0!Z?17F'_#6WPB_Z#D/_ ']_^M1_PUM\(O\ H.0_]_?_ *U
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M* "O*/VY_P#DT?Q[_P!@%_\ T-:]7KRC]N?_ )-'\>_]@%__ $-: /B?0/\
MD!67_7I'_P"@BK=5- _Y 5E_UZ1_^@BK= !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7TE_P3V_YF_\ [A__ +<U\VU])?\ !/;_
M )F__N'_ /MS0!])4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
ME'[<_P#R:/X]_P"P"_\ Z&M>KUY1^W/_ ,FC^/?^P"__ *&M 'Q/H'_("LO^
MO2/_ -!%6ZJ:!_R K+_KTC_]!%6Z "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "OI+_@GM_S-_P#W#_\ VYKYMKZ2_P"">W_,W_\
M</\ _;F@#Z2HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O*/VY_
M^31_'O\ V 7_ /0UKU>O*/VY_P#DT?Q[_P!@%_\ T-: /B?0/^0%9?\ 7I'_
M .@BK=5- _Y 5E_UZ1_^@BK= !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !7TE_P3V_YF_P#[A_\ [<U\VU])?\$]O^9O_P"X?_[<
MT ?25%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y1^W/_R:/X]_
M[ +_ /H:UZO7E'[<_P#R:/X]_P"P"_\ Z&M 'Q/H'_("LO\ KTC_ /015NJF
M@?\ ("LO^O2/_P!!%6Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_L7R:=\,O@_HFD>+K'6](LOALWAS2XK2\&HRWL,200M$JL0T9D)7.,)OZH"
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** /R;HHHK]T/\ = *_62OR;K]9*^%XU_Y<?]O?^VG\+_32_P"9
M#_W-?^ZX4445\*?PN%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/HH [#_A=OBS_H&Z/_X*HZ/^%V^+/^@;H_\ X*HZX^B@#L/^%V^+/^@;H_\
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M_P#@JCH_X7;XL_Z!NC_^"J.N/HH [#_A=OBS_H&Z/_X*HZ/^%V^+/^@;H_\
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M /0UKU>O*/VY_P#DT?Q[_P!@%_\ T-: /B?0/^0%9?\ 7I'_ .@BK=5- _Y
M5E_UZ1_^@BK= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5MH+757<4[GH/[17[<&@> +B3P)\)(HM=\1._DM-$#);VDA.-OR_ZV3/&Q>
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M1_\ H(JW530/^0%9?]>D?_H(JW0 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7L7@7XK7ESX:U[0;O4IKF&VU-1&;&]@\YV,<KO(8I<$!UPS!G - 'U=1110
M5Y1^W/\ \FC^/?\ L O_ .AK7J]>4?MS_P#)H_CW_L O_P"AK0!\3Z!_R K+
M_KTC_P#015NJF@?\@*R_Z](__015N@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ JIKVOZ)X7TB?7_$>JP65E:QE[BZN90B1KZDFN/^./[1'P
M[^ VB_;O%>H>=?S1DV.D6S SW!Z9Q_ F>KGC@XR>*^;M,\,_M!_MY>(4U[Q1
M=-H'@NWG)@15/D@ XQ$IP9Y.H,C?*.>GW:]; Y5/$4_;UY>SI+>3Z^45U?\
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M>L?^#%?\*X30/^0%9?\ 7I'_ .@BK= '8?VU\%/^A+UC_P &*_X4?VU\%/\
MH2]8_P#!BO\ A7'T4 =A_;7P4_Z$O6/_  8K_A1_;7P4_P"A+UC_ ,&*_P"%
M<?10!V']M?!3_H2]8_\ !BO^%']M?!3_ *$O6/\ P8K_ (5Q]% '8?VU\%/^
MA+UC_P &*_X4?VU\%/\ H2]8_P#!BO\ A7'T4 =A_;7P4_Z$O6/_  8K_A1_
M;7P4_P"A+UC_ ,&*_P"%<?10!V']M?!3_H2]8_\ !BO^%']M?!3_ *$O6/\
MP8K_ (5Q]% '8?VU\%/^A+UC_P &*_X4?VU\%/\ H2]8_P#!BO\ A7'T4 =A
M_;7P4_Z$O6/_  8K_A1_;7P4_P"A+UC_ ,&*_P"%<?10!V']M?!3_H2]8_\
M!BO^%']M?!3_ *$O6/\ P8K_ (5Q]% '8?VU\%/^A+UC_P &*_X4?VU\%/\
MH2]8_P#!BO\ A7'T4 =A_;7P4_Z$O6/_  8K_A1_;7P4_P"A+UC_ ,&*_P"%
M<?10!V']M?!3_H2]8_\ !BO^%']M?!3_ *$O6/\ P8K_ (5Q]% '8?VU\%/^
MA+UC_P &*_X4?VU\%/\ H2]8_P#!BO\ A7'T4 =A_;7P4_Z$O6/_  8K_A1_
M;7P4_P"A+UC_ ,&*_P"%<?10!V']M?!3_H2]8_\ !BO^%']M?!3_ *$O6/\
MP8K_ (5Q]% '8?VU\%/^A+UC_P &*_X4?VU\%/\ H2]8_P#!BO\ A7'T4 =A
M_;7P4_Z$O6/_  8K_A1_;7P4_P"A+UC_ ,&*_P"%<?10!V']M?!3_H2]8_\
M!BO^%']M?!3_ *$O6/\ P8K_ (5Q]% '8?VU\%/^A+UC_P &*_X4?VU\%/\
MH2]8_P#!BO\ A7'T4 =A_;7P4_Z$O6/_  8K_A1_;7P4_P"A+UC_ ,&*_P"%
M<?10!V']M?!3_H2]8_\ !BO^%']M?!3_ *$O6/\ P8K_ (5Q]% '8?VU\%/^
MA+UC_P &*_X4?VU\%/\ H2]8_P#!BO\ A7'T4 =A_;7P4_Z$O6/_  8K_A1_
M;7P4_P"A+UC_ ,&*_P"%<?10!V']M?!3_H2]8_\ !BO^%']M?!3_ *$O6/\
MP8K_ (5Q]% '8?VU\%/^A+UC_P &*_X4?VU\%/\ H2]8_P#!BO\ A7'T4 =A
M_;7P4_Z$O6/_  8K_A1_;7P4_P"A+UC_ ,&*_P"%<?10!V']M?!3_H2]8_\
M!BO^%']M?!3_ *$O6/\ P8K_ (5Q]% '8?VU\%/^A+UC_P &*_X4?VU\%/\
MH2]8_P#!BO\ A7'T4 =A_;7P4_Z$O6/_  8K_A1_;7P4_P"A+UC_ ,&*_P"%
M<?10!V']M?!3_H2]8_\ !BO^%']M?!3_ *$O6/\ P8K_ (5Q]% '8?VU\%/^
MA+UC_P &*_X4?VU\%/\ H2]8_P#!BO\ A7'T4 =A_;7P4_Z$O6/_  8K_A1_
M;7P4_P"A+UC_ ,&*_P"%<?10!V']M?!3_H2]8_\ !BO^%']M?!3_ *$O6/\
MP8K_ (5Q]% '8?VU\%/^A+UC_P &*_X4?VU\%/\ H2]8_P#!BO\ A7'T4 =A
M_;7P4_Z$O6/_  8K_A1_;7P4_P"A+UC_ ,&*_P"%<?10!V']M?!3_H2]8_\
M!BO^%']M?!3_ *$O6/\ P8K_ (5Q]% '8?VU\%/^A+UC_P &*_X4?VU\%/\
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M^A+UC_P8K_A7'T5XI^+G8?VU\%/^A+UC_P &*_X4?VU\%/\ H2]8_P#!BO\
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M *$O6/\ P8K_ (5Q]% '8?VU\%/^A+UC_P &*_X4?VU\%/\ H2]8_P#!BO\
MA7'T4 =A_;7P4_Z$O6/_  8K_A7O/[$=YX-O)/$Q\':-=V:JMG]J%W<"0N3Y
M^S&.F,-GUR/2OE:OI+_@GM_S-_\ W#__ &YH ^DJ*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KRC]N?_DT?Q[_V 7_]#6O5Z\H_;G_Y-'\>_P#8
M!?\ ]#6@#XGT#_D!67_7I'_Z"*MU4T#_ ) 5E_UZ1_\ H(JW0 4444 %%%%
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M=VS^?\5BL3C<1/$8B;G4FVY2DVY2;U;;>K;ZMA1114F 4444 %%%% !1110
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** /G']N/\ 9\O]7MX_C_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%?+W[;'P.UKPKKD'[3_PFWVNH:=.DNM+:KRK*0%N@._99!T(P2/O&OJ&H[NT
MM;^UEL;VW2:&:-HYHI5#*ZD8*D'@@CC%=N7XZIE^)56.JV:Z-/=,^V\/^-\P
MX XDIYGADIPLX5:;^&K2EI.G):JS6UT[22=G:QQ'[._QQT7X]?#NW\5V.R&_
MAQ#K%BK<V\X'..^QOO*?0XZ@UW=?&?BK2?$7[!O[0$/B[P[!/<>#-><J]NK$
M@PYR\!S_ ,M(R=R$]1QGEZ^P/#WB#1O%>A6GB7P]?QW5C?0+-:W$9X=&&0?;
MZ=1TKJS7 T\/*->AK2J:Q?;O%^:_KJ?2>*G!&79!BJ&=Y"W4RK')SH2_D?VZ
M$][3INZLW=I;MJ5KE%%%>0?DH4444 %%%% !1110 4444 %%%% !1110 444
M4 %?27_!/;_F;_\ N'_^W-?-M?27_!/;_F;_ /N'_P#MS0!])4444 %%%% !
M1110 5Y-^V'^QY\,_P!LSX:1>!/'EU>Z;?Z9>"^\->)-)DV7FD7JCY9HV[CI
MN0\$ $%6567UFO-/C3\//C=JWQ%\)_%3X)>,M$MKCP]9ZE8ZMX>\16TQM=7M
MKMK1\>?$2UO)&]HI5Q')G>P(QD$ ^6/V#OVI/CM^SWXM\)_L@?M::$NH:3XK
MO-1M_AE\2[+[NIS0W,OFV]XI)*S,X8AOO9= =X;S*] _X+7_ /)@VM_]C+HO
M_I?#6C\'/V4OBI\0==^'OC[]HQ=)TBR^&VK:IJ7A[PEH\DMQ)/J-Q<3;;JZN
M)$C^2-&)CB2,9+!V<_<'4_\ !0?]F;XG?M>_ R7X&> M?T+1H+S4;2\N]6U9
MII'0V\PE6-(HTP<E5RQ<8&1MYR #WBO _P!ME?\ A9GB/X9?LJ0?/'XY\8QZ
MCXDA_A;1-)VWURK8Y"R3K9P>_GD5[=X:D\2RZ);OXPL[&#4MI%U'IMR\L&[)
MY1G1&P1@X(XSC)QD\'HGP8\1/^U?KG[0OBK4K*6S3P=:>'O"%E;NYEM8C.]S
M?2RAE"AI91;*-I/RVXS@G% %[]H7]F7X)?M5>"HOAY\>?!?]NZ/!>"[ALSJ-
MS;!)PC(LF8)$)8*[ 9/&XU\R? GX.^.?^">/[;?A/]G3X>^.]8USX/\ Q4TO
M59-'T+6[HSR>&M1L81<.(G/2)T.T<#<7^;+(';Z)_:+\.?M9:M>>&]:_9:^(
M_A/26TZ\F/B'1?&&DR36NK0.J! )8?WL+(0Y&S&XN,G"X:7X?_![QG<^/[;X
MT_'7Q)I>K>)K#2Y=/T2RT.PD@T_1H)FC:X,0E=Y)9I3%$'F8K\D:JJ)ERX!Z
M31110!QGQF^)OB_X9:997_A#X.ZUXQDNIVCFMM%DC5K=0N0[;R.">.*^?/VK
M?VC_ (L>*_V=?%WAS6_V2?&&AVEWI+1SZM?7$!AM5W+\[A3G'T]:^MJ\H_;G
M_P"31_'O_8!?_P!#6@#Y1\'^ /#-]X1TN]N/BAI5M)-IT#R6\L;[HF,:DH<=
MQT_"M'_A6WA/_HKFC_\ ?N3_  KA- _Y 5E_UZ1_^@BK= '8?\*V\)_]%<T?
M_OW)_A1_PK;PG_T5S1_^_<G^%<?10!V'_"MO"?\ T5S1_P#OW)_A1_PK;PG_
M -%<T?\ []R?X5Q]% '8?\*V\)_]%<T?_OW)_A1_PK;PG_T5S1_^_<G^%<?1
M0!V'_"MO"?\ T5S1_P#OW)_A1_PK;PG_ -%<T?\ []R?X5Q]% '8?\*V\)_]
M%<T?_OW)_A1_PK;PG_T5S1_^_<G^%<?10!V'_"MO"?\ T5S1_P#OW)_A1_PK
M;PG_ -%<T?\ []R?X5Q]% '8?\*V\)_]%<T?_OW)_A1_PK;PG_T5S1_^_<G^
M%<?10!V'_"MO"?\ T5S1_P#OW)_A1_PK;PG_ -%<T?\ []R?X5Q]% '8?\*V
M\)_]%<T?_OW)_A1_PK;PG_T5S1_^_<G^%<?10!V'_"MO"?\ T5S1_P#OW)_A
M1_PK;PG_ -%<T?\ []R?X5Q]% '8?\*V\)_]%<T?_OW)_A1_PK;PG_T5S1_^
M_<G^%<?10!V'_"MO"?\ T5S1_P#OW)_A1_PK;PG_ -%<T?\ []R?X5Q]% '8
M?\*V\)_]%<T?_OW)_A1_PK;PG_T5S1_^_<G^%<?10!V'_"MO"?\ T5S1_P#O
MW)_A1_PK;PG_ -%<T?\ []R?X5Q]% '8?\*V\)_]%<T?_OW)_A1_PK;PG_T5
MS1_^_<G^%<?10!V'_"MO"?\ T5S1_P#OW)_A1_PK;PG_ -%<T?\ []R?X5Q]
M% '8?\*V\)_]%<T?_OW)_A1_PK;PG_T5S1_^_<G^%<?10!V'_"MO"?\ T5S1
M_P#OW)_A1_PK;PG_ -%<T?\ []R?X5Q]% '8?\*V\)_]%<T?_OW)_A1_PK;P
MG_T5S1_^_<G^%<?10!V'_"MO"?\ T5S1_P#OW)_A1_PK;PG_ -%<T?\ []R?
MX5Q]% '8?\*V\)_]%<T?_OW)_A1_PK;PG_T5S1_^_<G^%<?10!V'_"MO"?\
MT5S1_P#OW)_A1_PK;PG_ -%<T?\ []R?X5Q]% '8?\*V\)_]%<T?_OW)_A1_
MPK;PG_T5S1_^_<G^%<?10!V'_"MO"?\ T5S1_P#OW)_A1_PK;PG_ -%<T?\
M[]R?X5Q]% '8?\*V\)_]%<T?_OW)_A1_PK;PG_T5S1_^_<G^%<?10!V'_"MO
M"?\ T5S1_P#OW)_A1_PK;PG_ -%<T?\ []R?X5Q]% '8?\*V\)_]%<T?_OW)
M_A1_PK;PG_T5S1_^_<G^%<?10!V'_"MO"?\ T5S1_P#OW)_A1_PK;PG_ -%<
MT?\ []R?X5Q]% '8?\*V\)_]%<T?_OW)_A1_PK;PG_T5S1_^_<G^%<?10!V'
M_"MO"?\ T5S1_P#OW)_A1_PK;PG_ -%<T?\ []R?X5Q]% '8?\*V\)_]%<T?
M_OW)_A1_PK;PG_T5S1_^_<G^%<?10!V'_"MO"?\ T5S1_P#OW)_A1_PK;PG_
M -%<T?\ []R?X5Q]% '8?\*V\)_]%<T?_OW)_A1_PK;PG_T5S1_^_<G^%<?1
M0!V'_"MO"?\ T5S1_P#OW)_A1_PK;PG_ -%<T?\ []R?X5Q]% '8?\*V\)_]
M%<T?_OW)_A1_PK;PG_T5S1_^_<G^%<?10!V'_"MO"?\ T5S1_P#OW)_A7GG[
M2OQ#^%7[-GP[F\9:U\2]/U._D!CTC0[&-_/OIO09X1!D%G/"CU8JIP?C?\;?
M"'P*\&2^+/%,^^5\IIVGQN!+>2XX1?0#JS=%'J2 ?FWX+_!WQU^V'\07^.OQ
MQ:1?#\<NVQL5RB7*JQQ!$.JPJ<[FZL<C))9A[&79?3J4WBL4^6C'[Y/^5?K_
M %;]A\._#[+L?@*G%/%$W1RC#NS:TGB*G2A16C;>TI+X5?56<H;_ .R]^S)X
MB_;*\:S_ +1'[2'C.RT[11,/[,TV\WC[<%)Q'&@^Y;)TR3ESGKEFK[2@^&'@
MRVA2VMOBMHL<<:A8XTA<*J@8   X KC;2TM;"UBL;&VCA@AC$<,,2!510,!0
M!P !P!4E<^8YA4Q]5-KEA'2,5LE_6[/GO$+Q!S'C[-(5)P5'"T5R8>A#2G1I
MK1))63DTES2M=OM%12[#_A6WA/\ Z*YH_P#W[D_PH_X5MX3_ .BN:/\ ]^Y/
M\*X^BO//S\[#_A6WA/\ Z*YH_P#W[D_PH_X5MX3_ .BN:/\ ]^Y/\*X^B@#L
M/^%;>$_^BN:/_P!^Y/\ "C_A6WA/_HKFC_\ ?N3_  KCZ* .P_X5MX3_ .BN
M:/\ ]^Y/\*/^%;>$_P#HKFC_ /?N3_"N/HH [#_A6WA/_HKFC_\ ?N3_  H_
MX5MX3_Z*YH__ '[D_P *X^B@#L/^%;>$_P#HKFC_ /?N3_"C_A6WA/\ Z*YH
M_P#W[D_PKCZ* .P_X5MX3_Z*YH__ '[D_P */^%;>$_^BN:/_P!^Y/\ "N/H
MH [#_A6WA/\ Z*YH_P#W[D_PH_X5MX3_ .BN:/\ ]^Y/\*X^B@#L/^%;>$_^
MBN:/_P!^Y/\ "C_A6WA/_HKFC_\ ?N3_  KCZ* .P_X5MX3_ .BN:/\ ]^Y/
M\*/^%;>$_P#HKFC_ /?N3_"N/HH [#_A6WA/_HKFC_\ ?N3_  H_X5MX3_Z*
MYH__ '[D_P *X^B@#L/^%;>$_P#HKFC_ /?N3_"C_A6WA/\ Z*YH_P#W[D_P
MKCZ* .P_X5MX3_Z*YH__ '[D_P */^%;>$_^BN:/_P!^Y/\ "N/HH [#_A6W
MA/\ Z*YH_P#W[D_PH_X5MX3_ .BN:/\ ]^Y/\*X^B@#L/^%;>$_^BN:/_P!^
MY/\ "C_A6WA/_HKFC_\ ?N3_  KCZ* .P_X5MX3_ .BN:/\ ]^Y/\*/^%;>$
M_P#HKFC_ /?N3_"N/HH [#_A6WA/_HKFC_\ ?N3_  H_X5MX3_Z*YH__ '[D
M_P *X^B@#L/^%;>$_P#HKFC_ /?N3_"C_A6WA/\ Z*YH_P#W[D_PKCZ* .P_
MX5MX3_Z*YH__ '[D_P */^%;>$_^BN:/_P!^Y/\ "N/HH [#_A6WA/\ Z*YH
M_P#W[D_PH_X5MX3_ .BN:/\ ]^Y/\*X^B@"U\7?V8_A?\9? 5[X#\3_%?1_*
MN4W6]PL+E[:8?<E7CJ#^8)!X)KY0_9"\;ZG\ ?C?>_LC_&_Q1;:?8/?O'I&L
M2;I+:*=CE"K=?)G&"IQ\KL,@;F(^I:\5_;-_9O7XT>#!XH\+V8_X2718F:TV
M##7D(Y: GN>K)_M9'&XD>WE6+HN,L%B7^[GU_EETDOU/VKPKXLRBIAJ_!?$L
MK9;C6N6;WPV(VA6C?97M&ILG'5OE4D_IK_A6WA/_ **YH_\ W[D_PH_X5MX3
M_P"BN:/_ -^Y/\*^7?V*OVD&^+?A,^!/&-X?^$ET2$+*TQ^>]MQ\HEYY+KPK
M^^&_B./<J\W&82M@<1*C56J_'S7DS\ZXOX4S?@GB*ODV91M5I.U^DHO6,XOK
M&2LT_D[--'8?\*V\)_\ 17-'_P"_<G^%'_"MO"?_ $5S1_\ OW)_A7'T5S'S
M1V'_  K;PG_T5S1_^_<G^%'_  K;PG_T5S1_^_<G^%<?10!V'_"MO"?_ $5S
M1_\ OW)_A1_PK;PG_P!%<T?_ +]R?X5Q]% '8?\ "MO"?_17-'_[]R?X4?\
M"MO"?_17-'_[]R?X5Q]% '8?\*V\)_\ 17-'_P"_<G^%'_"MO"?_ $5S1_\
MOW)_A7'T4 =A_P *V\)_]%<T?_OW)_A1_P *V\)_]%<T?_OW)_A7'T4 =A_P
MK;PG_P!%<T?_ +]R?X4?\*V\)_\ 17-'_P"_<G^%<?10!V'_  K;PG_T5S1_
M^_<G^%>\_L1^'=*\.R>)DTKQ7::J)ULS(UHK 0[?/P#GUW''^Z:^5J^DO^">
MW_,W_P#</_\ ;F@#Z2HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"O*/VY_^31_'O_8!?_T-:]7KRC]N?_DT?Q[_ -@%_P#T-: /B?0/^0%9?]>D
M?_H(JW530/\ D!67_7I'_P"@BK= !1110 4444 %%%% !1110 4444 %%%%
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MVIRV;7PI]Q_PG^%GC[]M?XC/\9_C$TL'ABVF*6=E&Q59U4\6\/<1@_?DZDY
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M/;_F;_\ N'_^W- 'TE1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%>4?MS_\FC^/?^P"_P#Z&M>KUY1^W/\ \FC^/?\ L O_ .AK0!\3Z!_R K+_
M *](_P#T$5;JIH'_ " K+_KTC_\ 015N@ HHHH **** "BBB@ HHHH ****
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MN34,=1C_ ,N:[_Y>I?\ /NL];])/5N3ER^N4445\^?@(4444 %%%% !1110
M4444 %%%% !7TE_P3V_YF_\ [A__ +<U\VU])?\ !/;_ )F__N'_ /MS0!])
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7E'[<_P#R:/X]_P"P
M"_\ Z&M>KUY1^W/_ ,FC^/?^P"__ *&M 'Q/H'_("LO^O2/_ -!%6ZJ:!_R
MK+_KTC_]!%6Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB\-C\-#$8>:G":NFMF@HHHK(Z HHHH **** "BBB@ KZ2_X)[?\ ,W_]P_\
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M\:/^%0?$S_H3;S_OD?XUC_\ "0Z__P!!R\_\"7_QH_X2'7_^@Y>?^!+_ .-
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MEY_X$O\ XT ;'_"H/B9_T)MY_P!\C_&C_A4'Q,_Z$V\_[Y'^-8__  D.O_\
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MD?XUC_\ "0Z__P!!R\_\"7_QH_X2'7_^@Y>?^!+_ .- &Q_PJ#XF?]";>?\
M?(_QH_X5!\3/^A-O/^^1_C6/_P )#K__ $'+S_P)?_&C_A(=?_Z#EY_X$O\
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M\:/^%0?$S_H3;S_OD?XUC_\ "0Z__P!!R\_\"7_QH_X2'7_^@Y>?^!+_ .-
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M"\0>3N>/X=J^:U^A?[3G[+W_  T78>&]+@\<_P!A6WAJ*XCM;==,^T1[)1"
MJ+YJ",*(0,#/4=,5Y-_PZ\_ZKC_Y;/\ ]TU]3A.)LE^KQO:EO:*4FDD]-4M6
MU9M]VS_2[Z.GC!X;^'G@WE?#^?YLWC*/MG4<J5>3O4Q%:JM84Y1M::LE)V5D
M]4T?)M?8G_!)SPAXF\5_\)]_PCNC37?V?^RO.\H [-WVS&?K@_E6;_PZ\_ZK
MC_Y;/_W37K_[*?[-VH?LO?V]]A^(\VI_VY]EW^58FT\KR?.QG$K[\^;[8QWS
MQPYYGF5XS*ZE&C4O)VLK26TD^JML>KXX>.'A?QAX7YAE&49A[7$5?9<L?95X
MWY:].<O>G3C%6C%O5J]K+6R/=_\ A4'Q,_Z$V\_[Y'^-'_"H/B9_T)MY_P!\
MC_&L?_A(=?\ ^@Y>?^!+_P"-'_"0Z_\ ]!R\_P# E_\ &OSX_P ^C8_X5!\3
M/^A-O/\ OD?XT?\ "H/B9_T)MY_WR/\ &L?_ (2'7_\ H.7G_@2_^-'_  D.
MO_\ 0<O/_ E_\: -C_A4'Q,_Z$V\_P"^1_C1_P *@^)G_0FWG_?(_P :Q_\
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M\1/K7K/2\GO&+^%6T6BB4445XY^/A1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 5Y1^W/_P FC^/?^P"__H:UZO7E'[<__)H_CW_L O\
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M.<#SX64'Z$CFJ=>GZ3^TE=O%]E\4^%X+A&&'>V?;D>ZMD'\Q5S^TOV>?&_\
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MX)[?\S?_ -P__P!N:^;:^DO^">W_ #-__</_ /;F@#Z2HHHH **** "BBB@
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MS X,49SMDDSQL4EL@\<&@#U&BH[V\L].LY=0U"ZC@MX(FDGGF<*D:*,LS$\
M  DD]*\]\!_M??LJ_%+Q5;>!OAK^T9X*U_6;W?\ 9-*T?Q+;7-Q-L0NVV.-R
MS8568X' !/:@#T:BBB@ KRC]N?\ Y-'\>_\ 8!?_ -#6O5Z\H_;G_P"31_'O
M_8!?_P!#6@#XGT#_ ) 5E_UZ1_\ H(JW530/^0%9?]>D?_H(JW0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@D#-<K_P6\\&^$M2_8JOO&-_X9L)M7T_Q%HZ6.J26B&X@5KU%94D(W*I#L"
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M0\I_21\8X5IRH9BJ<9.Z@J-%Q@K)*,%.G)QBDE97[MWDVW\._P##KS_JN/\
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MN6R21Q]%=A_PNWQ9_P! W1__  51T?\ "[?%G_0-T?\ \%4=>>>T<?178?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\3[[+26.FV9XV0O^\<?[3]OH,?C7$$DG).2>IKXQ>'_B7XI/VO'6+^I8&6V
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7E'[<__)H_CW_L O\
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M4/[:OP>_=_%KX2_VE:Q?ZV]ETQH^G_3>WS"/^^31_JQ'$ZX#%4ZOE?DE_P"
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M%T.9XB?^/B0;(_\ OIL _ADUW>E_ '0=!M1JGQ$\511QK]Z*&01IGTWMR?H
M#7Y=QAXR^'7!-;ZMC\:IXF]E0HIU:SETCR0NXM].?E7F=N'R[%XE<T8V7=Z+
M[V>60037,JP6T+22.<*B*22?0 =:[+PQ\"/'.O[9[VU73H&YWW?#X]D'/YXK
MJ)_BU\+_  %"UE\/_#:W$H&TSJFQ3]7;+M^6/>N-\3_&7QYXFW1/JILX&_Y8
M6.8QCW;.X_GCVKX?_6WQQX\TX>RJ&58:7_+_ !KYJS7>.&A?EEY5+Q?<Z?89
M;A?XL^=]H[??_D=HO@3X,_#91+XOUE;^[49\B4YY]HD[?[V15#7?VB?LUO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5])?\$]O^9O_ .X?_P"W-?-M?27_  3V_P"9O_[A_P#[<T ?25%%% !1110
M4444 %?*_P#P4I^/%[\&?$_P?T?QEXCU30/AEXF\9S6GQ%U_2;J6VDBC6 &U
MMWN(2)(89)2S2%&5C' PSC<#]45ROQ.\._"7XI6,GP(^*NBZ=K-OXCTJYG?0
M=1@\Q;JV@D@260<<%'N(,,"&5G4KR,@ \,_9-^!5KIFB_#SXP_!GQIJUKI,F
MJ:RGB?28/$D]QI>JV#F^%O.())'C\Q)A;%9(PI96;<6&,8G_  6:NO'WA?\
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M6-2GNI3_ !SR%B/89Z#VKI_[:^"G_0EZQ_X,5_PH_MKX*?\ 0EZQ_P"#%?\
M"OU'@_PVX%X"H\F18"G1=K.:7-4E_BJ2O.7HY6\CAQ&,Q6*=ZLV_R^[8X^BN
MP_MKX*?]"7K'_@Q7_"C^VO@I_P!"7K'_ (,5_P *^X.8X^BNP_MKX*?]"7K'
M_@Q7_"C^VO@I_P!"7K'_ (,5_P * ./HKL/[:^"G_0EZQ_X,5_PH_MKX*?\
M0EZQ_P"#%?\ "@#CZ*[#^VO@I_T)>L?^#%?\*/[:^"G_ $)>L?\ @Q7_  H
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M_P!"7K'_ (,5_P * ./HKL/[:^"G_0EZQ_X,5_PH_MKX*?\ 0EZQ_P"#%?\
M"@#CZ*[#^VO@I_T)>L?^#%?\*/[:^"G_ $)>L?\ @Q7_  H X^BNP_MKX*?]
M"7K'_@Q7_"C^VO@I_P!"7K'_ (,5_P * ./HKL/[:^"G_0EZQ_X,5_PH_MKX
M*?\ 0EZQ_P"#%?\ "@#CZ*[#^VO@I_T)>L?^#%?\*/[:^"G_ $)>L?\ @Q7_
M  H X^BNP_MKX*?]"7K'_@Q7_"C^VO@I_P!"7K'_ (,5_P * ./HKL/[:^"G
M_0EZQ_X,5_PH_MKX*?\ 0EZQ_P"#%?\ "@#CZ*[#^VO@I_T)>L?^#%?\*/[:
M^"G_ $)>L?\ @Q7_  H X^BNP_MKX*?]"7K'_@Q7_"C^VO@I_P!"7K'_ (,5
M_P * ./HKL/[:^"G_0EZQ_X,5_PH_MKX*?\ 0EZQ_P"#%?\ "@#CZ*[#^VO@
MI_T)>L?^#%?\*/[:^"G_ $)>L?\ @Q7_  H X^BNP_MKX*?]"7K'_@Q7_"C^
MVO@I_P!"7K'_ (,5_P * ./HKL/[:^"G_0EZQ_X,5_PH_MKX*?\ 0EZQ_P"#
M%?\ "@#CZ*[#^VO@I_T)>L?^#%?\*/[:^"G_ $)>L?\ @Q7_  H X^BNP_MK
MX*?]"7K'_@Q7_"C^VO@I_P!"7K'_ (,5_P * ./HKL/[:^"G_0EZQ_X,5_PH
M_MKX*?\ 0EZQ_P"#%?\ "@#CZ*[#^VO@I_T)>L?^#%?\*/[:^"G_ $)>L?\
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MJW_"N3J(_L3[69O/SY.SS#%YW[W[,9/L^_GRJ]CHH YGXN?!_P  ?''P//\
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M %\X+&#]./>O:RKZ2O@WG4^2GG.#4^L:].KAVGV;KTZ<?NDUYF%3Z07&5/\
MY&G"V$JKO+!4JJ?_ ()JN7_DJ?D?.'_"PO\ @I+H9_XF'@C[9CK_ ,2RUDS_
M -^6%)_PU+^W/HG&L?L^>>B_>D/A:^_]"23;^E>W:GXW_:V\% K\0?V&_%8$
M?^LE\,WT6J@^X6 '^9K!N/VW?A5H5RME\0?"_B[PM,3@Q:_X=DB(/?A2Q_2O
MU#*>(<FXBCS96L+BUWP]6G5_]-3F>=4^D7X?MVS7AG TGUO1K87_ -+M8\O_
M .&_/C?H_'B;]GX(5^]^[N8/_0U:IK/_ (*=VZOY6K_!:6(@_,8==#'\FA'\
MZ]KT']J_]G/Q'M&G_%[2(]W3[=,;7_T<$Q766&M^!_&D/_$LU?2=6CQD>1<1
M3C'X$UW5JF#H?[QE[C_V]./YH]+"^*_@9G&_"]*=^M''U5]R2:/SB^/_ ,3K
M+XR?%O5OB1IVE2V4.I"WV6LT@9D\NWCB.2.#DH3^-<=7JG[:]C9:;^TWXFLM
M.LXK>%#9[(H(PBKFR@)P!P,DD_C6;\ OV:/B5^T=_P )-_PKS3_._P"$7\/3
M:K>94GS=GW+=,=99,-M'?8WI7V&*SS)<@X?CF./JQH8>$87E-VC%2Y8Q3;[M
MJ/FV?Z:<)9MD>#\.\MQ\4L/A?JV'<5*7-[.$J<%"+F]9-)J/,]6]>IY[7U+^
MS[_PSQ\ /@+I/[07CO3UOO$NJ-<_V;:RLLDI>*XDB @0\1C" M(<D9//(4_+
M5?2?['?[&MU\9K33OB/\19IKK059X]%T:"1G>[V2N&!QS'%YGF?*,%CN/ .6
MZ,ZGE]+ NICJSITHZRMHY))^[?I?=OLGMNOYX^FOG_&&1^$F'I\.-JMB<73H
MR:DXQ5.5'$3DYVWA>$;Q^T[*S^%R>$_A_P#&;]O'QFGCSXCWDVC^#K29A:0P
MY"[<\QVZM]]SC#3,,9]<!!];^"/ WA3X<^&K?PCX+T6&PL+5<1PPCJ>[,3RS
M'J6.2:](\%?LZ^*KFRM[,:=;Z+80QJD$3H%,: 8"K$OW0!V.VNL'@[X*?#0>
M9XGU1=1O$_Y82'><_P#7)>!_P/-?R?QM])?@=8Y91D[GCZT=(8;!0=9KI>4X
M_N[W^)N3<=?=WO\ YJ<+< /)(RQ>(ESXBIK4K5-'+R2^S'M%>5WHK>9:!X2\
M2>*)O(T#1I[DYP61,(OU8\#\37>Z#^SK-%#_ &CXX\0Q6D*#,D5NPR![NWRK
M^1I-?_:+N4A_L_P3X?BLX5&(Y;A02![(ORK^9K@M>\5^(_$\_GZ]K,]R<Y59
M'^5?HHX'X"OB+?2"X^W]CD6%EZ8G%M?A2A=>DXOO8^O_ .$K"]ZLO_ 8_P";
M/3CXU^"OPU!C\*Z2NH7B<>?$-YS_ -=7Z?\  <BN7\3?'GQQKVZ#3YTTV!N-
MMJ/GQ[N><^XQ7$T5[W#_ (!\ Y5C5F.9PGF6,ZUL9-UY7\HR_=I)_#[MU_,9
MU<TQ52/)"T(]HZ?\$?<7%Q=S-<W4[RR.<O)(Q9F/N3UIE%%?M,(0IP4(*R6B
M2V2\CS=PHHHJ@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *^DO^">W_,W_ /</_P#;FOFVOI+_ ()[?\S?_P!P_P#]N: /I*BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\H_;G_Y-'\>_P#8!?\
M]#6O5Z\H_;G_ .31_'O_ & 7_P#0UH ^)] _Y 5E_P!>D?\ Z"*MU4T#_D!6
M7_7I'_Z"*MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%% !1110 4444 %%%% !1110 5])?\$]O^9O_P"X?_[<U\VU])?\$]O^9O\
M^X?_ .W- 'TE1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>4?MS
M_P#)H_CW_L O_P"AK7J]>4?MS_\ )H_CW_L O_Z&M 'Q/H'_ " K+_KTC_\
M015NJF@?\@*R_P"O2/\ ]!%6Z "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "OI+_@GM_S-_\ W#__ &YKYMKZ2_X)[?\ ,W_]P_\
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MA2/6VG"1QES&HQM:0XVJ-V"Q SSFO8?V&?VPM4_:D\.>(?#'Q(^'DWA#XB>
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M?VV_"?[.GP]\=ZQKGP?^*FEZK)H^A:W=&>3PUJ-C"+AQ$YZ1.AVC@;B_S99
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M%'_##>K_ /0W7O\ X(E_^2* /!:*]Z_X8;U?_H;KW_P1+_\ )%'_  PWJ_\
MT-U[_P"")?\ Y(H \%HKWK_AAO5_^ANO?_!$O_R11_PPWJ__ $-U[_X(E_\
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MKW_P1+_\D4?\,-ZO_P!#=>_^")?_ )(H \%HKWK_ (8;U?\ Z&Z]_P#!$O\
M\D4?\,-ZO_T-U[_X(E_^2* /!:*]Z_X8;U?_ *&Z]_\ !$O_ ,D4?\,-ZO\
M]#=>_P#@B7_Y(H \%HKWK_AAO5_^ANO?_!$O_P D4?\ ##>K_P#0W7O_ ((E
M_P#DB@#P6BO>O^&&]7_Z&Z]_\$2__)%'_##>K_\ 0W7O_@B7_P"2* /!:*]Z
M_P"&&]7_ .ANO?\ P1+_ /)%'_##>K_]#=>_^")?_DB@#P6BO>O^&&]7_P"A
MNO?_  1+_P#)%'_##>K_ /0W7O\ X(E_^2* /!:*]Z_X8;U?_H;KW_P1+_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%OH.D^+;&>>_\0M [(\KN"([:*1T80@?,R%79E#@+A_\$0O^4;7@;_K]U?\
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M,M_VM_CEX6\!0Q+-X*^%WBF+Q!XIOP,I?:W C"STV,]'$1E,]QU"XAC^\SA
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M%O 4,2S>"OA=XIB\0>*;\#*7VMP(PL]-C/1Q$93/<=0N(8_O,X3WR@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "LOQMXV\)?#?PEJ/CSQYXAM=)T;2;5
M[G4=1O90D4$2C)9B?R ZDD 9)H\;>-O"7PW\):CX\\>>(;72=&TFU>YU'4;V
M4)%!$HR68G\@.I) &2:_#_\ X*>_\%/?%O[;/BU_ 7@*:ZTGX:Z3=;M.TYB4
MEU:53@7=R!^:1]$!R<L>/H.'^'\5GV*Y8Z4U\4NWDN[?1?-GQ?&G&F7\'Y?[
M2I[U:7P0ZM]WVBNKZ[+4_<#P3XV\)?$CPEIWCSP'XAM=6T;5K5;G3M1LI0\4
M\3#(92/R(Z@@@X(K4K\*_P#@F%_P4]\6_L3>+4\!>/9KK5OAKJUUNU'3E)>7
M296.#=VP/YO'T<#(PPY_<#P3XV\)?$CPEIWCSP'XAM=6T;5K5;G3M1LI0\4\
M3#(92/R(Z@@@X(HX@X?Q60XKEEK3?PR[^3[-=5\T'!?&F7\89?[2G[M:/QPZ
MI]UWB^CZ;/4U*YCXF?&KX1?!C3XM6^+GQ+T/PS:3-MBNM=U*.UB8YQ@-(0,\
M],UT]>8?ML:=I^J_L<_%:SU2QAN8?^%=:T_E3Q!UW)93.K8/&0RA@>Q (Y%?
M/GVAZ)H.O:'XIT2T\2^&=8M=0T[4+9+BQO[*=98;B%U#)(CJ2&5@000<$&N=
MM_CU\%;OQ^WPIMOBGH4GB=%W/X?34HS>JN[;N,.=X7=QNQC/>OBC]D_XB^-?
M^"9/Q?T7]D'X]^(9[[X3>/%6Z^%'C2^;Y=+NI0K2:;<-T0%W'/ #,KX"RMY?
MU'IMO!_PW_K-UY*^;_PI[3$\S;SM_M6_.,^F: /8:*\4\<?M9>*X/#?BOQW\
M%?@A/XTT'P5=7=MK6H#7XK)[N:TS]KCL8VC?[282KHQ<Q!I$9$+D&N9\2_\
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M8$)&@E0&3=E5 /4ZY+XG_'OX)?!1()?C!\6/#_A=+D@6\FOZK%:)*3GA6D8
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MZ#XHL=>34+.#4'&8[2]Q'&;:1P#M9?-C)#?/A2P /<Z*\OU[]H37-0^+VO\
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M-3_HY+_RSM9_^0Z_!FBOTG_4[+/YY_?'_P"1/](O^)/?#/\ Z"\9_P"#*/\
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M=Z5XDU)]>2TO;B6T"&[DM+9HF66.(/G,DL1;:VT'C/>>)_VK/"=OX;^'&H>
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M!^%GA_\ 8[\+_M/ZUX9GT;1]<TBP;1/"^FQI-<R3W.U+:PMT78KR,S*B@;5
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M]EE]N2/VFD^9^2>R[=6'!?A'A*> ^L9TI>UGM",G'D79N+3<GU5[+;<^2/\
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MBAWL\G 7(!() KZTT#P?X2\*Z=)H_A?PMIVFVDTA>:UL+&.&.1B I8J@ )(
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MYE9@?4$@]:G\._#7X<^$+YM4\)^ -$TNY:,QM<:=I4,$A0D$J610<$@''L*
M/FS]G7_@IW^S3\2?V?O"T>B^)[>]\?3Z7;:<GPWB1O[2EU9(U3[.L6TD1^8N
M?/(\M$^=BH5L>]:I^T)\'M"^-VD_LW:UXWMX/'&MZ-)JNF:!Y$I>>T0N&D$@
M3RQS%)A2P8B-B 0#6MI'PL^&'A_Q9=>/-!^'&@V6N7P(OM:M-'@BN[@$Y.^9
M5#OD^I-7I_"?A6Y\2P>,[GPUI\FL6MJ]M;:L]DAN886.6B64C<J$@$J#@D4
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M:A:)-'N&<-M<$9&3S[TS0/!_A'PGI\ND^%O"VG:;:S.7FMM/L8X8Y&( +,J
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
..%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263540595600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-22705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEUROCRINE BIOSCIENCES, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0525145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">12780 El Camino Real,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San&#160;Diego,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">617-7600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NBIX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,097,146,859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,587,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the registrant&#8217;s definitive proxy statement relating to the registrant&#8217;s annual meeting of stockholders to be filed pursuant to Regulation 14A within 120 days following the end of the registrant&#8217;s fiscal year ended December&#160;31, 2022 are incorporated by reference into Part III of this Form 10-K.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000914475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263540533408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AuditorInformationAbstract', window );"><strong>Auditor Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst&#160;& Young LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Diego, California<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_AuditorInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Auditor Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_AuditorInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263544436048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 262.9<span></span>
</td>
<td class="nump">$ 340.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities available-for-sale</a></td>
<td class="nump">726.4<span></span>
</td>
<td class="nump">370.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">350.0<span></span>
</td>
<td class="nump">185.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">35.1<span></span>
</td>
<td class="nump">30.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">79.1<span></span>
</td>
<td class="nump">45.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,453.5<span></span>
</td>
<td class="nump">972.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">305.9<span></span>
</td>
<td class="nump">315.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Debt securities available-for-sale</a></td>
<td class="nump">299.4<span></span>
</td>
<td class="nump">560.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">87.0<span></span>
</td>
<td class="nump">97.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRestricted', window );">Equity securities</a></td>
<td class="nump">102.1<span></span>
</td>
<td class="nump">63.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">58.6<span></span>
</td>
<td class="nump">58.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">37.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">25.0<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,368.7<span></span>
</td>
<td class="nump">2,072.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">347.6<span></span>
</td>
<td class="nump">225.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible senior notes</a></td>
<td class="nump">169.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">20.7<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">537.7<span></span>
</td>
<td class="nump">245.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible senior notes</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">335.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent operating lease liabilities</a></td>
<td class="nump">93.5<span></span>
</td>
<td class="nump">105.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">29.7<span></span>
</td>
<td class="nump">12.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">660.9<span></span>
</td>
<td class="nump">698.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5.0 million shares authorized; no shares issued and outstanding</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 220.0 million shares authorized; 96.5 million and 94.9 million shares issued and outstanding, respectively</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">2,122.4<span></span>
</td>
<td class="nump">2,011.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(7.9)<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(406.8)<span></span>
</td>
<td class="num">(635.8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">1,707.8<span></span>
</td>
<td class="nump">1,374.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 2,368.7<span></span>
</td>
<td class="nump">$ 2,072.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRestricted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of restricted investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=127002003&amp;loc=SL6242269-115581<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=109249958&amp;loc=SL6224234-111729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRestricted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263540613168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">220,000,000<span></span>
</td>
<td class="nump">220,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">96,500,000<span></span>
</td>
<td class="nump">94,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">96,500,000<span></span>
</td>
<td class="nump">94,900,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263540203360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements Income and Comprehensive Income - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 1,488.7<span></span>
</td>
<td class="nump">$ 1,133.5<span></span>
</td>
<td class="nump">$ 1,045.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenues</a></td>
<td class="nump">23.2<span></span>
</td>
<td class="nump">14.3<span></span>
</td>
<td class="nump">10.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">463.8<span></span>
</td>
<td class="nump">328.1<span></span>
</td>
<td class="nump">275.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">105.3<span></span>
</td>
<td class="nump">164.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">752.7<span></span>
</td>
<td class="nump">583.3<span></span>
</td>
<td class="nump">433.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">1,239.7<span></span>
</td>
<td class="nump">1,031.0<span></span>
</td>
<td class="nump">882.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">249.0<span></span>
</td>
<td class="nump">102.5<span></span>
</td>
<td class="nump">163.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(7.1)<span></span>
</td>
<td class="num">(25.8)<span></span>
</td>
<td class="num">(32.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) on equity securities</a></td>
<td class="nump">30.8<span></span>
</td>
<td class="nump">20.9<span></span>
</td>
<td class="num">(17.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible senior notes</a></td>
<td class="num">(70.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(18.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_InvestmentIncomeAndOtherNet', window );">Investment income and other, net</a></td>
<td class="nump">11.2<span></span>
</td>
<td class="nump">3.8<span></span>
</td>
<td class="nump">12.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(35.1)<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
<td class="num">(56.3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before provision for (benefit from) income taxes</a></td>
<td class="nump">213.9<span></span>
</td>
<td class="nump">101.4<span></span>
</td>
<td class="nump">106.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for (benefit from) income taxes</a></td>
<td class="nump">59.4<span></span>
</td>
<td class="nump">11.8<span></span>
</td>
<td class="num">(300.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">154.5<span></span>
</td>
<td class="nump">89.6<span></span>
</td>
<td class="nump">407.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized (loss) gain on debt securities available-for-sale, net of tax</a></td>
<td class="num">(9.1)<span></span>
</td>
<td class="num">(3.5)<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 148.3<span></span>
</td>
<td class="nump">$ 86.1<span></span>
</td>
<td class="nump">$ 407.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share, basic (in USD per share)</a></td>
<td class="nump">$ 1.61<span></span>
</td>
<td class="nump">$ 0.95<span></span>
</td>
<td class="nump">$ 4.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share, diluted (in USD per share)</a></td>
<td class="nump">$ 1.56<span></span>
</td>
<td class="nump">$ 0.92<span></span>
</td>
<td class="nump">$ 4.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">95.8<span></span>
</td>
<td class="nump">94.6<span></span>
</td>
<td class="nump">93.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">98.9<span></span>
</td>
<td class="nump">97.9<span></span>
</td>
<td class="nump">97.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 1,440.9<span></span>
</td>
<td class="nump">$ 1,090.1<span></span>
</td>
<td class="nump">$ 994.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nbix_CollaborationRevenueMember', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 47.8<span></span>
</td>
<td class="nump">$ 43.4<span></span>
</td>
<td class="nump">$ 51.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_InvestmentIncomeAndOtherNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment income and other net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_InvestmentIncomeAndOtherNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nbix_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nbix_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263539028768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 636.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 1,768.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="num">$ (1,132.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">407.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">407.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments', window );">Equity component of repurchased convertible senior notes, net</a></td>
<td class="num">(47.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuances of common stock under stock plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances of common stock under stock plans</a></td>
<td class="nump">29.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">1,126.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">1,849.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="num">(725.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">89.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">$ (3.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="text">Accounting Standards Update 2020-06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 134.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuances of common stock under stock plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances of common stock under stock plans</a></td>
<td class="nump">27.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">1,374.0<span></span>
</td>
<td class="num">$ (32.3)<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">2,011.4<span></span>
</td>
<td class="num">$ (106.8)<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
<td class="num">(635.8)<span></span>
</td>
<td class="nump">$ 74.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">154.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(6.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">173.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuances of common stock under stock plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances of common stock under stock plans</a></td>
<td class="nump">44.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 1,707.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 2,122.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7.9)<span></span>
</td>
<td class="num">$ (406.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of subsequent adjustments to additional paid in capital for convertible financial instruments where a component of equity and a component of debt are recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263543282672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 154.5<span></span>
</td>
<td class="nump">$ 89.6<span></span>
</td>
<td class="nump">$ 407.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">173.1<span></span>
</td>
<td class="nump">134.2<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">15.1<span></span>
</td>
<td class="nump">10.9<span></span>
</td>
<td class="nump">8.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">16.2<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Change in fair value of equity securities</a></td>
<td class="num">(30.8)<span></span>
</td>
<td class="num">(20.9)<span></span>
</td>
<td class="nump">17.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income taxes</a></td>
<td class="nump">19.1<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
<td class="num">(310.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible senior notes</a></td>
<td class="nump">70.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">18.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other</a></td>
<td class="nump">4.1<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(162.2)<span></span>
</td>
<td class="num">(28.4)<span></span>
</td>
<td class="num">(30.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(2.6)<span></span>
</td>
<td class="num">(2.5)<span></span>
</td>
<td class="num">(10.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">114.6<span></span>
</td>
<td class="nump">56.8<span></span>
</td>
<td class="nump">26.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet', window );">Other assets and liabilities, net</a></td>
<td class="num">(17.2)<span></span>
</td>
<td class="num">(9.2)<span></span>
</td>
<td class="num">(23.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash flows from operating activities</a></td>
<td class="nump">339.4<span></span>
</td>
<td class="nump">256.5<span></span>
</td>
<td class="nump">228.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of debt securities available-for-sale</a></td>
<td class="num">(621.2)<span></span>
</td>
<td class="num">(800.1)<span></span>
</td>
<td class="num">(735.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sales and maturities of debt securities available-for-sale</a></td>
<td class="nump">511.0<span></span>
</td>
<td class="nump">697.9<span></span>
</td>
<td class="nump">750.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of business, net of cash acquired</a></td>
<td class="num">(42.7)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRestrictedInvestments', window );">Purchases of equity securities</a></td>
<td class="num">(7.7)<span></span>
</td>
<td class="num">(4.6)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="num">(16.5)<span></span>
</td>
<td class="num">(23.4)<span></span>
</td>
<td class="num">(10.9)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Cash flows from investing activities</a></td>
<td class="num">(177.1)<span></span>
</td>
<td class="num">(130.2)<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuances of common stock under benefit plans</a></td>
<td class="nump">44.7<span></span>
</td>
<td class="nump">27.5<span></span>
</td>
<td class="nump">29.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repurchases of convertible senior notes</a></td>
<td class="num">(279.0)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(186.9)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash flows from financing activities</a></td>
<td class="num">(234.3)<span></span>
</td>
<td class="nump">27.4<span></span>
</td>
<td class="num">(157.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(1.3)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Change in cash and cash equivalents and restricted cash</a></td>
<td class="num">(73.3)<span></span>
</td>
<td class="nump">153.7<span></span>
</td>
<td class="nump">74.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">344.0<span></span>
</td>
<td class="nump">190.3<span></span>
</td>
<td class="nump">115.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash at end of period</a></td>
<td class="nump">270.7<span></span>
</td>
<td class="nump">344.0<span></span>
</td>
<td class="nump">190.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosure:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Non-cash capital expenditures</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets acquired through operating leases</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">23.4<span></span>
</td>
<td class="nump">12.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">6.6<span></span>
</td>
<td class="nump">8.6<span></span>
</td>
<td class="nump">11.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">$ 14.4<span></span>
</td>
<td class="nump">$ 5.1<span></span>
</td>
<td class="nump">$ 15.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current operating assets after deduction of current operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263624383664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text">Organization and Summary of Significant Accounting Policies<div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization and Business. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neurocrine Biosciences, Inc. and its subsidiaries, or Neurocrine Biosciences, the Company, we, our or us, is a neuroscience-focused biopharmaceutical company focused on discovering, developing and delivering innovative therapies to help ease the burden of debilitating disorders and diseases.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a single business segment, which includes all activities related to the research, development and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine and neuropsychiatric disorders.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Neurocrine Biosciences as well as our wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments that are readily convertible into cash without penalty and have an original maturity of three months or less at the time of purchase to be cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded net of customer allowances for prompt payment discounts, chargebacks, and any allowance for credit losses. Our estimate for the allowance for credit losses, which has not been significant to date, is determined based on existing contractual payment terms, actual payment patterns of our customers, and individual customer circumstances.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our exposure to credit losses may increase if our customers are adversely affected by changes in healthcare laws, coverage and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current COVID-19 pandemic, or other customer-specific factors. It is possible that there could be a material adverse impact from potential adjustments of the carrying amount of trade receivables as customers&#8217; cash flows are impacted by their response to the COVID-19 pandemic.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities consist of investments in certificates of deposit, corporate debt securities and securities of government-sponsored entities. We classify debt securities as available-for-sale. Debt securities available-for-sale are recorded at fair value, with unrealized gains and losses included in other comprehensive income or loss, net of tax. We exclude accrued interest from both the fair value and amortized cost basis of debt securities. A debt security is placed on nonaccrual status at the time any principal or interest payments become 90 days delinquent. Interest accrued but not received for a debt security placed on nonaccrual status is reversed against interest income.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income includes amortization of purchase premium or discount. Premiums and discounts on debt securities are amortized using the effective interest rate method. Gains and losses on sales of debt securities are recorded on the trade date in investment income and other, net, and determined using the specific identification method.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allowance for Credit Losses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For debt securities available-for-sale in an unrealized loss position, we first assess whether we intend to sell, or it is more likely than not that we will be required to sell, the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivables on debt securities available-for-sale were $4.7 million and $2.2 million, respectively, as of December&#160;31, 2022 and 2021. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized cost basis of the debt security. Uncollectible accrued interest receivables associated with an impaired debt security are reversed against interest income upon identification of the impairment. No accrued interest receivables were written off during 2022, 2021 or 2020.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record cash equivalents, debt securities available-for-sale and equity security investments at fair value based on a fair value hierarchy that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The fair value hierarchy consists of the following three levels:</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in debt securities available-for-sale are classified as Level 2 and carried at fair value. We estimate the fair value of debt securities available-for-sale by utilizing third-party pricing services. These pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. Such inputs include market pricing based on real-time trade data for similar instruments, issuer credit spreads, benchmark yields, broker/dealer quotes and other observable inputs. We validate valuations obtained from third-party pricing services by understanding the models used, obtaining market values from other pricing sources and analyzing data in certain instances.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We deem transfers between levels of the fair value hierarchy to have occurred at the end of the reporting period during which the event or change in circumstances that caused the transfer occurred.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is valued at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on the first-in, first-out method. We assess the valuation of our inventory on a quarterly basis and adjust the value for excess and obsolete inventory to the extent management determines that the cost cannot be recovered based on estimates about future demand. Inventory costs resulting from these adjustments are recognized as cost of sales in the period in which they are incurred. When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#8217;s judgment, we capitalize pre-launch inventory costs prior to regulatory approval.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets using the straight-line method. Equipment is depreciated over an average estimated useful life of 3 to 7 years. Leasehold improvements are depreciated over the shorter of their estimated useful lives or the remaining lease term. Depreciation expense was $15.1 million for 2022, $10.9 million for 2021 and $8.6 million for 2020.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. In addition, costs that we incur to complete the business combination, such as legal and other professional fees, are expensed as selling, general and administrative when incurred.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill, Intangible Assets and Other Long-Lived Assets. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired, including intangible assets and in-process research and development, or IPR&amp;D, and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&amp;D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;D asset is amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;D asset is expensed in the period of abandonment.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and IPR&amp;D are not amortized; however, they are reviewed for impairment at least annually, as of October 1, and more frequently if an event occurs indicating the potential for impairment. Goodwill and IPR&amp;D are considered to be impaired if the carrying value of the reporting unit or IPR&amp;D asset exceeds its respective fair value.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform our goodwill impairment analysis at the reporting unit level, which aligns with our reporting structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of the reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the reporting unit with the carrying value, including goodwill. If the carrying amount of the reporting unit exceed the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our identifiable intangible assets with a finite life are typically comprised of acquired product rights. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#8217; respective estimated useful lives.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform regular reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign currency.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Assets and liabilities are translated into the reporting currency using the exchange rates in effect on the consolidated balance sheet dates. Equity accounts are translated at historical rates, except for the change in retained earnings during the period, which is the result of the income statement translation process. Revenue and expense accounts are translated using the weighted average exchange rate during the period. The cumulative translation adjustments associated with the net assets of foreign subsidiaries are recorded in accumulated other comprehensive income (loss) in the accompanying consolidated statements of stockholders&#8217; equity.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue when the customer obtains control of promised goods or services in an amount that reflects the consideration which we expect to receive in exchange for such goods or services. Revenue is recognized using a five-step model: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the United States, we sell INGREZZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (valbenazine) primarily to specialty pharmacy providers and distributors and ONGENTYS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (opicapone) primarily to wholesale distributors. We recognize net product sales when the customer obtains control of our product, which occurs at a point in time, typically upon delivery of our product to the customer.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, payors, and other third parties. Such estimates are based on information received from external sources (such as written or oral information obtained from our customers with respect to their period-end inventory levels and sales to end-users during the reporting period), as supplemented by management&#8217;s judgement. Our process for estimating reserves established for these variable consideration components does not differ materially from historical practices. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant categories of sales discounts and allowances are as follows:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Discounts.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Product discounts are based on payment terms extended to our customers at the time of sale, which include incentives offered for prompt payment. We maintain a reserve for product discounts based on our historical experience, including the timing of customer payments. To date, actual product discounts have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are obligated to pay rebates for mandated discounts under the Medicaid Drug Rebate Program. The liability for such rebates consists of invoices received for claims from prior quarters that remain unpaid, or for which an invoice has not been received, and estimated rebates for the current applicable reporting period. Such estimates are based on actual historical rebates by state, estimated payor mix, state and federal regulations, and relevant contractual terms, as supplemented by management&#8217;s judgement. Our rebate accrual calculations require us to project the magnitude of our sales that will be subject to these rebates. There is a significant time-lag in our receiving rebate notices from each state (generally, several months or longer after a sale is recognized). Estimated rebates are recorded as a reduction of revenue in the period the related sale is recognized. To date, actual government rebates have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The difference between the list price, or the price at which we sell our products to our customers, and the contracted price, or the price at which our customers sell our products to qualified healthcare professionals, is charged back to us by our customers. In addition to actual chargebacks received, we maintain a reserve for chargebacks based on estimated contractual discounts on product inventory levels on-hand in our distribution channel. To date, actual chargebacks have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payor and Pharmacy Rebates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are obligated to pay rebates as a percentage of sales under payor and pharmacy contracts. We estimate these rebates based on actual historical rebates, contractual rebate percentages, sales made through the payor channel, and purchases made by pharmacies. To date, actual payor and pharmacy rebates have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient Financial Assistance.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> To help patients afford our products, we offer free trial vouchers to qualifying new patients and financial assistance to qualified patients with prescription drug copay requirements. We accrue for patient financial assistance based on estimated claims and the cost per claim we expect to receive in connection with inventory that remains in the distribution channel at period end. To date, actual patient financial assistance has not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distributor and Other Fees.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In connection with the sales of our products, we pay distributor and other fees, which are generally recorded as a reduction of revenue, to certain customers that provide us with inventory management, data, and/or distribution services. Costs associated with such services are expensed as selling, general and administrative to the extent we can demonstrate a separable benefit and fair value for such services. To date, actual distributor and other fees have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We offer our customers product return rights primarily limited to errors in shipment, damaged product, and expiring product, provided it is within a specified period of the product expiration date, as set forth in the associated distribution agreement. Where actual returns history is not available, we estimate a returns allowance based on benchmarking data for similar products and industry experience. Such estimates are recorded as a reduction of revenue in the period the related sale is recognized. Once product is returned, it is destroyed. To date, actual product returns have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenues. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into collaboration and license agreements under which we out-license certain rights to our product candidates to third parties. The terms of these arrangements typically include payment to us for one or more of the following: non-refundable, up-front license fees; development, regulatory, and/or commercial milestone payments; and royalties on net sales of the out-licensed products.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use, and benefit from, the license. For licenses that are bundled with other promises, we assess the nature of the combined performance obligation to determine whether it is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestones.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the inception of each arrangement that includes development, regulatory, and/or commercial milestones, we evaluate whether achieving the milestones is considered probable and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Amounts for milestones that are not within our control, such as when achievement of a specified event is dependent on the development activities of a third party or approvals from regulators, are not considered probable of being achieved until such specified event occurs. Revenue is recognized from the satisfaction of performance obligations in the amount billable to the customer.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For arrangements that include sales-based royalties, and under which the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Each quarterly period, sales-based royalties are recorded based on estimated quarterly net sales of the associated collaboration products. Differences between actual results and estimated amounts are adjusted for in the period in which they become known, which typically follows the quarterly period in which the estimate was made. To date, actual royalties received have not differed materially from our estimates.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents and debt securities available-for-sale. We have established guidelines to limit our exposure to credit risk by diversifying our investment portfolio with low-risk investment-grade debt securities with maturities of up to three years and by placing our investments with high-credit-quality financial institutions to maintain liquidity. To date, we have not experienced any credit losses and do not believe we are exposed to any significant credit risk in connection with these financial instruments.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into agreements for the distribution of INGREZZA with a limited number of specialty pharmacy providers and distributors and all of our product sales of INGREZZA are to these customers. Four of these customers represented approximately 89% of our total product sales for 2022 and approximately 95% of our accounts receivable balance as of December&#160;31, 2022.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenues. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenues includes third-party manufacturing, transportation, freight, and indirect overhead costs primarily for the manufacture and distribution of INGREZZA and ONGENTYS drug product sold, manufacturing costs in connection with our supply of valbenazine drug product under our collaboration with Mitsubishi Tanabe Pharma Corporation, royalty fees on net sales of elagolix, amortization of intangible assets, and adjustments for excess and obsolete inventory to the extent management determines that the cost cannot be recovered based on estimates about future demand.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development, or R&amp;D. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses primarily consist of preclinical and clinical trial costs, payroll and benefits costs, including stock-based compensation associated with employees involved in R&amp;D activities, certain facility-based costs, and costs associated with our collaborative arrangements, including event-based milestones. All such costs are expensed as R&amp;D when incurred.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Acquisitions. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for acquisitions of assets (or groups of assets) that do not meet the definition of a business using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets (or group of assets) acquired on the basis of their relative fair value(s) on the measurement date. No goodwill is recognized in an asset acquisition. Intangible assets acquired in an asset acquisition for use in R&amp;D activities which have no alternative future use are expensed as IPR&amp;D on the acquisition date. Future costs to develop these assets are expensed as R&amp;D when incurred.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Expense. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs are expensed as selling, general and administrative when incurred. Advertising expense was $149.7 million for 2022, $139.8 million for 2021 and $64.8 million for 2020.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant stock options to purchase our common stock to eligible employees and directors and also grant certain employees restricted stock units, or RSUs, and performance-based restricted stock units, or PRSUs. Additionally, we allow employees to participate in an employee stock purchase plan, or ESPP.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of stock options and shares to be issued under the ESPP using the Black-Scholes option-pricing model on the date of grant. RSUs are valued based on the closing price of our common stock on the date of grant. The fair value of equity instruments expected to vest is recognized and amortized on a straight-line basis over the requisite service period of the award, which is generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzIyMzk4_faec3abd-c6f8-404f-adcd-432a19a48776">three</span> to four years; however, certain provisions in our equity compensation plans provide for shorter vesting periods under certain circumstances. The fair value of shares to be issued under the ESPP is recognized and amortized on a straight-line basis over the purchase period, which is generally six months. PRSUs vest upon the achievement of certain predefined company-specific performance-based criteria. Expense related to PRSUs is generally recognized ratably over the expected performance period once the predefined performance-based criteria for vesting becomes probable.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our income tax provision is computed under the asset and liability method. Significant estimates are required in determining our income tax provision. Some of these estimates are based on interpretations of existing tax laws or regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our income tax provision in the period of such reversal.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities based on the technical merits of the position. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings Per Share.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share are computed using the weighted average number of common shares outstanding during the period. Diluted earnings per share are computed using the treasury stock method and reflect the weighted average number of common and potentially dilutive shares outstanding during the period, excluding those which effect would be anti-dilutive.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we entered into the First Supplemental Indenture to the 2017 Indenture, pursuant to which we irrevocably elected to settle the principal amount of the 2.25% fixed-rate convertible senior notes due May&#160;15, 2024, or the 2024 Notes, in cash upon conversion and to settle any conversion premium in either cash or shares of our common stock. As a result, only the shares required to settle any conversion premium are considered dilutive under the if-converted method. Further, PRSUs for which the performance condition has not been achieved are excluded from the calculation of diluted earnings per share.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NTk5NDY_b11908b6-457c-4872-91a0-7e1b27137ced">ASU 2020-06</span>.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In August 2020, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2020-06,&#160;Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity's own equity. Among other changes, <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NjA1MDc_b11908b6-457c-4872-91a0-7e1b27137ced">ASU 2020-06</span> removed the separation models for convertible instruments with cash or beneficial conversion features. Instead, entities now account for convertible debt instruments wholly as debt, unless certain other conditions are met. The adoption of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NjA3NTA_b11908b6-457c-4872-91a0-7e1b27137ced">ASU 2020-06</span> prospectively reduces reported interest expense and increases (decreases) reported net income (loss), and resulted in a reclassification of certain conversion feature balance sheet amounts from stockholders&#8217; equity to liabilities as it relates to the 2.25% fixed-rate convertible senior notes due May&#160;15, 2024, or the 2024 Notes. We adopted <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NjEwNzc_b11908b6-457c-4872-91a0-7e1b27137ced">ASU 2020-06</span> on January&#160;1, 2022, using the modified retrospective transition method, which allowed for a cumulative-effect adjustment in the period of adoption and did not require restatement of prior period amounts. Under this transition method, the cumulative effect of the accounting change increased the carrying amount of the 2024 Notes by $42.2 million, reduced deferred tax liabilities by $9.9 million, reduced additional paid-in capital by $106.8 million and reduced the accumulated deficit by $74.5 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263541864064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
<td class="text">Collaboration and License Agreements<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our existing collaboration and license agreements, we may be required to make potential future payments of up to $10.8 billion upon the achievement of certain event-based milestones. Such contingent payments are recorded when paid or payable.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Heptares Therapeutics Limited, or Heptares.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We entered into a collaboration and license agreement with Heptares, which became effective in December 2021, to develop and commercialize certain compounds containing sub-type selective muscarinic M1, M4, or dual M1/M4 receptor agonists, which compounds we have the exclusive rights to develop, manufacture and commercialize worldwide, excluding in Japan, where Heptares retains the rights to develop, manufacture, and commercialize all compounds comprised of M1 receptor agonists, subject to certain exceptions. With respect to such rights retained by Heptares, we retain the rights to opt in to profit sharing arrangements, pursuant to which we and Heptares will equally share in the operating profits and losses for such compounds in Japan. Subject to specified conditions, we may elect to exercise such opt-in rights with respect to each such compound either before initiation of the first proof of concept Phase II clinical trial for such compound or following our receipt from Heptares of the top-line data from such clinical trial for such compound. We are responsible for all development, manufacturing, and commercialization costs of any collaboration product. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Heptares $100.0 million upfront, which, including certain transaction-related costs, was expensed as IPR&amp;D in 2021. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the FDA's acceptance of our investigational new drug application for NBI-1117568 for the treatment of schizophrenia in June 2022, we paid Heptares a milestone of $30.0 million, which was expensed as R&amp;D in 2022.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Heptares may be entitled to receive potential future payments of up to $2.6 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until the date on which the royalty term for such licensed product has expired in such country. On a licensed product-by-licensed product and country-by-country basis, royalty payments would commence on the first commercial sale of a licensed product and terminate on the later of (i) the expiration of the last patent covering such licensed product in such country, (ii) a number of years from the first commercial sale of such licensed product in such country and (iii) the expiration of regulatory exclusivity for such licensed product in such country.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate the agreement in its entirety or with respect to one or more targets upon 180 days&#8217; written notice to Heptares during the research collaboration term and upon 90 days&#8217; written notice to Heptares following the expiration of the research collaboration term. Following the expiration of the research collaboration term, Heptares may terminate the agreement on a target-by-target basis in the event that we do not conduct any material development activities outside of Japan with respect to a certain compound or licensed product within the applicable target class for a continuous period of not less than 365 days and do not commence any such activities within 120 days of receiving written notice. Either party may terminate the agreement, subject to specified conditions, (i) in the event of material breach by the other party, subject to a cure period, (ii) if the other party challenges the validity or enforceability of certain intellectual property rights, subject to a cure period, or (iii) if the other party becomes insolvent or takes certain actions related to insolvency.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Pharmaceutical Company Limited, or Takeda.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2020, we entered into an exclusive license agreement with Takeda, pursuant to which we acquired the exclusive rights to develop and commercialize certain early-to-mid stage psychiatry compounds, including luvadaxistat, NBI-1065845, NBI-1065846 and four non-clinical stage compounds. Luvadaxistat and the 4 non-clinical stage compounds have each been designated as a royalty-bearing product. NBI-1065845 and NBI-1065846 are currently each designated as a profit-share product. We are responsible for all manufacturing, development, and commercialization costs of any royalty-bearing product. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to NBI-1065845 and NBI-1065846, we and Takeda will equally share in the operating profits and losses. Takeda retains the rights to opt-out of the profit-sharing arrangements, pursuant to which Takeda would be entitled to receive potential future payments upon the achievement of certain event-based milestones with respect to such compounds and receive royalties on the future net sales of such compounds (in lieu of equally sharing in the operating profits and losses). Takeda may elect to exercise such opt-out right for such compound immediately following the completion of a second Phase II clinical trial for such compound, or, under certain circumstances related to the development and commercialization activities to be performed by us, before the initiation of a Phase III clinical trial for such compound.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Takeda $120.0 million upfront, which, including certain transaction-related costs, was expensed as IPR&amp;D in 2020. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the approval of our clinical trial application for NBI-1070770 for the treatment of major depressive disorder in July 2022, we paid Takeda a milestone of $5.0 million, which was expensed as R&amp;D in 2022.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Takeda may be entitled to receive potential future payments of up to $1.9 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any royalty-bearing product.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until the date on which, (i) for any royalty-bearing product, the royalty term has expired in such country; and (ii) for any profit-share product, for so long as we continue to develop, manufacture, or commercialize such licensed product.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a licensed product-by-licensed product and country-by-country basis, royalty payments would commence on the first commercial sale of a royalty-bearing product and terminate on the later of (i) the expiration of the last patent covering such royalty-bearing product in such country, (ii) a number of years from the first commercial sale of such royalty-bearing product in such country and (iii) the expiration of regulatory exclusivity for such royalty-bearing product in such country.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate the agreement in its entirety or in one or more (but not all) of the United States, Japan, the European Union and the United Kingdom, or, collectively, the major markets, upon six months&#8217; written notice to Takeda (i) with respect to all licensed products prior to the first commercial sale of the first licensed product for which first commercial sale occurs, or (ii) with respect to all licensed products in one or more given target classes, as defined in the agreement, prior to the first commercial sale of the first licensed product in such target class for which first commercial sale occurs. We may terminate the agreement in its entirety or in one or more (but not all) of the major markets upon 12 months&#8217; written notice to Takeda (i) with respect to all licensed products following the first commercial sale of the first licensed product for which first commercial sale occurs, or (ii) with respect to all licensed products in one or more given target classes following the first commercial sale of the first licensed product in such target class for which first commercial sale occurs. Takeda may terminate the agreement, subject to specified conditions, (i) if we challenge the validity or enforceability of certain Takeda intellectual property rights or (ii) on a target class-by-target class basis, in the event that we do not conduct any material development or commercialization activities with respect to any licensed product within such target class for a specified continuous period. Subject to a cure period, either party may terminate the agreement in the event of any material breach, solely with respect to the target class of a licensed product to which such material breach relates, or in its entirety in the event of any material breach that relates to all licensed products.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Idorsia Pharmaceuticals Ltd., or Idorsia.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2020, we entered into a collaboration and license agreement with Idorsia, pursuant to which we acquired the global rights to NBI-827104, a potent, selective, orally active and brain penetrating T-type calcium channel blocker in clinical development for the treatment of a rare pediatric epilepsy and other potential indications, including essential tremor. We are responsible for all manufacturing, development, and commercialization costs of any collaboration product.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Idorsia $45.0 million upfront, which was expensed as IPR&amp;D in 2020. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. Under the terms of the agreement, Idorsia may be entitled to receive potential future payments of up to $1.7 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate the agreement, in its entirety or with respect to a particular compound or development candidate, upon 90 days&#8217; written notice to Idorsia. Further, in the event a party commits a material breach and fails to cure such material breach within 90 days after receiving written notice thereof, the non-breaching party may terminate the agreement in its entirety immediately upon written notice to the breaching party.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Xenon Pharmaceuticals Inc., or Xenon. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we entered into a collaboration and license agreement with Xenon to identify, research and develop sodium channel inhibitors, including NBI-921352 and three preclinical candidates, which compounds we have the exclusive rights to develop and commercialize. We are responsible for all development and manufacturing costs of any collaboration product, subject to certain exceptions.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Xenon $50.0 million upfront, including a purchase of approximately 1.4 million shares of Xenon common stock (at $14.196 per share). We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. The purchased shares were recorded at a fair value of $14.1 million after considering Xenon&#8217;s stock price on the measurement date and certain transfer restrictions applicable to the shares. The remaining $36.2 million of the purchase price, which includes certain transaction-related costs, was expensed as IPR&amp;D in 2019.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the European Union&#8217;s approval of our clinical trial application for NBI-921352 for the treatment of focal onset seizures in adults in September 2021, we paid Xenon a regulatory milestone of $10.0 million, including a purchase of approximately 0.3 million shares of Xenon common stock (at $19.9755 per share). The purchased shares were recorded at a fair value of $4.6 million after considering Xenon&#8217;s stock price on the measurement date and certain transfer restrictions applicable to the shares. The remaining $5.4 million of the milestone payment was expensed as R&amp;D in 2021.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the FDA's acceptance of our amended KAYAK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">study protocol in January 2022, we paid Xenon a regulatory milestone of $15.0 million, including a purchase of approximately 0.3 million shares of Xenon common stock (at $31.855 per share). The purchased shares were recorded at a fair value of $7.7 million after considering Xenon&#8217;s stock price on the measurement date. The remaining $7.3 million of the milestone payment was expensed as R&amp;D in 2022.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Xenon may be entitled to receive potential future payments of up to $1.7 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product. Xenon retains the right to elect to co-develop one product in a major indication, pursuant to which Xenon would receive a mid-single digit percentage increase in royalties earned on the future net sales of such product in the United States and we and Xenon would equally share in the development costs of such product in the applicable indication, except where such development costs relate solely to the regulatory approval of such product outside the United States.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until the expiration of the royalty term for such product in such country. Upon the expiration of the royalty term for a particular licensed product and country, the license obtained by us with respect to such product and country will become fully paid, royalty free, perpetual and irrevocable. We may terminate the agreement upon 90 days&#8217; written notice to Xenon, provided that such unilateral termination will not be effective for certain products until we have used commercially reasonable efforts to complete certain specified clinical studies. Either party may terminate the agreement in the event of a material breach in whole or in part, subject to specified conditions.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voyager Therapeutics, Inc., or Voyager.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we entered into a collaboration and license agreement with Voyager, pursuant to which we acquired certain rights to develop and commercialize the NBIb-1817 for Parkinson&#8217;s disease program, Friedreich&#8217;s ataxia program and two undisclosed programs. We are responsible for all development costs of any collaboration product, subject to certain co-development and co-commercialization rights retained by Voyager. In February 2021, we notified Voyager of our termination of the NBIb-1817 for Parkinson&#8217;s disease program, which became effective August 2, 2021. The termination did not apply to any program other than the NBIb-1817 for Parkinson&#8217;s disease program.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Voyager $165.0 million upfront, including a purchase of approximately 4.2 million shares of Voyager common stock (at $11.9625 per share). We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. The purchased shares were recorded at a fair value of $54.7 million after considering Voyager&#8217;s stock price on the measurement date and certain transfer restrictions applicable to the shares. The remaining $113.1 million of the purchase price, which includes certain transaction-related costs, was expensed as IPR&amp;D in 2019. In addition, we paid Voyager $5.0 million upfront, which was expensed as IPR&amp;D in 2019, to acquire the rights outside the United States to the Friedreich&#8217;s ataxia program.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Voyager may be entitled to receive potential future payments of up to $1.3 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless terminated earlier, the agreement will continue in effect until the expiration of the last to expire royalty term with respect to any collaboration product or the last expiration or termination of any exercised co-development and co-commercialization rights by Voyager as provided for in the agreement. We may terminate the agreement upon 180 days&#8217; written notice to Voyager prior to the first commercial sale of any collaboration product or upon one year after the date of notice if such notice is provided after the first commercial sale of any collaboration product.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BIAL &#8211; Portela &amp; Ca, S.A., or BIAL.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We acquired the United States and Canada rights to ONGENTYS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(opicapone) from BIAL in 2017, and launched ONGENTYS in the United States in September 2020 as an FDA-approved add-on treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing motor fluctuations. We are responsible for all commercialization costs of ONGENTYS in the United States and Canada and rely on BIAL for the commercial supply of ONGENTYS.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the license agreement, BIAL may be entitled to receive potential future payments of up to $75.0 million upon the achievement of certain event-based milestones. In addition, with respect to ONGENTYS, in the event we fail to meet certain minimum sales requirements for a particular year in comparison to our annual sales forecast for such year, we would be obligated to pay BIAL an amount equal to the difference between the actual net sales and minimum sales requirements for such year. Further, upon our written request to BIAL 12 months prior to the estimated expiration of the term of a licensed product, we will negotiate the continuation of BIAL&#8217;s supply of such licensed product after the term. After the term, and if BIAL is no longer supplying such licensed product, BIAL would be entitled to receive a low double-digit royalty on our future quarterly net sales of such licensed product.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until a generic product with respect to such licensed product is sold in a country and sales of such generic product are greater than a specified percentage of total sales of such licensed product in such country.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate the agreement upon nine months&#8217; written notice to BIAL. BIAL may terminate the agreement in the event we fail to meet the minimum sales requirements for any two years, or under certain circumstances involving a change of control of Neurocrine Biosciences. Under certain circumstances where BIAL elects to terminate the agreement in connection with a change of control of Neurocrine Biosciences, BIAL would be obligated to pay us a termination fee. Either party may terminate the agreement if the other party materially breaches the agreement and does not cure the breach within a specified notice period, or upon the other party&#8217;s insolvency.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mitsubishi Tanabe Pharma Corporation, or MTPC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We out-licensed the rights to valbenazine in Japan and other select Asian markets to MTPC in 2015. In December 2020, we entered into a commercial supply agreement with MTPC, pursuant to which we agreed to supply MTPC with valbenazine drug product for commercial use in Japan and other select Asian markets. MTPC is responsible for all development, manufacturing, and commercialization costs of valbenazine in such markets.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, MTPC launched DYSVAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (valbenazine) in Japan for the treatment of tardive dyskinesia. In connection with MTPC's first commercial sale of DYSVAL in Japan, we received a milestone payment of $20.0 million in 2022. ASC 606 provides a royalty exception for a sales-based or usage-based royalty promised in exchange for a license of intellectual property. Under the royalty exception, the milestone would be recognized as revenue only when the later of (1) the subsequent sale or usage occurs or (2) the performance obligation to which some or all of the sales-based or usage-based royalty has been allocated has been satisfied (or partially satisfied). As the milestone related to a license of intellectual property and was contingent upon MTPC&#8217;s first commercial sale of DYSVAL in Japan, the milestone was recognized as revenue in the second quarter of 2022. In addition, we receive royalties at tiered percentage rates on MTPC net sales of DYSVAL.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our license agreement with MTPC, we may be entitled to receive potential future payments of up to $30.0 million upon the achievement of certain sales-based milestones and are entitled to receive royalties at tiered percentage rates on future MTPC net sales of valbenazine for the longer of 10 years or the life of the related patent rights. MTPC may terminate the agreement upon 180 days&#8217; written notice to us. In such event, all out-licensed product rights would revert to us.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AbbVie Inc., or AbbVie. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We out-licensed the global rights to elagolix to AbbVie in 2010. AbbVie is responsible for all development and commercialization costs of elagolix.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, AbbVie launched ORILISSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(elagolix tablets) in the United States for the treatment of moderate to severe pain associated with endometriosis. In June 2020, AbbVie launched ORIAHNN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(elagolix, estradiol and norethindrone acetate capsules and elagolix capsules) in the United States for the treatment of heavy menstrual bleeding related to uterine fibroids in premenopausal women. We receive royalties at tiered percentage rates on AbbVie net sales of elagolix and recognized elagolix royalty revenue of $21.2&#160;million for 2022, $22.3&#160;million for 2021 and $19.2&#160;million for 2020.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our license agreement with AbbVie, we may be entitled to receive potential future payments of up to $366.0 million upon the achievement of certain event-based milestones and are entitled to receive royalties at tiered percentage rates on future AbbVie net sales of elagolix for the longer of 10 years or the life of the related patent rights. AbbVie may terminate the agreement upon 180 days&#8217; written notice to us. In such event, all out-licensed product rights would revert to us.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263545406192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Diurnal Acquisition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Diurnal Acquisition</a></td>
<td class="text">Diurnal AcquisitionOn November 1, 2022, we completed our acquisition of Diurnal Group plc, or Diurnal, a United Kingdom-headquartered, specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. We believe our acquisition of Diurnal presents an opportunity to accelerate the establishment of our clinical development and commercial capabilities in the United Kingdom to the benefit of patient communities and other stakeholders.<div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate purchase price of this acquisition was $55.2&#160;million in cash. The acquisition was accounted for in accordance with FASB ASC 805 as a Business Combinations and, accordingly, Diurnal&#8217;s results of operations have been consolidated in Neurocrine Biosciences&#8217; financial statements since the date of acquisition. Pro forma results of operations for the years ended December 31, 2022 and 2021 would not be materially different as a result of this acquisition and therefore are not presented. In connection with the acquisition, we recognized transaction costs of $1.7&#160;million, which were expensed as selling, general and administrative and primarily consisted of investment banker, advisory, legal and other professional fees.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the consideration paid for Diurnal and the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consideration</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Recognized amounts of identifiable assets acquired and liabilities assumed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total identifiable net assets acquired</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263624333920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Debt Securities</a></td>
<td class="text">Debt Securities<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income (loss) and fair value of debt securities available-for-sale, aggregated by major security type and contractual maturity.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.252%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.075%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Contractual<br/>Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">296.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">293.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">277.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">735.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">726.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 to 3 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">255.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">357.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 to 3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">299.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">563.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">560.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, our security portfolio consisted of 253 debt securities available-for-sale, including 199 such securities that were in an unrealized loss position but of high credit quality. Unrealized losses on these investments were primarily due to changes in interest rates. We do not intend to sell these investments and it is not more likely than not that we will be required to sell these investments before recovery of their amortized cost basis. No allowance for credit losses was recognized as of December&#160;31, 2022 or 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents debt securities available-for-sale that were in an unrealized loss position as of December&#160;31, 2022, aggregated by major security type and length of time in a continuous loss position.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">299.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">198.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">306.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents debt securities available-for-sale that were in an unrealized loss position as of December&#160;31, 2021, aggregated by major security type and length of time in a continuous loss position.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">428.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">428.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263542799088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of investments, which were measured at fair value on a recurring basis.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.464%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.398%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Leveling</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">262.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">262.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">548.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">548.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">321.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">321.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities&#8211;biotechnology industry</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,398.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">372.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,025.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,338.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">396.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">931.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of equity security investments, which were measured at fair value on a recurring basis using significant unobservable inputs (Level 3):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain (loss) included in earnings </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfers out of Level 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Unrealized gains and losses on equity security investments which were measured at fair value on a recurring basis using significant unobservable inputs (Level 3) and are included in other income (expense), net.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Certain of our equity security investments were transferred from Level 3 to Level 1 during 2022 and 2021 as the associated holding period restriction expired.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263541954576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Senior Notes</a></td>
<td class="text">Convertible Senior Notes<div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;2, 2017, we completed a private placement of $517.5 million in aggregate principal amount of 2.25% fixed-rate convertible senior notes due May&#160;15, 2024, or the 2024 Notes, and entered into the 2017 Indenture with respect to the 2024 Notes. Interest on the 2024 Notes is due semi-annually on May 15 and November 15 of each year.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with authoritative guidance in effect at the time of issuance, we were required to separately account for the liability and equity components of the 2024 Notes. The initial carrying value of the liability component of $368.3 million was calculated using a 7.50% assumed borrowing rate, which reflected the market interest rate for a similar non-convertible instrument at the date of issuance. The equity component of $149.2 million, which was treated as a discount on the liability component and amortized over the seven-year term of the 2024 Notes using the effective interest rate method, was determined by deducting the fair value of the liability component from the par value of the 2024 Notes and recorded as an increase to additional paid-in capital on the issuance date. In addition, we allocated transaction costs of $14.7 million related to the issuance of the 2024 Notes to the liability and equity components based on their relative values on the issuance date. Transaction costs attributable to the liability component were being amortized over the seven-year term of the 2024 Notes using the effective interest rate method, while transaction costs attributable to the equity component were recorded as a reduction to additional paid-in capital on the issuance date.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2020, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $136.2 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9 million in cash. We accounted for the partial repurchase of the 2024 Notes as a debt extinguishment. As a result, we attributed $130.7 million of the aggregate repurchase price to the liability component based on the fair value of the liability component immediately before extinguishment. The fair value of the liability component was calculated at settlement using a discounted cash flow analysis with a discount rate of 3.37%, which was the market rate for similar notes that have no conversion rights. The difference of $56.3 million between the fair value of the aggregate consideration remitted to certain holders of the 2024 Notes and the fair value of the liability component was attributed to the reacquisition of the equity component and recorded as a reduction to additional paid-in capital. The carrying amount of the liability of $112.4 million at settlement was recognized as a reduction to the 2024 Notes and resulted in an $18.4 million loss on extinguishment, which we recognized in 2020.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, we adopted <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNDc2NA_b11908b6-457c-4872-91a0-7e1b27137ced">ASU 2020-06</span> using the modified retrospective transition method, which allowed for a cumulative-effect adjustment in the period of adoption and did not require restatement of prior period amounts. Under this transition method, the cumulative effect of the accounting change increased the carrying amount of the 2024 Notes by $42.2 million, reduced deferred tax liabilities by $9.9 million, reduced additional paid-in capital by $106.8 million, and reduced the accumulated deficit by $74.5 million.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2022, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $210.8 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $279.0 million in cash. We accounted for the partial repurchase of the 2024 Notes as a debt extinguishment, which resulted in the recognition of a $70.0 million loss on extinguishment in 2022.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the 2024 Notes as of December&#160;31, 2022.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.846%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unamortized Debt</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the 2024 Notes as of December&#160;31, 2021.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.846%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unamortized Debt</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">464.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the interest expense of the 2024 Notes.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Coupon interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we entered into the First Supplemental Indenture to the 2017 Indenture, pursuant to which we irrevocably elected to settle the principal amount of the 2024 Notes in cash upon conversion and to settle any conversion premium, calculated based on the per share volume-weighted average price for each of the 30 consecutive trading days during the observation period (as more fully described in the 2017 Indenture), in either cash or shares of our common stock.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial conversion rate for the 2024 Notes, which is subject to adjustment in some events (as provided for in the 2017 Indenture), is 13.1711 shares of common stock per $1,000 principal amount and equivalent to an initial conversion price of approximately $75.92 per share, reflecting a conversion premium of approximately 42.5% above the closing price of $53.28 per share of our common stock on April&#160;26, 2017.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may redeem for cash all or part of the 2024 Notes if the last reported sale price (as defined in the 2017 Indenture) of our common stock has been at least 130% of the conversion price then in effect (equal to $98.70 as of December&#160;31, 2022) for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading-day period ending on, and including, the trading day immediately before the date which we provide notice of redemption.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes may convert the 2024 Notes at any time prior to the close of business on the business day immediately preceding May&#160;15, 2024, only under the following circumstances:</span></div><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">during any calendar quarter (and only during such calendar quarter), if the last reported sale price of our common stock for at least&#160;20&#160;trading days (whether or not consecutive) during a period of&#160;30&#160;consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than&#160;130%&#160;of the conversion price (equal to $98.70 as of December&#160;31, 2022) on each applicable trading day;</span></div><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">during the&#160;five business-day period immediately after any&#160;five&#160;consecutive trading-day period (the measurement period) in which the trading price (as defined in the 2017 Indenture) per&#160;$1,000&#160;principal amount of the 2024 Notes for each trading day of the measurement period was less than&#160;98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day;</span></div><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.03pt">upon the occurrence of specified corporate events, including a merger or a sale of all or substantially all of our assets; or</span></div><div style="margin-bottom:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.57pt">if we call the 2024 Notes for redemption, until the close of business on the business day immediately preceding the redemption date.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after January&#160;15, 2024, until the close of business on the scheduled trading day immediately preceding May&#160;15, 2024, holders of the 2024 Notes may convert the 2024 Notes at any time.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the conditional conversion feature described under (i) above was triggered as of December 31, 2022, holders of the 2024 Notes may convert the 2024 Notes at any time during the period beginning on January 1, 2023, and ending at the close of business on March 31, 2023. Accordingly, the 2024 Notes have been classified as a current liability as of December 31, 2022. The future conditional convertibility of the 2024 Notes will be monitored at each quarterly reporting date and analyzed dependent upon market prices of our common stock during the prescribed measurement periods.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, holders will receive the principal amount of their 2024 Notes in cash and any excess conversion value, calculated based on the per share volume-weighted average price for each of the 30 consecutive trading days during the observation period (as more fully described in the 2017 Indenture), in either cash or shares of our common stock.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we undergo a fundamental change (as defined in the 2017 Indenture), subject to certain conditions, holders of the 2024 Notes may require us to repurchase for cash all or part of their 2024 Notes at a repurchase price equal to 100% of the principal amount of the 2024 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, if a make-whole fundamental change (as defined in the 2017 Indenture) occurs prior to January&#160;15, 2024, we would, in certain circumstances, increase the conversion rate for a holder who elects to convert their notes in connection with the make-whole fundamental change.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes are our general unsecured obligations that rank senior in right of payment to all of our indebtedness that is expressly subordinated in right of payment to the 2024 Notes, and equal in right of payment to our unsecured indebtedness. The 2024 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by us. The 2017 Indenture contains customary events of default with respect to the 2024 Notes, including that upon certain events of default, 100% of the principal and accrued and unpaid interest on the 2024 Notes will automatically become due and payable.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263541840016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible Assets<div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Diurnal in November 2022, we recognized goodwill of $5.2&#160;million for the excess consideration transferred over the net assets acquired, reflecting the expected revenue and cost synergies of the combined company and assembled workforce.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the carrying amount of goodwill.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill recognized in connection with business combination</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information relating to our recognized intangible assets as of December&#160;31, 2022.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.861%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net <br/>Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Developed product rights</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the estimated annual amortization expense for our finite-lived intangible assets. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2024</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2025</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2026</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2027</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263540578576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Balance Sheet Details<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_OtherBalanceSheetDetailsAbstract', window );"><strong>Other Balance Sheet Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Other Balance Sheet Details</a></td>
<td class="text">Other Balance Sheet Details<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tenant improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Scientific equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(51.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued employee related costs </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current branded prescription drug fee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">347.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">344.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_OtherBalanceSheetDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other balance sheet details.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_OtherBalanceSheetDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI https://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263542016848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">Earnings Per Share<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share were calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income - basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">407.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per share:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares which have been excluded from diluted per share amounts because their effect would have been anti-dilutive were 4.6 million for 2022, 4.1 million for 2021 and 2.5 million for 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263545347536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Equity Incentive Plan.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, our stockholders approved an amendment and restatement of the 2020 Equity Incentive Plan (as so amended and restated, the Amended 2020 Plan). The Amended 2020 Plan provides for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards, and other awards. As of December 31, 2022, 7.9&#160;million shares of common stock remain available for future grant under the Amended 2020 Plan.</span><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Amended 2020 Plan, the number of shares of common stock available for issuance will be: (i) reduced by (a) one share for each share issued pursuant to an appreciation award (as defined in the Amended 2020 Plan) granted under the Amended 2020 Plan and (b) 2.13 shares for each share issued pursuant to a full value award (as defined in the Amended 2020 Plan) granted under the Amended 2020 Plan on or after May 18, 2022; and (ii) increased by (a) one share for each share subject to an appreciation award that becomes available again for issuance under the terms of the Amended 2020 Plan and (b) 2.13 shares for each share subject to a full value award that becomes available again for issuance under the terms of the Amended 2020 Plan on or after May 18, 2022.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2011 Equity Incentive Plan.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2011, we adopted the 2011 Equity Incentive Plan, or the 2011 Plan. The 2011 Plan was a stockholder-approved plan pursuant to which outstanding awards have been made, but from which no further awards can or will be made.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Employee Stock Purchase Plan.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, our stockholders approved an amendment and restatement of the 2018 Employee Stock Purchase Plan (as so amended and restated, the Amended 2018 ESPP). As of December 31, 2022, 0.6&#160;million shares of common stock remain available for future issuance under the Amended 2018 ESPP.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effect of stock-based compensation expense on our consolidated statements of income and comprehensive income by line-item follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense by award-type follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PRSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, unrecognized stock-based compensation expense by award-type and the weighted-average period over which such expense is expected to be recognized, as applicable, was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.726%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.729%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrecognized Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Recognition Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSUs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PRSUs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Typically, stock options have a 10-year term and vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzIwMTc_50d14189-4f30-4d95-85d1-8b0107a221f2">three</span> to four-year period. The exercise price of stock options granted is equal to the closing price of our common stock on the date of grant. We estimate the fair value of stock options using the Black-Scholes option-pricing model on the date of grant. The Black-Scholes option-pricing model incorporates various and highly sensitive assumptions including expected volatility, term and interest rates. The weighted-average grant-date fair values of stock options granted were $32.05 for 2022, $45.02 for 2021 and $45.67 for 2020.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option granted was estimated on the date of grant using the Black-Scholes option-pricing valuation model with the following weighted-average assumptions: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected option term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.3 years</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average valuation assumptions were determined as follows:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The expected volatility of common stock is estimated based on the historical volatility of our common stock over the most recent period commensurate with the estimated expected term of our stock options.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The expected option term is estimated based on historical experience as well as the status of the employee. For example, directors and officers have a longer expected option term than all other employees. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The risk-free interest rate for periods within the contractual life of a stock option is based upon observed interest rates appropriate for the expected term of our employee stock options. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have not historically declared or paid dividends and do not intend to do so in the foreseeable future. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents summary of activity related to stock options.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76.38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.5 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">362.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.4 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of stock options exercised was $39.7 million for 2022, $58.0 million for 2021 and $40.2 million for 2020. Cash received from stock option exercises was $37.0 million for 2022, $20.7 million for 2021 and $23.5 million for 2020.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs typically vest over a four-year period and may be subject to a deferred delivery arrangement at the election of eligible employees. The fair value of RSUs is based on the closing sale price of our common stock on the date of issuance. The total fair value of RSUs that vested was $72.4 million for 2022, $64.3 million for 2021 and $49.7 million for 2020.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of activity related to RSUs.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant Date <br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99.96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">276.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-Based Restricted Stock Units. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PRSUs vest based on the achievement of certain predefined Company-specific performance criteria. Any unvested PRSUs will expire if it is determined the related performance criteria has not been met during the applicable <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzU0OTc1NTg0OTAyMA_025ee6ff-3e68-4066-aa62-f80b858bd74f">three</span> to four-year performance period. The fair value of PRSUs is estimated based on the closing sale price of our common stock on the date of grant. The fair value of PRSUs that vested during 2020 was $13.5&#160;million. No PRSUs vested during 2021 or 2022.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of activity related to PRSUs.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>PRSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant Date <br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109.31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Amended 2018 ESPP, eligible employees may purchase shares of our common stock at a discount semi-annually based on a percentage of their annual compensation. The discounted purchase price is equal to the lower of 85% of (i) the market value per share of the common stock on the first day of the offering period or (ii) the market value per share of common stock on the purchase date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263545408032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents income before the provision for income taxes from continuing domestic and foreign operations.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">213.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of the provision for (benefit from) income taxes for continuing operations.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(287.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(310.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(300.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for (benefit from) income taxes on earnings subject to income taxes differs from the statutory federal rate due to the following: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal income taxes at 21%</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State income tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Branded prescription drug fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Officer compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired tax attributes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(296.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(300.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the significant components of our deferred tax assets. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">405.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">413.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net of deferred tax assets and liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">372.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">369.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(67.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">305.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">315.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, our deferred tax assets were primarily the result of net operating loss carry forwards, capitalized research costs, acquired intangible assets and tax credit carryforwards. As of December 31, 2022 and 2021, we recorded a valuation allowance of $67.0 million and $54.8 million, respectively, against our gross deferred tax asset balance.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of each reporting date, management considers new evidence, both positive and negative, that could affect its assessment of the future realizability of our deferred tax assets. As of December&#160;31, 2022, management determined there was sufficient positive evidence to conclude that it is more likely than not deferred tax assets of $305.9 million are realizable. The recorded valuation allowance of $67.0 million consisted primarily of state and foreign net operating loss carryforwards and state credit carryforwards for which management cannot conclude it is more likely than not to be realized.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had state and foreign income tax net operating loss carryforwards of $324.6 million and $60.1 million, respectively. We had no federal income tax operating loss carryforwards as of December&#160;31, 2022. California net operating losses will begin to expire in 2031 unless previously utilized and the net operating losses related to other states will begin to expire in 2026. Foreign net operating losses will carry forward indefinitely unless previously utilized.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we had federal and state R&amp;D tax credit carryforwards of $98.2 million and $72.5 million, respectively. Federal R&amp;D tax credits will begin to expire in 2037 unless previously utilized. California R&amp;D tax credits carry forward indefinitely, while R&amp;D tax credits related to other states will begin to expire in 2033 unless previously utilized.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the future utilization of our net operating loss and R&amp;D tax credit carryforwards to offset future taxable income may be subject to an annual limitation, pursuant to Internal Revenue Code Sections 382 and 383, as a result of ownership changes that could occur in the future. No ownership changes have occurred through December&#160;31, 2022.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize interest and penalties related to income tax matters in income tax expense. As of December&#160;31, 2022, we had accruals for interest and penalties related to income tax matters of $0.5 million and $0.4 million, respectively. Interest and penalties related to income tax matters were not material for 2021 or 2020.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to taxation in the United States and various state and foreign jurisdictions. Tax years for 2002 for federal, inception for California, 2015 to 2019 for other significant state jurisdictions, and 2019 and forward for foreign are subject to examination by tax authorities due to the carryforward of unutilized net operating losses and R&amp;D tax credits.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of activity related to unrecognized tax benefits.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase (decrease) related to prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase related to current year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements related to prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expiration of the statute of limitations for the assessment of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had $74.8 million of unrecognized tax benefits that, if recognized and realized, would affect the effective tax rate, subject to changes in the valuation allowance. We do not expect a significant change in our unrecognized tax benefits in the next 12 months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263542077984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating leases that have commenced have terms that expire beginning 2024 through 2031 and consist of office space and research and development laboratories, including our corporate headquarters. Certain of these lease agreements contain clauses for renewal at our option. As we were not reasonably certain to exercise any of these renewal options at commencement of the associated leases, no such options were recognized as part of our operating lease right-of-use, or ROU, assets or operating lease liabilities.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;8, 2022, we entered into a lease agreement for a four-building campus facility to be constructed in San Diego, California, pursuant to which we also secured a six-year option for the construction of a fifth building and an option to purchase the entire campus facility, which will consist of office space and research and development laboratories, in the future. Upon completion of construction, we expect to utilize the campus facility as our new corporate headquarters. This lease has not commenced for accounting purposes. Under the terms of the lease, on a building-by-building basis, base rent will be subject to a 10-month rent abatement period following the respective lease commencement date, which dates will be determined in the future based upon achievement of substantial completion of construction with respect to each such building in the condition suitable for the installation of our furniture, fixtures, and equipment, and on which date we will record a lease liability, corresponding right-of-use asset, and begin lease expense recognition with respect to each such building. After the rent abatement period, monthly base rent will be $6 per square foot, subject to annual escalations of 3% during the initial <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90ZXh0cmVnaW9uOjU1NzA4M2I5OTQyZTQ5ZGNiMzRhNmEyZjc1ZjExNGFjXzcxNDY4MjU1ODI4MDk_9da6dfa7-7ad5-4e15-990b-61663bd419f1">13.6-year</span> lease term, which term we have the option to renew for two additional terms of five years each.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present supplemental operating lease information.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.9 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.8 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash related to letters of credit issued in lieu of cash security deposits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximate future minimum lease payments under operating leases were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2027</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accreted interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpmYjg1MmU0NGUwYmY0ZDA3YTVmNjZhM2QxM2VkNmYxMC90YWJsZXJhbmdlOmZiODUyZTQ0ZTBiZjRkMDdhNWY2NmEzZDEzZWQ2ZjEwXzEwLTAtMS0xLTEzOTA2Mg_85571070-dcc5-4354-8358-dbaa0e075ba0">Less current operating lease liabilities included in other current liabilities</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Amounts presented in the table above exclude $17.2 million for 2024, $33.3 million for 2025, $41.9 million for 2026, and $479.7 million thereafter of approximate non-cancelable future minimum lease payments under operating leases that have not yet commenced.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263541954576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Retirement Plan</a></td>
<td class="text">Retirement PlanWe have a 401(k) defined contribution savings plan, or the 401(k)&#160;Plan. The 401(k) Plan is for the benefit of all qualifying employees and permits voluntary contributions by employees up to 60% of base salary limited by the IRS-imposed maximum. Employer contributions were $10.3 million for 2022, $8.1 million for 2021 and $6.7 million for 2020.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263543232608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Legal Proceedings</a></td>
<td class="text">Legal Proceedings<div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021 and 2022, we received notices from (i) Teva Pharmaceuticals Development, Inc., (ii) Lupin Limited, (iii) Crystal Pharmaceutical (Suzhou) Co. Ltd., (iv) Sandoz Inc. and (v) Zydus Pharmaceuticals (USA) Inc. that each company had filed an abbreviated new drug application, or ANDA, with the FDA seeking approval of a generic version of INGREZZA. These companies represented that their respective ANDAs each contained a Paragraph IV Patent Certification alleging that certain of our patents covering INGREZZA are invalid and/or will not be infringed by the manufacture, use or sale of the medicine for which the ANDA was submitted.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We filed suit in the United States District Court for the District of Delaware during 2021 and 2022, against (i) Teva Pharmaceuticals, Inc., Teva Pharmaceuticals Development, Inc., Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd. (entity dismissed), (ii) Lupin Limited, Lupin Pharmaceuticals, Inc., Lupin Inc. and Lupin Atlantis Holdings S.A., (iii) Crystal Pharmaceutical (Suzhou) Co., Ltd., Crystal Pharmatech Co., Ltd., (iv) Sandoz Inc., Sandoz International GmbH (entity dismissed) and Sandoz AG (entity dismissed) and (v) Zydus Pharmaceuticals (USA) Inc., Zydus Worldwide DMCC, Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited d/b/a Zydus Cadila) and Zydus Healthcare (USA) LLC (entity dismissed). Sandoz Inc. has been joined in the cases against Crystal Pharmaceutical (Suzhou) Co., Ltd. and Crystal Pharmatech Co., Ltd. These cases have been consolidated in the United States District Court for the District of Delaware and the trial is currently scheduled for January 2, 2024.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also filed suit in the United States District Court for the District of New Jersey during 2021 and 2022 against Zydus Pharmaceuticals (USA) Inc., Zydus Worldwide DMCC, Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited d/b/a Zydus Cadila) and Zydus Healthcare (USA) LLC and these cases were dismissed in favor of continued prosecution of the Delaware proceedings against the same entities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may also become subject to other legal proceedings or claims arising in the ordinary course of our business. We currently believe that none of the claims or actions pending against us is likely to have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Given the unpredictability inherent in litigation, however, we cannot predict the outcome of these matters.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263541855104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2023, we entered into a new strategic collaboration with Voyager, under which we agreed to pay Voyager $175&#160;million upfront, including a $39&#160;million equity investment, to acquire the worldwide rights to Voyager&#8217;s GBA1 gene therapy program for Parkinson&#8217;s disease and other GBA1-mediated diseases and three gene therapy programs directed to rare central nervous system targets, each enabled by Voyager&#8217;s next-generation TRACER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> capsids. The effectiveness of the collaboration agreement and the closing of the sale and issuance of Voyager common stock are expected to be completed prior to the end of the first quarter of 2023 and are subject to certain conditions including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and other customary closing conditions.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263540383248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_OrganizationAndBusinesDescriptionPolicyPolicyTextBlock', window );">Organization and Business</a></td>
<td class="text"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization and Business. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neurocrine Biosciences, Inc. and its subsidiaries, or Neurocrine Biosciences, the Company, we, our or us, is a neuroscience-focused biopharmaceutical company focused on discovering, developing and delivering innovative therapies to help ease the burden of debilitating disorders and diseases.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a single business segment, which includes all activities related to the research, development and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine and neuropsychiatric disorders.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Neurocrine Biosciences as well as our wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments that are readily convertible into cash without penalty and have an original maturity of three months or less at the time of purchase to be cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded net of customer allowances for prompt payment discounts, chargebacks, and any allowance for credit losses. Our estimate for the allowance for credit losses, which has not been significant to date, is determined based on existing contractual payment terms, actual payment patterns of our customers, and individual customer circumstances.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our exposure to credit losses may increase if our customers are adversely affected by changes in healthcare laws, coverage and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current COVID-19 pandemic, or other customer-specific factors. It is possible that there could be a material adverse impact from potential adjustments of the carrying amount of trade receivables as customers&#8217; cash flows are impacted by their response to the COVID-19 pandemic.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Debt Securities</a></td>
<td class="text"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities consist of investments in certificates of deposit, corporate debt securities and securities of government-sponsored entities. We classify debt securities as available-for-sale. Debt securities available-for-sale are recorded at fair value, with unrealized gains and losses included in other comprehensive income or loss, net of tax. We exclude accrued interest from both the fair value and amortized cost basis of debt securities. A debt security is placed on nonaccrual status at the time any principal or interest payments become 90 days delinquent. Interest accrued but not received for a debt security placed on nonaccrual status is reversed against interest income.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income includes amortization of purchase premium or discount. Premiums and discounts on debt securities are amortized using the effective interest rate method. Gains and losses on sales of debt securities are recorded on the trade date in investment income and other, net, and determined using the specific identification method.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock', window );">Allowance for Credit Losses</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allowance for Credit Losses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For debt securities available-for-sale in an unrealized loss position, we first assess whether we intend to sell, or it is more likely than not that we will be required to sell, the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.</span>Accrued interest receivables on debt securities available-for-sale were $4.7 million and $2.2 million, respectively, as of December&#160;31, 2022 and 2021. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized cost basis of the debt security. Uncollectible accrued interest receivables associated with an impaired debt security are reversed against interest income upon identification of the impairment. No accrued interest receivables were written off during 2022, 2021 or 2020.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record cash equivalents, debt securities available-for-sale and equity security investments at fair value based on a fair value hierarchy that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The fair value hierarchy consists of the following three levels:</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in debt securities available-for-sale are classified as Level 2 and carried at fair value. We estimate the fair value of debt securities available-for-sale by utilizing third-party pricing services. These pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. Such inputs include market pricing based on real-time trade data for similar instruments, issuer credit spreads, benchmark yields, broker/dealer quotes and other observable inputs. We validate valuations obtained from third-party pricing services by understanding the models used, obtaining market values from other pricing sources and analyzing data in certain instances.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We deem transfers between levels of the fair value hierarchy to have occurred at the end of the reporting period during which the event or change in circumstances that caused the transfer occurred.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is valued at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on the first-in, first-out method. We assess the valuation of our inventory on a quarterly basis and adjust the value for excess and obsolete inventory to the extent management determines that the cost cannot be recovered based on estimates about future demand. Inventory costs resulting from these adjustments are recognized as cost of sales in the period in which they are incurred. When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#8217;s judgment, we capitalize pre-launch inventory costs prior to regulatory approval.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets using the straight-line method. Equipment is depreciated over an average estimated useful life of 3 to 7 years. Leasehold improvements are depreciated over the shorter of their estimated useful lives or the remaining lease term. Depreciation expense was $15.1 million for 2022, $10.9 million for 2021 and $8.6 million for 2020.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations and Asset Acquisitions</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. In addition, costs that we incur to complete the business combination, such as legal and other professional fees, are expensed as selling, general and administrative when incurred.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Acquisitions. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for acquisitions of assets (or groups of assets) that do not meet the definition of a business using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets (or group of assets) acquired on the basis of their relative fair value(s) on the measurement date. No goodwill is recognized in an asset acquisition. Intangible assets acquired in an asset acquisition for use in R&amp;D activities which have no alternative future use are expensed as IPR&amp;D on the acquisition date. Future costs to develop these assets are expensed as R&amp;D when incurred.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill, Intangible Assets and Other Long-Lived Assets</a></td>
<td class="text"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill, Intangible Assets and Other Long-Lived Assets. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired, including intangible assets and in-process research and development, or IPR&amp;D, and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&amp;D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;D asset is amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;D asset is expensed in the period of abandonment.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and IPR&amp;D are not amortized; however, they are reviewed for impairment at least annually, as of October 1, and more frequently if an event occurs indicating the potential for impairment. Goodwill and IPR&amp;D are considered to be impaired if the carrying value of the reporting unit or IPR&amp;D asset exceeds its respective fair value.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform our goodwill impairment analysis at the reporting unit level, which aligns with our reporting structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of the reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the reporting unit with the carrying value, including goodwill. If the carrying amount of the reporting unit exceed the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our identifiable intangible assets with a finite life are typically comprised of acquired product rights. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#8217; respective estimated useful lives.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform regular reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign currency</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign currency.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Assets and liabilities are translated into the reporting currency using the exchange rates in effect on the consolidated balance sheet dates. Equity accounts are translated at historical rates, except for the change in retained earnings during the period, which is the result of the income statement translation process. Revenue and expense accounts are translated using the weighted average exchange rate during the period. The cumulative translation adjustments associated with the net assets of foreign subsidiaries are recorded in accumulated other comprehensive income (loss) in the accompanying consolidated statements of stockholders&#8217; equity.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue when the customer obtains control of promised goods or services in an amount that reflects the consideration which we expect to receive in exchange for such goods or services. Revenue is recognized using a five-step model: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.</span><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the United States, we sell INGREZZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (valbenazine) primarily to specialty pharmacy providers and distributors and ONGENTYS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (opicapone) primarily to wholesale distributors. We recognize net product sales when the customer obtains control of our product, which occurs at a point in time, typically upon delivery of our product to the customer.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, payors, and other third parties. Such estimates are based on information received from external sources (such as written or oral information obtained from our customers with respect to their period-end inventory levels and sales to end-users during the reporting period), as supplemented by management&#8217;s judgement. Our process for estimating reserves established for these variable consideration components does not differ materially from historical practices. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant categories of sales discounts and allowances are as follows:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Discounts.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Product discounts are based on payment terms extended to our customers at the time of sale, which include incentives offered for prompt payment. We maintain a reserve for product discounts based on our historical experience, including the timing of customer payments. To date, actual product discounts have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are obligated to pay rebates for mandated discounts under the Medicaid Drug Rebate Program. The liability for such rebates consists of invoices received for claims from prior quarters that remain unpaid, or for which an invoice has not been received, and estimated rebates for the current applicable reporting period. Such estimates are based on actual historical rebates by state, estimated payor mix, state and federal regulations, and relevant contractual terms, as supplemented by management&#8217;s judgement. Our rebate accrual calculations require us to project the magnitude of our sales that will be subject to these rebates. There is a significant time-lag in our receiving rebate notices from each state (generally, several months or longer after a sale is recognized). Estimated rebates are recorded as a reduction of revenue in the period the related sale is recognized. To date, actual government rebates have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The difference between the list price, or the price at which we sell our products to our customers, and the contracted price, or the price at which our customers sell our products to qualified healthcare professionals, is charged back to us by our customers. In addition to actual chargebacks received, we maintain a reserve for chargebacks based on estimated contractual discounts on product inventory levels on-hand in our distribution channel. To date, actual chargebacks have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payor and Pharmacy Rebates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are obligated to pay rebates as a percentage of sales under payor and pharmacy contracts. We estimate these rebates based on actual historical rebates, contractual rebate percentages, sales made through the payor channel, and purchases made by pharmacies. To date, actual payor and pharmacy rebates have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient Financial Assistance.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> To help patients afford our products, we offer free trial vouchers to qualifying new patients and financial assistance to qualified patients with prescription drug copay requirements. We accrue for patient financial assistance based on estimated claims and the cost per claim we expect to receive in connection with inventory that remains in the distribution channel at period end. To date, actual patient financial assistance has not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distributor and Other Fees.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In connection with the sales of our products, we pay distributor and other fees, which are generally recorded as a reduction of revenue, to certain customers that provide us with inventory management, data, and/or distribution services. Costs associated with such services are expensed as selling, general and administrative to the extent we can demonstrate a separable benefit and fair value for such services. To date, actual distributor and other fees have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We offer our customers product return rights primarily limited to errors in shipment, damaged product, and expiring product, provided it is within a specified period of the product expiration date, as set forth in the associated distribution agreement. Where actual returns history is not available, we estimate a returns allowance based on benchmarking data for similar products and industry experience. Such estimates are recorded as a reduction of revenue in the period the related sale is recognized. Once product is returned, it is destroyed. To date, actual product returns have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenues. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into collaboration and license agreements under which we out-license certain rights to our product candidates to third parties. The terms of these arrangements typically include payment to us for one or more of the following: non-refundable, up-front license fees; development, regulatory, and/or commercial milestone payments; and royalties on net sales of the out-licensed products.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use, and benefit from, the license. For licenses that are bundled with other promises, we assess the nature of the combined performance obligation to determine whether it is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestones.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the inception of each arrangement that includes development, regulatory, and/or commercial milestones, we evaluate whether achieving the milestones is considered probable and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Amounts for milestones that are not within our control, such as when achievement of a specified event is dependent on the development activities of a third party or approvals from regulators, are not considered probable of being achieved until such specified event occurs. Revenue is recognized from the satisfaction of performance obligations in the amount billable to the customer.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For arrangements that include sales-based royalties, and under which the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Each quarterly period, sales-based royalties are recorded based on estimated quarterly net sales of the associated collaboration products. Differences between actual results and estimated amounts are adjusted for in the period in which they become known, which typically follows the quarterly period in which the estimate was made. To date, actual royalties received have not differed materially from our estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents and debt securities available-for-sale. We have established guidelines to limit our exposure to credit risk by diversifying our investment portfolio with low-risk investment-grade debt securities with maturities of up to three years and by placing our investments with high-credit-quality financial institutions to maintain liquidity. To date, we have not experienced any credit losses and do not believe we are exposed to any significant credit risk in connection with these financial instruments.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into agreements for the distribution of INGREZZA with a limited number of specialty pharmacy providers and distributors and all of our product sales of INGREZZA are to these customers. Four of these customers represented approximately 89% of our total product sales for 2022 and approximately 95% of our accounts receivable balance as of December&#160;31, 2022.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Revenues</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenues. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenues includes third-party manufacturing, transportation, freight, and indirect overhead costs primarily for the manufacture and distribution of INGREZZA and ONGENTYS drug product sold, manufacturing costs in connection with our supply of valbenazine drug product under our collaboration with Mitsubishi Tanabe Pharma Corporation, royalty fees on net sales of elagolix, amortization of intangible assets, and adjustments for excess and obsolete inventory to the extent management determines that the cost cannot be recovered based on estimates about future demand.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development, or R&amp;D. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses primarily consist of preclinical and clinical trial costs, payroll and benefits costs, including stock-based compensation associated with employees involved in R&amp;D activities, certain facility-based costs, and costs associated with our collaborative arrangements, including event-based milestones. All such costs are expensed as R&amp;D when incurred.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Expense</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Expense. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs are expensed as selling, general and administrative when incurred. Advertising expense was $149.7 million for 2022, $139.8 million for 2021 and $64.8 million for 2020.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant stock options to purchase our common stock to eligible employees and directors and also grant certain employees restricted stock units, or RSUs, and performance-based restricted stock units, or PRSUs. Additionally, we allow employees to participate in an employee stock purchase plan, or ESPP.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of stock options and shares to be issued under the ESPP using the Black-Scholes option-pricing model on the date of grant. RSUs are valued based on the closing price of our common stock on the date of grant. The fair value of equity instruments expected to vest is recognized and amortized on a straight-line basis over the requisite service period of the award, which is generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzIyMzk4_faec3abd-c6f8-404f-adcd-432a19a48776">three</span> to four years; however, certain provisions in our equity compensation plans provide for shorter vesting periods under certain circumstances. The fair value of shares to be issued under the ESPP is recognized and amortized on a straight-line basis over the purchase period, which is generally six months. PRSUs vest upon the achievement of certain predefined company-specific performance-based criteria. Expense related to PRSUs is generally recognized ratably over the expected performance period once the predefined performance-based criteria for vesting becomes probable.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our income tax provision is computed under the asset and liability method. Significant estimates are required in determining our income tax provision. Some of these estimates are based on interpretations of existing tax laws or regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our income tax provision in the period of such reversal.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities based on the technical merits of the position. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income Per Share</a></td>
<td class="text"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings Per Share.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share are computed using the weighted average number of common shares outstanding during the period. Diluted earnings per share are computed using the treasury stock method and reflect the weighted average number of common and potentially dilutive shares outstanding during the period, excluding those which effect would be anti-dilutive.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we entered into the First Supplemental Indenture to the 2017 Indenture, pursuant to which we irrevocably elected to settle the principal amount of the 2.25% fixed-rate convertible senior notes due May&#160;15, 2024, or the 2024 Notes, in cash upon conversion and to settle any conversion premium in either cash or shares of our common stock. As a result, only the shares required to settle any conversion premium are considered dilutive under the if-converted method. Further, PRSUs for which the performance condition has not been achieved are excluded from the calculation of diluted earnings per share.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted and Issued Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NTk5NDY_b11908b6-457c-4872-91a0-7e1b27137ced">ASU 2020-06</span>.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In August 2020, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2020-06,&#160;Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity's own equity. Among other changes, <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NjA1MDc_b11908b6-457c-4872-91a0-7e1b27137ced">ASU 2020-06</span> removed the separation models for convertible instruments with cash or beneficial conversion features. Instead, entities now account for convertible debt instruments wholly as debt, unless certain other conditions are met. The adoption of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NjA3NTA_b11908b6-457c-4872-91a0-7e1b27137ced">ASU 2020-06</span> prospectively reduces reported interest expense and increases (decreases) reported net income (loss), and resulted in a reclassification of certain conversion feature balance sheet amounts from stockholders&#8217; equity to liabilities as it relates to the 2.25% fixed-rate convertible senior notes due May&#160;15, 2024, or the 2024 Notes. We adopted <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NjEwNzc_b11908b6-457c-4872-91a0-7e1b27137ced">ASU 2020-06</span> on January&#160;1, 2022, using the modified retrospective transition method, which allowed for a cumulative-effect adjustment in the period of adoption and did not require restatement of prior period amounts. Under this transition method, the cumulative effect of the accounting change increased the carrying amount of the 2024 Notes by $42.2 million, reduced deferred tax liabilities by $9.9 million, reduced additional paid-in capital by $106.8 million and reduced the accumulated deficit by $74.5 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_OrganizationAndBusinesDescriptionPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Description Policy [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_OrganizationAndBusinesDescriptionPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI https://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 35<br> -Paragraph 7A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515542&amp;loc=SL120269220-210453<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3D<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL120267969-210447<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922895-210455<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 35<br> -Paragraph 13A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515542&amp;loc=SL120267917-210453<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 35<br> -Paragraph 8A<br> -URI https://asc.fasb.org/extlink&amp;oid=124266218&amp;loc=SL120267834-210445<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 30<br> -Paragraph 4A<br> -URI https://asc.fasb.org/extlink&amp;oid=124256539&amp;loc=SL120269210-210444<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919260-210447<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL120267845-210446<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919253-210447<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919272-210447<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 30<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=124256539&amp;loc=SL120254536-210444<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3C<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL120267966-210447<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 30<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=124268681&amp;loc=SL120267897-210452<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919244-210447<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3D<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267862-210455<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.M.Q4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122651532&amp;loc=SL122037091-237805<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3C<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267859-210455<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267853-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossFinancialInstrumentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263541895184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Diurnal Acquisition (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Estimated Fair Values of the Assets Acquired and Liabilities Assumed at the Date of Acquisition</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the consideration paid for Diurnal and the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consideration</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Recognized amounts of identifiable assets acquired and liabilities assumed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total identifiable net assets acquired</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263540594592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Amortized cost, gross unrealized gain (loss) positions and estimated fair value for available-for-sale debt securities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income (loss) and fair value of debt securities available-for-sale, aggregated by major security type and contractual maturity.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.252%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.075%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Contractual<br/>Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">296.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">293.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">277.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">735.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">726.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 to 3 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">255.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">357.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 to 3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">299.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">563.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">560.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Gross unrealized losses and fair value available-for-sale investments in unrealized loss position</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents debt securities available-for-sale that were in an unrealized loss position as of December&#160;31, 2022, aggregated by major security type and length of time in a continuous loss position.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">299.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">198.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">306.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents debt securities available-for-sale that were in an unrealized loss position as of December&#160;31, 2021, aggregated by major security type and length of time in a continuous loss position.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">428.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">428.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263540594800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Investments measured at fair value on recurring basis</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of investments, which were measured at fair value on a recurring basis.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.464%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.398%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Leveling</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">262.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">262.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">548.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">548.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">321.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">321.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities&#8211;biotechnology industry</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,398.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">372.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,025.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,338.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">396.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">931.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of equity securities measured at fair value on recurring basis using significant unobservable inputs</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of equity security investments, which were measured at fair value on a recurring basis using significant unobservable inputs (Level 3):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain (loss) included in earnings </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfers out of Level 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Unrealized gains and losses on equity security investments which were measured at fair value on a recurring basis using significant unobservable inputs (Level 3) and are included in other income (expense), net.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Certain of our equity security investments were transferred from Level 3 to Level 1 during 2022 and 2021 as the associated holding period restriction expired.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263541855104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Convertible senior notes net of discounts and deferred financing costs</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the 2024 Notes as of December&#160;31, 2022.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.846%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unamortized Debt</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the 2024 Notes as of December&#160;31, 2021.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.846%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unamortized Debt</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">464.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the interest expense of the 2024 Notes.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Coupon interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263540232192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of the Carrying Amount of Goodwill</a></td>
<td class="text"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the carrying amount of goodwill.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill recognized in connection with business combination</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Information Relating to our Recognized Intangible Assets</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information relating to our recognized intangible assets as of December&#160;31, 2022.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.861%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net <br/>Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Developed product rights</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Information Relating to our Recognized Intangible Assets</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information relating to our recognized intangible assets as of December&#160;31, 2022.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.861%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net <br/>Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Developed product rights</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Estimated Annual Amortization Expense for our Finite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the estimated annual amortization expense for our finite-lived intangible assets. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2024</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2025</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2026</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2027</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263542760480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Balance Sheet Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_OtherBalanceSheetDetailsAbstract', window );"><strong>Other Balance Sheet Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventories</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tenant improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Scientific equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(51.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Accounts Payable and Accrued Liabilities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued employee related costs </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current branded prescription drug fee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">347.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock', window );">Reconciliation of Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">344.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_OtherBalanceSheetDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other balance sheet details.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_OtherBalanceSheetDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of reconciliation of cash cash equivalents and restricted cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263545347536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Net Income Per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share were calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income - basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">407.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per share:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263542760352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share based compensation</a></td>
<td class="text">The effect of stock-based compensation expense on our consolidated statements of income and comprehensive income by line-item follows:<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense by award-type follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PRSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, unrecognized stock-based compensation expense by award-type and the weighted-average period over which such expense is expected to be recognized, as applicable, was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.726%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.729%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrecognized Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Recognition Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSUs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PRSUs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted-average assumptions for stock option grants using black-scholes option-pricing model</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option granted was estimated on the date of grant using the Black-Scholes option-pricing valuation model with the following weighted-average assumptions: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected option term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.3 years</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary and changes in stock options outstanding</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents summary of activity related to stock options.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76.38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.5 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">362.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.4 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary and changes in restricted stock units outstanding</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of activity related to RSUs.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant Date <br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99.96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">276.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of activity related to PRSUs.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>PRSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant Date <br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109.31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263544366608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income Before the Provision for Income Taxes from Continuing Domestic and Foreign Operations</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents income before the provision for income taxes from continuing domestic and foreign operations.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">213.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Components of the Provision for (Benefit from) Income Taxes for Continuing Operations</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of the provision for (benefit from) income taxes for continuing operations.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(287.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(310.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(300.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Provision for (benefit from) income taxes on earnings subject to income taxes differs from statutory federal rate</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for (benefit from) income taxes on earnings subject to income taxes differs from the statutory federal rate due to the following: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal income taxes at 21%</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State income tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Branded prescription drug fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Officer compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired tax attributes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(296.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(300.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of deferred tax assets</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the significant components of our deferred tax assets. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">405.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">413.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net of deferred tax assets and liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">372.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">369.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(67.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">305.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">315.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Activity related to unrecognized tax benefits</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of activity related to unrecognized tax benefits.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase (decrease) related to prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase related to current year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements related to prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expiration of the statute of limitations for the assessment of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263542849424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of supplemental operating lease information</a></td>
<td class="text"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present supplemental operating lease information.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.9 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.8 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash related to letters of credit issued in lieu of cash security deposits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of minimum lease payments for operating lease liabilities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximate future minimum lease payments under operating leases were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2027</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accreted interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpmYjg1MmU0NGUwYmY0ZDA3YTVmNjZhM2QxM2VkNmYxMC90YWJsZXJhbmdlOmZiODUyZTQ0ZTBiZjRkMDdhNWY2NmEzZDEzZWQ2ZjEwXzEwLTAtMS0xLTEzOTA2Mg_85571070-dcc5-4354-8358-dbaa0e075ba0">Less current operating lease liabilities included in other current liabilities</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Amounts presented in the table above exclude $17.2 million for 2024, $33.3 million for 2025, $41.9 million for 2026, and $479.7 million thereafter of approximate non-cancelable future minimum lease payments under operating leases that have not yet commenced.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263531441696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>May 02, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff', window );">Accrued interest receivables write-off threshold period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Accrued interest receivables</a></td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="nump">$ 4,700,000<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff', window );">Accrued interest receivables write-off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,100,000<span></span>
</td>
<td class="nump">10,900,000<span></span>
</td>
<td class="nump">8,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,700,000<span></span>
</td>
<td class="nump">$ 139,800,000<span></span>
</td>
<td class="nump">$ 64,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="text">Accounting Standards Update 2020-06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Accounting Standards Update 2020-06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible senior notes</a></td>
<td class="nump">$ 335,100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 335,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(635,800,000)<span></span>
</td>
<td class="num">$ (406,800,000)<span></span>
</td>
<td class="num">(635,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember', window );">2.25% Convertible senior notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible senior notes</a></td>
<td class="nump">335,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">335,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible senior notes</a></td>
<td class="nump">42,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">9,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="nump">106,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 74,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_ESPPPurchasePeriod', window );">ESPP purchase period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Share-based compensation arrangement by share-based payment award, award requisite service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Share-based compensation arrangement by share-based payment award, award requisite service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Revenue, Product and Service Benchmark | Customer Concentration Risk | Largest four customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Customer Concentration Risk | Largest four customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_ESPPPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ESPP Purchase Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_ESPPPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization and summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period when accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), is considered uncollectible and written off, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3C<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267859-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of writeoff of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized by reversing interest income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3D<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267862-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nbix_LargestFourCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nbix_LargestFourCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263530525616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Additional Information (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 105.3<span></span>
</td>
<td class="nump">$ 164.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,488.7<span></span>
</td>
<td class="nump">1,133.5<span></span>
</td>
<td class="nump">1,045.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Heptares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Idorsia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Xenon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.3<span></span>
</td>
<td class="nump">$ 5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_UpfrontPaymentsMade', window );">Upfront payments made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.855<span></span>
</td>
<td class="nump">$ 19.9755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue', window );">Equity securities purchase date fair value amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Equity securities cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Xenon | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_SaleOfStockNumberOfSharesSoldInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Voyager</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="nump">$ 113.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_UpfrontPaymentsMade', window );">Upfront payments made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.9625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue', window );">Equity securities purchase date fair value amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Voyager | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_SaleOfStockNumberOfSharesSoldInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | BIAL &#8211; Portela &amp; Ca, S.A.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | MTPC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_PotentialMilestonePaymentReceipts', window );">Potential milestone payment receipts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | MTPC | Patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_PatentTerm', window );">Patent term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | AbbVie Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_PotentialMilestonePaymentReceipts', window );">Potential milestone payment receipts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 366.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | AbbVie Inc. | Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.2<span></span>
</td>
<td class="nump">$ 22.3<span></span>
</td>
<td class="nump">$ 19.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | AbbVie Inc. | Patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_PatentTerm', window );">Patent term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments made for milestones under a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_PatentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of the patent, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_PatentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_PotentialMilestonePaymentReceipts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential later stage milestone payments and royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_PotentialMilestonePaymentReceipts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_PotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of potential milestone payments to be paid under a license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_PotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_SaleOfStockNumberOfSharesSoldInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares sold by the collaboration partner per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_SaleOfStockNumberOfSharesSoldInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_UpfrontPaymentsMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payments made under a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_UpfrontPaymentsMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI) and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_HeptaresTherapeuticsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_HeptaresTherapeuticsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_TakedaPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_TakedaPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_IdorsiaPharmaceuticalsLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_IdorsiaPharmaceuticalsLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_XenonPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_XenonPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_VoyagerTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_VoyagerTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_BIALPortelaCaSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_BIALPortelaCaSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_MitsubishiTanabePharmaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_MitsubishiTanabePharmaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_AbbVieIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_AbbVieIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263541887184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Diurnal Acquisition - Additional Information (Details) - Diurnal Group Plc<br> $ in Millions</strong></div></th>
<th class="th">
<div>Nov. 01, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Aggregate purchase price</a></td>
<td class="nump">$ 55.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related costs</a></td>
<td class="nump">$ 1.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=nbix_DiurnalGroupPlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=nbix_DiurnalGroupPlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263530415232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Diurnal Acquisition - Estimated Fair Values of the Assets Acquired and Liabilities Assumed at the Date of Acquisition (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Nov. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract', window );"><strong>Recognized amounts of identifiable assets acquired and liabilities assumed</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.4<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=nbix_DiurnalGroupPlcMember', window );">Diurnal Group Plc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Consideration</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash</a></td>
<td class="nump">$ 55.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration transferred</a></td>
<td class="nump">55.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract', window );"><strong>Recognized amounts of identifiable assets acquired and liabilities assumed</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="nump">12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">32.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsAcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other assets</a></td>
<td class="nump">12.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndOtherAccruedExpenses', window );">Accounts payable and other accrued expenses</a></td>
<td class="num">(10.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total identifiable net assets acquired</a></td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndOtherAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accounts Payable And Other Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndOtherAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsAcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Acquired In-Process Research And Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsAcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=nbix_DiurnalGroupPlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=nbix_DiurnalGroupPlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263536290656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt Securities - Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized cost, current</a></td>
<td class="nump">$ 735.8<span></span>
</td>
<td class="nump">$ 370.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Unrealized gain, current</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Unrealized loss, current</a></td>
<td class="num">(9.4)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent', window );">Fair value, current</a></td>
<td class="nump">726.4<span></span>
</td>
<td class="nump">370.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Amortized cost, noncurrent</a></td>
<td class="nump">304.5<span></span>
</td>
<td class="nump">563.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent', window );">Unrealized gain, noncurrent</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent', window );">Unrealized loss, noncurrent</a></td>
<td class="num">(5.3)<span></span>
</td>
<td class="num">(2.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent', window );">Fair value, noncurrent</a></td>
<td class="nump">299.4<span></span>
</td>
<td class="nump">560.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized cost, current</a></td>
<td class="nump">156.2<span></span>
</td>
<td class="nump">204.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Unrealized gain, current</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Unrealized loss, current</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent', window );">Fair value, current</a></td>
<td class="nump">156.0<span></span>
</td>
<td class="nump">204.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized cost, current</a></td>
<td class="nump">296.2<span></span>
</td>
<td class="nump">128.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Unrealized gain, current</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Unrealized loss, current</a></td>
<td class="num">(3.2)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent', window );">Fair value, current</a></td>
<td class="nump">293.0<span></span>
</td>
<td class="nump">128.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Amortized cost, noncurrent</a></td>
<td class="nump">259.5<span></span>
</td>
<td class="nump">358.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent', window );">Unrealized gain, noncurrent</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent', window );">Unrealized loss, noncurrent</a></td>
<td class="num">(4.3)<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent', window );">Fair value, noncurrent</a></td>
<td class="nump">255.4<span></span>
</td>
<td class="nump">357.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Securities of government-sponsored entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized cost, current</a></td>
<td class="nump">283.4<span></span>
</td>
<td class="nump">37.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Unrealized gain, current</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Unrealized loss, current</a></td>
<td class="num">(6.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent', window );">Fair value, current</a></td>
<td class="nump">277.4<span></span>
</td>
<td class="nump">37.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Amortized cost, noncurrent</a></td>
<td class="nump">45.0<span></span>
</td>
<td class="nump">204.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent', window );">Unrealized gain, noncurrent</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent', window );">Unrealized loss, noncurrent</a></td>
<td class="num">(1.0)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent', window );">Fair value, noncurrent</a></td>
<td class="nump">$ 44.0<span></span>
</td>
<td class="nump">$ 203.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DebtSecuritiesAvailableForSaleFairValueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Fair Value, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DebtSecuritiesAvailableForSaleFairValueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Fair Value, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263540592624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt Securities - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>security</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions', window );">Debt securities available for sale position number of positions</a></td>
<td class="nump">253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of debt securities available-for-sale in an unrealized loss position</a></td>
<td class="nump">199<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt securities available for sale position number of positions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263536347200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Debt securities in Unrealized Loss Position (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months, Fair Value</a></td>
<td class="nump">$ 32.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months, Unrealized Losses</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer, Fair Value</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer, Unrealized Loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total Fair Value</a></td>
<td class="nump">32.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total Unrealized Losses</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months, Fair Value</a></td>
<td class="nump">199.5<span></span>
</td>
<td class="nump">$ 428.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months, Unrealized Losses</a></td>
<td class="num">(1.9)<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer, Fair Value</a></td>
<td class="nump">299.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer, Unrealized Loss</a></td>
<td class="num">(5.6)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total Fair Value</a></td>
<td class="nump">498.6<span></span>
</td>
<td class="nump">428.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total Unrealized Losses</a></td>
<td class="num">(7.5)<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Securities of government-sponsored entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months, Fair Value</a></td>
<td class="nump">107.7<span></span>
</td>
<td class="nump">230.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months, Unrealized Losses</a></td>
<td class="num">(2.5)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer, Fair Value</a></td>
<td class="nump">198.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer, Unrealized Loss</a></td>
<td class="num">(4.5)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total Fair Value</a></td>
<td class="nump">306.1<span></span>
</td>
<td class="nump">230.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total Unrealized Losses</a></td>
<td class="num">$ (7.0)<span></span>
</td>
<td class="num">$ (1.0)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263530237616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Details) - Fair value measurements recurring - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair value</a></td>
<td class="nump">$ 1,398.6<span></span>
</td>
<td class="nump">$ 1,338.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair value</a></td>
<td class="nump">548.4<span></span>
</td>
<td class="nump">485.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Securities of government-sponsored entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair value</a></td>
<td class="nump">321.4<span></span>
</td>
<td class="nump">240.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities&#8211;biotechnology industry</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair value</a></td>
<td class="nump">102.1<span></span>
</td>
<td class="nump">63.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=nbix_CashAndMoneyMarketFundMember', window );">Cash and money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair value</a></td>
<td class="nump">262.9<span></span>
</td>
<td class="nump">340.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair value</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair value</a></td>
<td class="nump">156.0<span></span>
</td>
<td class="nump">204.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">372.8<span></span>
</td>
<td class="nump">396.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Securities of government-sponsored entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Equity securities&#8211;biotechnology industry</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">102.1<span></span>
</td>
<td class="nump">52.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Cash and money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">262.9<span></span>
</td>
<td class="nump">340.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">1,025.8<span></span>
</td>
<td class="nump">931.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">548.4<span></span>
</td>
<td class="nump">485.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Securities of government-sponsored entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">321.4<span></span>
</td>
<td class="nump">240.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Equity securities&#8211;biotechnology industry</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Cash and money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">156.0<span></span>
</td>
<td class="nump">204.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Securities of government-sponsored entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Equity securities&#8211;biotechnology industry</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Cash and money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=nbix_CashAndMoneyMarketFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=nbix_CashAndMoneyMarketFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263536370784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Reconciliation of Equity Securities Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRestricted', window );">Balance at beginning of period</a></td>
<td class="nump">$ 63.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRestrictedInvestments', window );">Purchases</a></td>
<td class="nump">7.7<span></span>
</td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) included in earnings</a></td>
<td class="nump">30.8<span></span>
</td>
<td class="nump">20.9<span></span>
</td>
<td class="num">(17.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRestricted', window );">Balance at ending of period</a></td>
<td class="nump">102.1<span></span>
</td>
<td class="nump">63.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair value measurements recurring | Equity securities&#8211;biotechnology industry</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRestrictedInvestments', window );">Purchases</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair value measurements recurring | Equity securities&#8211;biotechnology industry</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRestricted', window );">Balance at beginning of period</a></td>
<td class="nump">11.0<span></span>
</td>
<td class="nump">38.2<span></span>
</td>
<td class="nump">55.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) included in earnings</a></td>
<td class="nump">20.8<span></span>
</td>
<td class="nump">20.9<span></span>
</td>
<td class="num">(17.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3', window );">Transfers out of Level 3</a></td>
<td class="num">(31.8)<span></span>
</td>
<td class="num">(52.7)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRestricted', window );">Balance at ending of period</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 11.0<span></span>
</td>
<td class="nump">$ 38.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRestricted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of restricted investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=127002003&amp;loc=SL6242269-115581<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=109249958&amp;loc=SL6224234-111729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRestricted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263530965152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 02, 2017 </div>
<div>USD ($) </div>
<div>d </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments', window );">Equity component of repurchased convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000,000.0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">18,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="text">Accounting Standards Update 2020-06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Accounting Standards Update 2020-06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible senior notes</a></td>
<td class="nump">$ 335,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 335,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(635,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(406,800,000)<span></span>
</td>
<td class="num">(635,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible senior notes</a></td>
<td class="nump">42,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="num">(9,900,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,900,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="num">(106,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(106,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">74,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember', window );">2.25% Convertible senior notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal Amount</a></td>
<td class="nump">381,200,000<span></span>
</td>
<td class="nump">$ 517,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,400,000<span></span>
</td>
<td class="nump">381,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_CarryingAmountOfLiabilityComponentUponIssuance', window );">Carrying amount of the liability component upon issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 368,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Assumed borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Carrying amount of the equity component upon issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Convertible senior notes term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Transaction cost related to issuance of convertible senior note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Aggregate principal amount repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,800,000<span></span>
</td>
<td class="nump">$ 136,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Aggregate repurchase price paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 279,000,000<span></span>
</td>
<td class="nump">186,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment', window );">Fair value of the liability component immediately before extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments', window );">Equity component of repurchased convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_CarryingAmountOfLiabilityComponentAtSettlement', window );">Carrying amount of the liability component at settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible senior notes</a></td>
<td class="nump">$ 335,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 335,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00131711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_DebtInstrumentConvertibleConversionPremium', window );">Conversion premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Market price of common stock (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Redemption rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember', window );">2.25% Convertible senior notes due 2024 | Conversion Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive common stock trading days | d</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percentage of common stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleStockPriceTrigger', window );">Common stock price trigger (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold common stock trading days | d</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember', window );">2.25% Convertible senior notes due 2024 | Conversion Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_PrincipalAmountOnConversionRate', window );">Principal amount on conversion rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold common stock trading days | d</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice', window );">Minimum percentage of common stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember', window );">2.25% Convertible senior notes due 2024 | Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0337<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_CarryingAmountOfLiabilityComponentAtSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of the liability component at settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_CarryingAmountOfLiabilityComponentAtSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_CarryingAmountOfLiabilityComponentUponIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the liability component upon issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_CarryingAmountOfLiabilityComponentUponIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DebtInstrumentConvertibleConversionPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of excess of the price paid for the convertible note over the closing stock price on the closing date of the convertible note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DebtInstrumentConvertibleConversionPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of the liability component immediately before extinguishment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum percentage of the product of the common stock trading price multiplied by the conversion rate during the measurement period as compared to the principal note amount that triggers a conversion option on the notes, if it falls below this percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_PrincipalAmountOnConversionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Principal amount on conversion rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_PrincipalAmountOnConversionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of subsequent adjustments to additional paid in capital for convertible financial instruments where a component of equity and a component of debt are recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of the entity's common stock which would be required to be attained for the conversion feature embedded in the debt instrument to become effective.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DebtInstrumentConversionAxis=nbix_ConversionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DebtInstrumentConversionAxis=nbix_ConversionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DebtInstrumentConversionAxis=nbix_ConversionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DebtInstrumentConversionAxis=nbix_ConversionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263540219536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Senior Notes - 2024 Notes (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 02, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Net Carrying Amount</a></td>
<td class="nump">$ 169,400,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Net Carrying Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">335,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember', window );">2.25% Convertible senior notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal Amount</a></td>
<td class="nump">170,400,000<span></span>
</td>
<td class="nump">381,200,000<span></span>
</td>
<td class="nump">$ 517,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet', window );">Unamortized Debt, Discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(43,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized Debt, Issuance Costs</a></td>
<td class="num">(1,000,000.0)<span></span>
</td>
<td class="num">(2,900,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Net Carrying Amount</a></td>
<td class="nump">169,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Net Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">335,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair Value, Amount</a></td>
<td class="nump">$ 268,000,000.0<span></span>
</td>
<td class="nump">$ 464,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount (premium).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28567-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263542782800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes - Interest Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_DebtInstrumentCouponInterest', window );">Coupon interest</a></td>
<td class="nump">$ 5.9<span></span>
</td>
<td class="nump">$ 8.5<span></span>
</td>
<td class="nump">$ 11.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance costs</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">17.3<span></span>
</td>
<td class="nump">21.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense, Total</a></td>
<td class="nump">$ 7.1<span></span>
</td>
<td class="nump">$ 25.8<span></span>
</td>
<td class="nump">$ 32.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DebtInstrumentCouponInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Coupon Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DebtInstrumentCouponInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263545866816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=nbix_DiurnalGroupPlcMember', window );">Diurnal Group Plc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=nbix_DiurnalGroupPlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=nbix_DiurnalGroupPlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263536199152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, at beginning period</a></td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recognized in connection with business combination</a></td>
<td class="nump">5.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments</a></td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, at ending period</a></td>
<td class="nump">$ 5.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263543198768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Intangible Assets Amortized Over Estimated Useful Lives (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total intangible assets, net</a></td>
<td class="nump">$ 37.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed product rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 34.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 33.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263542671632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Estimated Annual Amortization Expense for Finite-Lived Intangible Assets (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Year ending December 31, 2023</a></td>
<td class="nump">$ 3.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Year ending December 31, 2024</a></td>
<td class="nump">3.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Year ending December 31, 2025</a></td>
<td class="nump">3.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Year ending December 31, 2026</a></td>
<td class="nump">3.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Year ending December 31, 2027</a></td>
<td class="nump">3.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">$ 16.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263545929040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Balance Sheet Details - Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_OtherBalanceSheetDetailsAbstract', window );"><strong>Other Balance Sheet Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 12.0<span></span>
</td>
<td class="nump">$ 11.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">5.6<span></span>
</td>
<td class="nump">3.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">17.5<span></span>
</td>
<td class="nump">15.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 35.1<span></span>
</td>
<td class="nump">$ 30.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_OtherBalanceSheetDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other balance sheet details.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_OtherBalanceSheetDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263530514432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Balance Sheet Details - Property and Equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 124.9<span></span>
</td>
<td class="nump">$ 110.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(66.3)<span></span>
</td>
<td class="num">(51.9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">58.6<span></span>
</td>
<td class="nump">58.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">37.9<span></span>
</td>
<td class="nump">34.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nbix_ScientificEquipmentMember', window );">Scientific equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">58.8<span></span>
</td>
<td class="nump">51.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">21.5<span></span>
</td>
<td class="nump">18.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 6.7<span></span>
</td>
<td class="nump">$ 5.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nbix_ScientificEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nbix_ScientificEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263544477360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Balance Sheet Details - Accounts Payable and Accrued Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_OtherBalanceSheetDetailsAbstract', window );"><strong>Other Balance Sheet Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued employee related costs</a></td>
<td class="nump">$ 72.8<span></span>
</td>
<td class="nump">$ 50.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_RevenueRelatedReservesForDiscountsAndAllowances', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">131.9<span></span>
</td>
<td class="nump">62.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AccruedResearchAndDevelopmentExpenseCurrent', window );">Accrued development costs</a></td>
<td class="nump">39.1<span></span>
</td>
<td class="nump">32.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AccruedBrandedPrescriptionDrugFee', window );">Current branded prescription drug fee</a></td>
<td class="nump">27.5<span></span>
</td>
<td class="nump">28.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accounts payable and other accrued liabilities</a></td>
<td class="nump">76.3<span></span>
</td>
<td class="nump">51.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total accounts payable and accrued liabilities</a></td>
<td class="nump">$ 347.6<span></span>
</td>
<td class="nump">$ 225.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_AccruedBrandedPrescriptionDrugFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Branded Prescription Drug Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_AccruedBrandedPrescriptionDrugFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expense current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_OtherBalanceSheetDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other balance sheet details.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_OtherBalanceSheetDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_RevenueRelatedReservesForDiscountsAndAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue-related reserves for discounts and allowances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_RevenueRelatedReservesForDiscountsAndAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263536199152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Balance Sheet Details - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_OtherBalanceSheetDetailsAbstract', window );"><strong>Other Balance Sheet Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 262.9<span></span>
</td>
<td class="nump">$ 340.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 270.7<span></span>
</td>
<td class="nump">$ 344.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_OtherBalanceSheetDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other balance sheet details.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_OtherBalanceSheetDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263544471952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Schedule of Net Income (Loss) Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income - basic</a></td>
<td class="nump">$ 154.5<span></span>
</td>
<td class="nump">$ 89.6<span></span>
</td>
<td class="nump">$ 407.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income - diluted</a></td>
<td class="nump">$ 154.5<span></span>
</td>
<td class="nump">$ 89.6<span></span>
</td>
<td class="nump">$ 407.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">95.8<span></span>
</td>
<td class="nump">94.6<span></span>
</td>
<td class="nump">93.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">98.9<span></span>
</td>
<td class="nump">97.9<span></span>
</td>
<td class="nump">97.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_EarningsPerShareBasicAndDilutedEPSAbstract', window );"><strong>Earnings per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in USD per share)</a></td>
<td class="nump">$ 1.61<span></span>
</td>
<td class="nump">$ 0.95<span></span>
</td>
<td class="nump">$ 4.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in USD per share)</a></td>
<td class="nump">$ 1.56<span></span>
</td>
<td class="nump">$ 0.92<span></span>
</td>
<td class="nump">$ 4.16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_EarningsPerShareBasicAndDilutedEPSAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Basic and Diluted EPS</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_EarningsPerShareBasicAndDilutedEPSAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126962052&amp;loc=d3e4991-113900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1500-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263544481280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Schedule of Anti-Dilutive Shares Excluded from Diluted Per Share Amounts (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember', window );">Stock options restricted stock and convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from diluted per share amounts (in shares)</a></td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263539281280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 31, 2011</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair values of stock options granted (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.05<span></span>
</td>
<td class="nump">$ 45.02<span></span>
</td>
<td class="nump">$ 45.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Stock options exercised in period intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.7<span></span>
</td>
<td class="nump">$ 58.0<span></span>
</td>
<td class="nump">$ 40.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received from stock option exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.0<span></span>
</td>
<td class="nump">20.7<span></span>
</td>
<td class="nump">23.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Discounted purchase price percentage of common stock authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual term of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Total intrinsic value vested in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72.4<span></span>
</td>
<td class="nump">64.3<span></span>
</td>
<td class="nump">49.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember', window );">PRSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of PRSUs vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 13.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember', window );">PRSUs | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember', window );">PRSUs | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nbix_Amended2020EquityIncentivePlanMember', window );">Amended 2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grant (in shares)</a></td>
<td class="nump">7,900,000<span></span>
</td>
<td class="nump">7,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward', window );">Number of shares reduced pursuant to appreciation award (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted', window );">Number of shares reduced pursuant to any full value award granted (in shares)</a></td>
<td class="nump">2.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward', window );">Number of shares increased by returning shares subject to appreciation award (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward', window );">Number of shares increased returning shares subject to any full value award (in shares)</a></td>
<td class="nump">2.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nbix_TwoThousandAndElevenEquityIncentivePlanMember', window );">2011 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of common stock authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nbix_Amended2018EmployeeStockPurchasePlanMember', window );">Amended 2018 Employee Stock Purchase Plan | ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grant (in shares)</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Increased By Returning Shares Subject To An Award</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Increased By Returning Shares Subject To Appreciation Award</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Reduced Pursuant To Appreciation Award</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Reduced Pursuant To Award Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nbix_Amended2020EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nbix_Amended2020EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nbix_TwoThousandAndElevenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nbix_TwoThousandAndElevenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nbix_Amended2018EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nbix_Amended2018EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263544414480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Compensation Cost Related to Share-Based Compensation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 173.1<span></span>
</td>
<td class="nump">$ 134.2<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">115.4<span></span>
</td>
<td class="nump">85.8<span></span>
</td>
<td class="nump">66.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 57.7<span></span>
</td>
<td class="nump">$ 48.4<span></span>
</td>
<td class="nump">$ 33.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263536289024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Share-based Compensation Expense by Award-type (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 173.1<span></span>
</td>
<td class="nump">$ 134.2<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">62.6<span></span>
</td>
<td class="nump">60.5<span></span>
</td>
<td class="nump">47.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">86.4<span></span>
</td>
<td class="nump">62.5<span></span>
</td>
<td class="nump">44.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember', window );">PRSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">20.1<span></span>
</td>
<td class="nump">7.6<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="nump">$ 3.6<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263543153536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Share-based Compensation Expense (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized Expense</a></td>
<td class="nump">$ 106.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-Average Recognition Period</a></td>
<td class="text">2 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized Expense</a></td>
<td class="nump">$ 151.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-Average Recognition Period</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember', window );">PRSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized Expense</a></td>
<td class="nump">$ 33.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263530415952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Weighted-Average Assumptions for Stock Option Grants using Black-Scholes Option-Pricing Model (Details) - Stock options<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility of common stock</a></td>
<td class="nump">42.60%<span></span>
</td>
<td class="nump">45.90%<span></span>
</td>
<td class="nump">48.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263544448352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Activity Related to Stock Options (Details)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning Balance, Outstanding (in shares) | shares</a></td>
<td class="nump">7.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">2.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(0.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares) | shares</a></td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending Balance, Outstanding (in shares) | shares</a></td>
<td class="nump">9.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Exercisable (in shares) | shares</a></td>
<td class="nump">6.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning Balance, Outstanding (in USD per share) | $ / shares</a></td>
<td class="nump">$ 76.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in USD per share) | $ / shares</a></td>
<td class="nump">81.27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in USD per share) | $ / shares</a></td>
<td class="nump">52.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled (in USD per share) | $ / shares</a></td>
<td class="nump">96.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending Balance, Outstanding (in USD per share) | $ / shares</a></td>
<td class="nump">79.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in USD per share) | $ / shares</a></td>
<td class="nump">$ 72.27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual Term and Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term, Outstanding</a></td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding | $</a></td>
<td class="nump">$ 362.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Exercisable | $</a></td>
<td class="nump">$ 281.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263538860064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary and Changes in Restricted Stock Units Outstanding (Details)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance, Unvested (in shares) | shares</a></td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Released (in shares) | shares</a></td>
<td class="num">(0.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled (in shares) | shares</a></td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance, Unvested (in shares) | shares</a></td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning Balance, Unvested (in USD per share) | $ / shares</a></td>
<td class="nump">$ 99.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in USD per share) | $ / shares</a></td>
<td class="nump">83.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Released (in USD per share) | $ / shares</a></td>
<td class="nump">96.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled (in USD per share) | $ / shares</a></td>
<td class="nump">94.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending Balance, Unvested (in USD per share) | $ / shares</a></td>
<td class="nump">$ 92.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Unvested, weighted average remaining contractual term (in years)</a></td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Unvested, aggregate intrinsic value | $</a></td>
<td class="nump">$ 276.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember', window );">PRSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance, Unvested (in shares) | shares</a></td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Released (in shares) | shares</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled (in shares) | shares</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance, Unvested (in shares) | shares</a></td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning Balance, Unvested (in USD per share) | $ / shares</a></td>
<td class="nump">$ 109.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in USD per share) | $ / shares</a></td>
<td class="nump">80.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Released (in USD per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled (in USD per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending Balance, Unvested (in USD per share) | $ / shares</a></td>
<td class="nump">$ 101.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Unvested, weighted average remaining contractual term (in years)</a></td>
<td class="text">9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Unvested, aggregate intrinsic value | $</a></td>
<td class="nump">$ 60.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263530417360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income Before the Provision for Income Taxes from Continuing Domestic and Foreign Operations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="nump">$ 218.0<span></span>
</td>
<td class="nump">$ 101.4<span></span>
</td>
<td class="nump">$ 106.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(4.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before provision for (benefit from) income taxes</a></td>
<td class="nump">$ 213.9<span></span>
</td>
<td class="nump">$ 101.4<span></span>
</td>
<td class="nump">$ 106.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263536351632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of the Provision for (Benefit from) Income Taxes for Continuing Operations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 17.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">20.3<span></span>
</td>
<td class="nump">6.3<span></span>
</td>
<td class="nump">10.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current taxes</a></td>
<td class="nump">37.4<span></span>
</td>
<td class="nump">6.3<span></span>
</td>
<td class="nump">10.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">27.5<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
<td class="num">(287.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(5.5)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(23.2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred taxes</a></td>
<td class="nump">22.0<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="num">(310.7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for (benefit from) income taxes</a></td>
<td class="nump">$ 59.4<span></span>
</td>
<td class="nump">$ 11.8<span></span>
</td>
<td class="num">$ (300.6)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263539215264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Provision for Income Taxes on Earnings Subject to Income Taxes Differs from Statutory Federal Rate (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income taxes, rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Federal income taxes at 21%</a></td>
<td class="nump">$ 44.9<span></span>
</td>
<td class="nump">$ 21.3<span></span>
</td>
<td class="nump">$ 22.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income tax, net of federal benefit</a></td>
<td class="nump">11.8<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee', window );">Branded prescription drug fee</a></td>
<td class="nump">6.5<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes', window );">Loss on extinguishment of convertible senior notes</a></td>
<td class="nump">12.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation expense</a></td>
<td class="num">(2.5)<span></span>
</td>
<td class="num">(11.3)<span></span>
</td>
<td class="num">(6.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost', window );">Officer compensation</a></td>
<td class="nump">9.2<span></span>
</td>
<td class="nump">7.0<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Change in tax rate</a></td>
<td class="num">(1.3)<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_IncomeTaxReconciliationExpirationOfTaxCredits', window );">Expired tax attributes</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research credits</a></td>
<td class="num">(29.9)<span></span>
</td>
<td class="num">(22.0)<span></span>
</td>
<td class="num">(39.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">7.4<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="num">(296.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for (benefit from) income taxes</a></td>
<td class="nump">$ 59.4<span></span>
</td>
<td class="nump">$ 11.8<span></span>
</td>
<td class="num">$ (300.6)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Loss On Extinguishment Of Convertible Senior Notes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_IncomeTaxReconciliationExpirationOfTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation, expiration of tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_IncomeTaxReconciliationExpirationOfTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation nondeductible expense branded prescription drug fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation nondeductible expense officer compensation cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32059-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263531396032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of Deferred Tax Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 27.4<span></span>
</td>
<td class="nump">$ 90.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">108.9<span></span>
</td>
<td class="nump">129.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment', window );">Capitalized research and development</a></td>
<td class="nump">91.1<span></span>
</td>
<td class="nump">17.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Stock-based compensation expense</a></td>
<td class="nump">45.9<span></span>
</td>
<td class="nump">38.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_DeferredTaxAssetsOperatingLeasesAssets', window );">Operating lease assets</a></td>
<td class="nump">26.8<span></span>
</td>
<td class="nump">29.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">80.7<span></span>
</td>
<td class="nump">86.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">24.9<span></span>
</td>
<td class="nump">21.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">405.7<span></span>
</td>
<td class="nump">413.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes', window );">Convertible senior notes</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(9.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(21.0)<span></span>
</td>
<td class="num">(23.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(11.8)<span></span>
</td>
<td class="num">(10.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(32.8)<span></span>
</td>
<td class="num">(43.9)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_DeferredTaxAssetsLiabilitiesGross', window );">Net of deferred tax assets and liabilities</a></td>
<td class="nump">372.9<span></span>
</td>
<td class="nump">369.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(67.0)<span></span>
</td>
<td class="num">(54.8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 305.9<span></span>
</td>
<td class="nump">$ 315.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development costs capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DeferredTaxAssetsLiabilitiesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets (liabilities) gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DeferredTaxAssetsLiabilitiesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DeferredTaxAssetsOperatingLeasesAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating leases assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DeferredTaxAssetsOperatingLeasesAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities convertible senior notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities operating leases liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263539257840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, valuation allowance</a></td>
<td class="nump">$ 67,000,000<span></span>
</td>
<td class="nump">$ 54,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets</a></td>
<td class="nump">305,900,000<span></span>
</td>
<td class="nump">315,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carry forwards</a></td>
<td class="nump">108,900,000<span></span>
</td>
<td class="nump">$ 129,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationInterestAccrued', window );">Interest accrued</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAccrued', window );">Penalties accrued</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would affect effective tax rate</a></td>
<td class="nump">74,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and local jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forward, net</a></td>
<td class="nump">324,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carry forwards</a></td>
<td class="nump">72,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign tax authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forward, net</a></td>
<td class="nump">60,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal tax authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forward, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carry forwards</a></td>
<td class="nump">$ 98,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263539257008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at January 1</a></td>
<td class="nump">$ 64.6<span></span>
</td>
<td class="nump">$ 60.8<span></span>
</td>
<td class="nump">$ 63.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increase related to prior year tax positions</a></td>
<td class="nump">4.7<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">(Decrease) related to prior year tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase related to current year tax positions</a></td>
<td class="nump">15.2<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlements related to prior year tax positions</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Expiration of the statute of limitations for the assessment of taxes</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at December 31</a></td>
<td class="nump">$ 84.5<span></span>
</td>
<td class="nump">$ 64.6<span></span>
</td>
<td class="nump">$ 60.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263540525328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Narrative Information (Details)<br></strong></div></th>
<th class="th">
<div>Feb. 08, 2022 </div>
<div>USD ($) </div>
<div>renewalOption</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding', window );">Lessee option term for construction of fifth building</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_RentAbatementPeriod', window );">Rent abatement period</a></td>
<td class="text">10 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot', window );">Monthly base rent per square foot | $</a></td>
<td class="nump">$ 6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_AnnualRentEscalationPercentage', window );">Annual rent escalation percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">13 years 7 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_NumberOfRenewalOptions', window );">Number of lease renewal options | renewalOption</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_AnnualRentEscalationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual Rent Escalation Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_AnnualRentEscalationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease Monthly Base Rent Per Square Foot</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of term of lessee's option for the construction of a fifth building under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_NumberOfRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of renewal options under the terms of the lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_NumberOfRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_RentAbatementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rent Abatement Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_RentAbatementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263530891632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 16.3<span></span>
</td>
<td class="nump">$ 15.3<span></span>
</td>
<td class="nump">$ 10.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of operating lease liabilities</a></td>
<td class="nump">$ 16.9<span></span>
</td>
<td class="nump">$ 12.6<span></span>
</td>
<td class="nump">$ 8.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">5.30%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash related to letters of credit issued in lieu of cash security deposits</a></td>
<td class="nump">$ 7.8<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash related to letters of credit issued in lieu of cash security deposits</a></td>
<td class="nump">$ 7.8<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263543341120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Future Minimum Lease Payments Under Operating Lease Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Year ending December 31, 2023</a></td>
<td class="nump">$ 17.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Year ending December 31, 2024</a></td>
<td class="nump">17.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Year ending December 31, 2025</a></td>
<td class="nump">15.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">Year ending December 31, 2026</a></td>
<td class="nump">15.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">Year ending December 31, 2027</a></td>
<td class="nump">16.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">54.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments</a></td>
<td class="nump">137.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less accreted interest</a></td>
<td class="nump">26.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">110.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less current operating lease liabilities included in other current liabilities</a></td>
<td class="nump">17.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent operating lease liabilities</a></td>
<td class="nump">93.5<span></span>
</td>
<td class="nump">$ 105.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo', window );">Non-cancelable future minimum lease payments under operating leases not yet commenced for 2024</a></td>
<td class="nump">17.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree', window );">Non-cancelable future minimum lease payments under operating leases not yet commenced for 2025</a></td>
<td class="nump">33.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour', window );">Non-cancelable future minimum lease payments under operating leases not yet commenced for 2026</a></td>
<td class="nump">41.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive', window );">Non-cancelable future minimum lease payments under operating leases not yet commenced for thereafter</a></td>
<td class="nump">$ 479.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263540568848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Defined contribution plan, maximum employee contribution percentage</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contribution plan, employer contribution amount</a></td>
<td class="nump">$ 10.3<span></span>
</td>
<td class="nump">$ 8.1<span></span>
</td>
<td class="nump">$ 6.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140263538797904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Voyager - Collaborative Arrangement - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 08, 2023</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_UpfrontPaymentsMade', window );">Upfront payments made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_UpfrontPaymentsMade', window );">Upfront payments made</a></td>
<td class="nump">$ 175.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nbix_BusinessAcquisitionEquityInvestmentToAcquireTheWorldwideRights', window );">Equity investment to acquire the worldwide rights</a></td>
<td class="nump">$ 39.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_BusinessAcquisitionEquityInvestmentToAcquireTheWorldwideRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Equity Investment To Acquire The Worldwide Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_BusinessAcquisitionEquityInvestmentToAcquireTheWorldwideRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_UpfrontPaymentsMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payments made under a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_UpfrontPaymentsMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_VoyagerTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_VoyagerTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>nbix-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nbix="http://www.neurocrine.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nbix-20221231.xsd" xlink:type="simple"/>
    <context id="if7643571a4d04563b796b60bef5361e9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic07db2f2e87d4ef895cb2823ce1bd349_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7a07412530754a858e0fecb90db3cba4_I20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="i4dad9397c8114dc994a1d55e36926d3d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i092dab9242464bf7bd7bddb6a8629472_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5fc4cf231a09409ca4f633d2a52d1059_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib02b2e314d9843b6beb8c5b163f3331b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ieadd249b6bd54f3f882b31ca68b01cd6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i639fef176a3f4b5ca32c8c373750fe46_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic3a57832bc8048d593cd85c6dc2a6362_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia6e4c87aa559406d86302c9502431650_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5487fc19d1994eb39121318350a3e13a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie0742d6ae0d04338b0b3b537053da2dd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i925cca476463400d82eec5ed1c25941d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4a17ccdbf08849ba857638d5a36314ed_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie9e7a539304246b48b58f35e4a888e14_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib9a3f2cd6f5941a6bcecb7ae1f54d627_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5fe0390d99064b149bfb4f7d84cd1ab2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6d19e967388d41128ce3a6f556f600be_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie0ee7b0ff1c946b390b1cd119381b62f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie1660cd4b7b54e359345103c0e942aa8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8f63238a40484e0ab018374a8829b7a0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i78e8a22fcfd640478484ade7992b19eb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5f7dfb474ad94c65bc4bb9ac91172dc9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8a88ab4de251408db4aa98552134a56a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id7e33c1feaa549568d96ca0b5a1289e4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6eb7229899cc4ef8a964dc3ed073c87c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5a5dcf16fd4c454093a5adc50ec3dbf4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7839db0dc61d4c4e8853cf6e19e54d9a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5b99420940c34cd38a2ca2831819f03a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic68171adb3f24de9bed3bd6b62a8b5f1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1431ff2fdef24f178c1a21ede2c5c504_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i72e83c4aadc74dfe9f04f4780dec95d0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie5ed360a12ed4ff2b4e907ef5bc21e00_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icd0f70dc50c24e3ebdef035671ebad8d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6110ec902f424e9786d861ac3a49b372_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia89fc8fb19434c28a5b37e944ef95c17_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ica83f9a3025b4dce8f0663374896f3ea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i90432f146b89477b90abd98f33694f6b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9398bcb69b16420d9cf3703d6c3c8b15_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2faddbeacae241608429e772b0492fe7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie5989ae77b9e4f9bab21d80812e7179d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i423520348d804b1da2a2f946632d1239_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2b9ae80dc18341fabe82e98052d1b03a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifbefd953596945ebb57cb8b4260d4036_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i369eac3be33e4aaeb739e76899443560_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib8a35373f04d4f25aabbae9b053dfc86_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nbix:LargestFourCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3ee7b53986f840f69575c96ddd148ff6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nbix:LargestFourCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i42a4d7de80254904a89f6619754861e0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4b5b4f7eab2446ce84ea30524cbd6aa0_I20170502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-02</instant>
        </period>
    </context>
    <context id="i52de095faa4e4144bb37c3dd09f49c99_D20211231-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7b26f825c6434881a754e7e6c53ed556_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i49d358b74dad468eb33569aa9c5ac1c8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:HeptaresTherapeuticsLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i07a1cddc781641a8845184519e26357f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:HeptaresTherapeuticsLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1528f057e30c40d383e6a6ca39cf5e6c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:HeptaresTherapeuticsLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0f5830ad533c4847b9f38b89925e51ec_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7449f5d91b314ce9840e1b298ee98b5a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6b886e104da64c1fa92f25fa93dc1395_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i868635e691954212a665a735b175d9cc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:IdorsiaPharmaceuticalsLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i440c81bdf19642fba2eda39e1baadf0e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:IdorsiaPharmaceuticalsLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idd82456387ea428d8220b9c69e68b5a5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i61160aa576a54fed889d400313bcb4aa_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib362d8b9fffd4556aaef9b4388175d10_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1de27f6ad9554d338fb10badbf2b6cc6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia98ab6db9c434e4dbbefda09d3b887fb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1dd2cca8016742d7affa71c15d311c24_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i56425aa7040a45e28f54bc219c6c40d3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ieb20bc9532234865b09c7dc5f22a26fc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia5b5c0571ff04f84bac746f261a35bef_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3558292be26a40eea22ad957b4eb1826_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7701cdc56953401b8c556dba9626d9e9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i68a2f3aa551740a2a1bc3a14aaf7c9fa_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ic667970352ec4acca922a861f9e43c76_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i42ebb9eaffae4c9eac346888ea44b0d4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i67a8f10be8224d60b4e1657e6dade015_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:BIALPortelaCaSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i59539b84d7aa486da424a835877b0fc9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic013c8b18d624578b99159e4ff5581c7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5a3cc531fe0541f4b8e3a1edcfbd0a17_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iee6e68341d9841438fa8702438a7dac5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6f13730346f24079965eeb3a7fe0ff59_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idda4399247c446cebc1ede65c5bec2b9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i61790d0b66be4586a7c469931f4ab4d7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6d60a74b87dc498c97bc171751a50ac9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9d13692c26a440998d78e8fffc7d8570_D20221101-20221101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nbix:DiurnalGroupPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="i5a8688d19b0c4b7f9f790a262226d2ea_I20221101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nbix:DiurnalGroupPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-01</instant>
        </period>
    </context>
    <context id="i2a6f8fd190a2433584205fa45bfd8bcb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i001676d240734d81bdb16bacb8df878e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2dc4af282e2e4830bb4c5589ec647f1f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4e6ecccda3454d2d97a48bbbed7a06c4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idc59d3c4ac034bfc85c224da99f57d0f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i76c8c1dcfb3247a6b15b3036d4069cbc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id63f24106d73460cb43b5496689583ba_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iea0e6362bc9a41baa6232f3d791b1b30_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5b718dc4ea4045ddb88690b0606e023f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8286a497677b4b46a9e257151dfe0240_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5e2f6bb95ef942549f5717766447bf89_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6b0d1aff1c264abba7252395e73cacd2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9258781d2d9a48c3abc627b4e38a38f6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icacc4e9a05c844698340e3f6ee1020e9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie3469d1c34084c0caf63fea3b7ad7ad0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i55208f6888cb4f1aa1161cb859460aa3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i88ef2bfe4b974f9dbf50fa97b715887d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icb0138cfa605465396a47f3dd519480e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id8f1b78aab9747879b7bf25dd9a9712c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic12ec9940933424ea6839c2a0d9170e3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6e86195663524f63a9bd0a9f18bf1cbf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5eb4267dd8494bd9b9dcaabe2416461d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i654c80e71bff4d869218415b7e3dc0a0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i007cfabe3a8849bab803ba60c015eab2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3a9b7472fc7b4972acb2ac9f7cef302d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibeb578648cbe47d9949ee6e34fe0ad99_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iae37ac3f84054636b37554762cc34e63_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie46d509c4cb348eeba80e5d4d37e4475_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i439770d7fd6f4f859128c5157c9235a1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if2b42a9d8bc44f1ea40843385e1e20d1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i10967d72424a4f7791a64e8d6c259d64_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia49862c3506f4b74acff88c95716b232_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i61c8a28f6dfe4ed090fe32a6157f5e6c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i592eaf87071c432cb1c6e78bf7a7e092_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4474116f1b674daca505b919ccc95074_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i699cec09a8334f4c8b6ac965045cb456_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1ddb56fada71460eba444fd3d97f4b69_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib57d06337718492f9cfef217012538ee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4fd315b303184968b952d7bb6d9c6472_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8e1a8fc8f38c4c8aa7c1dae7f202b3b4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idec09e5a03864099989354c76b828527_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i31b04184eff74bf4b5192930aacadfec_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i26120348d6074f35b090ebbda6b3fcf0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifc55062153d94ad7b8d61e6d19057c50_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if47e96c65cb74988b1f42acee047add6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2d61b3503a4e475e8484e3f0377b2a11_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibf22fe030fdf4397978434417c7b8788_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i23f85f7c13a54d018aba01edd3e7dbf6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i69926a6399c34cf885a190c0d20df7f3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib5a5bad1ec804fe58946f735c8b3b59a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3416e3592d234d7aa0dc1a6d0c4492e2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if164f03cdc61491492728ca7e7517143_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7a0f1b836d0749b486fff5c035616613_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i19826127b8b3400a9e18b46be425bc61_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6ce1cf497c004f079441d676651e2808_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8373d29f581740ec8093f00de6a55275_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id96df92d50994507814aa00688b39486_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iedb24ff2ca7b44618a98e55d5e02fb8a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i170c112de5b842e4b59047014a54dcc0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9fc84fce9b6f4f4494703d493708167e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i607d3acd1b9a45c49ba0983930259c41_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i738cf7daafb54a76adcadab34123ba8f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8e243caf058841239f5b24d4011ad3df_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i202b3b88d9ac4d138f5675ec9220d37e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4971e09f913f4c90bd8fd83e1d0fcd54_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia3f57bcb850140d7aa4beb063512caf3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idd3d786e58da41c8ab668363ea9b72d4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie68e2d5dfa5744d28e808e7184b1ac64_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1910f568982940418f0b3f4ef8742b36_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iea06eb619bca46279cd1e26fd668574c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i35bad398da4e4adb94afe6a3edc6fbd6_D20170502-20170502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-02</startDate>
            <endDate>2017-05-02</endDate>
        </period>
    </context>
    <context id="id330e3069fc840d18f4175221a90fd47_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i48eccd3ba1b3454495acdad169d5d6f5_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i629ba4e4ef664986a91d0ae915e45857_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibb0ec417ca564717bb097aa83567533a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i601493722ddc4060955049e1e99ec96e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iaee95a0d57144ecaa3a678d3909bf7b2_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9bf8e6cfdf3742479b08b59beb60be53_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i48dd18e80c3e4426a4bf9c87e59b2aa4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic5ecf9e10df34a7a853f2e59470d0f7f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i17f7971a67b44e4798fe7f7d49131fe4_D20170502-20170502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbix:DebtInstrumentConversionAxis">nbix:ConversionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-02</startDate>
            <endDate>2017-05-02</endDate>
        </period>
    </context>
    <context id="if30740e0928241cb97cfb0ed6563a982_I20170502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbix:DebtInstrumentConversionAxis">nbix:ConversionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-02</instant>
        </period>
    </context>
    <context id="ibfcb863f462042bbaf5db27efbc920d6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbix:DebtInstrumentConversionAxis">nbix:ConversionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i134fefee8f064cab9634e36d3fc21cfa_D20170502-20170502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbix:DebtInstrumentConversionAxis">nbix:ConversionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-02</startDate>
            <endDate>2017-05-02</endDate>
        </period>
    </context>
    <context id="i18d39a0874004a4dbfac9a59054c0309_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if6282ace541846298e168b3652f98351_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibfdc712fb9f342aca6ae054a16698cef_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib36cc15a97d94e96a193bf977c9bcc64_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1cfcd3b4d7074f90897906a633ffcd5c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iad805873aae044c699ba94c98221a05f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nbix:ScientificEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8a4a256d6b68420ca9418a64a947bc8b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nbix:ScientificEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if5947e62d00f451eb3a24072ec5328d8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0d163cbc8c3d4cef88df04d4844d353c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3ae1d4d52be44bc3bc2ba9cfc000d178_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3f931f023a9b4e74be1c9df8a59da030_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic7d26b322bb24bff8ec6e47dcf836515_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nbix:StockOptionsRestrictedStockAndConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idaf8254dea124bfb9e7456439c9c6107_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nbix:StockOptionsRestrictedStockAndConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if2bedeff3c8c43e6a805d773f9fd4669_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nbix:StockOptionsRestrictedStockAndConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i25f7e10858b24f7fae2103c935cfd949_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nbix:Amended2020EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i213982ce809548e292c18f6215fa9e6b_D20220518-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nbix:Amended2020EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-18</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id479e592bc6b4c9fb00c946120287b70_I20110531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nbix:TwoThousandAndElevenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-05-31</instant>
        </period>
    </context>
    <context id="i695a8fab0f384006baa1447f58213de8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nbix:Amended2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5bdd80fdaea2455ba085c93bafcf958a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i56babcc72eb54154a6b2bbf854d97490_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia8089736b115438bae00a39b3e804807_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if8bb02545f4e412b99ba7d4bcfab2fbd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie3dd11bd409d4809a79dea85436f4401_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i901a3c0cc12a478b90f47154a36d3711_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic6946e8304b548468ab27182f7a4d25b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic7178f777b084a969408727f29c9743f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i85732a5f6db74d908155c57c3c4f6f54_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic76478c478fb48838837717f4d08aac5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i45d277e0630f42518902ef7c75a787b7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibb26118589cd4a7f9365abf100167588_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i87dac2801c32400a82446d8538afc4cf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2383f1847c08462b992435e6a74d3b13_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4445191c2fc34a93a6035559db9ca75f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i76fab03eca0a475d8e8c0d679f6b27b8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6d5d3961550840ffb667ec48e12d4486_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9983074f75e943bf8e1b6ffe1be8dfaa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if0960363045f4c3fa3cbebd5f5dd1c92_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iab54417bdda84f5da649889184df892f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if3f2d647e6d24e838c79ec0e84ee0b98_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9b22ddd5cfee4bba8e30c82f31d98316_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i67cf3f5a803b4310944b01aeae80d081_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i60b1905034ee4ddfb0d307e7deb147c0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ife8d2c8c602c417081f5a70afe7b7414_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic887499617c2453682a9ed77390375fe_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i229630d0b4d149969094372fd9771fee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibf71df6caa1445c7a59724087fa5d3fa_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i216211ef6a3c4bf293c5a051308c8517_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i71608a5505e146ccaf00cf18ac3af453_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iec21f5b659784393b128ecb098d076d0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3cd52a694c0b4753b93edf35c2915881_D20220208-20220208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2022-02-08</startDate>
            <endDate>2022-02-08</endDate>
        </period>
    </context>
    <context id="if8d41d8e8ddc41f1ba3f1ca687d9551d_I20220208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2022-02-08</instant>
        </period>
    </context>
    <context id="ic8bcdc018b3641e5b570fb899c943e20_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5576346c88f84a9aa3ea6be5a075ead3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iced58b51ca3c40e3942fff0f7f450577_I20230108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-08</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>nbix:segment</measure>
    </unit>
    <unit id="security">
        <measure>nbix:security</measure>
    </unit>
    <unit id="d">
        <measure>utr:D</measure>
    </unit>
    <unit id="renewaloption">
        <measure>nbix:renewalOption</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV80L2ZyYWc6Zjc1ZTJmYjM0ZWU3NGIyMmFjMThjZmJlNDc4NzJkNWYvdGFibGU6MDg1NjU2MTQ1YjZjNDhjM2JhYWZmNGQ3M2FlZjdlNjYvdGFibGVyYW5nZTowODU2NTYxNDViNmM0OGMzYmFhZmY0ZDczYWVmN2U2Nl8zLTEtMS0xLTEzOTA2Mg_1e0af2c1-047f-49b2-a706-b05fd584bf82">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV80L2ZyYWc6Zjc1ZTJmYjM0ZWU3NGIyMmFjMThjZmJlNDc4NzJkNWYvdGFibGU6MDg1NjU2MTQ1YjZjNDhjM2JhYWZmNGQ3M2FlZjdlNjYvdGFibGVyYW5nZTowODU2NTYxNDViNmM0OGMzYmFhZmY0ZDczYWVmN2U2Nl80LTEtMS0xLTEzOTA2Mg_4c0ded36-9687-4059-bf67-4b1854978904">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV80L2ZyYWc6Zjc1ZTJmYjM0ZWU3NGIyMmFjMThjZmJlNDc4NzJkNWYvdGFibGU6MDg1NjU2MTQ1YjZjNDhjM2JhYWZmNGQ3M2FlZjdlNjYvdGFibGVyYW5nZTowODU2NTYxNDViNmM0OGMzYmFhZmY0ZDczYWVmN2U2Nl81LTEtMS0xLTEzOTA2Mg_b5e88375-ce37-4af3-a289-5820466f257e">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV80L2ZyYWc6Zjc1ZTJmYjM0ZWU3NGIyMmFjMThjZmJlNDc4NzJkNWYvdGFibGU6MDg1NjU2MTQ1YjZjNDhjM2JhYWZmNGQ3M2FlZjdlNjYvdGFibGVyYW5nZTowODU2NTYxNDViNmM0OGMzYmFhZmY0ZDczYWVmN2U2Nl82LTEtMS0xLTEzOTA2Mg_f52c30e8-e167-4106-89e0-504fdd35a398">0000914475</dei:EntityCentralIndexKey>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzE2LTAtMS0xLTE0NDY4Ng_07167cb8-6fd5-4735-8780-8b07212a106b">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="ifbefd953596945ebb57cb8b4260d4036_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzIyMzk4_faec3abd-c6f8-404f-adcd-432a19a48776">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="i52de095faa4e4144bb37c3dd09f49c99_D20211231-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NTk5NDY_b11908b6-457c-4872-91a0-7e1b27137ced">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="i52de095faa4e4144bb37c3dd09f49c99_D20211231-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NjA1MDc_b11908b6-457c-4872-91a0-7e1b27137ced">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="i52de095faa4e4144bb37c3dd09f49c99_D20211231-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NjA3NTA_b11908b6-457c-4872-91a0-7e1b27137ced">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="i52de095faa4e4144bb37c3dd09f49c99_D20211231-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NjEwNzc_b11908b6-457c-4872-91a0-7e1b27137ced">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:NumberOfReportableSegments
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzMvZnJhZzo4YjE2MDBjYzI4MTg0YzdlOWNiYTg4Yzg0MDZlYmNmNC90ZXh0cmVnaW9uOjhiMTYwMGNjMjgxODRjN2U5Y2JhODhjODQwNmViY2Y0XzQ3_060008ea-65f9-48d5-9445-1b304ba4094c"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzMvZnJhZzo4YjE2MDBjYzI4MTg0YzdlOWNiYTg4Yzg0MDZlYmNmNC90ZXh0cmVnaW9uOjhiMTYwMGNjMjgxODRjN2U5Y2JhODhjODQwNmViY2Y0XzQ3_601a319f-9f60-409c-bb6d-782d428d1ad0"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="i52de095faa4e4144bb37c3dd09f49c99_D20211231-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNDc2NA_b11908b6-457c-4872-91a0-7e1b27137ced">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i35bad398da4e4adb94afe6a3edc6fbd6_D20170502-20170502"
      decimals="8"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTEvZnJhZzpjZDIyOGFmMDZjMDg0NDk3YTg2ZWFlNWQ5NWUxMWQ0OC90YWJsZTpjMTZkN2IzMzU3N2E0ZmE1YmJlNzMyYjBiNGE5NmRkYS90YWJsZXJhbmdlOmMxNmQ3YjMzNTc3YTRmYTViYmU3MzJiMGI0YTk2ZGRhXzItMS0xLTEtMTM5MDYy_b2b328c1-3792-43e5-865f-adacc7c277d1"
      unitRef="number">0.00131711</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i9b22ddd5cfee4bba8e30c82f31d98316_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzIwMTc_50d14189-4f30-4d95-85d1-8b0107a221f2">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ife8d2c8c602c417081f5a70afe7b7414_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzU0OTc1NTg0OTAyMA_025ee6ff-3e68-4066-aa62-f80b858bd74f">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="if8d41d8e8ddc41f1ba3f1ca687d9551d_I20220208"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90ZXh0cmVnaW9uOjU1NzA4M2I5OTQyZTQ5ZGNiMzRhNmEyZjc1ZjExNGFjXzcxNDY4MjU1ODI4MDk_9da6dfa7-7ad5-4e15-990b-61663bd419f1">P13Y7M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpmYjg1MmU0NGUwYmY0ZDA3YTVmNjZhM2QxM2VkNmYxMC90YWJsZXJhbmdlOmZiODUyZTQ0ZTBiZjRkMDdhNWY2NmEzZDEzZWQ2ZjEwXzEwLTAtMS0xLTEzOTA2Mg_85571070-dcc5-4354-8358-dbaa0e075ba0">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGV4dHJlZ2lvbjo5NDlhN2EyZWRhZmI0ZWUyYTk5OGFlNWRjMThmOTIyY18zMjY0_e689d1fb-db1e-4205-88c8-f94dd09db2ee">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGFibGU6MzlkNDcxNDJhZDgzNDkzNzg5MzU1YzE0NmZhOWFkZWYvdGFibGVyYW5nZTozOWQ0NzE0MmFkODM0OTM3ODkzNTVjMTQ2ZmE5YWRlZl8wLTAtMS0xLTEzOTA2Mg_71393ac0-3855-402b-aa9f-5be97bcaa9d4">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGV4dHJlZ2lvbjo5NDlhN2EyZWRhZmI0ZWUyYTk5OGFlNWRjMThmOTIyY18zMjYx_2b1ea06b-18d2-4da3-96a5-da6c2153a094">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGV4dHJlZ2lvbjo5NDlhN2EyZWRhZmI0ZWUyYTk5OGFlNWRjMThmOTIyY18zMjYx_1bf46a56-9501-496e-9508-94f138614a26">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGFibGU6MzFiOWM1MGU4ODQ3NGIxNDkyNWEwZmY2OGMwZjIyOWEvdGFibGVyYW5nZTozMWI5YzUwZTg4NDc0YjE0OTI1YTBmZjY4YzBmMjI5YV8wLTAtMS0xLTEzOTA2Mg_95f85c5f-2579-4d6b-8762-bb238073a3c0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGV4dHJlZ2lvbjo5NDlhN2EyZWRhZmI0ZWUyYTk5OGFlNWRjMThmOTIyY18zMjcx_8a9d18ee-1a27-45f5-b38a-ff27583ee8bf">0-22705</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGV4dHJlZ2lvbjo5NDlhN2EyZWRhZmI0ZWUyYTk5OGFlNWRjMThmOTIyY18zMjcy_e06d5e6f-c757-442b-9523-445ed4e70f4c">NEUROCRINE BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGFibGU6NjkwNzMyYTE2YzcxNDk3YTgwM2JiZTZmYzI5ZDY4NDQvdGFibGVyYW5nZTo2OTA3MzJhMTZjNzE0OTdhODAzYmJlNmZjMjlkNjg0NF8wLTAtMS0xLTEzOTA2Mg_5874c26e-3dfd-43ee-9910-0612ffec2f29">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGFibGU6NjkwNzMyYTE2YzcxNDk3YTgwM2JiZTZmYzI5ZDY4NDQvdGFibGVyYW5nZTo2OTA3MzJhMTZjNzE0OTdhODAzYmJlNmZjMjlkNjg0NF8wLTQtMS0xLTEzOTA2Mg_c0577915-573b-450c-9e0f-d0106ba9ae29">33-0525145</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGFibGU6NjkwNzMyYTE2YzcxNDk3YTgwM2JiZTZmYzI5ZDY4NDQvdGFibGVyYW5nZTo2OTA3MzJhMTZjNzE0OTdhODAzYmJlNmZjMjlkNjg0NF8zLTAtMS0xLTEzOTA2Mg_04a888b9-b727-4de7-bf71-f1d5b34faaab">12780 El Camino Real,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGFibGU6NjkwNzMyYTE2YzcxNDk3YTgwM2JiZTZmYzI5ZDY4NDQvdGFibGVyYW5nZTo2OTA3MzJhMTZjNzE0OTdhODAzYmJlNmZjMjlkNjg0NF8zLTEtMS0xLTEzOTA2Mg_d76dd1df-0648-4fbf-abb4-8781a7f42b1a">San&#160;Diego,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGFibGU6NjkwNzMyYTE2YzcxNDk3YTgwM2JiZTZmYzI5ZDY4NDQvdGFibGVyYW5nZTo2OTA3MzJhMTZjNzE0OTdhODAzYmJlNmZjMjlkNjg0NF8zLTItMS0xLTEzOTA2Mg_cb865987-80ad-400e-b6f3-681b1195fc65">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGFibGU6NjkwNzMyYTE2YzcxNDk3YTgwM2JiZTZmYzI5ZDY4NDQvdGFibGVyYW5nZTo2OTA3MzJhMTZjNzE0OTdhODAzYmJlNmZjMjlkNjg0NF8zLTQtMS0xLTEzOTA2Mg_01a7d682-20cd-4138-9de5-4aa639ac15f1">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGV4dHJlZ2lvbjo5NDlhN2EyZWRhZmI0ZWUyYTk5OGFlNWRjMThmOTIyY18zMjYy_dd853f04-17ba-47a6-9baf-9aa422cf0274">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGV4dHJlZ2lvbjo5NDlhN2EyZWRhZmI0ZWUyYTk5OGFlNWRjMThmOTIyY18zMjcz_e5ef6d3a-1387-4f33-95fe-83dd6403d5b4">617-7600</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGFibGU6Y2ZhNDE2Y2UzMTg4NGZjNjk3NjAwNzRmMDQ3NTliZjIvdGFibGVyYW5nZTpjZmE0MTZjZTMxODg0ZmM2OTc2MDA3NGYwNDc1OWJmMl8wLTAtMS0xLTEzOTA2Mg_c8641494-4121-4b80-9606-6b8e2d58304a">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGFibGU6Y2ZhNDE2Y2UzMTg4NGZjNjk3NjAwNzRmMDQ3NTliZjIvdGFibGVyYW5nZTpjZmE0MTZjZTMxODg0ZmM2OTc2MDA3NGYwNDc1OWJmMl8wLTItMS0xLTEzOTA2Mg_d765480c-1447-43aa-aa63-4d8b76b85733">NBIX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGFibGU6Y2ZhNDE2Y2UzMTg4NGZjNjk3NjAwNzRmMDQ3NTliZjIvdGFibGVyYW5nZTpjZmE0MTZjZTMxODg0ZmM2OTc2MDA3NGYwNDc1OWJmMl8wLTQtMS0xLTEzOTA2Mg_df69a2d1-281d-4417-b26c-78c07194edac">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGV4dHJlZ2lvbjo5NDlhN2EyZWRhZmI0ZWUyYTk5OGFlNWRjMThmOTIyY18zMjY1_44ff449f-2d5d-4aa5-ac6b-39ae8fe28aa3">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGV4dHJlZ2lvbjo5NDlhN2EyZWRhZmI0ZWUyYTk5OGFlNWRjMThmOTIyY18zMjY5_09f2f3dd-6966-4f41-8f62-004bcb5bbc31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGV4dHJlZ2lvbjo5NDlhN2EyZWRhZmI0ZWUyYTk5OGFlNWRjMThmOTIyY18zMjc0_6ae967bf-529a-47a8-b6d8-803b7d4315b0">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGV4dHJlZ2lvbjo5NDlhN2EyZWRhZmI0ZWUyYTk5OGFlNWRjMThmOTIyY18zMjYz_6755f574-4014-4011-8617-9e526e1aa973">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGFibGU6NjNjN2QzOGVjNDcxNGYxOTlmN2UyZTg4ODQ4ZDNjYTIvdGFibGVyYW5nZTo2M2M3ZDM4ZWM0NzE0ZjE5OWY3ZTJlODg4NDhkM2NhMl8wLTAtMS0xLTEzOTA2Mg_8c7fa84e-29e4-4d8d-bb45-5ee784d4aa25">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGFibGU6NjNjN2QzOGVjNDcxNGYxOTlmN2UyZTg4ODQ4ZDNjYTIvdGFibGVyYW5nZTo2M2M3ZDM4ZWM0NzE0ZjE5OWY3ZTJlODg4NDhkM2NhMl8wLTEwLTEtMS0xMzkwNjI_528078ba-b90d-47f7-9562-aa20add5dcc8">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGFibGU6NjNjN2QzOGVjNDcxNGYxOTlmN2UyZTg4ODQ4ZDNjYTIvdGFibGVyYW5nZTo2M2M3ZDM4ZWM0NzE0ZjE5OWY3ZTJlODg4NDhkM2NhMl8wLTEzLTEtMS0xMzkwNjI_8333250b-7d19-42a2-8cce-65480c483f70">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGV4dHJlZ2lvbjo5NDlhN2EyZWRhZmI0ZWUyYTk5OGFlNWRjMThmOTIyY18zMjY3_7a8aed9d-d5ee-4068-bf75-b72c2819af7c">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGV4dHJlZ2lvbjo5NDlhN2EyZWRhZmI0ZWUyYTk5OGFlNWRjMThmOTIyY18zMjcw_e2fc7fce-635d-4074-a012-8d7c8a5ba899">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="ic07db2f2e87d4ef895cb2823ce1bd349_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGV4dHJlZ2lvbjo5NDlhN2EyZWRhZmI0ZWUyYTk5OGFlNWRjMThmOTIyY18yODQ0_d4b78842-10ae-4c05-bc4b-914b50754e67"
      unitRef="usd">8097146859</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i7a07412530754a858e0fecb90db3cba4_I20230131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGV4dHJlZ2lvbjo5NDlhN2EyZWRhZmI0ZWUyYTk5OGFlNWRjMThmOTIyY18yODU4_f5157723-2111-4d13-95a4-4702b525c92f"
      unitRef="shares">96587911</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xL2ZyYWc6OTQ5YTdhMmVkYWZiNGVlMmE5OThhZTVkYzE4ZjkyMmMvdGV4dHJlZ2lvbjo5NDlhN2EyZWRhZmI0ZWUyYTk5OGFlNWRjMThmOTIyY18zMjY4_53b45824-4ad4-4cfc-a6e8-f90e2d4cd0c7">Portions of the registrant&#x2019;s definitive proxy statement relating to the registrant&#x2019;s annual meeting of stockholders to be filed pursuant to Regulation 14A within 120 days following the end of the registrant&#x2019;s fiscal year ended December&#160;31, 2022 are incorporated by reference into Part III of this Form 10-K.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMDkvZnJhZzowZDE5OWE4YzRjMDU0M2UyODViZDI1OTg0M2M5ZmI1MC90YWJsZTowZDJiNjllY2VmYjI0YmM3ODc3NjliYTI4OGQ3MzZkMC90YWJsZXJhbmdlOjBkMmI2OWVjZWZiMjRiYzc4Nzc2OWJhMjg4ZDczNmQwXzEtMC0xLTEtMTM5MDYyL3RleHRyZWdpb246OTUxMDc2ODE0Nzk1NDQ0Njg4ZWY3NTE4YjU5YzRkNGNfNzE_c888568b-b882-4487-83f9-96db3a167cf1">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTIvZnJhZzo5YTY3NzcxNWZlODc0ODUwOTFhZThkYTZiZWQxNzMxNi90ZXh0cmVnaW9uOjlhNjc3NzE1ZmU4NzQ4NTA5MWFlOGRhNmJlZDE3MzE2XzEwOTk1MTE2NDI0MDc_28a766d5-ea66-46dc-af80-7e65ade0866b">Ernst&#160;&amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTIvZnJhZzo5YTY3NzcxNWZlODc0ODUwOTFhZThkYTZiZWQxNzMxNi90ZXh0cmVnaW9uOjlhNjc3NzE1ZmU4NzQ4NTA5MWFlOGRhNmJlZDE3MzE2XzEwOTk1MTE2NDI0MDg_74c79d34-3603-402b-9571-20b89c49e93c">San Diego, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzQtMS0xLTEtMTM5MDYy_7d88d2a6-a63b-4a40-b443-388987a05f81"
      unitRef="usd">262900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzQtMy0xLTEtMTM5MDYy_420e945e-8ce5-4036-ba01-4eb04d60a18d"
      unitRef="usd">340800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzUtMS0xLTEtMTM5MDYy_5c7a6eff-8cfe-4e30-813c-d3f88363beef"
      unitRef="usd">726400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzUtMy0xLTEtMTM5MDYy_57479d49-d19b-4f70-ab6e-1928400ba4da"
      unitRef="usd">370500000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzYtMS0xLTEtMTM5MDYy_ece3759d-e9f4-4ce8-b865-a1334aa80186"
      unitRef="usd">350000000.0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzYtMy0xLTEtMTM5MDYy_c5e56e86-de51-4b7a-b363-667236182ee7"
      unitRef="usd">185500000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzctMS0xLTEtMTM5MDYy_66d6b95d-0946-4546-bacf-3ec65405303e"
      unitRef="usd">35100000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzctMy0xLTEtMTM5MDYy_517095fa-3e65-4714-90d4-a6f687a328a9"
      unitRef="usd">30500000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzgtMS0xLTEtMTM5MDYy_d465a0d4-8b65-43e3-a937-925b84a10fb3"
      unitRef="usd">79100000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzgtMy0xLTEtMTM5MDYy_5e207fe6-6c06-4a1f-85ec-d2589e7d3851"
      unitRef="usd">45500000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzktMS0xLTEtMTM5MDYy_0305e29e-7114-4537-ae8f-97d29b580fac"
      unitRef="usd">1453500000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzktMy0xLTEtMTM5MDYy_00417097-878c-4f2d-936b-6b0182497258"
      unitRef="usd">972800000</us-gaap:AssetsCurrent>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzEwLTEtMS0xLTEzOTA2Mg_2431415e-0029-4217-8fd4-bd7165650d61"
      unitRef="usd">305900000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzEwLTMtMS0xLTEzOTA2Mg_b420578d-dd8e-46dc-a1d9-dc9a2f933d87"
      unitRef="usd">315100000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzExLTEtMS0xLTEzOTA2Mg_460f7283-0cb9-4640-9498-68db8de69e85"
      unitRef="usd">299400000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzExLTMtMS0xLTEzOTA2Mg_0af6b5f8-408b-44a8-88bf-0962a150d5ee"
      unitRef="usd">560700000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzEyLTEtMS0xLTEzOTA2Mg_13a653a3-735a-4a4f-97cc-3fe2aa60f203"
      unitRef="usd">87000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzEyLTMtMS0xLTEzOTA2Mg_391f4017-f2b7-4885-89b5-5e15d478cb06"
      unitRef="usd">97200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:EquitySecuritiesFvNiRestricted
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzEzLTEtMS0xLTEzOTA2Mg_c2af92ee-03b2-46f7-ad21-8648926ef58b"
      unitRef="usd">102100000</us-gaap:EquitySecuritiesFvNiRestricted>
    <us-gaap:EquitySecuritiesFvNiRestricted
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzEzLTMtMS0xLTEzOTA2Mg_bd0d83ed-0c22-434d-9726-83b6621088e9"
      unitRef="usd">63700000</us-gaap:EquitySecuritiesFvNiRestricted>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzE0LTEtMS0xLTEzOTA2Mg_15e8ba2b-02ff-4ac7-b91a-e17448ceda32"
      unitRef="usd">58600000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzE0LTMtMS0xLTEzOTA2Mg_c785f941-d105-40d0-afbd-7278fe5ddde7"
      unitRef="usd">58600000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzE1LTEtMS0xLTE1OTY3NQ_2d3a99c7-0b72-45e1-b112-538dbe4bc0f2"
      unitRef="usd">37200000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzE1LTMtMS0xLTE1OTY3NQ_41b22751-79b4-459e-89f6-23d1ea66d57d"
      unitRef="usd">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzE1LTEtMS0xLTEzOTA2Mg_a8edbf62-615e-4078-a024-0ec3c10f3dc8"
      unitRef="usd">25000000.0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzE1LTMtMS0xLTEzOTA2Mg_7eae4173-d1b3-4c6c-aa96-d256f6ed186b"
      unitRef="usd">4400000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzE2LTEtMS0xLTEzOTA2Mg_18ac2bf0-ad6a-415e-81bc-cb085fa63a08"
      unitRef="usd">2368700000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzE2LTMtMS0xLTEzOTA2Mg_07964962-98e0-4c48-b84b-3b76295feeab"
      unitRef="usd">2072500000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzIwLTEtMS0xLTEzOTA2Mg_34001b47-8ec6-475f-a2f1-6b6190dd3b73"
      unitRef="usd">347600000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzIwLTMtMS0xLTEzOTA2Mg_123640a5-8dc6-4b73-9405-670cbe78784d"
      unitRef="usd">225800000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzIxLTEtMS0xLTEzOTA2Mg_06d87f8d-6243-4452-a794-511d94d1b6c7"
      unitRef="usd">169400000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzIxLTMtMS0xLTEzOTA2Mg_f174bf38-c128-4306-a93d-910bbfbb15b1"
      unitRef="usd">0</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzIyLTEtMS0xLTEzOTA2Mg_15da109b-bdb3-4969-b684-7ac6c1486cbd"
      unitRef="usd">20700000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzIyLTMtMS0xLTEzOTA2Mg_941b8a84-9e9b-4ae2-8f4e-085e739c349d"
      unitRef="usd">20000000.0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzIzLTEtMS0xLTEzOTA2Mg_f88f82ff-4a9b-4ad0-9015-257b2a80f8a2"
      unitRef="usd">537700000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzIzLTMtMS0xLTEzOTA2Mg_1da9b122-b111-438d-8416-09e80cfd2c6b"
      unitRef="usd">245800000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzI0LTEtMS0xLTEzOTA2Mg_f33ef9ba-7a8e-4332-9ea7-86b5cb90ed70"
      unitRef="usd">0</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzI0LTMtMS0xLTEzOTA2Mg_f1146f79-daec-40ff-876c-66bf23e15a94"
      unitRef="usd">335100000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzI1LTEtMS0xLTEzOTA2Mg_4c4e08e1-2fba-43b0-b965-2083f5563d33"
      unitRef="usd">93500000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzI1LTMtMS0xLTEzOTA2Mg_b1cd2be5-4c30-40ce-85d0-91e4189cea07"
      unitRef="usd">105300000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzI2LTEtMS0xLTEzOTA2Mg_8a8ad718-44d3-44fe-980b-c8501b5a9a41"
      unitRef="usd">29700000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzI2LTMtMS0xLTEzOTA2Mg_8f10b4a0-e19c-4ea0-b7c7-bf7226d2b01f"
      unitRef="usd">12300000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzI3LTEtMS0xLTEzOTA2Mg_a5f987ac-3cc8-4c57-a210-2b5a8880a0e8"
      unitRef="usd">660900000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzI3LTMtMS0xLTEzOTA2Mg_957ed284-c779-4da4-870b-a7d1321b2e96"
      unitRef="usd">698500000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMwLTAtMS0xLTEzOTA2Mi90ZXh0cmVnaW9uOmM4N2YxZTIzMmM0MTRjYzg4MWI0NGE2NmU5MDZkMTAxXzIy_21cc254e-8df2-427d-83c4-6a60e2a301d5"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMwLTAtMS0xLTEzOTA2Mi90ZXh0cmVnaW9uOmM4N2YxZTIzMmM0MTRjYzg4MWI0NGE2NmU5MDZkMTAxXzIy_73056a57-c295-458d-bf8e-b040efdf0284"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMwLTAtMS0xLTEzOTA2Mi90ZXh0cmVnaW9uOmM4N2YxZTIzMmM0MTRjYzg4MWI0NGE2NmU5MDZkMTAxXzM2_04cb343c-613e-4f03-aedf-5997c1ecd347"
      unitRef="shares">5000000.0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMwLTAtMS0xLTEzOTA2Mi90ZXh0cmVnaW9uOmM4N2YxZTIzMmM0MTRjYzg4MWI0NGE2NmU5MDZkMTAxXzM2_a8406b56-e4e1-415a-847f-3a7a047c1549"
      unitRef="shares">5000000.0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMwLTAtMS0xLTEzOTA2Mi90ZXh0cmVnaW9uOmM4N2YxZTIzMmM0MTRjYzg4MWI0NGE2NmU5MDZkMTAxXzU4_af32f3e6-1c2f-43ff-a474-8cc1bdc22956"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMwLTAtMS0xLTEzOTA2Mi90ZXh0cmVnaW9uOmM4N2YxZTIzMmM0MTRjYzg4MWI0NGE2NmU5MDZkMTAxXzU4_cef4a5ff-c60d-4fef-8ee3-956b2f6cf355"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMwLTAtMS0xLTEzOTA2Mi90ZXh0cmVnaW9uOmM4N2YxZTIzMmM0MTRjYzg4MWI0NGE2NmU5MDZkMTAxXzU4_d1f7e0ba-fc20-4faf-a595-c51425ffc68b"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMwLTAtMS0xLTEzOTA2Mi90ZXh0cmVnaW9uOmM4N2YxZTIzMmM0MTRjYzg4MWI0NGE2NmU5MDZkMTAxXzU4_fad599ca-9be9-4664-8cbf-d796725aef8a"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMwLTEtMS0xLTEzOTA2Mg_74dcc676-231a-4507-ad6e-d18964209501"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMwLTMtMS0xLTEzOTA2Mg_396fc95e-076d-45df-a549-932fbc7bad13"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMxLTAtMS0xLTEzOTA2Mi90ZXh0cmVnaW9uOjE1ZWNhZGNhOGVhMjQ0MTk4N2EwYjk1YmEyOGRmMDQ5XzE5_bad1a00e-f1c3-487d-869d-c048dadd7d9d"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMxLTAtMS0xLTEzOTA2Mi90ZXh0cmVnaW9uOjE1ZWNhZGNhOGVhMjQ0MTk4N2EwYjk1YmEyOGRmMDQ5XzE5_fd07d181-0054-448e-bdce-9e83210e14c2"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMxLTAtMS0xLTEzOTA2Mi90ZXh0cmVnaW9uOjE1ZWNhZGNhOGVhMjQ0MTk4N2EwYjk1YmEyOGRmMDQ5XzMz_17f74f47-8cd2-482c-aa40-72c0c24c074c"
      unitRef="shares">220000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMxLTAtMS0xLTEzOTA2Mi90ZXh0cmVnaW9uOjE1ZWNhZGNhOGVhMjQ0MTk4N2EwYjk1YmEyOGRmMDQ5XzMz_78514a11-03a4-4a46-b044-37b6c698f524"
      unitRef="shares">220000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMxLTAtMS0xLTEzOTA2Mi90ZXh0cmVnaW9uOjE1ZWNhZGNhOGVhMjQ0MTk4N2EwYjk1YmEyOGRmMDQ5XzU1_c3a04999-0521-433d-be22-11ee2860050f"
      unitRef="shares">96500000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMxLTAtMS0xLTEzOTA2Mi90ZXh0cmVnaW9uOjE1ZWNhZGNhOGVhMjQ0MTk4N2EwYjk1YmEyOGRmMDQ5XzU1_f3f8661c-ed58-4931-9b51-a79d4c0100ab"
      unitRef="shares">96500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMxLTAtMS0xLTEzOTA2Mi90ZXh0cmVnaW9uOjE1ZWNhZGNhOGVhMjQ0MTk4N2EwYjk1YmEyOGRmMDQ5XzYy_332052f9-f5bf-46d6-9b63-124ff967bd4a"
      unitRef="shares">94900000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMxLTAtMS0xLTEzOTA2Mi90ZXh0cmVnaW9uOjE1ZWNhZGNhOGVhMjQ0MTk4N2EwYjk1YmEyOGRmMDQ5XzYy_9ec3e64f-6523-44f8-b07f-b3b0f18603dc"
      unitRef="shares">94900000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMxLTEtMS0xLTEzOTA2Mg_ba281561-1b27-4083-ab00-f4e56f8b4ebf"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMxLTMtMS0xLTEzOTA2Mg_79e5e9b8-d8cc-4b2b-bc8a-90f0401b5565"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMyLTEtMS0xLTEzOTA2Mg_609a0e6b-6d56-43a6-b895-582a6edee966"
      unitRef="usd">2122400000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMyLTMtMS0xLTEzOTA2Mg_7c2e2a72-7ff5-4142-8445-a7eddf2eaae2"
      unitRef="usd">2011400000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMzLTEtMS0xLTEzOTA2Mg_909f568e-007b-4b96-8adf-62562f1c8686"
      unitRef="usd">-7900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzMzLTMtMS0xLTEzOTA2Mg_5cc81d9c-61dd-4060-92db-ba9d638733b4"
      unitRef="usd">-1700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzM0LTEtMS0xLTEzOTA2Mg_dcde9ced-d4ed-4520-8cbb-a92680738a08"
      unitRef="usd">-406800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzM0LTMtMS0xLTEzOTA2Mg_aa7848b1-bd99-4372-ae2b-bb374d67353d"
      unitRef="usd">-635800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzM1LTEtMS0xLTEzOTA2Mg_f35d34e8-762e-4ac4-92c2-4672df479068"
      unitRef="usd">1707800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzM1LTMtMS0xLTEzOTA2Mg_830b272e-4a42-4c9b-84b5-b9ab9d660a7d"
      unitRef="usd">1374000000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzM2LTEtMS0xLTEzOTA2Mg_d1a56d1e-3040-468e-9a12-aecf45951e94"
      unitRef="usd">2368700000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTUvZnJhZzowNzk1NjU3NTNlZmQ0Zjk0YTk1YjY3ZmI4MTJjMjFhMi90YWJsZTowMzI0NTNhYzE5Mjg0NDZlYjcwYzRkZGI5MDI3YzM4Ny90YWJsZXJhbmdlOjAzMjQ1M2FjMTkyODQ0NmViNzBjNGRkYjkwMjdjMzg3XzM2LTMtMS0xLTEzOTA2Mg_831b67e4-1b84-4224-b7c8-e67d11065fd6"
      unitRef="usd">2072500000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5fc4cf231a09409ca4f633d2a52d1059_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzMtMS0xLTEtMTM5MDYy_f30af27e-ed42-41b7-b440-514b36bc5c11"
      unitRef="usd">1440900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib02b2e314d9843b6beb8c5b163f3331b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzMtMy0xLTEtMTM5MDYy_d5366caa-9132-46c4-9ab5-ffdb2171cb02"
      unitRef="usd">1090100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieadd249b6bd54f3f882b31ca68b01cd6_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzMtNS0xLTEtMTM5MDYy_6de3df9a-2c06-4342-a186-401a122417c0"
      unitRef="usd">994100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i639fef176a3f4b5ca32c8c373750fe46_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzQtMS0xLTEtMTM5MDYy_9bbf3b2b-a317-43b4-94be-ae06c4b87288"
      unitRef="usd">47800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic3a57832bc8048d593cd85c6dc2a6362_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzQtMy0xLTEtMTM5MDYy_6b3b6ca5-a4aa-4eae-9c3a-6a67c9eadb2f"
      unitRef="usd">43400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia6e4c87aa559406d86302c9502431650_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzQtNS0xLTEtMTM5MDYy_a230a769-1305-4a9e-b630-bb97ff98f225"
      unitRef="usd">51800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzUtMS0xLTEtMTM5MDYy_5b0b9a15-7eaf-4219-856a-78f21e6399de"
      unitRef="usd">1488700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzUtMy0xLTEtMTM5MDYy_b8bf14fe-673d-49aa-83bd-efcf4e86c404"
      unitRef="usd">1133500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzUtNS0xLTEtMTM5MDYy_467e0cc5-1958-4695-be88-271b271c38e5"
      unitRef="usd">1045900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzctMS0xLTEtMTM5MDYy_268bf74a-eabd-443a-ae34-42c712bf2b9e"
      unitRef="usd">23200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzctMy0xLTEtMTM5MDYy_1cadd107-6ead-4a23-8478-688ffd1d9918"
      unitRef="usd">14300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzctNS0xLTEtMTM5MDYy_94d9a669-bdfe-4506-beb6-bcb4c1031c02"
      unitRef="usd">10100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzgtMS0xLTEtMTM5MDYy_5a9120b2-1841-4f74-a80c-5f8d7f603ed6"
      unitRef="usd">463800000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzgtMy0xLTEtMTM5MDYy_b638a411-6b2c-4c3b-90b3-48931b4283ea"
      unitRef="usd">328100000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzgtNS0xLTEtMTM5MDYy_0ff13715-af8a-4434-ab66-3674855b5ec2"
      unitRef="usd">275000000.0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzktMS0xLTEtMTM5MDYy_738d76a6-550d-4d26-bdb3-ed30fb0b9a75"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzktMy0xLTEtMTM5MDYy_747c2aa8-9ffe-4eef-b4e0-924337bc4c90"
      unitRef="usd">105300000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzktNS0xLTEtMTM5MDYy_ddb3a0e8-f4a5-491f-86da-a05910a23b53"
      unitRef="usd">164500000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzEwLTEtMS0xLTEzOTA2Mg_f824d1be-6688-435a-84e1-c21fa91b7523"
      unitRef="usd">752700000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzEwLTMtMS0xLTEzOTA2Mg_c1c6d886-4ce6-4e55-8f68-bb5d95595d5a"
      unitRef="usd">583300000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzEwLTUtMS0xLTEzOTA2Mg_424b59df-e3db-435f-83a0-925e5371f7fa"
      unitRef="usd">433300000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzExLTEtMS0xLTEzOTA2Mg_c36fd5d8-4a48-4fc8-b4da-c4d4bdc0ee41"
      unitRef="usd">1239700000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzExLTMtMS0xLTEzOTA2Mg_6e27c5b6-5aba-4f02-be80-bf7feee68851"
      unitRef="usd">1031000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzExLTUtMS0xLTEzOTA2Mg_28e25748-9ce7-42e7-8173-5da14ad4a36f"
      unitRef="usd">882900000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzEyLTEtMS0xLTEzOTA2Mg_d410cba1-beed-4fc1-93e5-c6156fb77215"
      unitRef="usd">249000000.0</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzEyLTMtMS0xLTEzOTA2Mg_7eea631e-69d7-4fd7-a7c3-62efda208246"
      unitRef="usd">102500000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzEyLTUtMS0xLTEzOTA2Mg_21cffb17-8028-4157-8800-1acaf7ca5a09"
      unitRef="usd">163000000.0</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzE0LTEtMS0xLTEzOTA2Mg_b8483a90-19fa-48d6-af3a-6d00bf4d7d4c"
      unitRef="usd">7100000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzE0LTMtMS0xLTEzOTA2Mg_eaee69d6-15b9-414d-bceb-11e7031bc76f"
      unitRef="usd">25800000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzE0LTUtMS0xLTEzOTA2Mg_c0974d9b-5e66-4284-9e1f-4b68f1b40e6f"
      unitRef="usd">32800000</us-gaap:InterestExpense>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzE1LTEtMS0xLTEzOTA2Mg_f143cb61-9d78-435d-b765-096135e8495f"
      unitRef="usd">30800000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzE1LTMtMS0xLTEzOTA2Mg_0eb43425-7811-46ed-a21b-36b559fe539a"
      unitRef="usd">20900000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzE1LTUtMS0xLTEzOTA2Mg_dd83d60c-1638-4953-a8a0-b525710f626e"
      unitRef="usd">-17700000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzE2LTEtMS0xLTEzOTA2Mg_ec9f7e1d-c2bc-4e95-a6b5-62494f218ea4"
      unitRef="usd">-70000000.0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzE2LTMtMS0xLTEzOTA2Mg_eec6223a-211c-440d-9ace-e344a32ed4a2"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzE2LTUtMS0xLTEzOTA2Mg_74d3c9af-e985-413a-b619-8fcd71c48424"
      unitRef="usd">-18400000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <nbix:InvestmentIncomeAndOtherNet
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzE3LTEtMS0xLTEzOTA2Mg_8efa2674-7ad3-43f4-8b48-273ba8cfa093"
      unitRef="usd">11200000</nbix:InvestmentIncomeAndOtherNet>
    <nbix:InvestmentIncomeAndOtherNet
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzE3LTMtMS0xLTEzOTA2Mg_2469bf01-8d10-4dfc-b4e7-61ea74be81ca"
      unitRef="usd">3800000</nbix:InvestmentIncomeAndOtherNet>
    <nbix:InvestmentIncomeAndOtherNet
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzE3LTUtMS0xLTEzOTA2Mg_094aa4df-8395-469f-a8b8-4787068878ab"
      unitRef="usd">12600000</nbix:InvestmentIncomeAndOtherNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzE4LTEtMS0xLTEzOTA2Mg_b6448f16-5a73-498c-a07c-8473a173fd95"
      unitRef="usd">-35100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzE4LTMtMS0xLTEzOTA2Mg_e73834e5-b790-4198-940d-6d58efee42aa"
      unitRef="usd">-1100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzE4LTUtMS0xLTEzOTA2Mg_85988397-60a9-4bf8-8736-00400bd3ada6"
      unitRef="usd">-56300000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzE5LTEtMS0xLTEzOTA2Mg_49fe5997-d12a-4295-8638-4a9b1dd02c41"
      unitRef="usd">213900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzE5LTMtMS0xLTEzOTA2Mg_59bf6390-5d42-4945-b432-6edf1f7671b6"
      unitRef="usd">101400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzE5LTUtMS0xLTEzOTA2Mg_1bf9fd98-32ce-452d-b9e7-0547ad49f911"
      unitRef="usd">106700000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzIwLTEtMS0xLTEzOTA2Mg_5040c680-3725-4528-8446-4e64d4d42291"
      unitRef="usd">59400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzIwLTMtMS0xLTEzOTA2Mg_7753ed81-d031-471b-99ec-7cc54f313ccf"
      unitRef="usd">11800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzIwLTUtMS0xLTEzOTA2Mg_cb3d7e03-e08d-44a9-b871-22f4a438f275"
      unitRef="usd">-300600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzIxLTEtMS0xLTEzOTA2Mg_9bd0d171-904d-45de-8d6b-84402cc9d6da"
      unitRef="usd">154500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzIxLTMtMS0xLTEzOTA2Mg_c64a57e9-11a3-4c67-8b0e-6664bbfc6058"
      unitRef="usd">89600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzIxLTUtMS0xLTEzOTA2Mg_7f691186-d086-4293-945a-b6caa0a58729"
      unitRef="usd">407300000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzIyLTEtMS0xLTE1NDk0OA_91de403b-5ca8-4f66-b4ae-afbddbafdf59"
      unitRef="usd">-2900000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzIyLTMtMS0xLTE1NDk1NQ_fe521fab-5ae4-4e2f-af9f-d4cbb3f4ffb5"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzIyLTUtMS0xLTE1NDk1OQ_e48a355e-6025-40fe-8841-7118aadb5e9b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzIyLTEtMS0xLTEzOTA2Mg_211d682f-50b7-4e1e-992c-b7b7eef13dd6"
      unitRef="usd">-9100000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzIyLTMtMS0xLTEzOTA2Mg_aa05c4e2-20de-45ff-bae9-023a4183c00d"
      unitRef="usd">-3500000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzIyLTUtMS0xLTEzOTA2Mg_363ac106-029f-4d96-8bc0-ed8323a83a52"
      unitRef="usd">400000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzIzLTEtMS0xLTEzOTA2Mg_3934fa46-df99-4573-b56f-b45810690655"
      unitRef="usd">148300000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzIzLTMtMS0xLTEzOTA2Mg_c4f7a149-5d15-4e8c-9319-4dc24c2255cb"
      unitRef="usd">86100000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzIzLTUtMS0xLTEzOTA2Mg_c0bdfeb3-b842-4c97-9c40-35e2ec6c98ce"
      unitRef="usd">407700000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzI0LTEtMS0xLTEzOTA2Mg_9064c675-4e97-4adf-b9dd-cf61acec71ba"
      unitRef="usdPerShare">1.61</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzI0LTMtMS0xLTEzOTA2Mg_93d441bd-4cae-43be-8fe4-bef6e6300a6c"
      unitRef="usdPerShare">0.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzI0LTUtMS0xLTEzOTA2Mg_072a1952-0bdc-44a6-b6ea-4072420e4406"
      unitRef="usdPerShare">4.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzI1LTEtMS0xLTEzOTA2Mg_8928e5d4-698c-4378-8bf5-83345173c666"
      unitRef="usdPerShare">1.56</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzI1LTMtMS0xLTEzOTA2Mg_04095a57-8df9-4fac-a608-464178dd13be"
      unitRef="usdPerShare">0.92</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzI1LTUtMS0xLTEzOTA2Mg_51b183cd-dc26-481a-8af2-16aef2767941"
      unitRef="usdPerShare">4.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzI2LTEtMS0xLTEzOTA2Mg_6bbfb488-0fc2-4a55-81cb-d5edb09ec681"
      unitRef="shares">95800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzI2LTMtMS0xLTEzOTA2Mg_5edf2d70-4720-49d4-b207-775af8225833"
      unitRef="shares">94600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzI2LTUtMS0xLTEzOTA2Mg_1f62954e-f575-4d25-b9b3-96ed26a018b5"
      unitRef="shares">93100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzI3LTEtMS0xLTEzOTA2Mg_7621b5b2-3226-47c7-9698-6f24388a692e"
      unitRef="shares">98900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzI3LTMtMS0xLTEzOTA2Mg_b5845dc5-95cc-4086-a30a-a0281eb367e1"
      unitRef="shares">97900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMTgvZnJhZzo0MzFjYjRmZjQwNWQ0MGMwYjc4YWUxOWQ4YTg2MzJhZC90YWJsZTowYTJhMGYzOGNkOGE0MmJlOGJhN2U1ODFmYWNlNmU0Ni90YWJsZXJhbmdlOjBhMmEwZjM4Y2Q4YTQyYmU4YmE3ZTU4MWZhY2U2ZTQ2XzI3LTUtMS0xLTEzOTA2Mg_e53aff8f-ad04-4c40-abb8-b6b8325e6259"
      unitRef="shares">97800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="i5487fc19d1994eb39121318350a3e13a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzItMS0xLTEtMTM5MDYy_0338f6d5-bfe9-496a-8748-dfd4cd3ba422"
      unitRef="shares">92300000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5487fc19d1994eb39121318350a3e13a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzItMy0xLTEtMTM5MDYy_2b980438-5245-41d2-9ffa-844ee4941425"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie0742d6ae0d04338b0b3b537053da2dd_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzItNS0xLTEtMTM5MDYy_ae1a34fb-49c0-4fd4-81e8-6552ba05f8ca"
      unitRef="usd">1768100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i925cca476463400d82eec5ed1c25941d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzItNy0xLTEtMTM5MDYy_53a3883a-b83b-4dae-9343-e8e6ef0adb17"
      unitRef="usd">1400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4a17ccdbf08849ba857638d5a36314ed_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzItOS0xLTEtMTM5MDYy_565dc8fd-39e2-414c-ba98-7c391fc0a27c"
      unitRef="usd">-1132700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie9e7a539304246b48b58f35e4a888e14_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzItMTEtMS0xLTEzOTA2Mg_0b946f47-f9d5-4882-87d6-f5388054436b"
      unitRef="usd">636900000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ib9a3f2cd6f5941a6bcecb7ae1f54d627_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzMtOS0xLTEtMTM5MDYy_788d83aa-b1c7-4506-958a-6b20047207a7"
      unitRef="usd">407300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzMtMTEtMS0xLTEzOTA2Mg_49de1a07-83ec-4f64-91f0-314cdde487da"
      unitRef="usd">407300000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i5fe0390d99064b149bfb4f7d84cd1ab2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzQtNy0xLTEtMTM5MDYy_27de39f8-805b-4791-9533-4d9e303fa689"
      unitRef="usd">400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzQtMTEtMS0xLTEzOTA2Mg_be379a94-2cd7-4dd0-9f2f-8af733c71792"
      unitRef="usd">400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6d19e967388d41128ce3a6f556f600be_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzUtNS0xLTEtMTM5MDYy_5222e7ae-e4ad-480e-95f8-077aaa878511"
      unitRef="usd">100000000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzUtMTEtMS0xLTEzOTA2Mg_ddc423c6-ee57-423f-8bef-4263c10bf653"
      unitRef="usd">100000000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments
      contextRef="i6d19e967388d41128ce3a6f556f600be_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzYtNS0xLTEtMTM5MDYy_5ecc9df6-752b-46ff-a6ed-ba7aff22ce92"
      unitRef="usd">47500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzYtMTEtMS0xLTEzOTA2Mg_69dc0ad8-d88f-4fc5-a6b4-509a1e82bdf9"
      unitRef="usd">47500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ie0ee7b0ff1c946b390b1cd119381b62f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzctMS0xLTEtMTM5MDYy_94e75899-bd98-426a-a7aa-6f41d9b3a9db"
      unitRef="shares">1200000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6d19e967388d41128ce3a6f556f600be_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzctNS0xLTEtMTM5MDYy_0585f49a-8ca6-4b6f-82b5-405ebf62131e"
      unitRef="usd">29100000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzctMTEtMS0xLTEzOTA2Mg_c37488ae-cca9-4abb-a15e-41b5852eab41"
      unitRef="usd">29100000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="ie1660cd4b7b54e359345103c0e942aa8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzgtMS0xLTEtMTM5MDYy_0d57119e-5bce-4ff8-8026-4902c090671d"
      unitRef="shares">93500000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ie1660cd4b7b54e359345103c0e942aa8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzgtMy0xLTEtMTM5MDYy_e0443bc2-b348-4aa3-9b2b-dedef92878fd"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8f63238a40484e0ab018374a8829b7a0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzgtNS0xLTEtMTM5MDYy_ad23f674-35c2-46bf-b325-9e4609f0f677"
      unitRef="usd">1849700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i78e8a22fcfd640478484ade7992b19eb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzgtNy0xLTEtMTM5MDYy_e358f8cb-c3ee-4b35-8491-b4cc4c1d17a0"
      unitRef="usd">1800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5f7dfb474ad94c65bc4bb9ac91172dc9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzgtOS0xLTEtMTM5MDYy_73338f62-aa83-4440-a86d-c253a95b16b9"
      unitRef="usd">-725400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8a88ab4de251408db4aa98552134a56a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzgtMTEtMS0xLTEzOTA2Mg_6d5b8123-1efc-4240-8bb3-16abb29b411d"
      unitRef="usd">1126200000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="id7e33c1feaa549568d96ca0b5a1289e4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzktOS0xLTEtMTM5MDYy_d08b26c8-6cee-4ec3-b32e-28649a7f8f2c"
      unitRef="usd">89600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzktMTEtMS0xLTEzOTA2Mg_f9b05340-fb85-4f79-bb78-102b8107caec"
      unitRef="usd">89600000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6eb7229899cc4ef8a964dc3ed073c87c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzEwLTctMS0xLTEzOTA2Mg_b52af0de-540d-42ee-ac75-ad336dcd5e10"
      unitRef="usd">-3500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzEwLTExLTEtMS0xMzkwNjI_3b90b59f-718d-4155-8530-8b20fe2cecaa"
      unitRef="usd">-3500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5a5dcf16fd4c454093a5adc50ec3dbf4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzExLTUtMS0xLTEzOTA2Mg_d3319fbd-ed04-44bd-9d97-258bd0235b1b"
      unitRef="usd">134200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzExLTExLTEtMS0xMzkwNjI_d04233a4-f85e-4cd8-80b2-cbfb91a96aed"
      unitRef="usd">134200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i7839db0dc61d4c4e8853cf6e19e54d9a_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzEyLTEtMS0xLTEzOTA2Mg_a4b66bb1-de46-47a4-9ad0-1d968c692190"
      unitRef="shares">1400000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5a5dcf16fd4c454093a5adc50ec3dbf4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzEyLTUtMS0xLTEzOTA2Mg_a4d7d1ba-6fc7-484d-b521-d21139bd4369"
      unitRef="usd">27500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzEyLTExLTEtMS0xMzkwNjI_1c25b08d-74e9-48ab-a16f-6b1c73c90a4c"
      unitRef="usd">27500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="i5b99420940c34cd38a2ca2831819f03a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzEzLTEtMS0xLTEzOTA2Mg_99c3562c-24d6-4a37-b734-dbbeb5f7714b"
      unitRef="shares">94900000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5b99420940c34cd38a2ca2831819f03a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzEzLTMtMS0xLTEzOTA2Mg_a7cee5b1-83be-4722-b07f-f2111ca20517"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic68171adb3f24de9bed3bd6b62a8b5f1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzEzLTUtMS0xLTEzOTA2Mg_ac9c7a18-82fe-44ca-9681-18caf2e4c02d"
      unitRef="usd">2011400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1431ff2fdef24f178c1a21ede2c5c504_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzEzLTctMS0xLTEzOTA2Mg_1f69ff25-f300-45c2-b948-a64d9654734a"
      unitRef="usd">-1700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i72e83c4aadc74dfe9f04f4780dec95d0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzEzLTktMS0xLTEzOTA2Mg_45e244ac-50a2-4374-8cd8-4228327e67ec"
      unitRef="usd">-635800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzEzLTExLTEtMS0xMzkwNjI_a5521df2-9e3a-47ee-bc2a-df2693699688"
      unitRef="usd">1374000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ie5ed360a12ed4ff2b4e907ef5bc21e00_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzE0LTktMS0xLTEzOTA2Mg_2b9fa284-e3af-4cec-8caa-5bfcca7f2457"
      unitRef="usd">154500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzE0LTExLTEtMS0xMzkwNjI_4b6c8771-0e5b-4aef-b964-36055062e2e6"
      unitRef="usd">154500000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="icd0f70dc50c24e3ebdef035671ebad8d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzE1LTctMS0xLTEzOTA2Mg_906ef4ff-63a1-4e68-aa4c-e723cba1c057"
      unitRef="usd">-6200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzE1LTExLTEtMS0xMzkwNjI_2b9f45e0-9821-4650-bf90-51d25f23adf9"
      unitRef="usd">-6200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i6110ec902f424e9786d861ac3a49b372_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzE2LTUtMS0xLTE0NDI5OA_bf961e78-d933-4e82-8d25-256d2d135181"
      unitRef="usd">-106800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia89fc8fb19434c28a5b37e944ef95c17_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzE2LTktMS0xLTE0NDMwMQ_4f265b26-5d55-43c3-be2a-fa63ed73990d"
      unitRef="usd">74500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ica83f9a3025b4dce8f0663374896f3ea_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzE2LTExLTEtMS0xNDQzMDE_474a53be-7a7d-429b-b719-093a3b81f7a3"
      unitRef="usd">-32300000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i90432f146b89477b90abd98f33694f6b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzE2LTUtMS0xLTEzOTA2Mg_f0489695-5b3b-4c33-b5f5-432bb9eabf59"
      unitRef="usd">173100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzE2LTExLTEtMS0xMzkwNjI_140f3c07-7cb1-41cb-8edd-1e44876ed26d"
      unitRef="usd">173100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i9398bcb69b16420d9cf3703d6c3c8b15_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzE3LTEtMS0xLTEzOTA2Mg_b5175d6a-e588-4efe-bb13-4a3b6c236174"
      unitRef="shares">1600000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i90432f146b89477b90abd98f33694f6b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzE3LTUtMS0xLTEzOTA2Mg_4d42633b-0a41-4e11-a299-5a90d0b9d28e"
      unitRef="usd">44700000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzE3LTExLTEtMS0xMzkwNjI_99783052-7458-44a6-84e3-1cee714cbf26"
      unitRef="usd">44700000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="i2faddbeacae241608429e772b0492fe7_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzE4LTEtMS0xLTEzOTA2Mg_bb732e81-1a6a-4aad-ae77-948c5d5404bc"
      unitRef="shares">96500000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2faddbeacae241608429e772b0492fe7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzE4LTMtMS0xLTEzOTA2Mg_dce960e9-4c76-4b43-9b08-9521a87e9b8a"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie5989ae77b9e4f9bab21d80812e7179d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzE4LTUtMS0xLTEzOTA2Mg_67e2b298-f578-4fc0-a509-447b155c0c8f"
      unitRef="usd">2122400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i423520348d804b1da2a2f946632d1239_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzE4LTctMS0xLTEzOTA2Mg_3b962dec-2652-4419-a307-3338440c141b"
      unitRef="usd">-7900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2b9ae80dc18341fabe82e98052d1b03a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzE4LTktMS0xLTEzOTA2Mg_95366976-9566-46da-8f9c-003e139b452c"
      unitRef="usd">-406800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjEvZnJhZzo1NTkzMjdlYjZhMzA0ZDMzOTAyYzNiOTZhNGY5ZGE1OS90YWJsZTo4YmI1Y2U0MDcxZDA0YTUwOTJlNzRjZDdiZTM3YTU4MS90YWJsZXJhbmdlOjhiYjVjZTQwNzFkMDRhNTA5MmU3NGNkN2JlMzdhNTgxXzE4LTExLTEtMS0xMzkwNjI_940a40c5-fcce-447e-af9b-08cdb5bebe94"
      unitRef="usd">1707800000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzMtMS0xLTEtMTM5MDYy_49a26619-acb3-42f8-a265-a0e3211a2d83"
      unitRef="usd">154500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzMtMy0xLTEtMTM5MDYy_91f2df98-0ad8-47f5-90f0-d579cd028857"
      unitRef="usd">89600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzMtNS0xLTEtMTM5MDYy_d99fd5dd-fa21-4016-b855-7e5ed0f8a887"
      unitRef="usd">407300000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzUtMS0xLTEtMTM5MDYy_607988c6-90ab-48f5-88f7-2f8f2be883e3"
      unitRef="usd">173100000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzUtMy0xLTEtMTM5MDYy_0e7887c8-ce7b-4abb-ac75-50696747cab9"
      unitRef="usd">134200000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzUtNS0xLTEtMTM5MDYy_8e8b5604-f4ec-4e7a-b626-23df2808cd81"
      unitRef="usd">100000000.0</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzYtMS0xLTEtMTM5MDYy_5cb75860-0308-4acf-b27a-256b1b6553e4"
      unitRef="usd">15100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzYtMy0xLTEtMTM5MDYy_cb280b56-60c8-411b-a84e-c46e20279b61"
      unitRef="usd">10900000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzYtNS0xLTEtMTM5MDYy_088ac90f-afd3-4003-b1a2-962248beddf4"
      unitRef="usd">8600000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzctMS0xLTEtMTM5MDYy_1929737d-9d04-4eb3-85c2-dd37fb135ab0"
      unitRef="usd">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzctMy0xLTEtMTM5MDYy_46a4570d-2524-4268-b182-bdae5eef979e"
      unitRef="usd">16200000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzctNS0xLTEtMTM5MDYy_73800a04-d6a8-4fa6-957d-248301349463"
      unitRef="usd">20000000.0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzgtMS0xLTEtMTM5MDYy_78618dc5-ec6e-4e40-af89-0dbd0d18ea73"
      unitRef="usd">1200000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzgtMy0xLTEtMTM5MDYy_4fff50e5-c852-4664-9bf6-20bcccea9af8"
      unitRef="usd">1100000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzgtNS0xLTEtMTM5MDYy_6bed529d-0311-4299-afa0-9d7e2e44fef4"
      unitRef="usd">1400000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzktMS0xLTEtMTQ0Njg4_aac17e89-9b71-4146-b442-97b8b96e03ca"
      unitRef="usd">500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzktMy0xLTEtMTQ0Njg4_28e496f3-ad43-4cee-a65d-80b4b761b519"
      unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzktNS0xLTEtMTQ0Njg4_67a84755-f1bd-44ab-b8cd-5f88381f2ac6"
      unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzktMS0xLTEtMTM5MDYy_304f1a78-a492-499b-8203-2bc41f223125"
      unitRef="usd">30800000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzktMy0xLTEtMTM5MDYy_25e98bcc-3d69-469b-949e-46ffe608fd17"
      unitRef="usd">20900000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzktNS0xLTEtMTM5MDYy_45f24f89-6a57-4d44-afa8-5d4e95fbdfb9"
      unitRef="usd">-17700000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzEwLTEtMS0xLTEzOTA2Mg_2fb96d71-5fba-46a0-a80d-cddc342d9f9a"
      unitRef="usd">19100000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzEwLTMtMS0xLTEzOTA2Mg_7fbc892f-38df-4244-a074-383e2d099007"
      unitRef="usd">4300000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzEwLTUtMS0xLTEzOTA2Mg_62e5cf8b-c15d-431b-b7db-bbe10e059317"
      unitRef="usd">-310700000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzExLTEtMS0xLTEzOTA2Mg_ad16e86c-8327-49bf-a317-f2f5159b7d0a"
      unitRef="usd">-70000000.0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzExLTMtMS0xLTEzOTA2Mg_21da8804-0145-47d1-b465-5468b3c88f1e"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzExLTUtMS0xLTEzOTA2Mg_9783336f-8c1c-4a96-88ec-f07fcc548e65"
      unitRef="usd">-18400000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzEyLTEtMS0xLTEzOTA2Mg_bc7574c4-526a-4cab-9164-4826181551d1"
      unitRef="usd">4100000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzEyLTMtMS0xLTEzOTA2Mg_f61378f3-408a-4d98-8b0b-f7a6d858b329"
      unitRef="usd">4400000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzEyLTUtMS0xLTEzOTA2Mg_7a142865-0165-4d3c-bea6-35c0419cb5c1"
      unitRef="usd">3700000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzE0LTEtMS0xLTEzOTA2Mg_3e3763bc-090c-40df-9833-dcf59e684a1d"
      unitRef="usd">162200000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzE0LTMtMS0xLTEzOTA2Mg_8559ea87-8d20-41fb-8bff-8d44484cbe32"
      unitRef="usd">28400000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzE0LTUtMS0xLTEzOTA2Mg_65797047-bb7a-437f-b076-ab3154b806f1"
      unitRef="usd">30500000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzE1LTEtMS0xLTEzOTA2Mg_8de08df2-54d5-4213-b062-aa3b19440d12"
      unitRef="usd">2600000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzE1LTMtMS0xLTEzOTA2Mg_21d402d8-dbf3-4f56-b1f6-def4b43099d0"
      unitRef="usd">2500000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzE1LTUtMS0xLTEzOTA2Mg_363f0a19-55c7-4fd3-ae46-82d1b8eaaa8f"
      unitRef="usd">10700000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzE2LTEtMS0xLTEzOTA2Mg_94f9783c-c534-4c9d-a67b-09f9d92ba3b3"
      unitRef="usd">114600000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzE2LTMtMS0xLTEzOTA2Mg_585964db-de9b-442c-9a2d-9790faca5886"
      unitRef="usd">56800000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzE2LTUtMS0xLTEzOTA2Mg_c57f7628-b013-40a4-92cf-31e90ebd3411"
      unitRef="usd">26900000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzE3LTEtMS0xLTEzOTA2Mg_29d9f80b-8984-409e-a5cb-74c1590fadf4"
      unitRef="usd">17200000</us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzE3LTMtMS0xLTEzOTA2Mg_a4ec212d-d034-4014-b76f-a65abf4b1dd1"
      unitRef="usd">9200000</us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzE3LTUtMS0xLTEzOTA2Mg_c2251131-e63d-422c-8a17-784202ed807e"
      unitRef="usd">23600000</us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzE4LTEtMS0xLTEzOTA2Mg_5abaf7e9-8968-4dff-a58a-b5cec37ab2d6"
      unitRef="usd">339400000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzE4LTMtMS0xLTEzOTA2Mg_c72a85af-526f-49b6-8ac9-d57707132e46"
      unitRef="usd">256500000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzE4LTUtMS0xLTEzOTA2Mg_89d27ece-3c6c-4d0e-9d71-b6fd0362063b"
      unitRef="usd">228500000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzIxLTEtMS0xLTEzOTA2Mg_077ca221-5c2b-4346-bb44-806975f64960"
      unitRef="usd">621200000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzIxLTMtMS0xLTEzOTA2Mg_7a5f1560-9a06-490e-ac75-8eacb5740ee7"
      unitRef="usd">800100000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzIxLTUtMS0xLTEzOTA2Mg_855982e6-a97e-4b8b-9cb0-fe7b5ad8bfc6"
      unitRef="usd">735500000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzIyLTEtMS0xLTEzOTA2Mg_05b52e81-34c7-4904-a704-be8feff0f7eb"
      unitRef="usd">511000000.0</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzIyLTMtMS0xLTEzOTA2Mg_99ca0a45-9ce3-41be-bd72-4f52c5115fca"
      unitRef="usd">697900000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzIyLTUtMS0xLTEzOTA2Mg_62cbcb82-5d74-40b4-b5af-a5f07192e018"
      unitRef="usd">750500000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzI0LTEtMS0xLTE0NDY3Mg_a5e14d69-0f0f-49f3-94e2-8eef08e14466"
      unitRef="usd">42700000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzI0LTMtMS0xLTE0NDY3Mg_de59cd40-7a26-4aa3-9e39-dca0977bbf99"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzI0LTUtMS0xLTE0NDY3Mg_acc523fa-4f15-4aa4-9e22-240f5aad254d"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzI0LTEtMS0xLTEzOTA2Mg_b1206cc5-eb91-4490-b73d-0f31e1226780"
      unitRef="usd">7700000</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzI0LTMtMS0xLTEzOTA2Mg_488368d3-6074-4a1a-9ded-72423c4aa910"
      unitRef="usd">4600000</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzI0LTUtMS0xLTEzOTA2Mg_63d42227-4590-4ece-ac91-78119e1981bd"
      unitRef="usd">0</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzI1LTEtMS0xLTEzOTA2Mg_d48d9688-d993-4b51-869b-ca45f5fdf92c"
      unitRef="usd">16500000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzI1LTMtMS0xLTEzOTA2Mg_4492530f-e143-46e2-af97-9e68a9d6001b"
      unitRef="usd">23400000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzI1LTUtMS0xLTEzOTA2Mg_c40e10e7-72cb-4553-a938-87cf992c1d0b"
      unitRef="usd">10900000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzI2LTEtMS0xLTEzOTA2Mg_f0c843c9-f1ee-473e-8249-181131fab018"
      unitRef="usd">-177100000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzI2LTMtMS0xLTEzOTA2Mg_5a315a64-4ed6-448a-b2c5-74c42dbf7198"
      unitRef="usd">-130200000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzI2LTUtMS0xLTEzOTA2Mg_29cff954-6143-4fda-a454-c6a9f7c45ed2"
      unitRef="usd">4100000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzI5LTEtMS0xLTEzOTA2Mg_8f0b6615-6a94-4cdf-b136-19f67b4948aa"
      unitRef="usd">44700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzI5LTMtMS0xLTEzOTA2Mg_74de0a7a-2e4f-4aa4-b501-abecce2dc9ef"
      unitRef="usd">27500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzI5LTUtMS0xLTEzOTA2Mg_81224a6e-9b8c-4f8e-87ce-7e2d0f7d01b8"
      unitRef="usd">29100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzMwLTEtMS0xLTEzOTA2Mg_69382533-5783-4311-9902-072d1c958fb4"
      unitRef="usd">279000000.0</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzMwLTMtMS0xLTEzOTA2Mg_facb7393-19e3-4070-9cf3-f470fd8059c0"
      unitRef="usd">100000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzMwLTUtMS0xLTEzOTA2Mg_2fc5c0cb-9136-4f70-ac13-c8e4689bc420"
      unitRef="usd">186900000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzMxLTEtMS0xLTEzOTA2Mg_bb893a91-e420-4965-96bb-a4a124e865ef"
      unitRef="usd">-234300000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzMxLTMtMS0xLTEzOTA2Mg_2835c221-17ab-4186-b115-320b62731056"
      unitRef="usd">27400000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzMxLTUtMS0xLTEzOTA2Mg_1883f4f5-6e0e-414a-95f5-84329f828cb7"
      unitRef="usd">-157800000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzMzLTEtMS0xLTE2Mjg2Ng_5b0652e5-8a73-4296-aaf0-19413d94c18d"
      unitRef="usd">-1300000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzMzLTMtMS0xLTE2Mjg3Mw_30a8555a-9712-4e16-840e-cdc1903ea3e9"
      unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzMzLTUtMS0xLTE2Mjg4MA_a864ec28-d387-4be3-9eb5-cefc9ed7ad65"
      unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzMyLTEtMS0xLTEzOTA2Mg_958b1548-dc2a-4f50-97cb-c02245eacb1d"
      unitRef="usd">-73300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzMyLTMtMS0xLTEzOTA2Mg_67684bbe-a878-48ed-8ab2-ec71eb4c8c03"
      unitRef="usd">153700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzMyLTUtMS0xLTEzOTA2Mg_8a808b78-ec0c-4db7-ab9f-4d5bdcd3ece3"
      unitRef="usd">74800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzMzLTEtMS0xLTEzOTA2Mg_39a7f121-6a4c-45ad-b591-1f7e385e80aa"
      unitRef="usd">344000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8a88ab4de251408db4aa98552134a56a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzMzLTMtMS0xLTEzOTA2Mg_1b4db030-a67c-43d2-9f5b-f45f7ed458e3"
      unitRef="usd">190300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie9e7a539304246b48b58f35e4a888e14_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzMzLTUtMS0xLTEzOTA2Mg_9395811d-2c79-463b-93b4-ae75f4f178f0"
      unitRef="usd">115500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzM0LTEtMS0xLTEzOTA2Mg_963d1e44-b092-43bd-a87a-104b124e8af1"
      unitRef="usd">270700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzM0LTMtMS0xLTEzOTA2Mg_2d3667a5-b884-4655-a042-7464cf1b7168"
      unitRef="usd">344000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8a88ab4de251408db4aa98552134a56a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzM0LTUtMS0xLTEzOTA2Mg_5f4b6342-0f94-4e99-892f-108fa2bf094e"
      unitRef="usd">190300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzM3LTEtMS0xLTEzOTA2Mg_53e10ea0-d838-49e3-a41e-f0b1f6d5f777"
      unitRef="usd">700000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzM3LTMtMS0xLTEzOTA2Mg_3b95a863-02de-41fc-8810-f4f546d2e990"
      unitRef="usd">1900000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzM3LTUtMS0xLTEzOTA2Mg_ad19d7f1-a225-4bcf-94b4-8d9a3693552a"
      unitRef="usd">1400000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzM4LTEtMS0xLTEzOTA2Mg_1aa74f07-6081-48e5-bcda-e2f6e9bae7a9"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzM4LTMtMS0xLTEzOTA2Mg_5ce48be2-ef34-4222-b589-38665fec8e63"
      unitRef="usd">23400000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzM4LTUtMS0xLTEzOTA2Mg_073400eb-e5a1-4b5a-bdad-7ebaf161dde8"
      unitRef="usd">12800000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:InterestPaidNet
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzM5LTEtMS0xLTEzOTA2Mg_5933ccef-c843-4d26-96c7-f745ce351e0a"
      unitRef="usd">6600000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzM5LTMtMS0xLTEzOTA2Mg_ffe84b82-cc41-41d4-85d1-5cb42797008d"
      unitRef="usd">8600000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzM5LTUtMS0xLTEzOTA2Mg_758dcf87-c4c4-4567-83c3-541b43afc4ad"
      unitRef="usd">11600000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzQwLTEtMS0xLTEzOTA2Mg_e8b2d8b5-9a7a-4c25-8ddd-44a7bad0d8e0"
      unitRef="usd">14400000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzQwLTMtMS0xLTEzOTA2Mg_abdaa349-48af-4cdd-82ea-de9de9d35ace"
      unitRef="usd">5100000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMjQvZnJhZzozNjNmM2EzMjFjMGE0MjJlODdjYTU2YjdlZTE0OGU0ZS90YWJsZTozZWExNDhjZGE4YjM0NTk5Yjk3ZWFhMWEzM2E1ODdkZS90YWJsZXJhbmdlOjNlYTE0OGNkYThiMzQ1OTliOTdlYWExYTMzYTU4N2RlXzQwLTUtMS0xLTEzOTA2Mg_3eefb3b6-3153-4d10-9e0d-7e083dfa3c35"
      unitRef="usd">15300000</us-gaap:IncomeTaxesPaid>
    <us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI4NTEy_a0576aeb-f9a3-45e5-b759-417de8c9ef8b">Organization and Summary of Significant Accounting Policies&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Organization and Business. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Neurocrine Biosciences, Inc. and its subsidiaries, or Neurocrine Biosciences, the Company, we, our or us, is a neuroscience-focused biopharmaceutical company focused on discovering, developing and delivering innovative therapies to help ease the burden of debilitating disorders and diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in a single business segment, which includes all activities related to the research, development and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine and neuropsychiatric disorders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Neurocrine Biosciences as well as our wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash Equivalents. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid investments that are readily convertible into cash without penalty and have an original maturity of three months or less at the time of purchase to be cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable are recorded net of customer allowances for prompt payment discounts, chargebacks, and any allowance for credit losses. Our estimate for the allowance for credit losses, which has not been significant to date, is determined based on existing contractual payment terms, actual payment patterns of our customers, and individual customer circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our exposure to credit losses may increase if our customers are adversely affected by changes in healthcare laws, coverage and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current COVID-19 pandemic, or other customer-specific factors. It is possible that there could be a material adverse impact from potential adjustments of the carrying amount of trade receivables as customers&#x2019; cash flows are impacted by their response to the COVID-19 pandemic.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Debt Securities. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt securities consist of investments in certificates of deposit, corporate debt securities and securities of government-sponsored entities. We classify debt securities as available-for-sale. Debt securities available-for-sale are recorded at fair value, with unrealized gains and losses included in other comprehensive income or loss, net of tax. We exclude accrued interest from both the fair value and amortized cost basis of debt securities. A debt security is placed on nonaccrual status at the time any principal or interest payments become 90 days delinquent. Interest accrued but not received for a debt security placed on nonaccrual status is reversed against interest income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest income includes amortization of purchase premium or discount. Premiums and discounts on debt securities are amortized using the effective interest rate method. Gains and losses on sales of debt securities are recorded on the trade date in investment income and other, net, and determined using the specific identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Allowance for Credit Losses. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For debt securities available-for-sale in an unrealized loss position, we first assess whether we intend to sell, or it is more likely than not that we will be required to sell, the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#x2019;s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued interest receivables on debt securities available-for-sale were $4.7 million and $2.2 million, respectively, as of December&#160;31, 2022 and 2021. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized cost basis of the debt security. Uncollectible accrued interest receivables associated with an impaired debt security are reversed against interest income upon identification of the impairment. No accrued interest receivables were written off during 2022, 2021 or 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record cash equivalents, debt securities available-for-sale and equity security investments at fair value based on a fair value hierarchy that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The fair value hierarchy consists of the following three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in debt securities available-for-sale are classified as Level 2 and carried at fair value. We estimate the fair value of debt securities available-for-sale by utilizing third-party pricing services. These pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. Such inputs include market pricing based on real-time trade data for similar instruments, issuer credit spreads, benchmark yields, broker/dealer quotes and other observable inputs. We validate valuations obtained from third-party pricing services by understanding the models used, obtaining market values from other pricing sources and analyzing data in certain instances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We deem transfers between levels of the fair value hierarchy to have occurred at the end of the reporting period during which the event or change in circumstances that caused the transfer occurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is valued at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on the first-in, first-out method. We assess the valuation of our inventory on a quarterly basis and adjust the value for excess and obsolete inventory to the extent management determines that the cost cannot be recovered based on estimates about future demand. Inventory costs resulting from these adjustments are recognized as cost of sales in the period in which they are incurred. When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#x2019;s judgment, we capitalize pre-launch inventory costs prior to regulatory approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets using the straight-line method. Equipment is depreciated over an average estimated useful life of 3 to 7 years. Leasehold improvements are depreciated over the shorter of their estimated useful lives or the remaining lease term. Depreciation expense was $15.1 million for 2022, $10.9 million for 2021 and $8.6 million for 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. In addition, costs that we incur to complete the business combination, such as legal and other professional fees, are expensed as selling, general and administrative when incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill, Intangible Assets and Other Long-Lived Assets. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets acquired, including intangible assets and in-process research and development, or IPR&amp;amp;D, and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&amp;amp;D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;amp;D asset is amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;amp;D asset is expensed in the period of abandonment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill and IPR&amp;amp;D are not amortized; however, they are reviewed for impairment at least annually, as of October 1, and more frequently if an event occurs indicating the potential for impairment. Goodwill and IPR&amp;amp;D are considered to be impaired if the carrying value of the reporting unit or IPR&amp;amp;D asset exceeds its respective fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform our goodwill impairment analysis at the reporting unit level, which aligns with our reporting structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of the reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the reporting unit with the carrying value, including goodwill. If the carrying amount of the reporting unit exceed the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our identifiable intangible assets with a finite life are typically comprised of acquired product rights. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#x2019; respective estimated useful lives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform regular reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign currency.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Assets and liabilities are translated into the reporting currency using the exchange rates in effect on the consolidated balance sheet dates. Equity accounts are translated at historical rates, except for the change in retained earnings during the period, which is the result of the income statement translation process. Revenue and expense accounts are translated using the weighted average exchange rate during the period. The cumulative translation adjustments associated with the net assets of foreign subsidiaries are recorded in accumulated other comprehensive income (loss) in the accompanying consolidated statements of stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue when the customer obtains control of promised goods or services in an amount that reflects the consideration which we expect to receive in exchange for such goods or services. Revenue is recognized using a five-step model: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Product Sales.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In the United States, we sell INGREZZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (valbenazine) primarily to specialty pharmacy providers and distributors and ONGENTYS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (opicapone) primarily to wholesale distributors. We recognize net product sales when the customer obtains control of our product, which occurs at a point in time, typically upon delivery of our product to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, payors, and other third parties. Such estimates are based on information received from external sources (such as written or oral information obtained from our customers with respect to their period-end inventory levels and sales to end-users during the reporting period), as supplemented by management&#x2019;s judgement. Our process for estimating reserves established for these variable consideration components does not differ materially from historical practices. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our significant categories of sales discounts and allowances are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Discounts.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Product discounts are based on payment terms extended to our customers at the time of sale, which include incentives offered for prompt payment. We maintain a reserve for product discounts based on our historical experience, including the timing of customer payments. To date, actual product discounts have not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Rebates.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We are obligated to pay rebates for mandated discounts under the Medicaid Drug Rebate Program. The liability for such rebates consists of invoices received for claims from prior quarters that remain unpaid, or for which an invoice has not been received, and estimated rebates for the current applicable reporting period. Such estimates are based on actual historical rebates by state, estimated payor mix, state and federal regulations, and relevant contractual terms, as supplemented by management&#x2019;s judgement. Our rebate accrual calculations require us to project the magnitude of our sales that will be subject to these rebates. There is a significant time-lag in our receiving rebate notices from each state (generally, several months or longer after a sale is recognized). Estimated rebates are recorded as a reduction of revenue in the period the related sale is recognized. To date, actual government rebates have not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Chargebacks.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The difference between the list price, or the price at which we sell our products to our customers, and the contracted price, or the price at which our customers sell our products to qualified healthcare professionals, is charged back to us by our customers. In addition to actual chargebacks received, we maintain a reserve for chargebacks based on estimated contractual discounts on product inventory levels on-hand in our distribution channel. To date, actual chargebacks have not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Payor and Pharmacy Rebates.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We are obligated to pay rebates as a percentage of sales under payor and pharmacy contracts. We estimate these rebates based on actual historical rebates, contractual rebate percentages, sales made through the payor channel, and purchases made by pharmacies. To date, actual payor and pharmacy rebates have not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Patient Financial Assistance.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; To help patients afford our products, we offer free trial vouchers to qualifying new patients and financial assistance to qualified patients with prescription drug copay requirements. We accrue for patient financial assistance based on estimated claims and the cost per claim we expect to receive in connection with inventory that remains in the distribution channel at period end. To date, actual patient financial assistance has not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distributor and Other Fees.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In connection with the sales of our products, we pay distributor and other fees, which are generally recorded as a reduction of revenue, to certain customers that provide us with inventory management, data, and/or distribution services. Costs associated with such services are expensed as selling, general and administrative to the extent we can demonstrate a separable benefit and fair value for such services. To date, actual distributor and other fees have not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Returns.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We offer our customers product return rights primarily limited to errors in shipment, damaged product, and expiring product, provided it is within a specified period of the product expiration date, as set forth in the associated distribution agreement. Where actual returns history is not available, we estimate a returns allowance based on benchmarking data for similar products and industry experience. Such estimates are recorded as a reduction of revenue in the period the related sale is recognized. Once product is returned, it is destroyed. To date, actual product returns have not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Revenues. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into collaboration and license agreements under which we out-license certain rights to our product candidates to third parties. The terms of these arrangements typically include payment to us for one or more of the following: non-refundable, up-front license fees; development, regulatory, and/or commercial milestone payments; and royalties on net sales of the out-licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses of Intellectual Property.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use, and benefit from, the license. For licenses that are bundled with other promises, we assess the nature of the combined performance obligation to determine whether it is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestones.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; At the inception of each arrangement that includes development, regulatory, and/or commercial milestones, we evaluate whether achieving the milestones is considered probable and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Amounts for milestones that are not within our control, such as when achievement of a specified event is dependent on the development activities of a third party or approvals from regulators, are not considered probable of being achieved until such specified event occurs. Revenue is recognized from the satisfaction of performance obligations in the amount billable to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; For arrangements that include sales-based royalties, and under which the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Each quarterly period, sales-based royalties are recorded based on estimated quarterly net sales of the associated collaboration products. Differences between actual results and estimated amounts are adjusted for in the period in which they become known, which typically follows the quarterly period in which the estimate was made. To date, actual royalties received have not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents and debt securities available-for-sale. We have established guidelines to limit our exposure to credit risk by diversifying our investment portfolio with low-risk investment-grade debt securities with maturities of up to three years and by placing our investments with high-credit-quality financial institutions to maintain liquidity. To date, we have not experienced any credit losses and do not believe we are exposed to any significant credit risk in connection with these financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into agreements for the distribution of INGREZZA with a limited number of specialty pharmacy providers and distributors and all of our product sales of INGREZZA are to these customers. Four of these customers represented approximately 89% of our total product sales for 2022 and approximately 95% of our accounts receivable balance as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Revenues. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of revenues includes third-party manufacturing, transportation, freight, and indirect overhead costs primarily for the manufacture and distribution of INGREZZA and ONGENTYS drug product sold, manufacturing costs in connection with our supply of valbenazine drug product under our collaboration with Mitsubishi Tanabe Pharma Corporation, royalty fees on net sales of elagolix, amortization of intangible assets, and adjustments for excess and obsolete inventory to the extent management determines that the cost cannot be recovered based on estimates about future demand.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development, or R&amp;amp;D. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D expenses primarily consist of preclinical and clinical trial costs, payroll and benefits costs, including stock-based compensation associated with employees involved in R&amp;amp;D activities, certain facility-based costs, and costs associated with our collaborative arrangements, including event-based milestones. All such costs are expensed as R&amp;amp;D when incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Asset Acquisitions. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for acquisitions of assets (or groups of assets) that do not meet the definition of a business using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets (or group of assets) acquired on the basis of their relative fair value(s) on the measurement date. No goodwill is recognized in an asset acquisition. Intangible assets acquired in an asset acquisition for use in R&amp;amp;D activities which have no alternative future use are expensed as IPR&amp;amp;D on the acquisition date. Future costs to develop these assets are expensed as R&amp;amp;D when incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising Expense. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advertising costs are expensed as selling, general and administrative when incurred. Advertising expense was $149.7 million for 2022, $139.8 million for 2021 and $64.8 million for 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We grant stock options to purchase our common stock to eligible employees and directors and also grant certain employees restricted stock units, or RSUs, and performance-based restricted stock units, or PRSUs. Additionally, we allow employees to participate in an employee stock purchase plan, or ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair value of stock options and shares to be issued under the ESPP using the Black-Scholes option-pricing model on the date of grant. RSUs are valued based on the closing price of our common stock on the date of grant. The fair value of equity instruments expected to vest is recognized and amortized on a straight-line basis over the requisite service period of the award, which is generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzIyMzk4_faec3abd-c6f8-404f-adcd-432a19a48776"&gt;three&lt;/span&gt; to four years; however, certain provisions in our equity compensation plans provide for shorter vesting periods under certain circumstances. The fair value of shares to be issued under the ESPP is recognized and amortized on a straight-line basis over the purchase period, which is generally six months. PRSUs vest upon the achievement of certain predefined company-specific performance-based criteria. Expense related to PRSUs is generally recognized ratably over the expected performance period once the predefined performance-based criteria for vesting becomes probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Our income tax provision is computed under the asset and liability method. Significant estimates are required in determining our income tax provision. Some of these estimates are based on interpretations of existing tax laws or regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our income tax provision in the period of such reversal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities based on the technical merits of the position. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Earnings Per Share.&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share are computed using the weighted average number of common shares outstanding during the period. Diluted earnings per share are computed using the treasury stock method and reflect the weighted average number of common and potentially dilutive shares outstanding during the period, excluding those which effect would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, we entered into the First Supplemental Indenture to the 2017 Indenture, pursuant to which we irrevocably elected to settle the principal amount of the 2.25% fixed-rate convertible senior notes due May&#160;15, 2024, or the 2024 Notes, in cash upon conversion and to settle any conversion premium in either cash or shares of our common stock. As a result, only the shares required to settle any conversion premium are considered dilutive under the if-converted method. Further, PRSUs for which the performance condition has not been achieved are excluded from the calculation of diluted earnings per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NTk5NDY_b11908b6-457c-4872-91a0-7e1b27137ced"&gt;ASU 2020-06&lt;/span&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In August 2020, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2020-06,&#160;Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2013; Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity's own equity. Among other changes, &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NjA1MDc_b11908b6-457c-4872-91a0-7e1b27137ced"&gt;ASU 2020-06&lt;/span&gt; removed the separation models for convertible instruments with cash or beneficial conversion features. Instead, entities now account for convertible debt instruments wholly as debt, unless certain other conditions are met. The adoption of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NjA3NTA_b11908b6-457c-4872-91a0-7e1b27137ced"&gt;ASU 2020-06&lt;/span&gt; prospectively reduces reported interest expense and increases (decreases) reported net income (loss), and resulted in a reclassification of certain conversion feature balance sheet amounts from stockholders&#x2019; equity to liabilities as it relates to the 2.25% fixed-rate convertible senior notes due May&#160;15, 2024, or the 2024 Notes. We adopted &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NjEwNzc_b11908b6-457c-4872-91a0-7e1b27137ced"&gt;ASU 2020-06&lt;/span&gt; on January&#160;1, 2022, using the modified retrospective transition method, which allowed for a cumulative-effect adjustment in the period of adoption and did not require restatement of prior period amounts. Under this transition method, the cumulative effect of the accounting change increased the carrying amount of the 2024 Notes by $42.2 million, reduced deferred tax liabilities by $9.9 million, reduced additional paid-in capital by $106.8 million and reduced the accumulated deficit by $74.5 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock>
    <nbix:OrganizationAndBusinesDescriptionPolicyPolicyTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI4NTEz_66c3f847-fae0-49ac-80f9-b58d8abe4b25">&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Organization and Business. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Neurocrine Biosciences, Inc. and its subsidiaries, or Neurocrine Biosciences, the Company, we, our or us, is a neuroscience-focused biopharmaceutical company focused on discovering, developing and delivering innovative therapies to help ease the burden of debilitating disorders and diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in a single business segment, which includes all activities related to the research, development and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine and neuropsychiatric disorders.&lt;/span&gt;&lt;/div&gt;</nbix:OrganizationAndBusinesDescriptionPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI4NTE0_8f77c789-300a-4e2f-9981-1a5f855823d4">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Neurocrine Biosciences as well as our wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI4NTAw_c262cbea-658f-46d7-83cf-02fde2ffc8a6">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.&lt;/span&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI4NTA5_eb2c241c-b0ad-4758-879a-3df00026a3da">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash Equivalents. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid investments that are readily convertible into cash without penalty and have an original maturity of three months or less at the time of purchase to be cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI4NTE2_af3f4a18-ea83-4949-bdd8-5dedf1be24d9">&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable are recorded net of customer allowances for prompt payment discounts, chargebacks, and any allowance for credit losses. Our estimate for the allowance for credit losses, which has not been significant to date, is determined based on existing contractual payment terms, actual payment patterns of our customers, and individual customer circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our exposure to credit losses may increase if our customers are adversely affected by changes in healthcare laws, coverage and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current COVID-19 pandemic, or other customer-specific factors. It is possible that there could be a material adverse impact from potential adjustments of the carrying amount of trade receivables as customers&#x2019; cash flows are impacted by their response to the COVID-19 pandemic.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI4NTAx_dff549be-f894-4b05-a3d0-3d5073461c32">&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Debt Securities. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt securities consist of investments in certificates of deposit, corporate debt securities and securities of government-sponsored entities. We classify debt securities as available-for-sale. Debt securities available-for-sale are recorded at fair value, with unrealized gains and losses included in other comprehensive income or loss, net of tax. We exclude accrued interest from both the fair value and amortized cost basis of debt securities. A debt security is placed on nonaccrual status at the time any principal or interest payments become 90 days delinquent. Interest accrued but not received for a debt security placed on nonaccrual status is reversed against interest income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest income includes amortization of purchase premium or discount. Premiums and discounts on debt securities are amortized using the effective interest rate method. Gains and losses on sales of debt securities are recorded on the trade date in investment income and other, net, and determined using the specific identification method.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI2MTk_f6a323ca-5211-427d-a37b-6f1650f75c53">P90D</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff>
    <us-gaap:CreditLossFinancialInstrumentPolicyTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI4NTA1_9f3e74b1-523e-4f34-ac86-9b10096c8f13">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Allowance for Credit Losses. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For debt securities available-for-sale in an unrealized loss position, we first assess whether we intend to sell, or it is more likely than not that we will be required to sell, the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#x2019;s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.&lt;/span&gt;Accrued interest receivables on debt securities available-for-sale were $4.7 million and $2.2 million, respectively, as of December&#160;31, 2022 and 2021. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized cost basis of the debt security. Uncollectible accrued interest receivables associated with an impaired debt security are reversed against interest income upon identification of the impairment. No accrued interest receivables were written off during 2022, 2021 or 2020.</us-gaap:CreditLossFinancialInstrumentPolicyTextBlock>
    <us-gaap:InterestReceivableCurrent
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzQ1NzQ_79224275-3cae-4293-bd73-776c78d504ad"
      unitRef="usd">4700000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzU0OTc1NTg2NTQ2MA_7002c419-3386-49bb-b78c-a30276c2a0b2"
      unitRef="usd">2200000</us-gaap:InterestReceivableCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzUwMDk_1f9ab590-9e72-48e8-beff-b695f3bacec1"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzUwMDk_6d0efb6c-0605-4e3f-99e5-b7652948a043"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzUwMDk_fe5226b2-5a23-4d6c-a9cf-3cfb1ab7e31f"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI4NTE3_30663884-0c37-4b62-a67e-7abf0110c2bf">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record cash equivalents, debt securities available-for-sale and equity security investments at fair value based on a fair value hierarchy that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The fair value hierarchy consists of the following three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in debt securities available-for-sale are classified as Level 2 and carried at fair value. We estimate the fair value of debt securities available-for-sale by utilizing third-party pricing services. These pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. Such inputs include market pricing based on real-time trade data for similar instruments, issuer credit spreads, benchmark yields, broker/dealer quotes and other observable inputs. We validate valuations obtained from third-party pricing services by understanding the models used, obtaining market values from other pricing sources and analyzing data in certain instances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We deem transfers between levels of the fair value hierarchy to have occurred at the end of the reporting period during which the event or change in circumstances that caused the transfer occurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI4NTAy_713869b6-3be2-4ca1-aa9a-61c7c5bb4882">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is valued at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on the first-in, first-out method. We assess the valuation of our inventory on a quarterly basis and adjust the value for excess and obsolete inventory to the extent management determines that the cost cannot be recovered based on estimates about future demand. Inventory costs resulting from these adjustments are recognized as cost of sales in the period in which they are incurred. When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#x2019;s judgment, we capitalize pre-launch inventory costs prior to regulatory approval.&lt;/span&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI4NTEw_f1626c6b-3168-4f5e-8320-b14f533caf12">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets using the straight-line method. Equipment is depreciated over an average estimated useful life of 3 to 7 years. Leasehold improvements are depreciated over the shorter of their estimated useful lives or the remaining lease term. Depreciation expense was $15.1 million for 2022, $10.9 million for 2021 and $8.6 million for 2020.&lt;/span&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ifbefd953596945ebb57cb8b4260d4036_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2Xzg1Njc_154f2b20-8ebb-4e9e-a9f9-405016b0032f">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i369eac3be33e4aaeb739e76899443560_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2Xzg1NzM_f81d7bc9-1d82-40fa-acd7-03af1334e1fb">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:Depreciation
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2Xzg3MTk_4187aa3f-3d6e-4599-a1d5-d90953be134d"
      unitRef="usd">15100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2Xzg3MzA_4158498a-c259-45bd-8bfd-f7995bbe1b9f"
      unitRef="usd">10900000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2Xzg3NDQ_9d4c8037-1dd0-4f1d-ab39-94a0d756f1d6"
      unitRef="usd">8600000</us-gaap:Depreciation>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzIxOTkwMjMyOTYzNDY_abb1bebc-b26f-4867-be3c-d99eb11ad2d5">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. In addition, costs that we incur to complete the business combination, such as legal and other professional fees, are expensed as selling, general and administrative when incurred.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Asset Acquisitions. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for acquisitions of assets (or groups of assets) that do not meet the definition of a business using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets (or group of assets) acquired on the basis of their relative fair value(s) on the measurement date. No goodwill is recognized in an asset acquisition. Intangible assets acquired in an asset acquisition for use in R&amp;amp;D activities which have no alternative future use are expensed as IPR&amp;amp;D on the acquisition date. Future costs to develop these assets are expensed as R&amp;amp;D when incurred.&lt;/span&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzU0OTc1NTgxNzk2NzM_4d10e98d-221e-4168-87b5-656582f9289d">&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill, Intangible Assets and Other Long-Lived Assets. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets acquired, including intangible assets and in-process research and development, or IPR&amp;amp;D, and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&amp;amp;D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;amp;D asset is amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;amp;D asset is expensed in the period of abandonment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill and IPR&amp;amp;D are not amortized; however, they are reviewed for impairment at least annually, as of October 1, and more frequently if an event occurs indicating the potential for impairment. Goodwill and IPR&amp;amp;D are considered to be impaired if the carrying value of the reporting unit or IPR&amp;amp;D asset exceeds its respective fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform our goodwill impairment analysis at the reporting unit level, which aligns with our reporting structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of the reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the reporting unit with the carrying value, including goodwill. If the carrying amount of the reporting unit exceed the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our identifiable intangible assets with a finite life are typically comprised of acquired product rights. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#x2019; respective estimated useful lives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform regular reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzIxOTkwMjMzMDE2NTg_a3e81d84-9f9a-4566-b28a-6e7f35f17896">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign currency.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Assets and liabilities are translated into the reporting currency using the exchange rates in effect on the consolidated balance sheet dates. Equity accounts are translated at historical rates, except for the change in retained earnings during the period, which is the result of the income statement translation process. Revenue and expense accounts are translated using the weighted average exchange rate during the period. The cumulative translation adjustments associated with the net assets of foreign subsidiaries are recorded in accumulated other comprehensive income (loss) in the accompanying consolidated statements of stockholders&#x2019; equity.&lt;/span&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI4NTE5_f86278ad-0eca-469a-b2e9-3d2d85d422d2">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue when the customer obtains control of promised goods or services in an amount that reflects the consideration which we expect to receive in exchange for such goods or services. Revenue is recognized using a five-step model: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.&lt;/span&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Product Sales.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In the United States, we sell INGREZZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (valbenazine) primarily to specialty pharmacy providers and distributors and ONGENTYS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (opicapone) primarily to wholesale distributors. We recognize net product sales when the customer obtains control of our product, which occurs at a point in time, typically upon delivery of our product to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, payors, and other third parties. Such estimates are based on information received from external sources (such as written or oral information obtained from our customers with respect to their period-end inventory levels and sales to end-users during the reporting period), as supplemented by management&#x2019;s judgement. Our process for estimating reserves established for these variable consideration components does not differ materially from historical practices. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our significant categories of sales discounts and allowances are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Discounts.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Product discounts are based on payment terms extended to our customers at the time of sale, which include incentives offered for prompt payment. We maintain a reserve for product discounts based on our historical experience, including the timing of customer payments. To date, actual product discounts have not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Rebates.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We are obligated to pay rebates for mandated discounts under the Medicaid Drug Rebate Program. The liability for such rebates consists of invoices received for claims from prior quarters that remain unpaid, or for which an invoice has not been received, and estimated rebates for the current applicable reporting period. Such estimates are based on actual historical rebates by state, estimated payor mix, state and federal regulations, and relevant contractual terms, as supplemented by management&#x2019;s judgement. Our rebate accrual calculations require us to project the magnitude of our sales that will be subject to these rebates. There is a significant time-lag in our receiving rebate notices from each state (generally, several months or longer after a sale is recognized). Estimated rebates are recorded as a reduction of revenue in the period the related sale is recognized. To date, actual government rebates have not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Chargebacks.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The difference between the list price, or the price at which we sell our products to our customers, and the contracted price, or the price at which our customers sell our products to qualified healthcare professionals, is charged back to us by our customers. In addition to actual chargebacks received, we maintain a reserve for chargebacks based on estimated contractual discounts on product inventory levels on-hand in our distribution channel. To date, actual chargebacks have not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Payor and Pharmacy Rebates.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We are obligated to pay rebates as a percentage of sales under payor and pharmacy contracts. We estimate these rebates based on actual historical rebates, contractual rebate percentages, sales made through the payor channel, and purchases made by pharmacies. To date, actual payor and pharmacy rebates have not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Patient Financial Assistance.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; To help patients afford our products, we offer free trial vouchers to qualifying new patients and financial assistance to qualified patients with prescription drug copay requirements. We accrue for patient financial assistance based on estimated claims and the cost per claim we expect to receive in connection with inventory that remains in the distribution channel at period end. To date, actual patient financial assistance has not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distributor and Other Fees.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In connection with the sales of our products, we pay distributor and other fees, which are generally recorded as a reduction of revenue, to certain customers that provide us with inventory management, data, and/or distribution services. Costs associated with such services are expensed as selling, general and administrative to the extent we can demonstrate a separable benefit and fair value for such services. To date, actual distributor and other fees have not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Returns.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We offer our customers product return rights primarily limited to errors in shipment, damaged product, and expiring product, provided it is within a specified period of the product expiration date, as set forth in the associated distribution agreement. Where actual returns history is not available, we estimate a returns allowance based on benchmarking data for similar products and industry experience. Such estimates are recorded as a reduction of revenue in the period the related sale is recognized. Once product is returned, it is destroyed. To date, actual product returns have not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Revenues. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into collaboration and license agreements under which we out-license certain rights to our product candidates to third parties. The terms of these arrangements typically include payment to us for one or more of the following: non-refundable, up-front license fees; development, regulatory, and/or commercial milestone payments; and royalties on net sales of the out-licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses of Intellectual Property.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use, and benefit from, the license. For licenses that are bundled with other promises, we assess the nature of the combined performance obligation to determine whether it is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestones.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; At the inception of each arrangement that includes development, regulatory, and/or commercial milestones, we evaluate whether achieving the milestones is considered probable and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Amounts for milestones that are not within our control, such as when achievement of a specified event is dependent on the development activities of a third party or approvals from regulators, are not considered probable of being achieved until such specified event occurs. Revenue is recognized from the satisfaction of performance obligations in the amount billable to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; For arrangements that include sales-based royalties, and under which the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Each quarterly period, sales-based royalties are recorded based on estimated quarterly net sales of the associated collaboration products. Differences between actual results and estimated amounts are adjusted for in the period in which they become known, which typically follows the quarterly period in which the estimate was made. To date, actual royalties received have not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI4NTA2_da3be698-a6c1-40d3-a6f3-95f50e35c746">&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents and debt securities available-for-sale. We have established guidelines to limit our exposure to credit risk by diversifying our investment portfolio with low-risk investment-grade debt securities with maturities of up to three years and by placing our investments with high-credit-quality financial institutions to maintain liquidity. To date, we have not experienced any credit losses and do not believe we are exposed to any significant credit risk in connection with these financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into agreements for the distribution of INGREZZA with a limited number of specialty pharmacy providers and distributors and all of our product sales of INGREZZA are to these customers. Four of these customers represented approximately 89% of our total product sales for 2022 and approximately 95% of our accounts receivable balance as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib8a35373f04d4f25aabbae9b053dfc86_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NTY2NTc_7e2ba347-f0dd-4519-b2d7-cf2424f18783"
      unitRef="number">0.89</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3ee7b53986f840f69575c96ddd148ff6_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NTY3Mzc_6d798cb4-ee50-43a8-b524-1bb640269ac2"
      unitRef="number">0.95</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI4NTAz_5c267712-c99b-47f6-af6d-4f1a999588a0">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Revenues. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of revenues includes third-party manufacturing, transportation, freight, and indirect overhead costs primarily for the manufacture and distribution of INGREZZA and ONGENTYS drug product sold, manufacturing costs in connection with our supply of valbenazine drug product under our collaboration with Mitsubishi Tanabe Pharma Corporation, royalty fees on net sales of elagolix, amortization of intangible assets, and adjustments for excess and obsolete inventory to the extent management determines that the cost cannot be recovered based on estimates about future demand.&lt;/span&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI4NTEx_a365c7c2-8fbf-4ef4-adac-ecdfceff3ae3">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development, or R&amp;amp;D. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D expenses primarily consist of preclinical and clinical trial costs, payroll and benefits costs, including stock-based compensation associated with employees involved in R&amp;amp;D activities, certain facility-based costs, and costs associated with our collaborative arrangements, including event-based milestones. All such costs are expensed as R&amp;amp;D when incurred.&lt;/span&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI4NTIw_3aafbbb8-4650-477f-846e-e9db1edf138f">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising Expense. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advertising costs are expensed as selling, general and administrative when incurred. Advertising expense was $149.7 million for 2022, $139.8 million for 2021 and $64.8 million for 2020.&lt;/span&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2OTM0MjM_320831f9-ac3d-4fc6-b34b-ed476496708d"
      unitRef="usd">149700000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2OTM0NTI_6648c7ac-892c-4216-9424-b72cc516caec"
      unitRef="usd">139800000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2OTM0ODA_d0c07ff9-770b-4d9e-b898-f6720fba745a"
      unitRef="usd">64800000</us-gaap:AdvertisingExpense>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI4NTIx_45bccba0-23f3-4e34-8aac-37eabbee2ce4">&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We grant stock options to purchase our common stock to eligible employees and directors and also grant certain employees restricted stock units, or RSUs, and performance-based restricted stock units, or PRSUs. Additionally, we allow employees to participate in an employee stock purchase plan, or ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair value of stock options and shares to be issued under the ESPP using the Black-Scholes option-pricing model on the date of grant. RSUs are valued based on the closing price of our common stock on the date of grant. The fair value of equity instruments expected to vest is recognized and amortized on a straight-line basis over the requisite service period of the award, which is generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzIyMzk4_faec3abd-c6f8-404f-adcd-432a19a48776"&gt;three&lt;/span&gt; to four years; however, certain provisions in our equity compensation plans provide for shorter vesting periods under certain circumstances. The fair value of shares to be issued under the ESPP is recognized and amortized on a straight-line basis over the purchase period, which is generally six months. PRSUs vest upon the achievement of certain predefined company-specific performance-based criteria. Expense related to PRSUs is generally recognized ratably over the expected performance period once the predefined performance-based criteria for vesting becomes probable.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i369eac3be33e4aaeb739e76899443560_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzIyNDA0_36d6648b-eb9c-4143-8c0f-0d70690457a5">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <nbix:ESPPPurchasePeriod
      contextRef="i42a4d7de80254904a89f6619754861e0_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzIyNjg1_bdfadde1-ac36-47ec-8f9c-af3f5fcaae45">P6M</nbix:ESPPPurchasePeriod>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI4NTA4_51867a14-294c-475b-b5a0-8bc7f0b33326">&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Our income tax provision is computed under the asset and liability method. Significant estimates are required in determining our income tax provision. Some of these estimates are based on interpretations of existing tax laws or regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our income tax provision in the period of such reversal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities based on the technical merits of the position. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI4NTIy_a255666a-4faf-4950-be92-966680749335">&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Earnings Per Share.&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share are computed using the weighted average number of common shares outstanding during the period. Diluted earnings per share are computed using the treasury stock method and reflect the weighted average number of common and potentially dilutive shares outstanding during the period, excluding those which effect would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, we entered into the First Supplemental Indenture to the 2017 Indenture, pursuant to which we irrevocably elected to settle the principal amount of the 2.25% fixed-rate convertible senior notes due May&#160;15, 2024, or the 2024 Notes, in cash upon conversion and to settle any conversion premium in either cash or shares of our common stock. As a result, only the shares required to settle any conversion premium are considered dilutive under the if-converted method. Further, PRSUs for which the performance condition has not been achieved are excluded from the calculation of diluted earnings per share.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4b5b4f7eab2446ce84ea30524cbd6aa0_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NTc2MTQ_8d782fd5-97a8-4b26-8dc2-09f8a81a0d3b"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzI4NTA0_cb2b4fb5-57e5-402d-8d56-2d37bc7d53a8">&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NTk5NDY_b11908b6-457c-4872-91a0-7e1b27137ced"&gt;ASU 2020-06&lt;/span&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In August 2020, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2020-06,&#160;Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2013; Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity's own equity. Among other changes, &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NjA1MDc_b11908b6-457c-4872-91a0-7e1b27137ced"&gt;ASU 2020-06&lt;/span&gt; removed the separation models for convertible instruments with cash or beneficial conversion features. Instead, entities now account for convertible debt instruments wholly as debt, unless certain other conditions are met. The adoption of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NjA3NTA_b11908b6-457c-4872-91a0-7e1b27137ced"&gt;ASU 2020-06&lt;/span&gt; prospectively reduces reported interest expense and increases (decreases) reported net income (loss), and resulted in a reclassification of certain conversion feature balance sheet amounts from stockholders&#x2019; equity to liabilities as it relates to the 2.25% fixed-rate convertible senior notes due May&#160;15, 2024, or the 2024 Notes. We adopted &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NjEwNzc_b11908b6-457c-4872-91a0-7e1b27137ced"&gt;ASU 2020-06&lt;/span&gt; on January&#160;1, 2022, using the modified retrospective transition method, which allowed for a cumulative-effect adjustment in the period of adoption and did not require restatement of prior period amounts. Under this transition method, the cumulative effect of the accounting change increased the carrying amount of the 2024 Notes by $42.2 million, reduced deferred tax liabilities by $9.9 million, reduced additional paid-in capital by $106.8 million and reduced the accumulated deficit by $74.5 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4b5b4f7eab2446ce84ea30524cbd6aa0_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NjEwMDU_8d782fd5-97a8-4b26-8dc2-09f8a81a0d3b"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i7b26f825c6434881a754e7e6c53ed556_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NjEzOTQ_ab6805cc-c8e2-4d42-a97f-fd70c8b37e80"
      unitRef="usd">42200000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i7b26f825c6434881a754e7e6c53ed556_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NjE0MzU_b1a7c797-e094-4508-8b50-c99e7fa1d9e0"
      unitRef="usd">-9900000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i7b26f825c6434881a754e7e6c53ed556_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NjE0Nzg_2e77ce7d-d0e0-4cfd-b7f4-f2955414de9a"
      unitRef="usd">-106800000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i7b26f825c6434881a754e7e6c53ed556_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzAvZnJhZzo2MzZkM2Y1NWVmMjg0YTI4ODdmMzY0NWJjMDNjMWYwNi90ZXh0cmVnaW9uOjYzNmQzZjU1ZWYyODRhMjg4N2YzNjQ1YmMwM2MxZjA2XzEwOTk1MTE2NjE1MjE_fd21ee6f-67bc-4df7-b9cc-b168c633a8ba"
      unitRef="usd">74500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzIxNTEy_71ed5d03-83ed-468c-9de0-73c635ca247d">Collaboration and License Agreements&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of our existing collaboration and license agreements, we may be required to make potential future payments of up to $10.8 billion upon the achievement of certain event-based milestones. Such contingent payments are recorded when paid or payable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Heptares Therapeutics Limited, or Heptares.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We entered into a collaboration and license agreement with Heptares, which became effective in December 2021, to develop and commercialize certain compounds containing sub-type selective muscarinic M1, M4, or dual M1/M4 receptor agonists, which compounds we have the exclusive rights to develop, manufacture and commercialize worldwide, excluding in Japan, where Heptares retains the rights to develop, manufacture, and commercialize all compounds comprised of M1 receptor agonists, subject to certain exceptions. With respect to such rights retained by Heptares, we retain the rights to opt in to profit sharing arrangements, pursuant to which we and Heptares will equally share in the operating profits and losses for such compounds in Japan. Subject to specified conditions, we may elect to exercise such opt-in rights with respect to each such compound either before initiation of the first proof of concept Phase II clinical trial for such compound or following our receipt from Heptares of the top-line data from such clinical trial for such compound. We are responsible for all development, manufacturing, and commercialization costs of any collaboration product. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the agreement, we paid Heptares $100.0 million upfront, which, including certain transaction-related costs, was expensed as IPR&amp;amp;D in 2021. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the FDA's acceptance of our investigational new drug application for NBI-1117568 for the treatment of schizophrenia in June 2022, we paid Heptares a milestone of $30.0 million, which was expensed as R&amp;amp;D in 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, Heptares may be entitled to receive potential future payments of up to $2.6 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until the date on which the royalty term for such licensed product has expired in such country. On a licensed product-by-licensed product and country-by-country basis, royalty payments would commence on the first commercial sale of a licensed product and terminate on the later of (i) the expiration of the last patent covering such licensed product in such country, (ii) a number of years from the first commercial sale of such licensed product in such country and (iii) the expiration of regulatory exclusivity for such licensed product in such country.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may terminate the agreement in its entirety or with respect to one or more targets upon 180 days&#x2019; written notice to Heptares during the research collaboration term and upon 90 days&#x2019; written notice to Heptares following the expiration of the research collaboration term. Following the expiration of the research collaboration term, Heptares may terminate the agreement on a target-by-target basis in the event that we do not conduct any material development activities outside of Japan with respect to a certain compound or licensed product within the applicable target class for a continuous period of not less than 365 days and do not commence any such activities within 120 days of receiving written notice. Either party may terminate the agreement, subject to specified conditions, (i) in the event of material breach by the other party, subject to a cure period, (ii) if the other party challenges the validity or enforceability of certain intellectual property rights, subject to a cure period, or (iii) if the other party becomes insolvent or takes certain actions related to insolvency.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Takeda Pharmaceutical Company Limited, or Takeda.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In 2020, we entered into an exclusive license agreement with Takeda, pursuant to which we acquired the exclusive rights to develop and commercialize certain early-to-mid stage psychiatry compounds, including luvadaxistat, NBI-1065845, NBI-1065846 and four non-clinical stage compounds. Luvadaxistat and the 4 non-clinical stage compounds have each been designated as a royalty-bearing product. NBI-1065845 and NBI-1065846 are currently each designated as a profit-share product. We are responsible for all manufacturing, development, and commercialization costs of any royalty-bearing product. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to NBI-1065845 and NBI-1065846, we and Takeda will equally share in the operating profits and losses. Takeda retains the rights to opt-out of the profit-sharing arrangements, pursuant to which Takeda would be entitled to receive potential future payments upon the achievement of certain event-based milestones with respect to such compounds and receive royalties on the future net sales of such compounds (in lieu of equally sharing in the operating profits and losses). Takeda may elect to exercise such opt-out right for such compound immediately following the completion of a second Phase II clinical trial for such compound, or, under certain circumstances related to the development and commercialization activities to be performed by us, before the initiation of a Phase III clinical trial for such compound.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the agreement, we paid Takeda $120.0 million upfront, which, including certain transaction-related costs, was expensed as IPR&amp;amp;D in 2020. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the approval of our clinical trial application for NBI-1070770 for the treatment of major depressive disorder in July 2022, we paid Takeda a milestone of $5.0 million, which was expensed as R&amp;amp;D in 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, Takeda may be entitled to receive potential future payments of up to $1.9 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any royalty-bearing product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until the date on which, (i) for any royalty-bearing product, the royalty term has expired in such country; and (ii) for any profit-share product, for so long as we continue to develop, manufacture, or commercialize such licensed product.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On a licensed product-by-licensed product and country-by-country basis, royalty payments would commence on the first commercial sale of a royalty-bearing product and terminate on the later of (i) the expiration of the last patent covering such royalty-bearing product in such country, (ii) a number of years from the first commercial sale of such royalty-bearing product in such country and (iii) the expiration of regulatory exclusivity for such royalty-bearing product in such country.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may terminate the agreement in its entirety or in one or more (but not all) of the United States, Japan, the European Union and the United Kingdom, or, collectively, the major markets, upon six months&#x2019; written notice to Takeda (i) with respect to all licensed products prior to the first commercial sale of the first licensed product for which first commercial sale occurs, or (ii) with respect to all licensed products in one or more given target classes, as defined in the agreement, prior to the first commercial sale of the first licensed product in such target class for which first commercial sale occurs. We may terminate the agreement in its entirety or in one or more (but not all) of the major markets upon 12 months&#x2019; written notice to Takeda (i) with respect to all licensed products following the first commercial sale of the first licensed product for which first commercial sale occurs, or (ii) with respect to all licensed products in one or more given target classes following the first commercial sale of the first licensed product in such target class for which first commercial sale occurs. Takeda may terminate the agreement, subject to specified conditions, (i) if we challenge the validity or enforceability of certain Takeda intellectual property rights or (ii) on a target class-by-target class basis, in the event that we do not conduct any material development or commercialization activities with respect to any licensed product within such target class for a specified continuous period. Subject to a cure period, either party may terminate the agreement in the event of any material breach, solely with respect to the target class of a licensed product to which such material breach relates, or in its entirety in the event of any material breach that relates to all licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Idorsia Pharmaceuticals Ltd., or Idorsia.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In 2020, we entered into a collaboration and license agreement with Idorsia, pursuant to which we acquired the global rights to NBI-827104, a potent, selective, orally active and brain penetrating T-type calcium channel blocker in clinical development for the treatment of a rare pediatric epilepsy and other potential indications, including essential tremor. We are responsible for all manufacturing, development, and commercialization costs of any collaboration product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the agreement, we paid Idorsia $45.0 million upfront, which was expensed as IPR&amp;amp;D in 2020. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. Under the terms of the agreement, Idorsia may be entitled to receive potential future payments of up to $1.7 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may terminate the agreement, in its entirety or with respect to a particular compound or development candidate, upon 90 days&#x2019; written notice to Idorsia. Further, in the event a party commits a material breach and fails to cure such material breach within 90 days after receiving written notice thereof, the non-breaching party may terminate the agreement in its entirety immediately upon written notice to the breaching party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Xenon Pharmaceuticals Inc., or Xenon. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, we entered into a collaboration and license agreement with Xenon to identify, research and develop sodium channel inhibitors, including NBI-921352 and three preclinical candidates, which compounds we have the exclusive rights to develop and commercialize. We are responsible for all development and manufacturing costs of any collaboration product, subject to certain exceptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the agreement, we paid Xenon $50.0 million upfront, including a purchase of approximately 1.4 million shares of Xenon common stock (at $14.196 per share). We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. The purchased shares were recorded at a fair value of $14.1 million after considering Xenon&#x2019;s stock price on the measurement date and certain transfer restrictions applicable to the shares. The remaining $36.2 million of the purchase price, which includes certain transaction-related costs, was expensed as IPR&amp;amp;D in 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the European Union&#x2019;s approval of our clinical trial application for NBI-921352 for the treatment of focal onset seizures in adults in September 2021, we paid Xenon a regulatory milestone of $10.0 million, including a purchase of approximately 0.3 million shares of Xenon common stock (at $19.9755 per share). The purchased shares were recorded at a fair value of $4.6 million after considering Xenon&#x2019;s stock price on the measurement date and certain transfer restrictions applicable to the shares. The remaining $5.4 million of the milestone payment was expensed as R&amp;amp;D in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the FDA's acceptance of our amended KAYAK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;study protocol in January 2022, we paid Xenon a regulatory milestone of $15.0 million, including a purchase of approximately 0.3 million shares of Xenon common stock (at $31.855 per share). The purchased shares were recorded at a fair value of $7.7 million after considering Xenon&#x2019;s stock price on the measurement date. The remaining $7.3 million of the milestone payment was expensed as R&amp;amp;D in 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, Xenon may be entitled to receive potential future payments of up to $1.7 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product. Xenon retains the right to elect to co-develop one product in a major indication, pursuant to which Xenon would receive a mid-single digit percentage increase in royalties earned on the future net sales of such product in the United States and we and Xenon would equally share in the development costs of such product in the applicable indication, except where such development costs relate solely to the regulatory approval of such product outside the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until the expiration of the royalty term for such product in such country. Upon the expiration of the royalty term for a particular licensed product and country, the license obtained by us with respect to such product and country will become fully paid, royalty free, perpetual and irrevocable. We may terminate the agreement upon 90 days&#x2019; written notice to Xenon, provided that such unilateral termination will not be effective for certain products until we have used commercially reasonable efforts to complete certain specified clinical studies. Either party may terminate the agreement in the event of a material breach in whole or in part, subject to specified conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Voyager Therapeutics, Inc., or Voyager.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, we entered into a collaboration and license agreement with Voyager, pursuant to which we acquired certain rights to develop and commercialize the NBIb-1817 for Parkinson&#x2019;s disease program, Friedreich&#x2019;s ataxia program and two undisclosed programs. We are responsible for all development costs of any collaboration product, subject to certain co-development and co-commercialization rights retained by Voyager. In February 2021, we notified Voyager of our termination of the NBIb-1817 for Parkinson&#x2019;s disease program, which became effective August 2, 2021. The termination did not apply to any program other than the NBIb-1817 for Parkinson&#x2019;s disease program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the agreement, we paid Voyager $165.0 million upfront, including a purchase of approximately 4.2 million shares of Voyager common stock (at $11.9625 per share). We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. The purchased shares were recorded at a fair value of $54.7 million after considering Voyager&#x2019;s stock price on the measurement date and certain transfer restrictions applicable to the shares. The remaining $113.1 million of the purchase price, which includes certain transaction-related costs, was expensed as IPR&amp;amp;D in 2019. In addition, we paid Voyager $5.0 million upfront, which was expensed as IPR&amp;amp;D in 2019, to acquire the rights outside the United States to the Friedreich&#x2019;s ataxia program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, Voyager may be entitled to receive potential future payments of up to $1.3 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless terminated earlier, the agreement will continue in effect until the expiration of the last to expire royalty term with respect to any collaboration product or the last expiration or termination of any exercised co-development and co-commercialization rights by Voyager as provided for in the agreement. We may terminate the agreement upon 180 days&#x2019; written notice to Voyager prior to the first commercial sale of any collaboration product or upon one year after the date of notice if such notice is provided after the first commercial sale of any collaboration product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;BIAL &#x2013; Portela &amp;amp; Ca, S.A., or BIAL.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We acquired the United States and Canada rights to ONGENTYS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(opicapone) from BIAL in 2017, and launched ONGENTYS in the United States in September 2020 as an FDA-approved add-on treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing motor fluctuations. We are responsible for all commercialization costs of ONGENTYS in the United States and Canada and rely on BIAL for the commercial supply of ONGENTYS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the license agreement, BIAL may be entitled to receive potential future payments of up to $75.0 million upon the achievement of certain event-based milestones. In addition, with respect to ONGENTYS, in the event we fail to meet certain minimum sales requirements for a particular year in comparison to our annual sales forecast for such year, we would be obligated to pay BIAL an amount equal to the difference between the actual net sales and minimum sales requirements for such year. Further, upon our written request to BIAL 12 months prior to the estimated expiration of the term of a licensed product, we will negotiate the continuation of BIAL&#x2019;s supply of such licensed product after the term. After the term, and if BIAL is no longer supplying such licensed product, BIAL would be entitled to receive a low double-digit royalty on our future quarterly net sales of such licensed product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until a generic product with respect to such licensed product is sold in a country and sales of such generic product are greater than a specified percentage of total sales of such licensed product in such country.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may terminate the agreement upon nine months&#x2019; written notice to BIAL. BIAL may terminate the agreement in the event we fail to meet the minimum sales requirements for any two years, or under certain circumstances involving a change of control of Neurocrine Biosciences. Under certain circumstances where BIAL elects to terminate the agreement in connection with a change of control of Neurocrine Biosciences, BIAL would be obligated to pay us a termination fee. Either party may terminate the agreement if the other party materially breaches the agreement and does not cure the breach within a specified notice period, or upon the other party&#x2019;s insolvency.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Mitsubishi Tanabe Pharma Corporation, or MTPC&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We out-licensed the rights to valbenazine in Japan and other select Asian markets to MTPC in 2015. In December 2020, we entered into a commercial supply agreement with MTPC, pursuant to which we agreed to supply MTPC with valbenazine drug product for commercial use in Japan and other select Asian markets. MTPC is responsible for all development, manufacturing, and commercialization costs of valbenazine in such markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, MTPC launched DYSVAL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (valbenazine) in Japan for the treatment of tardive dyskinesia. In connection with MTPC's first commercial sale of DYSVAL in Japan, we received a milestone payment of $20.0 million in 2022. ASC 606 provides a royalty exception for a sales-based or usage-based royalty promised in exchange for a license of intellectual property. Under the royalty exception, the milestone would be recognized as revenue only when the later of (1) the subsequent sale or usage occurs or (2) the performance obligation to which some or all of the sales-based or usage-based royalty has been allocated has been satisfied (or partially satisfied). As the milestone related to a license of intellectual property and was contingent upon MTPC&#x2019;s first commercial sale of DYSVAL in Japan, the milestone was recognized as revenue in the second quarter of 2022. In addition, we receive royalties at tiered percentage rates on MTPC net sales of DYSVAL.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of our license agreement with MTPC, we may be entitled to receive potential future payments of up to $30.0 million upon the achievement of certain sales-based milestones and are entitled to receive royalties at tiered percentage rates on future MTPC net sales of valbenazine for the longer of 10 years or the life of the related patent rights. MTPC may terminate the agreement upon 180 days&#x2019; written notice to us. In such event, all out-licensed product rights would revert to us.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;AbbVie Inc., or AbbVie. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We out-licensed the global rights to elagolix to AbbVie in 2010. AbbVie is responsible for all development and commercialization costs of elagolix.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, AbbVie launched ORILISSA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(elagolix tablets) in the United States for the treatment of moderate to severe pain associated with endometriosis. In June 2020, AbbVie launched ORIAHNN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(elagolix, estradiol and norethindrone acetate capsules and elagolix capsules) in the United States for the treatment of heavy menstrual bleeding related to uterine fibroids in premenopausal women. We receive royalties at tiered percentage rates on AbbVie net sales of elagolix and recognized elagolix royalty revenue of $21.2&#160;million for 2022, $22.3&#160;million for 2021 and $19.2&#160;million for 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of our license agreement with AbbVie, we may be entitled to receive potential future payments of up to $366.0 million upon the achievement of certain event-based milestones and are entitled to receive royalties at tiered percentage rates on future AbbVie net sales of elagolix for the longer of 10 years or the life of the related patent rights. AbbVie may terminate the agreement upon 180 days&#x2019; written notice to us. In such event, all out-licensed product rights would revert to us.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <nbix:PotentialMilestonePayments
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzE3Nw_fbda8826-2355-486f-bdec-e93992497c03"
      unitRef="usd">10800000000</nbix:PotentialMilestonePayments>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i49d358b74dad468eb33569aa9c5ac1c8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzE1NjI_5330120c-b0ff-46fc-8e85-66d9fd14496a"
      unitRef="usd">100000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i07a1cddc781641a8845184519e26357f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzE5NTY_99cee119-cfbe-41c8-9573-281789255a5e"
      unitRef="usd">30000000</us-gaap:ResearchAndDevelopmentExpense>
    <nbix:PotentialMilestonePayments
      contextRef="i1528f057e30c40d383e6a6ca39cf5e6c_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzIxMjI_629c6727-caff-4fbe-9fbb-e636fa9baaad"
      unitRef="usd">2600000000</nbix:PotentialMilestonePayments>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i0f5830ad533c4847b9f38b89925e51ec_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzU1NzY_c6250dda-c7d0-4519-95b2-c2cbb0d81935"
      unitRef="usd">120000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7449f5d91b314ce9840e1b298ee98b5a_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzEwOTk1MTE2NTAxMjc_8a065020-b2dc-41e7-8801-6cd8349df8c7"
      unitRef="usd">5000000</us-gaap:ResearchAndDevelopmentExpense>
    <nbix:PotentialMilestonePayments
      contextRef="i6b886e104da64c1fa92f25fa93dc1395_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzEwOTk1MTE2NTEzNzc_63ee740b-a493-4784-b266-2deb42b26282"
      unitRef="usd">1900000000</nbix:PotentialMilestonePayments>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i868635e691954212a665a735b175d9cc_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzkyODQ_db16b7bd-1be6-4575-a734-c4cc6a633fdb"
      unitRef="usd">45000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <nbix:PotentialMilestonePayments
      contextRef="i440c81bdf19642fba2eda39e1baadf0e_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5Xzk1NTU_8fa4e1af-e3bb-40ab-8dfc-8186763b43af"
      unitRef="usd">1700000000</nbix:PotentialMilestonePayments>
    <nbix:UpfrontPaymentsMade
      contextRef="idd82456387ea428d8220b9c69e68b5a5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzEwNjE1_9eae4d9c-fc4f-4724-a5a9-4258c2fad853"
      unitRef="usd">50000000</nbix:UpfrontPaymentsMade>
    <nbix:SaleOfStockNumberOfSharesSoldInTransaction
      contextRef="i61160aa576a54fed889d400313bcb4aa_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzEwNjY1_6ffb0d7c-b9f3-4268-ba44-a6c7942142c2"
      unitRef="shares">1400000</nbix:SaleOfStockNumberOfSharesSoldInTransaction>
    <us-gaap:SharePrice
      contextRef="idd82456387ea428d8220b9c69e68b5a5_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzEwNzAx_406d66d7-415d-42ff-bb41-14ac082c5ffb"
      unitRef="usdPerShare">14.196</us-gaap:SharePrice>
    <us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue
      contextRef="idd82456387ea428d8220b9c69e68b5a5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzEwODg4_296fc093-26c7-44db-b606-49404d7b9d5d"
      unitRef="usd">14100000</us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="ib362d8b9fffd4556aaef9b4388175d10_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzExMDI3_e7a1b81e-4f3b-4d7a-bb5e-715f865d01e1"
      unitRef="usd">36200000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <nbix:MilestonePayment
      contextRef="i1de27f6ad9554d338fb10badbf2b6cc6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzExMzQz_7fda1285-3948-47b4-9824-c158edec19e4"
      unitRef="usd">10000000</nbix:MilestonePayment>
    <nbix:SaleOfStockNumberOfSharesSoldInTransaction
      contextRef="ia98ab6db9c434e4dbbefda09d3b887fb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzExMzg1_ce8412e1-4d27-483b-8dbe-426b208768e4"
      unitRef="shares">300000</nbix:SaleOfStockNumberOfSharesSoldInTransaction>
    <us-gaap:SharePrice
      contextRef="i1de27f6ad9554d338fb10badbf2b6cc6_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzExNDIx_7e3b4c64-fe19-49a2-95db-cc7b5d6fa684"
      unitRef="usdPerShare">19.9755</us-gaap:SharePrice>
    <us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue
      contextRef="i1de27f6ad9554d338fb10badbf2b6cc6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzExNDkw_5080612d-f9d5-4bed-954b-df36074327c0"
      unitRef="usd">4600000</us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1dd2cca8016742d7affa71c15d311c24_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzExNjI5_ac78ebf4-a9df-4e70-b36e-749edb8db20d"
      unitRef="usd">5400000</us-gaap:ResearchAndDevelopmentExpense>
    <nbix:MilestonePayment
      contextRef="i56425aa7040a45e28f54bc219c6c40d3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzExODIx_a8491912-a11f-471b-8b21-b741a74b6ee2"
      unitRef="usd">15000000</nbix:MilestonePayment>
    <nbix:SaleOfStockNumberOfSharesSoldInTransaction
      contextRef="ieb20bc9532234865b09c7dc5f22a26fc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzExODYz_34ef2452-6e95-4cfd-8165-e1925c53a2ff"
      unitRef="shares">300000</nbix:SaleOfStockNumberOfSharesSoldInTransaction>
    <us-gaap:SharePrice
      contextRef="i56425aa7040a45e28f54bc219c6c40d3_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzExODk5_f9ad4cdb-3a7a-4bc2-b84f-51a96c837e12"
      unitRef="usdPerShare">31.855</us-gaap:SharePrice>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="i56425aa7040a45e28f54bc219c6c40d3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzExOTY4_8d108318-bc84-4f5f-8017-6c3c7f210deb"
      unitRef="usd">7700000</us-gaap:EquitySecuritiesFvNiCost>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia5b5c0571ff04f84bac746f261a35bef_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzEyMDQ4_7112f759-f87e-428f-900d-5c6b5851c893"
      unitRef="usd">7300000</us-gaap:ResearchAndDevelopmentExpense>
    <nbix:PotentialMilestonePayments
      contextRef="i56425aa7040a45e28f54bc219c6c40d3_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzEyMjI4_cf76ea95-a51e-44a0-820e-b5a769df6c20"
      unitRef="usd">1700000000</nbix:PotentialMilestonePayments>
    <nbix:UpfrontPaymentsMade
      contextRef="i3558292be26a40eea22ad957b4eb1826_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzE0NDEy_01b931df-8627-4304-9925-f4d0b44b64cb"
      unitRef="usd">165000000</nbix:UpfrontPaymentsMade>
    <nbix:SaleOfStockNumberOfSharesSoldInTransaction
      contextRef="i7701cdc56953401b8c556dba9626d9e9_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzE0NDYy_b4ee26f7-bdb0-41f3-8dc3-6cc561077885"
      unitRef="shares">4200000</nbix:SaleOfStockNumberOfSharesSoldInTransaction>
    <us-gaap:SharePrice
      contextRef="i3558292be26a40eea22ad957b4eb1826_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzE0NTAw_47704e80-1c2c-400a-8ab8-d407167962e2"
      unitRef="usdPerShare">11.9625</us-gaap:SharePrice>
    <us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue
      contextRef="i3558292be26a40eea22ad957b4eb1826_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzE0Njg3_f681f560-848a-4a1d-b886-5a0718748d3f"
      unitRef="usd">54700000</us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i68a2f3aa551740a2a1bc3a14aaf7c9fa_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzE0ODI4_a95e006a-785b-4b32-b813-f83962a12f7f"
      unitRef="usd">113100000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="ic667970352ec4acca922a861f9e43c76_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzE0OTY0_79670aad-5b78-47d3-b807-6b09a86c5256"
      unitRef="usd">5000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <nbix:PotentialMilestonePayments
      contextRef="i42ebb9eaffae4c9eac346888ea44b0d4_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzE1MjAx_d1f5b294-3b14-4cb9-acf0-8ca5199e6c2a"
      unitRef="usd">1300000000</nbix:PotentialMilestonePayments>
    <nbix:PotentialMilestonePayments
      contextRef="i67a8f10be8224d60b4e1657e6dade015_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzE2NTEw_9940066b-db6e-4ea1-a48c-fe187bc5896d"
      unitRef="usd">75000000</nbix:PotentialMilestonePayments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i59539b84d7aa486da424a835877b0fc9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzEwOTk1MTE2NTI3OTg_c3eff52c-d7c2-4615-8c8d-06e47a8c4451"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <nbix:PotentialMilestonePaymentReceipts
      contextRef="ic013c8b18d624578b99159e4ff5581c7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzE5OTI1_21675e6c-0d02-441b-86f2-a2bbf1765636"
      unitRef="usd">30000000</nbix:PotentialMilestonePaymentReceipts>
    <nbix:PatentTerm
      contextRef="i5a3cc531fe0541f4b8e3a1edcfbd0a17_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzIwMTA2_2733a95f-9842-4681-9780-9b87d6c11b30">P10Y</nbix:PatentTerm>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee6e68341d9841438fa8702438a7dac5_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzE2NDkyNjc0NzI3NTg_3a197b10-37fe-457e-921c-7b7d8f700a38"
      unitRef="usd">21200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f13730346f24079965eeb3a7fe0ff59_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzIxOTkwMjMyODU4NDE_797871e5-29fa-473c-80a9-f12b82bc3c01"
      unitRef="usd">22300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idda4399247c446cebc1ede65c5bec2b9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzIxOTkwMjMyODU4NTc_13f4bb00-76ec-4b8e-97ec-bc2af9785385"
      unitRef="usd">19200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <nbix:PotentialMilestonePaymentReceipts
      contextRef="i61790d0b66be4586a7c469931f4ab4d7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzIxMTUw_a4e75db5-3247-44f5-9fa4-74f620623c79"
      unitRef="usd">366000000</nbix:PotentialMilestonePaymentReceipts>
    <nbix:PatentTerm
      contextRef="i6d60a74b87dc498c97bc171751a50ac9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzkvZnJhZzo4NDM0ZDRlMWQ2ZGQ0MGIyYmM5YzgxZjU4YWZlOGI1OS90ZXh0cmVnaW9uOjg0MzRkNGUxZDZkZDQwYjJiYzljODFmNThhZmU4YjU5XzIxMzMw_ff0502a2-f19b-469f-afc5-f503c2c4e361">P10Y</nbix:PatentTerm>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzYvZnJhZzoxZWZhN2M0YWRmZjE0MThhYjVjOWE2MDhlMmYyMWMxOC90ZXh0cmVnaW9uOjFlZmE3YzRhZGZmMTQxOGFiNWM5YTYwOGUyZjIxYzE4XzQ5NDc4MDIzMjg4MDE_35ee2751-b398-4069-b62d-82d35cde606f">Diurnal AcquisitionOn November 1, 2022, we completed our acquisition of Diurnal Group plc, or Diurnal, a United Kingdom-headquartered, specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. We believe our acquisition of Diurnal presents an opportunity to accelerate the establishment of our clinical development and commercial capabilities in the United Kingdom to the benefit of patient communities and other stakeholders.&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate purchase price of this acquisition was $55.2&#160;million in cash. The acquisition was accounted for in accordance with FASB ASC 805 as a Business Combinations and, accordingly, Diurnal&#x2019;s results of operations have been consolidated in Neurocrine Biosciences&#x2019; financial statements since the date of acquisition. Pro forma results of operations for the years ended December 31, 2022 and 2021 would not be materially different as a result of this acquisition and therefore are not presented. In connection with the acquisition, we recognized transaction costs of $1.7&#160;million, which were expensed as selling, general and administrative and primarily consisted of investment banker, advisory, legal and other professional fees.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the consideration paid for Diurnal and the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Recognized amounts of identifiable assets acquired and liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquired in-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts payable and other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i9d13692c26a440998d78e8fffc7d8570_D20221101-20221101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzYvZnJhZzoxZWZhN2M0YWRmZjE0MThhYjVjOWE2MDhlMmYyMWMxOC90ZXh0cmVnaW9uOjFlZmE3YzRhZGZmMTQxOGFiNWM5YTYwOGUyZjIxYzE4XzIxOTkwMjMyNTkzNDg_033e0b2a-d53a-45a3-bdaa-c00e3781af2a"
      unitRef="usd">55200000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i9d13692c26a440998d78e8fffc7d8570_D20221101-20221101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzYvZnJhZzoxZWZhN2M0YWRmZjE0MThhYjVjOWE2MDhlMmYyMWMxOC90ZXh0cmVnaW9uOjFlZmE3YzRhZGZmMTQxOGFiNWM5YTYwOGUyZjIxYzE4XzE2NDkyNjc0NTQ3MTY_c62417cb-4444-4e5a-94b4-8127b7c51663"
      unitRef="usd">1700000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzYvZnJhZzoxZWZhN2M0YWRmZjE0MThhYjVjOWE2MDhlMmYyMWMxOC90ZXh0cmVnaW9uOjFlZmE3YzRhZGZmMTQxOGFiNWM5YTYwOGUyZjIxYzE4XzQ5NDc4MDIzMjg4MDU_0d925d7d-ac46-4978-b144-8736af07d04c">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the consideration paid for Diurnal and the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Recognized amounts of identifiable assets acquired and liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquired in-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts payable and other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i9d13692c26a440998d78e8fffc7d8570_D20221101-20221101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzYvZnJhZzoxZWZhN2M0YWRmZjE0MThhYjVjOWE2MDhlMmYyMWMxOC90YWJsZTplYjMzZjRlMDRiNjQ0MTcxOGEwY2I5NWY0ZmU1ZjJlMC90YWJsZXJhbmdlOmViMzNmNGUwNGI2NDQxNzE4YTBjYjk1ZjRmZTVmMmUwXzItMS0xLTEtMTQ0MDQx_73bda619-664f-4d32-813d-c403dd0a32c2"
      unitRef="usd">55200000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i9d13692c26a440998d78e8fffc7d8570_D20221101-20221101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzYvZnJhZzoxZWZhN2M0YWRmZjE0MThhYjVjOWE2MDhlMmYyMWMxOC90YWJsZTplYjMzZjRlMDRiNjQ0MTcxOGEwY2I5NWY0ZmU1ZjJlMC90YWJsZXJhbmdlOmViMzNmNGUwNGI2NDQxNzE4YTBjYjk1ZjRmZTVmMmUwXzUtMS0xLTEtMTQ0MDQx_1f911b39-adb7-489d-bec6-416521ea97b3"
      unitRef="usd">55200000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i5a8688d19b0c4b7f9f790a262226d2ea_I20221101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzYvZnJhZzoxZWZhN2M0YWRmZjE0MThhYjVjOWE2MDhlMmYyMWMxOC90YWJsZTplYjMzZjRlMDRiNjQ0MTcxOGEwY2I5NWY0ZmU1ZjJlMC90YWJsZXJhbmdlOmViMzNmNGUwNGI2NDQxNzE4YTBjYjk1ZjRmZTVmMmUwXzEtMS0xLTEtMTQzNTk0_baff9cde-87b1-4c1e-ac7f-b76c128e6ee9"
      unitRef="usd">12500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i5a8688d19b0c4b7f9f790a262226d2ea_I20221101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzYvZnJhZzoxZWZhN2M0YWRmZjE0MThhYjVjOWE2MDhlMmYyMWMxOC90YWJsZTplYjMzZjRlMDRiNjQ0MTcxOGEwY2I5NWY0ZmU1ZjJlMC90YWJsZXJhbmdlOmViMzNmNGUwNGI2NDQxNzE4YTBjYjk1ZjRmZTVmMmUwXzctMS0xLTEtMTYwMDYx_d478eef6-2756-4d32-b5eb-8df4aeccf74a"
      unitRef="usd">32600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <nbix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsAcquiredInProcessResearchAndDevelopment
      contextRef="i5a8688d19b0c4b7f9f790a262226d2ea_I20221101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzYvZnJhZzoxZWZhN2M0YWRmZjE0MThhYjVjOWE2MDhlMmYyMWMxOC90YWJsZTplYjMzZjRlMDRiNjQ0MTcxOGEwY2I5NWY0ZmU1ZjJlMC90YWJsZXJhbmdlOmViMzNmNGUwNGI2NDQxNzE4YTBjYjk1ZjRmZTVmMmUwXzQtMS0xLTEtMTQzNTk0_995a0651-e4d0-434a-bc2d-f6fcb98f16e8"
      unitRef="usd">3200000</nbix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsAcquiredInProcessResearchAndDevelopment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
      contextRef="i5a8688d19b0c4b7f9f790a262226d2ea_I20221101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzYvZnJhZzoxZWZhN2M0YWRmZjE0MThhYjVjOWE2MDhlMmYyMWMxOC90YWJsZTplYjMzZjRlMDRiNjQ0MTcxOGEwY2I5NWY0ZmU1ZjJlMC90YWJsZXJhbmdlOmViMzNmNGUwNGI2NDQxNzE4YTBjYjk1ZjRmZTVmMmUwXzYtMS0xLTEtMTQzNTk0_eda5f66e-b14d-43ea-839b-959e7d81bd00"
      unitRef="usd">12400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <nbix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndOtherAccruedExpenses
      contextRef="i5a8688d19b0c4b7f9f790a262226d2ea_I20221101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzYvZnJhZzoxZWZhN2M0YWRmZjE0MThhYjVjOWE2MDhlMmYyMWMxOC90YWJsZTplYjMzZjRlMDRiNjQ0MTcxOGEwY2I5NWY0ZmU1ZjJlMC90YWJsZXJhbmdlOmViMzNmNGUwNGI2NDQxNzE4YTBjYjk1ZjRmZTVmMmUwXzExLTEtMS0xLTE0NDA0Mw_5d056b64-cb95-4894-8e86-9df89b95777c"
      unitRef="usd">10700000</nbix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndOtherAccruedExpenses>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="i5a8688d19b0c4b7f9f790a262226d2ea_I20221101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzYvZnJhZzoxZWZhN2M0YWRmZjE0MThhYjVjOWE2MDhlMmYyMWMxOC90YWJsZTplYjMzZjRlMDRiNjQ0MTcxOGEwY2I5NWY0ZmU1ZjJlMC90YWJsZXJhbmdlOmViMzNmNGUwNGI2NDQxNzE4YTBjYjk1ZjRmZTVmMmUwXzctMS0xLTEtMTQzNTk0_983da9cf-7183-4414-a108-5f233eaef05f"
      unitRef="usd">50000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:Goodwill
      contextRef="i5a8688d19b0c4b7f9f790a262226d2ea_I20221101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xMzYvZnJhZzoxZWZhN2M0YWRmZjE0MThhYjVjOWE2MDhlMmYyMWMxOC90YWJsZTplYjMzZjRlMDRiNjQ0MTcxOGEwY2I5NWY0ZmU1ZjJlMC90YWJsZXJhbmdlOmViMzNmNGUwNGI2NDQxNzE4YTBjYjk1ZjRmZTVmMmUwXzE0LTEtMS0xLTE0NDA0NA_369f170e-96fe-4fca-af70-636b1bc66733"
      unitRef="usd">5200000</us-gaap:Goodwill>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90ZXh0cmVnaW9uOjJlYjkwZGUyMDczYjRkMWQ5ZWM4NzZjZDIwYTNlMWExXzExOTg_9d6e818b-fb42-4fad-a497-b0c4554b02e0">Debt Securities&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income (loss) and fair value of debt securities available-for-sale, aggregated by major security type and contractual maturity.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0 to 1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;156.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;156.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0 to 1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;296.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;293.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0 to 1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;283.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;277.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;735.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;726.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;370.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;370.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1 to 3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;255.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;357.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1 to 3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;203.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;304.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;299.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;563.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;560.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, our security portfolio consisted of 253 debt securities available-for-sale, including 199 such securities that were in an unrealized loss position but of high credit quality. Unrealized losses on these investments were primarily due to changes in interest rates. We do not intend to sell these investments and it is not more likely than not that we will be required to sell these investments before recovery of their amortized cost basis. No allowance for credit losses was recognized as of December&#160;31, 2022 or 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents debt securities available-for-sale that were in an unrealized loss position as of December&#160;31, 2022, aggregated by major security type and length of time in a continuous loss position.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12 Months or Longer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;199.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;299.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;498.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;107.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;198.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;306.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents debt securities available-for-sale that were in an unrealized loss position as of December&#160;31, 2021, aggregated by major security type and length of time in a continuous loss position.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12 Months or Longer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;428.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;428.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;230.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;230.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90ZXh0cmVnaW9uOjJlYjkwZGUyMDczYjRkMWQ5ZWM4NzZjZDIwYTNlMWExXzExOTk_12fbe71f-90f6-4688-8445-d3c0a665b8d2">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income (loss) and fair value of debt securities available-for-sale, aggregated by major security type and contractual maturity.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0 to 1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;156.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;156.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0 to 1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;296.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;293.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0 to 1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;283.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;277.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;735.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;726.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;370.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;370.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1 to 3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;255.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;357.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1 to 3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;203.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;304.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;299.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;563.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;560.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i2a6f8fd190a2433584205fa45bfd8bcb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzItMy0xLTEtMTM5MDYy_3e386e66-5cb7-427d-8fab-41b1a2fd25af"
      unitRef="usd">156200000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i2a6f8fd190a2433584205fa45bfd8bcb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzItNS0xLTEtMTM5MDYy_0221ad20-9f68-484e-84a0-a11b1ffa33e3"
      unitRef="usd">0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i2a6f8fd190a2433584205fa45bfd8bcb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzItNy0xLTEtMTM5MDYy_50897855-cdb4-4335-b363-90296a0eb6e6"
      unitRef="usd">200000</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueCurrent
      contextRef="i2a6f8fd190a2433584205fa45bfd8bcb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzItOS0xLTEtMTM5MDYy_25bb3eb9-41d4-40ef-8f75-a28e784590d2"
      unitRef="usd">156000000.0</nbix:DebtSecuritiesAvailableForSaleFairValueCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i001676d240734d81bdb16bacb8df878e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzItMTEtMS0xLTEzOTA2Mg_598fa9fd-c71e-46a3-b460-216b59774dd2"
      unitRef="usd">204800000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i001676d240734d81bdb16bacb8df878e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzItMTMtMS0xLTEzOTA2Mg_d2c6ed7f-484d-4001-8d9e-8bee3df31c65"
      unitRef="usd">0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i001676d240734d81bdb16bacb8df878e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzItMTUtMS0xLTEzOTA2Mg_6e4e5380-2a61-4dc5-8351-7d71b0904a13"
      unitRef="usd">0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueCurrent
      contextRef="i001676d240734d81bdb16bacb8df878e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzItMTctMS0xLTEzOTA2Mg_04668cea-35a0-4a74-9c43-a2ba65970a12"
      unitRef="usd">204800000</nbix:DebtSecuritiesAvailableForSaleFairValueCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i2dc4af282e2e4830bb4c5589ec647f1f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzMtMy0xLTEtMTM5MDYy_505d2910-73c1-4db6-b507-e0e2ab9f5b75"
      unitRef="usd">296200000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i2dc4af282e2e4830bb4c5589ec647f1f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzMtNS0xLTEtMTM5MDYy_dd33c003-4c03-4184-9eb9-c0017a8ab9f3"
      unitRef="usd">0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i2dc4af282e2e4830bb4c5589ec647f1f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzMtNy0xLTEtMTM5MDYy_15cdbe8a-cb59-406f-8c08-b24c6124a80f"
      unitRef="usd">3200000</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueCurrent
      contextRef="i2dc4af282e2e4830bb4c5589ec647f1f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzMtOS0xLTEtMTM5MDYy_f13d6360-7ea0-4025-95bc-f5003fb2146e"
      unitRef="usd">293000000.0</nbix:DebtSecuritiesAvailableForSaleFairValueCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i4e6ecccda3454d2d97a48bbbed7a06c4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzMtMTEtMS0xLTEzOTA2Mg_3577d3b6-d7b4-46e2-b1a7-83559999bc99"
      unitRef="usd">128200000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i4e6ecccda3454d2d97a48bbbed7a06c4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzMtMTMtMS0xLTEzOTA2Mg_127d1175-bc7a-4b04-9145-24124bc9ce1d"
      unitRef="usd">0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i4e6ecccda3454d2d97a48bbbed7a06c4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzMtMTUtMS0xLTEzOTA2Mg_d1813ace-1455-4594-99c0-57047cf5ab8c"
      unitRef="usd">100000</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueCurrent
      contextRef="i4e6ecccda3454d2d97a48bbbed7a06c4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzMtMTctMS0xLTEzOTA2Mg_fbdd69d4-8e65-4bdd-909b-4b2779d98b1f"
      unitRef="usd">128100000</nbix:DebtSecuritiesAvailableForSaleFairValueCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="idc59d3c4ac034bfc85c224da99f57d0f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzQtMy0xLTEtMTM5MDYy_9ba4fa76-b067-4d69-8ffd-c53a66b14257"
      unitRef="usd">283400000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="idc59d3c4ac034bfc85c224da99f57d0f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzQtNS0xLTEtMTM5MDYy_fa662529-10e1-4bc0-8bdc-ab3032832a84"
      unitRef="usd">0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="idc59d3c4ac034bfc85c224da99f57d0f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzQtNy0xLTEtMTM5MDYy_d2025924-ca1d-444a-944f-6cc6241ab902"
      unitRef="usd">6000000.0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueCurrent
      contextRef="idc59d3c4ac034bfc85c224da99f57d0f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzQtOS0xLTEtMTM5MDYy_120deac8-a580-4ff0-a80b-9c9cf88fdc35"
      unitRef="usd">277400000</nbix:DebtSecuritiesAvailableForSaleFairValueCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i76c8c1dcfb3247a6b15b3036d4069cbc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzQtMTEtMS0xLTEzOTA2Mg_bbaa74fa-028f-4f32-952c-15a0584a0fb2"
      unitRef="usd">37600000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i76c8c1dcfb3247a6b15b3036d4069cbc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzQtMTMtMS0xLTEzOTA2Mg_fbe38e35-2e33-4278-8a74-a06cbe2a7def"
      unitRef="usd">0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i76c8c1dcfb3247a6b15b3036d4069cbc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzQtMTUtMS0xLTEzOTA2Mg_f367737b-3c47-46e4-82f0-edb032c3109c"
      unitRef="usd">0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueCurrent
      contextRef="i76c8c1dcfb3247a6b15b3036d4069cbc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzQtMTctMS0xLTEzOTA2Mg_90cf8d7a-de29-4f76-bbcb-1a4db88eb007"
      unitRef="usd">37600000</nbix:DebtSecuritiesAvailableForSaleFairValueCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzUtMy0xLTEtMTM5MDYy_91931eea-382c-46fb-9326-15a690812a70"
      unitRef="usd">735800000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzUtNS0xLTEtMTM5MDYy_02ee5f5c-326b-480d-a8c8-a05883be7f31"
      unitRef="usd">0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzUtNy0xLTEtMTM5MDYy_fe4780a3-f5c4-468b-90cd-b161695e7d9a"
      unitRef="usd">9400000</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueCurrent
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzUtOS0xLTEtMTM5MDYy_660f02fe-5f5e-4c5c-a936-4329256a07ac"
      unitRef="usd">726400000</nbix:DebtSecuritiesAvailableForSaleFairValueCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzUtMTEtMS0xLTEzOTA2Mg_996106e0-b089-4351-8a4e-909a56dc0b3b"
      unitRef="usd">370600000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzUtMTMtMS0xLTEzOTA2Mg_f8fc0479-0921-4177-bae4-ad024a4f8d95"
      unitRef="usd">0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzUtMTUtMS0xLTEzOTA2Mg_ea7b7016-9583-426e-9648-6e863ec1b92d"
      unitRef="usd">100000</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueCurrent
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzUtMTctMS0xLTEzOTA2Mg_25537f00-1130-4091-ae5f-5c84e215d317"
      unitRef="usd">370500000</nbix:DebtSecuritiesAvailableForSaleFairValueCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="i2dc4af282e2e4830bb4c5589ec647f1f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzctMy0xLTEtMTM5MDYy_1221f67e-4257-44c2-9b9d-1f593fe9f5c4"
      unitRef="usd">259500000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
      contextRef="i2dc4af282e2e4830bb4c5589ec647f1f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzctNS0xLTEtMTM5MDYy_df1c4ce6-adaa-4f17-8e6c-ad050e15400c"
      unitRef="usd">200000</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
      contextRef="i2dc4af282e2e4830bb4c5589ec647f1f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzctNy0xLTEtMTM5MDYy_d865ef90-ea1f-4065-8470-d7ae25b954f0"
      unitRef="usd">4300000</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent
      contextRef="i2dc4af282e2e4830bb4c5589ec647f1f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzctOS0xLTEtMTM5MDYy_e691f368-3b25-43e2-9fef-18849de74671"
      unitRef="usd">255400000</nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="i4e6ecccda3454d2d97a48bbbed7a06c4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzctMTEtMS0xLTEzOTA2Mg_9dedc74d-138a-4c88-ae7d-720f35e3436b"
      unitRef="usd">358900000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
      contextRef="i4e6ecccda3454d2d97a48bbbed7a06c4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzctMTMtMS0xLTEzOTA2Mg_45d226f9-5b77-401d-91e5-6d4d86b5d034"
      unitRef="usd">0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
      contextRef="i4e6ecccda3454d2d97a48bbbed7a06c4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzctMTUtMS0xLTEzOTA2Mg_3805495f-6136-40d3-b4c0-103cdcfff682"
      unitRef="usd">1500000</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent
      contextRef="i4e6ecccda3454d2d97a48bbbed7a06c4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzctMTctMS0xLTEzOTA2Mg_ce086329-f89d-4d4b-b6f2-2e555c6c4f46"
      unitRef="usd">357400000</nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="idc59d3c4ac034bfc85c224da99f57d0f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzgtMy0xLTEtMTM5MDYy_415c96d9-d609-47cd-a736-eea8c680a34f"
      unitRef="usd">45000000.0</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
      contextRef="idc59d3c4ac034bfc85c224da99f57d0f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzgtNS0xLTEtMTM5MDYy_86711686-924b-4fef-ace4-8a974df45f9e"
      unitRef="usd">0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
      contextRef="idc59d3c4ac034bfc85c224da99f57d0f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzgtNy0xLTEtMTM5MDYy_1dc29d3d-bd02-4e77-9ae3-273b0b177dbb"
      unitRef="usd">1000000.0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent
      contextRef="idc59d3c4ac034bfc85c224da99f57d0f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzgtOS0xLTEtMTM5MDYy_7fe264d4-c9db-43e0-8315-00bbe5f18157"
      unitRef="usd">44000000.0</nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="i76c8c1dcfb3247a6b15b3036d4069cbc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzgtMTEtMS0xLTEzOTA2Mg_87fa9e89-3053-4325-8d45-7fc73410b227"
      unitRef="usd">204300000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
      contextRef="i76c8c1dcfb3247a6b15b3036d4069cbc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzgtMTMtMS0xLTEzOTA2Mg_8ecdb91d-baf1-425e-895e-83335a24e829"
      unitRef="usd">0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
      contextRef="i76c8c1dcfb3247a6b15b3036d4069cbc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzgtMTUtMS0xLTEzOTA2Mg_19176066-a2c9-4366-a5b2-1f28d2c518c2"
      unitRef="usd">1000000.0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent
      contextRef="i76c8c1dcfb3247a6b15b3036d4069cbc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzgtMTctMS0xLTEzOTA2Mg_6bf26ffb-3e29-4fe8-a822-20d8939ff9c9"
      unitRef="usd">203300000</nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzktMy0xLTEtMTM5MDYy_04babe93-fce9-4b1e-9f2a-0175852ae8e2"
      unitRef="usd">304500000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzktNS0xLTEtMTM5MDYy_4c922fff-7141-4b6c-b70a-3f3514318271"
      unitRef="usd">200000</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzktNy0xLTEtMTM5MDYy_f156df97-2207-42a5-91b8-2cea6b4276ab"
      unitRef="usd">5300000</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzktOS0xLTEtMTM5MDYy_13d77070-0a36-4c73-a4e8-101ef9e9f8db"
      unitRef="usd">299400000</nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzktMTEtMS0xLTEzOTA2Mg_01978005-59f0-4726-9b01-e5bea9d50ed7"
      unitRef="usd">563200000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzktMTMtMS0xLTEzOTA2Mg_2a0ec82c-27a1-4fdd-a2ce-11f19c2a3209"
      unitRef="usd">0</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzktMTUtMS0xLTEzOTA2Mg_6c08bd73-3de1-4cc3-810f-1700ad9be894"
      unitRef="usd">2500000</nbix:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTozMDNiYWQ1OTFiODU0YzhjYTYyMzI1MTJhMjRlOGIwNi90YWJsZXJhbmdlOjMwM2JhZDU5MWI4NTRjOGNhNjIzMjUxMmEyNGU4YjA2XzktMTctMS0xLTEzOTA2Mg_40c34db4-c5e3-4867-a141-3e87b92f9d70"
      unitRef="usd">560700000</nbix:DebtSecuritiesAvailableForSaleFairValueNoncurrent>
    <nbix:DebtSecuritiesAvailableForSalePositionNumberOfPositions
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90ZXh0cmVnaW9uOjJlYjkwZGUyMDczYjRkMWQ5ZWM4NzZjZDIwYTNlMWExXzMyOA_eafcc19c-f170-4fdc-8b9a-6e689faa7f75"
      unitRef="security">253</nbix:DebtSecuritiesAvailableForSalePositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90ZXh0cmVnaW9uOjJlYjkwZGUyMDczYjRkMWQ5ZWM4NzZjZDIwYTNlMWExXzM3Nw_e0c71297-868a-4963-b46c-40a726f9b07f"
      unitRef="security">199</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90ZXh0cmVnaW9uOjJlYjkwZGUyMDczYjRkMWQ5ZWM4NzZjZDIwYTNlMWExXzExOTc_19fe1764-afe7-444b-a056-ebf51d7288b1">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents debt securities available-for-sale that were in an unrealized loss position as of December&#160;31, 2022, aggregated by major security type and length of time in a continuous loss position.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12 Months or Longer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;199.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;299.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;498.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;107.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;198.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;306.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents debt securities available-for-sale that were in an unrealized loss position as of December&#160;31, 2021, aggregated by major security type and length of time in a continuous loss position.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12 Months or Longer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;428.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;428.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;230.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;230.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i2a6f8fd190a2433584205fa45bfd8bcb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTpjNDk3MjE4MGRhY2I0ODA1ODY0ODE4NzgwYzg1ZWIxYi90YWJsZXJhbmdlOmM0OTcyMTgwZGFjYjQ4MDU4NjQ4MTg3ODBjODVlYjFiXzItMS0xLTEtMTM5MDYy_911933e5-41d6-48bb-a504-29b9b9033665"
      unitRef="usd">32100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i2a6f8fd190a2433584205fa45bfd8bcb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTpjNDk3MjE4MGRhY2I0ODA1ODY0ODE4NzgwYzg1ZWIxYi90YWJsZXJhbmdlOmM0OTcyMTgwZGFjYjQ4MDU4NjQ4MTg3ODBjODVlYjFiXzItMy0xLTEtMTM5MDYy_0f220a9a-889b-4e23-9912-63e66804a02c"
      unitRef="usd">200000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i2a6f8fd190a2433584205fa45bfd8bcb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTpjNDk3MjE4MGRhY2I0ODA1ODY0ODE4NzgwYzg1ZWIxYi90YWJsZXJhbmdlOmM0OTcyMTgwZGFjYjQ4MDU4NjQ4MTg3ODBjODVlYjFiXzItNS0xLTEtMTM5MDYy_e18aeecb-d3cf-43c0-9e23-1d668442d00a"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i2a6f8fd190a2433584205fa45bfd8bcb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTpjNDk3MjE4MGRhY2I0ODA1ODY0ODE4NzgwYzg1ZWIxYi90YWJsZXJhbmdlOmM0OTcyMTgwZGFjYjQ4MDU4NjQ4MTg3ODBjODVlYjFiXzItNy0xLTEtMTM5MDYy_c3e5f89a-3adf-468f-9e7a-4889a718af49"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i2a6f8fd190a2433584205fa45bfd8bcb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTpjNDk3MjE4MGRhY2I0ODA1ODY0ODE4NzgwYzg1ZWIxYi90YWJsZXJhbmdlOmM0OTcyMTgwZGFjYjQ4MDU4NjQ4MTg3ODBjODVlYjFiXzItOS0xLTEtMTM5MDYy_26c060d7-5b6a-40a2-add7-b0209af557c9"
      unitRef="usd">32100000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i2a6f8fd190a2433584205fa45bfd8bcb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTpjNDk3MjE4MGRhY2I0ODA1ODY0ODE4NzgwYzg1ZWIxYi90YWJsZXJhbmdlOmM0OTcyMTgwZGFjYjQ4MDU4NjQ4MTg3ODBjODVlYjFiXzItMTEtMS0xLTEzOTA2Mg_eb414ad6-b893-4dba-8247-3e8a687f5f99"
      unitRef="usd">200000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i2dc4af282e2e4830bb4c5589ec647f1f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTpjNDk3MjE4MGRhY2I0ODA1ODY0ODE4NzgwYzg1ZWIxYi90YWJsZXJhbmdlOmM0OTcyMTgwZGFjYjQ4MDU4NjQ4MTg3ODBjODVlYjFiXzMtMS0xLTEtMTM5MDYy_659c0f87-7f43-4a2f-baf5-f50398d79695"
      unitRef="usd">199500000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i2dc4af282e2e4830bb4c5589ec647f1f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTpjNDk3MjE4MGRhY2I0ODA1ODY0ODE4NzgwYzg1ZWIxYi90YWJsZXJhbmdlOmM0OTcyMTgwZGFjYjQ4MDU4NjQ4MTg3ODBjODVlYjFiXzMtMy0xLTEtMTM5MDYy_49e1834a-7505-410b-a2e2-73c1d0b52ef7"
      unitRef="usd">1900000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i2dc4af282e2e4830bb4c5589ec647f1f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTpjNDk3MjE4MGRhY2I0ODA1ODY0ODE4NzgwYzg1ZWIxYi90YWJsZXJhbmdlOmM0OTcyMTgwZGFjYjQ4MDU4NjQ4MTg3ODBjODVlYjFiXzMtNS0xLTEtMTM5MDYy_47bd9db7-c837-4ead-abd0-d3b6646b8188"
      unitRef="usd">299100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i2dc4af282e2e4830bb4c5589ec647f1f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTpjNDk3MjE4MGRhY2I0ODA1ODY0ODE4NzgwYzg1ZWIxYi90YWJsZXJhbmdlOmM0OTcyMTgwZGFjYjQ4MDU4NjQ4MTg3ODBjODVlYjFiXzMtNy0xLTEtMTM5MDYy_3460620b-8a14-4a91-967c-bf5106cbb09a"
      unitRef="usd">5600000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i2dc4af282e2e4830bb4c5589ec647f1f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTpjNDk3MjE4MGRhY2I0ODA1ODY0ODE4NzgwYzg1ZWIxYi90YWJsZXJhbmdlOmM0OTcyMTgwZGFjYjQ4MDU4NjQ4MTg3ODBjODVlYjFiXzMtOS0xLTEtMTM5MDYy_57c06038-5e9f-486d-bce9-7771b8702631"
      unitRef="usd">498600000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i2dc4af282e2e4830bb4c5589ec647f1f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTpjNDk3MjE4MGRhY2I0ODA1ODY0ODE4NzgwYzg1ZWIxYi90YWJsZXJhbmdlOmM0OTcyMTgwZGFjYjQ4MDU4NjQ4MTg3ODBjODVlYjFiXzMtMTEtMS0xLTEzOTA2Mg_3ad8062b-24ba-42af-ae92-a540d0e1f447"
      unitRef="usd">7500000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="idc59d3c4ac034bfc85c224da99f57d0f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTpjNDk3MjE4MGRhY2I0ODA1ODY0ODE4NzgwYzg1ZWIxYi90YWJsZXJhbmdlOmM0OTcyMTgwZGFjYjQ4MDU4NjQ4MTg3ODBjODVlYjFiXzQtMS0xLTEtMTM5MDYy_776eb9e3-aedb-4c3d-8285-34f740779f78"
      unitRef="usd">107700000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="idc59d3c4ac034bfc85c224da99f57d0f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTpjNDk3MjE4MGRhY2I0ODA1ODY0ODE4NzgwYzg1ZWIxYi90YWJsZXJhbmdlOmM0OTcyMTgwZGFjYjQ4MDU4NjQ4MTg3ODBjODVlYjFiXzQtMy0xLTEtMTM5MDYy_218e4267-fd62-447b-8e13-8d108cb58e1c"
      unitRef="usd">2500000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="idc59d3c4ac034bfc85c224da99f57d0f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTpjNDk3MjE4MGRhY2I0ODA1ODY0ODE4NzgwYzg1ZWIxYi90YWJsZXJhbmdlOmM0OTcyMTgwZGFjYjQ4MDU4NjQ4MTg3ODBjODVlYjFiXzQtNS0xLTEtMTM5MDYy_69dd39bb-bdca-4cc5-b979-84736040c6b0"
      unitRef="usd">198400000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="idc59d3c4ac034bfc85c224da99f57d0f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTpjNDk3MjE4MGRhY2I0ODA1ODY0ODE4NzgwYzg1ZWIxYi90YWJsZXJhbmdlOmM0OTcyMTgwZGFjYjQ4MDU4NjQ4MTg3ODBjODVlYjFiXzQtNy0xLTEtMTM5MDYy_f14d6b54-9600-4209-b7c5-39deb3cf1897"
      unitRef="usd">4500000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="idc59d3c4ac034bfc85c224da99f57d0f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTpjNDk3MjE4MGRhY2I0ODA1ODY0ODE4NzgwYzg1ZWIxYi90YWJsZXJhbmdlOmM0OTcyMTgwZGFjYjQ4MDU4NjQ4MTg3ODBjODVlYjFiXzQtOS0xLTEtMTM5MDYy_713fe567-319e-4697-ac97-87f91531ee8d"
      unitRef="usd">306100000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="idc59d3c4ac034bfc85c224da99f57d0f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZTpjNDk3MjE4MGRhY2I0ODA1ODY0ODE4NzgwYzg1ZWIxYi90YWJsZXJhbmdlOmM0OTcyMTgwZGFjYjQ4MDU4NjQ4MTg3ODBjODVlYjFiXzQtMTEtMS0xLTEzOTA2Mg_75040b27-c652-42df-aabd-82a39a611f11"
      unitRef="usd">7000000.0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i4e6ecccda3454d2d97a48bbbed7a06c4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZToxZmQyODYwMzg4ZDk0ZDY3ODBhYTBhM2FjNmM2ZThiMy90YWJsZXJhbmdlOjFmZDI4NjAzODhkOTRkNjc4MGFhMGEzYWM2YzZlOGIzXzItMS0xLTEtMTM5MDYy_d34a56d8-c0b8-4e3f-b183-3d57059729fd"
      unitRef="usd">428600000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i4e6ecccda3454d2d97a48bbbed7a06c4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZToxZmQyODYwMzg4ZDk0ZDY3ODBhYTBhM2FjNmM2ZThiMy90YWJsZXJhbmdlOjFmZDI4NjAzODhkOTRkNjc4MGFhMGEzYWM2YzZlOGIzXzItMy0xLTEtMTM5MDYy_268463fb-f1bc-4b97-b902-9700cc6015df"
      unitRef="usd">1600000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i4e6ecccda3454d2d97a48bbbed7a06c4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZToxZmQyODYwMzg4ZDk0ZDY3ODBhYTBhM2FjNmM2ZThiMy90YWJsZXJhbmdlOjFmZDI4NjAzODhkOTRkNjc4MGFhMGEzYWM2YzZlOGIzXzItNS0xLTEtMTM5MDYy_2b8a7c15-69ce-4060-a30c-dac7b6ddef60"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i4e6ecccda3454d2d97a48bbbed7a06c4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZToxZmQyODYwMzg4ZDk0ZDY3ODBhYTBhM2FjNmM2ZThiMy90YWJsZXJhbmdlOjFmZDI4NjAzODhkOTRkNjc4MGFhMGEzYWM2YzZlOGIzXzItNy0xLTEtMTM5MDYy_daafae54-b55c-45b3-b0d0-25d93412875f"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i4e6ecccda3454d2d97a48bbbed7a06c4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZToxZmQyODYwMzg4ZDk0ZDY3ODBhYTBhM2FjNmM2ZThiMy90YWJsZXJhbmdlOjFmZDI4NjAzODhkOTRkNjc4MGFhMGEzYWM2YzZlOGIzXzItOS0xLTEtMTM5MDYy_3b5947fb-a7d1-4c51-b15e-87dbf99ff518"
      unitRef="usd">428600000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i4e6ecccda3454d2d97a48bbbed7a06c4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZToxZmQyODYwMzg4ZDk0ZDY3ODBhYTBhM2FjNmM2ZThiMy90YWJsZXJhbmdlOjFmZDI4NjAzODhkOTRkNjc4MGFhMGEzYWM2YzZlOGIzXzItMTEtMS0xLTEzOTA2Mg_cb91e726-6f7c-41fa-9a82-b4770f0d902b"
      unitRef="usd">1600000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i76c8c1dcfb3247a6b15b3036d4069cbc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZToxZmQyODYwMzg4ZDk0ZDY3ODBhYTBhM2FjNmM2ZThiMy90YWJsZXJhbmdlOjFmZDI4NjAzODhkOTRkNjc4MGFhMGEzYWM2YzZlOGIzXzMtMS0xLTEtMTM5MDYy_3acb220a-a2c7-4f3e-93b6-bc3597582f08"
      unitRef="usd">230500000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i76c8c1dcfb3247a6b15b3036d4069cbc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZToxZmQyODYwMzg4ZDk0ZDY3ODBhYTBhM2FjNmM2ZThiMy90YWJsZXJhbmdlOjFmZDI4NjAzODhkOTRkNjc4MGFhMGEzYWM2YzZlOGIzXzMtMy0xLTEtMTM5MDYy_96d5ac88-1fea-4238-91dd-febe0ba1de75"
      unitRef="usd">1000000.0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i76c8c1dcfb3247a6b15b3036d4069cbc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZToxZmQyODYwMzg4ZDk0ZDY3ODBhYTBhM2FjNmM2ZThiMy90YWJsZXJhbmdlOjFmZDI4NjAzODhkOTRkNjc4MGFhMGEzYWM2YzZlOGIzXzMtNS0xLTEtMTM5MDYy_14026b03-b3a3-414a-a9c1-1d64f606f8ea"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i76c8c1dcfb3247a6b15b3036d4069cbc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZToxZmQyODYwMzg4ZDk0ZDY3ODBhYTBhM2FjNmM2ZThiMy90YWJsZXJhbmdlOjFmZDI4NjAzODhkOTRkNjc4MGFhMGEzYWM2YzZlOGIzXzMtNy0xLTEtMTM5MDYy_d2b3eac3-e988-4f0e-8a2a-4e9377ed7ef9"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i76c8c1dcfb3247a6b15b3036d4069cbc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZToxZmQyODYwMzg4ZDk0ZDY3ODBhYTBhM2FjNmM2ZThiMy90YWJsZXJhbmdlOjFmZDI4NjAzODhkOTRkNjc4MGFhMGEzYWM2YzZlOGIzXzMtOS0xLTEtMTM5MDYy_a9fe6300-df61-4687-bc33-834d270d064d"
      unitRef="usd">230500000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i76c8c1dcfb3247a6b15b3036d4069cbc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDIvZnJhZzoyZWI5MGRlMjA3M2I0ZDFkOWVjODc2Y2QyMGEzZTFhMS90YWJsZToxZmQyODYwMzg4ZDk0ZDY3ODBhYTBhM2FjNmM2ZThiMy90YWJsZXJhbmdlOjFmZDI4NjAzODhkOTRkNjc4MGFhMGEzYWM2YzZlOGIzXzMtMTEtMS0xLTEzOTA2Mg_8e566e13-2e0a-44b0-8228-a0f070f5dd2e"
      unitRef="usd">1000000.0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90ZXh0cmVnaW9uOmUzYWI0ZDY1YTQ3ZDRiMzY5OTI4ZGI5ZDJkNGQxODc5XzUxOA_11ff65ef-950a-42c7-8116-7b4ddf8a4f2c">Fair Value Measurements&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of investments, which were measured at fair value on a recurring basis.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.464%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Leveling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Leveling&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;262.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;262.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted cash:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;156.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;156.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;548.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;548.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;485.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;485.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;321.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;321.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;240.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;240.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities&#x2013;biotechnology industry&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,398.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;372.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,025.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,338.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;396.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;931.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of equity security investments, which were measured at fair value on a recurring basis using significant unobservable inputs (Level 3):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchases &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized gain (loss) included in earnings &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Transfers out of Level 3 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(31.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(52.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%"&gt;_________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Unrealized gains and losses on equity security investments which were measured at fair value on a recurring basis using significant unobservable inputs (Level 3) and are included in other income (expense), net.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2) Certain of our equity security investments were transferred from Level 3 to Level 1 during 2022 and 2021 as the associated holding period restriction expired.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90ZXh0cmVnaW9uOmUzYWI0ZDY1YTQ3ZDRiMzY5OTI4ZGI5ZDJkNGQxODc5XzUxNg_4abe7061-88d1-48c0-9b3d-c2c94dda6a3e">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of investments, which were measured at fair value on a recurring basis.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.464%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Leveling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Leveling&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;262.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;262.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted cash:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;156.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;156.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;548.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;548.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;485.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;485.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;321.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;321.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;240.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;240.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities&#x2013;biotechnology industry&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,398.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;372.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,025.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,338.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;396.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;931.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:Investments
      contextRef="id63f24106d73460cb43b5496689583ba_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzQtMS0xLTEtMTM5MDYy_8e99137c-95b2-424c-8d29-bebfcaa957d1"
      unitRef="usd">262900000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iea0e6362bc9a41baa6232f3d791b1b30_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzQtMy0xLTEtMTM5MDYy_abdbc3b3-6fc5-492e-8bbb-e620d80fa445"
      unitRef="usd">262900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5b718dc4ea4045ddb88690b0606e023f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzQtNS0xLTEtMTM5MDYy_a494a4c2-cc88-4301-a190-340ed48e50d9"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8286a497677b4b46a9e257151dfe0240_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzQtNy0xLTEtMTM5MDYy_b1955d96-f54d-4c64-8a0d-0c674f8b8fc7"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i5e2f6bb95ef942549f5717766447bf89_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzQtOS0xLTEtMTM5MDYy_7084492f-de04-47f1-9bfb-f7c30ce99654"
      unitRef="usd">340800000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6b0d1aff1c264abba7252395e73cacd2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzQtMTEtMS0xLTEzOTA2Mg_ebdaee5a-915e-45b4-9d1c-697e647b56ce"
      unitRef="usd">340800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9258781d2d9a48c3abc627b4e38a38f6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzQtMTMtMS0xLTEzOTA2Mg_b2aca89e-29e0-4871-9057-41b0b03a943b"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icacc4e9a05c844698340e3f6ee1020e9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzQtMTUtMS0xLTEzOTA2Mg_671bdc7a-63df-4372-a426-f511590a631d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="ie3469d1c34084c0caf63fea3b7ad7ad0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzYtMS0xLTEtMTM5MDYy_74419944-012d-465f-b6d8-a030ad178d46"
      unitRef="usd">7800000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i55208f6888cb4f1aa1161cb859460aa3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzYtMy0xLTEtMTM5MDYy_03ea3df9-d271-43fa-9072-56038bc79e78"
      unitRef="usd">7800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i88ef2bfe4b974f9dbf50fa97b715887d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzYtNS0xLTEtMTM5MDYy_a70bd651-175b-468a-8703-3a512a7dbdce"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icb0138cfa605465396a47f3dd519480e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzYtNy0xLTEtMTM5MDYy_c27eefdd-a469-4770-bfdb-a09520efc0e6"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="id8f1b78aab9747879b7bf25dd9a9712c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzYtOS0xLTEtMTM5MDYy_085ae7c4-3991-4467-a997-37824c29b259"
      unitRef="usd">3200000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic12ec9940933424ea6839c2a0d9170e3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzYtMTEtMS0xLTEzOTA2Mg_970f1536-f742-4ac3-a6c8-5176b913c657"
      unitRef="usd">3200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6e86195663524f63a9bd0a9f18bf1cbf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzYtMTMtMS0xLTEzOTA2Mg_2ed7fa9d-cbf4-4fa4-8a6f-9d837f6c5946"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5eb4267dd8494bd9b9dcaabe2416461d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzYtMTUtMS0xLTEzOTA2Mg_b9215266-c18a-4b24-8841-848115b56cf6"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i654c80e71bff4d869218415b7e3dc0a0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzgtMS0xLTEtMTM5MDYy_cb86ea86-a3b7-424d-816c-dde5e03967d7"
      unitRef="usd">156000000.0</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i007cfabe3a8849bab803ba60c015eab2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzgtMy0xLTEtMTM5MDYy_c095358d-3eb8-41d0-bf8a-02e7390b175b"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3a9b7472fc7b4972acb2ac9f7cef302d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzgtNS0xLTEtMTM5MDYy_4b3a86a4-cb8c-41d3-8970-ae1fca97316b"
      unitRef="usd">156000000.0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibeb578648cbe47d9949ee6e34fe0ad99_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzgtNy0xLTEtMTM5MDYy_96c91fd8-38e3-4ac0-acbd-b9dc76a48360"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="iae37ac3f84054636b37554762cc34e63_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzgtOS0xLTEtMTM5MDYy_483e7e53-a21b-46f9-8e64-23ddde8cd975"
      unitRef="usd">204800000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie46d509c4cb348eeba80e5d4d37e4475_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzgtMTEtMS0xLTEzOTA2Mg_c3d1d65f-f788-4c7e-832d-df0a3563f61a"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i439770d7fd6f4f859128c5157c9235a1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzgtMTMtMS0xLTEzOTA2Mg_522c9a94-839f-4b7e-995f-49b394c3081f"
      unitRef="usd">204800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if2b42a9d8bc44f1ea40843385e1e20d1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzgtMTUtMS0xLTEzOTA2Mg_c3706799-58b2-4b4a-953e-1929f9121488"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i10967d72424a4f7791a64e8d6c259d64_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzktMS0xLTEtMTM5MDYy_f7d6cc71-1903-4346-bdf7-7d03c535fba9"
      unitRef="usd">548400000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia49862c3506f4b74acff88c95716b232_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzktMy0xLTEtMTM5MDYy_6c7b185c-58b2-41d0-bda5-79d1052349f9"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i61c8a28f6dfe4ed090fe32a6157f5e6c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzktNS0xLTEtMTM5MDYy_563c6684-10dc-4e6b-a676-1d882d0328b9"
      unitRef="usd">548400000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i592eaf87071c432cb1c6e78bf7a7e092_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzktNy0xLTEtMTM5MDYy_82064331-3359-4147-a5e3-935eff3cf4e2"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i4474116f1b674daca505b919ccc95074_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzktOS0xLTEtMTM5MDYy_b4e15e90-7afd-4a72-a466-b651c3188daa"
      unitRef="usd">485500000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i699cec09a8334f4c8b6ac965045cb456_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzktMTEtMS0xLTEzOTA2Mg_3fcc6a17-4e05-4d51-b70a-bdb1831fbec4"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1ddb56fada71460eba444fd3d97f4b69_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzktMTMtMS0xLTEzOTA2Mg_8be82e11-f0a8-4b64-8331-04f92924cb7b"
      unitRef="usd">485500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib57d06337718492f9cfef217012538ee_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzktMTUtMS0xLTEzOTA2Mg_3e0c36c1-0961-44e7-96e2-c1b6d901a96b"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i4fd315b303184968b952d7bb6d9c6472_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEwLTEtMS0xLTEzOTA2Mg_17e91672-40e9-4844-851b-ce11867b64ca"
      unitRef="usd">321400000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8e1a8fc8f38c4c8aa7c1dae7f202b3b4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEwLTMtMS0xLTEzOTA2Mg_da2f748a-7dca-46a9-81bc-bb1aef97c424"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idec09e5a03864099989354c76b828527_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEwLTUtMS0xLTEzOTA2Mg_21d3b865-8dbd-404f-ae71-eb01ba74160c"
      unitRef="usd">321400000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i31b04184eff74bf4b5192930aacadfec_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEwLTctMS0xLTEzOTA2Mg_9c7866ad-615f-4958-a972-27cb2bb65349"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i26120348d6074f35b090ebbda6b3fcf0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEwLTktMS0xLTEzOTA2Mg_b9161e6c-7c49-4616-9a5b-3c4ffcd93d98"
      unitRef="usd">240900000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifc55062153d94ad7b8d61e6d19057c50_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEwLTExLTEtMS0xMzkwNjI_77b9ac72-c6a9-4d89-bda6-689dba0c73c1"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if47e96c65cb74988b1f42acee047add6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEwLTEzLTEtMS0xMzkwNjI_aea05c42-f1ab-458f-85f5-4e3e0324964c"
      unitRef="usd">240900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2d61b3503a4e475e8484e3f0377b2a11_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEwLTE1LTEtMS0xMzkwNjI_956ea3bb-1f5a-4434-acf5-e2a110760d52"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="ibf22fe030fdf4397978434417c7b8788_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEyLTEtMS0xLTEzOTA2Mg_3bb6d315-22ef-4008-a795-7c8b50e208e9"
      unitRef="usd">102100000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i23f85f7c13a54d018aba01edd3e7dbf6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEyLTMtMS0xLTEzOTA2Mg_c76368b2-2bbe-4eed-8ace-c1da7e4a2d9b"
      unitRef="usd">102100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i69926a6399c34cf885a190c0d20df7f3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEyLTUtMS0xLTEzOTA2Mg_adb2a83c-768f-4273-9a4c-9d26d9499917"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib5a5bad1ec804fe58946f735c8b3b59a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEyLTctMS0xLTEzOTA2Mg_69caa9fa-907e-4b69-8ecb-1686e1773f3d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i3416e3592d234d7aa0dc1a6d0c4492e2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEyLTktMS0xLTEzOTA2Mg_693dd4d3-a5b7-4f35-bb25-eb463811b5bd"
      unitRef="usd">63700000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if164f03cdc61491492728ca7e7517143_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEyLTExLTEtMS0xMzkwNjI_f5a6ecab-4927-4508-8eb4-92995554aed9"
      unitRef="usd">52700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7a0f1b836d0749b486fff5c035616613_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEyLTEzLTEtMS0xMzkwNjI_57ecc8fa-8af8-4e5f-8d64-22e3d7a5ad92"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i19826127b8b3400a9e18b46be425bc61_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEyLTE1LTEtMS0xMzkwNjI_a687a052-1681-4572-9f36-d87a088e9d63"
      unitRef="usd">11000000.0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i6ce1cf497c004f079441d676651e2808_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEzLTEtMS0xLTEzOTA2Mg_6579b7f7-75bd-4072-9d51-70a3ae6053c5"
      unitRef="usd">1398600000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8373d29f581740ec8093f00de6a55275_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEzLTMtMS0xLTEzOTA2Mg_305e6549-ddd6-4c34-8a5e-ffc86bfb8de9"
      unitRef="usd">372800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id96df92d50994507814aa00688b39486_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEzLTUtMS0xLTEzOTA2Mg_22c03f64-4fdc-4993-a33b-51ee5b2d8eb1"
      unitRef="usd">1025800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iedb24ff2ca7b44618a98e55d5e02fb8a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEzLTctMS0xLTEzOTA2Mg_564cb860-2741-4757-ad69-3b2e35ff0f24"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i170c112de5b842e4b59047014a54dcc0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEzLTktMS0xLTEzOTA2Mg_04d05b68-ef8d-4366-9064-6104f41dc4f6"
      unitRef="usd">1338900000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9fc84fce9b6f4f4494703d493708167e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEzLTExLTEtMS0xMzkwNjI_c09accd6-5222-4aed-aa20-667c7b693f95"
      unitRef="usd">396700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i607d3acd1b9a45c49ba0983930259c41_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEzLTEzLTEtMS0xMzkwNjI_d3898901-32b3-411c-a208-1111f7fb5bac"
      unitRef="usd">931200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i738cf7daafb54a76adcadab34123ba8f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo5ZWY2MzE2YmUwNWM0ZjFmYjBiMmNjYzExMWNhOTIzYS90YWJsZXJhbmdlOjllZjYzMTZiZTA1YzRmMWZiMGIyY2NjMTExY2E5MjNhXzEzLTE1LTEtMS0xMzkwNjI_c5ce3e0c-e7ad-45ae-b125-76628e84f38f"
      unitRef="usd">11000000.0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90ZXh0cmVnaW9uOmUzYWI0ZDY1YTQ3ZDRiMzY5OTI4ZGI5ZDJkNGQxODc5XzUxNw_a04b2491-418f-4399-9660-4caf752f4eda">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of equity security investments, which were measured at fair value on a recurring basis using significant unobservable inputs (Level 3):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchases &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized gain (loss) included in earnings &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Transfers out of Level 3 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(31.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(52.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%"&gt;_________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Unrealized gains and losses on equity security investments which were measured at fair value on a recurring basis using significant unobservable inputs (Level 3) and are included in other income (expense), net.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2) Certain of our equity security investments were transferred from Level 3 to Level 1 during 2022 and 2021 as the associated holding period restriction expired.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:EquitySecuritiesFvNiRestricted
      contextRef="i19826127b8b3400a9e18b46be425bc61_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo0MDEyZjNmMmU3MWU0ZDgxOWZhMDJlZDI2YjUxYzk1MC90YWJsZXJhbmdlOjQwMTJmM2YyZTcxZTRkODE5ZmEwMmVkMjZiNTFjOTUwXzItMS0xLTEtMTM5MDYy_93d57a4d-0d53-47ad-90be-7b9d0f3735a8"
      unitRef="usd">11000000.0</us-gaap:EquitySecuritiesFvNiRestricted>
    <us-gaap:EquitySecuritiesFvNiRestricted
      contextRef="i8e243caf058841239f5b24d4011ad3df_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo0MDEyZjNmMmU3MWU0ZDgxOWZhMDJlZDI2YjUxYzk1MC90YWJsZXJhbmdlOjQwMTJmM2YyZTcxZTRkODE5ZmEwMmVkMjZiNTFjOTUwXzItMy0xLTEtMTM5MDYy_0a100269-5e1b-4c64-b41e-81a065573b23"
      unitRef="usd">38200000</us-gaap:EquitySecuritiesFvNiRestricted>
    <us-gaap:EquitySecuritiesFvNiRestricted
      contextRef="i202b3b88d9ac4d138f5675ec9220d37e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo0MDEyZjNmMmU3MWU0ZDgxOWZhMDJlZDI2YjUxYzk1MC90YWJsZXJhbmdlOjQwMTJmM2YyZTcxZTRkODE5ZmEwMmVkMjZiNTFjOTUwXzItNS0xLTEtMTM5MDYy_b40b979f-0e4a-4322-8659-de7cd3381255"
      unitRef="usd">55900000</us-gaap:EquitySecuritiesFvNiRestricted>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="i4971e09f913f4c90bd8fd83e1d0fcd54_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo0MDEyZjNmMmU3MWU0ZDgxOWZhMDJlZDI2YjUxYzk1MC90YWJsZXJhbmdlOjQwMTJmM2YyZTcxZTRkODE5ZmEwMmVkMjZiNTFjOTUwXzMtMS0xLTEtMTM5MDYy_a3c63265-b691-4b25-8c84-3adcb747d291"
      unitRef="usd">0</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="ia3f57bcb850140d7aa4beb063512caf3_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo0MDEyZjNmMmU3MWU0ZDgxOWZhMDJlZDI2YjUxYzk1MC90YWJsZXJhbmdlOjQwMTJmM2YyZTcxZTRkODE5ZmEwMmVkMjZiNTFjOTUwXzMtMy0xLTEtMTM5MDYy_eb88e077-7a65-4e44-9b6f-4d580e0dbf74"
      unitRef="usd">4600000</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="idd3d786e58da41c8ab668363ea9b72d4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo0MDEyZjNmMmU3MWU0ZDgxOWZhMDJlZDI2YjUxYzk1MC90YWJsZXJhbmdlOjQwMTJmM2YyZTcxZTRkODE5ZmEwMmVkMjZiNTFjOTUwXzMtNS0xLTEtMTM5MDYy_fb0c6d44-c2c6-43bd-a2a8-914d54aac91a"
      unitRef="usd">0</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ie68e2d5dfa5744d28e808e7184b1ac64_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo0MDEyZjNmMmU3MWU0ZDgxOWZhMDJlZDI2YjUxYzk1MC90YWJsZXJhbmdlOjQwMTJmM2YyZTcxZTRkODE5ZmEwMmVkMjZiNTFjOTUwXzQtMS0xLTEtMTM5MDYy_4fb7ee57-aa3a-455a-ab33-732c8125b183"
      unitRef="usd">20800000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i1910f568982940418f0b3f4ef8742b36_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo0MDEyZjNmMmU3MWU0ZDgxOWZhMDJlZDI2YjUxYzk1MC90YWJsZXJhbmdlOjQwMTJmM2YyZTcxZTRkODE5ZmEwMmVkMjZiNTFjOTUwXzQtMy0xLTEtMTM5MDYy_cf6b3a97-f1e9-4c5d-94a1-c7920f636a9f"
      unitRef="usd">20900000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="iea06eb619bca46279cd1e26fd668574c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo0MDEyZjNmMmU3MWU0ZDgxOWZhMDJlZDI2YjUxYzk1MC90YWJsZXJhbmdlOjQwMTJmM2YyZTcxZTRkODE5ZmEwMmVkMjZiNTFjOTUwXzQtNS0xLTEtMTM5MDYy_6ec954c2-0123-4bda-b132-d1596a7afa1a"
      unitRef="usd">-17700000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="ie68e2d5dfa5744d28e808e7184b1ac64_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo0MDEyZjNmMmU3MWU0ZDgxOWZhMDJlZDI2YjUxYzk1MC90YWJsZXJhbmdlOjQwMTJmM2YyZTcxZTRkODE5ZmEwMmVkMjZiNTFjOTUwXzUtMS0xLTEtMTM5MDYy_9e5b11df-914c-440f-a757-a5dc7780919d"
      unitRef="usd">31800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="i1910f568982940418f0b3f4ef8742b36_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo0MDEyZjNmMmU3MWU0ZDgxOWZhMDJlZDI2YjUxYzk1MC90YWJsZXJhbmdlOjQwMTJmM2YyZTcxZTRkODE5ZmEwMmVkMjZiNTFjOTUwXzUtMy0xLTEtMTM5MDYy_2e99cfb6-0f2e-41d3-a8b8-0ed6d755f1eb"
      unitRef="usd">52700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="iea06eb619bca46279cd1e26fd668574c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo0MDEyZjNmMmU3MWU0ZDgxOWZhMDJlZDI2YjUxYzk1MC90YWJsZXJhbmdlOjQwMTJmM2YyZTcxZTRkODE5ZmEwMmVkMjZiNTFjOTUwXzUtNS0xLTEtMTM5MDYy_920c6e39-a72b-44de-a9a4-a38f8a6d4887"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:EquitySecuritiesFvNiRestricted
      contextRef="ib5a5bad1ec804fe58946f735c8b3b59a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo0MDEyZjNmMmU3MWU0ZDgxOWZhMDJlZDI2YjUxYzk1MC90YWJsZXJhbmdlOjQwMTJmM2YyZTcxZTRkODE5ZmEwMmVkMjZiNTFjOTUwXzYtMS0xLTEtMTM5MDYy_11ad9bfc-3b24-4db6-a8aa-e1fe689c1341"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiRestricted>
    <us-gaap:EquitySecuritiesFvNiRestricted
      contextRef="i19826127b8b3400a9e18b46be425bc61_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo0MDEyZjNmMmU3MWU0ZDgxOWZhMDJlZDI2YjUxYzk1MC90YWJsZXJhbmdlOjQwMTJmM2YyZTcxZTRkODE5ZmEwMmVkMjZiNTFjOTUwXzYtMy0xLTEtMTM5MDYy_28cd8ce1-70aa-45f9-be21-b27bd04d92ca"
      unitRef="usd">11000000.0</us-gaap:EquitySecuritiesFvNiRestricted>
    <us-gaap:EquitySecuritiesFvNiRestricted
      contextRef="i8e243caf058841239f5b24d4011ad3df_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDUvZnJhZzplM2FiNGQ2NWE0N2Q0YjM2OTkyOGRiOWQyZDRkMTg3OS90YWJsZTo0MDEyZjNmMmU3MWU0ZDgxOWZhMDJlZDI2YjUxYzk1MC90YWJsZXJhbmdlOjQwMTJmM2YyZTcxZTRkODE5ZmEwMmVkMjZiNTFjOTUwXzYtNS0xLTEtMTM5MDYy_22af6d1b-1c1b-4a65-84f6-af35cf4d5bb2"
      unitRef="usd">38200000</us-gaap:EquitySecuritiesFvNiRestricted>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzgxMDM_a0f8eab5-0588-4d1f-9af5-c872d472a318">Convertible Senior Notes&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May&#160;2, 2017, we completed a private placement of $517.5 million in aggregate principal amount of 2.25% fixed-rate convertible senior notes due May&#160;15, 2024, or the 2024 Notes, and entered into the 2017 Indenture with respect to the 2024 Notes. Interest on the 2024 Notes is due semi-annually on May 15 and November 15 of each year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with authoritative guidance in effect at the time of issuance, we were required to separately account for the liability and equity components of the 2024 Notes. The initial carrying value of the liability component of $368.3 million was calculated using a 7.50% assumed borrowing rate, which reflected the market interest rate for a similar non-convertible instrument at the date of issuance. The equity component of $149.2 million, which was treated as a discount on the liability component and amortized over the seven-year term of the 2024 Notes using the effective interest rate method, was determined by deducting the fair value of the liability component from the par value of the 2024 Notes and recorded as an increase to additional paid-in capital on the issuance date. In addition, we allocated transaction costs of $14.7 million related to the issuance of the 2024 Notes to the liability and equity components based on their relative values on the issuance date. Transaction costs attributable to the liability component were being amortized over the seven-year term of the 2024 Notes using the effective interest rate method, while transaction costs attributable to the equity component were recorded as a reduction to additional paid-in capital on the issuance date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fourth quarter of 2020, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $136.2 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9 million in cash. We accounted for the partial repurchase of the 2024 Notes as a debt extinguishment. As a result, we attributed $130.7 million of the aggregate repurchase price to the liability component based on the fair value of the liability component immediately before extinguishment. The fair value of the liability component was calculated at settlement using a discounted cash flow analysis with a discount rate of 3.37%, which was the market rate for similar notes that have no conversion rights. The difference of $56.3 million between the fair value of the aggregate consideration remitted to certain holders of the 2024 Notes and the fair value of the liability component was attributed to the reacquisition of the equity component and recorded as a reduction to additional paid-in capital. The carrying amount of the liability of $112.4 million at settlement was recognized as a reduction to the 2024 Notes and resulted in an $18.4 million loss on extinguishment, which we recognized in 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2022, we adopted &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNDc2NA_b11908b6-457c-4872-91a0-7e1b27137ced"&gt;ASU 2020-06&lt;/span&gt; using the modified retrospective transition method, which allowed for a cumulative-effect adjustment in the period of adoption and did not require restatement of prior period amounts. Under this transition method, the cumulative effect of the accounting change increased the carrying amount of the 2024 Notes by $42.2 million, reduced deferred tax liabilities by $9.9 million, reduced additional paid-in capital by $106.8 million, and reduced the accumulated deficit by $74.5 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the second quarter of 2022, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $210.8 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $279.0 million in cash. We accounted for the partial repurchase of the 2024 Notes as a debt extinguishment, which resulted in the recognition of a $70.0 million loss on extinguishment in 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the 2024 Notes as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unamortized Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Leveling&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;169.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the 2024 Notes as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unamortized Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Leveling&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;381.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(43.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;335.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;464.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the interest expense of the 2024 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Coupon interest&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, we entered into the First Supplemental Indenture to the 2017 Indenture, pursuant to which we irrevocably elected to settle the principal amount of the 2024 Notes in cash upon conversion and to settle any conversion premium, calculated based on the per share volume-weighted average price for each of the 30 consecutive trading days during the observation period (as more fully described in the 2017 Indenture), in either cash or shares of our common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The initial conversion rate for the 2024 Notes, which is subject to adjustment in some events (as provided for in the 2017 Indenture), is 13.1711 shares of common stock per $1,000 principal amount and equivalent to an initial conversion price of approximately $75.92 per share, reflecting a conversion premium of approximately 42.5% above the closing price of $53.28 per share of our common stock on April&#160;26, 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may redeem for cash all or part of the 2024 Notes if the last reported sale price (as defined in the 2017 Indenture) of our common stock has been at least 130% of the conversion price then in effect (equal to $98.70 as of December&#160;31, 2022) for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading-day period ending on, and including, the trading day immediately before the date which we provide notice of redemption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2024 Notes may convert the 2024 Notes at any time prior to the close of business on the business day immediately preceding May&#160;15, 2024, only under the following circumstances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(i)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt"&gt;during any calendar quarter (and only during such calendar quarter), if the last reported sale price of our common stock for at least&#160;20&#160;trading days (whether or not consecutive) during a period of&#160;30&#160;consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than&#160;130%&#160;of the conversion price (equal to $98.70 as of December&#160;31, 2022) on each applicable trading day;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ii)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt"&gt;during the&#160;five business-day period immediately after any&#160;five&#160;consecutive trading-day period (the measurement period) in which the trading price (as defined in the 2017 Indenture) per&#160;$1,000&#160;principal amount of the 2024 Notes for each trading day of the measurement period was less than&#160;98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(iii)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.03pt"&gt;upon the occurrence of specified corporate events, including a merger or a sale of all or substantially all of our assets; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(iv)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.57pt"&gt;if we call the 2024 Notes for redemption, until the close of business on the business day immediately preceding the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On or after January&#160;15, 2024, until the close of business on the scheduled trading day immediately preceding May&#160;15, 2024, holders of the 2024 Notes may convert the 2024 Notes at any time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the conditional conversion feature described under (i) above was triggered as of December 31, 2022, holders of the 2024 Notes may convert the 2024 Notes at any time during the period beginning on January 1, 2023, and ending at the close of business on March 31, 2023. Accordingly, the 2024 Notes have been classified as a current liability as of December 31, 2022. The future conditional convertibility of the 2024 Notes will be monitored at each quarterly reporting date and analyzed dependent upon market prices of our common stock during the prescribed measurement periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon conversion, holders will receive the principal amount of their 2024 Notes in cash and any excess conversion value, calculated based on the per share volume-weighted average price for each of the 30 consecutive trading days during the observation period (as more fully described in the 2017 Indenture), in either cash or shares of our common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If we undergo a fundamental change (as defined in the 2017 Indenture), subject to certain conditions, holders of the 2024 Notes may require us to repurchase for cash all or part of their 2024 Notes at a repurchase price equal to 100% of the principal amount of the 2024 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, if a make-whole fundamental change (as defined in the 2017 Indenture) occurs prior to January&#160;15, 2024, we would, in certain circumstances, increase the conversion rate for a holder who elects to convert their notes in connection with the make-whole fundamental change.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2024 Notes are our general unsecured obligations that rank senior in right of payment to all of our indebtedness that is expressly subordinated in right of payment to the 2024 Notes, and equal in right of payment to our unsecured indebtedness. The 2024 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by us. The 2017 Indenture contains customary events of default with respect to the 2024 Notes, including that upon certain events of default, 100% of the principal and accrued and unpaid interest on the 2024 Notes will automatically become due and payable.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i4b5b4f7eab2446ce84ea30524cbd6aa0_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzMjEyOA_cb3505f0-7d11-4ef3-a1c9-16525e9b2922"
      unitRef="usd">517500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4b5b4f7eab2446ce84ea30524cbd6aa0_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzMjE2NQ_8d782fd5-97a8-4b26-8dc2-09f8a81a0d3b"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <nbix:CarryingAmountOfLiabilityComponentUponIssuance
      contextRef="i4b5b4f7eab2446ce84ea30524cbd6aa0_I20170502"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzMjU2Mw_3f198dd8-5f67-4aeb-818f-2be3a39c0aa9"
      unitRef="usd">368300000</nbix:CarryingAmountOfLiabilityComponentUponIssuance>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="i35bad398da4e4adb94afe6a3edc6fbd6_D20170502-20170502"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzMjU5MA_550cf0c8-aad8-41f4-9f02-db8d40895899"
      unitRef="number">0.0750</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="i4b5b4f7eab2446ce84ea30524cbd6aa0_I20170502"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzMjc0OQ_e0f62ac0-5e24-4e88-87a1-caca9d625b9e"
      unitRef="usd">149200000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:DebtInstrumentTerm
      contextRef="i35bad398da4e4adb94afe6a3edc6fbd6_D20170502-20170502"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzQzOTgwNDY1Mzc5NTU_c5566527-47cf-423e-94f4-a570d03b39ec">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i4b5b4f7eab2446ce84ea30524cbd6aa0_I20170502"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzMzEzMA_bccd779f-0ba5-4152-9fb8-b1803fbb903c"
      unitRef="usd">14700000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtInstrumentTerm
      contextRef="i35bad398da4e4adb94afe6a3edc6fbd6_D20170502-20170502"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzQzOTgwNDY1Mzc5NTY_3e2c317b-4b59-4670-af0f-a3d7844d44b3">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="id330e3069fc840d18f4175221a90fd47_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzMzY5NQ_d186da92-296f-4fc3-9574-0c38f145d67d"
      unitRef="usd">136200000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:RepaymentsOfDebt
      contextRef="i48eccd3ba1b3454495acdad169d5d6f5_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzMzc3NA_6abc82f0-ecc8-40c3-867d-013a996e998f"
      unitRef="usd">186900000</us-gaap:RepaymentsOfDebt>
    <nbix:FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment
      contextRef="i48eccd3ba1b3454495acdad169d5d6f5_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzMzg5MQ_d55db1b4-e213-40e7-9149-ad6d7eb4422c"
      unitRef="usd">130700000</nbix:FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i629ba4e4ef664986a91d0ae915e45857_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNDE3NQ_b1e2526a-8a7f-4901-8f3f-f0043cc5a0df"
      unitRef="number">0.0337</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments
      contextRef="i48eccd3ba1b3454495acdad169d5d6f5_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNDI3NA_14d1683f-8dc4-4368-b490-15b26d5028fd"
      unitRef="usd">56300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments>
    <nbix:CarryingAmountOfLiabilityComponentAtSettlement
      contextRef="i48eccd3ba1b3454495acdad169d5d6f5_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNDU3Ng_7a75810a-bd62-43e3-8834-372d84d16def"
      unitRef="usd">112400000</nbix:CarryingAmountOfLiabilityComponentAtSettlement>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ibb0ec417ca564717bb097aa83567533a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNDY1NA_115addce-cb6e-44a3-860e-b12309049fe5"
      unitRef="usd">-18400000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i7b26f825c6434881a754e7e6c53ed556_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNTA3Mw_ab6805cc-c8e2-4d42-a97f-fd70c8b37e80"
      unitRef="usd">42200000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i7b26f825c6434881a754e7e6c53ed556_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNTExNA_b1a7c797-e094-4508-8b50-c99e7fa1d9e0"
      unitRef="usd">-9900000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i7b26f825c6434881a754e7e6c53ed556_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNTE1Nw_2e77ce7d-d0e0-4cfd-b7f4-f2955414de9a"
      unitRef="usd">-106800000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i7b26f825c6434881a754e7e6c53ed556_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNTIwMQ_fd21ee6f-67bc-4df7-b9cc-b168c633a8ba"
      unitRef="usd">74500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i601493722ddc4060955049e1e99ec96e_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNTM1MA_93d23992-35da-4d57-9b3f-4f3a9409e015"
      unitRef="usd">210800000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:RepaymentsOfDebt
      contextRef="iaee95a0d57144ecaa3a678d3909bf7b2_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNTQzNg_d114252f-b043-440d-bd48-3c9babf48e23"
      unitRef="usd">279000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i9bf8e6cfdf3742479b08b59beb60be53_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNTU3Mg_f9056ffc-9bf1-4aa3-92d0-74017fc36e2b"
      unitRef="usd">-70000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzQzOTgwNDY1Mzc5NTc_0a786499-e622-4420-a0e3-51b03fb2f1bb">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the 2024 Notes as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unamortized Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Leveling&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;169.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the 2024 Notes as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unamortized Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Leveling&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;381.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(43.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;335.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;464.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the interest expense of the 2024 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Coupon interest&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i48dd18e80c3e4426a4bf9c87e59b2aa4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90YWJsZTpjOTJlMDg0MTViY2U0MGE3YmNmYTQ3MzJkNGNmNzY3MC90YWJsZXJhbmdlOmM5MmUwODQxNWJjZTQwYTdiY2ZhNDczMmQ0Y2Y3NjcwXzItMS0xLTEtMTQwMTY4_8b64d1da-2f31-495a-ab89-262d5f519764"
      unitRef="usd">170400000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="i48dd18e80c3e4426a4bf9c87e59b2aa4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90YWJsZTpjOTJlMDg0MTViY2U0MGE3YmNmYTQ3MzJkNGNmNzY3MC90YWJsZXJhbmdlOmM5MmUwODQxNWJjZTQwYTdiY2ZhNDczMmQ0Y2Y3NjcwXzItMy0xLTEtMTQwMTY4_16a09ccc-e2b8-49ea-95ff-57ccabe298aa"
      unitRef="usd">0</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i48dd18e80c3e4426a4bf9c87e59b2aa4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90YWJsZTpjOTJlMDg0MTViY2U0MGE3YmNmYTQ3MzJkNGNmNzY3MC90YWJsZXJhbmdlOmM5MmUwODQxNWJjZTQwYTdiY2ZhNDczMmQ0Y2Y3NjcwXzItNS0xLTEtMTQwMTY4_117bfdda-334f-4fd6-bbb1-8a63f2a2b48a"
      unitRef="usd">1000000.0</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="i48dd18e80c3e4426a4bf9c87e59b2aa4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90YWJsZTpjOTJlMDg0MTViY2U0MGE3YmNmYTQ3MzJkNGNmNzY3MC90YWJsZXJhbmdlOmM5MmUwODQxNWJjZTQwYTdiY2ZhNDczMmQ0Y2Y3NjcwXzItNy0xLTEtMTQwMTY4_82456780-8282-4e1b-b7c7-9bfe9d3d2662"
      unitRef="usd">169400000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i48dd18e80c3e4426a4bf9c87e59b2aa4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90YWJsZTpjOTJlMDg0MTViY2U0MGE3YmNmYTQ3MzJkNGNmNzY3MC90YWJsZXJhbmdlOmM5MmUwODQxNWJjZTQwYTdiY2ZhNDczMmQ0Y2Y3NjcwXzItOS0xLTEtMTQwMTY4_59c223db-aca7-443e-bb40-9f294b72341c"
      unitRef="usd">268000000.0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic5ecf9e10df34a7a853f2e59470d0f7f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90YWJsZTpkOTcwMzUwMTQ2MjY0NzY4ODhhNzkyMDUzZGJjYjZjZC90YWJsZXJhbmdlOmQ5NzAzNTAxNDYyNjQ3Njg4OGE3OTIwNTNkYmNiNmNkXzItMS0xLTEtMTQwMTY4_da253e66-90bb-4b23-8e3a-284e52dcde1f"
      unitRef="usd">381200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="ic5ecf9e10df34a7a853f2e59470d0f7f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90YWJsZTpkOTcwMzUwMTQ2MjY0NzY4ODhhNzkyMDUzZGJjYjZjZC90YWJsZXJhbmdlOmQ5NzAzNTAxNDYyNjQ3Njg4OGE3OTIwNTNkYmNiNmNkXzItMy0xLTEtMTQwMTY4_75726d90-e479-4e5a-8f19-da852aa05ca7"
      unitRef="usd">43200000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ic5ecf9e10df34a7a853f2e59470d0f7f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90YWJsZTpkOTcwMzUwMTQ2MjY0NzY4ODhhNzkyMDUzZGJjYjZjZC90YWJsZXJhbmdlOmQ5NzAzNTAxNDYyNjQ3Njg4OGE3OTIwNTNkYmNiNmNkXzItNS0xLTEtMTQwMTY4_bbc30dc3-81aa-4b83-80d6-9bb76817e2c6"
      unitRef="usd">2900000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="ic5ecf9e10df34a7a853f2e59470d0f7f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90YWJsZTpkOTcwMzUwMTQ2MjY0NzY4ODhhNzkyMDUzZGJjYjZjZC90YWJsZXJhbmdlOmQ5NzAzNTAxNDYyNjQ3Njg4OGE3OTIwNTNkYmNiNmNkXzItNy0xLTEtMTQwMTY4_081ed243-f4c2-452b-ac48-aa411fb7dbe8"
      unitRef="usd">335100000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ic5ecf9e10df34a7a853f2e59470d0f7f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90YWJsZTpkOTcwMzUwMTQ2MjY0NzY4ODhhNzkyMDUzZGJjYjZjZC90YWJsZXJhbmdlOmQ5NzAzNTAxNDYyNjQ3Njg4OGE3OTIwNTNkYmNiNmNkXzItOS0xLTEtMTQwMTY4_285bb8c5-fdfd-41f8-8123-941de090c166"
      unitRef="usd">464700000</us-gaap:DebtInstrumentFairValue>
    <nbix:DebtInstrumentCouponInterest
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90YWJsZTpkODRhMjcxMTZkMDI0OWNhODFlMWUzM2Q1ODIwN2IxNS90YWJsZXJhbmdlOmQ4NGEyNzExNmQwMjQ5Y2E4MWUxZTMzZDU4MjA3YjE1XzItNS0xLTEtMTQwMTY4_66fe81aa-a032-4f39-9df2-eb3030f7ce29"
      unitRef="usd">5900000</nbix:DebtInstrumentCouponInterest>
    <nbix:DebtInstrumentCouponInterest
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90YWJsZTpkODRhMjcxMTZkMDI0OWNhODFlMWUzM2Q1ODIwN2IxNS90YWJsZXJhbmdlOmQ4NGEyNzExNmQwMjQ5Y2E4MWUxZTMzZDU4MjA3YjE1XzItNy0xLTEtMTQwMTY4_5912d272-0274-4187-a280-9deb0c530076"
      unitRef="usd">8500000</nbix:DebtInstrumentCouponInterest>
    <nbix:DebtInstrumentCouponInterest
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90YWJsZTpkODRhMjcxMTZkMDI0OWNhODFlMWUzM2Q1ODIwN2IxNS90YWJsZXJhbmdlOmQ4NGEyNzExNmQwMjQ5Y2E4MWUxZTMzZDU4MjA3YjE1XzItNS0xLTEtMTQwMjEz_1d6fe18d-caf5-4a69-b12f-458c5a2120b2"
      unitRef="usd">11400000</nbix:DebtInstrumentCouponInterest>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90YWJsZTpkODRhMjcxMTZkMDI0OWNhODFlMWUzM2Q1ODIwN2IxNS90YWJsZXJhbmdlOmQ4NGEyNzExNmQwMjQ5Y2E4MWUxZTMzZDU4MjA3YjE1XzMtNS0xLTEtMTQwMTY4_9289fd6c-bf3f-4b1c-bb55-b5d2a8b4190b"
      unitRef="usd">1200000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90YWJsZTpkODRhMjcxMTZkMDI0OWNhODFlMWUzM2Q1ODIwN2IxNS90YWJsZXJhbmdlOmQ4NGEyNzExNmQwMjQ5Y2E4MWUxZTMzZDU4MjA3YjE1XzMtNy0xLTEtMTQwMTY4_93fac2a5-eaf7-4337-a820-ba11783b468a"
      unitRef="usd">17300000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90YWJsZTpkODRhMjcxMTZkMDI0OWNhODFlMWUzM2Q1ODIwN2IxNS90YWJsZXJhbmdlOmQ4NGEyNzExNmQwMjQ5Y2E4MWUxZTMzZDU4MjA3YjE1XzMtNS0xLTEtMTQwMjEz_a2152edf-eaf5-4067-b4f4-a11c073fc4df"
      unitRef="usd">21400000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:InterestExpense
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90YWJsZTpkODRhMjcxMTZkMDI0OWNhODFlMWUzM2Q1ODIwN2IxNS90YWJsZXJhbmdlOmQ4NGEyNzExNmQwMjQ5Y2E4MWUxZTMzZDU4MjA3YjE1XzQtNS0xLTEtMTQwMTY4_6e8541c0-40b7-4e4c-92b0-84f3177d7f7f"
      unitRef="usd">7100000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90YWJsZTpkODRhMjcxMTZkMDI0OWNhODFlMWUzM2Q1ODIwN2IxNS90YWJsZXJhbmdlOmQ4NGEyNzExNmQwMjQ5Y2E4MWUxZTMzZDU4MjA3YjE1XzQtNy0xLTEtMTQwMTY4_442bda04-5473-4cfd-ac15-993885e92b6a"
      unitRef="usd">25800000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90YWJsZTpkODRhMjcxMTZkMDI0OWNhODFlMWUzM2Q1ODIwN2IxNS90YWJsZXJhbmdlOmQ4NGEyNzExNmQwMjQ5Y2E4MWUxZTMzZDU4MjA3YjE1XzQtNS0xLTEtMTQwMjEz_f3a788dc-5a38-4ad1-8397-c5d5c7fdd9f2"
      unitRef="usd">32800000</us-gaap:InterestExpense>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i17f7971a67b44e4798fe7f7d49131fe4_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNjEzNw_da7e4504-89f7-4e85-a332-4c07fd8820b2"
      unitRef="d">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <nbix:PrincipalAmountOnConversionRate
      contextRef="if30740e0928241cb97cfb0ed6563a982_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNjQzNQ_cb39c6e4-cb99-4087-bc48-8f8b8d074ee0"
      unitRef="usd">1000</nbix:PrincipalAmountOnConversionRate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i4b5b4f7eab2446ce84ea30524cbd6aa0_I20170502"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNjUxOQ_1c176d83-077a-4e2e-b017-759316a8ae8c"
      unitRef="usdPerShare">75.92</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <nbix:DebtInstrumentConvertibleConversionPremium
      contextRef="i4b5b4f7eab2446ce84ea30524cbd6aa0_I20170502"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNjU4Mw_47b779b9-dfe1-44a5-9c33-f0ade1817a80"
      unitRef="number">0.425</nbix:DebtInstrumentConvertibleConversionPremium>
    <us-gaap:SharePrice
      contextRef="i4b5b4f7eab2446ce84ea30524cbd6aa0_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNjYxNA_0d810886-dc26-4564-a466-741d3f7c9860"
      unitRef="usdPerShare">53.28</us-gaap:SharePrice>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i17f7971a67b44e4798fe7f7d49131fe4_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNjc5Ng_48c122a8-408a-43d7-a460-0b86c4190741"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleStockPriceTrigger
      contextRef="ibfcb863f462042bbaf5db27efbc920d6_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNjg0OQ_ded4fd99-a5ad-45a3-9608-ef4e849100ae"
      unitRef="usdPerShare">98.70</us-gaap:DebtInstrumentConvertibleStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i17f7971a67b44e4798fe7f7d49131fe4_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNjg3Nw_fb99f8fe-2b8e-41e1-a787-b4c85460c13b"
      unitRef="d">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i17f7971a67b44e4798fe7f7d49131fe4_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNjkzNA_da7e4504-89f7-4e85-a332-4c07fd8820b2"
      unitRef="d">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i17f7971a67b44e4798fe7f7d49131fe4_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNzM4MQ_fb99f8fe-2b8e-41e1-a787-b4c85460c13b"
      unitRef="d">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i17f7971a67b44e4798fe7f7d49131fe4_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNzQ0Ng_da7e4504-89f7-4e85-a332-4c07fd8820b2"
      unitRef="d">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i17f7971a67b44e4798fe7f7d49131fe4_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNzU2OA_48c122a8-408a-43d7-a460-0b86c4190741"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleStockPriceTrigger
      contextRef="ibfcb863f462042bbaf5db27efbc920d6_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNzYwNg_ded4fd99-a5ad-45a3-9608-ef4e849100ae"
      unitRef="usdPerShare">98.70</us-gaap:DebtInstrumentConvertibleStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i134fefee8f064cab9634e36d3fc21cfa_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNzY2NA_4d141455-2198-4c7e-b55c-ed83048a322f"
      unitRef="d">5</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i134fefee8f064cab9634e36d3fc21cfa_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNzcxMA_4d141455-2198-4c7e-b55c-ed83048a322f"
      unitRef="d">5</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <nbix:PrincipalAmountOnConversionRate
      contextRef="if30740e0928241cb97cfb0ed6563a982_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNzgyNQ_cb39c6e4-cb99-4087-bc48-8f8b8d074ee0"
      unitRef="usd">1000</nbix:PrincipalAmountOnConversionRate>
    <nbix:MinimumPercentageOfTradingPriceToLastReportedSalePrice
      contextRef="i134fefee8f064cab9634e36d3fc21cfa_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzNzkxOA_47104114-51d2-436d-b208-024ecebb32e8"
      unitRef="number">0.98</nbix:MinimumPercentageOfTradingPriceToLastReportedSalePrice>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i17f7971a67b44e4798fe7f7d49131fe4_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzOTE5NA_da7e4504-89f7-4e85-a332-4c07fd8820b2"
      unitRef="d">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="i35bad398da4e4adb94afe6a3edc6fbd6_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTgzOTU0MQ_c962eaef-1be6-4367-822d-6f09ced073a9"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="i35bad398da4e4adb94afe6a3edc6fbd6_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNDgvZnJhZzo5OTM3ZWJkNWQwYmQ0YTgzOWVkOWEyYTk0MTE3ZWFjMy90ZXh0cmVnaW9uOjk5MzdlYmQ1ZDBiZDRhODM5ZWQ5YTJhOTQxMTdlYWMzXzU0OTc1NTg0MDQ5Ng_c962eaef-1be6-4367-822d-6f09ced073a9"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGV4dHJlZ2lvbjpiYWVkYzViZjNkODQ0NmUzYWFkZWEyNDY5YzEyMzRlOF8yMTk5MDIzMjU4ODc5_bd3e1444-b713-4e36-b28b-5a09ef1ab643">Goodwill and Intangible Assets&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of Diurnal in November 2022, we recognized goodwill of $5.2&#160;million for the excess consideration transferred over the net assets acquired, reflecting the expected revenue and cost synergies of the combined company and assembled workforce.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the carrying amount of goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill recognized in connection with business combination&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents information relating to our recognized intangible assets as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Developed product rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the estimated annual amortization expense for our finite-lived intangible assets. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:Goodwill
      contextRef="i5a8688d19b0c4b7f9f790a262226d2ea_I20221101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGV4dHJlZ2lvbjpiYWVkYzViZjNkODQ0NmUzYWFkZWEyNDY5YzEyMzRlOF8xNjQ5MjY3NDQ3MzU2_733ab158-c072-4ccc-aacd-c25672892219"
      unitRef="usd">5200000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGV4dHJlZ2lvbjpiYWVkYzViZjNkODQ0NmUzYWFkZWEyNDY5YzEyMzRlOF8yMTk5MDIzMjU4ODgy_c1394c7c-4d94-4eaf-ab34-e9427fb197aa">&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the carrying amount of goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill recognized in connection with business combination&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGFibGU6OTg2N2M3ZjBlMDM1NDc0MGExNzMzOTQ0YzI5NTU4MGIvdGFibGVyYW5nZTo5ODY3YzdmMGUwMzU0NzQwYTE3MzM5NDRjMjk1NTgwYl8xLTEtMS0xLTE0NDcwOQ_f4374835-7c7d-44e7-9ed8-69e6d5a5db9c"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGFibGU6OTg2N2M3ZjBlMDM1NDc0MGExNzMzOTQ0YzI5NTU4MGIvdGFibGVyYW5nZTo5ODY3YzdmMGUwMzU0NzQwYTE3MzM5NDRjMjk1NTgwYl8yLTEtMS0xLTE0NDcwOQ_29f972a9-c5dc-40e2-8472-c781427b2f66"
      unitRef="usd">5200000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGFibGU6OTg2N2M3ZjBlMDM1NDc0MGExNzMzOTQ0YzI5NTU4MGIvdGFibGVyYW5nZTo5ODY3YzdmMGUwMzU0NzQwYTE3MzM5NDRjMjk1NTgwYl8zLTEtMS0xLTE1MDk1Mg_a8fb2645-c8d4-4f9b-860b-c1bf94fb7bd8"
      unitRef="usd">200000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGFibGU6OTg2N2M3ZjBlMDM1NDc0MGExNzMzOTQ0YzI5NTU4MGIvdGFibGVyYW5nZTo5ODY3YzdmMGUwMzU0NzQwYTE3MzM5NDRjMjk1NTgwYl8zLTEtMS0xLTE0NDcwOQ_e2ae4248-5416-4172-ab50-2c6f4e740c22"
      unitRef="usd">5400000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGV4dHJlZ2lvbjpiYWVkYzViZjNkODQ0NmUzYWFkZWEyNDY5YzEyMzRlOF8yMTk5MDIzMjU4ODg1_33cd858d-c0f3-4263-9c83-211d63c6adb6">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents information relating to our recognized intangible assets as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Developed product rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGV4dHJlZ2lvbjpiYWVkYzViZjNkODQ0NmUzYWFkZWEyNDY5YzEyMzRlOF8yMTk5MDIzMjU4ODg1_77f7964c-21b8-4c48-8baa-61ad951fe163">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents information relating to our recognized intangible assets as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Developed product rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i18d39a0874004a4dbfac9a59054c0309_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGFibGU6NDE3ZDg0N2ZmNTU5NGZhZmEwNjc0OTllOGNlMmExNGIvdGFibGVyYW5nZTo0MTdkODQ3ZmY1NTk0ZmFmYTA2NzQ5OWU4Y2UyYTE0Yl8xLTEtMS0xLTE2Mjk5Nw_338ae044-1b49-4f36-aecf-c901d1c94c95">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if6282ace541846298e168b3652f98351_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGFibGU6NDE3ZDg0N2ZmNTU5NGZhZmEwNjc0OTllOGNlMmExNGIvdGFibGVyYW5nZTo0MTdkODQ3ZmY1NTk0ZmFmYTA2NzQ5OWU4Y2UyYTE0Yl8xLTMtMS0xLTE0NDczNQ_e867784b-e8ac-4bfa-b83e-9f843033da81"
      unitRef="usd">34300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if6282ace541846298e168b3652f98351_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGFibGU6NDE3ZDg0N2ZmNTU5NGZhZmEwNjc0OTllOGNlMmExNGIvdGFibGVyYW5nZTo0MTdkODQ3ZmY1NTk0ZmFmYTA2NzQ5OWU4Y2UyYTE0Yl8xLTUtMS0xLTE0NDczNQ_c73598d6-7179-46b2-a3f1-f05130a58b69"
      unitRef="usd">500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if6282ace541846298e168b3652f98351_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGFibGU6NDE3ZDg0N2ZmNTU5NGZhZmEwNjc0OTllOGNlMmExNGIvdGFibGVyYW5nZTo0MTdkODQ3ZmY1NTk0ZmFmYTA2NzQ5OWU4Y2UyYTE0Yl8xLTctMS0xLTE0NDczNQ_54338056-d99a-404c-81a6-ee467bf7b84c"
      unitRef="usd">33800000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ibfdc712fb9f342aca6ae054a16698cef_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGFibGU6NDE3ZDg0N2ZmNTU5NGZhZmEwNjc0OTllOGNlMmExNGIvdGFibGVyYW5nZTo0MTdkODQ3ZmY1NTk0ZmFmYTA2NzQ5OWU4Y2UyYTE0Yl8yLTEtMS0xLTE1MDk1NA_97cf99bd-e89c-475b-b4e2-21b248449373"
      unitRef="usd">3400000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ibfdc712fb9f342aca6ae054a16698cef_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGFibGU6NDE3ZDg0N2ZmNTU5NGZhZmEwNjc0OTllOGNlMmExNGIvdGFibGVyYW5nZTo0MTdkODQ3ZmY1NTk0ZmFmYTA2NzQ5OWU4Y2UyYTE0Yl80LTctMS0xLTE0NDczNQ_b19899d0-f77a-46a9-984d-bd5efb684f68"
      unitRef="usd">3400000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGFibGU6NDE3ZDg0N2ZmNTU5NGZhZmEwNjc0OTllOGNlMmExNGIvdGFibGVyYW5nZTo0MTdkODQ3ZmY1NTk0ZmFmYTA2NzQ5OWU4Y2UyYTE0Yl8zLTctMS0xLTE3MzA0Ng_0064d339-dd55-4850-8256-fcf07f300c79"
      unitRef="usd">37200000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGV4dHJlZ2lvbjpiYWVkYzViZjNkODQ0NmUzYWFkZWEyNDY5YzEyMzRlOF8yMTk5MDIzMjYyMTAz_4f8b1b92-fed7-4af1-98ce-7e1d369749e0">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the estimated annual amortization expense for our finite-lived intangible assets. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGFibGU6ZGMzNjQ2OTE5YzUyNDE5NWI0MjhlM2Q1YmQ0MmI5ZWYvdGFibGVyYW5nZTpkYzM2NDY5MTljNTI0MTk1YjQyOGUzZDViZDQyYjllZl8xLTEtMS0xLTE3MDU3Ng_a1a5a602-bc26-4811-b423-be5f5adb872d"
      unitRef="usd">3500000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGFibGU6ZGMzNjQ2OTE5YzUyNDE5NWI0MjhlM2Q1YmQ0MmI5ZWYvdGFibGVyYW5nZTpkYzM2NDY5MTljNTI0MTk1YjQyOGUzZDViZDQyYjllZl8yLTEtMS0xLTE3MDU3Ng_3253dacf-fb87-476f-b1ad-503e82b264ef"
      unitRef="usd">3500000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGFibGU6ZGMzNjQ2OTE5YzUyNDE5NWI0MjhlM2Q1YmQ0MmI5ZWYvdGFibGVyYW5nZTpkYzM2NDY5MTljNTI0MTk1YjQyOGUzZDViZDQyYjllZl8zLTEtMS0xLTE3MDU3Ng_6c4efba5-00cc-4ccd-957b-03d5c69fb371"
      unitRef="usd">3500000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGFibGU6ZGMzNjQ2OTE5YzUyNDE5NWI0MjhlM2Q1YmQ0MmI5ZWYvdGFibGVyYW5nZTpkYzM2NDY5MTljNTI0MTk1YjQyOGUzZDViZDQyYjllZl80LTEtMS0xLTE3MDU3Ng_28aa28ad-dc8b-4c0d-bf5d-010413f1f791"
      unitRef="usd">3500000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGFibGU6ZGMzNjQ2OTE5YzUyNDE5NWI0MjhlM2Q1YmQ0MmI5ZWYvdGFibGVyYW5nZTpkYzM2NDY5MTljNTI0MTk1YjQyOGUzZDViZDQyYjllZl81LTEtMS0xLTE3MDU3Ng_e8ad3682-325e-4d5c-b86e-7df37cb241f1"
      unitRef="usd">3500000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzE3L2ZyYWc6YmFlZGM1YmYzZDg0NDZlM2FhZGVhMjQ2OWMxMjM0ZTgvdGFibGU6ZGMzNjQ2OTE5YzUyNDE5NWI0MjhlM2Q1YmQ0MmI5ZWYvdGFibGVyYW5nZTpkYzM2NDY5MTljNTI0MTk1YjQyOGUzZDViZDQyYjllZl82LTEtMS0xLTE3MDU3Ng_d1b60230-25c3-4646-b783-e09d4fa01e93"
      unitRef="usd">16300000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90ZXh0cmVnaW9uOmVhMzc2ZTcwMzkyYjQyMTk4OTAyOWNjNTNmZmY0NjJhXzQ1MA_2fcef701-45e4-4c8e-9dfd-813a147cad3b">Other Balance Sheet Details&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net, consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tenant improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Scientific equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;124.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(66.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(51.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued employee related costs &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revenue-related reserves for discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;131.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current branded prescription drug fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts payable and other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;347.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;225.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;262.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;340.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;270.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;344.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90ZXh0cmVnaW9uOmVhMzc2ZTcwMzkyYjQyMTk4OTAyOWNjNTNmZmY0NjJhXzQ1MQ_facdb9ea-faf8-4fb5-b99d-e71a594c99a0">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTpkZGMzYWU0MGU2YWI0NWQ2YjhmMDUyODI2MDA4ZTJhYy90YWJsZXJhbmdlOmRkYzNhZTQwZTZhYjQ1ZDZiOGYwNTI4MjYwMDhlMmFjXzItMS0xLTEtMTM5MDYy_cadae040-3a2c-4a4b-a01b-87c4b4e1b55d"
      unitRef="usd">12000000.0</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTpkZGMzYWU0MGU2YWI0NWQ2YjhmMDUyODI2MDA4ZTJhYy90YWJsZXJhbmdlOmRkYzNhZTQwZTZhYjQ1ZDZiOGYwNTI4MjYwMDhlMmFjXzItMy0xLTEtMTM5MDYy_bc0a01f9-0ace-49b4-9af7-eb2e5e184ca9"
      unitRef="usd">11200000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTpkZGMzYWU0MGU2YWI0NWQ2YjhmMDUyODI2MDA4ZTJhYy90YWJsZXJhbmdlOmRkYzNhZTQwZTZhYjQ1ZDZiOGYwNTI4MjYwMDhlMmFjXzMtMS0xLTEtMTM5MDYy_4e2ddbad-66e6-42e3-8d1b-b4ed3646b6c0"
      unitRef="usd">5600000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTpkZGMzYWU0MGU2YWI0NWQ2YjhmMDUyODI2MDA4ZTJhYy90YWJsZXJhbmdlOmRkYzNhZTQwZTZhYjQ1ZDZiOGYwNTI4MjYwMDhlMmFjXzMtMy0xLTEtMTM5MDYy_1bed4afb-6813-4814-8130-1ebfd186267d"
      unitRef="usd">3600000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTpkZGMzYWU0MGU2YWI0NWQ2YjhmMDUyODI2MDA4ZTJhYy90YWJsZXJhbmdlOmRkYzNhZTQwZTZhYjQ1ZDZiOGYwNTI4MjYwMDhlMmFjXzQtMS0xLTEtMTM5MDYy_1a9b1ef9-1698-4657-8800-f2e6428588ae"
      unitRef="usd">17500000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTpkZGMzYWU0MGU2YWI0NWQ2YjhmMDUyODI2MDA4ZTJhYy90YWJsZXJhbmdlOmRkYzNhZTQwZTZhYjQ1ZDZiOGYwNTI4MjYwMDhlMmFjXzQtMy0xLTEtMTM5MDYy_70c0b199-ef0e-45b1-85c9-e25f57f52558"
      unitRef="usd">15700000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTpkZGMzYWU0MGU2YWI0NWQ2YjhmMDUyODI2MDA4ZTJhYy90YWJsZXJhbmdlOmRkYzNhZTQwZTZhYjQ1ZDZiOGYwNTI4MjYwMDhlMmFjXzUtMS0xLTEtMTM5MDYy_9291c246-270a-4753-b36d-0b4024b21ada"
      unitRef="usd">35100000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTpkZGMzYWU0MGU2YWI0NWQ2YjhmMDUyODI2MDA4ZTJhYy90YWJsZXJhbmdlOmRkYzNhZTQwZTZhYjQ1ZDZiOGYwNTI4MjYwMDhlMmFjXzUtMy0xLTEtMTM5MDYy_68e14d65-c09b-4af0-ac19-9701ff7d8d84"
      unitRef="usd">30500000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90ZXh0cmVnaW9uOmVhMzc2ZTcwMzkyYjQyMTk4OTAyOWNjNTNmZmY0NjJhXzQ1Mg_77f9d426-0617-4b2d-b007-aa4f50bb8e69">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net, consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tenant improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Scientific equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;124.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(66.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(51.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib36cc15a97d94e96a193bf977c9bcc64_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo4NjYyOTE4MDkzNzI0OTk0YTBiNDFkNDQ2NWQyOWJjMi90YWJsZXJhbmdlOjg2NjI5MTgwOTM3MjQ5OTRhMGI0MWQ0NDY1ZDI5YmMyXzItMS0xLTEtMTM5MDYy_a47d423b-9fe8-49f3-abd3-23bf870f4540"
      unitRef="usd">37900000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1cfcd3b4d7074f90897906a633ffcd5c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo4NjYyOTE4MDkzNzI0OTk0YTBiNDFkNDQ2NWQyOWJjMi90YWJsZXJhbmdlOjg2NjI5MTgwOTM3MjQ5OTRhMGI0MWQ0NDY1ZDI5YmMyXzItMy0xLTEtMTM5MDYy_622d32fa-648f-48f0-9c27-8d403eb4c941"
      unitRef="usd">34900000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iad805873aae044c699ba94c98221a05f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo4NjYyOTE4MDkzNzI0OTk0YTBiNDFkNDQ2NWQyOWJjMi90YWJsZXJhbmdlOjg2NjI5MTgwOTM3MjQ5OTRhMGI0MWQ0NDY1ZDI5YmMyXzMtMS0xLTEtMTM5MDYy_3431c9a5-e193-4c8b-91d8-2681fe85f924"
      unitRef="usd">58800000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8a4a256d6b68420ca9418a64a947bc8b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo4NjYyOTE4MDkzNzI0OTk0YTBiNDFkNDQ2NWQyOWJjMi90YWJsZXJhbmdlOjg2NjI5MTgwOTM3MjQ5OTRhMGI0MWQ0NDY1ZDI5YmMyXzMtMy0xLTEtMTM5MDYy_10149c70-5ca6-4240-a98d-c54aebdef42b"
      unitRef="usd">51600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if5947e62d00f451eb3a24072ec5328d8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo4NjYyOTE4MDkzNzI0OTk0YTBiNDFkNDQ2NWQyOWJjMi90YWJsZXJhbmdlOjg2NjI5MTgwOTM3MjQ5OTRhMGI0MWQ0NDY1ZDI5YmMyXzQtMS0xLTEtMTM5MDYy_1da52e3f-be8b-4814-9812-282ac0ef50c7"
      unitRef="usd">21500000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0d163cbc8c3d4cef88df04d4844d353c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo4NjYyOTE4MDkzNzI0OTk0YTBiNDFkNDQ2NWQyOWJjMi90YWJsZXJhbmdlOjg2NjI5MTgwOTM3MjQ5OTRhMGI0MWQ0NDY1ZDI5YmMyXzQtMy0xLTEtMTM5MDYy_27a94bc6-8aa5-43e0-b0ac-f2a43a5226d9"
      unitRef="usd">18100000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3ae1d4d52be44bc3bc2ba9cfc000d178_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo4NjYyOTE4MDkzNzI0OTk0YTBiNDFkNDQ2NWQyOWJjMi90YWJsZXJhbmdlOjg2NjI5MTgwOTM3MjQ5OTRhMGI0MWQ0NDY1ZDI5YmMyXzUtMS0xLTEtMTM5MDYy_f03a73af-579b-4bfe-8b14-fa233318ae85"
      unitRef="usd">6700000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3f931f023a9b4e74be1c9df8a59da030_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo4NjYyOTE4MDkzNzI0OTk0YTBiNDFkNDQ2NWQyOWJjMi90YWJsZXJhbmdlOjg2NjI5MTgwOTM3MjQ5OTRhMGI0MWQ0NDY1ZDI5YmMyXzUtMy0xLTEtMTM5MDYy_f794b868-a99d-4a05-a8e8-939a8c6e40eb"
      unitRef="usd">5900000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo4NjYyOTE4MDkzNzI0OTk0YTBiNDFkNDQ2NWQyOWJjMi90YWJsZXJhbmdlOjg2NjI5MTgwOTM3MjQ5OTRhMGI0MWQ0NDY1ZDI5YmMyXzYtMS0xLTEtMTM5MDYy_7fcf210e-80bf-493b-a778-ccfe2732dc9a"
      unitRef="usd">124900000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo4NjYyOTE4MDkzNzI0OTk0YTBiNDFkNDQ2NWQyOWJjMi90YWJsZXJhbmdlOjg2NjI5MTgwOTM3MjQ5OTRhMGI0MWQ0NDY1ZDI5YmMyXzYtMy0xLTEtMTM5MDYy_5f48ed2a-e3da-4828-bfa2-41ee116e97fd"
      unitRef="usd">110500000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo4NjYyOTE4MDkzNzI0OTk0YTBiNDFkNDQ2NWQyOWJjMi90YWJsZXJhbmdlOjg2NjI5MTgwOTM3MjQ5OTRhMGI0MWQ0NDY1ZDI5YmMyXzctMS0xLTEtMTM5MDYy_ccbf0e33-7933-45e7-a766-8c475cf924be"
      unitRef="usd">66300000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo4NjYyOTE4MDkzNzI0OTk0YTBiNDFkNDQ2NWQyOWJjMi90YWJsZXJhbmdlOjg2NjI5MTgwOTM3MjQ5OTRhMGI0MWQ0NDY1ZDI5YmMyXzctMy0xLTEtMTM5MDYy_b8e2bd5e-0ea5-4685-8a99-905037664d78"
      unitRef="usd">51900000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo4NjYyOTE4MDkzNzI0OTk0YTBiNDFkNDQ2NWQyOWJjMi90YWJsZXJhbmdlOjg2NjI5MTgwOTM3MjQ5OTRhMGI0MWQ0NDY1ZDI5YmMyXzgtMS0xLTEtMTM5MDYy_5ba6f99f-97af-4d83-8c0f-1fbba70bcdc1"
      unitRef="usd">58600000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo4NjYyOTE4MDkzNzI0OTk0YTBiNDFkNDQ2NWQyOWJjMi90YWJsZXJhbmdlOjg2NjI5MTgwOTM3MjQ5OTRhMGI0MWQ0NDY1ZDI5YmMyXzgtMy0xLTEtMTM5MDYy_875d1c32-15a5-47ba-8357-76a1a869a5cf"
      unitRef="usd">58600000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90ZXh0cmVnaW9uOmVhMzc2ZTcwMzkyYjQyMTk4OTAyOWNjNTNmZmY0NjJhXzQ1Mw_d62c5184-82dd-4d91-a5a5-9fdbc47b0a06">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued employee related costs &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revenue-related reserves for discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;131.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current branded prescription drug fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts payable and other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;347.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;225.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo3YzNlMGM0Y2RiODM0MzFhYTY3YzU1NzVhNDhmMmVkYS90YWJsZXJhbmdlOjdjM2UwYzRjZGI4MzQzMWFhNjdjNTU3NWE0OGYyZWRhXzItMS0xLTEtMTM5MDYy_937b5427-1fff-4942-9f78-d837ca25ca24"
      unitRef="usd">72800000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo3YzNlMGM0Y2RiODM0MzFhYTY3YzU1NzVhNDhmMmVkYS90YWJsZXJhbmdlOjdjM2UwYzRjZGI4MzQzMWFhNjdjNTU3NWE0OGYyZWRhXzItMy0xLTEtMTM5MDYy_614f5056-9734-4ab4-ae93-1298ae658822"
      unitRef="usd">50600000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <nbix:RevenueRelatedReservesForDiscountsAndAllowances
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo3YzNlMGM0Y2RiODM0MzFhYTY3YzU1NzVhNDhmMmVkYS90YWJsZXJhbmdlOjdjM2UwYzRjZGI4MzQzMWFhNjdjNTU3NWE0OGYyZWRhXzMtMS0xLTEtMTM5MDYy_cea543df-c7c5-4c5c-8847-e37d78ff0ad6"
      unitRef="usd">131900000</nbix:RevenueRelatedReservesForDiscountsAndAllowances>
    <nbix:RevenueRelatedReservesForDiscountsAndAllowances
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo3YzNlMGM0Y2RiODM0MzFhYTY3YzU1NzVhNDhmMmVkYS90YWJsZXJhbmdlOjdjM2UwYzRjZGI4MzQzMWFhNjdjNTU3NWE0OGYyZWRhXzMtMy0xLTEtMTM5MDYy_2622191d-b7a2-4c73-aa39-d7a647dbb7c2"
      unitRef="usd">62700000</nbix:RevenueRelatedReservesForDiscountsAndAllowances>
    <nbix:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo3YzNlMGM0Y2RiODM0MzFhYTY3YzU1NzVhNDhmMmVkYS90YWJsZXJhbmdlOjdjM2UwYzRjZGI4MzQzMWFhNjdjNTU3NWE0OGYyZWRhXzQtMS0xLTEtMTM5MDYy_e635b0c9-9bd1-4da2-92ec-781ae326f404"
      unitRef="usd">39100000</nbix:AccruedResearchAndDevelopmentExpenseCurrent>
    <nbix:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo3YzNlMGM0Y2RiODM0MzFhYTY3YzU1NzVhNDhmMmVkYS90YWJsZXJhbmdlOjdjM2UwYzRjZGI4MzQzMWFhNjdjNTU3NWE0OGYyZWRhXzQtMy0xLTEtMTM5MDYy_3c32a768-9fc8-4205-93f7-2a4718afbda7"
      unitRef="usd">32400000</nbix:AccruedResearchAndDevelopmentExpenseCurrent>
    <nbix:AccruedBrandedPrescriptionDrugFee
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo3YzNlMGM0Y2RiODM0MzFhYTY3YzU1NzVhNDhmMmVkYS90YWJsZXJhbmdlOjdjM2UwYzRjZGI4MzQzMWFhNjdjNTU3NWE0OGYyZWRhXzUtMS0xLTEtMTM5MDYy_608e8e39-e2db-4f76-b95f-01a2144bfcce"
      unitRef="usd">27500000</nbix:AccruedBrandedPrescriptionDrugFee>
    <nbix:AccruedBrandedPrescriptionDrugFee
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo3YzNlMGM0Y2RiODM0MzFhYTY3YzU1NzVhNDhmMmVkYS90YWJsZXJhbmdlOjdjM2UwYzRjZGI4MzQzMWFhNjdjNTU3NWE0OGYyZWRhXzUtMy0xLTEtMTM5MDYy_61002a5e-2494-46ee-8670-42987f7e157a"
      unitRef="usd">28600000</nbix:AccruedBrandedPrescriptionDrugFee>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo3YzNlMGM0Y2RiODM0MzFhYTY3YzU1NzVhNDhmMmVkYS90YWJsZXJhbmdlOjdjM2UwYzRjZGI4MzQzMWFhNjdjNTU3NWE0OGYyZWRhXzYtMS0xLTEtMTM5MDYy_751d7fb1-2b0d-4643-9208-39b7957d2a59"
      unitRef="usd">76300000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo3YzNlMGM0Y2RiODM0MzFhYTY3YzU1NzVhNDhmMmVkYS90YWJsZXJhbmdlOjdjM2UwYzRjZGI4MzQzMWFhNjdjNTU3NWE0OGYyZWRhXzYtMy0xLTEtMTM5MDYy_bc8a684b-bcda-417d-ad7a-ca4edadbae1f"
      unitRef="usd">51500000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo3YzNlMGM0Y2RiODM0MzFhYTY3YzU1NzVhNDhmMmVkYS90YWJsZXJhbmdlOjdjM2UwYzRjZGI4MzQzMWFhNjdjNTU3NWE0OGYyZWRhXzctMS0xLTEtMTM5MDYy_d634183b-48e6-4a1d-bf3a-434812bf59c3"
      unitRef="usd">347600000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTo3YzNlMGM0Y2RiODM0MzFhYTY3YzU1NzVhNDhmMmVkYS90YWJsZXJhbmdlOjdjM2UwYzRjZGI4MzQzMWFhNjdjNTU3NWE0OGYyZWRhXzctMy0xLTEtMTM5MDYy_660f0f3a-524d-4af2-a9d4-b81ad8d2caac"
      unitRef="usd">225800000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90ZXh0cmVnaW9uOmVhMzc2ZTcwMzkyYjQyMTk4OTAyOWNjNTNmZmY0NjJhXzQ1NA_140d3a8f-5cb8-4124-a13e-7b317a951a02">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;262.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;340.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;270.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;344.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTpjZjFjNzRmMDE4Mzg0OGZkOGEzOWE2Nzg0MjQ2MjIyNy90YWJsZXJhbmdlOmNmMWM3NGYwMTgzODQ4ZmQ4YTM5YTY3ODQyNDYyMjI3XzItMS0xLTEtMTM5MDYy_76ef77e0-00dc-4d6e-94fc-810c85f2143d"
      unitRef="usd">262900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTpjZjFjNzRmMDE4Mzg0OGZkOGEzOWE2Nzg0MjQ2MjIyNy90YWJsZXJhbmdlOmNmMWM3NGYwMTgzODQ4ZmQ4YTM5YTY3ODQyNDYyMjI3XzItMy0xLTEtMTM5MDYy_7bc5cf76-6247-4cec-a4b2-6d03ba4f742d"
      unitRef="usd">340800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTpjZjFjNzRmMDE4Mzg0OGZkOGEzOWE2Nzg0MjQ2MjIyNy90YWJsZXJhbmdlOmNmMWM3NGYwMTgzODQ4ZmQ4YTM5YTY3ODQyNDYyMjI3XzMtMS0xLTEtMTM5MDYy_7bd54788-16c0-4f02-9f40-137653c6312d"
      unitRef="usd">7800000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTpjZjFjNzRmMDE4Mzg0OGZkOGEzOWE2Nzg0MjQ2MjIyNy90YWJsZXJhbmdlOmNmMWM3NGYwMTgzODQ4ZmQ4YTM5YTY3ODQyNDYyMjI3XzMtMy0xLTEtMTM5MDYy_1fe5c994-b01d-403c-848c-eee206861dc9"
      unitRef="usd">3200000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTpjZjFjNzRmMDE4Mzg0OGZkOGEzOWE2Nzg0MjQ2MjIyNy90YWJsZXJhbmdlOmNmMWM3NGYwMTgzODQ4ZmQ4YTM5YTY3ODQyNDYyMjI3XzQtMS0xLTEtMTM5MDYy_c5dc2fd8-67b7-43fa-b71e-9653c617303b"
      unitRef="usd">270700000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTQvZnJhZzplYTM3NmU3MDM5MmI0MjE5ODkwMjljYzUzZmZmNDYyYS90YWJsZTpjZjFjNzRmMDE4Mzg0OGZkOGEzOWE2Nzg0MjQ2MjIyNy90YWJsZXJhbmdlOmNmMWM3NGYwMTgzODQ4ZmQ4YTM5YTY3ODQyNDYyMjI3XzQtMy0xLTEtMTM5MDYy_f7733321-b5b1-495b-a94c-5e8e26e52d98"
      unitRef="usd">344000000.0</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90ZXh0cmVnaW9uOjUwZDA3ZDllZmQwODRhOGI5Y2Y3ODVlOGM5NzY5NjJjXzIyOQ_17db00f6-13d3-4bd8-9002-45378996cf14">Earnings Per Share&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings per share were calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;154.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;407.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares which have been excluded from diluted per share amounts because their effect would have been anti-dilutive were 4.6 million for 2022, 4.1 million for 2021 and 2.5 million for 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90ZXh0cmVnaW9uOjUwZDA3ZDllZmQwODRhOGI5Y2Y3ODVlOGM5NzY5NjJjXzIzMA_2179e199-8143-4835-970b-39b05ab85c65">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings per share were calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;154.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;407.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzItMS0xLTEtMTM5MDYy_01d2327e-a89a-4b12-ac91-cf26ba488aed"
      unitRef="usd">154500000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzItMS0xLTEtMTM5MDYy_37687ad4-20a3-482a-84e6-88937936dfe0"
      unitRef="usd">154500000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzItMy0xLTEtMTM5MDYy_7d128a5e-ec04-4289-a7e6-496a797f8bec"
      unitRef="usd">89600000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzItMy0xLTEtMTM5MDYy_bddeea5e-049b-4718-a368-ae47228b7630"
      unitRef="usd">89600000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzItNS0xLTEtMTM5MDYy_4e1a998b-3c66-4aa2-9852-51324126baaa"
      unitRef="usd">407300000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzItNS0xLTEtMTM5MDYy_7f2a1f1c-5213-4357-876f-c5f774b0ce63"
      unitRef="usd">407300000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzQtMS0xLTEtMTM5MDYy_149bc02b-8215-476b-9f16-fabec7450561"
      unitRef="shares">95800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzQtMy0xLTEtMTM5MDYy_59dadf71-deed-40d5-b517-c065fabdc17b"
      unitRef="shares">94600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzQtNS0xLTEtMTM5MDYy_2e1dc6ef-0a22-4e5b-9d1c-5668f94d8c9b"
      unitRef="shares">93100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzUtMS0xLTEtMTQ0NzU0_720485e1-9f07-4b44-8568-20b6f63ca5b8"
      unitRef="shares">3100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzUtMy0xLTEtMTQ0NzU0_761bfcd5-f67b-4e17-afc2-fe13c5d859cf"
      unitRef="shares">3300000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzUtNS0xLTEtMTQ0NzU0_d4c04b12-1464-4bf9-9e07-115e1e4f10f8"
      unitRef="shares">4700000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzEwLTEtMS0xLTEzOTA2Mg_a4c020e0-c1ff-48d3-a501-d8eaf9d8ac61"
      unitRef="shares">98900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzEwLTMtMS0xLTEzOTA2Mg_5fddf87c-75a7-47e8-84de-6ae254a16034"
      unitRef="shares">97900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzEwLTUtMS0xLTEzOTA2Mg_b3ea9868-7e6f-41a1-b934-b0854c79d32e"
      unitRef="shares">97800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzEyLTEtMS0xLTEzOTA2Mg_e98f0c22-5615-458d-83c6-63c5c6673ac7"
      unitRef="usdPerShare">1.61</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzEyLTMtMS0xLTEzOTA2Mg_5e93c517-354a-4ac7-917c-dd34e0714650"
      unitRef="usdPerShare">0.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzEyLTUtMS0xLTEzOTA2Mg_5df6e98a-bc3b-4f31-aa99-b84205c0a424"
      unitRef="usdPerShare">4.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzEzLTEtMS0xLTEzOTA2Mg_3fa1522a-0f35-483f-81cb-42d9c5c47ea6"
      unitRef="usdPerShare">1.56</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzEzLTMtMS0xLTEzOTA2Mg_17659869-c428-4aaf-96f4-71d2819b991f"
      unitRef="usdPerShare">0.92</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90YWJsZTpmNTFiYjdkNGJiOWY0MjU3ODNjOTdhOTcxYzdiNDYwZC90YWJsZXJhbmdlOmY1MWJiN2Q0YmI5ZjQyNTc4M2M5N2E5NzFjN2I0NjBkXzEzLTUtMS0xLTEzOTA2Mg_43c099b1-7aa2-48eb-9bda-c19b65deaccb"
      unitRef="usdPerShare">4.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic7d26b322bb24bff8ec6e47dcf836515_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90ZXh0cmVnaW9uOjUwZDA3ZDllZmQwODRhOGI5Y2Y3ODVlOGM5NzY5NjJjXzE5NQ_6fd227d8-631e-4458-af5c-b0d07ea0d73d"
      unitRef="shares">4600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idaf8254dea124bfb9e7456439c9c6107_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90ZXh0cmVnaW9uOjUwZDA3ZDllZmQwODRhOGI5Y2Y3ODVlOGM5NzY5NjJjXzIwNg_3b1d9e83-62df-4767-b904-ac42d8c28ab5"
      unitRef="shares">4100000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if2bedeff3c8c43e6a805d773f9fd4669_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNTcvZnJhZzo1MGQwN2Q5ZWZkMDg0YThiOWNmNzg1ZThjOTc2OTYyYy90ZXh0cmVnaW9uOjUwZDA3ZDllZmQwODRhOGI5Y2Y3ODVlOGM5NzY5NjJjXzIyMA_42473040-5354-4a86-bbc8-268387297691"
      unitRef="shares">2500000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzUxNjQ_04a0f3cd-59f6-4d02-a387-7f950fb94356">Stock-Based Compensation&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Equity Incentive Plan.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, our stockholders approved an amendment and restatement of the 2020 Equity Incentive Plan (as so amended and restated, the Amended 2020 Plan). The Amended 2020 Plan provides for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards, and other awards. As of December 31, 2022, 7.9&#160;million shares of common stock remain available for future grant under the Amended 2020 Plan.&lt;/span&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Amended 2020 Plan, the number of shares of common stock available for issuance will be: (i) reduced by (a) one share for each share issued pursuant to an appreciation award (as defined in the Amended 2020 Plan) granted under the Amended 2020 Plan and (b) 2.13 shares for each share issued pursuant to a full value award (as defined in the Amended 2020 Plan) granted under the Amended 2020 Plan on or after May 18, 2022; and (ii) increased by (a) one share for each share subject to an appreciation award that becomes available again for issuance under the terms of the Amended 2020 Plan and (b) 2.13 shares for each share subject to a full value award that becomes available again for issuance under the terms of the Amended 2020 Plan on or after May 18, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2011 Equity Incentive Plan.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2011, we adopted the 2011 Equity Incentive Plan, or the 2011 Plan. The 2011 Plan was a stockholder-approved plan pursuant to which outstanding awards have been made, but from which no further awards can or will be made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2018 Employee Stock Purchase Plan.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, our stockholders approved an amendment and restatement of the 2018 Employee Stock Purchase Plan (as so amended and restated, the Amended 2018 ESPP). As of December 31, 2022, 0.6&#160;million shares of common stock remain available for future issuance under the Amended 2018 ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effect of stock-based compensation expense on our consolidated statements of income and comprehensive income by line-item follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;173.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;134.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense by award-type follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PRSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;173.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;134.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, unrecognized stock-based compensation expense by award-type and the weighted-average period over which such expense is expected to be recognized, as applicable, was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.729%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrecognized Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Recognition Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;151.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PRSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Typically, stock options have a 10-year term and vest over a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzIwMTc_50d14189-4f30-4d95-85d1-8b0107a221f2"&gt;three&lt;/span&gt; to four-year period. The exercise price of stock options granted is equal to the closing price of our common stock on the date of grant. We estimate the fair value of stock options using the Black-Scholes option-pricing model on the date of grant. The Black-Scholes option-pricing model incorporates various and highly sensitive assumptions including expected volatility, term and interest rates. The weighted-average grant-date fair values of stock options granted were $32.05 for 2022, $45.02 for 2021 and $45.67 for 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each stock option granted was estimated on the date of grant using the Black-Scholes option-pricing valuation model with the following weighted-average assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected option term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average valuation assumptions were determined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The expected volatility of common stock is estimated based on the historical volatility of our common stock over the most recent period commensurate with the estimated expected term of our stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The expected option term is estimated based on historical experience as well as the status of the employee. For example, directors and officers have a longer expected option term than all other employees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The risk-free interest rate for periods within the contractual life of a stock option is based upon observed interest rates appropriate for the expected term of our employee stock options. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;We have not historically declared or paid dividends and do not intend to do so in the foreseeable future. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents summary of activity related to stock options.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except weighted average data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of &lt;br/&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;362.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.4 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;281.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic value of stock options exercised was $39.7 million for 2022, $58.0 million for 2021 and $40.2 million for 2020. Cash received from stock option exercises was $37.0 million for 2022, $20.7 million for 2021 and $23.5 million for 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs typically vest over a four-year period and may be subject to a deferred delivery arrangement at the election of eligible employees. The fair value of RSUs is based on the closing sale price of our common stock on the date of issuance. The total fair value of RSUs that vested was $72.4 million for 2022, $64.3 million for 2021 and $49.7 million for 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of activity related to RSUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except weighted average data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of &lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant Date &lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;99.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;276.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Performance-Based Restricted Stock Units. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PRSUs vest based on the achievement of certain predefined Company-specific performance criteria. Any unvested PRSUs will expire if it is determined the related performance criteria has not been met during the applicable &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzU0OTc1NTg0OTAyMA_025ee6ff-3e68-4066-aa62-f80b858bd74f"&gt;three&lt;/span&gt; to four-year performance period. The fair value of PRSUs is estimated based on the closing sale price of our common stock on the date of grant. The fair value of PRSUs that vested during 2020 was $13.5&#160;million. No PRSUs vested during 2021 or 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of activity related to PRSUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except weighted average data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of &lt;br/&gt;PRSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant Date &lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.8 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Amended 2018 ESPP, eligible employees may purchase shares of our common stock at a discount semi-annually based on a percentage of their annual compensation. The discounted purchase price is equal to the lower of 85% of (i) the market value per share of the common stock on the first day of the offering period or (ii) the market value per share of common stock on the purchase date.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i25f7e10858b24f7fae2103c935cfd949_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzEwOTk1MTE2NDQwNTQ_bd5910c4-8f6b-490f-b962-a48e0e201c74"
      unitRef="shares">7900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <nbix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward
      contextRef="i213982ce809548e292c18f6215fa9e6b_D20220518-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzU0OTc1NTg0MDYwNw_c695a531-3695-4cbe-bfd3-5f6f9bb66ab6"
      unitRef="shares">1</nbix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward>
    <nbix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted
      contextRef="i213982ce809548e292c18f6215fa9e6b_D20220518-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzU0OTc1NTg0MDYyNg_fe441992-bcc8-43ee-95d2-00c2cc6b29d1"
      unitRef="shares">2.13</nbix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted>
    <nbix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward
      contextRef="i213982ce809548e292c18f6215fa9e6b_D20220518-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzU0OTc1NTg0MDYxOA_22eb330c-a405-431e-a909-2269c1e2fbda"
      unitRef="shares">1</nbix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward>
    <nbix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward
      contextRef="i213982ce809548e292c18f6215fa9e6b_D20220518-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzU0OTc1NTg0MDYzNA_bbc5a0c9-e4ff-40fd-9a1a-f1bb75797e7e"
      unitRef="shares">2.13</nbix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="id479e592bc6b4c9fb00c946120287b70_I20110531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzE2NDkyNjc0ODgxMjI_f0452b47-5315-4ddd-a17a-dc5f6e080411"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i695a8fab0f384006baa1447f58213de8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzEwOTk1MTE2NDY0MTA_f54bbdcb-e52b-456f-9aa8-ab45e1b667ca"
      unitRef="shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzUxNjU_0e55e018-4305-4b2c-a418-b4be1761c2ee">The effect of stock-based compensation expense on our consolidated statements of income and comprehensive income by line-item follows:&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;173.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;134.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense by award-type follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PRSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;173.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;134.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, unrecognized stock-based compensation expense by award-type and the weighted-average period over which such expense is expected to be recognized, as applicable, was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.729%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrecognized Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Recognition Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;151.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PRSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5bdd80fdaea2455ba085c93bafcf958a_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTphMjc4YzI0ZTEzNmQ0MTQ4YTllZjFlNDQwMmYzY2VmNS90YWJsZXJhbmdlOmEyNzhjMjRlMTM2ZDQxNDhhOWVmMWU0NDAyZjNjZWY1XzItMS0xLTEtMTM5MDYy_e72e4c82-26f5-4e13-ad54-1eb9cf8aa054"
      unitRef="usd">115400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i56babcc72eb54154a6b2bbf854d97490_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTphMjc4YzI0ZTEzNmQ0MTQ4YTllZjFlNDQwMmYzY2VmNS90YWJsZXJhbmdlOmEyNzhjMjRlMTM2ZDQxNDhhOWVmMWU0NDAyZjNjZWY1XzItMy0xLTEtMTM5MDYy_26e5575a-9411-4f40-b8ad-472c03f24587"
      unitRef="usd">85800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia8089736b115438bae00a39b3e804807_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTphMjc4YzI0ZTEzNmQ0MTQ4YTllZjFlNDQwMmYzY2VmNS90YWJsZXJhbmdlOmEyNzhjMjRlMTM2ZDQxNDhhOWVmMWU0NDAyZjNjZWY1XzItNS0xLTEtMTM5MDYy_eca0e3f8-2d25-43a4-a41b-6f276ee5bfbe"
      unitRef="usd">66300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if8bb02545f4e412b99ba7d4bcfab2fbd_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTphMjc4YzI0ZTEzNmQ0MTQ4YTllZjFlNDQwMmYzY2VmNS90YWJsZXJhbmdlOmEyNzhjMjRlMTM2ZDQxNDhhOWVmMWU0NDAyZjNjZWY1XzMtMS0xLTEtMTM5MDYy_7982255d-767e-468a-a554-4b98ce61903c"
      unitRef="usd">57700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie3dd11bd409d4809a79dea85436f4401_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTphMjc4YzI0ZTEzNmQ0MTQ4YTllZjFlNDQwMmYzY2VmNS90YWJsZXJhbmdlOmEyNzhjMjRlMTM2ZDQxNDhhOWVmMWU0NDAyZjNjZWY1XzMtMy0xLTEtMTM5MDYy_031d762d-c74e-403d-be91-5496e481102e"
      unitRef="usd">48400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i901a3c0cc12a478b90f47154a36d3711_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTphMjc4YzI0ZTEzNmQ0MTQ4YTllZjFlNDQwMmYzY2VmNS90YWJsZXJhbmdlOmEyNzhjMjRlMTM2ZDQxNDhhOWVmMWU0NDAyZjNjZWY1XzMtNS0xLTEtMTM5MDYy_4cd0f42a-d189-498d-b90f-89b286b7b3f7"
      unitRef="usd">33700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTphMjc4YzI0ZTEzNmQ0MTQ4YTllZjFlNDQwMmYzY2VmNS90YWJsZXJhbmdlOmEyNzhjMjRlMTM2ZDQxNDhhOWVmMWU0NDAyZjNjZWY1XzQtMS0xLTEtMTM5MDYy_031a7949-f457-41bd-ae74-0f07e032d3e4"
      unitRef="usd">173100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTphMjc4YzI0ZTEzNmQ0MTQ4YTllZjFlNDQwMmYzY2VmNS90YWJsZXJhbmdlOmEyNzhjMjRlMTM2ZDQxNDhhOWVmMWU0NDAyZjNjZWY1XzQtMy0xLTEtMTM5MDYy_56bba6cf-9692-4a19-bc52-54072bba6d0b"
      unitRef="usd">134200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTphMjc4YzI0ZTEzNmQ0MTQ4YTllZjFlNDQwMmYzY2VmNS90YWJsZXJhbmdlOmEyNzhjMjRlMTM2ZDQxNDhhOWVmMWU0NDAyZjNjZWY1XzQtNS0xLTEtMTM5MDYy_ba1d7298-40a3-4c7c-8251-41475928aa70"
      unitRef="usd">100000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic6946e8304b548468ab27182f7a4d25b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo1ZDhhN2MzNzIzZjk0YmIzYmQ1MWQ3ODg0OGMxZDMyZi90YWJsZXJhbmdlOjVkOGE3YzM3MjNmOTRiYjNiZDUxZDc4ODQ4YzFkMzJmXzItMS0xLTEtMTM5MDYy_0da70f11-4f3a-4002-beb6-76d8922621a2"
      unitRef="usd">62600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic7178f777b084a969408727f29c9743f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo1ZDhhN2MzNzIzZjk0YmIzYmQ1MWQ3ODg0OGMxZDMyZi90YWJsZXJhbmdlOjVkOGE3YzM3MjNmOTRiYjNiZDUxZDc4ODQ4YzFkMzJmXzItMy0xLTEtMTM5MDYy_187cb670-9196-4e17-8044-97ee09d3957e"
      unitRef="usd">60500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i85732a5f6db74d908155c57c3c4f6f54_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo1ZDhhN2MzNzIzZjk0YmIzYmQ1MWQ3ODg0OGMxZDMyZi90YWJsZXJhbmdlOjVkOGE3YzM3MjNmOTRiYjNiZDUxZDc4ODQ4YzFkMzJmXzItNS0xLTEtMTM5MDYy_2c9fa85b-a3c5-488c-85aa-806deaca34a4"
      unitRef="usd">47500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic76478c478fb48838837717f4d08aac5_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo1ZDhhN2MzNzIzZjk0YmIzYmQ1MWQ3ODg0OGMxZDMyZi90YWJsZXJhbmdlOjVkOGE3YzM3MjNmOTRiYjNiZDUxZDc4ODQ4YzFkMzJmXzMtMS0xLTEtMTM5MDYy_7ab67484-42f9-44fe-a44d-11e9229b4e7e"
      unitRef="usd">86400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i45d277e0630f42518902ef7c75a787b7_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo1ZDhhN2MzNzIzZjk0YmIzYmQ1MWQ3ODg0OGMxZDMyZi90YWJsZXJhbmdlOjVkOGE3YzM3MjNmOTRiYjNiZDUxZDc4ODQ4YzFkMzJmXzMtMy0xLTEtMTM5MDYy_da8d4bb0-f363-4d3f-8254-17990056125d"
      unitRef="usd">62500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibb26118589cd4a7f9365abf100167588_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo1ZDhhN2MzNzIzZjk0YmIzYmQ1MWQ3ODg0OGMxZDMyZi90YWJsZXJhbmdlOjVkOGE3YzM3MjNmOTRiYjNiZDUxZDc4ODQ4YzFkMzJmXzMtNS0xLTEtMTM5MDYy_e40979b9-3bda-4fed-8ca7-f227b8155bbb"
      unitRef="usd">44200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i87dac2801c32400a82446d8538afc4cf_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo1ZDhhN2MzNzIzZjk0YmIzYmQ1MWQ3ODg0OGMxZDMyZi90YWJsZXJhbmdlOjVkOGE3YzM3MjNmOTRiYjNiZDUxZDc4ODQ4YzFkMzJmXzQtMS0xLTEtMTM5MDYy_d94f4112-6142-406d-bb6e-7c9ba9616b9c"
      unitRef="usd">20100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2383f1847c08462b992435e6a74d3b13_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo1ZDhhN2MzNzIzZjk0YmIzYmQ1MWQ3ODg0OGMxZDMyZi90YWJsZXJhbmdlOjVkOGE3YzM3MjNmOTRiYjNiZDUxZDc4ODQ4YzFkMzJmXzQtMy0xLTEtMTM5MDYy_1b57222d-5bcc-4555-be96-46a7b31d65a3"
      unitRef="usd">7600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4445191c2fc34a93a6035559db9ca75f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo1ZDhhN2MzNzIzZjk0YmIzYmQ1MWQ3ODg0OGMxZDMyZi90YWJsZXJhbmdlOjVkOGE3YzM3MjNmOTRiYjNiZDUxZDc4ODQ4YzFkMzJmXzQtNS0xLTEtMTM5MDYy_a3d6d3c0-a8b0-458f-9a99-18acc4e82663"
      unitRef="usd">5300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i76fab03eca0a475d8e8c0d679f6b27b8_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo1ZDhhN2MzNzIzZjk0YmIzYmQ1MWQ3ODg0OGMxZDMyZi90YWJsZXJhbmdlOjVkOGE3YzM3MjNmOTRiYjNiZDUxZDc4ODQ4YzFkMzJmXzUtMS0xLTEtMTM5MDYy_e1912d40-b0c7-45dd-acdd-d0e7e7a20ac5"
      unitRef="usd">4000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6d5d3961550840ffb667ec48e12d4486_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo1ZDhhN2MzNzIzZjk0YmIzYmQ1MWQ3ODg0OGMxZDMyZi90YWJsZXJhbmdlOjVkOGE3YzM3MjNmOTRiYjNiZDUxZDc4ODQ4YzFkMzJmXzUtMy0xLTEtMTM5MDYy_1f7847c4-5875-4e87-b6ed-494068a02355"
      unitRef="usd">3600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9983074f75e943bf8e1b6ffe1be8dfaa_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo1ZDhhN2MzNzIzZjk0YmIzYmQ1MWQ3ODg0OGMxZDMyZi90YWJsZXJhbmdlOjVkOGE3YzM3MjNmOTRiYjNiZDUxZDc4ODQ4YzFkMzJmXzUtNS0xLTEtMTM5MDYy_5492f774-6f01-4656-b1c9-b660174c5093"
      unitRef="usd">3000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo1ZDhhN2MzNzIzZjk0YmIzYmQ1MWQ3ODg0OGMxZDMyZi90YWJsZXJhbmdlOjVkOGE3YzM3MjNmOTRiYjNiZDUxZDc4ODQ4YzFkMzJmXzYtMS0xLTEtMTM5MDYy_0b970afa-3ca8-4f13-b3b0-a7273bb4cff4"
      unitRef="usd">173100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo1ZDhhN2MzNzIzZjk0YmIzYmQ1MWQ3ODg0OGMxZDMyZi90YWJsZXJhbmdlOjVkOGE3YzM3MjNmOTRiYjNiZDUxZDc4ODQ4YzFkMzJmXzYtMy0xLTEtMTM5MDYy_e420b048-fdc3-4e4f-99b1-53e25682dffb"
      unitRef="usd">134200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo1ZDhhN2MzNzIzZjk0YmIzYmQ1MWQ3ODg0OGMxZDMyZi90YWJsZXJhbmdlOjVkOGE3YzM3MjNmOTRiYjNiZDUxZDc4ODQ4YzFkMzJmXzYtNS0xLTEtMTM5MDYy_a33a46a5-75aa-4a93-8dae-63b95a6b3c04"
      unitRef="usd">100000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="if0960363045f4c3fa3cbebd5f5dd1c92_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTpmYTU0ZTY1ZWQ2MGI0NTY1OTk0YjhmNmFjNGMxY2Q0Yi90YWJsZXJhbmdlOmZhNTRlNjVlZDYwYjQ1NjU5OTRiOGY2YWM0YzFjZDRiXzEtMS0xLTEtMTM5MDYy_2ccb153f-825a-4759-b44c-cfe23451f92f"
      unitRef="usd">106100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ic6946e8304b548468ab27182f7a4d25b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTpmYTU0ZTY1ZWQ2MGI0NTY1OTk0YjhmNmFjNGMxY2Q0Yi90YWJsZXJhbmdlOmZhNTRlNjVlZDYwYjQ1NjU5OTRiOGY2YWM0YzFjZDRiXzEtMy0xLTEtMTM5MDYy_9bc885ea-b4db-4465-9726-de77f40e7ebc">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="iab54417bdda84f5da649889184df892f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTpmYTU0ZTY1ZWQ2MGI0NTY1OTk0YjhmNmFjNGMxY2Q0Yi90YWJsZXJhbmdlOmZhNTRlNjVlZDYwYjQ1NjU5OTRiOGY2YWM0YzFjZDRiXzItMS0xLTEtMTM5MDYy_cf50e1bb-82ca-4525-82b9-21bd6c2ddec9"
      unitRef="usd">151400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ic76478c478fb48838837717f4d08aac5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTpmYTU0ZTY1ZWQ2MGI0NTY1OTk0YjhmNmFjNGMxY2Q0Yi90YWJsZXJhbmdlOmZhNTRlNjVlZDYwYjQ1NjU5OTRiOGY2YWM0YzFjZDRiXzItMy0xLTEtMTM5MDYy_ae30aaa3-310d-48b6-89ad-541625035985">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="if3f2d647e6d24e838c79ec0e84ee0b98_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTpmYTU0ZTY1ZWQ2MGI0NTY1OTk0YjhmNmFjNGMxY2Q0Yi90YWJsZXJhbmdlOmZhNTRlNjVlZDYwYjQ1NjU5OTRiOGY2YWM0YzFjZDRiXzMtMS0xLTEtMTcwNzc2_cd91ed90-6ddc-48df-b709-678e73f2080b"
      unitRef="usd">33600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ic6946e8304b548468ab27182f7a4d25b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzUxNjM_7afd24f5-e3f7-4768-9fb5-e4e8f1c321e3">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i67cf3f5a803b4310944b01aeae80d081_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzUxNjY_29eb77e6-62f0-48dc-bb15-bb23441ddd0d">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzI0ODk_326bc7e1-268c-4864-81cd-9b66f1b69aa9"
      unitRef="usdPerShare">32.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzI1MDA_2007f4f7-2d32-412e-bee2-31f450b1d00b"
      unitRef="usdPerShare">45.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzI1MTQ_2052b63e-6b50-47df-836e-9705ed2e21f6"
      unitRef="usdPerShare">45.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzUxNjc_303cb28d-b169-45bc-b003-f23cfe365374">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each stock option granted was estimated on the date of grant using the Black-Scholes option-pricing valuation model with the following weighted-average assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected option term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ic6946e8304b548468ab27182f7a4d25b_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZToyNmRhYzkxZTM4OWI0Nzc4YWM4YTE3Y2YyNjQ2YzQyNi90YWJsZXJhbmdlOjI2ZGFjOTFlMzg5YjQ3NzhhYzhhMTdjZjI2NDZjNDI2XzItMS0xLTEtMTM5MDYy_0b767148-7482-45e9-aef8-5fb3f00766cb"
      unitRef="number">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ic7178f777b084a969408727f29c9743f_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZToyNmRhYzkxZTM4OWI0Nzc4YWM4YTE3Y2YyNjQ2YzQyNi90YWJsZXJhbmdlOjI2ZGFjOTFlMzg5YjQ3NzhhYzhhMTdjZjI2NDZjNDI2XzItMy0xLTEtMTM5MDYy_f07ed641-2807-45f1-9747-6df1d9343323"
      unitRef="number">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i85732a5f6db74d908155c57c3c4f6f54_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZToyNmRhYzkxZTM4OWI0Nzc4YWM4YTE3Y2YyNjQ2YzQyNi90YWJsZXJhbmdlOjI2ZGFjOTFlMzg5YjQ3NzhhYzhhMTdjZjI2NDZjNDI2XzItNS0xLTEtMTM5MDYy_09af2844-768f-4062-a725-4fcf4e159756"
      unitRef="number">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ic6946e8304b548468ab27182f7a4d25b_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZToyNmRhYzkxZTM4OWI0Nzc4YWM4YTE3Y2YyNjQ2YzQyNi90YWJsZXJhbmdlOjI2ZGFjOTFlMzg5YjQ3NzhhYzhhMTdjZjI2NDZjNDI2XzMtMS0xLTEtMTM5MDYy_101cc0bc-4bb6-4258-8e82-6146cf72fd1e"
      unitRef="number">0.426</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ic7178f777b084a969408727f29c9743f_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZToyNmRhYzkxZTM4OWI0Nzc4YWM4YTE3Y2YyNjQ2YzQyNi90YWJsZXJhbmdlOjI2ZGFjOTFlMzg5YjQ3NzhhYzhhMTdjZjI2NDZjNDI2XzMtMy0xLTEtMTM5MDYy_29d86b7e-ae20-46b7-b3c9-162307bd3150"
      unitRef="number">0.459</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i85732a5f6db74d908155c57c3c4f6f54_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZToyNmRhYzkxZTM4OWI0Nzc4YWM4YTE3Y2YyNjQ2YzQyNi90YWJsZXJhbmdlOjI2ZGFjOTFlMzg5YjQ3NzhhYzhhMTdjZjI2NDZjNDI2XzMtNS0xLTEtMTM5MDYy_bb39473d-403e-4f73-9eb4-3696bc270db1"
      unitRef="number">0.485</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ic6946e8304b548468ab27182f7a4d25b_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZToyNmRhYzkxZTM4OWI0Nzc4YWM4YTE3Y2YyNjQ2YzQyNi90YWJsZXJhbmdlOjI2ZGFjOTFlMzg5YjQ3NzhhYzhhMTdjZjI2NDZjNDI2XzQtMS0xLTEtMTM5MDYy_da9adb43-6666-4344-a925-3fffa393cba7"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ic7178f777b084a969408727f29c9743f_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZToyNmRhYzkxZTM4OWI0Nzc4YWM4YTE3Y2YyNjQ2YzQyNi90YWJsZXJhbmdlOjI2ZGFjOTFlMzg5YjQ3NzhhYzhhMTdjZjI2NDZjNDI2XzQtMy0xLTEtMTM5MDYy_95b9a9af-14a8-4fd2-a181-921063cf7d8d"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i85732a5f6db74d908155c57c3c4f6f54_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZToyNmRhYzkxZTM4OWI0Nzc4YWM4YTE3Y2YyNjQ2YzQyNi90YWJsZXJhbmdlOjI2ZGFjOTFlMzg5YjQ3NzhhYzhhMTdjZjI2NDZjNDI2XzQtNS0xLTEtMTM5MDYy_d434d44e-e525-4877-91d5-7dfdfd1f6341"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic6946e8304b548468ab27182f7a4d25b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZToyNmRhYzkxZTM4OWI0Nzc4YWM4YTE3Y2YyNjQ2YzQyNi90YWJsZXJhbmdlOjI2ZGFjOTFlMzg5YjQ3NzhhYzhhMTdjZjI2NDZjNDI2XzUtMS0xLTEtMTM5MDYy_42eb8dff-cc6c-48f4-adb7-199119ed95e0">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic7178f777b084a969408727f29c9743f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZToyNmRhYzkxZTM4OWI0Nzc4YWM4YTE3Y2YyNjQ2YzQyNi90YWJsZXJhbmdlOjI2ZGFjOTFlMzg5YjQ3NzhhYzhhMTdjZjI2NDZjNDI2XzUtMy0xLTEtMTM5MDYy_1c40f486-6471-4a70-8ad0-05dabae69511">P5Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i85732a5f6db74d908155c57c3c4f6f54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZToyNmRhYzkxZTM4OWI0Nzc4YWM4YTE3Y2YyNjQ2YzQyNi90YWJsZXJhbmdlOjI2ZGFjOTFlMzg5YjQ3NzhhYzhhMTdjZjI2NDZjNDI2XzUtNS0xLTEtMTM5MDYy_fc0810df-372c-4263-9a4c-9ec01e2536f3">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzUxNjg_aaab0fa8-54ef-44e8-b7cb-2e86c846705e">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents summary of activity related to stock options.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except weighted average data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of &lt;br/&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;362.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.4 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;281.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTowZjY2YTZhYTgzNDA0NzM3YmFmMzQwMDc1YWEyMTk2NS90YWJsZXJhbmdlOjBmNjZhNmFhODM0MDQ3MzdiYWYzNDAwNzVhYTIxOTY1XzEtMS0xLTEtMTM5MDYy_7dda68f5-e6d3-4e84-b2be-e130cdcaaa07"
      unitRef="shares">7700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTowZjY2YTZhYTgzNDA0NzM3YmFmMzQwMDc1YWEyMTk2NS90YWJsZXJhbmdlOjBmNjZhNmFhODM0MDQ3MzdiYWYzNDAwNzVhYTIxOTY1XzEtMy0xLTEtMTM5MDYy_ba1af229-42ec-4e4a-bea3-34de787eab17"
      unitRef="usdPerShare">76.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTowZjY2YTZhYTgzNDA0NzM3YmFmMzQwMDc1YWEyMTk2NS90YWJsZXJhbmdlOjBmNjZhNmFhODM0MDQ3MzdiYWYzNDAwNzVhYTIxOTY1XzItMS0xLTEtMTM5MDYy_42f8698b-7f31-4582-aad2-a3c556b7d26b"
      unitRef="shares">2200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTowZjY2YTZhYTgzNDA0NzM3YmFmMzQwMDc1YWEyMTk2NS90YWJsZXJhbmdlOjBmNjZhNmFhODM0MDQ3MzdiYWYzNDAwNzVhYTIxOTY1XzItMy0xLTEtMTM5MDYy_a8a3f958-a784-4343-8592-bee92dccf773"
      unitRef="usdPerShare">81.27</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTowZjY2YTZhYTgzNDA0NzM3YmFmMzQwMDc1YWEyMTk2NS90YWJsZXJhbmdlOjBmNjZhNmFhODM0MDQ3MzdiYWYzNDAwNzVhYTIxOTY1XzMtMS0xLTEtMTM5MDYy_7aac8826-afa9-4e6f-8167-e591863164b4"
      unitRef="shares">700000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTowZjY2YTZhYTgzNDA0NzM3YmFmMzQwMDc1YWEyMTk2NS90YWJsZXJhbmdlOjBmNjZhNmFhODM0MDQ3MzdiYWYzNDAwNzVhYTIxOTY1XzMtMy0xLTEtMTM5MDYy_518ebb70-e352-4920-aced-b90f49561a90"
      unitRef="usdPerShare">52.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTowZjY2YTZhYTgzNDA0NzM3YmFmMzQwMDc1YWEyMTk2NS90YWJsZXJhbmdlOjBmNjZhNmFhODM0MDQ3MzdiYWYzNDAwNzVhYTIxOTY1XzQtMS0xLTEtMTM5MDYy_e8c4ecc7-2037-4ed2-9deb-70736685bc11"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTowZjY2YTZhYTgzNDA0NzM3YmFmMzQwMDc1YWEyMTk2NS90YWJsZXJhbmdlOjBmNjZhNmFhODM0MDQ3MzdiYWYzNDAwNzVhYTIxOTY1XzQtMy0xLTEtMTM5MDYy_0b564828-f5e2-433e-a73b-5e7f3133cc5d"
      unitRef="usdPerShare">96.28</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTowZjY2YTZhYTgzNDA0NzM3YmFmMzQwMDc1YWEyMTk2NS90YWJsZXJhbmdlOjBmNjZhNmFhODM0MDQ3MzdiYWYzNDAwNzVhYTIxOTY1XzUtMS0xLTEtMTM5MDYy_249e2646-5cda-400f-8318-13e8c50868a9"
      unitRef="shares">9000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTowZjY2YTZhYTgzNDA0NzM3YmFmMzQwMDc1YWEyMTk2NS90YWJsZXJhbmdlOjBmNjZhNmFhODM0MDQ3MzdiYWYzNDAwNzVhYTIxOTY1XzUtMy0xLTEtMTM5MDYy_0d7946f8-e3a6-45f1-aa53-07f851bb6583"
      unitRef="usdPerShare">79.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTowZjY2YTZhYTgzNDA0NzM3YmFmMzQwMDc1YWEyMTk2NS90YWJsZXJhbmdlOjBmNjZhNmFhODM0MDQ3MzdiYWYzNDAwNzVhYTIxOTY1XzUtNS0xLTEtMTM5MDYy_0e1e03ea-8c5a-43e5-9eab-57e71614f241">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTowZjY2YTZhYTgzNDA0NzM3YmFmMzQwMDc1YWEyMTk2NS90YWJsZXJhbmdlOjBmNjZhNmFhODM0MDQ3MzdiYWYzNDAwNzVhYTIxOTY1XzUtNy0xLTEtMTM5MDYy_5e0ee085-99f7-40d8-b5ef-6e0e09c0094b"
      unitRef="usd">362800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTowZjY2YTZhYTgzNDA0NzM3YmFmMzQwMDc1YWEyMTk2NS90YWJsZXJhbmdlOjBmNjZhNmFhODM0MDQ3MzdiYWYzNDAwNzVhYTIxOTY1XzYtMS0xLTEtMTM5MDYy_90b2e7aa-cc57-417b-9c14-fea182499bee"
      unitRef="shares">6000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTowZjY2YTZhYTgzNDA0NzM3YmFmMzQwMDc1YWEyMTk2NS90YWJsZXJhbmdlOjBmNjZhNmFhODM0MDQ3MzdiYWYzNDAwNzVhYTIxOTY1XzYtMy0xLTEtMTM5MDYy_95593107-5c4a-4629-887d-5da031b2f7e7"
      unitRef="usdPerShare">72.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTowZjY2YTZhYTgzNDA0NzM3YmFmMzQwMDc1YWEyMTk2NS90YWJsZXJhbmdlOjBmNjZhNmFhODM0MDQ3MzdiYWYzNDAwNzVhYTIxOTY1XzYtNS0xLTEtMTM5MDYy_cdd05805-1e69-415d-86ff-f58e015ab8db">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTowZjY2YTZhYTgzNDA0NzM3YmFmMzQwMDc1YWEyMTk2NS90YWJsZXJhbmdlOjBmNjZhNmFhODM0MDQ3MzdiYWYzNDAwNzVhYTIxOTY1XzYtNy0xLTEtMTM5MDYy_994aa284-6840-4e2a-8a03-55fb91d7c465"
      unitRef="usd">281900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzU0OTc1NTg0ODI3Mw_badab349-632a-4467-8cc2-6ab5f26463fa"
      unitRef="usd">39700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzU0OTc1NTg0ODI4Ng_7c7e3639-5896-4f33-8aba-bfd9bdcff7fb"
      unitRef="usd">58000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzU0OTc1NTg0ODMwMg_b95a032b-a76f-46a4-a9a4-b3c5a1bbadbd"
      unitRef="usd">40200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzU0OTc1NTg0ODM2MQ_b94f1682-a5fd-4b06-9510-f92bf7fb9f6e"
      unitRef="usd">37000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzU0OTc1NTg0ODM3NA_e02a014c-81ee-4ef9-9eb8-bff89bc45c92"
      unitRef="usd">20700000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzU0OTc1NTg0ODM5MA_e7f7eee4-1327-4cb6-b743-9f3050539021"
      unitRef="usd">23500000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ic76478c478fb48838837717f4d08aac5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzUxNjk_14db9a30-70a6-4a42-91e6-00ea769f269d">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="ic76478c478fb48838837717f4d08aac5_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzU0OTc1NTg0NjczNg_1f20d709-43d8-49ac-9c77-e1daf8c34b01"
      unitRef="usd">72400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="i45d277e0630f42518902ef7c75a787b7_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzU0OTc1NTg0Njc0OQ_1efbbdac-bc91-4477-a2bf-3e3bcfc05539"
      unitRef="usd">64300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="ibb26118589cd4a7f9365abf100167588_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzU0OTc1NTg0Njc2NQ_e5f9b3e8-544c-4efd-a109-777178e49ee2"
      unitRef="usd">49700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzUxNzA_2f90c4e1-c925-4389-a52b-e09fb44fec45">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of activity related to RSUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except weighted average data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of &lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant Date &lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;99.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;276.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of activity related to PRSUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except weighted average data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of &lt;br/&gt;PRSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant Date &lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.8 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i60b1905034ee4ddfb0d307e7deb147c0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTpjOTNkZjg1OThlYTU0NDhlYWU5NDRhYWRjMmI1ZWMwNS90YWJsZXJhbmdlOmM5M2RmODU5OGVhNTQ0OGVhZTk0NGFhZGMyYjVlYzA1XzEtMS0xLTEtMTM5MDYy_5de8a9fb-3c3e-4383-a78d-a51895b39393"
      unitRef="shares">2000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i60b1905034ee4ddfb0d307e7deb147c0_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTpjOTNkZjg1OThlYTU0NDhlYWU5NDRhYWRjMmI1ZWMwNS90YWJsZXJhbmdlOmM5M2RmODU5OGVhNTQ0OGVhZTk0NGFhZGMyYjVlYzA1XzEtMy0xLTEtMTM5MDYy_73998a98-75c1-4a65-acb9-c09e5afff5ff"
      unitRef="usdPerShare">99.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ic76478c478fb48838837717f4d08aac5_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTpjOTNkZjg1OThlYTU0NDhlYWU5NDRhYWRjMmI1ZWMwNS90YWJsZXJhbmdlOmM5M2RmODU5OGVhNTQ0OGVhZTk0NGFhZGMyYjVlYzA1XzItMS0xLTEtMTM5MDYy_7d69c15a-f39d-42a3-926c-730cfa42b1ee"
      unitRef="shares">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic76478c478fb48838837717f4d08aac5_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTpjOTNkZjg1OThlYTU0NDhlYWU5NDRhYWRjMmI1ZWMwNS90YWJsZXJhbmdlOmM5M2RmODU5OGVhNTQ0OGVhZTk0NGFhZGMyYjVlYzA1XzItMy0xLTEtMTM5MDYy_bd3ca249-1f11-4f34-8bb3-2e967ea4bfee"
      unitRef="usdPerShare">83.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ic76478c478fb48838837717f4d08aac5_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTpjOTNkZjg1OThlYTU0NDhlYWU5NDRhYWRjMmI1ZWMwNS90YWJsZXJhbmdlOmM5M2RmODU5OGVhNTQ0OGVhZTk0NGFhZGMyYjVlYzA1XzMtMS0xLTEtMTM5MDYy_0b0f4e12-9a58-4b27-8e5e-c1700ad41512"
      unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic76478c478fb48838837717f4d08aac5_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTpjOTNkZjg1OThlYTU0NDhlYWU5NDRhYWRjMmI1ZWMwNS90YWJsZXJhbmdlOmM5M2RmODU5OGVhNTQ0OGVhZTk0NGFhZGMyYjVlYzA1XzMtMy0xLTEtMTM5MDYy_d7a9c079-ecba-488e-917d-2745de60b765"
      unitRef="usdPerShare">96.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ic76478c478fb48838837717f4d08aac5_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTpjOTNkZjg1OThlYTU0NDhlYWU5NDRhYWRjMmI1ZWMwNS90YWJsZXJhbmdlOmM5M2RmODU5OGVhNTQ0OGVhZTk0NGFhZGMyYjVlYzA1XzQtMS0xLTEtMTM5MDYy_71c887e7-a631-4940-9548-ed27277ceb2f"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ic76478c478fb48838837717f4d08aac5_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTpjOTNkZjg1OThlYTU0NDhlYWU5NDRhYWRjMmI1ZWMwNS90YWJsZXJhbmdlOmM5M2RmODU5OGVhNTQ0OGVhZTk0NGFhZGMyYjVlYzA1XzQtMy0xLTEtMTM5MDYy_7dbb0f79-ca07-41b1-9fea-0477129a707a"
      unitRef="usdPerShare">94.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="iab54417bdda84f5da649889184df892f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTpjOTNkZjg1OThlYTU0NDhlYWU5NDRhYWRjMmI1ZWMwNS90YWJsZXJhbmdlOmM5M2RmODU5OGVhNTQ0OGVhZTk0NGFhZGMyYjVlYzA1XzUtMS0xLTEtMTM5MDYy_35513344-8017-4f52-8903-73a4e26e8f0b"
      unitRef="shares">2300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="iab54417bdda84f5da649889184df892f_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTpjOTNkZjg1OThlYTU0NDhlYWU5NDRhYWRjMmI1ZWMwNS90YWJsZXJhbmdlOmM5M2RmODU5OGVhNTQ0OGVhZTk0NGFhZGMyYjVlYzA1XzUtMy0xLTEtMTM5MDYy_180b9f2c-7e34-4987-a52a-551a632f857f"
      unitRef="usdPerShare">92.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="ic76478c478fb48838837717f4d08aac5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTpjOTNkZjg1OThlYTU0NDhlYWU5NDRhYWRjMmI1ZWMwNS90YWJsZXJhbmdlOmM5M2RmODU5OGVhNTQ0OGVhZTk0NGFhZGMyYjVlYzA1XzUtNS0xLTEtMTM5MDYy_d715bede-6224-4511-b627-82f609bc639c">P1Y3M18D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="iab54417bdda84f5da649889184df892f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTpjOTNkZjg1OThlYTU0NDhlYWU5NDRhYWRjMmI1ZWMwNS90YWJsZXJhbmdlOmM5M2RmODU5OGVhNTQ0OGVhZTk0NGFhZGMyYjVlYzA1XzUtNy0xLTEtMTM5MDYy_3bc4460e-6192-4f2b-bc56-8512d5994343"
      unitRef="usd">276600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ic887499617c2453682a9ed77390375fe_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzE2NDkyNjc0NzcyNzM_aa5a5a15-c1dc-438f-8383-029616d91b6d">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i4445191c2fc34a93a6035559db9ca75f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzU0OTc1NTgzNTIyOQ_13eefbfe-f925-4a58-91fc-314234236ca4"
      unitRef="usd">13500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i2383f1847c08462b992435e6a74d3b13_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzU0OTc1NTgzNTU4NQ_331ca298-d3c2-407e-8bd1-fec8d38f8bad"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i87dac2801c32400a82446d8538afc4cf_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzU0OTc1NTgzNTU4NQ_9d55b973-faae-4df8-981a-b9439290df7b"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i229630d0b4d149969094372fd9771fee_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo4YTM0ZjlhODBhMzk0MDg1ODk5ZjNjNTU2OGUwMzc0Ny90YWJsZXJhbmdlOjhhMzRmOWE4MGEzOTQwODU4OTlmM2M1NTY4ZTAzNzQ3XzEtMS0xLTEtMTM5MDYy_55cfe178-99e3-4880-b366-239e080834d3"
      unitRef="shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i229630d0b4d149969094372fd9771fee_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo4YTM0ZjlhODBhMzk0MDg1ODk5ZjNjNTU2OGUwMzc0Ny90YWJsZXJhbmdlOjhhMzRmOWE4MGEzOTQwODU4OTlmM2M1NTY4ZTAzNzQ3XzEtMy0xLTEtMTM5MDYy_9c09b06b-eaa4-4725-a591-8de29f80a277"
      unitRef="usdPerShare">109.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i87dac2801c32400a82446d8538afc4cf_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo4YTM0ZjlhODBhMzk0MDg1ODk5ZjNjNTU2OGUwMzc0Ny90YWJsZXJhbmdlOjhhMzRmOWE4MGEzOTQwODU4OTlmM2M1NTY4ZTAzNzQ3XzItMS0xLTEtMTM5MDYy_8e939bba-0977-484a-9d3c-c05920143ca8"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i87dac2801c32400a82446d8538afc4cf_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo4YTM0ZjlhODBhMzk0MDg1ODk5ZjNjNTU2OGUwMzc0Ny90YWJsZXJhbmdlOjhhMzRmOWE4MGEzOTQwODU4OTlmM2M1NTY4ZTAzNzQ3XzItMy0xLTEtMTM5MDYy_6bfbab6a-defc-47a4-a639-bebe6ec61a1b"
      unitRef="usdPerShare">80.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i87dac2801c32400a82446d8538afc4cf_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo4YTM0ZjlhODBhMzk0MDg1ODk5ZjNjNTU2OGUwMzc0Ny90YWJsZXJhbmdlOjhhMzRmOWE4MGEzOTQwODU4OTlmM2M1NTY4ZTAzNzQ3XzMtMS0xLTEtMTM5MDYy_fc906344-f496-4d2f-9605-bcf40cd44a30"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i87dac2801c32400a82446d8538afc4cf_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo4YTM0ZjlhODBhMzk0MDg1ODk5ZjNjNTU2OGUwMzc0Ny90YWJsZXJhbmdlOjhhMzRmOWE4MGEzOTQwODU4OTlmM2M1NTY4ZTAzNzQ3XzMtMy0xLTEtMTM5MDYy_4924dc16-36b7-4e49-8465-4d42279c4ec6"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i87dac2801c32400a82446d8538afc4cf_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo4YTM0ZjlhODBhMzk0MDg1ODk5ZjNjNTU2OGUwMzc0Ny90YWJsZXJhbmdlOjhhMzRmOWE4MGEzOTQwODU4OTlmM2M1NTY4ZTAzNzQ3XzQtMS0xLTEtMTM5MDYy_aee3fa83-d00b-43f5-8094-47a251ae08ce"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i87dac2801c32400a82446d8538afc4cf_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo4YTM0ZjlhODBhMzk0MDg1ODk5ZjNjNTU2OGUwMzc0Ny90YWJsZXJhbmdlOjhhMzRmOWE4MGEzOTQwODU4OTlmM2M1NTY4ZTAzNzQ3XzQtMy0xLTEtMTM5MDYy_02e387be-7f39-4c09-9bc1-ba0ad5b7dc95"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="if3f2d647e6d24e838c79ec0e84ee0b98_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo4YTM0ZjlhODBhMzk0MDg1ODk5ZjNjNTU2OGUwMzc0Ny90YWJsZXJhbmdlOjhhMzRmOWE4MGEzOTQwODU4OTlmM2M1NTY4ZTAzNzQ3XzUtMS0xLTEtMTM5MDYy_05fd0e15-96dd-4cfd-aa98-9147c3387200"
      unitRef="shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="if3f2d647e6d24e838c79ec0e84ee0b98_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo4YTM0ZjlhODBhMzk0MDg1ODk5ZjNjNTU2OGUwMzc0Ny90YWJsZXJhbmdlOjhhMzRmOWE4MGEzOTQwODU4OTlmM2M1NTY4ZTAzNzQ3XzUtMy0xLTEtMTM5MDYy_ca6cce5f-9b46-406c-8d10-ef3cf54ae4ad"
      unitRef="usdPerShare">101.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i87dac2801c32400a82446d8538afc4cf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo4YTM0ZjlhODBhMzk0MDg1ODk5ZjNjNTU2OGUwMzc0Ny90YWJsZXJhbmdlOjhhMzRmOWE4MGEzOTQwODU4OTlmM2M1NTY4ZTAzNzQ3XzUtNS0xLTEtMTM5MDYy_48e4397a-dff5-47b8-99eb-d6577e60cc31">P0Y9M18D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="if3f2d647e6d24e838c79ec0e84ee0b98_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90YWJsZTo4YTM0ZjlhODBhMzk0MDg1ODk5ZjNjNTU2OGUwMzc0Ny90YWJsZXJhbmdlOjhhMzRmOWE4MGEzOTQwODU4OTlmM2M1NTY4ZTAzNzQ3XzUtNy0xLTEtMTM5MDYy_64c8d5ed-a73d-47fb-b3dd-94bf24ef0ceb"
      unitRef="usd">60500000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="ibf71df6caa1445c7a59724087fa5d3fa_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjAvZnJhZzpkZWFlNDdhNmUxZTg0OGQwYTJlMmRjNWQyZDg1NWE4ZS90ZXh0cmVnaW9uOmRlYWU0N2E2ZTFlODQ4ZDBhMmUyZGM1ZDJkODU1YThlXzQ5OTU_65473d91-462f-4226-a6f2-6acd83297113"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90ZXh0cmVnaW9uOjA1ZTFlOWYxMzA1OTQwY2I4YmQ1ODQ1YmQ5NGE0MzExXzM3NTQ_061df3e1-7abf-498d-a64a-61c8ab8e77fa">Income Taxes&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents income before the provision for income taxes from continuing domestic and foreign operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;213.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the components of the provision for (benefit from) income taxes for continuing operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(287.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(23.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(310.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Provision for (benefit from) income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(300.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for (benefit from) income taxes on earnings subject to income taxes differs from the statutory federal rate due to the following: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal income taxes at 21%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State income tax, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Branded prescription drug fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss on extinguishment of convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Officer compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expired tax attributes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(29.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(22.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(39.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(296.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Provision for (benefit from) income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(300.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the significant components of our deferred tax assets. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;129.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capitalized research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;405.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;413.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(23.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(32.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(43.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net of deferred tax assets and liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;372.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;369.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(67.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(54.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;305.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;315.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, our deferred tax assets were primarily the result of net operating loss carry forwards, capitalized research costs, acquired intangible assets and tax credit carryforwards. As of December 31, 2022 and 2021, we recorded a valuation allowance of $67.0 million and $54.8 million, respectively, against our gross deferred tax asset balance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of each reporting date, management considers new evidence, both positive and negative, that could affect its assessment of the future realizability of our deferred tax assets. As of December&#160;31, 2022, management determined there was sufficient positive evidence to conclude that it is more likely than not deferred tax assets of $305.9 million are realizable. The recorded valuation allowance of $67.0 million consisted primarily of state and foreign net operating loss carryforwards and state credit carryforwards for which management cannot conclude it is more likely than not to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, we had state and foreign income tax net operating loss carryforwards of $324.6 million and $60.1 million, respectively. We had no federal income tax operating loss carryforwards as of December&#160;31, 2022. California net operating losses will begin to expire in 2031 unless previously utilized and the net operating losses related to other states will begin to expire in 2026. Foreign net operating losses will carry forward indefinitely unless previously utilized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, we had federal and state R&amp;amp;D tax credit carryforwards of $98.2 million and $72.5 million, respectively. Federal R&amp;amp;D tax credits will begin to expire in 2037 unless previously utilized. California R&amp;amp;D tax credits carry forward indefinitely, while R&amp;amp;D tax credits related to other states will begin to expire in 2033 unless previously utilized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the future utilization of our net operating loss and R&amp;amp;D tax credit carryforwards to offset future taxable income may be subject to an annual limitation, pursuant to Internal Revenue Code Sections 382 and 383, as a result of ownership changes that could occur in the future. No ownership changes have occurred through December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize interest and penalties related to income tax matters in income tax expense. As of December&#160;31, 2022, we had accruals for interest and penalties related to income tax matters of $0.5 million and $0.4 million, respectively. Interest and penalties related to income tax matters were not material for 2021 or 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to taxation in the United States and various state and foreign jurisdictions. Tax years for 2002 for federal, inception for California, 2015 to 2019 for other significant state jurisdictions, and 2019 and forward for foreign are subject to examination by tax authorities due to the carryforward of unutilized net operating losses and R&amp;amp;D tax credits.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of activity related to unrecognized tax benefits.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at January 1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increase (decrease) related to prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increase related to current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlements related to prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expiration of the statute of limitations for the assessment of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, we had $74.8 million of unrecognized tax benefits that, if recognized and realized, would affect the effective tax rate, subject to changes in the valuation allowance. We do not expect a significant change in our unrecognized tax benefits in the next 12 months.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90ZXh0cmVnaW9uOjA1ZTFlOWYxMzA1OTQwY2I4YmQ1ODQ1YmQ5NGE0MzExXzIxOTkwMjMyNjQ0MDk_f2f9f5ab-efa7-4862-ae57-c2ace642e558">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents income before the provision for income taxes from continuing domestic and foreign operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;213.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTpmNzFiNjY0YjRjYzI0ZWFmOWMwOThlYTEzYmYwODQ1Mi90YWJsZXJhbmdlOmY3MWI2NjRiNGNjMjRlYWY5YzA5OGVhMTNiZjA4NDUyXzItMS0xLTEtMTcxNDk0_7accda6c-60a5-41f8-a3cb-6244c666cc7b"
      unitRef="usd">218000000.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTpmNzFiNjY0YjRjYzI0ZWFmOWMwOThlYTEzYmYwODQ1Mi90YWJsZXJhbmdlOmY3MWI2NjRiNGNjMjRlYWY5YzA5OGVhMTNiZjA4NDUyXzItMy0xLTEtMTcxNTAx_8308f1b5-6d56-4cb9-be6a-6e58f381a86d"
      unitRef="usd">101400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTpmNzFiNjY0YjRjYzI0ZWFmOWMwOThlYTEzYmYwODQ1Mi90YWJsZXJhbmdlOmY3MWI2NjRiNGNjMjRlYWY5YzA5OGVhMTNiZjA4NDUyXzItNS0xLTEtMTcxNTA4_2b15f596-d7d6-4bd5-b8da-e97ba66446dc"
      unitRef="usd">106700000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTpmNzFiNjY0YjRjYzI0ZWFmOWMwOThlYTEzYmYwODQ1Mi90YWJsZXJhbmdlOmY3MWI2NjRiNGNjMjRlYWY5YzA5OGVhMTNiZjA4NDUyXzMtMS0xLTEtMTcxNDk0_5c3deba2-4225-456c-a966-b9a27c6c663d"
      unitRef="usd">-4100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTpmNzFiNjY0YjRjYzI0ZWFmOWMwOThlYTEzYmYwODQ1Mi90YWJsZXJhbmdlOmY3MWI2NjRiNGNjMjRlYWY5YzA5OGVhMTNiZjA4NDUyXzMtMy0xLTEtMTcxNTAx_95bf4914-9f24-44c7-9c04-6ffed27564bb"
      unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTpmNzFiNjY0YjRjYzI0ZWFmOWMwOThlYTEzYmYwODQ1Mi90YWJsZXJhbmdlOmY3MWI2NjRiNGNjMjRlYWY5YzA5OGVhMTNiZjA4NDUyXzMtNS0xLTEtMTcxNTA4_9de62087-57c2-46a0-965b-4b52f691e013"
      unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTpmNzFiNjY0YjRjYzI0ZWFmOWMwOThlYTEzYmYwODQ1Mi90YWJsZXJhbmdlOmY3MWI2NjRiNGNjMjRlYWY5YzA5OGVhMTNiZjA4NDUyXzQtMS0xLTEtMTcxNDk0_0aca913b-d31d-4c98-910a-c3d6e8e2f274"
      unitRef="usd">213900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTpmNzFiNjY0YjRjYzI0ZWFmOWMwOThlYTEzYmYwODQ1Mi90YWJsZXJhbmdlOmY3MWI2NjRiNGNjMjRlYWY5YzA5OGVhMTNiZjA4NDUyXzQtMy0xLTEtMTcxNTAx_7ef46d9c-1b63-4f12-947f-ee75db003fc3"
      unitRef="usd">101400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTpmNzFiNjY0YjRjYzI0ZWFmOWMwOThlYTEzYmYwODQ1Mi90YWJsZXJhbmdlOmY3MWI2NjRiNGNjMjRlYWY5YzA5OGVhMTNiZjA4NDUyXzQtNS0xLTEtMTcxNTA4_9ae68501-1b72-4652-a434-d03d6407a446"
      unitRef="usd">106700000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90ZXh0cmVnaW9uOjA1ZTFlOWYxMzA1OTQwY2I4YmQ1ODQ1YmQ5NGE0MzExXzM3NTU_6367ed5e-6abd-4af8-92d0-ee580ff93bd5">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the components of the provision for (benefit from) income taxes for continuing operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(287.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(23.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(310.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Provision for (benefit from) income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(300.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzMtMS0xLTEtMTM5MDYy_617696ab-b17f-4fff-a931-90eab2eed5eb"
      unitRef="usd">17100000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzMtMy0xLTEtMTM5MDYy_ab61aa94-cf51-4f6a-a44a-3b7db89262ed"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzMtNS0xLTEtMTM5MDYy_13fab059-920d-493c-8afd-75138f99d64c"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzQtMS0xLTEtMTM5MDYy_a4543e8d-73ef-49a4-a326-c7eaa533cfd8"
      unitRef="usd">20300000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzQtMy0xLTEtMTM5MDYy_37cd82c6-6edf-4410-a9e1-5d7b753a7377"
      unitRef="usd">6300000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzQtNS0xLTEtMTM5MDYy_e4b1dfd4-25c3-400c-bc92-8e3bac3d573d"
      unitRef="usd">10100000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzUtMS0xLTEtMTM5MDYy_c7f05460-3aa1-4f91-b6c3-de5cd3b333e3"
      unitRef="usd">37400000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzUtMy0xLTEtMTM5MDYy_1a2ff063-82bc-47b9-9d5a-383dbbdaa97c"
      unitRef="usd">6300000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzUtNS0xLTEtMTM5MDYy_21eb59e1-72a5-44d9-a3a2-385c6fadd3a2"
      unitRef="usd">10100000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzctMS0xLTEtMTM5MDYy_104d0c54-c018-4f74-8610-27ab0e4fc5ad"
      unitRef="usd">27500000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzctMy0xLTEtMTM5MDYy_9194b92c-db6c-44a0-89d9-63777208dbd6"
      unitRef="usd">5900000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzctNS0xLTEtMTM5MDYy_bc5fc2c7-718a-410a-b340-a88f9eb05374"
      unitRef="usd">-287500000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzgtMS0xLTEtMTM5MDYy_ccc3c6ca-d919-495e-adf3-8ba7458e1dc8"
      unitRef="usd">-5500000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzgtMy0xLTEtMTM5MDYy_b349592c-06d3-4081-b598-5ca317534d7a"
      unitRef="usd">-400000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzgtNS0xLTEtMTM5MDYy_dd3604f5-d9a9-4504-94e2-0b6565b9e53f"
      unitRef="usd">-23200000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzktMS0xLTEtMTM5MDYy_ac29b239-4f5b-4d04-81bb-c38e766ba1d8"
      unitRef="usd">22000000.0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzktMy0xLTEtMTM5MDYy_7ac1d302-7407-4549-ab42-f39e4f3b13e6"
      unitRef="usd">5500000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzktNS0xLTEtMTM5MDYy_26b5e5df-359b-42b1-bef2-2056b1b94ee8"
      unitRef="usd">-310700000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzEwLTEtMS0xLTEzOTA2Mg_ef4af46e-1e9d-4f5b-a9cd-ab2563c7e202"
      unitRef="usd">59400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzEwLTMtMS0xLTEzOTA2Mg_6daca9bf-789c-4f33-b6a7-221af56006f1"
      unitRef="usd">11800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToxMWRhN2QzZGYxNWE0YzJjOWJiYTI4ZWRjYThlYWEzYi90YWJsZXJhbmdlOjExZGE3ZDNkZjE1YTRjMmM5YmJhMjhlZGNhOGVhYTNiXzEwLTUtMS0xLTEzOTA2Mg_e816c29d-59b0-4383-9def-c732616bc96b"
      unitRef="usd">-300600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90ZXh0cmVnaW9uOjA1ZTFlOWYxMzA1OTQwY2I4YmQ1ODQ1YmQ5NGE0MzExXzM3NTY_91fa09d2-e266-4f87-ad6a-41e3505324a1">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for (benefit from) income taxes on earnings subject to income taxes differs from the statutory federal rate due to the following: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal income taxes at 21%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State income tax, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Branded prescription drug fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss on extinguishment of convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Officer compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expired tax attributes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(29.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(22.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(39.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(296.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Provision for (benefit from) income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(300.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzItMC0xLTEtMTM5MDYyL3RleHRyZWdpb246MzEzN2EzYWU2Y2Y5NDdkMTk3Y2VmNGIyNTI4NGZmNGJfMjg_27c82d69-1296-42d4-86ff-abc232eaad2c"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzItMC0xLTEtMTM5MDYyL3RleHRyZWdpb246MzEzN2EzYWU2Y2Y5NDdkMTk3Y2VmNGIyNTI4NGZmNGJfMjg_80f75563-8c3f-4229-b601-cc5d2532f483"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzItMC0xLTEtMTM5MDYyL3RleHRyZWdpb246MzEzN2EzYWU2Y2Y5NDdkMTk3Y2VmNGIyNTI4NGZmNGJfMjg_b789158a-55c6-42ac-a103-f2d69e4a933b"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzItMS0xLTEtMTM5MDYy_6a8191b6-f39c-464a-9999-3a17143fac52"
      unitRef="usd">44900000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzItMy0xLTEtMTM5MDYy_9b1fade0-6c9c-4560-9509-89f9c0593937"
      unitRef="usd">21300000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzItNS0xLTEtMTM5MDYy_2146b277-4ab0-42f1-b4b1-c2b1769f69cf"
      unitRef="usd">22400000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzMtMS0xLTEtMTM5MDYy_c2a0ef77-24fb-429a-ba25-46b7ed43b61d"
      unitRef="usd">11800000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzMtMy0xLTEtMTM5MDYy_d00ef1b9-959a-4015-8942-f50a9725856a"
      unitRef="usd">6200000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzMtNS0xLTEtMTM5MDYy_d27cacf8-716f-4023-9876-573455d4476a"
      unitRef="usd">5500000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <nbix:IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzUtMS0xLTEtMTM5MDYy_5c418079-4ad3-40cc-bd9f-5401da8447cf"
      unitRef="usd">6500000</nbix:IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee>
    <nbix:IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzUtMy0xLTEtMTM5MDYy_cff1e71c-b2c2-4f41-85c0-0cd12741ba48"
      unitRef="usd">4800000</nbix:IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee>
    <nbix:IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzUtNS0xLTEtMTM5MDYy_1f30b0dd-0329-4d2e-b790-3b0a2e7dd71c"
      unitRef="usd">4900000</nbix:IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee>
    <nbix:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzUtMS0xLTEtMTcyMTI3_bad41ff3-f622-4043-ac37-560adc5c6be7"
      unitRef="usd">12000000.0</nbix:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes>
    <nbix:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzUtMy0xLTEtMTcyMTM0_ba5cf874-f571-40e1-a15d-b49a763e68ff"
      unitRef="usd">0</nbix:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes>
    <nbix:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzUtNS0xLTEtMTcyMTQx_1c906a46-81f1-4f3e-a031-e9be3b2d0cc5"
      unitRef="usd">0</nbix:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzYtMS0xLTEtMTM5MDYy_480ba12a-0f7a-4d33-99fb-2acf99a30279"
      unitRef="usd">-2500000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzYtMy0xLTEtMTM5MDYy_07e6b66a-7c1a-4f2e-9da3-5ae746117d21"
      unitRef="usd">-11300000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzYtNS0xLTEtMTM5MDYy_f08f8086-aae4-4309-a6e8-3f71d5d850db"
      unitRef="usd">-6700000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <nbix:IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzctMS0xLTEtMTM5MDYy_8b745ad9-6a11-4047-8ad1-f9b3dff41a3e"
      unitRef="usd">9200000</nbix:IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost>
    <nbix:IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzctMy0xLTEtMTM5MDYy_bed38923-14ef-4c8b-87d0-fae6596e90e6"
      unitRef="usd">7000000.0</nbix:IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost>
    <nbix:IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzctNS0xLTEtMTM5MDYy_86434135-4b90-4be5-b1d7-f3066b17cbb4"
      unitRef="usd">3700000</nbix:IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzgtMS0xLTEtMTM5MDYy_2846ed06-ba7d-455c-8774-44bda577b4d6"
      unitRef="usd">-1300000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzgtMy0xLTEtMTM5MDYy_2d8bde20-97c1-485a-a840-b3b79e92f6c5"
      unitRef="usd">200000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzgtNS0xLTEtMTM5MDYy_a10133b9-42fc-4cf6-a6a4-6eeb88e1798e"
      unitRef="usd">3300000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <nbix:IncomeTaxReconciliationExpirationOfTaxCredits
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzktMS0xLTEtMTM5MDYy_e30c9d35-4aa0-47a8-b748-96be00f0cf61"
      unitRef="usd">0</nbix:IncomeTaxReconciliationExpirationOfTaxCredits>
    <nbix:IncomeTaxReconciliationExpirationOfTaxCredits
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzktMy0xLTEtMTM5MDYy_7ee7fb1f-a415-4477-a5dd-965851292b22"
      unitRef="usd">600000</nbix:IncomeTaxReconciliationExpirationOfTaxCredits>
    <nbix:IncomeTaxReconciliationExpirationOfTaxCredits
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzktNS0xLTEtMTM5MDYy_61c71cf8-2c7f-4b64-af0b-cd3df98d4836"
      unitRef="usd">1100000</nbix:IncomeTaxReconciliationExpirationOfTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzEwLTEtMS0xLTEzOTA2Mg_3a1ad8bf-ffc2-4c4f-9222-2ec64d6f0abe"
      unitRef="usd">29900000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzEwLTMtMS0xLTEzOTA2Mg_e5fc4655-7900-41eb-a717-44e6d2e0ae72"
      unitRef="usd">22000000.0</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzEwLTUtMS0xLTEzOTA2Mg_82c48d87-7d34-4d6c-8bad-3b69fcb9b735"
      unitRef="usd">39000000.0</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzExLTEtMS0xLTEzOTA2Mg_3cd4d803-8ea1-4d39-8733-0af2cc5f4f86"
      unitRef="usd">7400000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzExLTMtMS0xLTEzOTA2Mg_4c956464-311d-4f5e-a8d0-2f7c91d3d761"
      unitRef="usd">5000000.0</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzExLTUtMS0xLTEzOTA2Mg_bdc68d23-0315-4223-b4ef-751c1a6d59dd"
      unitRef="usd">-296300000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzEyLTEtMS0xLTEzOTA2Mg_2bb7d480-ef2f-4466-a354-67294de5ee56"
      unitRef="usd">1300000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzEyLTMtMS0xLTEzOTA2Mg_ed109126-3466-4a46-8d68-998260bdc29b"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzEyLTUtMS0xLTEzOTA2Mg_35ce6bd6-7f6b-4194-b55f-474118dc49db"
      unitRef="usd">500000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzEzLTEtMS0xLTEzOTA2Mg_89c51617-ee50-4001-a4bf-26c1cc423335"
      unitRef="usd">59400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzEzLTMtMS0xLTEzOTA2Mg_62d718ec-2b65-4d65-b399-1c55d8ee90ad"
      unitRef="usd">11800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2YzgwMzIwNmFmZDY0NjFiOTc4OGEzMDdlYjYwNWEwYi90YWJsZXJhbmdlOjZjODAzMjA2YWZkNjQ2MWI5Nzg4YTMwN2ViNjA1YTBiXzEzLTUtMS0xLTEzOTA2Mg_4d2879bd-18b3-4b05-bf4d-0dcc84d50b71"
      unitRef="usd">-300600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90ZXh0cmVnaW9uOjA1ZTFlOWYxMzA1OTQwY2I4YmQ1ODQ1YmQ5NGE0MzExXzM3NTc_b3af6882-e8a0-4c76-a56c-9f64cea40db4">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the significant components of our deferred tax assets. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;129.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capitalized research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;405.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;413.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(23.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(32.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(43.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net of deferred tax assets and liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;372.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;369.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(67.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(54.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;305.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;315.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzMtMS0xLTEtMTM5MDYy_3e965711-701a-4102-8036-47b63afd2221"
      unitRef="usd">27400000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzMtMy0xLTEtMTM5MDYy_96e5feee-bfd3-4eae-8c73-174d354b5fd8"
      unitRef="usd">90300000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzQtMS0xLTEtMTM5MDYy_6a3abba9-5ad8-42b7-b384-95a558319ba6"
      unitRef="usd">108900000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzQtMy0xLTEtMTM5MDYy_027f756c-5f28-4a67-8f67-7170768d9f7a"
      unitRef="usd">129700000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <nbix:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzUtMS0xLTEtMTM5MDYy_c62ac4da-3a8c-49d4-b208-c37259503484"
      unitRef="usd">91100000</nbix:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <nbix:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzUtMy0xLTEtMTM5MDYy_00bf90bf-b49a-4c21-a472-507dcb6e391f"
      unitRef="usd">17900000</nbix:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzYtMS0xLTEtMTM5MDYy_bdc494bf-0db5-4e2b-9969-4cfb66bdf657"
      unitRef="usd">45900000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzYtMy0xLTEtMTM5MDYy_ee38725b-ca04-4db2-a18f-705fe2811dbd"
      unitRef="usd">38900000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <nbix:DeferredTaxAssetsOperatingLeasesAssets
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzctMS0xLTEtMTM5MDYy_4c26e0ec-7a7c-4161-a669-31d5748ce02b"
      unitRef="usd">26800000</nbix:DeferredTaxAssetsOperatingLeasesAssets>
    <nbix:DeferredTaxAssetsOperatingLeasesAssets
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzctMy0xLTEtMTM5MDYy_1a14ecad-749e-4f7a-9422-726ee2de22a5"
      unitRef="usd">29300000</nbix:DeferredTaxAssetsOperatingLeasesAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzgtMS0xLTEtMTM5MDYy_6400f06a-cd85-4660-8fb7-08fc34f75017"
      unitRef="usd">80700000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzgtMy0xLTEtMTM5MDYy_f3af938d-bf63-4a3c-ab05-fa27ee2b883c"
      unitRef="usd">86100000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzktMS0xLTEtMTM5MDYy_9547b9aa-1a30-4a79-b99d-eefda27e88b1"
      unitRef="usd">24900000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzktMy0xLTEtMTM5MDYy_87041893-ada3-4601-b630-c855ed509d1b"
      unitRef="usd">21600000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzEwLTEtMS0xLTEzOTA2Mg_313f45ae-00cc-4fab-b4ee-766868979899"
      unitRef="usd">405700000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzEwLTMtMS0xLTEzOTA2Mg_2138134d-3011-45a0-a47e-0cd35b310c13"
      unitRef="usd">413800000</us-gaap:DeferredTaxAssetsGross>
    <nbix:DeferredTaxLiabilitiesConvertibleSeniorNotes
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzEyLTEtMS0xLTEzOTA2Mg_f83b9ea8-55f1-49bc-8e6a-9acb10955d0c"
      unitRef="usd">0</nbix:DeferredTaxLiabilitiesConvertibleSeniorNotes>
    <nbix:DeferredTaxLiabilitiesConvertibleSeniorNotes
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzEyLTMtMS0xLTEzOTA2Mg_eb351b06-e931-4e9d-95d0-9ea0757430d4"
      unitRef="usd">9900000</nbix:DeferredTaxLiabilitiesConvertibleSeniorNotes>
    <nbix:DeferredTaxLiabilitiesOperatingLeasesLiabilities
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzEzLTEtMS0xLTEzOTA2Mg_f101c689-2ad3-4e5d-8fb1-3e1983517f6d"
      unitRef="usd">21000000.0</nbix:DeferredTaxLiabilitiesOperatingLeasesLiabilities>
    <nbix:DeferredTaxLiabilitiesOperatingLeasesLiabilities
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzEzLTMtMS0xLTEzOTA2Mg_5ae28b31-078e-4828-b646-88a9f3094c6f"
      unitRef="usd">23300000</nbix:DeferredTaxLiabilitiesOperatingLeasesLiabilities>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzE0LTEtMS0xLTEzOTA2Mg_88fd71c7-5c0a-470a-b0bf-b7f45cfee534"
      unitRef="usd">11800000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzE0LTMtMS0xLTEzOTA2Mg_eb8be0c4-5e8e-4402-a5ac-43accef425e5"
      unitRef="usd">10700000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzE1LTEtMS0xLTEzOTA2Mg_73098579-2948-4d41-bf8f-2b39cb1e4010"
      unitRef="usd">32800000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzE1LTMtMS0xLTEzOTA2Mg_86892ab9-41c9-4e39-935c-3ee1a8bced28"
      unitRef="usd">43900000</us-gaap:DeferredIncomeTaxLiabilities>
    <nbix:DeferredTaxAssetsLiabilitiesGross
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzE2LTEtMS0xLTEzOTA2Mg_d1a86425-9ae5-4ad9-be0b-af03ebbdff05"
      unitRef="usd">372900000</nbix:DeferredTaxAssetsLiabilitiesGross>
    <nbix:DeferredTaxAssetsLiabilitiesGross
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzE2LTMtMS0xLTEzOTA2Mg_8c6206e3-96ea-4969-bde3-a2c367ea155d"
      unitRef="usd">369900000</nbix:DeferredTaxAssetsLiabilitiesGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzE3LTEtMS0xLTEzOTA2Mg_74508b56-294d-4fef-aed1-764fcbf16434"
      unitRef="usd">67000000.0</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzE3LTMtMS0xLTEzOTA2Mg_981b69fb-1bbf-4796-9259-f48f441853fa"
      unitRef="usd">54800000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzE4LTEtMS0xLTEzOTA2Mg_3564549e-4e35-4c20-8bb5-1788c9a9481b"
      unitRef="usd">305900000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZToyNGYyNjFjYTZkNmI0ZTVmYjI1M2YzOGJiNzYxMzcyZi90YWJsZXJhbmdlOjI0ZjI2MWNhNmQ2YjRlNWZiMjUzZjM4YmI3NjEzNzJmXzE4LTMtMS0xLTEzOTA2Mg_2a1db7a9-9fe4-4416-bd97-d3870aeacce6"
      unitRef="usd">315100000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90ZXh0cmVnaW9uOjA1ZTFlOWYxMzA1OTQwY2I4YmQ1ODQ1YmQ5NGE0MzExXzYyNw_74508b56-294d-4fef-aed1-764fcbf16434"
      unitRef="usd">67000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90ZXh0cmVnaW9uOjA1ZTFlOWYxMzA1OTQwY2I4YmQ1ODQ1YmQ5NGE0MzExXzYzNA_981b69fb-1bbf-4796-9259-f48f441853fa"
      unitRef="usd">54800000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90ZXh0cmVnaW9uOjA1ZTFlOWYxMzA1OTQwY2I4YmQ1ODQ1YmQ5NGE0MzExXzEwMzA_3564549e-4e35-4c20-8bb5-1788c9a9481b"
      unitRef="usd">305900000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90ZXh0cmVnaW9uOjA1ZTFlOWYxMzA1OTQwY2I4YmQ1ODQ1YmQ5NGE0MzExXzEwODU_74508b56-294d-4fef-aed1-764fcbf16434"
      unitRef="usd">67000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i216211ef6a3c4bf293c5a051308c8517_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90ZXh0cmVnaW9uOjA1ZTFlOWYxMzA1OTQwY2I4YmQ1ODQ1YmQ5NGE0MzExXzU0OTc1NTgxOTU3NA_39645a37-4c67-44fc-8d16-22d30b827c0a"
      unitRef="usd">324600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i71608a5505e146ccaf00cf18ac3af453_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90ZXh0cmVnaW9uOjA1ZTFlOWYxMzA1OTQwY2I4YmQ1ODQ1YmQ5NGE0MzExXzU0OTc1NTgxOTU4Mg_7ca0a8df-9591-4eed-aad3-9573d6b5a26d"
      unitRef="usd">60100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="iec21f5b659784393b128ecb098d076d0_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90ZXh0cmVnaW9uOjA1ZTFlOWYxMzA1OTQwY2I4YmQ1ODQ1YmQ5NGE0MzExXzU0OTc1NTgxOTU5MA_7b3c6b24-d6e9-4251-9bd4-33797c7532cb"
      unitRef="usd">0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="iec21f5b659784393b128ecb098d076d0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90ZXh0cmVnaW9uOjA1ZTFlOWYxMzA1OTQwY2I4YmQ1ODQ1YmQ5NGE0MzExXzE2Nzc_3ffed27d-7ae2-469f-97ed-db538a35fad7"
      unitRef="usd">98200000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i216211ef6a3c4bf293c5a051308c8517_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90ZXh0cmVnaW9uOjA1ZTFlOWYxMzA1OTQwY2I4YmQ1ODQ1YmQ5NGE0MzExXzE2ODQ_a5e4eee3-a155-4aa7-b11b-efcc923ca07d"
      unitRef="usd">72500000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:IncomeTaxExaminationInterestAccrued
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90ZXh0cmVnaW9uOjA1ZTFlOWYxMzA1OTQwY2I4YmQ1ODQ1YmQ5NGE0MzExXzU0OTc1NTgyMjY4Mg_efbb0a12-22ab-4e98-af87-fbcd57fc3e62"
      unitRef="usd">500000</us-gaap:IncomeTaxExaminationInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAccrued
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90ZXh0cmVnaW9uOjA1ZTFlOWYxMzA1OTQwY2I4YmQ1ODQ1YmQ5NGE0MzExXzU0OTc1NTgyMjcwMQ_e05c5abe-7fb1-4482-a8e2-96190c7b8dcb"
      unitRef="usd">400000</us-gaap:IncomeTaxExaminationPenaltiesAccrued>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90ZXh0cmVnaW9uOjA1ZTFlOWYxMzA1OTQwY2I4YmQ1ODQ1YmQ5NGE0MzExXzM3NTg_0190ea75-2180-45d1-be6b-d2a479df0a11">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of activity related to unrecognized tax benefits.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at January 1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increase (decrease) related to prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increase related to current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlements related to prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expiration of the statute of limitations for the assessment of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2ODRlYTI1Y2Q0NTg0MDdkYWRjM2I4ZGM2MTMwYzYxMS90YWJsZXJhbmdlOjY4NGVhMjVjZDQ1ODQwN2RhZGMzYjhkYzYxMzBjNjExXzItMS0xLTEtMTM5MDYy_e8d45611-6fea-4193-ab11-45e993891201"
      unitRef="usd">64600000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i8a88ab4de251408db4aa98552134a56a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2ODRlYTI1Y2Q0NTg0MDdkYWRjM2I4ZGM2MTMwYzYxMS90YWJsZXJhbmdlOjY4NGVhMjVjZDQ1ODQwN2RhZGMzYjhkYzYxMzBjNjExXzItMy0xLTEtMTM5MDYy_ab185d22-a40c-4108-9526-ad0091b030e2"
      unitRef="usd">60800000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ie9e7a539304246b48b58f35e4a888e14_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2ODRlYTI1Y2Q0NTg0MDdkYWRjM2I4ZGM2MTMwYzYxMS90YWJsZXJhbmdlOjY4NGVhMjVjZDQ1ODQwN2RhZGMzYjhkYzYxMzBjNjExXzItNS0xLTEtMTM5MDYy_243ce682-39c5-4849-9234-31faed19e31a"
      unitRef="usd">63900000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2ODRlYTI1Y2Q0NTg0MDdkYWRjM2I4ZGM2MTMwYzYxMS90YWJsZXJhbmdlOjY4NGVhMjVjZDQ1ODQwN2RhZGMzYjhkYzYxMzBjNjExXzMtMS0xLTEtMTM5MDYy_4f02e5d6-81b8-458b-8127-37c66d51ac59"
      unitRef="usd">4700000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2ODRlYTI1Y2Q0NTg0MDdkYWRjM2I4ZGM2MTMwYzYxMS90YWJsZXJhbmdlOjY4NGVhMjVjZDQ1ODQwN2RhZGMzYjhkYzYxMzBjNjExXzMtMy0xLTEtMTM5MDYy_9de93aa2-5abe-40e3-9517-80d16f8dee1a"
      unitRef="usd">600000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2ODRlYTI1Y2Q0NTg0MDdkYWRjM2I4ZGM2MTMwYzYxMS90YWJsZXJhbmdlOjY4NGVhMjVjZDQ1ODQwN2RhZGMzYjhkYzYxMzBjNjExXzMtNS0xLTEtMTM5MDYy_d8f173ff-204e-45bd-90e5-7decfdc44c90"
      unitRef="usd">5700000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2ODRlYTI1Y2Q0NTg0MDdkYWRjM2I4ZGM2MTMwYzYxMS90YWJsZXJhbmdlOjY4NGVhMjVjZDQ1ODQwN2RhZGMzYjhkYzYxMzBjNjExXzQtMS0xLTEtMTM5MDYy_b34b1ed1-8ef3-48ef-974e-ec24e933bfe2"
      unitRef="usd">15200000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2ODRlYTI1Y2Q0NTg0MDdkYWRjM2I4ZGM2MTMwYzYxMS90YWJsZXJhbmdlOjY4NGVhMjVjZDQ1ODQwN2RhZGMzYjhkYzYxMzBjNjExXzQtMy0xLTEtMTM5MDYy_e2f9d5a3-783d-4650-859f-4a2123a0fa83"
      unitRef="usd">4900000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2ODRlYTI1Y2Q0NTg0MDdkYWRjM2I4ZGM2MTMwYzYxMS90YWJsZXJhbmdlOjY4NGVhMjVjZDQ1ODQwN2RhZGMzYjhkYzYxMzBjNjExXzQtNS0xLTEtMTM5MDYy_0d03a4f1-fc4f-48fe-8e8d-15d3308c70fe"
      unitRef="usd">3900000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2ODRlYTI1Y2Q0NTg0MDdkYWRjM2I4ZGM2MTMwYzYxMS90YWJsZXJhbmdlOjY4NGVhMjVjZDQ1ODQwN2RhZGMzYjhkYzYxMzBjNjExXzUtMS0xLTEtMTM5MDYy_a95cc886-5d89-413f-8480-4059922eb35c"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2ODRlYTI1Y2Q0NTg0MDdkYWRjM2I4ZGM2MTMwYzYxMS90YWJsZXJhbmdlOjY4NGVhMjVjZDQ1ODQwN2RhZGMzYjhkYzYxMzBjNjExXzUtMy0xLTEtMTM5MDYy_30d7a163-a91c-449a-aacd-01d9a45153e6"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2ODRlYTI1Y2Q0NTg0MDdkYWRjM2I4ZGM2MTMwYzYxMS90YWJsZXJhbmdlOjY4NGVhMjVjZDQ1ODQwN2RhZGMzYjhkYzYxMzBjNjExXzUtNS0xLTEtMTM5MDYy_f087fea1-b422-4aa5-87d8-bab8a32c293a"
      unitRef="usd">200000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2ODRlYTI1Y2Q0NTg0MDdkYWRjM2I4ZGM2MTMwYzYxMS90YWJsZXJhbmdlOjY4NGVhMjVjZDQ1ODQwN2RhZGMzYjhkYzYxMzBjNjExXzYtMS0xLTEtMTM5MDYy_11fdb366-1aac-48fa-aa55-9950c6034ae0"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2ODRlYTI1Y2Q0NTg0MDdkYWRjM2I4ZGM2MTMwYzYxMS90YWJsZXJhbmdlOjY4NGVhMjVjZDQ1ODQwN2RhZGMzYjhkYzYxMzBjNjExXzYtMy0xLTEtMTM5MDYy_93ff0208-a080-4ca9-93d1-850676f466af"
      unitRef="usd">1700000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2ODRlYTI1Y2Q0NTg0MDdkYWRjM2I4ZGM2MTMwYzYxMS90YWJsZXJhbmdlOjY4NGVhMjVjZDQ1ODQwN2RhZGMzYjhkYzYxMzBjNjExXzYtNS0xLTEtMTM5MDYy_875c35e4-f566-40a9-9c28-ba20f82b2df8"
      unitRef="usd">1100000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2ODRlYTI1Y2Q0NTg0MDdkYWRjM2I4ZGM2MTMwYzYxMS90YWJsZXJhbmdlOjY4NGVhMjVjZDQ1ODQwN2RhZGMzYjhkYzYxMzBjNjExXzctMS0xLTEtMTM5MDYy_0d9bd7cd-7293-4970-bea7-f8cc88c22b5b"
      unitRef="usd">84500000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2ODRlYTI1Y2Q0NTg0MDdkYWRjM2I4ZGM2MTMwYzYxMS90YWJsZXJhbmdlOjY4NGVhMjVjZDQ1ODQwN2RhZGMzYjhkYzYxMzBjNjExXzctMy0xLTEtMTM5MDYy_3d171912-9bb4-4998-b0ed-8e8e8d28748f"
      unitRef="usd">64600000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i8a88ab4de251408db4aa98552134a56a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90YWJsZTo2ODRlYTI1Y2Q0NTg0MDdkYWRjM2I4ZGM2MTMwYzYxMS90YWJsZXJhbmdlOjY4NGVhMjVjZDQ1ODQwN2RhZGMzYjhkYzYxMzBjNjExXzctNS0xLTEtMTM5MDYy_818be51b-dcb6-4fe5-b9b8-9023df2964f5"
      unitRef="usd">60800000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjMvZnJhZzowNWUxZTlmMTMwNTk0MGNiOGJkNTg0NWJkOTRhNDMxMS90ZXh0cmVnaW9uOjA1ZTFlOWYxMzA1OTQwY2I4YmQ1ODQ1YmQ5NGE0MzExXzM1MTk_54b2e6e4-2cd5-4b98-be10-73f714f89c38"
      unitRef="usd">74800000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90ZXh0cmVnaW9uOjU1NzA4M2I5OTQyZTQ5ZGNiMzRhNmEyZjc1ZjExNGFjXzIyNTE_c9a938ee-5637-4f23-8a2c-c8ccd077f283">Leases&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our operating leases that have commenced have terms that expire beginning 2024 through 2031 and consist of office space and research and development laboratories, including our corporate headquarters. Certain of these lease agreements contain clauses for renewal at our option. As we were not reasonably certain to exercise any of these renewal options at commencement of the associated leases, no such options were recognized as part of our operating lease right-of-use, or ROU, assets or operating lease liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February&#160;8, 2022, we entered into a lease agreement for a four-building campus facility to be constructed in San Diego, California, pursuant to which we also secured a six-year option for the construction of a fifth building and an option to purchase the entire campus facility, which will consist of office space and research and development laboratories, in the future. Upon completion of construction, we expect to utilize the campus facility as our new corporate headquarters. This lease has not commenced for accounting purposes. Under the terms of the lease, on a building-by-building basis, base rent will be subject to a 10-month rent abatement period following the respective lease commencement date, which dates will be determined in the future based upon achievement of substantial completion of construction with respect to each such building in the condition suitable for the installation of our furniture, fixtures, and equipment, and on which date we will record a lease liability, corresponding right-of-use asset, and begin lease expense recognition with respect to each such building. After the rent abatement period, monthly base rent will be $6 per square foot, subject to annual escalations of 3% during the initial &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90ZXh0cmVnaW9uOjU1NzA4M2I5OTQyZTQ5ZGNiMzRhNmEyZjc1ZjExNGFjXzcxNDY4MjU1ODI4MDk_9da6dfa7-7ad5-4e15-990b-61663bd419f1"&gt;13.6-year&lt;/span&gt; lease term, which term we have the option to renew for two additional terms of five years each.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present supplemental operating lease information.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except weighted average data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.8 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash related to letters of credit issued in lieu of cash security deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Approximate future minimum lease payments under operating leases were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less accreted interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpmYjg1MmU0NGUwYmY0ZDA3YTVmNjZhM2QxM2VkNmYxMC90YWJsZXJhbmdlOmZiODUyZTQ0ZTBiZjRkMDdhNWY2NmEzZDEzZWQ2ZjEwXzEwLTAtMS0xLTEzOTA2Mg_85571070-dcc5-4354-8358-dbaa0e075ba0"&gt;Less current operating lease liabilities included in other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%"&gt;_________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Amounts presented in the table above exclude $17.2 million for 2024, $33.3 million for 2025, $41.9 million for 2026, and $479.7 million thereafter of approximate non-cancelable future minimum lease payments under operating leases that have not yet commenced.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <nbix:LesseeOperatingLeaseOptionTermToConstructFifthBuilding
      contextRef="i3cd52a694c0b4753b93edf35c2915881_D20220208-20220208"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90ZXh0cmVnaW9uOjU1NzA4M2I5OTQyZTQ5ZGNiMzRhNmEyZjc1ZjExNGFjXzcxNDY4MjU1ODI4MDc_ad5b2987-4e87-41d0-9996-c38d637a6b92">P6Y</nbix:LesseeOperatingLeaseOptionTermToConstructFifthBuilding>
    <nbix:RentAbatementPeriod
      contextRef="i3cd52a694c0b4753b93edf35c2915881_D20220208-20220208"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90ZXh0cmVnaW9uOjU1NzA4M2I5OTQyZTQ5ZGNiMzRhNmEyZjc1ZjExNGFjXzcxNDY4MjU1ODI4MDg_17d67139-0105-4e25-89cc-b232829be315">P10M</nbix:RentAbatementPeriod>
    <nbix:LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot
      contextRef="if8d41d8e8ddc41f1ba3f1ca687d9551d_I20220208"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90ZXh0cmVnaW9uOjU1NzA4M2I5OTQyZTQ5ZGNiMzRhNmEyZjc1ZjExNGFjXzE2ODE_c986d85c-038e-48d7-bc25-ae4773fdeee8"
      unitRef="usd">6</nbix:LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot>
    <nbix:AnnualRentEscalationPercentage
      contextRef="if8d41d8e8ddc41f1ba3f1ca687d9551d_I20220208"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90ZXh0cmVnaW9uOjU1NzA4M2I5OTQyZTQ5ZGNiMzRhNmEyZjc1ZjExNGFjXzE3MzQ_82c77f81-d5e9-4e02-8042-998e18a9d5f1"
      unitRef="number">0.03</nbix:AnnualRentEscalationPercentage>
    <nbix:NumberOfRenewalOptions
      contextRef="if8d41d8e8ddc41f1ba3f1ca687d9551d_I20220208"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90ZXh0cmVnaW9uOjU1NzA4M2I5OTQyZTQ5ZGNiMzRhNmEyZjc1ZjExNGFjXzE4MTk_baa9c2b7-fb22-44d5-a855-4d560ea88ed5"
      unitRef="renewaloption">2</nbix:NumberOfRenewalOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="if8d41d8e8ddc41f1ba3f1ca687d9551d_I20220208"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90ZXh0cmVnaW9uOjU1NzA4M2I5OTQyZTQ5ZGNiMzRhNmEyZjc1ZjExNGFjXzE4NDI_d4d24688-e19f-4781-b825-2e7edc26af33">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90ZXh0cmVnaW9uOjU1NzA4M2I5OTQyZTQ5ZGNiMzRhNmEyZjc1ZjExNGFjXzIyNTI_87aaa0ea-db95-4af6-ac1a-6786ec215317">&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present supplemental operating lease information.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except weighted average data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.8 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash related to letters of credit issued in lieu of cash security deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpkMzJmNDI4MWQ1M2Y0MzIwYTYxMjE4OTE1MWI5MTk4OS90YWJsZXJhbmdlOmQzMmY0MjgxZDUzZjQzMjBhNjEyMTg5MTUxYjkxOTg5XzItMS0xLTEtMTM5MDYy_2deebd46-1e2c-4019-9b3a-ba7e396468a6"
      unitRef="usd">16300000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpkMzJmNDI4MWQ1M2Y0MzIwYTYxMjE4OTE1MWI5MTk4OS90YWJsZXJhbmdlOmQzMmY0MjgxZDUzZjQzMjBhNjEyMTg5MTUxYjkxOTg5XzItMy0xLTEtMTM5MDYy_1ecfddcc-55c5-4330-84a0-fb14e1009123"
      unitRef="usd">15300000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpkMzJmNDI4MWQ1M2Y0MzIwYTYxMjE4OTE1MWI5MTk4OS90YWJsZXJhbmdlOmQzMmY0MjgxZDUzZjQzMjBhNjEyMTg5MTUxYjkxOTg5XzItNS0xLTEtMTM5MDYy_9ce3b2a6-f8df-497c-9008-bf3a48326866"
      unitRef="usd">10100000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpkMzJmNDI4MWQ1M2Y0MzIwYTYxMjE4OTE1MWI5MTk4OS90YWJsZXJhbmdlOmQzMmY0MjgxZDUzZjQzMjBhNjEyMTg5MTUxYjkxOTg5XzMtMS0xLTEtMTM5MDYy_58a87548-d1e8-4db6-a582-8bac9dab64cc"
      unitRef="usd">16900000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpkMzJmNDI4MWQ1M2Y0MzIwYTYxMjE4OTE1MWI5MTk4OS90YWJsZXJhbmdlOmQzMmY0MjgxZDUzZjQzMjBhNjEyMTg5MTUxYjkxOTg5XzMtMy0xLTEtMTM5MDYy_5c1dd0f1-1067-4783-b7c1-427ea60800e5"
      unitRef="usd">12600000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpkMzJmNDI4MWQ1M2Y0MzIwYTYxMjE4OTE1MWI5MTk4OS90YWJsZXJhbmdlOmQzMmY0MjgxZDUzZjQzMjBhNjEyMTg5MTUxYjkxOTg5XzMtNS0xLTEtMTM5MDYy_51342715-41d7-40db-b3f2-3882bb549522"
      unitRef="usd">8600000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpkMzJmNDI4MWQ1M2Y0MzIwYTYxMjE4OTE1MWI5MTk4OS90YWJsZXJhbmdlOmQzMmY0MjgxZDUzZjQzMjBhNjEyMTg5MTUxYjkxOTg5XzctMy0xLTEtMTM5MDYy_78057c3c-49d7-4b6d-a1d4-a25d1aaeab07">P7Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpkMzJmNDI4MWQ1M2Y0MzIwYTYxMjE4OTE1MWI5MTk4OS90YWJsZXJhbmdlOmQzMmY0MjgxZDUzZjQzMjBhNjEyMTg5MTUxYjkxOTg5XzctNS0xLTEtMTM5MDYy_3e257c0d-12a0-4c1a-9f1e-677e8f169434">P8Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpkMzJmNDI4MWQ1M2Y0MzIwYTYxMjE4OTE1MWI5MTk4OS90YWJsZXJhbmdlOmQzMmY0MjgxZDUzZjQzMjBhNjEyMTg5MTUxYjkxOTg5XzgtMy0xLTEtMTM5MDYy_3561e0d9-17a0-4bd3-b169-c45ed74d9b4e"
      unitRef="number">0.053</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i092dab9242464bf7bd7bddb6a8629472_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpkMzJmNDI4MWQ1M2Y0MzIwYTYxMjE4OTE1MWI5MTk4OS90YWJsZXJhbmdlOmQzMmY0MjgxZDUzZjQzMjBhNjEyMTg5MTUxYjkxOTg5XzgtNS0xLTEtMTM5MDYy_5b1866ae-051c-453a-be09-b97afbdf4f81"
      unitRef="number">0.052</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="ic8bcdc018b3641e5b570fb899c943e20_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpkMzJmNDI4MWQ1M2Y0MzIwYTYxMjE4OTE1MWI5MTk4OS90YWJsZXJhbmdlOmQzMmY0MjgxZDUzZjQzMjBhNjEyMTg5MTUxYjkxOTg5XzktMy0xLTEtMTM5MDYy_9ed0f313-e1c3-4c9d-859b-b77965a5478a"
      unitRef="usd">7800000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i5576346c88f84a9aa3ea6be5a075ead3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpkMzJmNDI4MWQ1M2Y0MzIwYTYxMjE4OTE1MWI5MTk4OS90YWJsZXJhbmdlOmQzMmY0MjgxZDUzZjQzMjBhNjEyMTg5MTUxYjkxOTg5XzktNS0xLTEtMTM5MDYy_a792adfe-67e1-437f-963c-7118e3a88b20"
      unitRef="usd">3200000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90ZXh0cmVnaW9uOjU1NzA4M2I5OTQyZTQ5ZGNiMzRhNmEyZjc1ZjExNGFjXzIyNTA_a1b9a962-7551-450b-b635-c074272dceed">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Approximate future minimum lease payments under operating leases were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less accreted interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpmYjg1MmU0NGUwYmY0ZDA3YTVmNjZhM2QxM2VkNmYxMC90YWJsZXJhbmdlOmZiODUyZTQ0ZTBiZjRkMDdhNWY2NmEzZDEzZWQ2ZjEwXzEwLTAtMS0xLTEzOTA2Mg_85571070-dcc5-4354-8358-dbaa0e075ba0"&gt;Less current operating lease liabilities included in other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%"&gt;_________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Amounts presented in the table above exclude $17.2 million for 2024, $33.3 million for 2025, $41.9 million for 2026, and $479.7 million thereafter of approximate non-cancelable future minimum lease payments under operating leases that have not yet commenced.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpmYjg1MmU0NGUwYmY0ZDA3YTVmNjZhM2QxM2VkNmYxMC90YWJsZXJhbmdlOmZiODUyZTQ0ZTBiZjRkMDdhNWY2NmEzZDEzZWQ2ZjEwXzEtMS0xLTEtMTM5MDYy_9b0ff4f0-0ee0-4ca5-b944-7ab9c50445e5"
      unitRef="usd">17900000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpmYjg1MmU0NGUwYmY0ZDA3YTVmNjZhM2QxM2VkNmYxMC90YWJsZXJhbmdlOmZiODUyZTQ0ZTBiZjRkMDdhNWY2NmEzZDEzZWQ2ZjEwXzItMS0xLTEtMTM5MDYy_54d2f171-9828-4542-9518-faf5980ceac3"
      unitRef="usd">17400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpmYjg1MmU0NGUwYmY0ZDA3YTVmNjZhM2QxM2VkNmYxMC90YWJsZXJhbmdlOmZiODUyZTQ0ZTBiZjRkMDdhNWY2NmEzZDEzZWQ2ZjEwXzMtMS0xLTEtMTM5MDYy_9a1c4bb6-d060-46eb-ab20-723921198d02"
      unitRef="usd">15900000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpmYjg1MmU0NGUwYmY0ZDA3YTVmNjZhM2QxM2VkNmYxMC90YWJsZXJhbmdlOmZiODUyZTQ0ZTBiZjRkMDdhNWY2NmEzZDEzZWQ2ZjEwXzQtMS0xLTEtMTM5MDYy_ab4b74bd-3fca-4b4a-bf69-674afa0a89eb"
      unitRef="usd">15700000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpmYjg1MmU0NGUwYmY0ZDA3YTVmNjZhM2QxM2VkNmYxMC90YWJsZXJhbmdlOmZiODUyZTQ0ZTBiZjRkMDdhNWY2NmEzZDEzZWQ2ZjEwXzUtMS0xLTEtMTM5MDYy_0cff1927-05cf-4348-a3fd-569a2087be5b"
      unitRef="usd">16000000.0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpmYjg1MmU0NGUwYmY0ZDA3YTVmNjZhM2QxM2VkNmYxMC90YWJsZXJhbmdlOmZiODUyZTQ0ZTBiZjRkMDdhNWY2NmEzZDEzZWQ2ZjEwXzYtMS0xLTEtMTM5MDYy_13018f2a-8647-452a-bdb9-3bf901599520"
      unitRef="usd">54400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpmYjg1MmU0NGUwYmY0ZDA3YTVmNjZhM2QxM2VkNmYxMC90YWJsZXJhbmdlOmZiODUyZTQ0ZTBiZjRkMDdhNWY2NmEzZDEzZWQ2ZjEwXzctMS0xLTEtMTM5MDYy_94c5c4e3-de56-40f4-9a6b-7878928eadad"
      unitRef="usd">137300000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpmYjg1MmU0NGUwYmY0ZDA3YTVmNjZhM2QxM2VkNmYxMC90YWJsZXJhbmdlOmZiODUyZTQ0ZTBiZjRkMDdhNWY2NmEzZDEzZWQ2ZjEwXzgtMS0xLTEtMTM5MDYy_fb3934bd-aa61-4c53-b97a-325247d9da9a"
      unitRef="usd">26400000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpmYjg1MmU0NGUwYmY0ZDA3YTVmNjZhM2QxM2VkNmYxMC90YWJsZXJhbmdlOmZiODUyZTQ0ZTBiZjRkMDdhNWY2NmEzZDEzZWQ2ZjEwXzktMS0xLTEtMTM5MDYy_e1a926fa-3190-49c9-9131-d254b86a2eb2"
      unitRef="usd">110900000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpmYjg1MmU0NGUwYmY0ZDA3YTVmNjZhM2QxM2VkNmYxMC90YWJsZXJhbmdlOmZiODUyZTQ0ZTBiZjRkMDdhNWY2NmEzZDEzZWQ2ZjEwXzEwLTEtMS0xLTEzOTA2Mg_29d8c9ea-cfbc-4ddf-bf35-edb4fdb22664"
      unitRef="usd">17400000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90YWJsZTpmYjg1MmU0NGUwYmY0ZDA3YTVmNjZhM2QxM2VkNmYxMC90YWJsZXJhbmdlOmZiODUyZTQ0ZTBiZjRkMDdhNWY2NmEzZDEzZWQ2ZjEwXzExLTEtMS0xLTEzOTA2Mg_a04adfcb-4996-4728-8bbd-4a3a8c3da9d4"
      unitRef="usd">93500000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90ZXh0cmVnaW9uOjU1NzA4M2I5OTQyZTQ5ZGNiMzRhNmEyZjc1ZjExNGFjXzIwODM_33f06b5b-d025-4db5-abc5-1d0ea5615ff4"
      unitRef="usd">17200000</nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo>
    <nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90ZXh0cmVnaW9uOjU1NzA4M2I5OTQyZTQ5ZGNiMzRhNmEyZjc1ZjExNGFjXzIwOTY_fbd790a7-2a16-49ad-8a0b-b44428264f56"
      unitRef="usd">33300000</nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree>
    <nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90ZXh0cmVnaW9uOjU1NzA4M2I5OTQyZTQ5ZGNiMzRhNmEyZjc1ZjExNGFjXzIxMDk_390e71fd-35a3-46c6-950b-1b035136c8d3"
      unitRef="usd">41900000</nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour>
    <nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive
      contextRef="i4dad9397c8114dc994a1d55e36926d3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjYvZnJhZzo1NTcwODNiOTk0MmU0OWRjYjM0YTZhMmY3NWYxMTRhYy90ZXh0cmVnaW9uOjU1NzA4M2I5OTQyZTQ5ZGNiMzRhNmEyZjc1ZjExNGFjXzIxMjY_f7b9c3c7-91d2-42cf-b45f-13d9657feefc"
      unitRef="usd">479700000</nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjkvZnJhZzo4NTlmNzQzOGJiZmQ0OWZjODkzMmYwMWQyZTIyYzJmNC90ZXh0cmVnaW9uOjg1OWY3NDM4YmJmZDQ5ZmM4OTMyZjAxZDJlMjJjMmY0XzMzMQ_e65c118f-1b10-484c-964c-030b4898e5d3">Retirement PlanWe have a 401(k) defined contribution savings plan, or the 401(k)&#160;Plan. The 401(k) Plan is for the benefit of all qualifying employees and permits voluntary contributions by employees up to 60% of base salary limited by the IRS-imposed maximum. Employer contributions were $10.3 million for 2022, $8.1 million for 2021 and $6.7 million for 2020.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjkvZnJhZzo4NTlmNzQzOGJiZmQ0OWZjODkzMmYwMWQyZTIyYzJmNC90ZXh0cmVnaW9uOjg1OWY3NDM4YmJmZDQ5ZmM4OTMyZjAxZDJlMjJjMmY0XzIxNQ_e1341f5b-c437-40c1-b90b-3f1053160cd2"
      unitRef="number">0.60</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjkvZnJhZzo4NTlmNzQzOGJiZmQ0OWZjODkzMmYwMWQyZTIyYzJmNC90ZXh0cmVnaW9uOjg1OWY3NDM4YmJmZDQ5ZmM4OTMyZjAxZDJlMjJjMmY0XzI5Nw_90626ca7-39b6-4de2-ac46-86f97f36d76a"
      unitRef="usd">10300000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i5d09f8682ad54538b6fd3363b20bc590_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjkvZnJhZzo4NTlmNzQzOGJiZmQ0OWZjODkzMmYwMWQyZTIyYzJmNC90ZXh0cmVnaW9uOjg1OWY3NDM4YmJmZDQ5ZmM4OTMyZjAxZDJlMjJjMmY0XzMwOA_dee9d593-680b-4adf-8fbe-f65e2ca8aa94"
      unitRef="usd">8100000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ica03dcf8555e4fc58dc68198617df351_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNjkvZnJhZzo4NTlmNzQzOGJiZmQ0OWZjODkzMmYwMWQyZTIyYzJmNC90ZXh0cmVnaW9uOjg1OWY3NDM4YmJmZDQ5ZmM4OTMyZjAxZDJlMjJjMmY0XzMyMg_6a97908f-8c99-4a48-98ef-8c6883fdbab4"
      unitRef="usd">6700000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzQ2L2ZyYWc6MDFjZDZmOTlhYjgzNGJjZTljMjIxMGUyOWEzMGNmYzkvdGV4dHJlZ2lvbjowMWNkNmY5OWFiODM0YmNlOWMyMjEwZTI5YTMwY2ZjOV8yMTk5MDIzMjYxNjQ5_0ad1a5a0-f176-4d4f-b4a5-f492565ea948">Legal Proceedings&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2021 and 2022, we received notices from (i) Teva Pharmaceuticals Development, Inc., (ii) Lupin Limited, (iii) Crystal Pharmaceutical (Suzhou) Co. Ltd., (iv) Sandoz Inc. and (v) Zydus Pharmaceuticals (USA) Inc. that each company had filed an abbreviated new drug application, or ANDA, with the FDA seeking approval of a generic version of INGREZZA. These companies represented that their respective ANDAs each contained a Paragraph IV Patent Certification alleging that certain of our patents covering INGREZZA are invalid and/or will not be infringed by the manufacture, use or sale of the medicine for which the ANDA was submitted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We filed suit in the United States District Court for the District of Delaware during 2021 and 2022, against (i) Teva Pharmaceuticals, Inc., Teva Pharmaceuticals Development, Inc., Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd. (entity dismissed), (ii) Lupin Limited, Lupin Pharmaceuticals, Inc., Lupin Inc. and Lupin Atlantis Holdings S.A., (iii) Crystal Pharmaceutical (Suzhou) Co., Ltd., Crystal Pharmatech Co., Ltd., (iv) Sandoz Inc., Sandoz International GmbH (entity dismissed) and Sandoz AG (entity dismissed) and (v) Zydus Pharmaceuticals (USA) Inc., Zydus Worldwide DMCC, Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited d/b/a Zydus Cadila) and Zydus Healthcare (USA) LLC (entity dismissed). Sandoz Inc. has been joined in the cases against Crystal Pharmaceutical (Suzhou) Co., Ltd. and Crystal Pharmatech Co., Ltd. These cases have been consolidated in the United States District Court for the District of Delaware and the trial is currently scheduled for January 2, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also filed suit in the United States District Court for the District of New Jersey during 2021 and 2022 against Zydus Pharmaceuticals (USA) Inc., Zydus Worldwide DMCC, Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited d/b/a Zydus Cadila) and Zydus Healthcare (USA) LLC and these cases were dismissed in favor of continued prosecution of the Delaware proceedings against the same entities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we may also become subject to other legal proceedings or claims arising in the ordinary course of our business. We currently believe that none of the claims or actions pending against us is likely to have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Given the unpredictability inherent in litigation, however, we cannot predict the outcome of these matters.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="if7643571a4d04563b796b60bef5361e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzM5L2ZyYWc6OTIxM2U5YmM5M2JkNDM5Yzk1YjhiYTlmMjFhYzJkOTAvdGV4dHJlZ2lvbjo5MjEzZTliYzkzYmQ0MzljOTViOGJhOWYyMWFjMmQ5MF8yMTk5MDIzMjU3OTAy_edf3c711-8287-4c14-b8e8-be84b682ced8">Subsequent Events&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 8, 2023, we entered into a new strategic collaboration with Voyager, under which we agreed to pay Voyager $175&#160;million upfront, including a $39&#160;million equity investment, to acquire the worldwide rights to Voyager&#x2019;s GBA1 gene therapy program for Parkinson&#x2019;s disease and other GBA1-mediated diseases and three gene therapy programs directed to rare central nervous system targets, each enabled by Voyager&#x2019;s next-generation TRACER&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; capsids. The effectiveness of the collaboration agreement and the closing of the sale and issuance of Voyager common stock are expected to be completed prior to the end of the first quarter of 2023 and are subject to certain conditions including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and other customary closing conditions.&lt;/span&gt;</us-gaap:SubsequentEventsTextBlock>
    <nbix:UpfrontPaymentsMade
      contextRef="iced58b51ca3c40e3942fff0f7f450577_I20230108"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzM5L2ZyYWc6OTIxM2U5YmM5M2JkNDM5Yzk1YjhiYTlmMjFhYzJkOTAvdGV4dHJlZ2lvbjo5MjEzZTliYzkzYmQ0MzljOTViOGJhOWYyMWFjMmQ5MF81NDk3NTU4MTYxMTc_d5a978d1-cc22-445d-a8d5-eb4c590b1d9e"
      unitRef="usd">175000000</nbix:UpfrontPaymentsMade>
    <nbix:BusinessAcquisitionEquityInvestmentToAcquireTheWorldwideRights
      contextRef="iced58b51ca3c40e3942fff0f7f450577_I20230108"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OTUyMjMzMDE5NDQ0MThiYThjM2ZiM2JjMDJmMDhlL3NlYzpkNzk1MjIzMzAxOTQ0NDE4YmE4YzNmYjNiYzAyZjA4ZV8xNzM5L2ZyYWc6OTIxM2U5YmM5M2JkNDM5Yzk1YjhiYTlmMjFhYzJkOTAvdGV4dHJlZ2lvbjo5MjEzZTliYzkzYmQ0MzljOTViOGJhOWYyMWFjMmQ5MF81NDk3NTU4MTYxMzE_a163e08e-ef53-4cbf-88d5-39f75182d087"
      unitRef="usd">39000000</nbix:BusinessAcquisitionEquityInvestmentToAcquireTheWorldwideRights>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>89
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MP? +)D^ XVM*Q7%'7N!4C3_Z#U!+ P04    " !5@$E68B.H2#T"  #$!0
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M"](FF/VC$/H4V /ZQIW]!5!+ P04    " !5@$E6<ZK]@AH&   W&@  &
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MQ';0IZ:3H+;@]<)&+(.,4D 6PK9AC1) (60:6!W^=8M@_9WTY30LHD-5D&.
MD;)C6:A52-;2[]NN97@C*+*41;S>,&LLM93;]\K:44/Q6BB>%LJ;Z.LI*:#;
M)/GR6+"(<HZ*%\#SI"&9(VB>(@".%":%E&L;$^#\%IRO!7</! 8FZ27:TQPF
M;%H!"F-HW D7Y00^4Q4F7QK+VB%2 9*E',^2<,E2MM67&N#"9L<33"VR/YD
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MP/Z^S;+R\P?^YJSS^^3N_@%02P,$%     @ 58!)5GRNOG<R"   VB<  !@
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M@#R ?ZG@/[F\=<9GMEP5GUTLBLM'EY>WS/=90,=G--]G9^:;V6;Q/U?KKO=
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MM=L4J2&$\OM0;6/<P!SJGMY")W;9F*$EV9BC"I@>]:+#&,[0&/J%: Y.&N.
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M*@P.4]315)4$H%D8:/28Q!ME1]W^0)*="V"$B,I(1 OP+5!+86AIBQY7L'.
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MX$W:S/=LU$@J[60K_8<&1U-B2&Z?Q9YQ$.1\SQ&J"?V#<P5TKE2,!=9RD[K
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M=S5^#4ZS Z5&@;:-8U9"J 7,M+[846XXF]%#A%7'1[K $M%T$,SKC;(9Z'B
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M,N8@![!?>I^V"S&P^R_A[%]02P,$%     @ 58!)5E_?,Z%(!0  ] X  !D
M  !X;"]W;W)K<VAE971S+W-H965T,3$N>&ULW5=;;]LV%/XKA!<4"9#*NOK2
M)@:2M-T*M$/1R_HP[(&6:8FK)*HD9=?[]?L.Y8O4VFGR-& ODDB>\YT+S_DH
M7JV5_F)R(2S[5A:5N1[DUM;/AD.3YJ+DQE.UJ+"R5+KD%D.=#4VM!5\XI;(8
MAKX_&I9<5H/9E9M[IV=7JK&%K,0[S4Q3EEQO;D6AUM>#8+";>"^SW-+$<'95
M\TQ\$/93_4YC--RC+&0I*B-5Q;187@]N@F>W,<D[@3^D6)O.-Z-(YDI]H<'K
MQ?7 )X=$(5)+"!ROE;@314% <./K%G.P-TF*W>\=^BL7.V*9<R/N5/%9+FQ^
M/9@,V$(L>5/8]VK]F]C&DQ!>J@KCGFS=RB:PF#;&JG*KC'$IJ_;-OVWST%&8
M^"<4PJU"Z/QN#3DO7W#+9U=:K9DF::#1APO5:<,Y6=&F?+ :JQ)Z=O9"S"W[
M(-)&2RN%N1I:@-+2,-T"W+8 X0F (&1O565SPUY6"['H PSAS=ZE<.?2;7@O
MX@N1>BP*+EGHA^$]>-$^Q,CA12?P7E<K82P*R9I+YN+EU8*]_-I(N^F$SOZ\
MF1NK429_'<M":R,^;H-:YYFI>2JN!^@-(_1*#&9/?@E&_O-[(HCW$<3WH3]D
MDQX%P#[F@BU5@8Z45<8LGQ>".;^1(V:QR$NEK?Q'+%BJC+UD386.+]Q$ADYW
M&2R4,>C+5&656Z#I-&W*IN 60P4<#?42P#EU\4I !&/!SDGUPH$LN=1LQ8M&
M,+5$.\%/<_"3K[@LR+NGH)^GAA?BDO$LTR)S)N8;M,+?2N]4-LQN:N%P4]0D
M[67#"\A8M^IA]U-1SN$6E5=O< [O2UD48 IX=M?1OMFGXM,A";]2$CKC-Y2+
M5Q3+(\7O5%D*G4H8JGD-9WQF%0O81G!MV!D+DI$7XOWDETD8A,_Q=>Y[X<5V
MQ<<[]&-OTI,X?+5K=TK72B-C/^2W9RR<DJF=\GE$9L)I!"-!..FN^%YPX>:"
M;DUA^S*U$KJB3GMJ:B12:<2*T3%CD\B+#Y (!<;&8\Q%8V^T7]B]W>09&T?)
M=[&>3[V8LC$.1] ]@Z#O)'OY"BZV*\D]N0C(O6B?^#"90OR,^2[]Y[$77;C9
MI#633+QIWTS@)<Y,0D$\)B\]PW&"?._3$E!:XAA3M)/1=PNA'V$.)K'6<379
MNCJ=.E>34?1]!86MJ\G(]\;LQKG8:P8BWDNFFDYC(6D6C"$5=9:1QG7X$OF(
M'M2T:/RB61#9!-,I_@#2O*MA<V[96FCA.*3JLHTCF5H9Z<[P>6/):HZCEJ5(
MHK3L*WK4]?:GOA)EOB(N,X2Z/P%:,[66^ 61Q88M0#Q(?YKS*H,*[,O*0L18
M1E5B//89I:)8I:Q; ;5 ''\5Q1%L(AZX)(T3!Q$(5L@O F808>4FMZ'BE ?"
M7( _<0Y1.9Q&G8LE(1'3HHPVE  (@3OZ)$T_)Q+^_JX8)V;G54HDKW>)VB9E
MS7NDS8_O/H,>WH%W_U'Q\ZU_^-Z>\.2AA%^(*K.Y2PY^&ITQ=PC(JE&-Z=OR
MV!MAZ!2$/X?_E\,7#+Q1J ?-/BH+9NX?#HZW.]7VL_$/%(^.#<&=!RH_1MT]
MD=.L=48-Y;H?G##=]7W0\L"(QO%TXACQ?$Q=_QAB K8_!D,<&", 5MS284MV
M_JBU-28^^H]+)?@_E,KI?8[#[3X&[;X>*YJ^S./V.HS\71WYI_![,L=^;(>=
MFPB*/G/W+8/L-I5M+R7[V?V5[J:]R1S$V_O@6ZXS66$[Q!*J.*F2 =/M':L=
M6%6[>\U<6=R2W&>.:ZG0)(#UI5)V-R #^XON[%]02P,$%     @ 58!)5HW*
M4B"X!   Q0L  !D   !X;"]W;W)K<VAE971S+W-H965T,3(N>&ULO58+;]LV
M$/XKA!H4#I#*$F4[3IH8:)(6&[ "05_#, P#+9TMHA2IDI3=[-?OCI(5*6U2
M;!AFP"*/.MY]]]1=[(W][$H S[Y62KO+J/2^/I].75Y")5QL:M#X9F-L)3R2
M=CMUM051A$N5FO(D64PK(76TN@AGMW9U81JOI(9;RUQ35<+>78$R^\LHC0X'
M[^2V]'0P75W48@OOP7^L;RU2TUY*(2O03AK-+&PNHU?I^=6,^ /#)PE[-]@S
MLF1MS&<B?BXNHX0 @8+<DP2!RPZN02D2A#"^=#*C7B5='.X/TM\$V]&6M7!P
M;=2OLO#E9;2,6 $;T2C_SNQ_@LZ>.<G+C7+AR?8M;S:+6-XX;ZKN,B*HI&Y7
M\;7SP^#",GGD N\N\("[5110W@@O5A?6[)DE;I1&FV!JN(W@I*:@O/<6WTJ\
MYU=OA+3LDU -L+<@7&,!/>[=Q=2C<&*9YIV@JU80?T10RME;HWWIV&M=0#$6
M,$54/31^@';%GY1X WG,LO2$\83S)^1EO:E9D)?]V-0;Z7)ER%K'?G^U=MYB
M=OSQ/:-;D;/OBZ2*.7>UR.$RPI)P8'<0K9X_2Q?)RR< SWK LZ>D_Y/8_"M!
M[$,);&,4%J;46^;%6@$+=M!+<2A49C9,ZATX'VZ=L'TI\Y+MP0*K6G$%$YYM
M2,LN:*%RPY+-&VM),I:-=#'#@$*U!AN".B("P%]@!XK8Q]1$:DQ\I;"&W7%[
MS-)NY=V:/7I^+5S)A"Y83AOXTDA$2&:<W[^JC(8[+"K[&9O@IM&%8T>,+WA\
M-EB?/UORE+\<[;)9$B\'Z[<\[]!K5N8>6@"H%*R7&YD+CZF'CBV@-DYZ=HH"
MZ'^X>%BSF(?_P_,;6'OFR,/22Q0E=D(J"N +;-0O'-J(NDQ5@<VE4*P6-;HZ
MG2_BI!<QIG@R&Z@?4]?&UL8B9(0[5CN?+>-9SS>F9LMY/'^$>G\O IVP-3NP
MFK+KA:LQS(8R"JF6(>/I0.J8XNCYLT>HUQAL?S= >_[M4>!-7ZZE\9"7VBBS
MO<-D+[#Q8N*G"8_3[ODP (LL/F5SCH_>GRFZ\XBE)]G9,EY06ISRD!;I2<+G
M#Q($N;)E2*SL;(%"CMA9EF*<CUHQ/ZA,+"VC<ZFD")\V="&,++O[+PJ6-8[V
M3FYUR%CM6:/-FKI<P"-UW2":25=JQ^?L-Q"V;?_C\AZ7,+5S>J3T2-B54$+G
M0(#6L)5:DU*T"!-6FN+@$/33,KAG/D>OW38V+_%;[.[3"SU^V'_4.)XH^1?"
MV.)8PB;8ZE&OU+EJ"!L>(5#2@^A3 H3!X90ZD_0T/CUF'ZS0;@,6D[/QA.70
M32;\F$TP3DM<*/;'O<Z!%8 M98A_$/2!)7\^]@N0'IC@0I\B,ZA@]%/1_I^"
M'0 )"R.O&E]BQ/'$5, F\!4G1P?')TR#CX/OJ/M11- ]IK%/FT$&^"X09,/&
MFJH/A#=]QR^:8$7(*@(5,DLXAEAP<0;['[7?TJB"^+JPV*XQ4_D@4(D:XN]]
MLJ>#T0J;Z38,D([EIM&^G;+ZTWY&?=6.9O?L[8#[5M@MA5+!!J\F\>D\8K8=
M&EO"FSH,:FOC<>P+VQ+G;+#$@.\W!KM41Y""?G)?_0U02P,$%     @ 58!)
M5G\9E@;=#   UR@  !D   !X;"]W;W)K<VAE971S+W-H965T,3,N>&ULY5I;
M<^.V%?XK&,>;L6=D6J)\W=N,=]-,MM.D.]G=9#J=/D D)"%+$ER E*S^^G[G
M +Q(HFPG:9J'OE@F"1R<ZW<NY,NUL9_=4JE*W.=9X5X=+:NJ?'Y^[I*ERJ6+
M3*D*/)D;F\L*EW9Q[DJK9,J;\NP\'H^OSG.IBZ/7+_G>>_OZI:FK3!?JO16N
MSG-I-V]49M:OCB9'S8T?]6)9T8WSUR]+N5 ?5/6I?&]Q==Y2276N"J=-(:R:
MOSJZFSQ_<T'K><%/6JU=[W]!DLR,^4P7[])71V-B2&4JJ8B"Q,]*O5591H3
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M7D#?%]:&[8 =[-Z"L[\!4$L#!!0    ( %6 258W1Z*:% ,  -T&   9
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;)55;6_3,!#^*Z> $$A;WMNUI:VT
MLB'X,#0Q 4*(#VYR:2P<.]C.,OX]9Z<-9=HF^&+']_+<<S[?9=DK_</4B!;N
M&B'-*JBM;1=19(H:&V9"U:(D3:5TPRP=]2XRK496>J=&1&D<3Z.&<1FLEUYV
MK==+U5G!)5YK,%W3,/UK@T+UJR )#H*/?%=;)XC6RY;M\ ;MI_9:TRD:44K>
MH#1<2=!8K8+S9+')G;TW^,RQ-T??X#+9*O7#'=Z7JR!VA%!@81T"H^T6WZ 0
M#HAH_-QC!F-(YWC\?4!_ZW.G7+;,X!LEOO#2UJM@%D")%>N$_:CZ=[C/9^+P
M"B6,7Z$?;+,X@*(S5C5[9V+0<#GL[&Y_#T<.L\<<TKU#ZGD/@3S+"V;9>JE5
M#]I9$YK[\*EZ;R+'I2O*C=6DY>1GUY=,2RYW!JY1PTW--"XC2[A.&Q5[C,V
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MF_@"K8 W['N02:G^=)5@)120<[B'TRZ8N.!XZY35 %1G$2IP\0)(BW+V;Q3
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MM\VH,DU\J?6ZKO2Z=7/8I*G3\;'+ G\,^,@U&T6[L&LP/ K@LA"><</3:GQ
M_G$R?G,RD-^;%91/DDU_M\%T'"VQQ0D)X2+%&#Z TAQ8$G@:<"%1Q%QJ4Q5"
MN,Z5RY:XIGL@@"! I\P,N>LVB"9H6=4"%E0I:/PFD?#P702^)O9C22<K-+ T
M@39S_D[S6-'ATRYYE0.?ICQQM00IILZ^_4GS*$UN=?'U9$YV:EA A"X,Z1N
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MM6;4+H'6"Z7L;N(VZ)O]]#=02P,$%     @ 58!)5CB+?*WG!0  H0X  !D
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M[C*97GQT\.O-:@H;U,'"BGH/M34;*RJ@^04/PCY+[8P>]'/ID'H:A,[!L$E
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MD.ED?'$6=8UQV'A3A[F?4JBF"LN2GFVTK$#RPAA_V+"#X8_ \E]02P,$%
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M&DDI095*$GD;R_CX]2F>!>>OYQ+9SWBL7,I?!)6\9/NTWV\Q=T<5X)NMK^F
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MH+3=!&VB39# :-IJKOWB!PM*=E49V%8'+#RBFA]"&RPHCP5_]IN5BENR2"3
M!G3H^0$Z*]:VT7=Q[2$4H/QDT=.OJ^*U'U8"%R]RY<V&Q44LKPY6ID)/6P%
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M]@M>=JCQ./GYBXQKV_)3'<;[,3J?<@71IA-+T*+QC5"N':@=ZQ.>X7E-=I<
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M+3!PP/B<=SSG0O=]UGL"A-8/,@C)Q0@T#R2GT4N!J'<V4F]T5V6<7S:'C6[
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M:)*"B1E7VNH %1%NH63MI"T>IU5>G!XGB<UZHMD_@-ZX0K-NTC@X#>:-,G,
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M(=J$)%:*YT$T"ME!=8=UF3),:4@&L4AR*S#;<5QF96IK$^A'HGF&CI>&.E:
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MNH]4"RT*>P>8"8TW"ONZQ"L<2*. \H40>KLP 9I+X?0'4$L#!!0    ( %6
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MCC\, _9%K^1#/J0HCG?6??-KQ #/C39^DJQ#V-QDF:_6V$B?V@T:NEE:U\A
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M#A *3*RSP.AQBZ<HA#-$,'ZN;0:-2Z>X_;ZQ_M''3K$LF,%3);[QU.:3X"B
M%#-6"7NE5G_@.IZ!LY<H8?POK-:R40!)9:PJULJ$H."R?K*[=1[V48C7"K''
M73OR*,^89=.Q5BO03IJLN1<?JM<F<%RZHEQ;3:><].STDU+IB@L!3*9P(2V3
M2[X0"#-CT!IX>\-H9=Z-0TO.G$J8K W/:\/Q"X:[,7Q1TN8&SF6*Z6,#(:%L
MH,8;J/.XU>(9)AWH==]#',5QB[U>$WK/V^N]+O0S;A*A3*41_IXMC-5$H']V
MY:'VTM_MQ375L2E9@I. NL:@OL5@>OBF.XQ.6F+H-S'TVZQ/KZE)TXI JPQL
MCG#*M+[G<@FS0E72NNU-F+N@MQK?#?V&O&1*4#,[-];1 _RII)PY"$E.B40#
M7-;+#2+6(%JN$77@+0D5]$;]:=YM,,^98#)!8,8)4]6Q6*#>5+X+!W#XYBCN
MQB=-:/1U2-12\E^8.K>)DG+=]"MN<UA4AB(SA@Z*!9?,GPPZ,5!?4]>20J4U
MRN0>J,C2B%J I?]2^Q4^KHB$VV'%!&O0Z4-+30=-30=[U_1"UM]=!^@*'3*7
M= 6JTK1N@G[&WEW%;O7ZBF+S+6SZ";9'!6FPL;JS7L@@T2$E7TQ[[CS0XJO!
MK!+PF6<(G[2B.CYE^2Q)JJ(B!.2.MK3EOVI8?]*M=H:W=/64=%1JE5:)!>V^
MU :Z$=RC\W8 O7ZG1X^H,W"+7N>(3/ZLN':IO;PZ9$5Y<D9)IJ\]E]RB$Z):
M/Q#1K6Z49>)YM.]!$@A2&!&'6M@Q;-@Q_"WL:/7Z/SM^,SM&#3M&>[/CW%A>
MU%%+69'W1\&?W]%<9UP!M:_)1X_]PV>:D?9D3"N25UX>V&!F-6:VC1F?8*[S
M_4%XS,]R^\+U\IVJ"BA3A^ IRWJ^=H-6F?X>,H,]9(9[R(S6,I0WFK@S2R<'
MT!T2'7=Q)=P: PO42S_LNEN/PJXGPF:WF:=G]1CY(%X/XU^87G)I0&!&JE%G
M1)>'K@?<>F%5Z8?*A;(THOK7G/X3H'8"=)XI93<+YZ#YES']#U!+ P04
M" !5@$E6$U=:6H\$   ,#   &0   'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6RE5UUOVS84_2N$5PP)D,F6;%E)9AM(G 8KT&*!DZT/PQYHZMHF2I$J2<7)
MO]^]E*RX@2($ZX-%\>O<PW,/*7JV-_:;VP%X]E0H[>:#G??EY7#HQ X*[B)3
M@L:>C;$%]UBUVZ$K+? \3"K4,!F-IL."2SU8S$+;G5W,3.65U'!GF:N*@MOG
M:U!F/Q_$@T/#2FYWGAJ&BUG)MW /_J_RSF)MV*+DL@#MI-',PF8^N(HOKS,:
M'P;\+6'OCMX9K61MS#>J?,KG@Q$1 @7"$P+'XA&6H!0!(8WO#>:@#4D3C]\/
MZ+=A[;B6-7>P-.JKS/UN/C@?L!PVO%)^9?9_0+.>E/"$42X\V;X>.\6(HG+>
M%,UDK!=2UR5_:G0XFG ^>F-"TDQ( N\Z4&!YPSU?S*S9,TNC$8U>PE+#;"0G
M-27EWEOLE3C/+_[T.[#LFBNN!;#[X(,;\%PJQTX>^%J!.YT-/4:B\4/1H%[7
MJ,D;J''"OACM=XY]U#GD/P(,D6++,SGPO$YZ$6] 1&P<G[%DE"0]>.-VW>.
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MC>W4B]R=]#9<>12.-^'42[B?-\!A#5"4RCP#X!>RUE\8%[R0)9AJ%'*$0JX
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M>AW?3A7<P>6GX5S'3$W#"IP'U!(&]2,&BQ?/DF'\^@S9O">;GT-?W%,'EJU
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M5I;$QG]N2=U1.P>R5TK9P\(EZ/\7BU]02P,$%     @ 58!)5OTR%9\,!@
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M.*!L L9W4IJ#88>@?\+BOU!+ P04    " !5@$E6'DL7+@H$  !C%   &0
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M3/":L,) 7M]0*EX.B@]K]8?4Q?]02P,$%     @ 58!)5OI&K2Q. @  $@4
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M3P2X;@([Q]LF=GUA/<]0-%?\:*$+!WA_8:U_=L(@]<]@_AM02P,$%     @
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M^1IM^!Y$%$*D.C+6?_"XT)'KT7G!N))0&XZO(?LXUWT\?GW!N)+:FX2\1N]
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M]?M5HK"^>E)\?>7^ZTKG_P-02P,$%     @ 58!)5OGEG1QP!   9!0  !D
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MZ[!%>J25WBB^2PYY5EPI'B676\ A"&.@WZ^Y[E/9C?E ?K X_P]02P,$%
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M>:^_Z/8Y9^\R!JJ8)(+%002+EW2[C_?;0J9AZ5E$JTBHCO^BU]PW,WNZ4 E
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M8A*@B6GP@'APT]O6(K&+[;2,7X^=A-"N;MBF]*&)DWN.[SG)O;$G.RY^R#6
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MDFAV@,U \4V])YISI7=8]>E:[YI!F !]?\GU$J4=F&U6MP]/_P!02P,$%
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M8<:-UTKH4:+M5/2.\V1+*$68)>B<*<Q6Y)8"FDD)2J(W#7VSE M%?D."/FU
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MJUNTZDB6EQ?1@DEUK97-M?KP *X#U/,E8W+7T7=;\RD3_0902P,$%     @
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M6X#K2RG-;F(;5O-_2GX#4$L#!!0    ( %6 25;2:^GVP0,  (H.   9
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MWY&8W!DH])\N]0>75/^29,F%R([4'[;J#\]^XJXLM?(W106.I,^:LE2BU,Z
MT'U9PNI30ZZZ%*]/OG$GV[:YC0>]T=C?'@K991,>VR2O;:+>L+6IP_8/2G<!
M:N-:H,;T1$?K\M6NMEUVZIK+B_49=M^Z63[3U*W[GJH-PSK 88V40>\3^J7J
M=EA/C"Q=@UA)@^W&#7/\@P!E#7!_+;$R-!-[0/M/$O\'4$L#!!0    ( %6
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MZM3:ZJ7G>4V6=R3+3!TT9U)55:89J3H6N5Z@YA>,R5U')R@K8_\/4$L#!!0
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M..VH944US"5_9H4I)\%#0 I8TQTW3_+P*S1ZAI8OEUR[7W)H;*. Y#MMI&C
MZ(%@E?^G+TT<3@#QZ U T@"2"T R? /0;P#]6P&#!C!PD?%27!PR:F@Z5O)
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MD>L&ZON*,7DLZ '**_SD'U!+ P04    " !5@$E6#QZ\_?($  #^%P  &0
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M'/R]$5S(3Y-\"4YOB,!)RL_ "?  5R&TJ?[RO/;@-DE3&4P^.ZG?CCPA4U,
MO;A,8UJD@5K2@ C<TERL./B4S\E\WX$GUZ1:&/2R,%-D]7A#8A<$\!P@'R'P
M,+L!IR=[^10_EDA!58) 1PI;(MW/'AHSMEJI;KWD:QR3L2/;D1.V)<[D]]]@
MY/]AP116F$+M/6C!]&V3/1(&Z**H61.\\ /@]2IX/>N23<DRR7.UU:8XQ7E,
MSB7.K=R8<E.>RHU4U.8,_-M8I0)_$2'2$11W;2=HY&T;0$45J,@*ZD^&\T,
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MU^?<:YO+\LCX+[$#D.BIR*E863LIRUO'$<D."BQL5@)5;S+&"RS5D&\=47+
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MZB/-XT[]-P"N >I]QIA\'N@%FG\;T5]02P,$%     @ 58!)5GC#%):>!
MHQ   !D   !X;"]W;W)K<VAE971S+W-H965T-C4N>&ULK9AM;^,V#(#_BN#=
MABO0.I;M.$V7!&CC'G; BBO:W?9AV ?%H1.MMI63Y"3W[R?9KN,7Q>V ZX?6
M+R2MAZ1$LK,#XR]B"R#1,4TR,;>V4NYN1B,1;2$EPF8[R-2;F/&42'7+-R.Q
MXT#6A5*:C%S'"48IH9FUF!7/'OEBQG*9T P>.1)YFA+^_0X2=IA;V'I]\$0W
M6ZD?C!:S'=G ,\BONT>N[D:UE35-(1.498A#/+=N\4V( ZU02/Q)X2 :UTBC
MK!A[T3>?UW/+T2N"!"*I31#U9P]+2!)M2:WC6V74JK^I%9O7K]8_%? *9D4$
M+%GR%UW+[=RZMM :8I(G\HD=?H,*:*SM12P1Q6]TJ&0="T6YD"RME-4*4IJ5
M?\FQ<D1#08&:%=Q*P>TJ^&<4O$K!>Z^"7RGXA6=*E,(/(9%D,>/L@+B65M;T
M1>',0EOATTS'_5ER]98J/;GXG$4L!?0'.8) 5^B1LSTM8JI2"K5>JF?WA&<T
MVPCTG*_^58%#DK5E0AK'P 6*.4O1LR0REXQ_1Y]@#9PDZ(E(0!]#D(0FXD)]
M[NMSB#Y^N$ ?$,W0 TT2]64Q&TD%II<WBBJ(NQ+"/0.!7?3 ,KD5Z#Y;P[IM
M8*0\4KO%?77+G3MH,83(1AZ^1*[CNH8%+=^OC@WJX?O5G0$:KPZR5]CSW@RR
MBI"($B9R#NCOVY607&V\?TP>+RWZ9HOZ-+H1.Q+!W%+'C0"^!VOQRT\X<'XU
M>>M'&@M_D+&6)_W:D_Z0]<5K)M/2HU)G_27B*J]-/BQMX3+,^@3>+QQ;)\2^
MZ9QW285O2;5PQC7.^'_C("*1BW\V\93&)HTE^+X][>#TA5QL>QT:@Y!K^V:8
MH(8)!F'T>0,-E$N4J;K)8A17E"O((*;21%9:OFZL!V/[ND/6%PILMP/6EQG;
M8S/7I.::#'+=<:)/-:33.>)T5]3+-<\W"LR8=A/#.L<=EKZ,W^4-33)3,\MU
MS7(]R/([$T4E@:-4A22G8JMZB")($<OVP"5=)8 $9%25GXQ),%:#\AM!,UJ=
M."S[(DZ';DBBQ3:MV:9OY!^+7JYT$[)6-*GJS 0I8@5'?6T,U;3GXBNW%RN#
M$.YO*8-48$_,2-@YM0?.(-27.*81\!:0L4 [O<]/;3QM_72P*I5F!"8=)H-5
M[RQ3H^7!@TS++<DV^J30I\39P[LRTG9[U^M+@Y33.Q0,0E[#4AO#/6&X@QCW
MQQWE*M<T!)&2TU5^9K]4A@9VP[(2:7,$78Z^$+;/E"!\:D[P8,5>/*DJ37BT
M19&BH=),X!DVRK17>RJQH"76BX9!R#MSKN%38X"'.X-34NU)DI<;GR1JK")9
M9,XOOX<T:93 "LCOK77<Q>G;4:X)SN;7J3? P\W!%[D%;ESYV) &O8TQ?O,$
M-MAQSA5+?.H"\' ;T!YA/E9%OQA)+EJ-CA$MZ#4FXVD_*GVI?KL0&J2N/*>Y
MJTK"46-Z2X%OBBE8J!,WSV0YL=1/ZTG[MI@O.\_O] 1>3(4G,^7X_D#XAF8"
M)1 KDXX]49[GY41<WDBV*V;$%9-JXBPNMT!4VZ0%U/N8J5I<W>@/U/^76/P'
M4$L#!!0    ( %6 258L5"(;$@0  %@/   9    >&PO=V]R:W-H965T<R]S
M:&5E=#8V+GAM;*V749.;-A#'OXJ&9CK)3 T(; Q7FYG$GD[N(>W-79(^RUBV
M-2<D*LGVM9^^$A",+4'NX>[A+&!W^:VTVC]:G+EXE@>,%7@I*9-+[Z!4=1<$
MLCC@$DF?5YCI)SLN2J3TI=@'LA(8;6NGD@91&"9!B0CS\D5][T'D"WY4E##\
M(( \EB42_W["E)^7'O1^W'@D^X,R-X)\4:$]?L+J6_4@]%701=F2$C-). ,"
M[Y;>1WBW@JEQJ"V^$WR6O3$PJ6PX?S87]]NE%QHB3'&A3 BD?TYXA2DUD33'
M/VU0KWNG<>R/?T3_HTY>)[-!$J\X_9MLU6'II1[8XATZ4O7(SY]QF]#,Q"LX
ME?5_<&YM0P\41ZEXV3IK@I*PYA>]M!/1<X#3 8>H=8A>ZQ"W#G&=:$-6I[5&
M"N4+P<] &&L=S0SJN:F]=3:$F65\4D(_)=I/Y?>LX"4&7]$+EF "5KRL.,-,
M2<!W8(UW6 B\-8_!1RFQOOU^C14B5'[0UM^>UN#]NP_@'2 ,?"&4ZH61BT!I
M+A,]*%J&3PU#-,"PQH4/8O@;B,(H<KBO7N\.K]T#/1O=E$3=E$1UO'@P7INU
MTEFC.NL[5U)-E*D[BME^=[)"!5YZ>G])+$[8RW_]!2;A[ZX4WRC85<)QEW \
M%CW_4W<+W1<$4H3M >4Z9><J-E'F=133'DYY-/>GB^#43\0VRD(_[HRN *<=
MX'04\%&GC$1Q (AM]1X]Z>93Z5:B0*&7B2@G;!,Q[7' ,/6S&UJ'593Y<S?N
MK,.=C>*N4$44HN0_74-B -V%/+-@,NB'6?_O!M_V@/->CE?T24>?C-(_*5X\
M3TQKW +=&[1>2%1W7/QBQMA%GE@<TYDUU[91G [!SCO8^2CL7Y>RQ9JXW:XN
MQ+GU]BCQTQM$AU$V5+QIAYB.(MXSA=B>;.@876J]. U[9=C0.8R2H?JX0LTZ
MU&Q\-M4!"Q=>9L_+U%I?AQ'T$S<1#"_Z%(XR?>5Z*QEAONW)3IT)[4(,9]9$
MNLQ@W*N&:]:>EL+7*P<E:$,H402[Y:.-]4;Z\5;1KC._2"8<%:A\Q=D)"U57
MN<2,< $85VX9:4,EO=D/;Q<HLA9HD@WU"GC1.3@N=+?=HK=$3M#8 IV8+XQK
MU-A&C>*AI@$OD@?'-6]P+T);LR806JW,:18.21N\:!L<%S?'?OS9--HJ-8DC
M&]AA-HT'%_TB9W!<S^JOFYVK@]2:_#-XAVK-(ZOWN<R2X8J]R!L<U[?OB!X;
M]454G[@0*YSZVT:YJM3$ZGJVNDUFT\&N=]$W."YP9H)?VY]3Z^LP#NTO!9<9
MG/GPAC3H'7O,F?,+$GO"I-[<.^VG:UU7E&B.<<V%XE5]$MIPI<]5]?"@C[Y8
M& /]?,=USVHOS.&J.TSG_P-02P,$%     @ 58!)5NW,I]#] P  6!,  !D
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M-6:'6RS<NX#M6W9#U89AJ!S6*!6-YEB"RK\/?F)D[>[D7!J\X=VPQ"<5E-V
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M+>O*J&YH4=I:X5%HK#SL8X;5)$@3@._70NA]PWR@K4^C_P!02P,$%     @
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M]./6E'%VT#%\'.S%0N &X K6=-[L![G9^S>U-+!NZT%[D$5I+SK!<O?;E>M
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MJK.:ZD;QC3GNF'.E>&$NUY1 $G0#>+_D7+W<Z!.4YL1L\A]02P,$%     @
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MN5LN<$2#L@9X/Y/2;#;603OTL]]02P,$%     @ 58!)5EL1"1BG @  W0@
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M=V]R:V)O;VLN>&ULQ9I+<^(X$(#_BHI3]L""G\RD0JK(<U.52:@PFSU."5N
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M2P$"% ,4    " !5@$E66A8"Z>T    K @  $0              @ &O
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " !5@$E6F5R<(Q &  "<)P
M$P              @ '+ 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( %6 259Y0+KXT <  )DO   8              " @0P(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " !5@$E68B.H2#T"  #$!0
M&               @($2$   >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L!
M A0#%     @ 58!)5G.J_8(:!@  -QH  !@              ("!A1(  'AL
M+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( %6 258VDHJ>Z@(
M $T*   8              " @=48  !X;"]W;W)K<VAE971S+W-H965T-"YX
M;6Q02P$"% ,4    " !5@$E650.XKAT'  #F(0  &               @('U
M&P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ 58!)5FR:
ME$]8"   6TX  !@              ("!2",  'AL+W=O<FMS:&5E=',O<VAE
M970V+GAM;%!+ 0(4 Q0    ( %6 259\KKYW,@@  -HG   8
M  " @=8K  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " !5
M@$E6CDZMLY<F  !B>@  &               @($^-   >&PO=V]R:W-H965T
M<R]S:&5E=#@N>&UL4$L! A0#%     @ 58!)5F^C\#7H%0  ;EL  !@
M         ("!"UL  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0
M   ( %6 25828779A04  #$,   9              " @2EQ  !X;"]W;W)K
M<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ 58!)5E_?,Z%(!0  ] X
M !D              ("!Y78  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q0
M2P$"% ,4    " !5@$E6C<I2(+@$  #%"P  &0              @(%D?
M>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( %6 259_&98&
MW0P  -<H   9              " @5.!  !X;"]W;W)K<VAE971S+W-H965T
M,3,N>&UL4$L! A0#%     @ 58!)5K]F&,@(!   V0D  !D
M ("!9XX  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " !5
M@$E6+-B"LS$$   7"@  &0              @(&FD@  >&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( %6 258W1Z*:% ,  -T&   9
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M970R,"YX;6Q02P$"% ,4    " !5@$E6.(M\K><%  "A#@  &0
M    @($JN0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (
M %6 25;-BN/UQ0,  !0(   9              " @4B_  !X;"]W;W)K<VAE
M971S+W-H965T,C(N>&UL4$L! A0#%     @ 58!)5NQB8I^4)P  6(,  !D
M             ("!1,,  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"
M% ,4    " !5@$E6G7=?PR\#  !"!P  &0              @($/ZP  >&PO
M=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( %6 25:L\]FCO00
M " .   9              " @77N  !X;"]W;W)K<VAE971S+W-H965T,C4N
M>&UL4$L! A0#%     @ 58!)5C 1\<K?!   T0P  !D              ("!
M:?,  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " !5@$E6
M0\&CUD$#  #7!P  &0              @(%_^   >&PO=V]R:W-H965T<R]S
M:&5E=#(W+GAM;%!+ 0(4 Q0    ( %6 25895C^,YP,  '$,   9
M      " @??[  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%
M  @ 58!)5A-76EJ/!   # P  !D              ("!%0 ! 'AL+W=O<FMS
M:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " !5@$E6./[U2=X"   [!@
M&0              @(';! $ >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+
M 0(4 Q0    ( %6 25;],A6?# 8  $L1   9              " @? ' 0!X
M;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ 58!)5D:L,=5U
M!@  N!(  !D              ("!,PX! 'AL+W=O<FMS:&5E=',O<VAE970S
M,BYX;6Q02P$"% ,4    " !5@$E60\JY,BH$  "Z"@  &0
M@('?% $ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( %6
M25;L_3E1C@@  !-+   9              " @4 9 0!X;"]W;W)K<VAE971S
M+W-H965T,S0N>&UL4$L! A0#%     @ 58!)5B+ 26LC"P  #(<  !D
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M=#,Y+GAM;%!+ 0(4 Q0    ( %6 258[7JYB: 0  /(6   9
M  " @00\ 0!X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @
M58!)5OG;J9)T"   NE0  !D              ("!HT ! 'AL+W=O<FMS:&5E
M=',O<VAE970T,2YX;6Q02P$"% ,4    " !5@$E6^>6='' $  !D%   &0
M            @(%.20$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4
M Q0    ( %6 25;@*JF82@L  #5W   9              " @?5- 0!X;"]W
M;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ 58!)5L*+5DEF P
MDP\  !D              ("!=ED! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX
M;6Q02P$"% ,4    " !5@$E6:=FQ.>,"   ["   &0              @($3
M70$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( %6 25;^
M.-JKC0(  )8)   9              " @2U@ 0!X;"]W;W)K<VAE971S+W-H
M965T-#8N>&UL4$L! A0#%     @ 58!)5M^#Q=^O @  @08  !D
M     ("!\6(! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %6 25:VJEN]#P,  -8(   9              "
M@<!R 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ 58!)
M5A&2!YB% @  JP8  !D              ("!!G8! 'AL+W=O<FMS:&5E=',O
M<VAE970U,RYX;6Q02P$"% ,4    " !5@$E6TFOI]L$#  "*#@  &0
M        @('"> $ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0
M   ( %6 259/QD$AZP(  )\(   9              " @;I\ 0!X;"]W;W)K
M<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ 58!)5JA=61*U"   FU0
M !D              ("!W'\! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q0
M2P$"% ,4    " !5@$E6GK?99V #  "$#@  &0              @('(B $
M>&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( %6 258GG:NF
MX ,  ),5   9              " @5^, 0!X;"]W;W)K<VAE971S+W-H965T
M-3@N>&UL4$L! A0#%     @ 58!)5KA_F<H2 P  )0L  !D
M ("!=I ! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    " !5
M@$E6!\&/^T0#  #4"0  &0              @(&_DP$ >&PO=V]R:W-H965T
M<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( %6 25;U,S*L( 0  ,X/   9
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M970V-2YX;6Q02P$"% ,4    " !5@$E6+%0B&Q($  !8#P  &0
M    @(%AK $ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    (
M %6 25;MS*?0_0,  %@3   9              " @:JP 0!X;"]W;W)K<VAE
M971S+W-H965T-C<N>&UL4$L! A0#%     @ 58!)5O'\]ZW) P  TPP  !D
M             ("!WK0! 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"
M% ,4    " !5@$E634G8E= "  "P!P  &0              @('>N $ >&PO
M=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( %6 25:FQ9N\O@,
M *L.   9              " @>6[ 0!X;"]W;W)K<VAE971S+W-H965T-S N
M>&UL4$L! A0#%     @ 58!)5@ODL$DN!   /1,  !D              ("!
MVK\! 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"% ,4    " !5@$E6
ML&_88K<"    "   &0              @($_Q $ >&PO=V]R:W-H965T<R]S
M:&5E=#<R+GAM;%!+ 0(4 Q0    ( %6 259;$0D8IP(  -T(   9
M      " @2W' 0!X;"]W;W)K<VAE971S+W-H965T-S,N>&UL4$L! A0#%
M  @ 58!)5D,]$?9H P  GQ<   T              ( !"\H! 'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    " !5@$E6EXJ[',     3 @  "P
M@ &>S0$ 7W)E;',O+G)E;'-02P$"% ,4    " !5@$E6)M\*<) %   U,
M#P              @ &'S@$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
M58!)5K?' S!" @  0BL  !H              ( !1-0! 'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ 58!)5OC# AT& @  3RH  !,
M             ( !OM8! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     %$
,40 N%@  ]=@!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>225</ContextCount>
  <ElementCount>420</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>64</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements Income and Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome</Role>
      <ShortName>Consolidated Statements Income and Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CollaborationandLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Diurnal Acquisition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/DiurnalAcquisition</Role>
      <ShortName>Diurnal Acquisition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Debt Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/DebtSecurities</Role>
      <ShortName>Debt Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Convertible Senior Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.neurocrine.com/role/ConvertibleSeniorNotes</Role>
      <ShortName>Convertible Senior Notes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Other Balance Sheet Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/OtherBalanceSheetDetails</Role>
      <ShortName>Other Balance Sheet Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Retirement Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/RetirementPlan</Role>
      <ShortName>Retirement Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Legal Proceedings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/LegalProceedings</Role>
      <ShortName>Legal Proceedings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Diurnal Acquisition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/DiurnalAcquisitionTables</Role>
      <ShortName>Diurnal Acquisition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/DiurnalAcquisition</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Debt Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/DebtSecuritiesTables</Role>
      <ShortName>Debt Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/DebtSecurities</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/FairValueMeasurements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Convertible Senior Notes (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.neurocrine.com/role/ConvertibleSeniorNotesTables</Role>
      <ShortName>Convertible Senior Notes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/ConvertibleSeniorNotes</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Other Balance Sheet Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/OtherBalanceSheetDetailsTables</Role>
      <ShortName>Other Balance Sheet Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/OtherBalanceSheetDetails</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/EarningsPerShare</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/ShareBasedCompensation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/IncomeTaxes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/Leases</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Collaboration and License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>Collaboration and License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Diurnal Acquisition - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/DiurnalAcquisitionAdditionalInformationDetails</Role>
      <ShortName>Diurnal Acquisition - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Diurnal Acquisition - Estimated Fair Values of the Assets Acquired and Liabilities Assumed at the Date of Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/DiurnalAcquisitionEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedattheDateofAcquisitionDetails</Role>
      <ShortName>Diurnal Acquisition - Estimated Fair Values of the Assets Acquired and Liabilities Assumed at the Date of Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Debt Securities - Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails</Role>
      <ShortName>Debt Securities - Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Debt Securities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetails</Role>
      <ShortName>Debt Securities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Debt securities in Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails</Role>
      <ShortName>Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Debt securities in Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Fair Value Measurements - Reconciliation of Equity Securities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Reconciliation of Equity Securities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Convertible Senior Notes - Additional Information (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails</Role>
      <ShortName>Convertible Senior Notes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Convertible Senior Notes - 2024 Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails</Role>
      <ShortName>Convertible Senior Notes - 2024 Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Convertible Senior Notes - Interest Expense (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails</Role>
      <ShortName>Convertible Senior Notes - Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Goodwill and Intangible Assets - Intangible Assets Amortized Over Estimated Useful Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Intangible Assets Amortized Over Estimated Useful Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Goodwill and Intangible Assets - Estimated Annual Amortization Expense for Finite-Lived Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/GoodwillandIntangibleAssetsEstimatedAnnualAmortizationExpenseforFiniteLivedIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Estimated Annual Amortization Expense for Finite-Lived Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Other Balance Sheet Details - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails</Role>
      <ShortName>Other Balance Sheet Details - Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Other Balance Sheet Details - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails</Role>
      <ShortName>Other Balance Sheet Details - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Other Balance Sheet Details - Accounts Payable and Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails</Role>
      <ShortName>Other Balance Sheet Details - Accounts Payable and Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Other Balance Sheet Details - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Other Balance Sheet Details - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Earnings Per Share - Schedule of Net Income (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/EarningsPerShareScheduleofNetIncomeLossPerShareDetails</Role>
      <ShortName>Earnings Per Share - Schedule of Net Income (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Earnings Per Share - Schedule of Anti-Dilutive Shares Excluded from Diluted Per Share Amounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/EarningsPerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails</Role>
      <ShortName>Earnings Per Share - Schedule of Anti-Dilutive Shares Excluded from Diluted Per Share Amounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Share-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Share-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Share-Based Compensation - Compensation Cost Related to Share-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails</Role>
      <ShortName>Share-Based Compensation - Compensation Cost Related to Share-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Share-Based Compensation - Schedule of Share-based Compensation Expense by Award-type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Share-based Compensation Expense by Award-type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Share-Based Compensation - Schedule of Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Share-Based Compensation - Weighted-Average Assumptions for Stock Option Grants using Black-Scholes Option-Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails</Role>
      <ShortName>Share-Based Compensation - Weighted-Average Assumptions for Stock Option Grants using Black-Scholes Option-Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Share-Based Compensation - Summary of Activity Related to Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails</Role>
      <ShortName>Share-Based Compensation - Summary of Activity Related to Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Share-Based Compensation - Summary and Changes in Restricted Stock Units Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails</Role>
      <ShortName>Share-Based Compensation - Summary and Changes in Restricted Stock Units Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Income Taxes - Income Before the Provision for Income Taxes from Continuing Domestic and Foreign Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/IncomeTaxesIncomeBeforetheProvisionforIncomeTaxesfromContinuingDomesticandForeignOperationsDetails</Role>
      <ShortName>Income Taxes - Income Before the Provision for Income Taxes from Continuing Domestic and Foreign Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Income Taxes - Components of the Provision for (Benefit from) Income Taxes for Continuing Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforBenefitfromIncomeTaxesforContinuingOperationsDetails</Role>
      <ShortName>Income Taxes - Components of the Provision for (Benefit from) Income Taxes for Continuing Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Income Taxes - Provision for Income Taxes on Earnings Subject to Income Taxes Differs from Statutory Federal Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails</Role>
      <ShortName>Income Taxes - Provision for Income Taxes on Earnings Subject to Income Taxes Differs from Statutory Federal Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Components of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Leases - Narrative Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/LeasesNarrativeInformationDetails</Role>
      <ShortName>Leases - Narrative Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Leases - Supplemental Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/LeasesSupplementalInformationDetails</Role>
      <ShortName>Leases - Supplemental Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - Leases - Summary of Future Minimum Lease Payments Under Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Summary of Future Minimum Lease Payments Under Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - Retirement Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/RetirementPlanAdditionalInformationDetails</Role>
      <ShortName>Retirement Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="nbix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/SubsequentEvents</ParentRole>
      <Position>73</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 7 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:DebtInstrumentConvertibleConversionRatio1, us-gaap:LesseeOperatingLeaseTermOfContract, us-gaap:NumberOfOperatingSegments, us-gaap:NumberOfReportableSegments, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 -  nbix-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="nbix-20221231.htm">nbix-20221231.htm</File>
    <File>nbix-20221231.xsd</File>
    <File>nbix-20221231_cal.xml</File>
    <File>nbix-20221231_def.xml</File>
    <File>nbix-20221231_lab.xml</File>
    <File>nbix-20221231_pre.xml</File>
    <File>q4-2022xexhibit211.htm</File>
    <File>q4-2022xexhibit231.htm</File>
    <File>q4-2022xexhibit311.htm</File>
    <File>q4-2022xexhibit312.htm</File>
    <File>q4-2022xexhibit32.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>nbix-20221231_g1.jpg</File>
    <File>nbix-20221231_g2.jpg</File>
    <File>nbix-20221231_g3.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="906">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>95
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nbix-20221231.htm": {
   "axisCustom": 1,
   "axisStandard": 29,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 906,
    "http://xbrl.sec.gov/dei/2022": 37
   },
   "contextCount": 225,
   "dts": {
    "calculationLink": {
     "local": [
      "nbix-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nbix-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "nbix-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nbix-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nbix-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "nbix-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 625,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 14,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 18
   },
   "keyCustom": 52,
   "keyStandard": 368,
   "memberCustom": 21,
   "memberStandard": 40,
   "nsprefix": "nbix",
   "nsuri": "http://www.neurocrine.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.neurocrine.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Diurnal Acquisition",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.neurocrine.com/role/DiurnalAcquisition",
     "shortName": "Diurnal Acquisition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Debt Securities",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.neurocrine.com/role/DebtSecurities",
     "shortName": "Debt Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.neurocrine.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Convertible Senior Notes",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.neurocrine.com/role/ConvertibleSeniorNotes",
     "shortName": "Convertible Senior Notes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Goodwill and Intangible Assets",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.neurocrine.com/role/GoodwillandIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Other Balance Sheet Details",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.neurocrine.com/role/OtherBalanceSheetDetails",
     "shortName": "Other Balance Sheet Details",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Earnings Per Share",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.neurocrine.com/role/EarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Share-Based Compensation",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.neurocrine.com/role/ShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.neurocrine.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.neurocrine.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.neurocrine.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Retirement Plan",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.neurocrine.com/role/RetirementPlan",
     "shortName": "Retirement Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Legal Proceedings",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.neurocrine.com/role/LegalProceedings",
     "shortName": "Legal Proceedings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.neurocrine.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbix:OrganizationAndBusinesDescriptionPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "23",
     "role": "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbix:OrganizationAndBusinesDescriptionPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Diurnal Acquisition (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.neurocrine.com/role/DiurnalAcquisitionTables",
     "shortName": "Diurnal Acquisition (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Debt Securities (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.neurocrine.com/role/DebtSecuritiesTables",
     "shortName": "Debt Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.neurocrine.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Convertible Senior Notes (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.neurocrine.com/role/ConvertibleSeniorNotesTables",
     "shortName": "Convertible Senior Notes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Other Balance Sheet Details (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.neurocrine.com/role/OtherBalanceSheetDetailsTables",
     "shortName": "Other Balance Sheet Details (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i4dad9397c8114dc994a1d55e36926d3d_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.neurocrine.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i4dad9397c8114dc994a1d55e36926d3d_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Earnings Per Share (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.neurocrine.com/role/EarningsPerShareTables",
     "shortName": "Earnings Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Share-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.neurocrine.com/role/ShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.neurocrine.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.neurocrine.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:MarketableSecuritiesPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i4dad9397c8114dc994a1d55e36926d3d_I20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:MarketableSecuritiesPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i4dad9397c8114dc994a1d55e36926d3d_I20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i4dad9397c8114dc994a1d55e36926d3d_I20221231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "nbix:PotentialMilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Collaboration and License Agreements - Additional Information (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
     "shortName": "Collaboration and License Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i4dad9397c8114dc994a1d55e36926d3d_I20221231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "nbix:PotentialMilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i9d13692c26a440998d78e8fffc7d8570_D20221101-20221101",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Diurnal Acquisition - Additional Information (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.neurocrine.com/role/DiurnalAcquisitionAdditionalInformationDetails",
     "shortName": "Diurnal Acquisition - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i9d13692c26a440998d78e8fffc7d8570_D20221101-20221101",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationAcquisitionRelatedCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i4dad9397c8114dc994a1d55e36926d3d_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Diurnal Acquisition - Estimated Fair Values of the Assets Acquired and Liabilities Assumed at the Date of Acquisition (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.neurocrine.com/role/DiurnalAcquisitionEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedattheDateofAcquisitionDetails",
     "shortName": "Diurnal Acquisition - Estimated Fair Values of the Assets Acquired and Liabilities Assumed at the Date of Acquisition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i9d13692c26a440998d78e8fffc7d8570_D20221101-20221101",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i4dad9397c8114dc994a1d55e36926d3d_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Debt Securities - Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails",
     "shortName": "Debt Securities - Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i4dad9397c8114dc994a1d55e36926d3d_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i4dad9397c8114dc994a1d55e36926d3d_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nbix:DebtSecuritiesAvailableForSalePositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "security",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Debt Securities - Additional Information (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetails",
     "shortName": "Debt Securities - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i4dad9397c8114dc994a1d55e36926d3d_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nbix:DebtSecuritiesAvailableForSalePositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "security",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i4dad9397c8114dc994a1d55e36926d3d_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i4dad9397c8114dc994a1d55e36926d3d_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i2a6f8fd190a2433584205fa45bfd8bcb_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Debt securities in Unrealized Loss Position (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails",
     "shortName": "Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Debt securities in Unrealized Loss Position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i2a6f8fd190a2433584205fa45bfd8bcb_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i6ce1cf497c004f079441d676651e2808_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Investments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i6ce1cf497c004f079441d676651e2808_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Investments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i092dab9242464bf7bd7bddb6a8629472_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiRestricted",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Fair Value Measurements - Reconciliation of Equity Securities Measured at Fair Value on Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Reconciliation of Equity Securities Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i4971e09f913f4c90bd8fd83e1d0fcd54_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireRestrictedInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "ica03dcf8555e4fc58dc68198617df351_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Convertible Senior Notes - Additional Information (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
     "shortName": "Convertible Senior Notes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i4b5b4f7eab2446ce84ea30524cbd6aa0_I20170502",
      "decimals": "-5",
      "lang": "en-US",
      "name": "nbix:CarryingAmountOfLiabilityComponentUponIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i4dad9397c8114dc994a1d55e36926d3d_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Convertible Senior Notes - 2024 Notes (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails",
     "shortName": "Convertible Senior Notes - 2024 Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i48dd18e80c3e4426a4bf9c87e59b2aa4_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "nbix:DebtInstrumentCouponInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Convertible Senior Notes - Interest Expense (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails",
     "shortName": "Convertible Senior Notes - Interest Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "nbix:DebtInstrumentCouponInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i4dad9397c8114dc994a1d55e36926d3d_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
     "shortName": "Goodwill and Intangible Assets - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i092dab9242464bf7bd7bddb6a8629472_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails",
     "shortName": "Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i4dad9397c8114dc994a1d55e36926d3d_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Goodwill and Intangible Assets - Intangible Assets Amortized Over Estimated Useful Lives (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails",
     "shortName": "Goodwill and Intangible Assets - Intangible Assets Amortized Over Estimated Useful Lives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "ibfdc712fb9f342aca6ae054a16698cef_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i4dad9397c8114dc994a1d55e36926d3d_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Goodwill and Intangible Assets - Estimated Annual Amortization Expense for Finite-Lived Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsEstimatedAnnualAmortizationExpenseforFiniteLivedIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Estimated Annual Amortization Expense for Finite-Lived Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i4dad9397c8114dc994a1d55e36926d3d_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Statements Income and Comprehensive Income",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
     "shortName": "Consolidated Statements Income and Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i4dad9397c8114dc994a1d55e36926d3d_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Other Balance Sheet Details - Inventories (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails",
     "shortName": "Other Balance Sheet Details - Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i4dad9397c8114dc994a1d55e36926d3d_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i4dad9397c8114dc994a1d55e36926d3d_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Other Balance Sheet Details - Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails",
     "shortName": "Other Balance Sheet Details - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i4dad9397c8114dc994a1d55e36926d3d_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i4dad9397c8114dc994a1d55e36926d3d_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Other Balance Sheet Details - Accounts Payable and Accrued Liabilities (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails",
     "shortName": "Other Balance Sheet Details - Accounts Payable and Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i4dad9397c8114dc994a1d55e36926d3d_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i4dad9397c8114dc994a1d55e36926d3d_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Other Balance Sheet Details - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Other Balance Sheet Details - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i4dad9397c8114dc994a1d55e36926d3d_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Earnings Per Share - Schedule of Net Income (Loss) Per Share (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.neurocrine.com/role/EarningsPerShareScheduleofNetIncomeLossPerShareDetails",
     "shortName": "Earnings Per Share - Schedule of Net Income (Loss) Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "ic7d26b322bb24bff8ec6e47dcf836515_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Earnings Per Share - Schedule of Anti-Dilutive Shares Excluded from Diluted Per Share Amounts (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.neurocrine.com/role/EarningsPerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails",
     "shortName": "Earnings Per Share - Schedule of Anti-Dilutive Shares Excluded from Diluted Per Share Amounts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "ic7d26b322bb24bff8ec6e47dcf836515_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Share-Based Compensation - Additional Information (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails",
     "shortName": "Share-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Share-Based Compensation - Compensation Cost Related to Share-Based Compensation (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails",
     "shortName": "Share-Based Compensation - Compensation Cost Related to Share-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i5bdd80fdaea2455ba085c93bafcf958a_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Share-Based Compensation - Schedule of Share-based Compensation Expense by Award-type (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails",
     "shortName": "Share-Based Compensation - Schedule of Share-based Compensation Expense by Award-type (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "ic6946e8304b548468ab27182f7a4d25b_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if0960363045f4c3fa3cbebd5f5dd1c92_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Share-Based Compensation - Schedule of Share-based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails",
     "shortName": "Share-Based Compensation - Schedule of Share-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if0960363045f4c3fa3cbebd5f5dd1c92_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i5487fc19d1994eb39121318350a3e13a_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Statements of Stockholders' Equity",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i5487fc19d1994eb39121318350a3e13a_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "ic6946e8304b548468ab27182f7a4d25b_D20220101-20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Share-Based Compensation - Weighted-Average Assumptions for Stock Option Grants using Black-Scholes Option-Pricing Model (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails",
     "shortName": "Share-Based Compensation - Weighted-Average Assumptions for Stock Option Grants using Black-Scholes Option-Pricing Model (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "ic6946e8304b548468ab27182f7a4d25b_D20220101-20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i092dab9242464bf7bd7bddb6a8629472_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Share-Based Compensation - Summary of Activity Related to Stock Options (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails",
     "shortName": "Share-Based Compensation - Summary of Activity Related to Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i092dab9242464bf7bd7bddb6a8629472_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i60b1905034ee4ddfb0d307e7deb147c0_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Share-Based Compensation - Summary and Changes in Restricted Stock Units Outstanding (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails",
     "shortName": "Share-Based Compensation - Summary and Changes in Restricted Stock Units Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i60b1905034ee4ddfb0d307e7deb147c0_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Income Taxes - Income Before the Provision for Income Taxes from Continuing Domestic and Foreign Operations (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.neurocrine.com/role/IncomeTaxesIncomeBeforetheProvisionforIncomeTaxesfromContinuingDomesticandForeignOperationsDetails",
     "shortName": "Income Taxes - Income Before the Provision for Income Taxes from Continuing Domestic and Foreign Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Income Taxes - Components of the Provision for (Benefit from) Income Taxes for Continuing Operations (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforBenefitfromIncomeTaxesforContinuingOperationsDetails",
     "shortName": "Income Taxes - Components of the Provision for (Benefit from) Income Taxes for Continuing Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Income Taxes - Provision for Income Taxes on Earnings Subject to Income Taxes Differs from Statutory Federal Rate (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails",
     "shortName": "Income Taxes - Provision for Income Taxes on Earnings Subject to Income Taxes Differs from Statutory Federal Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i4dad9397c8114dc994a1d55e36926d3d_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Components of Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i4dad9397c8114dc994a1d55e36926d3d_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i4dad9397c8114dc994a1d55e36926d3d_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Income Taxes - Additional Information (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i4dad9397c8114dc994a1d55e36926d3d_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExaminationInterestAccrued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i092dab9242464bf7bd7bddb6a8629472_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "ie9e7a539304246b48b58f35e4a888e14_I20191231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i3cd52a694c0b4753b93edf35c2915881_D20220208-20220208",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbix:LesseeOperatingLeaseOptionTermToConstructFifthBuilding",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Leases - Narrative Information (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.neurocrine.com/role/LeasesNarrativeInformationDetails",
     "shortName": "Leases - Narrative Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i3cd52a694c0b4753b93edf35c2915881_D20220208-20220208",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbix:LesseeOperatingLeaseOptionTermToConstructFifthBuilding",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Leases - Supplemental Information (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.neurocrine.com/role/LeasesSupplementalInformationDetails",
     "shortName": "Leases - Supplemental Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i4dad9397c8114dc994a1d55e36926d3d_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - Leases - Summary of Future Minimum Lease Payments Under Operating Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails",
     "shortName": "Leases - Summary of Future Minimum Lease Payments Under Operating Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i4dad9397c8114dc994a1d55e36926d3d_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - Retirement Plan - Additional Information (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.neurocrine.com/role/RetirementPlanAdditionalInformationDetails",
     "shortName": "Retirement Plan - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "i3558292be26a40eea22ad957b4eb1826_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "nbix:UpfrontPaymentsMade",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - Subsequent Events (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.neurocrine.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "iced58b51ca3c40e3942fff0f7f450577_I20230108",
      "decimals": "-6",
      "lang": "en-US",
      "name": "nbix:UpfrontPaymentsMade",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Collaboration and License Agreements",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.neurocrine.com/role/CollaborationandLicenseAgreements",
     "shortName": "Collaboration and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20221231.htm",
      "contextRef": "if7643571a4d04563b796b60bef5361e9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 64,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r744",
      "r745",
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r744",
      "r745",
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r744",
      "r745",
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r744",
      "r745",
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r744",
      "r745",
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "nbix_AbbVieIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AbbVie Inc.",
        "label": "AbbVie Inc. [Member]",
        "terseLabel": "AbbVie Inc."
       }
      }
     },
     "localname": "AbbVieIncMember",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_AccruedBrandedPrescriptionDrugFee": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Branded Prescription Drug Fee",
        "label": "Accrued Branded Prescription Drug Fee",
        "terseLabel": "Current branded prescription drug fee"
       }
      }
     },
     "localname": "AccruedBrandedPrescriptionDrugFee",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_AccruedResearchAndDevelopmentExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expense current.",
        "label": "Accrued Research And Development Expense Current",
        "terseLabel": "Accrued development costs"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_Amended2018EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended 2018 Employee Stock Purchase Plan",
        "label": "Amended 2018 Employee Stock Purchase Plan [Member]",
        "terseLabel": "Amended 2018 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "Amended2018EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_Amended2020EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended 2020 Equity Incentive Plan",
        "label": "Amended 2020 Equity Incentive Plan [Member]",
        "terseLabel": "Amended 2020 Equity Incentive Plan"
       }
      }
     },
     "localname": "Amended2020EquityIncentivePlanMember",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_AnnualRentEscalationPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Rent Escalation Percentage",
        "label": "Annual Rent Escalation Percentage",
        "terseLabel": "Annual rent escalation percentage"
       }
      }
     },
     "localname": "AnnualRentEscalationPercentage",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesNarrativeInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nbix_AuditorInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auditor Information",
        "label": "Auditor Information [Abstract]"
       }
      }
     },
     "localname": "AuditorInformationAbstract",
     "nsuri": "http://www.neurocrine.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current",
        "terseLabel": "Unrealized gain, current"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Noncurrent",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Noncurrent",
        "terseLabel": "Unrealized gain, noncurrent"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current",
        "negatedTerseLabel": "Unrealized loss, current"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Noncurrent",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Noncurrent",
        "negatedLabel": "Unrealized loss, noncurrent"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_BIALPortelaCaSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BIAL \u2013 Portela &amp; Ca, S.A.",
        "label": "BIAL \u2013 Portela &amp; Ca, S.A. [Member]",
        "terseLabel": "BIAL \u2013 Portela &amp; Ca, S.A."
       }
      }
     },
     "localname": "BIALPortelaCaSAMember",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_BusinessAcquisitionEquityInvestmentToAcquireTheWorldwideRights": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Equity Investment To Acquire The Worldwide Rights",
        "label": "Business Acquisition, Equity Investment To Acquire The Worldwide Rights",
        "terseLabel": "Equity investment to acquire the worldwide rights"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInvestmentToAcquireTheWorldwideRights",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndOtherAccruedExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/DiurnalAcquisitionEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedattheDateofAcquisitionDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accounts Payable And Other Accrued Expenses",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accounts Payable And Other Accrued Expenses",
        "negatedTerseLabel": "Accounts payable and other accrued expenses"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndOtherAccruedExpenses",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/DiurnalAcquisitionEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedattheDateofAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsAcquiredInProcessResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/DiurnalAcquisitionEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedattheDateofAcquisitionDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Acquired In-Process Research And Development",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Acquired In-Process Research And Development",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsAcquiredInProcessResearchAndDevelopment",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/DiurnalAcquisitionEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedattheDateofAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_CarryingAmountOfLiabilityComponentAtSettlement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of the liability component at settlement.",
        "label": "Carrying Amount Of Liability Component At Settlement",
        "terseLabel": "Carrying amount of the liability component at settlement"
       }
      }
     },
     "localname": "CarryingAmountOfLiabilityComponentAtSettlement",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_CarryingAmountOfLiabilityComponentUponIssuance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of the liability component upon issuance.",
        "label": "Carrying Amount Of Liability Component Upon Issuance",
        "terseLabel": "Carrying amount of the liability component upon issuance"
       }
      }
     },
     "localname": "CarryingAmountOfLiabilityComponentUponIssuance",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_CashAndMoneyMarketFundMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions, and funds that invest in short-term money-market instruments, for example, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Cash And Money Market Fund [Member]",
        "terseLabel": "Cash and money market funds"
       }
      }
     },
     "localname": "CashAndMoneyMarketFundMember",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_CollaborationRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration revenue.",
        "label": "Collaboration Revenue [Member]",
        "terseLabel": "Collaboration revenue"
       }
      }
     },
     "localname": "CollaborationRevenueMember",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_ConversionPeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion Period One",
        "label": "Conversion Period One [Member]",
        "terseLabel": "Conversion Period One"
       }
      }
     },
     "localname": "ConversionPeriodOneMember",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_ConversionPeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion Period Two",
        "label": "Conversion Period Two [Member]",
        "terseLabel": "Conversion Period Two"
       }
      }
     },
     "localname": "ConversionPeriodTwoMember",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_DebtInstrumentConversionAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Conversion",
        "label": "Debt Instrument, Conversion [Axis]",
        "terseLabel": "Debt Instrument, Conversion [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentConversionAxis",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nbix_DebtInstrumentConversionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Conversion",
        "label": "Debt Instrument, Conversion [Domain]",
        "terseLabel": "Debt Instrument, Conversion [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentConversionDomain",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_DebtInstrumentConvertibleConversionPremium": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of excess of the price paid for the convertible note over the closing stock price on the closing date of the convertible note.",
        "label": "Debt Instrument Convertible Conversion Premium",
        "terseLabel": "Conversion premium"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPremium",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nbix_DebtInstrumentCouponInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InterestExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Coupon Interest",
        "label": "Debt Instrument, Coupon Interest",
        "terseLabel": "Coupon interest"
       }
      }
     },
     "localname": "DebtInstrumentCouponInterest",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_DebtSecuritiesAvailableForSaleFairValueCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-Sale, Fair Value, Current",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Current",
        "terseLabel": "Fair value, current"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleFairValueCurrent",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_DebtSecuritiesAvailableForSaleFairValueNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-Sale, Fair Value, Noncurrent",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Noncurrent",
        "verboseLabel": "Fair value, noncurrent"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleFairValueNoncurrent",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities available for sale position number of positions.",
        "label": "Debt Securities Available For Sale Position Number Of Positions",
        "terseLabel": "Debt securities available for sale position number of positions"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSalePositionNumberOfPositions",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development costs capitalized.",
        "label": "Deferred Tax Assets Capitalized Research And Development",
        "terseLabel": "Capitalized research and development"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopment",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_DeferredTaxAssetsLiabilitiesGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets (liabilities) gross.",
        "label": "Deferred Tax Assets Liabilities Gross",
        "totalLabel": "Net of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesGross",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_DeferredTaxAssetsOperatingLeasesAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets operating leases assets.",
        "label": "Deferred Tax Assets Operating Leases Assets",
        "terseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeasesAssets",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities convertible senior notes.",
        "label": "Deferred Tax Liabilities Convertible Senior Notes",
        "negatedTerseLabel": "Convertible senior notes"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesConvertibleSeniorNotes",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities operating leases liabilities.",
        "label": "Deferred Tax Liabilities Operating Leases Liabilities",
        "negatedTerseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOperatingLeasesLiabilities",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_DiurnalGroupPlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Diurnal Group Plc",
        "label": "Diurnal Group Plc [Member]",
        "terseLabel": "Diurnal Group Plc"
       }
      }
     },
     "localname": "DiurnalGroupPlcMember",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/DiurnalAcquisitionAdditionalInformationDetails",
      "http://www.neurocrine.com/role/DiurnalAcquisitionEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedattheDateofAcquisitionDetails",
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_ESPPPurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ESPP Purchase Period",
        "label": "ESPP Purchase Period",
        "terseLabel": "ESPP purchase period"
       }
      }
     },
     "localname": "ESPPPurchasePeriod",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nbix_EarningsPerShareBasicAndDilutedEPSAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Per Share, Basic and Diluted EPS",
        "label": "Earnings Per Share, Basic and Diluted EPS [Abstract]",
        "terseLabel": "Earnings per share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedEPSAbstract",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsPerShareScheduleofNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nbix_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Loss On Extinguishment Of Convertible Senior Notes",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Loss On Extinguishment Of Convertible Senior Notes",
        "terseLabel": "Loss on extinguishment of convertible senior notes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLossOnExtinguishmentOfConvertibleSeniorNotes",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of the liability component immediately before extinguishment.",
        "label": "Fair Value Of Liability Component Immediately Before Extinguishment",
        "terseLabel": "Fair value of the liability component immediately before extinguishment"
       }
      }
     },
     "localname": "FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_HeptaresTherapeuticsLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Heptares Therapeutics Limited",
        "label": "Heptares Therapeutics Limited [Member]",
        "terseLabel": "Heptares"
       }
      }
     },
     "localname": "HeptaresTherapeuticsLimitedMember",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_IdorsiaPharmaceuticalsLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Idorsia Pharmaceuticals Ltd",
        "label": "Idorsia Pharmaceuticals Ltd [Member]",
        "terseLabel": "Idorsia"
       }
      }
     },
     "localname": "IdorsiaPharmaceuticalsLtdMember",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_IncomeTaxReconciliationExpirationOfTaxCredits": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation, expiration of tax credits.",
        "label": "Income Tax Reconciliation Expiration Of Tax Credits",
        "terseLabel": "Expired tax attributes"
       }
      }
     },
     "localname": "IncomeTaxReconciliationExpirationOfTaxCredits",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation nondeductible expense branded prescription drug fee.",
        "label": "Income Tax Reconciliation Nondeductible Expense Branded Prescription Drug Fee",
        "terseLabel": "Branded prescription drug fee"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation nondeductible expense officer compensation cost.",
        "label": "Income Tax Reconciliation Nondeductible Expense Officer Compensation Cost",
        "terseLabel": "Officer compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes [Line Items]",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nbix_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes [Table]",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nbix_InvestmentIncomeAndOtherNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment income and other net.",
        "label": "Investment Income And Other Net",
        "terseLabel": "Investment income and other, net"
       }
      }
     },
     "localname": "InvestmentIncomeAndOtherNet",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_LargestFourCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Largest Four Customers",
        "label": "Largest Four Customers [Member]",
        "terseLabel": "Largest four customers"
       }
      }
     },
     "localname": "LargestFourCustomersMember",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease Monthly Base Rent Per Square Foot",
        "label": "Lessee Operating Lease Monthly Base Rent Per Square Foot",
        "terseLabel": "Monthly base rent per square foot"
       }
      }
     },
     "localname": "LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesNarrativeInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of term of lessee's option for the construction of a fifth building under operating lease.",
        "label": "Lessee Operating Lease Option Term To Construct Fifth Building",
        "terseLabel": "Lessee option term for construction of fifth building"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionTermToConstructFifthBuilding",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesNarrativeInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nbix_MilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments made for milestones under a collaboration agreement.",
        "label": "Milestone Payment",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "MilestonePayment",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum percentage of the product of the common stock trading price multiplied by the conversion rate during the measurement period as compared to the principal note amount that triggers a conversion option on the notes, if it falls below this percentage.",
        "label": "Minimum Percentage Of Trading Price To Last Reported Sale Price",
        "terseLabel": "Minimum percentage of common stock price trigger"
       }
      }
     },
     "localname": "MinimumPercentageOfTradingPriceToLastReportedSalePrice",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nbix_MitsubishiTanabePharmaCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the Mitsubishi Tanabe Pharma Corporation.",
        "label": "Mitsubishi Tanabe Pharma Corporation [Member]",
        "terseLabel": "MTPC"
       }
      }
     },
     "localname": "MitsubishiTanabePharmaCorporationMember",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Five",
        "label": "Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Five",
        "terseLabel": "Non-cancelable future minimum lease payments under operating leases not yet commenced for thereafter"
       }
      }
     },
     "localname": "NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Four",
        "label": "Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Four",
        "terseLabel": "Non-cancelable future minimum lease payments under operating leases not yet commenced for 2026"
       }
      }
     },
     "localname": "NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Three",
        "label": "Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Three",
        "terseLabel": "Non-cancelable future minimum lease payments under operating leases not yet commenced for 2025"
       }
      }
     },
     "localname": "NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Two",
        "label": "Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Two",
        "terseLabel": "Non-cancelable future minimum lease payments under operating leases not yet commenced for 2024"
       }
      }
     },
     "localname": "NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_NumberOfRenewalOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of renewal options under the terms of the lease.",
        "label": "Number Of Renewal Options",
        "terseLabel": "Number of lease renewal options"
       }
      }
     },
     "localname": "NumberOfRenewalOptions",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesNarrativeInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nbix_OrganizationAndBusinesDescriptionPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Description Policy [Text Block]",
        "label": "Organization And Busines Description Policy [Policy Text Block]",
        "terseLabel": "Organization and Business"
       }
      }
     },
     "localname": "OrganizationAndBusinesDescriptionPolicyPolicyTextBlock",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and summary of significant accounting policies.",
        "label": "Organization And Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Summary Of Significant Accounting Policies [Table]",
        "label": "Organization And Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nbix_OtherBalanceSheetDetailsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other balance sheet details.",
        "label": "Other Balance Sheet Details [Abstract]",
        "terseLabel": "Other Balance Sheet Details [Abstract]"
       }
      }
     },
     "localname": "OtherBalanceSheetDetailsAbstract",
     "nsuri": "http://www.neurocrine.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nbix_PatentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of the patent, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Patent term",
        "terseLabel": "Patent term"
       }
      }
     },
     "localname": "PatentTerm",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nbix_PerformanceBasedRestrictedStockUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock units which are awarded to employees after certain performance targets are met.",
        "label": "Performance Based Restricted Stock Unit [Member]",
        "terseLabel": "PRSUs"
       }
      }
     },
     "localname": "PerformanceBasedRestrictedStockUnitMember",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_PotentialMilestonePaymentReceipts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential later stage milestone payments and royalties.",
        "label": "Potential Milestone Payment Receipts",
        "terseLabel": "Potential milestone payment receipts"
       }
      }
     },
     "localname": "PotentialMilestonePaymentReceipts",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_PotentialMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of potential milestone payments to be paid under a license agreement.",
        "label": "Potential Milestone Payments",
        "terseLabel": "Potential milestone payments"
       }
      }
     },
     "localname": "PotentialMilestonePayments",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_PrincipalAmountOnConversionRate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Principal amount on conversion rate.",
        "label": "Principal Amount On Conversion Rate",
        "terseLabel": "Principal amount on conversion rate"
       }
      }
     },
     "localname": "PrincipalAmountOnConversionRate",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_RentAbatementPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rent Abatement Period",
        "label": "Rent Abatement Period",
        "terseLabel": "Rent abatement period"
       }
      }
     },
     "localname": "RentAbatementPeriod",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesNarrativeInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nbix_RevenueRelatedReservesForDiscountsAndAllowances": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue-related reserves for discounts and allowances.",
        "label": "Revenue Related Reserves For Discounts And Allowances",
        "terseLabel": "Revenue-related reserves for discounts and allowances"
       }
      }
     },
     "localname": "RevenueRelatedReservesForDiscountsAndAllowances",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_SaleOfStockNumberOfSharesSoldInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares sold by the collaboration partner per stock transaction.",
        "label": "Sale of Stock, Number of Shares Sold in Transaction",
        "terseLabel": "Sale of stock (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesSoldInTransaction",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nbix_ScientificEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scientific equipment.",
        "label": "Scientific Equipment [Member]",
        "terseLabel": "Scientific equipment"
       }
      }
     },
     "localname": "ScientificEquipmentMember",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the 2.25% Convertible Senior Notes Due in May 2024.",
        "label": "Senior Convertible Notes Two Point Two Five Percent Due In May Two Thousand Twenty Four [Member]",
        "terseLabel": "2.25% Convertible senior notes due 2024"
       }
      }
     },
     "localname": "SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Increased By Returning Shares Subject To An Award",
        "label": "Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Increased By Returning Shares Subject To An Award",
        "terseLabel": "Number of shares increased returning shares subject to any full value award (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAnAward",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Increased By Returning Shares Subject To Appreciation Award",
        "label": "Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Increased By Returning Shares Subject To Appreciation Award",
        "terseLabel": "Number of shares increased by returning shares subject to appreciation award (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreasedByReturningSharesSubjectToAppreciationAward",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Reduced Pursuant To Appreciation Award",
        "label": "Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Reduced Pursuant To Appreciation Award",
        "terseLabel": "Number of shares reduced pursuant to appreciation award (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAppreciationAward",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Reduced Pursuant To Award Granted",
        "label": "Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Reduced Pursuant To Award Granted",
        "terseLabel": "Number of shares reduced pursuant to any full value award granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReducedPursuantToAwardGranted",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options, restricted stock and convertible senior notes.",
        "label": "Stock Options Restricted Stock And Convertible Senior Notes [Member]",
        "terseLabel": "Stock options restricted stock and convertible senior notes"
       }
      }
     },
     "localname": "StockOptionsRestrictedStockAndConvertibleSeniorNotesMember",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsPerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of reconciliation of cash cash equivalents and restricted cash.",
        "label": "Summary Of Reconciliation Of Cash Cash Equivalents And Restricted Cash [Table Text Block]",
        "terseLabel": "Reconciliation of Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nbix_TakedaPharmaceuticalCompanyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Takeda Pharmaceutical Company Limited",
        "label": "Takeda Pharmaceutical Company Limited [Member]",
        "terseLabel": "Takeda"
       }
      }
     },
     "localname": "TakedaPharmaceuticalCompanyLimitedMember",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_TwoThousandAndElevenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand And Eleven Equity Incentive Plan [Member].",
        "label": "Two Thousand And Eleven Equity Incentive Plan [Member]",
        "terseLabel": "2011 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandAndElevenEquityIncentivePlanMember",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_UpfrontPaymentsMade": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payments made under a collaboration agreement.",
        "label": "Upfront Payments Made",
        "terseLabel": "Upfront payments made"
       }
      }
     },
     "localname": "UpfrontPaymentsMade",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_VoyagerTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Voyager therapeutics.",
        "label": "Voyager Therapeutics [Member]",
        "terseLabel": "Voyager"
       }
      }
     },
     "localname": "VoyagerTherapeuticsMember",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_XenonPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xenon Pharmaceuticals Inc",
        "label": "Xenon Pharmaceuticals Inc [Member]",
        "terseLabel": "Xenon"
       }
      }
     },
     "localname": "XenonPharmaceuticalsIncMember",
     "nsuri": "http://www.neurocrine.com/20221231",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r241",
      "r242",
      "r392",
      "r417",
      "r703",
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r195",
      "r247",
      "r254",
      "r260",
      "r320",
      "r489",
      "r490",
      "r491",
      "r523",
      "r524",
      "r554",
      "r557",
      "r559",
      "r560",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r195",
      "r247",
      "r254",
      "r260",
      "r320",
      "r489",
      "r490",
      "r491",
      "r523",
      "r524",
      "r554",
      "r557",
      "r559",
      "r560",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r195",
      "r247",
      "r254",
      "r260",
      "r320",
      "r489",
      "r490",
      "r491",
      "r523",
      "r524",
      "r554",
      "r557",
      "r559",
      "r560",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r304",
      "r722",
      "r798",
      "r854"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r376",
      "r377",
      "r378",
      "r379",
      "r448",
      "r654",
      "r674",
      "r695",
      "r696",
      "r720",
      "r728",
      "r736",
      "r796",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r376",
      "r377",
      "r378",
      "r379",
      "r448",
      "r654",
      "r674",
      "r695",
      "r696",
      "r720",
      "r728",
      "r736",
      "r796",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r304",
      "r722",
      "r798",
      "r854"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r302",
      "r656",
      "r721",
      "r735",
      "r791",
      "r792",
      "r798",
      "r853"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r302",
      "r656",
      "r721",
      "r735",
      "r791",
      "r792",
      "r798",
      "r853"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r376",
      "r377",
      "r378",
      "r379",
      "r431",
      "r448",
      "r480",
      "r481",
      "r482",
      "r629",
      "r654",
      "r674",
      "r695",
      "r696",
      "r720",
      "r728",
      "r736",
      "r790",
      "r796",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r376",
      "r377",
      "r378",
      "r379",
      "r431",
      "r448",
      "r480",
      "r481",
      "r482",
      "r629",
      "r654",
      "r674",
      "r695",
      "r696",
      "r720",
      "r728",
      "r736",
      "r790",
      "r796",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r241",
      "r242",
      "r392",
      "r417",
      "r704",
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate202006Member": {
     "auth_ref": [
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity.",
        "label": "Accounting Standards Update 2020-06 [Member]",
        "terseLabel": "Accounting Standards Update 2020-06"
       }
      }
     },
     "localname": "AccountingStandardsUpdate202006Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r248",
      "r249",
      "r250",
      "r307",
      "r308",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r489",
      "r490",
      "r491",
      "r523",
      "r524",
      "r538",
      "r539",
      "r540",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r593",
      "r594",
      "r598",
      "r599",
      "r600",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r764"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "terseLabel": "Accounting Standards Update [Extensible List]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued liabilities",
        "totalLabel": "Total accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and other accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r305",
      "r306"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r96",
      "r204"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r209",
      "r668",
      "r682",
      "r686"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r25",
      "r28",
      "r147",
      "r619",
      "r677",
      "r678",
      "r752",
      "r753",
      "r754",
      "r761",
      "r762",
      "r763"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r8",
      "r734"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "negatedTerseLabel": "Additional paid in capital",
        "terseLabel": "Additional paid in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r8"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r489",
      "r490",
      "r491",
      "r761",
      "r762",
      "r763",
      "r837"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r248",
      "r249",
      "r250",
      "r251",
      "r260",
      "r307",
      "r308",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r489",
      "r490",
      "r491",
      "r521",
      "r522",
      "r523",
      "r524",
      "r538",
      "r539",
      "r540",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r593",
      "r594",
      "r598",
      "r599",
      "r600",
      "r601",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r658",
      "r659",
      "r660",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of subsequent adjustments to additional paid in capital for convertible financial instruments where a component of equity and a component of debt are recognized.",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments",
        "negatedTerseLabel": "Equity component of repurchased convertible senior notes, net",
        "verboseLabel": "Equity component of repurchased convertible senior notes"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r122",
      "r123",
      "r451"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash from operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising Expense"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r495"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r484"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r38",
      "r49",
      "r157",
      "r411"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r33",
      "r411",
      "r596",
      "r756"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r411",
      "r596",
      "r718",
      "r719",
      "r756"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InterestExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discount and issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r49",
      "r81",
      "r89"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Anti-dilutive shares excluded from diluted per share amounts (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsPerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsPerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsPerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsPerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r165",
      "r183",
      "r208",
      "r237",
      "r293",
      "r296",
      "r300",
      "r316",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r546",
      "r548",
      "r574",
      "r734",
      "r794",
      "r795",
      "r843"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r199",
      "r213",
      "r237",
      "r316",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r546",
      "r548",
      "r574",
      "r734",
      "r794",
      "r795",
      "r843"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r148"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Fair value of assets on recurring basis"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r70",
      "r340"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Debt securities available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r455",
      "r456",
      "r457",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r536",
      "r726",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DiurnalAcquisitionAdditionalInformationDetails",
      "http://www.neurocrine.com/role/DiurnalAcquisitionEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedattheDateofAcquisitionDetails",
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r134",
      "r135",
      "r536",
      "r726",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DiurnalAcquisitionAdditionalInformationDetails",
      "http://www.neurocrine.com/role/DiurnalAcquisitionEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedattheDateofAcquisitionDetails",
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DiurnalAcquisitionAdditionalInformationDetails",
      "http://www.neurocrine.com/role/DiurnalAcquisitionEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedattheDateofAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r133"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Acquisition related costs"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DiurnalAcquisitionAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r139",
      "r140",
      "r141"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DiurnalAcquisitionEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedattheDateofAcquisitionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Aggregate purchase price",
        "totalLabel": "Total consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DiurnalAcquisitionAdditionalInformationDetails",
      "http://www.neurocrine.com/role/DiurnalAcquisitionEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedattheDateofAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Consideration Transferred [Abstract]",
        "terseLabel": "Consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DiurnalAcquisitionEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedattheDateofAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r142",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Diurnal Acquisition"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DiurnalAcquisition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DiurnalAcquisitionEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedattheDateofAcquisitionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "totalLabel": "Total identifiable net assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DiurnalAcquisitionEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedattheDateofAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DiurnalAcquisitionEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedattheDateofAcquisitionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DiurnalAcquisitionEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedattheDateofAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets [Abstract]",
        "terseLabel": "Recognized amounts of identifiable assets acquired and liabilities assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DiurnalAcquisitionEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedattheDateofAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DiurnalAcquisitionEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedattheDateofAcquisitionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DiurnalAcquisitionEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedattheDateofAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DiurnalAcquisitionEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedattheDateofAcquisitionDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DiurnalAcquisitionEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedattheDateofAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations and Asset Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r58",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Organization and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r54",
      "r55",
      "r56"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Non-cash capital expenditures"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r51",
      "r202",
      "r698"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RestrictedCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r45",
      "r51",
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash and cash equivalents and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r45",
      "r156"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Change in cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r542",
      "r543",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration and License Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollateralAxis": {
     "auth_ref": [
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of collateral or no collateral, from lender's perspective.",
        "label": "Collateral Held [Axis]",
        "terseLabel": "Collateral Held [Axis]"
       }
      }
     },
     "localname": "CollateralAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollateralDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Category of collateral or no collateral, from lender's perspective.",
        "label": "Collateral Held [Domain]",
        "terseLabel": "Collateral Held [Domain]"
       }
      }
     },
     "localname": "CollateralDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r98",
      "r374",
      "r375",
      "r692",
      "r793"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "Legal Proceedings"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LegalProceedings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r761",
      "r762",
      "r837"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r7",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r7",
      "r734"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 220.0 million shares authorized; 96.5 million and 94.9 million shares issued and outstanding, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r29",
      "r219",
      "r221",
      "r228",
      "r664",
      "r670"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r62",
      "r63",
      "r154",
      "r155",
      "r304",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r62",
      "r63",
      "r154",
      "r155",
      "r304",
      "r687",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r62",
      "r63",
      "r154",
      "r155",
      "r304",
      "r691",
      "r856"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r179",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r62",
      "r63",
      "r154",
      "r155",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r62",
      "r63",
      "r154",
      "r155",
      "r304",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r145",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertibleDebtCurrent": {
     "auth_ref": [
      "r1"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Convertible Debt, Current",
        "terseLabel": "Net Carrying Amount",
        "verboseLabel": "Convertible senior notes"
       }
      }
     },
     "localname": "ConvertibleDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Convertible Debt, Noncurrent",
        "terseLabel": "Convertible senior notes",
        "verboseLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "ConvertibleDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r723",
      "r725",
      "r855"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r35",
      "r656"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of revenues"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r800"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Revenues"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSupplementalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSupplementalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditLossFinancialInstrumentPolicyTextBlock": {
     "auth_ref": [
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r329",
      "r331",
      "r332",
      "r333",
      "r334",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341",
      "r342",
      "r343",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status.",
        "label": "Credit Loss, Financial Instrument [Policy Text Block]",
        "terseLabel": "Allowance for Credit Losses"
       }
      }
     },
     "localname": "CreditLossFinancialInstrumentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforBenefitfromIncomeTaxesforContinuingOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r759",
      "r833",
      "r835"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforBenefitfromIncomeTaxesforContinuingOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforBenefitfromIncomeTaxesforContinuingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r131",
      "r518",
      "r528",
      "r759"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforBenefitfromIncomeTaxesforContinuingOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current taxes"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforBenefitfromIncomeTaxesforContinuingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r759",
      "r833",
      "r835"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforBenefitfromIncomeTaxesforContinuingOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforBenefitfromIncomeTaxesforContinuingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r61",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r104",
      "r236",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r405",
      "r412",
      "r413",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Convertible Senior Notes"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r166",
      "r168",
      "r181",
      "r243",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r395",
      "r401",
      "r402",
      "r403",
      "r404",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r597",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r757"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.",
        "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component",
        "terseLabel": "Carrying amount of the equity component upon issuance"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r101",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price (in USD per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r21",
      "r106",
      "r107",
      "r109",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Conversion ratio"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of the entity's common stock which would be required to be attained for the conversion feature embedded in the debt instrument to become effective.",
        "label": "Debt Instrument, Convertible, Stock Price Trigger",
        "terseLabel": "Common stock price trigger (in USD per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Threshold consecutive common stock trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Threshold percentage of common stock price trigger"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Threshold common stock trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r158",
      "r161",
      "r389",
      "r597",
      "r716",
      "r717"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "verboseLabel": "Principal Amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r403",
      "r573",
      "r716",
      "r717"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "verboseLabel": "Fair Value, Amount"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r20",
      "r158",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Assumed borrowing rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r20",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMeasurementInput": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.",
        "label": "Debt Instrument, Measurement Input",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "DebtInstrumentMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r22",
      "r243",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r395",
      "r401",
      "r402",
      "r403",
      "r404",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r597",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r757"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of principal amount of debt redeemed.",
        "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed",
        "terseLabel": "Redemption rate"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRepurchasedFaceAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of the original debt instrument that was repurchased.",
        "label": "Debt Instrument, Repurchased Face Amount",
        "terseLabel": "Aggregate principal amount repurchased"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasedFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r22",
      "r106",
      "r108",
      "r109",
      "r110",
      "r157",
      "r158",
      "r161",
      "r178",
      "r243",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r395",
      "r401",
      "r402",
      "r403",
      "r404",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r414",
      "r597",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r757"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Convertible senior notes term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": {
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r797"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount (premium).",
        "label": "Debt Instrument, Unamortized Discount (Premium), Net",
        "negatedTerseLabel": "Unamortized Debt, Discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period when accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), is considered uncollectible and written off, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Debt Securities, Available-for-Sale, Accrued Interest, Threshold Period, Writeoff",
        "terseLabel": "Accrued interest receivables write-off threshold period"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff": {
     "auth_ref": [
      "r343"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of writeoff of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized by reversing interest income.",
        "label": "Debt Securities, Available-for-Sale, Accrued Interest Writeoff",
        "terseLabel": "Accrued interest receivables write-off"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccruedInterestWriteoff",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": {
     "auth_ref": [
      "r340",
      "r772"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Current",
        "totalLabel": "Amortized cost, current"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent": {
     "auth_ref": [
      "r340",
      "r772"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent",
        "totalLabel": "Amortized cost, noncurrent"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r315",
      "r348",
      "r713"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "12 Months or Longer, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r315",
      "r348"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedTerseLabel": "12 Months or Longer, Unrealized Loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r315",
      "r348",
      "r713"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Less Than 12 Months, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r315",
      "r348"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedLabel": "Less Than 12 Months, Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r312",
      "r344",
      "r713"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "totalLabel": "Total Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r313",
      "r345"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTotalLabel": "Total Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r311",
      "r713",
      "r778"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Gross unrealized losses and fair value available-for-sale investments in unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r314",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of debt securities available-for-sale in an unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r759",
      "r834",
      "r835"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforBenefitfromIncomeTaxesforContinuingOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforBenefitfromIncomeTaxesforContinuingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforBenefitfromIncomeTaxesforContinuingOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r159"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Transaction cost related to issuance of convertible senior note"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r159",
      "r797"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedLabel": "Unamortized Debt, Issuance Costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r500",
      "r501"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r49",
      "r131",
      "r519",
      "r527",
      "r528",
      "r759"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforBenefitfromIncomeTaxesforContinuingOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforBenefitfromIncomeTaxesforContinuingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r4",
      "r5",
      "r167",
      "r180",
      "r513"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "nbix_DeferredTaxAssetsLiabilitiesGross",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r500",
      "r501"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "negatedTerseLabel": "Deferred tax liabilities",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes and Tax Credits",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r759",
      "r834",
      "r835"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforBenefitfromIncomeTaxesforContinuingOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforBenefitfromIncomeTaxesforContinuingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r514"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "nbix_DeferredTaxAssetsLiabilitiesGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r831"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "terseLabel": "Deferred tax assets",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r129",
      "r832"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r129",
      "r832"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r128",
      "r129",
      "r832"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development credits",
        "verboseLabel": "Research and development tax credit carry forwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "auth_ref": [
      "r129",
      "r832"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r515"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance",
        "terseLabel": "Deferred tax assets, valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r129",
      "r832"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r447"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Defined contribution plan, employer contribution amount"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/RetirementPlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Defined contribution plan, maximum employee contribution percentage"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/RetirementPlanAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r49",
      "r94"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed product rights"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r454",
      "r485",
      "r486",
      "r488",
      "r493",
      "r729"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r229",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r261",
      "r264",
      "r274",
      "r275",
      "r276",
      "r280",
      "r560",
      "r561",
      "r665",
      "r671",
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Earnings per share, basic (in USD per share)",
        "verboseLabel": "Basic (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/EarningsPerShareScheduleofNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r229",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r264",
      "r274",
      "r275",
      "r276",
      "r280",
      "r560",
      "r561",
      "r665",
      "r671",
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Earnings per share, diluted (in USD per share)",
        "verboseLabel": "Diluted (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/EarningsPerShareScheduleofNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r59",
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Income Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r583"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r239",
      "r503",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal income taxes, rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued employee related costs"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r487"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized Expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-Average Recognition Period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r105",
      "r195",
      "r223",
      "r224",
      "r225",
      "r244",
      "r245",
      "r246",
      "r249",
      "r257",
      "r259",
      "r283",
      "r320",
      "r419",
      "r489",
      "r490",
      "r491",
      "r523",
      "r524",
      "r559",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r590",
      "r619",
      "r677",
      "r678",
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue": {
     "auth_ref": [
      "r572"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI) and investment in equity security without readily determinable fair value.",
        "label": "Equity Securities, FV-NI and without Readily Determinable Fair Value",
        "terseLabel": "Equity securities purchase date fair value amount"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.",
        "label": "Equity Securities, FV-NI, Cost",
        "terseLabel": "Equity securities cost"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiRestricted": {
     "auth_ref": [
      "r637",
      "r688",
      "r690"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of restricted investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Restricted",
        "periodEndLabel": "Balance at ending of period",
        "periodStartLabel": "Balance at beginning of period",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiRestricted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r672",
      "r776"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      },
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "negatedLabel": "Change in fair value of equity securities",
        "terseLabel": "Unrealized gain (loss) on equity securities",
        "verboseLabel": "Unrealized gain (loss) included in earnings"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r77",
      "r182",
      "r737",
      "r738",
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Equity securities\u2013biotechnology industry"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r563",
      "r564",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r148",
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Investments measured at fair value on recurring basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r150",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of equity securities measured at fair value on recurring basis using significant unobservable inputs"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r403",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r564",
      "r626",
      "r627",
      "r628",
      "r716",
      "r717",
      "r723",
      "r724",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r563",
      "r564",
      "r566",
      "r567",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r403",
      "r433",
      "r438",
      "r564",
      "r626",
      "r723",
      "r724",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r403",
      "r433",
      "r438",
      "r564",
      "r627",
      "r716",
      "r717",
      "r723",
      "r724",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r403",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r564",
      "r628",
      "r716",
      "r717",
      "r723",
      "r724",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": {
     "auth_ref": [
      "r568"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3",
        "negatedTerseLabel": "Transfers out of Level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r403",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r626",
      "r627",
      "r628",
      "r716",
      "r717",
      "r723",
      "r724",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r569",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair value measurements recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r152",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r309",
      "r310",
      "r327",
      "r328",
      "r329",
      "r330",
      "r335",
      "r347",
      "r349",
      "r350",
      "r414",
      "r418",
      "r550",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r713",
      "r773",
      "r774",
      "r775",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Useful Life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r206",
      "r369"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsEstimatedAnnualAmortizationExpenseforFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Year ending December 31, 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsEstimatedAnnualAmortizationExpenseforFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "Year ending December 31, 2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsEstimatedAnnualAmortizationExpenseforFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "Year ending December 31, 2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsEstimatedAnnualAmortizationExpenseforFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "Year ending December 31, 2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsEstimatedAnnualAmortizationExpenseforFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "Year ending December 31, 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsEstimatedAnnualAmortizationExpenseforFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r366",
      "r368",
      "r369",
      "r371",
      "r657",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r88",
      "r661"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r82",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r88",
      "r657"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign tax authority"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r49",
      "r102",
      "r103"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      },
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss on extinguishment of convertible senior notes",
        "terseLabel": "Loss on extinguishment of convertible senior notes"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r205",
      "r354",
      "r662",
      "r714",
      "r734",
      "r779",
      "r786"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, at ending period",
        "periodStartLabel": "Goodwill, at beginning period",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DiurnalAcquisitionEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedattheDateofAcquisitionDetails",
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r356",
      "r714"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill recognized in connection with business combination"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r79",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill, Intangible Assets and Other Long-Lived Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r360"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "Acquired IPR&amp;D"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r238",
      "r529"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesIncomeBeforetheProvisionforIncomeTaxesfromContinuingDomesticandForeignOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesIncomeBeforetheProvisionforIncomeTaxesfromContinuingDomesticandForeignOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r31",
      "r162",
      "r170",
      "r190",
      "r293",
      "r295",
      "r299",
      "r301",
      "r666",
      "r711"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.neurocrine.com/role/IncomeTaxesIncomeBeforetheProvisionforIncomeTaxesfromContinuingDomesticandForeignOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before provision for (benefit from) income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/IncomeTaxesIncomeBeforetheProvisionforIncomeTaxesfromContinuingDomesticandForeignOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r238",
      "r529"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesIncomeBeforetheProvisionforIncomeTaxesfromContinuingDomesticandForeignOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesIncomeBeforetheProvisionforIncomeTaxesfromContinuingDomesticandForeignOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r239",
      "r504",
      "r511",
      "r517",
      "r525",
      "r531",
      "r533",
      "r534",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationInterestAccrued": {
     "auth_ref": [
      "r829"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of estimated interest accrued as of the balance sheet date arising from income tax examinations.",
        "label": "Income Tax Examination, Interest Accrued",
        "terseLabel": "Interest accrued"
       }
      }
     },
     "localname": "IncomeTaxExaminationInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAccrued": {
     "auth_ref": [
      "r829"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of estimated penalties accrued as of the balance sheet date arising from income tax examinations.",
        "label": "Income Tax Examination, Penalties Accrued",
        "terseLabel": "Penalties accrued"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r240",
      "r258",
      "r259",
      "r292",
      "r502",
      "r526",
      "r532",
      "r673"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforBenefitfromIncomeTaxesforContinuingOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for (benefit from) income taxes",
        "totalLabel": "Provision for (benefit from) income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/IncomeTaxesComponentsoftheProvisionforBenefitfromIncomeTaxesforContinuingOperationsDetails",
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r222",
      "r498",
      "r499",
      "r511",
      "r512",
      "r516",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r828"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r497",
      "r503"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "terseLabel": "Change in tax rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r503"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Federal income taxes at 21%"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r828"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r828"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r828"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State income tax, net of federal benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r828"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "Research credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r46",
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current operating assets after deduction of current operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Current Assets and Liabilities, Net",
        "negatedLabel": "Other assets and liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r265",
      "r266",
      "r267",
      "r276",
      "r453"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/EarningsPerShareScheduleofNetIncomeLossPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Effect of dilutive securities (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsPerShareScheduleofNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r367",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-Lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r83",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r80",
      "r86"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Total intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r159",
      "r172",
      "r226",
      "r291",
      "r595"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      },
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "totalLabel": "Interest Expense, Total"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r232",
      "r234",
      "r235"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r750"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest Receivable, Current",
        "terseLabel": "Accrued interest receivables"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Federal tax authority"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r78",
      "r700"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r211",
      "r699",
      "r734"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r201",
      "r210",
      "r282",
      "r351",
      "r352",
      "r353",
      "r655",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r78",
      "r702"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r78",
      "r701"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Investments": {
     "auth_ref": [
      "r188"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.",
        "label": "Investments",
        "verboseLabel": "Fair value"
       }
      }
     },
     "localname": "Investments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r77",
      "r163",
      "r176",
      "r191",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Debt Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r841"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of supplemental operating lease information"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Tenant improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Leases [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSupplementalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Leases [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSupplementalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r842"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of minimum lease payments for operating lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r612"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r612"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r612"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "Year ending December 31, 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r612"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "Year ending December 31, 2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r612"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "Year ending December 31, 2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r612"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "Year ending December 31, 2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r612"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "Year ending December 31, 2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r612"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "verboseLabel": "Less accreted interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r840"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesNarrativeInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r840"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesNarrativeInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSupplementalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r17",
      "r237",
      "r316",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r547",
      "r548",
      "r549",
      "r574",
      "r710",
      "r794",
      "r843",
      "r844"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r12",
      "r169",
      "r186",
      "r734",
      "r758",
      "r777",
      "r839"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r19",
      "r200",
      "r237",
      "r316",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r547",
      "r548",
      "r549",
      "r574",
      "r734",
      "r794",
      "r843",
      "r844"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Debt securities available-for-sale"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Debt Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r838"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r233"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r233"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r45",
      "r47",
      "r50"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r32",
      "r50",
      "r171",
      "r189",
      "r198",
      "r217",
      "r220",
      "r225",
      "r237",
      "r248",
      "r252",
      "r253",
      "r254",
      "r255",
      "r258",
      "r259",
      "r272",
      "r293",
      "r295",
      "r299",
      "r301",
      "r316",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r561",
      "r574",
      "r711",
      "r794"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r261",
      "r262",
      "r273",
      "r276",
      "r293",
      "r295",
      "r299",
      "r301",
      "r711"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net income - basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsPerShareScheduleofNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r263",
      "r268",
      "r269",
      "r270",
      "r271",
      "r273",
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Net income - diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsPerShareScheduleofNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted and Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other expense, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other (expense) income:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r767"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r767"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r293",
      "r295",
      "r299",
      "r301",
      "r711"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r607",
      "r733"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSupplementalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r603"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r603"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Less current operating lease liabilities included in other current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r603"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Noncurrent operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r605",
      "r608"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSupplementalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r602"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r611",
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSupplementalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r610",
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSupplementalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r128"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carry forward, net"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r212",
      "r734"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r207"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent": {
     "auth_ref": [
      "r143",
      "r144",
      "r146"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent",
        "negatedTerseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r214",
      "r215",
      "r216"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized (loss) gain on debt securities available-for-sale, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r30",
      "r105",
      "r218",
      "r221",
      "r227",
      "r584",
      "r589",
      "r590",
      "r663",
      "r669",
      "r752",
      "r753"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r18",
      "r734"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]",
        "terseLabel": "Patents"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r39",
      "r69",
      "r230"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedLabel": "Purchases of debt securities available-for-sale"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r40",
      "r541"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DiurnalAcquisitionEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedattheDateofAcquisitionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DiurnalAcquisitionEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedattheDateofAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisition of business, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireRestrictedInvestments": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.",
        "label": "Payments to Acquire Restricted Investments",
        "negatedLabel": "Purchases of equity securities",
        "terseLabel": "Purchases"
       }
      }
     },
     "localname": "PaymentsToAcquireRestrictedInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r431",
      "r432",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r449",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Retirement Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/RetirementPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r6",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in USD per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r6",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r6",
      "r734"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 5.0 million shares authorized; no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Issuances of common stock under benefit plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r69",
      "r230",
      "r231"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "terseLabel": "Sales and maturities of debt securities available-for-sale"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r43",
      "r120"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Cash received from stock option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r95",
      "r203"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r97",
      "r187",
      "r667",
      "r734"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r97",
      "r693",
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, plant and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r768",
      "r769",
      "r770",
      "r771"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Repayments of Convertible Debt",
        "negatedTerseLabel": "Repurchases of convertible senior notes"
       }
      }
     },
     "localname": "RepaymentsOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r755"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "terseLabel": "Aggregate repurchase price paid in cash"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.",
        "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r124",
      "r192",
      "r851"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r51",
      "r57",
      "r164",
      "r184",
      "r202"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r51",
      "r57",
      "r689"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_RestrictedCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash related to letters of credit issued in lieu of cash security deposits",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSupplementalInformationDetails",
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r9",
      "r111",
      "r185",
      "r681",
      "r686",
      "r734"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r195",
      "r244",
      "r245",
      "r246",
      "r249",
      "r257",
      "r259",
      "r320",
      "r489",
      "r490",
      "r491",
      "r523",
      "r524",
      "r559",
      "r677",
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r289",
      "r290",
      "r294",
      "r297",
      "r298",
      "r302",
      "r303",
      "r304",
      "r428",
      "r429",
      "r656"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r430",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r609",
      "r733"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets acquired through operating leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r799"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueProductLineMember": {
     "auth_ref": [
      "r766"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from specified product or service, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources.",
        "label": "Revenue, Product and Service Benchmark [Member]",
        "terseLabel": "Revenue, Product and Service Benchmark"
       }
      }
     },
     "localname": "SalesRevenueProductLineMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Accounts Payable and Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsPerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Amortized cost, gross unrealized gain (loss) positions and estimated fair value for available-for-sale debt securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r71",
      "r72",
      "r73",
      "r74",
      "r75",
      "r76",
      "r173",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-Sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r134",
      "r135",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DiurnalAcquisitionAdditionalInformationDetails",
      "http://www.neurocrine.com/role/DiurnalAcquisitionEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesAssumedattheDateofAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r836"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Components of the Provision for (Benefit from) Income Taxes for Continuing Operations"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r22",
      "r106",
      "r108",
      "r109",
      "r110",
      "r157",
      "r158",
      "r161",
      "r178",
      "r716",
      "r718",
      "r760"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Convertible senior notes net of discounts and deferred financing costs"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Components of deferred tax assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Net Income Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Provision for (benefit from) income taxes on earnings subject to income taxes differs from statutory federal rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r118",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Share based compensation"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r82",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Information Relating to our Recognized Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsIntangibleAssetsAmortizedOverEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r714",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of the Carrying Amount of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Income Before the Provision for Income Taxes from Continuing Domestic and Foreign Operations"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r91",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Information Relating to our Recognized Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r0",
      "r13",
      "r14",
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Estimated Fair Values of the Assets Acquired and Liabilities Assumed at the Date of Acquisition"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DiurnalAcquisitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r450",
      "r452",
      "r455",
      "r456",
      "r457",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary and changes in restricted stock units outstanding"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r112",
      "r113",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary and changes in stock options outstanding"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Weighted-average assumptions for stock option grants using black-scholes option-pricing model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r732",
      "r830"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Activity related to unrecognized tax benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Estimated Annual Amortization Expense for our Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative expense"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r729"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, award requisite service period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r729"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Canceled (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending Balance, Unvested (in shares)",
        "periodStartLabel": "Beginning Balance, Unvested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending Balance, Unvested (in USD per share)",
        "periodStartLabel": "Beginning Balance, Unvested (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Unvested, weighted average remaining contractual term (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Released (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r474"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "verboseLabel": "Total fair value of PRSUs vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Released (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility of common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of common stock authorized for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for future grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual Term and Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r474"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Stock options exercised in period intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair values of stock options granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending Balance, Outstanding (in shares)",
        "periodStartLabel": "Beginning Balance, Outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Stock Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending Balance, Outstanding (in USD per share)",
        "periodStartLabel": "Beginning Balance, Outstanding (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r476"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r475"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r455",
      "r456",
      "r457",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r458",
      "r477",
      "r478",
      "r479",
      "r480",
      "r483",
      "r492",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price (in USD per share)",
        "verboseLabel": "Market price of common stock (in USD per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested",
        "terseLabel": "Unvested, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "terseLabel": "Total intrinsic value vested in period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r730"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Contractual term of stock options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected option term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Discounted purchase price percentage of common stock authorized for issuance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and local jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r24",
      "r105",
      "r195",
      "r223",
      "r224",
      "r225",
      "r244",
      "r245",
      "r246",
      "r249",
      "r257",
      "r259",
      "r283",
      "r320",
      "r419",
      "r489",
      "r490",
      "r491",
      "r523",
      "r524",
      "r559",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r590",
      "r619",
      "r677",
      "r678",
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r283",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r6",
      "r7",
      "r105",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuances of common stock under stock plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r6",
      "r7",
      "r105",
      "r111",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r6",
      "r7",
      "r111",
      "r114"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuances of common stock under stock plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r7",
      "r10",
      "r11",
      "r68",
      "r734",
      "r758",
      "r777",
      "r839"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r591",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r591",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r591",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r591",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r620",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Other Balance Sheet Details"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetails"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Disclosure:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r309",
      "r310",
      "r414",
      "r418",
      "r550",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r773",
      "r774",
      "r775",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r248",
      "r249",
      "r250",
      "r251",
      "r260",
      "r307",
      "r308",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r489",
      "r490",
      "r491",
      "r521",
      "r522",
      "r523",
      "r524",
      "r538",
      "r539",
      "r540",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r593",
      "r594",
      "r598",
      "r599",
      "r600",
      "r601",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r658",
      "r659",
      "r660",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Type of Adoption"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r836"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r801",
      "r852"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "terseLabel": "Securities of government-sponsored entities"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r496",
      "r505"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at December 31",
        "periodStartLabel": "Balance at January 1"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r506"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedTerseLabel": "(Decrease) related to prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r508"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "negatedTerseLabel": "Settlements related to prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r507"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increase related to current year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r506"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Increase related to prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r509"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedLabel": "Expiration of the statute of limitations for the assessment of taxes"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r510"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would affect effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r64",
      "r65",
      "r66",
      "r284",
      "r285",
      "r287",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r263",
      "r276"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/EarningsPerShareScheduleofNetIncomeLossPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding, diluted (in shares)",
        "totalLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/EarningsPerShareScheduleofNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted-average common shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/EarningsPerShareScheduleofNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r261",
      "r276"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/EarningsPerShareScheduleofNetIncomeLossPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares outstanding, basic (in shares)",
        "verboseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/EarningsPerShareScheduleofNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28567-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(h))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124256539&loc=SL120269210-210444",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124256539&loc=SL120254536-210444",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124266218&loc=SL120267834-210445",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL120267845-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919260-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919272-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL120267966-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL120267969-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 6.M.Q4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122651532&loc=SL122037091-237805",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124268681&loc=SL120267897-210452",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13A",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=125515542&loc=SL120267917-210453",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=125515542&loc=SL120269220-210453",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL120267853-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL120267859-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL120267862-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32059-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=127002003&loc=SL6242269-115581",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r697": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82921835-210448",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r741": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r742": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r743": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r744": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r745": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r746": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r747": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r748": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r749": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27340-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org/topic&trid=2122208",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "https://asc.fasb.org/topic&trid=2122478",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r840": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r841": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r842": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r843": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r844": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r845": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r846": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r847": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r848": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r849": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r850": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r851": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r852": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r853": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r854": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r855": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r856": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r857": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r858": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r859": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r860": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r861": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r862": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r863": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>96
<FILENAME>0000914475-23-000011-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000914475-23-000011-xbrl.zip
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ME?&^-)3]LC?LGA3P6J&WU$B#!W ;-'/L-*?88;N'ZZ2Y]@J0L,F:;<#.&?@
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M4/ H0",9%WC:N4D0K0(6RE+!2=2*<CS_#OB\V_A^\L-&[R0FT6IPML%^1I@
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M)?U+BI_SX\&?)[D?'+S$"/V?I>K,Y;_ZQZ:W_)<M7\#UX\_CVWQULU3DS'1
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MH-Y"88Q_R7O)O:WDP8P$U$91-@8'H1'S/MBX,0JF;%0Y]QH/0!OO*M]O?3Q
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M-7'Y[U8Q5W7$9E]'CXGU>L4 ?OG/,$\Z ^1%M6*XK%(<]&\>I*<IX/G\6[4
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MR-0UN>R//+\!% \;+ZGU<R7HKX1+8OX<2WWG$8CD.:>\)G&-& [*NR]LK:J
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MU3.DY3/,Q#/%]90SI]9<_CH(?,Z:XDJ%^S>F!Q@=C=F#X@J@]%GCF]CL'X"
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M-AW/5I.S02^&A%F[-N\0S\8Y-))"NO: /SN?.X&U9(8@F)'K>#BB(V99TJ'
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MO<P_%@ DZWE^-V7X.K]X]$C(Q9#:J33#]HMS'[)C,L>Z/R4J83D^!<I)F6X
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M88Z81-5V#W[CSR<IH/L,P/&XX)WM@$?WMOGA!@S Q:*6V&Z1\_S@R$'U#!W
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M< $Z01,7^;"#]#))T,WD\7GD)M.=:*,6?%Y1-Y6;C9+'KNDP-FWOWG,VY=9
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MK/Q$6AO( 2N5J9BN8O1M>,[HV&<SSHZ(($D;.,BF+GVW:![[4CJ,9Z%K8R9
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MDB^ 9:E5'4QVHPY#V#VXW1),MQO[#3?6I\A<\6LG,\?055CY/@+;^= 0#@&
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MN"]/H3W<YQ3:<VT%>1&R!6\=A^TO29SHO=N]M^GO!]-83 !E_#/_Z)JBG1F
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M(D.J0]4B6H4=O*C+M!1H5=MUJM1)I3M&,>QTWI ?WRQ7]"IM'&[?.:<W2;8
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M_)4D" 6 5?(+C\-*HJ@#5@D(_^B;H174HT!X\.",G\:/C!?'KC4*1$X'1W3
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M'E!T_N5B/+P56+U5^X'GH:@DS<F=P89=\LEKK[O<C48K9.74WBF9@&0P(L4
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MA^@C054U7Y9%V51)W5#I<3@ORY:H BHR=37,)&KS# 7<PKRARB^P-0 TPK?
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M/>F(:7]2J+5(Q1F)]"3S\"CV+&;]RO\J)$:H6LBOL?4!"8H9/H*A'&M(0]B
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M-_]Y\6,49 DX5;B7L\/,95LLU_/%#\V-(^XHW24P!#O@19<"&I]A(#&4"GN
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M0)45)'YN'!,Z%*-\G?+T$DC(\&,SXQ<85B6SGHK)$C67%D!C-;+9@D5BJ/D
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M&0O=&YXS.A4W!+WZWA)K2DHS$CY0SQ!OA>N<DM/SF<U96FK1GYY?*3-B5^=
M,7"4\-+OU,6S\\6/5!1X;1J4UG,QZ#)?O;ULX8J>B<U=T_^^^5 6&.Z!P,0<
M""T<DKK=JBVW9G5UH<A__O$"Z?_UO]-]3"%%NH2BB2-C!@N(%5BX%4G0LI%3
M&1?:@K0U[.\2(RAG"IE_(44;ZG  5,SP06GL]< 5JZ[W[C)))4LO&I88)5Z&
M3H$P-J;J&7&K/?*\%+I((Z/;6B1[6=P71UJ\"(J0A.+$?-F..#"-Y>*A3;,$
MKV.\^2O<0-BJQ2L@!0/[">,W*'IJHMR\:MZB++_CHIIXV9WR4 +DTJ='6<H-
M] F=&TT7"NZ,"_?;Z\FA"?';*NY6 EK.OCAIFP+40$R93CC?XKDQ+E;:9 ,C
M5S J &LR/Z&@"U@852 6=WL4BX%*FA73]^('DC O4L69E4@^K"X@DW_P[]F1
MW/$5M.M)IADL-[->B,;EZG#$Z@^;^4W9Q>KHGC":\U"9$?RN=N)NU#VJ.R F
M5;),E'I-N$XE)HI#))L%S?)!!+CG,EE'$9S?L[SV79T3)].5@SOK9Z%%,$80
MMXW+.Y( H?"+[ ,X(+F"7'8<!/F!* '#]O_4(MLLGN6^6(R/E\" '''@R4ZK
MY+%D#1<_3:+1%DQ$SR*$CVB,C: ZN42"OO!7BISY<IT):WZG""Q*:+1:AXR<
M9_XJ=@9S3IQ5/I1G[F>&"W4!>9^L6_9E6W<EWLO,6@@S3M+R(ACO9.W(&WWO
M"L)]&0D Q#-P>)B"./X>K](VE< "19.<O, U40F'\SP=Y,[ZWPI>5 VMWX>V
M[$!VJ4T\=[IB@%P8M-?T02UP'NE)W@UK>6$!F?4N&28D3G%@I,PRL4U/^A)&
MR\CXM[$ 2Z"VX,6E,! D6&6&Q7DN\<A"K=Q8R!@GVAFO1Q;,K P@* C)(8!/
M:JH1NNKCW[.);^U?[&*X'+Q#S%T4K_UK4.YN\5?\A[ PVEGB;3Z-T,MZ+=/V
M"[:60GEC2XHP#+[\Y4(\_KD*>;;XY-D3/S_>3/8"^Z-<%4XBB7O^?OX&#A#V
MMM)2_L#;#;/SP^"'PG^)68GHKC_\\(:X$4._2]@O-/VAT\6/QAD%('Z=$IJ9
ML&/NC GRF !>C11E3R7V0DA4HV3P$YAB<WSSD^=/8&$H+N77T+]Y+\S[J-^F
M.XI6T=)'C.NRCU;'>T1$P=<,_5FS/MLV*]:+5'=%%V*R(T8(JD\^?:+L9QW?
M)MT^0@G<NB43>=;RFC?DJLG"#C>Z!-9:?0_*_F,TR2&4R2=X->:830*Q\A4@
M3[[BOC$X7F5(4Y9^J*_+8H 5D8X?PO;R=(*'L*6L3U \$9_AXL6%=8EBO0=D
M?(N=RUNLN<^Y<(1T1$UOAZ]2=?#I-T53#SV:FQS]XMDW,H7S4T6\.WZ"_$ZM
MI3V-K@^1M80CD"9.G3:>4'_LM5"=>%=NALW,7&(*_O0\\[L[DO_!)"&B59Y*
M5Z1S3+G8(5("*:B=*B2=^.6@I$=3D&,70HEM_/%4H8L3[EQXE4]-+H[22Q(/
M&)/.F+>8]=&,4@S !^_X8NBOA*P?JT ]SW"&N>(;?$#RXW2%B) 6*)R%VD44
MW*&R&Q?"QCM*#K#S>_1L?ZR2SU59N3!H?FXND9X?6R39F^35TU"1#R%#(R<4
MME6'T?7#@XW0A8*S9J2 #"V;SN\*[\O'NHZPI])U_^%W))]@R@O;;=# (=Y9
MNAC=.V0J&25*T:V_/R<ND;)RLL*^3IE']1;2\\"W\5^-%RN[4?\%9702)L?
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M$N> :IN@N]2;&A]*<H*(W(+.-D*:E8&'LP7E+?I.HE^:9LK\843Y,/R_^5U
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M W4&;5Q0O"5 6U$?B1S\Z?2/_@@*DJWMOVS:R[R6A'IW8-B;&SP$ZO3<CAI
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M05[D(DI8$D"[T?7(,1A]-V!)J,"A^L-ZTN./)@7KSQ)@K['=F=A,N7,*AZ-
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M:!(3@DACUT4HZC@X/GZ?Y5=#U&Z(\:<90' &C4V70FQPGN@5 E;F'F3.TNE
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MLD#P"O,<IA2>@H 4V3+SZ,",\J]@E\L2-UANIKDT01ZO&,-D%Y,$2B_4UF1
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M6:!"4"<9]TA,TN)#+Z1AT#6"G72F8&$X,XY4%L93(;(0_8B"RQ4Y7%9YW:,
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M3PFW%LE653R _ IKWT_F^S$WX?OI6=7S_53!8]MM@AF]T(H;7:4) P=3.Z#
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MY=H,!]8J@P-#?8F"0N+,=\OB!7^#/7 &S'.:Q5M2" .0"O+KAHP-9Z!=F*I
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M1^^KN A'%U0YPD*N,><N&X,5CZAU&E,EQHXHU\!)IN>AK*Y&?F2 0E'$N9S
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MR41UT.,7XY?3!#L."HQ34A,_C]H(PN@A-E.DMG3..'N".Z,-YM[O^<.AP :
MBZ^.U?QHF$C@<M"'CFWF0X^;IZE>>K)O;+8MW!EYR>[E.ACCAF!3RK3S;!:Y
MPA9N4>0$9]S/KL:@>0J^Y:V:[%-VA)<[<FI'>.T(7\DOO!7'7@DO^-9MV9U<
MX,]SRYYIRZJ/V,B:U=3:X_W<_"V=7K-;17]+[3"L"7BUM.]V3< U 6\W 5?7
MX_T<>E+M.]%HMD0!6JE6>GLA,7IFW8VJZF=DM];NG5*?T0.?4<MXS)9AS\92
M+<3 LJC1K83V]@)<=%JWU7@KI-<^\3-J&S663]7/""[66^9*U>IUC=NX GU9
M:\OI6G%[:#E]6UR-^H@>+"?[*< V5E],?W9F43@:<2:4",30G]Y.8&^O0F""
M9KTNA$BMM3WT(5G]&H.QZH?47_]>K57K];?YG>/Z(YF!J9!SGYL+VUY?9M<J
MW,.?T;K>D/J,'MJ%;3X!-;NZHOIX21;]P_4P?EXY 9O8H&HSK'U[:V5S>[0=
MV3$UMSQ[;FE9O8=O&U]S2\TM6\DM5G?]?D:5X9:JEFJO7NUCI6GY)YB5EM9,
MWB\IE$]#>YB7EU<+[X9![&/%;3BDVO4XK9(E %)5:NZ"4NU[L%]4[/KYW(F%
M=G"@1>(,'F;X5 0(GB:><I4XHQ$"TL;B/TFQE'5KP'XM+(2>.!&5RROTWUR]
M/^[$**OL$!(RL[22WX67^D%"M<07(N;B:G@>2WG5;AZD9<&T]2XBO[HBPOGB
M3W=W/M#&YF%]X>/8/?=_A9/S2 2^LS4(O.;\WAJ;W]N[[>N'!$<]FX98^QW3
MG!@& 8B8X8() GCA)0O0R_-GU* Z;A_X8P9##&-!  .C\%)$6@S+!.,U$;@K
M2!M3$8W]('T?;M'1'P<#W>R9W?2-N%8G^ND'<1BD",-RT@WM\MP'HW@@7*Q.
MA_L#48DO:%H[R5D23^DX*L&4:XIOSBHF^7W/$G3IQ,IIO+Y-5K]-"&!9H3ND
M&-@$*H^\[)^INP4A30C+(H]X#HPS!PP!-U("@B-$J(LS$;BS%-DBO;2",-#+
M+ZZ5T3VVXFX2N:S[.U].11D*,DCO6V:K;=&+)OY(3.)90QLE%X[G7/F(NE$B
M^%" XJ.FT6GW[/;<WQU\8NS\"!%W!J%I8@*G]V-29QO7BM^"]*4A3;/;[O2>
M]@UYBQ,6 >8@K';"/:MK&C;^;G]?WSWY>D)' .<"3R/ZSS028_CIXKFL0C3#
MT$5>#_#^BX7_*XFDXGBR>]3;T??V]VO<^I0FVNTMP*VODFY0Q')2>>SUQ4Q]
M(92D2.]F$!G8'R2\SWNX$AKFIJ[6J+Q,(MW9U>Y6N.-<F :Z69: 9L$[1XE'
M8%+Q#*XQ9XIH6^J^I;?#Y@J<7^1,9NF33^J6NVFSRRX\1QLFHY$V0SP;H./B
MWH/Q-W7\0$%IP78 U>)87N%(LBWG>T_M>G8\-QERX>(YW^FXJB1ALZ3S!Y*J
MY72D2<F&AUF 3L-&.9D,RGKS+$J_DFX]ZR*L54V4'02R==@E2F(W/ O@8:]L
M%V#;BEV,2G8#&?+=WL[_@'[FNF(R=0)79,RSPO5PDU+>T'[K-ENWG8(#AX*(
M5?_<^;;SSWNAQ4ZSO<*VEZBBZ/'66\T2U#R$*\0!7KP]/7Q4S0!-7Y)$TQ!>
MR5;6;^V;"2*O)A"[* DWC0@9M.SXC:[1[1K7FGG;PEOFC;Q%K-5NVC=MY'X2
MA1,!Z_@2^#G_W2WV=]$BK[X>P+MIK+:;UFJ"JG0//QV]WS\Z_79"N[7475H)
M\EOS)L[7%?PAZPHJ<2<O<P/&S@CT-6GN7R*"*JI2O(BI<X5_JOH(^@D0@OM3
M'RCP8:0'V?PPCD,7-#3XG,Y?C">C<";H<K\(1Q=\N:\ K]K43I:]8^S,M.$H
M<:<)AB,(MYF!75%AE?_BQY 38<@P0C1=9TJ0K4$XI:E)C1^M@0BE;)S@?&+Z
MD):'6BQ>:8PDR[[1_+I!3PPD+JX?QV!/5()2[V)/N>>H4.$!34H*8ZY7[R5.
M];EP/#=,@FG>4B*;55H/*#3Z1<T"O;^N$Y\OIRHE<3)@;:<0*]'$?Q)_.N,C
M(2L9Q<P5S'(J8)9&LYV^#T@/Q#5-F4\988YC%=Q!$T6?^AB620F7,\R!?IA@
MQ)5P$U) P<(  HEB%=!!2B#5"Y:,!A&8/-/+4">+A\F2[_()1KJB,2I,<K'7
M3VKQC<2S\J53-)S2_J&(L[PPO!OYV+72 <Z.5<M,XD.DA>I?2#<8I@]%M:;=
M[-Z.;#.C-$? VF^=G"8"BXC.\+X=D>R4CI]QZ!'.M_+B*C,Y_T;GTHF\:K@7
MUKPEYRHY/B&?U?Y =HYX/JA>T[*K&NE"$C?^=)R,IOYD)$I=5*3-NQP%P,])
M+A Q385['L#*SF:-7!G-D$]D)DE+L4YV.1+<NOSX,:^[VS84V''AHL"=/ CT
MSU'H(O+]LB8##0UV^^#S\7\[X\F;O1K#_2G HF_59)\RAGO=S+3&<'\&Z-HU
MAOO:6U9CN*^]9<^Z@6FJTH$Z-9$JW3+_4@WU_MR ALF;;+VI(M9P#99=T_!J
MZ"]&NVYP6E?@;7V!G=FQ;PL0^FSKYVX3]_X-/459A"4<9EZLU"6]),-FXLSR
MH81D,HQ@%MI0"&V21'&"X149E<@EXZ@1/F :""8-GU(VE4A@OV/MHS_VIZM'
MQQY[.Q<"W[_9G5R,FY(Q3+.7A92HU^:$:WA&LT;I?L<W;'A<LN/Q]5L>\R '
M7AC%/J7=1V/'I3UW1K#K4Z])DSUU?@IO_ON;#^7Y)71W*I70716/^8D (@_.
M&MI[$5"_5*2I'0]6**MU+@0YRD_>$\7OE!3LU([R[?,];]5D:T=Y[2BO'>5;
M[<*L'>6UH[QVE-^K^9UJ<F<Y3<XI:'*U?_RY^1:[[?4;-CP+WV)-P5M"P>W>
MK5O:/&T*?NY$O&5T;+<V3\?/VCN^1O&X<EYE[EK,E,\2QK.T[>N*Q^$]8Q&Y
M6 NFP#<N1"$?%W\UB!PR<#G#%_8(#C.($WA2.SAZ?[S__?L.:&5T'#$^X\+,
M'#@2;>0D@7O.B?N'SHQ3XCG! 4L5E-^>*P8F_)+8&0FJ%G 97@J6-))UJ#()
M'E^AML*[(8,^#-9*F+?ZS<X&$^;KBH^ZXF,5UBVK\\@HO,BV<3*9A%'*-S=S
M,+Z>&5$]<VM^SK&Q0E*Z%S8T^SEF6(<-RU+>JQ&4H%(1;9^GV8#W3.OT_*?@
MR-^JR3[EJ$.Y!ZV..M11AR?E#ZZC#G7489NC#I5NU': 1P&ZME(GZ^#"<W/-
MONPVS84+Y7D[96O:W1;:M=K-7DV\=41A>R,*+UO6)DEXH\&$Y]"I]DL0"9@#
MYI"?(6K+RU$8QZ_0?2>=U[%PDX@ 4)Y9_]J64?>OK?H964:S7Y]1M<_HI=EM
M=E>7\-7K75M](?X19#:)["N,\B5^?*XB;VX8T"PIR" "Q&L/PNDM9?GVMKU_
MV36:QMI:1H74X2=^/G>J@*^/Z>%$>:]I/PH;/1M]_" ?^G?#L<B0[QI:(!;0
M09ZX\F":3:M6\*I]1NMW.Z^/Z*'9R&IV'N^,-J2'5U=HGX931(NGA!^A$GY*
MA/6*;JVZS_>S[_/]LM6^?5CJ$5M\/ZSWOV:4FE',FD]J/JGYY$8^:7>:K2UD
ME*=8U9,U@UA4&1M+^A)Z8C"=]^_*?@R8/]]=H<51)"9)Y)[+E'O95Z;4.XPC
MX!.Q@%]XVG\2)\)VV_ 4E^5PV8COIAUN".I)/C1T?.IDGW";."H5*8029[GZ
MAK@!*\O*'HK)6.C2YKZ(4U*P:0_"9!I/L1$X51%XW%3,"R>J_<3.R1>JPM"-
M#C[_IQ/ [&<:;#W/'9^1E0DS7XR\6+5;I-'+IGC_)08;;C&R*E5M]!CYH%;<
M4CX&1_94Q\81W GB6AI'Y^/F:7P(/X*'BS1NW%A^=%\"YK;5)I^C\,*/55NW
ME[*A%S6>>J4=L"?Q%)MDK5=859>G;%O%QU9-]BF7I]2@6'5YRC,H'*C+4^KR
ME/O?LF<-BC6GVPT*NIV,$E,#U+IZY;E5 +3[3;O&%:H)>&L)V#37SAYX%@3\
MW&EXR\CX9<L ,[FB=2RKN\\?V5_.CDS8&&Y4@$J-%F'_] ML_.YQ&W5RV@DO
M10>-I_@+_/_)-(QF]$ !%RL1Z"AU(^$A0@T#BTYEH]JL"5?:U)T&54V,@Q!M
MVL1E_V'6:[8(MC.)Q-A/QMK$\3W5BWU3WO:F=A!H2 G<']<9C=+5!V*JA1-<
M#4X$"W<TUXE@"V!EU'!9.W<NL!&O" A":J8E4Y]K?7"-E_C5F8.]ZG_B &I8
MQ(H:<X=GV/^T^<.:P$R/3DWF?5*3N*(>;CADBGWDQ'&(?8QA:/)'+X4N(@);
ME1SI_&F6?A1/YZB#VZKP*6(WD(C#(MAG.6<QY$T$+8DE_E+)QDS/G6D>I,R[
M>6N:VA[O"%*X,Z#.S/3G<!@#>3K!#+E#QU>H?%:L,XNGUU Q,E@0IC\@'"@<
M@/#ND,68%,VZ,4A*\^UNI1J#7!=2>$21("-E>0.ZR!SYB.MO5K^3ZU"D'IKG
M<I;U(X5D%B<##$]*9$"4UE+Z8RA-LO]H%%XB#E[*"APK&PKJGXZ4#B\14PJC
MY;VI')G"QD5ES#N4:UP0;T6.+;D9*7 8*X3(DHDVF$F',K((S HG@M&Y01C^
M_!UGX/DPH4C ;X%W\8-%^4;H<>,)2#8**.;>BK\?.9</$&B];73M");/0;0:
MP^TIQ)VV:K)/.4A68[C50;)G$+ZH@V1UD&Q+@V35K;I!I8RU]SKN]>S"!NW-
MM^E]$G&#FH*WA()[_;5+,FL"K@FX.JNVC6XU>QH][9*1(-5Z;F@BD39VP"<F
M48A1+.ZUHI+U51_O-,2#+D1R/6J.^Y_$9R<X_'S]AC+D[4L[O+BP7NKHC7TL
MAG#:H2H J%!9R]9W'-DHC>2:VF0_YS*<221B-_(GDCBR^AU8,A!'&(AK.\JK
MT&IZ6&F_^ NA.5&$BRC4E*Q,IA6N)VDL[>YR=QXJ+EK%*;BY43Z"P5$S X.,
MR8B";6F(X$$#&(M\YGO_>.%[W7[;LEHMP^S;MFWV!D[/;0T'K8%K6$.C)_[=
M-U\\"G-:-]G?Q)P??2!%#Z.?>"J[S@3=8MJQB&%OW%QJYL-'S5>;_PG/$T\[
M74KE)>)7#.:-L'$4QZZY+Y7/S:Y<>0:1.H.&-@1=)!^3HI9=H$GX$_KS&G'(
MO8_FL9DN@;5@!L TV ++QV] )&.8/Q[.F+6!+?%CZK 5A3]8 N,\<(H1EM1%
M(B?6IAIRXI2X,@#9I9D2_V@,FW$>-[4/(!,O$ SJ$B2^$X#LT<Y UL RQ$J;
MP$(CM^@(A@NPRJ]\,7A5XC90T@+<.R,Q%7FQD*4L4)>W"S$*)[1%L-JSR!D#
M1>4%G/]+RI!<ODVL34:P$N$U-3C0L8,EAN(GOMQQ.<T"<VR2P<AW<3"XTBXP
MD"G+$8$6?Z*LN3R'8\7^9CACOA*H]]G0N8#;!<4U/IM$<0+_HHY:V,X,)X#I
M"@.ZDU2>C2HV'?H!R#EN/\?2/9DFD4CGZ8SBD">;>U(=[O0<=-\SS -!8CN#
MR<.V^2@W:4\XEIJ]82SP O?C<?DA4TJ')U"R)A$)7\[6\& ;*/PKWZI.T;EP
M_!$O&Z8NHG%,NSGA8"4L.<$TIB%2'$QK+LL(E^KY<92D9;5GHW" :^/IPK_4
MMKM.$C,GX4.[G_X^V-/-OD:WUMAWZ1UQ$N/VPL\HQT7R!.J5R<C#]"/06J;:
M.(P$!9)]%^XG8H<DSE&!)&75UXX?+IP+<,P9W9UX<U&$G$ATI.19=0/,!P$U
MQZ/=/H9%<"+/)YC\NW3'=Q5=;W4,&E1ZRUPMI/FTP[JM389UE\8Y^ML9*JWC
MHW<)?VUC\.I.(=)-A?RV<>/,QXCZI6M^##2,'.8>YH8V.$,4U4&P44F51EV4
M%12^%A=[&'"^8EVE\:RJ-,R&U>LUNQ5M8/[8D9>:F+>-F+M6TZ@H,6\(L+O2
MI/<UC*AP1CK[7J^BP=P:F/@QQWC@1AJ/>JA2KU!N._)CWP7Q_HE*T:T2E':[
M==MLH2VZV&NJJ]+:^G YW[*RO4+W[U:([(\4(RC([9'/M8C/KVU=N]5=V\*I
M^S$\\"%9=OLQFV8\M)/H\?2X2ZFBR]C11O&/ZQS&.V]-M;FT;Z[/I1O<G8JK
MFS5O/&?>Z%K=._J>'H4WKL\-?GZP$;TJPT94#6-[>9+&+@:@WHW"<@R#K<G-
MJ/$!MG&R-3Y C0]0Y[]L=>5VC0]PQ[27>LM6V++[ ]&NNH>8]+,AZF=<\Y+A
MS65YZ#6(P'.K8&VU:O3LFH*WF8*M=J>&P:@I>)LIV.I5DX*?4P!]7CWB0L?K
MU:,G'J%]:7:[ZW06KD/H#WY +:-IU0=4V0.RF^;69SALI?3.2HKO*+U7S2NL
M'NV]M%KV+=I=5TCS?>('9'5O:WG79_1P-VR[V^P]"A,])^5[7P(5#+&I"$,X
M$4Z_ L@/ ZYO) ".N4+'9Z>4KR/4:XWO@8_GO_]?SS*M-W7R<7U,SS[]>#<%
MX[NF1#T2\33R"1$*O]]H(IU1)V%N9G>JS<PONZU;&#H;VIOMB [4_/&,^<-L
MM^X(^% S2<TD3YQ)NO:]U+G</X]4%>I[S<3R+'V</;B?TO2DG:P/Z+;T7;T9
MPMQ=(1OKX<#-&=ATTP#G<X":EXR)'?G8(A'Q5].UX&L<UP7>FF+_25> A8 ,
M5(:_?0T^;1@@TK7@V20Q4 (V:N2U*_C/*1@;@V3*!T.]<7'^L43X) QG/^;?
MX&?P$BR?1(10^C$L6':=E1BR\VN(< -SE=>E:Y!PLSJ5U=#?0&ZXH7@^\'ZY
M$_0&A3--RSL'4H,UW8#1BS.=^F,D)IBL.OPGA.U>+>;AGV? [_ENT7< ?F>T
MY4T#IE="A-[Q:CA(4S.>Q=50EHE22MW4?CHC322R/3^) J(0[2B\X'(*F@02
M\V^VU>P6T/_)3</0PGZL&MZRY]TEE&ZOH21+KMNM B!6;0* >"4G,0;A5 (/
M*JI?1"6<Y>@[5IC^OW5SLY- UT4V^)<($$:[I!OQN[T=<O%UWZ20SP@7+2?@
MC/F2^.?.MYU_*L+9*$UTFNT5B**DP!+5,KW5+*ERPR;J.,"+MZ>'VKU,>D5"
MCJ>)AQW-PVD(KWS"U\K*C'?O+*$XPFYV;LL1^TD$UR3L_I< GLZ8 SO=7S@I
ME'UZ8X .A#WO)Q.0T5SNB2+CZ(\#O6^9K;:%;QN&^$NX!$%0Q,+_E405$<1W
MO&#>I=DC3^2"N8'0R[)ER@E]H1W,;Y9I-'LI43IG9Q'BSU/3G0#;*P -C5&=
MO;%W#*E7^1%R+X+!7/FZ;G^N'1*NY=JF1G.:%- [V.V>XO$X3J1Z/4S5JA#/
M+G1_:F#LPSBJG0QV:'C*:O1:9%#LN#-'%&:KT[0>CBC,7J?97T84Y<V(;M^!
MQWZQA@PH*_5_UF +_2J#+3QZ Z)#('&Z=^E&.LYUQJG\[7,@%9YS)QH[KDA(
M=04>]))X&LT:V-S$A5E-L=&)H\5 B?X0?H+XHJDH #U*R!R?^8X]V%(HH1XH
MPP2;<A7:\,13YXPE^-)./+)U3]J!!R>AS'Z8A>=[L/7*]L'68&.4-B,1G('L
MR$\MG@B*6K,YI#K38+,9%X0A/ 230ZUQ3.J7$^/"+T" POSFVHJY;LCH&=(3
M-9U-1$,N[ I4NP;(0%B [*;E!]*SE;",+9E^4ZO\W71ZGG7I"00>IQ/-< /$
M%=PEL.-X&PR2&!Z,8<-DUR#4IVG[L'44_CI(X"##)(8+6GI4N(L2[-,E=R4:
MB.R,X 'JKY/;?^[.Y_G8,2?&]CP)XIH \8@@:[]#0T8^^_:4Y\9!-4+=6VJF
MY.F$NW:*SSE1@[Z4_7@R6L[UN:(.19X@6H(K"_9UI@WAU@VCF-KDC1**"ZS.
M]2J4H&.\Z76KHX)0P(#PPM>ZV7NT,T=;P^J\>3R3M;@WIHW6]8NWI ME/C0I
M7?!DE6^PH7TZ>K]_=/KM!/YU?/#QX.1DA_ZU\^'H"(GM=]!.]KZ=_+WS\4U]
M4O=W4EED(J:6;'AQ<&LU/##I#BU(_M2*+6O&5I_5/7/5V('+?9IX(M<P#R^T
ME=OEU2=TCR>4,@ZYAB9@PZ4N'^7MRG,0^8'J$[EOGLE4WS"FT-%%.+J@N(_L
MR\A6]AFH%Z DS%*_W?:<S%*?W-:=%1X1!4:N[>B)'MM"0"]5ZS@&X9''(V9D
MWO'$ 8MH>PYSVX\.7I"@OIU$,DJ.1[)@4-7G\1#G491V0W^D[B!J5(M_8)->
MM.&S8 2PDT"+S<U][8X<?PQ?@%(.9KMSYG/+6C2<(QF74<Y?^"K7?U8^CPD;
M9S1Z?>SWJLV/)X+TC*EPSP.8R1DI&EF_NKQ.6+/@?9Y%?J,UE8V$W8;1'<'N
MBQQ7X!&M[F&J3^,V M$'38 K(4M;2:.SJ.!XJKS'+Y<"J!R=Z&D["U$"I"ZO
M2Z&=.Q>BX!>^QG]V.Q]99>+-^U=P)6%:SA_*T[F78\3F/=/EFHKXH^::S%$/
MDC[*#_2;XI4MAD!+4XH.2%&6OT:D/L?DA4YABGRA0A#F,^]0;P\P:=,500Q&
M&%C'TDL;1BKO*64X(6.E:*_ITU GNPW]U\$Y9QAA!FF4G%T3?$"*3O-#F]I7
M-,/!()](WS:.(*Y\-L57F6;C.I_W)$3=!M\JV2G-3@01DTSP=[]1!'\@HZ?)
M).1(CN.>^[ &6@ :.]+_C:FK4WU H?0TYQ&6<2Q Q\+ACN"-FJ5XW05=#?/=
MZ689IGW<XRE\D*554MM[/P<M+L5<7ARLLA753]+XE$O$,QN4GT#GI_+K\AE[
M&/@>C70*9D_!DHP=ES.I%Z+B%\XHX5!XN]VTN(Q!A</Q.G==,1)444]9S#%F
M&OGQN3K;0N+/BH2KPNM? A^/]I] K1[R!1^[2IF@_..I3^HYC),$F7',NG>,
M <'S<.2):(&(6ILAHO*4R.K?G$ J?X*9B@&R'E%*BW/H48B1K80GJP7P,A4G
M<^>8A#Q\?X<SYTQ$#9G,PA'.2\DU)"A )*A?@3#HMM-,"ID"G7==.-IOK?[R
M'+0&DQO+3#RZRS :>9>^!Z()ET:B6KXKS4%[_\>.J9T!Q> 3D3.9*4<P'>MG
M!]L7Q;F<-<^/*>,^HR(<01^#74<4(K]7R?"PS-+1<:!()K2$6N2@K@%+B("R
M A%=8'@QGL5 8=H4*$*@H!4@%.$ ,$_/PY3^^94$J.#BN^0!G![O[.X?;V.&
MZ6->^BAG8M\#>8#A8D'8(%A$(<-S+!$*EX&Z -+R!W<4QM*S0XEASHC)1:5[
MX1>*Y L97T@%&!M69#$0::H!IHYA9I(J'.%:$%)H_2B>SF48M:0'4.3CUNH2
MQ30U+A_(L9:L1O'EHO!-(AJ#M%.2BVYE]H%@HM2EXY..@"4UH2?9&W_S >:A
MG[@@O_3C$(8.M1U0 :91 I,\&*/?6$K-';8TS'ZWT\!4!9D7W<AQ%M?1H Q2
M6YK-?;D(?79Y31VCN!?/)J_IUBFWN8R_$\[XPSN_-GZ*"L"A,V-MSD(-P.R2
M!I ))$P"\B\HLW+DN*FN_EO;[#;;^83(ZU,PK:;5_B^08E?"TR.Z0I<F9'J@
M9Z:3,MNDE]CD<T7)@W_(<]0.KDN_Y%2JTG3=124G%A,GHO0LN=K1#&[:LW#*
MUWU.-8Z+5592KU2R,YL=7?A9)NE\OBI,JIC7W% &&HBOT:QQPW;.O>LV.:P\
MA7RN\_P49)9K4]NA]:EF*7PPK=2T 'W.:-HKIN+.33P28]A%*BR:8N(4WE+5
MM[!VIFQ"CX2;UIVB=0SD!$H"Y0O2@<RH*"YWM>96SG=I>EO[D9N,8RHA L)^
MAP2-"C7<F-(ZX0L1+23B&RHG'0J'#.[%T2_Q05"'SXC$G<+Y:=G1+:=>7([D
MT/FOG"DMC=P2'D>W*"V3=80!& D!A9+#S+@PE7%!I8.<FR?K7?'.IQ6D*7DA
MRB3,W9#S;"TZ,(HS0KMCA$\*)QKY(LWU1C6#CP3_%48YKO#HS"[#9.3-^S30
M5*& CN XWF^M7/$!'%6J>/UF%C/":4(45((12)&ZAA,R<F?6++ 0.4AD!<]L
M\7"JSR"G18KQ0A3M5/Y-^8WH^D]-;(R1I<6U+BB.\(5TC 6S%+N))*]T&ZEZ
M:]@86#L8?H$7<^%!7O=FY1)=>0.@!*:L:.Y7T5Q5@2R,0O\!F%X)FP>1(!T[
M4U/)/T5,XXFADXRF?"5<0Y]Y#1SHGLZWX.W*C];04!%3QYXC'53V9?DW_CL)
M)H[OY6@UD%43)  D:<-%+NA&E82):GWU_1)%)TWG[DZ:"C+0FMKL1_(WU+IK
M3G=-\I)CQ/X8XB^*\Y!3D6 @Z$\&9Z"OR0(6N9N**&-Z'H7)V3G\T3(56D7L
M\QT08KHVJ*D3T( 5I%QY?J%T&828C3^?C^.&T20D%^FY<#RID\8KI]0_JD?Y
MG1A$>)6S\M=K+-&C'3Z'G+N$5%-2T?5!XH\\E8R4Q!B:0T_O+'6"!"#K$XFB
MH)W .O=\T,$;VBZ0(XP3^$Z#,S;060\/98[&41RR\":+)?:O]!EV^0LG:5FI
MDA_T!JF2P;S\(4CN=&(2<$,^ALJ NAS8'3/U*5I8F+VJZ*!\^XW0#!LU%$MI
M:E_HKF!S3$X[OXP4\X0OGF3J4^4)K79NEU$+!"I$;VXY)2I@!SD6\0>ZEO!(
M%0VG8:,1ESK*T=>H7JW*K6)N*(#$@J?HP)[@68.RHTZ,8@283GG%13\R4#;V
M W^<C"7/I&$S-@VP^M%%-65$KKAY27?[ZL+N.M6%#UV>MHOJ%\:(=ABL!Q?\
M&0['53&=?5GX5/URM4^,] -Z8ZSL;0<,N!D("$43&;&E%IX2%: (\L\FTM-/
M!4H<%"7]L910Z7Y3F0Y A5R<*[&/(H^T7E)6G6Q[I8:)T#X<5Y"E8V(B)7$6
M@V/I?X+OH\GMC&%K7(>,J_<[.Y_9G<[OS?N48U$^76EWH;D9.)S%FH:5584;
M'_N/Q#O++=%A-&]9+!Y&Y*D:,Z81"G;$T$'<G!Q*DA)N0:PP$E0V$AX26*$$
M+:!]HJ H\!ZGC\"&^QS^%A@!E?'-.#>]HG:/QFPNRTG","'B5(@5"[ ES8R$
MR:[@(R7DI1CO %>6CC&(5:,@<ABX"J44)0B<^Y''-6$JX!E0(2#&E=C\@8U(
MQA,F']XX4GQ&&'97P0>L-@LIX)1S\!<<$@VYT2E1\HV'\^)0+&X2"TGG)^Y#
M=EIPM272T'>B:(9?4B0Y=TPRT)Z=5#I1-!IA=AZ6AH/XA(]0H2 X)H[L<N5F
M$Z,,"==RT@S1><%(&6JC"B<FEZFP-*:%70JC?/A!^Y >"GK$X#C]F#=39E&D
M8Q+'\81Q$I+KT(KG<EM9$Z_RDTJXH?H7*#(WB(%Q6A%U#5/C2>=S*Y:Q,YZS
M@\2#*&3QJJE658(5/!)3[;/,ZSY!!);:2,OK7"0 94K3')!<Q((QPIICB025
MXM2E&20H[<(H'Y5<"E^7"HZ0.)NA:3@6.HT<=RI]]V2+2? ^D&V@=X51/F&D
M(%?Y2LL% -BAGF)8D>R'=Z/<I=F1">"I\+Q$M%!.TBSW<MDB&BK/*A_3)84?
M2Y!EA%F]-KV><?=X4Z6[/QC-,OA!RCVGS?&G^#0<PX#FRAM6X%.\L:*8T7K(
MB5EPW<.=D'"(=?YJ^T7;#280RL 0"]59 *J<,/(.IY):W=6X5E4*/RH*[8)X
M;6H'0RQ]R4MYV/$9)S9Y/S#NO' O\PFYY DC\0SD+V0;D "=Q0$EZ2L<)?9?
MX[5$XZ%XJL//6?C9W(+P<Y6NA?<A,%) *NVQ&# 1/Z8D_LIN[!"$ZIE23R<4
MM*+)2?4M\%*5F#DT4PD/A0<BPO>T/4P^Y37AQ8>)3BPEE1(WH\'BQ#U/1Y>.
M$5+[L!;'=T6<4V=1ZZ+:&G5/8#@X]4N0F.)0H?1ZD\6!3S&/$T@J#0J,'FL,
MER$R?5D&GE+,C/R:6:Q%4:[\!T4CFQ59\HL2)[B'&6!1JKQ+V933X>4[&KG7
MTDT#5O]5@_4EFM50X&4Q4I67I%WFK1-U>254/AN-X\R R!92N$HQS08#7YFC
M2\GJHJACI9[?0NE+?IR3YG"DH<:0)?+M9QE%J_>F6J]4IKU4X87-*1'C53#:
MU^3C@X!B**?.U6-S\">Z4VDV4^<*;W&V1O#<T$-(F,,9OTH@V9QQ-=/& DQ4
M.-J3<LT\RH5"@58\P>EAROE7]G(8"S]+[7Q1;MQ2E&H2B:FD<.K#)5V).-[(
MN8PY'I=R05/[FM,N,#HF(HK1PL^76(Z*G]/T.JE]X",H@6!M0B&QR;A;%C @
MB3&O6)5:./@6&!%6DT0XSR]RS^$<>(,;*\T6-TAM,>]29DQ+?2O#>X3I32]Q
MAE3*#8.FOULV.N<I^E$NJR.WG$R^*5WL)2P/O<+1+ \S^0H#]2)P.%L15TV'
MZZ>JE-IS=+C3YRPGB[./%[(>6<\4H!%J[%@AWY=2@Y&DYRV LBW-K@#6;,E)
M._)_HC())QN0;*(CCI%*TW2,B),TY"8O#IQWZI!EDGE?PSC-^T6J@N=\*I!0
MNB][5$8L0K\J8<L>!/A&QQ?$L=3:E7%3N@?.&5QX,>>:E"T^92[E\Y&U3G-A
MI[Q?2>F\F8,) ]TP)GMM(C_V?!E7H+L)MM-UY+4M>2G;"J6(4S": @^ISV^5
M/2ODNOI1+C&U*)^4KX"OITPZ25\3L1UOJLK/;929/D[!M)E+SL%]NLT1P*LY
MOX3=^[ BOC"90V6% I'&H& IY<<M%^GS1HG4IG@%Y*:<S^<Q&AE%T*V;+0B>
MGZ.1!@\H8T)SA3A.WLZC['8.I\F9*N-E25Z106E+EP(6+8<OFL1(2H]#5V0M
M@L;#H:LYK+31Z"Z$P!J;4L PP(92-^0,G]P)2YH@R:! A]CE[<ODF!M?GT5#
MI199,I];1X? "*MR>&C'2_/@#C*_>!6<ANM$'M<+/,[%' N1FS ($9]N/*?*
ML)L)14&T</'F%'3EC9(L6C*5U!7>*(])D1V6@;S>@>Q:-Y/=?9S?:F1W@"4Z
MW9W[4O^M6YHF?V$BA#^5K1U  L$'(_7W7A;5TG8H"G/(-:O'?OSS$>VP%7=<
M9;4=HX1;8\J/Q^32P0*\%L;,:FEJ'J5:@'+U,ZTZ/0?=0T?5/X_!KL*G/J49
MAN3_Q:.4]U(.ASV' N13,&HB'>>Y?$'0B[$D:2K+D\82 6H,RM[8_X7R8^:+
MD<=.<:2/G!MXE/:2H0L99D[N *DGL,Z5SH^N59X<ZBW800:>'_F@JG&F(GZB
M_X=H<Y;W(F0N=TS2S&5?TLLH.P(M/\X[F1 M4RXC)AIY9#[ 1OI#[H-2V.QX
M;DZY_<[E>'(V,@U+LI.1Y:XH)P/$:.2<B4(:;O$0,*]5L+-)7"'D"Z:4C(%,
MSJ6[6C/_*P>%79P?3"^BA9"\)G]YQ*K;LC1[VG,Y'&=WXIOI\7/'RX<:,Q\W
M6;".'V75NW-TE#9MD;H<;0,#O>XE:;22=H^2Q7/%8(O[D6$LP+4AS6B5D"!3
M@-D-GTTUNVED03TQB3KLVOV>N=^MY>[W=:[9SHMGX;1?_5J7"8U5N]K?I8QQ
MDFF#**].DLED1'_C';'G3)W;ZUS]E72N-P_/ TL"[?M?CC_M'A\<[6M_''PZ
MV3W8/]K=/VEH!T>[RR5%529_<+2W_R_M])-V^F%?V_UT=/+IX\'>SNG^GO;N
MX&CG:/=@YZ-V<@H?'.X?G9[<I.Q@A34!^OR?[.BB!!RU@:32Y4DL7JM_O/'\
M>#)R9J_]@&9&#[TIGG1)M3;M'7^=L7O38):7G<7EF^773?IJKJTE?]=O-:V^
MN?1KH[G\N^N&M9MMH[_2J#?T0[^Q3?WB3U?M0P^G]?!4!Z?$$_/0+4'FVFL*
M#G#]_6<0^H4VI"MNS[K]9].;H63IP^']W)@W+/W_G,K,13N/Q/ ?+_[?"M+:
MM-"/@ H; 8CG((J.Q9D?<Q+^YV0 ]TL^>?:='XW_[W?G[2,%KDA6:"\_[^Y\
M^D,[V'NM_9]_]3H(@Z.$4D?)!P:[<XR[X ^[';O5[IJ.[1EVN],:=/N=0<<8
MB&&[U3%%_]][J H;IF'J^ _3:IDOM  LFW^\\(3_>B?Q_&D8X8H/O!?R%FS]
M/1OLA1<?K>.+;ZW#Q/NQ?_']??_'I_%?K4^G7V:'/PY_'>[MMX_V_C(.3\_]
M;Z?G/PZM[_ZA]>>/P[T_QX=[YZ./K:/1MU^3GT>_?IJ'/PY^'?[:N?IT^I<!
M$MW^-H;_^W4T_O;CR/_V:V?V_<>._?WOWM7AWL^+[\&?Y]]_A9??8?Q/7_%W
MQS#F%^/0^C+[M/>W_WWOP/QT>@9_'[:_CP_,P]V^\>WKG_'W4WSF3__HQVCT
MS?H;QCXPOHT/6Y_VW!9\!G,\L#^]_ZMU^.O[S_29?_UY/AA[HT\__OAY.#ZP
M/GW]^\?WK[".'\<P+]<^^N7"9W^>'_XXL[_ON3#COR[_]6M_>KAK7'T\A?^>
M'K8/][[-/K:.1^+#\>S[5V\RL.P.[!&L!9[=VS=P_;A/1SC&UV^MHU-8TX\O
M;5C7SZ/W1\.C7_O_=GN]7KO3&^B#7L_2;;O7U7NM85_O=[Q!RS$[77=HOGAK
M@S9;H(.WK^94QEL)WYL$48E.0/)ZN7"N)=2:$JICYX5-[C#KZZ7BA]<FQ(S,
M"?R',Z+0P\FY$-@<J/14:Q:MP%S6/.5.ISHL*D1U#N]QYK+.X?7F6#3G&B"5
MD**,Z"38#<>32)R+($;W,7]1<_#3X& @@DZW.AQ<']X:AV>9UW+P">+#24P6
M"?BG[1/^8<V\3^;\.[V:>;?S\.QKF3?K\%PSZY,Y[TZ_9M;M/+SNB[<I#A_U
M.<AS;EETK>;:)W/P7>,ZKOV=HE^YV%K=1[LTXZ"UD8P#= I6+>, ^\)4)JI]
MZYC.2NEPF(#P2 L[9<&;-VI2\.P_0B?R&"H?\=%#QJ \$DD4NA&,I/WAA]2)
ME2JB#P*W2N (Y<O]-/&#'-I<^153F34L36'D#"V,I E/-NG VC(GF$ED[NP6
M'4@/<4P>XIL.4'N)HU%?)./-+@])?YEO7BU#*"5Z@7^8"H$D+8G,9A$7M' _
M<X*Y!2<8?X&%EXLV-O<8:,B^\"J9F9*O"8Y?U@DQSG]:YY2KS^"VZ24 JXK>
MU<P9G/$EYF4HG%V$")#I^Z'">Y6[=&-^N-H_@D(."0^/B+"Q8GJYQ*FB'$&)
M^(MU$&EZGJP<DP PV1!I!8AJ(L7'B<FFUYUAMAMI*CG6:^0@C@C> #[:["DP
M! 1FT6,B)V% ?&F>-,O@CDIQD:HD?);G'B,&7IY[&V6X3Y3.B<BS('_3*D-Y
MPZA3S-TTGPAJ&-XC)?9+V8N%(:!>R<#^JT:>"M)6%93Q*B&+IU$XTC#SM[P$
M<1E <5K0!$*%:+)0%0CK.U#OV.5WZ/C!&2.,OXN<L;@,HY^$^,KM-.0\@1"F
M@A)B3R;()017\RDZ<P)9;)3NS2D"$(%RPD\QE-=+RS!;VE -_TIV,Z"^TW29
M2RNC@)G89S!C3&[%WL@$XJHE :5%#WU<I;Q ,"%:A$&5B&Y9,8X$2D0DL),O
MVE'8I/HOW>A4:.Y+(+QCA<W&=+1F84Z!X&56-DLN+@"F*KJ,C89A"DI->/>4
M[NX3BJ/,[.22?12+*?!*?G>SH4Y2YOTRP?EI+V'K7^7WO@&,!,,3&YIO^ _B
M_=T,.1SI]1-EWG^2N%<O3Y+!%$C0U>RNH5O&*_K-GB X?/]"9LM_$!XU/56#
M$]<1L@[LX3X6HV3L_^DRD-[KW. ]LZW;!G!,VG-E#B3<JC[=_Y'"G4F=KT(S
M7@K<M0R"SY%=E+A<,?8E4$#Q8D_/-,/I:VJ?DFC^*:Y%D1*.D50+2O'\<*4S
M*A2QTEW&4 "$%*9-^*[*,Q=80X@;H.RE])[CI#/5(R>/\3X0A1Y_9?#=BK>7
MW*&D/RCHCEQ)">$8*#TG#R>2C(2J$LUP/N0NGQ1+4O:O9)E'[LI10]*:JL0B
M2_41+!UD,-_L'%?72&B9VBGA*6;?RC-,JTHF(X>W!C3 %(V07D4 ?=35/H]O
MB$!_$1?44D7<Y;F0B%_7<,<P8DTAU8KQ3-1/&ND8LC )5'E$M$<0*Y@(<TFZ
M>%D4(V<K2SA=X5&1'JG_*38 %L+$2U^;M84JNYNNG5(COV'S4V"@'2I<9D8@
M/$N<2E,[P8+QW(_3Y8@KAT%"&E2?JDVQRDD"9PK"YW>1_<[@"!4.FL*<("CD
M7*'B-:@;A:TD93>;@"R95H.78ILFL<3-+T<E'#L>82%D$JY0QC[W"M1DT5*:
M!_I=/OFO*>XF[W*.*:CJWQ.D :2DFF%JYNRZ*C'^3?B]Q(6'SA3[[E1HVLN1
M+5TU=18@8YZZ["GILL=#@$F*MYRCOG: .>@2DCBC*924M$EYK&LH0\HR)RZ^
MB:!P"A=6X6MY2?'H;FK/\"WA3%]K+\U7TND0R_:<$APW*O!;BIB82IEK $II
M^)?6*\+:&EU(R4[7)M>3P[4U&HG@C$2!Q"^D^E!2?Q'"_"I#_N1BUVQ5.0XJ
M/XFTVM(9<8]= O% TRS'(4K36$6#=WZ*@#7OR_-P)%@P7@H%/=M <9";GV3]
M\LDQ93 G,P:X:BFU,+/2YY'/@[ST*IY4AG;O3]6YUM616:S"WAIPPJVIUS+;
M3=OH;+Q>JV<U6WV[.@5;UX9K'QV!SN (D<3$16V@!(0OAS=> -@M*^^:$Q$,
M\+"Q_2W\=+,I$O=:0[?T0,KKF?9$#%)\DK^R6-$I[/@&EWU=6LB]ZT7*$HY!
M%8ZI\SRI%/+:!ZM_<NY$8R?MT)!] 5)L&OF#1(*2L>%\4@Q_--)@AT)DSH(:
MZ*2CK1YLP$F7HF_%"@Z3&8IADS'\>O3^>/_[]QU"[L 8A)J01K<%3(40->%R
MSVR$U).1&1(Y$.L\BASN&[4W(U2),V>2 80JB#!E!S"$XP*C9TVE7\HM6Y0%
MV=YE&*$E$H-!3,ETR5"R4QU1M@DK-!S+(PN6J5B%6&!S><+4G/SI/[[\V?SU
M\1#EODN\VJA2IHV>\R190@32YB"M/(_)#SSD9=@?(VQ4A",@SA1UK.-N[&P
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MXJW9:]]=0ZBH*Z+Z&L)!< &T'D:^6!XW?NXFRJ8T [77,Q RM7192[JXBYI
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M[KU@^)%%-BZY&"&FON]/'E=(XUX]BN=Q8O,=A1T[&N1A&U^RQK.I,2H!+49
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M/<^^C?_.5,9_"X'Y_Y[U1S'L#OX8#3,[C0MI57I:B)[>S,F<64.SH\> :J2
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MH*6RTD*LM/-Q7D=.S3!0%T%*K2%;T8+&2,$SFJRA3@F6>2G_7/ZP4 V0=A;
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M0)D%9$: ;O9M6N-H"(3Y4F&84?YPR@[6VJ(/,5=2^:*+?#&CEH1Q2?(LE$1
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M<+VJETE4V3WU&GQ4&:[6.;!>"1!$&JE0>>M*!7V.<]HV5[BN"UQ;EY@5KJW
M=49KZJB=D 0A8?2 45EPDDE@/"2FRZ;?:<-/\H1T"*YM%NKNN(/_+)YFJ=EO
MIGNMNGU7SOSE4:\DLQ#)O)QUX85W2FA)@'"BLT_@$SB6F88)Z:B30O!8SA2(
MY3WX6HNRLQAMW8.O&%T&HU?]=N_R<I]= 9 D.^](:?;;-4;P*&.VAS).-H[
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MN)<^K_XDEO[?% J+$RX9R42>X<_TPX'_N9*YN)&+B<T:<'?E\':]QDH.LW=
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M=@*,51;0,P$ZA "(5CD;2-"Q;&;#&O^OM/- :&<%,K'2SG*T,R,3K0O6<C2
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ML$;D^H_B&Y?P% PZ4M7E%$?JJ6NN#+/F]12^#G.\Y7G0-JF*MNQ":QM[PKW
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M8T6LO2P*?4\$\.\HDKP(ME4(N*.E:]*>Z_U*A,&<M)L3\0*J]D+R@7B(R72
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M$1613$*MTRW%.;B;_])DI=Q_T^4WO0P9*AV'LW,IV5V++Y/8V9@^8M6$FAL
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MB"+\W&!XOO8++D+?E!<SZLW4V%CNX"-M2N/:HF&T.]B'#IWS-093)(G[Y2B
MME_LY8SU)E\N35XN35Z[R5<P>3,4E6)%[[+1-\X1  /ZRXX7+/."]P?!\:'\
M8EZ ?:XJU'-(.:../293$+%T1F_:=)*&-JPF:'ROTB3IMI>IT%2ZF_HR-G/-
MT7+$LT:RF5:7@Y3(_F>H&-O@6^<56JF\H3_M@?8WP0B'(UY+)4Z5,Z$@4 4-
M4(:KJBVYO".@50**0 GZ<@*:U96+_5'T22U,]V,,?1B[F<S$-D7*E$.1Z,>
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M7*#/,+\Q%TGFQU)Z,M.AQQ0+/9ZGA5>HU)>9B%*=^0\>,V!X&U/8]JQ85T.
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M_OGALXN3T_/S=Q?P_OO7\?]\/OIT<OKT:IP&P$N4'WD9,!6/ 15[N0(VF$9
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M$&W$1F!9U'&NN69@'WF%9(7'TI!Y/.:YQ\(XDV'!519'#Q['M\,8=K>7HV=
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MC2IT[Q)4;Z+$]T?QF,LTTZ)@'L]5X3&=^AX8HV"YL%PK =(L]!5FI5[C)72
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ME%M7!"<_T8NZDC4N\(^R:B3:#[KM!K)^4(-EIY52>H#Q3V]>[S(PZTY3619
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MF-]SH5L81S<*2IF0'!'240). [$!!''<.X4.,77LJ?SA6O#UK@S._D&O7YJ
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MGBFFK$PZ6K>T8J<DMF?>_E-QK^+>XCSW4\->C24^*K!-<':4HIGRG B:=XE
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MHOU6E0JR*A"@3I="V)[JO+3"[&3)_M;@*.Q<%I/#'7?8.D[]A,+1<D40SMY
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MVFG>:V683CPH],6FU*FMX%7!Z^6!US-@UPVEURMZS89>X[87-2Q%#H)D")R
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MK4'MN!_ML-B1;/<7DE?Y.=9)"@_H[O9C_!RE,-SF[*B\&VLM',WS#%%/Y]T
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M> @SU?U6&\1NJ\SS+JIV9*D[LQ>=29KNM7^HU<TE[F/HCAW,PQQ5$W]DJV$
MK / MC"I"AY\R]5F<]/':<$PREN^D.][_0#3(RA-K*GG#KU)S%DA+)FQI[+V
MK"U@N@=DR196DP>#%MX :>@5)X.UK"< >N7,3,C[>!"YLG\K!PIWPZ#4G*NR
M_GE>"A)U8V;&*?C7G^I/*U;VX>6G :6",;L+V%XF3S*M*)/' '-C!"RLZ&H\
MSM O6@TD.VH/2SF%P9^--[G9Z;WV"!;+5=;[&"O3W-7>51O2:]B0<'UG+R=^
M+7=#RB;P3_:87G>A'\..LN@6-8"*2'S?*SP\I<L"%"R'R]S)O"@74QE!*6.8
M&,XYT<YJSY)CSF.:L(Y'1!&U<;M_XJD*!=%?=1LM4%IM3O2K >(-$KV$LJXW
MU>=CKQ?RM&]WPR=0E.YQMMNW"Z=^KKG=[F6/SC[<\?<VF'4OK2&7[]F_Z>%%
M\ZN7S<Z']N''.FEVFI>'.\?PO<-VG7XX.?SX]TG]=(_N?JW_@''@P_WC[^'C
MWSS\OS_;A[3]W9V>M9J@2<W+OUN'IXUONS#&1N?@LOGUP[=#T*[&3E,T+]]?
MU"\_MW<_Z(OZ/FC4#HSO](#O[GAQY *+!&0).448R@>=R%'MD+#8Q$2L@S4I
M40_$,8;M?"B.D_"$4("\J#GW7 <:F!-!>BNPYWRC!M:W/<LV*JC+QM9D50J9
MOUZ76KDP$^4;R\2,7;?0HOOE &Z3_><PYQ;+_F0.?N5!?*Y1WEK*:Y8#%L=B
M'NS TB]1^'I;HWZW)"P-X!&3PE^TX*Q]@+CC;BL[8H\GZ_ZKH@2S-4RMEEH'
M8APLIE/))&6PI9)2*@,@>@[R /T'(/AY=;[)G-\MGN/%:_8]/QS\:)SNB?II
MD\&SL/KE 3U2C%E'A$8>J^RM\QY9ZP/R5$A%M8%I+QJGWM;-9MRX_:H*T[7#
M> #\L5_J\!!(]R#%?D'(OX\SI+IQ.#Y^+<6MGRV[J>(GY=7.RGIO_4S=QIMH
M[BQ5&UP TS]NQ2M/!NRSKC#"X)>S3'"+_1NNWW'YB.R\U_\&8_2S>^_3;D]?
MQD=TNVDBFM5>--F+CB^./&&&>^41#X;#7F03LHYQ% VG*CEBE+6S>\O*0>C^
MC6R_HKAC<:I4F!J%9!:6\V#B'?"VW[\HSNZN/!X3W%QD79<7O-F('AZM;<\&
M\;?)+_\*K<%9VU[\UNH6 RR^]*^;GDUQ-E>=LO HEV]?>UXW<>E]';>K&-]Y
M_/9F\=9,K<WR/<TWC5"WOHTWR:WO_>RRA&YJSNYTV5]TV5B)9AIZ(E/%!7]K
M#>%F_N=T I>Q'MW:&&L'_YRM>7J_ART/#Y[Y<7_Z<*5)>^.IWD#'E-]MNW"6
M+#Y/)T_7]O4UU[U^0UUOL:'!.D,YY9*[I%R ?X*30*:IX:H(C;Y+P?_%K#FU
M?L2 +F._]PH(\X>6^W@@=_>/:8/6V>'I[^WZ3ITT=CRN?WP/UZU?YGLW+S^)
MQOX!KW_\-/[.WW OT3W<[XG=G29K7H9._>/!.1!GW+C<.V_NOP<278?G_'Q:
M/_V6/5'GS;8N"UR7A:YA7/Y\=^\H<::X9@(IKP+B/"ID8M!(FBB#L"(XXS>
M4FN@D?]Z8XUO5QF&KCP94U;N@G.3J["KT@HIK)ZJ]^US=7.Z<@*.S<B=(G#D
MKR).I *O^X'7Q0+PHB891:W)1?G!5L.1(@W["_)*$S#4'$U2_LQ'4'7<>Q*5
M^]#KP\ON.$+37Y1NEG;I<KFN=OVP)MP+IJ,"HKL"T7AE_A@OS/[UNGRTK>Z_
M>X,5Z@.Z'K!T.05+I+X#SW=\9'5R5'*!O X<\60<TK!ZR!.7#$\.V+#>V,*/
MAZ7%T%!1IH>8M?2^F\%/^[7@G[5L>>5V[_+GY[7@.@\V&&:4UX3PX(WAE@0A
M(I.&RL#"^#CI'H9Q!=8/!>L)AXS41DZY1H(3B3@!^FB=P(AZF< :YMA3FCGD
MLKHV+T\MEMSL:?K@>Y5:/2T^Q5YP>/\2IV<Y1BSEUAGQWZWO<2[48S]/<G6R
M=G6R1HX8\T$+#5J!$T.<2H:,UPQ10H)D7MK@Y-S)VG.MYH=J)>^^DBKG.TGN
M8>E<+O:1JRTX:Y$DL,D)DB*1;-$9Z0H>AK:ZI8.Y"%@N$F3R9\J UQO^M2O,
MF<0'_*0<U5J?F7*SJ>7MYZ(//C/%F\+H!UWVY^]QOD:#E;@:K,2T.CH/6>/[
M10#&JSU"/QC$-&K7_MU*\1Z/-MMV>=UGX6._-QC4_IA$V"R(*WA;\['M_:@S
M3M.&R8!Q7?[\;.KU3TDC#FM%.NG/I.0-G![LQ.^QW3L#P9C42BILVMM/"^[P
M^'?NGOQ2(G(O5]-"0XCHP(S%6L%7.5A#+EEOK#!8<(\9OHLA=+OY4X)XQO#Y
M4HAAU+^(MK^V)E'I@8)KL^*S]+#3V#\0C8^')X>=]^>-4X]W]]OMW8^-=KWS
M_D=CW@,%SQ&R^<0..TW2V/^&#SL?.LW];=JXW!.[7P]XDQY<-/??XYD0#%H_
M_28:YV 2:QLQYX@X;A!/3"(;?4+>8!*(-]P;D9.#9KTTM3SMCU*+VZ!T.>KT
MRMS:]WOVU^*R3I)J:GT4G&@NJ=%@UFO'I*#):";(75W6/W&M%-SHU;BRGP](
MZM.N[-PE.&JIE.8.16T]XK #(*=91"9ISC!CP6JRL<7X)GOJ0*ZE^*DK,*O
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MWSL#D;OXJVV[P^UN>/^_H]993D=YTT'_QT=*)1,XE0A+HA PKH <Q@I9RY.
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M?'&51X6%3:W';)VN58G4>H5#? .F]<(XLT>?9:_:4]X[^^!U)!A,2G4MUR-
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M0Y'S7B,.6P0R(E"$L:?>2T=-*-PO9+[LT 1'[R"W0#L 1+_;]B@N76A!/F$
MQ0Y;6"Q$E[SZ7Z4XMP"U6[GJ3F$@OQK<_C1YI-\O/D>@=-GM6+[S9>1.HZ^0
M_&$Z\6-W^XC2Z!C#'H@X!B3/QQY J RB5!I/(DTNV/L@^:!<D=L1?'ABA_D
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M"C9--,C&I)%(CB6,E90^5RC9U&O0B?,%%.R_[[)3/66]_[<-6(_K<5X!UAH
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MFY9ROF1*P_Q<J[49A(R"TB5@Y,ICS25UQE#.1)16\< <84]7D&F.0I::/V)
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M9'4D<IF([<S9>I<TF/;) 7&<\')#>?!$(B8=6/F1&Z2Y% "-G%)E/ ?2N\2
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M:^Q\VL<2L(]%@I1U*=<B DH@N462>&V=C@I0L,1+D$ P"[/!QPEFPG-E<Z4
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MIQ6R0>; :IAI+!CEEDRKVW8I>&41LHPILB ]SZ%).S/59X-+HNVV >]ZM=[
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M7>G/]R:<)'#MT1:M?VL<-DX^T=VCSZW&-^C/T=>+O:,ZM'>+-8XV+QH7?YZ
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M81(<SM'/\'HU_/&<$)6&WTO#)U*<4L(T83P@A@E!H.LX!U*"POO A&,$>\)
MPPE[^ [C4VGX*Z@$<"/O2^LJJ=_]DK_<U6QZSF>\KAVJ=YUVT9HBXUYL-SO=
M6KO3GTSC4GF['RFHY5JBS&MS\:68BD:>B64O(?54:]*TTG!),V>BU4B(!&N2
M<1[I*"TRUCN"C1 !^ZJ$U M5ZEDR/L\[\.4.6EUI[XS:.UD SC%!')8H&@;:
M&TU !C06@49C)11G..2#=5,<S'?/]UQM7LTI5O8:=WQ=6UJSP- CDHNQ(+QK
MWU10-!L432M\E @F7FJ#J"TR&HF0 V$(8I$8#2BED@R%'WVR;OVS%+2N]KE>
M#H&H-'>.FCM!(H2-5#O@#UCIB+BF&CF92\EJ:Q+#AGN90'/9DI6B?RDLXO55
MI7]*OC#%ZWT=>*H]]MDQ!D\KBZA34,0K)#RVB"OXX8J4 BIQX5.,@O%;JGL]
MBZ52N1<6C!U4>OH8>CK%H:!=Q)XC$3,7X)@B*ZQ'G%D0T\2IB"*G )RR!_V2
M/0J+3 "F!,+,R9.P9'OESTD;+JO:5;;)O?&(3.$-"NP/+91!L$AHQ ,GR"6=
M$'7,>$<BQP2OK#'Z(-XPJSJ\()?#*U;Q>3..2L7GHN(3E",'MU&8*,2)AQ^1
M&628\(C%2*QV/@:J5]8X>] FQE.I^"L(S"U*WJ1ID;E%(M.'<I-7'\?W.#E#
MKH%6%<]W#^2B4\A) 'R28!(A8Z- '*8-@?'DD$V81>="2AB,):;HW!(6+0Q%
MJ2)V%R!BM]+T1]+T28[B)<4R,F1DM(CG[((NP)^6>B95M$2(G)E,3HNT6%!-
M?P6>D[]M:U"F0;6Y8K-M^_LE0GT5V[>/=D#H<A;61Y-0(=)LB,2F.4:XP-H)
MF1TC ?$4$[(Q$*0D3]XE(GG>4)&J"K=84GU]M.,^E;[.05\G&(31Q$F3'"+.
M)<25D<A085#B.G%.M&#)KJP)/@]'9N7(N+,CXP[GB^_(U,J>O&4PWJ$SR(=)
M1AUXF(&S:*-V]Z*;\Q^?A0;O1>!:UVP_D.X*MV?#;3[M5+:07!39)2,3N?@%
M1MHY@8C2VAMKN,[I(1B>7W;Y^>G+,SN!*N"L@'/!/&85<#X6<$X>=H<ES2EK
MD$F1(Z"X$KE@% I,*VQC#B>2 )Q$S"V]WO,#9T&:_]6W\%+X-S2_KXVZUAB<
M@&[XM7_#AZ..G-CN0;-]K;V_#S_)#90%E,Y5&PG^E3K2K([KO;R]MQ%]/'&Q
M6V/D32VSD3>USJ [==?O+'9C[;0+RM:%UM3ZAS&7-ARTBFW"=MXMO#H(U>GU
M:CZ7_ZR-ZG^^@;^GU$3TG5X?OK/^?X-F?E]S/(]PL=F86U&68RZ?.GKH:NV6
M7A1W98QX \V&M_DL$J%F:]\G?87Y ?^W"*QNFD5^_41T>W""0J>/A@]]\>BU
M]]]#[$_^;MMO9K!]M$[V=MZWMK]EI%HG\,ZS7;H%[_Q$MC<^$?A7-#YLXOK%
MYH__7@#:G3W$-58#?6H50@!B,LO</ZDWIIK[J7-_T5A_B)ME-/=O,@B=1OCP
M>VR= P0=V&:[UR_@[R!OJ$T!P9JSK3PWJY=K5@'^/P/[9T5W6'X/H9NGG6X!
MR\'VXYL:/-L>Q++$?:?=:\):V0/\/JO%[_ [].Y-#9I_6#OM])IY< HE:<<#
MF_]X [AO\XV#%L!I2C!^M69&:1B>7J]X*+PWKPUIT!]T,_9FR"]9UWG^[I;E
M91S*2VYPM2I=:W6(_=@]@2Z'_")XQYGMU7J#E)J^F;^_;/BH0[5^)W?5MP8A
MENV'A:39JYUTNOFX[G$LEC.8I'9GJJMH85:(<?I:(<0TA-@\@VL>9-%?K0_7
M)+@55VL[A]?81,4EED-:MC>^SH5,%&C:ZX-D7+%DD(=>'V"W %&8 ,#H]JUD
M>41KBXO+VZ:QWOR<VMEA$[#].I;;=H:O2YS["<0!'+J17,<PMICE[F49;;9+
M ;JQO W7&$5A$2IAM@,64VP5:\/O9\W0/QQ9^]?N&JZ&^.H6Z\ J&_1OO^6:
M0>:A=['[3.NHP6.C<^WG87?4FE.8!.1@0(^13=#8M[9U9L][*_^ZR0V &%P?
MP/&^ESU<^[?KPGU3WCHV,:6B"FJB=X$2K8&1*J*I<QK^$=R)8')=G,6E)[>M
M]6"R'=HP17&:16QVL3+_4H=F1&)*)!#WF*1E'I@]-<P+BP5A6'LMB+HK$E^=
M88<FO;O>H@J IP/P5[R]XPD\$]KVE0&Y9P96;LL4+-H2?@  (QT(0#,-##M-
ME<<V'P;A4W(UW]NR4R""V@J!121<>F\3QCX1;3VSB0M6S?^3S#_/,2_>8JM#
M0D:8G.TH!F1SLA$C% O2"4MSBA&)IW@4IQMWJ[5O):+,( _14Y*$D\(HS9EA
MCE -0(N-#EC)@*?+PU;C_7T%8HGRW<U)%D1]?5\YYJ6C' 49#>)4$&1<X(@Q
M!:Q9"48]L/AV9U(24@3#UK:NKQD_YUP_69)6:^^ B\"E[::=LO+ NIBK]P"I
M@L4ULZOXX[0)O O^H)@1$+,6&,? "L$@[0QZ0,4&_6;I""V\FV!43'UH0:RR
M)=JI=;*E6ZZ(/WL9E:NU][>RS-&M-SRS<".8O$W0A,P1;V_J##Z/!7=P#^G%
M2$"NR/;G_V=/3G_?N-7=/"NGN!^&W*U8];NB?3?PY//0J5XM-+=8>K1QX?=9
M@HFG*B!E(T5<&EAG%"!O<()IRT2R00'OUZMT?N1B7N2R$H0Y"0)\MF]%!&Z1
MH_N)R,=ZK$*.$(=B\MY0!B1$ <U0=%7<F6:\'T+*))#\=(50/X/=ZTO/M.?>
M#N9OLI.@-0W6[K.T,#:?Q>&Y5H,0"M>#;>6!N>:@+KM06M1#]_04VS)K_"^7
MASR8*>5]@N&SX<KL-QQQD!-[GATOO8$[RGYSN-QF+ %[OE5K-4^:_:(5;VJG
M@VYO8-O%%5O9^='.,A6_Q_8@UMYU0JQ]B84@]FI,EWN=3+,WF<+8:WNRG;-V
M[/8.FZ<U?VC;!S"6UWSW'>^AIWF:+X=BM=;H3+GIT'Z/Y>6%5_RPVQD<'-Y&
ME!9>#K('MWER"HJ<A\AFV/:QV[?-&]Z%D:.JUBD'Z-I7W0ACU:Z=#'K]THOF
M.P?MDLOUBVM;T-,(7]J3SB#/8;'?4'KB4.F)0]D3AZX\<3UXEBWV,P:G>749
M9-%RHRWV5OQ>R(+]D:71#OJ'G6ZS#VBS_JO&%\J<7W.SG<V4G8.'("V%.A=N
M05L3^!^EH[!YV.F$/#@NYA=>-F[QY_;;M6[F2(+8+>8!U.,T@@KE;9/KP'=M
MR&"1[.=ML)L#"? 7V[WXJZVI(9^TWG=!DTOW[+W>_DR;!Y<9#S9_P*RT"Q#:
M&K9_/7<JAHI)_,)>A3[M9M]%3,YA2RBBU+J<J5DCF[1"R?D@5/(L2KJRAG_"
M*68FEX\I!A]'DEO)P9WEP)_5/^U'+(#BNXA43H[+N:;(:K WC"0&>^5TR'X+
MO,KOS"VW[H,H1<Q67@'@ \!4H!$9G'*,2JW\%[\(5,_;L-=84Z95Y0Y(N3I_
MS7PWU+Z4%#:/SW?;S0QURA;"T:#;[(5F29]6:R#NM7,PEGK#@<&T^&7H&WB3
MQS2>%N_*'U]1\8S]1.3&P+^F^'+(H^$ES=3T><DNWW[CC6^&D6EPS[!5!6TO
MWCELX5AGXY4V%IP@1R4,.4">_S HPAOR,%PGHWDM&;0OW4Q3?4'3.6UO3")N
M!#;>1)ZD)&="$<L#YD(RIXQT$KN8!),DFOV-C#R88(*N(.@FZ'SQAS$,6G$[
M?6U?4128E3]B&PR9?N]SI]5Z7_9I)W/I'7C['ZV./WYU&%-G\+Q]D!P<K1*(
M$HT1%X$@%Z5#@5JN3$BP^, @1T#BT[R-"J!]?7/Q.=AVZN00A"QW1<1L-A][
ML9UCAD#,3P!EBEWRC'[?<XC0-4 ;7!.)0D+=4"@F06OMW^7#+W><BQ!@Z&;+
MGO;BV]$OOX=F[[1ES]\VVT5CBYM^OXET.5'P6/AOL1M=?GVU:[N*RYW;X>FY
MX9N'7Z\67XV%-)??";'*U>U?XU5RZW<_>RRAJYK3>SWVY]])?+\[EZNQ_$Z/
M_<5QRE\>=R9BXMHI1U[*B(BG.=NAQ_1<33W;L0M+:&VSG:.BKCO<;X3VWW%L
MGO6(SV5OBP>^+>+5_1WZ_QLPD2%OZTV<XYUVR&J&(PJ+/?-Y89]7A^]2X6Z9
M!HY4 W>_@<.S ,LRG&'_HXP[SR[&/VU[D#G3A/ \;@*N11N1^QZSK$Y1SGQ8
MY1;+[,6[>X:G)^GVQN?6[LX6V:7P'KBNOA&.=[]]AK9M\;T/=9J?M9M/4'X9
M/SVYRQL?_CZL'_U]M+=1F&QG#?KY$.ZYV#TZ/"[NN?CCJ'&4S;>MT<G)/CQ/
MU#=VS_>C#F V$X)DRNG&B&'(NJ)D<#2&:0,V%%E9D]/BW!8TV]C3'BFOH.RU
M0)FV6EO'0Z2"<*R#X]8:+00EC%LA;0%EN(*R)X.R\S$H ]S2(E"*+,<>H QK
M9 25R :,#7&8X4B+F,T74_*\@K(*RAX#RJ*)R@IF&,Z\S''MA$Y,1 X0IR/A
M&<J(J:#LJ:"L,<[**&<^2DT1,UX@KKE!AC*.&$GY2)B)C%B LFF)ZA<4REY!
M#MBMMN\6U7=_ YTI?OOG]9V$TVZSTRTV^FY$R+RR KTSH-2]MO;N 5>C><LQ
MJX-6WIU\W^V<?,S3]1'ZV,G7?AS-5H5M,V%;?=+BY G3*()$FC@-=J9V\!M5
MB"DO91#$>F%6UOB4LE\S0EN54G9A55L$;)*&!<X&P0733J; &*@XQ0ZF'Q>J
M34:J?7__4*7:CZK:XQ:8"=$P:RDJPHXXSEGL!5%(XT!DTB&7V<D11P_V)56J
MO;C9HKW%+/BDA0"#(GFA@Y>:&"V)"F!DD$*W\4BW[^\PV8B5;C^>;D^8)$$G
MHEA*,&D<=%NX@ R. BF8NA0\Y][@E37QH&J=55+I>]D;UXR,XH1$NS\O,^/%
MU@M^,6;&NW+"*L1Z(&)]FC0T'...Y 0Z.B:&./Q$1@%V14\Y\!3F4O8'$S'E
ME.7]G"@+Y/*MM'LA+(U*N^>FW>.V1J3)!&$94IH%Q*7 2 N3$+<9HBU.5K/L
M1IB7A[12[L53[J<R-2KE?ESEGC V<,#,\D10\AQ46J<(B[@.B @ ;ZR]PBFN
MK,UO^Z/:X;B3:GZ)_7ZK2/77JW8V7H#),=U%<FT6OS7[ASO%H>[UJ_-<2YL3
MZFEA[>ND16*-\%YKB430N0@Y2TCS?(0*"V,HC8X)OP(0IF'*?Z]\I$NK_T]E
ME%3Z_[SZ/VZS,!R4)9(A:XA'G!N+K/4!81*,Y8((E@N55/K_(O7_Y>R1_!H
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M9N+M.@9O ) 8-JN@&/"8DA1<RO+PC7!;68$:OFZ6Q<I&X-.$!X+I?:,&=1K
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M J6^GJ8N/'04$%6WX:7$.CV]!I+&QC%K['SE]5QK;<?O!V&-TH$@[RE%G(N
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MC )9\P/X>39G7NA$/D@D.#T>_M$) L?C-^O[ ]=?ETAWNED_UY=.3WUO[(Z
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MP8HUU2N-S/GHF6E=C7,;GCYIQG;D:":!9IQX3<'KF-[RC8 ,2O31&J[!H*:
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M$D0>K#5*B"1E:R5\&,1^E4YT0[,;.KE#*;8\E'YA."JF9^/\2YA76-_>EMV
M!X5;&Z0M8(J3H**W$'22X-#50CEG,;4^"G=/J'U*-IV*>2<0:CL&7E\FW_LT
M?-\_GE%876)M.@9&D!E2*1,LRQ&DC4QE8:0.K?WL_9#UZ@S.0ZFVXV76'9]V
M-G\8N.(L4]&0QM6B%C8@>(\)F!+&N2!4^TW,_=$=6!OR8_*JC>RZX]:FI!Q7
M%Y MNS*OJ\\'PB;%M<V@LZME,XXF LE)-\'J@%AXT*T+2P[!=V#'GQ^37ZWD
MUZ[0@A!<:^K]7;>NFWY??>'2.]_A=#BI7?*FM0_6"US]3S^OJDA>?DUG8?P1
M?PMS?%D*IOF@F(3"L@ B" 0E+;F;6#RX$AQS-@;3OJ/!24?844AZL>%[B9A>
M)M25DYJC(^^I.(@Y)0J>53)"R4(._FE"TBWH^I03ZS''MW1LZ$+\#Y$Q25[R
MS)#,9.&YGF^RX$+DH*5,,A!PQEMG:N^;,7G@0Y2/GI['BK]K>FY+9)JZ8@P:
M8(4"!L5D@%"O*[.N>,P^<Q\ZZ#]SKWV4!SY%^>CI>:SXVQTT6@[Q;;D\[+?C
MHR9X0!YH\(:<TI +#<3$!$XP#LQYQG@6238O:^Q@&'TZF/"("/_0A.I:<6_S
M>P1#YBGJ@F+K$<%8KW"/@0&:HNLIV)QXZV-X]W5[CRU[0R]%$9J!4\X3-32)
M(IH$@=.W]2BD*B<L>^OEQO:Q#+F]9=HA FAW1O\L3/%GTAK+'H0XGBVG9V"<
MSDJ3BM#*BNKO!Z@+$J0N)83H6(JM-]VV(^F3[WPB5C002<,[(3Y-,0U7"'@A
M%SNS7-O.<U#(-025.&2I"I-%N- \!W#Y^7WR4T]$A7M/?[M+:\YKA[%_+Q&L
M3K*^&,Z6%["]F^+Y<'$^B"GEI4NA>(V]4-6+F4(&[LF72*Z8$EOO,]P)JD\>
MWHFHTE90'?'G(CA:G@ ;!!-9J)=U\^3)XI&%@^ I3)*H,5L6A;;-[Q"Z!4^?
MK@EX$-8<(9Y3]\>P.G-AK0;IZ^YKU!&<]0:*\];XI.OU[ZTCT6;],<P#[SRU
M9E$',NON5JOEU<ST_W-Z<5A#4)91\GKYO*EWT9,O!=YI 2PYB5)D+53K4LV[
M,/7IAH*3>3H-Q73"=BM!U,8=-&8;I"&CJBWXX!)8)DI6F;-H6I]!:=)NQ?U@
M*JBMI-KV>MXRULT)CXM3'P.=,WH,"NH%E!3].PD^D8LOHW+1%";:7XNQ-[A]
M".5_+'W4C>!:'HF[EO.]>2WV +&0174&7%8*5(Z"QJ\E,,9T,0Z]]:U;0>V#
M:Z]$'_O!]%-S@75(I<UMVZLQ:^D(%F"H]SB4E,!+%<&:8(7F,07=_CKS6P#M
M19Z'+K;OGCSW%=$)%-"[\*V2N78536FZP/QF&.)PM-ZH3YGQ3'J2148,UT)
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M*@8'4?HV<NTA#&T![+>YY3/PD67.0@:AJH>#0@(M7F2I2L6,*C(HV=J)_ ;
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M8W:4W-M";ZW[<RR _=:-\.MO8?PG3E_.Z,?%CIZC<TJJNJ,K\@E2@A!<(,?
M>9FDL])OU@GAMJ?LWUS:G[*Z/B3=1^@8CFO;:7I;#4%Y@9]JOLM%T1O-1?:2
M _.$2@GKR%ST&EA5L7$6>?O L?5PG@!;6BME;X&IQL8456)@F250M)9"5#9#
M3LP$+57FKG7!VR,)3#T<1W961 ^6]+JP;IM90 RN%BRA18YE!XYK#<:)&,B7
MP&CRXTX0.@X?K(5^>DCI;AHKN<E8OB<0K:-I"X+TF9=Q'^T>>P)1XC%FGR6P
MD,C]B(+1#E#[$@ENO%:<M4^?/'ZFWC.!Z&B(NHU2>['3;LLTL#(CMP1)%VYK
MIS62%UH&7&G"S43,S1GWF%-"MM+U5BDAVRBJ!^_P7KD#18G:$B0 $[5[4#"U
MKUI64+PUUB?.<+F+_?>4D/URKG>U]K"@5>]I^O5FH@J/A?%<@Q1E 84"P;F@
M 4/Q7,E@8F[=SF<UDB=,IP:JZ<,7O0K$N78Y^G*,_YKA*'V=6PL1(^,J$I-C
MDJ"*2^"#+2"544$XCJ(T;]1S-ZPG[J,VUEL/9:%6W;I? EQ,J$T@[C$ <PG>
MP<,NVZAV@\"X%GK94Z3E,M2LF0\!(P2=:O,7Q<!K^C$SH56DA9KKUN?O!Z/.
MYE&5!V/.-NK85VSNY5I\<3O@B^'">>!.T\)KE 5G.*W#W%@M# M!]98T<PNN
MXPB,VDFAF\3@[J*-M=[;/K*H"7A'AN'I,-0'=.6F1;?W_.J&D/K+O.Y+;DLY
MV8K[Y*/-@KZJ&# X%+)8K95,T<2XEHVMP!T^)_#U599:EB@8$\!D8;7\;*EG
M?;8VF+)"U#3'Y7:_1Y$7^+I5MO:V8.9/_V/4Q0GYB-4ZGP=P?DN.9Y'\P9"F
M@Q 9V>F,=LYLZWF3"!!S8( ^TUI6LN+BT$F7VXSGP:<(;\'U73,R>^-)#^>2
MRTO9R\^_#Z]NX@<YB!(*^9L)-8)26H!+P8)D3#GEHY>B=:WRVQ$=/P_[T_X=
MAT4[J*X'(_MM^'I^8-8]2P1TC%?0KM=G<%((956!,F_+B:E <(%#L2%(6U"1
M8!H3;#-DWXG6IRI[.*5<-1VN*E#_2AJ8EYO6.F)@5H!PM>./-A&\T@QR0/2U
MA78NK8N(;X;L.^'Z5&4/L3:K7(5_#J<G-R2TY#]\*\^Y["\O(-[,IF_*>4;0
M@-5TPI(-.;FUB!WYNQ!8,, L>ND+EVA:[[T]#^D[Q8^2/#V<Z]]AFT27G%2)
MYFNQ!92A7<)+#!"LE*R0.$MS:F]C5A[&,3^_\)&.$Z=DO3YTH1ZE"?!<&X@H
MI5:)!X&]7:0]T6(]>W0-V^C]H17KX99CX0RL3+06)5U+4=.*22N1=-D8&WCK
MG*JG4JQG*];<LUC/%MH[>"&53<!^+];34N.[%>NYA[H.SK'HG0J:(_#B#"AN
M//A0:HU],JZ23'H_E\D/LUC/WJBUC9;V7&J#.\E-\@@AU.Z6R3OP-EG@P8@4
M6&9>]U:\[N&5VMA*D5N4VMA&"WT6Z[DE#D.Z1)MY4B!3K4#JO8?():?=G3N>
MC'-,]5CE\/$&U36RFIKHK<]XS5LB-C:!^#VH;D?5WB,TZCYZ.5!0'4JA6/!I
M$25&FS=X66I >Q;H6)':MSY)?\A!=7TS9QMU'"JH+GN3(PL!G-*$++-:_RP(
MJ-D06J=DHVJ=T/)P@^JV4NA]@NJVT48?%M":Q,/D8]0Q1O(1F 85N0$RQ2(P
M);P-#EE0S6M9/M84]YTLG0;Z.?84]TW&\CW%?1U-6Q"DU\SA>VCWV%/<A;5"
M!EJTA:<-03E+BW8T#+ 84X3!D&WK^Z'C9^H]4]R/AJC;*'5_&:&:6V-$)-M#
MU@@R6>,K(B80.AK/I;."M:XU\R@S0K?2[F89H=NHII<VF:>G88KC<'ZJJW1.
MHD@+G,F:G5$D..=I@$P$)[$>L+4^I_H6P=,VU';01@^A'U=H%O3?!$]/-M8R
ME@/5:MU!/VM5O8-P>RF2LH0+!=>VR  8Z@(5$@?:4&EKS5H:)9C3L7VKW'TH
M^Z[:J#WJ>AN9[L]*B+7@>70&Q+S7%1<,?#82)'>6^> R:UX!YUBLA-TTM-E.
MOXUX]Y7Y^+P;?:Z%-6GC>H^C83?^O9OBY%G.\\^N)E#IQF?S>,4=DAGO\90F
M^8F[CFXIY1"=<4Q[EE1V*EIT103-)=F$@4PXJP;W>-YN$[D6I;FR4E]?!L)Q
M'HW3J$$B<59EZ\&IHB$9QE**@6Q*V7@FKX&RZU+U[<>^# F?G76ST710T"I1
M#"<#W%6[.9#=C#)"$$2\8K)CL756WCHL^U^N6NA]>=5J(ND>/)1O<;VJ%9EP
M,GU'J_7[*7W);\G(IU^$CSA0(?@DE0%6VVTH)VM+\!@A9YJU12GA0NM@Y,W1
M/4:6---&^T+NX_'7ZJ;-*?RF7#AS7Y]W9Y^Z$2'\@_YY-9G,R-4GJ#E[GSD'
MSP(9=XR<^\"XJB7E5%))&[8<U[JVM/LVSWW8E.A;T#W$4ZQG[XM9=>.)O<,N
M#T(0,>OH(7G-B+E9@0N\KGU,TO9O;1*MPYPW0_:P"=.C%GJXG?H6Y373;IGR
M'T[PW.*_I/P@YA+(TF?@R-8'E5PFZ60!U@@T42<3<^O;\1W@/D96]:>O'@[:
MOH7^ <=G@\ $9R)S6AF#!F53 >]C@FA2$(5'[EWK$_N;*!XC,;:6[DU]Z]WU
M77 \QGQ^TX#/N\ET\NNX)L+RF+*)RH,)I:;380UE%0)B(1O*9IE9\Z81:\$\
M%NVWD/5-$IBVD_X=?IJ-TTF8$-(KU\MX7:0,!K2UKC9ARN1Z.0DI6<48&5+8
M_-YN UB/A1AMY7^3(G;W_F>?%@4;:L>;.!V@3TSRP""DF@N<$,$5,HD\#344
MF0(OK0\]EC$\#N7O)-F;FG8[.:N7=X^KW*=79V>8AV0;GW[]&4LWQE^^3,F8
MF0TG)Q7_(%NF4O0"#+<<E B*=C&A(7O+4/K"@ELZZEOCNNZ"XF&38K]*N,D>
MWW8KN18H.D^6&5C!R;YU$;(B'THIE! U+V!38D:BLD&UK@=^.Z*'39<>I+[B
M^&OG<]-G^;]GBX(^'[JK.XBW89A?C9Z'3\-I.%WR@]Z4:V[3O.#]+$[FH<S3
M:Y\VB#%R873M(F*([9%EB%(5X 69B(69F%H?L_8VF,=!Q>/0]0H6]WV*^VSZ
M'J?3\V((@YPLJAJ=I;'F 9+C#E%E#2X(+G.VP2R7N+OW*>[UYSYL"O4MZ!6D
MV/D8M]:-FM3"43AY,_IV*UZ8<T9I*ZT-X$BUM1*(!T\[,22I;2)7SXKF!5'O
M!/6P>=*/[%>P8^>#VV<I5183L/?3,,IAG"=_?,IDO/U2K_,G=;U[/9P0SI 2
M5X4!-S:#\N@A.))",2&4PCV+L?4I_X;0'@=3^M##"KXT"'/\9A_\O1O5H,[S
M8V$M8JK=.@J7H%BJ+8@5J]W3BLX9E3+M0]_6@'D<G&@CZQ4L:'8F^VJ4NC/\
M$+Y<B__]'8FES!L170'OR(A75F:"EBR@R;I&_QC: 'LZF5T#Z7$PHJ7<5_!B
MYV/:-=;TP'&&F=.J14QEH- S"(@9$K>6>Y&\<+ZY$[02RN/@00LYK]!_@S/8
M*8D$\R]A/**M;$*[VNQL5H-%,U%WF(:T=$7K2A0T3I5I_;+*DX_D F2&"BUF
M%W3[4]F[4#T.5C26_@J"W/OH]LY[YP^DZ\E)=YKIM0FFV73X&3^,0Z9QO A?
M)WS@#,;B21*2A$#[7A;@HRBUU7ER#IT,KM]SN2W /@XZ[4=7*UAV[R/>N7O^
M=CP<I>&G<+KPST?GR&L:0XV:&=B4A$96@$10"RM)!K%H"<;Z2.93T7PY16/-
MP<<=#WK8)&@NRA4!:HVC7:]'L5S'.>SX@$OC2JHULXVT) (C(!1##E1,WAI?
M;&3[BS%: O>PB=*O+E:P9N>$G@V0$O$3\H%/I?8M-<#J8E;;U])N:1VD[%2(
M*6ARO_?/FG-P3X8U]]#%"M;<^QAUOA!N!!//AK.S 1I+MG>2@(&3A84A$<ZL
M:A9 C>2V22['HJW97C9_YL.F0I\"7D&$G4],WY^$,<Y).9!DWS 3 IA2:/T2
MM!-&EFD3=,[;;(-6V+IDS]73'[;6=Y3F"L4V#BQ=9>]>Y6N\*>^G7?IS#OS#
M>/CQ(XX'4D3%2_3 LU6@F" Q".*IU#QX3.A-:,V&'2$_#@KM4V\K>-?@,'4-
M_IM08^08441 %FGMXYJ!RX)![91>T(B4>\[CNPW=(V?3;MI809S&0;&KB'_-
M*Q^@12')R("H:_.18 (MKPY!2C*A+!E4.K:N6[D5P$=.GYUULH)!]SZOG=M<
MOY& SV9GUQ?'!;9SEG>OPZ2&^G;C*>;WX72Q31LGR+_G$;ATM%P66C.C8P*4
M$4(5DV(6=^:X[_#\ATV3?0E^!5D:G]V^PXQGGZ87#MKUP2P=&]5WXAGF@2],
M&TD&7IH'B)<2R7*OX]'%!&NE83TG>FV/^6&S[2":6T&]QC&[YZ6CG)>Z5&,M
M<E:/D5P]$/ .LN&(29; FA?570%C7[V?]I#KM;54CZ4?T[?CF!<@RD8KQK6$
M0!MI/20@-U(X!\6@C#G:I$V_QLXAR[/MK-=;>;*U?'NHR?0MHM_#&2XJ$6V"
MJZ>B:^LP':;XVJXZNY4".PI\KX1062KM(A0MR,+V0A(^47-/HI6>:6%EOX<R
M?1/ACL)L>^/!%G)N7;_DO'S4-5]K7DGJPU_=VXX$1_^^''Z^,'->U*8XOX6O
M].J'DVXV":/\X2]Z_>O+;C:^*!"?C&0N6<@%)?GU/($+N4#*27@>BBQJLRRQ
MQL .;8S>5]W=D>BJAWI+RXE,M2KN?)(%'H)-+%0@M-_J>D%AT0-CW$L6T%O;
M.@)R'9;'8H8TD74/=7)6X5I,DTV0]62.K$=U&(.DC?8VH,0.HN_!,+D%8;;)
M2^L1I*/-6+E2HV=J/C5R8V7)@:O6:3?[)L4=QLF^.;&-Q/? A1?#R3SIH\92
M+;:S0,!**8'V54VXHJV9]:P X\PDJP)/I742Q=VH]F]WM-+A'=3840$-[8FU
M01!U'BU:B HTDBLP->!.)9_ HZ<?76 ,BY7&J(V,TMN>\M!-A;9B;%@G[59@
MEUV![X:VVEC84M.', ,::V83?>\@UM8>ZAT0N>?D>.=(^QOSM7@?@Z!D!LPB
M(B%37,2CU?B:/?YP"M]&FLU+J5Z%J\WK,KX976PLA4G.;4D@HBHU;\] <,*!
MY\4IC=%(M=FUZ=I'[&^;;JZ%KKD(6^_-RZ@^_-5=]*2A45DT"8P(\VY*$GPM
MCV8$TYA=SACTO11[^8A'JMC[B;#AC)V,IX/GYQE2P\_X2RF8I@O.E6>YFU^1
MGJ]4B8>BM &&6(W"1*8(V2+ E/82N?3%;%0AGAYXS2*GGZZL\4VQ/'0+K1>9
M-ZPRN@F^"\-B X3;'.[LR(Y#6'7]:',+JNR@BCTO)!>M4I1))G@-TH3:%,T4
M<)872$FFG*1SDF]4#NJ(R;+&(#P6KFRC@7UO-I>UI!8;8])*E.0(7*WNH(RV
MA)66V>Q2X9B-=IO=(NRZ\2SAVI]!TI=>M]F-=E%*#U=.UPJ.O>S&O^-?5Z5C
MWHZ[$7V;SOM>G_?Z%%)G6:OU\MJ$D=%D\EEET(;5&SQ3I&^=-KT5P(=NS_2O
ME1Y*:M?CU"N"7]!Z TQ]]81>@><PMU0]JG&YD6XK'?1P4;$26Y8^B%K>V3%;
M.TR4  X%JY?_AGX70VB>>[(_7MQQ475@6FPC^A[HL+8V&2F,,7/!W1@-]X&!
M92R LKQF[DD&QIB2,DO,Z]975QL!.T 7Y9UUN&EQN'LKX+ M$PFVFG_3O$WB
MC4_NL37B[:-8:H?H2R +U&/DTBJ=8Y#16A>R+8+51@IKVB'>>$8_+1"S5I@,
M-S6*O";7<PY1!0Y%.QYBT;1R]1M+?PFEMQ:(-#&,J-VS4HASJUV RY9#,(SS
MH L9?_W6#SK&EA#;Z'WC%HC;2+KW%HA_C,)91]/J?S!?W/8O"@G4>GE*99V2
M,&!3;3\>.;ER]!68LB:0S9^+M[V2XE9XCY$G[?312Q3YS?8W%59&QZ3DU2?T
M!$LF!2YJ$H1BVJ&ML4KME\>54!X+)7:7<P^!G$OU5I\OBJUJLMHSCP8,[=Y
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MA,4%]CR(3C+FC %&MAFY& K!>\O !!]I)GMC^ZB'=CNH)T?%MFI:<?6S>P+
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MXQX<E5YXDTY$+>J,-\,,V?J^@"M:@N=9FJ0QI#AXPN9H</O:,)3CAFT7U?8
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M5DF"E\I*^:BDC$[KK!)3)FY83;W1>J KHN]#5D6@+;1]USECM JC]>"-J+T
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M:9:NS)W0(AD I<,OJ!T@=DRIRE<9754P?1BO.H?.-8^HB\W DBUDXEH!,9H
M CTW7B;ATN"CVAKQ]K:2#K*2]@!87[G.7OC\<ZF/;WP6S4D!Q&>.W),RF #'
MLH; T+KBO$NBM5,_%&]O"^D@"VD/@/610>V-3])"P=%#5IE7.BBI@3D6H$[;
M 1>M Z&YE(X)+9K/<AR0O;?E=)#EM!_,GJXH=;PK:MV8]<9F-)GL6%&G;9?H
MP=LZ"R.E9**/+*O65T0<R%\Z2BVL-1<L#:2?PAR_5<T\7#Q*1I=Y\J!CLJ0K
MD<'1/@_HM2A%ZJ+:W^AU7"(XH?WQ9,)$O4'PI'S?[<5Q;G)17HJ:ZZES95E
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MYKM=(8M'AJQYZRZ*'^&:@$XZ[W1-0!>%->PY[3J*/G(;;8C E(Z@1.$07<J
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MP&1EBCD7@:T;^IY2,?Q>U%+WFQ-O.TFY!Z/D,46WY5"S<XR:F"D&O*A,&J7
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MNI F("!-.E&*J*"HB"@MH'] 042D28V*U @(2#4D* **( ("2@M%I!/I*I@
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M1\DI#$ 7S(V84NAA /*W9^\Q@,,]+\#)(+(@V' !U2W  -C_OA$#P+:A%1C
M3_XF))G+CP%\%Y%C "]<FT$=_%0N4&Z5];PL V@TU%$ [3T+LF8 +&<0>[+H
M-EHF7=V.^I#HX>'Z/<KLQ8NUN\]%;I'GW91O@B6LM:3FP_U@K_BW2^Q%%58?
MKWN;#YS(B7;%1@B;Z;+__TS$OD*H,2'SM$],&_-Z6IUAFE].Y@L#> C>8K6S
M ,STA?]'_C>)=0<#J(EJN$-],AU(XD "GK>[$,]]L86H@E,\R]?65^9JDZX:
MGA(^&F<6[3X\MN,;TUUC&IL?D[6"IV\/@**L#U?7KTO&G*_YI=UR\5O?3B'Y
M6#"QLDU4M8U5^OCBKOX)T!E3>>L(G,'\[D7(Z]SWT^YXXAHI 4-EZ3"^5E6=
MIBU@E6%BZ^_RXVK+$\A*(REA?MHP[K1SX'EWG.+W9,%'F'.L_D%9Q1=+S-Z&
M/^.WG2U8+=*B8MD-SS7U-]T7(:BYP(<6-?+0E?F-3Z!'D[G>GJ_8+?;?4%DQ
M)XUH0PPA7$NUQ[Q.-]AYSB=OH\J*W:Z;.("PP7-F=O)M%HV#=MH@_U[F_+(*
M.J8O?(OE_RH1V4"TJ#P'B3WF!T$G-(A1T=EN7L[JO!ZU$-=AP3(1!P5:WZFB
MI\G:E4]OS[J68:L'TS*LL2HCG"TZY\@, ,]_8.F(A(6M5>JN1^4H]E3W'[<]
MKQA?LTZ/H6*20GDA[R8.D;,)3^*B)3[F3P\K>U)M\+*#I>IK\>J:2NK)#SRC
M[V0MF3IJ6@],5B(;>U[*\))"&<#+>D^4 @%BFQ;\</;KD\*78^+7_3;*)AZQ
M: G]JHH);9^L0=712_[(6S<:WW*$#/3D+.1$)SR+/I%UX._DD(,*W4#;CSZ$
M6."H*19EYO'X.'MF&(/V64J+ &;6_!_YKTB!RGIVWT,OE3.0CMK:V+SX'F+1
ML^O4"!\DL0XFR@#TVL$: 0\7\R)1#NI&?%8K:9I%2A$,(&)T"K//9T=_C&A:
M(4)HG*<9@,9E&\Q.@"H=UK'FZJ__:))8IR7.[-^!Z(XC.V0>8A;L6<R\_CN$
MJQ-XOA,]%WC!FI<!\%0V(K<DPS>953T"-]6SS]NXU^L"&A[JV=M4^?(> 4(+
MC<)LB=)SF:3(;['BI>]V/*AO2=917O5**,?%%)\J/SNCW@RL>&,K=(>#/V:"
M_W/&L3C;L/9Y;M5!M!GM*YR])=B=\W75)>PQEN/1 F^&9[Y90*[N>/.K_ABV
M4J2H2*6[]Y.]4JLP4TB>TM-'"1>J;]!3M?FG\K&CD)>.9^,,/M=10.^^6+L
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MN<MQ_4!-GH[U#/Q5HY0>+>I=P2#B:^&'^CIP_)X:K?0) P#[,8#)008@\6@
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MFHEG6%5:V.+XEOZ0 AUC $F(RY/5'.4%6!*VY51JQ$^S@"$S50!L2X_1,F<
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M;8[K6"3L*I1 4KS?+)W(03_?._K7=\"@7F*FBAG AN<N:'M3.K02(H1HM&8
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MT:]9QS" %4DPL^;O%63Q2""H"#TZF>Y/.T9G3KP-79@D [A+QFP)0+KFD P
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MJNVC$5Z3SZ_275@8 "R.A)KW>>#6;1F-=(I&C+@P@$P4 PB5 .A1#&"Z#BV
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M']%?*RIX(?&:;Z?I\=KZ4/PBS!EE'!#(\T#A7ER@_C85FHI:H7--^[]Q7AR
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MB0>:?_?W SY9<GG(GTTO8?..\*VHG6/B9PI1=A.%ZX!=@_W6'H7MC '_[F]
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ML[%0+5KS3WMK\QPYF?H X/O3U?ZB[FZ'J_>S;U7E26Q<+"N)OX,E N6V-*D
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ML =T)E1 W',JX*"?"A EO2&@&0;QTB9_(P[</T,YD3TATZ"M^R[L9 66!-6
MF-+ KH[F0V P\4[A#Y*A?*T482R$V9!@160F?.Y2<,\L@HG[3;FW1IB:<;]7
M&9LE_8W\VIT$6B V:6J-.M8UU< #(Q\_18^CSI@CPKDXR,&E/LV2\KBY+"K
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M@/&?'BR&?.M4:5W@M05-("5(58%.P*BFH"\7^235&@)O5PP._)GUHX")@=[
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MF.*JQ9RKEYI$C";EH9;+G.>.)BCR*PS:#=I7(5(L8G4=I?B/V2K$-P;BAS/
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MUV1[/<37S44U]"2UO21+;.V8 *W5)<T/:X?/25-8+6$KN<@><##ZC#?X<[I
MBD;_EL1F26:E<T+@LI=NP9_LHP48Q9<3(VB-.G\&0  4AMZXZLX 9":C%&AA
M3!PH!C, HP)@&A^7F./CHKA-^LMG>G*#5@Q >QS]LB\&ML>-WZ8?^XL;SLI&
MM&2Z!$0A?/_J#9.J'0UBW'V4N\#[2=&3W7M/=8,6U54#3J3IQS( S&Z-_Z:O
M/Z_ ]T8MF=41ST\X]61<!7_7=F\\1JC]H>J9"L^#6.!<0&VH*^A^>:VZ=?'V
M2-=Z3!;[@W,GU3)12K12-=YQDFEK,BQ<;C2XCK>' 2@38#ORMDH8DSOKN7_L
M )FG=I0TH,\/N=DGKQ.Z*WT,9%]E,]3!<U/[X"XK(2_'W*6\@(E\8.Q]Y8'D
MTOZ_)@3D?C[EC"X%MKT2/GN]-.YUP5V+3@U5S:$7< W^83(KCA: :>6]FE"<
MVU/)K1 CT:]5/Q1-_^0E^(MK 5W.VOB+(-NX;##X?6;NJC"OUE%XLE]-G?5R
M#84P7>=+5":U>*F^( D:IW K]%@W(NAF^M.@%S3T.'#30+=:VEX2NT_SGZDR
M>BP]+IG.M,[]O RB+22<8@-YK>#+TA#PJ#4K*D%73ZMW&IK/SI]Z^Z!APWF2
MK@IY'HJ3?F^/?E!<.&4WW<2]+'.A,X8V? 71X(M,80!L09\\J?<(1M,*V.$2
M+XKR1R$-*'38.ZTU.B!81&0H9L6),RB[B&CQ=QP>3-:G^M?4HY'K^9NPW]N-
M,)()E(,^-#0[,2=IS+7$IN;L5U-DC:D-G/4ID286T;[+@]B<'C:B+E<'*L_S
MUN]OB%S,Q<6'L^-C3PJ'JD3:))-#4 #2\A))EIA0-[1_F3?0:TBRG,ODBL[)
MT5&>]8/'=*YGT('L5WM/#"R_?$U DAF $"4P*[0-*D[P3@W("_-.\M*LX7>,
M?CZ^M)SN>6WR.]"EA3P[DA@&>FGUJJ<[N[_.P#%_\F9[R-IP<67@B7-4FCO8
MQ$^G;1P875:U?_:,8>60R^A12.+Q.-6T@'SB-9-%1:D4CDM83QSB(_I*G0'>
MK>TS#GRIP_-&=-P9B\_.(Q)$H5E6#<5#35; YK6% .QD0>/7\Q[LUR(([)$S
MOVEYK3.7'I9$O5T9.&/[P6&^].*WQ[$/7:>K[E[S4CT>R!^:=P>>.?I<;M-C
MI(+08/?RXXWA,U5PP\C!9QZA]>A]&H3Z/H<GL!9X@ND)=GQ!!_)H^E=>&@#9
M2P/1]9;I2Y4,P,!'L"/U">E;%D0<WU6#0DH73(QG\-NV).$X8;)]I_^DZ)P]
MP0 47S#4Q2:#1XK4;D">]*.X2$Y6X.<IM)1 (\&NJK@K O"E@"-@CD:7>=!X
M\]S#=LR?"O@V"&0W.-L+"/BUMX89=5=+RR%U$LM(4<)=6RX;UZ]IWSE5^?-3
M^@5-'[6TYSMOE8(J9X$ AYFS$,4349D6_G?Z=W849)[0IGH]8.3FB(';%,]#
M:288UD8\HYP_9,+B]NA''+HYZ!+.-P37O^=PY]IA;M5;MLJ+-HF>DQ2OJ\<A
MNH1UNIZ%(0. I(!I1Y5H+,C>7CAXQV,<08.-,_'Q0C_W8MA'V,@/%^$'CC +
MQ'?OPV+"N&;HO.GG[*AO5[U%><ST3E[#WT<.)%-)A 2XRQS[.!-%GM3KR_3L
MMAR=MF4]EJ5U9'G%62ZED+,2N_O012,UA5ZI5DA+0=T6:74[GNW[&TD5XG5X
M[L:9;GOYT(Z%5N2YQ5X>L @-U*K9WOA%^'X!Y>QG(?A[QNS7ZOX\WI:(K*<J
MS/$!N1U,E-J^W:KZ61=N%W%_)1#X@/V8S[61[H(88@S]6WPJ4) >LP0LSZ-^
MJ?>DUS -:66A1);(PP#$L#)A\V<B?> Q$]6=]0^O!RS3O)ASW-]A:;\AR\39
M<V@&X*4T+3M>#K:XW<ETO'*%Y2#$F@FMAHFYS_ 8&DR;"<+K+2A>>I>U*"D'
MYU>^R100FI6EL:9AP@L#1=\,/S:U- .C MTVL<SG)8: ULGZM$M6L VFXQ#2
MZZ2CI4![2D:9B#*W/"K@QV8'S5=%]I\0VX%I=%<),[3C=<H,P'MFLPC)E)"(
M8_\Q9[8A!I,:&8#3'QM?K0U?M+([[.(V:)<I<$_X$HW3N+NEA31 QH%<-V]L
M)C8%Q!;*?X4&U9Z_:W:NC8<<##KH^)%_8W,'C%VPNIL#2Z&C97L@9_&F&'29
M42P);C0<Z:.W>"(COU99^V-[."L^&M%4'_HPFKQ,/%MM\6J$+A=A$>E^)=GQ
M42^EZ1GL\3YH##YG'UJGCI]XV"^Y73P[XD4Z7C<.B;[XP B19D2;U53D:53!
MEID,1GQ>C&XSB(NMJP2IY<;-26\4SJU<#_R0\!MQVT:;+4'A!WMW8QN[Z_L0
M323(G0HBE">V_*5EUW[^:?3GG^>[DC1Y10;XMB%BF7X'<JV2U(D+#+IA@<O5
M=?.HO#!UR.]N>93'O3K@X_JHT<P)*#?\D]H%EU/>9O*O%:3?WO![9.%[_/B#
M+15(]?ITKF15N5H*##PR;1-;%@?O(FQ/(.GJTFPP[!Z"+%7K-L9.U_*)8X+R
M)2!9OC#\GU9$!>T+\WNH(VB?P'336>81%D:'T(_Y#( 4 U"R7(I-H?=-*S$
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MBF<;_)W_ CXD;A;&/KY2(Y]I_MRBA(M5&.YC,P7W<.8UJ#^I,*%O(6@./Q@
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ME%9B_&C+A]54LVZ9*X<W_<JR U^1[5'D=SQ2 'U^"BWOH@":+^&9R4&S_!1
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MQ\GR6G,<8I]LK:Y((:PNK-19$R3P9FW0.XA6LYK08K8,V<&>P:G>RY$>9P&
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M[E(]#(G:.>\_>K7F#;EA'JF"/YZ'X<V!%PYZ;]\A=G<L$$R05X^+B8V,'J?
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M[$VFW1[A1BT.!PF[FG,HP!,$1N]]U=YRK.I'Y'V[\;IT%>=T_-L,6)/\_(R
MGFAY1N7CN1VFA!-T7\XK21?[2K'.E0S=[A'[JD(FX@P\[\)X5[EM:0+ADW+8
M(MT68PY$)=29_CS;D64;*\NRK7"M,05 Q>^V)#PBNXY]J)VWW*6]-\J]CO<=
M8U>#!CYGWEJM456ROJ1A[[I9;)T\0T*]]D9J&[8_PDN2;GW R<^ZVV+FO@?'
M&X$JN2M)V=!^_>!;=PIRQ,2.OVL+Y<P<[H,>&5]-F$1,UAEAY+=XLGR&ANAU
M];R&#UZ?_C 7XKG.X,]3WV0E\B;.FO%^KL+W.6.H9'3C@O1Z48S0)7'F>:.\
MLG7.)@[>)&X1,9^5=(OJ'39\LP[6#J%"SO&.;8G0.[\,?WKVW!#+JNE#EM&I
M7_!$D(NHI24LW%2ZD<5*Q_5C\?HMNC4;[N=/W H?O4B^$@127%,5]EEP"[>1
MKD=?%Q2HZ$@\O-=(NHEJ+CSMQN(SI3G\Q=3;=Z2"[I2'M*[](7S=I22JI"Z=
M!:?7=WEL>VH)^M['7KCYQ->M?DD(MA-G8T)X8EDW=\'N17^G=#$QVO_L.W[T
MD$C8 W4#_$4S*9QM$P6 _>!#9SK,8O>$7QQ(:$X=(+MVNS-E?!A"BB<.'UL1
MEX\#YY\WH$EQ7N9(56[NEP*]%54O7^Y$77)>F(KT=5F-YQR,?Z$D:#J?A]3#
MT^/>0*1P0I+T%0E>NSWY1/'QD0?D=PL]#4^*GMS!'+A#NOM/-&?G0L1?^L!:
MO%6%BF..]*IT/OG2J@G8E5<&B*H=)QLD*=SI?5*T,*BCKA7J.9FWGAK%I1LU
M]M90S!2;9^]]IY$U;0',MI;.7)J\8U0?,\2Z*GVK\_!T@S(>0[AGC3]Q+"OD
MUQ9_8_*<WH,+ABQGUSJQ2KC6:N\U<J/UFU?"^$_\%DZ=+(@OT;XF3) 8K; L
M\HM9/1Y+1<URK.G%G$^?^*HUU1E=D2RP3#<L![SFNY)-3FW$.,R_QC4_&ZME
M)8%[J-)0CBI5D-2A.\"P[Q;U5?4'@W8?$B6I<I,)=G-S';Y$A!%FW' Z>\_4
M61Z__H\XGH:)BC#M=:AMX+*Y7#U5IO%28;$*EO1TX/_U%.?_PH5.\__C!_^1
MAQ[_.XJ R*NR:*Y* [W,/Z2433#BDJVI#R:AN78IIKL7G]4@JU3R%U&1P%(]
MY/R$8,.@0;FN6+RWR/$B[P=DY<>WEYR$HLV?1@6WRSH$\.HC%J6U9X/K>''^
M(+SP\N)]K))8^/.7QP^K^."-0S_=Y?)%[\G&*GX.?=]%U:YSH,NJIWV,VIDZ
MQ="BSG[-D9&>/U9' M$-,)SF9L@"SVV-!*VZ2(/([UF0 I4\CT.04S>^7[2'
M/^,]M+=^>#2  EAQA[*3,I3=,#ZFLPS6N94V<=-\;B-18VZV!%N?U%N9"UUH
MNYTR)AO70B(WKBBX=LN&ITX*22Q3[QJ[(9'@_XI@T^?EYM.KNQ1S\A',:#NG
M&"T/[97LS)I%@EP0ESL8)_:G'/I=EL:$"Z$CO,KH#)^$QS%M\AS\'&-W3N)L
MP+P)OH*!IGW/81-JUD)P;&X;+]]+-AM@;:H,T?]6F<VC#R^OJ@1!MEE&:\LH
M@-M];XU&D>61R>DGN\YYEOG:UP1V>TV./SF8S&S6PQ[^/M:6W&DCBN;4^X)S
M-+!/:Q>G2KLZHC(IE2@YO_QD6YP"*-L96=(%\06PYQA&KGO8^M3>Z+ZVB=U=
M#6#Q)NP7[YDUS4T0;/#O7U>R2W5^=7RH\3+VV0=8B>CF7!@%P/@&!G!P7SMY
M6=*FV'D-*(,P=,Z,F16Q-7[/RJIQ^ELCJS1#V98M[O-&.,YWNMI)U<+9H; A
MH%$CZTO.!?8<<1:@&$MB6?21G@B-Z.^$V,[ @U5Y\A_.>_?WR*I"5%S+/1E;
M2PF_%K_1?)+()''\LCR)2=-;Y"XK-HJJ"^?@V55)J!^Y-_O,W7>,! [(-&V8
M'V4XH/FW#'^+[9G^)Z0(?6(4S)P"* QXY+,&5H9V QD/=F@J*N0^"94RLT[5
M-LB U0*<=>&1"S4C.,YZI\3LS];E-N$>^RQEP3GBVKM_?OEGT?"&5 9:,AP"
M_1E9860/"O%)V;HW'^#<;L,[[%KF+%^??$-'.O?QG>S^+$S7R*^5D9LF29GI
MA2? RY4G>8S%9),3>6SX*@855@O+_#.B O^-W&^C:C[E'7R+9U=T:R[TQ+4/
M/E_(U;6E_"E<?)!79@K@_L ;='^QQYN;-2SSQP'+I)L]-,SPAG>$Z\51S46Z
M6/+(.PJ@*6-4DZ!-;(6(@@/( ]"K(Q 3[-CCX?T.KI65^SD&FE7(!! FC1A0
M"<+"IZ$FTK^@6S\Y0YGIDVN\UK\U>!\XOM$<!94*$^-5_DP\_<+L,^0L=CL#
M PX]@2+RFER+LH3?N(Z894EX1PV#^'ISN3Z<# ?7>, ^K.\A)VG(VJ:U%("5
M_J[<K_)FR(O!'67U>1XCW1_OIJU[>:](C1QDCDEUKW+Y=,E\*C$$?SR>1+D[
M;^[\!M/EWV"ZXKR*P-O#>;^+D']^1N0$@ A2/FIF6'"PA$MYI$9IE6/W&3<]
M1Y$RZ&C;QU!FYJ3=Q_F<JB\SWZK$QX4:1UAH],W>0 1?78VN8\_Q6;U7-2RG
M\S+]/#N-8%!N,6T#$%^,U;' .WY3*F-XFZVE';&N^EJ%FT=T_U3H-H/1J*R_
MKD6?CG.MS_:UV&?QZF>X<FW7=WGY6Y:\W!C]/LV"EL>)S3:K<=9O@\AB/KF-
M^FG"1LEWX.8OCD?(OL@<,C^TTP\4+N1<?WI^C9VA^P'489P">(C=88+VJMX9
M$(QM_=J9]Z">:VJE]Z4==#1D02Q%Z6O>6*(1S,Z; @A5BF8\[$87VIJ,E%6]
MZO>.FD_]%;:5[UR9=OKIW,Y%F.)Q@B&VH3"[Q[9^6,+U)8_I X7OL)>(^CJJ
M '\SV$/@[ _U@9:N1)G44>7XF1-)*U)IN4[(F^$W/EO:0-$>3Y)SN[(;SK9E
MCDF0SGPD.YZ54('#7(::]R^:I\)"O5PM#'B2/WFZ"^OF<191+;A26(SR/?[S
MLE^'G]N22S9B5!,W)\K%)"_]/NX%+FBQ/0R+I@!H>A3L&CO%?P(\P9K07A#-
M"A6&B0:%4[*WL9[.9[+.PH^*;0*QW8>6@Q#AURFIW0S/CWU-W ZTH&D;TUOS
M,1RC!B8F&@,L3T^9IGABJN#1 N]SQ'@M_5663_BU1CV'$&5^C[_0WLG9N'=\
MJA%BCM?-@>@-I,ZNG3$;C)J:1AJ#1LR:&U3Q;@5$E=&<TE%QJ_N,VZLT-_@.
M^IU(?.Z[:,UP9=$<GUQ]?UW#+J4.#EN7B/- _8?)10$5]UKPGU..#(_65-/J
M&7N6Q%BD2P4NA6C3[;'^4F7 'RSLT+14'*8FZ#N@=MOFW8 ?.9%V^$ "7[/R
MD+6/$W[RDE;9ISC$W=%%OZ-&T%4?F+A0M%R/&MEB*KHI=S:F??--:4&8ZM<L
M4P.WLJTW?NEP@H.-VH5H3?4G_=XA/V!&%D/0R8I 5=T+]\F;H+8&<-U .8^B
MJ>4G^G!S&%3Z9HFE_H"E3@*YDP*XH("P/?^ZDG$$LGYSUO#W%QP40#C*)0"*
M>R+;+2(FTVC'_>DD H=B]]FPQK7B:M#EYR66-JLGL[!7C2TT XGWD%KL>H-%
MV^:(8WL@L- /%()ZV<_I/"PYY3JF%5A#512^L MO/09^Y>B$E8!F?S:)>]5X
M''LI1]#[2F1K?8G.2>ICO7Q%&_D#98<*\O!1[?7:>LY34]CT7/95\35R^0CQ
M%BF-J((]MJU.!FV)&_A-]PX$L)?[U8@8! [EB<KLO1):./AP#W-+WGAV:YMJ
M+YZ+C%$<%'YD6ZCD8.@^E^[PE#MXZ..Q?=PN:$L&J[@P9HAHY>+)UW:5$G][
M,<"@]@?K7J!A%<>=;0Y/\#<S-MRTQJ!6D-;XLZ1JVCK1!?M-9+9/B7W]P+2C
M?'0W58"*39.4'@\2V!EPV:]',,$]MRUUB/U)==PX[A808Y'R%K=A\C1S<GA:
M!XPF5G1"5G(*:%T6;68XS%?W;#1V'H&N0ER&]D+O#+Z 2>JX:K"2E< ?$$U5
MA6J-T&M#2Q-O,ZVG?FSBT'X(3TN&YHFFP^%##[?"(9C*QWT#4KF1&Q?-*PJ
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M8)##B@;GQ2B&AP5W<K\!)<G#?U  3<ZV%(!-^W'$%NKEW#&;E^0)G@+@6J
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MI5&@.58#[G6MI] EL#_O@LQ#2Z'S,V60.)PH67,+1FZP:"C JU-UU)$6%1_
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MZF\WLRA9NXX".,"B.O.IY&A_E0)H:GRT1T@FEV\"R\R(";Y4\8V!)9AT+SQ
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MF\UY*#\_]J9A1V8\GL=U-%+J%66' OZH7AM<Q(D61Z^+;DO> $LJI,A<Z%,
M&CM[-!X+8)H@1^<]I(X)QGO@8!'O%G8NMJE_!"4]JI<K-B)*J06I3:PY_0Q$
M21+EO,AZ>"]%93P-<)*#:RKOG1)6#T$T"^!<4+8\,D!NB:53S]>\6'-#=AM
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MF:0B[TE$7AP= Q9AMKY[XK8)70T!\F@'Q-GVQP9^'Q9+UO+!G3PU30>D[QJ
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M9TAY=A^8)3ZP_YVMZ4$9)X&SP^$LE;O%5L\Q8](_, 'EX]34/.&1:!S)[,Y
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MZH!MMT\-_9B^1NF(F1^I/98:=V_:<*T[$%^[I+C;2P?]_FH<AA9%WWZNNOC
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MWEL7\$J/B'T+TTI@_'*=S1L[U.SDY&03[%J&;F;3K[3W/@  @( :J28_I_S
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M[R*=*,+@,K<KOK).,?Y;#WK=#W:X.9AA,G&'+T^IJQ+% ;[V0N;>"G6\UO.
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MXS!! SB>/D<"^^!NUI->:B#\?<)0EU%CN&*WIL'X]:1%J(J5?9SY.XH#)>A
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MV3$MDMX?'?4:O$;^W\LT^$=1+ [#.9@+L%$,WN$*2XNH%HE/APFX6+KCH>]
M$^\O)W%4.^96176=D$,IZN?J;!_8T-6\\?*EJ2T:I27M:X-_]T-+? A:K+O
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M ($#Y-I])O:J]FU4$?!.G616!C:9">AJ(C(CF<"K7 ;?/D14GURTJ[]F=^[
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MZ5?8M1%RDKV,=H]>?A)#V&S!<(W#;Q*90+B& ;_LX\0#IM1+U][-0,R.(-5
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MC-=VT-%!L,1E^%Y2Y;[PK,EOIUF^('B;B(#@^@]D9R OWD-^!Q7&22?:N^3
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M'5CE'W8/PCJSAB079G5;9$;/U=9,N&'FM2(,;*B ;CYK@C'22ZT['8A9"VM
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MDS!_)P2MM-?0TT^&9(BG/AQ=\HZ'M;3,P,Y";DWBNO#N3OC8%;VJFUU;'WJ
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MRJ.$)396X.[0L!*R"#;%"B8#S_L@]MII[&!0A88>ZF&;WR&]H#? 4T%"#3F
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ML24&%Z\>4GO%_)-WFH!\1MXCK8"(#_P?^-&N3E-/875I7.S;DL<G]?WP. ]
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MHPL+I%[%3OOLI!DPJ9@6C!(;C-ANO0Y#!'4!4V7_&H"[[?+7M#+>GC+T6A:
MER+\@C3,0/30\8S,!'0'6C"(_73W)5![6DZ=!'!GA7:<#H[G<?]K1\=*Z/$
ML<1!YG" U2!<Q;73F6\BW)U?8_O$?L3FI^$]H58-(Q]T&%RD26=*8K!X(HT%
M$$JJ V:XCK<_392C'Q/+O?PY)XD93BRE/)?]_6-G13=/D+3KM-A'O\P"A -W
M)%Q!9+9IG,Y?KB&YWA:1S"I[T.(8'>S L,YD 4# &;@+H@5)9L_1V[[L:?4:
MR12@F@#YOF@FK$BU]518?T1)5$8\K!GOG9X+%(%;<3>@X@RV;1!2["YNH3\@
MR^/0D>:R[<4V<K8M1X*8O]^F7"7U'G$DG47F0G%XT&\/VYK$\=M$GI =C=O3
M%[ZQ . $%9"=U%J*E/HEMZAFG;@$QE2?J9V45,LL4-'2=?)97Q_P!+P'Q-<H
M[[XG]TP:=A#Z48$2Y[#Z_O4F:._G,SJ0D=.H3\":UY0/NY<H>O!N\O4Y>;?/
MO?'JUNY\K[,7()8FIC-=19A>3\>E&O#C'7-W<[CV#:V]W5X3YKGL:_Q[]^PU
MF*$!S!V2<A7OP1'].7TD&@&)T(2()C5^EA)ZFVH>D,> <]-\.Z@\>AU36R-:
M*6-XQ:0K0MD7 +> #[3 #Y-;0)2+8EQ_2M4F,\/U5EUG)#M'AQ*$M/OJ\J[Y
M:X,+."]GE2O\6Q&=LMX8BO!N'^WQGUW1L:)_G03PR_^)*A[_W=H!23;WJ=?.
M1U4N5V_)KC M>2@QKNE-Y#N9$W/?W*5Y/:X9M++)_T%FU7B_C7;5/:B<T\7[
M8F(UG0>9.@EV])/I+Y_OJDSX6F5+48,0B8^GH%>(/"6^MWA^B>(2$&N_T5Y9
M]=DQQ:*3?=<^ZP9G=*%UF'Z:GO6$SQ4.*#7]^IN@\+OM"-GVIS<4GIL-%1[+
M#.6!W7DP87W+N\$I5#5YX"XWR'HYY@ES"*P)U0"6F6SJ])A:]"MK<OTJV5YP
M5JK3T-,^SOQ0U( ,@8NFJKF)OV8!!E53J?&V?#W.N_?Q2;?"(=SQ-!;@.Z%
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MK_[D?< <U'*:D$R7&)F+4BK$1>N?/NV@SCV[(EN'D+6KNF%:T7-(T@@EK1<
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MQ7XYT/K]/%9KSKQTJ%C1QM/3T8=GON'$P>HM#F,=NUOM5NA>T$E_(%ZH52.
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MST5K&UQSOY;+ I@==)."G3R!2/2TXR-/S[  (M_/EHV<%4I?G\"%[11[O+-
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MY<*\8-;_</DMB)>_)-6 RDSZ;^R]=U03W+8O&O535$"D1#I104 BH"#2B:B
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MXO3F:*6:7()K)RTJ->*I__A9"Y36HQ38T%C?QGP 4,#4UG!'5\\?W@P:56[
M<IE]2%^$+_NU6UJE+0Q_^0Z*1A%F(#^56RRWB;Q+G$=B'4[+25X*ESK$V*,\
M'7DLPU>5(:JP2J7W1RK5YMU^_V#+Q#L&M] ;M*NSG=>1:VFH&E_!^PY3*?28
M(*^ /^.7LFX>#S^Y;/5V=JWF*>3]/8D+0TDF,Y8#AU@ /QL=C!;Q2R7:QA7-
MT63<E +;?=K# AQD ?Y$?S&%)^YAFF(%EI)-K76GN6_4.IW6[OC*/)V.&&.*
M,4='YU/]Q20NO-#6_SYUZ\?IZ S0N!I(Q<O\^TH_[/, X=#@-^K+9'NGMO"7
MV>@:W/OR_=ARYP+X,3^"$1D?>20WTT9^L"#C=.YL(.]H>?Z"HZ!@Q[G</1^-
MU_F'[Z96!UX&DI/7!EF ,UT\C"&FV8X;RG'?!_/=ZSH+X$-(#!2&[,^BG1K)
M!'JXW%[KECIA&,LTRII@^(,81V'C*B3,*I0%.'=W@UD;RWP%7H)$@4I#0_$"
MN67?!U5>*)6_KCC$F%\ &:UTY0S@HF<_%ZW&@EYZ#*,(IW>HN3G-1I:$E7M$
M%^686M@",H8%<$6*^8VJNP4O+Y5S-<=KFAT[&WMM)L'62R:F5N\,K?9Z[@*3
M **[+LVJ9.+4,YE;6/[I*\?3:,ZF;XB!6517=($[Q\<L7+L9N34L.3M,!4+G
M2J C"DE.:X=G8@^U=SD6M'D6[B;M*_/0_0:-3^<ELAGY/8B7%)]B]F4S8CT%
M$QRW9Z6'6B,Y[53VU;IIXQ.FA8A&@Z)'2Y(8 X4T.\1B\,-EX9N.DJ=C0O !
M>(DB$52BV;N]QS8I=LJ6.A/'=!RI.+,?;+>U*O:.+*YG0Q#=3SCIW0-$7'GM
M6GSAI$V' &+VA( Z &VVO;NZ03Z[WPPZ/DNLA0:=HB[X!(8<$) %$'%A'6"[
M7+FO+I]1M@^:_2[T R^<DVU3^_SS63E6>7@1E\"40X_VCG2IA+YT2_+5_S;@
M)&RK\><K=-E6=@3^BE]/BV#+^KY-57@/:?2F';3-Q'MJTUK/L0OBX[^Q*V'N
MV/KN\?';[_]8;GO6&\3VD6/["QN'(NA9.JID3@G47_97B@40B8>(^\7KP)HT
M/K  %6V0EAK(((T%Z.EI9!Z;PC099A"/LP"D<TR#Y3H@C3()&?W9@N<]-53A
MU9KO4@Q*47_M7P"9T"(.@X[IJ#F#!"^S $H-T)*)%DB0XQG:Z_V V"Q_H8)R
M/*^7H:UV[TX5!.@XTIDH=W<NE_Z5H<E$&WSJU0/.@>P%8._I@63SC,F)D)2B
MW*Q;I^N"CQDX_N*8@HLM8LH$FXR['* O3"PEQ1(^7=SD./V:.Z#2NKQ((37W
M2$%L3!<U@R/!WB$$)ZQN"#<.\(5<RRE2;L+R7\8 J#H_+<B'I[]) !]^<)RU
MUU2T+=N,;>+Y>:\IH&[@-=5U7%ZZXS#GK4\PS,[S5J#0$SS^/'/-9>)C;PI9
MVB:A.<@>O45,=&4!)E$]E2ZJ/*;P))%0MOBZPOA,(&$^XNN>UVPT8K\=NL^&
M)U?(' PN$2SSB"%394T!A+6,7-<Y82MUAU 3\HP%X&,!)"F>$?3B?OPY:KYQ
M=8R?EFY.<M3Z0>-D1[JNRCH+< +BYH:$UL9,-">1EZ^X!6^M_=#OC;T+H.6G
ME!O8IM1=R:)*?#[4Q%7#KW/KAK@F90RU5O$K"*?G0+W77 V/+K50L3F[Y+XZ
M+\Q59U L'OT$UF.DH-!GB?W<GWO\R[W/Z^E=AV\0[V1V\-_\9+[X:A/1J@/V
M:[4E<T1"GZ/ JL/9,3REKK[-7K--,,_GZXU:$:2?"+>S)LJF YFDC7!D0>E(
M=%U+40H]@^M2TC$BP6A[<=+FYI:1.0%J4X'PFBW^I2<F#S-*U'E4E.J6Y4,^
MY]RV-%AS[M>^:P2MYAO^X@!3V#7E>%>N22&5LXGK[)>:M%,IQ]Y.F;Z=3?<B
M]N'CBC2VQ8\DKF/A*[EK<R.OE(]>R>B07:\8L[F\][D,F@,[1^:8K@C& W\^
M^.67<9_9$4$>.8TLZ;BR<^<8J,:\]0^?HO+:C1G!;PS.&;>D5$21S?*5N.&;
MFTW>-,EKQH 3:XN_/'X"V\ _KQ/-EQ]B&N$H-N]_+&$!SE=@Z*YX.5)KM+<;
M9"<VM%E5,-WV5?5V\N>-=J_]!,F+;L]]O26CG$;QF2Q " <5PP+HQK*).6E&
M8 &$< DH"&G%9!"OI3>9FUUM<[[LW>49)8UP>EG<&['$GS6']BMW\D+)&6Y[
M08OGZ.?A2"K7?BQ39']*AL&-I9G4L  S9N-4CFEHJ(ZLB_*RK?  IG3UX]N?
M;8IQ4A:O9>TOG<U=;$QS2"&#J \QH2S MA!9D7G8B@4@1U (K^ <V\@73%!U
M[[9QZDH^(C+!>R/G9LQ41-ZD@)Y0PXGQ,J,AWS/CRZU>O^L^_J,3P/S_O?WU
MJS.+OZHI]_>OKJP-FL6OFX<:G@HPRTRX/,-G5 <,C"U\MOWJR+*RY;UDJ3<I
M53UAF2M]B2H*5A2#=E41Q[E<'9_:L,!9D<(0Y@QF0AI?BO!++;B)SI.3[B]\
MI(YP#F<!GL)R2DZ0=:Y9J]++,#Q4F?8##V(.7H*LI]0A/KJJ-AV],)>P"%Z6
MZE_+V"\G*_8>-OK20GBF KHJZQ_J'*.E2J?\_E*/!K0!>](U>K\#6:SX.#5[
MR888RCPZ,EK@Z9K,[:61MA8VQ5-\I$XG8BY=J6#;4J(<)-E@ZAL_C\;,WN_?
MKC&1!DEWCVOZL0 U0LU6GR*FW>H>;.C+R?6:Z^H)W)7]E_/JC[7OW-:DX]Z>
MS>.S2#O0?-"]?6%^80TXO8AR(2,>X,OLA_(ZCA\,$!"%+H/+&5$H08YP'2EK
M5Z\7F.)I_K-LN/NX?<M6?)IC2X5A6O*>>#>-!?C6%92_?W+QRA!;ZRI0?&[9
M_!IKXR3D%5V$6#)X0(IYD^IG1B1IV-#S6A-A@ZZC^WVI-$Q]\7:0@"D\'=1_
MYM\2!WX8/9)^K(+4VE3I _8<&;)7Y5,DY2L(1NS_?L)508>X>9#&^V'GF>_<
M_,6.#S./M$':Z](^EV1%1BS)\X3,W.)K>30(MPCLF"-,><U#1V9:3OI)3K=$
MYMBX[VLJ7ZV'^HH:+".V\PC2=)UQ>-CE<AE1]VD(E8H;K-.8M+&P:L^\Z#<P
MZSM==X&98G9&91!MT.&'#'OS93A*<U1>9<N2>;,$GH(I5:4G%GHQJT'SB.VO
M!+:1=D;2P)8+#&](YY _#WENT9L:S0*<W8-/,WBT0]2+WLE_XI;41!7CU)%9
M04ZDT)U+%?B^J0&Z@X>2R9D'9[Y6N-7 BJ2^+^@,?F>V$+C/D@VBLHD43JA.
MZRWAY\.H3ZC81<1ZQ&I7R?D^[)=/JWLE39/=IQIG9#'.#AF=V$;!\O=PC&3W
M/",=+]&1G0JGZI5N:UZA=1SE"_):L16<P0V_,BP<@013^$^]!]O/*9Z8CTW/
M?]X/I'0!MTJ]N$PX_+KH%,CMUJ?C9F]UKQ7^43@(AGR;98K057J9@M1GXF##
M/Q4 RK<;%Q+K+(C7\S'?Y7:9E03F"]>Q^X.$66 @"V -9^MQE>;S[9FTS/61
M]7L94&Y=TPP)B^8'4FBH*XC,\&(!;-AZ]IK*'GA?@05H._6#L);-?(78RK_#
M L2N8/>6)_9X<;WP$5_FS?)@%L -LBT)=TMG<[(!<1MRB+3+U"_#?&-K[,R
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M)0\B*"*U-3L15"\7,L=4469\!F>'T.CRV,P=ZZ\'GP5Q!ZIQC99I1 #?3[,
MAZ;\8E\^M4B[O#+YL>VNW-X3>@'*8U^#;E]#=9@!6SQ.,KQLW,H+=><!I -#
MI_UQO1:SAAD/)!\N-IYY,\L+C^?"<28^O'M#[31)%[AW?5^%FJ[(CSKS(\+(
M,:4;6/[N[>S&(>R"S;MU$7 R+W"VA[_QUU#F^UOE^=7&*3HVQ.6 Z+_RD8)2
MX<+H,?BFV \68 PY9VL.9=) [W;$D&SA,<(7TWN.4CW((KM3A?/9@=F.2/="
M[M)[)XKC=<<>6-HF%J*NDD^^&#I?9F*^MBOFV930II*(0&A3.LUW?M0U-Q4
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ML<0D<=Z@"7NXB\0"M(P6A<J^SBKHC#,\.]-IVZF=OZ;T"T/\L&1FNTDWI4*
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M8D&9R0_<=MUH<9:CC0YNP+I:PS]X96_$J#3DB /$@XWU@-,@OWBC[[*?(HX
M:6/DE7J-G8]DXP?I/XTK4TZ]3O2YICM+7(Q6[;@WJ$L']WV;L3WN[JI:M?E+
M-^ZZSL?C_+EM[1N?JK8F5LT^33AC3E#\D&N/RA++I!T?"/X1':$,OW[W,.</
M^Z0J#V#ZV8*\,D1Z$>SY _<3Z2>4YN^85[*A07? <S,?/?G/-CG"TH( S#<3
MRT\I LE*SO12/#5P6K^V4M*@^O3W5L8#BLKNQ.I(]J\E#,>V%:+2\E@_>O'7
MP]BWQ&Q_%\8@/??JH3\O@D=;YCU;[MW_Y?88)7&]P7OSPJWBBWFSLX4(J[P@
M>G!>2GF"2Y'+UO#$U>0K);F&9U\_.NDZ!IS^W%^MLVYZ][82[!9U9IJP:N-[
M>&"7R?T&>BB^$?J&/HG55Q/"I:-T23W-$D+5@4$&>M4A]Z<2[Q"6P90K*0[F
MRQ^8P&TUU'K=N0Y3+[33_(-DP!RUK?JMOX;)MB6N)GL<?0MC-\$&45<V6( #
M$W2PP2V20EW^K3A+Y]V[FF(*]HY,>X(9ZBT+L)#"O/9&_^4G63JXF/Q']3TZ
M9E+B,NI*-B908(T)8@Y3C:=^8\AIPDEK P7\O>LEWQ\;G!DC_GA(0JRP *&0
MXW0(B7#36%ZDU[0X7.$1H$-FL-@F&#AM7W*<6B>]6B.Y\14MW/$5'L@CVD-+
MQS$YOM/'J763-NC=:?VZRR)FG7':'8F.UW1%HX,4]P46D_= SWW"<&R2QN$B
MY;Y72KF)$7LE+-/S(')W/@9PP6Y+7DZ2/)&C]A/Y;=,3SYN=]!AZ*=I)FE9:
M@7E;MJFXECM5>,]ZJ-3\2W'*DMGM&9&$&/!*GOZ=L:L04ULT/Q^IS.P^SF%)
M.:U(O>6$A;IQHB8"WTE-WM$D?2[^1+]=G;(/31^2?'S5_^3S]XT1^^XI0-BG
MY]1[><5OLZ/RURR+TPW>&$@U!-WEGX>Y[Y2S_0#8L>V_Y.#D)Q<-(39>X2]4
M5$1GI9OHF-TPC6^*2:1U($F[3<^G(,-$&P-ZB<H>EOBR2R8).P9OKTL[X7B!
M2TP Z37E]S+898$R9>ECK6Y6"EM!+VB21H_)HPY,41VOB^4Z\GVMN/,L!IR9
MF84[>W<^(=EKS;E_Y_*,B;=A4.N\08S6H6G16&%$GT&FC99;D#+X:/=1!7\<
M&ZT^"I+>,J#>/XVO"'3!#RT\>LDA9+F#D\=4L_?R(.D(>*1Y/K[9]+ZUF\.4
MISM?=L),5G0T3+K?O*R"%LE>65@0];>RA;5CRRM"?;0]2J%?'AC[?J&/6R;$
ME%%L)&7=/X!RBFH5SDRYYN7:MD:G.19WD;SJVZWSS(E![TBMJZ%3XD[ZU [N
MYO7WVJ4'6WR4;K[B>GT1O![AK&=[[4_TF^5^T4B_=OQ@OHM#ZIFVC+@IG=QC
M6^"*0*M 3-P<H?0SUBL/=6[(;>V,R[SS]_NZ\8A)%N $'4(6L]Q)6LL8.VSU
MMDU:^=LO,.6//P.B^OP1;)G,QW&\Z^ P[#>MZQ'4FC+R'U<0RAWT\#"T)(Y,
M5!E?U8^]_L5<R/'Y ="?^=NFMLJ^OCK+E^8B8A]^BC@O\/L&'QV(_C'.2?11
MC!09V*FV:?I16V#6>XPCP79B_^2B1D@P6Q;X/G]TD<_0'@7RY0J+!A#[#PM0
M[F".F]VI X",=E8>QQ>&6#B)NN$^DM0D^+*?=]DZYY7_3"@CI#"0\_("IK9G
M=NO_\:#]']SN#Y09FTCTKB-EC/U@^>H,CER<.#FY!5QH'%047=W]\V,E&WWC
MMIF+#'3BEC"1]Z&2'&HX=QSJ7/B(:2.8^H-R4=U=$@2^:^F#=.C5>D#F-R*E
ME'H:[J3^\G#CG<748D)I^[ HO_QIB?SI$/ %O%Z17T78% 8$;ZD*?187J7SJ
ML;I46H(AO/O=AM!C]9_>&ZM+&+D5IDP-O3:V[Z+P%=%#+E8I01.+U6@[8J&
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M05=<+2@^;-%>S4VE^Q9MBC0HHR/]T!/!+V@[7)=2:\=)]?_5<JMCC*R2D>D
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MK3E+\TCXE,+70H%4<AE;)^#T0#_SZ0DY48%IVPR;ERFR4[67A2(:Q&O[?K,
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M!>HGO-.D+.Z62S HV8B_B^@49#719!#BI,F4K/8V UY@O 2%'VSOS_,-8VN
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MF'<HCBS!)I(%+S>Y5TD%<"_XQC(3*5$4Y(IZ@KWR&K&RM<NF6O()6TYL(IB
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MR_,O"QB '(O,+ZMKOWQ@CWG++,DG ",UQ7M<^%8W2_.?0[K/S,M';IMG@ZU
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M0B($#'7BS,^]?'9-F[^6_Y:T(HYJUT#VLM,NZ[?VB+X)M;=;@IN$0'U/3D"
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ME:AV$Q14\+CT2:PX^Z-*@;Y*LEEMF'YTU=H[OV+.R<-\<]9EF*7.R?8IL..
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MW<E=MN2J1XU:3.("N.1,HM_7ECQVX9"!RY\K]&"QZ;ZRS,?C:Q<!9R.ZX )
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M^643L(;K;Z1W.ZT!\R7P,RP!'O2D3ZYN\6CEC<N9)1(5NL.#L\EHD+I*  9
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M@,[3,1M(7="!!KN&8[X3.[*/WN<Q P5=K><!+X((L4YVI"HTZ8,0V5YL0<=
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M<T&W)/9_JZ"R)Y5H)BLT5!=5WIT:[A;^V9, _<_AZ3'CH;=EPPTWW!I3X!F
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M![VBOJ0;'EK*,'?YCS$&=?6 MI(DNB&>,?6;M;[1\"U@S@-=N+_P&.4(%NB
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MTU?^_$@=& C:?::D>2 -TSL#Q"*K_BX!_WD(1/UZ^PX^:4$@?L8^[>6;'38
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MBM_8#R,@)%5/R$%W0YS7E^;O B:X+&1AK4WVA')$;LQ/WF^RB"]<C0=HY^$
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M8B_Y<)X!L$8[XR.W3,8+:_*[ :_]ZJ2\:V-[+:X"@5AVP*E$Z$(]$]P>"\8
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MADMRL]'VG7P#GA^X98VC/LP<\+]CX76XW;ZN=].7=9/49EL^_S!/'KZU02J
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MLG0K@028WPN);KJ\]?ST0"/W"*O>EA/UPYSLGO)JO_#K%E-@@>E(*8,>S!@
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MW#5XI4P+Y@3U)AQ8M549]-"R&^Q\<CF&(W#:,9077A__JA4;!.S>DI,$2<&
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MU*KHS0 ^Z0$A<101I"D.#+^_Z,>(F)C%J!!_\ZH,ZZ\*<]RGG6I2C_$^TWG
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MW9K$L+@9TX:HWXZ)"E'F'/4L2[RX'S)$Z!U<IW#;.1=B!F^,7_:0O03$#U,
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M))JN448D18CM%C*=#Y6.JU/QV15 7%O_F-^1Q8U=*%V#[S( VM&0R"]@M-7
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MT*'H4^QYCO^K>GB6-3&_S1AF,R1102B;>2B?9WT[>R'?/O!;%AN5J1@3AVF
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ML,=<BJ3:_B>[VJJ;8CR==;?UY;2OF4G+O3546#!.]%M(+M)9D2F]S+1K^Z'
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M(;C#R=[Y2V.SO2CN+04G-O4Z61ZG$'CNH;5Y$%F;5"MTNMFSCG\-YH2YR##
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M6S+E?4079^CHR _;E5#JF3LVPO^=DYK_0RL8O,E--H4I$R%X8DHI::YL<31
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ME8#NP%,<29L!A:1T:X*&.O'HKGWSV8Z%0./LF\\> .[?*[P_._EAF-J(P&2
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MFD]V"^_75-\,P#? P4&!*MD(L]2OU6'6CPDL^4_[<$4);4P5@Z>,;G.Q+U0
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M8)=S'YEWFXTE9K<8CZ _MK"N<&!Q/J-HYO8A8#H3&PO<7MJ0ZL>SGT&X3Y>
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M$&D$,6HV89_#8*(+G+#).%X4,4FBZ-/ #$ZQ],BU_ //F8%23,W?JH/Z<+&
MJ8GU*:Z^D_2J$2>W7RUC(MS-#5[*IXS'N>YV-WJ]%O3._7U>8Q>+2K4E44KP
MSD(]C95T95X[V5'/GV<^WAA:[7W.ENG!::%Z$M3"8GW)I&W-)R<GKEH>P75$
M?O:[%[%OIV1LZ=.8OM^ZZ/EPBM;<Q:$QNX#NW,7,*$+F0%/IH^CP%BF1EWNY
M\R5+LS_E&CO1T&OL(())O_#+Q\&71DY?A?VH_YO56N:R\9K;JC(%/I_,@8FO
M&$(^P!?)D)J%K(40 WAK3$<J!9.QP$\^$PX,ZXQ8/8C<@VK +UL?AVYWH\>+
MUK6J-@]BT@.K,B"<880*!G^!JNU:\*!K: OB$JHZ*S>C7:@RZ_7D@UNW^5.'
MXQ\EF=]#D=*ELRCI<Z#>=/S?FJ>O?/RHOM2M[0MWU<SLY]9O:MD^'"@\^WK
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M*<=4A*O$_\Q::D[\3?@$V1<$A$GG\$+(34QJ7*3FMXE)3UY=VL2D^-* L:(
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M91%/Z@+9#8S7-E=<E%\SY8WGJ!MO&^1N),WAU^A!L>LB_H@%B'R>A-=Q8(8
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MPJ3#X3)3USP.C$A>UAOT^1-E):8%G:<^U]*B:$5C?^C*NW6/FX,[N??B0W;
M0_U)"\&075,WA^8@V8-]I"C>J72:B?W5$U569(<9_ZU($X#$4;V.M 9B&*<M
M.WU6).=E.+ 3OB_P<VS$ZDULYEPFMJY*<#SJ>$D+>%N'WT)B<TF-^S]=,F>U
M0:"T5EL ^[44C,G,R;O/UI9NZ%<Y/(Q3.,,XPRU"M0%VL^[EH%HP@G*%5<[V
MZERGBKH^V,;?;6U4"!@1J>TZH-[%@7U/9+W_E,@.@HA&F<P0WM4C!$%)HGN
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M':L0HQ:AWE^<#SWLIW\9NAK;>""4>4O$ 3 -/#LNO#=^H?#&%8V?'0H3CG7
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MM&BX2GYPP3/S@FG.P+C]'7G*Q!6% $FQWX3*GRH; ZIOJ*9K]?'GF\ SPNU
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MNKO9=XOVU7H;\I0$OV#597>DG0\@JBAWJOF8QR)Z"M5%"80+1)-#\.YULCT
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M6WL?%$'E19__G 3H=6%#.'YF]UX:DT>T6'!JU=_7\ID,; %2^;KC_:>D)4*
M %=4!ZO]X_IQRZF!6V\D^P^\GYE,1NA)Z<EG-&"LUE[F+NM?]M<;UJC4=>C)
M%M3,J:A[]TSIIYEW_#FN%Y%<=(&O:5] YT '#\M)@&WB' GP4'H=6.T;!1:.
M(=*#MF51&6:1!97Q \'J RI<J8,'2>U]U_6XN-9RX-H>[@6RLA9YQ_E$LV=.
M*J+>,>1EP<F]7F9_IH*34$OK\O(O4,6PS@BX9&9=,<^Y]4!J(+ZB1))"J5>/
M0 A; 77I2$1G7QQ7U+)G#Q%_%R4V4\?VW-!D)!LG$#9O=XP0G"0!7BQ=<FSD
M'BHIA#S"Y+6F7;CAY/Y\2D#R+>8C"5#\PWZ\W*61D'7(2XV#K7SW\!<P:9WR
MOE2>EZ%0IJ+= &5^_=T#_PEQ'+B1D8=-)@$BA BI\9FK:?AD( ML^L8V"?"H
M!M)Y)C^+M\0X=,3)C'<$]J2OT%+I!^3&'ZS.N#NTO.L;ZA(5%?DD5B<WI+(]
MM[D?#3IXC+<@ >PR$02&R39H+_( W,I! D#)-],6+ P]+MCD'5+3/?MZ!$LT
M6Z;O!C-M+XI@-$*:W5,K<3$/9I?<JI_$>+#+]3\!['VY2JGJ?<$K>NEJJQ#D
M.:;W;34<L+1)9$(3PSRP%CY6WYXJHJ1"569+\SP.DD<\0O7E"EO999;F&%<#
M#L>?$9^8 =&K8 [H!.LIL<)C;5>C@T,L?+,F3&-DKC_=C/WB_-5 G@)?35>[
M*P:L0Y\E]A8.M\EZVL951B6]\>+8=@FM%],)NZ8L"+F/Z__L+]S;F I?M>(.
M8"^3YM1D81>PHY,J+I:/O:JR1:UXS8S(#]'&(*.4I8"=L/-+FZT\V6.#8/$:
MW8>2HK4/LRH^7^"BY&X) 'C].(T,Q0/1Q]@2'"QO,Q";6[X4!1E\N&;<Q,I0
M&LLFP@*P6_OH<Q)9%FC6-4R%5\#-80*W.UGU2_R#>BU?%'_CR0-7"M4_H+AI
MG;S.3)]]_B/%,!.JA4TG^ 4.EK9*O_ ^=5:BEZQE%/J=@:@>B7/X1Z.'(&;J
M9H^5A2<I;O:Z7P]FNQM?ZD8SJVN>M?WPI+]@UF+6SS$XW*4_ ^_A8:R%]]*O
MN5&8MUCI[Q!4M.HO:X?5>;QDF[^C:B_7ARC;JHN&(E&K>F,5:W">5HEM99K6
M$<BM%1HY,-Y^E>J6J_"Z@G][>V(D%#=,X<+XT0YMJS39JH#G10<3D86X&"V,
M[H?77T@ AZKX6]['[BS&77;R)=>RVC#3/BS*MQ]G,Q+*6WG\PTS>J^0N3+>\
M]Y.Z>DVHJR147^^%_ME6BP0V&7,Q,O)/N8[]_'A)GY?8=P+7TH7>N9D8S/^&
M?Q*N>2KL+.X2#*-R@5ENN3%EF5#5PN/W?_@C>L",SK92A)A#71?SAK.7!0'2
MS<G#/XO!8.D>WT+ *RH5VTR,PIH@V5*U\N"T41I?;<RZ.>;O6&[6@K/R:OEN
MMUW5O/C>7D P/A"5\*>L9?(U=.\9E@0XE=[V6GOS;07!";F,4?\$:6$8'X@(
MF(:\J^6_K_R1#$UMM-XS7GJ<PO>05"3 %:_\D^MBLV&PA,.A,,,Q$L Q@?87
M8I42HQY5INL>L0JC+XN^*$*I+1C"_"%D[A56N+GU/B[/"0/#:F$DWHI]EJFL
MJ4OV<=:#I*<^FF_8NW^!]Z'H@L_PM<U&JDCWHY+M^L_C8LMW6]H]ON9+42O1
M!07^,.OEI3N<BX%-CZ\J?Q9THVW-#1#$_EJ0H0SW!%[5P%,VK.]?K@AF)@%4
M'3=%/&ULD*#MB1THZQS$%5/0:4/YN[-Q/7F%EF.L0]2%1B?&)-NJG>/";\&7
MZM-L13T*OGO!HLL2/;H:O:FGQ)C5$DWO819_3_ -HIQ_O-J/2TS/UU+XEA-'
MXNDH]]OHKSD1^7!W5W0RV7,=RPYQ9?DF3\^*!!Z4%XR$ OGI S'P-XM\\;_7
MP#T)/$X>A#K5RJKG&F_P:0S\$2?ZD!.QX5R*Q;K"$V==I=(%@CQ9NU=BG<J=
M#5R"\HX/3SBR.3%UW?"$-/G\HA5:D!Y:([Q,/&-J5B=3NKZ^0;3_&;<Y'?5F
MK /7<L8$S@)SMS=#HH<S(6(16/]URGVQ;W'6.57R[;>;&U?.%_90P*CYXI=1
MM] %G:WW"+G5[!"K,KSV9+7.K?+G$4H"G97!6<],!"+L8.H7UBXD9[3C'%8&
M*=K)-NZ>O')(\<+VU;G-<:'NA:.V;+/Z@^EZ<<"%D)#7<GQCT3^38G:WQXZ)
M+9>3UV._-!%KB:V_&W&J)("P&\:>V+)" LR:'(9#EM"11+VYU5Y"4"<)4%VR
M>?D#62GA!2<IP#7C/WV)-_:Y(*889)RRB"U$"><\)0]I?/Y,5]^Z->'[5<:$
M%.-0A9!C+6$EP(UB2\@#7 H:MBH<60WDW6*Q%1E15)&8*3NR4C )U0GPI&0W
M,+:_??>=_WVJ4!%XVUQ?L^S98XC%J(]8[6Q\GCS9PXND-.]4P#=L'_054(R<
MFGV%/,0A/^.E)PYI%0QTFEI4+1M8IFIK;U9J)3V8;_O:\2,D$9['1.3P7,I8
M4C@\V+FU?:OW.?*;UR#D!0;40U3$P0O]:5:2+9QZM9[,YK<$LR4^<_\5K<+%
M&&^<I/+KG'1:"5X=!T=368\5X,(*S7'(]M/PMMIDHZI:\QO5GG)")L;>%]:H
MKNOS3<"J%GXHLQ$^M8KA8$8>X.(MUB6W&HNWIME*!\!OX\#;Q=/<59MF)( ;
MP7D$(EDQPCQE8V\T\92E-N9[+.M]._DU08G)\,=6L;?ZG1=:_1:84/<V6'/,
M\"P_$V895X]CFJDP]&V6L' .A>F:\!2ZCYC/.D673&+$C2L+Q2_-JC_8MM[H
MTF?%.^-XG0IP55T\?&.*&CE*8YU!>98SI3IT.Q\%=N@T+E *A\6&&4+,*])T
M<0MHAB'[]#+4@*<>],5!.T'-FZPP*/R[$N0I^0LYH(B['_1N/0;9C!I8P0P-
MZ_L LV+!5YUAW-+@2];^^[I3U7$T^E9>A2HKR,HOE9QV36T!-I=^7SYXP!<L
M;V8!QL088,QV>F%K310\F64W,A73HU1+C7HLM"XOQ[[PI' (E4>]*(;ULY)=
MRXI@$N#P RH$?Y<,8BPHY/80"? G-]7'OJ]$)3BE8#5<9S'EEC("U)YA>W&*
M* ^Q0PM%(+_@(K71"XWME8Q*'SUU"_L^*B9\&.C)"Z%PY);WNX.7P=5@'-8B
MDL43<Y735[(T-+Q8RLKG'PHMW=!\%,UP.:)-H:J7RSXO$+G33P((<K8CC]9A
MA_9FV<0>T!91@ 28ANIO6VJ+SFHK,8#WG*!-K@XL"W+?RN')L,]E:+-5AS@!
M7"X"+X<YZLXN*)Z>H_GFIC<E'3/T&''1^*:BG,#/"T]#!DTQ5%TD  _> !=7
MZJ^Q\A$K+P[_?"?&$+6?PP"7%62*TWPZ<6=S:,R3RM(2A(?+_*D;<Y$\\_:(
M.SA5=)HV!M8M\=:6"]6L@\#!;&HGGF=P!HL?N1$GV?V$^IZ[=9TOB!^T0 0E
M$> KHE UI(_V FH5<9)=#+]&Y,<S8U(C\_$:R'&\SDJ+^[)E>]E,&U_2K%$L
ME9H)V\8(ID_QFBYN%V/5"V7&3:Z :7#:JY0VMKW.,_/=[#'#?HDLIL%Y;8\I
MV^04 DV%$Y0!D#OHX,4$EU7D6UMQQD5K^J^S\[8QJ4D/'ES@GZO@^N@07S_H
M@E>/L\)^Q[TLE0W)?PQU#Z#Q"-,-&@L-7EH8."0#Q>M;014?T]1@6>0HK&MS
MKBO['N[Z,HC1/V%5XNT.WHSK$B\6(N-;XMJC+NCZK%#NMEGVJW/*DP._*H@C
MV7+H'>BM6@Q/S">QB6?KXP]D--MS!4389]C??^W%\#3O[C:=.6VFR2>T?4/5
M1>59Z?2)WZ"9O:.=?'@Q/!!.AJUK3HO7T2Q1)>;SZEB&&?55M:<U=\)>*8=K
M\IW:C=D>?(3K2'1Z('VZQ>M@:'J..ARAW#\3ZX$QBWKVUM%6?.2WFT<M7U\R
ME4&+2>>5JYKM0]32>:5XGTE%UC,%G'VW5YLTDM%Y1(7I9A^S8+V/8)/(N==W
M_-GZV]:DX1B-U?48C/TR55=ZM1Q"^5M^B.,QZ[7BWKN76#_TV3=XA W1?Y<K
MM^J",TLO12*KECK*[G96=18XRQ]>G84Y#7TJ*PY_HL_W6@_33T76I0C"C\.E
M9$SK @('B6B9:FY T@1CY755.Y'52K61XK40<([0A =GVJB9?HP=P%TRZLKS
MC3IK!US31"7D"7SU>"=A-0YZ,*M@M5:P8#7?2P>IXJ=O;A!\K4+%+C?X!!.Y
M<T:9O+R@;X;9[Y9@VI:IK=V_E]ARG.RZ&_KP[9R?T6L WT>4$#HX#-JE? \0
M^G")8O= S$'IJ8FOF7AV\I<SY+;JE\B>C&'RC$_#'TT=<@Y_=?;%HDN]3K1N
MC* X]0>6BY:S<UIH3,>(@KBU#BC]1+/8FA68[IM,^A44$9K%M+YJ%L?Y:OZ-
M!.;5G?L(?@P(_T$]G02P_M/1OKC%R!;77H#GQC&N!&NOJ"T6>.19=A9L;D%=
MHIK?]U)DY?(E'W)KEKU$29N>:D$?#[#^S$\S1P[RZ&!TR N1O95SJU$FBKZK
M"7;5/]GTG5!MLGW.W"69Y+B=QS"1#=0(]@*J!/(8!U^%A9$C2$5IMWNO<&F]
MC26]=@D_WX3O47-^++[(=N$U8"Y)0SMAF;7#1E^WN1D7LN:%17)MJP984+%<
M3>S2!KY9 YP"6%'20*>$J&P!]&+%\CXUSIG(3?>[*^T&NW34^VONF8FO&I:Y
M6K6VVWKN9NC>2Y'%R"!7$"=('(6IVZ K.>:))(.2O7^:%N%3L^C*-^0U9+RW
MSIH]C<V\DVA!3\7.$XL4T+<K_E1%O)8-JPA6_^0UX9U6B&[.UAU_7PM7\;Q)
MO@.6%]DWQXQ3!><OV71[TAMLF_,RM9ZW\'=8&:HI\Q]?!45+SXB5/7=\VHB<
M =\^TT\-O3&O9\5%68*DLK#""DX\X$L9\[%[%<@]GC&07UT<($2V"J8D@-2*
MCV'FWBX!1G8!9F3U,+[IZ%0QRXVN)_,XMU)Q.GB>6([H[$!EA?CSN=0?LA<2
M?YOLOP'R2JP0LGQX>?R',#56)0KIN9S\\2SO?YK*M:G1?).U#LR>K#B3)@'Z
MOV[R'FT$D "Y+Q!P[RS^;5-"A#1+C7KR3L9H0XH9(I7]'%"EGK>CIG@V2VU&
M@B#J>4MP1?<8?#!]M$^7D$ ",%3+X?5=5FU8.TSK"H4K1Q?[!;\[I(CO<DK]
ML#L2S@[+\X6=(THY0^6;48H2JTW4A\/LCA*5>W+ R<?I;8D!<AOL&[QW!,)"
M9B&BF!M9JPF1RCP3WOUK&:.E3T'O$A8J/UV)'"FZ<&W7]CK:]X"7#3H%OX97
M_?(5KA':?WNPZQ';CW<!.NU<7!\^ANV:CL4Y:+DYX-R.TQ<&D@J/QS&;!%\I
M91:R.]&/B5;RTAFMR0+JV<@^>:>/ %FJ#Q7J"83>G)1).E\A%!' %4^ =?)&
M92NB28 >+65.R(/&RJER<3&.@UZ3JC>/K %ZU"8&L7]ZI?,A#&D-"%$DP \0
MII<0^9-L/-2 /23 09 R!0GPE0L^L%Z5T+A9OOV')>XU^Z4)2&CL'9W\'=FS
M']VJA-[O!=/A-#ID37^2=?U"36/X%1V%YI*-NVX2;RYS I9W?P50_3H]Z>R]
MS(F=1;,\D!L5%)B+*<[:4E$J)R_'5"-(]89X$;2P;BU.=17> 0LE2D[Y#+/-
M;,U64TYOHGQKKUU_<Z^ODM*(S>C=-#O55#7> T..,-I %R$")5]H2G%U72Q3
MHY8/MYA?9*V9.HC4+S,H&\2;TXFJ8NO)K@ $8_8O+/%G"!X<HND1>G\'LQJ4
MTZDV#NVK,[3_&7.+(A2V+(DD_'ZDA%TE 3)$1ZV.&(]=IQJU"%,5,TL2N^>6
ML\[K,X&V&V7?YM9%E4LH*J<6<6JPL3_EBGY==7/84(.W>V0=Y]([N]^5,$V>
MZHS>MPADM30C[8ZR7S(7B+^PK4,D7BK(;$19"B.3_@G':S*%$/_,\=P4+)GI
M?W/+[.=L(/<,P+Y<#=*"CMTCO,4[/NC]!B,!/I4]KHDSF046E0&CD_<E1NK0
MZKUKO#%$)D<0.G8[PRRL6D&.@^:N4O&\;J!J[89;7[N9[X.V86YZHT4(.PZ^
MQOMV5B*N6;ADV"7/?_O!RQH;;;:47/&YR>>2B=4K[P[9^.(O^L"JA/'OP)0D
M (J,CJ-QMD%H"J+>W34@(5B8&'$T+A18&:D#;#%?CZFY.>CM@I%+F$%TMMY/
M7CV.GZ5GL>I*E1^+\]&-=3A['/5BWNPG8?$5">#'&S3;%*7,!]'"(3&BW5!>
MM'I3'DY#![W0._,B8WW!7=R=B\6PW<+<;3[R$]M:DJX"]BD)D%2%J2)VPL],
M P>:<4[+O F+RABE_4AI;G"[K?28N&+FC, <;SJ?T..<.W,)HJ&J$DH:]TOY
MYXS// MP$NV^OZ5AS/H8J]/?P4/;*^ HY9N;P*OBS4)K3<Q3I<K#V!@0X[0E
MV[(]H??Z0XI8S&L5[G;*EOQ66S0H2A&&3EA+#4<?=_'< G%N6C;3"GI^+]B5
M6::Z/OWQZT]YEJ=AO=)'M$[-QFE'+]7'_F0Y)(7^?R"-ZV_YJ_S?)Z_\) I"
M@)4X^ HGDFY+MFY*1E;MRG!!HV L<YC;-]$K#)3^NY;*C.B6A%#\W?Q?ELZ5
MYIMHL6;;IQ??4I1<I=12S)9/MCQ\4MW2&(']T\Y*"=AKRTJ.* W8=Z2I+=DA
ME13E@5))U%?HJ)</+@:,0[]#63/;E7G095.YI;:;EMPGR%JKJ*<OGVG=$"9,
M78'4L5$E#P8>,<':\#+<9$_7J.,Y(0YR4?Q3^3''FI..Q,=&]@G@R/OD$?&%
M95C;[WW;O%5PY*E^5/,EOQ46C?'#H)BGC@R]SO<,8NUNJ%"P<<=YOS=H#@BD
MV?7R4;QQAI5%2W?=T7 **M^DKAV=LQ:'!U:4+:O1-+Z85GE&I? P5$MNO<6H
M+?O<2"L'#BK&VHD5M;=G%W\@E*VA9#-]\-UCXM3^4WETM%]@]#=5FEX>VO%6
M/IR^(1I;+"C#B@DPO"=(9:MRY4LHQ?ES[%1YSR$W<;HY$&[T?(9X!.JNZNU=
MC]O'Y8A[\0^X4DS8  "Y\K%H'9VYPL5:_<]]>$/<BSR\-?IC-L^4<'-M98"A
MO5!,CE:#GL;M4DF<20(#Y/Z(XM,5-KQTV71Y7MX7)X[27KH\2N;.*\RN?FQ;
M01R;A7EN'+]Z@XUV_)F %>"0R<_Q&R88(6PFS9ZN^)H!J(K>CIGBW*'K&:K^
MUZE26N1ADXVL;DW\0,>4)),,NIR9R?M\N8&)GPOCU$_:((W(+DN>W#SKZBAP
M,%BH.N[:N8[&%"&M"PY4]=()Z*458A:ZJ7U*F7,LO[&^HDJ*[4?S"R>]8X?[
M(L7R%;LV2DRUR ^+M4C5J!$HPR8/#RZE'+<XNWYRY/:,.725W>;*Y=R7EP$A
M(2=4IDK;T1C>G>3E%J^NM(R%K+VZE6\E/1(>/#'^7WL%&%/E;D[W[U#S3.YZ
M&U:.]_D%MFXDS$ 'B)2C1_1TH$V#)2>S62'4[-CZX@LG\2]"6K]G)F/HTS[-
MQ?6R#;I!#'%4*\ 8,QE48[.L:499Y4Z,X?C+ W=FKW<-?*'G-M]YS#'_FC":
MUU'MP].>2?H#VWD$8D!./OI7MZ_:M?N5V]!$O(D/?V#"SAU%Q5UAVZ#&M#]B
MNN5OMGM_%7S%/#\LQW^CTPB$,S-*"=O^.M!>O1GY\/SG^^W#5._HJ=@05+B0
MSWC.$8B 'VLD1*/$_W<7ZE5P@F9%0[U+HNO0PST3\XE;@(\4R1_M'!*/Q8AP
ME^*9;TY!;K0_2W-=WUFK<W,%,@M05ASJ1[8RHP<W9JMAM(ZG)E.2&]/3:C3+
M)$!U,>W#^,TC(C+?*G70FXC\$K"7AA89[^:M(@$B\#2K6N#;;UC06AY85I-$
M(7;/AA=/VY_1<Y>,2.\#'*$BZ+?HH:KGC:E)_)K-#0F#!P#FL"M7.[G517-R
MJI/7/7_[\8NF2(C17Z@CQ.!IN$;R>G)710E2[(I=8^4^ #>-KY=#7I_*!&]/
M-.NBE]0P$IUG<,H/\,>C-T+<W@1"IV<%+UQE%'FP.<^QY5@46&[V=2HAW=W?
M]/,9ES_'KKV.U8*?YMMV+E9)I^,2+K\@8_%-X\\7X^_/ @23XUTF%=F7N:G^
M9'"OCG@K*2LH2=_]T&!_'1CP,=L<;G2X:4/+=%:^NG/&P^AWQHGCT37<V^I\
M@J&,!'O/Y8T?SF&XFQR*ES^[!KFOU7A;4NW,+2]=\F]2P="%,4\E^'QY,+5)
M6QW]K-YTGFVPQ2(K_O?0RDC@Y2/M6Q*^4YS'=7)P.HC0F*($AK%+^6Y-0VNR
M,>J:?4.$@^KYBW-QK_F>'FN82L\9J'$*-E'NUC4I[J]&MH$OX2TS%K?-ZNIK
M)L5ZIGV4Y$$W5IBX0IHN7*5_'!8_W5_Z)RP%O8'RX,+. F4G:A;<U/F14^6/
M#M1ZE*U%8M=BWVGNN$P6YBCOM1%VA^5QN6C6#AA+?EW3E-B>F(_5*Q9N??VT
M_GHU*CZ'?[ME*?P\]+LR+5KB;;+M0I%_F$5L&.U>@Z<X#[\\\SGCY[Z"# K/
M6MRC!?9VZ!?G5R$VZ#1-3$%<L^1JS';FKQIZ^B8M%^ZF3U']?/ [3(*'W-0E
MY-B&W0G&JB@L'%D3M2]6FFW\H?_9KR3W?^OHB#+0'IC_5W)1NA\/=VT]NBN#
M43%G3.?N<^MKZZZWJN[WW$UP=:CQY.!M(]"08]=+>T1>JX4MB5P;C7OZBI7J
M[H!W2=-V(5[#O&*!W,SZB^M(FZZ6.:O\'OH0".<+]%F'O$.D]Z;[C<KQM8.<
MI,V4/[2*[@?L&U^9X]#?5FXDH/-\*K[,+UG#7&PY9XAS_#(HI31G<2JE@^#M
MNIR8IKIYT\J*KG9TFD8=KLP+<\X='%^E]*G2\4H4]M7KFWTVF54'":MX4=%5
M\,[Q"GUTQAOY[#S:*7AIU_GRHKS!'_-VWA>6P^*[0C7L;=/4]%],EQ,=DOSI
ML4_1X-?X1QDX-QW05,[]B&.K1L9FC7SCBP;PARH"M:)Y4ZT,FQS'7;OTO6:L
MLD4ECFCIYJL]O_A>V"VG&89'$=:\GXZ8N:F98(.C*JML^B1*W8X4[N^*+\>O
M3WE+?KLRP,ZMV6Y(_T3-WVUIQW[9HEQ<N;_0/U)GO)P7DF&3_>EB2=#5ON\:
M^,LMZ]&9HO,E3>8K^\JT.&=PA)DR155MLM:(./_!!XL[# D?)-V&.&]K_O@J
M;6:.8UT!785(CT.N%;4K[:44/$J<'19\;:UN;"?G W!O5_H:+#I2F$_87D)L
M?DUK<O%6U"'_7)7"(8=!VQ;[Y3X(AFYG+[!#F6U4V9I _C4#%9Y>@=E&>CKH
M,)$7C>QL@;7[ILWF.C9^TQX[J>QZ'OG]2:D _QU &Z^_=* ;DY*1?J$8A\OG
M#?G(MA8J0YP&56>1^Y'0Z/5':O5:]F=:-,(?I.9DCD@ A[RGN&VL+7HXH0!]
MB,IH;7DA'FG/')X[;=W-/L.[X/E88^.8;7.L)3I:UN\W\KN\U0]_(%Z*[@_E
M?C@>B0;SD@ <Y046A"R\Z*I^9*/?&Y\H:6[3)7V'(#?MK67I'=?O6LIV3^BM
M[<KO4'%1V,+5Z$U><KO[YX>?">!X=1JUCMB/$ABK-0TOH"0>C;8GQA:+%.+;
MSS?IDP>@K@9%ME+ .UBJ;)TM[_78;18VWG5]]W3\9LG!Q^R9'[]M6IC<,_:X
MX?8#1"[H4"LOSBJ@2"O7>79M=LFJWW6*U<])J%G[!T-?T[DKDA/)$QO22/3P
MBDP,NJZ]TM]>+RB3(*4EF-CSQ5 ]>)G2J(:)N6TS>M<QE\CY@Q>]$;;%6P$/
M<0>+?ZEH)2.:@[>73%;^4G@=[%EIK,=NQI'^.8C"G_0.I4OW$N@V-Y\ZTFVT
MWSZH\_55K" !!,XW:M\J8WZG9#/3A1?'Z>3BA:HFW:IC,K<_'(G6MKQ?THPW
MZ0.$S\:$]$((CI/*C$X<R&XQX=XJZ\7RBGS+FH]WU'^)S="G)PT8>0";W6/E
M+^\6YOTI\28*56ET0>+ES!B+(3?&I&'1EOH)+QM:;.P?U[C(V<6-6%7RWA5Z
MG[\*\U]@\V:>,] P/J/<+-^0Q;"V!<*ZEJB<>3@F;S345;10"R8-IKS@M+'^
MTY$TMU#1["/^5>LHE(V,N/?<S#H9<8@.T1^;=:[C;DE30D\8GIG<!Z<5S@W=
M9T<XY^M>\;O:;-A3V;5<(O#:)&2+6DE-Q_)>XQR:([!@&P=G=)X%MO%>\0^T
MT1[O;D1$/S90S/"++!?/T(2LTK7_I)XHO!"[+W<TK(T%ON:]]!P\4Z8HL<JV
MY_V[K%<Q[5KOFPS!]RM0-)_,2$%B3Z!9L=/2%3QO[A9-\-,57;J!([V?#77C
MG^,?!*M>''+)*QD;LSD\H;'J+L_XH'P1[9;6N4^]F<T]GE>?\4T_82!:)]_T
M76SR;V: 0W:;*3",R/"+>!E3$(77M_<*%B,!W@HRV&AX\+.]"]7?:WN@8321
ML5N8LY^9B3B))H,L_4TXU@T]C+^=N^8BIFHQYG-?/'4O*(BSQLHEBL)=8>2S
MH.36.8KD6$/(0T(ZGA=#TZ4!2JD1H[=R#:B;%>L+U7HEF3KP=4CA]:4]EZF;
M1;51OJ(EP</2.(<S99S^BGN><E%!WGI>V>,\D/&DP^\]F>Q/5P'L1Q3"4RTB
MT2+EFG\8GO^=KMQ_R_^[\E?NC?E?\M;^IQJQ_RW_5\(<&;#FQM'97<O#GHW.
MKX-1S,_-GDAQ8_+]9-!-ZI(C[QP/*#RC-Q1],'\\'-I[)I/-6H6PEYN[4FTW
M#IZG;?"]NQ/=FY,]O5J !L=Y@]YR7.!8BMQ/>S)^XZ5QEKUWOZ%Q:#D%1>+\
MDYJ61HHQU):[@<4B/X823D:88_/)<M-AO:K80<6=O-";6Z_."?^B=!%N S$T
MRV(4M.!&Z*%<0I[]A9Y%+4@4_^R*ZK4H9JV52+G>>TTG5."[!3D-\(L03?1&
MER[+FMF(M%#K>-E/QQ?UCE_>"!1>#&$0^0A0&=8>0^]''2)8G7I( /762,.*
MWSS7/=SG<E\:1<PN4/=MR15/T&K?S'GW+[F1S$.;L*O5M"[=LXB(VPC\KI>.
M6M(!JC\1DN=JMR_"1%@9R:X9-1A;F6I7\[)<Z@+3^_MU6P(CCKA5=TZGRN 5
MEB<,LIGQ2*DBDTW\(S,=#9U(JXM,9M(D  UG9V^O1OO2+"_&D 96$QS3ETRP
MO=L$78!'[(S^H-)18Q[$E:P*1S8S%CK6RD]]QHJ6O5S;J94\D=+:T$KA]"Q^
M>+#]S<Y+PXHJ?<Q +8 $B"<J^3.N9%=FF$5)+^W,'4<YF$/[%1L>:E+=XJ0K
M#MJ(-N-._\5D%@_K!$$$28#/Y.#H5AT,[]RH?P[OCY;HVGVF*]IIN8%-P;^J
MZ53%:JUVV14*2_''E\H-!117!3%ZURF<_J4O\0;$#4/Q .>5/P?"19  9\IC
MJRMN_,G]239C7X7,J$LU+@<H>M@P_V/UFF7@.K%Q.+]EB:L+CH'[;Z&=Q59N
MO]V(W1XW%@;8H<]CBU9"EH]+FT"SJ!6E^4T&_T;IEW*45IP?4)B7;\_A,G06
M)RG&O5"%I47-1E_:5XJ:5;"X%Z//:EUJ6^J475\R&W:C7OI=H1B_-TR-:]+"
MH")W?5KH]G=G;4;LKQ"M>IM<F(&BKSO?!48'H^QVSC+_<X1YG.&XNQ+P(O%9
MM/3M@_OGC.FT! ^9 *>B SZ@V<P5VS@(-HU'HC;@_7*F^8WZ!.)9'+O^ALU&
MN*+#9]R&#D=\2/'LUM3S72DK34XGXC9=<?!;RO#B1MJL])K_?+G-")KG.OA2
M1TM][P6<FQ^A*"Q%T.$*M# OWJ3-2N/E4S*TT9PQOO/A$RNOW2.IZON*>:AP
M42O[41S!D\>1TO2[G%96$349^C<T:P<^,=3[&/H_[5O+ *ZT;?YC6ZNA!;8J
M$=DLL:K+^F#BB+[*>?8;4T7=@2!,+O0<9XHV0C!X]>96VJM?2_9?<O[KRN[_
M3M;Q;AC6SB6ZY:^97?*16(@?ZOS40G.4T-(M=IJ#6[UZ!>=?RVO_(<6(9F%0
M76(4*^6Q&8@H"1*@JI3G1<A+,E2(M_TK5'C$W\J^B4M<6:)<<O0-[,G%*L0Y
M>[C993]*V-#4?MU@<CW Y^?7^[G!+<K!(9L-8_\G6].BE1]S(V5%[$:PO@6R
M;MSU.GM03.3EW!%ZPZ!S_;LF$-TU-];V1=;,+LON_9E[C@;<>Y "B.A7$P43
M'4]SWWWM4^O 7W$#(MD))98NL[K9>?82\!<!E_4O-&GOJP.*V@&QH7("TIY%
M^5GIM_++0_])8?S_I^OA_RW_;>%OK--I"K!+]NU_DNOVK.""W7*\RC$B'*^[
M3+#7PO@<K<<$K6*6]>D6\B.5OBG[L"4]4YRL'7 _:#]HXWZUQB6):'+\DM8R
M2("9-I[$$W>1B&UP_8D?MAY]! ^'.7!3:8[/KNRX2>SF1I7/9!BV6G^8UZ12
M/&SK?7RY[DQX6#@$;[$&BI2]W2[V1==*WU3I::*9'/X**$HZ"+M) B3==2(!
MGOH##R^)*JR^(P'"P1C[%5#7!<)DW([DKXQ,[&S_P=U@"DFR?CPK3F[.7YI-
M:<650&\%_YBPW3%[ 6O8QEEO IU+-FL69#M( /K2YZ(!JV5Z<GFS 5:.?4YL
M9PY.>-JGQ$X/(40GF%$]YJS^:.;]K<-K:MTN_H]@'7V$ D6CU?.0P;L=,C'_
M!WOO%=?$%_V+1D%04%!Z#PJ""(@*2$]$?C3Y8414I*N E$AO 0(1D-X$!*1&
MZ4B)=&D)O8B = @M)/2:2!L@A,OOO-V'>\_C.0__A_TX>V;V7NM;YK/7FAR\
MT)P=,E7G *R,+BS!3<31=.<B<1MJKJ>@[.P20]>"![6NSA3= *93T+V1,0/S
M-,N/Z:<@F7B&,(H=(G@?11$K_N]/WF-CUZI'.T(Z4_/-M-EN?+E_\._+FXR@
MZ&AK@ON+4]#;4Q#/&ID*#7O<2)Y.#N"OBEU:16H=/.P0N>0V>.CG=I?9O0'P
M=7]^"K)!'S[ "9Z"QOTU3D&ZR?6X22U^2<QDUD5YWN0YV.?9+E?)GP_+*W^\
M?456%$^;>W6LA4N&CL]AJ*#D,HE3D!P.^G>8=G$"YR#MW-[G[DW A!P-1'K<
M,L_A0Z/W724,^SO^3GD/*^V=;SA;=DN^JK@H(?X1>4$(GMAYH&_%N96..-][
M^0-[D/93%Q?_V(<8-C+Z8\ ]Y/7!(6B8;WX(A;GEG:YHY<?NCR%2WF]J990&
MF$4N+\>.SE Y@=("@.C,8V\$80UKP=ZKBLD?V21%/)].8-WF#0H5EZ8:'S<'
MN1OWX-D69V2^C%48X<]\:07 3X'3N+6#;XZ?@BIPY?L6NO;[J"J?0SS'UDRY
M[]9J["@3]>U EQ;@?A(_##OVWD_!^U=6]DX>;5$E@TY")U"MJ?6\"W!NWE,0
M5N2[07WMYN M>K9Z!A96C1\" =DU]NZ=:N,T_-R2YLDD9. 4Y%2[X(8C5]X
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MI]D3'^X9_WI9H(SNI1G1FO0Y_ $-W&&&_/BFIE@34R_Y%-1\A(M]$\N9O(6
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M_'4-C-YIZ= LHHT>H4.=I#!(7?* Z1^DC/>M6#43XE,SN@,]C1^.BLM.5(+
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M8.W F_&]*^)(U+4J?62ZD> 3G??M==PGKV5&.E&R[W@UE0,0@W"7%1>MI>4
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MJ!QG-W?$BN"FG4RC*-\/(F]S-W *A=3^GDXEX*YB+P#8G2X\*H[*2>07%.]
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MBCD G:8]+&<407T(D(A@X-4S@'5^.:QT;_OJU"/QIGI<BDWI]T\L+!=%YU.
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MH\Z!:,O+&]\HW%&JU[)9+_.^L(V"U;VKK[WL0O=@WVR_V\PV5M:BG(0YB]I
M"%\'224_P8__BU5"/WUSPGRN>7?PG_B>7="?W3@%1_IJ^SL%/IK(;7 [)B[%
MY-4X$?#_5I;0UF\NO8RJ_5*./EQAV/":0N_[&5GE4[UJ*,XM@LY=RE?J._P*
M3/J'7ED$S6JVV__L/-81]5#BZ1;Y1I#P*ZH==NV:M;_3((311(Z3#TBV':>@
MR#1(9@G"K]6$>_]9?8N/JX](Y[M$[VT^SAW$"T:@UCHX3GTWTS3*-"'-CUD3
M,= A$R-T?:C1WYX /6_'=;0<L5AS;#UDV;LX-:6=.&*C)W0*0G@*ZI+X'P-S
M9^J:$;&M03YHQS"OCB7C%[":647?NC?9>C[=_?6[J\CL[[V,'4.P[]B:DE\M
M3F-N!2,.=%#JG<^MX2U#515R:B.0]L57QNH1_D5L[L<]K 6,T;$<"0\Y.QW0
M?%A)I(RIOQ&1.]@C5?5N?Y&KS]?'G7KZ7:#ZJACT'_;.+4W18?Z7PT5K. Z(
MM#WXDJ-'>HP%_FA17J6CXJ.Q5O2+;E&NZ?7 KO=GY%2\Y#S%^JQF3%6<O';4
M;_.SJGZ,D,9KF)-S_;;V"-_N7 R8[P9@Q)!J997?@P%R7B7V#%<5FE[H?RC5
MQ<AT"6RXVL-JO=VT"<CL7-ET+$6=+6K\ZF>C_K3:CK-+6=\S-!%/071VM1:"
M45>\ZN7;_/,G+QWWI0H(^%WVC1]KDNQ \2-5YE$A]J0V20M[HZLY>&TA^L2&
MDXE.7X%E2+KI4)AUW<>RF3CU$A074*E'5@AS]NQS6-_PM4D+37/,*T_@ (%$
M$W0$?,>#P5%H@<6S$"^#@NS^^X@ALRD"2["_<AC,.W/0I;B\97N2U@J<4%1>
M $7'2C&HMI<U(JT'=L4EI20%_*:-,9$IGO A(" W.$F8DA8Q*S'E#[$<7WHN
M+2&ZCXK[MGL05MV+8K=3]L+8B9J:KB.VWK)]X+<J?!.?&!QLPKEP"JKT'(@N
M /P*9"*E/1K\Z,NK^?3L.WI[&%/&S'\'O'^_&MB#>57Z75-+7^2VFUOD^__:
MN?XSA.5":&VWFPQDC+W<B%@TO5U5(7OWZ7>>#S"E-46&',"*(JL-5,\K(M6S
MF3]6^0AQA:Z^L(D9(11?> <B,08A;C2:[@?5.T>@^53IR$.3T<F?^N4=#9XO
MT)M]8J6"H"=43M:6ACC@.:[*.P8"_HTLE3%UWC27ALU,J[L5GX+.2>'V?V6C
MFW"F4XO. Y8_ZXX;/*IIWM2JXX'\%8P2,$/Q";@&>/TB7I&OCK%Z5F\JR<SI
M'Z1KVO! D2ZN2-AUQ <3#I&A.@#N^3+AJD:$3(;E-DK%R7>UV_.TP?/E(+9_
M8Y4_W3\'?FRD4:GF3<1U.(H3#D*MQN73_:;2=>\\&[D9*=)3%WS5Y7<.6&+;
M_*/;)2MM09[SLML6*I0N4LC!!QJ;O=!]\FA3Z>"(;>VU_#SVI&L]_-#;9;EW
MF[?73="\$'E4*V9X5P\N+;$WQPY/N"AW\D!A0O#GA2\['YAO=2'W!#[MU_O-
MS@7]R9QVK-0_!;6H:44>-K3/<4&4D&I#INV0&V3;T"T/2:3:M(E_6\3\HX>+
MT=$J>TQMY+)QHE%GSZ[,AUX*8UOR_HZNZLL=#9:OT=WTL=\U+M@H\8H$CSSS
MU4Y?//B<F&A@#C/+QGK6 DV4E,XT/D18JQ#C$,/'0<:PXV?OCO4)=$N(/SH-
MZL*$!X@NL29N@F4'$""+D%HC=J_6[@]7YRVF.K8J<=!]<F&Y*+PS'-\O:_1K
M:_RM4Y7_@&9VY&%B&[3*LMU9")XE2MX.14KDK?%UIA;V<4^)V88.S4Z:?>>5
M%5N.#W?BP/Q+V E??UM:H*"Q6B^YY"^^GT$I30GWE*&'SUX,)1'/5Y2&E*5*
MF!H?7)G*3$UWN'!8ZZ3$"Y:V?X5T!T((N/ L\!E>H:_8/_!2WLV>[3\%:<5W
MZUX",4QO9AFK@V7,HG>_6^SH>DXD'QKB-%8<)'L#Y) .B?.EG5'9*T<:B. .
MW^E0%4%52#LAL&EJ6'SJV\*YM)UM#N1K8)(\H,]W!KA4_ODI#.L_O?N8C:)I
M?:9RD'4JCZ>PM02G@NGN[0&G@B$/HVCJ>V#5FV#YT5<F!JGD#/=(^SPVQ49[
M\&:AEQ^JZ7GX4Y RAB8O=X$Y56TP]O6QW^8=173)6E]+Y9R&[V$C;^2V]RN0
MI/^2N:-WGB<ZEN&AO].+Q><,2P%S"OPLFVR_3Z]RC8\-KM8ZVMS"QERM_'!)
MLGI*) LX,G*TO$7KI2D,T@2IRD!8V7J*GOT;Q[)?NFO]4UK7&+W$OV), 4D2
MFA^I55M/86C(G; 3XOMYLZK!\C:LID<(D: M4W5'^0V#>Q;#?>EGN_K4(2M?
MA;7QZ0'#;"PRD=05&R "1#VK  SG,U4,AN0F_V5?3QN)_J$GO";RP@9:1 AZ
MV%TZ$#HG(-\[(( ^3WU(I@;P4_[]E+HI6IWH7[H&TIUP<W&Y=-SUK?]BQZWC
ML9U+_Q$'+IWX) 3<SHRZ$)62:)D\68:GC]Z,O2N;;-6E]J'GR,C DL/,$OG,
M$E]!A#NJM)42MS=:16KC\X[%)QO8O)<#[LUQ;N+8('( 6H^2GTF ,2 "ADTH
M'F-O]]?T>AZ;3,F@B!>: LAKRHG-U=&61J@^6I1!D^BX,P N_K/_7;)9#A-#
M@Y*]8W>AK,C'9&RFO6.9WH+Q6II [*!4*MWEDM^^20,BO /RV[N;>3W8&J;_
M5YNF_]M[;O_/^/\?DDNXB30.<_:N9R'M,67=>4T/#0*/T/W8S_]/>^\9U%0;
M[OU&J:("BO02%!"DB/1.5 1$1$04I 9%I$1 >@N)H(!T 0$%(2(B4B,U]- #
M(B!=:DA"KPE"""0DAV?/G)EW?WAGSOOA['W.GF<FO\ED9JW)NG-?ZW]=_ZRU
MKANI09$F!M$O;"'*;1D R'^\W+$UY.VJ$#''Z\(^S54C2. =GZ%:JATI^8!I
M4A$TE.M)\J/?6\99'X7V,0 U'J#)Q18,]1;4I0;=ON8[6_H[AMK-I6R0LAD3
MOXLT(P6U82EW6JX&6V* 4PR "[T]]@N5;1)U0$7]7?(6ANWOF]_90<=F!;W6
M#2<5;PWW=4XE=R2_S;I[&STU<%[3VUF6G4.WU3[*2;O<R$B DU>C[V<#E0'P
M<Y^1O>KE-;<]U\ ']SJ=K4:$OW%ZAYS&VB?B@%T_)-@DIN41!2;4^S+>\6#F
MUX .J@M%@IYE-Y$*=2*>+<V5(2:]G]-IH,03<HP?QJFG_7+(R/B\\T7M^:G4
M(-_0*YHBRVN@6"P; X![%MS8IHTEH\E!- GKQ*"%\.Q^ZCU;]>G&T T&P'J"
M#5G#;?42<2^,?OIP[\+>4O*^Y_[?\_3?SB!FJ&<*@I+>SP!\GDA8 ^X\.<<
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MUQ-V7AK>M6[XS  4A+W'-O>O4N1$-##;7&TX\&OT*=5XAZ<*L*E!ZVB9&AG
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MBK?),'2[.CQR6 ZLXS5+Y;ZZ\8R@.: ,B:6H$(/HO.<I"?!__@*"O_ X&\X
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ME^[(967B7=^(5V>LF?.NI$QU*=6F/A]]PIZ:=-<%Y:1!U8.$=A]./ZB.6QO
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M3)XV[;*%5?$XN/.1K\T.NB\I?UU\$F%A?U*927T#7N60W+9]H V/Q^X-3#,
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MOX%_M>Y?_LMAXKM@(CK&ZT"J?[58,2+=K/__@7L$_W\$$V/R_P)02P,$%
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MUP'\GP?3 =!'-O:#')Q<X 5E?, !)F;F RS,?[P&OPT$OP=8^%D/'SM[D4W
MX@[[<2]!E:"XCP>E+Q4U"%GV$F54[WH'<W *BXB*B<O*R9\X>4I-74/SW'DM
M_<L&5PR-C$VLKM^PMKEYR];IGO-]EP>N;CZ/?9_X^3]]%O(B-"S\Y:N(^(0W
MB4G);]^E9&1F97_*^9S[I;BDM.Q;>45E56-3<TMKV_?VCK[^@<$A_/#(Z-3T
MS.S<[_F%Q272QN;6]LXN>6__3UQ, #/3_W7\;5S\8%P'6%B86=C_Q,5TP._/
M!?PLK,?.LAV^:,%^QTO@N$K00<%+<1^+&CBD52V)0G>]>SF%9=2F9$E_0OM7
M9/]]@07_3T7V?P?V_\0U"G S,X&#Q\P/0 &:54;$"> ?^\^S0IOIEKE6#+&\
MU<8ZH=/=CRWZZ6G5QCDIS9M'\A0.760Y<' Q8BDOCEROB90E?64 GR5WZ0FU
MP%/Y)LB(^Q3Z99TXV>K&@,[9G4C*JMS0[VG$*E?VI'1C?E?H&Z9XXWK QHP!
M<(<0$^BA4&JN P,@C2[7<:12)8B:M.<KN*U+-NX7I,[_]1+HU&O48?3/' :0
MJ("C:SNV&0#^\U05WD;8OB #V,CV8P!M#QA V$6R,0.XA*%?+V0 Y-4 24&F
M&0SQ.Y0#NF#% #H2)QF 9"9=C'U*GL:)WK.L9@ S92N/K[''H)N.4F48P$<8
M SAE@Z8^B27?@[S ;)UD ',FZPP@!E_4^X]7_WCUCU?_#:_<NY <E'-4[2&4
M*O+:3ZR.[KRKK?(.?%B1/N9=!TM[V*/\0X9[Y#;O#W/MNW4%V"-D)P8@ST_"
MT@F8?:,MX'^W=/WCU3]>_2_K%3*;8HCJAAZBLA)=FK760J?6ORY]P[AL>.J-
M^<A-X,]*([''K!+O'XG97H3_U;&=.@:0X$=RH56A%^W55Q[_D]%_O/K'J_]E
MO(*<1 K04E&2Y HRV>V7% 6^ X]4WNJ$;8V]V2C(W-B1[SS:K2EE;MPC@\_^
M=_<;::*YM)QE %;=8 RE><,+S&U_B<GPKZQD>.$#[Y%_%Q/D+^%@G3*>Z_C\
MVYA*__KXVI@(@-3SEYAZ_YKD':T3_WCUCU?_>/7?\LH+(EC'1882%H@QU80)
MC4!VZX3F)QHP7\1G^Q+1>W=E8"F7SM3?WH^*>8'OOS&#*9VG1M;Q,("B$C,&
M\'/TN6Y,Q(D/!_ZQ_SRKA$;J^S5BQ&+W@W\Q@(7PPN)*>$237^.Z*.]^B"-Z
M(?P#)YPY!L5-AM#KOZ'W9=W+"T4(%CT-:&8&,"R.9P &BG[7 0L#P?]TLXE!
M@ETAX249?.@C&$WFV8X6J2<,NN$%$6< :QP,("OV@E2;@> UIO\"8X]!X2<W
M/.FG&4 YC*805AM3X_-74OM?DA70P,9=$DM%(JT@VSIN\ ZM/WD9Z:'KT4_Q
M[J>50>8D R0!00N#_W03^G?S]U]9264 <7X-N!T-5]R^Q#7VHM[_FJS\;VLV
M9TD7/,DNTU,,X%HDCG9XNQ^O3CKC249,%RUG38!S//D#=^SS-BAK#3\#N!V)
MH DKU!0R$SAZ&F LX)R6 YO'!:')G_]AY3="B#8]+^F*9!>B:@.>SD>Z4C9E
MNDB]\M74-\--X%:G#-HY[9OJY0Z36>:0U@O8=AS9'1+- +9NZ1U%3UD$_ND5
MVUQT+F<&(+=+0%/$11B L9)" Y3P"K)A5W<4/5R%V[>2O"(NU9=M-.F.JSH9
MRP]U,3]<[KS;T=9F01_"'3D6YX Z2R8GGI>H,7O6M*%"P']#LC. X&RD.QDV
MS24]K8A"O-03M^;R_;1LY^C]3NS!FM=O]C:SEN1!,]2:F[A'.M9%L6 [7^1;
M<:[QT8HHHYBLV\'@J4"$T3G]B#Z-4%:TF^F$<D-2TKYC<J[KM_VL% <L_ZTN
M::/"EYDOK+Z>LZB?? [4YZPZG&^Q0Y,#PU<&C=HG$62G7>4I1',!UPQOTRI7
M*TJ\BN+X*M].L:OFQ9UD'95S*TOU>8=:C+#-L#'WG=?D\BG8*&[Z25P&TH+T
M*39K9&E=J"P,,RU1<314 ]L1EQ5T/8 )CD0W2/CF3<!VS.M**Y4\MM8/.XR-
MKND<'#TA>RRP_#L#>*6^%TI!,H#V6>0M!O!U +//.3#MM$)Z'?7$"[$^Z[Y6
M<2TA2=S<[E/RQ ^<!*1ZLD2J(!!+[X9PE>F:[\Q8#F!USGX:M__ET-'7I1/M
M(:%:723[-MY89C;!\1T\2622>".6%\E"YB'V-.BQ]1XG82*V& #GXFOXQ'BW
MT]>BM[97N T17:JY4XDFH3J>WX]Z0P_A"-]^:93C,Z1TB,)!GQ\4$HQ^2:J.
MCC=7SCU/N65]B0T%3X#^$AIS:/6/2*WV@8)0@97F=&U]<[Z\F(K#JF[O1,RA
M1)!FQ-U6&+!0IT(L6QA04[1ETJT9;CID=,^7+F+->O/)T8A-Y='^G4:BRTHD
M83G0JME4(S=_B;7?]&?^,$?AR(7QEEC^UDJ';I^H*#8=&T7#E;2<'/V;J,V;
MZ>L&*'7_2#J7"\EZV3)N"\+LKVWV57XVQ,*NNOW";IS<2PB%8/.4Z$?G<O+U
M*AB]A;Q&5$RK>Z_ZXKTU<:"8V9.7)/'45$2JXC6?ZO.VB,^%'JSR':C\WEN_
M)$EL:=-=[.9#6P'?RW@4+,ICUOK6!-ZDR%_[OA1X\"B^>;)LGBJDWX@K:8M4
M1HI,F7'1!=!"P^7):&G[/6%K%2?:K4?Y?=_/C7\!Q%I7ZX,$4%T;G:@6 Y_"
M!RN!@P8H)733<ITJ+<^/>ER/A:*!'J3%[*)T-0/SQ*@*R] 1")VS: HQRMPJ
M[,A%0H4P@(/05]AA@YSN9/B#XMHW6[%>-QZDQ4Y854B]+[Z@U:KTS-!;5E;2
ML>V7H 6<FX['$:^O'Z3WZ,E4$_U>;(62\)'YPVW/)ETW'CZ4F9_U8XJ*9X[*
M(!RZ>/NB4%16YKW=^T61B:,C$!\+>+06A"K<,UU6EQ_O+L5&]-U)DE#VN)O\
MI%]HZW!IWPD]"F\?[C+Z7NR8>SVN;"C\T:A(6@8YO54]4+\)W_WIP1O"T[BO
MTS?+CW@"?%Z5-M+:5PZ9+'^,C(\LT0O-B#C%Q;F!'87NO":B5]J(OS=;'$_7
M77X4585Z&Z/7^]F<O5/0=& SJMR 7:X8_7 ]<G2W'CV2TUIWGM@QJE&9K<\^
M4C?!GW3T7F7$\9:+8L?NR?A$!:7&*)#8&QWYR3T,@/4 &:=6+K+[Z\1@(SMN
MR)?Y6\_5\MG958GCYA(/'[#-I![PN=G>D?GF6'9Y( ZK*_*N..*%D/'*1/QF
M/Q7_7HVJ2;E+=2'-MWE(7ZLDOY]>5C"#-U\SE4MPP3JT.0MZV^>>R;IDEG'F
MT,^*5C:%?6'L;XFIRRA8RR2[G$^Y?8D]3>DP+B=E9<ZBJ7%B<DX@KC+P+G)L
M!.7->2*C2!W\>/[O[*^<Q['-\3RQC6XN/0.G-4"WXA:8AQ<R(H 3?V,*T&:5
M&BVV'!G/WN])?<7%J7R7CO %NE\J08)3\/BO/ ;@& _V![9*DKC%>P?,K(<A
MN6C;<!.$;!XG$HX>*=_,2SVEC/NC-8:@$N"5Q<@+#* Q@_)']O,2H'M22&T&
M<$<"31,OHQGX$O#NH;FYNQZ!0PQ ->YZK:'YF P=O#:.NN!ON+-.^X 4"I0<
MC&V)/3Q1Y;3[K'9JP.FVMF#%+V@!JHH!-$!QGIWHT9DFFWWK6E>/+.2%7J=;
MRHH%QGR.%\Q[O0['FTQ]S:_4-K9*/</<S0 (A? #5)Y<5/?N)-^825$_TCGS
MEVT;6S;B<(OZN+=)4>EA/J@_<'?FO,)7PG,[* >ZX20(J_([>.(+X6QJVJ4^
M^M#"24++SBV9O=KR5LQ+P3O9J]E:EG9PHOTDD0$0?_B_I)QHS8)3U5? AZ&;
M,M<0Y-.:S>NB5!6R#W%GOH%^&J\C[^.;9V^H,RJ5K?Z^(X/O4N6K-U_94\5_
MHPE@ Q1&>I$NP2+ >[WS[VR64J3P]=$[:95?8 &S"(HU+=W]V\28S;GETF>6
M8/ (]&PR517$\ZX>^DNA31NJ@-].$1&^DDS 1.[O1CBZ=R[W9S=E+WSSIQAL
M1>X4#_=P1B:>G@^*&TBTZGD1#[_EO4']6%1W7+$Q/C:9_J9GG%.!5&X#]LA1
MY+7WCD]+<4SD*ST&DXDE-90;+=_A^BH=$3!<,MD&Y =%\-7E*<38@59ZHZ(&
MC-N_Q^PES"^CZ]P[F9??)K4XSG!]EM4_\"'W]GD6@?R[LX51V;(B]P,-#5S(
M(8[]-0H?E\2[L4\/I66[$G4'!R>:/&)$XTQ5BU8 %OP<OA5+5GR\DS(W%]Z(
M8[GUR_6GD:6B2W.Q,3V>72*TU)GSY)*F<?S91*N6>[/8S@%\XMC[C_MY!B@U
M<L"_T'KLFB$>R4-8O=(,29?455J5E1[YY0I68)T9*AKU'?<-"F*>^^1!AR5;
M%DWQ*^6?1/NO_UP754OZ05AU]FJ.*[)F^LK;X?W%O^"-?8(["#!F\@.['0IM
M4%<&,(II0!?'/L<WHQ237.>K7C?DN&K<5N_:^G OE.7YETS6U%3 T/(ZI LF
MC&[PJ)/]Y69.%R/RAJJE0<EW!E-^[\-;9N)!.A4S=,KX6[*^BW!\PA*JS0(>
M/\F%)I2+SS[+KH'PUTDMEFLAXYG4U\-<XCF.F:\<>Y=J%%C3O(]?TFS"O72$
MD L(!=(MZ<(#3H.EDM9,N@4#MYB2/[)(W0AB-4GEN\@>9^>MY^@99M]!K36/
MB=C@'77:R2(:KN01O*8AH@Y&F_9G(V%]#^O=\Q:!]IL#KP]$!7<;<<6-/T>K
MZ8#4@/4;.=DOKS1=C"@2JE:@#%6LR_=$N%#OQ=P$Z^)(_O4$9-['O$C3=YBB
M 9MYEY46\!?/B3W-Z_PW03)Y/X0W:%NB[>;MH0(E[A2?[_X'KLT\!E*!YHKY
MWZ?8W+>,SMP^>)[]8T$VNR#FRMVL]^46#S*^ZJ#=\R?)(LW6=9+^3B264=]F
M6Y_Q\T9#<YEW^.\#KYD3VX$AU80H^_AJ!YY,H9,GRMTQR9!ONU0A]Q9QOQAU
M-#-2O+*\[Z%:Y6C?>@L/)TSWQ_='RYZ%G#*W@ZL[BAXZFT0)$)=1PSA).TN*
M%[EI!JV-HF7"*_E=Z)6(D=B'=^N2R'X,@"61W.9""FDL\N_7[\=2!7U/P&_5
M]F_[OPU\>TZ%)[_]V&DFR*GYW]CAQ3H)LN5,@WS#AC_"!,$I@2YF '=I,=#B
MIS=;&X0U@F+=O#Y-&<-2-NAU<\.6*8F&+ 60Y?7 GD[H<#*=LVRZ4L<KVU]A
M1GU%:RCNR]6D;W5R9[)$A"V+1H,#GRNTFC,]9+./-SV$*12BME!=B+_2" P@
M*EWSIYJ*G7&_^MB8PFF]S=DV[2PG/Q0P7XLVE6*U:R;"PI,MQGV9<NPB,:KK
M3],MUWOJ?.Q:3<H.#IE,%@S2M_&#HAU*T7[&>_1#DR#&,'M'G,B/_CNASWN$
MAL7-3E#!0O#$[-OP!$CZSZ^"R"ZW/MU#><P ^BK<AQ?^PTTCV#8<60'2!GL%
M.81V7994:$3S(6],!2K6G'?5OO5@=+ K2TY?O5[)4O/&^*7/\F*$9S8KLJCC
MZ 9GW.PJ>'.*$ B:6X%=/@/DQ7T&L)H_BFF"P@8A(, UW:0B&$!&.XD99)61
MZW1MZ]/HA[PQ*<CETW#1FL<K67SR))[QO(:>B:<'H8FH4A ;)7&S/V&T*!O<
M/K?Z-KX9%DH7()=,O>_A)>,N%)'8$AZ'RI37OM [5^_L^;GI/'<6WU,6&^<'
M5>:]@R/06CGOWI0OA5N#V,JR?4@BM A!%?)I%4:=ZZ-*DY(M(AV).]DJ8P;3
M)X\9>3[>O2O$G7T@/\Y%XI5$LFPYWUGX%P8@L"Y?!$Z(L6KCV?**<*/J)+$I
M[\*H8][Y^>=9^ X>QZ4@(M+%BH@VS>LB_NBK513/M*REW2<:>.UBYXB3:?S%
M6O&"1R+H+Y#2!8[^L3NG^GP=+E?B:HG<?B)L^DDJ&NE< NOQ[N\%9.V4T_P7
M^JC3HWMY$KV1V='1\E]PLWU43]19>A>T=+Y5,6 G@@S_M(06UO'ZO(A/E^_W
M6'NX1C5\>EJU%6^1)YUII'^2)?A@ QON0Q7=!7U_PJVM"5.JV:1H=[TZK,FL
MB*3QWL?7]]&4=)A,973:2.P%0 ;C1N,A+X+S_DM%$8FU&T-,;M@1&?6H"16Q
M)6FF&/QDB6Y'2$@?3_]0,AO2D3M=[7+B"Y\#0KE#CC_25V;_%BIGJ4!H+YRB
M"8[[79++'YW 2[4EMH0%"6WE<?J'Z#]E+3W4S+KY,?%=XOFYIE2TGYCTUNI-
MHX]OPJS%6(X$*\@+QR=?L8Q')'\NM6G%?7.A"N8UPHM;*Y"RV:X\,] CITXG
M"Y_TFK6[J<"-39,;DOU^[(6;UI'X2C%R.H*LZ-=ZO^9^>*,4JZG#"']MVO(Y
MN%GC C=EE:H@VF[J9&S0YK,3$4'=H;U!$PI&>5L1XJ[IW*3=L/Z&T:&<4W8W
MEY[8L+F+S3N%1@\^?V!ZA/7\(^-9+!JW;6;9?[G?<UORTF\%!2ZCE(#(=^,R
M7E<^E&B?)0!,,A3KXEB9I^D3/Z;W,*?&RPQ0]DAOL,L.-&0M)Z>X-&+8QI:%
M'^E]WY[D:S]NZ!42W/[P_<V32UQ&O#J?%QWM/J(;'M:='EOBKRLA8-C@PR&;
M34Y"$_GYNEFNL\ST/75^Y&BRS,Q'BJH!<H0B29^0XJ9AM]Y_?SSF6J,]/:%U
M5G$W?&WNL$JKD=1#%4!G>.."O-MKHXZH7.AEM]&RI-#LB27;Z'$-K< L,]V6
MP:87,2<&#G?_\ < 8_F^0J_'=$6.R/D^V2J%C?69>:IP_*0!'J&&>5%WN&QH
MM6 \8YE^]*FPV'<9 <E29[C+);$TXYX)H1:D)AC>&+EQ[.8K9"!(C/0''I?[
M'C:>JI0K39?M.2WL*GOKH*2(MPNE,8,7<S>K4A/J^*!0A%#>BCM(_RD%?"7%
M!F^K#Y1&8A-#>$KL.H )[ESJH4HQ*4+P19;=&]Z1D:4OH]XD_K3Y 2T/7_WH
M0CF*U"VN*"D.OTE*_]9GD.6ZRWWYY%>>S:Y@CLOCF0^.%MU6.2^]N$2VVUD
M_?(A1^Z4DU]Y3-.@TY*?8G<4-73U^@UJ^QTRS K7NN_?4DUR80#I@<"R_?;Y
MM#=/ZNHP0QC59\BJ2F0MN@#6B96D_X) ZHZYK7^&(Z^3Y%*:X[_M\VPNOC[:
MPWEX_,/1QYWW]A,<RRGJ( A=USL-(H90-"ZZ+ #[,IW7A</7(S<Q8.%U^KTP
M O7'3.$(U\E6/?LU" @919@5;#:J$\*N-GFHK/"]SW1N8M;0=J3:.$+NM!'3
MR(VH!P=OL!QB.M>N3@;I,:MF'U4HDXZO._F->-7ZR4ZCJ(1E. S0E]RS_P%
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M)=_)HO?\$B6%1R&/99$[6Z3D2\S,C=67+]>$C8JQ+=R-.,EDT"@D6U21I$,
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MBC( M]B7?0]^B0VI1W,UX7<Q=WNI9S_\(.HV5C^,OO_@NVL6,BKO\(=T &M
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M643$\,T;V[B=!&NQ[42CA/3;&94/2:O;R%>CQ67+KW$NA UL2%$ZT?LKG=R
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M->B-&03>SBP3DT#]Q@#9$T#G9K;Y-"#-MDK[CSF1\5^HP/O/%ESG((FJ.]J
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ME(3_]$N&[9A$1&<+!4>/P/6[.HDNL& 07HX&3"O1:7Z4P:\6D"=38[(,5V@
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MJ@BZ6'TC5H=OZ@_QU)7K!U//6UG,#=JDO'#T_'SG@OE0NE2"M#:3ZXV#]QG
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M4^O*SYM"&%=6'QUT6=8VO=ND;&!PB5P'(G+8PT>0:_KDBS3@E@P-2$U!4>O
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MI+@FV/^M+E*T*\4N-)+[@15E6XB(?#5ZN-)5J X=YL<9=O1M@K?H71,N<::
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M+,NZ1DAQ;$OO >MXTCJ$>(]UOQ-5OALO+I*HAPW.T93P$BSVBAQG3>25.I/
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M%.#=.)P\U&+-UN?SIF=1XN&]EDZ)2('CSG\DWQ_FL N\H-R@^7O$(I^I5H/
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M$4C@#:JSSUNVPMOG'3D>"36ZOC2.5?(]A1?,&L.L$=J:T)VF=?5) >6^T[X
M(J:3V("@W.P0J1,.( RBK_R>+3NE%;5D'?LBD8KTY/=7GQ52#P_<06Q*,V,\
M,(YTXF&W 0UX>--FQ485WYGRWL:O.M/%'VI?K.[O9$$>/J@Y0'4.P3R$#K<%
M*5RE^CTGYXU<T46U)-WI2= ICGG9_':J^7 EQ$C:^]Y[W^- /-!$_#J&6RRF
M5,VNWFW,"4@R>64[OT4)EG@"J6L4OZIAS?/,2#)11>A'KFZCWE._-:!4U)[+
M+/+%I7FBT8+F^.SG2.BM_^,9.^YUC]XI7F>F7<=HR A4PGFL%#]$Q#4-OEVN
M%7VFBD%T?C;23.&3LT;^_ V.'.^IU_\!_#Q(X0!/>:$ N.TOZ0>OW,J._*X\
M^,DQYA6N-6_-"."*H18;,M^CM"9Q0VODT#Z-(U3>LI(M551%PLO[J281(@UB
M7R[62@2LU8>K+$+G90.P2UQT(<9I9I9:'E8DX)%N_C58PO[2K#8/O+UAFVW
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MU.Q;6KJ#W7"%^WA!/EG[4,''*_%EJ"R+C0KX*F*H(RW8E.Q'.4T5()K294E
M"RY2XWJ\Z!7]Z:26]ZPKU\_R\''/6F@G>QK9AS:#=B,B5-;_) ,RJ1K5M)?L
M-T%H',,XY/UT>;_5Y54P6L":8\_?H&L__H:U:^^-C \9JA]P1'U$F-UATJ'
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MP=#(3#39F#]\?OTH&C3V%>\/Z81^UW"B[2N!K3;_ O&''XBLF'=;22LWZ!]
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M[(-,F%6P5[19"ZI$G31MSP9H;5E_T6C$2P_;!>A[\\GF)7Q>.OB_#(8A7]Z
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MX;A@T#(E$DAO@(%VT"SFE/QYE\.UKNZHQ8>CMT48D/[+ORY!2V>F !--Z%/
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M9XS6>'X8AW,I,2#R1H&J5+[ZJ=E,HOV$0U,ZGF ^IT>"/5$\.CJZTNX;.7E
MLC5)/RZ'*W3R+A<0@$ #;*A-SN^]6Y-5 RKJPIJVJI9NXIO?";Q6UWV+\W_8
M=RA262P,0(?J"#DBA#2U58E@FT_#'.^[&]4RQ)7Y*7%A+" GZ)6@-*V"SRQE
MR*5O*Z@77H=+]8!_RW"0C3_,WO=V,VH)^%P 2]B,I_(JK':D5C=CCP;KDWJC
MJ2:3]<@"X1_7R@>K.-*F9C[DYOIG^]ZKJ/U^1NGEIU7$"?(X92N"5AVJ:>=_
MTUDE_HC>F<193L[%IRH1<>G.3\/6,A$OJ9T<R8Z.]XZ<85O$/=!2?1/: ^RK
M;)2=7)23YVBN.Z_J%WNFYJFJT6_[ZL]MJ2T:!9\J CX:TF6#G4B#&4?)0L3%
M\84T($F>BO+Q)H5#7B7;2CX($!JW/!2?6EGR6791;MS .65N/9"VM:@B #_4
MF%-K$[B]L>/VPWX6]11=;M'&@'QO:C$DN?5@D6XH'Y\M_4TXNZO? >(ULU=F
M3_1?WI7[/3;^^9I:[X(BE;=C*VP8Z\SY0#%@,B:BD;0_)G37H6UV;U4GBUZ<
MWKZGWT-RMG]D;!(!0@0>,1H*C_ 5ER+_++4I?4@K$&MLBN+;PB?ZQETLM7\/
M/QU6..6E?KM^;'@ 2M1[.Q+*01[YM"."@$!OV;2A9V7?$;!((6^J2OP._:2Y
MZ=+ M)%TR.XJ7:\5765!14O' LM.\<QOV+&&P$0>;LTI%%2)F").FEPT5AGK
MBMG1@0N"A/5"Z1%BH2] *VZ$G>ZA@EXUPARZ:\%_OX6N^SS$@O[=C7-[&9'-
M@(Q%S<*6T7ZDF-:4C&-D+V(X?F.IE_? R<%-F1-G#-Q0>Y[=[3ERYZ+C3O33
M.?:BP4@<>80B&^Q.BQ\=Z!!('?ZL3+<AQ[0(OY[!ORJ_V+E<]HG#JX<]J=WS
M/.P2"%PXZ[U&?IN!D DAYLCKMQVK+/(>-9SW(J@1(4&4 .O1\=!/.)X7!.-L
M6_6[1G,0_8HK-^)#/MRI*T/4YA5)KTJAN\IW7!8=(K+*N#W2^K?L[(#A2[%@
M,!I(_U8713A!Q-TH)REU2,<&:Y!: CR$602>U>B8SNCM>:)GOB_VK9K(.QT'
M&I8!<4,)+B%X5^@\P<J#*.5Z3:&AYMTE T>;+DKS^3-7%OUD3QT_4W/ZQX-/
M'XH19,F!L?C8#%53!B3^TIN"E%)5CL=;H1%%,S_'SPS"7#4+M*0,R;-P_FN[
M+L^;#S903/AZTRD-JQVXJ:%TI&G)%7E-@W/]:ZZPN*V5RW(]:E:5F]>'0TH
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M?=1Y%:"YK;*+]/#@3V^HZ)6XQ'+5SD#J]\+H_092&Q _3#<J<AD,LOVH?.'
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MU,Q-J]8?5C!47D76G3$>>2+EEG'T1FMR5ZD^1^Q2/%EB]4.]9H 3NFU<._+
M\X9$@P++PJP'B0;G@B%R /W@.D4KM->.AZ3WF!I$U&L?ER&E?=PWKUJ!/%@^
M=+97-.>*48[(CVUGS^(/^[?Y&T\I^*);G+) APV1G)&R%')M4?I3_4_D#B:5
M6JEC07N#M4>PD0?H[(995+6R(2U='[88'H#;/W$-^5(8Z?1L[-K"'JX(7?;'
M^XES<V+(>09D= "/C03N(,C2L!@M#CQ'UTZ)CTU56?24^0O5V@S#5\EY8WU9
MIVB=:H+&S7%5:,JI=ATP+OMHR( XPZ 5 5L9PA'>'(Z+W-M20M"('.SV2"&.
M:!Y3H!4P"0<]]0,$R\H,*1(G^BSFAJJ>^Z-X.*X3F%#Y+*A^>_YK7,80SBN9
M,)\5]\1 C]>\F &9P<UF8WO@LWY'L?SRV-_19&FV!YMZ%=$ %W#W1VXD^K?1
M\D75V_F_TSHS \3"IA])2JIC-,@AH'^,!^V3*_2 I?_Z5@SYU21EE6?I-PY*
MB(!13;2,=\VTR OM\@Z)@M$+IX2/F72H?3%D[B=612*$0K_8"372.AZ5:IWO
M^UEDWS5:;GU%-40R +87N>%J(%'U('WD=J3*6'<KJ]F^@@V(Q;5<X=*\D[9W
M^]>N#N^\WUZ.E10R>:HAMV,2ZO8>"V]$LX9VB/.2.RC*] %Q*;)**?9)@P,Q
MHOCI4-0DDB(TWM_77)1CJ,XJV9ER)?;_8>\]H)K:UD;M( J*!9%>(P(B790F
M+2H" F)$$02$J*@T,2I=0I:*@B)%04!!B'20$I4F14(O(M($!(30>TDH84':
M75'W.?OL\WWW^^]_[W?^^X]Q]A@X9+G6.]_YSCG?DIWUO!J:;^0Y1KB)ZB/$
M_(AY^V&5OA"D@,G0@*:=^>&:XNJJ57>CP0/SZ*OK)<57HWN#NJS6HT]+GSY2
M28DS;ZK7[2M#=ZV:T^(V1[XH\9_O3Z$!O,OYC.W<HPD.H]7 3GT^YPZU.V"K
MM=(MON<3.>9[#(57.6RZ*M[G!C21(H;#PTA.P_A@C. ;N]R*V!1;F0)_2W8I
MMN7&[S-?ZUY%W*GMJ823K+,5(K;YS@[)UF8418X:MZTZA<\U],9<D#5<V1(C
M=YLQCPT'/6IMT4\+=NK8M2]*?E/+/3Z@G'LS]\<A,]',:]>D,O>&Q"$JHV8F
M%I?,8DG4S]FT"QD?0HI;*M -!D;E4<= 55(^Q:=+-X!\V*0]A30PD<O7AWM<
MR.-WB_PYT\')@[?1\=2>^27YU7VYC Z<A">RES"T0!@-N.YLT%O9=-E)ZC+^
MYG?X?G[QTQ.SX2%"*QP59F 2V7&DN(X(RC1$8#Q&$Q3,VE9S7=ME\C^TS:<_
MW*F:)WE\:=NU9^.=+3<><-0[*(A$WGYD^FQ0 7# 9=L7:F1LD>O,T$MGPI0)
MRA$EM2![%6H/82A+)*]X5(4?;+X  B3M[4V*GKB=4Q_\[A#?>KEL^ZPJ=NV'
MUD#)^:.;NS4;\+T-=I ?OSI="J^+"$S4(V]9#+[\;;B@N_PP_H?TLX&4A2JT
M$H^0>!EV8EQ1V"[$YV=[*3RH2NX?$GQ0[N4_@A?>:6SSS@8OU8F>Z]Z:L</J
MQ)GNG$H%.2%%)+_3B":--YAR"C0?16X'C>O@O+H!&6!L;<=CSX1#PI=+XX:?
MOMTEV4F\I%C)$?!FN&3]M+;,-HO7+IT=)FF#BV\#%K-:A>7;/+)R;-&%L4@S
MYX PJC7F8G$;$W8%)^8[4F]4;&Y<HY/SZN,UM\9N+<+NZZC/%5KT2,"1R(/]
M1LR'/U0L#Q@)\ZE"<<W-C]G#:_3%7DG&GWN>[B=#*/63NE25>ITGZ?BFS+VA
MD8-)T!$S"84R"7LP@)1RU$4ZRJ%[99ZC=_^EJY%"O.,#]P[YY CO]=)3F(=N
M]+5JKJS8U48[DE[[;GK#/%1#@YPY[!BVZ0 4.;-*K.+Z7\E,12_.E)1N+.2)
M=?$=J$;::3"\K=:7/GW2@,I9-IHK.3A$5V]4A9U13\@/H((W)YI/&^2"KW!K
M%(%^G_>']HI>O896'3C^WN6,W-GZ7")0!==%[(K?7YB.L2.7 [S\NE,T0_4O
M6(L2=IW/\NN5O$R8^1.)]')X)?%#ZT/@!G<_@?*XC2$U>Y<2"Z2[>MB[D%T$
M=]<HMCWY<K0XGN_5^8C&>MCP(W_-<,+0<T)^; UBJVO% 3(BG.:3ZJQ]<:>'
MG[]&TG4K-8GFJS9/AK:<,9&&;=/*<9255\5KNIA['+E+O-D$5%WOB%!R.1/T
MECMF$)? A U)05YM*(Y08!Q2H8DYT+."%$=2F#!!4.6<MN'@FP85+PGNF 7C
M'4,Y(79@T0,_Z9Y&PG<L@IY.&,I \+%:Y?%H/DKN&(T]64[6-IAH3K<]\;S?
MC((]RGNR>5]6XUZ==WM#>[X3WZ.J%P,), 8'&,_ZCJ*N"1Z,JNJK-LEJSO*]
MKUMTK="&O[Q0@W3PC,&2Y:28&*LQ>Y78U4*R; TQ9/!P0DI4;>ED2 (>!U+\
MS.2=OI<OP[^6*K4^OHFZ(AB@/.X\/[%>8>MUI/-V3:]+BXYRZ?YQJ.C2\=;M
MI*33'WDAOT]6+=-N@P9DE;J6$3V!$;G5X.Z;'2YY*9'GSU)3PC3#YLI&GVE=
MDY4-A7^\@7 ^EHNMFR>'7(CI]M.5W%\H+9>0=:MH[LO3Q,%+>['\HU!Y884.
MH21RT6-OEDOQ)=XDC.HTJLWJG&2XB*@]EXFN7MV[Q7*T//NB];P7VI_*^CA!
MT1/./H"(RAVXX')W1R.WOD=TW# GGN=S89.FW/#;*N!0:,#5G(ZE,H?@BU+\
MCU.)UXG)KBWKTRK/Q^#O(N9:1Q;[ BGHHG:,P8@[JI*PM6-CQD:I7$^^+F#$
MK >CV_%YZO/>L/-2VPH##ZGJWH_(PLIC>,!7)%F*#ZD!2EA[@T]^Y)B9.5D(
M%W 5"<OQ$?%4IJ8F/.5348A%J%E$O@UVWOFAX@$]$2M>1\(-H>_K2O%=D4J=
MHG0O/1+Z,GCA4/&WDCO80K)/0\1C0 !P5>G7L:(G,N"^,Y/#/D&8PY>*2RO>
M9]RT:P[\('@E)S3OZ.':^_QM\(27B;"Y/+Q-6P9^)F6 4GRZV\P@\B$NG[*,
MQ8;;QP;XK%Y;AMR2-\G[_75U) _F/'DB=[3>?&F6Z!I\^6,#]_M1OUO<CAH!
M=6Z0 96Q!WV)=<]I5J#?*)RG952HG#/;V#%C-O9TA[G:C>5ZR[(]-L?N'5J0
MO@=^A;%SCN!IO/F5%6P@:D1%$&,,MI!U:KVU-7 R79_M9Y^G:HIRC#]UJY]?
MUH>=Z6W>(=9)& K5YT%Q,[YB%<DGIO8QOO=<W2ZYN+/\ %MKOFZAVAC^O&9R
MV'RGC0)"P6W),1.GI.E^,1=;NK]ON2+(.QXZ+O&,[<(!1R2\@FL&.*\DOA4[
M*@BW^-F&8D,3]9K5<J,1-8*H4^GC':$--98NE+J[RUQN-(JT&3BVTD?"'B<8
MR5]Y[7SV*3%FL=LZ=G9#4.7N)Z.B3[&I9U%Q3JTHTAD5.%!=0H_ [G<UI<J6
M=NZ*W;5K%S7]PB']!\<!+M(BN+^U#OT0Q8FX2M@^'3=9"]EUJI1.Z]&.ID>O
M/;XQG"@;:;55VNC9H>(7STE'<]"@XF1H>O 0E*3J;K]BLT@SP?M5F*Y&:NT.
M(X1&U:U;9_M"6:,C5;-O2ON&=FQ-C7]F@[O(Q1\)'F<-%)-@/GW%L!U%IV'L
MB;#,E!;7_(5O6!-[A@HJ]N6LW=J9N=<5[DL,,^0K CF?P25),ACF#L07ZB#%
MG2M4N[KW4P6>#S=/+:9^C(?+YY^P<;RXZB3%KM54J0^'E*X#K4>1VV@Z8 (Y
MW[XM3YEV;K0)=Z;3T[[YQIISNLWY^\\>'5/[\"RM4?2\G=81? J&G;J%T<J$
M[42GE+<Q!)T)KF&!#1H9$S-*HNS//M]T,$^5>'A'X044+$.QG2)K<S6D77KG
MJEW$'&2Z"S=W*-X<#]6VB0D;2./RO;Y=F&NKE/2>K4)2!7RI>>,J7G[VN>7]
M'U:F+,]ECNY43" FE*TKK71//G%&O(/7$OHJW,_5 05K833#I(OV]B6=-/[A
M@>,_^EW:V1])$@*V-D[QFUW:]/7",RV=UDVST XXC>^;'5I\B&$?I:-K)3:3
MN^:\?1)%NM-M3ASH;-A^9"N_)G;Y3FFR6'WEF),^?H@([F?"PC!.2569M OT
M9*SD3&D=S4VO*_SI6UT-DL[.>O5#K]C?OA]Z>*R!2V%2)8@ HPD.HT%YW".,
MX- G:VOR_H3A:^X&5M\*FPM*/_I_3XJT:DZ6I^61Y(2& YWB!B,6R'S#'Y"6
MA:5F4"Z!\_<YF*7B<CS-?*$ ;6[7,5 F'7",U?B17 8"%)M"TFJ)DM>(^YWN
MYF94>7M#J<=]XD2X*A.V*:^5$D16@8K#JTA0M@_.83P^6R'1KC:_7R=)"/@0
MLY04.2I^J.QEZ-C-O<^,W.H10V_@9&^"^V)O\?!%IZ\/!J?<!-M6.302;#X@
M9A-2<6M= <9D'0H.#'B#\89*XDH4WU3?(T;6J*AX>WGW.[.T)KY$U_5S@L]4
ME<8/S?.\TWGAHS41:G]*]X5#(62O)<OHBKM,6$W"GLA'SB5*<M6+C$$?0K/!
M\&)O*X4=1%+M,(<[,1[9F!MDZQ#&/ON^M/ILF;P,]J:,B^]:HQ7OU"]?VV4T
M,HK]D<?&O\H]=V0('H'C+(P0 7E'$EH:GM"X,QI%JQGRY15!?GF[CYQ]I-OS
MRC++:OO>=:X/#XP46O0U@2KY%7&-A=D&!!L-^1:C0DZ(_-12F"IX1U3S4NH+
M$[;E2S]\OTZ>T?J^Y6XLC=>)$DU6F5<@"4PP8?4R-W5-WLP@4W_,;!,ZYKO9
M>5J2:U-PS;Q[^9Z24:V\ER;F+56VS1=6\KW-[R)P_J^7GYKJ]@U,*Q>;4K#9
MC"T14M >=ZIG;*$G(5P6@_-T,SV9L-W;RYP]VG6I+QHEIL>QT5U E8F^K)O^
M =16[%?LYA?%H17[+B:CU)SBS=4TO[8&/LL[_P1*TN0X[PX5$/A=</FM-/[#
MHP+O\P;"=&KB\(&BMG%&4R=NVS76[IH\:'[_QVMK%.O_&I <<LDI#0PM>B;-
M[4;[#%;^8V1-C57D,D5/6^.[Z8;3E7INX:4?3)CXY=/RA=KR_D9RS8R!F_((
M37%,E$:6K&F:C8&?V<#2A*DY+8J0;?P=L14K.$784B$"^E3I2P0W=138G2AZ
M_(S]9$WL\_=="4]5]7/<WB6'=)SUB'I1?/UVR$-+*Q81*O+!?].[\YO3%]0V
M3&'71V=/N8AVI_?I'>C3XQP_VBH(LDNI/*Y0N =,N'U$Q,G<73Y%HQ'3_#0K
MU>&D%S0;(?B2VI>[P+OH.0=;)LP3:]G@>9YZ C=(WZ*>)PVOV^ J&<]8LUY*
M7>JD/ET_8WUH[HQ;"4#8X-+O55ECPHY9TUXR81\)SU*:(AA^^+$#<#5_X=P
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M=E6,,XSO =7#9("^!3JAMG#&OCBLJB^! 06\7^)11X%JP>'%#=@T#N2$_^3
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MU*2H/]2$].4JK@)6#CC_!J1#:J+_ :%N_*MFLJ90H'3EJ!G+ZXAHSA\AJ^#
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M%-I1K0Y[?3O*9GAT[NKX+%H!&KD,)17%8]#_]= *(8$P9(-X]9G14<'VK>(
M9C.9^,CS#J&O-#%:3>-M ]M8_?AQ_YM2-P-FR5$49WI2N0E5F';AVZHP1I/2
M&\?9J6[.>T;)[6!-4.65U/J9S]I90HT-QQ%^V5%D=#5B$[BQI$/@!55J!J5*
M0]U-5MWEMV=83(F<D+;,-%4/R)'(M5MFPC1<'")S-Y=F>(' \W5)*A+;B>,%
M;C!AL($9;P=.=_9A_*/]9F6]>U_\./#QRCX#Z;E,L0C-AX:-NRZ,78I((PR%
M,_86?@11HRT[3 GNA=U2Y<Z$I\TQ_(;H],N70>N!*&CX'@=A8&?+F^DH7Z^1
M)=&3D5\U"J#*_.-EA7?X(E6;BEV@V1 0[&,MJ,]'<@JFJ7K<>G DO7WEHY+$
M>4[)"_7WGB?><K-U.>=1U('2F6:<K&M_G<$5&=U'(Z2WUJ'_"^*&0_];%D0<
M[Q;E9AM;@]\VH_VE8WUI1M-6/*=XSTG58!?A[0)#=T[[YL76#O*VZ[JGM*3Z
M/C7J7)V7OY(K$Y[A&GOPR%EA,Z.AK"I8:/C6/-^.V]4UW %7>AC]#*/WJ=W[
M"MVFU=%(*/N*1$ N[SIW"(H'X;1]%A=2(=#>?YY4>WBGE$WX4?/R^Y5>)ES+
MPD-\44*;'5]'ZX=1+8&J$^5FU-.^A^ <+H."$=6V2K5-,G.J#O&]BS87A#I]
M8N+/'.1T/FNR_:L6 H_E!YT@_[]I>BU&0H24_F1X5K2F=*+?M#.I*,0C]%JW
M.ENXUF3AF38L%TV/E%>@'B98B17N4,=$4:@[)0:W+=UED,]HSMI^UJ4\Q)42
MH("G=THR..NTTG$K-##;Z3&!!/?[S#7D8+C!VV_!^#H-=(9O1!V'K-VV%SE%
M,<^#5'/N+>75]8:LLCMK'6&'LEXBY1;9J1(1WD/@I1UV\=0]G.6JD-/O6O1^
MP5X;;!2/-/C:.DC[?)KM!ZR)@^ H%V4@7HODR_Q@-)0M%1K$F2GUZ;SEI-:W
MP/SP05S')VJ\,?<6P_:8+ ;0'3.'/</"!BR.*KD-YWY]ZC;4+*Y0YR.0/E!N
MB,X\$JXAM5/1>T(WVU'Z^G&VJDDA_!4H>KG/ / *27OS$4 ,S+?]"/KLV!%S
MRVUKI$G6EQ\<)M(&DF$<IX<J!2HW#]^C<L%[F;!AKXJWZEH5HKY&2B<1+U5X
MCQ?R<LR6^48<66OQ>9MD"3O(">/*],]MF2'^<)IS-:DSO:M23H-RB0?50-,U
M*!&Y!V7.IM+X$N 2;EU-)0BW.BS+B(CY9%8/WTK;3MZSM+V5WQ<Z=OO+'B#D
M%<(<31\LG.P\TI>[;P^'B99$8<D;7\"4E!?AGCH5=RTQ(LTVKU'1$]RS==_%
MJ(<GV"RO1E4N6AS7__PBJ^(#851V(^YT5(S<%94,)<(*;@DA"0SE(I8\K> 4
MI3Y@:C9D@]" VZ'>^A1'.H7<X>P@=G]1W9=V)(UHZ"0DL[!YWQ$1=?9L?D[V
M$I@/_FVY'<D)6ON(0L-O-.00:J=OQ-D+M?N6K3J4%M)Y'IPT7Y+4.28]JC76
M8YXZ+2 ![YCW'%#^3#3OS)6ZX#XWO^]"4I"ZD.6),YLRQ6 <6YQ$@(\)^]=\
M:':H5PZM]*0N?W4W3"2=NX;0*TBI[B8XTCUJ;\-W-(SL1)SG29M(N'TD/TXN
M69'OB8;^#_0MRZSY3K$9;#="3'\_HUL?_AX,S (-:0@2T:B$T?KN8(RO86UE
MS'XKKNN.XY<^9)ZO%-I2@?Z.XZ$)@OZC.^VHU@XDV2"O3\B(E0$SX^*/\>$X
MG21T=^$J$\8.>M0YP$4$BH?I*A?:ZHE@C*N 1:O[TFO\0H(IR5CL]NG;T2?S
M?+QST;.=-XE20I?'S;6,'&8)JVN+Q FL+^,+ :Z"W0.Y:35=BQ'N7>M[P,":
MTA>4D_D['E_]&*<7R4.S.T&]-V4ZVDW0+B#R]*-\^_0\ZKI[$F4?N.7[9!U5
M"2M?2WWOQ'$GW/*];E&'GU;5!.&-/_P^89=:"Z=%VQP##MIV&GY[);%F'FA8
M9.:6;O#B4#VO6[1N6.5HX36@YB!-C E+-A]"T_;/00EDEV7RN'6?GW2%"?9&
M;'!4BH@UE!L^I?.06/W?MF Z,0K)%Z8V$%5":@/*]?P/^CKZ:R]+A:@+<;VQ
M(2G,$'J)%*AT#<H#X:/ 'J#Z,!.VM9CB5]+):*8P845^+XNX"3[1$OH,U<#.
MW+L(VF'NJM8-Z4$.)JSZ9BLKG;,>1@?K\Y(THKS20'2-B&;P2G.ZRNUK:=-D
M.X/#_%QFR0=VF-X[9'PL1-[P6\;9/3YWS#'$<W=5LTU316-+2R_0KO^7KT)E
M+S!A.V@[0/30IROB=C5$[G*%-S/O@GA0+G%*A>530KNK['<?;)06DSB6JR),
M.TP":J\5H 1\SQF0C_<):(S:=B:5[5ZHGT^\4O1C_N)H'F>:=COE608_!6@A
M? O5$S2T-*=9TW(P4,*Z^3V4&IEU$N:4_*%@$;+>\+/5E!2^!DGE' 2F&F=7
M6JLK=K7I;D_-BQ[^Q&U.HL3D=2C%1+N(%TC&+QX\P7;'_[45.K2"#Y0=4>ON
M],VOZN-\,E%H=5*ZV[-1N4]&>L_NQMR"/1RWI\UXX.X'U"GNH%%-AF'UP\QB
MJ+"6\9A$?#]7K:&/H-^C(883S,VF^^H2LQQO<=I'VE^4E")R$+05>T;0-%X\
MY9%@I\NK&':E@CL7ZZN;;3Y<.631X/CPYBZ+>XU#@52/8<+VJ<&=[;DK$=S3
M MH"4>BRIG>=[I&#6]=4K_>+P%(43;3$(LUU'$@+42.Y&N8ZMAUSJP'Z2((;
M<#.JE@FSO'2,EFU:'.WC$)\/Q*Y\K\A+,SP;U6\)Y6"Q/[!&-%]HS7#0'Z,:
M$6E3V&WM"UCQ%DITI%V"BF7DR-)T\+8]AQHDNJ27/EYI</YZB)O(A+W7>$6^
M"W_8_!9SI4=%?2?Z[/-K^9WH-R%'<I3NK9](L[C0.!8CV22_*7S7L$/&,"H0
MP4W;GAE05N/ 02(&XV]'%$S;&GXJ>+DR(,)N'[:[@*_L79A\N*M'#+$[R9#O
MC->COT+(O"IXWQ_L^]1\JX.40G_.A/4PS@<G3ZN\O;CC@=(WVCR=\Y,/3_U[
MH\Q U\Q*B7M6YV(-6NLL.Y_O2@Y1X/WR!_!"5X'2 ZJ.,&%]W!3_'@S[4!E=
MP;Q+W26WMD>DMJ-NZX,C5L;"X4=$I9-#W>NW352< =%4.<8 8BN--PTTKD8)
MZTM,2TAT\J04Y-M=BVVVNC(Y&65V_8K-R_$GNCW3,ORJ%\N[9_$_<NF8!MD6
MMQ4Z@*^";VZABF [ =&"J#<8-#T)"ND/SUHS868=Y>(9AKR#QFWURXH"-+BQ
MB6"7><!]DO\0\6$%.[BGIEIB>X=CAZ?;T=-=.JEQ!FMIT:W*\^$F%'883,<5
MGZE4&R.HX#PKWG^B6@ HA7.ZZ$H<#J_/:HY1B0X8.)'2(N,#)73K: ;7_8 D
M6T9=HD[@Q7([JS*JHA67D:U;TFVQY\GA8P^O!/"ISMM @838FXZ\C]ATN:=P
M2LRWOWZ?GIF%?^BKI$#X%&F/7Z.5XK$QM8?>_/6@,44,;"$[CL@&JR_VH4>"
M8D<_<=8(PMTZ,3K)=@^+/KYTW*DE0%+FX##J43RD"3N)\&6[?^^@?!;^>OIB
M#F$SP;KG@XD/'['@=EA!&,.=\7391Y= >49/Q!RF(C%*!))QB.Z4>[K7Q\**
MHH8$IUNO>N6= D/?[5VUNESO@8+[HBD&]/P*WNDSOL:5J +!8%R5U=.Q/@V\
M2WQF\A2_E9G-9Y@65_XE[SKL$PN;S,RB'GM:\YT)$_UX/[@&MA':M0FXN4[9
MQ^4FV6#D; -NC^[)_E44#U'N^*CWHA+;]4O;[WRY$+/7$\;VA+J+T<10I">L
M$D*PTN2O*2FN6"ER>IY*:)SBLKG8;8X8\YQK(8>$RELK-U_:Y38SHV!6L%!V
M9T,A(^.'85Y<@#TQO@<@+,UAGE,]L(WZ"O0W4(D;Q#@,)5M3&]SA-#@PV>"7
M8Z9H8;)K_+G15/+S)S8\)S>S!6-=$&X1O3KU3%A!:RW^06GDC,B6V$?E,ICB
MC?'HNB\,]YI7EUT$MNR.OEVT_XQ][*(G_VH=_T$Z4:GB2TDL?A6?EQ)+\%^-
M4&G>Z.PT&$?T]U#.DX/G+Z=C$&UJXF9&G32]M%EXGW;'C ^OL6+FIN3')VYK
M7=_:&3"2(N,W8]PE0"'W]3?L,-USX-L^^7 8.\SRA07<6UDAF_"U"7M29E&-
M:(BN(WQ;UZ'8T:/*420<Y2G83#Y7WQ?^-', K)XF?.@T371Q&.S-\.,RFSAQ
M3SQY2W4,7'(RW8MP _B.0](S">]TCZ6"#X#-&$/2+$<'S=#UT>,S_;4W^:/?
MP2>LS[V0?O[Z&38^.2-VX*' ZYCBZ) )3"=N&3WIL=QPE@YEW6XJH13':J(@
MPEE/S5?XL5T\L+-_9&)!LBK<O(A"#>1>S ]=.O\>=8,F#B*&@?L(;D\\AR\"
M*8)]FI'.ISH@_=7/[RIZQ%LW:OT23*$PN6#B@XL7L?5;:[1&_'3Q<Y(@5$)^
M1X\65P)]\(L]-#8RTK  =!\Q]]9#7LPO+R)F_NA_DFCT4*&_,:FH<7I"\?'I
M.7*EQ"NR"L6<#-3B^O&5<,%%=24^7][JF.T[;#V0JA4NU5^K:K'6,9SQ\F+K
MKZH]\3G.6<$?L](H&M2<BO'B*VF+R\3YQ34B><8W8]Z%J@@"E +PXB!?]\WQ
M#K1[AF#<]=R;]P>_#LG9UYF(MCTP4#8R/KYU,R;#@\J'[9'0:K,>7@MEPIP#
M#M(TEAC-BC&[R^/"ZCX*;9-<DO+YH75I;<<NOP%4\HIE9BK1J70:2Y%K*O.Q
MT\\<TM]"VTTBS"V2.J$<Z:&[PT[E6@&7=,GTDE<E?FF7."8=IV"L_]B([88N
M<D?T76XZ"65F2X6 =20 ,I(X0V*F8@?YT;UO:O;'8)<R;CS[."X31GCT;8E[
MZ,XVSN%Y3HH /1-P*HPW D7)R^81U2I2NMI B%(^Y9*)CH7(X#C;9,PQB=&O
M?72!Y'R+\9MF9HL3S@,=3Z<P"D,$4!;YI&*?[^PI,GY>B7P('1(7E.C3!WIW
M[;"U1#[_=IE=LCKRB=CED+#^8'Y*[.-RJ1007QT7'%1HKB^:R\5HGU-6M+DM
M6CEE$<7^IN]VP^FN]X:6N0>6[ ;F3,NOM0;XXQ+BK.?$J<:,5NN[X5%4!.96
MIR=A,^JB>F6GKOE-X7D3/5Z-Y:P;CLK)A[X+\\\2\KGG)/3Y:$=+P13RX;HU
M!!]6?D".9Z;G[:#Y/87"AY)/9-Z9!ND<S^I[6SXYZRI7?UI[M8_N/B,GHY ;
MU=ULZ#&!Z#.@7"$;-R#[%(9P3Z4('9(DY'TTRJ(BOS3.PD=WO+VG^1C/<;8@
M?9N>;'^GZ<\'TN#>$BWNW@ST[>;!6)VYV $F;!?&@WH:6RW2&L%0LL-< 1&C
M'J31D8>JCR=?0:43]OQQA9.6>S(N<?4:6W&]P6].9 ,N >$XN%>8&K8#)Y)$
M%GQ4L-X-@,88)>$@T6IM3H4=7!E%BTK]FQ_)GW9;$0@Y8RI@=JUPU:SMSDW;
M.:*[J&[\*+I:APGCP;9@94$WTH*>RM&/Y>UVAIV.I4X/.KH%+(2%P\3O\<2P
M<_DU=%>8D8A0(C-"J"1L!_W/@\)DT^8J"=V _:(JO#8#4A==M!.JQUYU?@DZ
MQ?,Q<V";UM@-F6)L4+M1^5>?KGZ4&1,63Z!M%KF3V6\(U!/'<C 6)&/*9K(8
M44"Q0I'1AM5%A4AH=U(2M.NWDM._E[[.SCQPOPCWZKQCF,&UQXX/= C]!I1K
M9-2\>A9-_GT'?L4?N=T7J)7+GGTW<\XT"BG"QW;9\DET_.67F"\IBN6K#9TO
MSA.'B]I=TCJFB<O[B?RK$U;8,+LEWHQ-%?+T=";L,DH8S![U1(E@.<$E;ACM
MA*_5]K$**ZK28-=6L0^I+S_+9TL9S?1;DH[)SKLJZ+BF%CBGKMR>:FU5X<-6
M$N#0@539,2- %*O0-LS3%<C7B'XSM?NIN]ZB!GR?7<P%J2WGR;@?^9<2<G2H
MR+E)JH;OVE#$G%T632&2"3N*%E5/S^"/IB=\F;\J\_&04,) TBZ-6.%J>%F]
MVXRIW&=YB]=*J=&XU1]\<2^N=2O/;LQAEJG;&"UW<7-XTJZ>JM+YKPG^^*;,
MBT3B19>S)RD+7ZO.N6E+B1D]#XP6"US%)V4F%[S^,4!<==\::LD?NQJ ?(9P
MY?[.A-4C"@3G34A1]2GGVH9)G($.HD^S1;,F!/--BR5NQ.\^<2:(I[K\X]1@
MURJ=S])X(#C?SIX0_R/+OW/2OU>E[!)>B)Z+N*['2WD'&GL-M3@LF<M/'.E>
M,^_:%_'%S2QZQ]OQ0YI95M>N-3;>W+J79V[%\K.\ZY?,IKH!>&*%.#V*X*X3
ML _.,8AM+]6/'_IXA2KM4R0PKY_^CNU1;=B-R*!ZQ/BH%+6KC*H,E6HZJZV]
M3RDYWW2],L 'S0ZD4QNZ,6;[T[P47!<]]M5V?)Z1Y!GZ' D(ZUQPDE5?<^=/
MCCH[.9OW:3$))S\^/IV>D--)YWZAMMAK4->#(YW9SH2%EU*2DLV'[>QEJ0C#
M]P_\XC8$EP24O@;M#=%W"ZS!591[U>/GHZF[I^&%-[0EWCOA+X*'&RK@1SK5
MJ2=4'OT0D\J\=E/HII75CH>1AR.Y.RVM,-DQJ@S[LH4!!J7E"$XMC0B4*&#A
M>9.3.<0/^/GWHSN5D=O #,J3-O=R^&WAPH^EG4I/9W;N.GBGND-8Z'G/X>6H
M2+=97"^!XD=JG:LC?:BIDA#<T^*^O;"N:[5>=[8YN'X=)7;UWANV]O/&-WHR
M>T*QW[#\8-<(D7/:BLA.NYP"'JY51?G%%L=],Y.^T^]W<X>KR.#MA+K3WA%E
MW=D)=3I*]OB!V9ZFF\;R4=;3_MZH[H9J1/%:M1#!!0D>X*Z!\D??*XQC;R\Z
MWZH:,2[ZJGBCVV6_\F3ZHM('OC55P-=Z&DIE:4II(+QZPSJXP.S$NPZUL@MS
M\THI0A=&#+FRU[E(*KW<%(,H2D!L+5:)[/,XO@'.1SLG&Y\#!IW?N^4KYJ5'
MXZFAJ'IO_.>DHW"3+D-_>=-('Q_WC:*!3_QS%0'5R#Y++Y&BIKO2T71[PMZ?
MO,-_ 67:=[+20?<R^0;PK06J%1O=?L+^9"-$,1?AJX=4H2MF_[J^ O_0J.\G
M-N[/_;96_M)S];_5*'_MI37[UV9^_\_G=0U,J?&6.$BB,YZ^-9C\[E![.?IP
M8. /B5JQW?Z[%<Z&N/1;6EX[8&*JW )_A1-@[)X%MNF:W';,M#/;']?!<RUK
M:V/(^!&%UJ/@S*M&_93-I/,;A!'N7=-8^4Z9SL(P?>*Y]U&+Q[R$O%JOL$T9
M7SDBGCV)X&=4]W$D*9@-,V&['9S7V=<T+;:G-G)J'3E^Z/:WUQXS,$KFZ)6N
MM\ZMWS]4'*KYEIX4L7:U-,V3,6\]ACD[,!W645&83[^_D(A<(0C7B/DQ83':
M?E>, L:$&C=&!S_%#^/G:H: H$ZE'U;F.3.N_9%KEOU2QJVB?+"WQGF'%^V0
MHJ8* SYZ-ZP%QU_Z.KQ(,/$VP=>E;20Z4J48K9I8T02,VXB; 1I#CNZ\X71*
M5[+TRU!H-D]U>-7+Q!2X9;NAKY>K:4Y)*O;PJ^OJ^:<,:GL&YDIE>B%CVDA<
M^%^CEK.^K##&4 1ZTJ.8L&1;%D&]$K%T!\</S+::,F'M2O^RS4T,08Q-E_,R
M89=$B?2MUA^LP\ 4QNGX*@2%[1,3UO8(YB_SEV=VQ/$E:H0;[@H]:+F2YW:&
M%*7LT+X6L3XQR4E2_V9AF=I=7S!CBJOV&^L+:"FI?782=U[K[>JTYWFJ0:XC
M_$*BB^%=>SY_I"3=@TIX,O'".JW=N&").P_P(>MVA*R4'J D'EMM76#(QEDX
MQ!I*=#;JE]")M<NF"AU3*7U^G#V(,O /$7LW)M< WI8#>+/D")<Q^$7&XHA?
M&O^TI\6\;N L;H"&5$O^I!RBE_$LX/_W0XG[_GDPW4!D28E6R#;X#[F&2;N[
MZ(<#+_5&MZ#6)S*B5J$E,&EYA>0_XEP@O$-NLYN8*P_?I0/3R.20+Z/_$DKK
M_\<_NAY#* D]L!0Q<YF3"9-48D'R*QGZ^S H^*J$ 1/VS/#?;1+^#[1)^-^)
M8?=8;7HJY)BPGIAHR/O%_?1^.%:;'C[$; U4@[2[_U_L_OZ5/SOBORQ=7?)>
M+SO=LMY?)N8DGF\#)Y]APKX=9L+V677QL;X"R<]--T LR?S[^K^O__OZOZ__
M^_K_N^OF3O1\RD.J]7=,N(^?SIKGJ/!H'E0$P<BM#RYB3,%*Q(PF#U1U[F,%
MJR$\G ][,&(CU [WE>O?'>3_E1WD_QG$SPXT?<&8KW6NM-(%NF8$8T1>]"B3
M7 G7'X_>0#E9-TAD#)83JN!+'J@]3-B<:#HPM1-*+H3^XV:6=I9G./ZS9I;=
MK.WRGS:S5"\TA/U/^F>Z6_Q[R'\/^=\TI'T>+JOF5H1&[F0M=PN\-]H'*Y7F
M!_PUL0UWQ2UYWY6EAT##3Y_\#YU%79>N^<Y7JI6;E]:JUHW!3I-/3T-E-)U3
M7$-&E'5- FXU[%DWHW^O1S@46L[$YGA02@B+P]EC3K;5R&P]CI!EXKQ9ZSH5
MQV!H@NWT+#\F# $-1:R'IH)MB9B)7+C+SS])Z(O%+:\AZ#0T9)VSRPSL)!-&
M"&.H^6O +6,]VC+Q>HQOY4P8KH0)6QP%PN!_NKWWW49J6>(C0[]%2MHDC=[*
MA &BD!7_?+M$2W"7S(\5>856H% %,;D 4$'BJ/&?;Z?<T,]2GDRR</#_1PT1
M?[H___*JB8\>U_]L0GKQW&_-2J8LK1.9,%<'H/4'$[9&)M1'_.F!N>\!9^U;
MCR>7K_UYGL"?[[Y>\V^K_-LJ?[+*1RVO6?#DOO'X7@9ZTDX;>'K^7>R3 B:L
M]8085HHF?U'X];O.\.QS*<FO^++4W*1OB M=/;B(S#SRWT&C^+_MAUL,/-Q0
M%Q%JP$@NRF#"]O[\SKWHZ,A:O2H39J$ 9721J_^R]BT8:,RHQV /$W8+^:>>
MQW_O3?0?M1G^[^J__-?.0^4>E I(/1^R$[T4F+ZH_B^RRL\/FA*YH)'CP>=0
MW&G1A.*@*\LT'$#35XP1$_;.*AX*AX7_L@_@XC)H"8DLTLQK)FSCK,+WV09U
MY+J.'B^C#HJZ*ZEG_OH!G)-;:3 %FSB7L8?0B#M')&646#R-,A$:W-=C:^QF
MYU3K&.REAWQ#R;L;HI"D(#&O)7][_)@AWWF1?_[HQDHPPDLG0;"R8M\WQ;$E
MM)):_ZOA*&?W\/>'Y:HVB^W6DN)/, UY(6,Q%\T821$\<B O?9X?K"(U,+@\
MR"D&9$JP_R@W'U!M/.R[8$TU-A>Q?Z&DR!DD3Z[.$3[VXV#EGC<2V_#?F3#N
MV0T@I$ )8=-Q,Z6B4WV[9VE1R>/Q:V'?#KW;>*!@B9?PO'.N]GC.:ZN)1_SK
MLTS8%FGZVPHY##OX:MA=MA)[@%'=N>@9Y76;FQ*06[^N.VG?&R<K=8^#K2X
MH*J!-=;@?1)GI;YTSP*#F.L:=T+0VL?AK/%$8W.,>^:FB#<P*\^QMW4MGMZT
MGBDW^1#U3T\'>VB$+RNE"N38!ESQY+R@&]FNUD&\#>.FEBU0Z''YLB,ZZ8*Y
M%)N.].U,ZA$G="GG66167B!#1)2R"&T,ZW" = ^JR)YE:WN=/RF7EJ(:LT\U
MZE%"^\:J(?8HZ,/@.D\]2MM'ONH-WZ/VK7L3GUNNRL4.CE>^4GIM]<_GI#T5
M0_6R5PV&5>IV\HXB:C[QUCN(1Z=U%%[0_=Y]:MN^2Z;E-]FTKEWZ'%#G:>AA
MG*BSBW_TR)T;M*^E(;27]%S$3708$[:#"7/A%@7M:APT&"UMGOW?@KH[J?OK
M44JG3M:B(SD<FR525_%=GR1&S'+WU?O9>7XX)EKF*"QS;'_RZT^Y,K8Z"/ .
M/9GR(:T+16HK,>2OI3F!Q4FTG:!;KF]GK?+HZ<XK ^.&@=)+JMO%3' CU_=Z
M5'Y%;GJ1^N9UVOM2\S*IHF3"7B\D>"!V7H:<72>HP83M]&Q2 T=VRD]C1=N"
MLK0-7[,KF(BE/J]4Y.?PYYK5W\J$59VID/25;3@(HD>MXHK[?%_:#0Z*(^9L
MPP+WZ/L\.9XMOV8>\GV,-U1PFT=!$;JD3O&\UGK>Y$PT?_!(A*CS(#?I9LI(
MKM6&3@!7=0L^O>SK^.ZW"S]4>Z3>B-]16&H=$:3Q+8\*UJ&%-)Z2(HXS:HLC
MC>Q$_<VU7.^F58<N??X\'<GA_5:\G-;2G7[.(E:F4%OV[,&0UXD19(3M 7RC
M.2^#ZPC5D"9(MA0 >#UCNGBJFY5C1\3Y7*R-]IT<$ [7HDQNYKAZN\&4SD;6
MG.=Q'P6@?5T+E>45<.*GU*8W]H.]36HGEWI_U(E>$Q<Z%&-\<?<Q3N$QD3N1
M87+G!Y0:,VS5G>8H6*=/%JA@!&D)T7>8$2++L%!;9!BG,"2,J49 .Y1,?V9!
M6QI72MHCNH=[<1^_65<12>8J?>=&8N?9<L%I3 "^">^R<>U35@$P-^MV-=S8
M17-G6^TKZ0-#41T5PV3.QVJM7%/%<17Y #IMVOOVJSP5Y7&>NCV[<K[X;BJ(
M+>.7N]'5,M5U/NJV@Q%TTGA^HIU/8R5GX?R%;*24VMPWH'R_>V%FU*G"5PN?
MHTJ'UML/'[CB>S%4/N^H= C=K7U!NK1#T2FZV$R:IZQ(-=)RCXL!,6->H&>+
ME7)*>J';@K(%2I71CRAZ%#N7/=PO:J[]6=RMOO3#X=X+/U1W5XF0G.)=-N<M
M;'JP?;>?T/Z*[4Q8T (]!V6NKW7.GPG;ZAQU^Z.$P%.J@FC1'-4XZK53Q&I)
M*Z;;-,?.Y4;I"E>THTGJVARVT0*ES*@%B@HSYBV24=-]N:$B*F$K+[OMRG2N
M[]_^\DD#;NN5"[#O.U(32AQ.N\W(3[VX:'PZU;4A3M(0,TN]B?U&(>3#JTMN
MWD@+00K/#,\7V%FS%57H^P>=ZY+:+":QG5]\6\-7(NDTO*]F!-^ ?XJ5;,?X
MC.#F!P[U&+E]O,3X6E#<?R!.9J!4Z%FB<-"V!O6$(_XV'XW3(+<%S#+$XKI2
MC*/-?#;*X,F>%H86'_\:>E)29O>X1,%,W+P1VH#%HGWM'<7V[)2;1L*;?? :
M>;AJVT#M)N=)2:,QBGC=-:U5+56UJ(M3TP>20VJ7JO^69BA\P6IA.X@["=>I
MXO++(RI/K&N*-E(C^.,#PD?&/C>R72X2^G&/?==)]N<F3<;>:O'?5V84QE'@
M7<VY.B;,$,I!#HA N8F4M3V)2%D".<F.#H&&I)[:W$,!9X>[#RBADQ*KTKVU
M+"/F>1H^/='B*MF?)2M[U<S%M163'"*WXQ\_W"A/&8V=MR"54=RCC"-&-$.L
M:SZXCEA]0+W[,2!\PM_G]3'>^?I5ZO>OOE]W[N_XX:+Y?F;%^C.!M(+N?<H(
M<6*<44<RC/#FH#K5EK:/_@:=_IXD&.Y)][%X<BKL4I-2;M.QT \UAZ0^A(:^
MV[RC2WJPMBAF,J^=U2N5%3_/!QQG$$W?E7PJB[Y46/0D/<YJZO&;&,<56 \[
MR8P2! )4(V?-C9Z:%K_R8^D7?M##1T;G-#629/K@-V7#MJW;G#XJ%2>0F]8F
M$8/.FOIF_1JC1$_6EZ"YDCE#"I!;P$ J^BSI4V5!UZB=PF.KOK,+]WV:1+)I
M[8@#%S E4X9W]<1Y%\1MY_@L3G[A-U.M%(MT9G/.4=D*CM8P]-^55) &\2ZY
MW_M_-#G)=(4^N( 9JU^QABNXRV[.VKO;^,S1 6@EOY+ACST7MX+ N1YU_^@/
M'07]+BK*"Q?V[ M25UXXNOGU =E[2/X6S%ZP=6@Q0G]G1!UV2U>\79MTHIEG
MN494/\?SK;LV?7E<N^GV:T>\[IE"=^5[*R85&>Z_^B\_&L6+.>-V8N#98$9M
M<7.ZL[9YF;W#H!I:-EID5>>, #KY ?*R22&_S[L.]U[1@G]:%L@SA5%5@?93
MD&?BR((\T[?:@/.&M^&<##5?S=&>P-@ZARU=_79M(GY*,:0^Y V1$_5# E>-
M]E[U"/6:#+3_I/':\XJYF26?Q46?.MS301Y0="B>(.A+M+;GKNG^8,Q7'#1H
M0^HX>()MGY5'I+&AUHPOOU+FS&>33^'U(4->Q/!!#E)KU0J8]M8-=X4D'7/+
M=?O;)A?$P5.6)P9/(C4GE%_:OYI,0_MR-L3!Z[@YIO452%VCKMJ[LF$E^:7.
MTO>:A:4Y>O=EW[O]@]LV/<Y=KYOAD#I@HT^%JAYKE%^;Q1^;Z*\___FF:OZ+
M@=*\_+W$$_(@HV"RH33'B/Z2,)4.C+-;,F%CKJN+]YFP@M@:?!_"O$N=.]AA
M+WIW[W24M*!'P(.);\92<M=0Q/KX< [LQ='057X33>\G[@JRWU8^*TQRBT)^
M^03!"1^LK]Q%4QV!/S9SS'/15''Q=RW53SH8<E[K&E&\3&XON4K]R3\-&RTC
M'?<]_;5]XF27I74P391>6+&#T2:A#.SPY:Q7PL\^N;$6YJJ6W7]+\GC2R_*V
M9)*]T>%$MQ_R<:X]^Z>AK7P17XL,2=P%FB6'V=4GRG:4JV;D\YFLFA7<.UGI
MY,IQQ+N2^G8;)<M=R<9$,UG[K<)$F""#RX2J,;M1[1)#X,O95^+=)T&I7^K>
M06U15!"2&'^/,IJ^FY98G-[O*N+U0Y B:)'39F_;^,%0_N#G#X<BA7@:I0+/
M.[FM[)^AS-@F9\ULU 4'KY3EFEE^*N[TG+WPI5C0)S+'XGA@Y->YHV?T3/"O
M5UM!.<VYWN%Y6W/MV9'HT&*>H@Z*AF#LK<F^"Y>=&]=VAL1G]V=9>9>LU/'7
M8PZ"+4/H,)'#,Q4<9*O8$?\#C7N*<+?R2)&'!$Y0VR-U#G*\QRI@.W"[]+>"
ML34BG&$88_J3;-\8E*SIO>\_OBK#[^[7K!.5QW3L76^D]DZ?OYZ:O'9UP*8Y
M64\C1*%)7Y/11>0B.(D.[&\=D7TJ15KM?ALAD[KO\\3TF.7>PSR;T077[FUY
MGWC[M9CYJEF)%=JQ>RIS?D&JK#C$-QYS-M/S!D^TU-YE!W>R!^4%>)LD:T5:
MB!Y%\P!79["2+VK2>FL</?S4.X,,JU-Y2N"',X79I8><XO %*5W3RS*N)3']
MB?&&'HG:8-@P.DB$?1:K3-X5/YPK<_*<W]N+:>77'C>>N1#ZOJHZ')GFJT2@
M\=507$J_=5?I'[!]TDOAC#(CG,QGPNQM8??\%^I,7<J4&CZ4?=_P#FDDX9\6
M(,2=-4J)P?^#NO>.:JI]_D6CJ"B@"$B3$I6F("!-D!8K"+P0 2%2HR(B($:1
M$B%F"PI(5Q!0$%!I4B/2I(:.@(#T$B7T'DFH&]+.YOV^WW5_Y=ZSUCUGK;/6
M^8]-]C-[9IXIGTGV,Z,1+N%O6+&G#LC\)4TU>OZ\Y.>KAYZ\'P4)UWO-?J!J
M/D-9X-+_QEL0;!A<%*\:O0T4(K:4=EX4T^>CT8HFS[!A6;^U('LN)#C]GZG=
M__-;#SNC<O]+]0S;T/[_(=KQRJKGR)+XF04L)7_"H<=4[<5ECG*Y9PIUC"=T
M9RRBOHQ_9(Z*G/!_V[+=[L-G]^?[Y(]CL>0X"X4ZX!X;%IV0RE_2GB]F4GZO
M2L'EU-6>L[55SHA%M 1*2EZ'1[):]USE8*'AGD2+[$UX[A3CN-GU2;LSU:-5
MN29^U<M3^4X+P<QJ9?S/_50/XNO8-ZR?'D/?6SJF)S/]49\8".97G-C$XN?3
M)?<RJ4U3>4?T)G/M.,ITVYOW71!UYGB]'/T\\1.FTD&9T\"X]<:V+4,NSCKD
M]*EO^O/$_F)\68.Z[^'T0NWV(V&B$OOE:R,"]R^<6J<BE^KH%T=!3G0Q=:;\
MB4Q+T++TX9:9TN4OWUMVO8E=:3;:"KF0W/!^=MF-EFL>)^I9M,(S>3(_=D(O
MTM!K'5G!ANG/088TJWOL_];?=SB!UB[<)3;LBUDRX^]71>KA*U[PPX@E7@AI
M+?W/)O9:8T)U+[B.HWD7M)M658>':C?Y*:(ZUUU@?BEQ&3;XD]1U0CA.)_O>
M8&5-^U,.TG=4\*Y@5;T6=/TGW"]"+#ZX[VEJ<70)^(#@0>D#%Z\S2ZL<E(I[
M;[A6.->\A4^5)&KZ*K!Z@\69,$*.O@##L 3,'LLU]1L1<.L1"O/W)%5EHY9Y
M-L4#(9=>\<F@"X$C!YWSEPJ\2+F[V3"9R1^6W NM@1<V1+<'^\G[\6(7J%FU
M&XD\ELP"J[N)$Y,/NJ7S^P*&'L(V!%>&37Y45]64X='Z+'1_= _X25?W"Y22
MBLX]S1AL ()'5O%BBV!RQA%S] V\O2"UBU)-?PH6;3B ^5D@ZA)U)C)WQ'[>
MG%P\$I#P@Z?G:I!!"X?(A:W!7_T@#0+7?CM]*WY"NK1_SH89=IWOWM1<DJ+?
M<&?#2GR#&%8Y[MMGD]+:TT>O>/"[9IH6% 2%>BP]^4Y!7QN<Q3#XLEA&78T8
M.A<)F(LG=,OO;-J>_Q/?UJ 4)T5#$T=/4W/LX);1\PZFGOIGT.#;BZ.%3NN(
M2=3!SCQ-&E_0E2.H"TM!_V]OUSR&'P&FWH&5K#KAU&V9Q:P"IXEH1BQ"&!@Z
ML<J&7:[V=$+\S@&"6 9]B'!>JZW4SLT0AF(.-HU^V=7:T[$TU47VHV?A2NL>
M["I<HOYY;-0S@1&B$6+L#;EX<X3B IZ;$".2STNN-JP8__KJV6O'FZ5Z<DUY
MB&N+#6,=>.QZD VCF&,\'O,C,6=#GXH77OT8U_<I,%WRPW/[98H-%6W'C"#>
M6_3?:4RC$1\_*&5#G=Z>W72#R_+[OR5-2U7$R2W?KI!".)T\Q5!#1Y*W'/PT
M^K9R'L6^R+V$-:%^9<-T<(-..STBOZ2NV.!V?@428L-Z0A66V; A$LL4/8YA
M/E,$UK@87YA5-=JN0/&5EOIED?F,$RD KX@WM\;])).,Y,;"U/LKZ>O6EJ-$
M2S;,";.E 001-V E;-A/^8?=#S,LE+=29Z5^>DM9BF1)O!>>YJ"5]EXKZ0'N
MOUPF%-SZ^K64-INLU]$8J#41Z<U35"0I>'Y/#!:&HJ 8ZIMU7=L*^CNGG6.Z
MV+"HP?'E4)P"&W9@D**9B\50T+=80S3<"#!2151K6\6(:E*^_XX<;C9XU/=W
MFYL9Q'8>?.L^&[;I[!+T>#M9Q@,Q9LC:=:!-*ZPJ;)N5-XX8RR9+0.6&[4"5
M8 :H:?65)IN6EM_NZ);X./36]=CV8?[O^C;G+%I<CSTU(I1":DIAPPYY$X,1
M7P>#ULB'[5J=/_^NVHX>FMGKN'_&\WL>[T44C^'M(=W!65Z*&%T,G-V0JJ%N
M1GD1^6P7*[Q\/Y>.5 G=/J>H]$PI\"K<;XRB8W;#V>S\).(C%+:0% =?.A)W
MEJB]=JUI@KG[!F5]7YG#ZU]2@;??*U/C1\8^3\I?K3UV\$N;O. YO,+BO/<V
M:75@2>:4[E\2SA[J#&",96L#3R"7 8P4SL94^OX6-NS3"<(O")]"A0.G*1M&
MN$=<VX4.AO^7.X:ZPN'BZLK#DV-]DNHTB<PT_XR1C#S>0PGBGF:VICGIG%[V
M=U97K;$V)\=N3D]O'57>'"%N;,[X)>] [KU*U$,ED\O#+M8.AT0+,GLP-_N5
M%#\X=$CS_;'1:M&YM*RU%/P- _K/0ALI5/68#7LF!# 2' :;T:0L VKJ4E86
MPX;:F?1P4__$Z[QB/<2-*P:K95<S9F[\#N[GT[FIB3CYO4O@95B<T+9L#7U^
ML]B[-]_,8AKIQ5IT!^%G(90NS]+!:8"/Q[I$[DF>HNV+'7?PF[UFUUC5_T>J
M)&J&W&9UG;^<^\W-6==SS!F#)RTOH27GJSS&NZ+))3(Y.(T#$Z<2VTC&[LD:
MF@4??:MITZ]915QS22&<F#W/#NIL>#"CJE#T1VZ.)VDU61/<O ?F/U%;%-=K
M8E[8.QP6C=?!1ES]L&]ODE2\.+^1( XUCGX)IYK"1SA,JXI3C08')GBU>[;=
M!>\M>X0+OM:_Z<@YR=E^?T7_+J=@!A*?H9SG7^G!@J] 7NBE^[8M_>%JI R6
M#-#]RPA;Z.SMZ(GEX?D:.?R/HR[U^8]M*WI2Z?+UG2O;C0KE6"%5PXY7UXN=
M]#]]V^GF(-J#<)8 &A.K](]CCCBZ?6G"[!D\ZD=J=>4O4OM\2^K!Z%]/QH'^
MZ 82ZS#CKUZ\*DZ-NARI'G1OR3O\2OF-.\>*3;LG;^OD[K-<(V@R\Q#N  ^^
M'<]+MZ(Y6#8)?VXP^3GY4/+N_(P1\WO PN]MGI3$@=3";.W8'M/*[0W#CV;)
MYWJR/)R.Y#$J4U6 NMLED9RLPT28*V8*$=KY4>.'/8>\[?ZVUM@^A7/1"]>V
M45"XVA/?XZV(V'#I4\)HANM0\!/N,@^"58Z<;/3'&,*ON8]C@B GKSD)U%W4
MUW!<W*[NZ[B]2M@HK3[!YW&+UWP/=^]#1R&5Q7C=>,((;PAK3S=+!%0VH!)"
M*%=2HM-)BB55#F8_S]W5&WI?J-<JF\4K:OEB5F^VMQVYXEA1E)JT*!*D1?#1
M\U]F 8J' HEPP(,0>729\I1N, ]PZ_)3?#^Z5H1L.+\P+USYLWR I-$^"0KP
M[)K=G]>P?)3)PRS35R76LF'#+4W:T^DL@T+?PSUK YP\2K)MP6@O4RATP@CA
MB+'7B'V3 [KF$ZFA%2]V6_7TN=JZ$[52KOQ6BWXD>J4K/=_FHGR)O\EX,&&P
M;'HSZR=9\)P!7Q9OF!^.F,OL\$9<P.]B\/\DNI"#M@V?>XFTQ+DE_2EXV?#[
MUQG).UU_&A_JP&!C7*#_1@HSD7B/=R1W(XQV*%*"TOF.6H2L"+JOY&W3>':_
M[LOVJH?*'3I_7&%/L]X7K$L@C.[E9\8997>AE9(12L$IK?*.;=K*(-"5S:"S
M>M&<2S6[&0\'=;EO ?K9^V)*<S!*1Z2,ES'B421#+DV=FW?&;O+[I9*C_W-$
M@7R*:H[>TB5( D07-BS]U2"E)02J'#@RV;#!8O0V+(U7[K1\[/*V>!M?5O@;
MJ:_H*?RI'3_4O>)-$]CHI.D];_OK+$JH0O'S@]<YG_9QL$9T0VB$X9=X^%PA
M0P>Y-VD_,F3PKZ.HH=)HY>\KC.JW\Y$E8"S]&JDZA%(Y*?T6JF'J+;XZ?]NR
MO7QK<"B,.?*]V=]:"YL]=KQC@P#H"6\1JQ[%LG[F,TEVRQ!<\3 <AU",6H$]
M0YE9JJN2)?VCT/3SKSE?&'P];('V#!ASBUPW1T-UV6&<_R><,M61,$'@<U2,
MBLRH'106T)3C^/3YSX^''PX9'4--&-9JP<V9%55G2E?X*IOOGJ>MKH0'W\92
MG@%<&U"5W$)1\:7Q3O@RY#W.4HJ)/%C\M+!%XK6Z!YC]HCY<W"(3!VMA4W^T
MM&P[DUV1G(9H/&K+51B(Q<Q\SSK937 H^=.4K[LL@RE_^GV%+ K4>] ?8]LG
M?)O$V##5A@9)P1XEY6N:'1)Y*FDE)8E^E8=MHNF4WU?\  8_)\ND*QRQY  P
M3P97B[-^PHLP#;Q#[4UH;EV!R:"^]4H*UX)0 OTH2[@/,_TRV\?EF?STEWV3
M0=?2=._6/&7# A\R'E,-:]'A^.,#5;[Y;-@MUP1;-=M+B&&Y;[]/)<J22H]X
M:EF?DQ)'F<%C(GWW$[VO+/XN46!N PU%,?DS'RT>K'B:;BDTMT\S[T6/Y"BH
MU;-D>W&NX]4*Z.X"_'#Z0GSAZ(C]D_LI]U5/WO'(X^#)YMRS6R>L-]>U:?B/
MOVNV0GY@V,GT,_^QX,C=YFF6L!V*HI2M3GRVJI8Q68A_!G19(5YWR!4*@ Y=
MYS^%*;S9HO[[=L*/5-+,@'(4@GI-^1F:2R9469VD(K'.K J3D#SGHOI71%8@
MS]GGA+N$7C?&HWY=*QJP\Q-&[@0F"L\%(DQH ]7C1M*]:64#+E>A C)*Y6XG
MM_V%^--?;^YCR6KIN=T<''!UP&DF_"IEH+YGHX>N^Y;T1'<05Y K"#-@/+9F
M/] M!@)LV(OJZ)TFA*^!,:@,*9*K5][':M].#??BW8<%ZE*D>PCY>X,ZG]\2
M##?K^>LS3;4Q1_S^Z5\1@>\D5G_@[)E%" \V+"!%&.#']HX1 ]>J#VE>C]\>
M%<5(O8A]=F=%0WCH0.VO(=%C+M+7:X2927AUR*TN9%(3(O4UL>2&#8!;"E,V
M#+K7K89:/]Z\^BLHSJCAE$^\(?+=>0LSS@-67\-+$BLI^2SZ\>P<LQ54A8_#
M-MR#U:5_-M6"^98%QQ*:$FBD+KG@T\OKBA?7&]T0W?TI-J)1L.8;L7_<9P$Q
MH.ZF_BZLH4.L&00E7R0U/6HFV4*@N->)KG^AKB[EWKN0;Q:\M]T'$??1/ RE
M2F:J+)7<&"TVBM.@"LW=>J+N_S)_.OF$J,EUZS"+Q97GTY^$=#CO/Q_;:6\3
M^)+5"M_%$' >1W*T?C[[VD7XS9?Y"I[/FWM.[IUR%=+[PQPNEWX_49QM;I5O
MX7[EJ7!!Q89:%J^+,9^[G=NV*ZE\77B)3K=@:#&SO'22#6O]YH@Q7?>J>PN<
MSCB,",&5WXGY:!U3C4D/W*6EGBH$N$9S,<3!UU1(?T<["K)\\[ ]3SY]]1>9
M.$,Z;<<3\TOM>Y#4KM6X@_6:XH^IJ"6.B4B!B3+&$<N)KDA=O@^_L';U G.>
M9WIFR^Q<C(Z:6.E,&,CG]4@3GB$MR1H$NAEV%QOFQH:!I[J"]24T*(WZXM26
MD'A3]Z68X@>*OW1CF\K-#!.+ZO@V'E])BN-6>+PP>*><L-([."-LK%%"E!WU
M&"&G?ESK"H @Z"<XM_Y)G$\)B!K[K,&&";G%5H4RBS*'&[V^-[IU2+USM/)\
MCB%?/Q9S-O:U':(819FD/M^X0]1&A96T$A@&AZ]Z2?#S%O_.>7\8+6.A&[B?
M7SOFT/D3%<BH4:UN-LP9.9S:I'_LIWJEHGQ+@Y^-J;)9:=#M -G[AKOWFD<\
MB7K'<%\IVE!F?M7?R]@?#CE-(\"#+6H&A$O"YPO^,"Y6/,WHJ<UKV<T9/RUJ
M\]7F[4GITE^O]MY-?/-> +0B+3^-<="E*VTJ9HG0#<I\3#Z54HCM787;8G0$
MI'AC?6Y6MZ3\\P9MTXWL\:[##F?;]1"-/MD/!CV80Z/GI"/*/L7S^'.@KZ,F
MLBCS],<X"696E=Q'!ZQR_:CL3]:)N9$WJ+,5K(_.[@\6=P?_AB<)-I0W''$6
MJ55X'\6&%;+V]A5X$_: _M>J9E:6S<I2'JBL%AMWM#PPRK]=_F':W88TL#!/
M:)ZQP!695_\AS+O<31UW\B2>(;J9GNW=> &99#9.$?1_ZGXH_P/HTR9:PBWV
MLO%+J9!=J]#E8X%Y@7N/42^T^#'U"$V$$*!8.'P-32)-"C=%'V!(T3B;9>UR
MJV5UGAYT.=$I)=_$4T"SZXCL)@G" MZ7Z5I?<U]4WZKI4J]QM<&?'C!B.F94
MC"#\*P%/Q'7$?X\E70!X4JZ>R(7_L?/U=BU:!'>J.U]79D+"T-(YU:S[]N%+
MRG$:%1\/9PKZAJ9'!CX3D?0?_&((874><"M7<]AKI[9K+AV,P16V/]68J,\J
MO#VP7V7]UGH.F@.XLQP!%R?>HR F"93C@O'12B&%Q<K[A[_'2)]^47PEL/+%
MY=MWZGQ\< ]J1;0M3:VS+)V%?1@)R+,_%C26<B[Y2O<X8@CMCY<(D7#)*DZZ
M'HAB\<,EP6#RA=YAQC?K\SVF#]FP7V'2>W]M4\0/F7%JK"R' &.%<-@ZF:\E
MXU=66+$"ZFGJR$C4.]$2R0A<=LIYQ!C<'M54H\?,UQ?%+FY,T0PC\>KS1\D1
MNGSCV3*]NFKCE+.CW$GWFV3K3K>>[LZVEE\1W"I3^XR0#W"DT7Q97*_I9W$.
MH%T>*+<SJHV[^NQ*FXD_]FZ/.C6^Y\B)<U)-PRO#8GM4(R(>W3# #,N3R'9/
MO 8KZ:5GWUA\GM=33,/CDU]OWTI;%)(\T7-_W51IY:"A:570 \4"RAW^*^KW
M=Z&LQ0]?V,/GR$$W9)'A^XEW#YK0I9J.E@QD39CF2MVS/;)[9D']UJN>!\Y1
MNA&')1H.7X!%N<\ 0VJ3S6G4,M:!M$E>$71Y%;2[!K/7PDVB/(VG\CQXGK"6
MDU7@E\(6(8]/(!9UI .\TN#TI(+W(/X$.+#@#Z[KK/&;>#RX<^M-UV]7$;5X
MD;:OAV"SF5[DDC<"Q;=C5S=+PM:7IXK/C9O[R\@6D"#8L^OWML^JVS0;%D8N
MFVT (LB%0%/781!N55[6[Z'N\R7)J._384>2!HD;^^OS76O1V&6I,R)3SZV!
ML:0-;: 6&.+B%74WKQ**E4V;@""\XH77'R^V[=_SS"AL3ZW<^S :$E24:W 0
M0'8S#DY**'6?QIGDC+:FD?4^O?"X>#!7_L!Y-NR&>?>C]Y,/UP27R*5Q]?A.
M"#B:JHWK^/#9)\--J8VXR<=G(N\RNF41D8_]S6PU<EJ,-$6>^#)^84@8QR!)
MMV)7DQOT'D8L0V"=P?N ^5KW,;5K8K#!/5H2IT(5QW/V>"<-6WA[R/;4^P_?
MOLWSE=OG)ANFIL73\?X/ S<[B60(BHVAZ]#\O['XIR96M ?Y+J<"_\!Y1J3G
M,<<6\D_'&(H=QAX7_7*!<\_M,@!"LK Y-NP@<!.]TYM"_UA"[<B=%&$!-[\^
M8961CIN#QL[Q5^*O.!L>5-GU4G>R&L>DZFP4,2. .W#N#@A@<KB/Q)<]GBER
M6#1-,U%D+@IK\9X+EG&^]O#C>7M/52.YS.+K"L8Q/N:]'21D3.^:G8A%;)R@
M>6ZY^XH?8Y28O9:Z-$[WPTDQ/VM(I6-1UI6]58;3Q6F7!A6;JGL_3+T9Z1!_
MRR$M%<,IO<OQ'.3;JLSB*C5J="U>'KQ86E$\JD[3#%G%//8X@G8*%)VZE]KQ
M^-A#$K_]7H.%J@C::N1L"^]>?!^::H$)=#P&NHY3+EU8<>:\1JPN,C'R5E;N
M>)T^$D5*:+-(2MH3$7CF4W4OBVLY&SD!'&(< VV<I+B7A;&?= VJC3_<0.F3
M_KQAPVK=N=[\=O/JSYM5LO,=&%RQ)4^Q["P3,ZQ]?<W#8@!9RFQ)#8 G,OA#
M)C>?5Z&I:#/08?RWG/US:VIR0&7_.O<BUJ+'*.N;[XFS-C:D^/L/KHSK>!$,
MT> IS;IO>+'%T;-]2B4><L:]WJ%K.O>4\B<TM4L:Y?-F>K2F/>9#D,EMN[X]
M("6NDR,EI4M!%;H.V( JV;U?5V><%%SB^$SDPPD9^$MSM"249F01=P^J70"O
M9#%0-)FLC810C2>RVLHD%+97D>.-(E?9KR<V-N%1QA2)3M\WU=6V41M&<GA*
M*PEY>6UKT5WW.-S)6+B_K.S3P')!P>:6=_E210*EE]K2"'Q-R:+Y.U!#7F:
M_H^]O!YGN%4\38]=N/7K,OV66C%&R.1Y=3"N;&PR]1YHDH-51H)J'['/&_P$
M4Y_A1'TS"XJ$4@:^N-)L+LD_^=&3[M(>,1Y^]I#:^T2P@<6UF8N<B%0>(]<G
M"6-*L46-N<>M]&+O[]^_Z9X':=X-"9Z*?EGB8,(ZLKGT>XQ>VHL85ZT.'%W_
MJ$5R$4M7D=K5KRGDB9A_)OC>[CWZQ("E>72K GEF>>5>?X90.;E2I-RD'86I
ML_NC Y< ZM 0HM-LY'>-]\3&-F6+'7EZZ6)OVMFZ@+H&Y.F_&I@9.X!N'AU
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M-.7Z9<Y%R6.QETO+B=7]ZMQVX:&R<7NB:PPCB@ZCQ5-@'"5^"0Q5WSK>;2D
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MRK!AE\P@%I_O!\"<+1NB"QD2XB?$IQRT$IPV(!<--O)NPX"I:2@(B:<-6;"
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MN/Q;87G/L3*RT)A(;B#Y3.=#0RW=P5'O<7(9)R,1W02G<T#@\*,B!^(<X(P
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MX,Y\5M8(F@_:5PLB%1ZU?FM"P=5K'I.WG!&H-1M\=5CUQ:=G;5;1YJ^N/^[
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M@L^A9R'1$UZ_D$KOSM5\RYYM_34_7Q\Q;=0:;V9]%UR2V\LB7976N!L&6_0
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M> TX#.B D"N& :?'XI8/-5<@XTB]$:GABXU"=EWJ5V<R,A-PP]?V8NW&68G
MV+<U?@97IJ21TQ/ _32@_T]/W%7<XEYU\?"^&U&^NI::!Y_YB.9NU [RT:\9
M@(DW\8]^G3+FB7?^U=_!>FK9*:*RAV5*QK]+>(>+=%$FY@-9B>2,ESLWUG8[
MA% [,0^_2>[0Z5?NXW GUIHF%-A[B#CEL):NE]RUO1?%HG_C]I&DN\ WI Z\
M81-$DG)64W%N2H@<JBMT_ME%V(A6]>9M[M)&(8.9RW-JBVGZY-JG*UZ<#I N
MS 'MG65^]YT V7HDJ;U[1_L,-9RB&$:^#0TF&.)49Q.T<#N31D,Z^+2TOM[Y
M$E]YOYL-C59_:H1%/V=\1S*,$U%G%X?\/63]!M?;6'Y/KK-K4?=]2-C!00MV
MLP7#23F/?YB&!;&M^"Y/2P[.;GG)YSST%9E/3;]O]THZI0<LG0)6,9Q%-T/8
M*$_P^ILO-+WRX5Y!SPAS*:&@2N/CQ(263QB^XO@KD4U+8@.O8HL%6-U3(9%U
ML-(IRIX45XC73P?&K 2464Y+WO_$(#TXO,D23HN ;$'S[B[G(9H1'%"EST&A
MAHD!^Y*W$\=U)KA8NA^FW]KM;O7<L2&^(7GZ$R)G))/JA1]8^>PF2,Q.C 4W
M[Y/97O+]]N% /!HC&>+]FS!'H,(L49H<.88?E[F[I=<>I1I?OG*M6PD,5"H'
MX2[_ ' "!,9'WR;:XY\>:%"W1LT6,5/WW;?O9'[9LR;GYD#\R!LP#X8KJX(>
M(X]0@"1K]'%MV55?BC;!)EJQ[%,2.4C4W=7PW;RKQZECB3<" R[,/_ ZG7W]
M(&[V</E4"HN(V#UI#7D)$R=8=G.\?)K$M<J]JC2E/?22V-K#KVK2%R4\/^9%
M""7:D<P(LSJ@1 I;WMI8G2[<7=GKV/3  &R Q^YJ?+:J2^8<]"3#1 ?4;)CX
MH\)"=PQ'Y>?ZA,C<U53'1V=.^0E;+X+YN8.9.<];OBG&3+A/XV AN_ K.;DF
MY,QB# 0=0 < ]K=IK&0\@P<*X+F2-,-*/%+<[7WB-S]F@(?>W50<G]TVRXP-
M9FWW*C(SEPCA-ELV4;%RN5UTI"C^V%$ >X#C?-Y(^BN9K9NM;5J.'R:]T&_-
M]07>Z?Q/)V6#RL\1GY,&02N?$^%;YL6'^OM"!+(>U%/BX#R#(QK^WZB^/T\#
M!DDS9OS04G>FM'.UD7N</[B_%9Z(R8Y\ D#H>I;DO'>(,Q$9*+Z@(F7-95LY
M5@0Z'^!T95-_6*%$\6.H0[>'R/E/K^\E#\]$DD:.;T*>T?H1%<IPOL_J>S'S
M$2VM-S^:B.4^MGG^5/XZ]L?,5<XG3.U7M,\19*-VX6R/KMAZJ@>T9SUKN/\]
MOG#=3\M0*AD"-JCT!);V+3OFJK4L5K[YB-,N7T7W!K_%_>V<;B5%"2ONV9Z9
MXC$A^,Z_R%F54E&M.VE8+!&KU76DUCN]Y$#85'FN3_5!;84&>& 3JE,XL3(1
M4))1/7:%%5L=%:A4O@Q #IM%PSB2L$O/GX(XV]?.?ZVRG4_FOU ?<U&**3&J
M6](YN&NQ'DD,H+X[33([NW8PTHP)RC2*O:!/^]SK4%2X^LOPV/=3TDQ_R%-!
MMCVZ1<,NWT"\LR5;V:YWU!XK-:AYPC8I&:9[,,8PLWD/9?V_]\QO%'Q^1=.7
M#KBK(4EE/1QD01"::48[AGBDG [H3_AWVB+PSV=S0Q." G%-=,"Y#((A[<<@
M?-GXNN0K1(4/Y;UJBR)9N!)#/9^(9MPY4X[8NG$H;^["19LTAF1)_M,M-^$S
MY;YU4"Z\2Y2,4"M(R24\R\-7Q[ '@@>#]M6SDLA"/J"=!P*Y_U8%WPZ$!V>]
M_4@M%I9.-E_L5Y1*L)VI\WGU5<M4(*E?9. PLCCIJ^(NYW6(Q6[I82<#DBWG
M/RG=NJ[]GALN<K1P$X(W0.S+@GC0ZT O!B*T;SQ"+6-@OQ5M(!WPNQ=.!^1.
M-%(9;U%FS 772 ETP#T''RKO"(,YA(GJD^]0K#GSP029[;L'PF\C]QDO/&@@
M*] !/Z_MP,D"*,4E7\BK Q E6AZ^5@M?UD4S9G!7W)U>^$S61%A3S4L='VR"
M^</4H$EA"]_O?+]C*78#_%VEMA<B>L9XGK-8;+,#J'F,NK/@76\](;N[!73
M\CRR%T*2[:-D*[9 #B@,( G^C!Q$DL[7IE'C [X:L-8.-4D2QX';-C2V;3I
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M9T)^!A+\:>R*9$62!6-([D7GXR$(MUQ/8L5-Y:[/'HW=TO+A54;SY=:<!2?
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M:L?&]/'-".Y*;Y*5UZ3.-:;GR\<<O10>['A"9(<V(<F\M1536EKJ5$SAKHK
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M7G]67*/967(8U>"\H7$2:%J=LK&ZZO(B5OK.K]8# !NR'<D?9&-#_5X/(AO
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MKAN3E<=H@RF";?"SFL5MA4T_'OIFS=QE^"V/DHJ_^K:N\2YV_<\DT.MWR(_
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M'+(#B'\*'F\Q(443'&7#E?Y<B&;W\;-/9 MKATW"'@)NW'_D/&-!GF0INL,
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MSPR66B=J8XX231XG(L]!3-+Y_GI*F]., ]N;)W1R%VS>QV0FOH*]OTQAH+%
M6=.IF3=T "_4XGJ9DE=._J3:.;L#YLQ>R;FITT-B*UID<]BX(JH\OA?/0G2M
MJ";HSE1!HUQ:G[42S-L@7X2?>#&?3X^6!-3"C#&HZ$R6END[1"YJ$%3_IP-(
MTM4W8UDQZ8[C":\ I$'"J9U;8[R\7.IN7$;VX?UI@SD6YT:_542G5[H,/:GW
M^CN4-*&=SG]_/G5[N<%O9KIA;FYK+'K6+HS\ C8"YFZXZ=/=)8]B=3A<1[[\
M.2WN#ZD-B?EC_2J=_]5'V6[UTY[]@*!-%-[4OY!#C1JW.ZVDJSH\,PVIJ#BT
M&XOG<\H5JHZ.CG_[*(<_I09)$NY_#\>R43_OZAQ<WRZ"JOVR6D7&=%G1M 4S
M-(UH\@L(O($LJ4ZP@F5] 1]X9W$R=2#?\9S7+97NTT#-PAPZH"'?L>RYQTVM
MY6_<O6:U!\OHJ<B5D47B6$6-+J5<9R&/O!E@Z(L/L22(K9LCSDKO7;3'\2&/
M=V1*SZ_[5)$O=^Q\N1,X=>'D.UVH(/D&;;2#>&I@E@0D5&+ULF9G*PWO$N2C
MOKO[-CQ-BO>H>G*V3.<BJCLOXR[R!WPV"R.H>@/6FXOO::.QU:5@FK3RY 3$
M MGX?"G+^T\&VJTUQ]KJ33S/9/L*?</5LUA3\XY"K4A!MH6XUIG[>'4D-K\'
MKN0D9%D3L@%@^L:GQ9$BS/+]=*W0PL:3O&[WW-"H^B4'L86\7<RB^-"S'+V/
M-9(_47CN@[?VE(LD9KR^*:G<E:Q!D2$<_U/3]NVWI?ER:9- G,P"6*[NV+7K
M6M7&XSHWV&^#A)=V7!Y0BU4Y22W$*D)2&R+JD+UVSN*4,%GQ8QF$3U.F4/J%
MQDL^G2M#ZK=_,9]H.;:M?.[4R88TACP^)=E!\J.C%=/Y=-; 'P_3<XDN' &E
MWKW!WYR?=2@G<K^_I8*(OQAC"L?K@J/2N:F)+JK"4'928;X9B:_U,JQ69)W;
M;S@?XO3NC&MKSV(#I^L%I<2K2ET)O7?;)(I+RS-\<AJ0QO.#WM;ZFV[PVK2]
MN@W1"J_)$84"RNA/[PTQAJ>X34U7!3(@BVS@9MT)W,J6S%M1W>N0:9E6D83%
MEGGM IGD+%:RF]'%2B&6N\!'#*M[GR9JQ5 AO/Y9V=;#C1Y]CA"I<G4M4;'K
M,Q-:VC+ZML83]]_SYZ$V3C,&O_2[%+T+!,#Z([*A)J3D FMA\2\L-4/2F:M_
MMEN7K\PA8HC?S_2I ^Z#*9Q"[>8='U O!7E[\^\7-%Q%#15ZY'<,9?EL_!GJ
MNN+^=20YV?"L*/.MN^U:17Y1'1PFKF1S6>NH "(JN>!"@N.SQ(&10T_]"G1E
MS!(8KX$Z;6E.ZV\0(11]9UM5E29PM?7HM20+A1YGH=$81E")W-U@=Y0@GQ31
MR&"E!\-1)XMUX7Q3TY?[<_FWY6H*+"V $WW)O<_<[/A _J7(@\]SB\Q?("LI
MFZTBES^?'S>3C:U<=C-P-EA,W*C<KZ5E@%EI?Q'XIP0<A^ ,]"GIVIP.\A-,
M-6W"-Z,R5K.@R-8F\04!BM]2^<W$"!+?O8[CIG M806JYY ?E#@BH$ 'Z3U,
MD/R= /<SXE:)(T-O8YV8OT06QRW7ALU>WI/] ,0_ZP]$7**P_5P%S2C_I0@6
M'IR2W46<PVB\(NXX\268/\^_OI1U3>7\MRL?NGCRO@V9:\O,>#DH'WH$R'P.
M4V0WVHM,ZE[96$,WY/2:PS?ZR0]HG:I7?_\%.K@<2_-O<=>9?SQW5D .%!>W
MPQ)]KMLK\N"UFN@]%0)8"S:.*>='MKB,+1F2(F8+GRN'U3UT.E'TX=<CUQW+
MZ$3;3FSL_4TFWA,WU7PT*)P1Q 82>.[H8C.&%<J19TK1)D2'.3N]+*_$'Y ]
MO-KL0.S"T1*#%U*YSB7V;-]"RQ*_4K^J@(\N*$I2!+'WI!=J"=Q!N@W5O\;5
MR!U/1-WE;'C[XRN%OWF%QAB8Z/DX=%N)< 44(=KV/2$0ZL3S\,_76>\;>LWT
M0H'^*U0@%S4"[M0_WD.TPO.7KL+8"+!R@NB^QT1_V$7=TN09]5?0JM>QRTKM
M)Y5OO&([SPB?-K3(=M!;)#(A%:L8I7K)!P+&HZ,] IPOU0[OL4E"[.I"NP03
M"UZFJ'\)/'50O%W+[AY./4%% %W @;2;)"%LKX4)Z0-VB\TQ,<7CIJ.2>N$O
M#2?W,P/M7,U/YN7"-46TF;]H0#]\PLL2^PC>C,G4'2_;M^BRZ,,_'%ZQ\)3E
M<AP%G?;T="W;T+%9E"C"/?OD(77>+/5$ J1&>^QKX0'_2)D).!:BK[SB_LG:
MU.%^=4+:GC<\57^S\G'D4=I:4@-N:);C4QW7RZ1A%1".Y^6YW$5-W/,Q9EJ-
M'!>QL@5Q:I+$S/!ZP75WWF1(EP4H8/0CQ>?>&DAP4$\VG*"6W"+ ::QJ9!7*
M/=[$H<?&HYO/W.XLRJV?H@/<>H%;>;LN)/'*C4+9Q@#V(2PZ4(9Q3)_2<&]&
M[SH+)US7%9U1%Q>S=^.R^OSHTE49MF*F!\YW=6*#8LW[7/0HN6HP?<*Z9Y_*
M2+SUWT T1;?R$/X4!W=&3BBVHGA5_+G7Z_'/J+6M*4T*--&1#)L%T\FY_2_<
M@AXG%DW651\FOF(9@9?TK_=BD>-@K%721P\N;I!3V)ZNV1R;-+6+QX%O0$/-
M,BV/Q3 6]HX:X@$>)Q.-\2J52DGMB)":CE8G3Q,G;U,XEVGU&;VMTM9VRP/'
MUMB.I+?%M',H*P9LZ?\+!>&7K B*@9[3LFVC%5Z5)R6C+FPK=Z;XS$DO;(5]
M=>Z;4=J6U"K_E*U86SZ/MO"PUB'XK3ZJ]XNQD)RX<; '<\&;"[+1.OQA\@S9
MU6P 0I_>2^EH69V03DU_H#PZS:M?8ZX)G_7<!5(XW7$L%$G4& 8G/:A5LO2\
M3%?@RI4+SJ]-$8*:$X])H&X47@L1Q1B,C\)'*$='-ESU\6]ID!A1>;#/_6PM
MY9M)G!9K<RKOD\@S0>[:;M7S,9:,,?F("1'$&H)WBVPPF -75X67R<:=J-0_
MI\7<QIX?4'_U^M3-$UD?]=S&FNSG/AWOU;X=+SZ+VYR(A%%M#\H90*G&4^AR
M@NOS 5',="8X<*@R9M?E(P- 85.!L[';EHD*?A\;SJ=LN9^Y63U\^A;MZM15
M.N#]2#1)!+6.RJ;<(_%AMT+-IU,PI)Y6A9_^.JG%BPJI.;6E;6?X4",A4[9.
M55UQWW ,7]P$0GZ.)M\AZ6!'(S.<571Q;&<%)J;U[G ^^,VSR_X[NA4T,7,>
MOU$91!'+7%9X<V%(IR2XFXL9(/SFO,9\9LV]X3Q005E=/"C3LI\.T-896G3?
MKAK*4K>Z&+?G)#M0NEU*8X63'[^YO+3Q<)8AYM:WDDQ2L?!/?RY'AWI0.1RJ
MZZMB=#XRI7&'_G%DGS72N78%5R_XF*$YQ; _Z;QX/Y*^-LD&5\MQID 40[[.
MSZ%G81<9R?6&A@[NO]=YKZL/HHP+B2A$O78A2;Q&G*M[&\MPNAWF2A-J!0=/
M!RP4$\XXQ3+U=5W5;72[9.QX:#&71.'4F44V"S);K1YZ1Y6!^2#Z%\\"U?$;
MN]XE^@JJQC&94M<M]^R%WK\[W:@2CY'A5RR<=!DE5J:5529V&*'E_:6ELEQT
MK&GF,W1 V X+Y0*X?<*DFC TUY83N+'E@0I)*FG+6TG1Q>65?W?X<:K6.-EH
MW:GJ.#ZBJTV+;.ECB.->GR1#@!N\+"U;)',82TK[W?F(ES%E:5^DG,=9VX\U
MF'G&9UAJ-G[1@ZSU?U"]31HB"!$A*(+89[DTH6;4.7D=Y>1=)^6G9;&R);FA
MU*]_XKIDM]@H;?H KA/N,6 @K!F%?]8+;!.X-%HG3=CJN*0J0(KYL7I'J!<G
M'*3]V?3D0.DUF[#7&C/9['SO?9?X[I8_E\-M2+BN%>Z;[.G 1C$9X;&N:1H%
MCJHI%O;["F5;I!0;'&A]_*CP'SZJ\J,\7T\O2]N7JNK P=?!:+/*"3?<C+V6
M4 P/<S7(=3*P^\<QU4&\2_ K//BCASY'DZ_WKZ9LL\<V_#/?5_<O2KTYIQ*9
M][V:+?8!(-:'ZP!,!NOB:W$:&[[X%[1^[\O6V011)P<9>:?'S6K6 PFV48-F
MUD(+M;\NWBGYML[B2RX_'#+F\Y?QR7=7]!Q<RR-W)5!S)+U+3 +>3@[A4;V<
MGKW6F)9#F8P\JZK/H]TS.LFFWP"AV5]I#]"-@GA-?@F7"S[>.#J@38<4CO$I
M;2W(GD0D,#\=4TW=#&4H#QDT *RD Z)96E!C^SBO'R4\2]6#DT\_!@4U+"1B
MHK]_033791$9D"3R'4,^P8]QHL<DQRCR 3B 1=20GG L ):1P=67LS[BA^GA
M3,J']N/#%=\1T[MCR<]K=[5["$E[-DO <>Y96 39%C:.XJ'=(#4/R"-9WAQ.
M!0_I5_%M('_>5IH,X\2O7+D5+.$C$G>/EV69@R39UA[T'=:1GZ.38R[=UE=J
M"\F6:,Y:[ZO]82/ TD.NFO99']LR9_"'9$*<IG56^-45)U039 J]<^_<G,_\
M_0'(,15'!QQ#'E5\3++'H3?$R$I0OM"#OQA'^(3Y)Q3UEF_L_59_#?[^-?.1
MK)[UFUI[@0?+TY1=R'Q,FE*>7H4T<@DN_9RJNK,!'Q]J24KG8,#NN2?#_#\:
MABC*+YV4[W7M7)IFYFB<AW$MQX=G<$I$BO,<J^J/Q'"5@3_0 6P4C;GH<SH+
M*RGR69:WCS$_I0J%N5/T%HS\?^>UFCR/7]/1F8Y[]"W>1LMQ5Z.9@?2,Z8")
M:^E =B@3GE9LF^VH*IY^VG/C$7'%:;:TS $0)A(3>JJ@Q3_61[/=QX]X7[ -
M7)KSG@ZP3>W_J"36MA6R]1,9XNR1R1@I=FRK*M'44DN221;C[66SZ8-,A;^*
M'N?6HI:BL/*D#<*21EPK2YMY!!WPVI1:@ANY(/<**7ZS,_+9BT?A>H"PZ'LG
M&S+^4YDP6XG;1K;J/V/3D=UK:MO@SX<I><7$@5S]-V\:]$$[\ ^+@GAU,(]"
M-?D61.E*=+(<\%S_91D_#2G73B!A1\150/JOQL8(0Y^N#4.%</QHQ!E5KLG$
M)-W^S:(BI@>KI,T=_IR1JT*1*6"22&$9G WN(#MQ!VOI^*)\:(LRJ>SURJO-
MQ5WN:J"6V'RBC-8]7 F-#?K\+X,#!$D<W<%_$:<V#[LRI.+DACZ$E0:0:U\V
MV*5+]_D8O92*J$O+R&H2JJ 0"D.S#->KK/Q^_6CP;DA[>H]?0CZ7FBV'R$K
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MM:9?#%X3 1\0&XA0DQD 00-(T%VE TC,LG3 14OO$*@@TI)$;E?XO9P27ZF
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MZ0KD@6?G__?Y_WW^O];Y5*8'$.7_S0.L(F3KSCE_TY<V4HPKTWJP@##X\)]
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M(QF,[^,V)8DB\$BV)=_O+BJU$>^1^"K(G_3[FO'ES""8]%K1^XTUDW0VX10
MM CZ:;@PV;L%X6&WAYB80#4@)_CC'+;/>YR/^[QZI[1WV&YDC6T/8ND$U=5Q
M]3M.*X&H#.E[>BA&Q#E_4E1/^'#K/(^^)U03-@P\ >.E_Z:K$EG#J$$$S%H\
MCXNJOOD@]9I+B16VO_"<1$KH Q?)N[<)^_X$N';T^N5].)'):%HH\G:I5%7J
MC1TWOH,!9DY]4@T'^M?A@,W"3XS]HUN/!A#N%=41T#KQ=TVN, "OQY9BZZ\N
M[WFV"#PLQ=V,4C]N(0!\??0]99B6;XS:MV8 HM&=%S?Z=$J3*%CTO-=SF;=#
M=&WJM9%Z/4V0(PG8#$D[^-"J5!SB-;(1'5<\?TK5"<LW;3J('VW2]:Z"\]9+
M%?C7,M]?2N/E ?=@T\?<$PI*!CXG[?<F9*_,2!Y!9U.7NP#!JRO2\>&P:_ZL
M[1/SOZ+Q,\)D#_M1-[3@#NVZ);JF.IJ5]97S?"IKF:[P&K?)K^8HF4A21 <P
M LCM<W&HWH+$PB0&PX(Z["8.5E65']_^7DMHZL#?%$'QZ>N.*<V<=O$]3$DH
ML%ZI]6G>#-_J=DP3Y!^Q,SP6PNG(9&J\5*E9A3//8<*#]:;9*[ +@^T>.^E:
MMP7=UT_<["V7X;]G +PJHBL2$!AU"/TZ8&J2>"=<)5'O@>[QSY]P /5$UPPB
MHG63E;RM6S>J>7VVC[O5VB2]TD_U\%X.YS"/8L$S2***=.Z58Z'^QX0T#LZ^
MJH2HXA"1]KSDSPZ>03@&X.Q2HTP%.JDKC7!G^'%]W(VK7.W.GU^_X'D9T%26
M^"DTBLB-1>R%8VB?X4YV?NU"FJ8FR"Y9:UCZ8MD2(<OL9D)$2)3(=_^+-S6%
M#CSP&.H9%?C$]9^U"G$PC6 K$B)24[=LHJTPKPP1)-3B<+Y3\N&;M!NW?CYN
MEKZ\=.+$7=V:;;52B:<SZ:,SO@T1,OK)AJLRJ*5*S#0L80": A?&.('>8X@F
M-*ZA68\F3&3@0@6N1[A3;$13"EF=<LGPO-C%^R<GK_/=+9(H6ROVZ5AZEDHJ
M;MD.YBPGYQ=U3RA$7!J0&)-2U>'T.'-'4EK?5Q#[9IBH/F*O_<M"(=<.D9)*
M#7/Q+K"Q<ELL;:1DO=&%V9,AUN15ILUJDRR+"UWLKPQK<U/9AC:L!R_D:\B-
M?M&?UKO<[>B5Z]X38/CA:!U+U@:%?G(3#^1ZV%?(!"QY!"2G_Z"R@EM17P"[
MGB03\.J<-0. /2_I>?<;V>] E$9J#VA-&^@>_J"0F0!FU@W^R\?(M'Q--P*8
MQW\(AVQ#;],E_47&X97"PINER:TO;%^K*EZ+WT>T_[BB.8?@8.:S?!?UB([^
MB6@\L*GT7$CJS'@J)">V6S+=$Q"_[P8BK5A<[,3W%&7U=_?-$-$%N)J/!Y4O
M9YB.":JFF60W,D%BJ ?5+8F@OU:')Q7T#OI'M\A. X=';0_2<8 [?5F&SC$!
MH&G.9=M]*I]?!X(81F^GBU?&0:476_FKTN[ZK]Q*ZOL N\(>WU[,2XG&VI4N
MAB!^+5V6LNY:;J"68J:>A43H!G<1M5>P>Q;,_X*3_1XV_G!B -[Y-4.Q$!77
MK<JD^F=X0O^3IQ]B*&-=#,!1^%/X&0:@Z4[PI1E^V VJ'HG-1:AM>%&7N/!6
M48>SQ/!"O%>DY1W=R9*OM]TOZ%Q/'/$1(UB^RD$R$_+@09T6!_ZBM&D1?;1G
M'MY),\[&7*VDG6F#$N]Y3&#Q'F]><0NOBBJ0(:2C/M_MN&T^&E],^FPFOOJ:
MSZBRO&KNP:2J#/='(9I6GN-EZ83QJD97SZG":F,?IZV@XWP'290 ?Z0E#0EW
MSA3>\R3:81F )^3 *RC$&3ML1D&:6O0Q+8PO&S+_L]HQ1]<1$"X>)B_$ *PE
MT#[VWJWEJ@EX]F"7C2(%+.D[>#! VW&4*RFK'SGPV)^>6K. 3AE=FSX$2;EB
M-]#3(6W_YU@\S)/Y%!SK#3V+R/IX2(N=6L6*J.18&OZ)^7X]BN<+"%(#W.][
MP20 Q\S),GO^U$T^\D[_=X\K\*?\OC=^4J3N4H:;MZ(S*QL:7B0S !I\,KH%
M,Y;(Y6+C353_;R.9K?39_##ZI;_R&YIV^'@^?_/VB8XX;8X52+%CR!=7LX#P
M$V+E=YV>U$G729:_FU?Y+K$)RW9NO#14?PL?!.09MY6M-5E/@[9XCG]]Q57*
M  1_>$Z;>;8BE3UP  *E3'6.F-PJM:[=AA(72OG(711Q>N>T -, WE!UR/TD
MEO;#_/=*4S=0HREM.S;OG[B(!EQ*'NG]WO6A<-Y!@#*RLTB]88Z+H'&">$!$
M!P<&H/-58JJL;7*Z(18UTIVJH)3#_RH=LJ/- &0W/J)]@N.RX)P81VX1J']%
M<V!^I+*)Y4K3SJQR3W& 0YS**]_+XJ&* I^&GR:U^R-CM16#I89 [MQD:=7W
M]9RET.?GL@2)&W%BU=6#N7<R+04LWEN^\@$N\PO<,&]WGO;,Y[0QP4B6S2#!
M]39ZYBF1-HN^J0>TCE4+/B+K/S?29^3OVKY0$RJ0K$.2:&E4&MSM%WPNE!+A
MGSHZ>IB\GH.MC.Q.?8#2$SLO*N!U_,&+"3/?.]W+JGR^(86Z9Q]\_/\]=WP1
MC&59Q4%IG9#RL3C#CO40WEWB#> !R+[C?U(;_7_Q\%]L 1ZHQ<?"]X\Q (/Z
M?TL<9.:#D.(E(>DXQ*'!SI&U5__3_;&:%A\KH<I]61%J_RJ5[.C ,GEW:J_@
M%V #?%,C\;C6CJZ>O)=I5)V3!,F;H!=&A.O;9!K&CGZ]R@#H#CU^8:RJ)@5J
MSJD#MDA%D1<[9E >\9H.GM+C*ZPM*1PJI56??-4$62]!,75Q7Y"#U=Q ?ZPI
M.6*V5-]^>$[.T^>"8_R-AP[]74R'_9'#,E,XE[:0WA"T<_7[MZ3$.I!/%]F5
M_4V^X%A4YKW2E=1$&Y<9[R\>D?;R%(-J9B@KMMENDC2FY:C@#+MN3&5]@5DL
MV0-HI<$^.&P!OVFCQ^GEJ)]=KK"6/D?VF%/?'XI&2/E)Y$MI*XZ<"9E8>857
M=I%8+G;\H_E *_.YJ>O05A RX=";F$/@CVB\ZOQM7[?ZBL])4[_\OM;1M<"G
M?N9OP\\#GYP4Z8-94:^1(PJH"J1O".3R+[_;>*>(&/ IB6 G[2\^:R^#(,L;
M;\NLR.EWOH]4'@13A)=.SYZZJC?GPW&*]</+0-%D_)/O]':(S762O$0G U"^
M>L5L-&-O*P2QS   ,+IG(;RD_[K+SQ';_A+T5O#_Y1>JU*QC\#T)($T!Z?#E
M_QFX^'<\ZKU_(K:8A/LL:+6%F=('3/[.ZL.!#V[ HX"[^#P&8.G;%VZ'_W?5
MKDRJM1/R\"-A\SCH"W"P[OD"%?K,ZDFMZ3Y,CXX8VRX.7[04LD4IKW@S7>65
M:.=_LXP<#IN$;KG SV#63L\<"HW5C/W3%Z+7:1-(\K\5^(@(ZFD%@PH2:TSC
M99>TV$J_M)"%"+Z&MOJ>FHNQ\XZ.$M5B"?;") (>$0E_C)GP$MP1_!8N+)PW
M4@^"7S+(^E-.PR)F._K.Q!&T/D$P\'\6@]]36!^C7.^@& 0+UKX%HRU)L'!1
MBGX2RZL8UDVY[67Q&'@]SU[IJK=9K#1Q6H:X &=2OL 5_S_6QKQZ>5(S8!N%
M?H^:'1 SFK[HCYX =WC$@@EVPE?<"ETLY2[6 =.F'=]8/HROK7Z<169M@(VX
MSFS=1 $IYYXRHY YM%^6:.BJ]*%/6%?IA2GAI8X,2^A)K9/*-,Y_N.SA@ZBX
M$QCY"4R#83HN_PKAT6)#(J7&E RG7*)>&*!K4&%$S)M=2OJJEM0#U:,NE>.\
M4E#Y:2N("S,[*'+,@P4/QY8(\"8Q.K>;1K )X?549&.%! -@*+,=OV=";LBA
MGB33\/#SKGMC8VGW4MPY?B^7Y_R:=JPOE_^]$05S$NSANKZ#')@A!RTV]1^>
MJ_=F<I]S<&JJG<?XUFWL+F5FR>LQ+7-^G3N6 7C. (Q7M *_Q[<J<*UFL9'"
M\VB91:=LP,/9WAX!'I*.?FT7;K.$"MY[R7+TEOT-F@+M/<:9O7]" Z>2/BMG
MYR J5I%E<MW<^:-TC])C\*>S+U5S<GC4CF5X1E%_TJHQ+Y[22NH-O]@XIRF/
M)N ;SAK(B=<[NJ9_SL/63-U/MCUF87&\+F/[S2&8"34.R%*%5&Y:AE(=I]?4
MVF[?DP63)UNC-W5N/K5XH"?R25_HJ:]DW/#CFLPKVVM5% :@FP$(VU79/R<M
M'3XZ5C6SZ-$^ ?R8)D7-0J72/AYG (9B82C8GQD4DJH(#:=J%,.;91B 4Y"]
MALF41O!>_!]J:8&P;W"AJM.WJS);D#O,>#+Z@QFB7V,./9&3FX+!ZL3\5F/7
M(#@?V4&/I-50\5DLVFIHML[@4\PY4_$/N7&*,EFA23U+!1H:] \8G"N8MH#9
M'=5?C*=J>],+& "Z+0- ZX":T >@%7'Q%+=@7N+(6J^FQJR.X[G"/'MXF<VS
MM(N^H3JO[:\G'WO-9?&02P5AP "$/R;?8 #NI/^<(9N,,P"DHH,9.IMA83"8
M[$2L:_E++VE,[V^!B0P)EOBXFO"=N\ A6R3V@4\PEJ<0_/&U:JD%Y+AA4=1A
M:1#\W@RQ?9A@K>CUL:QDIXH"2]6^RP3G:T#*0W]6LSKB?KC[1F7(Z2T3M.H$
M*,IRM/FE'GN]JWAGRWEO7K5UJ#IL ,@JC .V"<^P]!?IEZRHNS740>UNYSW9
MGHMT=+R[9>'W)BG4,X,#%_*5HLG$>A9*S.@>#(RX37Z3YQ_=IBTW1!WP*.S0
M]&:?E[73/'#\H,Y;YWX;P\:-\@?^9':T49I6"WKNVL_SW%*?(DTP%RK#O"H*
MCG8-^?F>!3CK:"K$57ULQ\R%HJH^D,_O,W( A\ E^I)R"VKTJ/W.=/C\-LB!
MSK4,_AHL0;R7*9Z<.'3GQYN/>XYOC@ _(1,P'@KDR\= K#D-1-:6U4\;]1[B
M ILHY1;]W%!UA6?IK/EW5KS\D1:T!I!S=/QX!^[NOK5D-&OD[F?0CYU\ + B
M,;?^)_S[:T+5PET2- YTDAJ"9W(UJ@&*I!^KR0P=/*5N4V5<J9X%M,_R\J<Z
M S(Z+B3<ZI+6[_5,U+ME413RK#[)-W;W8-5CE?IKW!"WU)SADYSZ-SPCM[1+
M:1$,P*,I#\*S!D>2Q.S=ZVTX@BKV256CK+MRS:FIAHK^1)O$Q=0E-8V(U8^>
MN==*/ ONW.>ST .P?.$[^ JDGGO\.-94FTM:/+:H>/8%@/4FZY_5=:8;IQ,B
MJ$J0IBF)#O@?##&>R0D-->%,&WI. :?.=P\L]O[Y_&N2-A S9E29XZS@PQNQ
M=]_7K/[SDKTX Y  -V>VS0J^PP)]SP 0[X$.-)',5MK,T,2S,.Z:N@R .#V?
M ;!G>LC2"0SO/Q7LG)B7!L'Q-$E+$/G^+ISB0DEX@.H3Q;:JR]&3_45*-DOG
MJC[IS0OD%%H>B1##9>E"2/;AP2;X$*@^O_<?D=N_7$U]GL]?C CDFXZYP7']
M@_YM&9+Y3S@?_0*LE0% *8U-WWAK.KK+SBN/*+29GM) S>>^ RH* F\<*^K,
M_XI]&^>9_M$1Y&C^C(D*%'HVU8N&7STITH5"Z_JW*?%Y& _N/_QX9(O"F_UI
M=3+\6Q^^9XK+P&2JL"%M0:;Z:<*3&]N94;45A<<-!"9/+NE#F;$HFTR;!;ZW
MYR.IO@G6A:L4!*M_MW5!0Q0]DMWF9+^=!E\T_>CVZR50!, W"ZV*H)[UTR4?
M$%'U[+A8=LLA61]!AZ0']:,IE^>N"$<\S#&8\PQ=R2V7"&N_T7G(33_E0-%<
MA;+#1%RSKI-$<M-"&( H*J)\O)>M,\4S7$;BRKQQ1>(1.I_Y-)*S+["4"D(:
M!S, [#MJTK5>Q<9_-D>G,'B,L(\& W .WJ1"Y_+'SEJ,Q2K[*_>D8['+"ILO
MX)6>KCX2Y<^X5#;9DS(DD'=?S=8B(F?*^9MF1*B@X4IA#X __&9MD*^-"=AP
M:!95$WH_W^'@/8L*EZ+ AZ"Q!=7UB_G!!K1D^//<40\?3K!9:(<%?8Q(6\C3
MK+CE[;%P@C>TE38BKFK:V?'5''K7GQGKV$CX*7-\R#HZ//A"R3AY8N-W,R?I
MW9\)@Y[05?&: )5%L;.V.">^GCY!O-:($[9H"-P!EA&Q'\SP5+3@JY^Q9P 6
M%[T7XLF7]F-1H*/TT6F1P?7YQRZET;'RAWP>*;I;4\.$$7MEL4.G48Q3\&,"
MI_!/;<'A8)U9SMLB,GI#^.N34[]>EA?0G^X O P!7JY;'?134,J-%?HE<@:&
M;]?8T(VJD2TYL+S=>Y+BB"V,C7+:E);1MODVFU.@UL6D55]@@V-,I]:6!A/'
MC.J<J7+XST>G](6#T7Y_>BH<"F)$7ONZ+0Z)*!<994J_HF,Q70%TN%+<"YD8
M";/24O;E!0:@5!NLDTXKP#SO%X9AX3PE]9RX$$4*G=?;I\+D]WJXT["D8.LV
MX<V;%+9[PX*21).0?0HGO6T/_N.O0,Z(<NI;4])&*8\-MB @;E#V[9Y_Y(KB
MD6<$3Y8?4=0=6A+<#<0.ZZ[E[)X(O@3E(7_;^5Y'XIA8"M=C4HL<< 4HY2W@
M@\"&A"3Q2X@)L9_.-L(TF#.SJF%49LIC*Z: *!X/JH9@S"Z>XD^?.Q@L"=H+
M^>C>OD:04%N1,;H:(Y1O.&VV.H59F0G]H6CQV,Q^H@[K. "'$GV<EBS.FMY:
M_9?E<L_)3[0F6O4I11T[';LE1<M4H$M8VMS;_HVQ \2RN5R,3$]*NKK1Y>R:
M>([_>Q:LWJ,O23_YR)E$X-XDD;\9B-4@2+5Y"#U<K1U<39JR6I;208<_^8[J
M%$.G*_F+VEX[$K._/+.+W/M 6J3* %]#>>K-@$]K[2/\-*74:)L?FZ^1F8AJ
MK =$U <=!7+2>_@#J<5,6'#:-95?>L[KR7M9=@8@OD-AT=QHHWXALT9B?UO#
M9D/WP8\< 0Q*H2X9NGL=CM^%'L.^IUXA'9DD%M,0#EUK(,)6_:;]8*,TO.D>
M78&L& +^&9C:@GP#$Z[E[[M469+T/$ L\<W'@)@E%<[7N8\S4I_<!-G"L(@*
M+@3E#O7"<#H8%3<TRQ4M.*RI57I3LZ[ W>&@];;I]O%@M_:7IRQ7LIFDCGP)
ML6X2PL2OIU-Z6M$FW@0X6W>54,8@ U!2$Q/ZJ/HQ;8&MNZ-.KZ/!16\P/;EA
MR:IL&ORK/S]'/(]P-FD08K*[LU6[NJ6^B07A^ML4XJ8Y!^KY<<"SR]H<Q(;Y
M=DUP@:VMB<A<RNN"K4>GA(^>E']X_=MZ4>ZZG+UR(;Q)&^[@<8)\\X_K?FU(
M\J0O]NG8K@)_0T.GI,,OZ6</;_6#5O86T<^WP5%9P!&0.Q++ +0A3M3;S-*,
M6V8XJ<)/Y"4&E&I&I1I]'AJ^N"IM6S\^V8TUO0J0M:Z+CT=\9^*+4LI5ZAD2
M?ZPR_*1PW93V+]VA\/S2Z7/U#9?O7'MG96%;@4NH?*UZ^JK: D:.^\5HXEA?
M:>JW"87A*?GG13%^<5F&&\SL@OD=33]U9+;!<KL9<Y9Z6;DN,ZAI6GATD//$
M AX]*[5]ZV30%=YVBCZ@1F)3:-OC])+V5=HW#"X??EH)R.&:*GI^X-64B)(<
MU+Z<:03%6EK'+OFOSV2;R.81.'_QS:FI(1V87@_RMP2RTCOWZ1(UXM=*72%^
M?1*>[Q_?>0<#M%V@/N<F2](SIF4'Z->H5G7OHF<$_:N\$K_/-;_K:=J9>=E"
M9['[$49B1TS?_Y:^[:8GS<R M:M%-R[(F";%Q9G_V#+LM@[T*E:NBM GZ?^$
MGP3A/C,!A*85"8C??/?X.\EQJB10*V,L=8P?[/-R_2/'Q830 NFG+]_XG23]
M<5B$CF_BP&O;))T6$M6 E@M3\G=J9\:G>H/0O46384W7X]G+G9.Y=\4S)4]?
MUBR[+35Y4F7N$$D]%]6^X/%&]$3=U1Z5!-=9_[ZE>+4CI?-LX'P2( 3<$ @)
M@^/2$3]28S2OY[G6@EN6-G?ZC$8UZEP+@G4*?Q@+%S@^TNU_Z<KFEZHY7XJ0
MWK($S_LR "PN$YH?K.U4J+OH7Z-4\$=W^<;S] X&H,JIN6=S?+NC%M: ZQ>V
M[\CU?]MB;=D@6LA9[>(0::Q8Q[0&NP;VQ*8$(O9A%,T-V0\- [%B'!IT]O*9
M*8@5'UY:Y%_7[%Z;.RU>/N*^./CB4EAR:'U\H)]Z%\KWX(7J4]'8^-]% \IK
M8NBI_+D]2F8GO"T)5642P !DEMP*"3B'</+TT7B/"U5)T=,Z6M %^H!D0A_6
MO0JR*7&&H-".B 2>H3YH!([46P1AP+&5JW7?G'.SK/(6!#(N=[U[E#"(T6<
MW/K? XDE# "3N$5.S/;,37(*V6CXL2;(M8O=UFHQXL9#F9FV2?GOSN41ULBU
M5'QL4#N46_/:K(FK374MAF)?DXVUO_O]H/2\D>B=)_PO'K_^I>VP:F6*014J
M[SU)_06V6'7<A];XN*U]9=W+@U./V\$4-LNG_=_2V6HH*LX3MON^,*6&,7>)
MVUT.^4M^A4JY<+;/V;%'0.M717=Q3$+2'TZUH]C#QO@Q*-:8'4.J'$[DQ'@V
M<;YAO]O1(C:9+?'$SLVMSD'NU"! +HZPR<FZYTT&X^UN*51"PT4Y!S8=;ABG
M<W-/W!)'W.\2$"\)#AS:W 6_@?.LO7KG.R*OJ5&@XUS^LMVRZH.8K=^D[MV%
M@G:+T1]1OFN9Z%UJ]#NMRN1SZX)*""9TE:?U][J!.K3_E@;>4;U(\AA2_&QC
M,@[^EBY<1P%%4"_Z(;'+@\\%I,XH=N*V<A3$A#$!Y5:^2=9 %/@G?-SF)XAM
M4].-*#.K'Q%\G23<XB9"SQ2-(#@VI)&2A_D>!$4"_<V,/I$ZYW@A&%PZ_ =P
M[8"B#^O/MR!YO!N"DK(R"\&NA:"]AO6Z[*1:X%2;^F6S=P#?+8L&3C],I=/:
M)N4LO7<?=G[(A\D,:\L:9H$\MJ6HB BJ1LG,)+2K>OVTP/0!X/:?F]Z)?:^Y
MN)0R50UO?Q3)RTN;0C]#I-.KQ/GXK(QRDT?1X*<I*3O;D[M3QGN#-40X]<SB
M'?)XL0X'70HS*![.[O75H7KX<\R%JGC<=.P%4ZJT;@#_VE_Y6])OF*J_O$(T
ML%)G!:9!0L8XV!E83T'[7Z2\5.N]>2 ;6_^5U?VV>/+]''<3;K+T6$N# AZQ
MYDHDM,#.#,P/4*5RR%''A.!IVR&?A:;GPOR>/9/R%C46!5O3V(G:-;FNTZR_
M42'G%DY5:A2?=)>3"GL3\]/AN(%VNJ>UMJ$1ZFGC2&HBLQG"&[42%_O97KFH
MUKM3)WPI&$N8,GT" ? !O6, !*G'*=ID5ZN&.K+3K(DU]N& 4EW7W4$7-/_I
M=*LG^IH?666OT^B+GAY,W\65-4J#3]"[:J'OE':Q4N^5H[749?P//ST^87N$
MON/)3>8+$,&TFLCL_9VW6.%O2;A9'?^ F/_FQ=Q#I/B%V<S247V7#SLR>Y$)
M.EPG=25"9;[3&D&SZ[ I8(5?<ZNV6T->]ZKJ]UUSX7N"/T"KF1F(_1&'DQ3K
M!U? @4D-#$!M&K,SZW]0A?5SA2/%9C)&+QF KC0FAKGD@KA'3L+KMX*XZ)V'
M"BW(=VE925_(M6.Z%8,.(SX!\Y%RID\LTAXXYR34#X5/>#:YC>.<FC3/,-_0
M%"T]F!4O[$,N+;3V1[:?N9+^8!0%/=WWK/2EWG(PRC#GX)9D**Y\!:R<S(S6
M/*2(*&U)V,#,*;A3B$:;JB@'$1TM;I-I3Q\%RVTDSR=>.W5#4"#L]6W?"J,:
MUJ-US! 2:D?OF>'0O.A71,XW:!A66E<Y45T_@NKSG>4I+^C1.. ^S?V3+9@^
M\*"UN\NP(41UYXY7D/9==;?*)'39=-F,YRS\^[LT</,FEC(+;E$(FY9):H6>
M AJ%W%8C--CT/+YJXU C:8Z*4D*>(W4!3DC&C#JM=U&T_%D[@.C]9@76Y< +
M\9:DL(X]9+04Q:T%-8_Y=.+J4W%973<UVA];=]'02A NP1[XNUZ75$'(CZN_
MD2>?@&]-U +IH^PZ.JO2 IX^W&K->!<N.Y=D-].\ ^3'X,J@O#[[6,_'.*V3
M#VU 4'F'\YX\6OO&/H>C";$KCS\V7N27"EE+\H4U;NY$9I1RZ%::Y*9-;";;
MP>=FXCI"*&94+2+_FAOE5+#%$$QDR:$E#8;D13N?VP@*3PS*$:E0.<C$TJ"/
M/+=V5NU=*!=@38&J[1YOM%E)W!V7RW8INH.#("Y_,^'QM;7*.I6#UM;;*WV:
M<Y^MHAVX<H"76;XQG_@/>Y-9)%NP!-G&Y9HQ1LB_=OJ<[LK -PG-0-;J&#K?
M_KW4;]BE0[>\L%QCSKR2*\>N??EYQX+M"_=-0$'^IEZ>X0K6U#XA?G'3RA>B
M^V!@Z-TK2S<& /MKQJ_.;P'F!INPYQ_4-&$&X![HT5?L!FM4T-< 2.FWML2$
MB4C^4UTW6BV]O+Q@+[)0$_3I&3Y-1Y(^ 1(*=V0 (H0JT_@6(W/X[25&2J-/
MB55H1,:+A?+WQ.G['',7YE=[QII%UD#$((@0A4B8I%KU4#UGG@K"3<KT;%$"
MEN]P(P@YFH3O_;V,(5IYO(]&UC9Y!^")::H9G@N("NOSEP(1<I>6::,[2J;V
MHTH.6@\.5C1VI[MH/22= EI&4;4S[NOQN9VZ V_0YZ4Q!-&@_S4G<<_M--9@
M1()TI.I:QZR+LN'$G$F<Y#5W'M% 9&I,H$\9DS3A<? 8('LCVQ19=78/(5?Z
M*[Y 25UR"-KD._@PV:RX]@J0K;3^\@N>O)L"+**Q%'/8H#7W6@4QWHQ45G$^
M,*S7\=%0);SRO>2PO,!K"3WI/P#'SZ$9TDEO!VN1H73UD4:I8!EB?[0RADOU
M'4KD69^'C5Y0CM=H)[5=L-<EY;+%^XFK]S0L;IM0]*H&M+LV2A<;I[0,/IK=
M!X=8;XY34:LC+L/KKEL0.MLM LW<DM;0R+^L#@SS 0+!N!X;N[O^'H;Z0=$U
M]01O<<Z$SI\"L^\3>7!'77>+_DZM92(^<OT,T7PS#LKS,&#4'F@<JSVAT\DA
M:6S0>=AQ#)/I=&P^,M_)2=0%CI.AG_)^KG1IHF$=V(#<TH"2_?>9^.N0>9?W
MP/VI?09 QK6:+$%Q"[8AEY)T;A.K4!1Y_[J?M?>^2I3VO_<)V$B<Z#NGXM6W
M\+ ]-[/NIKSB0S:*:-2@G)1OV=VDYUU_J%-,P^UT%4J-5&( WLYPO#*PWK8D
M<:$O]EH6P4<-WHB%@4?*;+:0D+_+:Z'4JR2_"'<%[2LF)?ZKL_+YYV@Z;6;/
MO7^2[C[@L+D=(VXPE"TA 0"(J(G*D BS\LFE\":H]ED7H=+A*]_\O4:%E<^H
MG4Q-TM$LWR5X!KC]W&>'9L-YZD.^4N6(]RIF,:=G.KXMI9E4V$Y.&GB&F>[?
MW&C%WXXS%.,R<>!ZB,\T#"DTG.FRDO$=D,&&<#KUKK9G!.JIV+MO0K,ZFA!$
MXREO>[+;W[G8/T7,(4D/!S6!P=LN8'EP2K9OE EF"M(+KGPI4+[Q7('E#2F?
MSGY\MN]A/.@>.21;V/F\5_'ER LRN]OR^0Q X_._>CF&(YKFA517VA>J#LOR
M7I;BB*/KQ=0O89(I5I]$5_)&KX8\\3"*H)^2<I&*4XZ/F^&7__@YV&16@N/%
MU(,3B?@.^ETFI N.FD: M&Y8D+_>V]IU389Q$T/N2GMMC3R@"]X;V+FW187L
M>BF<@[<Q:7MHJ[\WF+5_B YT?N)B7E02RO\1B/SLQTW;MMU<CR"5@2:,]_)
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M:W$7$]K>/(9%1("(#Y$"$Q4G2ZF.^/C*.YDLW\-/2*W6CD)'F3=HDH9=\&]
M<4=#V93786!^YRR68;,AHU&1GM=93TD" Y%2/=H&CK:9-8^XKEE@7A07*X2!
MB*;@\;'9B]3E_&6T+UK(;7XNAD_BSC;?Y_A'YS81CV\GQC[G-%K^EK3UT9X!
MT C^8 ARLE-VD5&IGR6@BZCCRR"BF4><$/(M76@9RJ[)7[LX"VQ-CU]S%?87
M/JW[8DYRT(GLY\X;ZAF[-O/3=;R1E=XW?9X,HF@L8]CN@)X/W<N\6%8LJ:@I
M%R3;K=N;_CO"K"W]&,\#-T ,VX''GN+ )LA58<*\'5XY\]YM7A0X-)]TBZB;
MV<P %(<=@61P^$STJO7W*^60=6%O'NAI5I8JE^RZ]JQU;/C!/#H+C7;Y)0:%
M%.R1._;&O3AM=NH)HM3:-CXHGHNJ_1O2<JC5-F3?XRZ?7ZUP7;K0:UL#/:4K
M\$MMV8YVUMS+:Z1<,J7C$VP0>N25QP0$MU&'DW,/D,5C+!*G#_DF]] GL=D?
M.6)_7IWW4LR-B5EH//4;I@ ;GB&"[:1G6AHUB4;!%F1(;GZR2YE+3.]>51'
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M\"%2<V;:H=FM>1^^79B_6) %21C[6RZ&")?], 6)05-8HNURUJ-X_[PT1($
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M67U^]Q7GV '74W[?QP&,?/R'1W=LKZ3H-W/JJ*)0P4Y(#8I*#MW4!K(%&9]
MRF<;3-< .&7* AI@KG+,#(8.^5>.P.3SY7=#="D0;)?V%#"J%;!T)LS!AS^7
M(0JF'M(O^=$0D %D#_?N7CCD7L%#UT"ZB334#<?O6#,6((YD?BXRHMH2]H"M
M%V"@A#:0_!G-D"4\;X%EX>APE@$+2_510C?A'> PM;+PNZ7=["FP(Z9=_4-
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MO?L%KV#6Q$3^NR*>B"O3%NNS/FTL@'.0^1:F>9C*)M$P$4X$(8D#N!P<DYO
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MR/:"!?R\TXXD:4A!XF4G$K%K*["Y-$3682M<(;& %1KS.]W^3]=AJ=>%^5C
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MPN5@??+!#1FGY$RG,25&8!R6"3-_6S!LNS5PPD*;\0BY&J<=8P1I\8(51BQ
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M'T3'^;XU4%OY?O]3D*P!QH>!8GXKL1E;N#+649%=\/*A=,VQ".4NO)AU?&R
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M<YTZ0\J<92\UNT'&1-LJA_K\%JDK^&9VZ^#65!(OY1I5@G^L-/FZ%OIN/@O
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M="X=T=?4)HOM4"ZF"A#MB^+\VZVW_ *20>Z-!1GD>.T;8K);:SY^%.N0><W
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M:[5Z1;T70Z&?A6$:HX*4LYJ8FKPTB_N,T7Z^:_7U"X;$KD.6O3U$2#789B9
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M? Q_#L@:ZC5/,'P>3.PWF\I<]_<O9*TN<:ZX;._WG.,/1;O\]%&/9T=OHYO
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M\=*EO,A.C^F_P,LK]"9'H0O6>M==#\T4L.;MPIU]S@8VTF%MM3^%0X_CM3;
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MXG*L+ NL/>NXK[MD#D,8E&J6Q[+M""C&CLX,1%\_2+HVY=R/.)=>LM!;B\1
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M;E63+N()0F33/(0O.G5WMN)WVNB%T^T.?8SJ*U;M"VU.[O>U$34Y(M![F &
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M5O@R/!#;HVWQ>$1?:6-HZ\)C9[UC'SL#7H9*(A'-<X]@%,OX\VT("8(/[!G
MPY #\A='G^L\&% ?\7]H\7Y,/:GZL6WGBW.'/-_^%7?$1&;O4 [0Q$G)3R.
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M "4_']M<HU^/*BTH^&!](ZS@'&03'PM,%"&X.:5/+%#F^T9/Z9VWB_20>FC
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M2H4^?_1Z144CWD D9OBGA.+]Q(+WD *] ?K;S)PLTY+Y*2V&"QQ4Y!A'W=H
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M9I^5RXMNGWR3G@]7$MD0OUF!,#6;^_E)/ GI/[V+O7L#ZYD#3-)&0\;B<)O
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M@MT^0A%N<0^JGQP@!K_(X7W#U>UR+9=G(VDPA[R05+;C8L%XG7NTP-_3T.<
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M4^@UE37^0<BU/FT\$U]6XV^X +1"+J8 ,+>C0#O*"N\OE"4;=T]Q'#S)BV,
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M36-!Y1"R/.LG1Z*[&#JF&X&+ \6,3PGSOG<Y0616"JL5!;KRKR<!2P&_]FX
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M*D@HW;-SB61J"DOMG^4 M9J@"P<H\62R-Y22.>=;Q,%"40&*SA/Z\Q\<?U(
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M@[=29P]M#+G\W-7?#=?Y=Y\L^4[5+:Z=(#PD&T.=@Z'@AN+& -8+_>JSB_G
M](&_\<$=Q*9/%>,J3 D-%?:NC2\5(9V1:Z*!3ER8HW,F%_8J_U\^;>^,2>+1
M]@J3OJ[#WNK:KYO_R0;$+63#^]?[CRK8%7\M3SWANVSAH <Y3>79_O_1G93N
M@]/THEI\T6*MO7D#23&A'_5^DR,QE >3\XRZ/TKP>"L VZ1X'[/4?8D+>_@$
MVT61U#'U\J15G(N_\%"J2R&%6K7-K?^0B._QXMBF>$[7:WZWKM235N[Z;R8L
M7KC*3?:P(UZ3Y1$[@&H+D@(+2>^!:JKN-V]RWKREN) _N)^X-.-]Q& M66-[
ME&C.F8C&PCDLBYV'T'&#\P#.7SW'4(]$+_0NN(\7)W^B*+5@U.\:BWL<T#IS
MVO#XL=H2>YOC&4_3<J:]OND=+LQ3W)INW^'YAN2M>6H\@I5&A."2??O&J:@P
M<>8Y&DM:.W%&*4C.M2\^LW+/7L<C2^'R07/;]"RW["Q4E+G"%&4)H1@OP&[F
M63"XGD)[X5;J/Q6BGF*!O!ET2LFOOB>:^>%S3?9C[R./WV>P1\ZY93W.3M?\
M86I-;E['.I1[N*PD8^=)W<1QS]D6^QAMQDUP@'D%C&2$TTH3QN>UZSM]10*F
MS3:^;,JC[^*Q7^"3];VQWNV[JOV&M?W[IQ.PSIPV/,T<&0$7(]_ [_#=8?,Y
M4!:3/I/4-62L^SBUR^[PVSO'#K?=:=Y]T<M\A!3%)D->Y"G,:4Z#T=K+J+K(
M<ST>*[K&;]\8N^USBK[X1T>"0,L^WL.GXG_DODV.4ME+R,J?L\$,6?9[I(HP
MX>:FZ*12/,T2"(,J%TR&J[0@S?(-F1Y@EGQ7F81[,]R&<?7(?W0(YA-W^?Q#
M2H!;E%!:PH0(5,BC!UVHBC&(CO&.'\2HO [JHL -U>FE;4T=TG:W#3*BJ#%4
M"D\8U4W+)6OF;-W9Q%ES1D@$%<'#<N@B:0<>HBW&W+M^XTA) '!LZ%-U,I]P
MA*& ;G/Y^RF2V@AI%[L .9H]2 D-] H:104G>B<)#9CT62-DRD+GE94_NF<J
M7VOO$OXP7$V4I-[:=#/H*9M02*P:^CQ@$9PU[[F SRRV'K\'T"ZJ#-:.%F0Z
M!M'Y+U3@32H\O]J >;6_&1OV7"$^I=?S*?(67-H9%8Q^0RF"S\M2*8/!U&AB
MI+I<P*%.3EOV]-T3KD<*8%M>R4H\?;B]E.>TY&]/--*D;^$0T][?G23_D)??
ME3+4NE*N-+8XE,39+NK.5'?C&UWD<V64K\9,A+ND$O@TD^^Y-Z]%9*A]JGWR
MW&ZS6-KO2-$6YEW.%\-TG(1J;SK-[\!5WT#9;=V:0O<1G]TY"[X=S_'^[0G[
M+'''.WV<$PZ?2YGT)S7.[Q*F9\W),@%])LK.WA=5;Q-4$#F>9["KU;GE5FG/
M_BT\-WK##\[&)C1]6GLPPT.9KV=Z0^GO?1K>Y?5WQA[,B$[/*[5JEUL3M@.U
M<5NZ'^^/,=A_42#UK<_..[EFJ8>R-?*&6@_U1%\J4WQ-^;1>$\&ZAF/,L-\1
MBLMT;KM+9X_L/N.,>18H*^'J=G\T^/:$4+$TW_+=1?0-3BV<=M'(<_#.C">?
M;VY-_QGZQ)YB^H[C-?VFX5AZE*J\E+X\W\E]5WSW^_C:A&M5$>TO)"J(&J7/
M?F8>CP"Y,,YV(<@O6AC&)30=DD"WNK)>26.E+7X^SR^3;W+;^;FE;[A]RQ(G
M.TYWD<Z#!"YLJQN=4TA;K.ESV"/N'#PV_=)UY:M95V-K!)].OT"UIW#U$R!O
M6VM;1=+'AEU739[FZJ?ISJ]QQ %KS52#;E>C7/*XXXI+H_31]S3^ARN+0F[:
MI.KT+QW "52E8\3Q.5Z2"!E>0@ /H>;EZ<&-NUQH\[N?.A]UOP??_?WVC#6/
M:GSB<3VEBJTSS7MOI[[. I\S UGW*MAI][[*UC-&Q'ON4:2GB8R6;*,LHUW+
M-B%+XJ:3S;&;;5M_6_5=.UW=%DAEGN!T8N78SP*#M"(KE1TSW<2?EII=$BL)
MNYXH(/%>54;_@-3 :8IDFE)IB$3B'2^-TI'<5=;-DB_C^6%FCRS4W6>G,\GF
M#$^&.'VJGA"&W[;HA8PZ=6\='?:Z9Z*$&+)\WOT4=?32^/Z)L,<312>V'!2S
M63]<J3+*A<W+\Y0P%;^3Q4@R1E=?ZRFDRC->WW3T>J#9_%U$W=E9OC1[QX>X
MM@=]9"3V %!MQE$+M*'?_8[G92'4M?WDKCIN?9.L86SEM6_M^?GR.R<'"U,K
M66U]A3DFEDK-+QR=B[T';%&?^Q(,&AZYG;37M5SM1_>PO5^3I2N1D,D.L].Q
MV\#7@RUC!8\&BX]?NZR^N.<[>4 TY$CLL^>R4?QYY\8CV 8@G)Y7BRSFK4U5
M:\ *E[D6SWZT,I#_F-QW-9K6_/(%%+ID'O)M$0^G3FU;7JB,?.S;;)>"5*MZ
M3=; (H%J8\1^%IS]IF1QT]ET\ )H:]0K4Q(PU**=56;K?6E07]YC<^*F%#&3
MVF"[I'H*>-"GD1*19/,FDZ9?O=X0/RIURMJ48.OK5[+ONL5DFJOTR?UACKP>
MQ]/SQ,.ZGE+%(UV5UI6UF,T)EQKN!']UG5D96N 48//ZE>A&8U:1-(#**!M7
MV5/9E#XM\FUL?([^7$YV_YG<5?FPW^1V^\G<1;^@%.)8>U<;I(^ ":] T3'\
M%R_;(#?JS7R-V0"OTC2ET!-1Y\.VW'P[9#UI*?/B101E8_P%MIMSB*;<">I=
MO9K>1B4+W5"U=["WJU5R.$=Q?7)-4_#1;ZM*O?SF\Z&V_&8I459+7^YAS'/:
M%(O=@7-S_JMS&*:G&Z6$T, O<;DQ_2R5"^/[OG[OSA>;(K^DXVI&Q4UJ/]H[
M:PY^;)K\H,'0 '2YL"+%>?LQRH"175\)FL]U\&CZ[3Q;^;>S^:?5LW/S/PAO
MY ]$1O^B5@U.V!Z<I0*/ @T!R6,4MW7C?!9]Z-"E1,.KUE?NQYV9C#ENV'C7
M_L2+4UE;#RJ+X+6\[UR=/=ENFM([4R5HM'PJ%ZH]EC__MYICI/-HY>Q= 6;G
MCW6K7>C.ZTJ!O,YF2,*/@A<Z96XJ:FF5?CEDV5>O(Y2&_VMJXPLPEFHZ3@A-
M.T@;.$P>$K?OPY>%_+Y\[7J3-%X#&P14P[&*7WRMS](;JY%[RK]S-+I6<@B.
MW0LF30KVX7L_O5RY,2+]^]1._M]OKYNBE;#= ,V$$HHO]HD0;5!UF$'PT,?<
M/>?G=]U7.W5?X%L4^YO=SN/OM6 B,CLO2&29F9V?.=\QL9"\MCB<@UW:KCQ0
M_S6H#_!GXK()A/SBEI.+*D</%!<3HS.3_8;E;K^.*E*3AL$$#0FA"&%.-V4/
MV0T]9&O:31('PP98VVB/#B>7]'AK+KW).S$",[P>]>FU_@D),>R"8.W6QTZ-
M4"]80E>)/#_-A0D!KIYPW]6:CR&GU'0ZE?:<WJ=FUU[IR'S^XP"I#4310FO@
MO[%$7:GH+=\3UT4BW9>W7=U27/ [CZ'D9&H[S^5PG=T?K9Z</SX57U7J$$3)
M<O<:;C?^\$&>M-C2TD\>#MQ/0YF_IU%8PLPQ-C'LNJT]RJHK,']_@0E%>]4[
M;@M.US!"4U8J-F_1,P(NI*-+"_CHWQC),L_6?_,]V6Z73K?![\JX\C!D^!>J
MI;[<$Z4&LAOYBTLULD1C)*7  >TF+40G/7UP1,<P_9W00:LCD0?PI-RZ=]56
MO.DP X1RQL8;*]?I5H6.R 9D3)HZ6)3QQ4"NM(L@G[BM>N%MEYU)M<'HFI.$
ME)B5Z;=[5_5=A#%K]A7K,ZY'+:TL?<Q\B*EQF.ZSHAP^=/K,R-%>A'H@EKZ3
M_RIO5,EE1(-<NTYQG*&SDV[GY:YC^K[/O+.YL-&GFFUTH08*'*%J)ZN>=H"^
MJ;0TMK$UV\$HU(ZM\ CXJ!=430@\5H3D74'!?"&2PYTT8S7CLYI<W:2UM_HF
M:WB%'5\8JO#6VAG;5*#".,M.=@><^(.]1[82^P#J@>>>BE4?>A&-##3"4,QQ
M-8 B86J*I;</T[M*<4><URS3Q0XV+EJS1,=:I]H..M@TFW]+:M+&JO0;X76!
MZJLL=TT<4^,[1ZBHA>*;YT LV4,8\1W;=:B17;P'UU"& P^%UMKB8)#.="H%
MJ*FG-#6Q^ZJZW N::5M<W>6T4V:5%,?T@@28YS>.<J!UP440(K[ON;!Z\H"_
M_H-%[/ ]U3=K&^<[GCHDMB^P=ZEZ3RZ[8=%>?UZ7KD3E?1PHZTF%1]E$:2;#
MHUJF;PT.V]A=("HO37@\EF@^?'F;MU+PPVT-^FJ1]^2%Z>==AUB:IES8QQ(F
M8[%S7W9?%+Y63 .@HY^S$LBMLQS>V4&M<-(N4-:"]J/0Z+7=C;[H&Y_'W1KV
M7Q25BAAWE0H[ *4<1=:Y+L -!1YVJ2%L_VXMX$:2!K%=;;H]<CKN/H(E=9FH
M,\)C#W5P8U;K_:YOH%T?<J:]Z"^WBF>> :?.@K;:.DD.(L4)KY9E9:?X#[?N
M/REE&)QELXP#%>"U^-VS\!)B TH"5#,6P6[^?,U]QQ].SO=B'2QWR'C+%:E[
M,[],(4D=_G-1"78V>25E6=_G,REY[Q>87N.W[[TKB.MC%9+C@W3F2 Y.A"%*
M-4>,KL+::SN:GU0W9'Z;MGRYRQSUU/BN?"5J?^+DF;78]^_'#&7D0B2/=0C_
M\,B'G+>=G: N=731K(<$/YTUS8A57Q6U1LCVI$>(]3BE/OMZ!;9)+GD%-8AA
M7*(AYVU'GP7JCDL$A$T4/^FXFOOE>&;OTT=7(]0V;W\'._Y.9E3ZE<':'3@H
M?[1P;"NQL]*'><YWJI[#0W12];T=%?LZEUW/8QN>+C:><79(N,U8 S4PV#Y/
M::J8[4<U?IK).>J:F]359-N-,@;XU;+9P2PX4\,WKWY$GIY5K1)2OACZYK-\
MD(POSJ+B0X#M5]8'XN6CD\.:N:I'(CX:5/$=^ !_>!JK#E3;( Z!.??+N@/Y
MWVBF8/9/Z!U_ZUW'GZ.EOTRH0DBP-&B4&N36Z30A6DP\3^3+Z<XU;\:[WQX,
M%PFUJ$G&M1K*Q1G[=LRE,F5P REU<(&5V0YA+JP&G>_;;R;^N*V?X?.%]43:
M^@MOBL)<<>O=V*&( ?6\0YYB#8;HBO=KGHJ@F(:_F>'E9J,%$RY,-XX+NW^9
M32;) #6E["<(!;?(_3%C4Q?<CV[.X@UJ.2(9\& _\K$?;B[E)KX(8 F=ZZ^[
MNTFX!RM%HJN'BBG+Y<F]XVCK)!"LV45()R9AL)_JCG]XE0ZP]O=USIBZB8K^
M9L)T3365/!(0^(41W2YQ$GGOM@T7)HETB:>C&1XD4#\=#.8(:-M&2MAK: @X
M,0A'M]D<MVY>%M).U"4'1'^=332-3[=7B; RZNI8 1YTO0C*E&"I5F")1DOH
M\.4DEB"J5M67EX'HJ;R:K5F=/T,L?UNDA5;8NF<I:%/(63!Y8Q#&V6DS,+*:
M(H(XB-:'D@"_J.\;L^L>F;(\YAUOF$EPFOAZ!Q7Y,4B)BI]CI@<>3!R=&;1/
M>S)HW-M5S[A[3^J2L<+GMG=E/B>&;Z>]J=S!<(1$^KFAB^!UWTM29<>1X5[(
MWX9:=.B^APTF'O89RD4U2-^)7[OS_N'NP-BX7-^/!5,'*_7T&7Y^U]CBK![3
M)M> ;5GTNW<U9K$D$Q-.LILO<7ZKXUOL )EV48ERWY\+BRR![V!IT;X](\9-
MEU^OT>K)6+J6$",F[-+:$MU<;:4@<SW>X0'=EK&#_93L3'E4/A4=:$@]J9+>
M.6]S"6_1?[3VZ_!6=L]I08MS+K=XOGZ8H$?\( P2&)MHJ_/P<2FM1AMD1 DJ
M%"YP1/92.IWG206K'OW!_K=TSXL&NPNR>'EECNK,U'+X+CN-^7JX@"7TX'HN
M3*3$HCB-8AQ_*<VIM##NC\/OU]QU8NI-^K;+6VK[\7SP0[^[%1/7MYA'L9SJ
M5+P>0SQ8WHRZ-)WE+MR]5/6UK^";"DL@J2;V.[P('QEH>>H([Z7^C-H?TA?V
MO(3?=TG,W@A(H_%CBG7H0=[QK1^/\^_!?!OL.S>SMTENH>S'T)'?.)N5IOGO
MH]]'0W$2& BU!O5=-V; %*23C3SW'(V?D'"\D\%SS*^M,ET5&>CRH$')A8%D
M/U<&KE.".WVE*1LGK,8X!NFR&[(8R/=^'0HP-N49.)@=N1IS.^V4-2;.*].\
M6-"!-),T2A:YG:ER[>5Z&_%[03=S8+Z71F )RS*">P)51X-D1QL?LEK(TH%G
M8F]&5^5A&=I:M_>A'=7P1X#W<C\(Y7F3N&V<VC8,T]X-^B>G\;OC4J:)>EWJ
MN#G"^]K,AYIZ)5%+G@,BD_##D\_(-M]N62J*H49GOY<',N8QP]/F]\:F^".S
M"$ B>]'Q(T)J0RO8@X&ZM.%30"A4\@B"FGR%M^^^N2%B?<SVR%RN).XH^[<T
MV(B%X-Y;IZP?8+^BWU/JD .11C3>.I10X,U^SE%#EP(YD;P"O1.:1WG3]HG;
MYKP3J_X$"^KL(]^8K4/>A _$4!A%((+#FV('J<C#DOR0L\MH#HU92M/]B%-I
MO3!IGZ0=HC:2>_>%D_C356-DO<^2PIY@$V%-5PZ*^'S9A26R>PG8@_U$$NZ]
MN25N.M[W8?.,,VYAS=,=41/TO@6,1=\,/-JO#NP)5*.5YKU"[1R4:D]R5\YX
M%SNYIB _A+NP6W5(N,68B?B>=I"=IK[XB*3UQ)=@%'JNM,N#H)/NL5RLFOMV
MIB*EY=:G@F.-6[PTED)#R*-/14E2?C^VD6\@I?1H-2Z 5HW(44;+$??5V.$+
MUVYR80)+/'ZCEM/[++/X'S=/L_()Z.,:3P^=!_8Z.E?9+Y1+8PB!>ET !@ /
M+][/UT'>ELZGHC;733B<.5NK7CHKUW%8H!I]\O7O_E+/)04<7C%OGR%# =:=
M,)!"]3N ,<(T!9X%/*-"HB5/#.MJ#C8C1\]5:3$\-Z8U@#Z,F^#J&"XL6;I(
MLMP[,XL+<W8EP7$HU:,IN[^'*W@_;VW]0_:(I>&1NI6")L#)$3D?Q85)+;),
M&1V*?W :WM&X, :6\I[U<A^B\UOJP%>5EDG<2JKOI'FQB)3RZV$\6#4%DNQ#
MS9:]*)?EA:=?LUX02SI\*B_+%:5>.Y&0?B64(FD]8<T2PC"L037ZJA&(RPPT
MHU7W50:]G+WY_K1FCA_FB-6$._-)ZX/"P^?Y9)X8;%E26ED@:8,K4*:E?,8J
M!)XO!W&C_%(8\C8=/U\C^QD;/L>]<UC68T&#5/L/PU:_BT4ER,7=Q568-N6]
MR9_.[T;'JWLFXP][NV;-IENQ[NG,,A+825S8-?R =35C<#6*)&5OLAJ?7Y46
MGSF;_(C8[Q[[H5%BY.7AEY//H*36<S_(9VRO]![V,_(5I-@(*%KKD[:U2^+W
MM&_=!CW.?D?S/0A[#[S-G'P2OB6NX!P#%K4[(9RFS^'+H^(W!9XI!A_011N2
M%Z'BY'("QG910/78F>8[<7X>2VJG7LQ39 \J[K^S2;J*:8]M7T67*%:GD&&V
M8#I'X"#AZ.B'#R0F[Y!6AG&E?E$;;M^54&UR:);.X4Z/1SE9/LJZ0MU3P_<R
M$FZTY1V<G>'"3"AJK>311("_\0'2$<UW@;;-8V6ZP"N\_:3G\3.Q\5S8S?28
M2D?&+!JTPQ,;YZ9I.?PIF*QFC;POY3GGDEIOZ;/O%'DR%TAKH/MH)"H$SQ^H
M05427;[Y0U>38A)A7&'TUC271U9QRWR'>5^EK3X;UT:83\D+Q/94VK*SY!M2
MV?BK+P'GM6MU?J;UY([E&(Z(B4X)%V83='(V1_Z(G9M*B'+)DK$>5E_YQ =J
M%B_=T'9*<1$KNO*%1@ />=;QBV#P0B1^UJ[/E2B58'6TY->YWI(;<JH5Z1=B
MCS@]X+W1(OA\4]-%WP*"$<1C2TXK!0*H.Q5^K^KLI9+"QUD5O1IM=S"WLM./
M+%RY$6L!"]BM] 6)07Y9K>;"2CH>S:DO[NGPRL"(VT4??9[_9:N:K=JF,@,/
M:<V:N$K)[&KAT5-PEN"06;]<R7LPG_D[.#OF\C@_PU"H=AFE6U(Q+[M]Q*F.
MHB*VMAE_1BDQ^78P;K#")RAMQ!^K>.'K1";@W8)"D(%1/UZ68&,M9R\=-8^A
M$QJP.[JZS].PS]W9^->#K[P%AMJ0"T-'C9SB^A5O*Q[!E-&VXZ,HM$MPL=DM
M?NL^]]7-,5M2+>4$Y.2Q)*<V"/?]Y'5^QFEVQ#SR.B 8J%?157F^G!0]EO<A
MJZ0+ZN8O\!K':#W+<'!-/GMPQS&[)^2[NFUV$$VOPT$7?!AE;Z5KP!@%--(
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MNL,43(.QNXCM>)IW"P?5K,VJEB&@60L8YCBX>^.Y*7PS%/&182_L9Y[!S+=
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M#9AE)L/:5R8);*#' 1NX![V8EOU!\=<G/4FY\( *=8G-F]\,) +-R<@VE\W
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M_Y#"<ZWU#()UJ[N$UBI''JM@/--D@+*WL5C@A5_'A<GBV3NJU\O>LK-OLQQ
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M0").I(R!W9R7C;DEYA 2279'=AIJ.4I[5\Q%-&2."-LSLYI*!)^I6:"9NP$
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M\DVP*TT9\LG6S_AK7=:?R.7I$E6H)8\TG[1N9@DQ^YTS:5%T3Z;S ^Q>>NZ
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MC"D^@3[P,>*85E[\0YH@VKAB]/J>Q_*LH^R7)?J[YE\8T/''G-1'S&MCX(Z
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M*@JI+!U;@AC<YUR\I\N K>C?_WL 2\*U9E>6!2:CU:4BU(276%2@B<QRW/S
M#V"!:(L<E-CD>.JBF!]E<0Y-OG5/5X(= !,6__"K(H),#FIYZ3</-B\IMOV
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M'I,812O[@%4Y_,MC?ZQ2./K;*BV08H.,!DDK:W]#M);"[:-AV*M)7 D*9:$
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MQ[KV/TJX.X#RD, *SS\^T=1&3]SC ?&N_1T\<CBBYP?JK4@M@"SHZ-!.D"1
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M(V*FY3]82Y6D61)G(\8GX-+K-TWBR&?3JY%4@J0C7:9U)FHJ)C/&0EC7W%Q
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M_X0.9V1>39H0*WS427C;4<*3XC_V0#Y*\,TMVW I(TR>I+-+SB33HL4RJIF
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M8Q M<E;#:!::[ JB V#P,8:_INP7_+[\!4E)A5#B"=)__262Y(^EFD H[^G
MKF9(A29H[#X=V-LC:5/"J*:_;W]II^E)TV[_@Q]#KA4B*!2*$.T&+7^.#FS-
MTH&+C. A_/OFEU/#=" _F@Z\!M.6LO^F%HB[H39Q"$R#P]GIP'G&W[T1>P0Z
MD,CXIX3?SP%&N-*!04TZ\(W1$5_#OZT)7?DI^]]Z^ J17PVFD.A !T.+=8!^
MW_M200>6L^C /$-3UXC]75WF8R:&U-_[C2C4<\17\* 5B@9#S/71@3GD2\3T
M*!W8,41L1M"!<4[$W]0CL98O1AO]?7L/K@D\!UHN9O!L=?"F,V)3NP6+7T/L
M?\+N:="!]2CP7U?"11SD1+C;,FRY. W:9-TQ_WU[#VA/#KLG- /Y:_.#_KH*
MLDL4N+*$8<LM/'*/Z0^ ?P#\ ^ ? /\ ^ ? /P#^ ? /@'\ _ /@'P#_ /@'
MP#\ _@'P?R" .'04JH25(@XZX)(I10>>]Y,MR=>^T0$-VK=-&$[&)'IC[WN,
M)TZC7V!G$$WA<'S"1#OS+W:H7R%6\5 S89:T-30M2<.FEGG\A",UGI)_QC/6
MV,=4WM_R<@K&0,&-Y"J>)*_9NVOL'MPW/J+><)N4_?]Z30WY!\D_KO@'P#\
M_@'P/P' :O!)6@L8GT@BMPFP_P[^JY/X:"J2*DN60(S"^]E3U@.;'7[:%CBB
M^26V>?_V,;T!7<6VCM::-)=RZ]2UD3*G)T.F^K(Q3K]$'#=T77,G:[2?(_Z1
M'4WIP+]V[>H?"/_XX!\ _P#X!\#_#@"BP%R(QR"2B?J!055K.L"<2\00 Y)H
M$=2DN;U,NSSNR:VTLY.9$1_55@K_'MI:VO#DI@=-D@Y@#*@2X?5Q[QU(@XKR
MQN;VI;^"?;<<<.&E><8FUB _A>%ZJ?'$E7\,N3@=^%<@SC(Z\&>D_0\::7\
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MV.Y?+$ HYM1E5HICUO=.KZ [-4D*&[]R<,5.60U2U#RL.^X,"3$SF-L(?B;
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M^W%IDX</%Z8L)-33/ T,XM&04Q1]AD\_AZ);$%SRJ'!L&:Z9IT&4%*8=_VY
M/NWMW2"_\GR=4KP)UT^>@+KXT&\WU_F&Q[:T%V\NG7UO+U$=%!.7A17%VH'C
M4ATI'-B9B!;IYY.\Y6-K)UQJW@U(4HSYR_1.$*:R;H_=\'_Y],B#0^X.3[ZP
M>;T.6:Y+\#?S'/R5L__ =;&GEUS^LZ^VQB;:VGW%?CXX$UT('T95&C2.\< T
M";+$P%[I.BFWG/6T9O/ 5$Z^LC)M'[^*ZX<3.I[]C-HG$_VH6:HB9'V8? 4!
M]?QBVBI2R'+\@;689;3RP,'>VP>$E,Z',A^^(E@S>81$;J(#G*JJJ=@7%>.*
M+:-R4Y]J^CV,9H26/^0IJ><'\K<&1GQ!C*1\ 9<>39EE"(]3RQ9)#8D%=_VL
M-<@6"PJ8,O:(Q[;,O(<US832\04XKJ*]P"1-NV0DA5+D;^_A86Y@CEB>""A9
MES-?]$.O:9*UX2,3%X>SJ.ENY0:'86I]'B?S&:HS_FC"INDB"YKOG1V7>^@9
M\6,_OWRVJ, W$S^1-O!,Q!A\>Q-H5,F)=J&<8%MHH1TM%YD@XIS^_+J"-F]I
MX(M[>;'\N@5VQ3+ON17/CG9;B@[GD_=MFM,,C9*7KXWE4A3C-^@ )F!-.A_^
M#7L@EQ 7YOIQ8F7+Y<Q^2&Q# 5^"9:VR)#F)_^R,G/>5YO00B6$:UXK%Y$MU
M'I*Q.4'R3&7#^0&Y M?ZFQ,=/!>B @7-?:]W=7%>/6__<K8('HAHM*WS>3BZ
MV^AYV$5/PEG6Q<AE/]W_5P-$Q$+)W"6NT'3QR[IK+\PZA.Q),>^W;&DX$-$T
MR411YM2ROM:L\CDNY/$"V[MWJ*[0^WU:A]8=I*I'?\8,^<[5OU[8L1HC&MX!
MUT_B;BYK[[Z*ZA\?_H[)_=E@D;W!2X!$T<1)T[DP!_R91#R#P.]?S,6O_QJL
M,T O)Z S'#(=>![>\#EW9K-1>7..QWY;L I%$FU?,RB"#X*/HOT\.7Z,C9#2
M;@U8ZC8$RUTZV7BLN/2%\)JPPME#,7E"P%,E;"BJ7+$%' W"WT-&-1R/@+#B
M,8U$=[:^ONY)D"ODHM#;.JRBNN/H*<79^;:KK>[?!J'- 8[2%Q,:L$%;LM[4
M@0_;PRG?%=9VEW 58NA(FA!%DEKCAP!!PW<9HN4L[/A[DEGP'DJGWT/*-D$W
MV&CQF[9#/U_R\9CYM/1-UWG=R5$.8I?GJ IK: UK&_^Y-@')4R4V/Y<LI&*2
MS2254[XGK;Z:$6GTY@[UWYR4<F1:XWN<C,[=&4-KW"G6% WA-B8*1.&E1XV)
MZ7UTP!8;JL"[&.TQV2H@"K4M*:V(-6.6=^T].S$G-G;:COOQ44XV0/@36,XI
ME@X<.4QJS6J=5;MFC0]HUCWWJ84XP5U?%NL(_?IM[H[GM0N/1N9NRGZU"+%+
MSO/81T!>@AVDEB8ZT3LD4-9K\Z^@$O!:_(QG#%R* &G"1DV (AC>Q461//ZS
MV:WV0NV+!Z;IEQR:+]F).HLW#J;$,1TG0^$C#5=)K.0[%!$\XOD&^E2:=S2B
MV&G4_D7]8/<GY)/3$DY=G[IB:"91+%S@.MPC/8K)+(6L-FR- ,R]TC"--;1Z
M@P8G-$XZ*G5Q;2W;*0#%X2Z*]X_/>G#+,X>$R&WGG_]IMI)L'S_!]W4ZT%/\
MB?ZIWG26_0"B$O6C)!UPP86J!,3,ENDIFL0Y?AYTLWUL=/P#B^4CU55[.Z_,
MZVY\\:E>T0DIT/4:-%@_--'0M6PD,X2@02PE!$3\9N$1V$.J5S\N82RTBAYC
M1@?G5SGN^!V<"7C$(9R?#ZNZT2GA/=-0@OX: IHUJPAA6%>)5#$#9H+JK,PP
MQ9P/#3G47'/WKA F[GY=6D!5IL-Y319)H[DYNZ]'M5:16J1Y@BUQA)HL]U5=
MC#3<8L-$8 UK&.-3A//TN:=T5I[F$T]Q$GIS@O(^V?%\?/I??.:%LJZ^NP=E
M(GJN:#?%2,HLW7RD%),U2!FGS6Y_BR)L1('XLAG.LII3S'!%6:=)?+1"Q<.R
M%R(B"3]56;[,<=3WV+Y'(]69*"'4?+"+9^B^2&ZSE(%VV:"[D \:ID70_'!/
M4W[L=E>E_RMMCZ^PJF\27Q^?3X^)L2_*T_+Y.%1200N@%)$^%(^P>[T6,MK7
M(5+ N*W@B[@^'8E94!RH(C<::T\'#I&.3S<R$Q#$2,*1?#$,YIDM1J;D?!>A
M*9ZVX6_**7[F?N=5*PXK+B)#Z!PYV><[HOIX0@RON?L:Y>)YJ-GSD(Z6S*.3
M1*\$%2^?Q)%876>?:^2\4:K<Q/C:P(?,Z )SC+4_UG;[<A3>X$<[,;>,6@AG
M1YY&.#(< 1IF4.U^[4'_ 9&'U:8GJYD7;24.RGZ=U_>?HV 9QL:3(J;HP-B8
M-2E@.MIRXZQ3I0+[#^>&D_UK[BED#5.HX:ZN=\>")F]@3%?CY\-63YGEC?3E
MN:3&A@UT:2HB"[U783T^(U(;N99P?E@B6&L)_=T "6+#>G@^I7%4D3 S('8H
M&]2B[;[-;E.0:6E7Y2^A_"/^T%O//>R-C*8RO946&G[B0>T2K+SP[B#/UH@P
MLGK38O.B52:36Z1"D\TMW).<^XX-XB(BO-[YQ#B:A=6']%Q>9YAEX"K6Y#%,
MB6#>?M)V%A=;OL%- M_J@7.,"$E'5-RW?R"],1ETQ'',FVR"?O/#Z=5F]B=E
M8CYIE\9<3:B=$6U#/J4)$G9;I=F+<\^Y]+?;2HQ:CK9[.I]PLJ(MRWV=@"1W
M[*D,O[6 ]TV6YZXQF',@UO&^'.@@1;G/([4;=(84=WYS\G95]R#TMPQT9\MX
M%XM+K"QJ;6Q+*AXPAB,M&U*&)N,OY?F8-,26UYLE6P=!ML :2^AN5\2H#S&1
M&M\@!15M!I5S+ E<P^=&H\]\FVQ1X73F?'7;FFW6[EY865")6>09IGFW4(EM
MAXSZ0>'URKUWV/IO0[44%$6612SKPZ/_Z 98$FW %@Q0;.F 30<=R#:JYVY>
M] _[B-KW1]*!&UR+J'+2.)Z[#;RSC-V7E^A150B !NB MU>X:4_%#NG\,RX.
M_=L$O.&2X;_?0 2(*O_9]V'_2U']^\U!OUE4Q2XE#1L-7NNG SK3:-O_0-\D
MGI.&"4:XJ8WF<8T6<W63E./D- GG!Z^MK*Z(&)_GZ+U/Y=Q4&7K]ZUOAP/GB
MD5B7GN;^)(OBWJA:&;@BO&?B+ GT46C9Z!S5YHE>9:)+\W<$\<VVYF+>R@\^
M7E)G&PICWH)FMP*MOBR$775./LZ?4?I=Z-(2S_S)KSOW*J8S+Q$4<F:EV99Y
M)]#>PZE)V]]5MQ3]1=_Q/ST+G * 4T?L*N#(L([/)*BHD6K?UM@<LME'7ZQM
MUD7^IGZZBDCV7CUMC?5A*16M?OF^OKW!6;U+MLEWUJ3FC/MCSI)^C?%377^J
M<R$:;WQ(W3\' OU2P%O*K*DT)*-?G_>#ZJ_.S28)@<;;#:(M<VZ-KY16/GB.
M%GA@K/O=B1$1.YH61Y)/NSPIG'R=,3R[_P!5SGL1\VA&[V*_2=_Z3$/_^NSI
M1J_C'G<XM\\/+E,6J5$TM0DH:]M0)NO .@;J:)'V+=9!.%HW>9I'>=KZ<Z':
M;=6'B]N/L=>ZKLA\&2)ZFA#AVNL\"NX&BLWBO68)?;IE=$"T1RPK:HL5^A\[
MY81$;"I01, [<IIT(&OT]];Q[ 8E%L)L0-7[O?F.^0\-AO_OA<5BF/*,06I7
MGJ/VF='RU"0Z,/>4!*95Z3+\>0ZM,X2=8T70 2MA.M"C%XA>1=,!828&\=II
M@E!!(D!0_5\?(GA"DZ^6<?%J124+_UH/!/?51FUMG'$D!\VJ7:FB PV:GMHS
M2@3]@:XHL:Q:Y/E_=R"N&ZX&\^H#.Z(B-DGM-GT5(>:W0V>41'GE#.\(7^OF
M^G%'\&3MY^K#Z9]GZGFK(5$HUE6X.$6)(/I<7D!*/HW'G8>0>$XFHUAM\'/S
M3Y9O!:EA3R;W^Q=<=1,S+JT&3JX.DZVAHL0/>KY0HS&S_L7>+H@39NA"U"4>
MN_&*'FW)I\7WPA*N>*W8O"5PM*>:,_C6P95,R:&)6WWEP7>D+ZLFG102CUF[
M?OO(FRG@=H=0*@5&C8!YA9!5:#_.3 @,GUOUFK36FXXU4O!,LI=QUR#=C91=
MT@N!,&9>)Q+#8,<VFOD/3>^D_Z@CG,2-27,9" X=9 FC;>?<I@/%6EE%]CO0
MP=RZ\CTZT.SBV\Y*ZUOJM$=WT@16UM70Q !JM2H'60_:MM7<P-FC:NCJY>PP
M7#;NDEQ)&&M[EG1=,K'ZI^Z)$_[J22_).HC&FW6'R-=(H8@311F+T3#C@^%5
M)?WCMN$_7AV[X^"V]OC8-=/[<:29:@A)!-U8-B7]3)94LPF2-B'XM8^RE4XG
M]TE^T"!X7J4V2_FH7Z:&PD]0E$E%KK.3D1".L%\!W(F0\5_JEZLP2+*.@^3D
MR@'DDU,!G,<"#L2%EQ?F\MR\-*8'07GV[F6+PSNJ*]$C 32L<6H?8JJDQG?T
MN7,>1:*FK%1JZ[MS<5%+E-I-^9J#(1@6LNL4HMV &=Z3R131*L!6'QPML\"S
M5LPFTOKAW4';)!F&L(4*LWDS<^V-DUUA=ZE)=9KXXETMDN<'I^RV$JN6H91,
MOIZ&9CZHUT)@0N3L [:/TVTTG<P1?D4*.^X>JIN4_=@J[6$-K/$:T_<OPB%:
MX NZK**&W:Q9O=36F4MBQJ:/BXH+\*JZ-!8&<Q=]E(?X(=Y)!Z[+[S,34#3#
MW0(Z\".6E9:H#4$A\":>>]=.ZM(:S2#[!] ]!C%T8!-9#Z&U."&V4U6F<FG3
M+W=2%N\M%=!VP[<AY$=[*W3@\#II>!K\-%.=@(F"03Z%1#6!6<N]-,Y.J@U\
MG!$LN?5V[\W4/G! ^"DS.GN6#H2V.#&UV.A2Y 92;DXB*XL+>&I&5N8"'_FL
M+=#D-]$4#CHP=>8E^3K,GS?@Y7M%&U"?I-W NEOS:VX1:W:AQZ?\DY_HJ[QH
M#Z(>H19A'T^&JPN3>&9<<:Q016T\-E).3]W]9MN69EE<[]NLFPO*!P'A$YSH
M[PFRKUQ+/^0;9_,B[3(SS0,0J)\W8WF&DQ0JW%T7[1(H#5L3M),49SRJ'7UX
M#)K;N!_9T#^O;E5R6\' 50PH-_H(-^<1>!=Z3)A-W[,=.2K4""E#O>"V(H2_
MZWGY4E=-??!6BGG<49VVM_Q*G:<Y[>QB8FCN#+5YD8((?D^!#E+$1<$CJ>M)
MPD4'5 /Q;%^G@E:=M6?7; (9_G.0A/0A2!"+"2=CJ5N-V4ZR'V/=CCE80OL%
M?%[PW_%>]>H 3C5EN*":3;9]*)*K= "$LXY9ZM'W,1X%(TVI@8$H/08[.1+3
M%_[9UN#%<&R.YY<:=^?#9#48^GQQ2!VNK:&!FDD'G#<.P?LF0"A#?-)J7H#3
M]?H^SU?: 2X&XY+O7IE,3;^.'U,^S)I8CA: -P9Y-B_5B0HM#7^.]A34,YIM
M-F\WC"_I0CF?F7A<HDHI!)8 /O.OV%)SI#N-G?9C@A]Q<CEADN2]9>'.[J%3
MCG KS82(*_H]/+;"]^8\F\F3J^8ZYH6?,,&K%#J 7KEA\C'CDFF,E<42&50
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M6];0$C?@.UU]9F9I_MX-&UX^>+/10O9 P/7 >YQ4[4Y/;4JF\B[TUF.\3Z@
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M$=-&_$9FGEXJIS^^*Z]>7VZPSJ9R]?WKZS;NWWIM6"GWL0 J5!EW:Y6IN,^
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MIZ^1.)*.Q.\GX1)MN$CC"D%+ANOQE..!8]9W=64$/^J.%$!R.R/ ]+CB]K!
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M0P!1C&_4_/$9UR%5H,,[IC[^\Z*;CD8_KWXZ!$\W@Z 60",-8B0RUU4 /1%
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MX%KF8#]LNMA+)J6<WC)7M&8V*^+>CR\3;KO<:2IC%C<,><'S9@W%KHV<:7B
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MW4TT34#]#T-#CO^%M[C\SVXJ%?IK!5!E*<%% 'U20H/UA#U!"8:[AQ0$SRX
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M?[X\?52V;OS_0M+[$7K5-\QQ8]X8+C\;."$9I)T_71Y#^^!N]/E*0!*?8B>
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MJDC9)#>B-YDVWF0Y39M)24S^TE=:'49."C18;>G5\Y^E%\Q#//.X.%=7_)$
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M:2BWYWNI$I\@LOQ2M'P@N 57H8S:E8*?O"ZMQ ^\)8#F3ERSH1<+(,YFN%0
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M%&-O">VE#:2T]<&_^- '/6[8HN25%VNPZ4S0,O6 ZP?EHYL3W60&Z[M#YRF
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M7Q[\3;F:+#-#>U<K[1=?'I)?J;PWXKF]GA?$Z16ZNPW4T'4DIJ)#!&4]@G:
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M:W?4'Z@G%VRS<TCZ7TB&1PL6:,$//U_RUNQ?RPLY</3)-X.O!PF1[>C!D.O
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MBSH&M 5##RW8X;.YW]+7OWU-RV"W=^5]E]9]&UG3TAJ$SJE-VOL3;E/:<*U
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M_S.<""7=0;YQ*&HG/H&RKPD["Y(%RZLSA (,BV<?&,K$O?GF?WF("3HG+?J
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MKG3?.%^3W+,K'S$Q=Q1*O0AI'^:9"3T]W)YSDJQ1GGUC"-^58?>^5[7K^$0
MFG#5/T^BN5&E^]R[@ U()793$T&RZ]+&=H)CT3)0"?H#+!LC[^Z=FN9,M&9,
M/.C^1Y"F]UV!9S9L6G,1$TOW&[N4LP;1<?BLM95'WRXV^#GO/$";Z(EC"F/A
MQDF(UEO$U"4YH@U-&R;1DS.Z3EW73ONI]S LV01RZ\M/^L:N%<'+6]PLW7W&
MU]V+,^"=(*\=Y 7(KFL27(7IX.%G0?T=%%PQ-+X=[T8Z'IO+2+TQGDF9HZ_!
MWB9)6?6X0C,C4M/_TX?Z(7,1'F;*G=JK+1"PAS/GV,P]LFU>WJS]&J5$]VYZ
MRCV555A"<:.!T'+TW%[%DV4+SK^HL!W383M79*]RTY]E&Y6KOG.W51B.4,W]
MO"5EJDQS]CR$K-F-2-#T[++@H[Z8:1N>,%K]^=X=F.F +&@(;UHDQ>-)ECPX
M98+U$T?O<UDW:U)+%_K.W>!A!/R [$]$LM'XZ+QDR":>=LX#$!\/=(OO5I"D
M? TH[/;C3F\,"1" /PP0U;&5'2*B]_H1K6H(=QY18!C!U60+/[=F<(L,QU3H
M_29E%?O8MU5^N>$L%Z3E<JEK<\?IMDJ1PR_<9WV;Z;JGC2'K0(C6\J5[^<N*
MJSH8PQ"4[X\:^LCR81V1DW8#P&*D='T7DEX<#J62=EKA)QNN:D?'U(@'9GI]
M8FMR%\]+%4_P%[AGLZ@ZI'GD 1/$"A($]HSZB,33I:]&'B;:H=:#;8,CS!,+
MUPJ[=*9=SU]<4)98^OUXX<K4==&>+8=#[.88S03H@T@V^2XI3Z\/WR1WOX6Y
M!V(SPD_7^$D\F;<-3EWE,ST=7)W"[IHJZWBRB>T!ABA(4P+^,>J0=L<YBVYL
MIA RJ$C=V@-\&J9SV42RH[/-1&;,1#F]P.6)FZ+ZYQ-'_ ,ZW>5Y32(F'V"W
ML ![&MK8(;AB!D[<K?/)W-U!%XU"2:90]KK7F,=,T/%>&;A35Z7B9)F<Y,U4
MU:]TEYNH;_\.R#^!<JPC6=S4'17M+#:YNY2_H6W^UL,MPM7M'53>-=:FB]IK
M>_!2R\I8SVM,X5>'^GI_AM=TN*+PPO-?\8D:D?.HB74FB'\GM1M/#L,L?'?F
M&3VRL\L$@?[$!V@'W7M_<^?XX4'&%01>@X>8YL+1#:%>XFBQB%+[TC"Z:P^I
MV?K:M:P5\GFD^ZOIK6X(?A]UAY&"8$&QOB@#I:\-NT]]O;BU:;^WEHF]GHSR
M_BOF99N=3;@D42@=A8_&A:VUMJ//_*N6>D8<X#I'UEP")ZB#-[=.ZKT<H^L$
M[J?OB+:<Z9"0\5?KTOV9#]$N8:Q6>"%Y_C9I[/I993%!0A7S#>6ZY?7-D?#*
M2?IWYTP%E"( =&.=5<FR=:_HY\HW]A/XAF]7YAP^T04E&PWA<[%M")*Q[\DY
M9]@5:CP9;'UGW5F)+)[^J:&G\M)C_/YVF/$BU R8SA$F(]]!GB DJ5XM8J9>
MSA<GGW4AV7-GVWT__DZV=4';&8K$](XS+D%<P*_W\4=80? ]2E6SJ1%RF/C\
M*<NRCN]RCM/X#_4?%;NRCEY:#UX9][=V"E2GW4?W*:S\98)DGY=\\^@,\::G
M91#P>RZXC1T$P'50/+BD9[$0W18AQP29D*6:W(.L>W3RZF*69F=-F" 8=HT=
M=IWL17E.C25; UQ:I*WN?;@D$Q3OM&AZL6T]*=(WZK.0A]'9'=W9@U&C^FFZ
MZ-KM2[=K9)6C/VG^J6""U)N#+_5VI9D8$Y:#]\+A12JL1 L9>412[-Z<(]!N
M==@"0F3OYMRT)5?WOF3C,:$:36*)?A[-#AB38F=D5HN72)/FW@WSAHZN3&,F
M6JZXQ,;\"4Y^V3.G:TSUPK+D+.1HDPV9":*$ .TD\PQ&)2'KU.,QJZIJVAW;
MY5HAXW/+099ODI/DZ@1#* I4#@(X*EPYCNY'YL-=0U^B;EBE6DU:/C'I_'#]
MX_6G*>?D;016EV5@+:Y$@34:-@"GYE^U/OO(-T-CA@DZU9!J/6MY[[#3F*[=
MQP3IZ"@[[NI#&2759<HQ2)+EUO32HGZ&MX08QQMO[RW][J,O);@2QCZ2M'GD
M)WEWSS=C*(N,,E@(::;;F8,*(45;5#=0,Y;.H15FEGDD$V0_"4XX+E^^?6LF
M2[Y,M*_62 7.!0Q!>"WH J8$]RZH*#6 IM"NBC-U_^*DMU<]>$WJ#N_/6[_=
M[[3S9VN7')"Q<>.,>HPK!@PS)^-?Z2O#P!/>W^ RU.NPXG)EUQ,9SZ/<_TMH
M^?)P^'P:3.%R]&65@0N,-*F(Z=X^)ZQ:>,@?S&*\1\3MIO2&N(0(YTM>.!RF
MI;.2D8KPXN%?^P,H,$KQAHT/[WS_(R:FK61\+>CJ*A,D*4C D$R'.0?+X5,0
M\2;+($*D03?'C9?5H73CTENC%@CTDN? P$#WA^H%U\5;HH1F?3,Y"I'Q);!7
M]Q*AS)>#+OS+)Z-W7*/\TF3$VL.'!M]NZ'PB=4AU2?]I:^"A7K#8[%]B*;#;
M5&11Z-(-H,^1>%M4_?]@[[VCFOK:==$H(((TE=Z"@H(44:K4*$H3$>E*BXJ
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MJWPW$-%9IO4^0T.]YRDH"/E3]@S!IZN%(C!<*7.5H7KD==_#XJVO_S9OM0E
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M/Z1P-3A%I!BB.Q#X-2H@Y]5$^40<= *]ZT:1IE$5([)4>%/<7R?A[(7_0 7
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M%.?\2NSP>Z$"W9JR MX:>JBIBEN):.8CF!KC9*.\ VS9M486]MS<D< 7(@.
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M6,&S]14[C?]6-8K"G*EOKAI3F$/Z9FUP;S",>I2W]H0YZ9CX]9:W='K$(X)
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MU0J7\\*B24)//\ /DQ8&R5Y<.7Q>9DE\;DDC.^1'Y-FG1?<U>RS#H_ NVU2
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M_,7:B^I?+;L!Z0N?3\3YW<UYD<1I^P$DA/K1;&56H.5E2?//$(IN";0?AGT
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M*0^BS&L:ZBI?OTR1_%5_H_)LZANTC,SW-\K(T?+X8#!Q OMC"QV,V]O=TG;
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M \%]AE9#$N%00A*X(YA)X/36D4L3/@LUL#=5KV]WBCUNJ(#Q]S5 (&8P3XN
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M!LND]^_?5I<,M&9Z"^35KSJ8GL.VA.W1%'P&:1O&XFZ-".AG2@HO *,(P@4
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MJ=("EY9K<&9R,JADYG _8+G%M:@" \D7SY?H 4)M(7K,%MB:/0(XDP (#87
MYF3^Q2S BD9,8YX%N80QF8B RSLR,6Q(R%>2P@X7YF\ED:DCQ93G.0A&F@T;
M<A;T[M1YFBHFD=6X,P@%T KU8HF"K9A&$B6,=8 -6;/V ,[L&C'A.QEP@&[+
MJ;,AO'J?"YG8E0>;=3 F$SL1,Q@QA2%Y(S6!5]!MF=WG^B!]X?=7@ /LG]_A
MP^: WI92D/<1-@0FL96)S_CB0;=+YV)#/G8#M[M!:YA HR<.B_F4,A-!1[W)
M7-@DQ+$ZM;^&@HZ+8_2,&]M*,144]H,B>X B@S::N@ C!2"AP"O,]@78[@C_
MY$#8-F&ZAUESJ^=+. %A_$O"W"70) F[)L%1&K3  :]U,]_^AR$0=HU@=.]R
MS)5J@T;:GH3O'&5#_J:!X>*>  CO'M$W=P7LPP_*=,<6#H)J*.[0A %T&YA_
M$#,!@H*S.,IO\3V@)EN _A\,M<:9]9$)N0Q.AVTI< JUSK.L"6NPKY&+P_!M
M!I1Y"/-^KNH_W_2)QY ^-4!!Y3!LB&0)C#[N[P$BL:B)HWW:&JA[ ^X^6/DF
M$Z"=(4ET?+>=;E<A0^&7V$^.51Y-'EB4L>=9<91U%\P9N#<_@\TY7PIBZ=!(
MNC\;<H,'T+<%!8+3GZR&83840:T20:E%<S>MV9#U958G=ID;R@2PP'Y"YT:!
M3"<X,;.T3X)2M(#JJL-VU3\!)[6QN!';$M[_T,02G%;:Q#]-C!N<H!_!:?!2
M8?V*6L0Z/\, I2Z&TOMW/@<2GL6-^R??W$Z)!!!$^!KY/[!I1ZRMTIU+0S.!
MQW!F'#AKR<]QE#X"-S@7'=F0=BX<H*HWX E=7T%X\RR?%/Z7G)O2,ATP4IZV
M".9W!SB:,(+I L;F$1U*,Z:SZU\-N &E?[ )TY*X $S3/_U4+#@-H_3CN&%S
M3KN]EP*JMS NV)"FTG PQ'$^H)AY.SE20%#'RD.@%RSCNNF820-FMV5&72IP
MHI#TA UY#PI^80OL'U2O@N3$.@+=AM> 8IL%P4$G:D]O*0)]_\YHG5&'!4XT
MD< T^#YWEQ'S#\8.$IQU!+%M5+O+".2"@^-,&.\PSI.862:,<A9P*NFQOXYQ
MA8?L*XT@K'WP ^7*)U &V1 P'\ZYLB$_?8ALR(G,!21N>U,!M*@I&'@P$'N\
MU&-VW\^H"P1.+)+464<P_QHAC%9'OWV97@$*@ <%P.8_),SV-\PH+-_A9.V_
M 5H&NYW>HH.<9:IN-<)V1#%KJ;LC%L;2OS+L4+!:NM.4 >((_<W$8K*%AYOK
MX6';3^.GAFV\,_)&C^.EZ 'BH:07+4:WM7_=!N[\+/%\D6MD2J/X&H[HV^VX
MH*89QD"/'U%(2\<GPSEA6YNW;_91R.FGD8,F5S]T/PO(6SH:,/2BZO;XPKG2
M_F<;I\-R\DTM;@'HUH>+#H6WZ_W\80L=/\)WS Q-"+?#"_/61^;8D#WHRR[$
MO4Q'\6R7WO&Y+6AM_W."XNMTV.J>W[?JS6LVQ8X/+22%%=^C)^B5#SSO"*GM
M6WU@$.G?IX$<WIN;KL?Y:88@_+>T9W58JL6;_FK2N6_EH)1._^.*R)([=X3N
M@TDKP!*J([AV\MKKR)PR8^M<IQEL+UWA8EZAP1YU9.7HFBLF@3@]TYT%KO_T
M&YN4_VUOS<8"-Z,A.TCL[D[ JB4?,JY*BOFF1H0-R8^$_Z/I^?_\=N!;G0)\
M1I"_"8@3Z %$=;.X  ,>PN35\K-^SZ$9?<W( GJW@>6*%8S,?I6[+$V@2_4^
M.@G#3MUY^'WRM-_ 1L0*<1,=5@3\AE9A0K4/CG:XSI3D3^W-=8S2T^0IW#G,
MG*#74QDM!!%5*WF?XNLW*\??%3UXJG=\8XOI^G+ QZ;>9<=UC/%>?F7&K==
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MT"<6,.L3?0## SCWCLA=I;O+A-D"J:BJ\Y7&FQ'!.XG\':DD= %QC>H$#DH
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M3'TAN^]FYN&CY'@-#H+N0FAMQ@@]0:>AU^>@3DOT$H^'EAOSUK=@F(0E][I
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M.$N=0%JB#(X!;4#N,7#E$:BALL*0O*W?R<W/LI].S(=%9>6MV_$0!(@\"4*
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MTBVS/S"?XOB3C>H4?+P(5_]*@PXF6O7<0UVS7.%W3."Y88$:,2'+ F)I6KZ
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M+OXO%=+&3IE]?=3Q\1S]LW-[K^DO?4'-6./)6.6M/<PK&)=3H6LV&(CVY!K
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M,XI*OV'5)V6- _QW4(NO2KEX%?+G?Y/MW:!->QJ%P";!'G:-E/6;=: K8U/
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M(<$ I@BFAPO"I*ET/(4LA;J*D=G*^3Q'VE%R\5H]@IO/K>T0?#&MR< P03.
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M0%PTBZ 28(5>1&V?*71=8)AJ%D<]KAU?K4P.6)A&3.1'<SOU\DOE5JF>4A&
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MO69=:\WYFV.O[%DD7T$4/":9P?R<C>1'C?V%+$$WWI65L?68L*^*\5%^7=/
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M[<7S-IT]AWPXB,VNTNLE-&%J=ITLR.OJZM6<V[D\U1-0LGPO9F_"A<7=;8>
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M&X:,N1K??'4*."DH&*TBD\WW^(7%L\1\2_X<X9;EA64XR(5QOS7(2$VN1<(
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M%R@]6>(;MOUO[+UG5)-=MRX<145$0$&D"=$'!*4JBA2!B B(B*$(H4=$14!
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MLJ0FF-"]+)/$G.IU(JX[4KJP4.YRP&G!HHONR[_$UAVRP\7ZMU"OI0#&OL^
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M9GEY>=V<=->*\16^F+%SRED0)4V%:LCU;9XV[S4:P,#E^Y<K8$Y&_NR+FS2
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MIPM*WSB\L 0V2\%#B=?24XO(WI0ZY3-D$=S8URF';U9OJC*HRB9=BXG9\<]
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M1B@?MZ4!RD,:UP<FV\I[V#A%0B\'ZB8TC^D93<T/G Y9.AU7QCYT7.=29/
MY_[ 1AWI$K4W!=SH>)98_4N9#^\+43"#>(>$[A]>7!,4;AQ*,C;J8!V;R;Y?
M/%OMH"*S0T@N),L0%^A.XP'1+M-7_.>>A&QC.N>K%PDJ/X+'IG8P<_+% F[G
M\U@5FWA/==R59CTM4VZY@7^:#_IQ9/.2GVKBV[LDZ2OS*-]7<WNT9W]\R6I_
M.?Q:H?;]?Z>N^T_SU+L0W+$ZQ.^@-5<4*,MMPP ++9L4*R ; /?EYH!D=P4
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MA46I3VUETP JS @2%8T%KPW4@"QB=M+;U#QKQO<589WJVU0:@"[/$<.B3PV
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M-W)863F8@4**Q8KV]V[$B;E,%Y[_+!+>SYU+KW:15!_H8YRMI]==\XK;[B#
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M @+LU^&-I]V&(<IS018ZZ5C0_&Q1+O<&YB3!<QV;\G5Y:-Y6:%S0(;$-$9D
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MY6P#41O6_(60JR!8-'-DQ89[DD<G&;5K9N4_D;U_HEI-:5V7R8)@5ER>(MB
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MAY9^>43S@%_'G)NH!6WIEH19):4[.'J<?\;VD** V:T4=;*I[=Y2C[3 [=.
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M2XO(L<C(_B4OV^3#!%#X[E6Q")RFZ&3?CNN64H0?HLT6!.HK=F_2^A%^>:D
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MHYE#(RP_X,V9U.T?0WCN_*-$R"J2+ D2GXBHA<&XEB=EJ#UQB0'3XALWU"Z
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M.'0(FEMR 1^X8]-J\-:!XZ4'C@Q'B!TK==0Y&2]>I@")V1/O!PF#?(5I4DR
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ME/SM-I;W1ND+-BZ/!5!G],Q2P<GCIUKPUW?@/PE HL(^>I*E.!/]MRFR8TQ
M.RHV=?!R:S$EL+?-^VL/KT.[X#OEI_=>VB[:GASJ\Y'^B(]ES ))06"8R@1N
MX250;;8K8!PMM58D\GCC%!-0&0AC L*MOT:,,@$-Q7'@YXA)V$)L=("IN,C4
M B+^L67)>E;5/1^EI5TGG3-W:Z(>W7C\?#KIQG/0>_3B2,9>0!F8EF$+QUQ6
M7-N-KB<_@(RS8"V\8@7>1^6GV=+?HO6/%=#T*,G$W78L/VFY$.$\JM+B7&B@
M-NN0%"_F=+<H3^9-X%WG4_?'!MC#(41>\L,A\--P/T)LASAOU[ 9L<^R*MT2
M>D[4PKGJ[NN,9_;IZB'?(*HWY4Z?:Y3U@5A3[S,&F8#C(#VX#HZDA?S\>[/"
MZF<_5W)%<<KI^1M1A8DOBWGD!FZI/@/%8 WIT002K@--N<P$=*'/L065V1MQ
M%A<'PW[--!EXWN@_%\(0W_R^X1CK\4C!-+/>H'!1@/9U;^H++NA&M/;L.XFJ
M=UD5!W-H% %"%:&=1I*W2(/Q3( ;(CFPGW!>U^SF!EQOH2_K\H!<@4X;A)"L
M=>+LT/N[ T+9>U"*''+#A=C41_8C<:3H2RXH27^?E2=F&Y78.5%"AZ[<29"Y
M\4_J#K_-_+)-<F_OU1LRXBB*#*H3<HZ")-L/ZPN[E]AW$Y"<#C-?\KZH1Z.\
MLGA,TC;6'GQ]'>3?FSKY;9LBO[HIZ4(8/#<1,8CBK'0F@5-HU@B8-\+SR]U+
MU"NF4C4_-C@%C%Y\L#QXH.IU7-VF#/ZQ3@Z6CZS,/5AC+"RL]LL_JJB?T\K'
MYMJY87?'ZE#(R8IM&J\FX_(:_E(]F?BL;:L0K(%Y(C+S3':L\,R<%5J$Y:E>
MC"X1CG@L!P76#>7;*X<)B;Y?E1#_7?]>($Q<MW_YN3L\AEW"%J74^EKRSF-G
M?AB90ER$<[ :AE($%S@_R4X&G+^U;4ID2 E1[\1_6'Y\7<2FFTY6W%:)!7%C
M* @BR[>=A.H>9$Y>R_$N[N(X>!K_ /%7LZ[1T<' ;3\M8<\ZW9,U]Z;;.@6_
M2GX7*0] B,;@1ESJX3K58<HAXC>P#O\:_ S)=AC!30DONBE11-#6T$Z;E4E2
M^;0<]YO]3'Q5V2+L@UH:YQ#TP?H<$3+W:A+=KH?DL*=I_][[TU_ZYOS3R:&3
MQ6=?[_21OX9\_3Y/^W6SZY1TPF%0NX32"(@3T?9$/TPVR>?IL%*+;8&19^&L
MT]6[GV85;PO-!HLFMU0CK0Y#LX_*R8/T\A8MJ@I->JQ>])/)3(MCN*>,B,3;
M&C;]W9JW-?QB<;\__>IF2V++!)!Z2N87KT]OS45XUGL>6%EM!,K,7NIT*WC6
M;-<S-\1*$&P$,$4&$K,/Y88'45H7MWGG^LH]0LW>A=YI^M0GH-;\,ZC:>32Z
MW@FBK;^/!@/K9-O0DY'DKR2C9+ ;3*C?A4AMWQ&%G@ZVL7/J9_\5]G-7AJKO
M77?A]33/V=J2GCM3T <LPB ;(0KQI(I0D);_$ 2ZX='=99\B"U6?CTP -@W8
MU=+,.&T]CXMRDB/BDACB\#M$<%0])#Y;&:/>BHG72/3,Z<),IF;<5A"0TI%^
MJX:>F>8B64.OM-9$,@%9+ZQV882:;5%:NLYAP<:J=KE\/_I. U0//F%*SJ=D
M4$_1C"C2+&G<UMU^I)+DO5&(NO/M-UPVI/@>WJ.P6_1G0\G7R@C+%3'XQ/PK
MH]&Y:ESW=4N6R6_@_YS I.N+3E W.^7/SYL_]>GW/!]14$_O\4XMD5E*4Q_%
MGZ5:!"^2/>FY^^=%VW6YOJ-B<3P@Z35\ZJ0]Q<ATR$OZ$YMOD[5]B'Z-\8,R
M:Z6/*<>DO]!;ZTVYWK#  [+-\Z_)*+8.QRYN,3MUSXS+($6COB%MQ<4S;O%4
MW-=KAW-7'\WT=&OV64 WQAPBQM(V^QM0H?=GK4?_1EFB3=3^E;-@U_[0/6"W
M>O> QLM!-AW!*L.U8'$H/N_T3A&^[(KI(Z[8 #X>6^$IKR"MVCO!'R8*N$O@
MKZ1EQ9(B/E @;9,<K_;N^L/._0V%Q?H'FVK81:2[BU<T"5QZ_]7WU><T8VVQ
M= >5#<P\D&(%K$6U(\\)=5C:N 66O_CL?- O% *AD_N=BASK-T\W^4[JAD^*
M^1>N&3S,K+2C'S$!T&!S _X!G_\5=2WX%U&G*)09TGO$R$HV8L?FOVU+<-G%
MQ>(N7R8 HFO+!/18?>9ZJNEDX]ATCJ'Y/"&(UUK-I?I3;13=X&&629-/JBOC
M!+BK243A<"+GRX<>TSRHUEUU5EQ 264O@V'F/IES%-8;)0=I/**Z2\O&1*Z%
MC&)YQ^R+*A&;^8ADBZRVT#Y7@1 6TI4R 9W6I>;6^_%DM6!=6+E^#.S8>L5P
M-Y@\"68HE)D1=SO.CT &Z0TL+9J =L\O7[=TY$[O*P6A66E)^D<1Q9U@.* Q
MS5)6P3A*6;'*CSD^+3-U,)GTWQ8_Z(TAN_# _+])N8\,]A&QAT#M'F)6I_>(
M">O]XG"4IE*5MCG!*NUAEN6PJTP *6"OGQ\QR6]M0(?_FC6+1;@S@$OP>I4V
MJ##&3!1,WN=B @0?+E-$%Y\/:$!H.:Q(2D1_=2MG#']M4NFF_<HUB$%X0$-9
M=BW)1[ %_VMR0QQJ<?S79HF.HL%G-("TCRQFL9A!-F,])B/+@,($?$A?V%"D
M6E#QAT!^4ZH>[99/+G"0CIUB6=-;K+4Q1^)O"@X"D^G>3$"WXI:(PCC,,3SC
M?VOW5?1_:W?:C*I.,_9:;/_ !&#680R=A\OT+,9E#.0\8HF.9O$;--:MW'9<
M,OP] [SRC&)_@C&-W6<"?J*R<C6)@=7S9AYFLHZUUW2CW"I_?^!F6 F?4$OC
MFO?,S,:VTQLB)" !L"_!O<-JI"FYFM9)E*\IKVB:GL_3E@,%/7QWNC7^L2_0
M+D_D4^@1*GOECVP6H?AV_B3=_/]]O^'^4_A>TK\FD=H%T< 64F;D<6&V/L1Q
M^<3MI9\%RP=[92/^FBRR4@W]D8,2ASO4X(LC=55B[3=?]L@\*Q\XMF-^7_6;
M*M<>Q-<RKD+L^NG1S![!U^T0X<3B6]GC9H@VA$Q$VI !/^60KO9_5]&\_ROG
M_BVBZ@]H.;A$\.8($V"R\-\>7CH:MS1#8P6A#^K(^GR8^/^R<C<AR$U5)D &
MV 7=7V8":BN"0*S12;4W9 +0<HB]8P[@3:7![RAA)@"?Q1BHGPHV0IW^6\SX
M^)D)&/*\(;+W?]JS[1$#]V0A_/*JY>A606T-QG''3/+[\71WQ9J%TP_3HOBG
M)@2??[B87)@ZKCWJ\B$%(%&_$[3)1?5WFSU&O9^X()[=5==H^&W@:10KI01K
M;5ZGNJ\AN%V_L3) 5%&ZV6^^=VD!!-.DL"/K7A.9;SEL_FDZW:67L4"UP4\S
M5V3G&$;[8/9@B(3-BMB-EC$P T+#[A:3NCL@/#1SO C585194[%4="DI[=;J
M9W.H/:./":CJ6Y-W)\ D?CAC'LM@AJ?*.3_CZOU1U5D;2%CAY&3P5&=FW_6-
M5\8N[A=_)@5PAA^BZ\=NE3RXR@$XTX*6#5!*Z/*8[6%XK2P.<A=$0:07IFYQ
M#UNFH,@;2I@<:C-*@_:8_E5?A\CA@"%^^9#7%T0.)LD$5B]([D%#=_^!YPLG
M'<QBB6/#0$, PNYHMT,@^_(GYY!RCVN!7S-)=</]5SSN\[F6\A^Z+_;UH2>=
M%U?_:(0%I/1ZHFI_>+]EOXL)WW74^>3EQ&DZ,>:T6Y.,Y'V]@Y4@*#P"-;])
M>^C<;U%>LA^VZ8*K[!XV9@+8+XXL.?8MA(U#'SD@5YV&J/J,(35:L+>A39UH
MLO+ KY+=8@>.GYO]#TE&<5@Q1M\<IW_?=:?QH2\)_ \Q=\>*<F\4^*Z.XC\$
M(\AEI+FXNJD*V _$N8X(@?J^'G6CZ@\<%E=]?UL1T=9<CXRXH1_V$U)PKY>?
MJGT\Z?>ZU/IR+_V=?9W':+E;:ZB\W2:YN9JL9.#G*_Z5QTPQ*D7SRJ_N5^QP
M&'&0/$>2[1R,R[3CC%TH#ZYP>>P2\M*6]R)O6V4M>8&R!A*C "BA/^;/!UE9
MBH:XKD2KLG1=42AP,CCD0:X4)PFY H\]0N8,][\X-)0ZH^FQ_FQD&6FU69_J
M^8.%02[%*2 EQ _ASW_39]'OAW*6VVYB*D/(Z*(L/<-0_"K'!IYTM@T':)'U
M(UR_.>5(2BDQ:2N>A.^PI:_OHTNP?#0(Y=.BW I>WRS/G2% _.7A,N/7^EPU
MQ6\T):,[:W'F;I&==?IXCU?+8/XB)V]Q)%K>I:[UTQEWH^R7M:6@2OFU_1$#
MY[D2=(J^+]5GC2%#0M*D4&?VN"OF-'*M)XM/Y*V*QG"9$/:Y)A,7!=NA\7:(
M6)HQK'A-T/I*\X;W@>J#&6P^)A<6DSB\Z80W-<UU$FW_NLW-/MAS^ENCG(FQ
M66< QF#=>;M),8E4W&G&NS 8:=DA(=UH?^J>"<,>^+Y:>))C'!LTS 1XP81I
M)M@F,!><XUI!L=U2:^=P[HV]MLK)/Y-\,GFRVZ!$*_B ?;MPKJ=)< +?<)&@
MJXZFT!Q&W3V\>PC*C[WLCCI-$P]!K\4>/)!7%-)OW.-O8PPP 74/44!P73'F
M]\J(E]+=L[Y:QFJ^W9HDHVY4RNPE>A'<O) ".J]F)K^ ZLD<D:6_^.FU$XPN
M!R\X!\N2-2G0PK]:]Y0U Y&_KEW[HU9;=6*5I+DX\NL3_$ZQ\,NAF,U]U[]_
ML&=2'J4/_1C]O+:B';O5I4Q[Z^@_--<\ I7^YVJ0:E(38]EV3NT\O)9J&M$9
MJM618_\)]N-W=U%P_$T_/F?N:2#"S_8V^0=I,3@4(@",]>M>T-1WN%NH(X$+
M_0KGH*-;(*01@N30AKX>.S8=N/W\4VVK](#NJG!%.:%*NZ-JGQ<^Y<;8"SFT
MNMFIKZGPH>&,^9L"4KUV_1=2&L1Z*0+NH8N(BQ *+MI<%10!5;M(+AM;G1![
M%IIPM$@.I^-4-#"8H9;0\S/H4]EI]/T#A,>1%ODC_?T>.D4"F+DRJ;VI;^H3
MU>9_4O\75]/LV*$C 7EN38(3C]8(MYJI0%<X%*9^:R-K[M@DV'Q-P6C*AZ%]
M!GL.4;]#[NM)DDR5_*M'T]#LVRKUP&V#;5<FX!BJ 2M.NOR!T']YSG)810I;
M\^FV3/6UF_S%4.3<,82["B_\_'A!F%YL\U#A$W(RZ/:[)]/(VPGTFQ0]4GD[
M3D1?1Z(X?QJ=@YRSJQ8E^,PG4,6:-8M2')HAF$-@/\WENS:#KV0-/?MD:MBS
M^%V6T6KM]>,)<N@7M*K__^QX+3N*SIZ;Z/?I/F[0%<[E;"577)7=5*M?LS9I
MJA<O^<X[E?-427DS225VH%0H&\#>>\[Y"^G??J6(3:ZPB Y?06F;E9!4ZRDS
M,XE+=O<_5OSVYC.W$_K_VA"; R4^4HF6T*+$DKB^'X#XB4%Q^F8P6%&_V(C;
MD<.!.Z]P#7^2VXW_/KOOHK_=NV[:#JT%M[>J6(]LU57<QYNDZ"4J_K43SO-"
M90R]4@B/0T/S:PL@?[K,'1V9  $FP-*C7MS)BM&+6688=0*)%LB)^]N+@I%>
M--^%Z\K>M[OL>.*>U]9$]5RGYVC-/#+/#/Z3^4!'\N-+7R@8T:81<8YV@PC<
M!%XN)L".4[+:FV#D2Z-0K[&ZQ$2;H*S$L]@[;+(<263-HVH#!?\QW93_-H;R
MNS(BB@;JBHTMPL%&?@0H10'1OLU'NT6!SD]!SE \;4B:8]B:G?Z3R"=*4UVY
MMY-_59=>?/8Z'2H EQS%>8)?'9V?39Z'G@I>O#WBLV4V_1OQ0P@O6J109N\_
M/F#46W:54QL].:G +V%K8F*UPF(1N%OCTM-)8I88&G 7+!G E0S$J,1YN8ZL
MC+2$\5GF&;KIBS2D 0PY)RS&;"%-5:",X8B?8.)]G)@'$\!=AQ.&6XS8W_I=
MMYZ!==0E/PIKO>6B]T[W3>#E+?L(H46A5>E]NX3QC_PZ93EU!B8##_R':\)0
M:BS5; "7KJ3,D:'C_FC.OTTQN#+C\.?_G(LF>_ST%'Z=O1!W]@*';(HB*^W/
MO\.=I;D0MQ]24AB*Q,SFA:BFF [[AMHO_6Z7%4:V3J_(S20E+7XQB(@U-] .
MT^GUW$2D0?-X2I:-+3#[8=%\YE9/^0]%6?C)19$F"7;-U0O@RBA!WT%R^+I&
MI2MC*G7](BLK'(K'8XX-G4GCXLA5W.]-^%'!_Z@3@SFT^5=@.[12TSJ&XV,"
M;G-\OS9B2^%MSSS@UN?M_#)E)&,A;V7(+:=P<^E"F/4O%*9[P\6/:N(6BHB#
M7R'>7DP6N1RC[2-D)$YOO-22MKK55'WI]&'$<P[AGT<K"9,M5I(8Y0/5]EZ;
ML)=[5OM@X0HEA!?L- 4$B;;*EDVY2/QG6$-5PJ:OWJENN)FL8J7> +I[Z'(V
M,B5C'T?C724#QQ@G9ATIV]VIMSD2MBKZ*U(^B"7*5\7'*0^LF7P0!3PQ/M.X
ME'DQO-- P7?)!V9[7=G=HKQ4XDZ%^(8?$W"A4L6+QD:PW9L*\=D7VNO+:L!$
MGS6^DG]9KHQ#)O,[P*\_XC&B[1KC.&7]!Z[NJ^Y<HOY9 ICKSX2[%H1_I;IP
MVJYS]=K/'[&I@"N/YI)6(_]!R_<>=HG5AU<<V>\R :JZ644;%>-,0-8A>PA^
M\QC1VIC^&<NW[G1F;,GS6>L-\D%<<_;D N??938LE_F,Z;DD?/[0_1?)=[_U
M/974L4Q[%V2TZ)-%1) KZ2DTXS+[8%D3O-,L92,,=_Z/<H5[8-G]B7,1#CE<
MLNQ#-L_PGE0=Q@\$+U83;I?8S00(5ZCX;UZ<J<P+;1KJ))=>U.$6PNZY?^=X
MX:#26T#%E==9%',:RV,"&W"0]:T=K5+' 655*RR9^Z'"JY. ^6/0MXCZ@S:N
M> 0OS@O) YT*9NL4B7GM5S(QV5EJ[W:@9O=>0,Y9^=)#Q;HG\1?G_:#H.LME
M^H8"0H7&IOW(?T&NNZSJYQ/[8 N98^9\"B5B@)/LH 3%VWQ?OR)_P2@*6NW0
M.!0/2(WR+-BU34*:)(%\DE="M4HMG':\4ZN_DV4QE'>LX2L\X-\Z-)C1CQ5$
MM2$ (/&_659I-DZV?ZU\I^WO14O(MQ2I*<H#8L[97]S-WDM0U#5_F"=76<D$
MH YSK$K6OLW8]<ZQ1C[",V)JK@J8N ^,%T3Q1O!.-N1=VIOSP0U[N]CX5%2^
MGG:-E/$Y9TCXO,UI#(C<8;P;LK3(SH$\;W NLGN(]K:< 2:#9(ESFZ^I]^S_
M,3A)AO&$]<UKDP;^2.OA+-/Z:6TNF0HQ3TDV_6KGT12SB+>,;ESM=<Q&.[%(
M0UY9"D<Z3\-YC:'S.)Q_W3C&J[]A("3<=7_Q=3/;C%N%?*?E_:G6"4T%W4S[
M2S5GY/(_O/W?G1MC.5^A[I\&U5Z(N,MH'5SN)G@J&OR6'5LZ'RE>!=9 _0[-
MWA-Z8AJ<)C<JXW&U3,]:TWWB90'NO %F@ PTX+,67F,/1G1S30BVS=5Q=*".
M!0]V'&4VBJ]&*@NL0JJJ<_GJ,CI*Y7<S\I\_ON?&.>[$L>BT8'#6V-#3?ZOU
MMO_BT-^73  ?2,(=(8 5IR#;LD>FC8H\&]3^./2X]=9*W2TRE71Y+.1Z\:WA
MC7D\&U65T0LZ2W\'5RW].\N=]7!4U.*;?6*KJ5VV3N7RG]?224V&D4_E]*QA
MHCGCK=D)TEL->$?@EWGZ4OJ_TH7)K(W8>;HS.7>$H3N[%KK9G:A!A=5,_KG>
M 9X@R::1GADMAWSH2)E;!^VZ3C;/)<YQP*5)4]\/<KE)#4B)^GQ'M<;H#ZF+
MJ2&VT@&2J;$EUT]S7'P;9J+@8)D0.8%@T>OKAH6CC:Q(7,XC;D<CYI% 0(L>
M^G)!,$.!)-[4L/!EK>GCTZG*&Z [JC^-QAB-:&>*+?4B7(N.8J@&EQ.@,<IH
M#9W]"OVIZ;]8ESI=LZ]GGE[*CW]J989]H*-L-#"QIKJ]OSNX":%R4KC(+;C?
M*OHN9<&)D*P[*385AO%!YTRL;A4=G)9,E]EP,M2U7/EH]V(7>AG'_;++>F4'
MX;MK3>/MNDDJ(/^@YX/4\^D%)FGK5.E[+5T6=[,=*D<V^5LX_A*PDY0)(M=W
M5!TX"K<@1MIZS8DI+C^L4GV>XNFNFDPR*50#.HAQMYWPO4\!$E7:YFIQK[SA
MP/ED=:J><?2DJ[M8C^:O_N3AWM5,OU?7 ?_]@O8MDG0DC3V%"K/ZT',E!?)^
M ^5#/1@Z'!G;HL@$G BAL"_TAP>(MA-0//;E/B+/R\L,E5IKEPSXHKB"CE:P
M_4/ZZD44:#NY22+>&9;_S^HM/7=R^,>E!#U_-H#4Z]?((@_SV^/ZR,<U*RMK
M(< -/%6-8D^V(T:4+FR?F5V;_"B2672Y-""DHE\,PW/O;T*$VV*2]X]SYUN-
M5[/W>^7R&@X8%9^I6":@!%4$%Z]$M(E&G ].M!O5M-\6H-W()!\13$N7&+^K
M#PL#KW0S]*EIGML*"CK66EH6C9\:0X$<?Q%$0]AKD?MY_/WCI8MFS_ET//4V
M[\\\13Q]@DEF B[S[^-_P-[,<E $%S)8ZORUOI;+0JM*X$'*F'%(CM#<E233
MGW\6_:JU*R<31CY,=L'+#M1:'BTX KLEQ$<USB/,,&-[WK<$WJQU;5TE]0NO
M%0)W=/%=@DP T0CZ2BOWDNY'B^#*KI_?8!N>X8_.?P;.3),T_K $W(<#=*-<
MR;*)P_AH<_/+/1V5:";@-.T2T;Z-G"M(M(KV7*!S3EU2JGA]Z?U^4."E3P,G
M;>-EV;(IHF1[XDHJU3!B#ES'!,1K3@EIHKFFIC Q=N/_M#JOF%V,%-J3?S9W
M@/>@7_I_L??>44U]7;MH%!$; E(%(2H@*@)*[U&1+B(@($2(BD@3HM0 (5%Z
MDP@(" A1B@@(^2F])71$0*0W(23T'OJ&M!/?[Y_O?;_OW'ONN..^]YPQ?G^L
MP2!K9.UGS[WFG,^3O=::CZH,VD^+ZKNN8T9*=LPH*<LU<'(HY6=VD>N0F 1>
M.(P^4:4IW]D+>L[7PO=0UB;NB-05_T]E!8NF,%_CH;2.C<K,MU7GLF=C]J0)
M/XFI9'4P[93X#JH'Z4BOD<1&*FE<DTM+X]SY)-RB]AV6K)3T-D#Q=>8>[J^4
MIF1EO#"CL>^C'?B.,>QK@T!F#'<YYND CZQR<<\O!S:VZ/ZLB#6=D;I7+K(^
M53.P$O@RD00?@9/&$"J-UNI)JYF[WXCM7H4=K!EA?/:NL>*+K,E#=[7M0^H"
M/#[FC2X."BJK#/;8VSQH_=4-5^>(N_<HW,JBX="I(UI>+&HMU;WNUK?%9RW7
MM+2/Y0%J&$</4(ZWB$D&V0X@34B5$D$KN2[";Q__>C\]:<(7]V%?^J7&8WP:
M($7AJ$>7M(5!2&(4P8C)7\NBM)%QFYS,6=.U#NF$GT'RSSE !UH"^/ET*]N2
MGIW:Q2K\WC2-PY9@FHBC.DW/Y_$0RI9ZI\!RM]OSXE^_1[^R7;AT-_S!Y!,G
ME_KOJKA43266+WD!'!^6XHD3IF0B]YBT!Z.KO\P@>;PN*EAHNHUV$C^;]>F2
M[N;Y=$^KIU8Q)!.1)I1P&64G)==FV-FJG-PKJCS!?_\4][6_S@J-Q0UL<#3#
M  FG>@C8K7<Q.9EQEN*2.FIXA::!%H8*2$F$IEWRY=(U*5 '2:\8771+>]#]
MW'[9WZHMFO&3\/7//IT1W\$I!G?0T:P!V6P>.S?UT%;RC@^'AO'[0P]>&F45
M)!P0/X^)8(*^P4-1HJA?8@I D]/G)=N(&$T+WAO>::&4NK):QVR-1Y91-GKG
M=?=2*V&M=071>*?.O($+>%-O_<LS,PO>##>'5""5Y56W@2+*;C.*<]">K"5M
M]U>Z:57"0)*CP;1Y[IMO?YU0>&,@?O:Y6R?!$3L\5P_[)HLI&D$HFY@S@AY[
MIZW='<R-AB;?>R!Q(SON*H_AX\,**9J9UU:][[6-NQ=70VYB:Q."E'C>RK_1
MNS$9 A-&_GFI8X(\#*22H[:_%_ET<W2_$#=^X4:J&2:7Q[>W:S_X:L"-+A'[
MI7&,*A^=:8GRR/72@'Z<_K.G<[F$,K;SI*?XBB8[:;MOMF9LI\N(K)>YN@0W
MV:A0%?4MYCME</I"G6NTM+Z4C,VQRQIG""U<$8,P 6U1(*:A.F-F)3RCV,;P
MD=>+3]62C;KG5X)B%W\</11W;QL7#2']P!Z"S+L KYB@$!$P0P='F/^R9[E7
MG=2YXA'1C/JSZ11" U$RLRJLUQ'I+9_SSH_9#O _[NX=537<YXVFBC>)"?30
M>#^,S&>">Y>W[,2Z-&O<1(X("#VVK[QW%S0GM>AF_B=$C1^9L298M$!W[E!B
MB:4;-)_*?I]"G$";X\Z1*Y\R>1_!P4DSCMRW)#A+JV9ORJ^T75?OCF6"#B(Y
MJ3<0!@"\#0\.L>]CV^N!/XV#^G,<(,<?>>+Q6TSOQG<)ZR!=_<LO[@;*;1+F
M</E^K@\ZT(  #1/FC07$X?4F*G;&U!B"D&MR-#4NQ:_@5ODRI/KV<XG*?4-L
M !72@#KZ"W4&@)E2YL*]"^UX=?JF-HJ^/.M[\@(':TXPE-@PE$@P<>^Q[MSS
M#^!U1'GD?2>*0"93(&PH92!KJ=E:0+@BM,RM_?90 O!T5?74K,[ Z"6'>+[,
MG*QB0XGI!#<"/8/P&!R*+3G12FW89^O"E:(LED9+"2YUEP/"GK''GIG<<ZV:
M4FL)'."_2A\M]3Y3M^OOZL_19CH2P?*&4G DC:T02#<;/,L$A:I8"!<E)6,5
M#>%>5Q'#1P?(3QWIPT)6%N$>_E-#\UEA63-V:YN,!(["FBT&?@>1LG*)*DI3
MI!=L455KW7-_5B<EO%O>+I)_Q+Y2S9OP*M+1L5O#[OY!0Q"OO2D)#4A"ZHE'
M$5*P7^[GAF3EMM.]7*0BUV1)*6;ED6]L'EX 7Y"OY[]R_K?E.Z<TJD!T$E^B
M,8O-#F'-J])=\!&"%">2<A1%CA3W:M+T9%U_FG+,@>"C<G;V_O*=RS\M+8T%
M'M_A.QE@'<WXQ<I!=S AZ-*4R-QU@9H\5W6N*-EC]#PKRLJ/L0ZO5Z]FQ;-;
MV\YXC%2^E$?P;VWS6]"GJV8*+T!J,%>\]7\22[#+O)20'8?^<!S)77C.;%U(
M1WBI>IH\N\ 7R_W.,D[^QMFWNA*GCHI'+T%<(".)+"N6J825PKD0%7<'KVS5
M*5A@[MTO3<W"=,?S_+J2^03^MJF"C2.S;*G44DVY+TAY3X/QV%!O9VE_88\S
M3BE:Z9:(F1Y(]&6>F:Z!>Q:+!;\*^U^LX_K_JB'F&C.UM6@NX*TQ0TA&X3\*
M!,A,[00#_9"QGFZ&D1(H4/3_P7C\/B;R0[9]'L_D/A@7:KP;O?3QC:.=T,,0
MP)IEGC,01SN_^EWK@+P(F=G!6HT:S[9CI2G*/VY(J+_Z4:Q-61D299$7Z5\-
M4ZZ3,XAGN_JO4V?N*1BY*GF[/:V 430QWXUSG,?C^PLO-5@)G=VW0A(10TO6
MD2Q:#FWI]4\;BO"NLX+O+?DYG8E3/RD4&\=WLB[LZ0+XL";'A]^Z+QPF5TX=
MCXPN]:*'*\<?F=?A-M">G,6G:=XP3;'U8.0UF(9(5]DJ)=6),M8 J3E, VX$
MUX(^K23M%]YK)]V4^RK]?E5LY(Y3/#=D2>37287^:+H@X$0AZ@-FDV-@SOEX
MOM)R]DR;JT\R=3H,IGT>H\^"A$#'%C_CV$13+=LTC V*(X9G3I\4N7CG[NZG
MW41:PGQP]$7<V?W_Y1H4N#.  Q,DQ;..8TQB]PVVEWW^]9782ZVX?],Q-ES_
MY8478FXEB,4FU\C=5&\FJ+?2[5]^ OS_L+%U05Q,]\YI*S!!.)8=/LKXHDXR
M0?'Z.JS_A2!;MD,B5$-T^_%U+!VAP@B5_DJ!T:+V!>F(&TQ0UN!+9>?_66'J
MS<V=G6H ^WDQ^.CRA8B&NYLBHP?-QLZL09)0KP;<=4S*!MR?E-=6Q,T>/2RL
MQG<5DN$/+$NWFGF_?8\NSANB%*/%1#H_OC,*=1W+7I@3[-D;P8:Y;[4$@)L(
M$0&YS0'PZ-GRUE<GLT5K$Z^JR@R!DX+:UPMW#E%V7\L=SB79'([PW0A1(M"^
M.4K-:E%>V,>3T2.K/^1&5DW97,P*NMU<;\N_ZNCD(V'JD+I7PFN=("ZEE@/5
M)?LQ8/)/"QAGQ'WEO8*.9)>B1V*X$J*Q6-'D3E2M=(ZB*H_(_1\.GY1CK5J0
M%=0+-&0PN8/!3XR>$?:+5@RG*AH_]]U;K#2KT#+EWQ8-FA6HO<;WEL0$G:""
MV_=V+*+:-X^]>W9SR7O?2,Y28O\3)@X"[\9 **\!E-RA^5T-'Y&US$4#S+4/
MJA=1'_H@#\&O.DCTPS!AU[L7\;4B,DUQMY#<;A.U-E1E@+>5<2X%.E@:5M<O
MX;XB_G5I;RAK?M^D..03U&7GZA>!Y'GQ.*4SE^.":[]/7K[76FOIFP8[MAR$
M%X^YBK 7#-=)NFGV?GRQ?6QBPVJA[Q<M%Z"3]VB.U%OC%=$3]Q6I;A\/Q-T.
MNY\4>8CKIO0\+@Y;EA>J*47Y)'<,J9&FL5?L'@IQ+H?];LYYU*"==P'_=KUM
M>7,2$FG[5W]9T>'CZ1-L)M^O<!1?@A.<L!'[$1$INFC.49EH^H!E$U=;T0M]
MF59SG_<7ZAC5O_>C:?"F=_..'8+A^<_D[<DO[E:7EX^OE&<Z-1._P5OD(L '
MD;SYB$0; M4I:M8]?AA:['A$_TZ UP.33U%DV)C;E"6]\U10VHC>[43OBA I
MYRG-(>(@^ANQ"2HC9J(.X80>R:%V>MYGJ!6GD(B-X./(*^'.-+7<MD=SZ"^.
MTQ7E)K<\HS?#U/ESZM[[&>UG\-?>^O%\./:I6XK9Y_4R[]B\'_T.T\GMOH-T
MF[U4THHP>*1[)[YOI:S"9GEK[_GF [GO#>$*O?A\>C[!A>L$(H3T>B*"Q FE
M6IM5@@Q%7TH]=GB#V,7YK<\M,T&3Z"CU6MO,NJP6?W\PK50B&%59U'T2*4/!
MAJ[8$XU^?5EQ\!EMZCAAL/]^<,NS4_=(_\<[AC?M*_13TUZTFJ5;-SQ]]X-?
M*NI#@NOZW<0[NP$JA">83LB(4\OHSU=DZ17IFS6]FI""B58']=;/G46GWC^O
MY<$VXG,H\' 4+Y*K7VK=-(H&%8Q%.EV2]_\RX9!Z=$&H%:*^(\>#:F>".#6-
M$;O68F+1E\8K%&YVID)>%>&.HKI1!RD/>KH^S7,?CV0LEPB\P5#GT[J/)PTU
MY9[VK'DVOK7G[H6#3'W)4WV[U+M32L\R>A$=[%FA;[[Z &\(_4Z;IA>@KB(B
MR'D8F=:21S[9SLG+[+GO)_,W?LJW#6FYS== 1M&DN8;NEU;"?J%/8^X.291N
MC$I;SEXR@"A&C.+?K^\VR!VFW=Z VO<\K$G@"4T4,1![;ZD%V?$'T)_F%9PI
M"->N9[-@5>ED*:&?+DVL>55D_N7RA9F!HMM?-=V:WM$JV%_A0O.%[B:-JQI>
MA%AM!^V[]0.\.S;K;2$T)7)78!M*KM\AT7YO]EM?O^/,NP0$.*J8]\[ZI_3U
MXSLO8VS7NSJ:<HQ][?6JIAX?- K64K=>@(>BGQ(C,H_6"@; (V2L9NY8&1YX
MAO*!-F._S35A^-T(HT,3HA5N69YCGA\)(+<4*IA_^=%)9VKQSA#,@HB).GVJ
M\YHJSL$R\+[G)7N58*/V&]YV<+_\C;65%U0KP,N*XHJ0KE].\4U@WX2?NWVK
M !(6Y ;=T0?B*4LDJ>"MCN-NY4.:ED4&N!><:1X)Q.=@<>_Z0]:]^//T=&TQ
M1+IQB&DU9:9@K*GQ2(,Y1'B$ FG <B U8CFY;I:5)@K)+_]N6U<BGCFIL(2^
M_SZ[+!EC>@OYVN,RJ:6)"1H& O@MIV?D K2I\W/2]N//$H:7BV:INK7F81=%
M==P]LL55E?;RJ0\0)]?(X+9N[AND,<O*FF^1AK[Y0P<4,K7"@NK6IZ9:0RCZ
MC16"*4,\[?G5/&Z/BS:_CU=NX<3HL2CP8O4/1 A9*OJC0Q#Y\/ES9^=^S#S7
M[SN(DX^]UA=^5,L/93 W63T<)]A(5LW,<1?QM#!=:2\+]#,S'-^%*-G9*E^N
M9[$7CK( EMCJAC2;0-H&_>S92BMKWJGRMA[8L%'HH>.3MF>Z:;Q+NH/:%UW5
MQ[<7,$V;MQTQIA'Y.]K!>"P%UD1G(S&2!+ ?%OX:AK:"Z*.TML6 H5?!WU\<
MPVD9>N;L>W0/J::WO,]"<!4^_$SUOQ=78/S[]6!WC3W,ORBGW4<YQ45RRXU_
MZM:G)W>BAZ>Y6HO-=%$ORR%OGNSEC'_A,].5O_E?TWT>9-J. J>_3H,SP@?^
M4(_2BK4K^#.CV&T_>^5>DJ=ZV 6=^+66_V;E"[^.>8^[DBY]"P9Q$0P'8]"M
MN!X3Y;*;+\RMG 1])F/>#:?[9R<%<OQ(RYG@'>"/%"!%?(Y'M]8=CAZQBO]!
M*1V9(U"B%[&;2ZR<SDMS9LD3ZWM,$!9&B\1.V8?I0N#G4?DGES>)@*Z/Z=Z?
M15)1#$5THW0!NAO'N&6ZCKN9A8&?W<_1*.E&D_@'('-#3-!Y*:"'"3I2G,\$
M:1/V>""M=<>BM6I#%M^L=FO]T_CZM//5>;1])FCZ%A,DO'7YXLX&5X%.C>8N
M@\?.@A&$WCB/?@W^3^C<?GW.'ONN_3>>O_'\GX1']2(2_/E[DV<;][83QY[5
M3^QDY5G'P/P3RVK#V<>Q2W:2_+)?4G.>;TT5%2N9.=PM^'CO.4CH8(8N?U3O
MOVN=V_^?[<_:0U5ZEK82AGH02WO['P60WZ-ZL*<C"ISSF"!)^W^3\OKG%8__
M6 '\SZ69_QP>^F\ZN/!?RR[[_)=5D?^> U7_I"=E>@YD.@SH8S2LT%I\&$?G
M&M*XZ"$K3!!+_(E3]='M)];SZ"'$O>@E)!?+6ZPC6-D7#/\/^?=_=^HDQ10#
M^?8T9-T3OA)SE'AC_8K#M8DQ9$WDPGMK3),3]3;RW+C[B3= S>U0]QC-<HX>
MMY5JZ8["E+Y\%?/TYXF+&;C%H%58J^IO66'5*W:JCR^V.?=C5.0 QW6Y6B"%
M(7Q\)PJ\>:>-3B&2]&F*@BL\3-"M9321D\&_TSK F*=]'B6,@Y,<Z%@H(U@2
M0,?/,T%%(T[THZR_TTP0+7X=\D_?XD,WW4#U@+?^8T38,W?8*N;'ZT)ZSY[9
M]C'B%H]<$RV$[M$!F3?59X*D6&-@HI@@T@>",V9?RH$!P"G9?R!%LDSC"_FS
MJ?<8U<&5"?)&W?O'0)C/5DS0AR@4>!J\Y,O2_C<#('L0)D@":<JBW^S46^@>
M#?!N$SH,3/D%*]6G\WYE@I J@/68B#4U>R/[/P8*NEE!/V1,88+.,D'0;]W[
MO*S(Q6+O>^)D-. L-RK.B!IF@O BM(M,4'@P/0LRGX&AD@B-^.%_&.(_1EKD
M)\R?AT7L<>R/)Z-_96(8?ZH-@EG:_S_?_/^%.<%WBYB@&Z=HD.^0P>421N@6
M>@/-, "P_W+OD/]L&%RY,FY7?T;O'Z/LA\'WCZ20&#<8%8[8+:ELEB<P01OZ
MS4S0/]VYN>'4VJA7V]=T*.=AR,G5R9\_]"!*N'+?/P,9]^7QH9T& HQYI)$A
M].?U?;N?9_CXDKOR(0TUX/-()7I4<1D7CRX9'JW>GWF^_VV4=GOMNPJ?N4_2
M2V[&]Y^Y3U541#T*5CH6_Z$>Y)O_N7A96R"97\D$7K/(<&J?T[SQSFE W$)$
MX_."4*YSBV^L5:21[<7BIKE_I7;_B>+EH&>3611Z-Y<)6K']$^-&]1DN<#HF
M ,88^#=Z\W_?@C?&5I*[N=*OB'RE?H>ZQ9ZAN"DP>'#[T8MH@/60!S]P%D@+
M_N</LO_N_;OW[]Z_>__N_;OW?X/>0EL4AHZ]EKA2D:)F5R,K^9OPP*$(Y&S]
M4V9=OPEV!.*,CO)"5#-,A$7MB<8)+1.]+NR-;6SBWY;U)I6MM3_$M8'US:Z+
MJ;&(5A ED1'>3?LTS@2M%T!(./PI]*\1)NCM&(&A9-^F"T+,T91V&TWW12 ;
MZ7Y,4.MG%I/" X9,D(X3P^+/*9X#@:)_-C%1AHA'(?//F* ?[D26&F0Q/RI)
MBLZ)W3.I88*F+)>][W+$H9M@2 DFZ&,)$W2I DUSQ0!N:Z'8+67TC/(:$_3:
M^FO/WYC^QO0WIO\.4V$7\BA5'ZG1@U= WAV":^I,+]@.[<"&9;5;/"?\$I^U
MR_T0OU+YF*/S<.!3?-&7#)7&:JM$G)OP0&Y:4X$KPW2LF.V:@K^!N6;P<^5\
M\9<7V3H)_WQ1_7^YWO \B\;_%T. _\4&.(<_ZOV?#7'O7VU0%_=GG\<_&\+L
M7VVPHWZ1K0WR-Z:_,?V-Z7\-D[8Y/9O@O!:!T@04R*+';ZYSC95!"25[RDS0
MXRJ,[]B[#+Q3[,7&0C%3URW<OX2A3T!A8[7UZU*1(D%H"90NNP3/\%C^ 7:+
ML+\7TG11*]"J[/^(J/@WIK\Q_8WI?XJID_4YVJ4[/%,&L" '@8W6Y4;+1#JD
MHH^@&CS3AZ?8O/1 -!-O,5[Z%VU^%SQ_SY=5I,7,[[$1';Y\>H:O[[</AY[H
MAGQ?L>\KGO<5N]"SIEAT9\1CB_J]4Z%^^N5B0&Q(/&"9KJ'J3565<9_B@=;'
M\+W Z5H*L5$.OM2,^=\O8/[O&,3_QO0WIG\[IKU"LF +$W2,YC2($G.Q/X:O
M7#_\\1%Y'&)1'4Z\4R6F^^59AT2G[=6#^=[MW:=QN<[_GM> ?[>_V__1C;9(
M_U3*!)VAW6>"@J,!+]+3F'6'5AB7XO&UHS)4#.=B27WP/94KT!\V_,;*+>S5
MDUQ&='Y<)V$TY"X0_PG=8%8K VE\K7!KH/:II@!['2[29O!7JPGQW?WLC]\?
M3,TNF1>MG$TCL#PWQWB[7]+GCHD&$K)_#PXX!\S1-#K:T%N^$$$"Q0O"!(GA
M?  NBC$4X)K,0-\98$@"V63+EM]%/@(?R8$5F8$/SQ^?R5;X>CR^)J0_C8(#
M3 AP]#ZW-C<3-*D[Q 1)#O40CVQS10EC&[T@+4$*MWJ1SKKUE66430W;(PWP
M*_E^7@F5W5V#258#EY.#A*;@+L>+\^8BEDTH$#)\Y1$EVWP]+I]J1#.GT';V
MNUK?ER?;;O='E9U2YDQ.5Z.3:(7S8, O)8X)FE]&R:$G9]$,+=A5=(,64I=J
MN@!C5[J/.HF U@=TA]VI\^Q]@$BS29Y^L/<"?O>4MXCR<INHX2R^Z%>M(]6K
MO6AAH1#!2[IE:_% 3W:Z/'.NZ[X?YXR"K]YD5>N-V6HG_BY^?G=Q0M;0]GES
MEZZZ9S,5A7U;VG4]BGN*&0*-K= J^$Q919Q@=:5$N\+EEW91BVVGM6>+%0Z9
M=][\?%IBBW^:>(;@VAV&+7'_B8&OB[2 *7$=A1*X)X2176M[U]9[:O1FTPKV
MH34'-7)E#6QTC(1;X:'@R$C(,9H5X^R -YK+SO1R6Y[=F*+DY%N]&YD2)XPO
M+60F==@6WLVP+#0DU'C9>@\INM3).>XN(XI26H@Q3% %NAG#/T\\JOF <!S%
MA?!8*!W#"HR.R;1^+/S-57M6XG5,++?EVS#'QU#?!G0;X5M*&R88+UJS'M&(
M&^5MS90;4JP4GH5Q J/H%9$@0^M9YZD)@]>1APY42+QAR[.=8$U-P]$1**-E
M_U!R09;_ML:>;/34!3,U,VQ0#)@4394MSS?I-;H:,.(V7H:NZ7 [?3.OU,/<
MUFYA.@//!&FM(I<HV3O5(6VP;S*[K4'0IMT D];XW'&[15MCO874HJDKC:>:
M9E]3CE6H<@9[<B(W*7XDN3;LF'%]M5^+G  2-807=;$=,U9.(A'8PDN- Y_/
MW*O-/Y^L9D7:+;]J['0V:(^,X729D*=,%'YP$^@(S'5-_F8S/D8P/!]O5(W]
M? '/V8=V((XZ[=B?&D&R 5\_+>$YXEQDSU+R8C[:]1R6K,WQC*U-,+SX*]A0
MPM/U0=:BD8ES;\63;7QF #30-3HZ(4\HK\"#/KJ 2ZX8W==.!KM,P5^#_V*"
MVN 1F3SK<Q@/E!Q29KV,N.-87I0/=>]7'$OXD1VX^O3A\8^2&:_N3K-+=]NM
M0]OL+P.F3!#[!<#N!$-B4*1>6[-GMB_NM1+M4Z/&_$"]]\N*Y&*#BFD0RG=[
M3K !73'4C LC<"N"#Z/Z(,>MZ]V+[\A\09IEM\^Z=)U[6%"L\J-RVL/Q;=)W
M29":")IR+T,@"$QR>H6Z[-*3W(\20Q1T6/[.QIZ;MGRQ)7]$8:O -*GW?<:0
M4OI&2HW3G)C;^)YO995_DH&N3>6XG%*!VV [U)TZO+4VMD2>66O CCBUJN/C
M_5XXDD7FIWH5\[],7_N9HG)2G%/DTG<?\]4CTWSDVFS&T;8I4U$7]=T67"B$
M%VF<#V2W3/#VNZ^)XP?6'*M35XK/"5GZGTY_>+$H=M*_E#@Z9ADR%;%RC:J(
ME/OZPB_7!(F$YY]_'^)^4.!E!56FW)&F*]?\"<Q.F,R#G40:$2I[\1<0*#37
MA(JN6^41Y_9MAY@G8 NC:%?4[I@GAG&PN&A)Z>)>F,TEG7'J46,FZ* OVEOF
M_-R*RQ2&#TC<::9C4;P(B^9J_"OVYDVWT?WYW=ZQT\M3&J&>[X8]]+COU)B>
M?F3&Z,4*XB\BC>F?%=$C1))^U",*&Q/T1-0-MFX!O;++T^AYZ+FTPWL^-7.A
M%"''8R,1.T&AM <LIXA">@$O >QMBL_KBE#%!?574IRJ' /VEVXP0<5)8Z@!
M\%=W%A4S%7/&\N+%$.0E$J%%2X#K6U/!S;#)FE /Z3,%1\23Q?TZCR5\B;T6
M.Y5[^8[10H741"]!SEWF^\JBBS35*%JV2Y)_\<O,9DT"07_>GQ )>4S$$$]Z
M:V!YD!#Z9TTG,A??<'W?IT2RYY"OW\]L[?LVCO'B/X^<UEL\K&^["QE.W,%4
MTS]KLRU,7!EX)MZG>0/^XD)ZP5AC[F/JK4>&WAQOOA2_#KYSG"<Q=JA;$':*
MX(%[>=6?(46Q#F,H.BM'.U;C?QG$;?_RO16K-[(/U0JZ095A]$T(T0NUA7$Q
MFFJ<K5BEVMENLU[<M3F;!Q</?10/-Q?B?]0O=OWLJUHEB\$ET^2:W9*QLD['
M/-GD(.I"10$1/_?5S&#\9(#U+.,K59316!%0M[5+Y-M277/,U,\0:2MWMKK9
M_)<T(<ZKQ<&ORP$J"\7F*%K/89J8H!&I'<E?M?ZD+N,F+&\IM)M[9%%Y5]BG
M%J56FI%;96B992:$K)+E<S_SGDS0*326O?<=7ZXM^:?6&6*J19L=$"4=I4F2
M7SLU6N]F7JXH2=[5(23W/HWZ@+ULJVQN??8,;^RKA5MHBBE,3-.52!F$".KI
MH:<5_B3'+V#@2LCM?Q0>Y?S&"JI"MN^2& OPDM\/P<\&M^R5Z'7(TK%)KE#H
M\VNIJX0]V2R!Z<3RVFXFR!!#XS5*F0U>Z&"%:8,M^$LFZ!LD&L5)NQ[3'%#1
MAHT$<W_IG;A_,H:LI6>S<K\2I&85'S[3QB&Z]%L22"4=4>+T;33E=XXG.E^[
MLE]6Z'HURGM^V,.ZTFXDRF!:L/Y\;>&.YQ#!N0AF.\@[Y11.$\QRB?*(N)/8
MV&O4JSF&?W1A+V?/=ZO^S%![,J&D/(6JBVXPTE99P%_.7)RJW[?$)P5]GG_^
M6_.:J]_!0<ERFW)NHPN.R">>@N6N](4[BM1/=)G\M)E8*>TNY-H35# @18X(
M04GJO) +U81^1!1(>PHX]2A=A O(!QR^5N*PCE,$"DF$%;E1*9)]'A-T',O@
M[OXK!@M\0(W,,$&-)DE+,_2/*GM!Z %#C.N>Z<X$($+"#9--#R.# ,@GJ>!M
M.[!MQ=>!K7&940T3O9\/5O5B-/1\V<\]/TG+O,<SBNH;,@QD15 .^EM9<2;(
M6E$]-F;KVJG+CUSZ<X8V-PA2'8%[X]J$#_=J+_7/CB4O==EW^=ND,PZOST7A
M()/Y$.[:2Y#(,I=:&;?)2H\/OZ;Q25^RWI5E/C$X_LQZ;VR6#7)M6VD[(J;V
M!:D[8M]P0-.,S"G7%/#P8?BF=5W<('?;!Z+X 6PK7AX(8DDC!)#"!#T^ ]GG
M3T(2G*@ZR!- $=4$J;^.69',GU@<K%;.NY!$ I\HR^C<41[\^OV'HW?LH]3R
M8LM*B:]G:36/3]5=OHHO,J2]G<;#[Q%(KUVE[WBR(AB5)+AAJ\($G425(2!M
M$Z>!B$^BQHUX\5ZD2=[A88^MP/EB,N<"7EE<>R3/#C'5E*Q],:;)3_ML[PI-
M5ZD0II]C'"@\7E>=(/SHJ/OLU7O!]0XAW?Q[Y\B84? D5R,3A&&I29H?59EH
M-^_G9UL:X!=="V'/Z"H+6\6*@[IFOA\,MW]>V$K^<OB&U#C$#1;*N3[$.*9+
MF6NH$,Z83?T(0TBFVU)/S)[V>&8^.S-=\5MM3/R07AOE:]&5F?8?19VC0S\T
MAS:A_JM%WH[>5:L,OLQ,3[.*8@;4-:B;!(E%'5C?*7J1"SBTB8FLB^5Y'$WK
M-APH6OT4R19L(^ZIQ_49E\$BE#G$TJ2U>M@K04.2G.#"/@<&7BS3.SK<=1PF
M8N7YK8-/+KF^0>RA1<5[;G\Q?ZHKHYD)XM(^33M. .(IA;<PI+4X30Z^@(SP
MW*P?ZXKQS4T!'<D:8X\>GZ$U?S[TQD#3FL9WTIUK"K+,-@F/V8\+><0$'8W[
M>/@-NK0V?N[ZM^"^6Z_[SWG^ME+P,^IVN0%1DLIK'_E4YU=5)YV_-&"(NU=&
MR.TSW?BZG=+<S8^ 3\&6VXHKPEE.97^\[-H8]#>":CAX/EZQ:M# +FDV#M&H
M<9 [Y#QV(JZJ81L7OD-@*?:3M&O/D#JLJSX,N5V.H:([-R&E7T]A2E=_4VN[
M"1E=&>.FMGO2.P.  PD2AJ;<P47:PD,UM?( C\9%3NV-P"!E]C")U.(B_IRS
M/H_Y]8+"_(=6U,CC:#-Z&MH1&S)Z,N]%EESS]](Z.3-"F7OQE<&)D2<8M?E6
M'PDT]\V\X!M+*767XX,'?O)4^/91$V@5_;-YM,OFB;U]Z(N?">ENC,/+5*PI
M,$.9LEJ_01G'-',=MP<BU6(7!/8'2E,>M5ENZ*Q]WVKQW=Z0:N8"+D :[-PF
M9^;"-.5(&EILS7='O_;2]&?;=RI7&[&RAKGM3N9$?P/Q0RN@L#8\C8,R%(L4
MH40T"0MBMF-@W(B2.Z4"0]6YZ1J2[>8WU9PLG[JG^YU2.YNYG9D<L%BT280;
MHRX&S*]D$SK@W5M.IZEP1(PE!;N<L:YB_6M;HTO$JJ37UMB-KDV:S!28R/8T
M")7/# B!R2 /T.,8YY&/ >E)@L@$JA\KH+A4%'@[G&%\7ZDFV2!U2/*&PI-7
M:S C!I&X\90@ %D^0=P7MN[ ELC%H)\M04:H]=R 5 /L!!PI+H8YN. G_&7H
MX*)Q$$'<2&!!CZQ.TN^M(M%L,]\P06.L&1O4^HUP!;*R1B_=@1]B-*(4*2FQ
MI3*>2SOI0"X.ZE+QR]XX=U&X= V.^/I=J.ER:N3%2?>S(0U*VY*[KY%:GX"T
MIJ:4M)U4%[+H32F62V1N*-94O3X@N]X,#2QXZ7G][,-9O"^@P'+B)9;NRX'2
M3"CHI@RY!JY9)LC9SEGASE!4Y/NVF?"J%YWI!WYD'MT?BD2-BQT \T,\UEYJ
MG\2:U_0IKK@9X<OZ);Z^;;E2GAJ?%ZHZ?53<*G:J)&V\RLL\!]^'EA%AZ;@#
M,)G8+;,,_1US-"MSK="YIJR;NOD0":9<SA.:E)]%N%8;F-'709G9:G,"0BBI
MXX3?5/3RTF8%XQ@[51AY";"FRBVB5"@<8>ZUI\G8(\9.+Q[E+\BW\S6+O,L^
M-_9"EJCZ<"69_0;GD#JZ/*\%QP>T[2  ]LEQ*<MT_7Z\G)U+LG!RKH>1:OC]
MC_*?&R85.JM.S^A<FDPSGL!4%<[&!CTH1\^-=1;:&J<_S:&K^<&\K+2_E[*F
M*ID):I%J4B9R:\J\()M>;:%C3I8]&TK_QUSM+I>NP,736&Y^J 4XEX\\4T,)
M#R%)VTD]B.L)BXBZ_4UDNN:8K\F5JHYBFL!M]P95LU>88_0R[7/(&W0LP1$2
MBCY6ZS7E:.+7[/?Z$R*F)0"2(5V>PG;Q3:%\8<F[F<AKK3 '+K)B3K]EXN""
M;!31> ^*2_XH5*7T*1E>8V6]-^X^MXL-@-)\ 3<_,@;0^P"$D6QJ]6>%T%^G
M!E?2UA"+>(,@:MW7M"6?H,=-3?MV$WD%]F,+U>[O3;2Z9J8+^:[J95]97;YN
M"3IEJ JRGM':?8V>S/"#G80VOKAO![T:FA,P'6"YNY/0$7=A<V<F#N6>-[U2
M<<;Z(ZH+(J*$CB%23$QC=]1G\Y5K_$AV*M8]DP.R*J<]BMBQJ6QJ'G[LGK6;
M80\VC>#)&88R9-ST/K*L/*..XX[F]J66^9R564(WC6Y:78:-PW+6JN6ZJ'\J
M6N=HK+9/+VR]T(>34RIT?E2GT_/1][F$V*)!<9-IOXR/FY#<,X]'=249A^(?
M0+]+Q.EJG;Y_ACM(%\E%/<%H0I]D"7$U -H*YE6\3PLDRW$O&,ZT%_[8:,L;
M/E ^,3'N>2C0 ;0*5IY]QF/%!#F,B6!':G9^ -E4;9?=(6O4 7<E39,/MN.=
MCLHB:1!Y2:DW1]_%!>P9F4HDUD3(6.NN%>%MRY;<\*.0"PZGU2PL'<I3]A9\
M9OR6G-#B#CO'@3Y/;W!<&J$9+OK#NTZJS2_9=Y=Q<9 KWA'4.IQ@2'SFK''Q
M;*#UL!C7^EPXZMR"DSD%%UF*Y75IH)7X9Q-U_4Z2!OQ:FYW&E/8*J8=1'=I'
M >+Z\2GKJ-K QQ-2?_707(+<\IQ5$JJ^1C_U=?$0YO:M2;KVX?>1Q@TNH15O
M8G@U>+F&Q6$@%+$PRFH_$-@DIDG9[EL,D*E]O0.75ZQ\_B/TS>'YNR]5S:%"
M'/RON0(4'\G,L ,ZZ;![V D7+:TO4Z5/UA:ZW+7D-BL^[A\@@T\MB/'T/AU0
M&K?JT.T[=SIY]VZEP3D,?<X31#-Y"$A-2;U$23[H@I/ 9Q#P%FONXH7'/4IN
M@6VQ 7^]'GZUC8MC@ES7#B*U$G=22]>Q*R+KQYL6*#5W>I,T-2;]Y62%9XW?
M?TX@0^\/R59MJCV8>_:H\I#U#T)I2O/:2 O2A4)L 9>@4KVR$37&ZY(?*@<5
M@Y1GFTPWCD*J?=Z<G6@3Y?:P(T6=L<BFMNNB%<HSE,H)&37^8?#Q5G.&95#
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M>3BL\+Y+; _T0>.&SNE._U'Y;^770:?XMD\7M^V\>XGZR9+2*8U<L7>9H"P
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MH!>\PJ"J<QC#<:E?3P6?U* >G2PQ<7@<>)=L)_,NW_A6(E%KD*F\#TIZ,"/
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M4.).X94G*9"=0QQF6(/* Y3)[A%L.<<^WQFPR )*J2:RIE<[]E]DUN:(C;^
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MC^.8\ ' =7WX?H09S;FTI+[C3>'U@^92GRM[KKF[>)^1$*_?D"B*(0)P"GP
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M:V=;% +>AMWO;:T'.8PZEJ@^*+$-Q/,.L>'S?>^+59^G3+ O4%@/C?,'V5H
M"@[H&I]<(J^MM&N^ZZDP?1([H-[8->2E()RHBCV@\*%?%=\"3\L#4X2IY:8T
M#BB1$L:G+NVTB7VB<W4NG80H*SPY]6&M^'?J\T0CX>$21!]#/**=O!V/]\P=
M,X*6 M8(G>((?4VL(B&<(/7[3O(AL$016G+'DP."U9='P\*HWO1OUE"ZTA>
M1E-54]?^I&<W/>E3;6!&D9UZ9BJFHI@:WN @@]/3NS7\_FV:OF/3D.Z.>]]Z
M(%$M\I7][S*;_+HO 5%_T"L-?P7$J;@TA@5R#'V$>1)_A*E,A;?I%A[.TXJ\
M4^0WMJF+B0E(74^+?_+H\X*)V:%C+?=26=(,#?9@HS+%E%K8UQ5UX5.CUTSH
MA)^!8WM@9A=%"W=B7#I1TEGW@&/B1?V]D1YE:_7NL+_UE:GZ.6GWZ#%"T%&=
MJ[7N)QFV!>ZSM8_7%)U;3CN*5?,HACY>@8LN0:@PS<2HOR^;AHVE$0Z_ JS$
M10D^3D/OS6T; K_]B$FA\;"O0$10X[J+')"I#D*! ]I7#_RE]I&V5_/?+\FI
M "DDB(!?S\>9;Z-270W^ON>=[CNFAER5YJWNULDV["VY6O_N-GJ&H(%<O3DT
MC=E6*^#J8:N3T<'OO$Q55 J6 _K5P,L!*<$(NN%JD;X";>4G>E/D8<=N'NP7
M:H[LSV= $3*C&&EW"!3 S/JO,,J<^*)=@T1N])P>TCK\(?E+YG<+T)Z>D]AZ
M^B3K$P8^<86I@Z\=5@^S5G ;S>MS3+>*/-G ,'AS6SWV6]P/_9;IKU[IJ@M*
MQ\HK"/!HJ\W;%G640;UM_UTPU!;.A[C">H_WAR:RQ;\"6>4(26I"_:/38Y3P
MQH,CBKDNM1B9W$Q'E.;CGDEI\;5B7K"I,L5D]AL'=/>EL9Y[GTYI_/P0S$'K
ML_UY]8V4^^?BE%\Q/I^+G5[2+>;5]PU@XLO/>&R]4*B@;[(K<9MC?ZH2L!"&
M%7*4 Q)CJAH?CU"8'8N_AQ76OKW<;CZFN1#@:5N_@CMY0UCB_D+XFWXSO;V'
M_N(3.*!Z\&-F&$/;CW@L+&*1.E(8]]MU)>_:XO?"?IIN7"!68V/AIS*/8<MQ
MFXLAVPZO:Q>FP^":[6,7/38M#8BFOP>*/U0E<=N]@AR#']7>3QMXC!2*T+M&
M=>_E*]"SI)TLTJ37%05&PLQNV&E/Z<O=3G^3UKZ/4;K:P(#Z$FM+X\.B$P<K
M$6KD=2$/W?PJ('!GV^I62,/<PP/SAJ[\%_6=CI&3(LKT?48KPNK_;H>)CZ;Y
MH3W08XL_Z02US?;9(,H$XR)RV$,Z6B@)+&BD&4Y.,UZ^]6FEL;IP\DI-1O"1
MRT\7);U>O1"9A/,]WYB=C]9;G69X1*"[P.(8:!S^&$*6]Q%;Q9G :IP^??>L
MLU\.:V;OC2?RH6D#SZJ^J?:J:H5\<7<<R\-P0%4;,AS00T*,+#JK.<.>"J$<
M)U6!F?=IQ+9FXVZGI YC@>1#56N!14\#E$0^?MFY]D5"D5=R*H58$85!PI=0
MXH@[5 Z(??@2XY(O1,CHR,QY6B%^?[SN?>N0.KJ3KRQ60*GS>_S\B37;Q[$=
MCPXJ>A,0A@P/IA< I?6U$H50/F">B"#K+[2"[O$MN#!PF6P?0(]UO!*8V51M
M."W&:M.+Y1',LMI^L03!Z&PW/X"/D:^Q>D:@/OB&&T$ !]0.]A^$&[)_$3$!
M8RW3_FW&AZE)"4HT8@=1HI>V)"4U=?"$ [Q9>PC<6(R^>+GA=)%%U5$@[9_1
M1-4D)A=J \5<3FP<>'0K4^>7:QMLN#O<JY(D5IT#X_U]T]A!K?!3PX]K7N^J
MANAX*PX(GIZ8KFX8-C-]+T:/88X<DI-BO41(O ?R.W4-,*P$=IE@EEB4D9;%
MJ3S3ATZW%)_HDG5[]A6:BR\G3_XZ\\?,?_;?.M:GI[&>C%.(\V.U8V>7"*7)
MM>63WK=B!RT"[O^YNGJ_K9G!Y?5R[?4)=#L2G$B\TD!#I3&M[I]^(,0_83RA
MJ;1SZ>X]V0]\;V9%K$[QE$G=Z-)\%3VUIKMC#G6ML\F\/Q]U?A-Y%K;UY<):
M,N#?@:_-I010@]J[NR%'V$(1$'NJ=6/D;D%2HLXA%$9['/)T7OWT$X:Y\NWG
MK8H?>N1>T>;H6*@ NPN&DL%Q:^N*A:)NC?/["M%:.+8A75+$(6TPKLC;CN=^
MW\Q;:(X&M-AB!WZK4[_G4MCD]]V[R4"X-:L4Y:>9@I.&RR)4 7-2UBQ4Q:LV
MHV/,SK1LQ=*86?>M1K4C/J[6XG7J$=?S52&L7)1?!1_]!> >34ZHSF^7>I]B
ME!/%3D,0L<.!"N[]A^1%7O;P7S0Z<E'5U-X-.T4(6689[B+=K]KAU1LI*Y.[
M.W(D4P2$5$48H#]FE>!K_PX\0@LBU )FI0W+ M0QZ[+3U\ .7O)'DX^Y'^;?
M79.MWWM0MFJUF^$2,4R&=T"/,4\"KV;SH?N9#M3I)WBM&VZO/@7=NOW& /'=
M0>BLYMR]I.6#)S*;7/W])RLJ8IIUUNR_1"]%P]^&UR\640B0;J&#$7%D.H8Z
M8/W+9;.S43UV62J[]OYG*^>I-Z;>\GN_*]IC0A^/R7A+HGPX( $]B@QQ/[+]
M(P?49M>H1U^<-'J):Y\/G*Q'O<(CH^]U-R-C$ *_4#Z=_Z:]$78Y IJDS0BR
M%=\><H1[);M5ME#]<P D$O]CHF8]\US>JK$!PF;,^"BW1MB);+:QCS32!I)U
M-/=UOO>-4J_MV]MCV*2[<R=0(<U)[V[@^.K9BS@IS9UU5*.UZQK\Z5G@8PD]
M$KG8%\U:7_#<JDP&8!WP.HGN@8F^3K9$UG]L=O?_L-F864;9JZT=M.*A^"_&
M&V(B%P__L]EIF&5X+2]%BXQ^#*_U;@,+38_[GF6>I=522J:6H?OP]VIQ_>,M
MSRP6XCT5W<24^92-[@_]#K:B&,/107WK)H%37%W?6,,M;I];2E;K0?E5I:LP
M])G[:-X9>UT'4*6N^X8I:W''?C<]C[V<*A8+B]Y[49["^WRT,2,N:B"9ZP6K
MVAKKTRKNW4,X?O"E3B\?S7L E3EB=2)I8\1].O'GY=?5/?L8=AG8=V-62#T.
M2+/O*[')_R^>%+1IJ'KJ[:/#_Q7_%?][[,Q9L3[4HHXB?\UHL-!8"Y+/UI+Z
M@U_8:NPO#2?GL \3P@5'#Z0*\M1+YQN[4L_X_XFB0@BA="VJ'N4*P:;XTX\/
M0'AGGE9_/MG]\"V!>9#N[+MG)J>"7CY0#<7D*I^KS?);<:URQ/>P%H*.5GD/
M,CD@QZ(!IOV_1RS8 T1Q]37^F;TUU/ZB$^+IW,IV^@']"9HLK+SFS $U2\.>
M(%NKR!E< _CON6"A6$+]$V^:;@IILIS(]R?O;WN@)O]S:\'.>^CLA^5[LFHM
M'K>(_T*UXXS5_(_V% -9]!K:3 7)_@4:6E<?'?VJ6'^_U/Q4P\U+\FM.O$.X
M=X T5;,-7(-OG]0\ *C9Z$I9-TEZ6,"_%_Z^V[53@B(_;-D"_7N!3]PO.[J5
MB<'Y>_3VKOS6B#2[_L*I.AS_-@HQC9O[K0DHKJ>_^<HJK#*6)J*K(^I;&IL7
MTHM+O@=K6VX:)2_$Z-4^_9LZ-HX\2WN8/0L^[,=6&--4^#RX57Y#4Z/RSGF'
M-+$:\'!I:"?B+VV8+D1=[P0_,2?KQ1O!*IFG@&<]7P*BV^THKC@Q'J,;[LQ3
MO/X:I.WZFYY/?D%F"XU5@9)P?]XN-$&H$RZ"T DZP:W8!UD%F;Y'A[\\,W\M
M8B[T%W2FIYWGAWYO6/9,IC]LB,78&;=-]:T?U0L:@$4C<W4U4#Y%#%MV"T0,
M&RZ1L(Y0\P]^XT?_.3EC4Q/99A@NH!CXYHY>H-LS0=NOZ_].-X4G14ETH@%E
MU&/L<;*K#O[GWS01?]>7KI7#P1J2T+MV/&IA^R]1/!;F@N(:84^,#ZR@^;6U
M>!.UHRF" 8(_)UW7TWOUGG25>$XUQ<:]#I3L]OC+N[I"1;'%)%KAAYD0]BA[
MFMU6YX^B@&MBT /?TW<VMG%$?&K@!=7Y(B4GW2$W?-(%#DAG^X]EJ,V+QDI4
M]H[Z#J3)?B-C3J)#%D5'L0IP&NQ>O+"&U]?&H<(A1FMC[1L*?OC'*G0AXVWB
M_;/!3^TA\N+K^+KP)U6KJ%OPB;GV17NT*;7[J=+/VFDD_<!DRKF[DMD9VTCW
MCO -EMH2>!)&/\[E/4H&:5I*.@W.%@X2\145]:TT]]+(R"2N'(_8?K^@> !\
MAF N>_7"6@U##X!WH6OZ\ZDI7<(<4-"?G$;KRKQMR\(K";-IMAH*"]CZ_2:"
M-@8RJ;\53O[I<8#E:H.!%T$ QHNYUN<;[;SA*PUE3X?4S:13'KJ(FC#.,I7@
MB?ZS=Z@229-M'A<S5N_VGCTXF:&'U),TW&F8+@PM]%\( I2%.N:IFBVHU)XR
M_W-^:"&V'!!WW5K!]FL(\/DI?[YM4RJH17 C^)?3!JKU O+$I2)4FS0OY=+<
M5;84!U3&;M.]&K2_3O?E_O7\9_E(=YS']^ :&5@QL$E7'*Q"W;F!W,\T&G-M
MD5)J[PK\JW+Z!W/;4L9"\Q5C_,O&V<K?_;JQ11=;#A=G?[01NJ&FZ5H:/FP5
MV>Q\R6R+I/3.G5B2]V6E@EEG?(J5/D9_/ZJ!#:;5D\;BL.+EI1W69C<6FFGN
MWV="WME?-?IZ&2JGP-\9R6OLO+K?CLNZGY __YV2Y3.0B*^%=:+Y(CPOU==@
MDRYC\]O.?J--N>J]=+]KGF/RM6,H09_G5'-+U0@X 2_T@!A/%$3HS4[+HSKJ
M33XGMAU5W7,_><]#'N#E0D:#3C]R"+QW"T\PF1UX@MWS<8H5>\%.:4.SP]C?
MQ2953O]RH/OD#3/8_6_?OOUP(Q2?:CR\?!3#4(>(H_!VMQ@C2JXVT3/3Q!W#
M&(*<*\,R DK/!AY71J < !Z:9AM;C%J;%]+\/:I#N'?L;,W1&]<Q+S@@E<OH
M#N."%7-Z-!5%X2%!#@(DI"&P>(GV;G.R;,C5Y+'"T66%K!]"=:/\\R]IVXUR
M!2QE>@QPZR-" C DH7F69Y0XH/BZ.9,ZAEA4_3CNFU>"A;!*QO>L_:)^WN&&
ME\A-S98##'/KIEKBP@[-R)56T/0B=0[OTHL5*74J4+>W&=MD-D7YN$OJ&826
M%3LU8S.>XF?3B1L^RNPN-2+K@-0NF/X9*"EARK(*F)%D=YMEPR URZ_UM3>D
M??.6KTX<3XNQ,A0L. "]Z+^ _C?': U/ ?,R#5F/9P<(Q3#J6MJB3O?X*O;,
M48C6(_YQO0*;P1W8C2)4J\Y8!_O4,*8J#2_!=*05:4^P!_V+EV]@AN,\@:*S
M%MW7XKUXC^E+BE<JG;8,;LZR@#0H<T"@/@$$!#M""&!1:B/KV_"@9; 0!S2;
M/J.<9/_T3>/( P%SF/#Y5N?W(8/(X/@@0/PAL;I^U95JTDW\LMZ..@(DD;HR
M/JZXI+_(FIZ94LM]U:?K3&H<&T%)&XMUTU"S \DX<#NRD=]@)O]D7N[SR4,Y
M$\XWA8_<F0*Q9=M7X"<!<_:AO[2:%J34,!-"XH (8VY##]R-CPM49.,3'Z6+
M\1YWB*DIU;9T&_&S)!B[1FD$&/]..':^[3 C%#ZRT<3FWU5K(58/M 8E%JI^
MIFDFL.5\I32:;GX?'1OM)5]-4;ELYOS728%6E8.?+9H1'3(*8WBP>]G@L4\G
M?FT%F%]OJF^JR3<\F592U_M:+K&I68^NQ<T$[S(7-S?D&.XXMC[9(=/J(97\
M(=MD[W4TAO:\*V;E,ZL2[^GN2G])*VWG@,3^P$5. N&?@/-3%TI&<%GT"?Y,
M[6NR4+1<&PY6U!]].V?DU(_E8C7,@O?.5)F'PW*KS]0]= $'9!+*EF4Q##F@
MP5,_4>NO($#CUD ":K^1$-7<$CMLQ$=J@O"/>T#I^2G1\JU>63[NW8J;CWA)
M<$U4NQCR)WXK G>""_H!J)VSS3!Z. N-/(50HGD4E0%S<[AR&M3F:XTN=2F<
M<+7VJI)&Q>(!T9ZLA#M=O#,K-A<<5T76_=&7QOZM],+>8'A-<+OL%M>"Y .\
M4;/ FN52K@%V;._:U?MGO/A"BA^&#IK&W#+U#@@*62_)>,H!D719S1S0GXN
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M&80^>L!GUD=CH6G@Y+JCP?XQPAM<]>C128J MU%  4GO?4C"\+H0OG#D)W(
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M'LR\3%PN*/;2XCXO\K1:3'D],.WZGN ?$-: ]2IVM'J/SJE?P7O7/96S93Q
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MQRI1EE%]ES'TR2<0BB;O;GL=F3AFX1%68-Z2HG7BEI;0X<8YMR*&.%.ME1D
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M\RO?]2! 27*7'U#TUJ$+(<M(I';3\8P7\R!).(+1!(PS%B]>03\DH>+F[\O
M-?VC$TNRC=Z]/;<;*_OD8=X'S5 0%<P6-:MDES>KWH=+X,9U1:?8.A_EAEUK
MDA_AT\X_?.BU[VW,W\ON?R57KJF"3S#/3[*DV&]9R'E<-*H&$@77AI5UEO4@
M/X05=SJ*2)TC3ET2>NYL)>OG?&;.BI 5K'QA;JEIM[-O5Z=YYR9^)V3,M*06
MW'ZHB-5+Q_=#?J.A%4EX*K!3E)_3"ZH9;$\59<DSJKF 0\0VI*RKO(HM]6M]
M*;$B\<EZF<@O[+W1FNCIEY&=S2ZX+Q@J+-94$S$PJ\4N,-:8 T4#^>&2\WV=
M&90<5,)6GMCX .'JO:GK/ZO8;W>3SEU3[=5_?-?-BK"3Z5KQQFG"H8S"!>R;
M':R8^)4L:9'M68S:Q4] _B!X&K?5K(8+$/NW);HV6!1F[8@\ JW/6,DZYDO[
MXG-V^*% 8.\[CFYRH0;GEV0\TP'1VBS#V$=U=V9@J?.=B'/#S<J,A^*W,ESK
MQO-]MH&S']X,7 /J#8/[:L3.73G0L$$ <L -="LN #UCN6OFVL-$(GMR6/>X
M@&\7D4L^SG89Q2^"'Q9^6KF_9X3.''A59"==TG</<]CDJ==KQ# $4YQ4(SHY
M2'K41+)((9"E.GYL]1N.4QP6:O+_ #9_/$_RG]E$RTD-^EI#&*>U7V@9ZV%S
ML,EPKPC:E=<V*BD6:!5\UNJ)Z82PJ8;*TS16^)_&U7FO-IZYC';.H46F25AW
MFR$4:CCX7',K]6@M2LP_'1I&F?B)!_2H7SW/S[A;_WI_!/T=KZQ=9*-@S3+H
MQ&):HU[@*[.^#SW">5:G"1D'7XI4#O8UPO]]D$"I^"B#V=/57RGPA(9#<OWK
MY;;JWJMII6@,-300!\:)GXO?< ;P,=T4=RJ07-P*21&S)OO!2+,5^,C9C_+M
MG9J;;</2IT-MI;^%.8N%/Y"HM7(+1S&4B:T0OC#8'(RE14A4*Z ]5K&MKL,Q
MK7>1'A;V2KT#TR3!2X.2_XY/,V+M)UL3#\&]&!CTTLA2-D@<$[YM KJ9;U+%
MSMX9E$U+(N6$"*](/2'%!(&HUXFR8: .5!5EH\TI&3$N*MT34'IZ/';-GG(R
M _#CZ%SFOKV4N!1,!CTM^+W#ALE["!OGV?]WJ3=;B8[\NX&W0A+J"0N3/)D?
MRU%GW&9Z0U911W$^X$3ZGF=ASLMOWJ C7  6T0XMQJ.%E3Z<3'S/)D6%I%OS
M\>V@^! :#'?Z4W:YL2R50$)U!M%42(+)G[*F=!J2;\-0EYN<WW;XFZX8X#^&
M_7#/Z[QBC%Y#AE,OSCU&*#)TF99A4JUX[=2G\M>],!/&=S\X]2L4>R^J]@4I
M6SXW\SM[6;T/JWS4A$ "=:8^1QT%^21KM('V(PXP+#M"]IPMF+:,%T7>M;7G
MO <::L/]Z'[#YQ7W>WKVP-Z\ED[VV2P9H3_KK,AST,+^70VM>57V<]X.975F
M9VFCJ+'A=+T!2B(LU);=C'LL^@H!F&BT+%L&"2)D"X]C'<]D!/IQ 1B8\_MW
MK^0J?K\)2A=P]Q_^">T%^:5.F2,?]0V^1%%C&*GW,TB9.TE?[[(T2UUU1QTC
MJ<J%M6O$"V4?WUQ8_"*0T0*Y.VP<7LQIQV$M.T]P3H776SXW59?6U=3N*!?N
M\9,?]4PT4U+/^^[C*<@LZ%/95W4IE:$J2@F80R;+++;A!%B@T>Z$\J<;TCY[
ML65?)PLPF0WK'K'[M/0:OOG(1EDH&2]>ZA.M!6:$S"-=/?N1EEA/Z%.=#N3/
MJ]EM;\J7^XJ:GNV,L\&CUS4&32]P?IGN8Z-J9M2Y@&[\#OWPY[)0NJR!:7=
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M]N#36K>T":D<3"<$,CLIWOBI".WN>.<YG2@?;WE[_N_AMJP:@AMF'D*<U/2
MW89?2PNN%-9%(M+>;C#JO$DF3KIK:R W!&5^2O< /?X)E:O&B*&)4@%N*+G1
M7<>F5*/66&XCX[%+5VPC/SSG6;92?DHN].*M=LHO^G+H?T-VR&EO$)AH+Y8)
M;B0SDMC &H+$]A"!]]G>>YIA@R/TLWKNQI\=M6Z$^?0:S:JPU._K;OF1%,X
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MJ+"P*- +3,PR*Q7\O0SCS?7\;[ET9#<\)+$E<!%WR2VH9[K%<$$G0BE+N'9
M>.K1YW^ZC^XGO6>=<>F!F3;7SBA;!@O6<U@R5I$A>,M(E#0T>*&AJ#(DJQLE
M@DS9-1K5Z%<-).A4#<YYY"6\$@WE?;N4F)^ -0PX [ >>PCRKR5N_.M<V@4J
M!R50&,9#Y3S@C-M^U2H]-IYA&P$VEE.N0J":ZS3'16IUE/H[+"8#H^&@<4'V
MM3/  OK6U-09 /0@=B%4!/8*;]*!XX!J85"2$^@ZI21N4'UBG.>A]3+)KNVS
M5).BL[&SL5W):O6EYC(5N_YG?]]T&/_'U)Z?$'<X393!,W8+X^.@>]WP7S:[
M4R.;6[E3EDCA)EB$)[YC<W"TVZ?KU1D OP^9BJ/$NE(>*YE0= HSTTL\E1H/
MS#F7<B_ P;OO<A$NC27NPBQDVS, /4M!\71<\S_P.J_MEF]Q%V<_YM\/=;QT
M3C+S\-Z7S+H0?3/C=5^&Z_GO_WW$LG0,,9M0T(Z^M/13C!!9<YJ8>5C,E51,
M77)@;H"$ORZIT+.Q_3B+0353+?S'=LG_70NH8&(:"0Z[2-1:"GG2(21#P!V:
M1".03YOK*#WHK#X7;3_^I;?OET$F%PZ*_()9!B<UWN6CG(:!\T7H.LMHI>LO
M/4.O8[45!^IM2(]0B&AXZ\VO-ZX?B5FV$.,6)2/),O/\N_P>? B:C@8+F=*!
M,ENOQKBMOJP?Y<N79)L#^36'7HZ&;@7F=-B@S!N'A^W. &]@@7FPQWBOU$4T
M$P[NOL97<7YE<+<W14Y908^Y5MO"/BKL7%58EK'L#_U2Z<JPV.N%M_)CKP/^
MA_&Y%84<?;G2W)PC;6MUN??FWIV'"?=[79S:  %*>[G1P/D"=!T\TJ]X9%=#
M:KW.KMQ3KA@+LM?,=<^+61*=498"V<_JNH)S]8?M=M]0KD&=%J.B\B9AHM7K
M<V+#R^(6>T;?K MF[I7>@#[/>3J?N-ATXTNF_XLO.274%=7Z3U?:W%"-BZZ4
M^9T3>(7'R6Q7+)[3_'ZO6,X;EH.8!59A:$ /A=>$#0JQJI_8E^)[D?2X%J[
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M4$Q[4^[A4)02Z^TM)-HUG?5V?W(!/,7<DL?W>5_BQW40Z&G^XM;X1ZGBLO_
M"N^)U01P1RX-F2UX\0S [X'^A1*L@XX$#]49:G0G=XA,7;G]J>Y<V^Z Q,B,
MNTK-Y+"Y;Z79M.W(U@&_E-JFZG>S17KE-!Q_B?,=$;;WNA=<*LT5%[=ZC?1!
M+SDLU0DT/5C6#MREC3EI@OK1H<O;(JW#N/XA"7U823N-JJB%R^]$@$0%5*6;
M3[>3E7Y=2/RG+ 67[S%1,S<%"H0(9S&6O/"LHI'5%+A%BTT_0II,')*V*"O
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M/,PZ_8;8G4I:' J'"99!#8Y #03!A*X^T'I=1B.[Q'(D5OHY[YZ]]7D=E@,
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M48G "]='GOU6I8M:H^O&?I/SELK?^-HF-0@"OFH_8K SIMY2IA:>@3AUK]!
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M__;EH(%7E26>30'YY6XGLJ7<X]X69'WOQX7J+S]S-X!DVVAY:?(!O>(5@<,
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M/ZA^\9GU'(>CXIT02%.@B'#:^$WSI5%$I$.P]Q+V%QI4]^Y$)(\!'CGX.+
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M2KTF*9+C2%5)"PD8#LVLVT1TM,^2J<+H\PAI]U2+W$B9YWS2UQJ?\LH'8'A
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M("3\*8J4_L 3]9B]8P%R%()^3:FYBM7;U]YIGU&-+0>DR<-;CU3L>H$=B40
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M(CCTJO!T(=*R#KM]0TZ7*%_>W3Q^N,8M3O7TB-D#M6. D0L>Z=;-MYWZ'>D
M0X HO"0O[CCXQ8_:R:@H-_&A.Y\,ZK0ON'[GU5^D R#VI_M83TIYGKF UJ0&
M(\XB.M+4285Y%#50,2BBG@U^GS 7#<Y,5PQ_N%HD47;O_5Q%==3!L=MQIF+,
M)Y-BEW_>9!WYK:C^&B"2/S*BJ+UTP'L?QE)NPYWQP,&&:3;(<2S9F:*XV<^P
MD+BIW<BUS\8Z H1<PN?_,@O,@H/(NAU*"B+4X+%A8#[8@F7Y@"21(;J2L8%!
MOL6Z$BV95LB,V EA407+X1>T[.#]+VP''6&9C<?YB*T)>]RQ6HJYKD>4#MMU
MWBJ)PTN"L\7W@SJ"(>!:9D)B$Y0A+ _C0^C 8>0#D8IB(C*J/ A).](:G37!
MY^;UOLT'LN<P>V'UV=K8LRX@X4*80U+B*JBL;761++>$.NRC..K1C"ESC\05
M:O1IH4%+F+%#I1KG+SN;%PI).#Q.?G-'-R$L Z12>7D3U*@8 N$ [R<]))GB
M+$*\5X]VS_L_L!:1QCM;OD,I&%]=<3_AF#'-Q6+PF& Z/3C7G.*'9-,Z>[JD
MRM\A\6+E U\I\013\<2I8#7%,$R%ZDHL'A51O5U#R,5SO4P[2 K,M6[[Z/J2
M(!*DT*@=6S*F>N?]:[$K'>DGV,2,$WSC^0F5%'Z#;0'2NYD::#SH"!UP6N>Z
MW?1^%TL((5GA+?R5YWQD)-\_RHM036C5SSNTRZ-^\6>[?)"C!V$8UYWS!!(N
M#V?*T,V>Z)"H&K#O?V_M;^/65';7MQ2>WRZ\JYN>!R%D@MF0?:($-(UO"$O1
M ;PTVE9?D-5A1E<(AA@B!_Y&;O@T*?*ANY8X_%JA\_;G1MT3I[^=_Z)OP,,A
M)X8@*# [Z*:YUA\CJ*ZRDOTIJJ1A0K1IR>!)DEOZ\F,8NKGZ5J=\&=8U_&39
M 'Q3PB'9<N%MNE0'<&3LP8VIG_B>" @W/"CK,F/XB,*XKPX5R$]H'=&H2.'L
M.OM)B,5$1S:+BXDYV\GYZ/D7.*J2J."%_L*"AZN)#G79;SGXC15WS&X!F2/L
M0"G#.685)J9..X:!U1=?6AE%;]UP&=(4'G.RUAG,*GMPK^;:/13,OAB-@KA@
M1W)QD*;UT>&6*>4^+;T9MJ+-58F<$,UU_A[ETPU)=_OBA+QZAX<&_Z1@>ED[
MP-RD.KR;8J.&W6N/W,4;HA7O]AN75;N<$[C]?9_>$FS9"D*H@5O2@0N3#/E@
M,1YF^X,;D<[51!/TB(;\$,FD ]-Y&A"<+ZF4]J0:0F//+ )' 2M__8_,/Z#.
M_/A=^'?AWX5_%_Y=^+^Z\'(LJ9N(Q2U\Z68F.[96?^#[FKMBY5;%^=A;U\&&
MH'T;IUOTB"OIPR#:V#0G-7%4K+>CY&V/=I?,M.>>4KY59ME=_HG436A@H$1^
M[U:AQ7;(D+?V^2![*]L#_?UCYR1:NEM1O.(N&J5GI]EW+692*/RY,Z!66Q.C
M$&S)MPCNU,!7#L,%WDD&KP4SA=A GR]H=(W<_?ZP=68^6G"5DPR'170EH;A)
MDF,S\;5NPZR5E[W.;.$LJ#$_-]<;L$]0W A6&-P)<;#_4ONI^ H7/ER1PBL_
MOS8C'2'C$4]7[*TSZK+SS5;9[L_)9^F H-\<'>!"D ]%A\ %0]#-[,)//<OC
M!, N0GY]>/&RCRIT #ST;O/Q&U(B3<AC.YL.9$#I0'(-B*:M2SF#736@ U<P
M=$#.%T()P%SZ483::CM'NQ;$,#]GX]_3@<A&AG/\Y R2I%!)!Y1!;R"\&$=(
M+.B@-XSA'S]#'$QH[/"G)'VV_BIE.\O+OVLX[LG4^OBMQ9)B$W8L9P'O%UJ@
M]1AWS=N_ (WC%M:X%?BB6NG,2L=%$VT=3X0:P2*B_A3,D-R D"T6/'(T[(#,
MC+;NHXY I>="QYN9H5+PH\249W3@7D^<!>H 6'SJ',S>_*UV^<^8JZEQ(VO#
MO<<>/O>5>_ON;>U56;A>Z*"$U;LQ V>=L>VZR<&4S<T!,![NT:\;)G'T>;C6
MC/QV\EW]-PGA 7RSVV]?).4JNG)=J[=S]"'D=J]15^D 1V4+:I.SCPX0S$1!
M?S0(CA44O>][LO_^8=BIE_77:#=&_GL.^=^%_U9AM#_U&<4QC]1AQ*>7-VYU
MU<V\2W?;P.R9* WA%8?QMA] 6>U:_5X._4^"N6.,EB/. X AD/RD3IM0HT\5
M-IV/'Y&$5])]'F@GW4]KK#<AA9*O4!Y0"VKU%!M1HPLZ-9_Z4N?J,/)S[:=U
M0WY>4WMZCMKPTOWM@EN VJ%2GGAW@\F0*:,KF.Y=4 9!ZJG_CJAA=H"[\IE;
M/H61>;O.I@9(__$WYF,<MF83IE4_(&46JPWIL'UXHWUP\2AYOV9#FL&-PTK6
M8]<,SU,PR_=[1 2# ][&YB:15,C"L":\'4/?<7AMYPPJK+F[W]9_<WH#=?[B
MR'7=O7+1#)L[CWRG"P/\5I;))V$<TV:U 9/X'#1>"54[*!4]%_RBXTON&M=X
M/7'A.=?85L=Z_NN[!/[)0U56Y.](ODV:&0GEPU"T31-L*=_;M;2BHQ/F"N/>
ME =,#BKN_C0J+Y3*[#=X<].YVOU=YNW+V<Y'#H^-C;>*A4Q-G8D\&K<O+PXX
M'I*;$440<9M$/3'T^JBJ7E.9[^%+_I01)<,K, \M5UTAYU+@)/CVD>*VXS6Y
M!U)UJA%@.+RWF#8SS7V/?[MA<TSN(?A4T9%:EP'?)-N^%<(V\@VAPN_R^4X7
M3XM,"6E,M\J0DH6)M?)8($H-T80J._(^[Z+4"AT@RNJ=&/:^073.69]+N)V)
M2W](!SJO$1YI?F",W\3-('@[V0-^<'"SAH1T1H;?,["UT'\A,<3R8??9]8?5
MS%4V "T_!&;>4XCH1AU7CH]'<>&(_& ;C>RB$95\?LC2@[8IYJ(V<@<B4_PC
M&JK<U-_<9_E4U$JIWV#7@6:42Q$!%9'>/W>PT4TR)3)'.&_@BGGG6DR@/SDC
MR08=[\QWT[=K*M[V16T>E<ZH%2,\_T=V@Z*S,--IV)^J=& "0@?<7>?']@QH
M; S-?PY);:(#V_/!X(2_2>-_9FA0"8^?ZI]<*UJXEA')T2X>(V!\H5T\#6"N
M$XF5DG+XO/<3,L:ZG4T*)' ;N;KI/_ZPG*!;/:Q3\=Q#_4>_*M@D,,WHCG];
M"L6'6EDN[WB;#H1;D,_=;L];2C$1XBK=?\ H]7/E=?@"[0TH";BV']ZXSAB/
M9,[QQ3<A%#UJNOO5RJ(>*10U5:O>V_B:_^2Y8[OK:1/I"^N/=.LNGWX?EE4L
M'%T2>!%NLK6"*>2>\H0>*C'DZ919H)V\E7S4R^;[HT<#?-!*I;Z^W"F3LDJ[
MY;EY'$6,$#&#62W&2R-.4NX.+O113J.K6P\.W+D/:7+C<PS1Z-KM<1OYLH?&
M[33%LU#D"1-V_ 2%4,[PMS;),0YS[FLK_K[@++*W0$7>A_<\%VZ> 8XQ&=B\
MHO17J$A+=-YP$RBA ZKS<*0H"?7N<8',]-V#.,\]2&.32?];05TYZ[2@!87"
MLDS?D"AI]!G*][^>21X2+OLPC]LTENB>$DA0O6F6%'/XXM)!=&S]"1BR&?H)
MW3:.?&;'5?[&@W4Y02"AS]"B4TK)FC= (XC4OG1 Z='6MJT7EI]V%.:!7W^"
MKF7%OU*UMM/=T,]<J$SR3,C-E%G /H>)6^0FSPRQE\;J!'CU&W1B\GX@WN&0
MHGW3$V,Y(*6(BL['C[=OO['^>7%5#;V0@U6V*IV43*WN)U1&;D*.PGP[6Q!'
MO_,N-=(F'Y2_TU!ZL<?3&_KU1.C7_*T-J94VHF(SJA34DM\SBL;/TNS>>?G'
MGB?VK+U_39OYJ'TJR9XZM!R?5E_SH>L3-].S.4/"R^*@@7$:6QM#=YM/:]&!
MI<V%U4?)&7FX97E[\YCRZ.J!U_+B-<NN*IZ,QM*B;/X.=_[7@)T,69<V2CM$
M4I(D5(9?L<)&7I!U,_[)DAK0U3F(67RU\+WHHK::C:28B*5)I@AF&?%U#WP$
MIW!RYOJ4L/N-B&2KDA\54<LR>HM"144W%%++XJ^2,HD>7Y"L6N=I4L3YSR\_
M;<A/0]^XIH :COK8[W%E/>F&%Q?"AK>?4&MJ+RN&4WCN[0F&WGG%D>MWZC27
MEV;\5D_OLY0GK0$>A=!P; FJ!30FUNQ,]-M^-^1QKSR5TRVKZFR/LO_7&YG[
MQA2W+QSRARCX@?)J-7'=K(T:\I@(^-DLZY&1L9S.0&NGQ@SN]/6)M*P-U['M
M5\<2]<T_0G?KNX(T,1"2-+5P7HM[^LVVOWWN:T=77<NBA^>/V)J)TX%H<\BW
M3:-2D] 9! N",9RXZO<Y@QP)W2EC/C*9'$$%DR?.=2^Q4GY>IP/[]@XE^!?1
MHN0:T'85DOD?S6^T;SE.CP[YIQ*/.YJ>Z5KN*'>)VTAZ-TX'Q"OT+"4R]%CX
MC2V/W_QWE"_3#*I"<66&NXV;F0X\) 4,ZD8J.[W>W&8^L 0N=#?"F/5<W3SD
M*K8M3LW,)KW&59 <9J)SH+Q.C]W,/ZL%=OKL^AW;N&\H4-J.JY(H7C?;0*W&
M$[R:(>Q:;JYD4_@)3K?3@JZ2Y<?DFDWYXK6>#(I_:V?U'%6?>KPI[&;E_U2$
MK%%3.O46I8=4S*30=#=9(]1SH&T4-8KVMR7I[DHM%F=D9]YZ@#P=Z*D>M\Y*
MBVQOQ)H;VR"_],0@0*0YPO9 ZYCP[;F[<R[GK4N&*@'.KT&Z)T(GKX$'1RPB
MS)/U!6PUHKJ=^D@(U^1Y84D':\4V4^]ED\08_(Z)83<RT4HEKY<A?ET_&_^I
MH=,HN3DD2<:H+1H;"I8B03))G<T!.4\(G<U3Y]X,X!4P69,&;N+&!<#8>%VS
MN-XA)7W++.F.5C4A1Y$GP%Y<*ZW-M,)Z\ORVW+/;GRSO/-=(8-N_3VTZA/NS
MBCR\A2Q)82\?4(9&H(00AT@#YN7]]P=5DHC@1-9(J<_]6]:LJHU3C_<G:"'N
M79>/:A<RZ>C^_*E5N?XLK5$064;#%)!*9XS:XH\OFJA\_T0RTB5X1%JU=NJ4
M7S(1#CE%H^&O^W_;<!1IO@,$/^?.^(&.I@/V1F.Y^)XF[A$(/C<>XA1_V "?
MOQX*EA[>U.3T77R6:!?7('8XQ2MA+L=+\)6>.%/"[;,J*[4"1(5U&ELSMB()
MPZ-22D08':B,MR<*;F?A59JO[GIOE6-GH\\]W ]R'/VT@%"E;#)MMP@04UH]
MQDWM2-AI[M%AW'ICG=URTS =*&/9Y%U.&3-K-R@\9Q"B-OO];HCQ3QV9!V=/
M9R:SS][]=)4.M!CQZ9)Y$</0@]X0YBF[EFEHU' *^.APF4B=ONLKMW(5GE21
M$:T%^V-%&T+9#4S#AQK>,E\ 6?Q/VPDDFU.'_I$FV"\U3-'-:W!P<!4.C,Y_
M?4G<=4FO"#(3O\I#6)\^'[V]+K!TW(?2EVB?97WFW,3QUVT$R8"JF="8-+GY
MU7--D#+0ZAR>?[C6V'N,-61U07*_&?@:,,,CTY!FF/X5*[V0.XFV9DXVXC$:
M'TXIS:I,7)X3&&1,8;K+-CPX.\5G2CMI"SY#K+(YU*6M(Z6TN8,>)NY#YN:&
MY/*.;; <8@C+B] BQ=8?IG56Z_R(@F?MU;J8^">^=Y ".493*T[&Z4[^".+;
M?D2-HIPDA#7AUT6TK!8B88_/%2T'GE\F9WO4CM*!E[$]Z79>BR!V,!>)>1H3
M(=ADQ]QG/LG%V?T=I;QC"(G376I#'V-* P2^FW\N&.+)((Q(;Y@NT;YCFNF
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M?N3D_XJ7WDC(1']5.S;+C(>.^ETGU9&9X?=(#M/K++"EA68(&UB1A+K5?XJ
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M.*]/9CZRL4KC&:V9;)G:TY-8VG76'UM'/INX0M[=^,",7V>FB!%UOZP?1C2
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M_681ER9XZ<!)$N;I,$[_U_;+&?7KNEL5:3#9;3JPR4N^1RHGAA"":'W(\OZ
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M@\:\;B@7VZK75BK\V,%9,Z\\7LH?RUT%5R1.MA$AG"3STR$6X0&VDW&_BS_
M)0W!%1A;)",3=8RDK+YA^]7NC _T^(S804V"YVZ2HEO,M[CPE3"U1B?.K*A@
MVDY.FNW)DH;>>H$WP[<3,>_,_#6G*#ZV\;KFA8%DQ=64M!/[33"I6#OLK_.;
MWF"\/!T@I2S*8H/H +N,<KV=UI^KPI.2G@IA*<>@,]F!.@PKP^F<UR?*0_O2
M%>L5O5'W[>F >$'>U(%:.<NXC6)4?;!CW0B,64Q-=6EBJ<_2]8T+X3'&3^C^
M-]B)SY#B^VZ%Q^65<@L<7XS%_1C2[F%0VR__(S&@^*DY8,>MD]!3%0DMA_+1
M^@3E.-JZMF&/3RV?\H+7WDE5F_DO2H4HIG=M2_*)#]BX;X#7MLIVE']-RG67
M*9\I]9V(XIP?V0N,GZH>$-?NF%?O  .4T_A. MM[63Z-RU<[M-\&JTPB<&J[
M?-:Q %;D UN/HER8J@)L!B8!X? M6=(ZW61@R/S'XYW%/#ZN$#Z_P?G@*SB_
MU69^9#"H++>5#8&^!GF/J:!2)YL\'B:E/&S]5GUJY,'UCC@VY<LM?,N+:S.&
MJW_N26F/7U54B[E3546(V-S<G#\9]^4B2X$\X,]R&#GWG4^26_/DR%/MOAQ"
MN#?K5CW#&1#8U5GI6'!>X9)NXIGC6SQ*VBA[?4>[/5W(HD@<?AZ'#**=)YF#
M3OIRJ\7V#=XRX6O QEK%U=6#GN]>!%BF,Z,.6"H=#/+67CAWKDV.E._VJ J$
M78BQ&XB*N5H4;Z!Q*_(R(Q]+O\K\:T?'/W]^R$TNLHZO(!$V( E;AY>8/M)&
M9CVXQE]_2@B\W:>\O^9VEYF97_[I-1'^B/<L[!X)XQ+K+ANXGO*;K+K!&1*7
M=.^GO7$]'$%'.DQ'K*J*0U_AY9H@+)US&+ZUS(OM!A.CRI=*OG7\>N^Y X(%
MYU\V;()=)<$)I^>IC)B*OD-1)3V]*?/8QCZGZGM?TY!;#&@/$5._<?&2\IEW
M9CZ5LUN,9'&>(IU'&\54R*:W34>^>N5X]I3+^T+S-B%">VFK3W4<L"/GTF3;
MP2S>X&,L0N%$JN-'XUR_D.#$@*"^KL$K_)7%F(@@(0<E0+P&->#1H^+"_XWV
ME<N\WB=UZ0E[96K4B-G!+GF@NT7UN&_^[OMNX53K&F:^LH^++##J2?UT[9=H
MFX*^6Y*+:<8:QAJ_]\V/X"UG.V+0\J0NB9.^]X<&MERMGB\:JV688;?Y7^+%
M-DUT?DH3O1'-=]"\PU!)F?T[A-=:%JY6L7.&8+^^T?&Q+Y??BG5 ;_Q9#0?O
M^@X]R2#0X1M#]KEPNZG*D:UQZ%WNOL0Z1E)[1%5D=5,H0)[#.$M$@2NL0S%-
M=" T@V% ]:,YVR)W)I 3UVIB8BW/+K9?-3UJ5GMPKY-)84BAW?V.;53TMW06
MW5'*&LU%6\+$R^0-^-&LSA<,R*HP.<)-)NL49&*L4"\D?S"GTF-17UB<H][>
MG&K)Y=D'A>.13?L8GN>X-QMC^0YU.TJ?>.;F'HI:+?NJJSU[K9M6^V-]^ SR
M(;[CA\ZD#M%RV,4;$59GD)[7X?;5%:3U\A9TF/F*3U?A'>EQ /45;@,>SVJ9
M*=\/W:;I+T=(9($FZCZ9IU,^[?P1 VJ+Z-S@'A9K;7?W=G7<R+HXFI.8FH?J
M71Z<AOBM^"*B<*9RISO>0L'I3UGUGT#W1 >AB>Z)2;'%AC93,H,+.1M%F1.F
MWV-4M8; LU^1')3SOG7J[=@@*1.M@>DIZ_(/EIC$V\XS^_U<JQFGJ8U@6QUN
MIZC]UC?&0EL_HE^665^B S"5%>9:"_/&_%5%\TJ;"9_RG,FI2<Q,T!I7'.]:
MT4G9I0P9:C3&5H+7-0D>WK]:7JVQ:V\\Z3K O0]/29D[W&*9AR/"TKFGTTHP
M^$O.VV DO SZH(L.3$D.$R0A-A4*D%P96=?>C% <]J*O3OL=I"L^.7*7JGT&
M7CRTQ6$-T@N9JW!<A+/3@:8[0H,,,5&)/@\UKR_-D/YT7C><%;Q9(?R8PE&.
M*<7,9H&/TX'YCN?);1<DO8_Z[@&S/JUO36$OX*\6?3'[-[UX-W7EP9KU.50F
MJML<7_73L1MY\>07Q@6-3D6#>\.'2U$'#_XL'1GM.]2<7)@%M2.)R6;_H ,O
M1\,T[;G']J6#=*A$L2$*-]F+UF<N.<XY?2M5/?WP7M&$S,O#NM\Q,''33R47
ML6YQ2XG<U_<1#9AM$YI(=C+I7;-"S,&5J!@12J6$5N[DC 9DH/SG]0)%MDB*
MW%SAE3R29>L%Q<3:5970B:?(% [1/5^]F*^WC,2DUW%Z7*]R3Z0$R!8P,MVW
M[YE1$_CDM\K/YXTHC6Q:-C%\&IX2W1R!)IA^*[+AY]1E!1VVQ9T.&V_<HQBN
M187.1V)+&R6'XI,##F:*WJ*]CU@VB9*..7C#9L0%TL\BH@_<MD(DM?N#_DDZ
M8.7MVH)P-^M%,N)V&)A%/$&?,)K+O_=;3IVIY!YXHXT",9A?-:4#[V&JON&F
M!D,4Z4M#XI(5BJ"9VW3 -Q";N;,%"=(G&+Y7?E2 S^![!7</T 1%QGR]Y^7R
M_D[MNNQ I=7N1Z??_M%,8<VWG*PJ:8_7:*Y67I$Y4&'2S2#G)Q;Y#EU2!2^4
MWQZ&KE[<5R:GS$.=":@V]*T96V<)8F"".S' 5ND3O(*JT_\JP%#@]W9MO/K-
M'H^>#B&D\9/#6USX!U>ZI64SW+G\EFJ3:)/LMA=5-A_%?L_EW(O]+8%SM!0]
M2#1J&=<U_;"!,:QG]"7&2;G_/TI-_^!W-."LCMY@+EG[<YZ.\^55(8Z/KCT\
M:Q4ZL9ASNU"AB8]O2A&S#1&2=  =QKLCVZ$+D6@U96^BF.DD*/[0;?5J?.+^
M,?E;RA*BP#YUH'7N]N_=I;$LE=<S\ULA#?=.EA.P08EC.0LO/L/J38^"CS(8
M$CZ2<I20UQ=9<@NIM*M6(YEVZ)0<S-#3**%,C#!R8/EJU[4U?))U=-<B1IQG
M,/T"'6A\4A@?O[WT^+=1I7&*88CM6B5Y8-5X;&,<]>/,M,"8<\E0P;<NR]<J
M$7^ /Y6 34B>\W#6Q4K(6;.K$D:6.I+,E%,>QPT&H) Y!&L<-1)E9G)=87O^
MTP98?P4NNB$#GI!N-[B(>%E>B;DW$G6@#>>:IP/\>8>8P0>AX' 3YC0]")8[
MI!6LSCL 48H]4 D<SL=03L$_+P_'=!4810!GX@,,<TG1\[D;Y%N1[G.@J$-]
M=)RSJP"Y\?YOR5)FJM=3L#G0KG&9U;$7?97"3N(FNY".NK+2^N"53HH>C[-1
MN,%K481TMH<I5SN5'?QFRY9K!*,VFGU7U6^DF-K'STL5V$]X9S]Z&2,30#N,
M@F(['Y0NV7".7'QR\5)S(\Q@7C/C=AJ5<Z+L]Z%C??]!.#&*6BE1XFV)#R:Z
M1NYI.:Q!RCL+QSN60CR;--VD&^G )+DP5GK$&VSC^C,'V\3M3GE*ZELO)*48
M[LQ79NC<$5,XU4>T1-YQVJE98!H2.H'R_',+A6-CD'&4IB.25;PZPCLR@3ME
MZ+5"%!WPD($)ZKQJS5B8/8(I)+TQ[Q?:KBSF61I>!K"GGL%"\' 6:KT( =Z"
MOM9,50_>X=&WE(C,SS:&??=)$QR71R7ED6YB@LIC#!05JL]WI)2-I@L7BZJF
MYNLT5!I.$+7T&&RMB/SE/Z1<_VG:UD5 Q5*X\#,MY;[U<\S1,IO<FM6BUS C
M$APG$S_A##T_R$E>/C(<#QQ+ 48R&W9FZ<"F(9YY_MMZ#E2)E)SS:\VIK&9
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M,>,16)=3Q8CS8%GVL)[T;9"[3]:KJB."3-?0;*B D"ORUO$>!@VIY@X#PW3
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M]G%GJ [UNS.,C63@RDU:,[LP,0%.NMZ>>"EI[JD[GR/E*?S*\(<CLH2.:.4
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MR6=[)+]?/*ZG)OJ-]0A3MIT]SYTX'%6*G_ON8'&1TV:"=6-VVFE.78E]_1=
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M3];K"K]7AQU>/SWY:.IH<W3/YD_+TT.\X5RA>"Q1C!1.<#4'G<<XN)XW5T[
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M8O\FR(!Y&K'G$"9F>N)6NLZU ^%]34H+-:!M\=#VDK,#_R)GP9!Y&>) >KU
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ME[U(/L)X"IYFQPFH/"["O W5 B;%X0U]L.@[&OJ%=JE?C-%G?<;+OG4'MB>
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M>'OGY:[43JN)CEKZ[C<Q#8CM&]I7,M=%KPP6[Q[NS2'&)=0ID&WI-U@_794
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M.E+-F)6*NO#B>PS;#]I>0-VSV\5[)M)+PAP,D^.?. E7->*XS4"AS)S%G0J
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M;)7$/9Y0&%%YG^=C*9][MM,ZZ1C?_7,]0[8=8R9@960&C<ED"44>*+]IW%D
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MZ52-W0R("[FZ1.N2_Q$(J6LCN6@W[!N,_6V%,^=MDZ*W^'Q4Q+Z!&C)&/;B
M'UK)$5F1?8MZ.<> 3IN9<&GG'I[I442$<.- [:3ZF,) ?\7GV@3[>RS+8Q[N
M9"T"=.\(1%YOH*@0*QX(#7HH4J9+$+'DJ,ZIP>24QYIL>EV"HVLCZ^2;CA%9
M=V\+A/A8UX4R!- $)MVUD["2;["4X0%]ABX0@0R&N%,HQI63MXORLKB[/K*/
M651]SD/8]=J"B +\_B]QU\9@Q JT''5XJYYSVY\R3+M,=6PGS2.UZB&7AIV;
M6R6#RVL'QHQ>/$[I"#WE$:AN8<]"\%*O.98S4 ^<N8XT(/$]/; &G&A^U,A.
M2D>LE5HM?$CYY_38%NG]:0-S7X6_?UCU<^V?<-C,$7;*WH'^):13L 0I&H6"
MV?JS@DEE"$\R)( <IR8@+6K-CT K.G7=[?W>M$VE9.<MRW/\XA8#)A=0QS[(
MO\-),I'ULN(44WYE@.>B5H:WULB8%-?EA[6*[13OH>[8X+!C=0\ETL7:?"S*
M":^W>  %_]N#IJ X%;-HC=UMK5J@:9AQ!D <P%#:MF)+@+(%D:KW>Z>C(^*Q
M00[XB?J=HD^/O]P3J QM\;3Y*6DR\':0XD07%B(6I3-I"2'.^!934EK[2JM_
M+J06@B!E75H\5EX.-XELJ98-SOP\>_/>O!2D0"XA/K;\/E0&H%**!C%B=%.*
M4#]#.V5C<$FDL;5SYI=W6X''N%0ROY"8U_&#@L<DYX*%=C;Y]FZIE=1!*\S#
M)1$*; #\X-N/UE(-J\*&&5VL4.UA=_5@R,1#E<\G19X6N/G9:FN+?'BT#=H_
M G'# KJ%R"K;>E0M(KJ (G9SC&Y)S!(<V;#OFO1N=/E]1[5I?BB+)[M3_YWJ
MJ(K,'9ZWIDS<455;7094=K?U#BZA@JF[@]4YZ<M\LBT-XVC5GZYFBY,R\EG;
MOS@:FQ+D_![VZ/:C8HL="#43.K?Y.!VH"K2]*0@_)?0(%* A190IKZ5K/ABW
M[+H87&LJ0F\]9B\^*=<0<;C6KJB]4Z#H)3>BNF\"OFSO@CY!+4IAR ,&EE0F
MY45<QHWK=>MS'VKOG;TTBM"]:[' ]F'DW7G(ONOC_ZM=U;OPO+S_FWMOTUV>
ME(*D;0S;;=.7Y!A?Q\6NM.4++L7192Y[UJ\CZ9LKJ(LKZIRI=.G,T8:8H20I
M>T9TMQP'XTQS5S[NP_>^.QL9 U<>QS#<K[TYXUFJ5"S&D_VBX $Q\=M$]6/@
M!AF\+2W7')BFHX%=^+@Z%(,VSQGIZ(! F5=\>$HZ<?1=\94NH5"&9:T*)T/B
M3=<X[O,Y9#3IG&"Y)K;(I,Z3[#M4GP0_I@NT(#*P@K]@/ 3K^;L=,Q&GM^]Z
M/K^MF\2S/Z$W,?,$/2\9B:UB#,-$:GY;B8?<.0(E1]3""B 79^Z[6/^<A7AI
MIW V@++-XG*_QB@GUONASXQI0*Q()7=G["9:N+W>-^ ;2[Q3R&)V'^4-\R2<
M!2YRLDMN!#.,42*=U /4F5:@XH4E.=Q]E/1K\I5!56?KSMD-I/M"R)#.$N[T
M83XS[C.,$_E4C-GA([0QD!*[F[0$<>@ [%>LUO^&=U9>:BX.[@\W<1^&@#[7
MQS>V%?V6>8;@I!LPFB)6ZY\=@;ABK6UU$$:8%L17G1_%()JDVOKN24SO14T8
MB15(I6));;U&.0* &BFE.ZH<F7\]+EI#*T2I^7C(:G.KWU/O;-F_G_,&W *#
M.3/_E*H<5D-4$"1\JF1J?#A^N\2*_"&KZ^2=Z$CU5\7*C8'KQ=%7VY-%.3YR
MY5WP<;AY%PGZ[;J.UD!Y RX4A=XVL #Z+'+W&H66$SQ0U)%Y8&K@92;A+[Z?
M;.>\\N#6GWB<4:!A=L.*,3]YM_\W)0RI_)6P;S>I-.VX/K(^[;S^:*%?\\-H
MWDLQCI*3#\PYKBQ@2S'!>(+3$%843RQA& //2(CXHCR >\!#I#W':EI3+]S&
MK+9<2F[2)BV'.V#@5>)&]$M]OKOB\O'03DI4!LIXY0AT_(>'$:7P!:U;S6WB
M-GY"LZLBYVM;L5Z> 8&HO29Q39Q5)X&E5O5O$VEW6^TUBN_P*<87"W)%^L0A
M!L$"$)57_J5BX]>);GV[,D_9\VT@:VXCZ;J]2@X+>:ROPK*7B9AM6V:=&ZW8
M9N%]85(H6'X_^AP%XEAD,$WY>8DV0AM?,S S[F+<"NHO\T9^JU2H/P_Z/:(V
M,$-KIIIG_9(.&UYN8H*F!-V;!.=WOS5O6]N*%\F=>MUZMXW-)BN7,?EVY ?N
M2K+T6((.2T<'?$Z-EL,T=IBY(]"EPS+Z.=*G;A5;*GL1WNL=/M?5RT)+I95G
M#6KG]G$YWL)]]N.0Q;&9@2-0#HP#RF7&,3S$G[X$IG0Y*7)'1QPZJEU^_)RH
M9M$CM-?&5LKKZ8]IY=]Z51O@V $M.K $1-TZ]SBRWE,=RF+S0A^(_Q\_&-27
M'H&(7?;#*G2A41=?DZO(?*O3%@<5HT/F1 MZP)_M+P=P1B_N[.&C+GLB0A#E
M0"G*1.CE\-D$ER'#S/$9=MWO)XOE"X=.D]7'/C0)RU'T?X^^Y9R"ZE)S4G R
M2)@#]4]FR\V&L5\V^K&'CK3+/FZQ?I[^BH^2.1XZ7+_'HG**S8$AA3*G. T>
M@5C\84*X4YN5E=]=U_+<?T11!ZAII#N/YKT<O*$OXF4I)GK[HUM?R+ ,;&,]
M78BMGZ%X^)K.5H<L<J7@D^IV(K9%"591G:G7KI0ZC\.;1])1U1<E#=>>!Q-$
M'O;NZ(+G.4F^J4<@3SPW8^+?3(KO6'-<F,6[8*&^?T'^>I_S%[:M KG#W=/W
M=+1?/F@Q^:CD8 F2F3!#PC./0$&U<&)J5M>9,L;X,B>VSU4K*T)Q0A<N[!)(
M_2G:VI&8X-F"&PA]YGN/3QHRNU=;Q,7-#P6:#FP8XX:^=.'\?C@+1(?R-.27
M&ISUIV1W20(R6UQQ6J+<&3VA=E9-<KAA2N&"Y[K.*2_5^+A L^BB=#046;@Q
MU#':;YN YW$:+-Y-J2$^&PB,J%/&^GLJ4I_*->]GWA=[CZ0<L ;=]-+\T7UQ
M%2V.Z;V,YD0>T,*IG-O<=?,!:'!.GV1S!RR]ZT(<UT>,=Y5"S=TOHMJ71Q6S
M,R1NI&BR$$PY0'\Z2'2.@ZLH+J"<JG +L*1LD#U*:I&)_9'4+W4N_H/E;F:1
MJB_*N=<*/URP&TR]IS9*OWC@NWD$XH%J -RDBF'X@ZA2J1:@"$63$9\*^OW^
M-QO']^..!-KY%7NV5@I+UKIUXG[P]?XAB-[*(H;TARZ"6%E@< +N5<C.6]T4
MIU2.E(SRC\*LCF[A"_NWKGT2/GY,^^L<A,,I2 ,4AS=#JO3FS%=](L_T,@O1
M.I^8DQ:$NDC9=.X>I\.)?B'!RMVM[:WN>\?7HN^FWYS/D[JG6,W!.[3#!P=4
M/6HC#G1^8%NP*3 ON%A *<\>[W!:B^Y4L)SD+7G2"V7%QS5%-65JY[+8 SL1
M3ZY"O_'7?J_7!?(/KJ.@%+$DB!Q90W5I%XX#DB."@XG!0C9<;9+-^8,;:FQR
M#NF*&7_R+%;9[1?3*WL:#^O+*17#A_RTT,,RM&1;DAY6S/630:)>H,V="%XM
M9V2\]KSZ^FD/M62.:\.9QQ;.#C2F@+::P00K(CP=IPM'C\I(  45 5#M\5_M
M$=)6EQLUU ANP^JA%W*GK/UZU[-0C;T,1&>\Q8[::K>^KBV@R5?V(5[L\.ED
M ULE8^&A[QYKMRN<$#4 U:?",R!G#HQ0IV6T$6S+)48#3G]BZ#$1E9,.HN;O
M6L-.E48,!'S$W\O6U:SR^DHLD^DV0QZ!^L#SL<34P?IXR=UMKK:98ID2DE"T
M6);N%Y]E[_74L(#R"B:V:A2QY3:7S('"'IW'/L13[ Y&DS <*"VF!CV@Q4QS
MQM/A2N\F5,8CJOU;K&YVV-#RW%V_K/9SC73>=URCB=K-JH#8?@2H;=2GP]M@
M:0P1U"4@E(@19'PQ7'\F-K!]4?=0\ CD-KTMZR8U;G*@1TSZW&!QGRO)GRVQ
M=T'":0RJ@@J8@7!2/7OA7.%:J<OS-X 1JZY;YE4UL#D*X677'\%7<I]O6THF
MO,[;DR>&'(LW/O;_:9_;_]RVST8/@\4P00@.)*(??ARGRPR46-BK@+Q%#_?H
M-F[:8S\:^^$GMMZ-4K7O/]4J.#-J'PP,=:OLF@>^IK?&G+I0ZI[\A:+3=_?&
MO5):L+%D;+5>%>PT5)9)#,<Q08N^?0:%^^@941G%O-.9TP3]\BB4?'O!%8<H
MB\]5MB8#MX4^LA73UZGX!*:-F!\DY,33HTF;M2HNXR'%\_83]7?/J M6]CIR
M[G.^8#_YZ&+]#S+.@CEE)I3WGNU2. A&FM&CB>>#P[%IKC9UBT;VMP4U')4D
M1(L4T98J-U4X52W 9?>.0*=F4E3F?$17BPB6FD[KA9OXFVBMH=*3)-7;T(:\
MREAGQ G+3R61UVQ:E,8\1H-'^W?9D0J#RX(H]PHD?P]:IF.JI<3U1W#SMN&(
M_-ZHVBD..YAV#.C$>5#QH000=P1BESML"D<<GYOO/[CEC RQO"MTZSLA>)&:
M3G"4\%Z44FV0YF9),&?/#OR9 RB+T86X^V -6DDWADLA*3..0$&UZ_9DA @+
M>?SEG7S_(-O5O8C[9\^6L?WN/G5Q6&\CG>82UZY *[9]^E>E<7LJE0,P3ZJ(
M_S<47K[MVZR@(F,V][YY >L0J]'VGW,M$I@+V@MC0-##4#VJ2AI:D_'M"$0I
M=@LTO.4X'8F+F(A[.FZS=@1"#=P_OU),RYGWO3[Q"SN[0F[9J8@5Z5(@?6W&
M>8US2!4/>3M\W'&.Y[QNP58;$^>+S.]=.DDM:(Y$:U%:GU7U<^^F:UP=NC E
M);[ EL R+%'_8-BS02);::9F(K_UHT;SG!]Z^+'W>?4<ME/*)_6.+\V$V#I%
M50?O1*<.(N:622K;KPY47%%GJ%NA'OZ&0XF!T*=5KB+1ZA4"B;P+_!/W-[Z/
MN%QS> B#87KUG]&**,/;-BOP!_B6LP<^[90#$N/9JQ\>BG]S:#M%M,U*C;HV
M@V6C6V]VNP^Z8%_K; EH&0H^!:5P.[R>"QDY;-VB+<';BO5[-'0KGCO8Y-@U
M3FA?#<:7::D)8,+RG=1M#]M\&O9T=*E'5-#B3$CTL/6,W _L<W@#?A V6T3T
M@NH>%L$06FR RF7J3%(7O,KRL'[%EJ=7A;:6//@Y?_A>F^#EI3ORILDJ2CS>
M43S)6WC$4\:I'YB&U#Y\&HR7(>("J/5T& S;\+N)1DJJS@XBRM-V'!!+2^<G
M/@@ALNW*3>]Z+:8HF1,\5($;E,YAUV[L0U0P9=YD6NL7F0\;5_6=<LLFX.*'
MO24S]>?[O2+5=7ZN*FF_,G+X@?PK+9/JFN1SBW-PMYIWGU.K.LZK]OP[F0X"
M$FG?#E^CV8!7M-'#)Q!+$C;]G^@K9M#.3A79SVRUB*]-U"X%6HB>)_RP3/UL
M]/@Q;[OIB]MLE<9._9B3 !H!:)CG_ (B.J^4PA,(,69<"V=\O3O2YDQ&%174
M/.N.&ZO]U% C1?4;'S-6E>8G32=[%0N.Z)HUC\ME^I.MHQ- 59"26:E6S_,2
M7\\\0JD +H$U6@]K<9( VOAB".0WSD:2Y6R145</R2!DU*CI^3?.$:>8M>&M
MOT<@CIQ)E /58\L9""0/]U?'Z?1)+LYOM;I?FGJI<=<K2-6(/;<O?U_"DTVI
M:C@+=PJ.^L\>,Y4V*]@4PT9NK6,HX?8QE%F=*_3[W<EZI791FO7FM$,VO%GD
M9Y70^87V?Y\&<=R4J)Q?3I3E;+K*F\"8\!I)*UZ//J,GI[*37L=7*ORP92HL
MNAHQ2U2+%]#J-T3G5KAM?'@WOI6W)+X_$W"%-:?'CK,?3K&!SU<3.7OJYP+F
M:=Z';R"^@<0<*;I>5]>X7@Y_H'V';3AT3#&W^7B5]6KJ7(/!.>\/XA$J+P[Q
M7;&!<2O8.=.!)<T&.)]-+#5]B-I<>S7"LH;DS7*YC*CP%MF??<E(Y&./RF:P
M.<FW7QH^)'H$$FA!I!KR3N/]0,TSFKI(CST!0_:GCSM69B?HII11TG &8JB:
MC$_]IUP1KG RH\3T:HH_*P\IRC#_0?YP-PBURPPLMJNIF1FK0)2%5?63%1WE
MHE-R"VP*3*OM*EW]\]Z)GJT3V[<0=&&G@5(9.!]Z1.Q++>&X%T E&;U?-^!N
MJ9TZX7_Q*Q=HL_"[ ;_KOS\N0"P1?'+6U=]#C@+-P03>?J8>7*_[H3Q[\=XQ
M!<?K K=9'F2#?E5%@8_A!-S[.;IG^K"\GZ1KKAAYY5]JNR,HZJM:5C%BH*//
M*7$W)M\$K(N>_8?+]V5.$WJ83^R8+,N^C!#;-7_,B@LI$0Y=]<W:X:JO9.<+
M',&)H,P/'V-\<PC+*[X]N_.?>A@B[R8C=A]&X=0IONET3]*L;\(1R*:;X,CQ
M/D^?2V$6Q)Z\X.4A80&+7$*= LS>+FA,OZ#4]X>--)A+?M1/#?E\4D#^M)).
MLH,#VSL[3M8WU/J^(U *1C"/ 'NXS/=+(RYH=5]]QFU<KE, !M:.KIJW9<O]
M87(J:JLBFF+N!&!BR>"Y&9)'%@E[/$#R<]X/,4F95)F28^]?GBZHGQ;.UF%2
MAUXD^X=':@GV>;@HY@K\"XB)P&Z="/.,BA,.<P>:KEDY>YA(^CA&WGY5V9=P
MS8CKX+KXG;9DC6VR\TK6I9?RQ-.G0*#O:N !."].&NC[&P$3!3C-IC2ORPG>
M"C"\J=-1IIC,\]-"0G'EC>7O,GZ)PT:T+F- \@BT-4&.Q62#!2%B-=\-#-7)
M4F93P745I9Y2T1AO,Q]/Z);PF7VVE ]L"KTPKVVI%:T'>&)JJ6'K8=F;[N:G
M=#:R#^40U^RBTCHA,^30FI9([]$I.E?).*$ \F3%S8^CA5!JW[3R;WS#20#H
MD76=)SL:NGX*$= 7!2PBY60P-^ [.,UVE0I/#8HPLI=]Y!8@FJ9[IT=6?X;=
MRVM_QX]MOV)%I#Y= T-\"F[$;W.0C,[\SI(B.7:2F !4-6P+URN<GC[;>-4A
MYN\U+H,_I@WGN2Q^'X$ 52O B59W6$27HV00A].#]!8#R?Q9ND64S&*;D<]+
M5QOR DGOUNZD2V_MW1.3%3S!BFO^!@&3M+A^C/LQQ"BM)6\(-G+1M4'JGBD7
MQ./+T\M >2#VTAZ^*2QQ.0G#!3VUM!@ YT>+ [$7VW%,]SF?)666,+5S8?3K
MF'S1QHPNRS[GMA13>.H=OL;[\PMN+K/AH %8;K0ADMNZ.=O&TP;/:FQKF\=>
M*M;1JAC][9AOVI.X1>SYB-D6,EX8XP?.D9'[CTNWG9]9X4^T68#QHQ47P=*6
M+UP9/W<^OHZ]6#4LWC,[DFG*HP"I<@IX/_Q=*X/!39<&$B.UZ+$4;+_K*FEJ
M@(!+1MPGQ8/TO2[=!X' )L9JD39J5L^L@@6#]1>WBOGE:B5%SHFW;L_>$)_/
M/I?IF0[:RTD%M[9M_:4N#[G"DF"^RU*SR.F='>6.R?6QN:>Z@7)2!B7W!S'A
M7V2SE9(;%'0V0B;OXQ0.+K34IV.(KS$MS)((MXDYOJO'J]!'H^4I]C0:_M#B
M?C<,Z\Q]K&\HPZ_WNR(!=XIN# 3>T2R@;/;$Z#\(A+QQV6ZVT91R7GWT.]*Y
MX"(B[(O9*Y0Z<(?TQ4%OF1]U_EN0UMW%M247/XJ9:@B[OO3-DX\L('LGROA'
ML;,W5HKH0L.]X*95# @3M)N"9J,,#\!!S?]@Z;K+8DC#);<L4Z]L08O9OJ'5
M1I'KK\(*V>,='F,O'K[3Z@*_1'ZB76H9AYSP),:>@*J909^1O-K2)[9$/Q\;
M//NRJF^Y*P=U^X[,I79%K\.T:M1IP*T>V3H_3-CH#V;]X]XX3S,.V+V28/7^
MW(37Y_(9Z7=FEF1P"H8/XH;6@XO086-Z1B_$,V_]E+RI8R'@R]T^^9RGU/@[
MV]I_%(73>/ 1B%B/:=K._/?XQ 5*5!KGX_'XN=BHV7,SZ[.SOPFAX^_AL]6T
M2@!^((UR B8.--'3'KHM%/0[J,K/4I5OOX/C/NO_&\*B1CZJ7NWW1SS2/_%Q
M_ZRV?<_!M142?U]L)[7*G7Z6LM5V]4;PYV)%7ED""/[D#1+$\AWTJQ+B1FDB
MY>3LUORVE:9?^!;167*AS?^/)"Z7]W-A[?-U_5Q+4ZRU'><PC&*O];"2? 1*
MA'%C N<124V;RWPH::JAL:W+V*XN_ES]+PGYO.4#L]HW)B+B3;IWAM5TK\U'
MG85? BY2X8P3]50$62PY=0M/^43:2*/?4'RY-[UQB1+796#(T9@UOF2C-=?O
M*O+7_N9V5.Z8":A):^*/Z/2?R%W_"%8KX;?7+5[;C?R\<ER6<O'4W88N(<HP
MJ;[?(D2#<8H.^4:'2:^6>A/\BJWU$Z(VUD,%ZU8^KO[[QMES!!*'L-VA_.GU
M,&*B:#)3YQKC_2Q19^(J J,F4)>!X+>+&M,Y5?#^^]1;?;2M,-Z!&O&R7JUU
MV9Q/2[QQ2%@0(E%&C&K;_Y_&!S&Z V<*));*:=;:-0%1BV8?'&@\?>S8(^4!
MA $J0/IQIQS7"7(G&P5&K*1"9/1AQR&:$<_\(9^"X8R3!XB6RW^_KA7Y_+YP
MX8->,C6*J)Q%S1E&BT_3S<O\$B;Z7<O?O"U^-J=>_#Q__I;&@#[U@YT4\C+5
M5*W 1SMHUN&BNHFQ*$X>$"+#^6]A>N]#=68OUKE"1BGS-@_DW9+5QX<*.;[Q
M[(WP*[S=,%;;_JB0[4<XX^EXY;J$LY= 3():<3.@0;G?]U-M$YRT))&"]'*1
M*]8XMNAAP"GW..F#[-[Q,OYBO/<BW+*=&:8FQD1D(>&QX-5PQ(D'DE>YA61*
MJU6D:4VG$9=,],B2G E,3,TZ C7E;'^DK)!N]=M-[T+5?Q;I1SH*<A:N*11>
MN"KKX?SAG:7D@S\YK/A+&FA^NE)CEV%R4=\NG^F]D9\3@R]-ZDPKG:02?-<=
M;\==E/U=23>BS)!&D[2>W:1@XW5M--=>G6L9*BDW94\^P5[I97?/@E.F+QX:
M=%B"(59@FFP'L','?6/?<2IMW=1?_]Q;GV-YR5<8XT6.%E/0KPW!BN;KFJ@]
M2+-M27IR4.QTY<$EE,PWG($_K"FR9246"0FM_3X>T.'S8/6J1^QE3<F+LK;J
M8<)/KO<^S'K(SN9*,.\;39$!4[UG<G3!J9*\A>VHX[CI6EVD?.=[]M7=IS>-
M5O_E.U50L,DA*"O.S!V47L7'&E="=TMK#<TBY$YRMJO2XZR1I/BKB0EF(+__
M\^Z!TSHF&T9,/P*U&J31 VN013:';8Q/P6]_%HGIT_ !D[#[>19?*P>>$ 7.
MKZ0?GGW9^<XE6T7K?KCK3.SK(Y#.]GNM 4UEHF1+E==^DKN#B&;,O<K7B,"P
MP?FHUHV]7;,XLR,0WVWFXA4<@<9:CT!K*Z\P>]Y@RCH_< 9^*(5@>!@:'(&4
MG3;!A*>^]"-0*H,#O ^;Y@?2922.0-]V.8] R;J8OSIKA,/+S'>ET03LK[CE
MOP:5&.K(WRC&J5ZFS%([ KUB M6GX2M'H-61P_7Z8O(IZC<:_$:E!+R8ME84
M&-5VXV_G#\Z5\$;;K>7?IN?ZG39H2S/YL^0+P5OM6M0]C_W6A>G8O1]%Q#B^
M/_TR7&-TO4KX8=7&M?'M[3K-1@R*.O1V=!3RR!:R[_&?L^0$_03_<W\-XD":
M;:EVQ-LF$J2,B[^^,>.N"DAN;/_0DZ<=QU:YHS:OAFT#;"F-$TYP 5>4+H7N
M] -66C3V_9OZ)\VPKO,VO4U?PY[/;&RW[HSN_ZNUG*Y6S5ML7:Z&,N5.PA/T
M%[ 0S*?$=@C<NKM5\&;G'=4I93>\/K.4+]DV-S80HB4Q)2+V.K=H:>O819D[
M(\WSW3=HK8=OM!BL*"- C'2R9@X9>(V*J_>L"%B"36K<+8!<X"*\T#;?4#,[
MM2-1H/1(6SY-O)IE>&I&?_I/X9[+DMOKAJO)2NF7>>I>WZ[D3#B^(E)"YF='
M:@UV@"@5Z5T*Y3]CG.>R#.PF5HH7@@[PG1%J0^=7LB<S1U-P_'03X"0)"ZA[
M+B"MR!D_.R+;*7+AVSJNDWJ=62:;KAF;H8*M^R-?:-A"YF+;65O(/0:]5.'^
M3+]*"8<?8XANXID0#J@8#%<V6[FTA(6MY"05EW]@V@_N/^T""ZXU%SX;*%]1
M%>#]+!YM(Z[*_ST(RDM)QE7[UU\DN>MIU:@S/GK&%)Y+"]X^ FUDAAR[#N4<
M.7XJO.89X@$S.X+HMIQ9M5 !I(>&S^3ZO%-./^U3!/]!8](2_D$9?\YO>,99
MQBB,XKB)20<W7X/HD);3P<=K=?%\/__5O- (TB(7GO%NR//INV+Z.FGU08?S
M$:C;D7Z2.DS2KV!>_2E5L[H,=7'LMS@"?:S_3OE'[\K+/]YZ#+]]U5+#)Q4T
M3C0827I>G5W5$Y>[ F9%@LF:V2@C*F=OAV-GQ5/VE&&7B9<=2>^_2GFE?\K-
M_VHT[H=FH6BE((Y +1 #8K>*;<>!<"3&OV'B9;IMDSE64_I#V=_ _!9#GN=<
M(/HHT'9@#7#2*IGYXHLR 9ZN[*8WF*ZXK76+@D\T2VVT9?3G#KX%0>;54,8?
MSVT76U4_&DLM6ML;%5E$V0/[Q/H4N!3&6XLP[SHS_8>47)2TBS*H!/(^2@;:
M:#+(0Z?_-+V53>A1$/D*'3T+T_4.W &@XBC=EF"7;9R,GWT)ZNS,57^!Q,H0
M=C",^V K(0Q_X6.U8<4#ND@M<!,0<Z6D%$6_U.5F\_OCBKKO^J1(ZL:(]YGF
MV[<]V5CCH1> )FHUR78("ZC"MP:K4 K4G6=D-VXC+?'7A#=I]S6#Z$/C)_:F
MD?M2'?'<\@U>"YWQ"SJT[(9RYTV"V71JY>"ZF\<\1.S$\Q#SZS4P^< U;#8S
MD^1<&$MP%IPL7>40BW#K6>8-:@'T8K,$G-W<YC,.%'@N'9=$SB6T?PJ^&'_-
M0/(?+A[*S8R=-S!A>9C8@A5A%C44XY\5N=Q?7%*4MJ-GRQ(8,Y! &!V(">H5
M%E=&*5A(& A_W1IQDLB*/^!W 1:)3R(.8.R N6,SE?.A5KFMEOGX[G7SA(5W
MRQ$7W)<N'V\WFI?*GK3Y^K/"=PC/#V&AJEQE] (9Q& PO('WO4N@JY>3?<CO
M.=5WHR1+8DXJ4T!+_ A^03>@R&21#I3CMGU?^M\C7':;?'WU%10HX\_#>&VC
MX?$8RG6M',QQ]#FX)C:**F772#5X@-A=/3E<[2I_-<]4J)6MZ])EFT3LHD5H
M\A<_QNB2>-L,4\>]P#:K;)N7_13(.5:?&KX(VCPA>Z#Y H,(%'+7MOSC[/:P
M4"7DP=.B"X[#DZ4&0#!ED^R=%.,TD /ZCI-M2;'5E@I&7$W9T<7L<A0XL^VH
M]@,ZO7N /TI,)5EW>FQ<*4NWL"%S7O4,QTVSK'A6%C9Q=BX0 *>)3NL^P1 3
M"$U?*N>K" #WD/VMPL<L0LW_TAQ"D(J& OPJ]WX+CS[LP.4M4Q#ES2O7VTZC
MQ?TC2?2UWL>VK.+_#K=[,B,^#,:UB/4N)]V;M2GOIS3UIP6&REL:-WZ/)%^0
M9F/W<7^B9(H[\>/]2F49TUU<":>^QB:7GM*O/O<T.#L5L99VG L>\CE$EJ7T
M/3/SM ^K(=XD=S;X81K=LP9(&%^^"A>8U_FI_?4EA]/$]M2M]O/<A>!SYZ5M
MHI9;VY+N,E5M,.,KFIMB;U7KVR>CT$F]TJW7SA/>K:R4M/,DYWW32)HDVY^Y
M:^>O7T(3X&Q="#(F&\.F"%@=&-X**!6E&&3L1("%Z@J+4:*5P1!+*=5^];&G
MEI\*[;KB8_+3_SGUP/B@I^@7)F0F2*/]M5+]]SS.%J]/F(_?:>9;C8A(-E'7
MCM[8- $K,Y/S?-<5-"?Z&PP,\SX"9;IFQB#2$%!E#V#8+-_^\96(6NU?_Z.]
M*WV'NOW;HY2L@R+[$"J$LF09C!*%:NJV;TFRQX0P:AC9A<:2A#(DE)+LNV'&
MTHTL)<M,EAG=]FEFNN_&-[,]\WN.YWA>/7_ \^)^<;Z]7ESGY_J<Y_DYCNNZ
M0'IJNMP/)[-$5Z&74U5<&C^QM>@T/(FOD,0Y9A'06JW+7X8'4D&^)#B>>N\J
MRO**FIV;8YC_9&1%N+]K++^LY](D  D%ELEN>!XHZVT$5MI*<4-%33:W:RJL
MU.+H+=G5)W^[M)4+P1V^=-"9#^.KP!(^&[%1FQ3C''?[.[F';(>_SMM]$Q,3
MBWQH#9%&':?#AV'ST<QRP(>>018:(>&R?(7Z-"R_WT=D&(^E]O30=R1)\JY;
MLW]9_:I+KE*_@PSO=C3HC4$W3S2^@O/[:R*GXAY@?%(%#=B@3"V*GLB.>HW@
M,,RXF@03L5\--6Q%>B$93GB[70\G[Q+TP<%N)LL,5F15\ ?/WA&SWT2C/]A[
M:]@:-C^H586)4I0AY.&4D,3'$\6S1 NI\7?]R0-?;?:=,S-;/YYDI</)^463
MV)I.G(4T>ZL8-#4R)A_U&0+CP?<UVA4CEJ#9MXYU26&>V12=^*1^LU]^[*3%
MR,YUU@7T@#%?=P)[=<@F5$=Z0W^7T*#^@06]- I6 EG6_\$1G1")8!7=L]EO
M.5-PP+MB\<0S=TFD[IY,"-E7=#YL[H9V(WTQ5:'ZGS#E']7BI;I#>'V1!E7%
MYV)B^ZZ>\=C%BEC);JD89E,L>2""SSZT)"E)=:YFNB)LOE].,4BGYV;D0,5^
MLDMU$8;@<W#N*I @E$J=LT_Y2!]J.3-<^L<102_!','S253MJF#5A_F?$-/_
M\V=][JJ^1*B5>FNZ.-2)I7-1+? .]IE_K4RS+1)E3^@,DKU=U/1\R,2NSL'!
MX(ERX1^N3SP+ONIB\^L5FBNO.Z=OD#6!(,K)8R$UC,09VU/C'G30UOTYF6BC
MPG%/KXQB)9U.C7Q@K@Y@DGQGC QK@F7MW#K"FT_GNX7&0<XHWT\P](:P=?CB
M,W64[_W\>2#*6_;RWCG /FOT[SUYMP/?.X@ME1*AK<Z1+F2M,7*.USJF4R9V
M==:[P;TE(=$)D[-I_JPT'_YRUXE;DAMNE'=902<CV\*P4O4AX!9VE "3@DM_
M F?OJK\.N#F9#+:9_< #D3T!$C<)]]L0P@/)^*PGU;=R8#8*@;C;MQ[$DD3E
M9=I/^/TL_%+[Y4@"Q$)C<*V$@WJ;:^ =KNV48:S]WK1.,F>587<EZN)R=E?4
MMHK+NP(QDDJEO3/!.3LLYD<[YYC^0<#1A?[7^)=0\Q'B4W=\W5]]3N4]<VJL
M.UN>B84L)91K[PSM5GLJRFRV>+S4NBK:?;RNTW),$K1E#XII@+^C22.A>"N#
MML>30US9+S'N?@D,VS?N(^95_HI)=ZU-5XVY.7>Q(K>_R10XC49UC!K=_/[Y
MR5\F\28G:%<Z+7W=:D8^SC4X';X^4\X#1:Y!9'!!Z%1L&V;G10B]=J1Q*/[5
MMH+XN[W -\$NWYN>GQ<SN0N[,H:MT@HP<U5E<W@@02*"Z$N M)KD)A[DSA"H
MI>L$6L9>!*8:6;@&(W7YDMZ_:NOZMHRB1I7U[?Z@\T#FG; 0X &>*T_/??BY
M1XM,4C:8^7C[+#'AI8U\%$BW%21OJL02:>2\J/W/5?"PA'1(:[P5G(BJ7(N/
M7VR.\^E<5S;TO70K,1(YQZRD0ZA0EBH[E@$>@F6EV#%T2X%"^%2BY,;N9(@F
MIE"L+$(OO)YAR<Y-+_ (7$2H#$/5?RZ^[:1SL:QCB5]]&^$[-+HA)0ZC\:&W
MFU[^(IP,.QKL^:$->XDA_K@XI&])J['E4T;,R2@3_+6'JCZXX 'Z.IGZOOY-
M&'-)<+H*-^MW)G2W<3-2N*%*_<#QN]W5WI'I&L[FQ?B&M+W)C'JV^ENVR91>
M2YGI9=?2@ F,X%.Z7>232PL.=733_4I\B8-?_XP+5XY;::#JL$21[2,TAAX-
M7R[66HCG&B63 CB4J[DZ(<50^[_UQ"[U:YWB@7K, J6/&QG32/N9B0"6O_LA
M7XUT3U#L<L,:B*CCW(%>>L_<QV+ZEBPS3"PO.PJ%-U0TO=GQD^N?)&&U0<<D
MH^3Y#%R BR-%\9Z!6;47AJJ^_)-]B%IQ_GY>_NMK\,]-U8 Z_4:"D_/L.F!#
MCNN=)0?'O&V?TLUI9S2.:=":#=[\D,L+WK_JRFFR@))AJ>@F#'Y1D7(CESPI
M@9S$TXG(#(IO"4)KZE7SYPKQ@",%Z8^(:QX:DM"/AI+^/]>+Q@$I"B[-ABMB
MRRC$8T6M-"UHE,FTKIC:5&,HY]8:,]QS8_A<J?!Z4,'F$38WU-#N=4Y_ZOF+
MBTMJ 'H%)KOQ 8D8NB'\V=C2_.LT]9VQ^%FMBK0\/Y&J-R[:YI*F5%<U>FT:
M]1<-< AGF]PLQ<X/U3(?>51@=U9^2/Y.BI@'JT7G,"O F;"5$GYH%>K'[D\<
M<H4U(P:7Y3WX30F<#&NYY^,V4%KR\Y=B=D/+Q,>V61YH6\^C/<G5.%!"3FH*
MZ\#W?'P>1@W[%-#=[]";:WN]8R-]^^A7GQDC'IG#\*+B3D-!EPL.(5HX>C.A
M;J#*<Y+EYS/D3'\_!^G\B5LI0HOU:;'%.8]0.G3'57U"-TUBFZOTX%=W\M8:
M,7CM\-91DT/3/=(?#PEKISR7C![8ME:)XRO9YLP_V_R0LU;]W[/R&\BRRX[N
MY=8*@1Z.>56=(N^N0O??P+*<V:&<3&/<0H9/.T!EJ _<QV743MV&^'._MG65
MQHM=O-EJ&QB(-3UY+4(\^=#PQ68DACQ"F)2[45--H0D$=]6/1QZJZIBYUQ$4
M8VTO(C^39V _<KEP^UH(3-A*)MCDS9L-M%B/94"T_'B<;.DIJ2YLH+/@-:%!
M7&-Z-J.L?YE^85F)P+)V?!#L-7!#LY#P=.^+P97P:LN43'6_$^,5?ZXU:7&%
M)25.Z^0#K?Z49G[ION646$&1!L,)_@Z %P4L#A0.,A7XIGWG:=WVJ;*+OKI<
M5PA>/JO?R;<J494^DL[V\N,441K [ENQ?3?1S?^9HS](OTORELHOG.PUM*:C
M4U$G:L=> 5YX8FQ9F&%Q*0G>^%CN^RW0J=&D?9= MYE\ ^?(I^_5(O(B\SVG
MH,>8CEUIS_J'@_8$LBF+)[B27VJ\3XUO:/RMV2-PU?5DA;11@9*@D-@Y56>(
M,OO!"B:%!Z*[(3*63@.5%)8NV!Z[4E,9@*C;/NHHYN2MN]V9";TI+[*2IE1@
M#2H0V&L86#[4=Y@-G=%K163P0&(6T$H?7_0(=2+WY4"8YO\:C)96C C@.VC2
MYOD81^X6W<X]BX9>+?_Y2?.!!PRG>%I3\>'H"L,:LF\3)L5W"O"%7>9OH'L%
M1L+VEZLD3XYTO:C-0@FL@N60$6;4]?8PY\>._J>F#TO@'UK?.1G\74CP_3:V
M+:V8T' T<<BS>!@QCUYYG(L@8P^A[#];.$9&DW/W0>5ZKBMG%T;?S1^2EJ_,
M^@8V78_+/P/1/HCH8(?32>2YP>Z3]Y8SN0+3J',(A'X9 E&_>6WQ%9SSEX=+
M,C;R4^C"_$((\WI(FVSD.83@>=-P<HZV7=)-[=<K(%-0I+6*/'V=*Z+..H.*
MQ1 \$?V3"B1D[:#5L?+]0NGU+GT+M1<<."\?5!,3QS_8W0X,ZH^]ENG>M3[!
M P51_>T[^'SULU&-[3/4);\5C,2;K.,'FO(N]OC#")W1FQU!]0F69' :3JQ/
M97')%Q B3Z143KZVXIP/AUQ*7_CA-6NCD+Q>7FNL!#F4>)BX_,)UCIR1X=]U
M:^B]_[2JM'1_^N_DH+Q+5IU& HS=G0R*/A@CE4@TY('"B?&Q7.C,V@ON5+<_
M9J=0*RJZ?]1TL@[KL,95#"5>XX%2[D?4F!?U#0$Q=?WC =["5W:VU+=WLR7/
MS&F(L))AR>B#E?;J&>03Z5(!5PKJ-F17S+^?!?_Y\:.02H7*#(..((O,GWV*
M$^DYJ^OII^,E+K$\9@"RCNH^T['/[OX*UA,$.%'*&Q_0>]&WX$26\_/)%; (
M$+'LP#A;+;]\L"!&68^XH%>M#O5GD9_3:S25W45^(4@C!":L!4(59YDA#Y/3
MZQ&OM_9@@\$H#W1TS403)\.V152CN5OMF%%1ZO5*"VC>P;MA6U[Z^Y$ZE^GL
MI<-?>B#5I$TW@;3ADH-8!:]1.;\4NZ-AMV,^KKT%(&0, 9%^MC"$!Q+O4]E(
M5$E>@QM0Q,'VZ=.:B8F!4MKI%N7P>A *5[MM#F?#CN^-L:Z"H5SY'J_?-X(7
MU]%W1O2+,;1XM)4Y=;TZ #V@9W$5)\CV8&"9UX!/=4,U2((C4/(:>"SPYO(Q
M\[829.-.;V:G2NAAJ4"_%R\OB*?X>F#3T&(2G3R0L!D06<$#A22\I<*(D'EZ
M/#>6NH0H:8_E?/LQ$?W)9!@GW"?#=B@EKE),"##P]D\/I84_ZS>F?(R$S$;E
MK[?]O?D(!#2OQ/$#BD 81!1V!YS+ TD3.59'V39SOSQV(EI>M]O'^86(CV!?
M$R4*A#7RQQ&[WGBP=E0\3(3MR"E'!],6#I,G=VH98\RO@$L N5?M7OK7'\?F
M+BN45X8$UTVYVQ\AJ[?D'<C5+$.5G)RWU<UGQE$35G"Y2_J<LE^T ]SQW:YP
M3%:$+OG1!'2A=,DL/#5KG?0J:UQ<0VW538[HI5I):,A&H@GW>:#!2T?Q?9K\
M(V ".%WL.YUYHH>A3,M8^UP_<=KPE+#&SV'HG=3R;]>$ZA*_X9IG(*WM.^WO
M '5\5ZJ_UV.YUH;]6[-?,-]"G_) O:U/S03P&68Y'1L%C3*#Z $+%'H52ZR]
M6L@D -7DD']>G+]RD(3OLDT;?""BZ-3MW.G"%;#D;C#+S\_;/E>:(;ZHI>:R
MH)N)8IQGZ$#]I/OZF6RH4,KG"=_,^^U9?XPN7^C[MN'Q+C/^=O*9QL\:&DT?
M<D[/N[,:\+!THLD +=T30A _&!_8-FTT3[6=63?XUH59@JO1-!Y[VEDN_$FS
M5I;Y/UYD_1?_XE_\_P>$M_!?4$L#!!0    ( %6 25;;<2*-32T! 'M\#  5
M    ;F)I>"TR,#(R,3(S,5]L86(N>&ULW+UY;^0XEB_Z_WP*OAK@=A5@=FFA
MMKXS<^'<>A+(Q<AT3M]YB8< 5UM3X9!;4CC3\^D?24FQ+Z2"DM4#=&>ETQ)Y
MSH_BCX?D6?[E__Q\F(,G7E9YL?C77_P_>[\ OJ %RQ=W__K+M]MW,/WE__S;
M/_W3O_P_$/[?5U\^@#<%73[P10U>EQS7G($?>7T/_L9X]0<09?$ _E:4?^1/
M&,)_TR^]+AZ?R_SNO@:!%X2[ORW_$OAI%".10LIC#%$6$8B)E\&0<A8FL: !
MSJ[N_A(E&1;(I]#C*(,H(B$D+!4P"U'LA9224/Z+:G2>+_[XB_J#X(H#J=RB
MTC_^ZR_W=?WXE]]___'CQY]_DG+^YZ*\^SWPO/#W[NE?VL=_[CW_(]1/^UF6
M_:Y_NWJTR@\]*)OU?_^_'S]\I??\ <-\4=5X054'5?Z72O_CAX+B6F-^5BYP
M] GU$^P>@^J?H!_ T/_SSXK]\F__!$ #1UG,^1<N@/KOMR_OCW:9_:Z>^'W!
M[]3(WO R+]C7&I?U!TSX7$JO6ZN?'_F__E+E#X]SWOW;?<G%X6;G9;G5JI(R
M4U+ZL9+RGX]U]OL%XCN2M]Z7U8%P6MU/KF0\A>DG9^+>2G[@PPN\T<W%(C<?
MU-L%&^O;775UL>C#2^SJLRAJ/!_ALUAWLR'R7/W#!_FWMAO5T DRU?VTU+TA
M*O]9\P7C#5MN-0UR]J^_R+_-%B3_.7O#2?U>TGBI%[_7Q:)=,M\4#SA?S&B:
M^3Q.8^C[OER>D(@AB;" S ]]'H693SQ_5J\^[QE?P&]?.TET=\9]_6*A;WUD
MWI:\*I8E7:]X#_-#RYA<P=2:E_Z^P ^\>L3M"U)@91PT.OR;DA:LQ;T":X'!
M]T;D_^]??E\K>AG0\S'AF_]/0HZUAINV.L9"<*O3%T'R*( %W1)GKNRQHMR%
MI* VD#14IUZ05!8$?M"88O]LTL3O>\-[778BXI*>0;M]XG=:2#OSL89;GZZR
MRZUUJ0OK+Z)!4HKR"RA*QDNYGSB@UNJK75;P#N/'V:MEE2]X55W3OR_S*E>?
MRO7/O)K% H59%@40T221?\0(IB&1],H2CM/ CX,H,B'5,_U,C5 [,<&&G."[
MDM20#<[A>II#':(U,'_V <IXUAO"L#9N*JF!QD#@BF@EVB9^5U3P.Y_75?<O
MFAPT,9SK9112,%2U(P33Q^W(0-/,U^7# RZ?/XLO7,F<SW.]<'P6KW%UK_[_
M5G;UA.>2@ZKK!?O")2/E5)J(ZG>WF,SYK33H7DFE_IBQV/=3WV,P2R,"D>>'
M,$4HA$D:<I&RC/$0&YMD#@6;&MUL:P0* 93,5_I/L*$6P L&UHKIWUM8)RZ'
MUL (?*$!&YCQ6JW 9P%VANUS,VS[HW:]/VK@NU80* V!5M'&S'0Z1\UMTA<:
MT)$,V&Y@Y>PK]^8C56.F_^ [T[%<#ZSZ_9\=&;L#8'W2,G;9WWAF]  H;=G<
M0[3?ST!_OZ EQQ5_PYO_OE]\K66K]\5<ME$I,>KG+\5\_JXH?^"2S7Q,,4V\
M"/I)P.32*SR899X/4<QP%'(_"2FW,=PM^Y_:"MN)#W[M%/@-Y NPJ<.?0*,%
M^*[T *TBEO:^[3"9[0,&!'_@U7( W*VW#SW1<[2ML.U]U.U&3VAVMR%]F^E'
MA1_DAH?SSX^\E&2\N/N@>OR08R+9N7Z^P<_*5JC>+/DLR9B7H(A"EBD.Y"&"
M.*(9S+@(O3ABL<!T5J].ML].0]..K<COR/F]RTFH#^]!T<D-YGI&/K8"VQ&<
M,?AFS#8$I -36B/R%5@)#;345V E]Q6H"T XN,$Y<T=CME YXB_C;D<E+ELP
M=AG+^OU^5"4)C^=WB]?+LN0+^GQ;XD6%J3(AE;FH?YQKB[*Z*>:Y?&"U+4N3
MD/@1"V&(>0J1$ E,!?(@"SF/(B$8CQ(;^ZVW)%.SY%I% &TUL:.O_@-BQF>C
MP#PPP74(=TJ 32WTGG=3#] H KZW_S4YT;#FOHMA=42&_>48E1TOAFN7+B]O
ML!]_ON&"RRZ9-#"+!WZ+?UY+VJZK3[R>!5%,XTP$,"9A"%$0QC!+$(4B31+D
M89JE:6I#D,>[FAH#=I*"&O\$6$MI1X(G4#5C.3=8#7ZUW\+42 FDF*"1\PI(
M2=V1TWDT'+'/B8Y&I9?S"N_RA\$;?:ZJ[G')7TG+C;TN'AZYI"1] 59*.KKC
MRH)[];Q^I#7JKM4&]-/R@?#RL]"_K;YPMJ3R@659+?&BOBWT,W^5K=2<S;(4
MA32F'/HXE9M(AA/),UCN*6DD4$ 2:8DQ\SNL$22>&ETUHJM#]$H+#\I&>O#8
MBJ]V2WCQ#,1R/@=/>+[D "M]P%VC$/@U7[3O_F9S23+&UV%R#3:Q,1_Z?DQ)
M"[4R8%-AL*$Q>/4,]'.@>:[5&FB5)#LW7\QGT3Q4@59WT"D/;HOF6=#J/[7/
MPN92;6*?QUBW;9/Z3"SOYD8<LM.7=F,(,N)MWHBX;E_SC=EQWYT0J;]RNBSS
M.N?5]1/.Y^IZ46[,ON(Y_[8H.9[G_\W9AZ*2>[#&%>@=SLO_4.OISI5_1,(
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M2@T=[UD\/$B*TB8Z>%1R@[K,[^YX:>%JT'.0#'Q*AH=^X*6@0WVM@;K';W4
M6EIU>Z_4 )T>0"G2_&[X0;#PX!A^,$;RR;B]Y^#AX'2HY6\>RX(M:=W]N#5#
MZG;@FIGRL)S7^>,\ET-&GMN'5UF52EQSP):E7L95AQQ7R[+Q]WC46=P KE3K
MCUC[N!9MY[FDXD<\!XM"OH\UU<K?X+J;EQ7 F]T4CXV-L="OJY>D39$+D-=
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MAS&.)74PP6$693'DF$2!"#DQC"0YUL'4R*(5<94Z#SQ@T\B1HQ@:W/9>B,S
M?-"!THD'/EX.BL7MZX7@C'2U>O#+ 4MI!93ZWG(N]2G*QDC'=R77]Z&N;B-/
M0'3RJO'0>^/=(YZ0>NN2\-1SO7,M-UEJWN05G1?J>GH=,H-QB@+,I'GDQ1"%
M2033+ XD>@QYB4"!ST/+O,K'^IH:^VWD45H+VSM(YA3(9A:3(^@&IL?>J/7)
M<WP.#W<YC8_V-';^XG,J'\A5?/85%^?2JY#>&4$L#EB*H$_B#**$AC"+/<D@
M(8XX]02._'#VQ$M2]#N>7O5D\]5O]C?<Q[\.E+]JW7@O.:A>0]KGM+H73&-?
MIFUD%EA_GT,=8>\A,L@Y]KJ7%SS,WE/U](GV_N,]=DSO5QE &LZ1V['/]3TO
M59Y%'J'8\U$(:1(E<N<4QS#C.(64D8QZ&(5!(HQW3B<ZFIX-T8D*\F9A5,<'
MA9+V"BQ.9&6T@]=@4^4(M,&MAQ5>K2&AB@EI04\FL;2#RV*[Y0BVD;9=)SXW
M];6YVF 9@')RHW7J_?$V7 9:;&V\3)[OF3:]H]_/XEV^P N:X_F:G#OWP)C&
M@1\C#&/"4E61DL!44 \*+U1I#404,Z/,G%:]3HU0-PR&0H"5W!M&A>5%GAGV
M9@:8<T0'9EL#,*_&R7=N YRKW.9&?8Z;Q]P&AKV<Y58O]R.J:\:TSS.>JUH?
M[Q>O\6->X_DL%"+UF,\A2C-/;ODPAG(7Z$&>!A%GOF H9+.NM+HY0QWISF@&
M[92-'X&:UM*"1RFNRH)'&X'M&.D8R$G  B^A 60TI1!%/H68ICZD7HP()@G"
MS,KWXQ)T1V3\H6$UHW8'8 U,YALXW;0XO3Z#DS5/GT'!$3,?ZV54+CZCZB[[
MGGN\']_J2A-"3C)I:W[EY5-.\\7=87Z_E3U4AW_55$R?4<1"FF0AQ'[(( J(
M!W&8$1B0..4118BD@0U_N!1N:J3CP+!T.G9F)/52(S*TF7IH,,#W1DZ'5N@0
M\#FB1*>BC<JC0X"Z2[Z#]-&/L9OBC^M\J.^>/N7K,KDS/Q !BT0,4Z+*G"74
MAQF1&WF<(JP&7<29%0>?[FYJK-H6/JU6XMHQZAEL222\(,DR&&5I+->W1*YO
M-$P@XB0F 5/N.F36A%Q_K7%9CXWP;M?#X?P*RQ\I![@&A-_E"YU#1N[P&PF<
M@LYBFD8^BV 21P%$B <P\^7? HIPDC'LXR!I07^[8"\#>=?Q*(#S)J7=,&B;
MF0'N\!MX86_Y8#,Q^;O_@)_>7X&UN.Z6=S-8'"W89SH;=0DV4WQW435\RVZ9
MK,IZ]D55F?C(526)F<@2C)(H@K&?A"J>)8$XBE*5(3/V(A+$V*S:U$Z[4UOX
MOJJ+GZK.J;1A/ZX3@)AQPRYFITG@ B0&GNU'0'!HR!_1_=24EJ]L3&?YTWHJ
M[[8VRIP]HD(W.8_]NJ_CW\FHC(_XOXKR]1Q7U2<YK.U.-$U0FD6"0B0B#A&A
MF;2RL+1@PR!-LR!+.+5*$ME#AJG-[O/Q35= ZP&T(D!I<OZK=S9B9D;#P.,P
M,+<,,P0]7!)[@^C,5=%>@I%=&'M#M._:V+^IOBZ/CR6G38+$&?$R)'R>P1 '
M<NL3IP2FJ7)V1(3%/A/,3XV2"QYJ?&H4MRF;K4OC!F1F5-07B($YQ@B#'BZ*
M^\HZ\TO<:'ID9\1]I?8]$ \\TS.:7N7!>5]52\[>Z$Q[-\U1BT[ K7_Y6:?'
MJ][^Y"7-*[FG\ C.* L8%"Q&$$5R\F)" Q@S).*8XU1D47=C;39][87H<8\]
M] %=)UK_E/P]QL*,%0;"=T)58DE;_A,>+/_9:J<R13?ZZ3I[-Z</F>R#Y7NC
M["I.WEZ <4/D>P.T%QW?OZ4+W0P;^^AZP3[DF.1S?;S3[LC9Y\47=>2CY)&?
M85Y]6Q2DXN63BM!_OWA<UMMIHE<Q3'&<J!)*5(UH"A$/D;2&(@P#EC#F9R0,
M/*O:2D,*.S7K:BMLI$F(H?QV-Q3N#DP8T%E-6IV!5EI5;ERK#;3>8"?W_"6%
M P;];,RX?RH?P] 7W<-_!P/$X8TQ.*Y]/H<0]65<10<$_:B'Z9!]]MV8-X5W
M;O'/1K@-R53$!R6AX,@+(0M" E$@&,1>(F"8XC0-(\_SDV16%S6>F^[53_9G
MM<"L>AV.6*1(@'6EHVK\$^ >*:_.81PE0>)[.()1%*OC84SEEHH3*+( H4 :
M "RT\FUPB?$H1R0#XVMZ>.(,M<'/4UK 5*QX=TA[*LBKQ]F*$1;.CEM.]S;R
M"8R1ZON',F:O]6/ISX^\U/GX/LC%@O^-YW?W-6?73_)?[[B*_U41TU]PS=L,
M^+. )YY0-\-I*"1MQX3"U.<>](CP6)I0Q -B0RFV DR-8SJ) 6Y$!JR569>9
ML*,;Z\$PXY\A(1Z8D%:B RW[%5C!W8H/.OF!4N"JJ^;BCK#Z@N>(P:R['Y72
M^H*SRW&]VW&1)N/]0O($KW3[RB&"LW6UCQD+/)RI&W6!4@01"1DDW!,0,VF>
MT@ 1RJR2[9AW/36B:^0#>2MR4T5G7;?FDJP:)T? U,8: M?!S:V=W!N=W"V9
MM9#?G ?YPC0<)G@-DIGC9,<OF*S#!)#3^3N,6NA)7ZNT+)_%YLV%3JW,V>NB
MJBM]9$W4I467E6QUOH=%1%.2(9AX40811P)F7JQ<WU,:D03[-+$Z%KY,G,G1
MG+[N(=O7/1LW0GV3C5TX:(8L.-I0C'@YUW,4["G1"7BN:/(R8<:E3B? [=&I
MFU;[4>R10JM?N*H_J"X O_!*E1A<W+V3<'S CY64\OKQ<9Y3=:JJ"']9RW_Z
MD#_D38:9:A9+2])+?0]&'I.\BZ4]B9D(8)CZL0A%FF <V/DW#"#E%!T@'O-R
M5:Y9E5*L&KG5C_.UY$ 4I?ZU.NBK*DT3Z@7\TS:H:8C!-^/OEQK0D=+T'B^U
MO=(0K#0$BFB UE&-XUI+\'4]_AN*NEL(!AP%1ZO#$!*.NF0,"/'N.C)D5TY3
MMKS6%>2TE\F,(()9$L60D""&*!6QRMY"Y=+! X20%WK4ZN+F?)=3L\-W<HQ
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M$XA9X&<"TX":55<T[7!JAOE:9M (?=7FIM7Q5*W@X+L2W=#@-H;^-*4. >C
M;.D$2ZNJ*38 75!.Q:B;T>JLV"B]68#%ZKV>&<V7I.)_7_)%_?9)_J'.*_2G
M[O$@01PE,,*26U#D<8@#D4(:)"(249JPP*H&])%^ID8N:S&!EK,]2K,@DW/
MFIEE#N :F#IZ(66?)?PT#JY2@1_I9=Q\WZ=5W4OJ?>;Q2ZXNMQ-7=9GYGKML
M!&^6_%K(V?B?')?O)#G-8H\DR"<9#(4?0X14L5$_%5#$A/A)FH0^LB*+7E),
MC4IN[WG)L9*PSU6G[1#87((.".Q(UZ-["?162EPIQPC"M4?8%=#P Z4(4)JX
MOCOM":336U5;&5[@OK4G3(=O8OLV=DF59;7K*Q:R^?;RD,<)]A/,(=,E"$@4
MR"U8&$., B;M)1YA3NV+*^_T,C4^:VNHKJ3L4V]V%T@SUKH8GH%9:1>9 :Y>
M3T+@M)+L;A\O4$#VB)J'Z\8>>]C9=JC]5 5*>$885U>F$40L3F%*>0S3T.,B
MBQ/"/:LB;$=[FMJ\/V+H]W+(. YO[VW1Y-B@)UXNMD:#T,+Q?EYZ>W2:'LZ_
MX,9M:S.1;ULX.8K3.$ \A3Y6>6X(DOLA@3'DBB2B,$81\2]QW]KO<FJD\:9_
MNG #?,W(PBUJ [/&GA/7U78.</"]$7E =Z[C^ SDUG6@PQ=U[SH.P#DWKQ-O
M7ACTMEW$YO6]RA7Z?K%7/4%5RVG*W,SGQ0\LU9>;%.H)CQ.8>')K@K!(($Y(
M"#/?XVF:\2P25CF^+Q=I:B35B*X"\I\Z60'NA.T97==_O,Q(;=Q1&'KCI&\U
MU.W3.IJO8;MM[:[ >J@.%',!*R7!2DOW%_CND'<=2-A?H)>)/;P8P*/ABI>W
MW-,M2S>[*ENV3O(["S/D1ZJPC!?@5&X;A8IV##+HA8BF"4L21+"5N^VQGJ9&
MKKK$H.)5G=&T*5.E:@F6JUJ"1%5ML_2,.HJS&7LZ06]@4NP*5*UK-(*UG []
MD<Y!X<K'Z&@_X_H-G5-WSQ?H[ O]J*([J+XMKNG?EWG)O_"J+G-:<_9^\23_
MKG\[\],HP2RF,&2I#U$:"TA$A&" ,Y]F)**$)W9IM<TZ-IH(HV;*OFES*.D\
M0;PY:JU6SEEV_&$(/LD0RR3 D/I^"%$@1R +$PS#..-8FLZA%WHVI.T0^A$9
M? 7\(!B;$;9[Y 9F[TY@=0W9B@S6,H,-H=U1N1U(CGC=L--12=X.B%W&MWS;
M:0D&:<&6.CQZ*VUWFUZG<?N23]\45=XDWI?6I$>%E\* ZVHW"8.IGX5RKT\H
M"C+N9ZE5GBTW8DV-P3KQI='9Y,>4D[+-40N>E5. JJ#ZV$GOI)R"[4":T>#X
MPS,P39XHFK :M)V:"5V:L-9!5;UT<W;H7%5)Z(GTL(41;(6:0BV$GD :EC_H
MV[H[9[GJEO^L7\U5 GX?82^@"$./82&M2)Y"G.$ QC[W61PF:1I8520[W=W4
MN+<1[W+7MPU S;C2'4P#<^ 19S:5(45*"[2XSM-]G,-E0-^TC<Y>W EM7W$3
M;[,#;_4H7: R^ETOV,=BP9\_XO(/7K];RA^;J\TXHV$<DA *#\401=*FRR(F
M_P@]$2(4"Y09D<;9GJ;&%SK/H4K^^:"D!0]:7""DO(8D<A[;T_SA%+&!J4.#
M)>4$6E#02 J4J.?OB2U!L\C%[PJ\D7+K-V8!?5:GTO?JR\,5^,'G<_5?QA_4
MOS"N=P?RW_/Z'A"\^*.2\QR(?($7-,<2QT55Y_526Q-7^O/57RRH[['*8*=V
MC4"' 1=E#>4T>F@^;]A^WOFJL*I\6^7WY#_QP^-<+@JT>'C@I>[C$4L2NM*]
M\_)/%<!4L9ZZM9 O;>08QW<EYVU;=\43+Q?:FV!]5B9;Y66=BUPN%<UQ6JM?
M(WE1W_,2W.=W]_-G,,_E%IAMO/QG1S4#3#Z2DS4 3C8P7DY_$SVV<O0;O> R
MX=R'50*0(..($XQAA.52@ECJ04*%!V/!I4&:9AEFXO*D<Q^FFLJE,ZL^],W$
M<@Y?&\/4"6HC6::'LM"9@.@H%=T>-(.FH_OP,HE+#%4W2TNW_UK/2RKY.7R2
M'XB.6$PS'@01"Z!/? \BI IC94$&41PS% 5QEL69U6W(1N-3HPHE&U#"6=YY
M;.)E>+/1$X6A[R\Z )R'<AY2V-5=Q&;3X]XX'%!J[U[AT#,]]HVOEI6<WE6E
M;R>:$ZPF!&)].[&ZNKB]YW\KRCG[D3/^15IT=36C 0J)QS@D&4,08<(@EI,7
M4D0QQRJV 27&.\O+9)G:K&\#>/*5[.JB +>W=ZKX\H].?E!J!2PV5Q>.FL&>
M=;RQ&)A[.D7 AB97H!V<M3+@=GVU*O4!*X7 EY$'QV)O/-X@C;1['GJP[':5
M;N ]N>^\L(OQ=J9NL-C:NSIJLI\QJHI7O5\=E+PN9)=EG>LBU@7]XT955KN5
MM'S'RUD6I)01PJ&'$FF@4H%@RE7>9);Q!&5I*&*KY*;F74]M26O+(5=*SK;Z
M7-U(JO/2??OZ9IVQSC(]G<5XF)G"PZ \\&*ERW"NI58%J%=R7S5EJ($6';2R
MN[.D[?%R9&=;=#RJ%6X/R*Z-WJ.%?F1V)'W!9B$M)<%G\:X[8^YNJ]_^K/FB
M4C)]R*MZEK'$$QF.8<09EKMR+JF.! B*Q$\]DE /159G>JX$FQH1GDH5TBIW
M!5;JJ4/QE8(K_Q+P?:TC4$I:GA\Z&W0S/GV)H1R8;9V/XMN%G.FEMI$=GG&X
M1MX1;SL3:U16=PWF+N<[;[_'F8Y<663+CWC>1*M]7C1+3R4[47%P,X1PXL7J
MT@:I,  4II!DO@=YFK+$)P'/?*-BAR:=38VY5^*V&975/2U=26P166Z$M,%!
MBT/\AC[%74'7B H^+\!:6!UBZ1 ZBV,0AQ".=,YA\!6ZNAHW!.?D*<6Y-L8[
MAC#49NN<P?2=OLE]'A_GFM/Q7-W&OYL7/]XO1%$^-,&@1-K_F-:S*&5AG/I,
M!?TDDG2Q!TF(8BB"B"1I%!#+BO6&_4Z-?S?%W@A!_(MMRA\ST,U,VP&@')B*
MMU#4?EM*9K A-/C>B>TT.Y 54,YR!9GU.G+F("LH]O,(V;W>DYO40=PK:8<R
ME=!,6I=-XV6I0MBU4]>KY_4S;:C2]0]<LL_ZYK]Z5Y2"Y[6<H-7[1>/J_C>N
MCE\YNY84BN_XVY_*H:SB^C1C)J(L)HA%,$49ABB(,IAE@L#09QE-,&$DL<MG
M-K("4V/+U\HA;\[9Q<>KHW\)ALP[X?$=FL*56E#K!3:5!YO: _(,-A]L$0 :
M N7DW_J(;L"@/$,;(*Y !P5HL0 =&,TALL.%X87&T=4*,[;XXRY5+S0X>VO>
M2\G1;_'\M%1.M)_%ZD3G*[]KHLQCG@7$%QQ&09Q"%/(08H\F,$X"ZM,HH5EF
M%<E_M*>I+4>-H.H@M%@=G5:MK)8UU8^":[9P.(%L8(9?H[4^:/YZ#BW[^NKG
MD'!5:_UH/^/673^G[EX-]K,O]'4@:/(_O>/R'3S7)[O7"_9!#MC\%O]\^U,Q
M'&]C2%<;4N$CD289A00%#"*>20,Y)!CR(,QHD/@J#XJ=+T$/*:9&*YT2EH<
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MWDZ!^R]<57_L?GG+RP=_%J @2!.!8<Q)"I%(!4PSY;F,6)HB3_[5LRK=:"O
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M7C+'] ]8T7LI:]4^ 1_+7 >4/A2,S_N>L3KY#FR/9L<>W1%/=$]D@-#ZK?-
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MBH>?>3%G@J0RE@1B1F.]H!$<$IJD,.2,2TZRF,6.[A G^5.CH;WZL-3_M$(
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M# 77%!,C1C-.1PE3]6K6U'8*KPV-+?32]=9,_6G >_>8H*'>A:%)?+08H19
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MIY;69GM6J>U8C-D&=SM?CV\T!YXB]^WGRSKYE99#U&=V@,57I68;D>/6;'8
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MD.)YU8%>KZ+7F^' .A8R/&0S0#> R6_Y<FG(M%*@)XZIGI-8$E$H>:QQI$I
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M/(ABB!B.((U% &F&A" J9IEP6IX[RI\: =_>@-#13^PX7);NX.$&86!R]]$
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M-B8#\="=^N[Y2@S,_A[*L%7HM#:X1;O,Q*[97X51N]/?24N2\A)@H&K5=IM
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MM-<1NJ\ 8V.]W5R55H/=3J+EQ,92[/RBR4KQK&7E/4]N7-@G^CV387C@;^@
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MCF*SA<D%@QA%.:08,<@XSJ5.:4J%5R'0<P.-C4.;?.B=#B["2.G'DV=!=2/
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MH!72?<4_A>#U5?]&7/H^*?:"Q&OYOZ!X)Q/@U/,&,P,N*+-K"ERZK)LY8"A
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MH&*IRKC2.)5.]23O(_[82&R;5M^>)+6J@*+5I/U36>MB/;9L\0+T>CZO#ZH
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M7S:2@T9TT,H.C/!@(WT5E_\P!-@>[ID>01_(:=/I30_EU>D(WT5?C^\SA_,
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M]%*?IE*F--<8"FXC3#.:04)("I.$1#K!<895U@;U/PX0<NHIO].'MY\R\#@
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M'2HM9-L%2%[D3"I8[?[S=CI'/@DR2!.00FI!GK/2CH/3G(Y**X)++MM03 .
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M*1[)Q#(Y%K1/H^ >A-::"^NUB;PQ (?@8^2I&<^+X]&!T($9W1-C8U!8.#?
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M==!*+:OA;RQSG\_O) IR Q+$J.N#7&O!2\[HO"9^'848V;0N1W@*?>,8HO:
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M?74MAG'D :24H61>:X@X@D\4TB!JY(IQ%TKK=E9'$WL8*G^T//[SZ*X#D'Y
M<D_/\34)MM:;5<']?;K^\NI\M5Z<U4+:F]P)']!;E4&'.JE+"3+]MLZ;XUIQ
MP146WKI6YVD4'@;''^T68$ M=8!!8BEAY6KSL'6Z^L<VX5-_5VL<64DF@U2.
MD<TGZ^]$O4$+C$Q_5D[C +?<^\@Y#%T_VHU *_EW :75^EWY&.ZYW-!)>.\8
M RTK)R$;\(H)<-I8F8.TLK2.2_=3<QB0?K0[@4;2[P!''T@A1$"]>OV%;.]L
ML0FH-P-85WB1 126IV@L<*>KE34*G,H"A"4?-3,?A&K]PO( L@Y#UH]V!=!:
M'QU [$7>-,VE*/OSIHO#G?(BS6K343JU(QH25Q 0$16@I&,\L#KJMW5KQ4=(
M.@Q:/UJZOZ4>.H#5_6U[WEU,B7NS.>JGW[!F"R\2.L5I$AEW$+PG\:50!Z/3
M(1^=E=IG&4S["ORGDWD8_'ZT^X&A]=4!)"_[2]S>6E[4JUJ+Y%(R#<H:7V-E
M36CQV0B11!AN"NY1Y:L_VM5 $\EW@*#;/>'NU'5+PRDVX<!3'1:7';$338'D
M"WF9:*-M/I/G$9(.P]./=BG04@\=P.IW_/.:H):+.?TVX;5;_CMUEK;>SG))
MF\4'4-)+B#*2LUERT<7F(ECK.HRGTG@8\'ZT6X)!-=7OV[:[XQD_;0HW;U)^
M[!#)W7<--DKR/EK'&2B)TEH21J* D !'#I,AARE+X)P,4BP^A_P,]\4##I3\
MF+Y@/I_AN_(!T^+S?/I_,+_)U7,L4]RNNMHL2]!^46</ASB=;4=WK5;G9Y@W
MNKKF'W@3,=06T(:3?^"0@2>M@0U!N<!$UJ)ULJPQ"S_4B,JGX/-. #&BZCNV
MG#=F1IY@->_[GD'F6@YH+9\P,]!RD3(=RY",K&.7908O7(0B7.V]+ 2FUE?/
MSS?=\FJKO/@6IK,J\->+9<U77ZU5-]$\T0X)ET?8M0HJAN3.V@B9@B=0&"(X
MJ0)%4=KX''.]7AO,+!Y'\]@M*P=!WGX;^ R*[2!PN6DY;O/\QWR)85;/@5HS
M_WZQ/6PNRYIOL5Z/'FU#@<P]!Q5S !^T!88L!&]*+*+U-49#\L=]=OQ,\!Y+
MW?T>[_=.-CW^E'_HZX:<Q3K@F?_@Y$UKK&*U^X&AWX!B!,L@ T*(D>?HT3/5
M^AQ[EHFL6V]W)^'\;OZA;AK2P^>7836]UOF&#+IS3"G0VB HK\G<6]1@HTMU
MI(3R>; AK0?2V/'<UJ>@9^_CFB%4U<')?"!_?\P7<87+S3/<-_.OY^M;WLE5
M*5<LM0,W0BZ&HC%& G>.TQ]%*EJC8IJU?I[3F(5Q3^BQ@3R(HOL]E^\?!7S\
MP?S@]PTZOGC HWG/$%OKN--2.] ",ZB<-814+%A3=!$4GO#8.N<VS!#CJVBL
M?O^UIY/7'K]IB38Y"85( J4M><->T"]H0K;&E2B'RR_NHZK+T<9/0<7^L+B)
M(OHU.P_,##[>]CS^I<-//![0"CUM-FT,=!S:Q$%:4Z=A,PXNE'I0<>55$J*$
MUA[SL\X]OMHJ%\M>[9%<;(F<>8J1E8/:0@"\]!Z,S08Q129=\_*H_>3\2!.-
MGX*:_<;K-(UT$!1<L?)Z.I^N\>WT&]Z_U:]E)$LAP07R2%EB]=J:D5N:"VA5
M&UDH+ );EW\>0>:XSOT88!Q&@UV!] V=+N5@-D5A*4HFP>7Z&MA1;.ZSL)!2
MTJ5V,9"J]8W1D:2.VW%P#+ .I\F. +MX:$^^/E]7L9XM*,#;MHO=/1JXQ7LT
MW&Y*U91($E1]\12D*L""T]99H7WS"I&6](_;^_#YH?WL.N\W]MDWW?WXP.>1
M;VS5P?P)=)\8\FQ;1N]9[VK^$'J?M4F@N4TUTRPA!&LA:\E,1)7)YWQ,= >M
MU/*DWC47VCY47]\".&,Z2$\>,G>1W&0?+ 3+*<R/,>3"3$G-)Y4?2MLX44Q[
M(#QT]C;330>'[=XF0]<;6NFLM"#W0:.J'&V*V!PDYETT6$UMZYZ;CU,U3H R
M/,X:ZZ,#A%VKX=E6>J_>A^]US]3"R926YWB]=O'6;BH<2TP"01I9QUS' MYC
M I:CRSHQ9*)U8?XI](X3B3RG]1M8AR/B=2/%W;R5;<WMU77>NU(;==]JUKV9
M>TC"G:8ZL)W^[LY)X*25FH'AM6,I*[5Y-Y(O*EA]LJRRB_8@OZ,A4>/$$\,!
M=%2E]1L[W'[/=7S,L.>;&L4*A]#9Z%KD]E*7L$O:"V?)88N!U^Z)$<%SLE%D
MFXIW2LB06M=)[J.EW5%[>X5:LY!JDX7I['Q]YVD "C0<!07MK(X9$)8\BN(M
M),Y,4-(QYUH_LSR2U'$O29I@:/_9.IS2^K54]S^3/]Y>/?A]K69''DQSJ\*2
MRV0;G6G7EOR LU"/L=K>8D-4K$21:[8=-7J!3B]T*84<,%\*':R%CK,H#0.>
MF#*)\^R:MX(^C>*&=I PL_B.^!&7WZ;5[[A/<R]FFZ_<N Q7;ZUH%TX76TJO
M/3_-EG'F::O)0AN=,071DE<K-<82K2<'8;A+D<;,C%P6\WR8?L#BC@B/KD+S
M*\YWDG[Q9UCFCVMB:MNR9%5K(K?BJ*\+MY_=.I'J%#[CO0/I#/G.L4[%LCZ
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M*ND4Z[RP0#Y<K1!0*8 VG%OO+"_8^F'\30I.M4&;;ZMYJ=O5?38$@<& +;J
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M%H[0(;0<A"7SSW#\#:*=SM&VVX]6>%FX26 $KRV ZY"E( T8XYG&F#B%#<^
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MM(,8#%G38+UU*B71O#SE7D)&ONIOI^C;@ZA.EGH'T"'RSQ;SZ[.TG+0AZY)
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M9?C\^QT& 6K,?H<AVNT V0_4?VINC=EN[98:Z1<3P4=,('0TGDMG!6O=-79
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MT3)M8KOU!=E$XITBY\H8;?+2>@3IZ$90KM!E4&HZ!;FQLN3 5>LJCX>IF?;
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M9(KIT8)*2"XS.<O +?>!2SK:]4Z+F>BGWCKKZ$\WY]P/'SCQ>39I0+R_Y'N
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M68KY- NX\WW]EE5=S.J=+^LA6KI_S6;YK_%D0DOB%]+:]%,M6]CREK05)L0
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M]IMQ67[^:46+F7ZM9A"RSIB N[H"4$=B6BF0S@H2!V.B\.=@<L;[^SW2/@,
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MD35^?#MG.0.OQ*WPH:[/:5R GZCZ3BH/I= VWN04?1"$EA0>L+R@,Z9!*XC
M\RKGK$#OBD)6PMAH/&%J\<@5S[GI6YN6/&G:%47%VCHCD9E3Q$0A52D5MKF*
M\A52= HVBL*2W(ZIY%PNK9$U NNMEP:2T>:3/CQHI_T],/Y-^':;">C-B50+
M=.FEZ$SJ%HKCV N[[33M->MWJ +==//>[86=)L*"N'441FD71)=4&<R$!6J-
M;12$(1I_JIA90239F&8W%)US+&QLG=%*R4*!FN@]D[I@%G3=M#M;S7V ,]H-
MSEXOC;OW8>L$G>Y3L$'25843]#*L$-H'M.*=T(J"=B^./X,5Q4$4[!ACEGE7
M+/<!R>1E2*Z!C#J]G;/3(@?D%(T7)9<K2N$,65Q#W5?%'.O_4 ZW=\(R3MK!
M_['2=79"*0GB;2A%P=]$R8;D/B %!7T7J#J==KREK&V%ZJLDYQY@"1;(2D$_
M!MT9H$?<['-"<U5AM3H\@,]G'[H3-^TLF9G#1EW2XJZQLWV>Y*QFFS*!1<$P
M!R/N_/&2F'.BZ'0*@L$!@FK'QFQW#I.=/<0HR9&\H>K>(;7.UIU?/ /Z3UX1
M4-%UFTRC=T)4(.+"B5C'3!AX/[_]DBQH5)53=T6Q0K9I)VA$X>.74U7#%8<.
MK^BQ]^_&.*QF,,D968(3P$M/#%$&YYQN]N=2$:H\" F.2TVSS4N?,%URO,J8
M<(YU3/VU]%P:(Q=9&^0#;(85F*_/<,?5Y/4$&4>MH!W:(=) 8!JR.7@]7[;<
M?.D;\IC62UN]8#LY:(5W--_)KN6#!;K$XJ@1-S8,)28$?)E%Y2T*'X+"Z?21
M$;7^C>=P_7:#G9.8,0.J%,_GF,/F\"#I]K5[;F+B'TYUIP8:*Z$-.CR(TS[Z
M"#/E#)V>GO]E7+[SE.^BZ;O7ITNHLB-&9[*)A@ W9)]@^%]2.Y\LDUNS_O[%
M32GK:ZM,48YMS=MZE;-.X^ S"\ZAXE;F,<O6C\N#9WT1Y:[$CO\$4$L#!!0
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M2R6JSQQWA4-9;C) VOJ:)(JTB;T!OEB]$2E*#05DHT5DM&1(!(5X0"^6ELQ
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M"5N,2@7S)PBF"(U@@FKA'! E%_M,(9VFPCA^]"O3>#(%>&VB#(=!5EC?*:?
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M-B9@GU?P"G@&&1M']OCKRNQZ$?)_"@'S_8(K9.2<>/UC(_8U4_\P1>&&0E(
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MJ&>S&MIM#U*34_EVK[=7RU1@'G3S&])9GRR'[_O.E7Z5]S&^.2K\39"7+_I
MNO\D7YD$O,:!L' ]VL*R3;^4W[NN\3\&J4*HO]61PU-W"$=J%Y\802CY]NOY
M\_/S;>#[_9Q_Y,+$0__;GF8VL-K=JU&Y*B^&#<K#VSE_]+)4Q5/!;1<: C^%
M?=CET1M1:Y_E52]_Z>STOU!+ P04    " !5@$E6[9'0JI@%  "_+0  %0
M '$T+3(P,C)X97AH:6)I=#,R+FAT;>U:;6_:2!#^?K]B2G1I*N%77IH C43
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M^YYW"MYGKW/I]_[VT&5TW[N =K\+N>RTUV_W.[WV62%[]IC.+R^&E^V^#_X
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MVC> 5S[S5YNSEZR/_P-02P$"% ,4    " !5@$E6R&48QR%F P#ZO2$ $0
M            @ $     ;F)I>"TR,#(R,3(S,2YH=&U02P$"% ,4    " !5
M@$E6/X(S:[H5   >ZP  $0              @ %09@, ;F)I>"TR,#(R,3(S
M,2YX<V102P$"% ,4    " !5@$E6-'.QQ(<I   TI $ %0
M@ $Y? , ;F)I>"TR,#(R,3(S,5]C86PN>&UL4$L! A0#%     @ 58!)5@:M
M?- 69P  7IL$ !4              ( !\Z4# &YB:7@M,C R,C$R,S%?9&5F
M+GAM;%!+ 0(4 Q0    ( %6 25:- .N//!H% $LO!@ 4              "
M 3P-! !N8FEX+3(P,C(Q,C,Q7V<Q+FIP9U!+ 0(4 Q0    ( %6 25;G@GYA
M:5<( /PR"P 4              "  :HG"0!N8FEX+3(P,C(Q,C,Q7V<R+FIP
M9U!+ 0(4 Q0    ( %6 258YCFEJY10! *^* 0 4              "  45_
M$0!N8FEX+3(P,C(Q,C,Q7V<S+FIP9U!+ 0(4 Q0    ( %6 25;;<2*-32T!
M 'M\#  5              "  5R4$@!N8FEX+3(P,C(Q,C,Q7VQA8BYX;6Q0
M2P$"% ,4    " !5@$E6H2ILOIFR  #!, @ %0              @ '<P1,
M;F)I>"TR,#(R,3(S,5]P<F4N>&UL4$L! A0#%     @ 58!)5BL_4L ? P
MK!,  !8              ( !J'04 '$T+3(P,C)X97AH:6)I=#(Q,2YH=&U0
M2P$"% ,4    " !5@$E6<I'A+F<$  !M$P  %@              @ '[=Q0
M<30M,C R,GAE>&AI8FET,C,Q+FAT;5!+ 0(4 Q0    ( %6 25:'U<(M$P@
M %PF   6              "  99\% !Q-"TR,#(R>&5X:&EB:70S,3$N:'1M
M4$L! A0#%     @ 58!)5@)<O+/'!P  SR8  !8              ( !W804
M '$T+3(P,C)X97AH:6)I=#,Q,BYH=&U02P$"% ,4    " !5@$E6[9'0JI@%
M  "_+0  %0              @ '8C!0 <30M,C R,GAE>&AI8FET,S(N:'1M
64$L%!@     .  X HP,  *.2%     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
